| 1 | Probst, Daniel, Reymond, Jean-Louis. SmilesDrawer: Parsing and Drawing SMILES-Encoded Molecular Structures Using Client-Side JavaScript. J. Chem. Inf. Model. 2018, 58, 1, 1–7 |
| 2 | Therapeutic Goods Administration (TGA). 2022. Search the TGA website. [online] Available at: <https://tga-search.clients.funnelback.com/s/search.html?query=&collection=tga-artg> [Accessed 20 January 2022]. |
| 3 | Accessdata.fda.gov. 2022. Drugs@FDA: FDA-Approved Drugs. [online] Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm> [Accessed 20 January 2022]. |
| 4 | Drugs.ncats.io. 2022. NCATS Inxight Drugs. [online] Available at: <https://drugs.ncats.io/> [Accessed 20 January 2022]. |
| 5 | Balakrishnan R, et al. Isolongifolene attenuates rotenone-induced mitochondrial dysfunction, oxidative stress and apoptosis. Front Biosci (Schol Ed). 2018 Jan 1;10:248-261. |
| 6 | https://clinicaltrials.gov/ct2/show/NCT04445623?term=Prasugrel&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04505774?term=Prasugrel&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT02735707?term=Prasugrel&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04518735?term=Prasugrel&cond=COVID-19&draw=2&rank=4 |
| 7 | Wang W, et al. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2018 Nov 12;34(5):757-774.e7. |
| 8 | Masuda M, et al. Activating transcription factor 4 regulates stearate-induced vascular calcification. J Lipid Res. 2012 Aug;53(8):1543-52. |
| 9 | Liu G, et al. Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors. J Med Chem. 2007 Jun 28;50(13):3086-100. |
| 10 | Koeberle A, et al. Palmitoleate is a mitogen, formed upon stimulation with growth factors, and converted to palmitoleoyl-phosphatidylinositol. J Biol Chem. 2012 Aug 3;287(32):27244-54. |
| 11 | Kamphorst JJ, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A. 2013 May 28;110(22):8882-7. |
| 12 | H Hidaka, et al. N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a Calmodulin Antagonist, Inhibits Cell Proliferation. Proc Natl Acad Sci U S A. 1981 Jul;78(7):4354-7. |
| 13 | M Asano. Divergent Pharmacological Effects of Three Calmodulin Antagonists, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), Chlorpromazine and Calmidazolium, on Isometric Tension Development and Myosin Light Chain Phosphorylation in Intact Bovine Tracheal Smooth Muscle. J Pharmacol Exp Ther. 1989 Nov;251(2):764-73. |
| 14 | H Itoh, et al. Direct Interaction of Calmodulin Antagonists With Ca2+/calmodulin-dependent Cyclic Nucleotide Phosphodiesterase. J Biochem. 1984 Dec;96(6):1721-6. |
| 15 | Shigeyuki Yokokura, et al. Calmodulin Antagonists Induce Cell Cycle Arrest and Apoptosis in Vitro and Inhibit Tumor Growth in Vivo in Human Multiple Myeloma. BMC Cancer. 2014 Nov 26;14:882. |
| 16 | Kim H, et al. Sulfiredoxin inhibitor induces preferential death of cancer cells through reactive oxygen species-mediated mitochondrial damage. Free Radic Biol Med. 2016 Feb;91:264-74. |
| 17 | Ueno S, et al. Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAA receptor. J Neurosci. 1997 Jan 15;17(2):625-34. |
| 18 | Drug Metab Dispos 8:1284 (2000); Ned Tijdschr Geneeskd.151:1945 (2007) |
| 19 | Tridib Mondal, et al. ApoE: In Vitro Studies of a Small Molecule Effector. Biochemistry. 2016 May 10;55(18):2613-21. |
| 20 | Noguchi K, et al. Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa). Thromb Res. 2018 Aug;168:96-101. |
| 21 | Hothersall JD, et al. Sustained wash-resistant receptor activation responses of GPR119 agonists. Eur J Pharmacol. 2015 Sep 5;762:430-42. |
| 22 | Lan H, et al. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol. 2012 Apr;165(8):2799-807. |
| 23 | Yang JW, et al. GPR119: a promising target for nonalcoholic fatty liver disease. FASEB J. 2016 Jan;30(1):324-35. |
| 24 | Miller CP, et al. Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-129. |
| 25 | Jayaraman A, et al. Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology. 2014 Apr;155(4):1398-1406. |
| 26 | Solt LA, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012 Mar 29;485(7396):62-8. |
| 27 | Wang Y, et al. Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells. Biochem Pharmacol. 2015 Aug 15;96(4):315-22. |
| 28 | Wu MP, et al. Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of β2-AR/PI3K/AKT signaling pathway. Pharmacol Res. 2016 Feb;104:115-23. |
| 29 | Lee SR, et al. Acute oral intake of a higenamine-based dietary supplement increases circulating free fatty acidsand energy expenditure in human subjects. Lipids Health Dis. 2013 Oct 21;12:148. |
| 30 | https://clinicaltrials.gov/ct2/show/NCT04935476?term=DAPSONE&cond=covid&draw=2&rank=1 |
| 31 | Am J Opthalmol 126:400 (1998)| |
| 32 | DeSantis, L., Preclinical overview of brinzolamide. Surv Ophthalmol, 2000. 44 Suppl 2: p. S119-29. |
| 33 | Silver, L.H., Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group. Surv Ophthalmol, 2000. 44 Suppl 2: p. S147-53. |
| 34 | Ertongur S et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. |
| 35 | Ewa Zeslawska et al. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol. 2000 Aug 11;301(2):465-75. |
| 36 | Nicholson B, et al. Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci. 2008 Jun;17(6):1035-43. |
| 37 | https://clinicaltrials.gov/ct2/show/NCT04588441?term=ADENOSINE&cond=covid&draw=2&rank=1 |
| 38 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=FELODIPINE&cond=covid&draw=2&rank=2 |
| 39 | Chem Pharm Bull 25:2300 (1977); Phytochemistry 32:1083 (1993) |
| 40 | Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010 Oct;70(4):580-7. |
| 41 | Guo H, et al. Peiminine ameliorates bleomycin-induced acute lung injury in rats. Mol Med Rep. 2013 Apr;7(4):1103-10. |
| 42 | Dugasani S, et al. Comparative antioxidant and anti-inflammatory effects of |
| 43 | -gingerol, |
| 44 | -gingerol, [10]-gingerol and |
| 45 | -shogaol. J Ethnopharmacol. 2010 Feb 3;127(2):515-20. |
| 46 | Almada da Silva J, et al. Purification and differential biological effects of ginger-derived substances on normal and tumor cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 15;903:157-62. |
| 47 | J Int Med Res 10:160 (1982); Neuropsychobiology 14:17 (1985); Br J Psychiatry 150:164 (1987) |
| 48 | Stafford WC, et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med. 2018 Feb 14;10(428). pii: eaaf7444. |
| 49 | Kuo CC, et al. Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels. Mol Pharmacol. 2004 Feb;65(2):370-80. |
| 50 | Harty TP, et al. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000 Mar;39(1):47-55. |
| 51 | J Org Chem 50:2011 (1985) |
| 52 | Riendeau D, et al. Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg Med Chem Lett. 2004;14(5):1201-1203. |
| 53 | Paudel S, et al. Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators. Pharmaceutics. 2019;11(9):479. Published 2019 Sep 16. |Biochem. Pharmacol. (1991), 42(12), 2363-8; Biochem. Pharmacol. (1984), 33(15), 2473-8; J. Med. Chem. (1984), 27(2), 212-6 |
| 54 | Touré BB, et al. Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight. J Med Chem. 2016 May 26;59(10):4711-23. |
| 55 | Illana Gozes, et al. Novel compounds and methods for inhibiting cell death. US 20150141345 A1. |
| 56 | Severin G. Comprehensive high-performance liquid chromatographic methodology for the determination of thiothixene in bulk drug, finished product, and dissolution testing samples. J Pharm Sci. 1987 Mar;76(3):231-4. |
| 57 | Bodenstine TM, et al. Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. Cancer Res. 2010 Dec 1;70(23):10002-11. |
| 58 | Shenoy K, et al. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res. 2009 Mar 1;69(5):1941-50. |
| 59 | El-Kholy W, Macdonald PE, Lin JH, The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism. FASEB J. 2003 Apr;17(6):720-2. |
| 60 | Kristof AS, et al. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther. 2005 Sep;314(3):1134-43. |
| 61 | Hiroyuki Hisamichi, et al. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem. 2005 Aug 15;13(16):4936-51. |
| 62 | Lancet 243:49 (1944); J Am Pharm Assoc 40:267 (1951); J Am Coll Toxicol 4:65 (1985) |
| 63 | https://clinicaltrials.gov/ct2/show/NCT04900129?term=Diclofenac&cond=covid&draw=2&rank=1 |
| 64 | Zmijewski M, et al. Application of biocatalysis to drug metabolism: preparation of mammalian metabolites of a biaryl-bis-sulfonamide AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor potentiator using Actinoplanes missouriensis. Drug Metab Dispos. 2006 Jun;34(6):925-31. |
| 65 | Jones N, et al. AMPA receptor potentiation can prevent ethanol-induced intoxication. Neuropsychopharmacology. 2008 Jun;33(7):1713-23. |
| 66 | ARYL SULFONOHYDRAZIDES. WO2016198507 A1. |
| 67 | Dan Yuan, et al. Anti-inflammatory effects of rhynchophylline and isorhynchophylline in mouse N9 microglial cells and the molecular mechanism. International Immunopharmacology
 Volume 9, Issues 13–14, December 2009, Pages 1549–1554 |
| 68 | Houcai Huang, et al. Neuroprotective Effects of Rhynchophylline Against Ischemic Brain Injury via Regulation of the Akt/mTOR and TLRs Signaling Pathways. Molecules 2014, 19 (8): 11196-11210; doi:10.3390/molecules190811196 |
| 69 | Tai-Hyun Kang, et al. Protective effect of rhynchophylline and isorhynchophylline on in vitro ischemia-induced neuronal damage in the hippocampus: putative neurotransmitter receptors involved in their action. Life Sciences
 Volume 76, Issue 3, 3 December 2004, Pages 331–343 |
| 70 | Kinzo Matsumoto, et al. Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: Behavioural and electrophysiological studies. European Journal of Pharmacology
 Volume 517, Issue 3, 11 July 2005, Pages 191–199 |
| 71 | Von Nussbaum F, et al. Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73. |
| 72 | Tetrahedron Letters 1965: 669 |
| 73 | Qiang Qv.et al.Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology.Feb;141(2):809-20. 25. (2000). |
| 74 | Tracy L. Taras et al.In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 77(4-5):271-9,(2001). |
| 75 | Unkila M, et, al. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol. 2013 Nov;138:107-15. |
| 76 | Bruyniks N, et, al. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric. 2017 Jun; 20(3): 195-204. |
| 77 | J Med Chem 29:1553 (1986); J Nat Prod 53:186 (1990)| |
| 78 | Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin
 with targeted nanostructured lipid carriers against
 multidrug resistance
. Journal of Drug Targeting. |
| 79 | Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted
 nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8 |
| 80 | Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35(8):1295-9. |
| 81 | Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21(4):364-8. |
| 82 | Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11(9):747-56. |
| 83 | Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24(5):433-40. |
| 84 | Lin LT, et al. Paris Polyphylla Inhibits Colorectal Cancer Cells via Inducing Autophagy and Enhancing the Efficacy of Chemotherapeutic Drug Doxorubicin. Molecules. 2019 Jun 3;24(11). |
| 85 | Stiborova M, et al. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):13-23. |
| 86 | Stiborova M, et al. Ellipticine cytotoxicity to cancer cell lines - a comparative study. Interdiscip Toxicol. 2011 Jun;4(2):98-105. |
| 87 | Stiborova M, et al. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN?) mice and pure enzymes. Int J Mol Sci. 2014 Dec 25;16(1):284-306. |
| 88 | Ghavami M, et al. Biological Studies and Target Engagement of the 2- C-Methyl-d-Erythritol 4-Phosphate Cytidylyltransferase (IspD)-Targeting Antimalarial Agent (1 R,3 S)-MMV008138 and Analogs. ACS Infect Dis. 2018 Apr 13;4(4):549-559. |
| 89 | Yao ZK, et al. Determination of the active stereoisomer of the MEP pathway-targeting antimalarial agent MMV008138, and initial structure-activity studies. Bioorg Med Chem Lett. 2015 Apr 1;25(7):1515-9. |
| 90 | Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24(2):194-202. |
| 91 | Bavetsias V, et al. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem. 2012 Oct 25;55(20):8721-34. |
| 92 | Morshedi D, et al. Cuminaldehyde as the Major Component of Cuminum cyminum, a Natural Aldehyde with Inhibitory Effect on Alpha-Synuclein Fibrillation and Cytotoxicity. J Food Sci. 2015 Oct;80(10):H2336-45. |
| 93 | Okawa T, et al. Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure. J Med Chem. 2017 Aug 24;60(16):6942-6990. |
| 94 | Yu Q, et al. Inhibition of prostatic smooth muscle contraction by the inhibitor of G protein-coupled receptor kinase 2/3, CMPD101.Eur J Pharmacol. 2018 Jul 15;831:9-19. |
| 95 | Wang Z, et al. Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. ACS Med Chem Lett. 2017 Feb 9;8(3):327-332. |
| 96 | Fish PV, et al. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. |
| 97 | Baltatu OC, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA.
 Antidiuretic effects of the endothelin receptor antagonist avosentan.
 Front Physiol. 2012;3:103. |
| 98 | Konieczka K, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J.
 Effect of avosentan (SPP-301) in porcine ciliary arteries.
 Curr Eye Res. 2011 Feb;36(2):118-24. |
| 99 | Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group.
 J Am Soc Nephrol. 2010 Mar;21(3):527-35. |
| 100 | Dieterle W, Hengelage T.
 Absolute bioavailability and pharmacokinetics of avosentan in man.
 Int J Clin Pharmacol Ther. 2009 Sep;47(9):587-94. |
| 101 | Effect of SPP 301, an Endothelin Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes By Wang, Rong-Fang; Podos, Steven M.; Serle, Janet B.; Baltatu, Ovidiu C. From Current Eye Research (2011), 36(1), 41-46. |
| 102 | Nature 184: 1714 (1959); Biol Pharm Bull 29:684 (2006) |
| 103 | Aust J Chem 34:1779 (1981) |
| 104 | Van Schaick EA et al. Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol. 1996 Jul 25;308(3):311-4. |
| 105 | Jacobson KA et al. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci. 1998 May;19(5):184-91. |
| 106 | Drugs 45:85 (1993); Am J Cardiol 82:59N, 66N (1998); |
| 107 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Prednisolone&cntry=&state=&city=&dist= |
| 108 | Fales KR, et al. Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model. J Med Chem. 2017 Dec 14;60(23):9599-9616. |
| 109 | Zaghloul MS, et al. Crocin attenuates lung inflammation and pulmonary vascular dysfunction in a rat model of bleomycin-induced pulmonary fibrosis. Life Sci. 2019 Aug 26:116794. |
| 110 | Chang P, et al. Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain. 2016 Feb;139(Pt 2):431-43. |
| 111 | Kim S, et, al. Selective production of decanoic acid from iterative reversal of β-oxidation pathway. Biotechnol Bioeng. 2018 May;115(5):1311-1320. |
| 112 | Boison D, et, al. New insights into the mechanisms of the ketogenic diet. Curr Opin Neurol. 2017 Apr;30(2):187-192. |
| 113 | Biochem. J. (1990), 270(3), 691-5; Drugs (1986), 31(5), 430-48; J. Pharmacol. Exp. Ther. (1945), 85, 343-5 |
| 114 | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO 2015059668 A1? |
| 115 | Ma L, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15950-5. |
| 116 | Shirey JK, et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptorincreases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 2009 Nov 11;29(45):14271-86. |
| 117 | Russell JP, et al. Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity. J Pharmacol Exp Ther. 2019 Feb;368(2):299-307. |
| 118 | Russell JP, et al. Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations. Neurogastroenterol Motil. 2019 Apr;31(4):e13479. |
| 119 | Li NN, et al. Evidence for the Involvement of COX-2/VEGF and PTEN/Pl3K/AKT Pathway the Mechanism of Oroxin B Treated Liver Cancer. Pharmacogn Mag. 2018 Apr-Jun;14(54):207-213. |
| 120 | Yang P, et al. Oroxin B selectively induces tumor-suppressive ER stress and concurrently inhibits tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy. Toxicol Appl Pharmacol. 2015 Oct 15;288(2):269-79. |
| 121 | Clin Gastroenterol Hepatol 4:1395 (2006); Health Technol Assess 14:#24 (2010) |
| 122 | Thorisdottir H, Ratnoff OD, Maniglia AJ. Activation of Hageman factor (factor XII) by bismuth subgallate, a hemostatic agent. J Lab Clin Med. 1988;112(4):481‐486. |
| 123 | Puia SA, Renou SJ, Rey EA, Guglielmotti MB, Bozzini CE. Effect of bismuth subgallate (a hemostatic agent) on bone repair; a histologic, radiographic and histomorphometric study in rats. Int J Oral Maxillofac Surg. 2009;38(7):785‐789. |
| 124 | Hideshima T, et all. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 1;12(19):5887-94. |
| 125 | Schopf L, et al. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum. 2006 Oct;54(10):3163-73. |
| 126 | Ansaldi D, et al. Imaging pulmonary NF-kappaB activation and therapeutic effects of MLN120B and TDZD-8. PLoS One. 2011;6(9):e25093. |
| 127 | Nagashima K, et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Blood. 2006 Jun 1;107(11):4266-73. |
| 128 | Du K, et al. Mitochondria-targeted antioxidant Mito-Tempo protects against acetaminophen hepatotoxicity. Arch Toxicol. 2017 Feb;91(2):761-773. |
| 129 | Guo X, et al. Comparative Genotoxicity of TEMPO and 3 of Its Derivatives in Mouse Lymphoma Cells. Toxicol Sci. 2018 May 1;163(1):214-225. |
| 130 | Lv H, et al. TEMPO catalyzed oxidative dehydrogenation of hydrazobenzenes to azobenzenes. Org Biomol Chem. 2020 Apr 22. |
| 131 | Chen X, et al. Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling. Br J Cancer. 2020 May 5. |
| 132 | J Heterocyclic Chem 9: 1453 (1972); J Biol Chem 280:19078 (2005); FEBS J 273:2139 (2006) |
| 133 | Ohkubo M, et al. Heavy metal chelator TPEN attenuates fura-2 fluorescence changes induced by cadmium, mercury and methylmercury. J Vet Med Sci. 2016 Jun 1;78(5):761-7. |
| 134 | Rahal ON, et al. Chk1 and DNA-PK mediate TPEN-induced DNA damage in a ROS dependent manner in human colon cancer cells. Cancer Biol Ther. 2016 Nov;17(11):1139-1148. |
| 135 | E Aizenman, et al. Induction of neuronal apoptosis by thiol oxidation: putative role of intracellular zinc release. J Neurochem. 2000 Nov;75(5):1878-88. |
| 136 | Zheng MS, et al. Antiviral effect of mangiferin and isomangiferin on herpes simplex virus. Chin Med J (Engl). 1990 Feb;103(2):160-5. |
| 137 | Gerassim M Kitanov, et al. Mangiferin and isomangiferin in some Hypericum species. Biochemical Systematics and Ecology
 Volume 26, Issue 6, 1 September 1998, Pages 647–653 |
| 138 | Fraveto A, et al, Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PLoS One. 2015 Nov 16;10(11):e0142124. |
| 139 | Hoch L, et al. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. FASEB J. 2015 May;29(5):1817-29. |
| 140 | Ma W, et al. Reduced Smoothened level rescued Aβ-induced memory deficits and neuronal inflammation in animal models of Alzheimer's disease. J Genet Genomics. 2018 May 20;45(5):237-246. |
| 141 | J Org Chem 25:1073 (1960); Jacs 99:6639 (1977) |
| 142 | JACS 52:2461 (1930); J Chem Soc 1938: 513 |
| 143 | Linz K, et al. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther. 2014 Jun;349(3):535-48. |
| 144 | de Guglielmo G, et al. Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats. J Pharmacol Exp Ther. 2017 Sep;362(3):378-384. |
| 145 | Satat K, et al. Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain. Inflammopharmacology. 2017 Oct 25. |
| 146 | Christopher M. YATES. Metalloenzyme inhibitor compounds. WO2018165520A1. |
| 147 | Zhao G, et al. Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration. Mol Cancer Ther. 2017 Dec;16(12):2677-2688. |
| 148 | Stella W Nowotarska, et al. Mechanisms of Antimicrobial Action of Cinnamon and Oregano Oils, Cinnamaldehyde, Carvacrol, 2,5-Dihydroxybenzaldehyde, and 2-Hydroxy-5-Methoxybenzaldehyde Against Mycobacterium Avium Subsp. Paratuberculosis (Map). Foods. 2017 Aug 24;6(9):72. |
| 149 | Andrea Schabauer, et al. Gentisaldehyde and Its Derivative 2,3-Dihydroxybenzaldehyde Show Antimicrobial Activities Against Bovine Mastitis Staphylococcus aureus. Front Vet Sci. 2018 Jul 11;5:148. |
| 150 | https://clinicaltrials.gov/ct2/show/NCT04394117?term=Eprosartan&cond=Covid19&draw=2&rank=2 |
| 151 | Albright JD, et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem. 1998 Jul 2;41(14):2442-4. |
| 152 | Ghali JK, et al. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. IDrugs. 2010 Nov;13(11):782-92. |
| 153 | Beerman TA et al. Netropsin and bis-netropsin analogs as inhibitors of the catalytic activity of mammalian DNA topoisomerase II and topoisomerase cleavable complexes. Biochim Biophys Acta. 1991 Aug 27;1090(1):52-60. |
| 154 | Grant MA, et al. Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter. Biochem J. 2009 Feb 15;418(1):103-12. |
| 155 | Mishra K et al. Netropsin, a minor groove binding ligand: a potential radioprotective agent. Radiat Res. 2009 Dec;172(6):698-705. |
| 156 | Tumang J, et al. PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr4863. |
| 157 | Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. J Med Chem. 2017 Dec 14;60(23):9617-9629. |
| 158 | Hong YR, et al. [(4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl)-amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5953-7. |
| 159 | Hsieh MM, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007 Sep 15;110(6):2140-7. |
| 160 | Bernhardt WM, et, al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010 Dec;21(12):2151-6. |
| 161 | Katayama Y, et al. Inhibitory effects of Vesnarinone on cloned cardiac delayed rectifier K(+) channels expressed in a mammalian cell line. J Pharmacol Exp Ther. 2000 Jul;294(1):339-46. |
| 162 | Inage M, et al. Vesnarinone represses the fibrotic changes in murine lung injury induced by bleomycin. Int J Biol Sci. 2009;5(4):304-10. |
| 163 | Cavusoglu E, et al. Vesnarinone: a new inotropic agent for treating congestive heart failure. J Card Fail. 1995 Jun;1(3):249-57. |
| 164 | Matsumori A, et al. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994 Mar;89(3):955-8. |
| 165 | J Chem Soc 1954:1066; Ann Rev Plant Physiol 8:181 (1957); J Agric Food Chem 6:184 (1958); J Exp Botany,49:89 (1998) |
| 166 | Tavazoie MF, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Feb 8;172(4):825-840.e18. |
| 167 | Zhang, Chao, et al. Kinase modulation for the treatment of leukemias. From PCT Int. Appl. (2012), WO 2012158957 A2 20121122. |
| 168 | Zhang Chao, et al. 7-Azaindole derivatives and their preparation, pharmaceutical compositions and use for modulating c-kit and c-fms activity. From PCT Int. Appl. (2007), WO 2007013896 A2 20070201. |
| 169 | Matsumoto T, et al. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci. 2009 Feb;109(2):203-10. |
| 170 | Toyoda F, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats. J Diabetes Res. 2014;2014:672590. |
| 171 | Hefner G, et al. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey. J Neural Transm (Vienna). 2015 Nov;122(11):1609-17. |
| 172 | Bobo WV, et al. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. Hum Psychopharmacol. 2009 Jul;24(5):415-22. |
| 173 | Profiles Drug Subs 6:457 (1977); N Engl J Med 311:1353 (1984) |
| 174 | J Am Oil Chem Soc 51:321 (1974) |
| 175 | Canal-Raffin M, et al. Cytotoxicity of folpet fungicide on human bronchial epithelial cells. Toxicology. 2008 Jul 30;249(2-3):160-6. |
| 176 | https://clinicaltrials.gov/ct2/show/NCT04532931?term=Amodiaquine&cond=covid&draw=2&rank=1 |
| 177 | Cowburn AS, et al. z-VAD-fmk augmentation of TNF alpha-stimulated neutrophil apoptosis is compound specific and does not involve the generation of reactive oxygen species. |
| 178 | Yee SB, et al. zVAD-fmk, unlike BocD-fmk, does not inhibit caspase-6 acting on 14-3-3/Bad pathway in apoptosis of p815 mastocytoma cells. Exp Mol Med. 2006 Dec 31;38(6):634-42. |
| 179 | Sheen-Chen SM, et al. Effect of Boc-D-Fmk on hepatocyte apoptosis after bile duct ligation in rat and survival rate after endotoxin challenge. J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1276-9. |
| 180 | Chan YM, et al. Inhibition of caspases promotes long-term survival and reinnervation by axotomized spinal motoneurons of denervated muscle in newborn rats. Exp Neurol. 2003 Jun;181(2):190-203. |
| 181 | Anesth. Analg. (2002), 95(4), 789-790; Toxicol. Appl. Pharmacol. (1964), 6(1), 37-47; Arzneim. Forsch. (1963), 13(No. 3), 205-11 |
| 182 | Chemotherapy 14:195 (1969); Br Med J 328:545 (2004) |
| 183 | Cheng K, et al. Discovery of small-molecule inhibitors of the TLR1/TLR2 complex. Angew Chem Int Ed Engl. 2012 Dec 3;51(49):12246-9. |
| 184 | Aliakbar Tehrani Z, et al. Comparison of gas phase intrinsic properties of cytosine and thymine nucleobases with their O-alkyl adducts: different hydrogen bonding preferences for thymine versus O-alkyl thymine. J Mol Model. 2013;19(8):2993‐3005. |
| 185 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=SODIUM+GLUCONATE&cntry=&state=&city=&dist=&Search=Search |
| 186 | Kay GG, Harris AG. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin Exp Allergy. 1999 Jul;29 Suppl 3:147-50. |
| 187 | Menardo JL, Horak F, Danzig MR, Czarlewski W. A review of loratadine in the treatment of patients with allergic bronchial asthma. Clin Ther. 1997 Nov-Dec;19(6):1278-93; discussion 1523-4. |
| 188 | Monroe EW. Loratadine in the treatment of urticaria. Clin Ther. 1997 Mar-Apr;19(2):232-42. |
| 189 | Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994 Oct;48(4):617-37. |
| 190 | Roman IJ, Danzig MR. Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. Clin Rev Allergy. 1993 Spring;11(1):89-110. |
| 191 | Shahen M, et al. Dengue virus causes changes of MicroRNA-genes regulatory network revealing potential targets for antiviral drugs. BMC Syst Biol. 2018 Jan 4;12(1):2. |
| 192 | Kleine-Tebbe J, et al. Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allergy Clin Immunol. 1994;93(2):494-500. |Allergy (1987), 42(1), 57-63; Agents Actions (1984), 14(5-6), 590-7; Ann. Allergy (1987), 58(6), 407-11 |
| 193 | Phytochemistry 35: 1567 (1994) |
| 194 | Headache 22:167 (1982); Clin Pharmacokinet10:334 (1985); Teratology 51:344 (1995) |
| 195 | https://clinicaltrials.gov/ct2/show/NCT04784754?term=melatonin&cond=covid&draw=2&rank=2 |
| 196 | C Metcalfe, et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes |
| 197 | Chen DF, et al. Anti-AIDS agents--XXVI. Structure-activity correlations of gomisin-G-related anti-HIV lignans from Kadsura interior and of related synthetic analogues. Bioorg Med Chem. 1997 Aug;5(8):1715-23. |
| 198 | Ikeya Y, et al. The constituents of Schizandra chinensis Baill. I. Isolation and structure determination of five new lignans, gomisin A, B, C, F and G, and the absolute structure of schizandrin. Chem Pharm Bull (Tokyo). 1979 Jun;27(6):1383-94. |
| 199 | Am Rev Respir Dis 137(suppl):427 (1988); Eur J Pharmacol 155:117 (1988); Biochem Pharmacol 38:2291 (1989); Agents Actions 29:299 (1990) |
| 200 | Shi Y, et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature. 2019 Mar;567(7748):341-346. |
| 201 | Okoye-Okafor UC, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol. 2015 Nov;11(11):878-86. |
| 202 | Budke B, et al. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem. 2013 Jan 10;56(1):254-63. |
| 203 | Chen Z, et al. 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem. 2011 Dec 23;286(51):43951-8. |
| 204 | Kodama T, et al. Mechanisms underlying the relaxation by A484954, a eukaryotic elongation factor 2 kinase inhibitor, in rat isolated mesenteric artery. J Pharmacol Sci. 2018 May;137(1):86-92. |
| 205 | Kameshima S, et al. Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling. Am J Physiol Heart Circ Physiol. 2015 May 15;308(10):H1298-305. |
| 206 | Min SH, et al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis.Biochem Biophys Res Commun. 2010 Jan 1;391(1):1080-6. |
| 207 | Wisniewski T, et al. Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist.J Immunol Methods. 2010 Jan 31;352(1-2):101-10. |
| 208 | Pharmacol. Biochem. Prop. Drug Subst. (1977), 1, 183-213; Drugs (1977), 13(4), 241-65; Prostaglandins (1974), 6(2), 107-13 |
| 209 | Sonneveld, E., et al., Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol Sci, 2005. 83(1): p. 136-48. |
| 210 | Torri V,. Cyproterone acetate in the therapy of prostate carcinoma. Arch Ital Urol Androl. 2005;77(3):157-163. |
| 211 | Chen L, et al. Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5. BMC Cancer. 2017;17(1):179. Published 2017 Mar 7. |
| 212 | Migally N. Effect of cyproterone acetate on the structure of the adrenal cortex. Arch Androl. 1979;2(2):109-115. |
| 213 | Takiguchi M, et al. Cyproterone acetate induces a cellular tolerance to cadmium in rat liver epithelial cells involving reduced cadmium accumulation. Toxicology. 2001;165(1):13-25. |Arzneim Forsch 23:1550 (1973); J Steroid Biochem 19:591 (1983) |
| 214 | Usman Bacha, et al. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem Biol Drug Des. 2008 Jul;72(1):34-49. |
| 215 | Epilepsia (1995), 36 Suppl 2S2-12; Drugs (1993), 46(3), 409-27; Curr. Probl. Epilepsy (1986), 4, 147-63 |
| 216 | Harris PA, et al. Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. J Med Chem. 2017 Feb 23;60(4):1247-1261. |
| 217 | Br Heart J 69:293 (1993); Kidney Int. 65:1240 (2004); J Biol Chem 283:4588 (2008) |
| 218 | May PC1, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015 Jan 21;35(3):1199-210. |
| 219 | Dzyurkevich MS, et al. Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus. Sci Rep. 2017 Nov 22;7(1):16072. |
| 220 | Amin NB, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9. |
| 221 | Petersen M, et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int, 2008, 73(6), 705-715. |
| 222 | Tan SM, et al. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol, 2010, 298(5), H1415-1425. |
| 223 | Gellibert F, et al. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. J Med Chem. 2006, 49 |
| 224 | Arzneim Forsch 46:153 (1996); J Allergy Clin Immunol 98:1062 (1996) |
| 225 | Biochem Biophys Res Commun 13:394 (1963); J Pharmacol 14:47 (1983)| |
| 226 | Filipe Marques Gonçalves, et al. Signaling pathways underlying the antidepressant-like effect of inosine in mice. Purinergic Signal. 2017 Jun; 13(2): 203–214. |
| 227 | Ajith A. Welihinda, et al. The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias. Cell Signal. 2016 Jun; 28(6): 552–560. |
| 228 | Francisney Pinto Nascimento, et al. Adenosine A1 receptor-dependent antinociception induced by inosine in mice: pharmacological, genetic and biochemical aspects. Mol Neurobiol. 2015;51(3):1368-78. |
| 229 | Sara Cipriani, et al. Protection by inosine in a cellular model of Parkinson’s disease. Neuroscience. 2014 Aug 22; 274: 242–249. |
| 230 | Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56(4):481-95. |
| 231 | Arora D, et al. Deltamethrin induced RIPK3-mediated caspase-independent non-apoptotic cell death in rat primary hepatocytes. Biochem Biophys Res Commun. 2016 Oct 14;479(2):217-223. |
| 232 | Campos CA, et al. Anti-hyperalgesic and anti-inflammatory effects of citral with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models. Life Sci. 2019 Jul 15;229:139-148. |
| 233 | Drugs (1978), 16(3), 177-201; Arzneim. Forsch. (1975), 25(2), 224-30; J. Med. Chem. (1969), 12(5), 784-91 |
| 234 | Regul Toxicol Pharmacol 36:198 (2002) |
| 235 | Zhang Y, et al. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med. 2016 Jun;5(6):1251-8. |
| 236 | Zhao Y, et al. Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective. Oxid Med Cell Longev. 2016;2016:2124638. |
| 237 | Wu W, et al. Tetramethylpyrazine protects against scopolamine-induced memory impairments in rats by reversing the cAMP/PKA/CREB pathway. Behav Brain Res. 2013 Sep 15;253:212-6. |
| 238 | Kao TK, et al. Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats. Exp Neurol. 2013 Sep;247:188-201. |
| 239 | Baron BM, et al. Potent indole- and quinoline-containing N-methyl-D-aspartate antagonists acting at the strychnine-insensitive glycine binding site. J Pharmacol Exp Ther. 1992 Sep;262(3):947-56. |
| 240 | Wright SW, et al. 3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. Bioorg Med Chem Lett. 2003 Jun 16;13(12):2055-8. |
| 241 | Harden TK. Enigmatic GPCR finds a stimulating drug. Sci Signal. 2013 Oct 22;6(298):pe34. |
| 242 | Piali L, et, al. Cenerimod, a novel selective S1P 1 receptor modulator with unique signaling properties. Pharmacol Res Perspect. 2017 Dec;5(6):e00370. |
| 243 | Kano M, et, al. Attenuation of murine sclerodermatous models by the selective S1P 1 receptor modulator cenerimod. Sci Rep. 2019 Jan 24;9(1):658. |
| 244 | J Toxicol Clin Toxicol 36:713 (1998); J Emergency Med 41:166 (2011) |
| 245 | https://clinicaltrials.gov/ct2/show/NCT04483960?term=Nafamostat&cond=Covid19&draw=2&rank=7 |
| 246 | Myers SM, et al. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4. Eur J Med Chem. 2019 May 25;178:530-543. |
| 247 | D. W. Yesair, et al. Relationship of Phthalanilide-Lipid Complexes to Uptake and Retention of 2-Chloro-4′,4″-di(2-imidazolin-2-yl)terephthalanilide (NSC 60339) by Sensitive and Resistant P388 Leukemia Cells. CANCER RESEARCH 26 Part 1: 202-207, February 1966. |
| 248 | Yesair DW, et al. The retention or efflux of phthalanilide (NSC 60339)-lipid complexes by sensitive or resistant murine tumor cells and Escherichia coli B. Cancer Res. 1968 Feb;28(2):314-9. |
| 249 | Haynes KM, et al. Identification and Structure-Activity Relationships of Novel Compounds that Potentiate the Activities of Antibiotics in Escherichia coli. J Med Chem. 2017 Jul 27;60(14):6205-6219. |
| 250 | Abdali N, et al. Reviving Antibiotics: Efflux Pump Inhibitors That Interact with AcrA, a Membrane Fusion Protein of the AcrAB-TolC Multidrug Efflux Pump. ACS Infect Dis. 2017 Jan 13;3(1):89-98. |
| 251 | Feng Gao, et al. Synthesis, isolation, stereostructure and cytotoxicity of paclitaxel analogs from cephalomannine.Fitoterapia. 2013 Oct;90:79-84. |
| 252 | Jianhua Li, et al. Microbial transformation of cephalomannine by Luteibacter sp. J Nat Prod. 2007 Dec;70(12):1846-9. |
| 253 | Larsen IK, et al. Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase. J Biol Chem. 1992 Jun 25;267(18):12627-31. |
| 254 | Slatter JG, et al. Studies on the metabolic fate of caracemide, an experimental antitumor agent, in the rat. Evidence for the release of methyl isocyanate in vivo. Chem Res Toxicol. 1993 May-Jun;6(3):335-40. |
| 255 | Engers JL, et al. Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. J Med Chem. 2015 Sep 24;58(18):7485-500. |
| 256 | J Chem Soc 67: 649 (1895) |
| 257 | Escaich S, et al. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7. |
| 258 | Schiebel J, et al. An ordered water channel in Staphylococcus aureus FabI: unraveling the mechanism of substrate recognitionand reduction. Biochemistry. 2015 Mar 17;54(10):1943-55. |
| 259 | Moasser MM, et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15;59(24):6145-52. |
| 260 | Kraus GA, et al. New effective inhibitors of the Abelson kinase. Bioorg Med Chem. 2010 Sep 1;18(17):6316-21. |
| 261 | Windham TC, et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene. 2002 Nov 7;21(51):7797-807. |
| 262 | Hutchinson JH, et al. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J Med Chem. 2003 Oct 23;46(22):4790-8. |
| 263 | Pickarski M, et al. Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep. 2015 Jun;33(6):2737-45. |
| 264 | Xiaoyan Zhou, et al. An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model. Pharmacol Res Perspect. 2017 Oct;5(5):e00354. |
| 265 | He M, et al. A review on the pharmacological effects of vitexin and isovitexin. Fitoterapia. 2016 Dec;115:74-85. |
| 266 | Lima LKF, et al. A Brief Review on the Neuroprotective Mechanisms of Vitexin. Biomed Res Int. 2018 Dec 5;2018:4785089. |
| 267 | https://clinicaltrials.gov/ct2/show/NCT04252274?term=Darunavir&cond=covid&draw=2&rank=3 |
| 268 | Therapie 30:207, 259 (1975); Drugs 33:430 (1987) |
| 269 | Massey AJ, et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol. 2010 Aug;66(3):535-45. |
| 270 | Yang X, et al. Heat Shock Cognate 70 Inhibitor, VER-155008, Reduces Memory Deficits and Axonal Degeneration in a Mouse Model of Alzheimer's Disease. Front Pharmacol. 2018 Jan 30;9:48. |
| 271 | Kita K, et al. Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells. Cancer Sci. 2017 Sep;108(9):1820-1827. |
| 272 | Fukuda I, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol. 2009 Feb 27;16(2):133-40. |
| 273 | Lü JM, et al. Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro. Med Sci Monit. 2012 Aug;18(8):BR293-298. |
| 274 | Zhou C, et al. Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis. Chemotherapy. 2010;56(5):393-402. |
| 275 | Qiu F, et al. Pharmacological inhibition of SUMO-1 with ginkgolic acid alleviates cardiac fibrosis induced by myocardial infarction in mice. Toxicol Appl Pharmacol. 2018 Apr 15;345:1-9. |
| 276 | Korean J Food Sci Technol 40:707 (2008) |
| 277 | https://clinicaltrials.gov/ct2/show/NCT04865029?term=ESTRADIOL&cond=covid&draw=2&rank=1 |
| 278 | Estrada AA, et al. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36. |
| 279 | Rohner A, et al. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier. Mol Cancer Ther. 2012, 11(1), 57-65. |
| 280 | Schulze-Topphoff, Ulf., et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One (2012), 7(3), e33797. |
| 281 | Toubi E, et al. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. J Neuroimmunol. 2012 Oct 15;251(1-2):45-54. |
| 282 | Brück W, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24. |
| 283 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=ESTRADIOL+ACETATE&cntry=&state=&city=&dist= |
| 284 | https://clinicaltrials.gov/ct2/show/NCT04498936?term=Sofosbuvir&cond=covid&draw=2&rank=4 |
| 285 | Postgrad Med J 48:304 (1972); Arch Ophthalmol 108:520 (1990) |
| 286 | Vianello P, et al. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. J Med Chem. 2016 Feb 25;59(4):1501-17. |
| 287 | Handeli S, et al. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008 Mar;7(3):521-9. |
| 288 | Wu MY, et al. FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther. 2015 Jul 6;8:1651-70. |
| 289 | Liu L, et al. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget. 2016 Jul 26;7(30):47145-47162. |
| 290 | Atsuko Kita, et al. Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br J Pharmacol. 2004 Aug;142(7):1059-72. |
| 291 | Marcus Karlstetter, et al. Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis. J Neuroinflammation. 2014 Jan 8;11:3. |
| 292 | Li-Ming Zhang, et al. Involvement of allopregnanolone in the anti-PTSD-like effects of AC-5216. J Psychopharmacol. 2016 May;30(5):474-81. |
| 293 | Zhi-Kun Qiu, et al. The antidepressant-like activity of AC-5216, a ligand for 18KDa translocator protein (TSPO), in an animal model of diabetes mellitus. Sci Rep. 2016 Nov 25;6:37345. |
| 294 | Eur J Pharmacol 111:191 (1985); Physiol Behav 61:563 (1997); 83:456 (2006) |
| 295 | J Am Chem Soc 57:959 (1954); J.Pharmacol Exp Ther 283 979 (1997) |
| 296 | J Org Chem 16: 216 (1951) |
| 297 | Stud. Med. Chem. (1996), 1, 331-353; J. Pharmacol. Exp. Ther. (1957), 120, 399-407; Dtsch. Med. Wochenschr. (1955), 80, 351-3 |
| 298 | Winter GE, et al. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Mol Cell. 2017 Jul 6;67(1):5-18.e19. |
| 299 | Penning TD, et al. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious |
| 300 | Fleischer TC, et al. Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem Biol. 2010 Jun 25;17(6):659-664. |
| 301 | Skelton LA, et al. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry. 1998 Sep 1;33(1):56-66. |
| 302 | Wang TX, et al. Prosapogenin A induces apoptosis in human cancer cells in vitro via inhibition of the STAT3 signaling pathway and glycolysis. Oncol Lett. 2013 Nov;6(5):1323-1328. |
| 303 | Xu S, et al. An EP4 Antagonist ONO-AE3-208 Suppresses Cell Invasion, Migration, and Metastasis of Prostate Cancer. Cell Biochem Biophys. 2014 Apr 18. |
| 304 | Ren Y, et al. Prostaglandin E2 mediates connecting tubule glomerular feedback. Hypertension. 2013 Dec;62(6):1123-8. |
| 305 | Xu S, et al. Inhibitory effect of ONO-AE3-208 on the formation of bone metastasis of prostate cancer in mice. Zhonghua Nan Ke Xue. 2014 Aug;20(8):684-9. |
| 306 | Thieme K, et al. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Sci Rep. 2017 Jun 13;7(1):3442. |
| 307 | Dermatol. Clin. (2011), 29, 69-73; Drug Metab. Rev. (1990), 22(2-3), 161-78; Arch. Exp. Pathol. Pharmakol. (1934), 177, 103-12 |
| 308 | Efron P, et al. Anaphylactic reaction to isosulfan blue used for sentinel node biopsy: case report and literature review. Breast J. 2002 Nov-Dec;8(6):396-9. |
| 309 | Laurie SA, et al. Anaphylaxis to isosulfan blue. Ann Allergy Asthma Immunol. 2002 Jan;88(1):64-6. |
| 310 | Carboni JM, et al. BMS-754807, a small molecule inhibitor of IGF-1R/IR. Mol Cancer Ther, 2009, 8(12), 3341-3349. |
| 311 | Wittman MD, et al. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of IGF-1R kinase in clinical development. J Med Chem, 2009, 52(23), 7360-7363. |
| 312 | Kolb EA, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer, 2011, 56(4), 595-603. |
| 313 | Franks SE, et al. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes. 2016 Mar 1;9:134. |
| 314 | Hasegawa, K., et al., Wnt signaling orchestration with a small molecule DYRK inhibitor provides long-term xeno-free human pluripotent cell expansion. Stem Cells Transl Med, 2012. 1(1): p. 18-28. |
| 315 | Miyabayashi, T., et al., Indole derivatives sustain embryonic stem cell self-renewal in long-term culture. Biosci Biotechnol Biochem, 2008. 72(5): p. 1242-8. |
| 316 | IDrugs (2004), 7(1), 64-69; Cancer Chemother. Pharmacol. (2003), 52(Suppl. 1), S3-S15; Anticancer Res. (1991), 11(2), 773-6.| |
| 317 | Parker AR, et al. BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro. Mol Cancer Ther. 2010 Sep;9(9):2558-2567. |
| 318 | Hausheer FH, et al.Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol. 2010 Apr;65(5):941-951. |
| 319 | Cutler MJ, et al. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-542. |
| 320 | Habs MR,et al. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). Cancer. 1983 Feb 15;51(4):606-609. |
| 321 | Lorenz. et al. Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: Effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide 9(2) 64-76 (2003). |
| 322 | Kim, Y.M., Yun, J., Lee, C., et al. Oxyresveratrol and hydroxystilbene compounds. Inhbitory effect on tyrosinase and mechanism of action. J Biol Chem277(18) 16340-16344 (2002). |
| 323 | Shaida A Andrabi et al. Oxyresveratrol (trans-2,3′,4,5′-tetrahydroxystilbene) is neuroprotective and inhibits the apoptotic cell death in transient cerebral ischemia. Brain Res, 2004 Aug 13, 1017(1-2):98-107. |
| 324 | Vimolmas Lipipun, et al. Topical cream-based oxyresveratrol in the treatment of cutaneous HSV-1 infection in mice. Antiviral Res. 2011 Aug;91(2):154-60. |
| 325 | Teppo O Leino, et al. Azulene-based Compounds for Targeting Orexin Receptors. Eur J Med Chem. 2018 Sep 5;157:88-100. |
| 326 | Julia Peet, et al. Antiretroviral (HIV-1) Activity of Azulene Derivatives. Bioorg Med Chem. 2016 Apr 15;24(8):1653-7. |
| 327 | David A. Becker, et al. A new synthesis of substituted azulenes. Journal of the American Chemical Society, 111(1), 389-391. |
| 328 | Krishna SR, Rao BM, Rao NS.A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography.J Chromatogr Sci. 2010 Nov;48(10):807-10. |
| 329 | Ohtake A, Sato S, Sasamata M, Miyata K.The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.J Pharmacol Sci. 2010;112(2):135-41. Epub 2010 Feb 4. |
| 330 | Hoffstetter S, Leong FC.Solifenacin succinate for the treatment of overactive bladder.Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):345-50. |
| 331 | Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG.Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.Int J Clin Pract. 2008 Nov;62(11):1675-83. |
| 332 | Imamura T, et al.Combined treatment with a β3 -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats. Neurourol Urodyn. 2017 Apr;36(4):1026-1033. |
| 333 | Agius L, et al. Differences between human, rat and guinea pig hepatocyte cultures. A comparative study of their rates of beta-oxidation and esterification of palmitate and their sensitivity to R-etomoxir. Biochem Pharmacol. 1991 Oct 9;42(9):1711-5. |
| 334 | O'Connor RS, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018 Apr 19;8(1):6289. |
| 335 | Bernard K, et al. DRUG FOCUS: S 18986: A positive allosteric modulator of AMPA-type glutamate receptorspharmacological profile of a novel cognitive enhancer. CNS Neurosci Ther. 2010 Oct;16(5):e193-212. |
| 336 | Bourasset F, et al. Neuropharmacokinetics of a new alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat. Drug Metab Dispos. 2005 Aug;33(8):1137-43. |
| 337 | Lewis HD, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar;11(3):189-91. |
| 338 | Cedervall J, et al. Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice. Oncoimmunology. 2017 Apr 20;6(8):e1320009. |
| 339 | Liu L, et al. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J |
| 340 | Sodhi JK, et al. A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos. 2015 Jun;43(6):908-15 |
| 341 | Colombo M, et al. Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem. 2010 Apr 6;5(4):552-8. |
| 342 | Fiorucci S, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005 May;313(2):604-12. |
| 343 | Ghebremariam YT, et al. FXR agonist INT-747 upregulates DDAH expression and enhances sensitivity in high-salt fed Dahl rats. PLoS One. 2013 Apr 4;8(4):e60653. |
| 344 | Verbeke L, et al. The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats. Am J Pathol. 2015 Feb;185(2):409-19. |
| 345 | Pellicciari R, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002 Aug 15;45(17):3569-72. |
| 346 | Chen X, et al. The therapeutic effect of fraxetin on ethanol-induced hepatic fibrosis by enhancing ethanol metabolism, inhibiting oxidative stress and modulating inflammatory mediators in rats. Int Immunopharmacol. 2018 Mar;56:98-104. |
| 347 | Liu G, et al. Effect of fraxetin on proliferation and apoptosis in breast cancer cells. Oncol Lett. 2017 Dec;14(6):7374-7378. |
| 348 | N Engl J Med 268:36, 92 (1963); J Antimicrob Chemother 52:837 (2003) |
| 349 | Wang Y, et al. Homoisoflavonoids and the Antioxidant Activity of Ophiopogon japonicus Root. |
| 350 | Ito Y, et al. A novel agent, methylophiopogonanone B, promotes Rho activation and tubulin depolymerization. Mol Cell Biochem. 2007 Mar;297(1-2):121-9. Epub 2006 Oct 7. |
| 351 | J Sci Food Agric 5: 597 (1954); Biochim Biophys Acta 39:462 (1960); Trends Food Sci Technol 10:199 (1999); Asia Pac J Clin Nutr 17 167 (2008) |
| 352 | Parkanyi Cyril, et al. Convenient synthesis of arylazo derivatives of quinoxaline, 1,4-benzothiazine, and 1,4-benzoxazine. From Journal of Heterocyclic Chemistry (1984), 21(2), 521-4. |
| 353 | Stachlewitz RF, et al.A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection.J Pharmacol Exp Ther. 2005 Oct;315(1):36-41. |
| 354 | Andrew Burchat, et al. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection Bioorganic & Medicinal Chemistry Letters Volume 16, Issue 1, 1 January 2006, Pages 118-122 |
| 355 | Kojima S, et al. Molecular basis for the maintenance of envelope integrity in Selenomonas ruminantium:cadaverine biosynthesis and covalent modification into the peptidoglycan play a major role. J Nutr Sci Vitaminol (Tokyo). 2012;58(3):153-60. |
| 356 | Dela Vega AL, et al. Polyamines decrease Escherichia coli outer membrane permeability. |
| 357 | Harada H, et al. Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga. Anticancer Res. 2002 Sep-Oct;22(5):2587-90. |
| 358 | https://clinicaltrials.gov/ct2/show/NCT04542408?term=Edoxaban&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04516941?term=Edoxaban&cond=Covid19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-002234-32-IT |
| 359 | Naturwissenschaften 64:535 (1977); Carbohydr Res 128:235 (1984); Drugs 35:214 (1988) |
| 360 | Liu, Jing, "Synthesis of Resveratrol and Its Analogs, Phase-Transfer Catalyzed Asymmetric Glycolate Aldol Reaction, and Total Synthesis of 8,9-Methylamido-Geldanamycin" (2007). All Theses and Dissertations. 1415. |
| 361 | Br J Pharmacol 59:373 (1977); Neuropharmacology 17:13 (1978) |
| 362 | Zabkiewicz J, et al. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget. 2016 Mar 29;7(13):16650-62. |
| 363 | Drugs (1975), 9(6), 406-23; Chemotherapy (1972), 17(6), 392-404; J. Med. Chem. (1969), 12(5), 784-91 |
| 364 | Arch Derm 72:153 (1955); Artificial Cells Blood Substitutes Biotechnol 16:771 (1988) |
| 365 | J Pharmacol Exp Therap 132:295 (1961); JAMA 185:69 (1963) |
| 366 | Frank C. Dorsey, et al. Abstract 5245: Identification and characterization of the IDO1 inhibitor LY3381916. Cancer Research. 2018, 78(13). |
| 367 | Jolie Anne Bastian, et al. 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer. WO2017213919A1. |
| 368 | Am J Med Sci 111:213 (1896); JAMA XXVII:728 (1896) |
| 369 | Cho YS, et al. Ginsenoside rg2 inhibits lipopolysaccharide-induced adhesion molecule expression in human umbilical vein endothelial cell. Korean J Physiol Pharmacol. 2013 Apr;17(2):133-7. |
| 370 | Li N, et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease. J Ginseng Res. 2016 Jan;40(1):9-17. |
| 371 | J Chem Soc 1963:980; Tetrahedron 24: 1489 (1968); J Chem Ecology 25:923 (1999) |
| 372 | https://clinicaltrials.gov/ct2/show/NCT04420741?term=Iloprost&cond=covid&draw=2&rank=1 |
| 373 | Cancer Treat Rev23:35 (1997); Exp Rev Anticancer Ther 1:13 (2001) |
| 374 | Blackburn TP, et al. The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse. 2006 Jun 15;59(8):502-12. |
| 375 | Kennett GA, et al. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol. 1994 Mar;111(3):797-802. |
| 376 | Theile JW, et al. Role of 5-hydroxytryptamine2C receptors in Ca2+-dependent ethanol potentiation of GABA release onto ventral tegmental area dopamine neurons. J Pharmacol Exp Ther. 2009 May;329(2):625-33. |
| 377 | Quadri L, et al. 17 beta-(3-furyl)-5 beta-androstane-3 beta, 14 beta, 17 alpha-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem. 1997 May 23;40(11):1561-4. |
| 378 | Ferrari P, et al. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J Pharmacol Exp Ther. 1999 Mar;288(3):1074-83. |
| 379 | Matthias Lingemann, et al. The alpha-1 subunit of the Na<sup>+</sup>,K<sup>+</sup>-ATPase (ATP1A1) is required for macropinocytic entry of respiratory syncytial virus (RSV) in human respiratory epithelial cells. PLoS Pathog. 2019 Aug 5;15(8):e1007963. |
| 380 | Camilla F Wenceslau, et al. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: the role of Na<sup>+</sup>,K<sup>+</sup>-ATPase/cSRC pathway. J Hypertens. 2014 Mar;32(3):542-54. |
| 381 | Pharmaceut Chem J 11:60 (1977) |
| 382 | Fraser GL, et al. The NK3 Receptor Antagonist ESN364 Interrupts Pulsatile LH Secretion and Moderates Levels of Ovarian Hormones Throughout the Menstrual Cycle. Endocrinology. 2015 Nov;156(11):4214-25. |
| 383 | 1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. |
| 384 | Gadd MS, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 May;13(5):514-521. |
| 385 | Lombardi MS, et al. SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype. J Leukoc Biol. 2016 May;99(5):711-21. |
| 386 | Zhou J, et al. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts. Clin Cancer Res. 2017 Apr 15;23(8):1945-1954. |
| 387 | https://clinicaltrials.gov/ct2/show/NCT04363060?term=Amoxicillin&cond=covid&draw=2&rank=1 |
| 388 | Mao G,et al. Bruceine D Isolated from Brucea Javanica (L.) Merr. as a Systemic Feeding Deterrent for Three Major Lepidopteran Pests. J Agric Food Chem. 2019 Apr 17;67(15):4232-4239. |
| 389 | Cheng Z, et al. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways. Cancer Lett. 2017 Sep 10;403:195-205. |
| 390 | https://clinicaltrials.gov/ct2/show/NCT04622891?term=Clarithromycin&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04398004?term=Clarithromycin&cond=COVID-19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTs071210011 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/11/029305 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001882-36-GR |
| 391 | Zhang C, et al. Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System. Sci Rep. 2017 Jan 5;7:40115. |
| 392 | J Chem Soc 1927:2489; J Biol Chem 255:7941 (1980); 259:2675 (1984); J Pharmacol Exp Ther 218:509 (1981) |
| 393 | Hatcher JM, et al. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chem Biol. 2018 Apr 19;25(4):460-470.e6. |
| 394 | Fong TM, et al. Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2
 -methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents. J Pharmacol Exp T |
| 395 | Lin LS, et al. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J M |
| 396 | Tavolari S, et al. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis. 2008 Feb;29(2):371-80. |
| 397 | Alvaro-Gracia JM, et al. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford). 2004 Feb;43 Suppl 1:i21-5. |
| 398 | Laufer SA, et al. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem. 1994 Jun 10;37(12):1894-7. |
| 399 | Yu T, et al. Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR. ACS Med Chem Lett. 2018 Feb 27;9(3):256-261. |
| 400 | Sakanyan V, et al. Activation of EGFR by small compounds through coupling the generation of hydrogen peroxide to stable dimerization of Cu/Zn SOD1. Sci Rep. 2016 Feb 17;6:21088. |
| 401 | Xie F, et al. Identification, synthesis and evaluation of substituted benzofurazans as inhibitors of CREB-mediated gene transcription. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5371-5. |
| 402 | Wang WY, et al. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007;74(4):601-611. |
| 403 | Wang WY, et al. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol. 2006;70(4):1380-1389. |
| 404 | Life Sci. (1981), 29(12), 1271-5; Life Sci. (1964), 3, 695-702; Am. J. Cardiol. (1964), 13, 10-4 |
| 405 | Everaerts W et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis.Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084-9. |
| 406 | Xing Y, et al. Decreased Expression of TRPV4 Channels in HEI-OC1 Cells Induced by High Glucose Is Associated with Hearing Impairment. Yonsei Med J. 2018 Nov;59(9):1131-1137. |
| 407 | Lain S, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008;13(5):454-463. |
| 408 | Ladds MJGW, et al. Exploitation of DHODH and p53 activation as therapeutic targets - a case study in polypharmacology [published online ahead of print, 2020 Sep 8]. J Biol Chem. 2020;jbc.RA119.012056. |
| 409 | Marx C, et al. The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell line. Invest New Drugs. 2017 Nov 18. |
| 410 | Grbesa I, et al. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One. 2015 Apr 27;10(4):e0124670. |
| 411 | Yoon KB, et al. Induction of Nuclear Enlargement and Senescence by Sirtuin Inhibitors in Glioblastoma Cells. Immune Netw. 2016 Jun;16(3):183-8. |
| 412 | Eur J Pharmacol 310:115 (1996); TIPS 18:204 (1997) |
| 413 | Lankas GR, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005 Oct;54(10):2988-94. |
| 414 | Connolly BA, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potencyand in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13. |
| 415 | Talabostat |
| 416 | Adams S, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004 Aug 1;64(15):5471-80. |
| 417 | Cancer Res 35:1756 (1975); 38:2549 (1978); Clin Pharmokinet 12:223 (1987); Anal Profiles Drug Subs 19:575 (1990)| |
| 418 | Attia SM, et al. Molecular cytogenetic evaluation of the aneugenic effects of teniposide in somatic and germinal cells of male mice. Mutagenesis. 2012 Jan;27(1):31-9. |
| 419 | Li J, et al. Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma. World J Surg Oncol. 2006 Jul 6;4:41. |
| 420 | Sun YC, et al. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 2014 Aug 25;14:611. |
| 421 | Roh JH, et al. Purification, characterization, and crystallization of monoamine oxidase from Escherichia coli K-12. Biosci Biotechnol Biochem. 1994 Sep;58(9):1652-6. |
| 422 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Methylprednisolone&cntry=&state=&city=&dist= |
| 423 | Z Rao, et al. Study on the Synthesis of Cytarabine Hydrochloride and its Intermediate Ancitabine Hydrochloride. Fine Chemical Intermediates, 2013 |
| 424 | Stebbins JL et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A, 2008 Oct 28, 105(43):16809-13. |
| 425 | Boichot E, et al. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derivedfrom 9-benzyladenine. J Pharmacol Exp Ther. 2000 Feb;292(2):647-53. |
| 426 | Nghiem, P., G. Pearson, and R.G. Langley, Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol, 2002. 46(2): p. 228-41. |
| 427 | Gupta, A.K. and M. Chow, Pimecrolimus: a review. J Eur Acad Dermatol Venereol, 2003. 17(5): p. 493-503. |
| 428 | Stuetz, A., M. Grassberger, and J.G. Meingassner, Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg, 2001. 20(4): p. 233-41. |
| 429 | J Biochem (Tokyo) 54:25, 173, 412 (1963); J Chem Soc 1964:4107 |
| 430 | Crane EK, et al. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS One. 2015 Aug 6;10(8):e0135101. |
| 431 | Tovar C, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93. |
| 432 | M Ulrich, et al. Murine tumor models for the in vivo evaluation of natural compounds and their derivatives as new cancer therapeutics. München. 2016. |
| 433 | J Physiol 82:432 (1934); Phytochemistry 11:2547 (1972) |
| 434 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Dexamethasone&cntry=&state=&city=&dist= |
| 435 | Wada T, et al. Prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol. 2005 Sep;16(9):2615-25. |
| 436 | Xia L, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleosidenephrotoxicity. Am J Physiol Renal Physiol. 2009 Jun;296(6):F1307-13. |
| 437 | Kawakami H, et al. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode. Nephrol Dial Transplant. 2012 Apr; |
| 438 | Nosaka K, et al. An adenosine deaminase inhibitor prevents puromycin aminonucleoside nephrotoxicity. Free Radic Biol Med 1997 ;22 (4): 597-605. |
| 439 | Lacalle RA, et al. Cloning of the complete biosynthetic gene cluster for an aminonucleoside antibiotic, puromycin, and its regulated expression in heterologous hosts. EMBO J. 1992 Feb;11(2):785-92. |
| 440 | Gong W, et al. Estrogen-related receptor-α mediates puromycin aminonucleoside-induced mesangial cell apoptosis and inflammatory injury. Am J Physiol Renal Physiol. 2019 May 1;316(5):F906-F913. |
| 441 | Sdelci S, et al. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nat Chem Biol. 2016 Jul;12(7):504-10. |
| 442 | Zhao Yizhaiteng, et al. Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor. WO2016052697A1. |
| 443 | Matsumoto K, et al. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers. 1999;51(1):99-107. |
| 444 | Wadhawan M, et al. Inhibition of cathepsin B by E-64 induces oxidative stress and apoptosis in filarial parasite. PLoS One. 2014 Mar 25;9(3):e93161. |
| 445 | Baldzizhar R, et al. Anti-serpin antibody-mediated regulation of proteases in autoimmune diabetes. J Biol Chem. 2013 Jan 18;288(3):1612-9. |
| 446 | Blass G, et al. Chronic cathepsin inhibition by E-64 in Dahl salt-sensitive rats. Physiol Rep. 2016 Sep;4(17). pii: e12950. |
| 447 | Hong J, et al. D-ribose induces nephropathy through RAGE-dependent NF-κB inflammation. Arch Pharm Res. 2018 Aug;41(8):838-847. |
| 448 | http://en.wikipedia.org/wiki/Roxithromycin |Antimicrob Agents Chemother 24:209 (1983); 31:1147 (1987); J Antimicrob Chemother 20 Suppl B:1 (1987) |
| 449 | Mitsuo Miyazawa, t al. Volatile components of the Rhizomes of Rheum palmatum L.Flavour and Fragrance Journal. 1996 Jan. |
| 450 | Am. J. Med. (1985), 79(4B), 12-6; Agents Actions (1976), 6(6), 748-54; Agents Actions (1975), 5(3), 256-63 |
| 451 | Hao J, Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor. J Med Chem. 2019 Oct 10;62(19):8711-8732. |
| 452 | J Biol Chem 138:21, 513, 529 (1041); 142:941 (1942) |
| 453 | J Am Chem Soc 89: 5737 (1967) |
| 454 | Kwon D, et al. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Arzneimittelforschung. 2001;51(3):204-13. |
| 455 | Zheng M, et al. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2017;8(24):39143-39153. |
| 456 | JACS 57: 1111 (1935); 79: 5550 (1957); Chem Rev 67: 441 (1967) |
| 457 | J. Clin. Pharm. Ther. (1991), 16(1), 41-4; Cancer Biol. Ther. (2011), 11(3), 368-370 |
| 458 | Victoria Jackson-Patel, et al. Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies. |
| 459 | Parinuch Chumkaew, et al. Potent Cytotoxic Rocaglamide Derivatives From the Fruits of Amoora Cucullata. Chem Pharm Bull (Tokyo). 2006 Sep;54(9):1344-6. |
| 460 | California Med 104:363 (1966); Equine Vet J 5:162 (1973) |
| 461 | Chem Ind 1961:1037 |
| 462 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Voclosporin&cntry=&state=&city=&dist=&Search=Search |
| 463 | Woodhead AJ, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem. 2010 Aug 26;53(16):5956-69. |
| 464 | Kang MH, et al. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Jul 15;59(1):185-8. |
| 465 | He Y, et al. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat Chem Biol. 2017 Apr;13(4):389-395. |
| 466 | J Antimicrob Chemother14:105 (1984); Obstet Gynecol 64:530 (1984) |
| 467 | Pruniaux MP, et al. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways. Fundam Clin Pharmacol. 2010 Feb;24(1):73-82. |
| 468 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Estradiol&cntry=&state=&city=&dist= |
| 469 | Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. |
| 470 | Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC Res Notes. 2014 Apr 29;7:273. |
| 471 | Zajkowski T, et al. Stabilization of microtubular cytoskeleton protects neurons from toxicity of N-terminal fragment of cytosolic prion protein. Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2228-39. |
| 472 | https://clinicaltrials.gov/ct2/show/NCT04770740?term=Vitamin+K1&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04780061?term=Vitamin+K1&cond=COVID-19&draw=2&rank=2 |
| 473 | Eur J Dermatology 14:96 (2004); Dermatology 209: (2004); Bioorganic & Med Chem Lttrs 18:1359 (2008) |
| 474 | Chem Pharm Bull39:2906 (1991); Dig Dis Sci 43:35S (1998) |
| 475 | Fundam Appl Toxicol 7:299 (1986); Pharmacotherapy 7:25 (1987) |
| 476 | Kwiatkowski J, et al. Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues. ACS Med Chem Lett. 2019 Feb 15;10(3):318-323. |
| 477 | Nature 330:746 (1987); Semin Oncol 22 Suppl 10:1 (1995) |
| 478 | Cancer Treat Rev 17:233, 243 (1990); N Engl J Med 347:1739 (2002) |
| 479 | Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2. |
| 480 | R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway. |
| 481 | Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway. |
| 482 | Jose Manuel Perez Garcia, et al. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies. |
| 483 | Silberstein SD, et al.
 Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine.
 Cephalalgia. 2009 Nov;29 Suppl 2:17-27. |
| 484 | Chen Q, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016 May 18;533(7604):493-8. |
| 485 | Kim Y, et al. Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels. Neurotherapeutics. 2017 May 30. |
| 486 | Coxon CR, et al. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. J Med Chem. 2017 Mar 9;60(5):1746-1767. |
| 487 | Roecker AJ et al. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem. 2014 Feb;9(2):311-22. |
| 488 | Gotter AL et al. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep. 2016 Jun 3;6:27147. |
| 489 | https://clinicaltrials.gov/ct2/show/NCT04635605?term=METHYLENE+BLUE&cond=covid&draw=2&rank=7 |
| 490 | Ohrui H, et al. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec. 2006;6(3):133-43. |
| 491 | J Chem Soc 1954: 3651 |
| 492 | VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10. |
| 493 | Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. |
| 494 | https://clinicaltrials.gov/ct2/show/NCT04590586?term=Apremilast&cond=covid&draw=2&rank=1 |
| 495 | Helv Chim Acta 33: 313 (1950)| |
| 496 | Rama Reddy NR, et al. Next Generation Sequencing and Transcriptome Analysis Predicts Biosynthetic Pathway of Sennosides from Senna (<i>Cassia angustifolia</i> Vahl.), a Non-Model Plant with Potent Laxative Properties. PLoS One. 2015 Jun 22;10(6):e0129422. |
| 497 | Esposito F, et al. Sennoside A, derived from the traditional chinese medicine plant <i>Rheum L.</i>, is a new dual HIV-1 inhibitor effective on HIV-1 replication. Phytomedicine. 2016 Nov 15;23(12):1383-1391. |
| 498 | Ostrem JM, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 28;503(7477):548-551. |
| 499 | Toxicol Appl Pharmacol 2:344 (1960) |
| 500 | Dimitri E Grigoriadis, et al. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. |
| 501 | Biorg. Med. Chem. (2008), 16(20), 9101-9105; Mol. Pharmacol. (1987), 31(3), 284-93; Agents Actions (1978), 8(6), 587-605 |
| 502 | Phcog Rev 3:307 (2009)|Chem Commun 1968: 1392; mp 174-176 C (blackens) |
| 503 | Narjes, F, et al. The discovery of AZD0284, an inverse agonist of the nuclear receptor RORg. American Chemical Society, 2017 Drug Design and Delivery Symposium 26 October 2017 |
| 504 | Asimus S, et al. Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284 [published online ahead of print, 2020 Feb 17]. Br J Clin Pharmacol. 2020;10.1111/bcp.14253. |
| 505 | Biochem J 79:48 (1961); JACS 84:3400 (1962) |
| 506 | Nishiguchi GA, et al. Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers. J Med Chem. 2017 Jun 22;60(12):4869-4881. |
| 507 | Rama Reddy NR, et al. Next Generation Sequencing and Transcriptome Analysis Predicts Biosynthetic Pathway of Sennosides from Senna (<i>Cassia angustifolia</i> Vahl.), a Non-Model Plant with Potent Laxative Properties. PLoS One. 2015 Jun 22;10(6):e0129422. |
| 508 | Chen YC, et al. Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells. Life Sci. 2009 Jun 19;84(25-26):915-22. |
| 509 | Garcia-Jimenez A, et al. Action of tyrosinase on alpha and beta-arbutin: A kinetic study. PLoS One. 2017 May 11;12(5):e0177330. |
| 510 | Jiang L, et al. Investigation of the pro-apoptotic effects of arbutin and its acetylated derivative on murinemelanoma cells. Int J Mol Med. 2018 Feb;41(2):1048-1054. |
| 511 | Nalban N, et al. Arbutin Attenuates Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting TLR-4/NF-κB Pathway in Mice. Cardiovasc Toxicol. 2019 Sep 4. |Pharmazie 15: 650 (1960); 46:611 (1991); J Pharmacol Exp Ther 276:765 (1996); Pigment Cell Res 11:12, 206 (1998) |
| 512 | Wang J, et al. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinonesas Inhibitors of Kinases and Bromodomains. ACS Chem Biol. 2018 Sep 21;13(9):2438-2448 |
| 513 | J Clin Pharm Ther 27:343 (2002); Exp Opin Pharmacother 3:1211 (2002) |
| 514 | Zhang S, et al. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Res. 2015 Sep 15;75(18):3842-52. |
| 515 | Zhang S, et al. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects againstColorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Res. 2015 Sep 15;75(18):3842-52. |
| 516 | Eur J Pharmacol 179: 295 (1990) |
| 517 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=BETAMETHASONE&cntry=&state=&city=&dist= |
| 518 | Lan P, Romero FA, et al. Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase. J Med Chem. 2017 Nov 9;60(21):9040-9052. |
| 519 | Sun J, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 1999 Oct 1;59(19):4919-26. |
| 520 | N C Crespo, et al. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ. 2002 Jul;9(7):702-9. |
| 521 | Snyder DW, et al. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther. 1999 Mar;288(3):1117-24. |
| 522 | Hori Y, et al. Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61. |
| 523 | Pharmacological reports 58:246 (2006) |
| 524 | Bishop AC, et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature. 2000 Sep 21;407(6802):395-401. |
| 525 | Tandon M, et al. New pyrazolopyrimidine inhibitors of protein kinase d as potent anticancer agents for prostate cancer cells. PLoS One. 2013 Sep 23;8(9):e75601. |
| 526 | Tobacco Science 3:86 (1959); Phytochemistry 39:1383 (1995) |
| 527 | Gray NS, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8. |
| 528 | Bain J, et al. The specificities of protein kinase inhibitors: an update. Biochem J. 2003 Apr 1;371(Pt 1):199-204. |
| 529 | Villerbu N, et al. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int J Cancer. 2002 Feb 20;97(6):761-9. |
| 530 | Garai S, et al. B-973, a Novel α7 nAChR Ago-PAM: Racemic and Asymmetric Synthesis, Electrophysiological Studies, and in Vivo Evaluation. ACS Med Chem Lett. 2018 Oct 11;9(11):1144-1148. |
| 531 | Jessica Chinison, et al. Triptonide Effectively Inhibits Wnt/β-Catenin Signaling via C-terminal Transactivation Domain of β-catenin. Sci Rep. 2016; 6: 32779. |
| 532 | Ping Yang, et al. Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway. Toxicol LettPing Yang. 2017 Aug 15;278:9-17. |
| 533 | Souness JE, et al. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br J Pharmacol. 1989 Nov;98(3):725-34. |
| 534 | Chung-Pu Wu, et al. MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. Am J Cancer Res. 2020; 10(1): 164–178. |
| 535 | Maud Bollenbach, et al. Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model. Eur J Med Chem. 2019 Sep 1;177:269-290. |
| 536 | Zhisong Cao, et al. Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts. Cancer Res. 2009 Jun 1;69(11):4742-9. |
| 537 | Zhisong Cao, et al. Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts. Cancer Res. 2009 Jun 1;69(11):4742-9. |
| 538 | Xing Liu, et al. Correlation between the sensitivity of tumors to treatment with CZ48 and local concentrations of the active metabolite CPT within the tumors. Biomed Rep. 2013 Mar;1(2):202-206. |
| 539 | Volynets GP, et al. Identification of 3H-naphtho[1,2,3-de]quinoline-2,7-diones as inhibitors of apoptosis signal-regulating kinase 1 (ASK1). J Med Chem. 2011 Apr 28;54(8):2680-6. |
| 540 | Hao H, et al. NQDI-1, an inhibitor of ASK1 attenuates acute perinatal hypoxic-ischemic cerebral injury by modulating cell death. Mol Med Rep. 2016 Jun;13(6):4585-92. |
| 541 | Zhang M, et al. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). J Med Chem. 2018 Apr 12;61(7):3037-3058. |
| 542 | Peserico A, et al. A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth. J Cell Physiol. 2015 Oct;230(10):2447-2460. |
| 543 | JACS 61:2832 (1939); 63:422 (1941); 68:406 (1945); J Pharm Biomed Anal 48:127 (2008) |
| 544 | Therapeut Clin Risk Man 2:3 (2006); Bone 44:423 (2009); J Gastrointestin Liver Dis 20::141 (2011) |
| 545 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Ibrutinib&cntry=&state=&city=&dist= |
| 546 | Jortani SA, et al. Inhibition of Na,K-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem. 1996 Oct;42(10):1654-8. |
| 547 | Yang P, et al. Cellular location and expression of Na<sup>+</sup>, K<sup>+</sup>-ATPase α subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog. 2014 Apr;53(4):253-63. |
| 548 | Garofalo S, et al. The Glycoside Oleandrin Reduces Glioma Growth with Direct and Indirect Effects on Tumor Cells. J Neurosci. 2017 Apr 5;37(14):3926-3939. |
| 549 | Shoji JH, et al. Isolation of azomycin from Pseudomonas fluorescens. J Antibiot (Tokyo). 1989 Oct;42(10):1513-4. |
| 550 | Chem Commun 1968:1395; Phytochemistry 17: 1395 (1978); Phytopathology 71:521 (1981) |
| 551 | Wang L, et al. Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2. Oncotarget. 2018 Feb 6;9(76):34200-34212. |
| 552 | Li X, et al. Carnosol as a Nrf2 Activator Improves Endothelial Barrier Function Through Antioxidative Mechanisms. Int J Mol Sci. 2019;20(4):880. Published 2019 Feb 18. |
| 553 | Martin D, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem. 2004;279(10):8919-8929. |
| 554 | J Allergy Clin Immunol 76:703 (1985) |
| 555 | Watt GD, et al. Protective effect opf lodoxamide tromethamine on allergen inhalation challenge. J Allergy Clin Immunol. 1980 Oct;66(4):286-94. |
| 556 | Capron M,et al. Inhibitory effects of lodoxamide on eosinophil activation. Int Arch Allergy Immunol. 1998 Jun;116(2):140-6. |
| 557 | Barr ML, et al. Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. J Thorac Cardiovasc Surg. 1998 Mar;115(3):631-6; discussion 636-7. |
| 558 | Mann JS, et al. Inhaled lodoxamide tromethamine in the treatment of perennial asthma: a double-blind placebo-controlled study. J Allergy Clin Immunol. 1985 Jul;76(1):83-90. |
| 559 | J Med Chem 28:1558 (1985); J Antimicrob Chemother 19:611 (1987) |
| 560 | Bernard Christophe Barlaam, etal. Chemical compounds. Patent US20180111931. |
| 561 | Donghua Yin, et al. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther. 2003 Mar;304(3):1334-40. |
| 562 | Ioannis Simitsidellis, et al. Selective androgen receptor modulators (SARMs) have specific impacts on the mouse uterus. J Endocrinol. 2019 Sep;242(3):227-239. |
| 563 | Buchanan SG, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther, 2009, 8(12), 3181-3190. |
| 564 | Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75(21):4548-59. |
| 565 | Müller J, et al. Buparvaquone is active against Neospora caninum in vitro and in experimentally infected mice. Int J Parasitol Drugs Drug Resist. 2015 Feb 13;5(1):16-25. |
| 566 | Reimão JQ, et al. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. Exp Parasitol. 2012 Mar;130(3):195-9. |
| 567 | Garnier T, et al. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother. 2007 Oct;60(4):802-10. |
| 568 | Carnero A. Novel inhibitors of the PI3K family. Expert Opin Investig Drugs. 2009 Sep;18(9):1265-77. |
| 569 | Maira SM, et al. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr Top Microbiol Immunol, 2010, 347, 209-239. |
| 570 | Takashi Kei Kishimoto, et al. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses. US 20160074531 A1. |
| 571 | Mersereau JE, et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol. 2008 Feb 13;283(1-2):49-57. |
| 572 | Suh KS, et al. Protective effect of liquiritigenin against methylglyoxal cytotoxicity in osteoblastic MC3T3-E1 cells. Food Funct. 2014 Jul 25;5(7):1432-40. |
| 573 | Tao W, et al. Liquiritigenin reverses depression-like behavior in unpredictable chronic mild stress-induced mice by regulating PI3K/Akt/mTOR mediated BDNF/TrkB pathway. Behav Brain Res. 2016 Jul 15;308:177-86. |
| 574 | Herrero A, et al. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell. 2015 Aug 10;28(2):170-82. |
| 575 | Kato H, et al. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. Life Sci. 2011 Oct 24;89(17-18):603-8. |
| 576 | Fukuda-Tsuru S, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202. |
| 577 | Ideta T, et al. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci. 2015 Dec 8;16(12):29207-18. |
| 578 | Acta Pharmacologica Toxicologica 51: 250 (1982); Brain Res 1054:45 (2005); |
| 579 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=HYDROXYCHLOROQUINE+&cntry=&state=&city=&dist= |
| 580 | . Tanaka H, et al. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. Cancer Sci. 2014 Aug;105(8):1040-8. |
| 581 | Lautenschläger M, et al. Intestinal formation of trans-Crocetin from saffron extract (<i>Crocus sativus L.</i>) and in vitro permeation through intestinal and blood brain barrier. Phytomedicine. 2015 Jan 15;22(1):36-44. |
| 582 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=PINDOLOL&cond=Covid19&draw=2&rank=1 |
| 583 | https://clinicaltrials.gov/ct2/show/NCT04365257?term=PRAZOSIN&cond=covid&draw=2&rank=1 |
| 584 | Messoussi A, et al. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticanceragents. Chem Biol. 2014 Nov 20;21(11):1433-43. |
| 585 | Okada M, et al. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo. Oncotarget. 2016 May 10;7(19):27021-32. |
| 586 | Palmer SS, et al. Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models. Reprod Sci. 2016 Jan;23(1):11-23. |
| 587 | Sheila M Mitchell, et al. The effects of ponazuril on development of apicomplexans in vitro. J Eukaryot Microbiol. May-Jun 2005;52(3):231-5. |
| 588 | Sheila M Mitchell, et al. Efficacy of ponazuril in vitro and in preventing and treating Toxoplasma gondii infections in mice. J Parasitol. 2004 Jun;90(3):639-42. |
| 589 | Aust J Chem 24:2427 (1971); Phytochemistry 32:1083 (1993); J Nat Prod 58:1958 (1995) |
| 590 | Adam Becalski, et al. Semicarbazide Formation in Azodicarbonamide-Treated Flour: A Model Study. J Agric Food Chem. 2004 Sep 8;52(18):5730-4. |
| 591 | Pérez-Salvia M, et al. Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics. 2017 May 4;12(5):323-339. |
| 592 | Phillip CC Liu, et al. Abstract 3523: Discovery of a novel BET inhibitor INCB054329. |
| 593 | Liu ZM, et al. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Expert Opin Investig Drugs. 2015 May;24(5):611-21. |
| 594 | Ratziu V, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016 May;150(5):1147-1159. |
| 595 | Hanf R, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.Diab Vasc Dis Res. 2014 No |
| 596 | Zachary S. Zumsteg, et al. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. Clin Cancer Res. 2016 Apr 15; 22(8): 2009–2019. |
| 597 | Marian M. Deuker, et al. PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma. Cancer Discov. 2015 Feb; 5(2): 143–153. |
| 598 | Ndubaku CO, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem. 2013 Jun 13;56(11):4597-610. |
| 599 | Wang JL, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9. |
| 600 | Kessel D, et al. Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett. 2007 May 8;249(2):294-9. |
| 601 | Manero F, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 2006 Mar 1;66(5):2757-64. |
| 602 | Wong EH, et al. The anticonvulsant MK-801 is a potent N-Me-D-Asp antagonist. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7104-8. |
| 603 | Vardhan Reddy KH, et al. Convergent Strategy to Dizocilpine MK-801 and Derivatives. J Org Chem. 2018 Apr 6;83(7):4264-4269. |
| 604 | Huettner JE, et al. Block of N-Me-D-Asp-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1307-11. |
| 605 | Thomas DM, et al. MK-801 and dextromethorphan block microglial activation and protect against neurotoxicity. Brain Res. 2005 Jul 19;1050(1-2):190-8. |
| 606 | Brown TE, et al. The NMDA antagonist MK-801 disrupts reconsolidation of a cocaine-associated memory for conditioned place preference but not for self-administration in rats. Learn Mem. 2008 Dec 2;15(12):857-65. |
| 607 | Jiang L, et al. Decrease of growth and differentiation factor 10 contributes to neuropathic pain through N-Me-D-Asp receptor activation. Neuroreport. 2017 May 24;28(8):444-450. |
| 608 | Iijima Y, et al. Modification by MK-801 (dizocilpine), a noncompetitive NMDA receptor antagonist sensitization: evaluation by ambulation in mice. Nihon Shinkei Seishin Yakurigaku Zasshi. 1996 Feb;16(1):11-8. |
| 609 | Antimicrob Agents Chemother 19:82 (1981) |
| 610 | Chem Nat Compounds 34:295 (1998); J Asian Nat Prod Res 10:1093 (2008) |
| 611 | Annika Birgitta Margareta ÅSTRAND, et al. Compounds and methods for inhibiting jak. WO2017050938A1. |
| 612 | Miller BE, et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist?--in healthy adult subjects. BMC Pharmacol Toxicol. 2015 Jun 20;16:18. |
| 613 | Wang S, et al. Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction. J Med Chem. 2019 Mar 14;62(5):2772-2797. |
| 614 | Funahashi Y, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002;62(21):6116-6123. |
| 615 | Ito K, et al. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci. 2014;105(8):1023-1031. |
| 616 | Polycyclic Aromat. Compd. (2004), 24(4-5), 733-742; Mutat. Res., Genet. Toxicol. Test. (1984), 135(2), 97-103; Environ. Toxicol. Chem. (2005), 24(10), 2526-2532 |
| 617 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Maraviroc&cntry=&state=&city=&dist=&Search=Search |
| 618 | Arzneim Forsch 26:925 (1976)| |
| 619 | Lim KM, et al. Analysis of changes in microRNA expression profiles in response to the troxerutin-mediated antioxidant effect in human dermal papilla cells. Mol Med Rep. 2015 Aug;12(2):2650-60. |
| 620 | Zhang Z, et al. Troxerutin Attenuates Enhancement of Hepatic Gluconeogenesis by Inhibiting NOD Activation-Mediated Inflammation in High-Fat Diet-Treated Mice. Int J Mol Sci. 2016 Dec 25;18(1). pii: E31. |
| 621 | Badalzadeh R, et al. Beneficial effect of troxerutin on diabetes-induced vascular damages in rat aorta: histopathological alterations and antioxidation mechanism. Int J Endocrinol Metab. 2015 Apr 30;13(2):e25969. |
| 622 | J Neurochem 34:1247 (1980); J Neurosci18:156 (1998); J Clin Invest 122:2837 (2012) |
| 623 | Chou TF, et al.Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4834-9. |
| 624 | Zhang Y, et al. The AAA ATPase Vps4 Plays Important Roles in Candida albicans Hyphal Formation and is Inhibited by DBeQ. Mycopathologia. 2016 Jun;181(5-6):329-39. |
| 625 | Davidson Alan Hornsby, et al. Preparation of amino acid-based hydroxamic acids as histone deacetylase (HDAC) inhibitors. From PCT Int. Appl. (2008), WO 2008040934 A1 20080410. |
| 626 | Cassidy-Stone A, et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008 Feb;14(2):193-204. |
| 627 | Tanaka A, et al. A chemical inhibitor of DRP1 uncouples mitochondrial fission and apoptosis. Mol Cell. 2008 Feb 29;29(4):409-10. |
| 628 | Park SW, et al. A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina. Invest Ophthalmol Vis Sci. 2011 Apr 27;52(5):2837-43. |
| 629 | Iverson C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47. |
| 630 | Adovelande J, et al. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum. Biochem Pharmacol. 1998 Feb 15;55(4):433-40. |
| 631 | Dongay B, et al. Effect of fantofarone, a new Ca2+ channel antagonist, on angioplasty-induced vasospasm in an atherosclerotic rabbit model. Biochem Pharmacol. 1998 Jun 15;55(12):2047-50. |
| 632 | Darblade B, et al. Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle. World J Urol. 2005 Jun;23(2):147-51. |
| 633 | Kjekshus JK, et al. Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur J Heart Fail. 2009 Aug;11(8):771-8. |
| 634 | Nirogi R, et al. In-vivo rat striatal 5-HT4 receptor occupancy using non-radiolabelled SB207145. J Pharm Pharmacol. 2013 May;65(5):704-12. |
| 635 | Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30. |
| 636 | Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93. |
| 637 | McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36. |
| 638 | Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007 Jun 1;109(11):4739-41. |
| 639 | Saleh MN, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45. |
| 640 | Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21. |
| 641 | https://clinicaltrials.gov/ct2/show/NCT04834752?term=Pantoprazole&cond=Covid19&draw=2&rank=1 |
| 642 | Ligat G, et al. Identification of Amino Acids Essential for Viral Replication in the HCMV Helicase-PrimaseComplex. Front Microbiol. 2018 Oct 23;9:2483. |
| 643 | Wald A, et al. Helicase-primase inhibitor Pritelivir for HSV-2 infection. N Engl J Med. 2014 Jan 16;370(3):201-10. |
| 644 | Quenelle DC, et al. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis. Antiviral Res. 2018 Jan;149:1-6. |
| 645 | Weir HM, et al. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models. Cancer Res. 2016 Jun 1;76(11):3307-18. |
| 646 | De Savi C, et al. Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist. J Med Chem. 2015 Oct 22;58(20):8128-40. |
| 647 | Pan S, et al. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett. 2010 Mar 16;1(3):130-4. |
| 648 | Irvine DA, et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep. 2016 May 9;6:25476. |
| 649 | Kargl J, et al. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
 J Pharmacol Exp Ther. 2013 Jul;346(1):54-66. |
| 650 | Acta Pharmacol Toxicol 47:17 (1980) |
| 651 | Moradi-Afrapoli F, et al. Cinnamoylphenethyl amides from Polygonum hyrcanicum possess anti-trypanosomal activity. Nat Prod Commun. 2012 Jun;7(6):753-5. |
| 652 | Kim DK, et al. Inhibitory effect of trans-N-p-coumaroyl tryamine from the twigs of Celtis chinensis on the acetylcholinesterase. Arch Pharm Res. 2003 Sep;26(9):735-8. |
| 653 | Inhibition of IκB kinase-β protects dopamine neurons against lipopolysaccharide-induced neurotoxicity By Zhang, Feng; Qian, Li; Flood, Patrick M.; Shi, Jing-Shan; Hong, Jau-Shyong; Gao, Hui-Ming J Pharmacol Exp Ther. 2010 June; 333(3): 822-833. |
| 654 | Cooper MJ, et al. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. PLoS One. 2013 Jun 24;8(6):e66755. |
| 655 | Schneeweiss M, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103(5):799-809. |
| 656 | KIT/PDGFR Inhibitor DCC-2618. |
| 657 | Schneeweiss M, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103(5):799-809. |
| 658 | BLU-285, DCC-2618 Show Activity against GIST. Cancer Discov. 2017 Feb;7(2):121-122. |
| 659 | Stover CK, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000 Jun 22;405(6789):962-6. |
| 660 | Lenaerts AJ, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005 Jun;49(6):2294-301. |
| 661 | Manjunatha UH, et al. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother. 2006 Oct;50(10):3350-4. |
| 662 | Arzneim Forsch 17:523, 526, 534 (1967); 21:1907 (1971) |
| 663 | Linyan Xu, et al. Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells. Int J Med Sci. 2020; 17(10): 1375–1384. |
| 664 | Jian Ma, et al. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer. 2011 Jun 16;11:255. |
| 665 | Young Seop Chang, et al. MP28-10 COMBINED EFFECTS OF MELATONIN AND CLADRIBINE ON APOPTOSIS IN ISCHEMIA/REPERFUSION INJURY IN RAT BLADDER. THE JOURNAL OF UROLOGY. April 2016. 195 (4S): e375. |
| 666 | Crystal D Hayes, et al. Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice. PLoS One. 2012;7(10):e45841. |
| 667 | Yeung, P. K. F., et al. Pharmacokinetics of Cladribine in a Rat Model Following Subcutaneous and Intra-arterial Injections. Drug Metabol Drug Interact. 2008;23(3-4):291-8. |
| 668 | Zengerle M, et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. ACS Chem Biol. 2015;10(8):1770‐1777. |
| 669 | Minna Bui, et al. Heteroaryl btk inhibitors. WO2011029043A1 |
| 670 | McAfee Q, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A. 2012 May 22;109(21):8253-8. |
| 671 | Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23. |
| 672 | Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66. |
| 673 | Bai L, et al. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019 Nov 11;36(5):498-511.e17. |
| 674 | Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. |
| 675 | Liewen MB, et al. Growth and Inhibition of Microorganisms in the Presence of Sorbic Acid: A Review. J Food Prot. 1985 Apr;48(4):364-375. |
| 676 | Pu W, et al. Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellularcarcinoma development. Hepatology. 2018 Aug;68(2):547-560. |
| 677 | Lenta BN, et al. Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds from Allanblackia monticola and Symphonia globulifera. Molecules. 2007 Jul 20;12(8):1548-57. |
| 678 | Ciochina R, et al. Polycyclic polyprenylated acylphloroglucinols. Chem Rev. 2006 Sep;106(9):3963-86. |
| 679 | Li F, et al. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signalingcascades leading to the suppression of growth and survival of head and neck carcinoma. Cancer Prev Res (Phila). 2013 Aug;6(8):843-54. |
| 680 | Drugs 15:409 (1978); Am J Cardiol 57:1H (1986); N Engl J Med 337:365 (1997): Circulation 105:2549 (2002). |
| 681 | Saalau-Bethell SM, et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol. 2012 Nov;8(11):920-5. |
| 682 | Boolbol SK, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996 Jun 1;56(11):2556-60. |
| 683 | Gong EY, et al. Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells. Toxicol Lett. 2016 Sep 6;258:126-133. |
| 684 | Cha BK, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7(35):57213-57227. |Drugs 16:97 (1978); Dig Dis 12:259 (1994) |
| 685 | J Antimicrob Chemother 10:Suppl B:1 (1982); Drugs 32 Suppl 3:1 (1986) |
| 686 | J Biol Chem 202:801 (1953); Photochem Photobiol 39:851 (1984); 55:145 (1992) |
| 687 | Appl Microbiol 22:480 (1971); J Vet Intern Med 20:536 (2006)| |
| 688 | Jody L Gookin, et al. Efficacy of ronidazole for treatment of feline Tritrichomonas foetus infection. J Vet Intern Med |
| 689 | Kirkin V, et al. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem. 2001 Nov;268(21):5530-40. |
| 690 | Kirkin V, et al. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer. 2004 Dec 20;112(6):986-93. |
| 691 | Hiroyasu Koga, et al. Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis. Antimicrob Agents Chemother. 2012 Jun;56(6):3138-43. |
| 692 | Hiroyasu Koga, et al. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol. 2009;47(6):640-7. |
| 693 | LUZU (luliconazole) Cream, 1% for topical use |
| 694 | J Biol Chem 235:PC13 (1960); J Heart Lung Transplant 13:481 (1994); Cosmet Dermatol 21:76 (2008)| |
| 695 | Cardoso T, et al. Lactobionic Acid as a Potential Food Ingredient: Recent Studies and Applications. J Food Sci. 2019 Jul;84(7):1672-1681. |
| 696 | Vet Rec 79:590 (1966); J Parasitol 53:1085 (9167); J Pharm Pharmacol 22:26 (1970) |
| 697 | Yu L. Inhibitory effects of (S)- and (R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acids on tyrosinase activity. J Agric Food Chem. 2003 Apr 9;51(8):2344-7. |
| 698 | Cheng Y, et al. Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10). pii: E1551. |
| 699 | Selcher JC, et al. A necessity for MAP kinase activation in mammalian spatial learning. Learn Mem. 1999 Sep-Oct;6(5):478-90. |
| 700 | Yusaku Hori, et al. E7386, an orally active CBP/beta-catenin modulator, induces T cells infiltration into tumor and enhances antitumor activity of anti-PD-1 mAb in Wnt1 tumor syngeneic mice model. Cancer Res 2017;77(13 Suppl):Abstract nr 5172. |
| 701 | J Antimicrob Chemother 14:441 (1984); Antimicrob Agents Chemother 29:52 (1986); J Hosp Infect 7 Suppl A:47 (1986) |
| 702 | J Am Med Assoc 132:126 (1946); IARC Monographs 50:143 (1990) |
| 703 | Humphries-Bickley T, et al. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. Mol Cancer Ther. 2017 May;16(5):805-818. |
| 704 | Parry D, et al.
 Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
 Mol Cancer Ther. 2010 Aug;9(8):2344-53. |
| 705 | Feldmann G, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. |
| 706 | Zhang Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9(7):743. |
| 707 | Hou X, et al. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. J Med Chem. 2014 Nov 26;57(22):9309-22. |
| 708 | Can Med Assoc J 78:206 (1958) |
| 709 | Kaiser M, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8. |
| 710 | Lin K, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother. 2006 May;50(5):1813-22. |
| 711 | Perni RB, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2006 Mar;50(3):899-909. |
| 712 | Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065. |
| 713 | Wan H, et al. Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. ACS Med Chem Lett. 2015 Jul 12;6(8):850-5. |
| 714 | Mace TA, et al. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget. 2015 Dec 29;6(42):44509-22. |
| 715 | Makovski V, et al. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
 Int J Cancer. 2012 Mar 15;130(6):1420-9. |
| 716 | Nevo Y, et al. Chapman J. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
 PLoS One. 2011 Mar 22;6(3):e18049. |
| 717 | Charette N, et al. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
 Mol Cancer. 2010 Sep 22;9:256. |
| 718 | Liu K, et al. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. |
| 719 | J. Med. Chem. (1991), 34(7), 2231-41; J. Infect. Dis. (1991), 163(5), 966-70; Science (1990), 250(4986), 1411-13 |
| 720 | Godinho SA, et al. Causes and consequences of centrosome abnormalities in cancer. Philos Trans R Soc Lond B Biol Sci. 2014 Sep 5;369(1650). |
| 721 | Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1. Wu J, et al. ACS Chem Biol. 2013 Oct 18;8(10):2201-8. |
| 722 | Siemon G, et, al. [The effect of fominoben and oxyethyltheophylline in combination on pulmonary function and pulmonary hemodynamics in chronic-obstructive diseases of the airways (author's transl)]. Arzneimittelforschung. 1978;28(4):698-700. |
| 723 | Ufkes JG, et, al. Efficacy of theophylline and its N-7-substituted derivatives in experimentally induced bronchial asthma in the guinea-pig. Arch Int Pharmacodyn Ther. 1981 Oct;253(2):301-14. |
| 724 | Life Sci 17: 1777 (1975) |
| 725 | Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 Aug 15;62(16):4645-55. |
| 726 | Hegedus C, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012 Aug 1;84(3):260-7. |
| 727 | Takeda H, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 2013 Feb 15;319(4):417-23. |
| 728 | Inoue K, et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. Clin Cancer Res. 2012 Jul 15;18(14):3924-33. |
| 729 | Rai R, et al. A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis. Epigenetics. 2017;12(11):1004-1013. |
| 730 | Sun XJ, et al. The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis. Front Oncol. 2015 May 26;5:108. |
| 731 | Rai R, et al. Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis.J Cell Mol Med. 2019 Apr;23(4):3026-3031. |
| 732 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=TACROLIMUS&cntry=&state=&city=&dist=&Search=Search |
| 733 | ZHU, D., et al., In vitro activities of cefoselis compared to β-lactams and other antibacterial agents aganst gram-positive and gram-negative clinical isolates. Chinese Journal of Infection and Chemotherapy, 2011. 4: p. 002. |
| 734 | King, A., L. Bethune, and I. Phillips, The Comparative In Vitro Activity of FK-037 (Cefoselis), a New Broad-Spectrum Cephalosporin. Clin Microbiol Infect, 1995. 1(1): p. 13-17. |
| 735 | K Ohtaki, et al. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J Neural Transm (Vienna). 2004 Dec;111(12):1523-35. |
| 736 | Ann. Pharm. Fr(1970), 28(7-8), 497-509. ; Therapie (1967), 22(1), 137-47. ; Therapie (1965), 20(5), 1305-10. |
| 737 | Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1181-1189. |
| 738 | Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11(4):1026-1035. |
| 739 | Chen J, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9. |
| 740 | Bhumika D Patel, et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014 Mar 3;74:574-605. |
| 741 | Charles E Grimshaw, et al. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLoS One. 2016 Jun 21;11(6):e0157509. |
| 742 | Shiliang Li, et al. Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. J Med Chem. 2019 Mar 14;62(5):2348-2361. |
| 743 | Matsuzawa Y, et al. Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf. J Pharmacol Sci. 2009 Oct;111(2):182-92 |
| 744 | Invest Urol 12:381 (1975); 18:102 (1980) |
| 745 | Florian MC et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell, 2012 May 4, 10(5):520-30. |
| 746 | Peterson JR et al. Biochemical suppression of small-molecule inhibitors: a strategy to identify inhibitor targets and signaling pathway components. |
| 747 | Marschall M, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012 Feb;56(2):1135-7. |
| 748 | Goldner T, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93. |
| 749 | Lischka P, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010 Mar;54(3):1290-7. |
| 750 | Wildum S, et al. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59(6):3140-8. |
| 751 | Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood (2019) 134 (Supplement_1): 4319. |
| 752 | BTK Inhibitor ICP-022. |
| 753 | Pulm. Pharmacol. Ther. (1997), 10(2), 97-104; J. Pharmacol. Exp. Ther. (1974), 189(1), 616-25; J. Med. Chem. (1971), 14(9), 895-6 |
| 754 | https://clinicaltrials.gov/ct2/show/NCT04610502?term=Chlorpheniramine&cond=Covid19&draw=2&rank=1 |
| 755 | Jon I Williams, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010 Oct;26(10):2329-38. |
| 756 | Tsugunobu Andoh, et al. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur J Pharmacol. 2006 Oct 10;547(1-3):59-64. |
| 757 | Arzneim Forsch 15:1441 (1965); Anal Profiles Drug Subs 2:487 (1973) |
| 758 | Kalbhen DA, et al. Nutmeg as a narcotic. A contribution to the chemistry and pharmacology of nutmeg (Myristica fragrans).Angew Chem Int Ed Engl. 1971 Jun;10(6):370-4. |
| 759 | Dawidowicz AL, et al. Simple and rapid determination of myristicin in human serum.Forensic Toxicol. 2013 Jan;31(1):119-123. Epub 2012 Aug 15. |
| 760 | Yang X, et al. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int J Cancer. 2015 Oct 15;137(8):2029-39. |
| 761 | Duan Z, et al. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One. 2009 Oct 12;4(10):e7415. |
| 762 | Wu Q, et al. Characterization of the biosynthesis gene cluster for the pyrrole polyether antibiotic calcimycin(A23187) in Streptomyces chartreusis NRRL 3882. Antimicrob Agents Chemother. 2011 Mar;55(3):974-82. |
| 763 | Elliott JI, et al. IKCa1 activity is required for cell shrinkage, phosphatidylserine translocation and death in Tlymphocyte apoptosis. EMBO Rep. 2003 Feb;4(2):189-94. |
| 764 | Engedal N, et al. Modulation of intracellular calcium homeostasis blocks autophagosome formation. Autophagy. 2013 Oct;9(10):1475-90. |
| 765 | Mawatwal S, et al. Calcimycin mediates mycobacterial killing by inducing intracellular calcium-regulated autophagy in a P2RX7 dependent manner. Biochim Biophys Acta Gen Subj. 2017 Dec;1861(12):3190-3200. |
| 766 | Wang JP, et al. Effect of norathyriol, isolated from Tripterospermum lanceolatum, on A23187-induced pleurisy and analgesia in mice. Naunyn Schmiedebergs Arch Pharmacol. 1994 Jul;350(1):90-5. |
| 767 | Katayama R, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10(1):3604. Published 2019 Aug 9. |
| 768 | Fujiwara Y, et al. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget. 2018;9(34):23729-23737. Published 2018 May 4. |
| 769 | Flamme I, et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9(11):e111838. |
| 770 | J Neurosci 22:8942 (2002); Nature Med 8:143 (2002); J Biol Chem 278:3825 (2003); Clin Invest 116:1410 (2006) |
| 771 | Chen Z, et al. Novel 1,3,4-Selenadiazole Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity. J Med Chem. 2018 Dec 13. |
| 772 | J Pharm Exp Ther 89:205 (1947); 99:171 (1950) ; Arzneim Forsch 20:1024 (1970) |
| 773 | Rho JK, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 2014 Jan 1;74(1):253-62. |
| 774 | Shin JS, et al. NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. Invest New Drugs. 2014 Jun;32(3):389-99. |
| 775 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=L-Ascorbic+acid&cntry=&state=&city=&dist= |
| 776 | Chem Pharm Bull 34: 2506 (1986); 35: 3597 (1987) |
| 777 | Kaileh M, et al. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem. 2007 Feb 16;282(7):4253-64. Epub 2006 Dec 6. |
| 778 | Bargagna-Mohan P, et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol. 2007 Jun;14(6):623-34. |
| 779 | Kakar SS, et al. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget. 2017 Aug 10;8(43):74494-74505. |
| 780 | Moorthy BT, et al. Novel rhodanine derivatives induce growth inhibition followed by apoptosis. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6297-301. |
| 781 | Ajaybabu V Pobbati, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635. |
| 782 | Xuan Zhang, et al. Targeting of mutant p53-induced FoxM1 with Thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. Oncotarget. 2014 Nov 30;5(22):11365-80. |
| 783 | Aniruddha Sengupta, et al. The dual inhibitory effect of Thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma. Int J Oncol. 2013 Sep;43(3):803-12. |Nature 225:233 (1970); J Antibiot 36:799, 814, 831(1983); 42:1649 (1989) |
| 784 | Zhou Y, et al. Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother. 2014;58(3):1789-92. |
| 785 | van Pelt-Koops JC, et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob Agents Chemother. 2012 Jul;56(7):3544-8. |
| 786 | Rottmann M, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80. |
| 787 | Sun Q, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. |
| 788 | Lotilaner, et al. The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls). Parasit Vectors. 2017 Nov 1;10(1):530. |
| 789 | Rajamani S et al. The novel late Na+ current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations. Br J Pharmacol. 2016 Jul 23. |
| 790 | Justo F et al. Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation. Heart Rhythm. 2016 Sep;13(9):1860-7. |
| 791 | Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs. 2009 May;10(5):482-90. |
| 792 | Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2010 Feb;19(2):257-64. |
| 793 | Sentellas S, Ramos I, Albertí J et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 Mar 18;39(5):283-90. |
| 794 | Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:457-66. |
| 795 | Ma R, et al. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. Br J Cancer. 2018 May;118(11):1453-1463. |
| 796 | Kim YS, et al. Synthesis of 2',3',4'-trihydroxyflavone (2-D08), an inhibitor of protein sumoylation. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1094-7. |
| 797 | Fujino N, et al. Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype. Lab Invest. 2017 Sep;97(9):1047-1062. |
| 798 | Ghosh H, et al. Several posttranslational modifications act in concert to regulate gephyrin scaffolding and GABAergic transmission. Nat Commun. 2016 Nov 7;7:13365. doi: 10.1038/ncomms13365. |
| 799 | Kettle JG, et al. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy) quinazolin-4-yl]amino} phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J Med Chem. 2018 Oct 11;61(19):8797-8810. |
| 800 | Brit J Pharmacol 109: 200 (1993); Gen Pharmacol 31:503 (1998) |
| 801 | Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. |
| 802 | De Buck S, et al. Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197. CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700. |
| 803 | Large CH, et al. The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: potential for novel treatments for schizophrenia. J Pharmacol Exp Ther. 2011 Jul;338(1):100-13. |
| 804 | Lingling Zhang, et al. Inhibition of wild-type p53-induced phosphatase 1 promotes liver regeneration in mice by direct activation of mammalian target of rapamycin. Hepatology. 2015 Jun;61(6):2030-41. |
| 805 | S Rayter, et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene. 2008 Feb 14;27(8):1036-44. |
| 806 | Ren JX, et al. Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking. Biomed Pharmacother. 2017 May;89:376-385. |
| 807 | Murakami Y, et al. Dehydrodiisoeugenol, an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages. Arch Biochem Biophys. 2005 Feb 15;434(2):326-32. |
| 808 | Lv QQ, et al. Metabolic profiling of dehydrodiisoeugenol using xenobiotic metabolomics. J Pharm Biomed Anal. 2017 Oct 25;145:725-733. |
| 809 | T I Ng , et al. Selection and Characterization of Varicella-Zoster Virus Variants Resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. Antimicrob Agents Chemother. 2001 Jun;45(6):1629-36. |
| 810 | Currier MA, et al. Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.Mol Cancer Ther. 2017 Aug;16(8):1555-1565. |
| 811 | Reina JC, et al. A Quorum-Sensing Inhibitor Strain of Vibrio alginolyticus Blocks Qs-Controlled Phenotypes in Chromobacterium violaceum and Pseudomonas aeruginosa. Mar Drugs. 2019;17(9):494. Published 2019 Aug 24. |
| 812 | Kunimoto S, et al. Reversal of resistance by N-acetyltyramine or N-acetyl-2-phenylethylamine in doxorubicin-resistant leukemia P388 cells. J Antibiot (Tokyo). 1987;40(11):1651-1652. |
| 813 | Hai-Tao Xiao, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011 Sep;25(15):1418-22. |
| 814 | Hui-Qiang Wang, et al. Corydaline inhibits enterovirus 71 replication by regulating COX-2 expression. J Asian Nat Prod Res. 2017 Nov;19(11):1124-1133. |
| 815 | Teresa Kaserer, et al. Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists. Sci Rep. 2020 Aug 14;10(1):13804. |
| 816 | Hypertension 30:912 (1997); J Thorac Cardiovasc Surg 124:352 (2002) |
| 817 | Bougoudogo, F, Fournier, J. M.; Dodin, A. "In vitro sensitivity of Vibrio cholerae serotype 0:139 to an intestinal antiseptic tiliquinol-tilbroquinol combination". Bulletin de la Societe de pathologie exotique (1990) 87 (1): 38-40. |
| 818 | International Drug Names |
| 819 | Okura N, et al. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Lung Cancer.Clin Cancer Res. 2020 Jan 17. |
| 820 | Ruvolo PP, et al. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.Haematologica. 2017 Dec;102(12):2048-2057. |
| 821 | James RG, et al. WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling. PLoS One. 2012;7(12):e50457. |
| 822 | Haikarainen T, et al. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4. PLoS One. 2013 Jun 6;8(6):e65404. |
| 823 | Sadava D, et al. The effect of brassinolide, a plant steroid hormone, on drug resistant small-cell lung carcinoma cells. Biochem Biophys Res Commun. 2017 Nov 4;493(1):783-787. |
| 824 | Yusheng Hu, et al. Coixol Suppresses NF-κB, MAPK Pathways and NLRP3 Inflammasome Activation in Lipopolysaccharide-Induced RAW 264.7 Cells. Molecules |
| 825 | https://clinicaltrials.gov/ct2/show/NCT04751669?term=Tocopherol&cond=Covid19&draw=2&rank=2 |
| 826 | Jayathilaka K, et al. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15848-53. |
| 827 | Song J, et al. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Nat Commun. 2016 Jan 28;7:10548. |
| 828 | Smith MA,et al. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015 Nov 13;9:6083-94. |
| 829 | Schnell G, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015 Aug 17. pii: AAC.01229-15. |
| 830 | Expert Opin. Invest. Drugs (2007), 16(10), 1615-1625; Drugs (1992), 43(6), 873-88; Epilepsia (1987), 28(6), 693-8 |
| 831 | Wang JB, et al. l-tetrahydropalamatine: a potential new medication for the treatment of cocaine addiction. Future Med Chem. 2012 Feb;4(2):177-86. |
| 832 | Liu YL, et al. Effects of l-tetrahydropalmatine on locomotor sensitization to oxycodone in mice. Acta Pharmacol Sin. 2005 May;26(5):533-8. |
| 833 | Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406 |
| 834 | Alpert JS, et al. Chemistry, pharmacology, antiarrhythmic efficacy and adverse effects of tocainide hydrochloride, an orally active structural analog of lidocaine. Pharmacotherapy. 1983 Nov-Dec;3(6):316-23. |
| 835 | De Luca A,et al.Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds.Mol Pharmacol. 2003 Oct;64(4):932-45. |
| 836 | Gessier F, et al. Identification and characterization of small molecule modulators of the Epstein-Barr virus-induced gene 2 (EBI2) receptor. J Med Chem. 2014 Apr 24;57(8):3358-68. |
| 837 | Lee S, et al. Relative protective activities of quercetin, quercetin-3-glucoside, and rutin in alcohol-induced liver injury. J Food Biochem. 2019 Aug 5:e13002. |
| 838 | Tan C, et al. Modulation of nuclear factor-κB signaling and reduction of neural tube defects by quercetin-3-glucoside in embryos of diabetic mice. Am J Obstet Gynecol. 2018 Aug;219(2):197.e1-197.e8. |
| 839 | Sabine Bachmaier, et al. Nucleoside analogue activators of cyclic AMP-independent protein kinase A of Trypanosoma. Nat Commun. 2019 Mar 29;10(1):1421. |
| 840 | Int J Pharm 300:38 (2005) |
| 841 | Stemp G, et al. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem. 2000 May 4;43(9):1878-85. |
| 842 | Rui Song, et al. YQA14: A Novel Dopamine D3 Receptor Antagonist That Inhibits Cocaine Self-Administration in Rats and Mice, but Not in D3 Receptor-Knockout Mice. Addict Biol |
| 843 | Phytochemistry 17:1383 (1978) |
| 844 | Erpenbeck, V. J. et al. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers. Clinical pharmacology in drug development 5, 306-313, doi:10.1002/cpdd.244 (2016). |
| 845 | Sykes, D. A. et al.Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. Molecular pharmacology 89, 593-605, doi:10.1124/mol.115.101832 (2016). |
| 846 | Kim, S.J., et al., Geniposidic acid protects against D-galactosamine and lipopolysaccharide-induced hepatic failure in mice. J Ethnopharmacol, 2013. 146(1): p. 271-7. |
| 847 | Hsu, H.Y., et al., Comparisons of geniposidic acid and geniposide on antitumor and radioprotection after sublethal irradiation. Cancer Lett, 1997. 113(1-2): p. 31-7. |
| 848 | Harris PA et al. DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors. J Med Chem, 2016 Mar 10, 59(5):2163-78. |
| 849 | Lee HL, et al. Simultaneous flow cytometric immunophenotyping of necroptosis, apoptosis and RIP1-dependent apoptosis. Methods. 2018 Feb 1;134-135:56-66. |
| 850 | Sykes DB et al. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. National Center for Biotechnology Information (US); 2010-2013 Dec 15. |
| 851 | David B Sykes, et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. 2016 Sep 22;167(1):171-186.e15. |
| 852 | Timothy A Lewis, et al. Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia. ACS Med Chem Lett. 2016 Sep 28;7(12):1112-1117. |
| 853 | Kyle R. Simonetta, et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nature Communications. 2019 March. |
| 854 | Bath CP, et al. The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia. Eur J Pharmacol. 1996 Mar 28;299(1-3):103-12. |
| 855 | Lengyel C, et al. Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased repolarisation reserve in the development of proarrhythmic risk. Br J Pharmacol. 2004 Sep;143(1):152-8. |
| 856 | Olaharski AJ, et al. The flavoring agent Dihydrocoumarin reverses epigenetic silencing and inhibits sirtuindeacetylases. PLoS Genet. 2005 Dec;1(6):e77. |
| 857 | Modulation of Sirt1/NF-κB interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation. Biochem Pharmacol. 2019 Oct;168:452-464. |
| 858 | Robke L, et al. Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34. Angew Chem Int Ed Engl. 2017 Jul 3;56(28):8153-8157. |
| 859 | Dayal N, et al. Potently inhibiting cancer cell migration with novel 3H-pyrazolo[4,3-f]quinoline boronic acid ROCK inhibitors. Eur J Med Chem. 2019 Oct 15;180:449-456. |
| 860 | Yano W, et al. TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy. Mol Cancer Ther. 2018 Aug;17(8):1683-1693. |
| 861 | Guo B, et al. Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis. Clin Ther. 2017 Jul;39(7):1336-1346. |
| 862 | Biochem. Pharmacol. (1964), 13(2), 153-8; Arch. Int. Pharmacodyn. Ther. (1960), 126, 386-92. ; Therapie (1954), 9, 64-7. |
| 863 | Chou CJ, et al. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem. 2008 Dec 19;283(51):35402-35409. |
| 864 | Xu C, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol. 2009 Sep 25;16(9):980-989. |
| 865 | Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53(17):6337-54. |
| 866 | Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014 Aug;272(2):417-26. |
| 867 | Luo M, et al. Diethylaminobenzaldehyde is a covalent, irreversible inactivator of ALDH7A1. ACS Chem Biol. 2015 Mar 20;10(3):693-7. |
| 868 | Araki N, et al. Screening for androgen receptor activities in 253 industrial chemicals by in vitro reporter gene assays using AR-EcoScreen cells. Toxicol In Vitro. 2005 Sep;19(6):831-42. |
| 869 | X. Bao, et al. Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models. International Journal of Radiation Oncology Biology Physics |
| 870 | Diana I. Albu, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. OncoImmunology. |
| 871 | https://clinicaltrials.gov/ct2/show/NCT04937543?term=GLYCOPYRROLATE&cond=covid&draw=2&rank=1 |
| 872 | Alvarez C, et al. Brefeldin A (BFA) disrupts the organization of the microtubule and the actin cytoskeletons. Eur J Cell Biol. 1999 Jan;78(1):1-14. |
| 873 | Colanzi A, et al. Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9794-9. |
| 874 | Tseng CN, et al. Brefeldin A reduces anchorage-independent survival, cancer stem cell potential and migration of MDA-MB-231 human breast cancer cells. Molecules. 2014 Oct 29;19(11):17464-77. |
| 875 | Wang J, et al. Erythroleukemia cells acquire an alternative mitophagy capability. Sci Rep. 2016 Apr 19;6:24641. |
| 876 | Yu C, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2015 Feb 5;16(2):142-7. |
| 877 | Nozawa N, et al. Subcellular localization of herpes simplex virus type 1 UL51 protein and role of palmitoylation in Golgi apparatus targeting. J Virol. 2003 Mar;77(5):3204-16. |
| 878 | Jensen HL, Rygaard J, Norrild B. A time-related study of Brefeldin A effects in HSV-1 infected cultured human fibroblasts. APMIS. 1995;103(7-8):530-539. doi:10.1111/j.1699-0463.1995.tb01402.x |
| 879 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=TORSEMIDE&cond=COVID-19&draw=2&rank=1 |
| 880 | Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018. |
| 881 | Rohn TT, et al. Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int J Clin Exp Med. 2009 Nov 5;2(4):300-8. |
| 882 | Kuzelová K, et al. Dose-dependent effects of the caspase inhibitor Q-VD-OPh on different apoptosis-related processes. J Cell Biochem. 2011 Nov;112(11):3334-42. |
| 883 | Caserta TM, et al. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003 Aug;8(4):345-52. |
| 884 | Chen-Deutsch X, et al. Leuk Res. 2012 Jul;36(7):884-8.
 The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells. |
| 885 | Laforge M, et al. The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques. J Clin Invest. 2018 Apr 2;128(4):1627-1640. |
| 886 | Gianní M, et al. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood. 1996 Feb 15;87(4):1520-31. |
| 887 | Lu Y, et al. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580. Oncogene. 2010 Jun 24;29(25):3665-76. |
| 888 | Bosch A, et al. Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis. Breast Cancer Res. 2012 Aug 24;14(4):R121. |
| 889 | Bourne N, et al. Civamide (cis-capsaicin) for treatment of primary or recurrent experimental genital herpes. Antimicrob Agents Chemother. 1999 Nov;43(11):2685-8. |
| 890 | Antimicrob Agents Chemother 44:1604 (2000); Expert Opin Pharmacother 5:1117 (2004) |
| 891 | DEREK N. MIDDLEMISS, et al. 8-HYDROXY-2-(DI-n-PROPYLAMINO)-TETRALIN DISCRIMINATES BETWEEN SUBTYPES OF |
| 892 | Bard JA, et al. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422-6. |
| 893 | Mori T, et al. Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT. Psychopharmacology (Berl). 2016 Jun;233(12):2343-53. |
| 894 | Pei Z, et al. Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. |
| 895 | Shino M, et al. In vivo and in vitro evidence for the inhibition of homogentisate solanesyltransferase by cyclopyrimorate. Pest Manag Sci. 2019 Nov 27. |
| 896 | Shino M, et al. Action mechanism of bleaching herbicide cyclopyrimorate, a novel homogentisate solanesyltransferase inhibitor. J Pestic Sci. 2018 Nov 20;43(4):233-239. |
| 897 | Aronov, Alex M., et al. Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control. Journal of Medicinal Chemistry (2009), 52(20), 6362-6368. |
| 898 | Krepler C, et al. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 2016 Apr 1;22(7):1592-602. |
| 899 | Friesen WJ, et al. The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA. 2017;23(4):567-577. |
| 900 | Sun JG, et al. Clitocine potentiates TRAIL-mediated apoptosis in human colon cancer cells by promoting Mcl-1 degradation. Apoptosis. 2016;21(10):1144-1157. |
| 901 | Jorg Eberling, et al. Chemoselective Removal of Protecting Groups from O-Glycosyl Amino Acid and Peptide (Methoxyethoxy)ethyl Esters Using Lipases and Papain. J. Org. Chem., 1996, 61 (8), pp 2638–2646 |
| 902 | Ban HS, et al. The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth. Cell Death Dis. 2017 Jun 1;8(6):e2843. |
| 903 | Mutat. Res. (1975), 32(2), 115-32; Cancer (1972), 30(6), 1639-46; Expert Rev. Anticancer Ther. (2011), 11(3), 403-414 |
| 904 | Motoko Nakano, et al. Possible involvement of host defense mechanism in the suppression of rat acute reflux esophagitis by the particular histamine H2 receptor antagonist lafutidine. Pharmacology. 2012;90(3-4):205-11. |
| 905 | Tetsuhiro Sugiyama, et al. Lafutidine facilitates calcitonin gene-related peptide (CGRP) nerve-mediated vasodilation via vanilloid-1 receptors in rat mesenteric resistance arteries. J Pharmacol Sci. 2008 Mar;106(3):505-11. |
| 906 | Mitsuaki Okayama, et al. Protective effect of lafutidine, a novel histamine H2-receptor antagonist, on dextran sulfate sodium-induced colonic inflammation through capsaicin-sensitive afferent neurons in rats. Dig Dis Sci. 2004 Oct;49(10):1696-704. |
| 907 | Babich H, et al. In vitro cytotoxicity of (-)-catechin gallate, a minor polyphenol in green tea. Toxicol Lett. 2007 Jul 10;171(3):171-80. |
| 908 | J Med Chem 31:221 (1988); J Pharmacol Exp Ther 248:415 (1989) |
| 909 | Xiong Y, et al. Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis. J Med Chem. 2010 Jun 10;53(11):4412-21. |
| 910 | Przyklenk K, et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010 Feb;8(2):331-40. |
| 911 | Adams JW, et al. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J Pharmacol Exp Ther. 2009 Oct;331(1):96-103. |
| 912 | Sun X, et al. Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3671-5. |
| 913 | Colagiovanni DB, et al. A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma. Regul Toxicol Pharmacol. 2012 Feb;62(1):115-24. |
| 914 | Green LS, et al. Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. Biochemistry. 2012 Mar 13;51(10):2157-68. |
| 915 | Thomas M. Raffay, et al. Methods of treating respiratory disorders. Patent. US 20170209419 A1. |
| 916 | Sakipova Z, et al. Quantification of santonin in eight species of <i>Artemisia</i> from Kazakhstan by means of HPLC-UV: Method development and validation. PLoS One. 2017 Mar 16;12(3):e0173714. |J Chem Soc 1930:1110; Southern Med J 64:387 (1971); J Vet Pharmacol Therap 5:71 (1982); Jap J Parasit 34:325 (1985) |
| 917 | Hobl EL, et al. Tecarfarin: A Novel Vitamin K Antagonist. Thromb Haemost. 2017 Nov;117(11):2009-2011. |
| 918 | Bowersox SS, et al. Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. Thromb Res. 2010 Nov;126(5):e383-8. |
| 919 | Kwon D, et al. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) suppresses STING-mediated DNA sensing pathway through inducing mitochondrial fission. Biochem Biophys Res Commun. 2017 Aug 30. pii: S0006-291X(17)31704-7. |
| 920 | Sinha D, et al. Synergistic efficacy of Bisbenzimidazole and Carbonyl Cyanide 3-Chlorophenylhydrazonecombination against MDR bacterial strains. Sci Rep. 2017 Mar 17;7:44419. |
| 921 | Kawamoto A, et al. Measurement of technetium-99m sestamibi signals in rats administered a mitochondrial uncoupler and in a rat model of heart failure. PLoS One. 2015 Jan 16;10(1):e0117091. |
| 922 | Kondapalli C, et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2012 May;2(5):120080. |
| 923 | Leesnitzer LM, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002 May 28;41(21):6640-50. |
| 924 | Seargent JM, et al. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumor cells and promotes the anticancer effects of the PPARgamma agonist BRL 49653, independently of PPARgamma activation. Br J Pharmacol. 2004 Dec;143(8):933-7. |
| 925 | Sato K, et al. PPARγ antagonist attenuates mouse immune-mediated bone marrow failure by inhibition of T cell function.Haematologica. 2016 Jan;101(1):57-67. |
| 926 | Collino M, et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005 Aug;68(2):529-36. |
| 927 | Du K, et al. Mito-tempo protects against acute liver injury but induces limited secondary apoptosis during the late phase of acetaminophen hepatotoxicity. Arch Toxicol. 2018 Oct 15. |
| 928 | Razzetti R, et al. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol. 1995 Jun 16;75(18):7F-12F. |
| 929 | Maria Anna Zipeto, et al. ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell. 2016 Aug 4;19(2):177-191. |
| 930 | Rajagopal L, et al. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. Behav Brain Res. 2016 Feb 15;299:105-10. |
| 931 | Burgdorf J, et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015 Nov 12;308:202-11. |
| 932 | Eur J Biochem 51:329 (1975); J Clin Invest 72:1234 (1983) |
| 933 | Mathias Brault, et al. Plasma membrane depolarization induced by abscisic acid in Arabidopsis suspension cells involves reduction of proton pumping in addition to anion channel activation, which are both Ca<sup>2+</sup> dependent. Plant Physiol. 2004 May;135(1):231-43. |
| 934 | Andrew Leber, et al. Abscisic acid enriched fig extract promotes insulin sensitivity by decreasing systemic inflammation and activating LANCL2 in skeletal muscle. Sci Rep. 2020 Jun 26;10(1):10463. |
| 935 | McKnight LE, et al. Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B. ACS Med Chem Lett. 2012 Dec 13;3(12):975-979. Epub 2012 Sep 25. |
| 936 | Coonrod LA, et al. Reducing levels of toxic RNA with small molecules.ACS Chem Biol. 2013 Nov 15;8(11):2528-37. |
| 937 | Sharad K, et al. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6. |
| 938 | Ding M, et al. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Clin Exp Pharmacol Physiol. 2015 May;42(5):458-64. |
| 939 | Teshima Y, et al. Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway. Circulation. 2003 Nov 4;108(18):2275-81. |
| 940 | Chang HB, et al. Na(+)/H(+) exchanger in the regulation of platelet activation and paradoxical effects of cariporide. Exp Neurol. 2015 Oct;272:11-6. |
| 941 | O'Donnell ME, et al. Intravenous HOE-642 reduces brain edema and Na uptake in the rat permanent middle cerebral artery occlusion model of stroke: evidence for participation of the blood-brain barrier Na/H exchanger. J Cereb Blood Flow Metab. 2013 Feb;33(2):225-34. |
| 942 | Marino MJ et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73. |
| 943 | Récasens M, et al. Metabotropic glutamate receptors as drug targets. Curr Drug Targets. 2007;8(5):651-681. |
| 944 | Clin. Ther. (2004), 26(9), 1355-1367; J. Pain Symptom Manage. (2004), 28(2), 140-175; Int. Congr. Symp. Ser. - R. Soc. Med. (2000), 245, 45-53 |
| 945 | Phytochemistry 14:1829 (1975) |
| 946 | Neuropharmacology 21:803 (1982); Clin Neuropharmacol 8:1 (1985); Drugs 41:889 (1991) |
| 947 | May PC, et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci. 2011 Nov 16;31(46):16507-16516. |
| 948 | Zhang X, et al. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9734-9. |
| 949 | Ghosh AK, et al. Prospects of β-Secretase Inhibitors for the Treatment of Alzheimer's Disease. ChemMedChem. 2015 Sep;10(9):1463-6 |
| 950 | Filser S, et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry. 2015 Apr 15;77(8):729-39. |
| 951 | Mohamed AA, et al. Identification of a small molecule that selectively inhibits ERG-positive cancer cell growth. Cancer Res. 2018 Apr 30. pii: canres.2949.2017. |
| 952 | Cao G, et al. Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells. Eur J Pharmacol. 2016 Dec 15;793:101-108. |
| 953 | Zhang Z, et al. Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB. Mol Endocrinol. 2008 Jan;22(1):186-95. |
| 954 | Su F, et al. Protective effect of ginsenosides Rg1 and Re on lipopolysaccharide-induced sepsis by competitive binding to Toll-like receptor 4. Antimicrob Agents Chemother. 2015 Sep;59(9):5654-63. |
| 955 | Fiskus W, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014 Nov;28(11):2155-64. |
| 956 | Inui K, et al. Stepwise assembly of functional C-terminal REST/NRSF transcriptional repressor complexes as a drug target. Protein Sci. 2017 Feb 20 |
| 957 | Sumalatha M, et al. Isoorientin, a Selective Inhibitor of Cyclooxygenase-2 (COX-2) from the Tubers of Pueraria tuberosa. Nat Prod Commun. 2015 Oct;10(10):1703-4. |
| 958 | Ye T, et al. Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells. Onco Targets Ther. 2016 Dec 12;9:7481-7492. |
| 959 | Anilkumar K, et al. Evaluation of Anti-Inflammatory Properties of Isoorientin Isolated from Tubers of Pueraria tuberosa. Oxid Med Cell Longev. 2017;2017:5498054. |
| 960 | Toshiaki Sendo, et al. Carbazochrome sodium sulfonate (AC-17) reverses endothelial barrier dysfunction through inhibition of phosphatidylinositol hydrolysis in cultured porcine endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):175-80. |
| 961 | Toshiaki Sendo, et al. Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats. Eur J Pharmacol. 2002 Aug 23;450(2):203-8. |
| 962 | Draper JM, et al. Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther. 2011 Nov;10(11):2052-61. |
| 963 | Kus G, et al. Induction of apoptosis in prostate cancer cells by the novel ceramidase inhibitor ceranib-2. In Vitro Cell Dev Biol Anim. 2015 Nov;51(10):1056-63. |
| 964 | https://clinicaltrials.gov/ct2/show/NCT04365517?term=Sitagliptin&cond=covid&draw=1&rank=2 |
| 965 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Trandolapril&cond=COVID-19&draw=2&rank=2 |
| 966 | https://clinicaltrials.gov/ct2/show/NCT04636034?term=Ropivacaine&cond=Covid19&draw=2&rank=1 |
| 967 | Chen H, et al. Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. ACS Med Chem Lett. 2013 Feb 14;4(2):180-185. |
| 968 | Humphreys PG, et al. Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. J Med Chem. 2017 Jan 26;60(2):695-709. |
| 969 | Gierse J, et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther. 2010 Jul;334(1):310-7. |
| 970 | Bhave SR, et al. Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines. Front Oncol. 2013 Sep 17;3:236. |
| 971 | Cao P, et al. Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis. J Clin Invest. 2017 Apr 3;127(4):1517-1530. |
| 972 | Takeda K, et al. Potentiation of Acetylcholine-Mediated Facilitation of Inhibitory Synaptic Transmission by an Azaindolizione Derivative, ZSET1446 (ST101), in the Rat Hippocampus. J Pharmacol Exp Ther. 2016 Feb;356(2):445-55 |
| 973 | Yamaguchi Y, et al. Combination effects of ZSET1446/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampus. J Pharmacol Sci. 2013;123(4):347-55. Epub 2013 Nov 29. |
| 974 | Yamaguchi Y, et al. Effects of ZSET1446/ST101 on cognitive deficits and amyloid β deposition in the senescence accelerated prone mouse brain. J Pharmacol Sci. 2012;119(2):160-6. |
| 975 | Helv Chim Acta 57: 1301 (1974); Tet Lett 3413 (1974); JACS 97: 6144 (1975); PNAS 98: 4788 (2001) |
| 976 | Cao G, et al. Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway. Int J Mol Sci. 2016 Aug 29;17(9). pii: E1418. |
| 977 | Huang YL, et al. Possible mechanism of the anti-inflammatory activity of ruscogenin: role of intercellular adhesion molecule-1 and nuclear factor-kappaB. J Pharmacol Sci. 2008 Oct;108(2):198-205. |
| 978 | Row H, et al. HL271, a novel chemical compound derived from metformin, differs from metformin in its effects on the circadian clock and metabolism. Biochem Biophys Res Commun. 2016 Jan 15;469(3):783-9. |
| 979 | Bang E, et al. The Improving Effect of HL271, a Chemical Derivative of Metformin, a Popular Drug for Type II Diabetes Mellitus, on Aging-induced Cognitive Decline. Exp Neurobiol. 2018 Feb;27(1):45-56. |
| 980 | Sun Young Rha, et al. Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 38(15_suppl):3590-3590. |
| 981 | Arzneim Forsch 29:793, 1668 (1979); 30:73 (1980); Drugs 27:194 (1984) |
| 982 | Grygielko ET, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther, 2005, 313(3), 943-951. |
| 983 | Thomas M, et al. ALK5 mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol, 2009, 174(2), 380-389. |
| 984 | Laping NJ, et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res, 2007, 13(10), 3087-3899. |
| 985 | Mowbray CE, et al. Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5857-60. |
| 986 | Gregg D Cappon, et al. Developmental toxicity study of lersivirine in mice. Birth Defects Res B Dev Reprod Toxicol. 2012 Jun;95(3):225-30. |
| 987 | Norman P. et al. A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24. |
| 988 | Misaki K, et al. Aryl hydrocarbon receptor ligand activity of polycyclic aromatic ketones and polycyclic aromatic quinones. Environ Toxicol Chem. 2007 Jul;26(7):1370-9. |
| 989 | Ruiz FX, et al. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. Chem Biol Interact. 2013 Feb 25;202(1-3):178-85. |
| 990 | Hotta N, et al. Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats. Exp Physiol. 1995 Nov;80(6):981-9. |
| 991 | Boerma, M., et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase. Blood Coagul Fibrinolysis. 2008 Oct;19(7):709-18. |
| 992 | Lee, J.H., et al. Selective ROCK2 Inhibition In Focal Cerebral Ischemia. Ann Clin Transl Neurol. 2014 Jan 1;1(1):2-14. |
| 993 | https://clinicaltrials.gov/ct2/show/NCT04518735?term=WARFARIN&cond=covid&draw=2&rank=1 |
| 994 | Umemori Y, et al. Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumormarkers for breast and colorectal cancers. Clin Chim Acta. 2010 Dec 14;411(23-24):1894-9. |
| 995 | Hiramatsu K, et al. Diagnostic and prognostic usefulness of N1,N8-diacetylspermidine and N1,N12-diacetylsperminein urine as novel markers of malignancy. J Cancer Res Clin Oncol. 1997;123(10):539-45 |
| 996 | Proc. R. Soc. Med. (1971), 64(3), 243-9; Am. Surg. (1956), 22(12), 1225-32; Am. J. Dig. Dis. (1956), 1(11), 466-75 |
| 997 | Keith B Pfister, et al. Heteroaryl compounds as kinase inhibitors. 2011, WO2011026917A1. |
| 998 | Donghang Cheng, et al. Small Molecule Regulators of Protein Arginine Methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9. |
| 999 | Zhang, B., et al. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015 Sep 8;6(26):22799-811. |
| 1000 | Donghang Cheng, et al. Small Molecule Regulators of Protein Arginine Methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9. |
| 1001 | Baolai Zhang, et al. Arginine Methyltransferase inhibitor-1 Inhibits Sarcoma Viability in vitro and in vivo. Oncol Lett. 2018 Aug;16(2):2161-2166. |
| 1002 | Anesthesiology 11:606 (1950); Am J Health-System Pharm 54:388 (1997) |
| 1003 | Olivier Barret, et al. Adenosine 2A Receptor Occupancy by Tozadenant and Preladenant in Rhesus Monkeys. J Nucl Med. 2014 Oct;55(10):1712-8. |
| 1004 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=LISINOPRIL&cond=Covid19&draw=2&rank=2 |
| 1005 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=AZILSARTAN&cond=COVID-19&draw=2&rank=1 |
| 1006 | Acta Vet Scand 27:124 (1986); J Comp Pathol 97:21 (1987) |
| 1007 | Punit Saraon , et al. A Drug Discovery Platform to Identify Compounds That Inhibit EGFR Triple Mutants.Nat Chem Biol. 2020 May;16(5):577-586. |
| 1008 | JACS 81:2191 (1959) |
| 1009 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=ROSUVASTATIN+&cntry=&state=&city=&dist=&Search=Search |
| 1010 | Bamborough P, et al. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem. 2008 Dec 25;51(24):7898-914. |
| 1011 | Morgan BP, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett. 2010 Aug 20;1(9):472-7. |
| 1012 | Mamidi R, et al. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C. J Mol Cell Cardiol. 2015 Aug;85:262-72. |
| 1013 | Swenson AM, et al. Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle. J Biol Chem. 2017 Mar 3;292(9):3768-3778. |
| 1014 | J. Pharmacol. Exp. Ther. (1982), 222(3), 645-51; J. Pharm. Pharmacol. (1971), 23(6), 407-11; J. Pharmacol. Exp. Ther. (1967), 155(1), 1-12 |
| 1015 | Poncelet M, et al, Le Fur G. Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents. J Neural Transm Gen Sect. 1995;102(2):83‐90. |
| 1016 | Bachy A, et al. SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo. Eur J Pharmacol. 1993;237(2-3):299‐309. |
| 1017 | Zhong S, et al. Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-4562. |
| 1018 | Chen X, et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 2008 May 1;68(9):3169-3177. |
| 1019 | Oh S, et al. Antidiabetic and antiobesity effects of Ampkinone (6f), a novel small molecule activator of AMP-activated protein kinase. J Med Chem. 2010 Oct 28;53(20):7405-13. |
| 1020 | Kim SM, et al. Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist. J Med Chem. 2016 Oct 13;59(19):9150-9172. Epub 2016 Sep 27. |
| 1021 | Chen C, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478-85. |
| 1022 | Bianchetti A, et al. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol. 1990 Aug;100(4):831-9. |
| 1023 | Simiand J, et al. Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. Eur J Pharmacol. 1992 Aug 25;219(2):193-201. |
| 1024 | Claustre Y, et al. Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile. Neuroscience. 2008 Oct 2;156(2):353-64. |
| 1025 | Evans DM, et al. Exposure time versus cytotoxicity for anticancer agents.Cancer Chemother Pharmacol. 2019 Aug;84(2):359-371. |
| 1026 | Jung M, et al. Targeting BET bromodomains for cancer treatment. Epigenomics. 2015;7(3):487-501. |
| 1027 | Soejima R. Cefdinir. Jpn J Antibiot. 1992 Oct;45(10):1239-52. |
| 1028 | Labro MT, et al. Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome. J Immunol. 1994 Mar 1;152(5):2447-55. |Pediatr Infect Dis J 19:S141 (2000); 23:834 (2004); Drugs 64:1433 (2004) |
| 1029 | https://clinicaltrials.gov/ct2/show/NCT04834752?term=Lansoprazole&cond=covid&draw=2&rank=2 |
| 1030 | J Parasitol 68:616 (1983); 70:446 (1984)| |
| 1031 | Amanda L Garner, et al. Design, synthesis, and biological activities of closantel analogues: structural promiscuity and its impact on Onchocerca volvulus. J Med Chem. 2011 Jun 9;54(11):3963-72. |
| 1032 | Amanda L Garner, et al. Design, synthesis, and biological activities of closantel analogues: structural promiscuity and its impact on Onchocerca volvulus. J Med Chem. 2011 Jun 9;54(11):3963-72. |
| 1033 | Protopopova M. IACS-10759: A novel OXPHOS inhibitor which selectively kill tumors with metabolic vulnerabilities. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4380. doi:10.1158/1538-7445.AM2015-4380 |
| 1034 | Chen M, et al. Effect of monensin and lasalocid-sodium on the growth of methanogenic and rumen saccharolytic bacteria. Appl Environ Microbiol. 1979 Jul;38(1):72-7. |
| 1035 | Biochem J285:167 (1992); Br J Pharmacol 134:719 (2001); Mol Cancer Ther 6:1379 (2007) |
| 1036 | Arzneim Forsch 17:25 (1967) |
| 1037 | Purkey HE, et al. Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice. ACS Med Chem Lett. 2016 Aug 26;7(10):896-901. |
| 1038 | Ždralević M, et al. Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolism. J Biol Chem. 2018 Oct 12;293(41):15947-15961. |
| 1039 | Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. |
| 1040 | Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373. |
| 1041 | Irina N Gaisina, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52(7):1853-63. |
| 1042 | Hiroo Kuroki, et al. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977. |
| 1043 | Kim MH, et al. Indirubin, a purple 3,2- bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model. J Ethnopharmacol. 2013 Jan 9;145(1):214-9. |
| 1044 | Hsieh WL, et al. Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012 Aug;67(2):140-6. |
| 1045 | Zhang X, et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer. 2011 Nov 15;129(10):2502-11. |
| 1046 | Alex D, et al. Indirubin shows anti-angiogenic activity in an in vivo zebrafish model and an in vitro HUVEC model. J Ethnopharmacol. 2010 Sep 15;131(2):242-7. |
| 1047 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Minoxidil&cond=covid&draw=2&rank=1 |
| 1048 | 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH and their preparation. Patent WO 2013046136 A1 20130404 |
| 1049 | Li H, et al. Morusin suppresses breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis. J Exp Clin Cancer Res. 2015 Nov 4;34:137. |
| 1050 | Lee JC, et al. Morusin induces apoptosis and suppresses NF-kappaB activity in human colorectal cancer HT-29 cells. Biochem Biophys Res Commun. 2008 Jul 18;372(1):236-42. |
| 1051 | Lim SL, et al. Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. Am J Cancer Res. 2014 Dec 15;5(1):289-99. |
| 1052 | Goldstein DM et al. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase. J Med Chem. 2011 Apr 14;54(7):2255-65. |
| 1053 | A Marchese, et al. In vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in Italy. J Chemother. 2002 Dec;14(6):554-61. |
| 1054 | Marta Tikhomirov, et al. Pharmacokinetics of florfenicol and thiamphenicol in ducks. J Vet Pharmacol Ther. 2019 Jan;42(1):116-120. |Br J Vener Dis 47:379 (1971); Antimicrob Agents Chemother 14:788 (1978); Int J Odontostomat 2:7 (2008) |
| 1055 | Li YZ,et al. Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6. Oncotarget. 2017 Sep 8;8(61):103087-103099. |
| 1056 | Zhou B, et al. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.Cancer Res. 2013 Nov 1;73(21):6484-93. |
| 1057 | Chen MC, et al. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Mol Pharmacol. 2015 Jun;87(6):996-1005. |
| 1058 | Yudao Shen, et al. Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor. J Med Chem. 2020 May 28;63(10):5477-5487. |
| 1059 | Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60. |
| 1060 | Rorick-Kehn LM, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44. |
| 1061 | Jackson KJ, et al. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302on nicotine withdrawal in mice. Neuropharmacology. 2015 Oct;97:270-4. |
| 1062 | Wu D, et al. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat Chem Biol. 2019 Feb 25. |
| 1063 | Yue EW, et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem. 2009 Dec 10;52(23):7364-7. |
| 1064 | Huang X, et al. Synthesis of [(18) F] 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L): a novel potential PET probe for imaging of IDO1 expression. J Labelled Comp Radiopharm. 2015 Apr;58(4):156-62. |
| 1065 | Rahimian R, et al. Tropisetron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats. Eur J Clin Invest. 2013 Oct;43(10):1039-51. |
| 1066 | Swartz MM, et al. Tropisetron as a neuroprotective agent against glutamate-induced excitotoxicity and mechanisms of action. Neuropharmacology. 2013 Oct;73:111-21. |
| 1067 | Aminian A, et al. Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis. Neuroscience. 2013 Jun 15;248C:299-306. |
| 1068 | Rahimian R, et al. Tropisetron upregulates cannabinoid CB1 receptors in cerebellar granule cells: possible involvement of calcineurin. Brain Res. 2011 Oct 12;1417:1-8. |
| 1069 | Expert Opin Pharmacother 4:1157 (2003) |
| 1070 | J Pharmacol Exp Therap 81:116 (1944) |
| 1071 | Bodur E, et al. Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase. Arch Biochem Biophys. 2001 Feb 1;386(1):25-9. |
| 1072 | Allikmets LH, et al. Dissimilar influences of imipramine, benactyzine and promazine on effects of micro-injections ofnoradrenaline, acetylcholine and serotonin into the amygdala in the cat. Psychopharmacologia. 1969;15(5):392-403. |
| 1073 | Brezak MC, et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res. 2004 May 1;64(9):3320-5. |
| 1074 | Sha HH, et al. 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound. Biosci Rep. 2018 Feb 13;38(1). pii: BSR20171440. |
| 1075 | Filomeni G, et al. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther. 2008 Feb;7(2):371-9. |
| 1076 | Pellizzari Tregno F, et al. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma. Eur J Cancer. 2009 Sep;45(14):2606-17. |
| 1077 | Yea CM, et al. New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists. J Med Chem. 2008 Dec 25;51(24):8124-34. |
| 1078 | Eur J Pharmacol 10:131 (1970); Carcinogenesis 8:881 (1987) |
| 1079 | Wehn PM, et al. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem. 2018 Nov 8;61(21):9691-9721. |
| 1080 | Schmitt DM, et al. The use of resazurin as a novel antimicrobial agent against Francisella tularensis. Front Cell Infect Microbiol. 2013 Dec 6;3:93. |
| 1081 | Srimal RC,et al. Pharmacological studies on 2-(2-(4-(3-methylphenyl)-1-piperazinyl)ethyl) quinoline (centhaquin). I. Hypotensive activity.Pharmacol Res. 1990 May-Jun;22(3):319-29. |
| 1082 | Papalexopoulou K, et al. Centhaquin Effects in a Swine Model of Ventricular Fibrillation: Centhaquin and Cardiac Arrest.Heart Lung Circ. 2017 Aug;26(8):856-863. |
| 1083 | Antimicrob Agents Chemother 10:426 (1976); 19:625, 20:648 (1981)| |
| 1084 | Campoli-Richards DM, et al. Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1987 Oct;34(4):411-37. |
| 1085 | Myers JF, et al. Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans. J Cereb Blood Flow Metab. 2016 Jul 27 |
| 1086 | Zhang X, et al. Discovery of Novel Hepatitis B Virus Nucleocapsid Assembly Inhibitors. ACS Infect Dis. 2019 May 10;5(5):759-768. |
| 1087 | Wang P, et al. The Design and Synthesis of N-Xanthone Benzenesulfonamides as Novel Phosphoglycerate Mutase 1 (PGAM1) Inhibitors. Molecules. 2018 Jun 8;23(6). pii: E1396. |
| 1088 | Omar MA, et al. Utility of ninhydrin reagent for spectrofluorimetric determination of heptaminol in human plasma.Luminescence. 2018 Sep;33(6):1107-1112. |
| 1089 | Anantharaman S, et al. Ninhydrin-sodium molybdate chromogenic analytical probe for the assay of amino acids and proteins.rSpectrochim Acta A Mol Biomol Spectrosc. 2017 Feb 15;173:897-903. |
| 1090 | Medina-Rodríguez EM, et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep. 2017 Mar 3;7:43545. |
| 1091 | Riendeau D, et al.Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001 Feb;296(2):558-66. |
| 1092 | Kunak CS, et al. The Effect of Etoricoxib on Hepatic Ischemia-Reperfusion Injury in Rats. Oxid Med Cell Longev. 2015;2015:598162. |
| 1093 | Tanwar L, et al. Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis. Asian Pac J Cancer Prev. 2010;11(5):1329-33. |
| 1094 | Attia RT, et al. The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells. PeerJ. 2016 Jun 29;4:e2168. |
| 1095 | Che CL, et al. DNA microarray reveals different pathways responding to NSC 125973 and docetaxel in non-small cell lung cancer cell line. Int J Clin Exp Pathol. 2013 Jul 15;6(8):1538-48. |
| 1096 | Obi-Ioka Y, et al. Involvement of Wee1 in the circadian rhythm dependent intestinal damage induced by docetaxel. J Pharmacol Exp Ther. 2013 Oct;347(1):242-8. |
| 1097 | Li C, et al. Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. J Pharm Biomed Anal. 2016 Sep 5;128:286-93. |
| 1098 | Antimicrob Agents Chemother 11:852 (1977); 12:406 (1977); Lancet 1:620 (1980) |
| 1099 | Waaler J, et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res. 2011 Jan 1;71(1):197-205. |
| 1100 | Stratford EW, et al. The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med. 2014 Feb;3(1):36-46. |
| 1101 | Clin Toxicol 4:185 (1971); Drug Saf 28:89 (2005) |
| 1102 | Kim JW, et al. Triterpenoid Saponins Isolated from Platycodon grandiflorum Inhibit Hepatitis C Virus Replication. Evid Based Complement Alternat Med. 2013;2013:560417. |
| 1103 | Wang L, et al. Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death. Cancer Cell. 2015 Aug 10;28(2):240-52. |
| 1104 | Biochem Pharmacol 65:1741 (2003) |
| 1105 | Yu W, et al. Cyclosporine A Suppressed Glucose Oxidase Induced P53 Mitochondrial Translocation and Hepatic Cell Apoptosis through Blocking Mitochondrial Permeability Transition. Int J Biol Sci. 2016 Jan 1;12(2):198-209. |
| 1106 | Hoagland MS, et al. The p53 Inhibitor Pifithrin-α Is a Potent Agonist of the Aryl Hydrocarbon Receptor. J Pharmacol Exp Ther. 2005 Aug;314(2):603-10. |
| 1107 | Kuang SQ, et al. FOXE3 mutations predispose to thoracic aortic aneurysms and dissections. J Clin Invest. 2016 Mar 1;126(3):948-61. |
| 1108 | Ding YH, et al. Increasing the Depth of Mass-Spectrometry-Based Structural Analysis of Protein Complexes through the Use of Multiple Cross-Linkers. Anal Chem. 2016 Apr 19;88(8):4461-9. |
| 1109 | De Miranda BR, et al. The Nurr1 Activator 1,1-Bis(3'-Indolyl)-1-(p-Chlorophenyl)Methane Blocks Inflammatory Gene Expression in BV-2 Microglial Cells by Inhibiting Nuclear Factor κB. Mol Pharmacol. 2015 Jun;87(6):1021-34. doi: 10.1124/mol.114.095398. Epub 2015 Apr 9. |
| 1110 | Hammond SL, et al. A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro. Neurosci Lett. 2015 Oct 21;607:83-9. |
| 1111 | Zheng J, et al. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. 2013 Aug 9;288(32):23447-56. |
| 1112 | Sy SK, et al. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in drug-resistant pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2015 May 11. pii: AAC.04049-14. |
| 1113 | J Pharm Exp Therap 49:50 (1933); Ann Surg 103:535 (1936) |
| 1114 | Jean R. Rapin, et al. In vitro and in vivo effects of an extract of Ginkgo biloba (EGb 761), ginkgolide B, and bilobalide on apoptosis in primary cultures of rat hippocampal neurons. Drug Development Research, 1998, 45 (1):1-43 |
| 1115 | Matyas Koltai, et al. Ginkgolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion. European Journal of Pharmacology, 1989, 164 (2): 293-302 |
| 1116 | Am J Therapeutics 4:159 (1997); Pharmacotherapy 26:748 (2006) |
| 1117 | Sehon CA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem. 2008 Nov 13;51(21):6631-4. |
| 1118 | https://clinicaltrials.gov/ct2/show/NCT04738045?term=Lopinavir&recrs=abdef&cond=Covid19&draw=2&rank=1 |
| 1119 | Chen JK, et al. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6. |
| 1120 | Stanton BZ, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol. 2009 Mar;5(3):154-6. |
| 1121 | Lee S, et al. Combining Smoothened Agonist (SAG) and NEL-like protein-1 (NELL-1) Enhances Bone Healing. Plast Reconstr Surg. 2017 Feb 13 |
| 1122 | Fish EW, et al. Preaxial polydactyly following early gestational exposure to the smoothened agonist, SAG, in C57BL/6J mice. Birth Defects Res A Clin Mol Teratol. 2016 Nov 1 |
| 1123 | Guerrini G, et, al. Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration. J Cell Physiol. 2018 Dec; 233(12): 9799-9811. |
| 1124 | Pharmacol Toxicol USSR 54: 35 (1991); J Gen Chem 33: 2663 (1963) |
| 1125 | Cersosimo RJ, et al. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425-39. |
| 1126 | Ozkan, A., et al. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol, 2004. 56(4): p. 435-44. |
| 1127 | Bonadonna, G., et al. Drugs ten years later: epirubicin. Ann Oncol, 1993. 4(5): p. 359-69. |
| 1128 | Asanuma, F., et al. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27. Folia Microbiol (Praha), 1998. 43(5): p. 473-4. |
| 1129 | Kashima H, et al. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016 Jun 10;11(6):e0156643. |
| 1130 | Drugs 35:143 (1988); J Am Acad Dermatol 21:686 (1989) |
| 1131 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=QUININE&cntry=&state=&city=&dist=&Search=Search |
| 1132 | Schiedel M, et al. Structure-Based Development of an Affinity Probe for Sirtuin 2. Angew Chem Int Ed Engl. 2016 Feb 5;55(6):2252-6. |
| 1133 | Drugs (1978), 15(1), 33-52; Arzneim. Forsch. (1974), 24(10), 1633-6; J. Med. Chem. (1973), 16(7), 782-6 |
| 1134 | Schepetkin IA, et al. Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. Mol Pharmacol. 2012 Jun;81(6):832-45. |
| 1135 | Ji-Hye Kim, et al. Identification of a Novel SIRT7 Inhibitor as Anticancer Drug Candidate. Biochem Biophys Res Commun. 2019 Jan 8;508(2):451-457. |
| 1136 | Kozhikhova KV, et al. Preparation of chitosan-coated liposomes as a novel carrier system for the antiviral drug Triazavirin. Pharm Dev Technol. 2018 Apr;23(4):334-342. |
| 1137 | Loginova SIa, et al. Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture. Antibiot Khimioter. 2014;59(1-2):3-5. |
| 1138 | Loginova SY, et al. Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice. Antibiot Khimioter. 2015;60(7-8):11-3. |
| 1139 | Kyla. A. L. Collins, et al. Proteomic Analysis Defines Kinase Taxonomies Specific for Subtypes of Breast Cancer. Apr. 1, 2017. |
| 1140 | Felix S. Oppermann, et al. Large-scale Proteomics Analysis of the Human Kinome. Mol Cell Proteomics. 2009 Jul; 8(7): 1751-1764. |
| 1141 | Antimicrob Agents Chemother 13:784 (1978); 21:344 (1982) |
| 1142 | Zeitlin BD, et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res. 2006 Sep 1;66(17):8698-706. |
| 1143 | Mohammad RM, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res. 2007 Apr 1;13(7):2226-35. |
| 1144 | van Breemen RB, et al. Cyclooxygenase-2 inhibitors in ginger (Zingiber officinale). Fitoterapia. 2011 Jan;82(1):38-43. |
| 1145 | Keum YS, et al. Induction of apoptosis and caspase-3 activation by chemopreventive |
| 1146 | -paradol and structurally related compounds in KB cells. Cancer Lett. 2002 Mar 8;177(1):41-7. |
| 1147 | Gaire BP, et al. Neuroprotective effect of 6-paradol in focal cerebral ischemia involves the attenuation of neuroinflammatory responses in activated microglia. PLoS One. 2015 Mar 19;10(3):e0120203. |
| 1148 | Setoguchi S, et al. Pharmacokinetics of Paradol Analogues Orally Administered to Rats. J Agric Food Chem. 2016 Mar 9;64(9):1932-7. |
| 1149 | Battram, C., et al., In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-o ne (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther, 2006. 317(2): p. 762-70. |
| 1150 | Sturton, R.G., et al., Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther, 2008. 324(1): p. 270-5. |
| 1151 | Shinichi Oda*, et al. Development of an Optimized Synthetic and Purification Process of S-2367 (Velneperit), a Novel Neuropeptide Y (NPY) Y5 Receptor Antagonist. Org. Process Res. Dev., 2015, 19 (4), pp 531-536. |
| 1152 | Jon E Hawkinson, et al. Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2). ChemMedChem. 2017 Nov 22;12(22):1857-1865. |
| 1153 | Peterson L.G. Tricyclazole for Control of Pyricularia Oryzae on Rice: the Relationship of the Mode of Action and Disease Occurrence and Development. Pest Management in Rice. Springer, Dordrecht. |
| 1154 | G.Lazarovits, et al. Tricyclazole induces melanin shunt products and inhibits altersolanol a accumulation by Alternaria solani. Pesticide Biochemistry and Physiology |
| 1155 | J Am Chem Soc 71: 4158 (1955); Nature Medicine 16:279 (2010); Proc Natl Acad Sci 107:19961 (2010) |
| 1156 | Flaveny CA, et al. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell. 2015 Jun 24. pii: S1535-6108(15)00183-X. |
| 1157 | Smith SM, et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 2013 Jan;64:215-23. |
| 1158 | Vardigan JD, et al. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology (Berl). 2016 Jul;233(13):2441-50. |
| 1159 | Xie CI, et al. Daidzin, an antioxidant isoflavonoid, decreases blood alcohol levels and shortens sleep time induced by ethanol intoxication. Alcohol Clin Exp Res. 1994 Dec;18(6):1443-7. |
| 1160 | Keung WM, et al. Kudzu root: an ancient Chinese source of modern antidipsotropic agents. Phytochemistry. 1998 Feb;47(4):499-506. |
| 1161 | Keung WM, et al. Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1675-9. |
| 1162 | Moon TC, et al. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res. 1999 Dec;48(12):621-5. |
| 1163 | Lee SH, et al. Progress in the studies on rutaecarpine. Molecules. 2008 Feb 6;13(2):272-300. |
| 1164 | Jeon TW, et al. Immunosuppressive effects of rutaecarpine in female BALB/c mice.
 Toxicol Lett. 2006 Jul 1;164(2):155-66. |
| 1165 | Ke Y, et al. Scutellarin suppresses migration and invasion of human hepatocellular carcinoma by inhibiting the STAT3/Girdin/Akt activity. Biochem Biophys Res Commun. 2016 Dec 18. pii: S0006-291X(16)32174-X |
| 1166 | Yang LL, et al. Differential regulation of baicalin and scutellarin on AMPK and Akt in promoting adipose cell glucose disposal. Biochim Biophys Acta. 2016 Nov 27;1863(2):598-606. |
| 1167 | Wu CY, et al. Scutellarin attenuates microglia-mediated neuroinflammation and promotes astrogliosis in cerebral ischemia - a therapeutic consideration. Curr Med Chem. 2016 Nov 18. [Epub ahead of print] |
| 1168 | Li Q, et al. Scutellarin attenuates vasospasm through the Erk5-KLF2-eNOS pathway after subarachnoid hemorrhage in rats. J Clin Neurosci. 2016 Dec;34:264-270 |
| 1169 | Zhao S, et al. Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-κB and MAPK signaling pathway. Int Immunopharmacol. 2016 Nov;40:458-465 |
| 1170 | Zhang GH, et al. The anti-HIV-1 effect of scutellarin. Biochem Biophys Res Commun. 2005 Sep 2;334(3):812-6. |
| 1171 | Guagnano V, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T |
| 1172 | Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42. |
| 1173 | Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369. |
| 1174 | Li Y, et al. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies. Xenobiotica. 2010 Nov;40(11):721-9. |
| 1175 | Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. |
| 1176 | San José-Enériz E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424. |
| 1177 | Miyachi H, et al. Synthesis and antimuscarinic activity of a series of 4-(1-Imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. Bioorg Med Chem. 1999 Jun;7(6):1151-61. |
| 1178 | Yamazaki T, et al. Imidafenacin has no influence on learning in nucleus basalis of Meynert-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol. 2013 Dec;386(12):1095-102. |
| 1179 | Luo Z, et al. Epigoitrin, an Alkaloid From Isatis indigotica, Reduces H1N1 Infection in Stress-Induced Susceptible Model in vivo and in vitro. Front Pharmacol. 2019 Feb 7;10:78. |
| 1180 | Xiao P, et al. Antiviral activities against influenza virus (FM1) of bioactive fractions and representative compounds extracted from Banlangen (Radix Isatidis). J Tradit Chin Med. 2016 Jun;36(3):369-76. |
| 1181 | Psychopharmacologica 12:142 (1968); Anal Profiles Drug Subs 18:527 (1989) |
| 1182 | JACS 47:2727 (1925); J Chromatography 39: 182 (1969); Am Rev Respir Dis 111:703 (1975); Tubercle 59:135 (1978) |
| 1183 | https://clinicaltrials.gov/ct2/show/NCT04348305?term=Hydrocortisone&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04456439?term=Hydrocortisone&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT02735707?term=Hydrocortisone&cond=COVID-19&draw=2&rank=8 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20120215009014N354 https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN67000769 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20120215009014N354 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT02517489 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04348305 |
| 1184 | Abd-Alla, H. I.,et al. New bioactive compounds from <i>Aloe hijazensis</i>. Natural Product Research,2009,23(11), 1035–1049. |
| 1185 | Drugs 29:531 (1985); Am Heart J 109:1211 (1985) |
| 1186 | Biochem J 5:243 (1911); J Physiol 45:1 (1914); Acta Pharmacol Toxicol 10:338 (1954) |
| 1187 | Br J Opthalmol77:136 (1993); J Wilderness Med 5:34 (1994) |
| 1188 | Atta-ur-Rahman, et al. Bioactive constituents from Boswellia papyrifera. J Nat Prod. 2005 Feb;68(2):189-93. |
| 1189 | Wu TT, et al. β-Elemonic acid inhibits the cell proliferation of human lung adenocarcinoma A549 cells: The roleof MAPK, ROS activation and glutathione depletion. Oncol Rep. 2016 Jan;35(1):227-34. |
| 1190 | Kim YS, et al. Isolation of a new saponin and cytotoxic effect of saponins from the root of Platycodon grandiflorum on human tumor cell lines. Planta Med. 2005 Jun;71(6):566-8. |
| 1191 | Lain S, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. |
| 1192 | Jifei Miao, et al. Nuclear HMGB1 promotes the phagocytic ability of macrophages. Exp Cell Res. 2020 Aug 1;393(1):112037. |
| 1193 | https://clinicaltrials.gov/ct2/show/NCT04978051?term=Icatibant&cond=COVID-19&draw=2&rank=1 |
| 1194 | Evelyn CR, et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72. |
| 1195 | Jin W, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar;121(3):918-29. |
| 1196 | Chong NW, et al. STARS is essential to maintain cardiac development and function in vivo via a SRF pathway. PLoS One. 2012;7(7):e40966. |
| 1197 | Duggirala A, et al. cAMP-induced actin cytoskeleton remodelling inhibits MKL1-dependent expression of the chemotactic and pro-proliferative factor, CCN1. J Mol Cell Cardiol. 2014 Nov 18;79C:157-168. |
| 1198 | Sharma VK, et al. Chemoenzymatic convergent synthesis of 2'-O,4'-C-methyleneribonucleosides. J Org Chem. 2014 Jul 3;79(13):6336-41. |
| 1199 | Marek L, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56(2):427-36. |
| 1200 | Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2016 Jun 21;7(25):37966-37978. |
| 1201 | Trazzi S, et al. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Hum Mol Genet. 2016 Sep 15;25(18):3887-3907. |
| 1202 | J Chem Soc 87:145 (1905); J Soc Chem Ind 37:288 (1918)| |
| 1203 | Nihal Doğruöz Güngör, et al. Evaluation of bacterial resistance to Chloramine T Biocide and effects on Rifampicin Antibiotic Susceptibility as a consequence of biocide usage in Cooling System Biofilm including Legionella pneumophila. The Battle Against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs. |
| 1204 | J. Int. Med. Res. (1981), 9(1), 79-81; Science (1977), 197(4307), 994-6; J. Int. Med. Res. (1976), 4(6), 454-61 |
| 1205 | Borroto A, et al. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med. 2016 Dec 21;8(370):370ra184. |
| 1206 | Kang MS, et al. Inhibitory effect of methyl gallate and gallic acid on oral bacteria. J Microbiol. 2008 Dec;46(6):744-50. |
| 1207 | Hsieh TJ, et al. Protective effect of methyl gallate from Toona sinensis (Meliaceae) against hydrogen peroxide-induced oxidative stress and DNA damage in MDCK cells. Food Chem Toxicol. 2004 May;42(5):843-50. |
| 1208 | Lee H, et al. Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells. J Immunol. 2010 Dec 1;185(11):6698-705. |
| 1209 | Wang CR, et al. First report on isolation of methyl gallate with antioxidant, anti-HIV-1 and HIV-1 enzyme inhibitory activities from a mushroom (Pholiota adiposa). Environ Toxicol Pharmacol. 2014 Mar;37(2):626-37. |
| 1210 | Warner Lambert, et al. Some Neurochemical Properties of Pramiracetam (CI-879), A New Cognition-Enhancing Agent. |
| 1211 | Chang T, et al. Pharmacokinetics of oral pramiracetam in normal volunteers. J Clin Pharmacol. 1985 May-Jun;25(4):291-5. |
| 1212 | Deng C, et al. The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB. Clin Cancer Res. 2015 Jan 1;21(1):134-45. |
| 1213 | Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999 Apr 2;274(14):9587-99. |
| 1214 | van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13. |
| 1215 | "Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2017 Nov 15. " |
| 1216 | Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14. Epub 2006 Oct 26. |
| 1217 | Ocasio CA, et al. A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct. Oncotarget. 2016 Nov 1;7(44):71182-71197. |
| 1218 | J Biol Chem 267:8123 (!992); J Lab Clin Med 143:143 (2004) |
| 1219 | Ber 56: 2556 (1923); JACS 88: 2053 (1966); Tetrahedron 24: 2707 (1968); J Chem Soc 1984: 1035,1043 |
| 1220 | Zhang T, et al. Discovery of Potent and Selective Covalent Inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54. |
| 1221 | Wu W, et al. Divalent metal-ion transporter 1 is decreased in intestinal epithelial cells and contributes to the anemia in inflammatory bowel disease. Sci Rep. 2015 Nov 17;5:16344. |
| 1222 | J Pharmacol Exp Ther 275: 864 (1995) |
| 1223 | Adv Biochem Psychopharmacol 35:163 (1982); Drugs 25:451 (1983) |
| 1224 | Weiwen Liu, et al. Antitumor Activity and Mechanism of a Reverse Transcriptase Inhibitor, Dapivirine, in Glioblastoma. J Cancer. 2018 Jan 1;9(1):117-128. |
| 1225 | Bríd Devlin, et al. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013 Dec;100 Suppl:S3-8. |
| 1226 | Yven Van Herrewege, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother. 2004 Jan;48(1):337-9. |
| 1227 | Michael E Halwes, et al. Pharmacokinetic modeling of a gel-delivered dapivirine microbicide in humans. Eur J Pharm Sci. 2016 Oct 10;93:410-8. |
| 1228 | Peter S, et al. Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase. EMBO Mol Med. 2014 Dec;6(12):1525-41. |
| 1229 | Zhang, Qiang; Ma, Peng; Cole, Richard B.; Wang, Guangdi In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB2) in rat liver microsomes. European Journal of Pharmaceutical Sciences (2010), 41(1), 163-172. |
| 1230 | Klegeris, Andis; Bissonnette, Christopher J.; McGeer, Patrick L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. British Journal of Pharmacology (2003), 139(4), 775-786. |
| 1231 | New DC, Wong YH. BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett. 2003 Feb 11;536(1-3):157-60. |
| 1232 | Lyons ET, et, al. Haloxon: critical tests of antiparasitic activity in equids. Am J Vet Res. 1981 Jun;42(6):1043-5. |
| 1233 | Hart RJ, et, al. Cholinesterase activities of various nematode parasites and their inhibition by the organophosphate anthelmintic haloxon. Exp Parasitol. 1966 Jun;18(3):332-7. |
| 1234 | Tria GS, et al. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. J Med Chem. 2018 Apr 12;61(7):2837-2864. |
| 1235 | Zeng Z, et al. Arnebin-1 promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. Int J Mol Med. 2015 Sep;36(3):685-97. |
| 1236 | Sidhu GS, et al. Arnebin-1 accelerates normal and hydrocortisone-induced impaired wound healing. J Invest Dermatol. 1999 Nov;113(5):773-81. |
| 1237 | Arzneim Forsch 28:586. 605 (1978)| |
| 1238 | Michaelis M, et al. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Sci Rep. 2015 Feb 3;5:8202. |
| 1239 | Zhou X, et al. Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis. Cell Death Discov. 2018 Feb 14;4:18. |
| 1240 | Heil F, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97. |
| 1241 | Dzopalic T, et al. Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability. Int Immunopharmacol. 2010 Nov;10(11):1428-33. |
| 1242 | Pope BL, et al. In vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine). Int J Immunopharmacol. 1992 Nov;14(8):1375-82. |
| 1243 | Liu T, et al. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J Med Chem. 2012 Oct 25;55(20):8859-78. |
| 1244 | Lawrence NJ, et al. Cytotoxic Michael-type amine adducts of alpha-methylene lactones alantolactone and isoalantolactone. Bioorg Med Chem Lett. 2001 Feb 12;11(3):429-31. |
| 1245 | Khan M, et al. Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1 cells. Int J Biol Sci. 2012;8(4):533-47. |
| 1246 | Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27. |
| 1247 | Lin J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013 Apr 1;19(7):1760-72. |
| 1248 | Laraia L, et al. The cholesterol transfer protein GRAMD1A regulates autophagosome biogenesis. Nat Chem Biol. 2019 Jul;15(7):710-720. |
| 1249 | Acta Anaeth Scand 34:595 (1990); Chest c103:771 (1993) |
| 1250 | Liang QL, et al. [Structure modification on sesquiterpene lactones from Elephantopus scaber]. Yao Xue Xue Bao. 2007 Nov;42(11):1159-61. |
| 1251 | Hiradeve SM, et al. A review on pharmacology and toxicology of Elephantopus scaber Linn. Nat Prod Res. 2014;28(11):819-30. |
| 1252 | Spencer AG, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibitsNa+ uptake in humans. |
| 1253 | Connop BP et al.Novel effects of FCCP [carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone] on amyloid precursor protein processing. J Neurochem. 1999 Apr;72(4):1457-65. |
| 1254 | Tanpradit N, et al. Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) pre-exposure ensures follicle integrity during in vitro culture of ovarian tissue but not during cryopreservation in the domestic cat model. J Assist Reprod Genet. 2016 Dec;33(12):1621-1631. Epub 2016 Sep 17. |
| 1255 | Kondapalli C, et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2012 May;2(5):120080. |
| 1256 | Makoto Urai,et al. Potent Drugs That Attenuate anti-Candida Albicans Activity of Fluconazole and Their Possible Mechanisms of Action. J Infect Chemother. 2014 Oct;20(10):612-5. |
| 1257 | Wijtmans M, et al. Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem. 2012 May;51:184-92. |
| 1258 | Khan MS, et al. Design, synthesis, evaluation and thermodynamics of 1-substituted pyridylimidazo[1,5-a]pyridine derivatives as cysteine protease inhibitors. PLoS One. 2013 Aug 5;8(8):e69982. |
| 1259 | Toda G, et al. Calcium-activated neutral protease inhibitor (E-64c) and reperfusion for experimental myocardial infarction. Jpn Heart J. 1989 May;30(3):375-86. |
| 1260 | Radzey H, et al. E-64c-hydrazide: a lead structure for the development of irreversible cathepsin C inhibitors. ChemMedChem. 2013 Aug;8(8):1314-21. |
| 1261 | Ji Yeun Kim, et al. Safe, High-Throughput Screening of Natural Compounds of MERS-CoV Entry Inhibitors Using a Pseudovirus Expressing MERS-CoV Spike Protein. Int J Antimicrob Agents. 2018 Nov;52(5):730-732. |
| 1262 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=PREDNISOLONE+&cntry=&state=&city=&dist=&Search=Search |
| 1263 | Drugs Today (2003), 39(3), 157-74; Prog. Med. Chem. (1985), 21,111-135; Chemotherapy (1981), 27 Suppl 2, 107-20 |
| 1264 | https://clinicaltrials.gov/ct2/show/NCT04900129?term=Sodium+Salicylate&cond=covid&draw=2&rank=1 |
| 1265 | Nelson RM, et al.Electrophysiological actions of gamma-aminobutyric acid and clomethiazole on recombinant GABA(A) receptors.Eur J Pharmacol. 2002 Oct 11;452(3):255-62. |
| 1266 | Stresser DM, et al. Selective Time- and NADPH-Dependent Inhibition of Human CYP2E1 by Clomethiazole.Drug Metab Dispos. 2016 Aug;44(8):1424-30 |
| 1267 | Monica M. Mita, et al. A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors. Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 2577-2577. |
| 1268 | Hideshima T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10;277(19):16639-47. |
| 1269 | Vodanovic-Jankovic S, et al. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood. 2006 Jan 15;107(2):827-34. |
| 1270 | Oh-I S, et al. Central administration of interleukin-4 exacerbates hypothalamic inflammation and weight gain during high-fat feeding. Am J Physiol Endocrinol Metab. 2010 Jul;299(1):E47-53. |
| 1271 | Antimicrob Agents Chemother 13:536 (1978); J Antimicrob Chemother 6:113 (1980); J Pharmacol Exp Therap 226:226 (1983) |
| 1272 | Hong SW, et al. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis. 2013 Sep;34(9):2156-69. |
| 1273 | Son MK, et al. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Oncol Rep. 2013 Aug;30(2):801-8. |
| 1274 | Son MK, et al. SB365, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/mTOR signalling pathway. Food Chem. 2013 Jan 1;136(1):26-33. |
| 1275 | Yong Kim, et al. Pulsatilla saponin D: the antitumor principle from Pulsatilla koreana. Arch Pharm Res. 2004 Sep;27(9):915-8. |
| 1276 | Snowdy S, et al. A comparison of an A1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AVnodal conduction in guinea-pig. Br J Pharmacol. 1999 Jan;126(1):137-46. |
| 1277 | Fraser H, et al. N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside, an A1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats. J Pharmacol Exp Ther. 2003 Apr;305(1):225-31. |
| 1278 | Nibret E, et al. Biological activities of xanthatin from Xanthium strumarium leaves.Phytother Res. 2011 Dec;25(12):1883-90. |
| 1279 | Yu Y, et al. Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10355-64. |
| 1280 | Khuchtumur Bum-Erdene, et al. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction. Cell Chem Biol. 2019 Mar 21;26(3):378-389.e13. |
| 1281 | Ashford AL, et al. A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochem J. 2014 Jan 1;457(1):43-56. |
| 1282 | Chen H, et al. Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells. Oncotarget. 2017 Nov 28;9(17):13154-13166. |
| 1283 | Zhonghua Yi Xue Za Zhi 55:31 (1995) |
| 1284 | Jean Herman, et al. Autoimmune and inflammatory disorder therapy. From PCT Int. Appl. (2013), WO 2013034738 A1 |
| 1285 | Hooper AM, et al. Isoschaftoside, a C-glycosylflavonoid from Desmodium uncinatum root exudate, is an allelochemical against the development of Striga. Phytochemistry. 2010 Jun;71(8-9):904-8. |
| 1286 | Hamilton ML, et al. Elucidation of the biosynthesis of the di-C-glycosylflavone isoschaftoside, an allelopathic component from Desmodium spp. that inhibits Striga spp. development. Phytochemistry. 2012 Dec;84:169-76. |
| 1287 | Shu Shan Du, et al. Nematocidal flavone-C-glycosides against the root-knot nematode (Meloidogyne incognita) from Arisaema erubescens tubers. Molecules. 2011 Jun 20;16(6):5079-86. |
| 1288 | Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32. |
| 1289 | Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73. |
| 1290 | Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9. |
| 1291 | Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8. |
| 1292 | J Chem Soc 1959: 2679; 1963: 5573 |
| 1293 | Wenteng Chen, et al. CN128: A New Orally Active Hydroxypyridinone Iron Chelator. J Med Chem. 2020 Apr 23;63(8):4215-4226. |
| 1294 | https://clinicaltrials.gov/ct2/show/NCT04505098?term=Eicosapentaenoic+Acid&cond=Covid19&draw=2&rank=7 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001396-33-GB |
| 1295 | J Anim Sci 71:2439 (1993); 72:75 (1994) |
| 1296 | JACS 74:1868, 3455 (1992); Angewante Chemie Int Ed 4:846 (1965); Arzneim Forsch 20:1210 (1970) |
| 1297 | Langlois X, et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther. 2012 Jul;342(1):91-105. |
| 1298 | Ran X, et al. Farrerol Ameliorates TNBS-Induced Colonic Inflammation by Inhibiting ERK1/2, JNK1/2, and NF-κB Signaling Pathway. Int J Mol Sci. 2018 Jul 13;19(7). |
| 1299 | Cui B, et al. Farrerol attenuates β-amyloid-induced oxidative stress and inflammation through Nrf2/Keap1 pathway in a microglia cell line. Biomed Pharmacother. 2019 Jan;109:112-119. |
| 1300 | Dai F, et al. Farrerol inhibited angiogenesis through Akt/mTOR, Erk and Jak2/Stat3 signal pathway. Phytomedicine. 2016 Jun 15;23(7):686-93. |
| 1301 | Li B, et al. Farrerol overcomes the invasiveness of lung squamous cell carcinoma cells by regulating the expression of inducers of epithelial mesenchymal transition. Microb Pathog. 2019 Jun;131:277. |
| 1302 | Li Y, et al. Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-κB signaling pathways. Int Immunopharmacol. 2019 Oct;75:105739. |
| 1303 | Wang L, et al. Farrerol Ameliorates APAP-induced Hepatotoxicity via Activation of Nrf2 and Autophagy. Int J Biol Sci. 2019 Jan 29;15(4):788-799. |
| 1304 | JAMA 250:2469 (1983); J Environ Sci Health B28:413 (1993); Indian Vet J 74:565 (1997); |
| 1305 | Calamini B, et al. ML346: A Novel Modulator of Proteostasis for Protein Conformational Diseases.Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
 2012 Dec 17. |
| 1306 | Calamini B, et al. Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol. 2011 Dec 25;8(2):185-96. |
| 1307 | Sharif NA, et al. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol. 1994 Winter;10(4):653-64. |
| 1308 | Murota H, et al. Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67. |
| 1309 | Andoh T, et al. Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice. Eur J Pharmacol. 2000 Oct 6;406(1):149-52. |
| 1310 | Allen JE, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. |
| 1311 | Jimenez JM, et al. Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases. J Med Chem. 2013 Mar 14;56(5):1799-810. |
| 1312 | Kunitomo J, et al. Discovery of 1-[2-Fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a Highly Potent, Selective, and Orally Active Phosphodiesterase 10A (PDE10A) Inhibitor. J Med Chem. 2014 Nov 26;57(22):9627-43. |
| 1313 | Suzuki K, et al. In Vivo Pharmacological Characterization of TAK-063, a Potent and Selective Phosphodiesterase 10A Inhibitor with Antipsychotic-Like Activity in Rodents. J Pharmacol Exp Ther. 2014 Dec 18. pii: jpet.114.218552. |
| 1314 | Liou CJ, et al. Ginkgolide C Suppresses Adipogenesis in 3T3-L1 Adipocytes via the AMPK Signaling Pathway. Evid Based Complement Alternat Med. 2015;2015:298635. |
| 1315 | Ginkgolide C, et al. Ginkgolide C inhibits platelet aggregation in cAMP- and cGMP-dependent manner by activating MMP-9. Biol Pharm Bull. 2007 Dec;30(12):2340-4. |
| 1316 | Wood KW, et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5839-44. |
| 1317 | Mayes PA, et al. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E (CENP-E) inhibition. Int J Cancer. 2013 Feb 1;132(3):E149-57. |
| 1318 | Balamuth NJ, et al. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res. 2010 Apr 1;70(7):2749-58. |
| 1319 | Nguyen D, et al. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5. J Med Chem. 2019 Jan 24;62(2):928-940. |
| 1320 | Hatanaka H, Kino T, Miyata S, FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1988 Nov;41(11):1592-601. |
| 1321 | Teutsch M, Higer M, Wang D, Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin. Int Immunol. 1995 Mar;7(3):381-92. |
| 1322 | Mollison KW, Fey TA, Krause RA, Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models. Toxicology. 1998 Feb 6;125(2-3):169-81. |
| 1323 | Appel NM, et al. Dopamine D3 Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs. J Pharmacol Exp Ther. 2015 Sep;354(3):484-92. |
| 1324 | Micheli F, et al. 1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists. J Med Chem. 2010 Jan 14;53(1):374-91. |
| 1325 | Watahiki H, Yagishita S, Futai E, Ishiura S.CTF1-51, a truncated carboxyl-terminal fragment of amyloid precursor protein, suppresses the effects of Aβ42-lowering γ-secretase modulators.Neurosci Lett. 2012 Sep 27;526(2):96-9. Epub 2012 Aug 23. |
| 1326 | Wanngren J, Ottervald J, Parpal S, Portelius E, Str?mberg K, Borgeg?rd T, Klintenberg R, Juréus A, Blomqvist J, Blennow K, Zetterberg H, Lundkvist J, Rosqvist S, Karlstr?m H.Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.J Biol Chem. 2012 Jul 31. |
| 1327 | Wagner SL, Tanzi RE, Mobley WC, Galasko D.Potential Use of γ-Secretase Modulators in the Treatment of Alzheimer Disease.Arch Neurol. 2012 Jul 16:1-4. |
| 1328 | Bulic B, Ness J, Hahn S, Rennhack A, Jumpertz T, Weggen S.Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease.Curr Neuropharmacol. 2011 Dec;9(4):598-622. |
| 1329 | Kretner, Benedikt; Fukumori, Akio; Gutsmiedl, Amelie; Page, Richard M.; Luebbers, Thomas; Galley, Guido; Baumann, Karlheinz; Haass, Christian; Steiner, Harald. Attenuated A.beta.42 Responses to Low Potency .gamma.-Secretase Modulators Can Be Overcome for Many Pathogenic Presenilin Mutants by Second-generation Compounds. Journal of Biological Chemistry (2011), 286(17), 15240-15251. |
| 1330 | Swale DR, et al. An insecticide resistance-breaking mosquitocide targeting inward rectifier potassium channels in vectors of Zika virus and malaria. Sci Rep. 2016 Nov 16;6:36954. |
| 1331 | Nahoum V, et al. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17323-8. |
| 1332 | Bai A, et al. Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem. 2014 Dec 15;22(24):6933-44. |
| 1333 | Cameron KO, et al. Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy. J Med Chem. 2016 Sep 8;59(17):8068-81. |
| 1334 | Salatto CT, et al. Selective Activation of AMPK β1-Containing Isoforms Improves Kidney Function in a Rat Model of Diabetic Nephropathy. J Pharmacol Exp Ther. 2017 May;361(2):303-311. |
| 1335 | Hansen KB, et al. Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J Neurosci. 2011 Mar 9;31(10):3650-3661. |
| 1336 | Aneesh Sivaraman, et al. Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy. J Med Chem. 2020 May 28;63(10):5139-5158. |
| 1337 | J Chem Soc 1939:956; Biochem Syst Ecol 20:481 (1992) |
| 1338 | Ann Rev Biochem 20:441 (1951); Clin Pharmacol Ther 59:613 (1996) |
| 1339 | Robert Peery,et al. Synthesis and Identification of a Novel Lead Targeting Survivin Dimerization for Proteasome-Dependent Degradation. J Med Chem. 2020 Jun 9. |
| 1340 | Morinaga, A., et al., Effects of sex hormones on Alzheimer's disease-associated beta-amyloid oligomer formation in vitro. Exp Neurol, 2011. 228(2): p. 298-302. |
| 1341 | Begum, M., et al., Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice. Lab Invest, 2006. 86(3): p. 286-96. |
| 1342 | Hewitt, S.C. and K.S. Korach, Estrogenic activity of bisphenol A and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE) demonstrated in mouse uterine gene profiles. Environ Health Perspect, 2011. 119(1): p. 63-70. |JACS 76:2943 (1954); Biochem Prep 12:81 (1968); J Steroid Biochem 20:945 (1984) |
| 1343 | Liu G, et al. Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases. ACS Med Chem Lett. 2012 Sep 24;3(12):997-1002. |
| 1344 | Price GW, et, al. SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep; 356(3): 312-20. |
| 1345 | Geovanna NQ, et, al. Antinociceptive effect of (-)-epicatechin in inflammatory and neuropathic pain in rats. Behav Pharmacol. 2018 Apr; 29(2 and 3-Spec Issue): 270-279. |
| 1346 | Hagan JJ, et, al. Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. Eur J Pharmacol. 1997 Jul 23; 331(2-3): 169-74. |
| 1347 | Nitsch E, et al. Synergistic cytotoxic activity of treosulfan and LY 188011 in pancreatic cancer cell lines. Anticancer Res. 2014 Apr;34(4):1779-84. |
| 1348 | Peter T, et al. Programmed erythrocyte death following in vitro Treosulfan treatment. Cell Physiol Biochem. 2015;35(4):1372-80. |
| 1349 | Sjöö F, et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol. 2006 Jan;34(1):115-21. |
| 1350 | Rudolf K, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem. 2005 Sep 22;48(19):5921-31. |
| 1351 | Doods H, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000 Feb;129(3):420-3. |
| 1352 | Edvinsson L, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omentalarteries and in SK-N-MC cells. Eur J Pharmacol. 2002 Jan 2;434(1-2):49-53. |
| 1353 | Sixt ML, et al. Calcitonin gene-related peptide receptor antagonist Olcegepant acts in the spinal trigeminal nucleus. Brain. 2009 Nov;132(Pt 11):3134-41. |
| 1354 | Michot B, et al. Differential effects of calcitonin gene-related peptide receptor blockade by Olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat. Pain. 2012 Sep;153(9):1939-48. |
| 1355 | Ann 180:71 (1876); 230:225 (1885); J Chem Soc 127:1632 (1925) |
| 1356 | Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARα antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72. |
| 1357 | Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73. |
| 1358 | Khera AV, et al. Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36(43):3020-2. |
| 1359 | Vertosick FT Jr, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol. 1994;19(2):97-103. |
| 1360 | Morad SA, et al. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics. Biochim Biophys Acta. 2015 Jul;1851(7):919-28. |
| 1361 | Reddel RR,et al. N-desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in vitro. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1179-81. |
| 1362 | Yin Z, et al. Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab. 2012 Jul 1;303(1):E55-70. |
| 1363 | Botos I, et al. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2749-54. |
| 1364 | Hansen HP, et al. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int J Cancer. 2002 Mar 10;98(2):210-5. |
| 1365 | Giavazzi R, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998 Apr;4(4):985-92. |
| 1366 | Ricci S, et al. Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infect Dis. 2014 Dec 31;14:726. |
| 1367 | Russo LA, et al. Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus. Reprod Biol Endocrinol. 2009 Nov 4;7:124. |
| 1368 | J Am Vet Med Assoc 202:273 (1993) |
| 1369 | Park HJ, et al. 1-O-Hexyl-2,3,5-Trimethylhydroquinone Ameliorates l-DOPA-Induced Cytotoxicity in PC12 Cells. Molecules. 2019 Mar 1;24(5). pii: E867. |
| 1370 | Jung YR et al. Inhibitory Effect of 1-O-Hexyl-2,3,5-Trimethylhydroquinone on Dimethylnitrosamine-induced Liver Fibrosis in Male SD Rats. Toxicol Res. 2010 Sep;26(3):193-201. |
| 1371 | Hermes-Lima M, et al. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate. Biochim Biophys Acta. 2000 Oct 18;1523(2-3):154-60. |
| 1372 | Landschulz W, et al. A lipophilic iron chelator can replace transferrin as a stimulator of cell proliferation and differentiation. J Cell Biol. 1984 Feb;98(2):596-601. |
| 1373 | Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. |
| 1374 | Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004. |
| 1375 | Yie Y, et al. Ursolic acid inhibited growth of hepatocellular carcinoma HepG2 cells through AMPKα-mediated reduction of DNA methyltransferase 1. Mol Cell Biochem. 2014 Dec 30. |
| 1376 | Kim M, et al. The combination of ursolic acid and leucine potentiates the differentiation of C2C12 murine myoblasts through the mTOR signaling pathway. Int J Mol Med. 2015 Mar;35(3):755-62. |
| 1377 | Kim ES, et al. Ursolic acid inhibits the invasive phenotype of SNU-484 human gastric cancer cells. Oncol Lett. 2015 Feb;9(2):897-902. |
| 1378 | Li R, et al. Ursolic Acid Promotes Apoptosis of SGC-7901 Gastric Cancer Cells through ROCK/PTEN Mediated Mitochondrial Translocation of Cofilin-1. Asian Pac J Cancer Prev. 2014;15(22):9593-7. |
| 1379 | Hu Z, et al. Ursolic acid improves survival and attenuates lung injury in septic rats induced by cecal ligation and puncture. J Surg Res. 2014 Oct 22. pii: S0022-4804(14)00967-6. |Phytochemistry 10:3279 (1971); Cancer Lett 33:279 (1986) |
| 1380 | Purkey HE, et al. Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice. ACS Med Chem Lett. 2016 Aug 26;7(10):896-901. |
| 1381 | Biochem Pharmacol 50:1943 (1995); Cancer Chemother Pharmacol 40:376 (1997) |
| 1382 | Eur J Pharmacol 59:1 (1979); Arzneim Forsch 31:849 (1981); Drugs 35 Suppl 6:147 (1988) |
| 1383 | Murayama N, et al. SUN11602, a novel aniline compound, mimics the neuroprotective mechanisms of basic fibroblast growth factor. ACS Chem Neurosci. 2013 Feb 20;4(2):266-76. |
| 1384 | Murayama N, et al. SUN11602-induced hyperexpression of calbindin D-28k is pivotal for the survival of hippocampal neurons under neurotoxic conditions. Brain Res. 2015 Jan 12;1594:71-81. |
| 1385 | Ogino R, et al. SUN11602 has basic fibroblast growth factor-like activity and attenuates neuronal damage and cognitive deficits in a rat model of Alzheimer's disease induced by amyloid β and excitatory amino acids. Brain Res. 2014 Oct 17;1585:159-66. |
| 1386 | Sutherlin DP, et al. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem. 2010 Feb 11;53(3):1086-97. |
| 1387 | Nair MS, et al. Bioconversion of arteannuin B to artemisinin. J Nat Prod. 1993 Sep;56(9):1559-66. |
| 1388 | Ruiyuan Cao, et al. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro. RETURN TO JUST ACCEPTED MANUSCRIPTS. |
| 1389 | Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002. |
| 1390 | Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54. |
| 1391 | Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(1):120-7. |
| 1392 | Sousa LF, et al. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics (Sao Paulo). 2013;68(3):391-4. |
| 1393 | Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. |
| 1394 | Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016 Apr;75(4):721-9. |
| 1395 | Crespo J, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol. 2018 Jul 15;201(2):814-820. |
| 1396 | Villarino N, et al. Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli. Antimicrob Agents Chemother. 2012;56(8):4078-4086. |
| 1397 | Andersen NM, et al. Inhibition of protein synthesis on the ribosome by tildipirosin compared with other veterinary macrolides. Antimicrob Agents Chemother. 2012;56(11):6033-6036. |
| 1398 | Duquette SC, et al. Immunomodulatory effects of tulathromycin on apoptosis, efferocytosis, and proinflammatory leukotriene B4 production in leukocytes from Actinobacillus pleuropneumoniae-or zymosan-challenged pigs. Am J Vet Res. 2015;76(6):507-519. |
| 1399 | Curr Neurol Neurosci Reports 4:155 (2004); Sleep Med 10:661 (2009); J Clin Sleep Med 5:365 (2009) |
| 1400 | Terayama H, et al. Effect of acetamiprid on the immature murine testes. Int J Environ Health Res. 2018 Dec;28(6):683-696. |
| 1401 | Kong D, et al. Acetamiprid inhibits testosterone synthesis by affecting the mitochondrial function and cytoplasmic adenosine triphosphate production in rat Leydig cells. Biol Reprod. 2017 Jan 1;96(1):254-265. |
| 1402 | Drug Intell Clin Pharm 11:110 (1977); Clin Pediatr 16:901 (1977); Clin Toxicol 44:357 (2006)| |
| 1403 | Chen W, et al. Camphor--a fumigant during the Black Death and a coveted fragrant wood in ancient Egypt and Babylon--a review. Molecules. 2013 May 10;18(5):5434-54. |
| 1404 | Billen B, et al. Different ligands of the TRPV3 cation channel cause distinct conformational changes as revealedby intrinsic tryptophan fluorescence quenching. J Biol Chem. 2015 May 15;290(20):12964-74. |
| 1405 | Tran TA, et al. Camphor Induces Proliferative and Anti-senescence Activities in Human Primary Dermal Fibroblasts and Inhibits UV-Induced Wrinkle Formation in Mouse Skin. Phytother Res. 2015 Dec;29(12):1917-25. |
| 1406 | Crocker CE, et al. JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-hydroxydopamine Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Apr 20;2(4):207-212. |
| 1407 | Chambers JW, et al. Inhibition of JNK mitochondrial localization and signaling is protective against ischemia/reperfusion injury in rats. J Biol Chem. 2013 Feb 8;288(6):4000-11. |
| 1408 | Gao S, et al. Pharmacological Inhibition of c-Jun N-terminal Kinase Reduces Food Intake and Sensitizes Leptin's Anorectic Signaling Actions. Sci Rep. 2017 Feb 6;7:41795. |
| 1409 | Glover V, et al. Isatin: Identity with the Purified Endogenous Monoamine Oxidase Inhibitor Tribulin. Journal of Neurochemistry, 51(2), 656–659. |
| 1410 | Igosheva N, et al. Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells. Neurochem Int. 2005 Aug;47(3):216-24. |
| 1411 | McIntyre IM, et al. Serotonergic effects of isatin: an endogenous MAO inhibitor related to tribulin. J Neural Transm Gen Sect. 1990;79(1-2):35-40. |
| 1412 | Benned-Jensen T, et al. Ligand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist. J Biol Chem. 2011 Aug 19;286(33):29292-302. |
| 1413 | Shimada K, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol. 2016 Jul;12(7):497-503. |
| 1414 | Dixon SJ, et al. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol. 2015 Jul 17;10(7):1604-9. |
| 1415 | Burslem GM, et al. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation. Cancer Res. 2019 Jul 16. pii: canres.1236.2019. |
| 1416 | Mahameed M,et al. The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors. Cell Death Dis. 2019 Apr 1;10(4):300. |
| 1417 | Ghosh R, et al. Allosteric inhibition of the IRE1α RNase preserves cell viability and function during endoplasmic reticulum stress. Cell. 2014 Jul 31;158(3):534-48. |
| 1418 | Yallappa Rajashekar, et al. Acetylcholinesterase Inhibition by Biofumigant (Coumaran) From Leaves of Lantana Camara in Stored Grain and Household Insect Pests. Biomed Res Int. 2014;2014:187019. |
| 1419 | Paganelli FL, et al. Lipoteichoic acid synthesis inhibition in combination with antibiotics abrogates growth of multidrug-resistant Enterococcus faecium.Int J Antimicrob Agents. 2017 Mar;49(3):355-363. |
| 1420 | Lundgren, Karen., et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics (2009), 8(4), 921-929. |
| 1421 | B?ll B, et al. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin Cancer Res. 2009 Aug 15;15(16):5108-16. |
| 1422 | Yin X, et al. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 2010 Mar 1;126(5):1216-25 |
| 1423 | Zhang H, et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer. 2010 Mar 1;126(5):1226-34 |
| 1424 | Matsumoto K, et al. Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: behavioural and electrophysiological studies. Eur J Pharmacol. 2005 Jul 11;517(3):191-9. |
| 1425 | Cocco E, et al. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumoraggressiveness and target of KAT inhibitor CPTH2. Clin Epigenetics. 2018 Apr 4;10:44. |
| 1426 | Chimenti F, et al. A novel histone acetyltransferase inhibitor modulating Gcn5 network: cyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl)hydrazone. J Med Chem. 2009 Jan 22;52(2):530-6. |
| 1427 | Jacqueline Sayyah, Andrew Magis, David A. Ostrov, et al. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth . Mol Cancer Ther 2008;7(8):2308-18. |
| 1428 | Jacqueline Sayyah, Peter P. Sayeski. Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies. Current Oncology Reports. 2009, 11(2): 117-124. |
| 1429 | Ehab Atallah , Srdan Verstovsek . Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy. 2009,9 (5):663-670. |
| 1430 | Boll Chim Farm106:8 (1967); Anal Profiles Drug Subs 12:385 (1983) |
| 1431 | Silva KA, et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem. 2015 Apr 24;290(17):11177-87. |
| 1432 | Redell MS, et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011 May 26;117(21):5701-9. |
| 1433 | Bharadwaj U, et al. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016 May 3;7(18):26307-30. |
| 1434 | Zhang H, et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 2018 Nov 15;175(5):1244-1258.e26. |
| 1435 | Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31. |
| 1436 | Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61. |
| 1437 | Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25. |
| 1438 | Tuchman M, et al. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. Cancer Res. 1985 Nov;45(11 Pt 1):5553-6. |
| 1439 | Sensi M, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011 Dec;131(12):2448-57. |
| 1440 | Holland SJ, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010 Feb 15;70(4):1544-54. |
| 1441 | Lijnen HR, et al. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther. 2011 May;337(2):457-64. |
| 1442 | https://clinicaltrials.gov/ct2/show/NCT04816682?term=Silibinin&cond=covid-19&draw=2&rank=1 |
| 1443 | El-Halfawy OM, et al. Discovery of an antivirulence compound that reverses β-lactam resistance in MRSA. Nat Chem Biol. 2019 Nov 25. |
| 1444 | Chen M, et al. Effects of beta-adrenoceptor antagonists on Ca(2+)-overload induced by lysophosphatidylcholine in rat isolated cardiomyocytes. Br J Pharmacol. 1996 Jun;118(4):865-70. |
| 1445 | Hashizume H, et al. Effects of antiischemic drugs on veratridine-induced hypercontracture in rat cardiac myocytes. Eur J Pharmacol. 1994 Dec 12;271(1):1-8. |
| 1446 | Acta Med Scand 127:471 (1947); Renal Physiol 237:F291 (1979); J Pharmacol Exp Therap 283:1018 (1997) |
| 1447 | Jerry Leroy Adams, et al. 5-sulfamoyl-2-hydroxybenzamide derivatives. WO 2017153952 A1. |
| 1448 | Mamun-Ur Rashid, et al. In vitro activity of MCB3681 against Clostridium difficile strains. Anaerobe 28 (2014) 216-219. |
| 1449 | Mitani Y, et al. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012 Feb 8;32(6):2037-50. |
| 1450 | Elvang AB, et al. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem. 2009 Sep;110(5):1377-87. |
| 1451 | Justice NJ, et al. Posttraumatic stress disorder-like induction elevates β-amyloid levels, which directly activates corticotropin-releasing factor neurons to exacerbate stress responses. J Neurosci. 2015 Feb 11;35(6):2612-23. |
| 1452 | Portelius E, et al. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis. 2010;21(3):1005-12. |
| 1453 | Zhang L, et al. Mechanism of 2,3-butanediol stereoisomers formation in a newly isolated Serratia sp. T241. Sci Rep. 2016 Jan 12;6:19257. |
| 1454 | Clausen DM, et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther. 2010 Dec;335(3):715-27. |
| 1455 | Chauhan J, et al. Discovery of methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization. ChemMedChem. 2014 Oct;9(10):2274-85. |
| 1456 | Yap JL, et al. Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorg Med Chem Lett. 2013 Jan 1;23(1):370-4. |
| 1457 | J Biol Chem 192:569 (1951); Proc Natl Acad Sci 66:500 (1970); J Neurobiol 2:153 (1971) |
| 1458 | Bradwejn J, et al. Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-inducedactivation of hippocampal pyramidal neurons: a microiontophoretic study in the rat. Eur J Pharmacol. 1985 Jun 19;112(3):415-8. |
| 1459 | Debonnel G, et al. Pipequaline acts as a partial agonist of benzodiazepine receptors: an electrophysiological study in the hippocampus of the rat. Neuropharmacology. 1987 Sep;26(9):1337-42. |
| 1460 | Toxicol Appl Pharmacol 18:185 (1971); Anal Profiles Drug Subs 12:357 (1983) |
| 1461 | Am. J. Cardiol. (1965), 16(6), 841-6; Arzneim. Forsch. (1962), 12, 902-7; J. Am. Med. Assoc. (1959), 169(15), 1742-7 |
| 1462 | Arch Derm Syphilol 58:56 (1948); 67:479 (1953) |
| 1463 | http://www.ncbi.nlm.nih.gov/pubmed/10821781 |
| 1464 | Roberts C, et al. The effect of SB-269970, a 5-HT(7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. Br J Pharmacol. 2001 Apr;132(7):1574-80. |
| 1465 | Monti JM, et al. The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res. 2008 Aug 22;191(2):184-9. |
| 1466 | Nat. Rev. Neurol. (2010), 6(8), 420-421; CNS Drug Rev. (2007), 13(2), 224-239; Epilepsia (1964), 583-9 |
| 1467 | Hatzelmann A, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. |
| 1468 | Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53-67. |
| 1469 | Hatzelmann A, et al. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001 Apr;297(1):267-79. |
| 1470 | Richmond BW, et al. Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. Nat Commun. 2016 Apr 5;7:11240. |
| 1471 | Ding H, et al. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. Int Urol Nephrol. 2017 Jul 29. |
| 1472 | Verstovsek S, et al. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res, 2008, (3), 788-796. |
| 1473 | Hatiboglu MA, et al. The tumor microenvironment expression of p-STAT3 influences the efficacy of WP1066 in murine melanoma models. Int J Cancer, 2012, 131(1), 8-17 |
| 1474 | Ferrajoli A, et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res, 2007, 67(23), 11291-11299. |
| 1475 | Daigle SR, et al. Potent inhibition of DOT1L as treatment for MLL-fusion leukemia. Blood. 2013 Jun 25. [Epub ahead of print] |
| 1476 | Klaus CR, et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014 Sep;350(3):646-56. |
| 1477 | Smith GF, et al. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2721-2726. |
| 1478 | Chen BK, et al. Prophylactic efficacy of 5-HT4R agonists against stress. Neuropsychopharmacology. 2019 Oct 10. |
| 1479 | Grimwood S, et al. Translational receptor occupancy for the 5-HT4 partial agonist PF-04995274 in rats, non-human primates and healthy volunteers. Alzheimer’s Dement: J Alzheimer’s Assoc. 2011;7:S653. |
| 1480 | Timothy Nicholas1, et al. Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial. Advances in Alzheimer's Disease. Vol.2 No.3(2013). |
| 1481 | Martin LJ, et al. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Aug;13(8):568-80. |
| 1482 | Bordet T, et al. Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound. Pharmaceuticals (Basel). 2010 Jan 28;3(2):345-368 |
| 1483 | Bordet T, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007 Aug;322(2):709-20. |
| 1484 | Xiao WH, et al. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain. 2009 Dec 15;147(1-3):202-9 |
| 1485 | Sato H, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41. |
| 1486 | Shih DM, et al. Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice. FASEB J. 2013 Sep;27(9):3805-17. |
| 1487 | Sumaya IC, et al. Differential effects of a short-term high-fat diet in an animal model of depression in rats treated with the 5-HT3 receptor antagonist, ondansetron, the 5-HT3 receptor agonist, 2-methyl-5-HT, and the SSRI, fluoxetine. Pharmacol Biochem Behav. 2016 May;144:78-84. |
| 1488 | J Org Chem 16:1283 (1951); Acta Psychiatrica Scandinavica 81:162 (1990); J Pharmacy Pharmacol 47 :876 (1995) |
| 1489 | Qu XJ, et al. Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10. Anticancer Res. 2007 Jul-Aug;27(4B):2427-31. |
| 1490 | Nat. Prod. Comm. (2010), 5(12), 1999-2006; Curr. Bioact. Compd. (2006), 2(1), 57-66; Oral Surg., Oral Med., Oral Pathol. (1992), 73(6), 729-37 |
| 1491 | Gever JR, et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010 Jul;160(6):1387-1398. |
| 1492 | Munoz A, et al. Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3receptors. BJU Int. 2012 Oct;110(8 Pt B):E409-414. |
| 1493 | Piotr Wlaz, et al. Differential effects of glycine on the anticonvulsant activity of D-cycloserine and L-701,324 in mice. Pharmacological Reports 2011,63,1231-1234 |
| 1494 | Gabbita SP, et al. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. |
| 1495 | Cysewski P, et al. Theoretical description of the coding potential of diamino-5-formamidopyrimidines. Z Naturforsch C J Biosci. 1999 Mar-Apr;54(3-4):239-45. |
| 1496 | Lee SH, et al. A rapid and sensitive method for quantitation of nucleosides in human urine using liquid chromatography/mass spectrometry with direct urine injection. Rapid Commun Mass Spectrom. 2004;18(9):973-7. |
| 1497 | Periodic Reporting for period 1-AMPK-DIAB (A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes). |
| 1498 | J Chem Soc 1938:439; Biochem J 39:308 (1945) |
| 1499 | Chuang LF, et al. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochem Pharmacol. 1992 Feb 18;43(4):865-72. |
| 1500 | Wani MK, et al. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2000 Dec;110(12):2026-32. |
| 1501 | Hauge E, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol. 2012 Aug;167(2):288-95. |
| 1502 | Lee SY, et al. Vanillin attenuates negative effects of ultraviolet A on the stemness of human adipose tissue-derived mesenchymal stem cells. Food Chem Toxicol. 2016 Oct;96:62-9. |
| 1503 | Xu J, et al. Vanillin-induced amelioration of depression-like behaviors in rats by modulating monoamine neurotransmitters in the brain. Psychiatry Res. 2015 Feb 28;225(3):509-14. |
| 1504 | Zhang T, et al. A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nat Commun. 2018 Sep 13;9(1):3726. |
| 1505 | Halestrap AP. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem J. 1975 April; 148(1): 85-96. |
| 1506 | Wiemer EA, et al. The inhibition of pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei and its metabolic implications. Biochem J. 1995 Dec 1;312 ( Pt 2):479-84. |
| 1507 | Hinoi E, et al. A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35. Epub 2006 Jun 9. |
| 1508 | Patterson JN, et al. Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated secretion. J Biol Chem. 2014 May 9;289(19):13335-46. |
| 1509 | Zhong Y, et al. Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. Oncotarget. 2015 Nov 10;6(35):37758-69. |
| 1510 | Li WW, et al. Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo. J Med Chem. 2012 Apr 26;55(8):3852-66. |
| 1511 | Morand OH, et al. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997 Feb;38(2):373-90. |
| 1512 | Liang Y, et al. Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther. 2016 May 30;9:3223-32 |
| 1513 | Liang Y, et al. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat. 2014 Jul;146(1):51-62. |
| 1514 | Chuang JC, et al. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse. Biochem Pharmacol. 2014 Apr 1;88(3):351-63. |
| 1515 | J. Chem. Res. Synop. 1977: 154 |
| 1516 | Bymaster FP, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012 Jun;66(6):522-32. |
| 1517 | Baron BM, et al. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol. 1997 Apr 4;323(2-3):181-92. |
| 1518 | Butler KV, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc. 2010 Aug 11;132(31):10842-6. |
| 1519 | Hideshima T, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72. Epub 2005 Jun 3. |
| 1520 | Lu CY, et al. Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis. Int J Mol Sci. 2017 May 1;18(5). |
| 1521 | J Soc Chem Ind 53:956 (1934) |
| 1522 | Dowarah R, et al. Selection and characterization of probiotic lactic acid bacteria and its impact on growth, nutrient digestibility, health and antioxidant status in weaned piglets. PLoS One. 2018 Mar 8;13(3):e0192978. |
| 1523 | Zhang Y, et al. Baseline sensitivity and resistance risk assessmemt of Rhizoctonia cerealis to thifluzamide, a succinate dehydrogenase inhibitor. Pestic Biochem Physiol. 2015 Oct;124:97-102. |
| 1524 | Yang Y, et, al. Thifluzamide affects lipid metabolism in zebrafish (Danio reio). Sci Total Environ. 2018 Aug 15;633:1227-1236. |
| 1525 | Neil Anthony Pegg, et al. Pharmaceutical compounds. WO2018073586A1. |
| 1526 | Biochim Biophys Acta 201:453 !970); J Pharmacol Exp Therap 190:570 (1974); Trans IRE Professionsl Group 7:414 (2011) |
| 1527 | Eur J Pharmacol 57:107 (1979); 91:343 (1983; Am J Cardiol 51:1364 (1983) |
| 1528 | https://trialsearch.who.int/Trial2.aspx?TrialID=DRKS00021573; https://clinicaltrials.gov/ct2/results?cond=Covid19&term=PANTOPRAZOLE&cntry=&state=&city=&dist= |
| 1529 | Gen Pharmacol 30:639 (1998); Expert Opin Invest Drugs 11:117 (2002) |
| 1530 | Edouard Mullarky et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers
 Proc Natl Acad Sci U S A, 2016 Feb 16, 113(7):1778-83. |
| 1531 | Conroy MC, et al. Pharmacology, pharmacokinetics, and therapeutic use of meclofenamate sodium. Clin J Pain. 1991;7 Suppl 1:S44-8. |
| 1532 | Eleftheriou CG, et al. Meclofenamic acid improves the signal to noise ratio for visual responses produced by ectopicexpression of human rod opsin. Mol Vis. 2017 Jun 16;23:334-345. eCollection 2017. |
| 1533 | Huang Y, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015 Jan;43(1):373-84. |
| 1534 | Chem Abstracts 41: 4455 (1947); Eur J Pharmacol 177 215 (1990); Br J Pharmacol 124:386 (1998) |
| 1535 | Kazuki Yoshida, et al. P2X7 receptor antagonist activity of the anti-allergic agent oxatomide. Eur J Pharmacol. 2015 Nov 15;767:41-51. |
| 1536 | K Ohmori, et al. Pharmacological studies on oxatomide (KW-4354). (7) Antagonistic effects on chemical mediators. Nihon Yakurigaku Zasshi. 1983 May;81(5):399-409. |
| 1537 | Lin WH, et al. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br J Cancer. 2012 Jan 31;106(3):475-81. |
| 1538 | Chen CR et al. Gracillin induces apoptosis in HL60 human leukemic cell line via oxidative stress and cell cycle arrest of G1. Pharmazie. 2015 Mar;70(3):199-204. |
| 1539 | Harald Engelhardt, et al. New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors. |
| 1540 | Pyruvate kinase activators for use in therapy. WO2012151451A1. |
| 1541 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=L-Carnitine&cntry=&state=&city=&dist= |
| 1542 | Acta Cryst C 48:741 (1992) |
| 1543 | Kurtzberg LS, et al. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res. 2011 May 1;17(9):2777-87. |
| 1544 | Houghton PJ, et al. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Feb;58(2):200-9. |
| 1545 | Sooryakumar D, et al. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther. 2011 Aug;10(8):1490-9. |
| 1546 | Regul Toxicol Pharmacol 34:287 (2001); Cosmet Toiletries 118:47 (2003) |
| 1547 | Zaihui Zhang, et al. Heteropolycyclic inhibitors of protein kinases. US7196083B2. |
| 1548 | Woolley ML, et al. Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl). 2009 Jan;202(1-3):343-54. |
| 1549 | Wezenberg E, et al. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology. 2007 Jun;32(6):1272-83. |
| 1550 | https://clinicaltrials.gov/ct2/show/NCT03376854?term=Vecuronium&cond=Covid19&draw=2&rank=1 |
| 1551 | Fraser C, et al. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J Med Chem. 2016 May 26;59(10):4697-710. |
| 1552 | Scheuermann TH, et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol. 2013 Apr;9(4):271-6. |
| 1553 | Senavirathna LK, et al. Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling. Sci Rep. 2018 Feb 9;8(1):2709. |
| 1554 | Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation. 2018 Mar 1;15(1):64. |
| 1555 | Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092. |
| 1556 | Bello E, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. |
| 1557 | Colzani M, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteomics. 2014 Jun;13(6):1495-509. |
| 1558 | Bello E, et al. The tyrosine kinase inhibitor E-3810 combined with NSC 125973 inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther. 2013 Feb;12(2):131-40 |
| 1559 | J Pharmacol Exp Ther 58:337 (1936); Eur J Respir Dis 64 Suppl 128:417 (1983); Am J Opthalmol 107:7 (1989) |
| 1560 | Kim SH, et al. Icilin induces G1 arrest through activating JNK and p38 kinase in a TRPM8-independent manner. Biochem Biophys Res Commun. 2011 Mar 4;406(1):30-5. |
| 1561 | Frank J P Kühn, et al. Inhibition of TRPM8 by icilin distinct from desensitization induced by menthol and menthol derivatives. J Biol Chem. 2009 Feb 13;284(7):4102-11. |
| 1562 | Liang F, et al. Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteries. Can J Physiol Pharmacol. 2010 Aug;88(8):840-9. |
| 1563 | Frank Enseleit, et al. Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension. Ther Adv Cardiovasc Dis. 2010 Aug;4(4):231-40. |
| 1564 | H H Dao, et al. Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J Hypertens. 2001 Nov;19(11):1965-73. |
| 1565 | Pediatr Neurol 9:465 (1993); J Forensic Sci 40:382 (1995); Am J Psychiatry 155:1339 (1998); Int Clin Psychopharmacol 18:101 (2003) |
| 1566 | Tetrahedron Letters 1967:2737 |
| 1567 | Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. |
| 1568 | http://www.google.com/patents/WO2010022355A1cl=en |
| 1569 | Brendan T Freitas, et al. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS Infect Dis. 2020 May 19. |
| 1570 | O'Malley DP, et al. Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase. ACS Med Chem Lett. 2019 Sep 25;10(10):1486-1491. |
| 1571 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=FUROSEMIDE&cond=Covid19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04556864?term=FUROSEMIDE&cond=Covid19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04278404?term=FUROSEMIDE&cond=Covid19&draw=2&rank=4 |
| 1572 | Indian J Chem B 15:94 (1977) |
| 1573 | Kawaharada S, et al. ONO-8590580, a Novel GABAAα5 Negative Allosteric Modulator Enhances Long-Term Potentiation and Improves Cognitive Deficits in Preclinical Models. J Pharmacol Exp Ther. 2018 Jul;366(1):58-65. |
| 1574 | J Chem Soc 1939:925; Nat Prod Res 26:291 (2012) |
| 1575 | J Biol Chem 254:7558 (1979); 257:13704 (1982); Bone Marrow Transplant 30:135 (2002) |
| 1576 | ML418, et al. ML418: The First Selective, Sub-Micromolar Pore Blocker of Kir7.1 Potassium Channels. ACS Chem Neurosci. 2016 Jul 20;7(7):1013-23. |
| 1577 | Nijampatnam B, et al. Recent advances in the development of HBV capsid assembly modulators. Curr Opin Chem Biol. 2019 Jun;50:73-79. |
| 1578 | JAMA 282:1344 (1999); Drugs Aging 13:83 (1998) |
| 1579 | Tille JC, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basicfibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85. |
| 1580 | Daniel E. Jeffries, et al. Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy. ACS Med. Chem. Lett. 2019. |
| 1581 | Islam I, et al. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3819-25. |
| 1582 | Islam I, et al. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. |
| 1583 | Groth C, et al. Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP. Mol Pharmacol. 2010 Apr;77(4):567-74. |
| 1584 | Fuwa H, et al. Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors. ACS Chem Biol. 2007 Jun 15;2(6):408-18. |
| 1585 | Zheng YH, et al. Notch γ-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms. PLoS One. 2013 Dec 16;8(12):e83310. |
| 1586 | Xiao Z, et al. The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation. Int J Biochem Cell Biol. 2014 Oct;55:65-71. |
| 1587 | Xu F, et al. Beneficial health effects of lupenone triterpene: A review. Biomed Pharmacother. 2018 Jul;103:198-203. |
| 1588 | Xu F, et al. Lupenone is a good anti-inflammatory compound based on the network pharmacology. Mol Divers. 2019 Feb 22. |
| 1589 | Derenzini E, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011 Dec;1(12):e46. |
| 1590 | Scuto A, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011 Mar;25(3):538-50. |
| 1591 | McFarland BC, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 2011 Dec;10(12):2384-93. |
| 1592 | Xin H, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011 Nov 1;71(21):6601-10. |
| 1593 | Hedvat M, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-9 |
| 1594 | Ni J, et al. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 Jan;19(1):22-30. |
| 1595 | Chin Med J 113:948 (2000); Curr Opin Neurobiol. 11:327 (2001); Curr Opin Pharmacol 7: 39 (2007) |
| 1596 | Matthews R, et al. Tc-99m mebrofenin hepatobiliary scan in obstructive hepatobiliary disease: determining causes with early and late delayed imaging. World J Nucl Med. 2013 May;12(2):54-6. |
| 1597 | Morandi F, et al. Transsplenic portal scintigraphy using 99mTc-mebrofenin in normal dogs. Vet Radiol Ultrasound. 2007 May-Jun;48(3):286-91. |
| 1598 | de Graaf W, et al. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011 Apr;54(4):738-45. |
| 1599 | Zhu J, et al. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors. Eur J Med Chem. 2015;96:196-208. |
| 1600 | Jiewen Zhu, et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med. 2013 Mar;5(3):353-65. |
| 1601 | Maxime Rossi , Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010; 4: 291–297. |
| 1602 | Villa L, et al. Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters.Br J Pharmacol. 2013 May;169(1):230-8. |
| 1603 | Osman NI, et al.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Expert Opin Pharmacother. 2012 Oct;13(14):2085-96. |
| 1604 | Kawahara T, et al. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.Am J Cancer Res. 2015 Sep 15;5(10):2959-68. eCollection 2015. |
| 1605 | Expert Opin. Drug Metab. Toxicol. (2010), 6(8), 919-938; J. Med. Chem. (1974), 17(11), 1237-9; Chem. Pharm. Bull. (1977), 25(8), 1877-91 |
| 1606 | Teng X, Keys H, Jeevanandam A, Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6836-40. |
| 1607 | Jagtap PG, Degterev A, Choi S, Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007 Apr 19;50(8):1886-95. |
| 1608 | Teng X, Degterev A, Jagtap P, Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5039-44. |
| 1609 | Takahashi N, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012 Nov 29;3:e437. |
| 1610 | J. Pharm. Pharmacol. (1982), 34(6), 391-4; Acta Univ. Palacki. Olomuc., Fac. Med. (1973), 67, 155-92; Antidepressant Drugs, Proc. Int. Symp., 1st (1967), 208-16 |
| 1611 | Experientia 30:1265 (1974) |
| 1612 | Fraxin (50 mg/kg, p.o.) significantly blocks the CCl<sub>4</sub>-induced elevation of ALT and AST. Fraxin (10 and 50 mg/kg, p.o.) significantly reduces the GSSG levels (1.7±0.3 and 1.5±0.2 nM/g liver, respectively) compared with the GSSG levels of the CCl<sub>4</sub>-treated group<sup> |
| 1613 | </sup>. |
| 1614 | Whang WK, et al. Natural compounds,fraxin and chemicals structurally related to fraxin protect cells from oxidative stress. Exp Mol Med. 2005 Oct 31;37(5):436-46. |
| 1615 | Balmus G, et al. Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome. Nat Commun. 2018;9(1):1700. Published 2018 Apr 27. |
| 1616 | Liu H, et al. DNA damage induces N-acetyltransferase NAT10 gene expression through transcriptional activation. Mol Cell Biochem. 2007;300(1-2):249-258. |
| 1617 | Ma R, et al. Up regulation of NAT10 promotes metastasis of hepatocellular carcinoma cells through epithelial-to-mesenchymal transition. Am J Transl Res. 2016;8(10):4215-4223. Published 2016 Oct 15. |
| 1618 | Farrell DJ, et al. In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017 Feb 23;61(3). |
| 1619 | Biedenbach DJ, et al. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. |
| 1620 | O'Riordan W, et al. Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2017 May 24;61(6). |
| 1621 | So W, et al. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4956-61. |
| 1622 | Purich D. The Inhibitor Index A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons, Biologics, and Therapeutic Leads. ISBN 9781138739215 |
| 1623 | Wang Z, et al. Inhibition of H3K4 demethylation induces autophagy in cancer cell lines. Biochim Biophys Acta. 2017 Aug 8;1864(12):2428-2437. |
| 1624 | Bull Soc Chim France 4L1265 (1937); Phytochemistry 12:193 (1973); 13:1628 (1974); J Nat Prod 39:175,197 (1976); 45:277 (1982) |
| 1625 | Georgievska B, et al. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J Neurochem. 2013 May;125(3):446-56. |
| 1626 | Kraus JM, et al. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem. 2009 Mar 26;52(6):1639-47. |
| 1627 | Stellavato A, et al. Myclobutanil worsens nonalcoholic fatty liver disease: An in vitro study of toxicity and apoptosis on HepG2 cells. Toxicol Lett. 2016 Nov 16;262:100-104. |
| 1628 | Volberg T, et al. The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J. 1992 May;11(5):1733-42. |
| 1629 | Wessely O, et al. Distinct roles of the receptor tyrosine kinases c-ErbB and c-Kit in regulating the balance between erythroid cell proliferation and differentiation. Cell Growth Differ. 1997 May;8(5):481-93. |
| 1630 | Banerjee S, et al. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res. 2005 Mar;3(3):151-62. |
| 1631 | ARYL SULFONOHYDRAZIDES. WO 2013041119 A1. |
| 1632 | Halland N, et al. Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 Inhibitors. ACS Med Chem Lett. 2014 Oct 23;6(1):73-8. |
| 1633 | J Vet Med Sci 65:1275 (2003)| |
| 1634 | Chen Q, et al. Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food Chem Toxicol. 2009 Feb;47(2):328-34. |
| 1635 | Looft T, et al. Carbadox has both temporary and lasting effects on the swine gut microbiota. Front Microbiol. 2014 Jun 10;5:276. |
| 1636 | Lara E, et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009 Feb 12;28(6):781-91. |
| 1637 | Chen H, et, al. Metabolism of ginger component |
| 1638 | -shogaol in liver microsomes from mouse, rat, dog, monkey, and human. Mol Nutr Food Res. 2013 May;57(5):865-76. |
| 1639 | Zhu Y, et, al. Synthesis, evaluation, and metabolism of novel |
| 1640 | -shogaol derivatives as potent Nrf2 activators. Free Radic Biol Med. 2016 Jun;95:243-54. |
| 1641 | https://clinicaltrials.gov/ct2/show/NCT04706416?term=N-Acetyl-D-glucosamine&cond=covid&draw=2&rank=1 |
| 1642 | Floresta G, et al. Development of new HO-1 inhibitors by a thorough scaffold-hopping analysis. Bioorg Chem. 2018 Dec;81:334-339. |
| 1643 | Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. |
| 1644 | Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. |
| 1645 | Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102(4):755-764. |
| 1646 | Zhang L, et al. Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer. Autophagy. 2019 Mar;15(3):391-406. |
| 1647 | Shao S, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol. 2014 May;44(5):1661-1668. |
| 1648 | Xiao J, et al. Spautin-1 Ameliorates Acute Pancreatitis via Inhibiting Impaired Autophagy and Alleviating Calcium Overload. Mol Med. 2016 Aug 18;22. |
| 1649 | Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92. |
| 1650 | Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82. |
| 1651 | Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7. |
| 1652 | Southern Med J 50:1541 (1957) |
| 1653 | Wong KL, et al. Isosteviol acts on potassium channels to relax isolated aortic strips of Wistar rat. Life Sci. 2004 Mar 26;74(19):2379-87. |
| 1654 | Wong KL, et al. Isosteviol as a potassium channel opener to lower intracellular calcium concentrations in cultured aortic smooth muscle cells. Planta Med. 2004 Feb;70(2):108-12. |
| 1655 | Wong KL, et al. Antiproliferative effect of isosteviol on angiotensin-II-treated rat aortic smooth muscle cells. Pharmacology. 2006;76(4):163-9. |
| 1656 | Asad Ullah, et al. Bioactivity Profile of the Diterpene Isosteviol and its Derivatives. Molecules. 2019 Feb 14;24(4):678. |
| 1657 | Liang Y, et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio. 2013 Feb 5;4(1):e00558-12. |
| 1658 | McEachern KA, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy ofGaucher disease. Mol Genet Metab. 2007 Jul;91(3):259-68. |
| 1659 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Tofacitinib+&cntry=&state=&city=&dist=&Search=Search |
| 1660 | Luo C, et al. Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism. Mol Biol Rep. 2012 May;39(5):5459-64. |
| 1661 | Tan C, et al. Matrine induction of reactive oxygen species activates p38 leading to caspase-dependent cell apoptosis in non-small cell lung cancer cells. Oncol Rep. 2013 Nov;30(5):2529-35. |
| 1662 | Li X, et al. Regulation of endothelial nitric oxide synthase and asymmetric dimethylarginine by matrine attenuates isoproterenol-induced acute myocardial injury in rats. J Pharm Pharmacol. 2012 Aug;64(8):1107-18. |
| 1663 | Zhang B, et al. Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur J Pharm Sci. 2011 Dec 18;44(5):573-9. |J Nat Prod 44:236 (1981); J Agric Food Chem 39:189 (1991); J Forestry Res 17:323 (2006); Basic Clin Pharmacol Toxicol 107:906 (2010) |
| 1664 | Fr. (1969), FR 1581285 19690912 |
| 1665 | Skin Pharmacol 3:1 (1990); Clin Dermatol 15:723 (1997) |
| 1666 | https://clinicaltrials.gov/ct2/show/NCT04456439?term=PROMETHAZINE&cond=Covid19&draw=2&rank=1 |
| 1667 | Carney DW, et al. Structural optimization of a retrograde trafficking inhibitor that protects cells from infections by human polyoma- and papillomaviruses. Bioorg Med Chem. 2014 Sep 1;22(17):4836-47. |
| 1668 | Beesley AH, et al. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2007 Apr;137(2):109-16. |
| 1669 | DeAngelo DJ, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. |
| 1670 | https://clinicaltrials.gov/ct2/show/NCT04730206?term=Camostat&recrs=ab&cond=Covid19&phase=12&draw=2&rank=5 |
| 1671 | Hasegawa M, et al. Analysis on blast fungus-responsive characters of a flavonoid phytoalexin sakuranetin; accumulation in infected rice leaves, antifungal activity and detoxification by fungus. Molecules. 2014 Aug 4;19(8):11404-18. |
| 1672 | Bittencourt-Mernak MI, et al. Prophylactic and therapeutic treatment with the flavonone sakuranetin ameliorates LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2017 Feb 1;312(2):L217-L230. |
| 1673 | Arch Surg 75:780 (1957) |
| 1674 | Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29. |
| 1675 | Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. |
| 1676 | Bender T, Bariska J, Rojkovich B, Bálint G. Etofenamate levels in human serum and synovial fluid following iontophoresis. Arzneimittelforschung. 2001;51(6):489-92. |
| 1677 | Fraga A, de Almeida M, Moreira-da-Silva V et al. Intramuscular Etofenamate versus Diclofenac in the Relief of Renal Colic : A Randomised, Single-Blind, Comparative Study. Clin Drug Investig. 2003;23(11):701-6. |
| 1678 | Joana Marto, et al. Topical gels of etofenamate: in vitro and in vivo evaluation. Pharm Dev Technol. 2015;20(6):710-5. |
| 1679 | Erba, F., et al., Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug. Biochem Pharmacol, 2001. 61(3): p. 271-6. |
| 1680 | Aosasa, S., et al., Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock, 2001. 15(2): p. 101-5. |
| 1681 | Colasanti, M., et al., Effect of gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, on the nitric oxide pathway. Biochem Biophys Res Commun, 1998. 246(2): p. 453-6. |
| 1682 | Liu X, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010 Apr 29;115(17):3520-30. |
| 1683 | Koblish HK, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010 Feb;9(2):489-98. |
| 1684 | Fu R, et al. LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment. Br J Pharmacol. 2018 Jul;175(14):3034-3049. |
| 1685 | J Biol Chem 162:630 (1946) |
| 1686 | Cho JY, et al. In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from Saussurea lappa. Eur J Pharmacol. 2000 Jun 23;398(3):399-407. |
| 1687 | Masutani T, et al. Cynaropicrin is dual regulator for both degradation factors and synthesis factors in the cartilage metabolism. Life Sci. 2016 Aug 1;158:70-7. |
| 1688 | da Silva CF, et al. Activities of psilostachyin A and cynaropicrin against Trypanosoma cruzi in vitro and in vivo. Antimicrob Agents Chemother. 2013 Nov;57(11):5307-14. |
| 1689 | Mamand S, et al. Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. Sci Rep. 2018 Sep 21;8(1):14216. |
| 1690 | https://clinicaltrials.gov/ct2/show/NCT04330300?term=Nicardipine&cond=covid&draw=2&rank=1 |
| 1691 | https://clinicaltrials.gov/ct2/show/NCT04695197?term=Artemether&cond=COVID-19&draw=2&rank=1 |
| 1692 | Zhang P, et al. Discovery of Betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19(8):21 |
| 1693 | Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013 Apr;19(4):446-51. |
| 1694 | Hatse S, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol. 2005 Sep 1;70(5):752-61. |
| 1695 | Yang L, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007 Jan 15;67(2):651-8. |
| 1696 | Ye XS, et al. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models. Mol Cancer Ther. 2015 Nov;14(11):2463-72. |
| 1697 | Brain 115:1249 (1992); Int J Tryptophan Res 5:1 (2012) |
| 1698 | Drugs (1988), 35(3), 187-91; Contraception (1987), 36 Suppl, 1-5; FEBS Lett. (1987), 217(2), 221-6| |
| 1699 | Jiang W, et al. New progesterone receptor antagonists: phosphorus-containing 11beta-aryl-substituted steroids. Bioorg Med Chem. 2006 Oct 1;14(19):6726-32. |
| 1700 | Jurado R, et al. NSC 119875 cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep. 2009 Nov;22(5):1237-45. |
| 1701 | Sharrett-Field L, et al. Mifepristone Pretreatment Reduces Ethanol Withdrawal Severity In Vivo. Alcohol Clin Exp Res. 2013 Aug;37(8):1417-23. |
| 1702 | Yuehua You, et al. Progesterone Promotes Endothelial Nitric Oxide Synthase Expression Through Enhancing Nuclear Progesterone receptor-SP1 Formation. Am J Physiol Heart Circ Physiol. 2020 Jul 3. |
| 1703 | Krennhrubec K, et al. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8. |
| 1704 | Oehme I, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009 Jan 1;15(1):91-9. |
| 1705 | C Huang, et al. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A. 1997 May 27;94(11):5826-30. |
| 1706 | Bradley A Maron, et al. Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation. 2014 Jul 8;130(2):168-79. |
| 1707 | Eunyoung Byun, et al. Activation of NF-κB and AP-1 Mediates Hyperproliferation by Inducing β-Catenin and c-Myc in Helicobacter pylori-Infected Gastric Epithelial Cells. Yonsei Med J. 2016 May;57(3):647-51. |
| 1708 | Ye Sun, et al. Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos. J Exp Med. 2017 Jun 5;214(6):1753-1767. |
| 1709 | JACS 52:2538 (1930); J Enzym Inhib Med Chem 24:804 (2009)|Eur J Pharmacol 691:125 (2012) |
| 1710 | Can J Chem 34: 1562 (1956) |
| 1711 | Illendula A, et al. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. Science. 2015 Feb 13;347(6223):779-84. |
| 1712 | Zhao K, et al. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells. J Hematol Oncol. 2015 Apr 23;8:41. http://www.ncbi.nlm.nih.gov/pubmed/25902914 |
| 1713 | Dai Q, et al. Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells. Mol Carcinog. 2015 Aug 10. |
| 1714 | Wei L, et al. Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization. Cell Death Dis. 2015 Apr 9 |
| 1715 | Wu Y, et al. ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments. |
| 1716 | Wu Y, et al. DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses. ACS Med Chem Lett. 2019 Jul 2;10(8):1140-1147. |
| 1717 | Beck B, et al. Prospects for prostate cancer imaging and therapy using high-affinity TRPM8 activators. Cell Calcium. 2007 Mar;41(3):285-94. |
| 1718 | Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. |
| 1719 | Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. |
| 1720 | Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5. |
| 1721 | Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. |
| 1722 | Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21(2):130-42. |Cancer Chemother. Pharmacol. (1995), 36(5), 393-403; Oncol. Res. (1993), 5(12), 467-74; Chem. Pharm. Bull. (1991), 39(6), 1446-54 |
| 1723 | https://clinicaltrials.gov/ct2/show/NCT04946162?term=Tadalafil&cond=COVID-19&draw=2&rank=1 |
| 1724 | Andreev IA, et al. Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. Eur J Med Chem. 2015;96:250-8. |
| 1725 | N. Engl. J. Med. (1960), 263, 927-34; Antibiot. Annu. (1960), 776-84; J. Antimicrob. Chemother. (2000), 46(6), 917-9 |
| 1726 | Li X et al. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther. 2014 Apr;13(4):855-66. |
| 1727 | Shao W et al. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner. J Lipid Res. 2016 Aug;57(8):1564-73. |
| 1728 | Inoue K et al. Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation. Biochim Biophys Acta. 2015 Nov;1852(11):2432-41. |
| 1729 | Choi Y, et al. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J Biol Chem. 2003 Feb 28;278(9):7320-4. |
| 1730 | Kamisuki S, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009 Aug 28;16(8):882-92. |
| 1731 | Riv. Farmacol. Ter. (1982), 13(2), 111-22; Biochem. Pharmacol. (1976), 25(19), 2203-7; Atherosclerosis (1971), 14(3), 375-8 |
| 1732 | Mijatovic T, et al. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia. 2008 Jun;10(6):573-86. |
| 1733 | Tina Mahieu, et al. UNBS5162: A novel naphthalimide derivative with potent pro-autophagic effects in human cancer cells. Cancer Research, 2007 May; 67(9) Supplement. |
| 1734 | He D, et al. UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signaling pathway. Mol Med Rep. 2018 Jan;17(1):549-555. |
| 1735 | J.Neurochem. 63 Suppl 1:S49A (1994); 65:96 (1995) |
| 1736 | Lanier M, et al. Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure. ACS Med Chem Lett. 2017 Feb 8;8(3):316-320. |
| 1737 | Lin JH, et al. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33. |
| 1738 | Loomba R, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2trial. Hepatology. 2018 Feb;67(2):549-559. |
| 1739 | Yuan J, et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
 Am J Pathol. 2011 Oct;179(4):2091-9. |
| 1740 | Sanhaji M, et al. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
 Cell Cycle. 2012 Feb 1;11(3):543-53. |
| 1741 | Lee KS, et al. Pinning down the polo-box domain. Chem Biol. 2008 May;15(5):415-6. |
| 1742 | Reindl W, et al. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol. 2008 May;15(5):459-66. |
| 1743 | Can Med Assoc J 80:785 (1959); Am J Hematol 46:138 (1994); Pharmacother 23:533 (2003) |
| 1744 | WZ811, et al. Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007 Nov 15;50(23):5655-64. |
| 1745 | Li SH, et al. Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811. Am J Transl Res. 2016 Sep 15;8(9):3812-3821. |
| 1746 | J Clin Pharmacol 20:213 (1980); Drugs 23:250 (1982) |
| 1747 | Adv. Pharmacol. Chemother. (1973), 11, 151-220; Lancet (1960), 2(7150), 564-7; Br. Med. J. (1960), 2, 694-9 |
| 1748 | Chem Commun 1965:302 |
| 1749 | Nicolle LE. Pivmecillinam in the treatment of urinary tract infections.
 J Antimicrob Chemother. 2000 Aug;46 Suppl A:35-39. |
| 1750 | Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. |
| 1751 | Holme E, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet. 1989 Aug 26;2(8661):469-73. |
| 1752 | Br. J. Pharmacol. (2005), 144(4), 538-550; Drugs (2004), 64(19), 2237-2246; Int. J. Clin. Pract. (2004), 58(6), 606-611 |
| 1753 | Zhang Y, et al. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. J Med Chem. 2019 May 9;62(9):4716-4730. |
| 1754 | Tummala R K Reddy, et al.Three-dimensional Pharmacophore Design and Biochemical Screening Identifies Substituted 1,2,4-triazoles as Inhibitors of the Annexin A2-S100A10 Protein Interaction. ChemMedChem. 2012 Aug;7(8):1435-46. |
| 1755 | Andrew W Woodham, et al. Small Molecule Inhibitors of the Annexin A2 Heterotetramer Prevent Human Papillomavirus Type 16 Infection. J Antimicrob Chemother. 2015;70(6):1686-90. |
| 1756 | Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013 Oct;19(10):1264-72. |
| 1757 | Strachan DC, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. 2013 Dec 1;2(12):e26968. |
| 1758 | J Antibiot 23:551, 559 (1970); Drugs 27:548 (1984) |
| 1759 | Sanches M, et al. Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors. Nat Commun. 2014 Aug 28;5:4202. |
| 1760 | Wang Y, et al. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation . ACS Chem Biol. 2012,15;7(6):1040-8. |
| 1761 | Yamamoto T, et al. Estrogen-related receptor-γ regulates estrogen receptor-α responsiveness in uterine endometrial cancer. Int J Gynecol Cancer. 2012;22(9):1509-16. |
| 1762 | Yu S, et al. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer. Cancer Res. 2007;67(10):4904-14. |
| 1763 | Donna D. Yu, Barry Marc Forman. Identification of an agonist ligand for estrogen-related receptors ERRβ/γ. Bioorganic & Medicinal Chemistry Letters. 2005,15(5): 1311-1313. |
| 1764 | A Pacwa, et al. Interplay between estrogen-related receptors and steroidogenesis-controlling molecules in adrenals. In vivo and in vitro study. Acta Histochem. 2018 Jul;120(5):456-467. |
| 1765 | Casado J, et al. Alternated quinoid/aromatic units in terthiophenes building blocks for electroactive narrow band gap polymers. Extended spectroscopic, solid state, electrochemical, and theoretical study. J Phys Chem B. 2005 Sep 8;109(35):16616-27. |
| 1766 | Boschelli DH, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem, 2001, 44(23), 3965-3977. |
| 1767 | Golas JM, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res, 2003, 63(2), 375-381. |
| 1768 | Vultur A, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther, 2008, 7(5), 1185-1194. |
| 1769 | Golas JM, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res, 2005, 65(12), 5358-5364. |
| 1770 | Mol Pharmacol 54: 162 (1998) |
| 1771 | Lai MT et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652-63. |
| 1772 | Anderson MS et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20(4):397-405. |
| 1773 | Matsuda H, et al. Effects of nitroglycerin, adenosine, noradrenaline, and isoproterenol on the myocardial oxygen tension. Jpn Heart J. 1979 Nov;20(6):867-79. |
| 1774 | J. Steroid Biochem. Mol. Biol. (1994), 49(4-6), 261-7; Science (1958), 128, 478-80; Experientia (1958), 14, 151-2 |
| 1775 | Chem Ber 103:3752 (1970); Chemistry in Sri Lanka 14:17 (1997) |
| 1776 | One class has the naphthalene second dione compounds and its derivative of protease modification activities. CN107163044A. |
| 1777 | Agents Actions 15:627 (1984) |
| 1778 | https://clinicaltrials.gov/ct2/show/NCT04768179?term=ASPIRIN&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04365309?term=ASPIRIN&cond=Covid19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04808895?term=ASPIRIN&cond=Covid19&draw=2 https://clinicaltrials.gov/ct2/show/NCT04410328?term=ASPIRIN&cond=Covid19&draw=2 https://clinicaltrials.gov/ct2/show/NCT04937088?term=ASPIRIN&cond=Covid19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04466670?term=ASPIRIN&cond=Covid19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04363840?term=ASPIRIN&cond=Covid19&draw=2&rank=8 https://clinicaltrials.gov/ct2/show/NCT04425863?term=ASPIRIN&cond=Covid19&draw=2&rank=9 https://clinicaltrials.gov/ct2/show/NCT04498273?term=ASPIRIN&cond=Covid19&draw=2&rank=10 https://clinicaltrials.gov/ct2/show/NCT04368377?term=ASPIRIN&cond=Covid19&draw=2&rank=11 https://clinicaltrials.gov/ct2/show/NCT04324463?term=ASPIRIN&cond=Covid19&draw=2 https://clinicaltrials.gov/ct2/show/NCT04333407?term=ASPIRIN&cond=Covid19&draw=2&rank=14 https://clinicaltrials.gov/ct2/show/NCT04703608?term=ASPIRIN&cond=Covid19&draw=2&rank=16 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/04/032648 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/03/032060 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04768179 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20180205038626N7 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/09/028088 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/08/027503 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/07/026791 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04425863 |
| 1779 | Harris PA, et al. Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Med Chem Lett. 2013 Nov 4;4(12):1238-43. |
| 1780 | Biorg Khim 21: 695 (1995) |
| 1781 | Helv Chim Acta 17:1407 (1934); J Chem Soc 1940:1390; 1940:1483 |
| 1782 | Goossens JF, et al. DNA interaction of the tyrosine protein kinase inhibitor PD153035 and its N-methyl analogue. Biochemistry. 2001 Apr 17;40(15):4663-71. |
| 1783 | Zheng X, et al. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. J Med Chem. 2019 Jul 11;62(13):6003-6014. |
| 1784 | Kessler D, et al. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci U S A. 2019 Aug 6; 116(32):15823-15829. |
| 1785 | Dirk Kessler, et al. Drugging all RAS isoforms with one pocket. FUTURE MEDICINAL CHEMISTRY |
| 1786 | Tanjoni I, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther. 2010 May 15;9(10):764-77. |
| 1787 | Schuller M, et al. Discovery of a Selective Allosteric Inhibitor Targeting Macrodomain 2 of Polyadenosine-Diphosphate-Ribose Polymerase 14. ACS Chem Biol. 2017 Nov 17;12(11):2866-2874. |
| 1788 | Gokbulut C, et al. Comparative pharmacokinetics of levamisole-oxyclozanide combination in sheep and goats following per os administration. Can J Vet Res. 2014 Oct;78(4):316-20. |Experientia 1969:883; Br J Pharmac 50:435 (1974) |
| 1789 | Vernier JM, et al. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem. 1999 May 20;42(10):1684-6. |
| 1790 | Rao TS, et al. In vitro pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a nicotinic acetylcholine receptor ligand. Brain Res. 2003 Aug 15;981(1-2):85-98. |
| 1791 | Rao TS, et al. In vivo pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride (SIB-1553A), a novel cholinergic ligand: microdialysis studies. Brain Res. 2003 Oct 3;986(1-2):71-81. |
| 1792 | Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013. |
| 1793 | Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. |
| 1794 | Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443. |
| 1795 | Life Sci 76:71 (2002); World J Gastroenterol 14:4784 (2008) |
| 1796 | J Reprod Med 46:647 (2001); Contraception 16:541 (1977); 32:311 (1985) |
| 1797 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=PREDNISONE&cntry=&state=&city=&dist=&Search=Search |
| 1798 | Masashi Ohmi, et al. Identification of a novel 2-pyridyl-benzensulfonamide derivative, RQ-00203078, as a selective and orally active TRPM8 antagonist. Bioorg Med Chem Lett. 2014 Dec 1;24(23):5364-8. |
| 1799 | Yoshihiko Okamoto, et al. Blockade of TRPM8 activity reduces the invasion potential of oral squamous carcinoma cell lines. Int J Oncol. 2012 May;40(5):1431-40. |
| 1800 | Katsumata K, et al. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother. 2013 Mar;57(3):1339-46. |
| 1801 | Dai XQ, et al. Inhibition of TRPP3 channel by MK-870 and analogs. Mol Pharmacol. 2007 Dec;72(6):1576-85. |
| 1802 | Shi H, et al. Na+/H+ Exchanger Regulates Amino Acid-Mediated Autophagy in Intestinal Epithelial Cells. Cell Physiol Biochem. 2017;42(6):2418-2429. |
| 1803 | Zhu BY, et al. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis. |
| 1804 | Narita T, et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res. 2009 Oct 1;15(19):6128-6136. |
| 1805 | EMILIA C. CALVARESI, et al. SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE A AS AN ANTICANCER STRATEGY. |
| 1806 | Taylor (unpublished) |
| 1807 | Anggakusuma, et al. Effects of macelignan isolated from Myristica fragrans Houtt. on UVB-induced matrix metalloproteinase-9 and cyclooxygenase-2 in HaCaT cells. J Dermatol Sci |
| 1808 | Jiyoung Yeo, et al. Effects of a multi-herbal extract on type 2 diabetes. Chin Med. 2011 Mar 4;6:10. |
| 1809 | Chun-Ai Cui, et al. Macelignan attenuates LPS-induced inflammation and reduces LPS-induced spatial learning impairments in rats. Neurosci Lett. 2008 Dec 19;448(1):110-4. |
| 1810 | Li ML, et al. Pharmacological determinants of 9-aminocamptothecin cytotoxicity. Clin Cancer Res. 2001 Jan;7(1):168-74. |
| 1811 | de Souza PL, et al. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin Cancer Res. 1997 Feb;3(2):287-94. |
| 1812 | Jeha S, et al. Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leuk Lymphoma. 1998 Dec;32(1-2):159-64. |
| 1813 | https://clinicaltrials.gov/ct2/show/NCT04330300?term=Nitrendipine&cond=COVID-19&draw=2&rank=1 |
| 1814 | Quanz M, et al. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance. Mol Cancer Ther. 2018 Nov;17(11):2285-2296. |
| 1815 | Zhang W, et al. UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor. J Med Chem. 2014 Aug 28;57(16):7031-41. |
| 1816 | DeRyckere D, et al. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with CL14377 in Leukemia Models.Clin Cancer Res. 2017 Mar 15;23(6):1481-1492. |
| 1817 | ARVID CARLSSON, et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists. Nature 180, page1200 (1957). |
| 1818 | Caruso I, et al. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9. |
| 1819 | Thal LJ, et al. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Ann Neurol. 1980 Jun;7(6):570-6. |
| 1820 | Boiardi A, et al. 5-OH-Tryptophane in migraine: clinical and neurophysiological considerations. J Neurol. 1981;225(1):41-6. |
| 1821 | Trouillas P, et al. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol. 1988 Nov;45(11):1217-22. |
| 1822 | RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency |
| 1823 | Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways. |
| 1824 | Farmatsiya (Sofia) 27:1 (1977) [CA 90:23458c (1979)] |
| 1825 | Ehmann DE, et al.
 Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.
 Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8. |
| 1826 | Livermore DM, et al.
 Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).
 J Antimicrob Chemother. 2012 Jun;67(6):1354-8. |
| 1827 | Berkhout J, et al. Pharmacokinetics and penetration of GR20263 and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304. |
| 1828 | Meijer L, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243(1-2):527-36. |
| 1829 | Bai X, et al. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erk1/2/pparγ pathway. Oncotarget. 2016 Apr 27. |
| 1830 | Gary C, et al. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 2016 May 23. |
| 1831 | Anal Profiles Drug Subst Excip 23:153 (1994) |
| 1832 | Lansing TJ, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31. |
| 1833 | Didier C, et al. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia. Eur J Pharmacol. 2008 Sep 4;591(1-3):102-5. |
| 1834 | Ikezoe T, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia. 2009 Sep;23(9):1564-76. |
| 1835 | Tamas Oravecz, et al. LX1606 (aka LX1032), a Novel Inhibitor of Serotonin Synthesis, Alleviates Development of Inflammatory Bowel Disease in a Preclinical Model. |
| 1836 | Margolis, K.G., et al., Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut, 2013. |
| 1837 | Rasmussen SG, et al. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature. 2011 Jan 13;469(7329):175-80. |
| 1838 | https://clinicaltrials.gov/ct2/show/NCT04348305?term=Hydrocortisone&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04456439?term=Hydrocortisone&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT02735707?term=Hydrocortisone&cond=COVID-19&draw=2&rank=8 |
| 1839 | Quinlan CL, et al. Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A. Nat Chem Biol. 2017 Jul;13(7):785-792. |
| 1840 | Park JH, et al. NecroX-5 prevents breast cancer metastasis by AKT inhibition via reducing intracellular calcium levels. Int J Oncol. 2017 Jan;50(1):185-192. |
| 1841 | Thu VT, et al. NecroX-5 exerts anti-inflammatory and anti-fibrotic effects via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway in hypoxia/reoxygenation-treated rat hearts. Korean J Physiol Pharmacol. 2016 May;20(3):305-14. |
| 1842 | Mizutani A, et al. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci. 2018 Dec;109(12):4003-4014. |
| 1843 | Br J Pharmacol 114:510 (1995) |
| 1844 | Crew AP, et al. Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. J Med Chem. 2018 Jan 25;61(2):583-598. |
| 1845 | https://trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024520 |
| 1846 | Fabbro D, et al. PKC412--a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000 Feb;15(1):17-28. |
| 1847 | Gleixner KV, et al. Synergistic growth-inhibitory effects of Midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013 Sep;98(9):1450-7. |
| 1848 | Chi HT, et al. ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412. Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):87-92. |
| 1849 | Kwan R, et al. PKC412 normalizes mutation-related keratin filament disruption and hepatic injury in mice by promoting keratin-myosin binding. Hepatology. 2015 Dec;62(6):1858-69. |
| 1850 | Fabbro D, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther. 1999 May-Jun;82(2-3):293-301. |
| 1851 | Infection 5:163 (1977); Arzneim Forsch 29:1915 (1979); J Antimicrob Chemother 11 Suppl B: 1 (1983) |
| 1852 | Shevan Silva, Abstract A67: Preclinical efficacy of tarloxotinib bromide (TH-4000), a hypoxia-activated EGFR/HER2 inhibitor: rationale for clinical evaluation in EGFR mutant, T790M-negative NSCLC following progression on EGFR-TKI therapy. Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. |
| 1853 | Adam V. Patterson, Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. |
| 1854 | Choi S, et al.
 Activity of Tedizolid Phosphate (TR-701) in Murine Models of Infection with Penicillin-resistant and Penicillin-sensitive Streptococcus pneumoniae.
 Antimicrob Agents Chemother. 2012 Jun 19. |
| 1855 | Moody TW, et al. ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. Peptides. 2015 Feb;64:55-61. |
| 1856 | Eidem TM, et al. Drug-eluting cements for hard tissue repair: a comparative study using vancomycin and RNPA1000 to inhibit growth of Staphylococcus aureus. J Biomater Appl. 2014 Apr;28(8):1235-46. |
| 1857 | Eidem TM, et al. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28. |
| 1858 | Patrick D Olson, et al. Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular mRNA turnover, exhibit antimicrobial activity, and attenuate pathogenesis. PLoS Pathog. 2011 Feb 10;7(2):e1001287. |
| 1859 | Liston BW, et al. Perillyl alcohol as a chemopreventive agent in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Cancer Res. 2003 May 15;63(10):2399-403. |
| 1860 | Metab: Clin Exper 49:704 (2000); Neurosci 161:501 (2009); J Neurochem 114:291 (2010) |
| 1861 | Kenneth W. Duncan et al. Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Med. Chem. Lett., 2016, 7 (2), pp 162-166. |
| 1862 | Chiang K, et al. PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression. Cell Rep. 2017 Dec 19;21(12):3498-3513. |
| 1863 | https://clinicaltrials.gov/ct2/show/NCT04273581?term=THALIDOMIDE&cond=covid&draw=2&rank=1 |
| 1864 | 1. Griffett K, et al. The mammalian clock and chronopharmacology. Bioorganic & Medicinal Chemistry Letters, 2013, 23(7):1929-1934.. |
| 1865 | Hirota T, et al. High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol. 2010 Dec 14;8(12):e1000559. |
| 1866 | Ogunleye A, et al. Fatty acid composition of breast milk from Nigerian and Japanese women. J Nutr Sci Vitaminol (Tokyo). 1991 Aug;37(4):435-42. |
| 1867 | Yamori Y, et al. Dietary prevention of stroke and its mechanisms in stroke-prone spontaneously hypertensive rats--preventive effect of dietary fibre and palmitoleic acid. J Hypertens Suppl. 1986 Oct;4(3):S449-52. |
| 1868 | Martin LJ, et al. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75. |
| 1869 | Rezaul M. Karim, et al. An Advanced Tool To Interrogate BRD9. J. Med. Chem., 2016, 59 (10), pp 4459-4461 |
| 1870 | Briscoe CP, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol. 2006 Jul;148(5):619-28. |
| 1871 | Zhao YF, et al. Activation of ATP-sensitive potassium channels in rat pancreatic beta-cells by linoleic acid through both intracellular metabolites and membrane receptor signalling pathway. J Endocrinol, 2008, 198(3), 533-540. |
| 1872 | Fujita T, et al. A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation. J Invest Dermatol, 2011, 131(8), 1660-1667. |
| 1873 | Suski M, et al. Anti-atherosclerotic action of GW9508 - Free fatty acid receptors activator - In apoE-knockout mice. Pharmacol Rep. 2019 Aug;71(4):551-555. |
| 1874 | Thomas DR, et al. Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br J Pharmacol. 1998 Jul;124(6):1300-6. |
| 1875 | Indian J Chem 6: 252 (1968); J Sci Food Agricult 90:43 (2010)| |
| 1876 | Zhai ZJ, et al. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br J Pharmacol. 2014 Feb;171(3):663-75. |
| 1877 | Gupta S, et al. Broad-spectrum antiviral properties of andrographolide. Arch Virol. 2017 Mar;162(3):611-623. |
| 1878 | Thomson DW, et al. Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor. ACS Med Chem Lett. 2019 Mar 11;10(5):780-785. |
| 1879 | Pei Z, et al. Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. |
| 1880 | Koehler MF, et al. Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity. J Med Chem. 2012 Dec 27;55(24):10958-71. |
| 1881 | Dong H, et al. Enrichment and separation of antitumor triterpene acids from the epidermis of Poria cocos by pH-zone-refining counter-current chromatography and conventional high-speed counter-current chromatography. J Sep Sci. 2015 Jun;38(11):1977-82. |
| 1882 | Chen DQ, et al. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Free Radic Biol Med. 2019 Apr;134:484-497. |
| 1883 | Phytochemistry 15:572 (1976); African J Traditional, complimentary Med 11(4) (2014) |
| 1884 | Sturino CF, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem. 2007 Feb 22;50(4):794-806. |
| 1885 | Philipose S, et al. Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation. PLoS One. 2012;7(8):e40222. |
| 1886 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Eplerenone&cond=Covid19&draw=2&rank=1 |
| 1887 | Norbert Schmees, et al. 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides. WO2017202816A1. |
| 1888 | Kolstoe SE, et al. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23. |
| 1889 | Sahota T,et al. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 Feb;4(2):e15. |
| 1890 | Dai Z, et al. Current advance in biological production of malic acid using wild type and metabolic engineered strains. Bioresour Technol. 2018 Jun;258:345-353. |
| 1891 | Jonas DA, et al. Safety considerations of DNA in food. Ann Nutr Metab. 2001;45(6):235-54. |
| 1892 | Wurtman RJ, et al. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000 Oct 1;60(7):989-92. |
| 1893 | Machado-Vieira R, et, al. New therapeutic targets for mood disorders. ScientificWorldJournal. 2010 Apr 13;10:713-26. |Ber 43:3154 (1910); 45:608 (1912); J Neurochem 1:93 (1956); 64:378 (1995) |
| 1894 | Podolin PL, et al. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31. |
| 1895 | Phebus LA, Johnson KW, Zgombick JM, Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brainpenetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1997;61(21):2117-26. |
| 1896 | Jeong HJ, Chenu D, Johnson EE, Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey. Mol Pain. 2008 Nov 11;4:54. |
| 1897 | Cohen ML, Schenck K. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther. 1999 Sep;290(3):935-9. |
| 1898 | Arzneim Forsch 7:237 (1957); 13:324 (1963) |
| 1899 | Yuan Y et al. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012 Jul 20;7(7):1152-7. |
| 1900 | Pescatore, S.L. and C. Lindley, Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother, 2000. 1(3): p. 537-46. |
| 1901 | Petrides, P.E., Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost, 2006. 32(4 Pt 2): p. 399-408. |
| 1902 | Bai ZT, et al. Inhibition of invasion by N-trans-feruloyloctopamine via AKT, p38MAPK and EMT related signals in hepatocellular carcinoma cells. Bioorg Med Chem Lett. 2017 Feb 15;27(4):989-993. |
| 1903 | Aida K, et al. Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. Planta Med. 1990 Jun;56(3):254-8. |
| 1904 | Sato Y, et al. Isoliquiritigenin, one of the antispasmodic principles of Glycyrrhiza ularensis roots, acts in the lower part of intestine. Biol Pharm Bull. 2007 Jan;30(1):145-9. |
| 1905 | Zhang X. Natural antioxidant-isoliquiritigenin ameliorates contractile dysfunction of hypoxic cardiomyocytes via AMPK signaling pathway. Mediators Inflamm. 2013;2013:390890. |
| 1906 | Chen X, et al. Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling. J Mol Med (Berl). 2012 Nov;90(11):1311-9. |
| 1907 | Traboulsi H, et al. The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection. Antimicrob Agents Chemother. 2015 Oct;59(10):6317-27. |
| 1908 | Wang L, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun, 2013. 4: p. 2035. |
| 1909 | Banelli B, et al. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. Oncotarget. 2017 Apr 4. |
| 1910 | J Med Chem 41:658 (1998); J Clin Psychiatry 63:763 (2001); Eur J Pharmacol 441:137 (2002) |
| 1911 | U.S. Pat. Appl. Publ. (2012), US 20120028924 A1 |
| 1912 | Fitzpatrick LR, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60. |
| 1913 | Fitzpatrick LR, et al. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2010 Oct;16(10):1763-77. |
| 1914 | Rajabi M, et al. Antiproliferative activity of kinetin riboside on HCT-15 colon cancer cell line. Nucleosides Nucleotides Nucleic Acids. 2012;31(6):474-81. |
| 1915 | Choi BH, et al. Kinetin riboside preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells. Cancer Lett. 2008 Mar 8;261(1):37-45. |
| 1916 | https://clinicaltrials.gov/ct2/show/NCT04577378?term=ITRACONAZOLE&cond=covid&draw=2&rank=1 |
| 1917 | Ahn KS,et al. Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Planta Med. 1996;62(1):7-9. |
| 1918 | Li J, et al. Decursin inhibits the growth of HepG2 hepatocellular carcinoma cells via Hippo/YAP signaling pathway. Phytother Res. 2018;32(12):2456-2465. |
| 1919 | Kim S, et al. Decursin inhibits tumor growth, migration, and invasion in gastric cancer by down-regulating CXCR7 expression. Am J Cancer Res. 2019;9(9):2007-2018. Published 2019 Sep 1. |
| 1920 | Wang Z, et al. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands. J Med Chem. 2019 Sep 12;62(17):8152-8163. |
| 1921 | Bradić I, et al. [Hirschsprung's disease -- therapy and results]. Acta Chir Iugosl. 1975;22(2):183-95. |
| 1922 | Chua HC, et al. Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS One. 2016 Jun 22;11(6):e0157700. |
| 1923 | G. Boonen, et al. In vivo Effects of the Kavapyrones (+)-Dihydromethysticin and (±)-Kavain on Dopamine, 3,4-Dihydroxyphenylacetic Acid, Serotonin and 5-Hydroxyindoleacetic Acid Levels in Striatal and Cortical Brain Regions. Planta Medica 64 (1998) 507-510. |
| 1924 | Tang X, et al. Kavain Inhibition of LPS-Induced TNF-α via ERK/LITAF. Toxicol Res (Camb). 2016 Jan 1;5(1):188-196. |
| 1925 | Pediatrics 25:27 (1960) |
| 1926 | Patel S et al. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem. 2015 Jan 8;58(1):401-18. |
| 1927 | Kapil A, et al. Leishmanicidal activity of 2-benzoxazolinone from Acanthus illicifolius in vitro. Planta Med. 1994 Apr;60(2):187-8. |
| 1928 | Batish DR, et al. 2-Benzoxazolinone (BOA) induced oxidative stress, lipid peroxidation and changes in some antioxidant enzyme activities in mung bean (Phaseolus aureus). Plant Physiology and Biochemistry 44(11-12):819-27 |
| 1929 | Krawiecka M, et al. Synthesis and biological activity of novel series of 1,3-benzoxazol-2(3H)-one derivatives. Acta Pol Pharm. 2013 Mar-Apr;70(2):245-53. |
| 1930 | Miandji AM, et al. Synthesis and biological activities of some 1,3-benzoxazol-2(3H)-one derivatives as anti-quorum sensing agents. Arzneimittelforschung. 2012 Jul;62(7):330-4. |
| 1931 | Kanthasamy AG, et al. A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson's disease models. Free Radic Biol Med. 2006 Nov 15;41(10):1578-89. |
| 1932 | Knoblach SM, et al. Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J Cereb Blood Flow Metab. 2004 Oct;24(10):1119-32. |
| 1933 | Yakovlev AG, et al. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci. 1997, 17(19), 7415-7424. |
| 1934 | Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21(2):130-42. |
| 1935 | Ann NY Acad Sci 881:272 (1999); CNS Drug Reviews 8(:177 (2002) |
| 1936 | Gaali S, et al. Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51. J Med Chem. 2016 Mar 24;59(6):2410-22. |
| 1937 | Balsevich G, et al. Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function. Nat Commun. 2017 Nov 23;8(1):1725. |
| 1938 | Hartmann J, et al. Pharmacological Inhibition of the Psychiatric Risk Factor FKBP51 Has Anxiolytic Properties. J Neurosci. 2015 Jun 17;35(24):9007-16. |
| 1939 | Njoroge FG, et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res. 2008 Jan;41(1):50-9. |
| 1940 | Yao M, et al. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A ProteaseActivity. PLoS One. 2016 Mar 4;11(3):e0150894. |
| 1941 | Coilly A, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother. 2012 Nov;56(11):5728-34. |
| 1942 | Berenguer M, et al. New developments in the management of hepatitis C virus infection: focus on boceprevir. Biologics. 2012;6:249-56. |
| 1943 | Burton MJ, et al. Telaprevir and boceprevir in african americans with genotype 1 chronic hepatitis C: implications for patients and providers. South Med J. 2012 Aug;105(8):431-6. |
| 1944 | J Soc Chem Ind 53: 956 (1934) |
| 1945 | Syn Commun 20:2659 (1990) |
| 1946 | Malamas MS, et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004;47(21):5021-5040. |
| 1947 | Chaudhary SC, et al. Erb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014;7(2):186-198. |
| 1948 | Chan KKL, et al. Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer. Cancer Cell Int. 2018;18:65. Published 2018 May 1. |
| 1949 | https://clinicaltrials.gov/ct2/show/NCT04623385?term=TESTOSTERONE&cond=covid&draw=2&rank=1 |
| 1950 | Chem Pharm Bull 43:771 (1995); Tetrahedron 51:1143 (1995); J Pharmacol Exp Therap 309:641 (2004) |
| 1951 | Ellen Filvaroff, et al. Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies. WO2017120446A1. |
| 1952 | CC-90009 |
| 1953 | WO 2014102818 A1 |
| 1954 | Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 ( Pt 3):699-703. |
| 1955 | Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91. |
| 1956 | Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7. |
| 1957 | Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56. |
| 1958 | Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300. |
| 1959 | Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both DB01229-like and Leurocristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64(4):681-9. |
| 1960 | Toxicol Appl Pharmacol 18:185 (1971) |
| 1961 | FEBS Lett 218:55 (1987) |
| 1962 | Ishima T, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015 Apr;25(4):505-11. |
| 1963 | Yoshimi N, et al. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015 Mar;25(3):356-64. |
| 1964 | Irie H, et al. TAS0728, a covalent-binding, HER2-selective kinase inhibitor shows potent antitumor activity in preclinical models. Mol Cancer Ther. 2019 Feb 20. |
| 1965 | Fischer KG, et al. Characterization of a Na(+)-Ca(2+) exchanger in podocytes. Nephrol Dial Transplant. 2002 Oct;17(10):1742-50. |
| 1966 | Wang X, et al. Effects of amiloride, benzamil, and alterations in extracellular Na+ on the rat afferent arteriole and its myogenic response. Am J Physiol Renal Physiol. 2008 Jul;295(1):F272-82. |
| 1967 | Dai XQ, et al. Inhibition of TRPP3 channel by amiloride and analogs. Mol Pharmacol. 2007 Dec;72(6):1576-85. |
| 1968 | Castañeda MS, et al. Benzamil inhibits neuronal and heterologously expressed small conductance Ca2+-activated K+channels. Neuropharmacology. 2019 Nov 1;158:107738. |
| 1969 | Teiwes J, et al. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007 Jan;20(1):109-17. |
| 1970 | Luthi-Carter R, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7927-32. |
| 1971 | David M. Taylor, et al. A Brain-Permeable Small Molecule Reduces Neuronal Cholesterol by Inhibiting Activity of Sirtuin 2 Deacetylase. ACS Chem Biol. 2011 Jun 17;6(6):540-6. |
| 1972 | Cheon MG, et al. AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells. Cancer Lett. 2015 Jan 28;356(2 Pt B):637-45. |
| 1973 | Lee SD, et al. AK-1, a SIRT2 inhibitor, destabilizes HIF-1α and diminishes its transcriptional activity during hypoxia. Cancer Lett. 2016 Apr 1;373(1):138-45. |
| 1974 | MAXWELL DR, et al. Relative activity of some inhibitors of mono-amine oxidase in potentiating the action of tryptamine in vitro and in vivo. Br J Pharmacol Chemother. 1961 Dec;17:310-20. |
| 1975 | Martin LK, et al. A dose escalation and pharmacodynamic study of Triapine and radiation in patients with locally advanced pancreas cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e475-81. |
| 1976 | Yalowich JC, et al. The anticancer thiosemicarbazones Dp44mT and Triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα. Biochem Pharmacol. 2012 Jul 1;84(1):52-8. |
| 1977 | Whitnall M, et al. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14901-6. |
| 1978 | Kyani A, et al. Discovery and Mechanistic Elucidation of a Class of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma. ChemMedChem. 2018 Jan 22;13(2):164-177. |
| 1979 | Broberg BV, Glenth?j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009 Nov;206(4):631-40. |
| 1980 | A Carabaza, et al. Stereoselective Inhibition of Inducible Cyclooxygenase by Chiral Nonsteroidal Antiinflammatory Drugs. J Clin Pharmacol. 1996 Jun;36(6):505-12. |
| 1981 | B Averbeck, et al. Inflammatory Mediators Do Not Stimulate CGRP Release if Prostaglandin Synthesis Is Blocked by S(+)-flurbiprofen in Isolated Rat Skin. Inflamm Res. 2003 Dec;52(12):519-23. |
| 1982 | Lovly CM, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinaseinhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31. |
| 1983 | https://clinicaltrials.gov/ct2/show/NCT04343963?term=PYRIDOSTIGMINE&cond=Covid19&draw=2&rank=1 |
| 1984 | JACS 81:2220 (1959); Arzneim Forsch 12:314 (1962)|JACS 81:2220 (1959); Ann Pharmacother27:1183 (1993) |
| 1985 | Ou C, et al. Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus. Front Microbiol. 2015 Jun 16;6:592. |
| 1986 | Zhang B, et al. Molecular Mechanism of the Flavonoid Natural Product Dryocrassin ABBA against Staphylococcus aureus Sortase A. Molecules. 2016 Oct 26;21(11). |
| 1987 | Li B, et al. An Inhibitory Effect of Dryocrassin ABBA on Staphylococcus aureus vWbp That Protects Mice From Pneumonia. Front Microbiol. 2019 Jan 23;10:7. |
| 1988 | Fu RH, et al. Dryocrassin suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival. Cell Transplant. 2014;23(4-5):641-56. |
| 1989 | Han BR, et al. MAPK inhibitors enhance cell death in pyrogallol-treated human pulmonary fibroblast cells via increasing O<sub>2</sub><sup>•-</sup> levels. Oncol Lett. 2017 Jul;14(1):1179-1185. |
| 1990 | https://clinicaltrials.gov/ct2/show/NCT04826588?term=Succinic+acid&cond=Covid19&draw=2&rank=1 |
| 1991 | Park HH, et al. HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis. Exp Mol Med. 2018 Sep 20;50(9):125. |
| 1992 | Jung Y, et al. Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. Biochem Biophys Res Commun. 2018 Feb 5;496(2):508-514. |
| 1993 | Jung Y, et al. Eupatilin with PPARα agonistic effects inhibits TNFα-induced MMP signaling in HaCaT cells. Biochem Biophys Res Commun. 2017 Nov 4;493(1):220-226. |
| 1994 | Du L, et al. Eupatilin prevents H2O2-induced oxidative stress and apoptosis in human retinal pigment epithelial cells. Biomed Pharmacother. 2017 Jan;85:136-140. |
| 1995 | Takeuchi CS, et al. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). J Med Chem. 2013 Mar 28;56(6):2218-34. |
| 1996 | Zhu YR, et al. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models. Oncotarget. 2016 Aug 2;7(31):49527-49538. |
| 1997 | Naturvissenschaften 43:93 (1956); Anal Profiles Drug Subs 3:513 (1974) |
| 1998 | Xu JP, et al. Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action.J Drug Des Res. 2018;5(2). pii: 1070. Epub 2018 Aug 13. |
| 1999 | Shi J, et al. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization.J Virol. 2011 Jan;85(1):542-9. |
| 2000 | Br J Anaesth 52:501 (1980); J Pharmaceut Sci Technol 40:48 (1986) |
| 2001 | Hess J, et al. Assessment of the nematocidal activity of metallocenyl analogues of monepantel. Dalton Trans. 2016 Nov 28;45(44):17662-17671 |
| 2002 | Bahrami F, et al. Monepantel induces autophagy in human ovarian cancer cells through disruption of the mTOR/p70S6K signalling pathway. Am J Cancer Res. 2014 Sep 6;4(5):558-71. |
| 2003 | Raza A, et al. Increased expression of ATP binding cassette transporter genes following exposure of Haemonchus contortus larvae to a high concentration of monepantel in vitro. Parasit Vectors. 2016 Sep 29;9(1):522. |
| 2004 | Stuchlikova, et al. Monepantel induces hepatic cytochromes p450 in sheep in vitro and in vivo. Chem Biol Interact. 2015 Feb 5;227:63-8. ? |
| 2005 | Falconer SB, et al. Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing Klebsiella pneumoniae. ACS Infect Dis. 2015;1(11):533-543. |
| 2006 | Wu W, et, al. Millepachine showed novel antitumor effects in cisplatin-resistant human ovarian cancer through inhibiting drug efflux function of ATP-binding cassette transporters. Phytother Res. 2018 Dec; 32(12):2428-2435. |
| 2007 | Anticancer Res 29:3825 (2009); Endocrinol 154:968 (2013) |
| 2008 | Ilavenil S, et al. Trigonelline protects the cardiocyte from hydrogen peroxide induced apoptosis in H9c2 cells. Asian Pac J Trop Med. 2015 Apr;8(4):263-8. |
| 2009 | Joanna Folwarczna, et al. Effects of Trigonelline, an Alkaloid Present in Coffee, on Diabetes-Induced Disorders in the Rat Skeletal System. Nutrients. 2016 Mar; 8(3): 133. |
| 2010 | Ozçelik B, et al. Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids. Pharm Biol. 2011 Apr;49(4):396-402. |
| 2011 | Tetrahedron 21:1441, 3741 (1965); Chem Pharm Bull 28:708, 717 (1980); Phytochemistry 23:2972 (1984) |
| 2012 | Morandi A, et al. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res. 2013 Jun 15;73(12):3783-95 |
| 2013 | Andreucci E, et al. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget. 2016 Sep 2. doi: 10.18632/oncotarget.11826. [Epub ahead of print] |
| 2014 | Tsimafeyeu I, et al. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur J Cancer. 2016 Jul;61:20-8. |
| 2015 | Khochenkov DA, et al. Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2. Bull Exp Biol Med. 2015 Nov;160(1):84-7. |
| 2016 | Overgaard, J., et al., A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol, 1998. 46(2): p. 135-46. |
| 2017 | Roy, R.B., S.M. Laird, and L. Heasman, Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole. Br J Vener Dis, 1975. 51(4): p. 281-4. |
| 2018 | Henk, J.M., K. Bishop, and S.F. Shepherd, Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol, 2003. 66(1): p. 65-70. |
| 2019 | Peter Wardman, et al. Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes. Br J Radiol. 2019 Jan;92(1093):20170915. |
| 2020 | Zohreh Fakhrieh Kashan, et al. Therapeutic effects of Iranian herbal extracts against Trichomonas vaginalis. Iran Biomed J. 2017 Sep;21(5):285-93. |
| 2021 | Liu JR, et al. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma. Biochem Pharmacol. 2019 May; 163:458-471. |
| 2022 | https://clinicaltrials.gov/ct2/show/NCT02735707?term=Ticagrelor&cond=Covid19&draw=2&rank=3 |
| 2023 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=PYRIDOXINE+&cntry=&state=&city=&dist=&Search=Search |
| 2024 | T Nagano, et al. Enhancement of salivary secretion and neuropeptide (substance P, alpha-calcitonin gene-related peptide) levels in saliva by chronic anethole trithione treatment. J Pharm Pharmacol. 2001 Dec;53(12):1697-702. |
| 2025 | Sheng Huang, et al. Synthesis, Characterization, and In Vivo Evaluation of Desmethyl Anethole Trithione Phosphate Prodrug for Ameliorating Cerebral Ischemia-Reperfusion Injury in Rats. ACS Omega. 2020 Feb 24;5(9):4595-4602. |
| 2026 | Y Ukai, et al. Chronic anethole trithione treatment enhances the salivary secretion and increases the muscarinic acetylcholine receptors in the rat submaxillary gland. Arch Int Pharmacodyn Ther. 1984 Oct;271(2):206-12. |
| 2027 | JACS 48: 2987 (1926); Int J Immunopharmacol 18:693 (1996); Int J Sports Med 20:258 (1999); Mol Nutr Food Res 54:551 (2010) |
| 2028 | Cesar Torres-Luna, et al. Formation of Drug-Participating Catanionic Aggregates for Extended Delivery of Non-Steroidal Anti-Inflammatory Drugs from Contact Lenses. Biomolecules. 2019 Oct 10;9(10):593. |
| 2029 | Invest Opthamol Visual Sci 17:1941 (1978); Arch Opthamol 96:1839 (1978); Drugs 23:329 (1982) |
| 2030 | Atarashi H, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000 Aug;68(2):143-50. |
| 2031 | Okajima M, et al. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015 Aug 4;4(3):251-7. |
| 2032 | Bauer MR, et al. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5271-80. |
| 2033 | Synnott NC, et al. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett. 2018 Feb 1;414:99-106 |
| 2034 | Ali Y Benkherouf, et al. Hops Compounds Modulatory Effects and 6-prenylnaringenin Dual Mode of Action on GABA AReceptors. Eur J Pharmacol. 2020 Apr 15;873:172962. |
| 2035 | Am. Heart J. (1976), 92(5), 661-4; Adv. Drug Res. (1970), 5, 197-253; Circulation (1963), 28, 987-93 |
| 2036 | Kehrer JP et al. Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J. 2001 Jun 15. |
| 2037 | Gillard J et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1989 May;67(5):456-64. |
| 2038 | Mancini JA, et al. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol. 1992 Feb;41(2):267-72. |
| 2039 | J Am Pharm Sci 34: 78 (1945) |
| 2040 | Rao VA, et al. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009 Feb 1;69(3):948-57. |
| 2041 | Lovejoy DB, et al. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res. 2011 Sep 1;71(17):5871-80. |
| 2042 | Thirunarayanan N, et al. Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor. Front Endocrinol (Lausanne). 2012 Oct 9;3:120. |
| 2043 | Hoeflich KP, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2012 Jan 1;72(1):210-9. |
| 2044 | Choo EF, et al. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol. 2013 Jan;71(1):133-43. |
| 2045 | Wong H, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012 Jun 1;18(11):3090-9. |
| 2046 | Corazao-Rozas P, et al. Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors. Oncotarget. 2016 Feb 29. doi: 10.18632/oncotarget.7790. |
| 2047 | Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072. |
| 2048 | Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014;136(12):4551-4556. |
| 2049 | Horwath MC, et al. Antifungal Activity of the Lipophilic Antioxidant Ferrostatin-1. Chembiochem. 2017;18(20):2069-2078. |
| 2050 | Liu P, Feng Y, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cell Mol Biol Lett. 2020;25:10. Published 2020 Feb 27. |
| 2051 | Melania Guerrero Hue, et al. FP282 FERROPTOSIS-MEDIATED CELL DEATH IS DECREASED BY CURCUMIN IN RENAL DAMAGE ASSOCIATED TO RHABDOMYOLYSIS, Nephrology Dialysis Transplantation, Volume 34, Issue Supplement_1, June 2019, gfz106.FP282. |
| 2052 | https://clinicaltrials.gov/ct2/show/NCT04469114?term=Tofacitinib&cond=covid-19&draw=2&rank=4 |
| 2053 | Prog Clin Biol Res 34:271 (1979); Dev Pharmacol Ther 1:318 (1980); Lancet 1:643 (1982) |
| 2054 | Cur Med Res Opinion 5:366 (1978); Br J Clin Pharmacol 14:49 (1982); J Allergy Clin Immunol 103:223 (1999) |
| 2055 | Dey J, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007. |
| 2056 | Shimada T, et al. Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. Chem Res Toxicol. 2009 Jul;22(7):1325-33. |
| 2057 | Int J Clin Psychopharmacol 5:147 (1990); Drugs 55:277 (1998) |
| 2058 | Gonzalez-Cabrera PJ, et al. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol. 2008 Nov;74(5):1308-18. |
| 2059 | Blanco R, et al. The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss. Exp Eye Res. 2017 Nov;164:37-45. |
| 2060 | Heltweg B, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006 Apr 15;66(8):4368-77. |
| 2061 | Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. |
| 2062 | Skuza G, et al. Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats. Pol J Pharmacol. 2003 Nov-Dec;55(6):1149-52. |
| 2063 | Cancer Res 42:903 (1982); J Cell Physiol 144:229 (1990) |
| 2064 | Stakišaitis D, et al. The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo. Cancers (Basel). 2019 Aug 20;11(8). pii: E1210. |
| 2065 | Neurosci Lett 91: 194 (1988) |
| 2066 | Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. |
| 2067 | Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38. |
| 2068 | Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0864(20)30714-0. |
| 2069 | Welch CJ, et al. Preparation and evaluation of novel stationary phases for improved chromatographic purification of pneumocandin B0. J Chromatogr A. 2006 Jan 6;1101(1-2):204-13. |
| 2070 | Leonard WR Jr, et al. Synthesis of the antifungal beta-1,3-glucan synthase inhibitor CANCIDAS (caspofungin acetate) from pneumocandin B0. J Org Chem. 2007 Mar 30;72(7):2335-43. |
| 2071 | Maxam AM, et, al. A new method for sequencing DNA. Proc Natl Acad Sci U S A. 1977 Feb;74(2):560-4. |
| 2072 | Oh G, et, al. Cytosine modifications exhibit circadian oscillations that are involved in epigenetic diversity and aging. Nat Commun. 2018 Feb 13;9(1):644. |
| 2073 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=ISRADIPINE&cond=covid&draw=2&rank=1 |
| 2074 | Therapie 32:485 (1977); 36:123 (1981); Am J Cardiol 61:1210 (1988) |
| 2075 | Reed CW, et al. Discovery of an orally bioavailable and Central Nervous System (CNS) penetrant mGlu7 NegativeAllosteric Modulator (NAM) in vivo tool compound: N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962). J Med Chem. 2019 Jan 4. |
| 2076 | Infusionstherapie (1990), 17(4), 197-203, ; Nature (1967), 213(5073), 308-9, ; Minerva Med. (1963), 54, 2327-31 |
| 2077 | Chem Rev 12:181 (1933); J Biol Chem 280:34105 (2005) |
| 2078 | Zhong K, et al. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearanceof the conjugated metabolites. Antimicrob Agents Chemother. 2014 Jul;58(7):4153-61. |
| 2079 | Barry GD, et al. Novel agonists and antagonists for human protease activated receptor 2. J Med Chem. 2010 Oct 28;53(20):7428-40. |
| 2080 | Suen JY, et al. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol. 2012 Mar;165(5):1413-23. |
| 2081 | PLoS ONE 4:e7472 (2009) |
| 2082 | J Pharm Sci 48:212 (1959); Arzneim Forsch 20:548 (1970) |
| 2083 | Clin Pharmacol Ther 13:212 (1972); Fundamental Appl Toxicol 9:496 (1987) |
| 2084 | Rebecca VW, et al. PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer. ancer Discov. 2019 Feb;9(2):220-229. |
| 2085 | Lee CS, et al. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother. 2005 Aug;6(10):1725-34. |
| 2086 | Sengör B, et al. Effects of acitretin on spermatogenesis of rats. J Eur Acad Dermatol Venereol. 2006 Jul;20(6):689-92. |
| 2087 | Srimuangwong K, et al. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol. 2012 May 21;18(19):2383-9. |
| 2088 | Li F, et al. In vitro antioxidant and anti-inflammatory activities of 1-dehydro- |
| 2089 | -gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin. Food Chem. 2012 Nov 15;135(2):332-7. |
| 2090 | Srimuangwong K, et al. Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats. World J Gastroenterol. 2012 Dec 21;18(47):6951-9. |
| 2091 | http://www.drugsupdate.com/generic/view/1111 |
| 2092 | Kastrinsky DB, et al. Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34. |
| 2093 | J Neurochem 65: 889 (1995); Neurosci Lett 273: 163 (1999) |
| 2094 | Helv Chim Acta 33: 76 (1950) |
| 2095 | He M, et al. Pipecolic acid in microbes: biosynthetic routes and enzymes. J Ind Microbiol Biotechnol. 2006 Jun;33(6):401-7. |
| 2096 | Plecko B, et, al. Pipecolic acid as a diagnostic marker of pyridoxine-dependent epilepsy. Neuropediatrics. 2005 Jun;36(3):200-5. |
| 2097 | Chou TF, et al. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem. 2013 Feb;8(2):297-312. |
| 2098 | Chou TF, et al. Selective, reversible inhibitors of the AAA ATPase p97. Probe Reports from the NIH Molecular Libraries Program. April 14, 2011. |
| 2099 | Takeda O, et al. A comparative study on essential oil components of wild and cultivated Atractylodes lancea and A. chinensis. Planta Med. 1996 Oct;62(5):444-9. |
| 2100 | Hai-Ping Chen, et al. Insecticidal and repellant activities of polyacetylenes and lactones derived from Atractylodes lancea rhizomes. Chem Biodivers. 2015 Apr;12(4):593-8. |
| 2101 | Heine HS, et al. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother. 2010 Mar;54(3):991-6. |
| 2102 | Bennett JW, et al. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag. 2008 Feb;4(1):31-40. |
| 2103 | Hill, R. J. et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. The Journal of pharmacology and experimental therapeutics 327, 610-619, doi:10.1124/jpet.108.139006 (2008). |
| 2104 | https://clinicaltrials.gov/ct2/show/NCT04405102?term=Ozanimod&cond=covid&draw=2&rank=1 |
| 2105 | Rzymski T, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget. 2017 May 16;8(20):33779-33795. |
| 2106 | J Am Chem Soc 79: 5721 (1957); 88: 3408 (1966); J Org Chem 29: 3727 (1964)| |
| 2107 | Khan M, et al. Alantolactone induces apoptosis in HepG2 cells through GSH depletion, inhibition of STAT3 activation, and mitochondrial dysfunction. Biomed Res Int. 2013;2013:719858. |
| 2108 | Chun J, et al. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. Cancer Lett. 2015 Feb 1;357(1):393-403. |
| 2109 | He Q, et al. Inhibition of serine palmitoyltransferase by myriocin, a natural mycotoxin, causes inductionof c-myc in mouse liver. Mycopathologia. 2004 Apr;157(3):339-47. |
| 2110 | Amemiya F, et al. Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis. 2008 Feb 1;197(3):361-70. |
| 2111 | Ciesek S, et al. The suppressive effect that myriocin has on hepatitis C virus RNA replication is independent of inhibition of serine palmitoyl transferase. J Infect Dis. 2008 Oct 1;198(7):1091-3. |
| 2112 | Ha HJ, et al. Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease. J Med Chem. 2018 Jan 11;61(1):396-402. |
| 2113 | Lobell RB, et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther. 2002 Jul;1(9):747-758. |
| 2114 | Ghasemi S, et al. Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines. Adv Pharm Bull. 2013;3(1):73-77. |
| 2115 | https://clinicaltrials.gov/ct2/results?cond=Covid19&term=MYCOPHENOLIC+ACID&cntry=&state=&city=&dist= |
| 2116 | J Pharmacol Exp Ther 275:101 (1995); Clin Neuropharmacol 28:83 (2005) |
| 2117 | Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8. |
| 2118 | Fritsch C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13(5):1117-29. |
| 2119 | Gobin B, et al. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer. 2015 Feb 15;136(4):784-96. |
| 2120 | Pauly A, et al. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8172-80. |
| 2121 | Tsai S, et al. The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs. Vet Ophthalmol. 2013 Sep;16(5):370-6. |
| 2122 | Zheng J, et al. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway. Cell Mol Neurobiol. 2011 May;31(4):597-604. |
| 2123 | Ooi YH, et al. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5259-65. |
| 2124 | B'Ann True Gabelt, et al. Prostaglandin Subtype-Selective and Non-Selective IOP-Lowering Comparison in Monkeys. |
| 2125 | Vidya Balasubramanian, et al. CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivoand achieves complete regression in lymphoma xenograft models. Cancer Res October 1, 2014 74; 1697 |
| 2126 | Bradley WD, et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem Biol. 2014 Nov 20;21(11):1463-75 |
| 2127 | Vitorino P, et al. MAP4K4 regulates integrin-FERM binding to control endothelial cell motility. Nature. 2015 Mar 26;519(7544):425-30. |
| 2128 | Noa Shelach. Novel braf inhibitors and use there of for treatment of cutaneous reactions. WO2019026065A2. |
| 2129 | Nakahara T, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007 Sep 1;67(17):8014-21. |
| 2130 | Iisa T, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res. 2008 Oct 15;14(20):6496-504. |
| 2131 | Guo K, et al. A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model. Oncotarget. 2015 Aug 28;6(25):21137-47. |
| 2132 | Mondal S, et al. Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. Int J Cancer. 2019 Jan 1;144(1):178-189. |
| 2133 | Zhang Y, et al. Synergistic Effect of Colistin Combined with PFK-158 against Colistin-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00271-19. |
| 2134 | Pooran Chand, et al. Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic. WO2013148228A1. |
| 2135 | Kwon JS, et al. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. Int Clin Psychopharmacol. 2015;30(6):320-328. |
| 2136 | Q Rev Chem Soc 8:67 (1954) |
| 2137 | Arch. Ophthalmol. (1975), 93(10), 1011-4; Proc. Soc. Exp. Biol. Med. (1959), 101, 653-6; Metab., Clin. Exp. (1958), 7, 398-404 |
| 2138 | https://clinicaltrials.gov/ct2/show/NCT04712357?term=TENOFOVIR&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04685512?term=TENOFOVIR&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04519125?term=TENOFOVIR&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04812496?term=TENOFOVIR&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04405271?term=TENOFOVIR&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04334928?term=TENOFOVIR&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04359095?term=TENOFOVIR&cond=COVID-19&draw=2&rank=7 https://clinicaltrials.gov/ct2/show/NCT04890626?term=TENOFOVIR&cond=COVID-19&draw=2&rank=8 https://clinicaltrials.gov/ct2/show/NCT04575545?term=TENOFOVIR&cond=COVID-19&draw=2&rank=9 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04712357 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200421047155N1 |
| 2139 | Acta Psychiat Scand 52:237 (1975); Life Sci 80:74 (2006) |
| 2140 | https://clinicaltrials.gov/ct2/show/NCT04482595?term=Genistein&cond=COVID-19&draw=2&rank=1 |
| 2141 | Tardif KD, et al. Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Mol Cancer Ther. 2011 Dec;10(12):2267-2275. |
| 2142 | Neuropharmacology (1980), 19(7), 643-52; Am. J. Med. Sci. (1957), 234, 74-7; Ann. Neurol. (1979), 6(5), 410-4 |
| 2143 | Petersen DN, et al. A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation. Cell Chem Biol. 2016 Nov 17;23(11):1362-1371 |
| 2144 | Chem Ind 1962:1652; 1964:838, 1691; Naturwissenschaften 50:155 (1963) |
| 2145 | Zucconi BE, et al. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain LigandI-CBP112. Biochemistry. 2016 Jul 12;55(27):3727-34. |
| 2146 | Picaud S, et al. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer Res. 2015 Dec 1;75(23):5106-19. |
| 2147 | mixed galloyl esters of penta-o-galloylglucose (m-digalloyl shown)| |
| 2148 | Xi Chu, et al. Effects of Tannic Acid, Green Tea and Red Wine on hERG Channels Expressed in HEK293 Cells. PLoS One. 2015; 10(12): e0143797. |
| 2149 | Karuppagounder V, et al. Tannic acid modulates NFκB signaling pathway and skin inflammation in NC/Nga mice through PPARγ expression. Cytokine. 2015 Dec;76(2):206-13. |
| 2150 | Tojo M, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 2005 Nov;96(11):791-800. |
| 2151 | Chem Commun 1974:249; Chem Nat Compounds 38:161 (2002) |
| 2152 | Br J Dermatol 111:115 (1984); 114:493 (1986); J Am Acad Dermatol 17:1033 (1987) |
| 2153 | Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation. April 18, 2013 |
| 2154 | Jiang X, et al. Dracorhodin perchlorate regulates fibroblast proliferation to promote rat's wound healing. J Pharmacol Sci. 2018 Feb;136(2):66-72. |
| 2155 | He Y, et al. Dracorhodin perchlorate suppresses proliferation and induces apoptosis in human prostate cancer cell line PC-3. J Huazhong Univ Sci Technolog Med Sci. 2011 Apr;31(2):215. |
| 2156 | Chen X, et al. Dracorhodin perchlorate induces the apoptosis of glioma cells. Oncol Rep. 2016 Apr;35(4):2364-72. |
| 2157 | Mazzanti A, et, al. Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. J Am Coll Cardiol. 2017 Dec 19;70(24):3010-3015. |
| 2158 | Hermida JS, et, al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol. 2004 May 19;43(10):1853-60. |
| 2159 | Chimienti M, et, al. Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. Cardiovasc Drugs Ther. 1988 Dec;2(5):679-86. |Arzneim. Forsch. (1977), 27(3), 589-93; Therapie (1971), 26(1), 97-107; Experientia (1971), 27(9), 1100-1. |
| 2160 | https://clinicaltrials.gov/ct2/show/NCT04465695?term=Clofazimine&cond=COVID-19&draw=2&rank=1 |
| 2161 | Vo BN, et al. VU0810464, a non-urea G protein-gated inwardly rectifying K+ (Kir 3/GIRK) channel activator, exhibits enhanced selectivity for neuronal Kir 3 channels and reduces stress-induced hyperthermia in mice.Br J Pharmacol. 2019 Jul;176(13):2238-2249. |
| 2162 | Wieting JM,et al. Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators.ACS Chem Neurosci. 2017 Sep 20;8(9):1873-1879. |
| 2163 | Benaim G, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem. 2006 Feb 9;49(3):892-9. |
| 2164 | Sabatelli F, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. |
| 2165 | Sansone-Parsons A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006 May;50(5):1881-3. |
| 2166 | Veiga-Santos P, et al. Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents. 2012 Jul;40(1):61-71. |
| 2167 | Sun QN, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2. |
| 2168 | Williams H, et al. Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in asimulated home environment. Parasit Vectors. 2014 Jun 19;7:275. |
| 2169 | Walther FM, et al. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration. Parasit Vectors. 2014 Mar 6;7:86. |
| 2170 | Matthew C. Stubbs, et al. Abstract 5071: Preclinical characterization of the potent and selective BET inhibitor INCB057643 in models of hematologic malignancies. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5071. |
| 2171 | Smith AL, et al. Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK). J Med Chem. 2015 Feb 12;58(3):1426-41. |
| 2172 | Roest G, et al. The ER Stress Inducer l-Azetidine-2-Carboxylic Acid Elevates the Levels of Phospho-eIF2α and of LC3-II in a Ca2+-Dependent Manner. Cells. 2018 Nov 30;7(12). pii: E239. |
| 2173 | Sotgiu G et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther. 2015 Mar;13(3):305-15. |
| 2174 | Xavier AS et al. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014 Jul;5(3):222-4 |
| 2175 | Mallikaarjun S et al. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5976-85. |
| 2176 | Patterson S et al.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. Elife. 2016 May 24;5. |
| 2177 | Nguyen GH, et al. A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem Biol. 2013 Jan 24;20(1):55-62. |
| 2178 | Banerjee T, et al. A new development in DNA repair modulation: discovery of a BLM helicase inhibitor. Cell Cycle. 2013 Mar 1;12(5):713-4. |
| 2179 | J Am Chem Soc 76: 4245 (1954); Alkaloids 19: 81 (1981) |
| 2180 | J L Stigliani, et al. New Insights Into the Chemical Behavior of S-oxide Derivatives of Thiocarbonyl-Containing Antitubercular Drugs and the Influence on Their Mechanisms of Action and Toxicity. Ann Pharm Fr. 2019 Mar;77(2):126-135. |
| 2181 | P Khanna, et al. Characteristics of a Cytosolic Arylacylamidase Metabolizing Thiacetazone. J Pharmacol Exp Ther. 1992 Sep;262(3):1225-31. |
| 2182 | Anuradha Alahari, et al. Thiacetazone, an Antitubercular Drug That Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria. PLoS One. 2007 Dec 19;2(12):e1343. |
| 2183 | C A Peloquin, et al. Pharmacokinetic Evaluation of Thiacetazone. Pharmacotherapy. Sep-Oct 1996;16(5):735-41. |
| 2184 | Agents Actions Suppl. (1986), AAS 19, 169-75; Clin. Pharmacokinet. (1995), 28(3), 216-34; Arzneim. Forsch. (1956), 6, 124-7 |
| 2185 | Hanan EJ, et al. Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5186-9. |
| 2186 | Stephan Reinhard Künzel, et al. Hypoxia-induced epigenetic silencing of polo-like kinase 2 promotes fibrosis in atrial fibrillation. bioRxiv 445098 |
| 2187 | Huang CY. Inhibition of a Putative Dihydropyrimidinase from Pseudomonas aeruginosa PAO1 by Flavonoids and Substrates of Cyclic Amidohydrolases. PLoS One. 2015 May 19;10(5):e0127634. |
| 2188 | Kou X, et al. Ampelopsin attenuates brain aging of D-gal-induced rats through miR-34a-mediated SIRT1/mTORsignal pathway. Oncotarget. 2016 Nov 15;7(46):74484-74495. |
| 2189 | Chang H, et al. Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway. Carcinogenesis. 2014 Aug;35(8):1847-54. |
| 2190 | Václav Zima, et al. Unraveling the Anti-Influenza Effect of Flavonoids: Experimental Validation of Luteolin and its Congeners as Potent Influenza Endonuclease Inhibitors. Eur J Med Chem. 22 August 2020, 112754. |
| 2191 | Minke E. Binnerts, et al. Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. Molecular Cancer Therapeutics. December 2015 Volume 14, Issue 12 Supplement 2 |
| 2192 | Catherine A. Fabian, et al. Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase. Cancer Research July 2017 Volume 77, Issue 13 Supplement |
| 2193 | Chan MC, et al. Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain. PLoS One. 2015 Jul 6;10(7):e0132004. |
| 2194 | Lim D, et al. Discovery of a Small-Molecule Inhibitor of Protein-MicroRNA Interaction Using Binding Assay with a Site-Specifically Labeled Lin28. J Am Chem Soc. 2016 Oct 7. |
| 2195 | Grootendorst DC, et al. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther. 2003;16(6):341-7. |
| 2196 | Peter Norman. PDE4 inhibitors: sustained patenting activity as leading drugs near the market. Exp. Opin. Ther. Patents (2000) 10(9):1415-1427. |
| 2197 | Effect of substitution of plasticizer dibutyl phthalate with dibutyl sebacate on Eudragit® RS30D drug release rate control. |
| 2198 | Disease Models Mech 6 (2013) doi:10.1242/dmm.; 08243 |
| 2199 | Alexandros Ikonomidis, et al. In vitro and in vivo evaluations of oxacillin efficiency against mecA-positive oxacillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Nov;52(11):3905-8. |
| 2200 | R H Raynor, et al. Oxacillin-induced lysis of Staphylococcus aureus. Antimicrob Agents Chemother. 1979 Aug;16(2):134-40. |
| 2201 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Azilsartan&cond=Covid19&draw=2&rank=1 |
| 2202 | Clin Appl Thromb Hemost 8:169 (2002) |
| 2203 | J. Am. Chem. Soc. (1956), 78, 4498-9; Scand. J. Gastroenterol. (1984), 19(6), 820-3; Experientia (1968), 24(8), 791-2 |
| 2204 | Lorna Kategaya , et al. USP7 Small-Molecule Inhibitors Interfere With Ubiquitin Binding. Nature. 2017 Oct 26;550(7677):534-538. |
| 2205 | Galkin AV, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. |
| 2206 | Katayama R, et al. Therapeutic strategies to overcome PF-02341066 resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. |
| 2207 | Schonherr C, Activating ALK mutations found in neuroblastoma are inhibited by PF-02341066 and NVP-TAE684. Biochem J. 2011 Dec 15;440(3):405-13. |
| 2208 | Foulks JM, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia. 2014 May;16(5):403-12. |
| 2209 | Teng X, et al. Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6836-40. |
| 2210 | Jagtap PG, et al. Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007 Apr 19;50(8):1886-95. |
| 2211 | Teng X, et al. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5039-44. |
| 2212 | Takahashi N, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012 Nov 29;3:e437. |
| 2213 | Newton R, et al. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. Eur J Med Chem. 2016 Apr 13;112:20-32. |
| 2214 | Ghosh S, et al. 4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvateand 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride. Acta Crystallogr C. 2001 Jan;57(Pt 1):76-8. |
| 2215 | Chen CL, et al. Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharm Res. 1999 Jan;16(1):117-22. |
| 2216 | Helv Chim Acta 24:297 (1941) |
| 2217 | van Wyk JA, et al. Two field strains of Haemonchus contortus resistant to rafoxanide. Onderstepoort J Vet Res. 1987 Jun;54(2):143-6. |
| 2218 | Prichard RK, et al. The metabolic profile of adult Fasciola hepatica obtained from rafoxanide-treated sheep. Parasitology. 1978 Jun;76(3):277-88. |
| 2219 | Cornish RA, et al. The in vivo effects of rafoxanide on the energy metabolism of Fasciola hepatica. Int J Parasitol. 1977 Jun;7(3):217-20. |
| 2220 | Rafoxanide |
| 2221 | Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. |
| 2222 | https://clinicaltrials.gov/ct2/show/NCT04979923?term=LIDOCAINE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04609865?term=LIDOCAINE&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04885777?term=LIDOCAINE&cond=COVID-19&draw=2&rank=6 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04609865 |
| 2223 | Tierarztl. Praxis (1991), 19(1), 14-20; Antimicrob. Agents Chemother. (1990), 34(3), 496-7; VMR, Vet. Med. Rev. (1987), (2), 90-9 |
| 2224 | IARC Monographs 10:85 (1976); Anal Profiles Drug Subs 4:47 (1975); 15:701 (1986) |
| 2225 | Fundam Appl Toxicol 4:674 (1984); Food Chem Toxicol 23:419 (1985) |
| 2226 | Bin Ma, Tonika Bohnert, et al. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. J Med Chem. 2020 Jul 22. |
| 2227 | J Agric Food Chem 54:2951 (2006); Am J Epidem 166: 924 (2007); Br J Pharmacol 2 155:244 (2008); Neuropharmacol 58: 911 (2010) |
| 2228 | Maes MB, et al. In vivo effects of a potent, selective DPPII inhibitor: UAMC00039 is a possible tool for the elucidation of the physiological function of DPPII. Adv Exp Med Biol. 2006;575:73-85. |
| 2229 | Maes MB, et al. Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol. 2006 Jun 28;72(1):70-9. |
| 2230 | https://clinicaltrials.gov/ct2/show/NCT04394416?term=Imatinib+Mesylate&cond=covid&draw=2&rank=2 |
| 2231 | Xu MJ, et al. Inhibitory Effects of Danshen components on CYP2C8 and CYP2J2. Chem Biol Interact. 2018 Jun 1;289:15-22. |
| 2232 | Song J, et al. Activation of Nrf2 signaling by salvianolic acid C attenuates NF‑κB mediated inflammatory response both in vivo and in vitro. Int Immunopharmacol. 2018 Oct;63:299-310. |
| 2233 | Royer JF, et al. A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils. Eur J Clin Invest. 2008 Sep;38(9):663-71. |
| 2234 | Luker T, et al. Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6288-92. |
| 2235 | Snell N, et al. Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respir Med. 2013 Nov;107(11):1722-30. |
| 2236 | Guo W, et al. Effect of Leonurus stachydrine on myocardial cell hypertrophy. Zhong Yao Cai. 2012 Jun;35(6):940-3. |
| 2237 | Yin J, et al. Stachydrine, a major constituent of the Chinese herb leonurus heterophyllus sweet, ameliorates human umbilical vein endothelial cells injury induced by anoxia-reoxygenation. Am J Chin Med. 2010;38(1):157-71. |
| 2238 | Rathee P, et al. In vitro anticancer activity of stachydrine isolated from Capparis decidua on prostate cancer cell lines. Nat Prod Res. 2012;26(18):1737-40. |
| 2239 | Zhang C, et al. Effects of stachydrine on norepinephrine-induced neonatal rat cardiac myocytes hypertrophy and intracellular calcium transients. BMC Complement Altern Med. 2014 Dec 8;14:474. |
| 2240 | Zhang C, et al. Effect of stachydrine on endoplasmic reticulum stress-induced apoptosis in rat kidney after unilateral ureteral obstruction. J Asian Nat Prod Res. 2013;15(4):373-81. |
| 2241 | J Nat Prod 47: 901 (1984) |
| 2242 | Br J Haematol 132:615 (2006); Planta Med 76:133 (2010) |
| 2243 | Res. Vet. Sci. (2004), 76(2), 95-108; Br. Vet. J. (1979), 135(4), 318-23; Am. J. Vet. Res. (1978), 39(6), 1037-8 |
| 2244 | Nathanael S. Gray, et al. Degraders of wee1 kinase. WO2020069105A1. |
| 2245 | Reuberson J, et al. Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo. J Med Chem. 2018 Aug 9;61(15):6705-6723. |
| 2246 | J Chem Soc 1966:772; Magn Reson Chem 31: 340 (1993) |
| 2247 | Ann Intern Med 84:712 (1976); Med Clin North Am 66:169 (1982) |
| 2248 | Anticancer Drugs 2001:807; Biochem Pharmacol 67:523 (2004) |
| 2249 | Cancer Lett 168:125 (2001); Carcinogenesis 19:1697 (1998) |
| 2250 | Chen Y, et al. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma. Bioorg Med Chem. 2016 Mar 1;24(5):957-66. |
| 2251 | Benjamin R Bellenie, et al. Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. J Med Chem. 2020 Apr 23;63(8):4047-4068. |
| 2252 | Acta Diabetologica 31:236 (1994); PNAS 91 9253 (1994) |
| 2253 | Sun W, et al. Oroxin A from Oroxylum indicum prevents the progression from prediabetes to diabetes in streptozotocin and high-fat diet induced mice. Phytomedicine. 2018 Jan 1;38:24-34. |
| 2254 | He J, et al. Oroxin A inhibits breast cancer cell growth by inducing robust endoplasmic reticulum stress and senescence. Anticancer Drugs. 2016 Mar;27(3):204-15. |
| 2255 | Maxson JE, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. |
| 2256 | Matsuo Y, et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition ofcytokinesis. Sci Transl Med. 2014 Oct 22;6(259):259ra145. |
| 2257 | Lin A, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019 Sep 11;11(509). |
| 2258 | Lu H, et al. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. Cell Death Dis. 2019 Aug 5;10(8):583. |
| 2259 | Med Chem Res 19:498 (2010) |
| 2260 | Br J Pharmacol 118:915 (1996); 122:1061 (1997); Eur J Pharmacol 361:191 (1998) |
| 2261 | Mondal D, et al. Nelfinavir suppresses signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J. 2013 Spring;13(1):76-90. |
| 2262 | Kaldor SW, et al. Nelfinavir mesylate (AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85. |
| 2263 | Gills JJ, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that inducesendoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007 Sep 1;13(17):5183-94. |
| 2264 | Bono C, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 2012;97(7):1101‐1109. |
| 2265 | Sheng, L., H. Chen, and Y. Li, A HPLC method for determination of nicousamide in dog plasma and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci, 2007. 854(1-2): p. 99-103. |
| 2266 | Daniel T. Monaghan, et al. Positive and negative modulators of nmda receptors. WO 2012019106 A2. |
| 2267 | Van Goor F, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8. |
| 2268 | Phuan PW, et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014 Jul;86(1):42-51. |
| 2269 | Yang M, et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1237-47. doi: 10.1007/s00259-011-1742-z. Epub 2011 Mar 1. |
| 2270 | Gaballah K, et al. The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues. Br J Cancer. 2009 Aug 4;101(3):418-23. doi: 10.1038/sj.bjc.6605092. Epub 2009 Jul 21. |
| 2271 | Checkley D, et al. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging. 2003 Jun;21(5):475-82. |
| 2272 | Cywin CL, et al. Discovery of potent and selective PKC-theta inhibitors. Bioorg Med Chem Lett. 2007 Jan 1;17(1):225-30. |
| 2273 | Stephan Siegel, et al. 2,3-benzodiazepines. WO2014026997A1. |
| 2274 | Salgado VL, et al. Metaflumizone is a novel sodium channel blocker insecticide. Vet Parasitol. 2007 Dec 15;150(3):182-9. Epub 2007 Oct 23. |
| 2275 | Reger TS, et al. Pyridyl amides as potent inhibitors of T-type calcium channels. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1692-6. |
| 2276 | Matthaei J, et al. OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil. Clin Pharmacol Ther. 2019 Jan;105(1):190-200. |
| 2277 | Phytochemistry 16: 9 (1977) |
| 2278 | Tvrdeic A, et al. Dihydrogenated ergot compounds bind with high affinity to GABAA receptor-associated Cl- ionophore. Eur J Pharmacol. 1991 Sep 4;202(1):109-11. |
| 2279 | Tvrdeic A, et al. Dihydroergotoxine modulation of the GABAA receptor-associated Cl- ionophore in mouse brain. Eur J Pharmacol. 1992 Oct 6;221(1):139-43. |
| 2280 | Tvrdeic A, et al. Effect of ergot alkaloids on 3H-flunitrazepam binding to mouse brain GABAA receptors. Coll Antropol. 2003;27 Suppl 1:175-82. |
| 2281 | Abdul M, et al. Expression of gamma-aminobutyric acid receptor (subtype A) in prostate cancer. Acta Oncol. 2008;47(8):1546-50. |
| 2282 | Eltze T, et al. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol Pharmacol. 2008 Dec;74(6):1587-98. |
| 2283 | Arzneim Forsch 31:309 (1981) |
| 2284 | Te Du, et al. Vincamine as a GPR40 agonist improves glucose homeostasis in type 2 diabetic mice. J Endocrinol. 2019 Feb 1;240(2):195-214. |
| 2285 | Li Wu, et al. Vincamine prevents lipopolysaccharide induced inflammation and oxidative stress via thioredoxin reductase activation in human corneal epithelial cells. Am J Transl Res. 2018 Jul 15;10(7):2195-2204. eCollection |Br J Clin Pharmacol 9:100 (1980); N Engl J Med 305:1562 (1981) |
| 2286 | Oku, Y., et al., [Fungicidal activity of liranaftate against Trichophyton rubrum]. Nihon Ishinkin Gakkai Zasshi, 2002. 43(3): p. 181-7. |
| 2287 | Oku, Y., N. Takahashi, and K. Yokoyama, [Fungicidal activity of liranaftate against dermatophytes]. Nihon Ishinkin Gakkai Zasshi, 2009. 50(1): p. 9-13. |
| 2288 | Maruyama N, et, al. [Suppression of experimental inflammation by anti-fungal agent liranaftate in mice]. Nihon Ishinkin Gakkai Zasshi. 2010;51(1):7-11. |
| 2289 | Kobayashi M, et, al. [Anti-fungal drug liranaftate suppresses fungal element-promoted production of IL-8 in normal human keratinocytes]. Nihon Ishinkin Gakkai Zasshi. 2008;49(4):319-22. |
| 2290 | Hazel P, et al. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. ChemMedChem. 2017 Mar 7;12(5):372-380. |
| 2291 | Patel H, et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Mol Cancer Ther. 2018 Jun;17(6):1156-1166. |
| 2292 | https://clinicaltrials.gov/ct2/show/NCT04885530?term=Fluticasone&cond=covid&draw=2&rank=2 |
| 2293 | Wengner AM, et al. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity. Mol Cancer Ther. 2016 Apr;15(4):583-92. |
| 2294 | Ackermann TF, et al. EMD638683, a novel SGK inhibitor with antihypertensive potency. Cell Physiol Biochem. 2011;28(1):137-46. |
| 2295 | Chem Ind 1954:1320; Int J Biol Med Res 3:1242 (2012) |
| 2296 | Jia YS, et al. Antitumor Activity of Tenacissoside H on Esophageal Cancer through Arresting Cell Cycle and Regulating PI3K/Akt-NF-κB Transduction Cascade. Evid Based Complement Alternat Med. 2015;2015:464937. |
| 2297 | John A Butera, et al. Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation. J Med Chem. 2009 Feb 26;52(4):908-11. |
| 2298 | Elke De Vuyst, et al. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol. 2011 Jun;163(3):469-83. |
| 2299 | Witte HM, et al. Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2019 Jan;145(1):129-136. |
| 2300 | Görn M, et al. A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie. 2008 Apr;31(4):185-9. |
| 2301 | Fryer, A.D. and J. Maclagan, Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea-pig. Eur J Pharmacol, 1987. 139(2): p. 187-91. |
| 2302 | Harvey, K.L., A. Hussain, and H.L. Maddock, Ipratropium Bromide-Mediated Myocardial Injury in In Vitro Models of Myocardial Ischaemia/Reperfusion. Toxicol Sci, 2014. |
| 2303 | Maria Prat, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl amides as potent and long acting muscarinic antagonists. Bioorg Med Chem Lett. 2015 Apr 15;25(8):1736-1741. |
| 2304 | Wenhui Zhang, et al. Anti-inflammatory effects of formoterol and ipratropium bromide against acute cadmium-induced pulmonary inflammation in rats. Eur J Pharmacol. 2010 Feb 25;628(1-3):171-8. |
| 2305 | Ligresti A, et al. Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB<sub>1</sub> receptor ligand. Pharmacol Res. 2012 Aug;66(2):163-9. |
| 2306 | Ma J, et al. Yangonin blocks tumor necrosis factor-α-induced nuclear factor-κB-dependent transcription by inhibiting the transactivation potential of the RelA/p65 subunit. J Pharmacol Sci. 2012;118(4):447-54. |
| 2307 | Wruck CJ, et al. Kavalactones protect neural cells against amyloid beta peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. Mol Pharmacol. 2008 Jun;73(6):1785-95. |
| 2308 | Proc Soc Exp Biol Med 66:512 (1947); J Lab Clin Med 38:873 (1951) |
| 2309 | Eur J Clin Pharmacol 7:89 (1969); Arzneim Forsch 22:830 (1972) |
| 2310 | Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4751-60. |
| 2311 | Knani I, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 2016 Oct 22;5(12):1187-1199. |
| 2312 | Mukhopadhyay B, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 2015 May;61(5):1615-26. |
| 2313 | Neef S, et al. Reduction of SR Ca2+ leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailability. Basic Res Cardiol. 2017 Jul;112(4):45. |
| 2314 | J. Cosmet. Dermatol. (2006), 5(3), 196-203; Skin Ther. Lett. (2004), 9(6), 1-3; J. Microbiol. Biotechnol. (2010), 20(8), 1204-1209 |
| 2315 | Fluticasone |
| 2316 | Ishii N, et al. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12. |
| 2317 | Andoh T, et al. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol. 2014 May;23(5):359-61. |
| 2318 | Robb CM, et al. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb). 2017 Jul 4;53(54):7577-7580. |
| 2319 | Wagman JD, et al. The effect of fluphenazine decanoate on glucocorticoid production, reproductive cyclicity, and the behavioral stress response in the Persian onager (Equus hemionus onager). Zoo Biol. 2015 Nov;34(6):525-34. |
| 2320 | Uchida H, et al. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol. 2014 Dec;34(6):728-35. |
| 2321 | Weiss RB, et al. Long-acting neuroleptic use for reproductive management of non-domestic ungulates using the domestic goat (Capra hircus) as a model. Zoo Biol. 2014 May-Jun;33(3):204-11. |
| 2322 | PCT Int. Appl. (2011), WO 2011060746 A1 20110526. |
| 2323 | Friesland A, et al. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1261-6. |
| 2324 | Chou YY, et al. Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J Virol. 2016 Apr 14;90(9):4494-510. |
| 2325 | Kongsamut, S., et al., Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol, 1996. 317(2-3): p. 417-23. |
| 2326 | Sainati, S.M., et al., Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol, 1995. 35(7): p. 713-20. |
| 2327 | Albers, L.J., A. Musenga, and M.A. Raggi, Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs, 2008. 17(1): p. 61-75. |
| 2328 | J Cardiovasc Pharmacol 36:376 (2000); Br J Pharmacol 133:625 (2001); Eur Heart J 23:1481 (2003) |
| 2329 | Pottayil Govindan Nair Sasikumar, et al. 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators. WO2015033301A1. |
| 2330 | Bazhin AV, et al. The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer. Int J Cancer. 2016 Jul 1;139(1):130-9. |
| 2331 | Weniger M, et al. The Analgesic Effect of the Mitochondria-Targeted Antioxidant SkQ1 in Pancreatic Inflammation. Oxid Med Cell Longev. 2016;2016:4650489. |
| 2332 | Lee D, et al. Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases. J Med Chem. 2019 Jan 24;62(2):575-588. |
| 2333 | Carcinogenesis 18:1343 (1997); Cancer Res. 64:6424 (2004) |
| 2334 | Zhang J, et al. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9. |
| 2335 | Thanapprapasr D, et al. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun;14(6):1466-75. |
| 2336 | Goyal L, et al. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 Aug;9(8):1064-1079. |
| 2337 | Kalyukina M, et al. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. ChemMedChem. 2019 Feb 19;14(4):494-500. |
| 2338 | Lamarca A, et al. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer [published online ahead of print, 2020 Mar 12]. J Hepatol. 2020;S0168-8278(20)30165-3. |
| 2339 | Żymańczyk-Duda E, et al. Reductive capabilities of different cyanobacterial strains towards acetophenone as a model substrate - Prospect of applications for chiral building blocks synthesis. Bioorg Chem. 2019 Feb 25. pii: S0045-2068(18)31467-6. |
| 2340 | Hariharan S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrinreceptor antagonist, Cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007 Aug;18(8):1400-7. |
| 2341 | Liebel, F., et al., Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res, 2006. 298(4): p. 191-9. |
| 2342 | Pfaller, M.A. and D.A. Sutton, Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. Diagn Microbiol Infect Dis, 2006. 56(2): p. 147-52. |
| 2343 | Sur, R., et al., Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway. J Invest Dermatol, 2008. 128(2): p. 336-44. |
| 2344 | N Engl J Med 298:289 (1978); 302:250 (1980); Drugs 20:179 (1980) |
| 2345 | Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506. |
| 2346 | Patel PD, et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol. 2013 Nov;9(11):677-684. |
| 2347 | Phytochem 46:177 (1997); Neoplasa 56:387 (2009); Bioorg Med Chem Lett 20:1037 ((2010); African J Pharm Pharmacol 5: 1937 (2011) |
| 2348 | Chung S, Suzuki H, Miyamoto T, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec 21. |
| 2349 | Ji W, et al. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016 Apr 15;11(4):e0153518. |
| 2350 | Cho YS, et al. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. Biochem Biophys Res Commun. 2014 Apr 25;447(1):7-11. |
| 2351 | Jurmeister S, et al. Identification of potential therapeutic targets in prostate cancer through a cross-species approach. EMBO Mol Med. 2018 Feb 5. pii: e8274. |
| 2352 | Meel MH, et al. MELK inhibition in Diffuse Intrinsic Pontine Glioma. Clin Cancer Res. 2018 Jul 30. pii: clincanres.0924.2018. |
| 2353 | Hart PH, et al. Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm Res. 2000 Nov;49(11):619-26. |
| 2354 | Shapira S, et al. Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers. PLoS One. 2016 Jun 8;11(6):e0156540. |
| 2355 | Sulkowski PL, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologousrecombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017 Feb 1;9(375). |
| 2356 | Jun Yan He, et al. Salicin as a Multipurpose Therapeutic Approach for Colon Cancer. |
| 2357 | Li Y, et al. D(-)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models. Int Immunopharmacol. 2015 Jun;26(2):286-94. |Am J Med Sci 80:273 (1880); Arch Intern Med 101:997 (1958) |
| 2358 | Zhou H, et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell. 2010 Jun 15;17(6):560-73. |
| 2359 | Chen L, et al. Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα. Nat Commun. 2017 Jul 17;8:16066. |
| 2360 | Ibrahim Abdelwahab S, et al. In vitro and in vivo anti-inflammatory activities of columbin through the inhibition of cycloxygenase-2 and nitric oxide but not the suppression of NF-κB translocation. Eur J Pharmacol. 2012 Mar 5;678(1-3):61-70. |
| 2361 | A J Nok, et al. Columbin inhibits cholesterol uptake in bloodstream forms of Trypanosoma brucei-A possible trypanocidal mechanism.J Enzyme Inhib Med Chem. 2005 Aug;20(4):365-8. |
| 2362 | Yang G, et al. Development and validation of an UPLC-MS/MS method for the quantification of columbin in biological matrices: Applications to absorption, metabolism, and pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:13-8 |
| 2363 | Wang F, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013 May 3;340(6132):622-6. |
| 2364 | Miller AT, et al. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19. Sci Immunol. 2019 Oct 25;4(40). pii: eaaw2707. |
| 2365 | Martin, Matthew W.; Newcomb, John; Nunes, Joseph J.; et al. Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity. Journal of Medicinal Chemistry (2008), 51(6), 1637-1648. |
| 2366 | Liew, Chin Y.; Ma, Xiao H.; Liu, Xianghui; Yap, Chun W. SVM Model for Virtual Screening of Lck Inhibitors. Journal of Chemical Information and Modeling (2009), 49(4), 877-885. |
| 2367 | Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245. |
| 2368 | Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7. |
| 2369 | Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46. |Pharmacol Toxicol 74:244 (1994);Cardiovasc Drud Rev 14:286 (1996) |
| 2370 | Rosenthal AS, et al. An inhibitor of the Cdc2-like kinase 4 (Clk4). |
| 2371 | Huang PH, et al. Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med. 2013;2013:376123. |
| 2372 | Liu K, et al. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012 Jul;33(7):1406-11. |
| 2373 | Li SW, et al. Antiviral activity of aloe-emodin against influenza A virus via galectin-3 up-regulation. Eur J Pharmacol. 2014 Sep 5;738:125-32. |
| 2374 | Suboj P, et al. Aloe emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-κB. Eur J Pharm Sci. 2012 Apr 11;45(5):581-91. |
| 2375 | Katz A, et al. Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. J Biol Chem. 2010 Jun 18;285(25):19582-92. |
| 2376 | Wu SH, et al. Bufalin induces apoptosis in vitro and has Antitumor activity against human lung cancer xenografts in vivo. Environ Toxicol. 2017 Apr;32(4):1305-1317. |
| 2377 | Martin KR, et al. A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress. iScience. 2018 Oct 26;8:74-84. |
| 2378 | Toxicol Appl Pharmacol 1:240 (1959); N Engl J Med 308:357 (1983); 320:1238 (1989) |
| 2379 | US20180360805. |
| 2380 | Ponnusamy S, et al. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Res. 2017 Nov 15;77(22):6282-6298. |
| 2381 | Deng G, et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem. 2015 Jan 9;290(2):762-74. |
| 2382 | Preparation of quinazolinediones as Kif15 kinesin inhibitors for treating cellular proliferative disorders. Pat. Appl. Publ. (2004), US 20040053948 A1 20040318. |
| 2383 | Teng F, et al. Production of d-glucuronic acid from myo-inositol using Escherichia coli whole-cell biocatalyst overexpressing a novel myo-inositol oxygenase from Thermothelomyces thermophile. Enzyme Microb Technol. 2019 Aug;127:70-74. |
| 2384 | Cesen MH, et al. Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Cell Death Dis. 2013 Oct 3;4:e818. |
| 2385 | Spirkoski J, et al. Mast cell apoptosis induced by siramesine, a sigma-2 receptor agonist. Biochem Pharmacol. 2012 Dec 15;84(12):1671-80. |
| 2386 | Skuza G, et al. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J Physiol Pharmacol. 2006 Jun;57(2):217-29. |
| 2387 | Agrimol B, et al. Agrimol B suppresses adipogenesis through modulation of SIRT1-PPAR gamma signal pathway. Biochem Biophys Res Commun. 2016 Aug 26;477(3):454-60. |
| 2388 | T Nagatomo, et al. Binding Characteristics of <sup>3</sup>H-dihydroalprenolol to Beta-Adrenoceptors of Rat Heart Treated With Neuraminidase. Jpn J Pharmacol. 1983 Aug;33(4):851-7. |
| 2389 | A S Manning, et al. Abrupt Withdrawal of Chronic Beta-Blockade: Adaptive Changes in Cyclic AMP and Contractility. J Mol Cell Cardiol. 1981 Nov;13(11):999-1009. |
| 2390 | Hu S, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res. 2019 May 7. |
| 2391 | Shanhu Hu, et al. SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors. |
| 2392 | Dongcheng Dai, et al. Antiviral drugs for treatment of arenavirus infection. WO2013123215A2. |
| 2393 | Dennis P. Curran, et al. Synthesis of and intermediates for camptothecins. WO1999001456A1. |
| 2394 | Br. J. Pharmacol. (2011), 162(5), 1213-1224; Free Radical Biol. Med. (2008), 44(7), 1465-74; Free Radical Biol. Med. (1999), 27(9-10), 1103-13 |
| 2395 | Su-Lin Lee,et al Identification and Characterization of a Novel Integrin-Linked Kinase Inhibitor.J Med Chem. 2011 Sep 22; 54(18): 6364–6374 |
| 2396 | Liu TM, et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood. 2015 Jan 8;125(2):284-95. |
| 2397 | Allen, P.J., Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value. Neurosci Biobehav Rev, 2012. 36(5): p. 1442-62. |
| 2398 | Levey, A.S., et al., Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med, 2006. 145(4): p. 247-54. |J Biol Chem 81:73 (1929); JACS 93:5552 (1971) |
| 2399 | Nakao S et al. Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs. Bioorg Med Chem Lett, 2014 Feb 15, 24(4):1071-4. |
| 2400 | Biochem. Pharmacol. (1966), 15(1), 49-54; Br. J. Pharmacol. Chemother. (1964), 23, 313-29; J. Physiol. (1962), 162, 105-20, |
| 2401 | Zaneta Nikolovska-Coleska, et al. Small molecule inhibitors of mcl-1 and uses thereof. WO2015153959A2. |
| 2402 | Mahajan S, et al. VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 Mar 11. pii: jpet.114.221176. |
| 2403 | Cansfield AD, et al. CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model. ACS Med Chem Lett. 2016 Jun 10;7(8):768-73. |
| 2404 | Kerres N, et al. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6. Cell Rep. 2017 Sep 19;20(12):2860-2875. |
| 2405 | Mikołaj Słabicki, et al. Small-molecule-induced polymerization triggers degradation of BCL6. Nature. 2020 Nov 18. |
| 2406 | Ho H, et al. Structural basis for dual-mode inhibition of the ABC transporter MsbA. Nature. 2018 May;557(7704):196-201. |
| 2407 | J. Pharm. Pharmacol. (1963), 15, 212-14. ; J. Chem. Eng. Data (1962), 7, 265-6; (1957), GB 774635 19570515, |
| 2408 | Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4. |
| 2409 | Li K, et al. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019 Mar;27(3):244-256. |
| 2410 | Zhang H, et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019 Apr 3;37(15):2090-2098. |
| 2411 | Mengyuan Li, et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020 Oct;8(2):e000293. |
| 2412 | Bhatia S, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.Blood. 2018 Jul 19;132(3):307-320. |
| 2413 | Burlison JA, et al. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.J Am Chem Soc. 2006 Dec 6;128(48):15529-36. |
| 2414 | Rong P, et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014 Jan 15;4(3):229-39. |
| 2415 | Shams M, et al. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol Immunother. 2015 Mar;64(3):287-97. |
| 2416 | Arzneim. Forsch. (1961), 11, 1119-26; Acta Pharmacol. Toxicol. (1955), 11, 148-55; Helv. Chim. Acta (1941), 24, 36-40E. |
| 2417 | https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20190727044343N1 |
| 2418 | Iaconelli J, et al. HDAC6 Inhibitors Modulate Lys49 Acetylation and Membrane Localization of β-Catenin in Human iPSC-Derived Neuronal Cells. ACS Chemical Biology (2015), 10(3), 883-890. |
| 2419 | Tang D, et al. Metformin facilitates BG45-induced apoptosis via an anti-Warburg effect in cholangiocarcinoma cells. Oncol Rep. 2018 Apr;39(4):1957-1965. |
| 2420 | Hongbin Guo, et al. Metabolites profiling and pharmacokinetics of troxipide and its pharmacodynamics in rats with gastric ulcer. Sci Rep. 2020 Aug 12;10(1):13619. |
| 2421 | K Kusugami, et al. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants. Dig Liver Dis. 2000 May;32(4):305-11. |
| 2422 | Jun Tang, et al. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology |
| 2423 | J L Mateos, et al.[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review]. Drugs Today (Barc). 2010 Feb;46 Suppl A:1-25. |
| 2424 | Bo Wang, et al. Chronic administration of parecoxib exerts anxiolytic-like and memory enhancing effects and modulates synaptophysin expression in mice. BMC Anesthesiol. 2017 Nov 13;17(1):152. |
| 2425 | Lin-Yong Li, et al. Parecoxib inhibits glioblastoma cell proliferation, migration and invasion by upregulating miRNA-29c. Biol Open. 2017 Mar 15;6(3):311-316. |
| 2426 | Oyama K, et al. Antibacterial Effects of Glycyrrhetinic Acid and Its Derivatives on Staphylococcus aureus. PLoS One. 2016 Nov 7;11(11):e0165831. |
| 2427 | Ma FY, et al. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol. 2007 Feb;18(2):472-84. |
| 2428 | Vasilevskaya IA, et al. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents. Clin Cancer Res. 2015 Sep 15;21(18):4143-52. |
| 2429 | Ma FY, et al. Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab Invest. 2009 Apr;89(4):470-84. |
| 2430 | Qi W, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5. |
| 2431 | Yu G, et al. Protective effects of LM22A-4 on injured spinal cord nerves. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6526-32. eCollection 2015. |
| 2432 | Kajiya M, et al. BDNF mimetic compound LM22A-4 regulates cementoblast differentiation via the TrkB-ERK/Akt signaling cascade. Int Immunopharmacol. 2014 Apr;19(2):245-52 |
| 2433 | Drabikowska AK, et al. Inhibitor properties of some 5-substituted uracil acyclonucleosides, and 2,2'-anhydrouridines versus uridine phosphorylase from E. coli and mammalian sources. Biochem Pharmacol. 1987 Dec 1;36(23):4125-8. |
| 2434 | Cherrill DA, et al. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med. 1975 Nov;83(5):654-6. |
| 2435 | Singer I, et al. Demeclocycline-induced nephrogenic diabetes insipidus. In-vivo and in-vitro studies. Ann Intern Med. 1973 Nov;79(5):679-83. |
| 2436 | Forrest JN Jr, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med. 1978 Jan 26;298(4):173-7. |
| 2437 | Zhang Z, et al. Analytical method for the determination of meptyldinocap as the 2,4-dinitro-octylphenol metabolite in cucumber and soil using LC-MS/MS and a study of the residues in a Chinese cucumber field ecosystem. Pest Manag Sci. 2014 Jan;70(1):97-102. |
| 2438 | Acta Pharmacol Toxicol 4:265 (1948); Ecotoxicol Environ Saf 6:149 (1982)| |
| 2439 | Beckman ML, et al. Stereoselective inhibition of serotonin transporters by antimalarial compounds. Neurochem Int. 2014 Jul;73:98-106. |
| 2440 | Moffat D, et al. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem. 2010 Dec 23;53(24):8663-78. |
| 2441 | J Chem Soc 1969:33; Phytochem 11:3479 (1972); Anticancer Res 21:1905 (2001); Phytother Res 15:441 (2001); African J Biotech 10:16337 (2011) |
| 2442 | Kawasaki S, et al. Effects of hypnotic bromovalerylurea on microglial BV2 cells. J Pharmacol Sci. 2017 Jun;134(2):116-123. |
| 2443 | Mrongovius RI, et al. Comparison of the bromureide sedative-hypnotic drugs, bromvaletone (bromisoval) and carbromal, and their chloro analogues in mice. Clin Exp Pharmacol Physiol. 1976 Sep-Oct;3(5):443-7. |
| 2444 | Hartman JC, et al. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol. 2010 Jun;88 |
| 2445 | Tilton RG, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther. 2000;13(2):87-97. |
| 2446 | Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6. |
| 2447 | Li MH, et al. Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma. J Pharmacol Exp Ther. 2015 Sep;354(3):261-8. |
| 2448 | Guo C, et al. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem. 2011 Nov 10;54(21):7693-704. |
| 2449 | Han X, et al. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964. |
| 2450 | Billiard J, et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab. 2013 Sep 6;1(1):19. |
| 2451 | Cal West Med 37:405 (1932) |
| 2452 | Angewandte Chem IntL Ed 12:869 (1973); 37:1802 (1998); Horm Metab Res 19:233 (1987) |
| 2453 | J Chem Soc 1949: 3271; Biotechnol Biochem 61: 890 (1997) |
| 2454 | Moerke NJ, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 2007 Jan 26;128(2):257-67. |
| 2455 | Yi T, et al. 4EGI-1 targets breast cancer stem cells by selective inhibition of translation that persists in CSC maintenance, proliferation and metastasis. Oncotarget. 2014 Aug 15;5(15):6028-37. |
| 2456 | Wu M, et al. Anti-Cancer Effect of Cap-Translation Inhibitor 4EGI-1 in Human Glioma U87 Cells: Involvement of Mitochondrial Dysfunction and ER Stress. Cell Physiol Biochem. 2016;40(5):1013-1028. Epub 2016 Dec 12. |
| 2457 | https://clinicaltrials.gov/ct2/show/NCT04335123?term=Losartan&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04643691?term=Losartan&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04328012?term=Losartan&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04606563?term=Losartan&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04447235?term=Losartan&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04312009?term=Losartan&cond=COVID-19&draw=2&rank=8 https://clinicaltrials.gov/ct2/show/NCT04311177?term=Losartan&cond=COVID-19&draw=2&rank=9 https://clinicaltrials.gov/ct2/show/NCT04340557?term=Losartan&cond=COVID-19&draw=2&rank=10 |
| 2458 | J Pharmac Pharmacol 15 Suppl 1:97T (1963); J Biol Chem 267:1569 (1992) |
| 2459 | Drouin L, et al. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9. |
| 2460 | J Chem Soc C 1967:842; Indian J Chem Soc 7:977 (1969); J Biol Chem 288:23858 (2013) |
| 2461 | Drug Ther. Bull. (1999), 37(8), 57-8; Drugs (1995), 50(2), 317-33; J. Med. Chem. (1967), 10(5), 799-802| |
| 2462 | Mollmann, H., et al., Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharmaceutical research, 1995. 12(7): p. 1096-1100. |
| 2463 | Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs. 2001 Apr;10(4):733-40. |
| 2464 | ZuWallack AR, ZuWallack RL. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Expert Opin Pharmacother. 2004 Aug;5(8):1827-35. |
| 2465 | Lipson DA. Tiotropium bromide. Int J Chron Obstruct Pulmon Dis. 2006;1(2):107-14. |
| 2466 | Mamary AJ, Criner GJ. Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2009 Jun;3(3):211-20. |
| 2467 | Szmidt M. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)]. Pneumonol Alergol Pol. 2012;80(3):255-62. |
| 2468 | Seganish WM. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015). Expert Opin Ther Pat. 2016 Aug;26(8):917-32. |
| 2469 | Lee KL, et al. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13;60(13):5521-5542. |
| 2470 | J Pharmacol Exp Ther 105:166 (1952); Toxicol Appl Pharmacol 18:185 (1971); Crit Care Clin 7:639 (1991) |
| 2471 | Ching-Wen C, et al. p-Hydroxyacetophenone suppresses nuclear factor-κB-related inflammation in nociceptive and inflammatory animal models. J Nat Med. 2017 Apr;71(2):422-432. |
| 2472 | Ning Xi, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res 2014;74(19 Suppl):Abstract nr 1755. |
| 2473 | Toxicol Appl Pharmacol 22:332 (1972); Curr Ther Res 59:420 (1998) |
| 2474 | Tetrahedron 8:64 (1960); Phytochemistry 11:2283 (1972); 24:1027 (1985) |
| 2475 | Zhang N, et al. Biodegradable polymeric micelles encapsulated JK184 suppress tumor growth through inhibiting Hedgehog signaling pathway. Nanoscale. 2015 Feb 14;7(6):2609-24. |
| 2476 | Colavito SA, et al. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway. Breast Cancer Res. 2014 Sep 25;16(5):444. |
| 2477 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Hydrocortisone&cntry=&state=&city=&dist= |
| 2478 | Bocos C, et al. Effect of etofibrate on bile production in the normolipidemic rat. Gen Pharmacol. 1995 May;26(3):537-42. |
| 2479 | Zhang D, et al. Echinacoside inhibits amyloid fibrillization of HEWL and protects against Aβ-induced neurotoxicity. Int J Biol Macromol. 2014 Sep 2;72C:243-253. |
| 2480 | Zhu M, et al. Transient exposure to echinacoside is sufficient to activate Trk signaling and protect neuronal cells from rotenone. J Neurochem. 2013 Feb;124(4):571-80. |
| 2481 | Li F, et al. Antiosteoporotic activity of echinacoside in ovariectomized rats. Phytomedicine. 2013 Apr 15;20(6):549-57. |
| 2482 | Li F, et al. Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells. Fitoterapia. 2012 Dec;83(8):1443-50. |
| 2483 | Li X, et al. Echinacoside ameliorates D-galactosamine plus lipopolysaccharide-induced acute liver injury in mice via inhibition of apoptosis and inflammation. Scand J Gastroenterol. 2014 Aug;49(8):993-1000. |
| 2484 | Tang C, et al. Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 2020 Mar 19. pii: S0006-291X(20)30530-1. |
| 2485 | Rohde JM, et al. Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors. Bioorg Med Chem. 2018 May 1;26(8):1727-1739. |
| 2486 | Phytochemistry 42: 443 (1996) |
| 2487 | Pharmazie 8: 584 (1953); Biochim Biophys Acta 1001: 1 (1989)| |
| 2488 | Huang YT, et al. Aristolochic acid I interferes with the expression of BLCAP tumor suppressor gene in human cells. Toxicol Lett. 2018 Jul;291:129-137. |
| 2489 | Helv Chim Acta 27:1748 (1944); J Pharmacol Exp Therap 131:115 (1961) |
| 2490 | Oliveira MM, et al. Dihydrocaffeic Acid Prevents UVB-Induced Oxidative Stress Leading to the Inhibition of Apoptosis and MMP-1 Expression via p38 Signaling Pathway. Oxid Med Cell Longev. 2019 Jan 17;2019:2419096. |
| 2491 | Foster P, et al. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models. Mol Cancer Ther. 2015 Apr;14(4):931-40. |
| 2492 | Hasler CM, et al. Specific binding to protein kinase C by ingenol and its induction of biological responses. Cancer Res. 1992 Jan 1;52(1):202-8. |
| 2493 | Shen Y et al. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. J Med Chem. 2016 Sep 15. |
| 2494 | Wang J, et al. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth. Bioorg Med Chem. 2018 Nov 1;26(20):5435-5442. |
| 2495 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=NALBUPHINE+&cntry=&state=&city=&dist=&Search=Search |
| 2496 | N. R. Mirza, et al. NS11394 [3 -[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a Unique Subtype-Selective GABAA Receptor Positive Allosteric Modulator: In Vitro Actions, Pharmacokinetic Properties and in Vivo Anxiolytic Efficacy. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2008 Jul. |
| 2497 | G. Munro, J. A., et al. Comparison of the Novel Subtype-Selective GABAA Receptor-Positive Allosteric Modulator NS11394 [3′-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with Diazepam, Zolpidem, Bretazenil, and Gaboxadol in Rat Models of Inflammatory and Neuropathic Pain. Journal of Pharmacology and Experimental Therapeutics December 2008, 327 (3) 969-981. |
| 2498 | Martine Hofmann, et al. Assessment of the effects of NS11394 and L-838417, a2/3 subunit-selective GABAA receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. Behavioural Pharmacology 2012, 23:790–801. |
| 2499 | Antimicrob Agents Chemother 1:221 (1972); 3:657 (1973); 6:177 (1974); 9:140, 10:814 (1976) |
| 2500 | Dae Yong Kim, et al. Costunolide-A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential. Int J Mol Sci. 2019 Jun; 20(12): 2926. |
| 2501 | Minyan Wei, et al. Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells. Oncol Rep. 2020 Jun;43(6):1986-1994. |
| 2502 | Zhangxiao Peng, et al. Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway.Sci Rep. 2017; 7: 41254. |
| 2503 | Tetrahedron 25:4617(1969); An Acad Brasil Cienc 42 (suplemento): 45 (1970) |
| 2504 | Appl. Microbiol 7:199 (1959); Appl Environ Microbiol 9:278 (1961); IARC Monographs 4:259 (1974) |
| 2505 | http://en.irct.ir/trial/47475 |
| 2506 | Wu FL , et al. Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2'-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics. Cancer Lett. 2015 Jul 10;363(1):7-16. |
| 2507 | Hu N, et al. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine. Cell Physiol Biochem. 2017;44(6):2158-2173. |
| 2508 | Glazer RI, et al. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol. 1982 Mar;21(2):468-73. |
| 2509 | Kanzawa F, et al. Differences between 5-fluoro-2'-deoxyuridine and 5-fluorouridine in their cytotoxic effect on growth of murine lymphoma L5178Y cells in in vivo and in vitro systems. Eur J Cancer. 1980 Aug;16(8):1087-92. |
| 2510 | Sun XP, et al. ABT-737 Induces Apoptosis of Gastric Carcinoma Cells In Vitro and In Vivo.J Int Med Res. 2012;40(4):1251-64. |
| 2511 | Clerc P, et al. Polster BM.Rapid Detection of an ABT-737-Sensitive Primed for Death State in Cells Using Microplate-Based Respirometry.PLoS One. 2012;7(8):e42487. Epub 2012 Aug 3. |
| 2512 | Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov;10(5):375-88. |
| 2513 | Helv Chim Acta 4:100 (1921);19:1402 (1936); J Chem Soc 1950:1983; J Lab Clin Med 47:20 (1956); Fitoterapia 55:279 (1984); Antiviral Res 7:127 (1987); 10:289 (1988); 11:255 (1989)| |
| 2514 | Su X, et al. Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed Pharmacother. 2017 Sep 5;95:670-678 |
| 2515 | Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017 Sep 4;95:599-604. |
| 2516 | Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27(5):722-731. |
| 2517 | Xia Zhao, et al. A Simple Injectable Moldable Hydrogel Assembled from Natural Glycyrrhizic Acid with Inherent Antibacterial Activity. ACS Appl. Bio Mater. 2020, 3, 1, 648–653. |
| 2518 | Lei X, et al. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-β peptides. Sci Rep. 2015 Nov 16;5:16541. |
| 2519 | Drugs (1978), 15(3), 198-217; Dis. Nerv. Syst. (1975), 36(7), 361-4; Arzneim. Forsch. (1965), 15(8), 841-3 |
| 2520 | Kotschy A, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016 Oct 27;538(7626):477-482. |
| 2521 | Antimicrob Agents Chemother 33:1167 (1987); 34:89 (1990) |
| 2522 | Toxicology. 3rd ed. Wiley , NY 1981-1982, 2768; Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Hoboken, NJ. 2004.,3530 |
| 2523 | Lee G, et al. Anti-inflammatory and antioxidant mechanisms of urolithin B in activated microglia. Phytomedicine. 2019 Mar 1;55:50-57. |
| 2524 | Rodriguez J, et al. Urolithin B, a newly identified regulator of skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):583-597. |
| 2525 | J Pharmacol 8:351 (1977); Biochem Pharmacol 28:141 (1979); Arzneim Forsch 32:915, 955 (1982) |
| 2526 | Xu S, et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther. 2013 Jun;12(6):937-49. |
| 2527 | Kim YY, et al. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017 Sep 26;19(1):211. |
| 2528 | Thompson JE, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23. |
| 2529 | Nakagawa R, et al. Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17. J Immunol. 2011 Nov 1;187(9):4611-20. |
| 2530 | Papeo G, et al. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. J Med Chem. 2015 Sep 10;58(17):6875-98. |
| 2531 | Fernandez-Alba, J., et al., Fenticonazole nitrate for treatment of vulvovaginitis: efficacy, safety, and tolerability of 1-gram ovules, administered as ultra-short 2-day regimen. J Chemother, 2004. 16(2): p. 179-86. |
| 2532 | Rofida Albash, et al. Ultra-deformable liposomes containing terpenes (terpesomes) loaded fenticonazole nitrate for treatment of vaginal candidiasis: Box-Behnken design optimization, comparative ex vivo and in vivo studies. Drug Deliv. 2020 Dec;27(1):1514-1523. |
| 2533 | Sun K, et al. Subcellular distribution and biotransformation of phenanthrene in pakchoi after inoculation with endophytic Pseudomonas sp. as probed using HRMS coupled with isotope-labeling. Environ Pollut. 2018 Jun;237:858-867. |
| 2534 | Dupuy J, et al. Effect and localization of phenanthrene in maize roots. Chemosphere. 2016 Apr;149:130-6. |
| 2535 | https://clinicaltrials.gov/ct2/show/NCT04462367?term=Pancuronium&cond=Covid19&draw=2&rank=1 |
| 2536 | Scott JS, et al. Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329). J Med Chem. 2012 Nov 26;55(22):10136-47. |
| 2537 | Aneja B, et al. Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis. Eur J Med Chem. 2019 Feb 1;163:840-852. |
| 2538 | Griswold DE, et al. SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol. 1987 Oct 15;36(20):3463-70. |
| 2539 | Frasch SC, et al. p38 mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils. J Biol Chem. 1998 Apr 3;273(14):8389-97. |
| 2540 | M J DiMartino, et al. Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase. Agents Actions. 1987 Feb;20(1-2):113-23. |
| 2541 | L A Marshall, et al. Inhibitors of the p38 mitogen-activated kinase modulate IL-4 induction of low affinity IgE receptor (CD23) in human monocytes. J Immunol. 1998 Dec 1;161(11):6005-13. |
| 2542 | Reed D, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem. 2010 Apr 2;285(14):10786-96. |
| 2543 | Bista M, et al. On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. PLoS One. 2012;7(6):e37518. |
| 2544 | Wu X, et al. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer. J Med Chem. 2018 Dec 27;61(24):11280-11297. |
| 2545 | Smaill JB, et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000 Apr 6;43(7):1380-97. |
| 2546 | Djerf Severinsson EA, et al. The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochem Biophys Res Commun. 2011 Oct 28;414(3):563-8. |
| 2547 | McAndrews KM, et, al. Mechanisms associated with biogenesis of exosomes in cancer. Mol Cancer. 2019 Mar 30;18(1):52. |
| 2548 | Lee SW, et al. Phenolic compounds isolated from Psoralea corylifolia inhibit IL-6-induced STAT3 activation. Planta Med. 2012 Jun;78(9):903-6. |
| 2549 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=HYDRALAZINE&cond=COVID-19&draw=2&rank=1 |
| 2550 | Pundir S, et al. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification. Cancer Res. 2015 Oct 1;75(19):4164-4175. |
| 2551 | Lee Hoyun, et al. Preparation of quinoline sulfonyl derivatives for the treatment of cancer. From PCT Int. Appl. (2014), WO 2014134705 A1 20140912. |
| 2552 | Tournilhac O, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004 Jan 1;103(1):363-5. Epub 2003 Sep 11. |
| 2553 | Liang YB, et al. Downregulated SOCS1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type. Mol Med Rep. 2017 Nov;16(5):6405-6411. |
| 2554 | Sanhes L, et al. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases. Leukemia. 2003 Jun;17(6):1104-11. |
| 2555 | Weiss L, et al. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintainseffective graft-versus-leukemia effect after allogeneic stem cell transplantation in murinelymphocytic leukemia. Bone Marrow Transplant. 2003 Jan;31(1):11-5. |
| 2556 | Frank DA,et al. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999 Apr;5(4):444-7. |
| 2557 | Shaoqing Hu, et al.Evaluation of anti-apoptotic, anti-injury and antihepatitis
 B virus effects of isochlorogenic acid C in
 vitro. Journal of Medicinal Plants Research Vol. 6(16), pp. 3199-3206 30 April, 2012 |
| 2558 | Therapeutische Monatsh 17:208 (1903) |
| 2559 | J Pharmacol Exp Ther 130:222 (1960); Acta Pharmacol Toxicol 47:263 (1980) |
| 2560 | Tet Letters 1965: 3523; 1967: 220 |
| 2561 | Chen YY, et al. Methyl cinnamate inhibits adipocyte differentiation via activation of the CaMKK2-AMPK pathwayin 3T3-L1 preadipocytes. J Agric Food Chem. 2012 Feb 1;60(4):955-63. |
| 2562 | https://clinicaltrials.gov/ct2/show/NCT04351763?term=Verapamil&cond=Covid19&draw=2&rank=1 |
| 2563 | Gargett CE, et al. The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol. 1997 Apr;120(8):1483-90. |
| 2564 | Ravi RG, et al. Potent P2X7 Receptor Antagonists: Tyrosyl Derivatives Synthesized Using a Sequential Parallel Synthetic Approach. Drug Dev Res. 2001 Oct;54(2):75-87. |
| 2565 | Manosso LM, et al. Antidepressant-like effect of zinc is dependent on signaling pathways implicated in BDNF modulation. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jun 3;59:59-67. |
| 2566 | G M Bressa. et al. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14. |
| 2567 | Wadie I Najm, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord. 2004 Feb 26;5:6. |
| 2568 | Shelly C Lu, et al. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012 Oct;92(4):1515-42. |
| 2569 | Bodin NO, et al. Bacampicillin: a new orally well-absorbed derivative of ampicillin. Antimicrob Agents Chemother. 1975 Nov;8(5):518-25. |
| 2570 | Reprod Toxicol 12:217 (1998); JAMA 281:2189 (1999); 282:637 (1999) |
| 2571 | Afobazole, From Wikipedia |
| 2572 | Ganeshkumar Y, et al. Picroside I and Picroside II from Tissue Cultures of <i>Picrorhiza kurroa</i>. Pharmacognosy Res. 2017 Dec;9(Suppl 1):S53-S56. |
| 2573 | Sen Zhang, et al. Picroside I inhibits asthma phenotypes by regulating Tbet/GATA-3 ratio and Th1/Th2 balance in a murine model of asthma. Tropical Journal of Pharmaceutical Research September 2018; 17 (9): 1777-1782. |
| 2574 | Buset Ríos N, Rodríguez Esparragón F, Fernández-Andrade Rodríguez C, et al. Vascular and metabolic properties of manidipine . Nefrologia. 2011;31(3):268-74. |
| 2575 | Costa S, Zimetti F, Pedrelli M, et al. Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages. Pharmacol Res. 2010 Sep;62(3):265-70. |
| 2576 | Cavalieri L, Cremonesi G. Metabolic effects of manidipine. Am J Cardiovasc Drugs. 2009;9(3):163-76. doi: 10.2165/00129784-200909030-00004. |
| 2577 | Roca-Cusachs A, Triposkiadis F. Antihypertensive effect of manidipine. Drugs. 2005;65 Suppl 2:11-9. |
| 2578 | Nagaoka A. Pharmacologic characteristics of a new calcium antagonist, manidipine: beneficial effects on renal circulation and vascular changes. Am Heart J. 1993 Feb;125(2 Pt 2):560-5. |
| 2579 | Hwee DT, et al. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014 May 7;9(5):e96921. |
| 2580 | Eckburg PB, et al. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects. Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00892-19. |
| 2581 | Corbett D, et al. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00200-17. |
| 2582 | Larsen ST, et al. Effects of R-(+)- and S-(-)-limonene on the respiratory tract in mice. Hum Exp Toxicol. 2000 Aug;19(8):457-66. |
| 2583 | Zhu S, et al. Comprehensive Interactome Analysis Reveals that STT3B is Required for the N-Glycosylation of Lassa Virus Glycoprotein. J Virol. 2019 Sep 11. pii: JVI.01443-19. |
| 2584 | Lopez-Sambrooks C, et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat Chem Biol. 2016 Dec;12(12):1023-1030. |
| 2585 | Wakeling AE, et al. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991 Aug 1;51(15):3867-73. |
| 2586 | Osborne CK, et al. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004 Mar;90 Suppl 1:S2-6. |
| 2587 | Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56 |
| 2588 | Yu X, et al.MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.Mol Cancer. 2015 Dec 15;14:208. |
| 2589 | Julia Kuhn, et al. GPR30 estrogen receptor agonists induce mechanical hyperalgesia in the rat. Eur J Neurosci. 2008 Apr;27(7):1700-9. |Drugs (2011), 71(3), 363-380; Int. J. Cancer (1994), 56(2), 295-300; Cancer Res. (1991), 51(15), 3867-73 |
| 2590 | Alexander LT, et al. Type II Inhibitors Targeting CDK2. ACS Chem Biol. 2015 Sep 18;10(9):2116-25. |
| 2591 | Jones K, et al. Cancer Drug Discovery 2010: from molecules to medicine. Expert Rev Clin Pharmacol. 2010 Sep;3(5):613-5. |
| 2592 | C J Fowler, et al. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol. 1982 Nov 15;31(22):3555-61. |
| 2593 | Fuentes JA, et al. Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. |
| 2594 | Hyung Tae Lee, et al. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30(4):1587-92. |
| 2595 | Palma-Vargas JM, et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 1997 Oct;185(4):365-72. |
| 2596 | Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418. |
| 2597 | https://clinicaltrials.gov/ct2/show/NCT04631536?term=Folic+acid&cond=COVID-19&draw=2&rank=1 https://trialsearch.who.int/Trial2.aspx?TrialID=PACTR202005599385499 |
| 2598 | Levin ED, et al. Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats. J Psychopharmacol. 2014 Oct;28(10):915-22. |
| 2599 | Benedict T Green, et al. Actions of piperidine alkaloid teratogens at fetal nicotinic acetylcholine receptors. Neurotoxicol Teratol. May-Jun 2010;32(3):383-90. |
| 2600 | Hoppe Seyler's Z Physiol Chem 244:181 (1936); Drugs 21:90 (1981); Gastroenterology 91:1007 (1986)| |
| 2601 | Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7. |
| 2602 | Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14. |
| 2603 | Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10. |
| 2604 | Eur. J. Pharmacol. (2005), 506(3), 237-240; J. Pharmacol. Exp. Ther. (1968), 160(1), 243-8; J. Clin. Pharmacol. J. New Drugs (1968), 8(1), 42-53 |
| 2605 | J Rheumatol 2:437 (1975); 3:305 (1976); Eur J Clin Pharmacol 19:431 (1981) |
| 2606 | Stock NS, et al. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. J Med Chem. 2011 Dec 8;54(23):8013-29. |
| 2607 | Lorrain DS, et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. Eur J Pharmacol. 2010 Aug 25;640(1-3):211-8. |
| 2608 | Morita S, et al. Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes. Cell Metab. 2017 Apr 4;25(4):883-897.e8. |
| 2609 | Qiu XL, et al. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. J Med Chem. 2009 Mar 26;52(6):1757-67. |
| 2610 | Vranesic I, et al. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. Bioorg Med Chem. 2014 Nov 1;22(21):5790-5803. |
| 2611 | Jacquemont AS, et, al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011 Jan 5;3(64):64ra1. |
| 2612 | Petrov D, et, al. Mavoglurant as a treatment for Parkinson's disease. Expert Opin Investig Drugs. 2014 Aug;23(8):1165-79. |
| 2613 | Phytochemistry (Elsevier) (1977), 16(1), 9-18; J. Pharm. Pharmacol. (1987), 39(3), 153-7; J. Pharm. Pharmacol. (1987), 39(9), 752-4 |
| 2614 | Gillespie RJ, et al. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines. Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. |
| 2615 | Zhang Z, et al. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorg Med Chem. 2014 Aug 1;22(15):4001-4009. |
| 2616 | Tan, A.K., et al. Identification of the site of covalent attachment of nafcillin, a reversible suicide inhibitor of beta-lactamase. Biochem J, 1992. 281 ( Pt 1): p. 191-6. |
| 2617 | Palmer, D.L., et al. Bacterial wound colonization after broad-spectrum versus narrow-spectrum antibiotics. Ann Thorac Surg, 1995. 59(3): p. 626-31. |
| 2618 | Lawrence I. Mortin, et al. Rapid Bactericidal Activity of Daptomycin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Peritonitis in Mice as Measured with Bioluminescent Bacteria. Antimicrob Agents Chemother. 2007 May; 51(5): 1787–1794. |
| 2619 | Horne DB, et al. Discovery of TRPM8 Antagonist ( S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine. J Med Chem. 2018 Sep 27;61(18):8186-8201. |
| 2620 | Antimicrob Agents Chemother 1:221 (1972); 3:657 (1973); 10:814 (1976) |
| 2621 | https://clinicaltrials.gov/ct2/show/NCT04742725?term=GLUTATHIONE&cond=covid&draw=2&rank=2 |
| 2622 | Arzneim Forsch 27:1173 (1977); Therapie 35:5 (1980) |
| 2623 | Arzneim Forsch 30:1091, 1098 (1980); Clin Ther 4:121 (1981); Med Clin 76:18 (1981) |
| 2624 | Naga Rajiv Lakkaniga,et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression.Eur J Med Chem. 2020 Jul 12;203:112589. |
| 2625 | Chaturvedi A, et al. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia. 2017 Oct;31(10):2020-2028. |
| 2626 | Wang Y, et al. Nootkatone, a neuroprotective agent from Alpiniae Oxyphyllae Fructus, improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease. Int Immunopharmacol. 2018 Sep;62:77-85. |
| 2627 | Wang Y, et al. Nootkatone, a neuroprotective agent from Alpiniae Oxyphyllae Fructus, improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease. Int Immunopharmacol. 2018 Sep;62:77-85. |
| 2628 | J Pharm Pharmacol 54:1521 (2002)| |
| 2629 | Tian J, et al. Nerol-induced apoptosis associated with the generation of ROS and Ca<sup>2+</sup> overload in saprotrophic fungus <i>Aspergillus flavus</i>. Appl Microbiol Biotechnol. 2018 Aug;102(15):6659-6672. |
| 2630 | Tian J, et al. Nerol triggers mitochondrial dysfunction and disruption via elevation of Ca<sup>2+</sup> and ROS in <i>Candida albicans</i>. Int J Biochem Cell Biol. 2017 Apr;85:114-122. |
| 2631 | Bill MA, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer. 2010 Jun 25;9:165. |
| 2632 | Lin L, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreaticand breast cancer cells. Cancer Res. 2010 Mar 15;70(6):2445-54. |
| 2633 | Dhawan NS, et al. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature. 2016 Aug 24;537(7618):112-116. |
| 2634 | Iwatani-Yoshihara M, et al. Discovery and Characterization of a Eukaryotic Initiation Factor 4A-3-Selective Inhibitor That Suppresses Nonsense-Mediated mRNA Decay. ACS Chem Biol. 2017 Jul 21;12(7):1760-1768. |
| 2635 | hepatotoxic at clinical dose (600mg) |
| 2636 | Pharmacol Rev 45:309 (1993); J Biol Chem 281:22021 (2006); J Neural Transm 115:1087 (2008) |
| 2637 | Xie F, et al. Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity. J Med Chem. 2015 Jun 25;58(12):5075-87. |
| 2638 | Zhang B, et al. C1q-TNF-related protein-3 attenuates pressure overload-induced cardiac hypertrophy by suppressing the p38/CREB pathway and p38-induced ER stress. Cell Death Dis. 2019 Jul 8;10(7):520. |
| 2639 | Qin Y, et al. Interfering MSN-NONO complex-activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer. Sci Adv. 2020 Feb 19;6(8):eaaw9960. |
| 2640 | Guichard SM, et al. AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules. Mol Cancer Ther. 2015 Nov;14(11):2508-18. |
| 2641 | Seng KY, et al. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. Antimicrob Agents Chemother. 2015 Nov;59(11):6791-9. |
| 2642 | Raina K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9. |
| 2643 | Kudo Y, et al. Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease. Minim Invasive Ther Allied Technol. 2006;15(4):209-13. |
| 2644 | Furukawa K, et al. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET. J Neurol. 2010 May;257(5):721-7. |
| 2645 | Farmakol Toxsikol 20(6):46 (1957) |
| 2646 | Arzneim forsch 27:866 (1977); Anal Profiles Drug Subs 9:543 (1980) |
| 2647 | Biochem J 20: 293, 300 (1926)| |
| 2648 | Arici M, et al. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65(3):317-323. |
| 2649 | Corriveau S, et al. Levothyroxine treatment generates an abnormal uterine contractility patterns in an in vitro animalmodel. J Clin Transl Endocrinol. 2015 Sep 9;2(4):144-149. |
| 2650 | hepatotoxic at clinical dose (300mg) |
| 2651 | Lobachevsky PN, Vasireddy RS, Broadhurst S, Protection by methylproamine of irradiated human keratinocytes correlates with reduction of DNA damage. Int J Radiat Biol. 2011 Mar;87(3):274-83. |
| 2652 | Sprung CN, Vasireddy RS, Karagiannis TC, Methylproamine protects against ionizing radiation by preventing DNA double-strand breaks. Mutat Res. 2010 Oct 13;692(1-2):49-52. |
| 2653 | Martin RF, Broadhurst S, Reum ME, In vitro studies with methylproamine: a potent new radioprotector. Cancer Res. 2004 Feb 1;64(3):1067-70. |
| 2654 | Duffy RA, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokininNK1 receptor antagonist with centrally-mediated antiemetic effects inferrets. Pharmacol Biochem Behav. 2012 Jul;102(1):95-100. |
| 2655 | Dydrogesterone, From Wikipedia, the free encyclopedia |Drugs Aging (1997), 11(4), 309-32; Steroids (1966), 7(1), 1-10; Int. J. Fertil. (1964), 9, 585-95 |
| 2656 | Buti M, et al. Drugs in development for hepatitis B. Drugs. 2005;65(11):1451‐1460. |
| 2657 | Keam SJ. Telbivudine. Drugs. 2007;67(13):1917‐1929. |
| 2658 | Quinazolinedione derivatives useful for treating cellular proliferative disorders and disorders associated with Kif15 kinesin activity are described. US 20040053948 A1. |
| 2659 | Zhang E, et al. Glycycoumarin inhibits hepatocyte lipoapoptosis through activation of autophagy and inhibition of ER stress/GSK-3-mediated mitochondrial pathway. Sci Rep. 2016 Nov 30;6:38138. |
| 2660 | Song X, et al. Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase. Oncotarget. 2016 Oct 4;7(40):65732-65743. |
| 2661 | https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN16269648 |
| 2662 | Lin-Feng Wang, et al. Tert-butylhydroquinone ameliorates doxorubicin-induced cardiotoxicity by activating Nrf2 and inducing the expression of its target genes. Am J Transl Res. 2015; 7(10): 1724–1735. |
| 2663 | Hu H, et al. Dehydrocorydaline inhibits cell proliferation, migration and invasion via suppressing MEK1/2-ERK1/2 cascade in melanoma.Onco Targets Ther. 2019 Jul 2;12:5163-5175. |
| 2664 | XIAOJING SHI, et al. Tert-butylhydroquinone attenuates the ethanol-induced apoptosis of and activates the Nrf2 antioxidant defense pathway in H9c2 cardiomyocytes.Int J Mol Med. 2016 Jul; 38(1): 123–130. |
| 2665 | Sukumari-Ramesh S, et al. Post-Injury Administration of Tert-butylhydroquinone Attenuates Acute Neurological Injury AfterIntracerebral Hemorrhage in Mice.J Mol Neurosci. 2016 Apr;58(4):525-31. |
| 2666 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Guanfacine&cond=covid&draw=2&rank=1 |
| 2667 | Liza Leventhal, et al. Phosphodiesterase 9 inhibitor and levodopa therapy. WO 2017070293 A1. |
| 2668 | Sharifzadeh, M., et al., Post-training intrahippocampal infusion of nicotine-bucladesine combination causes a synergistic enhancement effect on spatial memory retention in rats. Eur J Pharmacol, 2007. 562(3): p. 212-20. |
| 2669 | Mafune, E., M. Takahashi, and N. Takasugi, Effect of vehicles on percutaneous absorption of bucladesine (dibutyryl cyclic AMP) in normal and damaged rat skin. Biol Pharm Bull, 1995. 18(11): p. 1539-43. |
| 2670 | Rundfeldt, C., et al., The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation. Arch Dermatol Res, 2012. |
| 2671 | Salehi F, et al. Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain. Fundam Clin Pharmacol. 2017 Aug;31(4):411-419. |
| 2672 | Shimojo M, et al. The cholinergic gene locus is coordinately regulated by protein kinase A II in PC12 cells. J Neurochem. 1998 Sep;71(3):1118-26. |
| 2673 | New Zealand J Ecology 23:161 (1999); Toxicol Rev 25:213 (2006) |
| 2674 | Arzneim Forsch 34:1010 (1984) |
| 2675 | Bettayeb K, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807. |
| 2676 | Kabadi SV, et al. CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014 Mar;34(3):502-13. |
| 2677 | Słabicki M, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K [published online ahead of print, 2020 Jun 3]. Nature. 2020;10.1038/s41586-020-2374-x. |
| 2678 | T Ochiai, et al. Pharmacological studies on 6-amino-2-fluoromethyl-3-(O-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. (II) Effects on the spinal reflex potential and the rigidity. Jpn J Pharmacol. 1982 Jun;32(3):427-38. |
| 2679 | Y Kudo, et al. Effects of afloqualone on vestibular nystagmus and the lateral vestibular nucleus. Jpn J Pharmacol. 1989 Aug;50(4):515-9. |
| 2680 | Vet Parasitol 13:145 (1983); Vet Rec 113:315 (1983) |
| 2681 | Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014. |
| 2682 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Folinic+acid&cntry=&state=&city=&dist= |
| 2683 | Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(1):44-51. |
| 2684 | Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012 Mar 29;1446:1-11. |
| 2685 | Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17(12):1652-6. |
| 2686 | Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 2011 Aug;51(8):1177-85. |
| 2687 | Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Dec;13(12):911-20. |
| 2688 | Drugs (1996), 52(6), 899-927; Invest. Radiol. (1990), 25 Suppl 1S113-4; Br. J. Radiol. (1986), 59(706), 987-91 |
| 2689 | Chapman J, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007 Sep;51(9):3346-53. |
| 2690 | Challa S, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7. |
| 2691 | Antimicrob Agents Chemother 9:102 (1976); Am J Trop Med Hyg.24:485 (1975); 28:559 (1979) |
| 2692 | Vaseva AV, et al. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. |
| 2693 | Neuropharmacol 27:399 (1988); Expert Rev Neurotherapeut 3:425 (2003) |
| 2694 | Denise RAGEOT, et al. Treatment of neurological disorders. WO2017198346A1. |
| 2695 | Chiara Borsari, et al. 4-(Difluoromethyl)-5-(4-((3 R,5 S)-3,5-dimethylmorpholino)-6-(( R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. J Med Chem. 2020 Nov 25;63(22):13595-13617. |
| 2696 | Ngonye Keroletswe, et al. A New 3-Prenyl-2-flavene and Other Extractives from Baphia massaiensis and Their Antimicrobial Activities. Natural Product Communications. |
| 2697 | J C Anderson, et al. The Effect of Incorporation of Cloxacillin in Liposomes on Treatment of Experimental Staphylococcal Mastitis in Mice. J Vet Pharmacol Ther. 1986 Sep;9(3):303-9. |
| 2698 | W Calame, et al. Influence of Etoposide and Cyclophosphamide on the Efficacy of Cloxacillin and Erythromycin in an Experimental Staphylococcal Infection. Antimicrob Agents Chemother. 1989 Jun;33(6):980-2. |
| 2699 | Peter H Nibbering, et al. 99mTc-Labeled UBI 29-41 Peptide for Monitoring the Efficacy of Antibacterial Agents in Mice Infected With Staphylococcus Aureus. J Nucl Med. 2004 Feb;45(2):321-6. |
| 2700 | Srivastava M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21;151(7):1474-87. |
| 2701 | Lin C, et al. Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells. Sci Rep. 2016 Oct 7;6:34531. |
| 2702 | Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil. 2011 Mar;23(3):193-200. |
| 2703 | Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs. 2010 Dec;13(12):921-8. |
| 2704 | J Soc Cosmet Chem 32:327 (1981) |
| 2705 | Liu T, et al. Mechanism of thioesterase-catalyzed chain release in the biosynthesis of the polyether antibiotic Nanchangmycin. Chem Biol. 2008 May;15(5):449-58. |
| 2706 | Rausch K, et al. Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus. Cell Rep. 2017 Jan 17;18(3):804-815. |
| 2707 | WO2018060317. |
| 2708 | Raboisson P, et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4853-8. |
| 2709 | Lin TI, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.Antimicrob Agents Chemother. 2009 Apr;53(4):1377-85. Epub 2009 Jan 26. |
| 2710 | Rajagopalan R, et al. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease. Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01569-16. |
| 2711 | Waldschmidt HV, et al. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2Inhibitors Based on Paroxetine. J Med Chem. 2017 Apr 13;60(7):3052-3069. |
| 2712 | N Eng J Med 324:746 (1991); Anal Profiles Drug Subs Excip 22:145 (1993) |
| 2713 | Park MH, et al. Anticancer effect of Tectochrysin in colon cancer cell via suppression of NF-kappaB activity and enhancement of death receptor expression. Mol Cancer. 2015 Jun 30;14:124. |
| 2714 | Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456. |
| 2715 | Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238. |
| 2716 | Cruz HG, et al. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. CNS Drugs. 2014 Apr;28(4):361-72. |
| 2717 | Malherbe P, et al. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol. 2009 Sep;76(3):618-31. |
| 2718 | Sifferlen T, et al. Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1539-42. |
| 2719 | Black SW, et al. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep. 2013 Mar 1;36(3):325-36. |
| 2720 | Dayot S, et al. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget. 2018 Jan 9;9(6):6952-6967. |
| 2721 | Su Hongjun, Medical composition containing morpholine azomycin phosphate, its formulation and application to prepare the medical preparations as anti-anaerobic bacteria agent, antitrichomonal agent and antiamebic agent |
| 2722 | Seitz L, et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest New Drugs. 2019 Aug;37(4):711-721. |
| 2723 | Daniel DiRenzo, et al. AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression [abstract]. |
| 2724 | Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24. |
| 2725 | Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9(1): p. 39-44. |
| 2726 | Tetrahedron 40: 235 (1984); Eur J Heart Failure 12:1274 (2010) |
| 2727 | Zhao G, et al. A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models. Molecular Cancer Therapeutics (2011), 10(11), 2200-2210. |
| 2728 | J Chem Soc 1963:983; 1970:205; Nature 207:1101(1965); Phytomedicine 15:533 (2008) |
| 2729 | de Moraes J, et al. Phytol, a diterpene alcohol from chlorophyll, as a drug against neglected tropical diseaseSchistosomiasis mansoni. PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2617. |J Chem Soc 1966: 2144 |
| 2730 | Conway JG, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83. |
| 2731 | Priceman SJ, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010 Feb 18;115(7):1461-71 |
| 2732 | Conway JG, et al. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther. 2008 Jul;326(1):41-50. |
| 2733 | Gos FMWR, et al. Antibacterial Activity of Endophytic Actinomycetes Isolated from the Medicinal Plant Vochysia divergens (Pantanal, Brazil). Front Microbiol. 2017 Sep 6;8:1642. |
| 2734 | Yang ZD, et al. Secondary Metabolites and PI3K Inhibitory Activity of Colletotrichum gloeosporioides, a Fungal Endophyte of Uncaria rhynchophylla. Curr Microbiol. 2019 Jul;76(7):904-908. |
| 2735 | Hu H, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018 Nov 29;175(6):1665-1678.e18. |
| 2736 | Ku BM, et al. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models. J Cancer Res Clin Oncol. 2014 May;140(5):757-67. |
| 2737 | R.T. Schermuly, H. Leuchte, H.A. Ghofrani, et al. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure. ERJ, 2003 ,22 (2): 342-347. |
| 2738 | D. Ukena, K. Rentz, C. Reiber, et al. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respiratory Medicine.1995, 89 ( 6) : 441-444. |
| 2739 | Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. European Journal of Pharmacology.1993, 230(1):9-14. |
| 2740 | Pan Z, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2007 Jan;2(1):58-61. |
| 2741 | Ge C, et al. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells. Cell Physiol Biochem. 2018;48(6):2302-2317. |
| 2742 | Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075-13080. |
| 2743 | Gibbons JA, et al. Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1057-69. |
| 2744 | Arch Intern Med 105:121 (1960); Austral New Zeal J Surg 39:207 (1969) |
| 2745 | Kamel A, et al. Metabolism, pharmacokinetics and excretion of the GABA(A) receptor partial agonist [(14)C]CP-409,092 in rats. Xenobiotica. 2010 Jun;40(6):400-14. |
| 2746 | J Med Chem 11:325 (1968); N Engl J Med 307:1037 (1982) |
| 2747 | Kim WH, et al. Ethyl gallate induces apoptosis of HL-60 cells by promoting the expression of caspases-8, -9, -3, apoptosis-inducing factor and endonuclease G. Int J Mol Sci. 2012;13(9):11912-22. |
| 2748 | Mohan S, et al. In vitro protection of biological macromolecules against oxidative stress and in vivo toxicity evaluation of Acacia nilotica (L.) and ethyl gallate in rats. BMC Complement Altern Med. 2014 Jul 21;14:257. |
| 2749 | https://clinicaltrials.gov/ct2/show/NCT04333550?term=DEFEROXAMINE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04361032?term=DEFEROXAMINE&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04389801?term=DEFEROXAMINE&cond=COVID-19&draw=2&rank=3 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200506047323N4 |
| 2750 | Pharmazie 3:5 (1948)|Bull Exp Biol Med 61:291 (1966); Engl J Med 286:141 (1973); Muscle Nerve 20:1146 (1997) |
| 2751 | Obst & Gynec 9:610 (1957); J Dent Res 62:135 (1983) |
| 2752 | Song JX, et al. HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy. 2014 Jan;10(1):144-54. |
| 2753 | Sakakibara I, et al. Effect of oxindole alkaloids from the hooks of Uncaria macrophylla on thiopental-induced hypnosis. Phytomedicine. 1998 Apr;5(2):83-6. |
| 2754 | N Engl J Med 308:1448 (1983); 310:1545 (1984); 327:782 (1992) |
| 2755 | Nebbioso A, et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity ofHDAC-MEF2 complexes. EMBO Rep. 2009 Jul;10(7):776-82. |
| 2756 | Venza I, et al. Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells. Pigment Cell Melanoma Res. 2013 Mar;26(2):193-204. |
| 2757 | Nebbioso A, et al. HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J Mol Endocrinol. 2010 Oct;45(4):219-28. |
| 2758 | Kassis H, et al. Class IIa histone deacetylases affect neuronal remodeling and functional outcome after stroke. Neurochem Int. 2016 Jun;96:24-31. |
| 2759 | Massey AJ, et al. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther. 2010 Apr;9(4):906-19. |
| 2760 | Niewidok N, et al. Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity. Transl Oncol. 2012 Oct;5(5):356-69. Epub 2012 Oct 1. |
| 2761 | Wu J, et al. Irradiation facilitates the inhibitory effect of the heat shock protein 90 inhibitor NVP-BEP800 on the proliferation of malignant glioblastoma cells through attenuation of the upregulation of heat shock protein 70. Exp Ther Med. 2014 Sep;8(3):893-898. Epub 2014 Jun 23. |
| 2762 | Zahm DS, et al. Comparison of the locomotor-activating effects of bicuculline infusions into the preoptic area and ventral pallidum. Brain Struct Funct. 2014 Mar;219(2):511-26. |
| 2763 | Johnston GA. Advantages of an antagonist: bicuculline and other GABA antagonists. Br J Pharmacol. 2013 May;169(2):328-36. |
| 2764 | Alam MM, et al. Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science. 2019 Aug 30;365(6456). pii: eaau1682. |
| 2765 | Arzneim Forsch 15:1441 (1965) |
| 2766 | GuoDong Zhang, et al. Predicting hiCE inhibitors based upon pharmacophore models derived from the receptor and its ligands. Science China Chemistry |
| 2767 | Esposito G, et al. Pivagabine: a novel psychoactive drug. Arzneimittelforschung. 1997 Nov;47(11A):1306-9. |
| 2768 | Serra M, et al. Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain. Psychoneuroendocrinology. 1999 Apr;24(3):269-84. |
| 2769 | Junjun Wu, et al. Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3485-8. |
| 2770 | Rashid HU, et al. Cyclen-based Gd3+ complexes as MRI contrast agents: Relaxivity enhancement and ligand design. Bioorg Med Chem. 2016 Nov 15;24(22):5663-5684. |
| 2771 | Liu WS, et al. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation. J Comput Aided Mol Des. 2019 Aug;33(8):759-774. |
| 2772 | Garcia Fortanet J, et al. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. J Med Chem. 2016 Sep 8;59(17):7773-82. |
| 2773 | Aronsen D, et, al. RU 24969-produced adipsia and hyperlocomotion: differential role of 5HT 1A and 5HT 1B receptor mechanisms. Pharmacol Biochem Behav. 2014 Sep; 124: 1-4. |
| 2774 | Brazell MP, et, al. The 5-HT1 receptor agonist RU-24969 decreases 5-hydroxytryptamine (5-HT) release and metabolism in the rat frontal cortex in vitro and in vivo. Br J Pharmacol. 1985 Sep; 86(1): 209-16. |
| 2775 | Yang Q, et al. Anti-thrombotic effects of α-linolenic acid isolated from Zanthoxylum bungeanum Maxim seeds. BMC Complement Altern Med. 2014 Sep 23;14:348. |
| 2776 | Desire L, et al. RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem. 2005 Nov 11;280(45):37516-25. |
| 2777 | Shutes A, et al. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem. 2007 Dec 7;282(49):35666-78. |
| 2778 | Onesto C, et al. Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. Methods Enzymol. 2008;439:111-29. |
| 2779 | Li YJ, et al. Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. Cell Chem Biol. 2018 Dec 5. pii: S2451-9456(18)30386-6. |
| 2780 | Pacifici GM, et al. Valpromide inhibits human epoxide hydrolase. Br J Clin Pharmacol. 1986 Sep;22(3):269-74. |
| 2781 | Gorres KL, et al. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus. MBio. 2016 Mar 1;7(2):e00113. |
| 2782 | Nakatani Y, et al. Neuroprotective effect of liquiritin as an antioxidant via an increase in glucose-6-phosphate dehydrogenase expression on B65 neuroblastoma cells. Eur J Pharmacol. 2017 Nov 15;815:381-390. |
| 2783 | Zeng C, et al. Liquiritin, as a Natural Inhibitor of AKR1C1, Could Interfere With the Progesterone Metabolism. Front Physiol. 2019 Jul 3;10:833. |
| 2784 | Porter RH,et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.Br J Pharmacol. 1999 Sep;128(1):13-20. |
| 2785 | Jenck F, et al. Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats.Eur Neuropsychopharmacol. 1998 Aug;8(3):161-8. |
| 2786 | Faassen F, et al. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.Int J Pharm. 2003 Sep 16;263(1-2):113-22. |
| 2787 | Xue X, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel-Lindau interaction through shape-based screening and cascade docking. PeerJ. 2016 Dec 15;4:e2757. |
| 2788 | Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. |
| 2789 | https://clinicaltrials.gov/ct2/show/NCT04424901?term=DIPYRIDAMOLE&cond=covid&draw=2&rank=1 |
| 2790 | Xiaowen Chen, et al. Toll-like receptor 4 is involved in a protective effect of rhein on immunoglobulin A nephropathy. Indian J Pharmacol. 2015 Jan-Feb; 47(1): 27–33. |
| 2791 | Hou ML, et al. The Drug-Drug Effects of Rhein on the Pharmacokinetics and Pharmacodynamics of Clozapine in Rat Brain Extracellular Fluid by In Vivo Microdialysis. J Pharmacol Exp Ther. 2015 Oct;355(1):125-34. |
| 2792 | Yan-Xi Zhou, et al. Rhein: A Review of Pharmacological Activities. Evid Based Complement Alternat Med. 2015; 2015: 578107. |
| 2793 | http://en.wikipedia.org/wiki/Temoporfin |
| 2794 | Chem. Zentralbl 1912 II:396 (1912) |
| 2795 | Gray LR, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013 Apr 16;8(4):e62196. |
| 2796 | Hou P, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015 Oct 20;5:15577. |
| 2797 | Mizutani T, et al. Nucleoside Reverse Transcriptase Inhibitors Suppress Laser-Induced Choroidal Neovascularization in Mice. Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7122-9. |
| 2798 | Cheng J, et al. Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways. J Cell Physiol. 2018 Mar;233(3):2502-2512. |
| 2799 | Lee SW, et al. Phenolic compounds isolated from Psoralea corylifolia inhibit IL-6-induced STAT3 activation. Planta Med. 2012 Jun;78(9):903-6. |
| 2800 | Kim DW, et al. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J Enzyme Inhib Med Chem. 2014 Feb;29(1):59-63. |
| 2801 | Li YG, et al. Fructus Psoraleae contains natural compounds with potent inhibitory effects towards human carboxylesterase 2. Fitoterapia. 2015 Jan 13;101C:99-106. d |
| 2802 | J Steroid Biochem Mol Biol 37:257 (1990); Recent Advances Polyphenol Res 1:293 (2008) |
| 2803 | Northrup AB, et al, Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. J Med Chem. 2013 Mar 28;56(6):2294-310. |
| 2804 | Bhardwaj V, et al. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 2012 Aug;7(8):1211-7. |
| 2805 | Rosato-Siri MD, et al. A Novel Modulator of Kv3 Potassium Channels Regulates the Firing of Parvalbumin-Positive Cortical Interneurons. J Pharmacol Exp Ther. 2015 Sep;354(3):251-60. |
| 2806 | Aust J Chem 19:525 (1966); J Inclusion Phenomena Macrocyclic Chem 72: 339 (2011) |
| 2807 | Arch Pharmakol Exp Pathol 268:348 (1971) |
| 2808 | Suwannarat, P., et al., Use of nitisinone in patients with alkaptonuria. Metabolism, 2005. 54(6): p. 719-28. |
| 2809 | Santra, S. and U. Baumann, Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother, 2008. 9(7): p. 1229-36. |
| 2810 | Alexandrou AJ, et al. Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release. PLoS One. 2016 Apr 6;11(4):e0152405. |
| 2811 | Theile JW, et al. The Selective Nav1.7 Inhibitor, PF-05089771, Interacts Equivalently with Fast and Slow Inactivated Nav1.7 Channels. Mol Pharmacol. 2016 Nov;90(5):540-548. |
| 2812 | Antimicro Agents Chemother 19:56, 20:171 (1981); Arzneim Forsch 33:269 (1983) |
| 2813 | Ying Xi, et al. Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline. Am J Respir Cell Mol Biol. 2014 Jan;50(1):51-60. |
| 2814 | https://clinicaltrials.gov/ct2/show/NCT04666753?term=GLUCOSAMINE&cond=covid&draw=2&rank=2 |
| 2815 | Brueckner B, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005 Jul 15;65(14):6305-11. |
| 2816 | Schirrmacher E, et al. Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases. Bioconjug Chem. 2006 Mar-Apr;17(2):261-6. |
| 2817 | Pasha Z, et al. Efficient non-viral reprogramming of myoblasts to stemness with a single small molecule to generate cardiac progenitor cells. PLoS One. 2011;6(8):e23667. |
| 2818 | J Org Chem 30: 1729 (1965); J Biol Chem 279:56053 (2004); |
| 2819 | Whittle BJ, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84(1):68-75. |
| 2820 | Ferrantino M, et al. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2011 Nov;12(16):2583-93. |
| 2821 | Ghonem N, et al. Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation. Am J Transplant. 2011 Nov;11(11):2508-16. |
| 2822 | Smadja DM, et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost. 2015 Oct;114(4):735-47. |
| 2823 | Kazemi Z, et al. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Mol Pharmacol. 2016 Jun;89(6):630-44. |
| 2824 | Nikam VS, et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J. 2010 Dec;36(6):1302-14. |
| 2825 | Napper AD, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005 Dec 15;48(25):8045-54. |
| 2826 | Sadikot T, et al. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol. 2013 Oct;11(8):478-88. |
| 2827 | Zhu J, et al. Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. Ann Neurol. 2013 Dec;74(6):893-904. |
| 2828 | Zhu J, et al. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Sci Rep. 2016 Jun 28;6:28861. |
| 2829 | Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29; 450(7170): 712–716. |
| 2830 | Scuto A, et al. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis. 2013 May; 4(5): e635. |
| 2831 | Gurt I, et al. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. |
| 2832 | Int J Immunopharmacol 6: 587 (1984); Nucleic Acids Res 25: 1890 (1997) |
| 2833 | J Am Pharmac Assoc 29:425 (1940); Food Cosmet Toxicol 5:141 (1967) |
| 2834 | Gong Y, et al. Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-anovel strategy for tumor-targeted therapy. Oncol Lett. 2017 Oct;14(4):4158-4166. |
| 2835 | Giustarini G, et al. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. |
| 2836 | Poon IK, et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature. 2014 Mar 20;507(7492):329-34. |
| 2837 | Gootz TD, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7. |
| 2838 | Kim YK, et al. Anticancer effects of CKD-602 (Camtobell?) via G2/M phase arrest in oral squamous cell carcinoma cell lines. Oncol Lett. 2015 Jan;9(1):136-142. |
| 2839 | Kim YY, et al. CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines. Oncol Rep. 2009 Jun;21(6):1413-9. |
| 2840 | Kim CY, et al. Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model. J Clin Neurosci. 2012 Feb;19(2):301-5. |
| 2841 | Wang Y, et al. Discovery of Biaryl Amides as Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors. ACS Med Chem Lett. 2015 May 26;6(7):787-792. |
| 2842 | Morrison BL, et al. Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis. Cancer Med. 2013 Oct;2(5):687-700. |
| 2843 | Mackman RL, et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-1643. |
| 2844 | Samuel D, et al. GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein. Antimicrob Agents Chemother. 2015 Nov;59(11):7109-12. |
| 2845 | Anderson DL. Doripenem. Drugs Today (Barc). 2006 Jun;42(6):399-404. |
| 2846 | Jones RN, et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004 Jul;54(1):144-54. Epub 2004 Jun 9. |
| 2847 | Sivaprakasam P, et al. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core. Bioorg Med Chem Lett. 2015 May 1;25(9):1856-63. |
| 2848 | Santiago de Oliveira Y, et al. The design of novel metronidazole benzoate structures: exploring stoichiometric diversity. Acta Crystallogr C Struct Chem. 2019 May 1;75(Pt 5):483-495. |
| 2849 | Am J Clin Nutrition 47:660 (1988); Amino Acids 23:381 (2002); Endocrinology 147:3276 (2006) |
| 2850 | Anne Marie Jeanne Bouillot, et al. 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors . PCT Int. Appl. (2009), WO 2009060053 A1 20090514. |
| 2851 | Chanteux H, et al. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. Drug Metab Dispos. 2015 Sep;43(9):1381-91. |
| 2852 | Davenport RJ, et al. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases? Drug Discov Today. 2007 Jul;12(13-14):569-76. |
| 2853 | Ind Eng Chem 33: 637 (1941) |
| 2854 | Moilanen AM, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms toandrogen signaling-directed prostate cancer therapies. Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007. |
| 2855 | Edy Meiyanto, et al. Curcumin Analog Pentagamavunon-1 (PGV-1) Sensitizes Widr Cells to 5-Fluorouracil Through Inhibition of NF-κB Activation. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):49-56. |
| 2856 | Beni Lestari, et al. Pentagamavunon-1 (PGV-1) Inhibits ROS Metabolic Enzymes and Suppresses Tumor Cell Growth by Inducing M Phase (Prometaphase) Arrest and Cell Senescence. Sci Rep . 2019 Oct 16;9(1):14867. |
| 2857 | https://clinicaltrials.gov/ct2/show/NCT04701606?term=Artesunate&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04387240?term=Artesunate&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04695197?term=Artesunate&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04475107?term=Artesunate&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04532931?term=Artesunate&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04374019?term=Artesunate&cond=COVID-19&draw=2&rank=6 https://trialsearch.who.int/Trial2.aspx?TrialID=PACTR202006899597082 |
| 2858 | William AD, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kina |
| 2859 | Pasha MK, et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42. |
| 2860 | Sun CC, et al. PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice. Biochem Biophys Res Commun. 2020 Mar 19;523(4):1020-1026. |
| 2861 | Zhang G, et al. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11127-32. |
| 2862 | Hwang SH, et al. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.J Med Chem. 2011 Apr 28;54(8):3037-50. |
| 2863 | Michael J. Chisamore, et al. Identification of Small Molecule Estrogen-Related |
| 2864 | Chen G, et al. Cell Synchronization by Double Thymidine Block. Bio Protoc. 2018 Sep 5;8(17). |
| 2865 | FIRKET H, et al. Autoradiographic visualization of synthesis of deoxyribonucleic acid in tissue culture with tritium-labelled thymidine. Nature. 1958 Jan 24;181(4604):274-5.FIRKET H, et al. Autoradiographic visualization of synthesis of deoxyribonucleic acid in tissue culture with tritium-labelled thymidine. Nature. 1958 Jan 24;181(4604):274-5. |
| 2866 | Izeradjene K, et al. Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independentdeletion of superantigen-reactive peripheral T cells. Int Immunol. 2001 Jan;13(1):85-93. |
| 2867 | Nacht M, et al. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. J Med Chem. 2013 Feb 14;56(3):712-21. |
| 2868 | Mol Pharmacol 3:274 (1967); Ann Intern Med 72:919 (1970); 73:607 (1970) |
| 2869 | Mégalizzi V, et al. 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia. 2007 May;9(5):358-69. |
| 2870 | Pestic Sci 6:537 (1975); 8:264 (1977); Arch Toxicol 67:510 (1993) |
| 2871 | Liang ZZ, et al. Oligofurostanosides from Asparagus cochinchinensis. Planta Med. 1988 Aug;54(4):344-6. |
| 2872 | Gai Y, et al. Pseudoprotodioscin inhibits SREBPs and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides. Fitoterapia. 2019 Nov;139:104393. |
| 2873 | Forsyth T, et al. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7653-8. |
| 2874 | Yonar D, et al. Effect of cis-(Z)-flupentixol on DPPC membranes in the presence and absence of cholesterol. Chem Phys Lipids. 2016 Jun;198:61-71. |
| 2875 | Kim MJ, et al. Loganin protects against pancreatitis by inhibiting NF-κB activation. Eur J Pharmacol. 2015 Oct 15;765:541-50. |
| 2876 | Tsai WH, et al. Ba-Wei-Di-Huang-Wan through its active ingredient loganin counteracts substance P-enhanced NF-κB/ICAM-1 signaling in rats with bladder hyperactivity. Neurourol Urodyn. 2015 Aug 19. |
| 2877 | Survey Anesthesiology 12:377 (1968); Acta Physiol Scand 141:289 (1991) |
| 2878 | Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884. |
| 2879 | Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948. |
| 2880 | Clin Perinatol 11:703 (1984) |
| 2881 | Panpan Wu, et al. Phytochemical Compositions of Extract From Peel of Hawthorn Fruit, and Its Antioxidant Capacity, Cell Growth Inhibition, and Acetylcholinesterase Inhibitory Activity. BMC Complement Altern Med. 2017 Mar 11;17(1):151. |
| 2882 | J Am Pharm Assoc Sci Ed 45:382 (1956); Toxicol Appl Pharmacol 18:185 (1971) |
| 2883 | Shima, Fumi, et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proceedings of the National Academy of Sciences of the United States of America (2013), 110(20), 8182-8187, S8182/1-S8182/10. |
| 2884 | Wurz RP, et al. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. |
| 2885 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=ETHACRYNIC+ACID&cond=Covid19&draw=2&rank=1 |
| 2886 | Chem Commun 1965: 302 |
| 2887 | Campbell DR, et al. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J Steroid Biochem Mol Biol. 1993 Sep;46(3):381-8. |
| 2888 | McGinn R et al. Adenosine receptor inhibition attenuates the suppression of postexercise cutaneous blood flow. J Physiol. 2014 Jun 15;592(12):2667-78. |
| 2889 | Tew GA et al. Aging and aerobic fitness affect the contribution of noradrenergic sympathetic nerves to the rapid cutaneous vasodilator response to local heating.
 J Appl Physiol (1985). 2011 May;110(5):1264-70 |
| 2890 | Cakir B et al.Leptin inhibits gastric emptying in rats: role of CCK receptors and vagal afferent fibers. Physiol Res. 2007;56(3):315-22. Epub 2006 Jun 22. |
| 2891 | Matthew et al. Structure-Based Drug Discovery of MRTX1257, a Selective, Covalent KRAS G12C Inhibitor with Oral Activity in Animal Models of Cancer. |
| 2892 | Toque HA, et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol. 2008 Sep 4;591(1-3):189-95. |
| 2893 | Khajista Jabeen, et al. Antifungal Compounds From Melia Azedarach Leaves for Management of Ascochyta Rabiei, the Cause of Chickpea Blight. Nat Prod Res. 2011 Feb;25(3):264-76. |
| 2894 | Rivera JC, et al. Tetrahydrobiopterin (BH4) deficiency is associated with augmented inflammation and microvascular degeneration in the retina. J Neuroinflammation. 2017 Sep 6;14(1):181. |
| 2895 | Lefranc F, et al. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol Cancer Ther. 2009 Jul;8(7):1739-50. |
| 2896 | Wahyuni DS, et al. The use of bio-guided fractionation to explore the use of leftover biomass in Dutch flower bulb production as allelochemicals against weeds. Molecules. 2013 Apr 17;18(4):4510-25. |
| 2897 | Arch Pathol Lab Med 100:127 (1976); J Pediatr Surg 18:131 (1983) |
| 2898 | Saporito MS, et al. MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. J Pharmacol Exp Ther. 2012 Jul;342(1):15-22. |
| 2899 | Ochman AR, et al. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J Pharmacol Exp Ther. 2012 Jul;342(1):23-32. |
| 2900 | PNAS 585: (1964); Gene 62:121 (1988); FEBS Letts 234:141 (1988); Kidney Internat 62:496 (2002) |
| 2901 | Nadezhda German, et al. Deconstruction of the α4β2 Nicotinic Acetylchloine (nACh) Receptor Positive Allosteric Modulator des-Formylflustrabromine (dFBr). J Med Chem. 2011 Oct 27;54(20):7259-67. |
| 2902 | Weltzin MM, et al. Desformylflustrabromine Modulates α4β2 Neuronal Nicotinic Acetylcholine Receptor High- and Low-Sensitivity Isoforms at Allosteric Clefts Containing the β2 Subunit. J Pharmacol Exp Ther. 2015 Aug;354(2):184-94. |
| 2903 | T Honoré, et al. Quinoxalinediones: Potent Competitive non-NMDA Glutamate Receptor Antagonists. Science. 1988 Aug 5;241(4866):701-3. |
| 2904 | Neuman RS, et al. Blockade of excitatory synaptic transmission by 6-cyano-7-nitroquinoxaline-2,3-dione(CNQX) in the hippocampus in vitro. Neurosci Lett. 1988 Sep 23;92(1):64-8. |
| 2905 | Alford S, et al. CNQX and DNQX block non-NMDA synaptic transmission but not NMDA-evoked locomotion in lamprey spinal cord. Brain Res. 1990 Jan 8;506(2):297-302. |
| 2906 | Pia Bäckström, et al. Attenuation of Cocaine-Seeking Behaviour by the AMPA/kainate Receptor Antagonist CNQX in Rats. Psychopharmacology (Berl). 2003 Feb;166(1):69-76. |
| 2907 | Kim M, et al. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol. 1993 Jan;59(1):5-8. |
| 2908 | Therapie 22:309 (1967); Food Chem Toxicol 37:789 (1999) |
| 2909 | Pan Q, et al. Inhibition of the angiogenesis and growth of Aloin in human colorectal cancer in vitro and in vivo. Cancer Cell Int. 2013 Jul 12;13(1):69. |
| 2910 | Tabolacci C, et al. Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation. Amino Acids. 2013 Jan;44(1):293-300. |
| 2911 | Cui Y, et al. Aloin protects against chronic alcoholic liver injury via attenuating lipid accumulation, oxidative stress and inflammation in mice. Arch Pharm Res. 2014 Dec;37(12):1624-33. |J Chem Soc 1932: 2573 |
| 2912 | Parasitol. Today (2000), 16(2), 71-77; Am. J. Trop. Med. Hyg. (1974), 23(2), 151-3; Parasitology (1975), 70(2), 273-85| |
| 2913 | Liu C, et al. In vivo and in vitro efficacies of mebendazole, mefloquine and nitazoxanide against cyst echinococcosis. Parasitol Res. 2015 Mar 15. |
| 2914 | Pawluk SA, et al. A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole. Clin Pharmacokinet. 2015 Apr;54(4):371-83. |
| 2915 | Speich B, et al. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. Lancet Infect Dis. 2015 Mar;15(3):277-84. |
| 2916 | Larsen AR, et al. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Mol Cancer Ther. 2015 Jan;14(1):3-13. |
| 2917 | JACS 79: 149 (1957) |
| 2918 | Kong M, et al. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft. Acta Biochim Biophys Sin (Shanghai). 2010 Nov;42(11):827-33. |
| 2919 | Liu J, et al. Polyphyllin I induces G2/M phase arrest and apoptosis in U251 human glioma cells via mitochondrial dysfunction and the JNK signaling pathway. Acta Biochim Biophys Sin (Shanghai). 2017 Jun 1;49(6):479-486. |
| 2920 | He J, et al. Polyphyllin I induces autophagy and cell cycle arrest via inhibiting PDK1/Akt/mTOR signal and downregulating cyclin B1 in human gastric carcinoma HGC-27 cells. Biomed Pharmacother. 2019 Sep;117:109189. |
| 2921 | Han X, et al. Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. J Med Chem. 2018 Oct 4. |
| 2922 | Koo CY, et al. Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. Mol Cancer Ther. 2017 Nov;16(11):2410-2421. |
| 2923 | Crawford TD, et al. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. J Med Chem. 2016 Dec 8;59(23):10549-10563. |
| 2924 | Infect. Dis. Ther. (1994), 9, 391-401; J. Antimicrob. Chemother. (1976), 2(4), 325-36; J. Pharm. Pharmacol. (1964), 16, 663-9| |
| 2925 | Jiang X, et al. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia. PLoS One. 2013 Aug 9;8(8):e72335. |
| 2926 | Khadrawy YA, et al. Cerebellar neurochemical and histopathological changes in rat model of Parkinson's disease induced by intrastriatal injection of rotenone. Gen Physiol Biophys. 2016 Nov 30. |
| 2927 | Guan Q, et al. RNA-Seq Expression Analysis of Enteric Neuron Cells with Rotenone Treatment and Prediction of Regulated Pathways. Neurochem Res. 2016 Nov 30. |
| 2928 | Kishore Kumar SN, et al. Morinda citrifolia mitigates rotenone-induced striatal neuronal loss in male Sprague-Dawley rats by preventing mitochondrial pathway of intrinsic apoptosis. Redox Rep. 2016 Nov 24:1-12. |
| 2929 | Zhang ZN, et al. Subcutaneous rotenone rat model of Parkinson's disease: dose exploration study. Brain Res. 2016 Nov 19. pii: S0006-8993(16)30776-4. |
| 2930 | Li N, et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem. 2003 Mar 7;278(10):8516-25. |Chem Rev 12: 181 (1933); Prog Chem Org Nat Prod 43: 1 (1983) |
| 2931 | Meyer SC, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28. |
| 2932 | Wu SC, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13;28(1):29-41. |
| 2933 | Walters MJ, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010 Oct;335(1):61-9. |
| 2934 | Bekker P, et al. CCR9 Antagonists in the Treatment of Ulcerative Colitis. Mediators Inflamm. 2015;2015:628340. |
| 2935 | Zhang J, et al. Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease. Bioorg Med Chem Lett. 2015 Sep 1;25(17):3661-4. |
| 2936 | Brown JH, et al. Activation and blockade of cardiac muscarinic receptors by endogenous acetylcholine and cholinesterase inhibitors. J Pharmacol Exp Ther. 1982 Oct;223(1):20-4. |
| 2937 | Gum GG, et al. Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma. Am J Vet Res. 1993 Feb;54(2):287-93. |
| 2938 | Yang H, et al. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006 May 1;66(9):4758-65 |
| 2939 | Guan Y, et al. Celastrol attenuates oxidative stress in the skeletal muscle of diabetic rats by regulating the AMPK-PGC1α-SIRT3 signaling pathway. Int J Mol Med. 2016 May;37(5):1229-38. |J Chem Soc 1963:2884; 1972:330; J Org Chem 30:1729 (1965); J Biol Chem 279:56053 (2004); J Mol Med 85:1421 (2007); Mol Biol Cell 19:1104 (2008) |
| 2940 | Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120(6):1262-1273. |
| 2941 | Keskin H, et al. Complex effects of flavopiridol on the expression of primary response genes. Cell Div. 2012 Mar 29;7:11. |
| 2942 | Kim KS, et al.Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem. 2000 Nov 2;43(22):4126-34. |
| 2943 | Jianliang Xu, et al. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Commun Signal. 2019 Jul 26;17(1):85. |
| 2944 | Ber 74:1851 (1941); J Chem Soc (C) 1967:145 ; Pharmaceut Biol 43:647 (2005) |
| 2945 | Hibasami H, et al. Induction of apoptosis by rhapontin having stilbene moiety, a component of rhubarb (<i>Rheum officinale Baillon</i>) in human stomach cancer KATO III cells. Oncol Rep. 2007 Aug;18(2):347-51. |
| 2946 | Rorick-Kehn LM, et al. A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models. Alcohol Clin Exp Res. 2016 May;40(5):945-54. |
| 2947 | https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04923347 |
| 2948 | Connie L. Erickson-Miller, et al. GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia. Blood 2007 110:510; |
| 2949 | Wippich F, et al. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell. 2013;152(4):791-805. |
| 2950 | Mirguet O, et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem. 2013 Oct 10;56(19):7501-15. |
| 2951 | Hauck S, et al. Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors. Bioorg Med Chem. 2016 Nov 15;24(22):5717-5729. |
| 2952 | Antimicrob Agents Chemother 49:4649 (2005); J Biol Chem 282:25395 (2007) |
| 2953 | Maziah M, et al. The Production of 9-methoxycanthin-6-one from Callus Cultures of (Eurycoma longifolia Jack) Tongkat Ali. Methods Mol Biol. 2009;547:359-69. |
| 2954 | Tripetch Kanchanapoom , et al. Canthin-6-one and b-carboline alkaloids from Eurycoma harmandiana. Phytochemistry 56 (2001) 383-386. |
| 2955 | Slusarczyk M, et al. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem. 2014 Feb 27;57(4):1531-42. |
| 2956 | Choi SS, et al. Antinociceptive mechanisms of orally administered decursinol in the mouse. Life Sci. 2003 Jun 13;73(4):471-85. |
| 2957 | Son SH, et al. Decursin and decursinol from Angelica gigas inhibit the lung metastasis of murine colon carcinoma. Phytother Res. 2011 Jul;25(7):959-64. |
| 2958 | J Chem Soc 1954:1171; Atherosclerosis 50:73 (1984) |
| 2959 | Naurex's First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement in Depression Scores within 24 Hours in Phase 2 Study for Major Depressive Disorder. January 28, 2015. |
| 2960 | J Pharmacol Exp Ther 63:369 (1938); Anal Profiles Drug Subs 6:423 (1977) |
| 2961 | J. Allergy and Clin. Immunol. (1981), 68(2), 91-7; Eur. J. Pharmacol. (1970), 12(1), 35-43; Arzneim. Forsch. (1967), 17(3), 362-4 |
| 2962 | Tröster A, et al. NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. ChemMedChem. 2018 Aug 20;13(16):1629-1633. |
| 2963 | Pharmazie (1957), 12, 396-401; Monatsh. Chem. (1957), 88, 330-5. |
| 2964 | Chem Nat Comp 1: 59 (1962) |
| 2965 | J Clin Psychiatry 43:1 (1982); Drugs 32:114 (1986); Pharmacotherapy 8:100 (1988) |
| 2966 | C R SeancesSoc Biol Ses Fil 152:1371 (1958); Can Psychiatr Assoc J 14:267 (1969); Br J Clin Pract 42:228 (1988) |
| 2967 | Durant ST, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018 Jun 20;4(6):eaat1719. |
| 2968 | J. Kahn, et al. Next-Generation ATM Kinase Inhibitors Under Development Radiosensitize Glioblastoma With Conformal Radiation in a Mouse Orthotopic Model. IJROBP. 2017. 99, 600-601. |
| 2969 | Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43(4):527-50. |
| 2970 | Fujita M, et al. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. J Exp Clin Cancer Res. 2017 Jul 3;36(1):91. |
| 2971 | Nazim UM, et al. PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget. 2017 Apr 18;8(16):26819-26831. |
| 2972 | Arzneim Forsch 20:1024 (1970); S Afr Med J 58:444 (1980) |
| 2973 | Roymans D, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8(1):167. |
| 2974 | Kim JW, et al. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother. 2006;40(3):472-478. |
| 2975 | Zobel T, et al. Telbivudine Reduces Parvovirus B19-Induced Apoptosis in Circulating Angiogenic Cells. Viruses. 2019;11(3):227. Published 2019 Mar 6. |
| 2976 | Smyth JT, et al. Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism. J Biol Chem. 2002;277(38):35061-35070. |
| 2977 | An P, et al. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007;13(9):1445-1448. |
| 2978 | https://clinicaltrials.gov/ct2/show/NCT04365127?term=Progesterone&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04865029?term=Progesterone&cond=COVID-19&draw=2&rank=2 |
| 2979 | Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20 |
| 2980 | Ruscoe JE, et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther. 2001 Jul;298(1):339-45. |
| 2981 | Boskovic ZV, ET AL. Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. ACS Chem Biol. 2016 Jul 15;11(7):1844-51. |
| 2982 | Eur. J. Pharmacol. (1977), 42(4), 347-54; J. Pharm. Sci. (1968), 57(5), 774-80 |
| 2983 | Mitchell JD, et al. In vitro pharmacodynamics of gamithromycin against Mycoplasma mycoides subspecies mycoides Small Colony. Vet J. 2013 Sep;197(3):806-11. |
| 2984 | F. Hildebrand, et al. Efficacy of Gamithromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia. J Vet Intern Med. 2015 Jan-Feb; 29(1): 333–338. |
| 2985 | Ikenoya M, et al. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7. |
| 2986 | Shibuya Y, et al. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol Aging. 2015 Jul;36(7):2248-2259. |
| 2987 | J. Drugs Dermatol. (2011), 10(11), 1282-1288; Antimicrob. Agents Chemother. (1981), 19(3), 386-9; Antimicrob. Agents Chemother. (1981), 19(3), 390-2 |
| 2988 | J Am Coll Toxicol 3:147 (1984); Clin Chim Acta 224:147 (1994); J Appl Toxicol 23:285 (2003) |
| 2989 | Brai A, et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc Natl Acad Sci U S A. 2016 May 10;113(19):5388-93. |
| 2990 | Lelais G, et al. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T79 |
| 2991 | Jia Y, et al. EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. Cancer Res. 2016 Mar 15;76(6):1591-602 |
| 2992 | Dooley KL, et al. Comparative carcinogenicity of the food pyrolysis product, 2-amino-5-phenylpyridine, and the known human carcinogen, 4-aminobiphenyl, in the neonatal B6C3F1 mouse. Cancer Lett. 1988 Jul;41(1):99-103. |
| 2993 | Stavenuiter JF, et al. Syntheses of 5-phenyl-2-pyridinamine, a possibly carcinogenic pyrolysis product of phenylalanine, and some of its putative metabolites. Carcinogenesis. 1985 Jan;6(1):13-9. |
| 2994 | Linda N. Casillas, et al. Prodrugs of amino quinazoline kinase inhibitor. PCT Int. Appl. (2014), WO 2014043446 A1 20140320. |
| 2995 | Wilson JD, et al. Azatadine maleate (Zadine): evaluation in the management of allergic rhinitis. N Z Med J. 1981 Aug 12;94(689):79-81. |
| 2996 | Tozzi S, et al. The pharmacology of azatadine, a potential antiallergy drug. Agents Actions. 1974 Oct;4(4):264-70. |
| 2997 | Wang B, Chen L, Zhen H, et al. Proteomic changes induced by podophyllotoxin in human cervical carcinoma HeLa cells. Am J Chin Med. 2013;41(1):163-75. |
| 2998 | Guerrero E, Abad A, Montenegro G, et al. Analgesic and anti-inflammatory activity of podophyllotoxin derivatives. Pharm Biol. 2013 Jan 31. |
| 2999 | Li M, Zhou L, Yang D, et al. Biochemical composition and antioxidant capacity of extracts from Podophyllum hexandrum rhizome. BMC Complement Altern Med. 2012 Dec 22;12:263. |
| 3000 | Prasad V, Chaudhuri AR, Curcio M, et al. Podophyllotoxin and nocodazole counter the effect of IKP104 on tubulin decay. J Protein Chem. 1998 Oct;17(7):663-8. |
| 3001 | Podophyllotoxin |JACS 73: 2909 (1951); 75: 1308 (1953); J Med Chem 32: 604 (1989); Pharmacol Ther 59: 163 (1993); J Prot Chem 17: 663 (1998) |
| 3002 | Romero FA, et al. GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). J Med Chem. 2017 Nov 22;60(22):9162-9183. |
| 3003 | Niu Q, et al. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J Clin Invest. 2019 Jul 22;129(8):3361-3373. |
| 3004 | Vansant G, et al. Block-And-Lock Strategies to Cure HIV Infection. Viruses. 2020 Jan 10;12(1). pii: E84. |
| 3005 | Brasier AR, et al. Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug Discov Today. 2020 Jan;25(1):126-132. |
| 3006 | Clin Obster Gynacol 11:573 (1984) |
| 3007 | O'Neil MM, et al. Differential Regulation of Gonadotropins in Response to Continuous Infusion of Native Gonadotropin-Releasing Hormone in the Winter Anovulatory Mare and Effects of Treatment With Estradiol-17β. J Equine Vet Sci. 2019 Apr;75:93-103. |
| 3008 | J Chem Soc 1960:3827; Chem Commun 1970:1388 |
| 3009 | J Org Chem 30: 1729 (1965) |
| 3010 | J Chem Soc 1961: 3705; Phytochemistry 10: 1845 (1971) |
| 3011 | Jones P, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85. |
| 3012 | Bridges KA, et al. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5(13):5076-86. |
| 3013 | Wang L, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30(6):2113-20. |
| 3014 | Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. |
| 3015 | Vashi P, et al. Methylmalonic Acid and Homocysteine as Indicators of Vitamin B-12 Deficiency in Cancer. PLoS One. 2016 Jan 25;11(1):e0147843. |
| 3016 | Plantevin Krenitsky V, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett. 2012 Feb 1;22(3):1433-8. |
| 3017 | Gan LT, et al. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol. 2014 Dec;61(6):1376-84. |
| 3018 | Reich N, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis. 2012 May;71(5):737-45. |
| 3019 | Tavernier SJ, et al. Regulated IRE1-dependent mRNA decay sets the threshold for dendritic cell survival. Nat Cell Biol. 2017 Jun;19(6):698-710. |
| 3020 | van der Horst G, et al. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia. 2011 Jun;13(6):516-25. |
| 3021 | Reeves KJ, et al. Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187. Int J Cancer. 2015 Apr 1;136(7):1731-40. |
| 3022 | https://clinicaltrials.gov/ct2/show/NCT04350593?term=Dapagliflozin&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04393246?term=Dapagliflozin&cond=COVID-19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/09/027829 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04595370 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04724837 |
| 3023 | JACS 74: 4365 (1952); J Pharmacol Exp Therap 116: 394 (1956) |
| 3024 | Keystone Symposia 2019 - Epigenetics and Human Disease |
| 3025 | Kati W, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11. |
| 3026 | Wood M, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124-35. |
| 3027 | Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86. |
| 3028 | Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors. Eur J Pharmacol. 2016 Oct 5;788:183-91. |
| 3029 | Radad K, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP+ and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 2014;52(2):179-86. |
| 3030 | Ayman N Saber, et al. Dissipation Dynamic, Residue Distribution and Processing Factor of Hexythiazox in Strawberry Fruits Under Open Field Condition. Food Chem. 2016 Apr 1;196:1108-16. |
| 3031 | R Nauen, et al. Acaricide Toxicity and Resistance in Larvae of Different Strains of Tetranychus Urticae and Panonychus Ulmi (Acari: Tetranychidae). Pest Manag Sci. 2001 Mar;57(3):253-61. |
| 3032 | https://clinicaltrials.gov/ct2/show/NCT04542213?term=Linagliptin&cond=Covid19&draw=2&rank=1 |
| 3033 | Cheng H et al. Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett, 2012 Nov 7, 4(1):91-7. |
| 3034 | Hideshima T, et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13162-13167. |
| 3035 | Liang M, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23;275(25):19000-8. |
| 3036 | Anders HJ, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest. 2002 Jan;109(2):251-9. |
| 3037 | Furuichi K, et al. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J Immunol. 2008 Dec 15;181(12):8670-6. |
| 3038 | Horuk R, et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem. 2001 Feb 9;276(6):4199-204. |
| 3039 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=NISOLDIPINE&cond=Covid19&draw=2&rank=1 |
| 3040 | Clin Exp Dermatol 17 Suppl 1:1 (1992); Drugs 49:103 (1995) |
| 3041 | Hejmadi MV, et al. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer. 1996 Feb;73(4):499-505. |
| 3042 | Manley E Jr, et al. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. J Pharmacol Exp Ther. 2013 Feb;344(2):368-77. |
| 3043 | Williams KJ, et al. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. Mol Cancer Ther. 2009 Dec;8(12):3266-75. |
| 3044 | Shin D, et al. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018 Dec;129:454-462. |
| 3045 | Heinemann B, et al. Inhibition of demethylases by GSK-J1/J4. Nature. 2014 Oct 2;514(7520):E1-2 |
| 3046 | Carta M, et al. The muscle relaxant thiocolchicoside is an antagonist of GAB<sub>A</sub>A receptor function in the central nervous system. Neuropharmacology. 2006 Sep;51(4):805-15. |
| 3047 | Br J Ophthalmol 66:386 (1982); 79:42 (1995)| |
| 3048 | Elia, A.C., et al., Transferability of oxytetracycline (OTC) from feed to carp muscle and evaluation of the antibiotic effects on antioxidant systems in liver and kidney. Fish Physiol Biochem, 2014. |
| 3049 | Pickens LB, et al. Oxytetracycline biosynthesis. J Biol Chem. 2010 Sep 3;285(36):27509-15. |
| 3050 | Oguz Guvenmez, et al. A New Treatment Method for Herpes Simplex Virus Type 1-related Skin Lesions. Scientific & Academic. 2019; 8(1): 6-8. |
| 3051 | J Pharm Sci 73:1657 (1984); Clin Ther 3:80 (1980); 6:388 (1984); Curr Ther Res 42:720 (1987) |
| 3052 | Cross BC, et al. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):E869-78. |
| 3053 | Zhang L, et al. IRE1 inhibition perturbs the unfolded protein response in a pancreatic β-cell line expressing mutant proinsulin, but does not sensitize the cells to apoptosis. BMC Cell Biol. 2014 Jul 10;15:29. |
| 3054 | Kemp K, et al. The serine-threonine kinase inositol-requiring enzyme 1α (IRE1α) promotes IL-4 production in T helper cells. J Biol Chem. 2013 Nov 15;288(46):33272-82. |
| 3055 | Tufanli O, et al. Targeting IRE1 with small molecules counteracts progression of atherosclerosis. Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1395-E1404. |
| 3056 | Nam ST, et al. Suppression of IgE-mediated mast cell activation and mouse anaphylaxis via inhibition of Sykactivation by 8-formyl-7-hydroxy-4-methylcoumarin, 4μ8C. Toxicol Appl Pharmacol. 2017 Oct 1;332:25-31. |
| 3057 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=PREGNENOLONE+&cntry=&state=&city=&dist=&Search=Search |
| 3058 | Wess J, et al. Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol Sci. 2013 Jul;34(7):385-92. |
| 3059 | Silva RR, et al. Evaluation of Functional Selectivity of NSC 170973, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Front Pharmacol. 2019 Jun 4;10:628. |
| 3060 | Zorn SH, et al. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol. 1994 Nov 15;269(3):R1-2. |
| 3061 | Manvich DF, et al. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep. 2018 Mar 1;8(1):3840. |
| 3062 | van der Peet PL, et al. Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs. MethodsX. 2018 Mar 23;5:257-267. |
| 3063 | Joseph Cichon, et al. Branch-specific dendritic Ca(2+) spikes cause persistent synaptic plasticity. Nature. 2015 Apr 9;520(7546):180-5. |
| 3064 | Scott D Ryan, et al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49(10):2250-8. |
| 3065 | Z Honda, et al. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. J Biol Chem. 1994 Jan 21;269(3):2307-15. |
| 3066 | Muhammad S Riaz, et al. Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria. Front Microbiol. 2018 Sep 11;9:1903. |
| 3067 | Jing Chu, et al. IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway. Biomed Res Int. 2019 Jul 4;2019:7201562. |
| 3068 | Nina Bögershausen, et al. RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome. J Clin Invest. 2015 Sep;125(9):3585-99. |
| 3069 | Liles JT, et al. ASK1 contributes to fibrosis and dysfunction in models of kidney disease. J Clin Invest. 2018 Oct 1;128(10):4485-4500. |
| 3070 | Budas GR, et al. ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018 Feb 1;197(3):373-385. |
| 3071 | Lee YH, et al. Baccatin III, a precursor for the semisynthesis of paclitaxel, inhibits the accumulation and suppressive activity of myeloid-derived suppressor cells in tumor-bearing mice. Int Immunopharmacol. 2014 Aug;21(2):487-93. |
| 3072 | Jaren W Landen, et al. Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth. Clin Cancer Res. 2004 Aug 1;10(15):5187-201. |
| 3073 | Yunfan Yang, et al. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics. 2015 Mar 2;5(7):656-66. |
| 3074 | Vartika Tomar, et al. Noscapine and Its Analogs as Chemotherapeutic Agent: Current Updates. Curr Top Med Chem. 2017;17(2):174-188. |
| 3075 | Bianca Lokhorst, et al. Interaction of OTC Drug Noscapine and Acenocoumarol and Phenprocoumon. Br J Clin Pharmacol. 2019 May;85(5):1041-1043. |
| 3076 | S A Ebrahimi, et al. Interaction of Noscapine With the Bradykinin Mediation of the Cough Response. Acta Physiol Hung. 2003;90(2):147-55. |
| 3077 | Avelar MM, et al. Procyanidin b2 cytotoxicity to mcf-7 human breast adenocarcinoma cells. Indian J Pharm Sci. 2012 Jul;74(4):351-5. |
| 3078 | Yang H, et al. Procyanidin B2 inhibits NLRP3 inflammasome activation in human vascular endothelial cells. Biochem Pharmacol. 2014 Dec 15;92(4):599-606. |
| 3079 | Wu S, et al. Procyanidin B2 attenuates neurological deficits and blood-brain barrier disruption in a rat model of cerebral ischemia. Mol Nutr Food Res. 2015 Oct;59(10):1930-41. |
| 3080 | Tamura M, et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52. Epub 2005 Sep 12. |
| 3081 | Ikenoya M, et al. Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J Neurochem. 2002 Apr;81(1):9-16. |
| 3082 | Lie M, et al. Accelerated neurite growth from spiral ganglion neurons exposed to the Rho kinase inhibitor H-1152. Neuroscience. 2010 Aug 25;169(2):855-62. |
| 3083 | Expert Opin. Pharmacother. (2000), 1(4), 835-840; Eur. J. Clin. Pharmacol. (1979), 16(6), 423-4; Arzneim. Forsch. (1976), 26(12), 2145-54 |
| 3084 | https://clinicaltrials.gov/ct2/show/NCT04509973?term=Betamethasone&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04649879?term=Betamethasone&cond=Covid19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04412291?term=Betamethasone&cond=Covid19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04462367?term=Betamethasone&cond=Covid19&draw=2&rank=4https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04734210 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20210311050671N1 |
| 3085 | Kwiatkowski N, et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol. 2010 May;6(5):359-68. |
| 3086 | Bäumer W , et al. The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs. Vet Dermatol. 2017 Feb; 28(1):46-e11. |
| 3087 | Ber 18: 79, 1928 (1885); J Pharmacol Exp Ther 104:20 (1952) |
| 3088 | Doyle K, et al. Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986). J Med Chem. 2016 Oct 27;59(20):9457-9472. |
| 3089 | Tetrahedron 25:2233 (1969); J Pharmacy Pharmacol 54:399 (2002); J Ethnopharmacol 81:111 (2002) |
| 3090 | Vet Dermatol 16:299 (2005); J Vet Pharmacol Ther 30:257 (2007) |
| 3091 | Ferreira de Freitas R, et al. Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening. J Med Chem. 2016 Jul 28;59(14):6838-47. |
| 3092 | Takaya J, et al. A Potent and Site-Selective Agonist of TRPA1. J Am Chem Soc. 2015 Dec 23;137(50):15859-64. |
| 3093 | Compt Rend 109:29 (1889); JACS 82:125 (1960) |
| 3094 | Nature 384:39 (1996) |
| 3095 | J Nutr 108:1215 (1978); Food Chemical Toxicol 47:2723 (2009) |
| 3096 | Proffitt KD, et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 2013 Jan 15;73(2):502-7. |
| 3097 | Cheng Y, et al. Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment. Oncotarget. 2015 Jun 10;6(16):14428-39. |
| 3098 | Shetty HU, et al. Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease. Clin Chem. 1996 Feb;42(2):298-302. |
| 3099 | Arch Surg 118:1431 (1983); Liver International 6:35 (1986) |
| 3100 | Dang L, et al. Effects of hypocrellin A on expression of vascular endothelial growth factor and endothelin-1 in human umbilical endothelial cells. Am J Chin Med. 2007;35(4):713-23. |
| 3101 | Ma YJ, et al. Enhanced Production of Hypocrellin A in Submerged Cultures of Shiraia bambusicola by Red Light. Photochem Photobiol. 2019 May;95(3):812-822. |
| 3102 | Fehr MJ, et al. Roles of oxygen and photoinduced acidification in the light-dependent antiviral activity of hypocrellin A. Biochemistry. 1995 Dec 5;34(48):15845-8. |
| 3103 | Ma G, et al. Antimicrobial and antileishmanial activities of hypocrellins A and B. Antimicrob Agents Chemother. 2004 Nov;48(11):4450-2. |
| 3104 | Ng YF, et al. Semen Astragali Complanati: an ethnopharmacological, phytochemical and pharmacological review. J Ethnopharmacol. 2014 Aug 8;155(1):39-53. |
| 3105 | Ng YF, et al. Semen Astragali Complanati: an ethnopharmacological, phytochemical and pharmacological review. J Ethnopharmacol. 2014 Aug 8;155(1):39-53. |
| 3106 | Mol. Aspects Med. (2010), 31(6), 513-539; J. Food Biochem. (2005), 29(3), 234-266; Cell. Mol. Targets Chemoprev. (1992), 147-60. |
| 3107 | Gullino PM, et al. N-nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst. 1975 Feb;54(2):401-14. |
| 3108 | Tsubura A, et al. Review: Animal models of N-Methyl-N-nitrosourea-induced mammary cancer and retinal degeneration with special emphasis on therapeutic trials. In Vivo. 2011 Jan-Feb;25(1):11-22. |
| 3109 | Johnson EM, et al. Effects of N-nitroso-N-methylurea on enzymatic ontogeny associated with teratogenesis. Teratology. 1968 May;1(2):179-91. |
| 3110 | Silvia Garbarino, et al. One-pot synthesis of α-haloketones employing a membrane-based semibatch diazomethane generator. Journal of Flow Chemistry volume 6, pages211-217(2016). |
| 3111 | Moon KY. N-nitroso-N-methylurea and N-nitroso-N-ethylurea induce upregulation of cellular NF-kappa B activity through protein kinase C-dependent pathway in human malignant keratinocytes. Arch Pharm Res. 2010 Jan;33(1):133-9. |
| 3112 | DeWeerd K, et al. Metabolism of the 18O-methoxy substituent of 3-methoxybenzoic acid and other unlabeled methoxybenzoic acids by anaerobic bacteria. Appl Environ Microbiol. 1988 May;54(5):1237-42. |
| 3113 | Fulcher, Emilee H, et al. Method for the treatment and prevention of the inflammatory diseases using Rho kinase inhibiting compounds. US 20090325960 A1. |
| 3114 | Yu WN, et al. Citronellol Induces Necroptosis of Human Lung Cancer Cells via TNF-α Pathway and Reactive Oxygen Species Accumulation. In Vivo. 2019 Jul-Aug;33(4):1193-1201 |
| 3115 | Grimm C, et al. Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48. |
| 3116 | Zhiqiang Xia, et al. ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. Antiviral Res. 2020 Aug 26;104922. |
| 3117 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=RETINYL+PALMITATE&cntry=&state=&city=&dist=&Search=Search |
| 3118 | Hatcher JM, et al. Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett. 2015 Apr 7;6(5):584-589. |
| 3119 | Girnita A, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004 Jan 1;64(1):236-42. |
| 3120 | Menu E, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. 2006 Jan 15;107(2):655-60. Epub 2005 Jul 26. |
| 3121 | Bieghs L, et al. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic. Oncotarget. 2014 Nov 30;5(22):11193-208. |
| 3122 | Tomizawa M, et al. Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. Oncol Lett. 2014 Nov;8(5):2023-2026. Epub 2014 Aug 27. |
| 3123 | Stromberg T, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006 Jan 15;107(2):669-78. Epub 2005 Sep 15. |
| 3124 | Kong YL, et al. Insulin deficiency induces rat renal mesangial cell dysfunction via activation of IGF-1/IGF-1R pathway. Acta Pharmacol Sin. 2016 Feb;37(2):217-27. |JACS 73: 2909 (1951); 75: 1308 (1953); J Med Chem 32: 604 (1989); Pharmacol Ther 59: 163 (1993); Cancer Res 64:236 (2004); Int. J. Cancer 121:1857 (2007) |
| 3125 | Sadler BM, Stein DS. Clinical pharmacology and pharmacokinetics of amprenavir. Ann Pharmacother. 2002 Jan;36(1):102-18. |
| 3126 | Esposito V, Verdina A, Manente L, Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol. 2013 Mar;228(3):640-5. |
| 3127 | Helsley RN, Sui Y, Ai N, Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice. Mol Pharmacol. 2013 Jun;83(6):1190-9. |
| 3128 | Psychopharmacology 127:73 (1996);132:296 (1997);159:266 (2002); Br J Psychiatry 175:120 (1999) |
| 3129 | Chen W, et al. Camphor--a fumigant during the Black Death and a coveted fragrant wood in ancient Egypt and Babylon--a review. Molecules. 2013 May 10;18(5):5434-54. |
| 3130 | Obstetrics Gynecol 17:90 (1961) |
| 3131 | Lavorini F, et al. Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study. Pulm Pharmacol Ther. 2016 Oct;40:91-4. |
| 3132 | Adcock JJ, et al. RSD931, a novel anti-tussive agent acting on airway sensory nerves. Br J Pharmacol. 2003 Feb;138(3):407-16. |
| 3133 | Abdelraheem WH, et al. Degradation and mineralization of organic UV absorber compound 2-phenylbenzimidazole-5-sulfonic acid (PBSA) using UV-254nm/H2O2. J Hazard Mater. 2015 Jan 23;282:233-40. |
| 3134 | Ronan B, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2014 Dec;10(12):1013-9. |
| 3135 | Pasquier B. SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells. Autophagy. 2015 Apr 3;11(4):725-6. |
| 3136 | Hildebrand JM, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15072-7. |
| 3137 | Sammond DM, et al. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. Bioorg Med Chem Lett. 2005;15(15):3519-3523. |
| 3138 | Nachbur U, et al. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nat Commun. 2015 Mar 17;6:6442. |
| 3139 | Guzik K, et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem. 2017 Jul 13;60(13):5857-5867. |
| 3140 | Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8(42):72167-72181. |
| 3141 | Dong Q, et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1315-9. |
| 3142 | Micel LN, et al. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Mol Cancer Ther. 2015 Feb;14(2):317-25. |
| 3143 | Wang Y, et al. CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell. 2015 Sep 24;163(1):174-186. |
| 3144 | Rao DN, et al. A comparative study of the redox-cycling of a quinone (rifamycin S) and a quinonimine (rifabutin) antibiotic by rat liver microsomes. Free Radic Biol Med. 1997;22(3):439-46. |
| 3145 | Kono Y. Oxygen Enhancement of bactericidal activity of rifamycin SV on Escherichia coli and aerobic oxidation of rifamycin SV to rifamycin S catalyzed by manganous ions: the role of superoxide. J Biochem. 1982 Jan;91(1):381-95. |
| 3146 | Huang H, et al. Rifamycin S and its geometric isomer produced by a newly found actinomycete, Micromonospora rifamycinica. Antonie Van Leeuwenhoek. 2009 Feb;95(2):143-8. |
| 3147 | Dominick Casalena, et al. Discovery of small molecule probe that shows anti-tubercular activity via <i>Mtb</i>bioA (DAPA synthase) enzyme inhibition. January 16, 2015. |
| 3148 | PLoS One |
| 3149 | Palmer BD, et al. 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J Med Chem. 2006 Aug 10;49(16):4896-911. |
| 3150 | Feng L, et al. Discovery of a Small-Molecule BMP Sensitizer for Human Embryonic Stem Cell Differentiation. Cell Rep. 2016 May 31;15(9):2063-75. |
| 3151 | Smaill JB, et al. Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpointkinases. Eur J Med Chem. 2008 Jun;43(6):1276-96. Epub 2007 Aug 6. |
| 3152 | Wang S, et al. Small-molecule modulation of Wnt signaling via modulating the Axin-LRP5/6 interaction. Nat Chem Biol. 2013 Sep;9(9):579-85. |
| 3153 | Fischer G, et al. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther. 1997 Dec;283(3):1285-92. |
| 3154 | Lynch DR, et al. Pharmacological characterization of interactions of RO 25-6981 with the NR2B (epsilon2) subunit. Eur J Pharmacol. 2001 Mar 30;416(3):185-95. |
| 3155 | Jiang M, et al. Antinociception and prevention of hyperalgesia by intrathecal administration of Ro 25-6981, a highly selective antagonist of the 2B subunit of N-methyl-D-aspartate receptor. Pharmacol Biochem Behav. 2013 Nov;112:56-63. |
| 3156 | J Pharmacol Exp Ther 99:57 (1950) |
| 3157 | Schnute ME, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88. |
| 3158 | MacRitchie N, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal. 2016 Aug;28(8):946-55. |
| 3159 | Hamada M, et al. Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. Cell Death Discov. 2017 Aug 14;3:17047. |
| 3160 | Brit J Ophthal 40:751 (1956); J Pharmacol Exp Ther 121:63 (1957) |
| 3161 | Ross-Macdonald P, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther. 2008 Nov;7(11):3490-8. |
| 3162 | Romarowski A, et al. PKA-dependent phosphorylation of LIMK1 and Cofilin is essential for mouse sperm acrosomal exocytosis. Dev Biol. 2015 Sep 15;405(2):237-49. |
| 3163 | Pharmacol Biochem Behav 32:607 (1989); Lancet 1:1014 (1985); CNS Drugs 19:445, 517 (2005) |
| 3164 | Kalin JH, et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 Jan 4;9(1):53. |
| 3165 | CR Seances Acad Sci Ser D 271:730 (1970); Antibiotics 3:34 (1975) |
| 3166 | J. Colloid Interface Sci. (1971), 37(2), 469-75; Gut (1985), 26(10), 1008-13; Gastroenterology (1985), 89(3), 489-93 |
| 3167 | Cerchietti LC, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010 Apr 13;17(4):400-11. |
| 3168 | https://clinicaltrials.gov/ct2/show/NCT04459286?term=Atazanavir&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04452565?term=Atazanavir&cond=Covid19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04468087?term=Atazanavir&cond=Covid19&draw=2&rank=3 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20210214050350N1 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200328046886N2 |
| 3169 | Hu W, et al. Dihydroartemisinin induces autophagy by suppressing NF-κB activation. Cancer Lett. 2014 Feb 28;343(2):239-48. |
| 3170 | Li YJ, et al. Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-κB in Eca109 and Ec9706 esophageal cancer cells. Cell Physiol Biochem. 2014;33(5):1527-36. |
| 3171 | Li HJ, et al. Dihydroartemisinin-praziquantel combinations and multiple doses of dihydroartemisinin in the treatment of Schistosoma japonicum in experimentally infected mice. Ann Trop Med Parasitol. 2011 Jun;105(4):329-33. |
| 3172 | Yap TA, et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3912-23. |
| 3173 | Xi Y, et al. AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 2016 Sep 9;478(1):330-6 |
| 3174 | Favata MF, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998 Jul 17;273(29):18623-32. |
| 3175 | Droebner K, et al. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res. 2011, 92(2), 195-203. |
| 3176 | Bessard A, et al. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene. 2008 Sep 11;27(40):5315-25. |
| 3177 | Ahnstedt H, et al. U0126 attenuates cerebral vasoconstriction and improves long-term neurologic outcome after stroke in female rats. J Cereb Blood Flow Metab. 2015 Mar;35(3):454-60. |
| 3178 | Fray MJ, et al. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorg Med Chem Lett. 2001 Feb 26;11(4):571-4. |
| 3179 | Yan HQ, et al. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells. Oncotarget. 2016 Sep 20;7(38):62070-62083. |
| 3180 | Hafez S, et al. Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke. Stroke. 2016 Mar;47(3):843-51. |
| 3181 | Huang Q, et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J Biol Chem. 2018 Mar 9;293(10):3535-3545. |
| 3182 | Chen H, et al. Identification and characterization of small molecules as potent and specific EPAC2 antagonists. J Med Chem. 2013 Feb 14;56(3):952-62. |
| 3183 | Wang H, et al. Dual-Targeting Small-Molecule Inhibitors of the Staphylococcus aureus FMN Riboswitch DisruptRiboflavin Homeostasis in an Infectious Setting. Cell Chem Biol. 2017 May 18;24(5):576-588. |
| 3184 | Howe JA, et al. Selective small-molecule inhibition of an RNA structural element. Nature. 2015 Oct 29;526(7575):672-7. |
| 3185 | Bhatia SP, et al. Fragrance material review on benzyl cinnamate. Food Chem Toxicol. 2007;45 Suppl 1:S40-8. Epub 2007 Sep 14. |
| 3186 | Biochem Biophys Res Commun 88: 1382 (1979) |
| 3187 | Kategaya L, et al. USP7 small-molecule inhibitors interfere with ubiquitin binding. Nature. 2017 Oct 26;550(7677):534-538. |
| 3188 | Phung-Ba V et al. Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. Eur J Pharmacol. 1995 Jan 16;288(2):187-92. |
| 3189 | https://clinicaltrials.gov/ct2/show/NCT04973449?term=Sucrose&cond=Covid19&draw=2&rank=1 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/08/027005 https://trialsearch.who.int/Trial2.aspx?TrialID=SLCTR/2021/008 |
| 3190 | Beaufils F, et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. J Med Chem. 2017 Sep 14;60(17):7524-7538. |
| 3191 | Wicki A, et al. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer. 2018 Jun;96:6-16. |
| 3192 | Drugs (1987), 34(6), 648-61; J. Med. Chem. (1970), 13(4), 684-8; J. Med. Chem. (1973), 16(5), 585-8 |
| 3193 | You L, et al. Development of a triazole class of highly potent Porcn inhibitors. Bioorg Med Chem Lett. 2016 Dec 15;26(24):5891-5895. |
| 3194 | Drugs (1991), 42(6), 1018-60; Antimicrob. Agents Chemother. (1988), 32(5), 656-62; Antimicrob. Agents Chemother. (1987), 31(6), 854-9 |
| 3195 | Eliseeva EV, et al. Effect of Hypotensive Drugs on Dynamics of Nitroxide-Producing Renal Function in Rats with Nephrogenic Hypertension. Bull Exp Biol Med. 2017 Jan;162(3):357-361. |
| 3196 | 19-Hydroxybaccatin III, 10-deacetylcephalomannine, and 10-deacetyltaxol: new antitumor taxanes from Taxus wallichiana. J Nat Prod. 1981 May-Jun;44(3):312-9. |
| 3197 | Michel Colin, et al. Process for the preparation of taxol and 10-deacetyltaxol. US4857653A. |
| 3198 | Helson L. Cephalomannine and 10-deacetyltaxol cytotoxicity in human glial and neuroblastoma cell-lines. Int J Oncol. 1993 Feb;2(2):297-9. |
| 3199 | Eur J Clin Pharmacol 19:149 (1981); Int J Pharmaceutics 38:139 (1987) |
| 3200 | Nature 174: 930 (1974) |
| 3201 | Wolf S, et al. Acute effect of metipranolol on the retinal circulation. Br J Ophthalmol. 1998 Aug;82(8):892-6. |
| 3202 | Muzalevskaya EN, et al. SQUALENE: PHYSIOLOGICAL AND PHARMACOLOGICAL PROPERTIES. Eksp Klin Farmakol. 2015;78(6):30-6. |
| 3203 | E Gnamusch, et al. Effect of squalene on the structure and function of fungal membranes. Journal of Dermatological Treatment. Volume 3, 1992 - Issue sup1 |
| 3204 | Ebrahim HY, et al. Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies. J Nat Prod. 2017 Apr 28;80(4):932-952. |
| 3205 | Francolini I, et al. Usnic acid, a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. Antimicrob Agents Chemother. 2004;48(11):4360-4365. |
| 3206 | J Chem Soc 1954:2012; Brit J Pharmacol 18:311 (1962); Experientia 30:1308 (1974) |
| 3207 | Ameeramja J, et al. Protocatechuic acid methyl ester ameliorates fluoride toxicity in A549 cells. Food Chem Toxicol. 2017 Nov;109(Pt 2):941-950. |
| 3208 | Ameeramja J, et al. Protocatechuic acid methyl ester modulates fluoride induced pulmonary toxicity in rats. Food Chem Toxicol. 2018 Aug;118:235-244. |
| 3209 | Xia CF, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013 Nov;9(6):666-76. |
| 3210 | Marquié M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015 Nov;78(5):787-800. |
| 3211 | Dvorak CA, et al. Identification and SAR of Glycine Benzamides as Potent Agonists for the GPR139 Receptor. ACS Med Chem Lett. 2015 Jul 20;6(9):1015-8. |
| 3212 | Liu C, et al. GPR139, an Orphan Receptor Highly Enriched in the Habenula and Septum, Is Activated by the Essential Amino Acids L-Tryptophan and L-Phenylalanine. Mol Pharmacol. 2015 Nov;88(5):911-25. |
| 3213 | J. Am. Chem. Soc. (1960), 82, 1132-5; Clin. Pharmacol. Ther. (1963), 4, 740-8; Curr. Ther. Res. (1963), 5, 401-6 |
| 3214 | Prog. Neuro-Psychopharmacol. Biol. Psychiatry (1988), 12(5), 629-37; Arzneim. Forsch. (1982), 32(8), 824-31; Agressologie (1972), 13(5), 285-9 |
| 3215 | Gardner B, et al. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol. 1998 Jul;124(5):978-84. |
| 3216 | Renodon A, et al. Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects.FEBS Lett. 1997 Apr 7;406(1-2):33-6. |
| 3217 | Wynalda MA, et al. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997 Oct;25(10):1211-4. |
| 3218 | Rana DG, et al. Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression. Ayu. 2014 Jan;35(1):90-7. |
| 3219 | Dieb W, et al. Nigrostriatal dopaminergic depletion increases static orofacial allodynia. J Headache Pain. 2016;17:11. |
| 3220 | Yao S, et al. Small Molecule Inhibition of CPS1 Activity through an Allosteric Pocket. Cell Chem Biol. 2020 Mar 19;27(3):259-268. |
| 3221 | Jing H, et al. Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Lett. 2010 Aug 28;294(2):167-77. |
| 3222 | Rohatgi N, et al. Novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets. PLoS One. 2013 May 1;8(5):e62012. |
| 3223 | Ghosh A, et al. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration inexperimental models of Parkinson's disease. Sci Transl Med. 2016 Dec 7;8(368):368ra174. |
| 3224 | Munro DD, et al. Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy. |
| 3225 | Michael Stewart, et al. Clobetasone butyrate for inflammatory skin conditions. |
| 3226 | Antiepileptic Drugs (1972), 275-81; Med. Welt (1978), 29(22), 919-26, ; Med. Press (1948), 220(5), 95-7, |
| 3227 | Hollister LE, et al. Acetophenazine and diazepam in anxious depressions. Arch Gen Psychiatry. 1971 Mar;24(3):273-8. |
| 3228 | Biochem J 36:113 (1942); J Chem Edu 46:198 (1971) |
| 3229 | Ferguson FM, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020 Apr 6. |
| 3230 | Cancer Res 48:5941 (1988); Carcinogenesis 27:1803 (2006); 30:321 (2009) |
| 3231 | Yasuno F, et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [11C]DAA1106. Psychiatry Res. 2012 Jul 30;203(1):67-74. |
| 3232 | DAA1106 |
| 3233 | Regueiro-Ren A, et al. Synthesis and biological activity of novel epothilone aziridines. Org Lett. 2001 Aug 23;3(17):2693-6. |
| 3234 | Pagano A, et al.
 Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends.
 Biochem Pharmacol. 2012 Aug 15;84(4):432-43. |
| 3235 | Oehler C, et al.
 The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
 Neuro Oncol. 2011 Sep;13(9):1000-10. |
| 3236 | Han H, et al. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 2019 Nov 11;36(5):483-497.e15. |
| 3237 | Akbulut O, et al. A Highly Potent TACC3 Inhibitor as a Novel Anti-cancer Drug Candidate. Mol Cancer Ther. 2020 Mar 26. pii: molcanther.0957.2019. |
| 3238 | Röhm S, et al. Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors. J Med Chem. 2019 Dec 12;62(23):10757-10782. |
| 3239 | Farmaco Ed Prat 30:252 (1974); Antimicrob Agents Chemother 7:441 (1975) |
| 3240 | Sakamoto K, et al. Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation. J Pharmacol Exp Ther. 2018 Aug;366(2):390-396. |
| 3241 | Okamoto M, et al. Identification of death-associated protein kinases inhibitors using structure-based virtual screening. J Med Chem. 2009 Nov 26;52(22):7323-7. |
| 3242 | Ayyagari VN, et al. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. BMC Cancer. 2014 Feb 4;14:61. |
| 3243 | Florent RL, et al. In vitro toxicity of bithionol and bithionol sulphoxide to Neoparamoeba spp., the causative agent of amoebic gill disease (AGD). Dis Aquat Organ. 2010 Sep 17;91(3):257-62. |
| 3244 | J Chem Soc 1953: 571 |
| 3245 | J Steroid Biochem 30:391 (1988)| |
| 3246 | Di Salle, E., et al., Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol, 1994. 49(4-6): p. 289-94. |
| 3247 | Miki, Y, et al. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2004 Sep 1;10(17):5717-23. |
| 3248 | Goss, P.E., et al., Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res, 2004. 10(17): p. 5717-23. |
| 3249 | Zaccheo, T., D. Giudici, and E. Di Salle, Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol, 1993. 44(4-6): p. 677-80. |
| 3250 | Lu D, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7. |
| 3251 | Zhou J, et al. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactiveoxygen species. Toxicol Lett. 2013 Oct 24;222(2):139-45. |
| 3252 | Klose J, et al. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916. |
| 3253 | Wang F, et al. Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo. PLoS One. 2012; 7(12): e50638. |
| 3254 | Qu H, et al. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8(7):578-82. |
| 3255 | https://clinicaltrials.gov/ct2/show/NCT04578236?term=Retinoic+acid&cond=covid&draw=2&rank=2 |
| 3256 | Lu ML, et al. Potential Signaling Pathways Involved in the Clinical Application of Oxymatrine. Phytother Res. 2016 Jul;30(7):1104-12. |
| 3257 | Wu C, et al. Oxymatrine inhibits the proliferation of prostate cancer cells in vitro and in vivo. Mol Med Rep. 2015 Jun;11(6):4129-34. |
| 3258 | Wu XL, et al. Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis. World J Gastroenterol. 2008 Apr 7;14(13):2100-5. |
| 3259 | Ding Y, et al. Oxymatrine Inhibits Bocavirus MVC Replication, Reduces Viral Gene Expression and Decreases Apoptosis Induced by Viral Infection. Virol Sin. 2019 Feb;34(1):78-87. |Forestry Res 17:323 (2006); Brain Res 1268:174 (2009); Basic Clin Pharmacol Toxicol 107:906 (2010) |
| 3260 | JACS 91:2684 (1969); Science 170:81 (1970)| |
| 3261 | Magnuson, B.A., et al., Aspartame: a safety evaluation based on current use levels, regulations, and toxicological and epidemiological studies. Crit Rev Toxicol, 2007. 37(8): p. 629-727. |
| 3262 | Humphries, P., E. Pretorius, and H. Naude, Direct and indirect cellular effects of aspartame on the brain. Eur J Clin Nutr, 2008. 62(4): p. 451-62. |
| 3263 | Arzneim. Forsch. (1968), 18(7), 791-8; Ther. Ggw. (1911), 51, 348-51 |
| 3264 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=NALTREXONE+&cntry=&state=&city=&dist=&Search=Search |
| 3265 | Schaeffer EM, et al.Selective Depletion of Uropathogenic E. coli from the Gut by a FimH Antagonist.SelectivJ Urol. 2018 Apr;199(4):874-875. |
| 3266 | Zlitni S, et al. Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation. Nat Chem Biol. 2013 Dec;9(12):796-804. |
| 3267 | Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122(1):71-7. |
| 3268 | Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18(5):563-8. |
| 3269 | Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261(2):368-77 |
| 3270 | Curr Ther Res 53:484 (1993); CNS Drugs 2:313 (1994) |
| 3271 | Tao H, et al. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened. Chem Biol. 2011 Apr 22;18(4):432-7. |
| 3272 | Verena V. Metz, et al. Induction of RAGE Shedding by Activation of G Protein-Coupled Receptors. PLoS One. 2012. |
| 3273 | M J M Gooden, et al. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. British Journal of Cancer (2014) 110, 1535–1544. |
| 3274 | N Milosch, et al. Holo-APP and G-protein-mediated signaling are required for sAPPa-induced activation of the Akt. Cell Death Dis. 2014 Aug 28;5:e1391. |
| 3275 | Rofecoxib, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290(2):551-60. |
| 3276 | Liu NN, et al. Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression. Clin Exp Ophthalmol. 2015 Jul;43(5):458-65. |
| 3277 | Stoppoloni D, et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer. 2010 Feb 2;9:27. |
| 3278 | Julie Kim,et al.The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitroand In Vivo.Mol Cancer Ther.2019 Nov;18(11):1973-1984. |
| 3279 | Drugs (2001), 61(3), 353-364; J. Med. Chem. (1970), 13(6), 1102-5; J. Med. Chem. (1967), 10(4), 530-3| |
| 3280 | Ryan A, et al. Activation of nitrofurazone by azoreductases: multiple activities in one enzyme. Sci Rep. 2011;1:63. |
| 3281 | CA 72:77299y (1970); Anla Profiles Drug Subs 12:683 (1983) |
| 3282 | Meng F, et al. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21;15:422. |
| 3283 | Zhang X, et al. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016 May 26;11(5):e0155289. |
| 3284 | Peeters SG, et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [<sup>18</sup>F]HX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 1;21(13):2984-92. |
| 3285 | Helv Chim Acta 9:1207 (1951); J Pharmacol Exper Therap 219:540 (1981); Arch Opthalmol 102:1385 (1984) |
| 3286 | Roberts AM, et al. Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. ACS Chem Biol. 2017 Apr 21;12(4):899-904. |
| 3287 | Müller J, et al. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem. 2008 Mar 25;9(5):723-7. |
| 3288 | J Chem Soc 1929:24; Biochem Pharmacol 45:67 (1993); The Antiseptic 99: 81 (2002) |
| 3289 | Beard RL, et al. Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8. |
| 3290 | J Am Chem Soc 72:1824 (1950) |
| 3291 | David E.Jackson, et al. Aryltetralin lignans from Podophyllum hexandrum and Podophyllum peltatum. Phytochemistry, 1984, 23(5): 1147-1152. |
| 3292 | Zilla MK, et al. 4'-Demethyl-deoxypodophyllotoxin glucoside isolated from Podophyllum hexandrum exhibits potential anticancer activities by altering Chk-2 signaling pathway in MCF-7 breast cancer cells. Chem Biol Interact. 2014 Dec 5;224:100-7. |
| 3293 | https://clinicaltrials.gov/ct2/show/NCT04900155?term=Ezetimibe&cond=COVID-19&draw=2&rank=1 |
| 3294 | Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720. |
| 3295 | Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264. |
| 3296 | Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22. |
| 3297 | Chua GNL, et al. Cytosine-Based TET Enzyme Inhibitors. ACS Med Chem Lett. 2019 Jan 31;10(2):180-185. |
| 3298 | Gao Y, et al. Effects of D-Pinitol on Insulin Resistance through the PI3K/Akt Signaling Pathway in Type 2Diabetes Mellitus Rats. J Agric Food Chem. 2015 Jul 8;63(26):6019-26. |
| 3299 | Moreira LN, et al. Activation of eNOS by D-pinitol Induces an Endothelium-Dependent Vasodilatation in MouseMesenteric Artery. Front Pharmacol. 2018 May 22;9:528. |
| 3300 | Rengarajan T, et al. D-pinitol promotes apoptosis in MCF-7 cells via induction of p53 and Bax and inhibition of Bcl-2 and NF-κB. Asian Pac J Cancer Prev. 2014;15(4):1757-62. |
| 3301 | Sethi G, et al. Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol Cancer Ther. 2008 Jun;7(6):1604-14. |
| 3302 | Shen J, et al. Protodioscin ameliorates fructose-induced renal injury via inhibition of the mitogen activated protein kinase pathway. Phytomedicine. 2016 Nov 15;23(12):1504-1510. |
| 3303 | Zhang X, et al. Potential neuroprotection of protodioscin against cerebral ischemia-reperfusion injury in rats through intervening inflammation and apoptosis. Steroids. 2016 Sep;113:52-63 |
| 3304 | Wang T, et al. Antihyperlipidemic effect of protodioscin, an active ingredient isolated from the rhizomes of Dioscorea nipponica. Planta Med. 2010 Oct;76(15):1642-6 |
| 3305 | Siebeneicher H et al. Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876. ChemMedChem. 2016 Aug 23. |
| 3306 | Ma Y, et al. Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876. Cancers (Basel). 2018 Dec 31;11(1). |
| 3307 | Christensen JG, et al. The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2019 Oct 28. pii: CD-19-1167. |
| 3308 | Kyriakos P. Papadopoulos, et al. A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. Journal of Clinical Oncology 2019 37:15_suppl, TPS3161-TPS3161. |
| 3309 | Osaki S, et al. L-arabinose feeding prevents increases due to dietary sucrose in lipogenic enzymes and triacylglycerol levels in rats. J Nutr. 2001 Mar;131(3):796-9. |
| 3310 | Huck JH, et al. Ribose-5-phosphate isomerase deficiency: new inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy. Am J Hum Genet. 2004 Apr;74(4):745-51. |
| 3311 | Nakamura T, et al. Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility. Bioorg Med Chem Lett. 2013 Feb 1;23(3):669-72. |
| 3312 | Adlard AL, et al. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer. 2014 Aug 15;135(4):820-9. |
| 3313 | Expert Opin. Pharmacother. (2010), 11(18), 3085-3093; Res. Clin. Stud. Headache (1978), 6, 6-12; J. Pharmacol. (1947), 90, 166-73| |
| 3314 | Colman, I., et al., Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med, 2005. 45(4): p. 393-401. |
| 3315 | Saper, J.R., et al., DHE in the pharmacotherapy of migraine: potential for a larger role. Headache, 2006. 46 Suppl 4: p. S212-20. |
| 3316 | Schaerlinger, B., et al., Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol, 2003. 140(2): p. 277-84. |
| 3317 | Forster M, et al. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket. Cell Chem Biol. 2016 Nov 17;23(11):1335-1340. |
| 3318 | Bartholomeusz GA, et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood. 2007 Apr 15;109(8):3470-8. |
| 3319 | Adv Carbohydr Chem 3:337 (1948); Anal Profiles Drug Subs 16:507 (1986) |
| 3320 | Drugs Aging (2005), 22(11), 967-977; Drugs Aging (1996), 8(4), 299-322; Bull. Soc. Chim. Fr. (1966), (6), 1838-46 |
| 3321 | https://clinicaltrials.gov/ct2/show/NCT04884490?term=TRIMETHOPRIM&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04470531?term=TRIMETHOPRIM&cond=Covid19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001466-11-GR |
| 3322 | Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. |
| 3323 | Takemura T, et al. 3,4-Dicaffeoylquinic Acid, a Major Constituent of Brazilian Propolis, Increases TRAIL Expression and Extends the Lifetimes of Mice Infected with the Influenza A Virus. Evid Based Complement Alternat Med. 2012;2012:946867. |
| 3324 | Liu X, et al. Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice. Basic Clin Pharmacol Toxicol. 2019;124(2):144-153. |
| 3325 | Ooi KL, et al. Cytotoxic, apoptotic and anti-α-glucosidase activities of 3,4-di-O-caffeoyl quinic acid, an antioxidant isolated from the polyphenolic-rich extract of Elephantopus mollis Kunth. J Ethnopharmacol. 2011;135(3):685-695. |
| 3326 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=METHYLDOPA&cond=covid&draw=2&rank=1 |
| 3327 | Zhou HJ, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009 May 14;52(9):3028-38. |
| 3328 | Chauhan D, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood, 2010, 116(23), 4906-4915. |
| 3329 | Muchamuel T, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med, 2009, 15(7), 781-787. |
| 3330 | Hagen Thieme, et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45. |
| 3331 | Xin Wen, et al. Prostaglandin F2α Induces Goat Corpus Luteum Regression via Endoplasmic Reticulum Stress and Autophagy. Front Physiol. 2020 Sep 11;11:868. |
| 3332 | Yurtsever Z, et al. First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes. Biochim Biophys Acta. 2016 Nov;1860(11 Pt A):2335-2344. |
| 3333 | Mehdi Bouhaddou, et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020 Aug 6;182(3):685-712.e19. |
| 3334 | Tijsma A, et al. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2. |
| 3335 | Sun L, et al. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5. |
| 3336 | Martin MW, et al. Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett. 2018 Jul 1;28(12):2143-2147. |
| 3337 | Gynecol Prat 15:247 (1964); Genitourin Med 73:397 (1997); Clin Infect Dis 49:914 (2009) |
| 3338 | O'Neill BT, et al. Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation. J Med Chem. 2018 May 24;61(10):4476-4504. |
| 3339 | M Titford. The long history of hematoxylin. Biotech Histochem. Mar-Apr 2005;80(2):73-8. |
| 3340 | Yilong Tu, et al. Hematoxylin Inhibits Amyloid β-Protein Fibrillation and Alleviates Amyloid-Induced Cytotoxicity. J Phys Chem B. 2016 Nov 10;120(44):11360-11368. |
| 3341 | Ada T Feldman, et al. Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 2014;1180:31-43. |
| 3342 | Robert D Cardiff, et al. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014 Jun 2;2014(6):655-8. |
| 3343 | Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776-82. |
| 3344 | Sun FX, et al. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003 Jan 1;63(1):80-5. |
| 3345 | Joto N, et al. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer. 1997 Aug 7;72(4):680-6. |
| 3346 | Bola BM, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014 Dec;13(12):2805-16. |
| 3347 | Polanski R, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014 Feb 15;20(4):926-37. |
| 3348 | Bold G, et al. A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. J Med Chem. 2016 Jan 14;59(1):132-46. |
| 3349 | Galyean ML, et al. Effects of arrival medication with tilmicosin phosphate on health and performance of newly received beef cattle. J Anim Sci. 1995 May;73(5):1219-26. |
| 3350 | Fittipaldi N, et al. Assessment of the efficacy of tilmicosin phosphate to eliminate Actinobacillus pleuropneumoniae from carrier pigs. Can J Vet Res. 2005 Apr;69(2):146-50. |
| 3351 | Chem Pharm Bull 33:3982 (1985): Phytochemistry 28:1778 (1989) |
| 3352 | Christodoulou MS, et al. Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors. Bioorg Med Chem. 2011 Mar 1;19(5):1649-57. |
| 3353 | Fernández-Cruz ML, et al. Biological and chemical studies on aryl hydrocarbon receptor induction by the p53 inhibitor pifithrin-α and its condensation productpifithrin-β. Life Sci. 2011 Apr 25;88(17-18):774-83. |
| 3354 | Da Pozzo E, et al. p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells. ACS Chem Neurosci. 2014 May 21;5(5):390-9. |
| 3355 | Jeffrey R. Jackson, et al. A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer. First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Sep 12-15, 2006. |
| 3356 | Yin Y, et al. Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells. Leuk Lymphoma. 2015 Jun;56(6):1813-20. |
| 3357 | Good JA, et al. Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. J Med Chem. 2013 Mar 14;56(5):1878-93. |
| 3358 | Akamatsu M, et al. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19. Sci Immunol. 2019 Oct 25;4(40). pii: eaaw2707. |
| 3359 | J Cell Biol 115:461 (1991);122:523 (1993); Eur J Biochem 248:30 (1997)| |
| 3360 | Obrecht AS, et al. Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors. Neuropharmacology. 2019 Nov 1;158:107749. |
| 3361 | Hashem AM, et al. Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases. PLoS One. 2009 Dec 17;4(12):e8350. |
| 3362 | Benchokroun Y, et al. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochem Pharmacol. 1995 Jan 31;49(3):305-13. |
| 3363 | Alison Roos, et al. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Oncotarget. 2017 Feb 14; 8(7): 12234–12246. |
| 3364 | Youtian Hu, et al. Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase. J Med Chem. 2019 Feb 14;62(3):1677-1683. |
| 3365 | Rengen Fan, et al. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biol. 2019 Jun; 16(6): 707–718. |
| 3366 | Kobori M, et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 2004 Jan;11(1):123-30. |
| 3367 | Sarveswaran S, et al. Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Int J Oncol. 2012 Dec;41(6):2191-9. |
| 3368 | Liu YQ, et al. Wedelolactone enhances osteoblastogenesis by regulating Wnt/β-catenin signaling pathway but suppresses osteoclastogenesis by NF-κB/c-fos/NFATc1 pathway. Sci Rep. 2016 Aug 25;6:32260. |
| 3369 | Wang S, et al. N-Oleoyl glycine, a lipoamino acid, stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun. 2015 Oct 23;466(3):438-43. |
| 3370 | Japan J Pharmacol 50:47 (1989); Arzneim Forsch 44:193 (1994) |
| 3371 | Kazi A, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer Res. 2019 Jun 21. |
| 3372 | Smith JA, et al. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005 Feb 1;65(3):1027-34. |
| 3373 | Yu Li, et al. The Affinity of RSK for Cylitol Analogues of SL0101 Is Critically Dependent on the B-ring C-4'-hydroxy. Chem Commun (Camb). 2020 Mar 10;56(20):3058-3060. |
| 3374 | Mender I, et al. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine. Cancer Discov. 2015 Jan;5(1):82-95. |
| 3375 | Hegde SS, et al. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties. J Pharmacol Exp Ther. 2014 Oct;351(1):190-9. |
| 3376 | Hughes AD, et al. Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β? agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD). J Med Chem. 2015 Mar 26;58(6):2609-22. |
| 3377 | Russo R, et al. Effects of 6-aminochrysene on liver microsomal enzyme activity. Xenobiotica. 1976 Apr;6(4):201-5. |
| 3378 | Lambelin G, et al. Carcinogenicity of 6-aminochrysene in mice. Eur J Cancer. 1975 May;11(5):327-34. |
| 3379 | Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63. |
| 3380 | Shishido Y, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res. 2013 Apr;33(4):1379-86. |
| 3381 | Maderna A, et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem. 2014 Dec 26;57(24):10527-43. |
| 3382 | Bao R, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 2009 Jun 15;15(12):4046-57. |
| 3383 | Stenderup K, et al. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol. 2014 Nov;94(6):672-6. |
| 3384 | Bao R, et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 2009 Dec;8(12):3296-306. |
| 3385 | Jin ZL, et al. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells. Exp Ther Med. 2018 Jun;15(6):5046-5050. |Acta Pharmacol Toxicol 4:265 (1949) |
| 3386 | Clin Toxicol 16:17 (1980); Anal Profiles Drug Subs 14:108 (1985) |
| 3387 | Naik R, et al. Synthesis and structure-activity relationship study of chemical probes as hypoxia induced factor-1α/malate dehydrogenase 2 inhibitors. J Med Chem. 2014 Nov 26;57(22):9522-38. |
| 3388 | Lee K, et al. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol. 2010 Oct 1;80(7):982-9. |
| 3389 | Song JG, et al. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein. |
| 3390 | Sato M, et al. LW6, a hypoxia-inducible factor 1 inhibitor, selectively induces apoptosis in hypoxic cells through depolarization of mitochondria in A549 human lung cancer cells. Mol Med Rep. 2015 Sep;12(3):3462-8. |
| 3391 | Nakano-Ito K, et al. E2012-induced cataract and its predictive biomarkers. Toxicol Sci. 2014 Jan;137(1):249-58. |
| 3392 | Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K.Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.J Alzheimers Dis. 2010;21(3):1005-12. |
| 3393 | Laco F, et al. Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. J Mol Cell Cardiol. 2015 Mar;80:56-70. |
| 3394 | Virtanen R, et al. Pharmacological evidence for the involvement of alpha-2 adrenoceptors in the sedative effect of detomidine, a novel sedative-analgesic. J Vet Pharmacol Ther. 1985 Mar;8(1):30-7. |
| 3395 | J Still, et al. Cardiovascular and respiratory effects of detomidine in isoflurane-anaesthetised horses. J S Afr Vet Assoc. 1996 Dec;67(4):199-203. |
| 3396 | Graub R, et al. Cell cycle-dependent phosphorylation of human CDC5 regulates RNA processing. Cell Cycle. 2008 Jun 15;7(12):1795-803. |
| 3397 | Brooks EE, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem. 1997 Nov 14;272(46):29207-11. |
| 3398 | Chen P, et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. J Med Chem. 2016 Feb 25;59(4):1410-24. |
| 3399 | Ai J, et al. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Mol Cancer Ther. 2018 Apr;17(4):751-762. |
| 3400 | Li J, et al. t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activatingNF-κB-p65. J Neurooncol. 2012 Jul;108(3):385-93. |
| 3401 | Liu JY, et al. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murinemodel of inflammation. Br J Pharmacol. 2009 Jan;156(2):284-96. |
| 3402 | Stephen Willingham, et al. Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies.Cancer Immunoly Research. September 25-28, 2016. |
| 3403 | Indarte M, et al. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors. Cancer Res. 2019 Jun 15;79(12):3100-3111. |
| 3404 | Apraiz, Aintzane., et al. Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochemistry and Cell Biology (2012), 90(2), 209-223. |
| 3405 | Bikman, Benjamin T., et al. Fenretinide Prevents Lipid-induced Insulin Resistance by Blocking Ceramide Biosynthesis. Journal of Biological Chemistry (2012), 287(21), 17426-17437. |
| 3406 | Cooper JP, et al. Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol. 2011 Jul;163(6):1263-75. |
| 3407 | Golubkov V, et al. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res. 2005 Jan-Feb;25(1A):249-53. |
| 3408 | Prinz H, et al. N-benzoylated phenoxazines and phenothiazines: synthesis, antiproliferative activity, and inhibition of tubulin polymerization. J Med Chem. 2011 Jun 23;54(12):4247-63. |
| 3409 | Overstreet DH, et al. Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with Desipramine in an animal model of depression. Pharmacol Biochem Behav. 2010 Aug;96(2):206-10. |
| 3410 | Mock ED, et al. Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice. Nat Chem Biol. 2020;16(6):667-675. |
| 3411 | Wei X, et al. Kojic acid inhibits senescence of human corneal endothelial cells via NF-κB and p21 signaling pathways. Exp Eye Res. 2018 Dec 28;180:174-183. |
| 3412 | J Am Chem Soc 61: 2832 (1939) |
| 3413 | Zocchi C, et al. Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol. 1996 Apr;117(7):1381-6. |
| 3414 | Varani K, et al. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Br J Pharmacol. 1996 Apr;117(8):1693-701. |
| 3415 | Xi J, et al. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol. 2009 Nov;47(5):684-90. |
| 3416 | Kuzumaki N, et al. Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer. PLoS One. 2012;7(10):e44368. |
| 3417 | Mediavilla-Varela M, et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013 Sep;14(9):860-8. |
| 3418 | Wardas J, et al. SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum. Brain Res. 2003 Jul 11;977(2):270-7. |
| 3419 | Wardas J, et al. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse. 2001 Aug;41(2):160-71. |
| 3420 | Anal Biochem 77: 106 (1977); Biochem J 260: 19 (1989); 324: 497 (1997) |
| 3421 | Salphati L, et al. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Drug Metab Dispos. 2014 Jul;42(7):1110-6. |
| 3422 | Becker CM, et al. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Neuro Oncol. 2015 Sep;17(9):1210-9. |
| 3423 | Arch Ophthalmol 51:663 (1954); Optomitry Vision Sci 74:1025 (1997) |
| 3424 | Nature 223:211 (1969); Cancer Res 62:2708 (2002); Mol Pharmacol 62:1255 (2002) |
| 3425 | Harriman G, et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1796-805. |
| 3426 | Beghyn, et al. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil. Bioorganic & Medicinal Chemistry Letters (2007), 17(3), 789-792. |
| 3427 | Daugan, et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogue. Journal of Medicinal Chemistry (2003), 46(21), 4533-4542. |
| 3428 | Porst H, et al. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. Expert Opin Pharmacother. 2012 Jul;13(10):1481-94. |
| 3429 | Frey MK, Lang I. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2012 Apr;13(5):747-55. |
| 3430 | Božović M, et al. <i>Calamintha nepeta</i> (L.) Savi and its Main Essential Oil Constituent Pulegone: Biological Activities and Chemistry. Molecules. 2017 Feb 14;22(2). |
| 3431 | Majikina A, et al. Involvement of nociceptive transient receptor potential channels in repellent action of pulegone. Biochem Pharmacol. 2018 May;151:89-95. |
| 3432 | Juruena, M.F., E.P. de Sena, and I.R. de Oliveira, Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis, 2011. 3: p. 75-85. |
| 3433 | Kane, J.M. and C.A. Tamminga, Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Investig Drugs, 1997. 6(11): p. 1729-41. |
| 3434 | Murdoch, D. and G.M. Keating, Sertindole : a review of its use in schizophrenia. CNS Drugs, 2006. 20(3): p. 233-55. |
| 3435 | Arch. Dermatol. (1969), 99(6), 753-6; Endocrinology (1965), 76(5), 916-27; Steroids (1964), 4(1), 1-30 |
| 3436 | David K Edwards V, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018 May 15;9(37):24576-24589. |
| 3437 | Dembele L, et al. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci Rep. 2017;7(1):2325. Published 2017 May 24. |
| 3438 | Zeeman AM, et al. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother. 2016;60(5):2858-2863. Published 2016 Apr 22. |
| 3439 | Turnbull AP, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017 Oct 26;550(7677):481-486. |
| 3440 | Hasako S, et al. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658. |
| 3441 | Hibiki Udagawa, et al. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol Cancer Res. 2019 Nov;17(11):2233-2243. |
| 3442 | Int J Dermatol 24:603 (1985); Crit Rev Toxicol 21:105 (1990); Mutag 7:433 (1992); J Pesticide Reform 18:14 (1998) |
| 3443 | Brit J Pharmacol 120:813 (1997); Arch Dis Child 84:430 (2001) |
| 3444 | Annalen 520:31 (1935); J Biol Chem 126:29 (1938); Indian J Exper Biol 37:415 (1999) |
| 3445 | Liu Z, et al. Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury. J Med Chem. 2019 Jun 13;62(11):5453-5469. |
| 3446 | Fortschr Med 97:883 (1979); Arzneim Forsch 33:453 (1983) |
| 3447 | Medhurst AD, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45. |
| 3448 | Guo RX, et al. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.Br J Pharmacol. 2009 May;157(1):104-17. |
| 3449 | Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65. |
| 3450 | J Pharmacol Exp Ther 186:173 (1973); J Urol 119:9 (1978); Urology17:320 (1981) |
| 3451 | Rheumatology (1999), 38 Suppl 11-3; Inflammation Res. (1998), 47(2), 79-85; Arzneim. Forsch. (1995), 45(10), 1093-5,| |
| 3452 | Vago T, et al. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneimittelforschung. 1995 Oct;45(10):1096-8. |
| 3453 | Werner MF, et al. Nimesulide-induced antipyresis in rats involves both cyclooxygenase-dependent and independent mechanisms. Eur J Pharmacol. 2006 Aug 14;543(1-3):181-9. |
| 3454 | Genç S, et al. The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture. Clin Exp Med. 2007 Mar;7(1):6-10. |
| 3455 | https://clinicaltrials.gov/ct2/show/NCT04937543?term=BECLOMETHASONE&cond=COVID-19&draw=2&rank=2 |
| 3456 | Costell MH, et al. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol. 2012 Jul 5;3:128. |
| 3457 | Zhao X, et al. Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study. Clin Pharmacokinet. 2016 May;55(5):615-24. |
| 3458 | Oudot A, et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011 Nov;60(5):1020-6. |
| 3459 | Suzuki H, et al. Bropirimine inhibits osteoclast differentiation through production of interferon-β. Biochem Biophys Res Commun. 2015;467(1):146‐151. |
| 3460 | Sarosdy MF, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology. 1998;51(2):226‐231. |
| 3461 | Arnold LD, et al. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70. |
| 3462 | Seo HH, et al. 7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine inhibits the proliferation and migration of vascular smooth muscle cells by suppressing ERK and Akt pathways. Eur J Pharmacol. 2017 Mar 5;798:35-42. |
| 3463 | Burchat AF, et al. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitorsof lck II. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2171-4. |
| 3464 | Antimicrob Agents Chemother 29:193 (1986); 30:689 (1986 |
| 3465 | https://clinicaltrials.gov/ct2/show/NCT04278404?term=AMINOCAPROIC+ACID&cond=covid&draw=2&rank=1 |
| 3466 | Antimicrob. Agents Chemother. (1979), 15(3), 392-5; Antimicrob. Agents Chemother. (1977), 12(3), 353-6; Mol. Pharmacol. (1970), 6(6), 604-16| |
| 3467 | Layton HW, et al. Efficacy of nithiamide in preventing and treating swine dysentery in experimentally inoculated pigs. Am J Vet Res. 1977 May;38(5):627-31. |
| 3468 | Wen Ma, et al. A Cell Membrane-Targeting Self-Delivery Chimeric Peptide for Enhanced Photodynamic Therapy and In Situ Therapeutic Feedback. Adv Healthc Mater. 2020 Jan;9(1):e1901100. |
| 3469 | Maksim V Kvach, et al. 5(6)-carboxyfluorescein revisited: new protecting group, separation of isomers, and their spectral properties on oligonucleotides. Bioconjug Chem. Sep-Oct 2007;18(5):1691-6. |
| 3470 | Knox K, et al. The Coumarin Glucoside, Esculin, Reveals Rapid Changes in Phloem-Transport Velocity in Response to Environmental Cues. Plant Physiol. 2018 Oct;178(2):795-807. |
| 3471 | Song Y, et al. Esculin ameliorates cognitive impairment in experimental diabetic nephropathy and induces anti-oxidative stress and anti-inflammatory effects via the MAPK pathway. Mol Med Rep. 2018 May;17(5):7395-7402. |
| 3472 | So L, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J Biol Chem. 2013 Feb 22;288(8):5718-31. |
| 3473 | Tomoyuki Hasegawa, et al. Process Development of ONO-2506: A Therapeutic Agent for Stroke and Alzheimer's Disease. Org. Process Res. Dev.200372168-171. |
| 3474 | Kato H, et al. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTPneurotoxicity in mice. Brain Res. 2004 Dec 24;1030(1):66-73. |
| 3475 | https://clinicaltrials.gov/ct2/show/NCT05004753?term=Artemisinin&cond=covid-19&draw=2&rank=1 |
| 3476 | J R Schultz, et al. Role of LXRs in Control of Lipogenesis. Genes Dev. 2000 Nov 15;14(22):2831-8. |
| 3477 | Rough JJ, et al. Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res. 2010 May 26;3:13. |
| 3478 | Todd G Kirchgessner, et al. Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils. Cell Metab. 2016 Aug 9;24(2):223-33. |
| 3479 | Keith A Houck, et al. T0901317 Is a Dual LXR/FXR Agonist. Mol Genet Metab. Sep-Oct 2004;83(1-2):184-7. |
| 3480 | Naresh Kumar, et al. The Benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-Alpha/Gamma Inverse Agonist. Mol Pharmacol. 2010 Feb;77(2):228-36. |
| 3481 | Mingming Gao, et al. The Liver X Receptor Agonist T0901317 Protects Mice From High Fat Diet-Induced Obesity and Insulin Resistance. AAPS J. 2013 Jan;15(1):258-66. |
| 3482 | Chem Ind 22:721 (1988) |
| 3483 | Prickaerts J, et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology. 2012 Feb;62(2):109 |
| 3484 | Thomas Papouin, et al. Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness. Neuron. 2017 May 17;94:1-15. |
| 3485 | Papouin T, et al. Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness. Neuron. 2017 May 17;94(4):840-854.e7. |
| 3486 | Maehara S, et al. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631. Eur J Pharmacol. 2017 Sep 15;811:110-116. |
| 3487 | Xiao B, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017. |
| 3488 | Bultot L, et al. Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle. Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E706-E719. |
| 3489 | Lumateperone |
| 3490 | Takasu T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007 May;321(2):642-7. |
| 3491 | C Brown , et al. The Monoamine Oxidase Inhibitor-Tyramine Interaction. J Clin Pharmacol. 1989 Jun;29(6):529-32. |
| 3492 | Gao Y, et al. Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5. |
| 3493 | Phytochemistry 21: 1063 (1982); Planta Medica 58: 389 (1992) |
| 3494 | Kemp JA, et al. 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6547-50. |
| 3495 | Yaksh TL, et al. Characterization of the Effects of L-4-Chlorokynurenine on Nociception in Rodents. J Pain. 2017 Oct;18(10):1184-1196. |
| 3496 | Croucher MJ, et al. 7-Chlorokynurenic acid, a strychnine-insensitive glycine receptor antagonist, inhibits limbic seizurekindling. Neurosci Lett. 1990 Oct 2;118(1):29-32. |
| 3497 | Takahiro Horinouchi, et al. Different Changes of Plasma Membrane Beta-Adrenoceptors in Rat Heart After Chronic Administration of Propranolol, Atenolol and Bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. |
| 3498 | M Takita, et al. Selectivity of Bevantolol Hydrochloride Towards Alpha- And Beta-Adrenoceptor Subtypes in Rat Cerebral Cortex. Jpn J Pharmacol. 1992 Feb;58(2):193-6. |
| 3499 | Soderholm JF, et al. Importazole, a small molecule inhibitor of the transport receptor importin-β. ACS Chem Biol. 2011 Jul 15;6(7):700-8. |
| 3500 | Yan WQ, et al. Effect of nuclear receptor inhibitor importazole on the proliferation and apoptosis of multiple myeloma cells. Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):323-6. |
| 3501 | https://clinicaltrials.gov/ct2/show/NCT04591210?term=Enalapril&cond=covid&draw=1&rank=2 |
| 3502 | N Z Med J 96:590 (1983); Rinsho Ketsueki 33:823 (1992); Rev Med Interne 17:859 (1996) |
| 3503 | Zhai D, et al. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2008 Jun;7(6):1639-46. |
| 3504 | Wang LH, et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling. Br J Cancer. 2014 Jan 21;110(2):341-52. |Tetrahedron 21: 1453 (1965); J Chem Soc(C) 1966:772; Tet Lett 1967:4201; Phytochemistry 41,: 815 (1996) |
| 3505 | Moret C, et al. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985 Dec;24(12):1211-9. |
| 3506 | Briley M, et al. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:9-14. |
| 3507 | Punekar NS, et al. Acetylcholinesterase inhibition by pitofenone: a spasmolytic compound. Biotechnol Appl Biochem. 1991 Dec;14(3):378-82. |
| 3508 | Bull Chem Soc Jpn 29:419 (1956) |
| 3509 | S. David Brown , et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1 |
| 3510 | J Nat Prod 49:690 (1986) |
| 3511 | Hong X, et al. In Vitro Glucuronidation of Wushanicaritin by Liver Microsomes, Intestine Microsomes and Expressed Human UDP-Glucuronosyltransferase Enzymes. Int J Mol Sci. 2017 Sep 19;18(9). pii: E1983. |
| 3512 | https://clinicaltrials.gov/ct2/show/NCT04865029?term=Estradiol&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04853069?term=Estradiol&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04359329?term=Estradiol&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04539626?term=Estradiol&cond=COVID-19&draw=2&rank=5 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/09/027622 |
| 3513 | Konze KD, et al. An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324-34. |
| 3514 | Corallo C, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18(1):228. |
| 3515 | Sen S, et al. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.
 Life Sci. 2012 Apr 13. |
| 3516 | Bruderer S, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
 AAPS J. 2012 Mar;14(1):68-78. |
| 3517 | Kim SJ, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.
 Transl Oncol. 2012 Feb;5(1):39-47. |
| 3518 | Ihle NT, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growthfactor receptor inhibitor ZD1839 in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther. 2005 Sep;4(9):1349-57. |
| 3519 | Bowles DW, et al. A Randomized, Phase II Trial of C225 With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clin Colorectal Cancer. 2016 Dec;15(4):337-344.e2. |
| 3520 | Sonolisib |
| 3521 | https://clinicaltrials.gov/ct2/show/NCT04533347?term=Tafenoquine&cond=Covid19&draw=2&rank=1; https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04533347 |
| 3522 | Kazuhiro Miwa, et al. Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor. doi/10.1021/jm200216q |
| 3523 | Daisuke Nakata, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014 Jan 15;723:167-74. |
| 3524 | JACS 62:869 (1910), J Org Chem 38:3729 (1973) |
| 3525 | Proc. Soc. Exp. Biol. Med. (1962), 109, 664-8; J. Org. Chem. (1961), 26, 2378-83; Scand. J. Gastroenterol. (1978), 13(3), 321-3 |
| 3526 | Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22. |
| 3527 | Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471. |
| 3528 | Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13(5):e0194568. |
| 3529 | Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003 Jun;994:96-102. |
| 3530 | Pfaus JG, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10201-4. |
| 3531 | Barrett TD, et al. Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor. Mol Pharmacol. 2011 |
| 3532 | Tong J, et al. Antidepressant effect of helicid in chronic unpredictable mild stress model in rats. Int Immunopharmacol. 2019 Feb;67:13-21. |
| 3533 | Int J Immunopharmacol 14:505 (1992); Lancet 348:519 (1996) |
| 3534 | Draoui N, et al. Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux. Mol Cancer Ther. 2014 Jun;13(6):1410-8. |
| 3535 | Dutil L, et al. Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada. Emerg Infect Dis. 2010 Jan;16(1):48-54. |
| 3536 | Yancey RJ Jr, et al. Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice. Am J Vet Res. 1987 Jul;48(7):1050-3. |
| 3537 | Salmon SA, et al. In vitro activity of ceftiofur and its primary metabolite, desfuroylceftiofur, against organisms of veterinary importance. J Vet Diagn Invest. 1996 Jul;8(3):332-6. |
| 3538 | https://clinicaltrials.gov/ct2/show/NCT04500639?term=Ibuprofen&cond=Covid19&draw=2&rank=1 |
| 3539 | Knutson SK, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012;8(11):890-6. |
| 3540 | Tang SH, et al. Effects of H3K27 methylation inhibitor EPZ005687 on apoptosis, proliferation and cell cycle of U937 cells and normal CD34 positive cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Dec;22(6):1561-6. |
| 3541 | Sangodkar J, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest. 2017 Jun 1;127(6):2081-2090. |
| 3542 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=ARGININE&cntry=&state=&city=&dist= |
| 3543 | Urwyler S, Campbell E, Fricker G, Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35(6):655-69. |
| 3544 | Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39. |
| 3545 | Moore JD, et al. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Oncotarget. 2014 Dec 30;5(24):12862-76. |
| 3546 | Sharlow ER, et al. Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J Biol Chem. 2008 Nov 28;283(48):33516-26. |
| 3547 | Venardos K, et al. The PKD inhibitor CID755673 enhances cardiac function in diabetic db/db mice. PLoS One. 2015 Mar 23;10(3):e0120934. |
| 3548 | Engers DW, et al. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. |
| 3549 | Whitley, R., et al., Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs, 1980. 20(4): p. 267-82. |
| 3550 | Suzuki M, et al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006;72(2):157-161. |Antimicrob Agents Chemother 1968:136, 180; Pharmacol Ther 8:143 (1980) |
| 3551 | https://clinicaltrials.gov/ct2/show/NCT04542850?term=AMINOLEVULINIC+ACID&cond=Covid19&draw=2&rank=2 |
| 3552 | Chem Pharm Bull 25:1335 (1977; Arzniem) Forsch 19:5 (1968) |
| 3553 | J Steroid Biochem 20:945 (1984) |
| 3554 | Drugs (1999), 57(2), 261-277; Eur. J. Clin. Pharmacol. (1990), 38(Suppl. 1), S35-S51; J. Pharmacol. Exp. Ther. (1972), 180(3), 732-42 |
| 3555 | Xu J, et al. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev. 2014 May;3(3):170-8. |
| 3556 | Tetrahedron 21: 1453 (1965) |
| 3557 | Arzneim Forsch 17:242 (1967); Curr Ther Res 9:537 (1967); 19:51 (1976) |
| 3558 | Ill Med J 119:398 (1961); Am J Psychiat 123:1303 (1967); Schizophr Res 53:25 (2002); Schizophr Bull 33:1379 (2007) |
| 3559 | J Chem Soc 1928:1504; Arch Pharmacal Res 21:140, 774 (1998); Eur J Pharmacol 513:237 (2005); World Acad Sci Eng Tech 60:215 (2011)| |
| 3560 | Dapson RW, et al. Brazilwood, sappanwood, brazilin and the red dye brazilein: from textile dyeing and folk medicine to biological staining and musical instruments. Biotech Histochem. 2015;90(6):401-23. |
| 3561 | Jia Y, et al. [Effect of brazilin on apoptosis and autophagy of tongue cancer Tca8113 cells and its molecular mechanism]. Nan Fang Yi Ke Da Xue Xue Bao. 2019 Mar 30;39(3):351-356. |
| 3562 | Weinmann D, et al, Brazilin blocks catabolic processes in human osteoarthritic chondrocytes via inhibition of NFKB1/p50. J Orthop Res. 2018 Sep;36(9):2431-2438. |
| 3563 | Miana M, et al. The lysyl oxidase inhibitor β-aminopropionitrile reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats. Dis Model Mech. 2015 Jun;8(6):543-51. |
| 3564 | Yang X, et al. Inactivation of lysyl oxidase by β-aminopropionitrile inhibits hypoxia-induced invasion and migration of cervical cancer cells. Oncol Rep. 2013 Feb;29(2):541-8. |
| 3565 | Doi K, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem. 2012 Mar 23;287(13):10224-35. |
| 3566 | Haste NM, et al. Pharmacological properties of the marine natural product marinopyrrole A against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Jul;55(7):3305-12. |
| 3567 | Gomez-Bougie P, et al. The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation. Br J Haematol. 2016 Aug 14. |
| 3568 | Eichhorn JM, et al. Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines. Cell Death Dis. 2013 Oct 24;4:e880 |
| 3569 | J Pharm Pharmacol 23:848 (1971); J Allergy Clin Immunol 77:326 (1986) |
| 3570 | Mangeng Cheng, et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2012 Mar;11(3):670-9. |
| 3571 | Hawkins JL, et al. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J Pharmacol Exp Ther. 2008 Sep;326(3):801-8. |
| 3572 | Uchida L, et al. Suppressive Effects of the Site 1 Protease (S1P) Inhibitor, PF-429242, on Dengue Virus Propagation. Viruses. 2016 Feb 10;8(2). pii: E46. doi: 10.3390/v8020046. |
| 3573 | Urata S, et al. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol. 2011 Jan;85(2):795-803. |
| 3574 | Fong TA, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res, 1999, 59(1), 99-106. |
| 3575 | Vajkoczy P, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia, 1999, 1(1), 31-41. |
| 3576 | Happé CM, et al. Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats.Am J Physiol Lung Cell Mol Physiol. 2016 Jun 1;310(11):L1088-97. |
| 3577 | Izquierdo-Garcia JL, et al. Metabolic Reprogramming in the Heart and Lung in a Murine Model of Pulmonary Arterial Hypertension. Front Cardiovasc Med. 2018 Aug 15;5:110. |
| 3578 | Zi D, et al. Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells. Int J Mol Sci. 2015 Nov 13;16(11):27228-51. |
| 3579 | Gontarewicz A, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008 Apr 15;111(8):4355-64. |
| 3580 | Fraedrich K, et al. Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model. Clin Cancer Res. 2012 Sep 1;18(17):4621-32. Epub 2012 Jul 2. |
| 3581 | Lee HJ, et al. The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7. |
| 3582 | Morini G, et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs. Digestion. 2003;68(2-3):124-32. Epub 2003 Nov 7. |
| 3583 | Etcheverry SB, et al. Three new vanadyl(IV) complexes with non-steroidal anti-inflammatory drugs (Ibuprofen, Naproxen and Tolmetin). Bioactivity on osteoblast-like cells in culture. J Inorg Biochem. 2002 Jan 1;88(1):94-100. |
| 3584 | Dairam A, et al. Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons. Metab Brain Dis. 2006 Sep;21(2-3):221-33. |
| 3585 | T D Warner, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8. |
| 3586 | DADAŞ, Yakup, et al. Synthesis and anticancer activity of some novel tolmetin thiosemicarbazides. Marmara Pharmaceutical Journal 19(3) • April 2015 |
| 3587 | Cho SD, et al. Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways. Cancer Res. 2007 Jan 15;67(2):674-83. |
| 3588 | David A, et al. Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. J Med Chem. 2014 Dec 26; 57(24): 10512–10526. |
| 3589 | Spierer O, et al. Comparative activity of antimicrobials against Pseudomonas aeruginosa, Achromobacter xylosoxidans and Stenotrophomonas maltophilia keratitis isolates. Br J Ophthalmol. 2018 May;102(5):708-712. |
| 3590 | J Chem Soc 1933:274 |
| 3591 | Indian J Chem 15:94, 492 (1977) |
| 3592 | Wells E, et al. Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mastcells. J Immunol. 1986 Dec 15;137(12):3941-5. |
| 3593 | Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation. Huang ZG, et al. PLoS One. 2013;8(3):e60827. |
| 3594 | Babich H, et al. Theaflavin-3-gallate and theaflavin-3'-gallate, polyphenols in black tea with prooxidant properties. Basic Clin Pharmacol Toxicol. 2008 Jul;103(1):66-74. |
| 3595 | Bauer MR, et al. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5271-80. |
| 3596 | Tet Lett 1960 (10): 26; Can J Chem 64: 837 (1986); Adv Med 1: 175 (1992) |
| 3597 | Eur J Neurosci 13:1861 (2001) |
| 3598 | Shugg RP, et al. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J Biol Chem. 2013 Dec 6;288(49):35346-57. |
| 3599 | Lopez-Guadamillas E, et al. PI3Kα inhibition reduces obesity in mice. Aging (Albany NY). 2016 Nov 4;8(11):2747-2753. |
| 3600 | Kokkonda S, et al. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparumDihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity. J Med Chem. 2016 Jun 9;59(11):5416-31. |
| 3601 | Phillips MA, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med. 2015 Jul 15;7(296):296ra111. |
| 3602 | Olguín-Reyes S, et al. Bergamottin is a competitive inhibitor of CYP1A1 and is antimutagenic in the Ames test. Food Chem Toxicol. 2012 Sep;50(9):3094-9. |
| 3603 | Wu HJ, et al. Bergamottin isolated from Citrus bergamia exerts in vitro and in vivo antitumor activity in lung adenocarcinoma through the induction of apoptosis, cell cycle arrest, mitochondrial membrane potential loss and inhibition of cell migration and invasion. Oncol Rep. 2016 Jul;36(1):324-32. |
| 3604 | Ma B, et al. Raddeanin A, a natural triterpenoid saponin compound, exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway. Toxicol Appl Pharmacol. 2018 Aug 15;353:87-101. |
| 3605 | Guo SS, et al. Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. 3.411World J Gastroenterol. 2019 Jul 14;25(26):3380-3391. |
| 3606 | Xia H, et al. Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer. J Cell Mol Med. 2019 May;23(5):3656-3664. |
| 3607 | Meng C, et al. Raddeanin A Induces Apoptosis and Cycle Arrest in Human HCT116 Cells through PI3K/AKT Pathway Regulation In Vitro and In Vivo. Evid Based Complement Alternat Med. 2019 May 26;2019:7457105. |
| 3608 | Zhenggang Zhou, et al. PBN Protects NP Cells From AAPH-induced Degenerative Changes by Inhibiting the ERK1/2 Pathway. Connect Tissue Res. 2020 Mar 30;1-10. |
| 3609 | Lei Zhao, et al. Reactive Oxygen Species Contribute to Lipopolysaccharide-Induced Teratogenesis in Mice. Toxicol Sci. 2008 May;103(1):149-57. |
| 3610 | Y Kotake, et al. Inhibition of NF-kappaB, iNOS mRNA, COX2 mRNA, and COX Catalytic Activity by phenyl-N-tert-butylnitrone (PBN). Biochim Biophys Acta. 1998 Nov 19;1448(1):77-84. |
| 3611 | R A Floyd. Antioxidants, Oxidative Stress, and Degenerative Neurological Disorders. Proc Soc Exp Biol Med. 1999 Dec;222(3):236-45. |
| 3612 | Vlajkovic SM, et al. Adenosine amine congener as a cochlear rescue agent. Biomed Res Int. 2014;2014:841489. |
| 3613 | Vlajkovic SM, et al. Adenosine amine congener mitigates noise-induced cochlear injury. Purinergic Signal. 2010 Jun;6(2):273-81. |
| 3614 | Abdelhalim A, et al. Antidepressant, Anxiolytic and Antinociceptive Activities of Constituents from Rosmarinus Officinalis. J Pharm Pharm Sci. 2015;18(4):448-59. |
| 3615 | Liu J, et al. Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound. Oncotarget. 2017 Apr 20;8(33):54236-54242. |
| 3616 | https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/03/031969 |
| 3617 | Johnson M, et al. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3339-43. |
| 3618 | Walser TC, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 2006 Aug 1;66(15):7701-7. |
| 3619 | Cambien B, et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer. 2009 Jun 2;100(11):1755-64. |
| 3620 | Jani JP, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther. 2010 Apr;9(4):883-94. |
| 3621 | Hook KE, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012 Mar;11(3):710-9. |
| 3622 | Proc Soc Exp Bio Med 29:125 (1931) |
| 3623 | Popovici-Muller, et al. Preparation of N-(piperidinecarbonylphenyl) sulfonamide compounds as pyruvate kinase modulators. From PCT Int. Appl. (2014), WO2014139144A1 20140918. |
| 3624 | Chem Pharm Bull 35:3270, 4117 (1987); Arch Int Pharmacodyn 304:206 (1990); Neurochem Res 19:1503 (1994) |
| 3625 | Choi HG, et al. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J Med Chem. 2010 Aug 12;53(15):5439-48. |
| 3626 | Lu X, et al. Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. Bioorg Med Chem Lett. 2015 Sep 1;25(17):3458-63. |
| 3627 | Cho, H., et al. First SAR study for overriding NRAS mutant driven acute myeloid leukemia. Journal of Medicinal Chemistry. |
| 3628 | J. Food, Agric. Environ. (2009), 7(2), 202-208; Tetrahedron (1965), 21(7), 1753-60; Proc. R. Soc. Med. (1962), 55, 861-3 |
| 3629 | Le Pogam S, et al.
 Characterization of HCV quasispecies dynamics upon short term dual-therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
 Antimicrob Agents Chemother. 2012 Nov;56(11):5494-5 |
| 3630 | Soriano V, et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother. 2011 Aug;66(8):1673-86 |
| 3631 | Guedj J, et al.
 Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
 Hepatology. 2012 Apr;55(4):1030-7. |
| 3632 | Coll Czech Chem Comm 35:124 (1970); J Nat Prod 40:384 (1977); Agents Actions 14:401 (1984); Alkaloids 28:78 (1986); Life Sci 49:315 (1991); J Cardiovasc Pharmacol 23:716 (1994) |
| 3633 | Bouché L, et al. Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains. J Med Chem. 2017 May 11;60(9):4002-4022. |
| 3634 | ACS Med Chem Lett 3:165 (2012) |
| 3635 | Kaniskan H?, et al. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70. |
| 3636 | Portugal J, Waring MJ. Assignment of DNA binding sites for 4',6-diamidine-2-phenylindole and bisbenzimide (Hoechst 33258). A comparative footprinting study. Biochimica et Biophysica Acta 949 (2): 158-68. |
| 3637 | Latt SA, Stetten G, Juergens LA, Recent developments in the detection of deoxyribonucleic acid synthesis by 33258 Hoechst fluorescence. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 23 (7): 493-505. |
| 3638 | a b c "Hoechst Stains". Invitrogren (Molecular Probes). |
| 3639 | N Eng J Med 281:1333, 1364 (1969); Postgrad Med J 56:488 (1980) |
| 3640 | Jili Zhu, et al. Catalpol protects mice against renal ischemia/reperfusion injury via suppressing PI3K/Akt-eNOS signaling and inflammation. Int J Clin Exp Med. 2015 Feb 15;8(2):2038-44. |
| 3641 | M Yamazaki, et al. Neuritogenic effect of natural iridoid compounds on PC12h cells and its possible relation to signaling protein kinases. Biol Pharm Bull. 1996 Jun;19(6):791-5. |
| 3642 | R Mehrotra, et al. In vitro studies on the effect of certain natural products against hepatitis B virus. Indian J Med Res. 1990 Apr;92:133-8. |
| 3643 | Respiration (1984), 45(2), 139-46; J. Allergy Clin. Immunol. (1983), 71(3), 317-23; Curr. Ther. Res. (1964), 6353-6 |
| 3644 | Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
 Cancer Res. 2010 Dec 15;70(24):10288-98. |
| 3645 | Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40. |
| 3646 | Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70. |
| 3647 | Kim JH, et al. Estrogen-related receptor γ is upregulated in liver cancer and its inhibition suppresses livercancer cell proliferation via induction of p21 and p27. Exp Mol Med. 2016 Mar 4;48:e213. |
| 3648 | Misra J, et al. ERRγ: a Junior Orphan with a Senior Role in Metabolism. Trends Endocrinol Metab. 2017 Apr;28(4):261-272. |
| 3649 | Kim DK, et al. Inverse agonist of nuclear receptor ERRγ mediates antidiabetic effect through inhibition of hepatic gluconeogenesis. Diabetes. 2013 Sep;62(9):3093-102. |
| 3650 | https://clinicaltrials.gov/ct2/show/NCT04746339?term=APIXABAN&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04650087?term=APIXABAN&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04801940?term=APIXABAN&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04512079?term=APIXABAN&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04498273?term=APIXABAN&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04788355?term=APIXABAN&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04736901?term=APIXABAN&cond=COVID-19&draw=2&rank=7 https://clinicaltrials.gov/ct2/show/NCT04412291?term=APIXABAN&cond=COVID-19&draw=2&rank=8 https://clinicaltrials.gov/ct2/show/NCT04828772?term=APIXABAN&cond=COVID-19&draw=2&rank=9 https://clinicaltrials.gov/ct2/show/NCT04518735?term=APIXABAN&cond=COVID-19&draw=2&rank=10 |
| 3651 | Mancuso R, et al. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice.Brain. 2019 Oct 1;142(10):3243-3264. |
| 3652 | Genovese MC, et al. Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.J Rheumatol. 2015 Oct;42(10):1752-60. |
| 3653 | Song TT, et al. Estrogenic activity of glycitein, a soy isoflavone. J Agric Food Chem. 1999 Apr;47(4):1607-10. |
| 3654 | Yoshida H, et al. Glycitein effect on suppressing the proliferation and stimulating the differentiation of osteoblastic MC3T3-E1 cells. Biosci Biotechnol Biochem. 2001 May;65(5):1211-3. |
| 3655 | Pan W, et al. Genistein, daidzein and glycitein inhibit growth and DNA synthesis of aortic smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Nutr. 2001 Apr;131(4):1154-8. |
| 3656 | Toxicol Appl Pharmacol 14:515 (1969) |
| 3657 | Ali K, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;509(7505):407-11. |
| 3658 | Meyers MJ, et al. 4-Aryl Pyrrolidines as a Novel Class of Orally Efficacious Antimalarial Agents. Part 1: Evaluation of 4-Aryl- N-benzylpyrrolidine-3-carboxamides. J Med Chem. 2019 Mar 22. |
| 3659 | Lee HM, et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMPactivity: relevance to cancer. Curr Med Chem. 2001 Feb;8(3):257-60. |
| 3660 | Liu Y, A chemically modified tetracycline (CMT-3) is a new antifungal agent. Antimicrob Agents Chemother. 2002 May;46(5):1447-54. |
| 3661 | Bildt MM, et al. CMT-3 inhibits orthodontic tooth displacement in the rat. Arch Oral Biol. 2007 Jun;52(6):571-8. |
| 3662 | Adams CM, et al. The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. J Med Chem. 2018 Feb 22;61(4):1622-1635. |
| 3663 | Böttcher J, et al. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3. Nat Chem Biol. 2019 Aug;15(8):822-829. |
| 3664 | Prog Brain Res 98:431 (1993); Br Med J 318:633 (1999) |
| 3665 | Saab BJ, et al. Short-term memory impairment after isoflurane in mice is prevented by the α5 γ-aminobutyric acid type A receptorinverse agonist L-655708. Anesthesiology. 2010 Nov;113(5):1061-1071. |
| 3666 | Rossi AB, et al. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol. 2006 Sep;118(3):749-755. |
| 3667 | Meltzer EO, et al. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol. 2005 Apr;115(4):791-796. |
| 3668 | Huang SM, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009 Oct 1;461(7264):614-620. |
| 3669 | Dregalla RC, et al. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging (Albany NY). 2010 Oct;2(10):691-708. |
| 3670 | Ao A, et al. DMH1, a Novel BMP Small Molecule Inhibitor, Increases Cardiomyocyte Progenitors and Promotes Cardiac Differentiation in Mouse Embryonic Stem Cells.,PLoS One. 2012;7(7):e41627. |
| 3671 | Zeng L, et al. Chondroprotective effects and multi-target mechanisms of Icariin in IL-1 beta-induced human SW 1353 chondrosarcoma cells and a rat osteoarthritis model. Int Immunopharmacol. 2014 Jan;18(1):175-81. |
| 3672 | Bai J, et al. Epigenetic downregulation of SFRP4 contributes to epidermal hyperplasia in psoriasis. J Immunol. 2015 May 1;194(9):4185-98. doi: 10.4049/jimmunol.1403196. Epub 2015 Mar 30. |
| 3673 | Narwal M, et al. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity. J Med Chem. 2013 Oct 24;56(20):7880-9. |
| 3674 | Liu D, et al. Wnt/β-catenin signaling participates in the regulation of lipogenesis in the liver of juvenile turbot (Scophthalmus maximus L.). Comp Biochem Physiol B Biochem Mol Biol. 2016 Jan;191:155-62. |
| 3675 | Chem Pharm Bull 40:3113 (1992) |
| 3676 | Aliment Pharmacol Ther 14:1567 (2000); Ann Rheum Dis 64: 89 (2005) |
| 3677 | Terao J, e al. Protection by quercetin and quercetin 3-O-beta-D-glucuronide of peroxynitrite-induced antioxidant consumption in human plasma low-density lipoprotein. Free Radic Res. 2001 Dec;35(6):925-31. |
| 3678 | Juergenliemk G, et al. In vitro studies indicate that miquelianin (quercetin 3-O-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. Planta Med. 2003 Nov;69(11):1013-7. |
| 3679 | Butterweck V, et al. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med. 2000 Feb;66(1):3-6. |
| 3680 | Yamazaki S, et al. Quercetin-3-O-glucuronide inhibits noradrenaline-promoted invasion of MDA-MB-231 human breast cancer cells by blocking β-adrenergic signaling. Arch Biochem Biophys. 2014 Sep 1;557:18-27. |
| 3681 | Ho L, et al. Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease. FASEB J. 2013 Feb;27(2):769-81. |
| 3682 | Choi YR, et al. Genistin: A Novel Potent Anti-Adipogenic and Anti-Lipogenic Agent. Molecules. 2020;25(9):2042. Published 2020 Apr 27. |
| 3683 | Liang Y, et al. A Comprehensive Screening and Identification of Genistin Metabolites in Rats Based on Multiple Metabolite Templates Combined with UHPLC-HRMS Analysis. Molecules. 2018;23(8):1862. Published 2018 Jul 26. |
| 3684 | Hwang ST, et al. Genistin attenuates cellular growth and promotes apoptotic cell death breast cancer cells through modulation of ERalpha signaling pathway [published online ahead of print, 2020 Oct 16]. Life Sci. 2020;263:118594. |
| 3685 | https://clinicaltrials.gov/ct2/show/NCT04909905?term=GLUTAMINE+%28D%29&cond=covid&draw=2&rank=1 |
| 3686 | Xiang Z, et al. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742. |
| 3687 | Morishita T, et al. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with BMS-354825. Oncotarget. 2016 Aug 2. |
| 3688 | Pan W, et al. Verteporfin can Reverse the NSC 125973 Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression. Cell Physiol Biochem. 2016;39(2):481-90. |
| 3689 | Donohue E, et al. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model.J Cancer. 2013 Aug 28;4(7):585-96. |
| 3690 | Smee DF, et al. Activities of JNJ63623872 and GS 4071 against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016 Dec;136:45-50. |
| 3691 | Fu Y, et al. JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses. Antiviral Res. 2016 Sep;133:23-31. |
| 3692 | Boyd MJ, et al. Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. Bioorg Med Chem Lett. 2015 May 1;25(9):1990-4. |
| 3693 | Byrn RA, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. |
| 3694 | T R S Satheeshmanikandan, et al. Liquid Chromatography - Tandem Mass Spectrometry for the Simultaneous Quantitation of Glipizide, Cilostazol and Its Active Metabolite 3, 4-dehydro-cilostazol in Rat Plasma: Application for a Pharmacokinetic Study. Arzneimittelforschung. 2012 Sep;62(9):425-32. |
| 3695 | Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3022. |
| 3696 | Scholz A, et al. BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr DDT02-02. doi:10.1158/1538-7445.AM2015-DDT02-02 |
| 3697 | Tronel C, et al. The specific PKR inhibitor C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component. Neurochem Int. 2014 Jan;64:73-83. |
| 3698 | Ito S, et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis.Eur J Pharmacol. 2004 Feb 23;486(3):325-33. |
| 3699 | Shaikh S, et al. The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content.Toxicol In Vitro. 2018 Apr;48:121-127. |
| 3700 | Kondratskyi A1, et al.Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death.Cell Death Dis. 2014 Apr 24;5:e1193. |
| 3701 | Barrett SD, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4. |
| 3702 | Henderson YC, et al. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1968-76. |
| 3703 | Judith S. Sebolt-Leopold, et al. The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential |
| 3704 | molecules 5:945 (2000), Vet Ther 3:453 (2002) |
| 3705 | J Antibiot 44:357 (1991); Res Vet Sci 75:217 (2003)| |
| 3706 | Davey RB, Pound JM, Klavons JA, Lohmeyer KH, Freeman JM, Olafson PU.
 Analysis of doramectin in the serum of repeatedly treated pastured cattle used to predict the probability of cattle fever ticks (Acari: Ixodidae) feeding to repletion.
 Exp Appl Acarol. 2012 Apr;56(4):365-74. doi: 10.1007/s10493-012-9525-1. |
| 3707 | Wang XJ, Zhang J, Wang JD, Huang SX, Chen YH, Liu CX, Xiang WS.
 Four new doramectin congeners with acaricidal and insecticidal activity from Streptomyces avermitilis NEAU1069.
 Chem Biodivers. 2011 Nov;8(11):2117-25. doi: 10.1002/cbdv.201000295. |
| 3708 | Gordana Panic, et al. Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015 Jul 31;9(7):e0003962. |
| 3709 | J. Hosp. Infect. (1998), 38(4), 283-95; Am. J. Infect. Control (1988), 16(4), 173-7; Infect. Control (1986), 7(5), 268-72 |
| 3710 | Jacques Yves Gauthier, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. |
| 3711 | Leung P, et al. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone. 2011 Oct;49(4):623-635. |
| 3712 | Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging. 2012;7:235-47. |
| 3713 | Yi C, et al. Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats. Sci Rep. 2017 Mar 17;7:44682. |
| 3714 | Mitchell SC et al. Asparagusic acid. Phytochemistry. 2014 Jan;97:5-10. |
| 3715 | Takasugi, Mitsuo, et al. Identification of asparagusic acid as a nematicide occurring naturally in the roots of asparagus. Chemistry Letters (1975), (1), 43-4. |
| 3716 | Yoshio Kitahara, et al. Asparagusic acid, a new plant growth inhibitor in etiolated young asparagus shoots. Plant and Cell Physiology (1972), 13(5), 923-25. |
| 3717 | J. Kay Noel, et al. Abstract C244: Development of the BET bromodomain inhibitor OTX015. Mol Cancer Ther November 2013 12; C244. |
| 3718 | Marie-Magdelaine Coudé, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 2015 Jul 10; 6(19): 17698–17712. |
| 3719 | Lu P, et al. The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. Sci Rep. 2016 Apr 12;6:24100 |
| 3720 | Vázquez R, et al. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with RAD001. Oncotarget. 2017 Jan 31;8(5):7598-7613. |
| 3721 | Jeong SK, et al. Sphingosine kinase 1 activation enhances epidermal innate immunity through sphingosine-1-phosphate stimulation of cathelicidin production. J Dermatol Sci. 2015 Sep;79(3):229-34. |
| 3722 | Xu T, et al. Oxysophocarpine induces anti-nociception and increases the expression of GABAAα1 receptors in mice.Mol Med Rep. 2013 Jun;7(6):1819-25. |
| 3723 | Liu, R., Peng, J., Wang, H., et al. Oxysophocarpine retards the growth and metastasis of oral squamous cell carcinoma by targeting the Nrf2/HO-1 axis. Cell Physiol. Biochem. 49(5), 1717-1733 (2018). |
| 3724 | Hua Lv, et al. Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J. 2013 Jan;15(1):250-7. |
| 3725 | Xiaoping Zhang, et al. Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models. Mol Cancer Ther. 2014 May;13(5):1105-16. |
| 3726 | S K A Divakar, et al. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia. 2016 Jan;30(1):86-93. |
| 3727 | Pharmacol Res Commun 16:875 (1984); Anal Profiles Drug Subs Excip 24:1 (1996) |
| 3728 | Bradford STJ, et al. High-throughput screens for agonists of bone morphogenetic protein (BMP) signaling identify potent benzoxazole compounds.J Biol Chem. 2019 Mar 1;294(9):3125-3136. |
| 3729 | J Chem Soc 1963: 3777 |
| 3730 | Zhou W, et al. Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer's Disease Models. ACS Chem Neurosci. 2016 Nov 16;7(11):1499-1507. |
| 3731 | Mihalak KB, et al. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9. |
| 3732 | Bagdas D, et al. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.Neuropharmacology. 2018 Aug;138:72-79. |
| 3733 | Elkins JM, et al. Comprehensive characterization of the Published Kinase Inhibitor Set. Nat Biotechnol. 2016 Jan;34(1):95-103. |
| 3734 | Demont EH, et al. 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. (2014) ACS Med Chem Lett. 5(11):1190-1195. |
| 3735 | Proc Chem Soc 1960:176; 1969:177 ; Nat Chem Biol 5:236 (2009) |
| 3736 | Manzaneque JM, et al. An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. |
| 3737 | Khalifa AE, et al. Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. Hum Exp Toxicol. 2004 Aug;23(9):439-45. |
| 3738 | Biochem J 102:313, 325 (1966); 128: 11P (1972); Nature 1966: 212, 1364; Phytochemistry 39:1383 (1995); J Nat Prod 46:174 (1983); J Org Chem 54:3390 (1989) |
| 3739 | Am J Vet Res 38:809 (1977); J Parasitol 66:929 (1980) |
| 3740 | M E Olson, et al. Amdinocillin Treatment of Catheter-Associated Bacteriuria in Rabbits. J Infect Dis. 1989 Jun;159(6):1065-72. |
| 3741 | Liu N, et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Org Biomol Chem. 2015 May 14;13(18):5147-57. |
| 3742 | Somana Siva Prasad, et al. A QUALITY BY DESIGN APPROACH FOR DEVELOPMENT OF SIMPLE AND ROBUST REVERSED PHASE STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF IBRUTINIB AND ITS IMPURITIES. |
| 3743 | Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. |
| 3744 | ilbert J, et al. (Z)-2-(3,4-Dichlorophenyl)-3-(1H-Pyrrol-2-yl)Acrylonitrile Exhibits Selective Antitumor Activity in Breast Cancer Cell Lines via the Aryl Hydrocarbon Receptor Pathway. Mol Pharmacol. 2018 Feb;93(2):168-177. |
| 3745 | Baker JR, et al. Dichlorophenylacrylonitriles as AhR Ligands That Display Selective Breast Cancer Cytotoxicity in vitro. ChemMedChem. 2018 Jul 18;13(14):1447-1458. |
| 3746 | Mark Tarleton, et al. Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound. Medicinal Chemistry Communication. January 20112. (1):31-37. |
| 3747 | Towatari T, et al. Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. FEBS Lett. 1991 Mar 25;280(2):311-5. |
| 3748 | Montaser M, et al. CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells. Biol Chem. 2002 Jul-Aug;383(7-8):1305-8. |
| 3749 | Yamashima T, et al. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis'. Eur J Neurosci. 1998 May;10(5):1723-33. |
| 3750 | Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15. |
| 3751 | Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5. |
| 3752 | Uchida A, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997 May;272(5 Pt 1):G1249-57. |
| 3753 | Liu M, et al. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011 Dec;11(12):2150-8. |
| 3754 | Toxicol Appl Pharmacol 20:89 (1971); J Hosp Infect 38:283 (1998) |
| 3755 | Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63. |
| 3756 | http://en.wikipedia.org/wiki/Lubiprostone |
| 3757 | Oner Z1, et al. The protective and therapeutic effects of linalool against doxorubicin-induced cardiotoxicity in Wistar albino rats. Hum Exp Toxicol. 2019 Apr 12:960327119842634. |
| 3758 | Jun HJ, et al. Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110. |
| 3759 | Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results. |
| 3760 | Hiroshi Tanaka, et al. Abstract 4179: Potent and selective TRK inhibitor CH7057288. AACR Annual Meeting 2017; April 1-5, 2017. |
| 3761 | O'Reilly T, et al. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes,Limitations, and Further Proposals. Transl Oncol. 2010 Apr;3(2):65-79. |
| 3762 | Lane HA, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res, 2009, 15(5), 1612-1622. |
| 3763 | Zhu Y, et al. Antitumor effect of the mTOR inhibitor Everolimus on human breast cancer stem cells in vitro and in vivo. Tumour Biol. 2012 Oct;33(5):1349-62. |
| 3764 | Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2018 Jan;109(1):103-111. |
| 3765 | Hu CM, et al. Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism. Oncogene. 2015 Mar 5;34(10):1220-30. |
| 3766 | J Agric Food Chem 19:200 (1971); Residue Rev 10:97 (1965) |
| 3767 | Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108(8):1657-1666. |
| 3768 | De Maeyer L, et al. The multiple target use of spirodiclofen (Envidor 240 SC) in IPM pomefruit in Belgium. Commun Agric Appl Biol Sci. 2009;74(1):225-232. |
| 3769 | Saad MA, et al. Potential effects of yohimbine and sildenafil on erectile dysfunction in rats. |
| 3770 | Docherty JR. Yohimbine antagonises α1A- and α1D-adrenoceptor mediated components in addition to the α2A-adrenoceptor component to pressor responses in the pithed rat. Eur J Pharmacol. 2012 Mar 15;679(1-3):90-4. |
| 3771 | Lahiri P, et al. Platelet responsiveness to yohimbine hydrochloride and MRS2179 in the context of the interaction between collagen and epinephrine in acute coronary syndrome. Blood Cells Mol Dis. 2009 Jul-Aug;43(1):105-10. |
| 3772 | https://clinicaltrials.gov/ct2/show/NCT04606069?term=Regadenoson&cond=covid&draw=2&rank=1 |
| 3773 | Henderson NC, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24. |
| 3774 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=TIMOLOL+&cntry=&state=&city=&dist=&Search=Search |
| 3775 | Sanger, G.J., et al., GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil, 2009. 21(6): p. 657-64, e30-1. |
| 3776 | Leming, S., et al., GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil, 2011. 23(10): p. 958-e410. |
| 3777 | Westaway, S.M., et al., Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-pi peridinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate. J Med Chem, 2009. 52(4): p. 1180-9. |
| 3778 | Broad, J., et al., Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol, 2012. 167(4): p. 763-74. |
| 3779 | Tang B, et al. Asiaticoside suppresses collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. h Dermatol Res. 2011 Oct;303(8):563-72. |
| 3780 | Wang X, et al. Effect of asiaticoside on endothelial cells in hypoxia‑induced pulmonary hypertension. Mol Med Rep. 2018 Feb;17(2):2893-2900. |
| 3781 | Zhang Z, et al. Asiaticoside ameliorates β-amyloid-induced learning and memory deficits in rats by inhibiting mitochondrial apoptosis and reducing inflammatory factors. Exp Ther Med. 2017 Feb;13(2):413-420. |Phytomedecine 13:668 (2006) |
| 3782 | JACS 99: 3864 (1977); J Chem Soc 1980: 311 |
| 3783 | Zoltán SZLÁVIK, et al. New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. WO2016207225A1. |
| 3784 | Weinstock J, et al. Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. ACS Med Chem Lett. 2012 Sep 11;3(10):789-92. |
| 3785 | Müller S, et al. Donated chemical probes for open science. Elife. 2018 Apr 20;7. pii: e34311. |
| 3786 | Chen S, et al. Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening. J Med Chem. 2014 Nov 13;57(21):9028-9041. |
| 3787 | JACS 49:1028 (1927) |
| 3788 | Nam MO, et al. Effects of a small molecule R-spondin-1 substitute RS-246204 on a mouse intestinal organoid culture. Oncotarget. 2017 Dec 26;9(5):6356-6368. |
| 3789 | J Acq Immune Defic Syndr Hum Retrovir 11:137 (1996); Biol Pharm Bull 30:2105 (2007) |
| 3790 | J Chem Educ 36:60 (1959); J Gen Microbiol 132: 973, 2761 (1986); Appl Microbiol Biotechnol 24:449 (1986); Chem Biochem Eng Q 15:127 (2001) |
| 3791 | Pachl F, et al. Characterization of a chemical affinity probe targeting Akt kinases. J Proteome Res. 2013 Aug 2;12(8):3792-800. |
| 3792 | Jacobsen K, et al. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017 Sep 4;8(1):410. |
| 3793 | Chemotherapy 14:195 (1969); Anal Profiles Drug Subs 11:523 (1982) |
| 3794 | Turcotte, S. et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer cell 14, 90-102, doi:10.1016/j.ccr.2008.06.004 (2008) |
| 3795 | Huard K, et al. Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK). J Med Chem. 2017 Sep 28;60(18):7835-7849. |
| 3796 | Friedel HA, et al. Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1989 Apr;37(4):491-522. |
| 3797 | Fells JI, et al. Identification of non-lipid LPA3 antagonists by virtual screening. Bioorg Med Chem. 2008 Jun 1;16(11):6207-17. |
| 3798 | Bonifácio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172(7):1739-52. |
| 3799 | Ferreira JJ, et al. Opicapone as an adjunct to L-DOPA in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-165. |
| 3800 | Lu SC, et al. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012 Oct;92(4):1515-42. |
| 3801 | SUBSTITUTED BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIBITORS. WO/2017/004519 A1 |
| 3802 | Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779. |
| 3803 | Vatolin S et al. Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma.
 Cancer Res. 2016 Jun 1;76(11):3340-50. |
| 3804 | Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005 Sep;11(9):936-43. |
| 3805 | Antibiot Chemother 2:234 (1952); 7:374 (1957) |
| 3806 | Guedes CES, et al. In vitro evaluation of the anti-leishmanial activity and toxicity of PK-11195. Mem Inst Oswaldo Cruz. 2018 Feb 5;113(4):e170345. |
| 3807 | Anal Profiles Drug Subs Excip 22:389 (1993) |
| 3808 | https://clinicaltrials.gov/ct2/show/NCT04446065?term=Epigallocatechin+Gallate&cond=covid-19&draw=2&rank=1 |
| 3809 | https://clinicaltrials.gov/ct2/show/NCT04727424?term=DOXAZOSIN&cond=COVID-19&draw=2&rank=1 |
| 3810 | Chao PK, et al. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, producespotent antinociceptive effects with safer properties than morphine. Neuropharmacology. 2019 Jul 3:107678. |
| 3811 | Stolk J,et al. Am J Respir Cell Mol Biol, 1994, 11(1), 95-102. |
| 3812 | Stefanska J, et al. Mediators Inflamm, 2008, 106507. |
| 3813 | Impellizzeri D et al. Effect of apocynin, a NADPH oxidase inhibitor, on acute lung inflammation. Biochem Pharmacol. 2011 Mar 1;81(5):636-48. |
| 3814 | Drugs (1981), 21(1), 1-22; Arzneim. Forsch. (1980), 30(4A), 695-702; J. Pharm. Sci. (1977), 66(4), 466-76 |
| 3815 | Jiang Y, et al. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. J Pharmacol Exp Ther. 2018 Feb;364(2):246-257. |
| 3816 | Hammers DW, et al. Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341. |
| 3817 | Donovan JM, et al. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 May;57(5):627-639. |
| 3818 | Anal Profiles Drug Subs 3:565 (1974) |
| 3819 | Antibiotics (1979), 5(1), 272-303; J. Bacteriol. (1947), 53, 205-11; J. Am. Chem. Soc. (1946), 68, 1390-1 |
| 3820 | Immunopharmacol. Immunotoxicol. (2009), 31(3), 339-351; Proc. R. Soc. Med. (1976), 69(Suppl. 2), 3-5; J. Med. (1980), 11(2-3), 107-16 |
| 3821 | Ciolino HP, et al. Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affectcytochrome P450 1A1 activity. Cancer Res. 1998 Jul 1;58(13):2754-60. |
| 3822 | Tong N, et al. Diosmin protects rat retina from ischemia/reperfusion injury. J Ocul Pharmacol Ther. 2012 Oct;28(5):459-66. |Arch Farmacol Toxicol 3:33 (1977); Arzneim Forsch 37:1149 (1987) |
| 3823 | Eye Ear Nose Throat Mon 50:101 (1971) |
| 3824 | Paolino M, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12. |
| 3825 | Kim HL, et al. Platycodin D, a novel activator of AMP-activated protein kinase, attenuates obesity in db/db mice via regulation of adipogenesis and thermogenesis. Phytomedicine. 2019 Jan;52:254-263. |
| 3826 | Santhosh KT, et al. Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes. Br J Pharmacol. 2011 Jul;163(6):1223-36. |
| 3827 | Hentschel T, et al. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology. 2007 Jan;106(1):124-31. |
| 3828 | Kishi T, et al. Effects of milrinone on left ventricular end-systolic pressure-volume relationship of rat hearts in situ. Clin Exp Pharmacol Physiol. 2001 Sep;28(9):737-42. |
| 3829 | Taylor MS, et al. Effect of milrinone on small mesenteric artery vasoconstriction: role of K(+) channels. Am J Physiol. 1999 Jul;277(1 Pt 1):G69-78. |Drugs (1988), 36(2), 158-92; Basic Res. Cardiol. (1989), 84 Suppl 185-103; Clin. Pharm. (1986), 5(3), 201-5 |
| 3830 | WO 2014145909 A2. |
| 3831 | Radiology 78:73 (1991); Acta Radiol 38:626 (1997) |
| 3832 | Khim.-Farm. Zh. (1989), 23(11), 1304-9; Methods Find. Exp. Clin. Pharmacol. (1988), 10(10), 629-33; Bull. Exp. Biol. Med. (1991), 111(3), 279-80, |
| 3833 | Free Rad Biomed 28:944 (2000) |
| 3834 | Peters DH, et al. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993 May;45(5):760-87. |
| 3835 | Giuseppina De Simone, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. |
| 3836 | 4'-O-Methylbavachalcone, et al. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J Enzyme Inhib Med Chem. 2014 Feb;29(1):59-63. |
| 3837 | Cool B, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab, 2006, 3(6), 403-416. |
| 3838 | Sanders MJ, et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem, 2007, 282(45), 32539-32548. |
| 3839 | Moreno D, et al, A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett, 2008, 583(17), 2650-2654. |
| 3840 | Yerra VG, et al. Adenosine Monophosphate-Activated Protein Kinase Abates Hyperglycaemia-Induced Neuronal Injury in Experimental Models of Diabetic Neuropathy: Effects on Mitochondrial Biogenesis, Autophagy and Neuroinflammation. Mol Neurobiol. 2017 Apr;54(3):2301-2312. |
| 3841 | J Pharmacol Exp Ther 42:1 (1931); Adv Cancer Res 11:1 (1968) |
| 3842 | Schwab M, et, al. Effects of betamethasone administration to the fetal sheep in late gestation on fetal cerebral blood flow. J Physiol. 2000 Nov 1;528(Pt 3):619-32. |
| 3843 | Xie W, et, al. Betamethasone affects cerebral expressions of NF-kappaB and cytokines that correlate with pain behavior in a rat model of neuropathy. Ann Clin Lab Sci. Winter 2006;36(1):39-46. |
| 3844 | Kubin ME, et, al. Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis. Acta Derm Venereol. 2017 Apr 6;97(4):449-455. |
| 3845 | Hofmann TH, et, al. Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. |Gut 3:312 (1962); J Endocrinol 165:79 (2000); Reprod Sci 17:186 (2010) |
| 3846 | Gao J, et al. Trilobatin Protects Against Oxidative Injury in Neuronal PC12 Cells Through Regulating Mitochondrial ROS Homeostasis Mediated by AMPK/Nrf2/Sirt3 Signaling Pathway. Front Mol Neurosci. 2018 Jul 30;11:267. |
| 3847 | Yin S, et al. Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope. FEBS Lett. 2018 Jul;592(13):2361-2377. |
| 3848 | Gees M, et al. Identification and Characterization of Novel CFTR Potentiators. Front Pharmacol. 2018 Oct 26;9:1221. |
| 3849 | Jang JC, et al. Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis. J Microbiol. 2017 Apr 20. |
| 3850 | Pang Y, et al. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob Agents Chemother. 2017 Apr 24;61(5). |
| 3851 | Chahine EB, et al. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014 Jan;48(1):107-15. |
| 3852 | Sarathy JP, et al. TBAJ-876 displays Bedaquiline-like mycobactericidal potency without retaining the parental drug's uncoupler activity. Antimicrob Agents Chemother. 2019 Nov 11. |
| 3853 | Baragaña B, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015 Jun 18;522(7556):315-20. |
| 3854 | Chen J, et al. Inhibition of cancer stem cell like cells by a synthetic retinoid. Nat Commun. 2018 Apr 11;9(1):1406. |
| 3855 | Cancer Metastasis Rev 6:615 (1987); Endocrin J 42:505 (1995) |
| 3856 | Li Y, et al. Mechanism of hepatic targeting via oral administration of DSPE-PEG-Cholic acid-modified nanoliposomes. Int J Nanomedicine. 2017 Feb 28;12:1673-1684. |
| 3857 | Pan X, et al. Cholic acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice. Drug Metab Dispos. 2017 Apr;45(4):346-352. |Biochem J 85: 236 (1962) |
| 3858 | Meier T, et al. Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Mol Cancer Ther. 2011 Nov;10(11):2168-78. |
| 3859 | Sanvitale CE, et al. A new class of small molecule inhibitor of BMP signaling. PLoS One. 2013 Apr 30;8(4):e62721. |
| 3860 | Kerr G, et al. A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis. 2015 Apr;18(2):209-17. |
| 3861 | Lung Biol. Health Dis. (2010), 237, 113-143; Pharmacotherapy (2009), 29(12), 1468-1481; Am. Rev. Respir. Dis. (1969), 99(5), 729-49 |
| 3862 | Hayashi K, et al. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. Biol Pharm Bull. 2010;33(7):1199-205. |
| 3863 | Yang S, et al. Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis. Anat Rec (Hoboken). 2012 Aug;295(8):1260-6. |
| 3864 | Swarup V, et al. Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J Antimicrob Chemother. 2008 Mar;61(3):679-88. |
| 3865 | Boeckler FM, et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5. |
| 3866 | Rauf SM, et al. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach. Protein J. 2013 Jan;32(1):68-74. |
| 3867 | Paulmurugan R, et al. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells. Oncotarget. 2018 Apr 20;9(30):21495-21511. |
| 3868 | Atractylenolide I, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I. Exp Dermatol. 2018 Feb;27(2):201-204. |
| 3869 | Gao H, et al. Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress. Exp Ther Med. 2018 Feb;15(2):1574-1579. |
| 3870 | Li W, et al. Atractylenolide I restores HO-1 expression and inhibits Ox-LDL-induced VSMCs proliferation, migration and inflammatory responses in vitro. Exp Cell Res. 2017 Apr 1;353(1):26-34. |
| 3871 | Huang JM, et al. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep. 2014 Jan 23;4:3840. |
| 3872 | Int Rec Med 164:18 (1951); Chim Ther 7:103 (1972); Indian Drugs 20:185 (1983) |
| 3873 | J Chem Soc 1938:1320; Biochem J 59:58 (1955) |
| 3874 | Pharmacol Res 38:65 (1998) |
| 3875 | Vu B, et al. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. ACS Med Chem Lett. 2013 Apr 2;4(5):466-9. |
| 3876 | Tovar C, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 2013 Apr 15;73(8):2587-97. |
| 3877 | Verreault M, et al. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2016 Mar 1;22(5):1185-96. |
| 3878 | Shripad V. Bhagwat, et al. Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations. Cancer Research. July 2017. |
| 3879 | Noble S, Goa KL. Loteprednol etabonate: clinical potential in the management of ocular inflammation. BioDrugs. 1998 Oct;10(4):329-39. |
| 3880 | Szelenyi I, Hochhaus G, Heer S et al. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20. |
| 3881 | Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie. 2000 Mar;55(3):178-83. |
| 3882 | Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008 Apr;92(4):455-9. |
| 3883 | Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623. |
| 3884 | Yuan T, et al. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism. Int J Clin Exp Pathol. 2015 May 1;8(5):5044-52. |
| 3885 | Jay Whelan. Linoleic Acid. Adv Nutr. 2013 May; 4(3): 311–312. |
| 3886 | Won JH, et al. Anti-inflammatory effects of madecassic acid via the suppression of NF-kappaBpathway in LPS-induced RAW 264.7 macrophage cells. Planta Med. 2010 Feb;76(3):251-7. |Bull Soc Chim Fr 1967: 1890; Phytochemistry 7: 1385 (1968); 28: 2852 (1989) |
| 3887 | https://clinicaltrials.gov/ct2/show/NCT05007522?term=Ketotifen&cond=Covid19&draw=2&rank=1 |
| 3888 | Dong-Jun Fu, et al. Discovery of Novel Tertiary Amide Derivatives as NEDDylation Pathway Activators to Inhibit the Tumor Progression in Vitro and in Vivo. Eur J Med Chem. 2020 Apr 15;192:112153. |
| 3889 | Munier-Lehmann H, et al. Original 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH). J Med Chem. 2015 Jan 22;58(2):860-77. |
| 3890 | Nimanthi Jayathilaka, et al. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul; 40(12): 5378–5388. |
| 3891 | Veronika V. Borutinskaite, et al. Histone deacetylase inhibitor BML-210 induces growth inhibition
 and apoptosis and regulates HDAC and DAPC complex
 expression levels in cervical cancer cells. Mol Biol Rep (2012) 39:10179–10186 |
| 3892 | Veronika Borutinskaite, et al. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug; 16(8): 18252–18269. |
| 3893 | Ind Eng Chem 35:321 (1943) |
| 3894 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=AMILORIDE&cond=COVID-19&draw=2&rank=1 |
| 3895 | J Indian Chem Soc 26:130 (1949) |
| 3896 | Doyle K, et al. Inhibitors Of The CFTR Chloride Ion Channel As Potential Treatment For 
 Acute Secretory Diarrhea: Development Of 5-membered Heterocycles Suitable For Pre-clinical Evaluation |
| 3897 | de Hostos EL, et al. Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25. |
| 3898 | Bae AS, et al. Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.
 J Clin Microbiol. 2011 Sep;49(9):3168-74. |
| 3899 | Hebner CM, et al. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.
 PLoS One. 2012;7(6):e39163. |
| 3900 | Wong KA, et al. Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a.
 Virology. 2012 Jul 20;429(1):57-62. |
| 3901 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=CHLORTHALIDONE&cond=covid&draw=2&rank=2 |
| 3902 | Pharmacol Toxicol 26:177 (1968); 27:295 (1969); Toxicol Appl Pharmacol 30:452 (1974) |
| 3903 | Ulven T, et al. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem. 2005 Feb 24;48(4):897-900. |
| 3904 | Hu WH, et, al. Synergy of Ginkgetin and Resveratrol in Suppressing VEGF-Induced Angiogenesis: A Therapy in Treating Colorectal Cancer. Cancers (Basel). 2019 Nov 20;11(12):1828. |
| 3905 | Ye ZN, et, al. Biflavone Ginkgetin, a Novel Wnt Inhibitor, Suppresses the Growth of Medulloblastoma. Nat Prod Bioprospect. 2015 Mar 29;5(2):91-97. |
| 3906 | Xiong M, et, al. Ginkgetin exerts growth inhibitory and apoptotic effects on osteosarcoma cells through inhibition of STAT3 and activation of caspase-3/9. Oncol Rep. 2016 Feb;35(2):1034-40. |
| 3907 | Li Q, et, al. Ginkgetin exerts anti-inflammatory effects on cerebral ischemia/reperfusion-induced injury in a rat model via the TLR4/NF-κB signaling pathway. Biosci Biotechnol Biochem. 2019 Apr;83(4):675-683. |
| 3908 | Lou J, et, al. Ginkgetin induces autophagic cell death through p62/SQSTM1-mediated autolysosome formation and redox setting in non-small cell lung cancer. Oncotarget. 2017 Oct 16;8(54):93131-93148. |
| 3909 | Wang J, et al. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res. 2012 Mar 15;18(6):1684-95. |
| 3910 | Evans SM, et al. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer. 1995 Oct;72(4):875-82. |
| 3911 | Dubey P et al. Comparative analyses of genotoxicity, oxidative stress and antioxidative defence system under exposure of methyl parathion and hexaconazole in barley (Hordeum vulgare L.) Environ Sci Pollut Res Int. 2015 Dec;22(24):19848-59. |
| 3912 | Wang Y et al. Monitoring tryptophan metabolism after exposure to hexaconazole and the enantioselective metabolism ofhexaconazole in rat hepatocytes in vitro.
 J Hazard Mater. 2015 Sep 15;295:9-16. |
| 3913 | Karlowsky JA, et al. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother. 2009 Aug;53(8):3544-8. |
| 3914 | Narasimha Rao K, et al. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei-Crystal structure, mode of action, and biological activity. Protein Sci. 2015 May;24(5):832-40. |
| 3915 | Yao J, et al. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). J Biol Chem. 2013 Dec 20;288(51):36261-71. |
| 3916 | Parsons JB, et al. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob Agents Chemother. 2013 May;57(5):2182-90. |
| 3917 | Pestic. Sci. (1979), 10(6), 473-7; Agric. Biol. Chem. (1972), 36(5), 817-23; Pestic. Sci. (1971), 2(4), 160-4 |
| 3918 | Politz O, et al. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. Int J Cancer. 2017 Jan 15;140(2):449-459. |
| 3919 | Ross, S.A., and ElSohly, M.A. The volatile oil composition of fresh and air-dried buds of Cannabis sativa. J. Nat. Prod. 59(1), 49-51 (1996). |
| 3920 | Gan D, et al. β-elemene enhances cisplatin-induced apoptosis in bladder cancer cells through the ROS-AMPK signaling pathway.Oncol Lett. 2020 Jan;19(1):291-300. |
| 3921 | Checker R, et al. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-κB. Free Radic Biol Med. 2012 Oct 1;53(7):1421-30. |
| 3922 | Lam PY, et al. Schisandrin B as a hormetic agent for preventing age-related neurodegenerative diseases. Oxid Med Cell Longev. 2012;2012:250825. |
| 3923 | Zeng KW, et al. Schisandrin B exerts anti-neuroinflammatory activity by inhibiting the Toll-like receptor 4-dependent MyD88/IKK/NF-κB signaling pathway in lipopolysaccharide-induced microglia. Eur J Pharmacol. 2012 Oct 5;692(1-3):29-37. |
| 3924 | Liu Z, et al. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition. PLoS One. 2012;7(7):e40480. |
| 3925 | Zhu S, et al. Protective effect of schisandrin B against cyclosporine A-induced nephrotoxicity in vitro and in vivo. Am J Chin Med. 2012;40(3):551-66. |
| 3926 | https://clinicaltrials.gov/ct2/show/NCT04570254?term=SULFANILAMIDE&cond=Covid19&draw=2&rank=1 |
| 3927 | Catz P, et al. Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography-tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 27;829(1-2):123-35. |
| 3928 | Jacobson MK, et al. Effect of myristyl nicotinate on retinoic acid therapy for facial photodamage. Exp Dermatol. 2007 Nov;16(11):927-35. |
| 3929 | Arch Pharmazie 295:383 (1962); Lancet 1:405 (1975); Veterinarana-Sbirka 80:6 (1982) |
| 3930 | Svobodova M, et al. Oleuropein as an inhibitor of peroxisome proliferator-activated receptor gamma. Genes Nutr. 2014 Jan;9(1):376. |
| 3931 | Gorzynik-Debicka M, et al. Potential Health Benefits of Olive Oil and Plant Polyphenols. Int J Mol Sci. 2018 Feb 28;19(3). pii: E686. |
| 3932 | Drugs (2003), 63(6), 597-623; Angew. Chem. (Int. Ed. Engl.) (2003), 42(43), 5274-93; Nature (1947), 160(4066), 463 |
| 3933 | Br J Pharmacol 37:140 (1969); Toxicol Appl Pharmacol 18:185 (1971); Drugs 33:31 (1987) |
| 3934 | Li X, et al. Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem. 2017 Oct 12;60(19):8011-8026. |
| 3935 | https://clinicaltrials.gov/ct2/show/NCT04928495?term=Acetylcysteine&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04374461?term=Acetylcysteine&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04900129?term=Acetylcysteine&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04545008?term=Acetylcysteine&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04419025?term=Acetylcysteine&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04703036?term=Acetylcysteine&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04792021?term=Acetylcysteine&cond=COVID-19&draw=2&rank=7 https://clinicaltrials.gov/ct2/show/NCT04455243?term=Acetylcysteine&cond=COVID-19&draw=2&rank=9 https://clinicaltrials.gov/ct2/show/NCT04370288?term=Acetylcysteine&cond=COVID-19&draw=2&rank=10 https://clinicaltrials.gov/ct2/show/NCT04755972?term=Acetylcysteine&cond=COVID-19&draw=2&rank=13 |
| 3936 | J Org Chem 25:1595 (1960) |
| 3937 | Oral Surg., Oral Med., Oral Pathol. (1968), 26(6), 848-55; Ann. Otol., Rhinol., Laryngol. (1955), 64, 1009-18. ; J. Pharmacol. (1911), 2, 513-30. |
| 3938 | Nakaya Y, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011 Jul;1(7):e29. |
| 3939 | Kuroda J, et al. NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. Leuk Res. 2014 May;38(5):619-24. |
| 3940 | Stalnecker CA, et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):394-9. |
| 3941 | J. Bacteriol. (1970), 103(3), 778-88; Biochem. Biophys. Res. Comm. (1962), 8377-82; CNS Drug Rev. (1995), 1(1), 74-90 |
| 3942 | Miscioscia E, et al. Measurement of 3-acetyl-11-keto-beta-boswellic acid and 11-keto-beta-boswellic acid in <i>Boswellia serrata</i> Supplements Administered to Dogs. BMC Vet Res. 2019 Aug 1;15(1):270. |
| 3943 | Parsons WH, et al. Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-3874. |
| 3944 | Chemotherapy (1973), 19(2), 109-14; J. Am. Chem. Soc. (1963), 85(24), 3943-53; J. Am. Chem. Soc. (1961), 83, 2773-5 |
| 3945 | J Chem Soc 1928:1022; Phytochemistry 22:2061 (1983); Prog Chem Org Nat Prod 43:1 (1983) |
| 3946 | Quan Wang J, et al. Discovery of new chromen-4-one derivatives as telomerase inhibitors through regulating expression of dyskerin. J Enzyme Inhib Med Chem. 2018 Dec;33(1):1199-1211. |
| 3947 | Itkin M, et al. The biosynthetic pathway of the nonsugar, high-intensity sweetener mogroside V from <i>Siraitia grosvenorii</i>.Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7619-E7628. |
| 3948 | Mol Pharmacol 37:477 (1990); J Neural Transm 105:133 (1998) |
| 3949 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Zanubrutinib&cntry=&state=&city=&dist=&Search=Search |
| 3950 | Eisinger M, et al. A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011 Jul;63(1):23-32. |
| 3951 | Can J Res 5: 651 (1931); J Chem Soc 1935:11; Biochem J 109:87 (1968); Am J Pathol156:607 (2000) |
| 3952 | Ann. Pharm. Fr(1991), 49(3), 127-38; Therapie (1974), 29(3), 435-46; Arzneim. Forsch. (1972), 22(10), 1791-3 |
| 3953 | Toledo LI, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol. 2011 Jun;18(6):721-7. |
| 3954 | Teng PN, et al. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol Oncol. 2015 Mar;136(3):554-61. |
| 3955 | Tsuboi R, et al. Hyperkeratotic chronic tinea pedis treated with neticonazole cream. Neticonazole Study Group. Int J Dermatol. 1996 May;35(5):371-3. |
| 3956 | Datta A, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. |
| 3957 | Gu L, et al. The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer. Invest New Drugs. 2020 Apr;38(2):221-228. |
| 3958 | Jain J, et al. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. |
| 3959 | Markland W, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000 Apr;44(4):859-66. |
| 3960 | Decker CJ, et al. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. Drugs Exp Clin Res. 2001;27(3):89-95. |
| 3961 | J Pharmacol Exp Ther 282:410 (1997); Biochem Pharmacol 63:89 (2002) |
| 3962 | Jiang JK, et al. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3356-3362. |
| 3963 | Xu H, et al. Stereoselective analysis of hydroxybupropion and application to drug interaction studies. Chirality. 2007 Mar;19(3):163-70. |
| 3964 | Bondarev ML, et al. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol. 2003 Aug 1;474(1):85-93. |
| 3965 | Volkow ND, et al. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry. 2005 Mar 15;57(6):640-6. |
| 3966 | Helv Chim Acta 46:1480 (1963) |
| 3967 | J Clin Psychiatry 56:395 (1995); Expert Opin Pharmacother 4:533 (2003) |
| 3968 | Pelosi LA, et al. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor BMS-790052. 
 Antimicrob Agents Chemother. 2012 Jul 30. |
| 3969 | McPhee F, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
 Antimicrob Agents Chemother. 2012 Aug 6. |
| 3970 | McPhee F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
Antimicrob Agents Chemother. 2012 Jul;56(7):3670-81. |
| 3971 | Pasquinelli C, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.
 Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44. |
| 3972 | Ann 575:162 (1952) |
| 3973 | Lane ME, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001 Aug 15;61(16):6170-7. |
| 3974 | Yu B, et al. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol. 2002 Oct 1;64(7):1091-100. |
| 3975 | Gao N, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol. 2006 Aug;70(2):645-55. |
| 3976 | Biochem J 29:2256 (1935); JACS 67:36 (1945); Aust J Chem 16:246 (1963)| |
| 3977 | Slominski A, et al. Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett. 2002 Jan 30;511(1-3):102-6. |
| 3978 | Tse AN, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res, 2007, 13(2 Pt 1), 591-602. |
| 3979 | Dai Y, et al. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res, 2010, 16(2), 376-383. |
| 3980 | Somers K, et al. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene. 2019 Jan 22. |
| 3981 | Seiradake, et al. Antifungal activity and mechanism of action of a benzoxaborole, AN2718, which is in development for the treatment of tinea pedis. 48th Annual ICAAC/46th Annual IDSA (2008). |
| 3982 | Arzneim Forsch 22:1260, 1276 (1972) |
| 3983 | Bernard Barlaam, et al. Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies. Cancer Research. July 2018. 78(13): Supplement. |
| 3984 | https://clinicaltrials.gov/ct2/show/NCT04573153?term=CARNITINE&cond=covid-19&draw=2&rank=2 |
| 3985 | Yamamoto Y, et al. Continuous combined intake of polydextrose and lactitol stimulates cecal fermentation and salivary IgA secretion in rats. J Oral Sci. 2017;59(4):603-610. |
| 3986 | Differentiation 19:1 (1981); Cancer Res 42:3248 (1982) |
| 3987 | Okazaki M, et al. Effects of clinofibrate on plasma fibrinogen level in high fructose diet-induced hyperlipidemic rats. In Vivo. 1994 Nov-Dec;8(6):1057-61. |
| 3988 | Shirai K, et al. Effect of clinofibrate on lipid metabolism of aorta in atherosclerotic rats. Artery. 1983;12(3):145-55. |
| 3989 | Suzuki K, et al. Effects of S-8527 (1,1-bis4'-(1"-carboxy'1"-methylpropoxy)-phenyl)-cyclohexane), a new hypolipidemic compound, on triglyceride metablolism in rats. Biochem Pharmacol. 1975 Jun 15;24(11-12):1203-7. |
| 3990 | Suzuki K, et al. Hypolipidemic effect of a new aryloxy compound, S-8527, in experimental animals. Jpn J Pharmacol. 1974 Jun;24(3):407-14. |
| 3991 | Richard DJ, et al. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. Bioorg Med Chem. 2013 Nov 1;21(21):6642-9. |
| 3992 | http://www.google.com/patents/WO2013173506A2cl=en |
| 3993 | http://www.google.it/patents/WO2010149769A1cl=en |
| 3994 | http://www.google.com/patents/WO2010010190A1cl=en |
| 3995 | Toxicol Appl Pharm 164:273 (2000) |
| 3996 | https://clinicaltrials.gov/ct2/show/NCT04433988?term=PENTOXIFYLLINE&cond=Covid19&draw=2&rank=1 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20110425006280N11 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200721048159N3 |
| 3997 | JACS 52:2538 (1930); J Enzym Inhib Med Chem 24:804 (2009) |
| 3998 | Ward RA, et al. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem. 2015 Jun 11;58(11):4790-801. |
| 3999 | Kumar R, et al. Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2016 Jun 5;125:140-4. |
| 4000 | Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311. |
| 4001 | Bedalov A, et al. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15113-8. |
| 4002 | Breitenstein A, et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res. 2011 Feb 1;89(2):464-72. |
| 4003 | Ota H, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006 Jan 12;25(2):176-85. |
| 4004 | Hoeflich KP, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2012 Jan 1;72(1):210-9. |
| 4005 | Juran Kato-Stankiewicz,et al. Inhibitors of Ras/Raf-1 Interaction Identified by Two-Hybrid Screening Revert Ras-dependent Transformation Phenotypes in Human Cancer Cells. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14398-403. |
| 4006 | Matthew D. Shair. Osw-1 analogs and conjugates, and uses thereof. US 20140135279 A1. |
| 4007 | Campos N, et al. Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis. Retrovirology. 2015 Apr 9;12:30. |
| 4008 | Janssen PAJ, et, al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem. 2005 Mar 24;48(6):1901-9. |
| 4009 | Azijn H, et, al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. |
| 4010 | Novosibirisk Inst Org Chem:131 (1998); Nanoscale Res Lett 2:291 (2007); Basic Clin Pharmacol Toxicol 102(5):453-8 (2008), |
| 4011 | Zhang L, et al. Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. Chem Sci. 2017 Apr 1;8(4):2687-2701. |
| 4012 | Indian J Chem B 15: 583 (1977); Phytochemistry 19: 651 (1980); Chem Pharm Bull 32: 3267 (1984) |
| 4013 | Van der Plas SE, et al. Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent. J Med Chem. 2018 Feb 22;61(4):1425-1435. |
| 4014 | Yeh HI, et al. A common mechanism for CFTR potentiators. J Gen Physiol. 2017 Dec 4;149(12):1105-1118. |
| 4015 | Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790. |
| 4016 | Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. |
| 4017 | Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4). |
| 4018 | Yamada K et al. Small-molecule WNK inhibition regulates cardiovascular and renal function. Nat Chem Biol. 2016 Nov;12(11):896-898. |
| 4019 | Desjardins P, et al. Contribution of the WNK1 kinase to corneal wound healing using the tissue-engineered human cornea as an in vitro model. J Tissue Eng Regen Med. 2019 Sep;13(9):1595-1608. |
| 4020 | Schaps D, et al. Therapeutic use of amezinium methylsulfate--a new, long acting, sympathomimetic--in paraspinal conduction anesthesia. Anasth Intensivther Notfallmed. 1984 Oct;19(5):235-9. |
| 4021 | Anthony P. Ford, et al. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013; 7: 267. |
| 4022 | Ford AP, In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal. 2012 Feb;8(Suppl 1):3-26. |
| 4023 | Liu F, et al. Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chem Biol. 2016 Jun 17;11(6):1537-43. |
| 4024 | J. Appl. Cosmetol. (1985), 3(1), 1-11; Food Cosmet. Toxicol. (1976), 14, Suppl., 765; Food Chem. Toxicol. (2007), 45 Suppl 1, S393-6, |
| 4025 | Narwal M, et al. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity. J Med Chem. 2013 Oct 24;56(20):7880-9. |
| 4026 | Chem Commun 1967:379 |
| 4027 | Down K et al. Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
 J Med Chem. 2015 Sep 24;58(18):7381-99. |
| 4028 | Allen SL, et al. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin Investig Drugs. 2011 Jul;20(7):995-1003. |
| 4029 | Andersson BS, et al. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15;47(4):1040-4. |
| 4030 | Ajani JA, et al. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun;6(2):79-85. |
| 4031 | Eur Rev Med Pharmacol Sci 5:227 (1983); Internista 10:153 (2002); Can J Physiol Pharmacol 87:893 (2009); Ther Clin Risk Manag. 7:83 (2011) |
| 4032 | Scan J Clin Lab Invest14:605 (1962); Eur J Periatr 125:135 (1977); J Neurochem 65:96 (1995); Mol Pharmacol 50:1665 (1997) |
| 4033 | https://clinicaltrials.gov/ct2/show/NCT04811339?term=BISMUTH+SUBSALICYLATE&cond=COVID-19&draw=2&rank=1 |
| 4034 | Ramkumar K, et al. Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor. Nat Commun. 2016 Oct 5;7:13084. |
| 4035 | Munshi N, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010 Jun;9(6):1544-53. |
| 4036 | Bai YL, et al. Quantitative analysis of tivantinib in rat plasma using ultra performance liquid chromatography with tandem mass spectrometry. J Pharm Biomed Anal. 2016 Jul 15;126:98-102. |
| 4037 | Peng SB, et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry, 2005, 44(7), 2293-2304. |
| 4038 | Oka M, et al. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood, 2008, 111(9), 4571-4579. |
| 4039 | Naka K, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature, 2010, 463(7281), 676-680. |
| 4040 | Hu C, et al. Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction. Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jan;49(1):74-80. |
| 4041 | Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419. |
| 4042 | Bertuzzi A, et al. Sebacic acid binding to human plasma albumin. Biochem Pharmacol. 1993 Feb 9;45(3):697-702. |
| 4043 | J Med Chem 31:1278 (1988) |
| 4044 | Li P, et al. Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases. J Med Chem. 2016;59(3):1149-1164. |
| 4045 | Snyder GL, et al. Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Psychopharmacology (Berl). 2016;233(17):3113-3124. |
| 4046 | Masood A, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on BIBW 2992. Semin Oncol. 2019 Jun;46(3):271-283. |
| 4047 | Francois Gonzalvez, et al. Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models. April 16-20, 2016; New Orleans, LA. |
| 4048 | Reem Suleiman, et al. The Role Of Notch In Th17 Differentiation. University of Massachusetts Amherst. 9-2013. |
| 4049 | Schwarzer R, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J. 2014 Jun 13;4:e217. |
| 4050 | Tanaka N, et al. Mechanism of action of bicyclomycin. J Antibiot (Tokyo). 1976 Feb;29(2):155-68. |
| 4051 | Kohn H, et al. The molecular basis for the mode of action of bicyclomycin.
 Curr Drug Targets Infect Disord. 2005 Sep;5(3):273-95. |
| 4052 | Park HG, et al. Bicyclomycin and dihydrobicyclomycin inhibition kinetics of Escherichia coli rho-dependent transcription termination factor ATPase activity. Arch Biochem Biophys. 1995 Nov 10;323(2):447-54. |
| 4053 | Nishida M. et al. Bicyclomycin, a new antibiotic. IV. Absorption, excretion and tissue distribution. J Antibiot (Tokyo). 1972 Oct;25(10):594-601. |
| 4054 | https://clinicaltrials.gov/ct2/show/NCT04707703?term=Isavuconazole&cond=covid&draw=2&rank=1 |
| 4055 | Jeong JW, et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother. 2010 Dec;54(12):5359-62. |
| 4056 | Kim TS, et al. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus. Antimicrob Agents Chemother. 2017 Aug 24;61(9). |
| 4057 | Makarov V et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
 EMBO Mol Med. 2014 Mar;6(3):372-83. |
| 4058 | Wei L, et al. Genomic profiling is predictive of response to CDDP treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. 2016 Nov 22;7(47):76374-76389. |
| 4059 | Smith MC, et al. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. Mol Cancer Ther. 2016 Oct;15(10):2344-2356 |
| 4060 | Raynor K, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4. |
| 4061 | Mundra JJ, et al. Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo. J Pharmacol Exp Ther. 2012 Aug;342(2):273-87. |
| 4062 | Chen YL, et al. Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. |
| 4063 | Portoghese PS, et al. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol. 1988 Jan 27;146(1):185-6. |
| 4064 | Fernández B, et al. Postnatal naltrindole treatments induce behavioural modifications in preweanling rats. Neurosci Lett. 2000 Mar 31;283(1):73-6. |
| 4065 | Antimicrob. Agents Chemother. (2007), 51(3), 1105-1106; J. Pharm. Sci. (1991), 80(6), 542-4; Mol. Pharmacol. (1982), 22(1), 140-4 |
| 4066 | Expert Opin Invest Drugs 17:565 (2008); Clin Drug Invest 29:87, 601(2009); J Clin Psychiatry 71:32 (2010) |
| 4067 | Lee CJ, et al. Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway. BMC Cancer. 2015 Aug 8;15:576. |
| 4068 | Ther. Adv. Musculoskel. Dis. (2010), 2(2), 95-104; Biorheology (2000), 37(1,2), 177-184; Drugs (1997), 53(1), 98-106 |
| 4069 | Jiang J, et al. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther. 2013 Feb;344(2):360-7. |
| 4070 | Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57(11):4454-65. |
| 4071 | Jiang J, et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3149-54. |
| 4072 | Li J, et al. PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells. Cancer Res. 2017 Nov 15;77(22):6253-6266. |
| 4073 | Chairungsrilerd N, et al. Gamma-mangostin, a novel type of 5-hydroxytryptamine 2A receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):25-31. |
| 4074 | Yokoyama T, et al. Discovery of γ-Mangostin as an Amyloidogenesis Inhibitor. Sci Rep. 2015 Aug 27;5:13570. |
| 4075 | Phytochem 14:584 (1975); Chem Pharm Bull 31:1567(1983); J Nat Prod 63:1265 (2000) |
| 4076 | Gilchrist IC, et al. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet. 2003;42(8):703-20. |
| 4077 | Currie KS, et al. Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase. J Med Chem. 2014 May 8;57(9):3856-73. |
| 4078 | Burke RT, et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 2014 Feb 28;5(4):908-15. |
| 4079 | Pitman MR et al. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget, 2015 Mar 30, 6(9):7065-83. |
| 4080 | Dimasi DP et al. Examining the Role of Sphingosine Kinase-2 in the Regulation of Endothelial Cell Barrier Integrity. Microcirculation, 2016 Apr, 23(3):248-65. |
| 4081 | Dos Santos LM, et al. Methionine and methionine sulfoxide treatment induces M1/classical macrophage polarization and modulates oxidative stress and purinergic signaling parameters. Mol Cell Biochem. 2017 Jan;424(1-2):69-78. |
| 4082 | Tanimura, Shinji, et al. Pharmaceutical composition containing aryl alkyl amine compound. WO 2017061621 A1. |
| 4083 | Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19(6):1493-8. |
| 4084 | Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56. |
| 4085 | Stewart CF, et al. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol. 1997;40(3):259-65. |
| 4086 | Shahane SA, et al. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format. J Biomol Screen. 2014 Jan;19(1):66-76. |
| 4087 | Sharifi H, et al. Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors. Adv Pharm Bull. 2013;3(1):203-6. |
| 4088 | Citó MC, et al. Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system. Braz J Med Biol Res. 2015 Jan;48(1):57-64. |
| 4089 | da Silva DC, et al. Neurotoxicity of the steroidal alkaloids tomatine and tomatidine is RIP1 kinase- and caspase-independent and involves the eIF2α branch of the endoplasmic reticulum. J Steroid Biochem Mol Biol. 2017 Jul;171:178-186. |
| 4090 | Toufike Kanouni, et al. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529. |
| 4091 | J Am Chem Soc 60: 2431 (1938) |
| 4092 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase. Patent WO 2008030584 A2. |
| 4093 | Bamborough, et al. Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery. Journal of Medicinal Chemistry (2008), 51(24), 7898-7914. |
| 4094 | Bamborough, Paul, et al. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics. Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4363-4368. |
| 4095 | Awale, Mahendra, et al. Molecular docking guided 3D-QSAR CoMFA analysis of N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase. Journal of Molecular Modeling (2008), 14(10), 937-947. |
| 4096 | J Am Chem Soc 76: 2792 (1954) |
| 4097 | Steroids 23:357 (1974) |
| 4098 | Hardwicke MA, et al. A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9. |
| 4099 | Life Sci 19: 701 (1976) |
| 4100 | Tolcher A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumors. Eur J Cancer. 2014 Mar;50(5):867-75. |
| 4101 | Phung TL, et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015 Jan 1;75(1):40-50. |
| 4102 | Chen B, et al. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS One. 2017 Aug 9;12(8):e0182891. |
| 4103 | Li W, et al. (S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. Sci Rep. 2017 Aug 30;7(1):10052. |
| 4104 | Ramos-Espiritu L, et al. Discovery of LRE1 as a specific and allosteric inhibitor of soluble adenylyl cyclase. Nat Chem Biol. 2016 Oct;12(10):838-44. |
| 4105 | Liu M et al. Cytotoxicity of the compounds isolated from Pulsatilla chinensis saponins and apoptosis induced by 23-hydroxybetulinic acid. Pharm Biol. 2015 Jan;53(1):1-9. |
| 4106 | Zhang DM et al. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm. 2012 Nov 5;9(11):3147-59. |
| 4107 | Zheng Y et al. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo. J Ethnopharmacol. 2010 Apr 21;128(3):615-22. |
| 4108 | Hillig RC, et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1interaction. Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560. |
| 4109 | Int J Pharmaceutics 179:65 (1999); J Agricultural Food Chem 59:3348 (2011) |
| 4110 | Arch Int Pharmacodyn ther 180:155 (1969); Biol Psychiatry 3:347 (1971); Drugs 29:189 (1995) |
| 4111 | Sujithra K, et al. Allyl methyl sulfide, an organosulfur compound alleviates hyperglycemia mediated hepatic oxidativestress and inflammation in streptozotocin - induced experimental rats. Biomed Pharmacother. 2018 Nov;107:292-302. |
| 4112 | Holzer P, et al. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem. 2015 Aug 27;58(16):6348-58 |
| 4113 | Nakao T, et al. Broflanilide: A meta-diamide insecticide with a novel mode of action. Bioorg Med Chem. 2016 Feb 1;24(3):372-7. |
| 4114 | Yu Y, et, al. Cardioprotective effects of Notoginsenoside R1 against ischemia/reperfusion injuries by regulating oxidative stress- and endoplasmic reticulum stress- related signaling pathways. Sci Rep. 2016 Feb 18;6:21730. |
| 4115 | Ma B, et, al. Notoginsenoside R1 attenuates amyloid-β-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. Int Immunopharmacol. 2014 Sep;22(1):151-9. |
| 4116 | Sun K, et, al. Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Life Sci. 2007 Jul 19;81(6):509-18. |
| 4117 | Yang H, et al. α-Pinene, a Major Constituent of Pine Tree Oils, Enhances Non-Rapid Eye Movement Sleep in Micethrough GABAA-benzodiazepine Receptors. |
| 4118 | Fell MJ, et al. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 2015 Dec;355(3):397-409. |
| 4119 | Dekeyser, M.A., McDonald, P.T., and Angle, G.W., Jr. The discovery of bifenazate, a novel carbazate acaricide Chimia 57(11), 702-704 (2003). |
| 4120 | Hiragaki S, et al. A novel action of highly specific acaricide; bifenazate as a synergist for a GABA-gated chloride channel of Tetranychus urticae [Acari: Tetranychidae]. Neurotoxicology. 2012 Jun;33(3):307-13. |
| 4121 | Haile PA et al. The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase. J Med Chem, 2016 May 26, 59(10):4867-80. |
| 4122 | Infect. Dis. Ther. (1994), 9, 403-9; Pharm. Weekbl. (1982), 117(22), 505-7; Am. Ind. Hyg. Assoc. J. (1989), 50(11), 579-85 |
| 4123 | Weber MA. Saralasin testing for renin-dependent hypertension. Arch Intern Med. 1979;139(1):93‐95. |
| 4124 | Schelling P, Ganten D, Speck G, Fischer H. Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol. 1979;98(3):503‐513. |
| 4125 | Campbell WB, Jackson EK, Graham RM. Saralasin-induced renin release: its blockade by prostaglandin synthesis inhibitors in the conscious rat. Hypertension. 1979;1(6):637‐642. |
| 4126 | Nique F, et al. Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator. J Med Chem. 2012 Oct 11;55(19):8236-47. |
| 4127 | Cozzoli A, et al. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res. 2013 Jun;72:9-24. |
| 4128 | Blanqué R, et al. Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization. BMC Musculoskelet Disord. 2014 Sep 3;15:291. |
| 4129 | Milburn-McNulty P, et al. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2015 Oct 28;(10):CD009472. |
| 4130 | Chenguang Niu, et al. Toxic effects of the Emamectin Benzoate exposure on cultured human bronchial epithelial (16HBE) cells. Environ Pollut. 2020 Feb;257:113618. |
| 4131 | Shaorong Luan, et al. Emamectin benzoate induces ROS-mediated DNA damage and apoptosis in Trichoplusia Tn5B1-4 cells. Chem Biol Interact. 2017 Aug 1;273:90-98. |
| 4132 | Özge Temiz, et al. Biopesticide emamectin benzoate in the liver of male mice: evaluation of oxidative toxicity with stress protein, DNA oxidation, and apoptosis biomarkers. Environ Sci Pollut Res Int. 2020 Jun;27(18):23199-23205. |
| 4133 | https://clinicaltrials.gov/ct2/show/NCT04406389?term=Argatroban&cond=COVID-19&draw=2&rank=1 |
| 4134 | Marco A.S. Baptista, et al. LRRK2 Kinase Inhibitors of Different Structural Classes Induce Abnormal Accumulation of Lamellar Bodies in Type II Pneumocytes in Non-Human Primates but are Reversible and Without Pulmonary Functional Consequences. |
| 4135 | Andersen MA, et al. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation. Neurobiol Dis. 2018 Aug;116:13-27. |
| 4136 | Andersen MA, et al. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology. 2018 Feb 15;395:15-22. |
| 4137 | Olson DE, et al. Discovery of the first histone deacetylase 6/8 dual inhibitors. J Med Chem. 2013 Jun 13;56(11):4816-4820. |
| 4138 | Tesh SA, et al. Innovative selection approach for a new antifungal agent mefentrifluconazole (Revysol®) and the impact upon its toxicity profile. Regul Toxicol Pharmacol. 2019 Aug;106:152-168. |
| 4139 | Chem Pharm Bull 32:4935 (1984) |
| 4140 | Dongcheng Dai, et al. Antiviral drugs for treatment of arenavirus infection. WO2013123215A2. |
| 4141 | Madu IG, et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439. |
| 4142 | J Am Chem Soc 72: 2381 (1950); Experientia 26: 473 (1970); J Agric Food Chem 24: 377 (1976) |
| 4143 | Markus Klein, et al. Boronic acid derivatives. WO2019038250A1. |
| 4144 | Wang Y, et al. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2014 Oct;19(5):372-81. |
| 4145 | Rah YC, et al. Ecabet sodium alleviates neomycin-induced hair cell damage. Free Radic Biol Med. 2015 Dec;89:1176-83. |
| 4146 | Kenji Kusumoto, et al. Ecabet sodium inhibits Helicobacter pylori lipopolysaccharide-induced activation of NADPH oxidase 1 or apoptosis of guinea pig gastric mucosal cells. Am J Physiol Gastrointest Liver Physiol |
| 4147 | J Clin Pharmacol 14:494 (1974)| |
| 4148 | Wink, D.A., et al., The effect of various nitric oxide-donor agents on hydrogen peroxide-mediated toxicity: a direct correlation between nitric oxide formation and protection. Arch Biochem Biophys, 1996. 331(2): p. 241-8. |
| 4149 | Garg, U.C. and A. Hassid, Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest, 1989. 83(5): p. 1774-7. |
| 4150 | Namazi, H., Sodium nitroprusside as a nitric oxide donor in a rat intestinal ischemia reperfusion model: a novel molecular mechanism. Clinics (Sao Paulo), 2008. 63(3): p. 405. |
| 4151 | Anastasiou D, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012 Oct;8(10):839-847. |
| 4152 | Palsson-McDermott EM, et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015 Jan 6;21(1):65-80. |
| 4153 | Cassilly CD, et al. SB-224289 Antagonizes the Antifungal Mechanism of the Marine Depsipeptide Papuamide A. PLoS One. 2016 May 16;11(5):e0154932. |
| 4154 | Hoplight BJ, et al. The effects of SB 224289 on anxiety and cocaine-related behaviors in a novel object task. Physiol Behav. 2005 Apr 13;84(5):707-14. Epub 2005 Apr 13. |
| 4155 | Gaster LM, et al. The selective 5-HT1B receptor inverse agonist SB-224289, potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. Ann N Y Acad Sci. 1998 Dec 15;861:270-1. |
| 4156 | Giardina GA, et al. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412). J Med Chem. 1999 Mar 25;42(6):1053-65. |
| 4157 | Houghton LA, et al. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil. 2007 Sep;19(9):732-43. |
| 4158 | Dawson LA, et al. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. |
| 4159 | https://clinicaltrials.gov/ct2/show/NCT04610567?term=METHOTREXATE&cond=covid&draw=2&rank=1 |
| 4160 | Fu Y, et al. Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo. Autophagy. 2018 Sep 20:1-17. |
| 4161 | Anal Profiles Drug SubsExcip 23:371 (1994) |
| 4162 | Jadav SP, et al. Ulipristal acetate, a progesterone receptor modulator for emergency contraception. J Pharmacol Pharmacother. 2012 Apr;3(2):109-11. |
| 4163 | Del Bello B, et al. Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study. Fertil Steril. 2019 Dec;112(6):1150-1159. |
| 4164 | Hild SA, et al. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod. 2000 Apr;15(4):822-9. |
| 4165 | Ciarmela P, et al. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells. Reprod Sci. 2014 Sep;21(9):1120-5. |
| 4166 | Attardi BJ, et al. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. |
| 4167 | Pohl O, et al. Carcinogenicity and chronic rodent toxicity of the selective progesterone receptor modulator ulipristal acetate. Curr Drug Saf. 2013 Apr;8(2):77-97. |
| 4168 | Pohl O, et al. A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeys. Regul Toxicol Pharmacol. 2013 Jun;66(1):6-12. |
| 4169 | Yde CW, et al. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitorDMAT. Cancer Lett. 2007 Oct 28;256(2):229-37. |
| 4170 | Lawnicka H, et al. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell Tissue Res. 2010 May;340( |
| 4171 | Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415(3):353-65. |
| 4172 | Sass G, et al. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol. 2011 Aug;39(2):433-42. |
| 4173 | Pluquet O, et al. The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem. 2003 Apr 4;278(14):11879-87. |
| 4174 | Shen H, et al. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J Pharmacol Exp Ther. 2001 Jun;297(3):1067-73. |
| 4175 | Afshin Kheradmand, et al. Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats. Iran J Basic Med Sci. 2016 May; 19(5): 490-496. |
| 4176 | Ranjeet Prasad Dash, et al. Use of sorbitol as pharmaceutical excipient in the present day formulations - issues and challenges for drug absorption and bioavailability. Drug Dev Ind Pharm. 2019 Sep;45(9):1421-1429. |Anesthesiology (2002), 96(2), 416-421; Neurol. Res. (1988), 10(2), 73-80; Stroke (1977), 8(4), 512-40 |
| 4177 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Colchicine&cntry=&state=&city=&dist= |
| 4178 | Tongfei Wu, et al. Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models. |
| 4179 | Tao H, et al. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations. Chem Pharm Bull (Tokyo). 2019;67(4):382-388. |
| 4180 | Weinstabl H, et al. Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis. J Med Chem. 2019 Jul 31. |
| 4181 | Drilon A, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017 Sep;7(9):963-972. |
| 4182 | J Econ Entomol 84:1266 (1991); Am J Vet Res 53:1409 (1992)| |
| 4183 | Moxidectin, From Wikipedia |
| 4184 | Kiesman WF, et al. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. |
| 4185 | Ensor CR, et al. Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2010 Oct;11(14):2405-15. |
| 4186 | Gill A, et al. Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against NSC 119875-induced acute kidney injury in rats. Am J Nephrol. 2009;30(6):521-6. |
| 4187 | Martínez González S, et al. Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor. Bioorg Med Chem Lett. 2012 May 15;22(10):3460-6. |
| 4188 | Mazumdar T, et al. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res. 2011 Feb 1;71(3):1092-102. |
| 4189 | Fu J, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013 Mar 1;330(1):22-32. |
| 4190 | Wickstrom M, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer. 2013 Apr 1;132(7):1516-24. |
| 4191 | Clark K, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104. |
| 4192 | Cameron AR, et al. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016 Aug 19;119(5):652-65. |
| 4193 | Melisi D, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther, 2008, 7(4), 829-840. |
| 4194 | Fransvea E, et al. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 2008, 47(5), 1557-1566. |
| 4195 | Zhang M, et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res, 2011, 71(23), 7155-7167. |
| 4196 | Harada K, et al. Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs. Acta Vet Scand. 2012 Mar 20;54:16. |
| 4197 | J Chem Soc 1945: 283 |
| 4198 | Xia Z, et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 8;52(1):74-86. |
| 4199 | Hiasa M, et al. Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia. 2015 Jan;29(1):207-17. |
| 4200 | Chang KH, et al. Lithocholic acid analogues, new and potent alpha-2,3-sialyltransferase inhibitors. Chem Commun (Camb). 2006 Feb 14;(6):629-31. |
| 4201 | Mayo Clin Proc 76:971 (2001); Ann Pharmacother 35:898 (2001) |
| 4202 | Moya M, et al. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact. 2010 Mar 30;184(3):376-87. |
| 4203 | Stack JH, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005 Aug 15;175(4):2630-4. |
| 4204 | Wannamaker W, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007 May;321(2):509-16. |
| 4205 | Ravizza T, et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia. 2006 Jul;47(7):1160-8. |
| 4206 | He XX, et al. Pelopuradazole, a new imidazole derivative alkaloid from the marine bacteria Pelomonas puraquae sp. nov. Nat Prod Res. 2014;28(9):680-2. |
| 4207 | https://clinicaltrials.gov/ct2/show/NCT04558463?term=Oseltamivir&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04516915?term=Oseltamivir&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04338698?term=Oseltamivir&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04255017?term=Oseltamivir&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04261270?term=Oseltamivir&cond=COVID-19&draw=2&rank=8 https://clinicaltrials.gov/ct2/show/NCT04457609?term=Oseltamivir&cond=COVID-19&draw=2&rank=9 https://clinicaltrials.gov/ct2/show/NCT04371601?term=Oseltamivir&cond=COVID-19&draw=2&rank=10 |
| 4208 | Wang Z, et al. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Sci Rep. 2015 Jul 29;5:12651. |
| 4209 | Bach A, et al. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci Rep. 2015 Jul 16;5:12157. |
| 4210 | Mujahid N, et al. A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Rep. 2017 Jun 13;19(11):2177-2184. |
| 4211 | https://clinicaltrials.gov/ct2/show/NCT04530422?term=Ledipasvir&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04498936?term=Ledipasvir&cond=Covid19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20100228003449N29 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/08/027345 |
| 4212 | Lee MD, et al. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J Clin Invest. 2004 Oct;114(8):1107-16. |
| 4213 | Chen DZ, et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry. 2000 Feb 15;39(6):1256-62. |
| 4214 | Wahl, R.C., et al. Hydroxamate inhibitors of human gelatinase B (92 kDa). Bioorganic & Medicinal Chemistry Letters 5(4), 349-352 (1995). |
| 4215 | Duke SO, et al. Modes of action of microbially-produced phytotoxins. Toxins (Basel). 2011 Aug;3(8):1038-64. |
| 4216 | Kruse MN, et al. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J. 2004 Mar 1;378(Pt 2):383-9. |
| 4217 | Chouaib S, et al. The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol. 1984 Apr;132(4):1851-7. |
| 4218 | Fernandez-Repollet E, et al. In vivo effects of prostaglandin E2 and arachidonic acid on phagocytosis of fluorescent methacrylate microbeads by rat peritoneal macrophages. J Histochem Cytochem. 1982 May;30(5):466-70. |
| 4219 | Haylor J, et al. Renal vasodilator activity of prostaglandin E2 in the rat anaesthetized with pentobarbitone. Br J Pharmacol. 1982 May;76(1):131-7. |
| 4220 | M S, et al. Sucralose administered in feed, beginning prenatally through lifespan, induces hematopoietic neoplasias in male swiss mice. Int J Occup Environ Health. 2016 Jan;22(1):7-17. |
| 4221 | Nabanita Kundu, et al. Sucralose promotes accumulation of reactive oxygen species (ROS) and adipogenesis in mesenchymal stromal cells. Stem Cell Res Ther. 2020 Jun 26;11(1):250. |Arch Oral Biol 27:693 (1982); Trends Biochem Sci 3:61 (1978) |
| 4222 | Cancer Res. (1979), 39(5), 1570-4; J. Med. Chem. (1978), 21(3), 291-4; Cancer Res. (1980), 40(5), 1516-8 |
| 4223 | Kinney GG, et, al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther. 2005 Apr; 313(1):199-206. |
| 4224 | Ye BH, et al. Preventive effect of gomisin J from Schisandra chinensis on angiotensin II-induced hypertension via an increased nitric oxide bioavailability. Hypertens Res. 2015 Mar;38(3):169-77. |
| 4225 | Kim M, et al. Gomisin J Inhibits Oleic Acid-Induced Hepatic Lipogenesis by Activation of the AMPK-Dependent Pathway and Inhibition of the Hepatokine Fetuin-A in HepG2 Cells. J Agric Food Chem. 2015 Nov 11;63(44):9729-39. |
| 4226 | Am Rev Respir Dis 141 Suppl,:A840 (1990);.Br J Pharmacol 112:795 (1994); J Pharm Pharmacol 48:112 (1996) |
| 4227 | Toxicol Appl Pharmacol 21: 405 (1972) |
| 4228 | Mol Pharm 21:594 (1982); Eur J Pharmacol 238:343 (1993); J Pharmacol Exp Ther 279:1335 (1996)) |
| 4229 | Eur J Med Chem 15:157 (1980); Clin Pharmacol Ther 28:790 (1980); Arzneim-Forsch 33:1525 (1983) |
| 4230 | Zins K, et al. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. PLoS One. 2013;8(9):e74924. Published 2013 Sep 11. |
| 4231 | Suzuki O, et al. Sialylation and glycosylation modulate cell adhesion and invasion to extracellular matrix in human malignant lymphoma: Dependency on integrin and the Rho GTPase family. Int J Oncol. 2015;47(6):2091‐2099. |
| 4232 | Guo A, et al. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Oncotarget. 2017 Feb 21;8(8):12953-12967. |
| 4233 | Coffey G, et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther. 2014 Dec;351(3):538-48. |
| 4234 | Ma J, et al. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Oncotarget. 2015 Dec 22;6(41):43881-96. |
| 4235 | Blunt MD, et al. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324. |
| 4236 | Kwon H ,et al. Induction of differentiation of U-937 cells by 2-chloro-3-amino-1,4-naphthoquinone. Res Commun Mol Pathol Pharmacol. 1997 Aug;97(2):215-27. |
| 4237 | Cheng WY, et al. Comprehensive evaluation of a novel nuclear factor-kappaB inhibitor, quinoclamine, by transcriptomic analysis. Br J Pharmacol. 2009 Jul;157(5):746-56. |
| 4238 | Tanizawa K, et al. Proteolytic enzymes. VI. Aromatic amidines as competitive inhibitors of trypsin. J Biochem. 1971 May;69(5):893-9. |
| 4239 | Katz BA, et al. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol. 2000 Apr;7(4):299-312. |
| 4240 | Takeshi Enomoto, et al.A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated With Schizophrenia. J Pharmacol Exp Ther |
| 4241 | Takeshi Enomoto, et al. The Preclinical Profile of DSR-141562: A Novel Phosphodiesterase 1 Inhibitor for the Treatment of Positive Symptoms, Negative Symptoms and Cognitive Impairments Associated with Schizophrenia.Proceedings for The 93rd Annual Meeting of the Japanese Pharmacological Society |
| 4242 | Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. |
| 4243 | Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28. |
| 4244 | Yeadon, A., et al., Suprofen. An overview of long-term safety. Pharmacology, 1983. 27 Suppl 1: p. 87-94. |
| 4245 | Dawood, M.Y. and F.S. Khan-Dawood, Differential suppression of menstrual fluid prostaglandin F2a, prostaglandin E2, 6-keto prostaglandin F1a and thromboxane B2 by suprofen in women with primary dysmenorrhea. Prostaglandins Other Lipid Mediat, 2007. 83(1-2): p. 146-53. |
| 4246 | Drexel M, et al. INH14, a Small-Molecule Urea Derivative, Inhibits the IKKα/β-Dependent TLR Inflammatory Response. Chembiochem. 2019 Mar 1;20(5):710-717. |
| 4247 | J Ind Hyg Toxicol 30:63 (1948) |
| 4248 | J Pharmacol Exp Ther 148:158 (1965); 322:214 (2007) |
| 4249 | Salcedo C, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17. |
| 4250 | Huang X, et al. Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation. J Phys Chem B. 2012 Jan 12;116(1):532-41. |
| 4251 | Porter DC, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804. |
| 4252 | J Econ Entomol 1946 39:78 (1946); Int Agrophysics 20:63 (2006) |
| 4253 | J Chem Soc 97:2258 (1910); 1931:2544 |
| 4254 | R Malaviya, et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther. 2000 Dec;295(3):912-26. |
| 4255 | Mycol Res 101:920 (1997); Indian J Exp Biol 38:1172 (2000); Chem Pharm Bull 52:1255 (2004) |
| 4256 | J. Bone Miner. Res. (2007), 22(10), 1640-1648; Therapie (1971), 26(5), 911-17; Mol. Pharmacol. (1970), 6(6), 597-603 |
| 4257 | Anesthesiology 28:246 (1967); Arch Dermatol 122:924 (1986) |
| 4258 | Jiang Y, et al. Vitamin K4 induces tumor cytotoxicity in human prostate carcinoma PC-3 cells via the mitochondria-related apoptotic pathway. Pharmazie. 2013 Jun;68(6):442-8. |
| 4259 | Obstet Gynecol 14:337 (1959); J Endocrinol 94, 267 (1982); J Clin Pharmacol 50:73 (2010) |
| 4260 | WARD, Richard, Andrew, et al. DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER. WO2017080979A1. |
| 4261 | Song J, et al. A ligand for the aryl hydrocarbon receptor isolated from lung. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14694-9. |
| 4262 | Nugent LF, et al. ITE, a novel endogenous nontoxic aryl hydrocarbon receptor ligand, efficiently suppresses EAU and T-cell-mediated immunity. Invest Ophthalmol Vis Sci. 2013 Nov 13;54(12):7463-9. |
| 4263 | Pang LP, et al. ITE inhibits growth of human pulmonary artery endothelial cells. Exp Lung Res. 2017 Oct;43(8):283-292. |
| 4264 | Vasta JD, et al. Selective Inhibition of Collagen Prolyl 4-Hydroxylase in Human Cells. ACS Chem Biol. 2016 Jan 15;11(1):193-9. |
| 4265 | Biochem Pharmacol 13:969 (1964); Eur J Cancer 7:11 (1971) |
| 4266 | Neelu Kanwar Rajawat, et al. Effect of β-cyfluthrin (Synthetic Pyrethroid) on Learning, Muscular Coordination and Oxidative Stress in Swiss Albino Mice. Toxicol Ind Health. 2019 May;35(5):358-367. |
| 4267 | https://clinicaltrials.gov/ct2/show/NCT04884490?term=SULFAMETHOXAZOLE&cond=covid&draw=2&rank=1 |
| 4268 | Guo Y, et al. Sinapine as an active compound for inhibiting the proliferation of Caco-2 cells via downregulation of P-glycoprotein. Food Chem Toxicol. 2014 May;67:187-92. |
| 4269 | Boulghobra D, et, al. Sinapine, but not sinapic acid, counteracts mitochondrial oxidative stress in cardiomyocytes. Redox Biol. 2020 Jul;34:101554. |
| 4270 | Li Y, et, al. Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota. Food Funct. 2019 Jun 19;10(6):3637-3649. |
| 4271 | Yates K, et, al. Determination of sinapine in rapeseed pomace extract: Its antioxidant and acetylcholinesterase inhibition properties. Food Chem. 2019 Mar 15;276:768-775. |
| 4272 | JACS 53: 4112 (1931) |
| 4273 | Tack J, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67. |
| 4274 | Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68(7):981-91. |
| 4275 | Odaka T, et al. Serotonin 5- HT4 receptor agonist (mosapride citrate). Nihon Rinsho. 2006 Aug;64(8):1491-4. |
| 4276 | Funaki M, et al. Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Sci Rep. 2017 Dec 5;7(1):16978. |
| 4277 | Okada H, et al. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet. Oncotarget. 2017 Jun 20;8(25):39978-39993. |
| 4278 | Honda M, et al. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191. |
| 4279 | Sidrauski C, et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife. 2013 May 28;2:e00498. |
| 4280 | Sidrauski C, et al. The small molecule ISRIB reverses the effects of eIF2α phosphorylation on translation and stressgranule assembly. Elife. 2015 Feb 26;4. doi: 10.7554/eLife.05033. |
| 4281 | Tottori K, et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001;41(8):976-988. |
| 4282 | Bermack JE, et al. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus. J Pharmacol Exp Ther. 2004;310(2):578-583. |
| 4283 | Dovey HF, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001 Jan;76(1):173-81. |
| 4284 | Zhou JX, et al. γ-secretase inhibition combined with NSC 119875 enhances apoptosis of nasopharyngeal carcinoma cells.Exp Ther Med. 2012 Feb;3(2):357-361. |
| 4285 | Li S, et al. DAPT protects brain against cerebral ischemia by down-regulating the expression of Notch 1 and nuclear factor κB in rats. Neurol Sci. 2012 Dec;33(6):1257-64. |
| 4286 | Tanimizu N, et al. Intrahepatic bile ducts are developed through formation of homogeneous continuous luminal network and its dynamic rearrangement in mice. Hepatology. 2016 Jul;64(1):175-88. |
| 4287 | Michael T. Chang, et al. Notch Drives Proliferation And Radiation Resistance Of Cancer Stem Cells In Adenoid Cystic Carcinoma. Yale University. January 2016. |
| 4288 | Majumder S, et al. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease. J Clin Invest. 2018 Jan 2;128(1):483-499. |
| 4289 | Yixin Tao, et al. β-catenin activation in hair follicle dermal stem cells induces ectopic hair outgrowth and skin fibrosis. J Mol Cell Biol. 2018 May 16. |
| 4290 | J Biochem 122:498 (1997); Biochem Biophys Res Commun 264:979 (1999) |
| 4291 | Sun Y, et al. [Effects of avermectin B1a on soil microorganism and earthworm (Eisenia fetida)]. Ying Yong Sheng Tai Xue Bao. 2005 Nov;16(11):2140-3. |
| 4292 | Sun Y, et al. Bioaccumulation and elimination of avermectin B1a in the earthworms (Eisenia fetida). Chemosphere. 2005 Jul;60(5):699-704 |
| 4293 | Huang J, et al. Avermectin B1a binds to high- and low-affinity sites with dual effects on the gamma-aminobutyric acid-gated chloride channel of cultured cerebellar granule neurons. J Pharmacol Exp Ther. 1997 Apr;281(1):261-6. |
| 4294 | Payne GT, et al. Activation of gamma-aminobutyric acid insensitive chloride channels in mouse brain synaptic vesicles by avermectin B1a.
 J Biochem Toxicol. 1991 Winter;6(4):283-92. |
| 4295 | J Chem Soc 1955:2948; Aust J Chem 13:390 (1960); Phytochemistry 11:2333 (1972); J Med Microbiol 55:201 (2006) |
| 4296 | Tamura, T., et al., Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology, 2005. 75(1): p. 45-52. |
| 4297 | Ohmori, K., et al., Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol, 2002. 88(4): p. 379-97. |
| 4298 | Yanni, J.M., et al., The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther, 1996. 12(4): p. 389-400. |
| 4299 | Kostich W, et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358(3):371-86. |
| 4300 | J Chem Soc 1939: 1047 |
| 4301 | Farnaby W, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019 Jul;15(7):672-680. |
| 4302 | Curr. Med. Chem. (2003), 3(4), 309-315; Int. J. Dermatol. (1977), 16(4), 267-73; Am. J. Med. Sci. (1947), 213(5), 608-10 |
| 4303 | https://clinicaltrials.gov/ct2/show/NCT04979884?term=CYCLOSPORINE&cond=covid&draw=2&rank=4 |
| 4304 | Aman MJ, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009 Sep;83(3):245-51. |
| 4305 | Planta Med 11: 465 (1963); Can J Physiol Pharmacol 75:1356 (1997) |
| 4306 | Kettle JG, et al. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT. J Med Chem. 2012 Feb 9;55(3):1261-73. |
| 4307 | Citron M, et al. Inhibition of amyloid beta-protein production in neural cells by the serine protease inhibitor AEBSF. Neuron. 1996 Jul;17(1):171-9 |
| 4308 | Nakabo Y, et al. Lysis of leukemic cells by human macrophages: inhibition by 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), a serine protease inhibitor. J Leukoc Biol. 1996 Sep;60(3):328-36. |
| 4309 | Buitrago-Rey R, et al. Evaluation of two inhibitors of invasion: LY311727 [3-(3-acetamide-1-benzyl-2-ethyl-indolyl-5-oxy)propane phosphonic acid] and AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride] in acute murine toxoplasmosis. J Antimicrob Chemother. |
| 4310 | Jiang YH, et al. Serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) inhibits the rat embryo implantation in vivo and interferes with cell adhesion in vitro. Contraception. 2011 Dec;84(6):642-8. |
| 4311 | Chem. Res. Toxicol. (1998), 11(12), 1529-35; Proc. Natl. Acad. Sci. U. S. A. (1996), 93(23), 12764-7; Br. J. Pharmacol. (1995), 115(6), 909-12 |
| 4312 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Eicosapentaenoic+acid&cntry=&state=&city=&dist= |
| 4313 | Probst P, et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. Vaccine. 2017 Apr 4;35(15):1964-1971. |
| 4314 | A Kupferman, et al. Fluorometholone acetate. A new ophthalmic derivative of fluorometholone. Arch Ophthalmol. 1982 Apr;100(4):640-1. |
| 4315 | Zuhal Alım, et al. Some Anti-Inflammatory Agents Inhibit Esterase Activities of Human Carbonic Anhydrase Isoforms I and II: An In Vitro Study. Chem Biol Drug Des. 2015 Oct;86(4):857-63. |
| 4316 | H M Leibowitz, et al. Fluoro metholone acetate: clinical evaluation in the treatment of external ocular inflammation. Ann Ophthalmol. 1984 Dec;16(12):1110-5. |
| 4317 | Zhang LN, et al. Novel small-molecule AMP-activated protein kinase allosteric activator with beneficial effects in db/db mice. PLoS One. 2013 Aug 20;8(8):e72092. |
| 4318 | Zhang J, et al. Progesterone metabolism in human fibroblasts is independent of P-glycoprotein levels and Niemann-Pick type C disease. J Steroid Biochem Mol Biol. 1999 Sep-Oct;70(4-6):123-31. |
| 4319 | de Mello Martins AGG, et al. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone. J Steroid Biochem Mol Biol. 2017 Nov;174:183-191. |
| 4320 | Chiappori AA, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9. |
| 4321 | Ber 63:120 (1930) |
| 4322 | Brian Lannutti, et al. Uses of indolinone compounds. US10159660B2. |
| 4323 | Spriano F, et al. The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clin Cancer Res. 2019 Aug 15;25(16):5167-5176. |
| 4324 | Alinari L, et al. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.Blood. 2015 Apr 16;125(16):2530-43. |
| 4325 | Webb LM, et al. PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis. J Immunol. 2017 Feb 15;198(4):1439-1451. |
| 4326 | Bull Johns Hopkins Hosp 67:163 (1940); J Mt Sinai Hosp 10:343 (1943) |
| 4327 | Rafferty SW, et al. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
 Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444-7. |
| 4328 | Sankar N. Maity, et al. Abstract 4772: Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20-lyase, in castrate-resistant prostate cancer models. 
 Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1 |
| 4329 | Vilimas T, et al. Pharmacokinetic evaluation of the perinucleolar compartment disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemother Pharmacol. 2018 Dec;82(6):1067-1080. |
| 4330 | Frankowski KJ, et al. Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Sci Transl Med. 2018 May 16;10(441). |
| 4331 | Lee Y, et al. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget. 2017 Jun 20;8(25):41091-41101. |
| 4332 | Joly S, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66(1):S690. |
| 4333 | Fiorucci S,et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) [published online ahead of print, 2020 Jun 19]. Expert Opin Investig Drugs. 2020;1-10. |
| 4334 | Phytochemistry 9:1669 (1970); Planta Med 72:34 (2006); Inflamm Res 56:487 (2012) |
| 4335 | Hawkinson JE, et al. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. J Pharmacol Exp Ther.2007 Aug;322(2):619-630. |
| 4336 | Chan WY, et al. In vitro antimicrobial activity of seven adjuvants against common pathogens associated with canine otitis externa.Vet Dermatol. 2019 Apr;30(2):133-e38. |
| 4337 | Skulason S, et al. A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis.J Oral Pathol Med. 2012 Jan;41(1):61-7. |
| 4338 | Anal Profiles Drug Subst 4:137 (1975) |
| 4339 | Widdowson KL. Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection. WO2016027249A1. |
| 4340 | Proc 18th Vertebra Pest Conf 1988:338, 345 |
| 4341 | Khavinson VKh. et al. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. |
| 4342 | Vanhee C, et al. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations. Drug Test Anal. 2015 Mar;7(3):259-64. |
| 4343 | Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003 Jun;135(6):590-2. |
| 4344 | Vladimir N Anisimov, et al.Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202 |
| 4345 | Koppová I, et al. Analysis of fatty acid composition of anaerobic rumen fungi. Folia Microbiol (Praha). 2008;53(3):217-20. |
| 4346 | Martin SA, et al. The discovery and early structural studies of arachidonic acid. J Lipid Res. 2016 Jul;57(7):1126-32. |
| 4347 | Zhang H, et al. Molecular determinants of magnolol targeting both RXRα and PPARγ. PLoS One. 2011;6(11):e28253. |
| 4348 | Choi SS, et al. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Life Sci. 2009 Jun 19;84(25-26):908-14. |
| 4349 | Zhao L, et al. Magnolol, a Natural Polyphenol, Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice. Molecules. 2017 Jul 20;22(7). pii: E1218. |
| 4350 | Liu F, et al. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. |
| 4351 | Xu J, et al. Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learning. Learn Mem. 2013 Jul 18;20(8):438-45. |
| 4352 | Schlumberger C, et, al. Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol Biochem Behav. 2010 Mar;95(1):23-30. |
| 4353 | Clem B, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008 Jan;7(1):110-20. |
| 4354 | Schoors S, et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014 Jan 7;19(1):37-48. |
| 4355 | Lea MA, Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism. Anticancer Res. 2015 Nov;35(11):5889-99. |
| 4356 | Mol. Biochem. Parasitol. (1990), 43(1), 89-95; J. Med. Chem. (1988), 31(1), 254-60; J. Med. Chem. (1967), 10(5), 867-76 |
| 4357 | Nature 209:1084 (1966); Brit Med J 4:93 (1968) |
| 4358 | Charneira C, et al. Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity. Chem Res Toxicol. 2011 Dec 19;24(12):2129-41. |
| 4359 | Hervey PS, et al. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs. 2000 Aug;60(2):447-79. |
| 4360 | Krivtsov AV, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 Dec 9;36(6):660-673.e11. |
| 4361 | Andrei V. Krivtsov, et al. Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia. Cancer Resceach. July 2018.Volume 78, Issue 13 Supplement. |
| 4362 | Eiki J, et al. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol. 2011 Dec;80(6):1156-65. |
| 4363 | Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8. |
| 4364 | Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13(5):e0196598. |
| 4365 | Qirui Guo, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. 2021 Feb 10;29(2):222-235.e4. |
| 4366 | Liu C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. Eur J Pharm Sci. 2019 Jan 15;127:151-160. |
| 4367 | Li X, et al. Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers. Front Pharmacol. 2018 Jun 20;9:643. |
| 4368 | European Food Safety Authority; Modification of existing MRLs for valifenalate (valiphenal) in tomatoes and aubergines on request. EFSA Journal 2009; 7(11):1388. |
| 4369 | Bourdonnec BL, et, al. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg Med Chem Lett. 2008 Mar 15;18(6):2006-12. |
| 4370 | Erowele GI, et, al. Alvimopan (Entereg), a Peripherally Acting mu-Opioid Receptor Antagonist For Postoperative Ileus. P T. 2008 Oct;33(10):574-83. |
| 4371 | Meerveld BG, et, al. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:46-53. |
| 4372 | Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8. |
| 4373 | Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6(10):761-70. |J Antibiotics 31:330 (1978); Biochem J 176:305 (1978); 191:209 (1980) |
| 4374 | Nicholson B et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31. |
| 4375 | Monica M. Mita et al. Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas Clin Cancer Res. 2010 Dec 1;16(23):5892-9. |
| 4376 | Bertelsen LB, et al. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int J Radiat Biol. 2011 Nov;87(11):1126-34. |
| 4377 | Neurology 57:1377 (2001); Drugs 62:1539 (2002) |
| 4378 | Luo Y, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther, 2005, 4(6), 977-986. |
| 4379 | Zhu QS, et al. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res, 2008, 68(8), 2895-2903. |
| 4380 | Zou Y, et al. Pre-clinical assessment of A-674563 as an anti-melanoma agent. Biochem Biophys Res Commun. 2016 Aug 12;477(1):1-8. |
| 4381 | Xu L, et al. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells. Biochem Biophys Res Commun. 2016 Apr 15;472(4):662-8. |
| 4382 | WO 2015089067 A1 |
| 4383 | Iva Stojkovska, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease. Cell Tissue Res. 2017. |
| 4384 | Christoph Arenz, et al. Recent advances and novel treatments for sphingolipidoses. Future Med. Chem. (2017) 9(14), 1687–1700. |
| 4385 | Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22. |
| 4386 | Naturwissenschaften 49: 281 (1962) |
| 4387 | Small molecule inhibitors of egfr and pi3k. WO 2016100347 A2 |
| 4388 | Lim JW, et al. Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem. 2018 Sep 5;157:405-422. |
| 4389 | Huang SM et al.,Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling., Nature. 2009 Oct 1;461(7264):614-20. |
| 4390 | Elizabeth Fox et al. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors Clin Cancer Res February 15, 2008 14; 1111 |
| 4391 | Aggarwal C, et al. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?,Cancer Biol Ther. 2012 Mar;13(5):247-63. |
| 4392 | Silver M, Rusk A, Phillips B, Beck E, Jankowski M, Philibert J, Hahn K, Hershey E, McKeegan E, Bauch J, Krivoshik A, Khanna C.,Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.,J Vet Intern Med. 2012 Mar-Apr;26(2):349-54. doi: 10.1111/j.1939-1676.2012.00892.x. Epub 2012 Feb 28. |
| 4393 | Gaynon PS, Harned TM; for the Therapeutic Advances in Childhood LeukemiaLymphoma (TACL) Consortium. |
| 4394 | Fang L, et al. A Small-Molecule Antagonist of the β-Catenin/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis. Cancer Res. 2016 Feb 15;76(4):891-901. |
| 4395 | Busby S, et al. Discovery of Inverse Agonists for the Liver Receptor Homologue-1 (LRH1; NR5A2). |
| 4396 | Corzo CA, et al. Antiproliferation activity of a small molecule repressor of liver receptor homolog 1. Mol Pharmacol. 2015 Feb;87(2):296-304. |
| 4397 | Bryan G, Anthony C et al. The structural basis of the inhibition of human glycosidases by
 castanospermine analogues. Biochem. J. (1990) 269, 227-231. |
| 4398 | Eisaku Tsujii et al. Nectrisine Is a Potent Inhibitor of a-Glucosidases, Demonstrating
 Activities Similarly at Enzyme and Cellular Levels. Biochemical and Biophysical Research Communications 220, 459-466 (1996) |
| 4399 | Pili R et al. The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, preventsangiogenesis, and inhibits tumor growth. Cancer Res. 1995 Jul 1;55(13):2920-6. |
| 4400 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=LABETALOL&cntry=&state=&city=&dist= |
| 4401 | Clin Pharmacol Ther 32:98 (1982); Dev Pharmacol Ther 6:315 (1983) |
| 4402 | Jan Beute, et al. A Pathophysiological Role of PDE3 in Allergic Airway Inflammation. JCI Insight. 2018 Jan 25;3(2):e94888. |
| 4403 | R C Dage, et al. Pharmacology and Pharmacokinetics of Enoximone. Cardiology. 1990;77 Suppl 3:2-13; discussion 27-33. |
| 4404 | M B Vroom, et al. Effect of Phosphodiesterase Inhibitors on Human Arteries in Vitro. Br J Anaesth. 1996 Jan;76(1):122-9. |
| 4405 | Park C, et al. Induction of G1 arrest and apoptosis by schisandrin C isolated from Schizandra chinensis Baill in human leukemia U937 cells. Int J Mol Med. 2009 Oct;24(4):495-502. |
| 4406 | Oh SY, et al. Anti-inflammatory effects of gomisin N, gomisin J, and schisandrin C isolated from the fruit of Schisandra chinensis. Biosci Biotechnol Biochem. 2010;74(2):285-91. |
| 4407 | Xin Mao, et al.Schisandrin C Ameliorates Learning and Memory Deficits by Aβ 1-42 -induced Oxidative Stress and Neurotoxicity in Mice. Phytother Res. 2015 Sep;29(9):1373-1380. |
| 4408 | Polletta L, et al. SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy. 2015;11(2):253-70. |
| 4409 | J Clin Oncol 14:527 (1996); Beitr Onkol 6:95 (1981) |
| 4410 | Daniel L. Flynn, et al. Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities. WO 2010051373 A1 |
| 4411 | Toskes PP, et al. The bentiromide test for pancreatic exocrine insufficiency. Pharmacotherapy. 1984 Mar-Apr;4(2):74-80. |
| 4412 | Lucki NC, et al. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. |
| 4413 | Devaiah BN, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32. |
| 4414 | Moros A, et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia. 2014 Oct;28(10):2049-59 |
| 4415 | Telliez JB, et al. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol. 2016 Dec 16;11(12):3442-3451. |
| 4416 | Chemotherapy 38:92 (1992) |
| 4417 | Wong TW, et al. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. Clin Cancer Res. 2011 Jun 15;17(12):4031-41. |
| 4418 | Marathe P, et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. |
| 4419 | Am J Med Sci 253:321 (1967); Toxicol Appl Pharmacol 18:185 (1971) |
| 4420 | Shan J, et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol. 2013 Aug;9(8):514-20. |
| 4421 | Md. Ataur Rahman, Angelicin induces apoptosis through intrinsic caspase-dependent pathway in human SH-SY5Y neuroblastoma cells. Molecular and Cellular Biochemistry
 October 2012, Volume 369, Issue 1-2, pp 95-104 |
| 4422 | Hye-Jeong Cho, et al. Antiviral activity of angelicin against gammaherpesviruses. Antiviral Research
 Volume 100, Issue 1, October 2013, Pages 75–83 |
| 4423 | Fang Liu, et al. Angelicin regulates LPS-induced inflammation via inhibiting MAPK/NF-κB pathways. Journal of Surgical Research
 Volume 185, Issue 1, November 2013, Pages 300–309 |
| 4424 | Ma H, et al. Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening. Eur J Med Chem. 2017 Jun 16;133:174-183. |
| 4425 | ShuYan Liu, et al. SEC-induced Activation of ANXA7 GTPase Suppresses Prostate Cancer Metastasis. Cancer Lett. 2018 Mar 1;416:11-23. |
| 4426 | ShuYan Liu, et al. A small molecule induces integrin β4 nuclear translocation and apoptosis selectively in cancer cells with high expression of integrin β4. Oncotarget. 2016 Mar 29; 7(13): 16282–16296. |
| 4427 | Chen CS, et al. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virushelicase. J Med Chem. 2009 May 14;52(9):2716-23. |
| 4428 | Yano H, et al. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem. 1993 Dec 5;268(34):25846-56. |
| 4429 | Moon EK, et al. Autophagy inhibitors as a potential antiamoebic treatment for Acanthamoeba keratitis. Antimicrob Agents Chemother. 2015 Jul;59(7):4020-5. |
| 4430 | Liu Y, et al. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem. 2007 Jan 26;282(4):2505-11. |
| 4431 | Wu Q, et al. Wortmannin inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro. J Huazhong Univ Sci Technolog Med Sci. 2009 Aug;29(4):451-6. |
| 4432 | Lemke LE, et al. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol. 1999;44(6):491-7. |
| 4433 | Liu Y, et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalianpolo-like kinase. Chem Biol. 2005 Jan;12(1):99-107. |
| 4434 | Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635. |
| 4435 | Lee A. Dawson et al. Vilazodone: A 5-HT1A Receptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders CNS Neuroscience & Therapeutics Volume 15, Issue 2, pages 107-117, June 2009 |
| 4436 | Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME.
 The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
 Curr Med Res Opin. 2012 Jan;28(1):27-39. |
| 4437 | Antimicrob. Agents Chemother. (1976), 10(2), 234-40; Arzneim. Forsch. (1970), 20(6), 821-4 |
| 4438 | Flygare JA, et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13. |
| 4439 | Zhang, Wenjuan; Xu, Jing; Liu, Fang. Heterodimers of histidine and amantadine as inhibitors for wild type and mutant M2 channels of influenza A. Chinese Journal of Chemistry (2010), 28(8), 1417-1423. |
| 4440 | Mallinger A, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J Med Chem. 2015 Feb 26;58(4):1717-35. |
| 4441 | Dale T, et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat Chem Biol. 2015 Dec;11(12):973-980. |
| 4442 | Zurab Surviladze, et al. Identification of a Small GTPase Inhibitor Using a High-Throughput Flow Cytometry Bead-Based Multiplex Assay. J Biomol Screen. 2010 Jan;15(1):10-20. |
| 4443 | Welsch ME, et al. Multivalent Small-Molecule Pan-RAS Inhibitors. Cell. 2017 Feb 23;168(5):878-889.e29. |
| 4444 | J Clin Psychiatry 68:677 (2007); Int Clin Psychopharmacol 22:338 (2007) |
| 4445 | Daouti S, et al. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res. 2008 Feb 15;68(4):1162-9. |
| 4446 | Ferretti C, et al. Inhibitory effect of theophylline, theophylline-7-acetic acid, ambroxol and ambroxol-theophylline-7-acetate on rat lung cAMP phosphodiesterase isoenzymes. Int J Tissue React. 1992;14(1):31-6. |
| 4447 | Méchin MC, et, al. Acefylline activates filaggrin deimination by peptidylarginine deiminases in the upper epidermis. J Dermatol Sci. 2016 Feb;81(2):101-6. |
| 4448 | Strom E, et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol. 2006 Sep;2(9):474-9. Epub 2006 Jul 23. |
| 4449 | Zhou Y, et al. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70. Oncol Rep. 2017 Jan;37(1):313-322. |
| 4450 | Glas M, et al. Neuroprotection with the P53-Inhibitor Pifithrin-μ after Cardiac Arrest in a Rodent Model. Shock. 2018 Feb;49(2):229-234. |
| 4451 | Izuhara Y, et al. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab. 2010 May;30(5):904-12. |
| 4452 | Yasui H, et al. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells. Thromb Res. 2013 Jul;132(1):100-5. |
| 4453 | Mashiko S, et al. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther. 2015;16(2):253-60. |
| 4454 | Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. |
| 4455 | Magee PJ, et al. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr. 2014 Feb;53(1):345-50. |
| 4456 | Brown NM, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis. 2010 May;31(5):886-93. |
| 4457 | Bielawski K, et al. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A.Biol Pharm Bull. 2006 Jul;29(7):1493-7. |Arzneim Forsch 20:1 (1970); Toxicol Appl Pharmacol 18:185 (1971); Arzneim Forsch 28:493 (1978) |
| 4458 | K. evans, et al. Effects of amino acids on the reproduction of Heterodera rostochiensis. Nematologica, 1971, 17(4), 495-500. |
| 4459 | Swennen Q, et al. Effects of dietary protein content and 2-hydroxy-4-methylthiobutanoic acid or DL-methionine supplementation on performance and oxidative status of broiler chickens. Br J Nutr. 2011 Dec;106(12):1845-54. |
| 4460 | Garlich JD. Response of broilers to DL-methionine hydroxy analog free acid, DL-methionine, and L-methionine. Poult Sci. 1985 Aug;64(8):1541-8. |
| 4461 | Phytochemistry 11:2283 (1972) |
| 4462 | Vassilev LT, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303(5659):844-8. |
| 4463 | Antimicrob Agents Chemother 14:807 (1978); 16:109, 127 (1979) |
| 4464 | Rose JB, et al. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. BJU Int. 2015 Aug 25. doi: 10.1111/bju.13261. |
| 4465 | Nutr Cancer 41:135 (2001); J Natl Cancer Inst 93:1224 (2001); Cancer Res 63:1325 (2003); Fitoterapia 83:1160 (2012); Oncology Rep 27:1041 (2012)| |
| 4466 | Yesil-Celiktas O, et al. Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines. Plant Foods Hum Nutr. 2010 Jun;65(2):158-63. |
| 4467 | Grace MS, et al. The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo. Br J Pharmacol. 2014 Aug;171(16):3881-3894. |
| 4468 | Kimura S, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005 Dec 1;106(12):3948-3954. |
| 4469 | Kamitsuji Y, et al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ. 2008, 15(11), 1712-2172. |
| 4470 | Yokota A, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007, 109(1), 306-314. |
| 4471 | Griswold DE, et, al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther. 1998 Nov;287(2):705-11. |
| 4472 | Hatzelmann A, et, al. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001 Apr;297(1):267-79. |
| 4473 | Barnette MS, et, al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther. 1998 Jan;284(1):420-6. |
| 4474 | Lobson C, et al. Fate of thiamethoxam in mesocosms and response of the zooplankton community. Sci Total Environ. 2018 Oct 1;637-638:1150-1157. |
| 4475 | Ludicke JC, et al. Thiamethoxam impairs honey bee visual learning, alters decision times, and increases abnormal behaviors. Ecotoxicol Environ Saf. 2020 Apr 15;193:110367. |
| 4476 | Yan R, et al. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016 Jul 14;5:13. |
| 4477 | Scott JD, et al. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer'sDisease. Med Chem. 2016 Dec 8;59(23):10435-10450. |
| 4478 | Shepheard S, et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia. 1999 Dec;19(10):851-8. |
| 4479 | Inagaki M, et al. Naphthalenesulfonamides as calmodulin antagonists and protein kinase inhibitors. Mol Pharmacol. 1986 Jun;29(6):577-81. |
| 4480 | https://clinicaltrials.gov/ct2/show/NCT04623619?term=Levocarnitine&cond=Covid19&draw=2&rank=1 |
| 4481 | Nishida Y, et al. Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside. Agents Actions. 1979 Dec;9(5-6):549-52. |
| 4482 | Pacher P, et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114. |
| 4483 | Shapiro TA, et al. Pharmacokinetics and metabolism of allopurinol riboside. Clin Pharmacol Ther. 1991 May;49(5):506-14. |
| 4484 | Were JB, et al. Effects of probenecid on the pharmacokinetics of allopurinol riboside. Antimicrob Agents Chemother. 1993 May;37(5):1193-6. |
| 4485 | Barlaam B, Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5155-62. |
| 4486 | Agents Actions 12:684 (1982); Clin Pharmacol Ther 39:89 (1986) |
| 4487 | Neil P Grimster, et al. Optimization of a Series of Potent, Selective and Orally Bioavailable SYK Inhibitors. Bioorg Med Chem Lett. 2020 Jul 24;127433. |
| 4488 | Xin Z, et al. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4298-302. |
| 4489 | von Roemeling CA, et al. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013 May 1;19(9):2368-80. |
| 4490 | Arch Biochem Biophys 317:19 (1995); OphthalmolVis Sci 39:1888 (1998) |
| 4491 | Walsh, S.W., Y. Wang, and A. Killian, AA-2414, an antioxidant and thromboxane receptor blocker, completely inhibits peroxide-induced vasoconstriction in the human placenta. J Pharmacol Exp Ther, 1999. 290(1): p. 220-6. |
| 4492 | Hunt DW, et al. Inhibition of Sebum Production with the Acetyl Coenzyme A Carboxylase Inhibitor OlumacostatGlasaretil. J Invest Dermatol. 2017 Mar 1. pii: S0022-202X(17)30186-0. |
| 4493 | Bissonnette R, et al. Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study. J Am Acad Dermatol. 2017 Jan;76(1):33-39. |
| 4494 | J Ocular Pharmacol Therapeut 23: 280 (2007) |
| 4495 | Ratni H, et al. Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach. J Med Chem. 2015 Mar 12;58(5):2275-89. |
| 4496 | Sini P, et al. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases. Mol Cancer Ther. 2016 Oct;15(10):2388-2398. |
| 4497 | LEE, Dae Yon, et al. NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME. Patent O2018212534A1 |
| 4498 | Zhang Q, et al. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med. 2012 Apr;4(4):298-312. |
| 4499 | Zhang Y, et al. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biol Ther. 2012 Aug;13(10):915-24. |
| 4500 | Nguyen D, et al. Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther. 2017 Oct;178:92-108. |
| 4501 | J Med Chem 23:973 (1980); Clin Pharmacol Ther 34:309 (1983); Am Heart J 116:473 (1988) |
| 4502 | Drexler HC. Synergistic Apoptosis Induction in Leukemic Cells by the Phosphatase Inhibitor Salubrinal and Proteasome Inhibitors. PLoS One. 2009;4(1):e4161. |
| 4503 | Hamamura K, et al. Salubrinal acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. Cell Signal. 2015 Apr;27(4):828-35. |
| 4504 | Bryant KF, et al. ICP34.5-dependent and -independent activities of salubrinal in herpes simplex virus-1 infected cells. Virology. 2008 Sep 30;379(2):197-204. |
| 4505 | Gwag BJ, et al. Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J Cereb Blood Flow Metab. 2007 Jun;27(6):1142-51. |
| 4506 | Sung IC, et, al. Neu2000, an NR2B-selective, Moderate NMDA Receptor Antagonist and Potent Spin Trapping Molecule for Stroke. Drug News Perspect. 2010 Nov; 23(9): 549-56. |
| 4507 | Nishant PV, et, al. Antioxidant Properties of Neu2000 on Mitochondrial Free Radicals and Oxidative Damage. Toxicol In Vitro. 2013 Mar; 27(2): 788-97. |
| 4508 | Nishant PV, et, al. Antioxidant Properties of Neu2000 on Mitochondrial Free Radicals and Oxidative Damage. Toxicol In Vitro. 2013 Mar; 27(2): 788-97. |
| 4509 | J Pharmacol Exper Ther 84:203, 211 (1945); Br J Opthalmol 80:549 (1946) |
| 4510 | Wang Y, et al. The discovery of a novel inhibitor of apoptotic protease activating factor-1 (Apaf-1) for ischemic heart: synthesis, activity and target identification. Sci Rep. 2016 Jul 22;6:29820. |
| 4511 | Cao, Xin, et al. Preparation of the retinoid compound and their application as anticancer agents. WO2017152725A1. |
| 4512 | Prahalada S, et al. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration. Horm Metab Res. 1999 Feb-Mar;31(2-3):133-7. |
| 4513 | Zheng H, et al. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol Endocrinol. 1997 Oct;11(11):1709-17. |
| 4514 | Hickey GJ, et al. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles. J Endocrinol. 1997 Feb;152(2):183-92. |
| 4515 | Jacks T, et al. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology. 1996 Dec;137(12):5284-9. |
| 4516 | Prog Chem Org Nat Prod 43: 1 (1983) |
| 4517 | Qu D, et al. Effect of dinitolmide intercalated into Montmorillonite on E. tenella infection in chickens. Parasitol Res. 2014 Mar;113(3):1233-8. |J. Appl. Anim. Res. (1995), 7(2), 153-9; Parasitology (1981), 83(2), 281-4; J. Parasitol. (1972), 58(4), 664-8 |
| 4518 | Liu Y, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012 Aug;11(8):1672-82. |
| 4519 | Anti-Infect. Agents Med. Chem. (2007), 6(2), 107-117; Bull. Chem. Soc. Jpn. (1959), 32, 81-4; J. Am. Chem. Soc. (1958), 80, 4115 |
| 4520 | Drugs Exp Clin Res 14:491 (1988); Clin Trials J 27:12 (1990) |
| 4521 | J Pharmacol Exp Ther 81:307 (1944); Am J Psychiatry 102:805 (1946); Life Sci 36:277 (1985) |
| 4522 | Patel S, et al. Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease. J Med Chem. 2017 Oct 12;60(19):8083-8102. |
| 4523 | Allegra CJ, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15;317(16):978-85. |
| 4524 | Fulton B, et al. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs. 1995 Apr;49(4):563-76. |
| 4525 | Sattler FR, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J Infect Dis. 1994 Jul;170(1):165-72. |
| 4526 | Wang F, et al. 6,2'-Dihydroxyflavone, a subtype-selective partial inverse agonist of GABAA receptor benzodiazepine site. Neuropharmacology. 2007 Sep;53(4):574-82. |
| 4527 | Wu X, et al. PAS kinase drives lipogenesis through SREBP-1 maturation. Cell Rep. 2014 Jul 10;8(1):242-55. |
| 4528 | Larsen PJ, et al. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol. 2008 Oct 31;596(1-3):173-9. |
| 4529 | Yousefi B, et al. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells. Tumour Biol. 2017 Oct;39(10):1010428317716501. |
| 4530 | Henriksen K, et al. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol. 2009 Aug 15;616(1-3):340-5. |
| 4531 | Blaya MO et al. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury.
 J Neurotrauma. 2014 Mar 1;31(5):476-86. |
| 4532 | Walker AK et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasinghippocampal neurogenesis. Mol Psychiatry. 2015 Apr;20(4):500-8. |
| 4533 | Junjie Bai, et al. The Small Molecule P7C3-A20 Exerts Neuroprotective Effects in a Hypoxic-Ischemic Encephalopathy Model via Activation of PI3K/AKT/GSK3β Signaling. Neuroscience. 2020 Jun 3;S0306-4522(20)30353-5. |
| 4534 | Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017. |
| 4535 | J S Afr Vet Assoc 50:47 (1979); Bull Environ Contam Toxicol, 42:389 (1989) |
| 4536 | Ryu CK, et al. Synthesis and antifungal evaluation of 6-hydroxy-1H-carbazole-1,4(9H)-diones. Bioorg Med Chem Lett. 2011 Jan 1;21(1):427-30. |
| 4537 | Huang Y, et al. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. J Med Chem. 2017 Mar 23;60(6):2215-2226. |
| 4538 | Li L, et al. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. PLoS One. 2017 Jan 10;12(1):e0169855. |
| 4539 | Qi W, et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat Chem Biol. 2017 Apr;13(4):381-388. |
| 4540 | Antony R Knight, et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. |
| 4541 | Jessica A. Knight, et al. Pharmacological Analysis of the Novel, Rapid, and Potent Inactivation of the Human 5-Hydroxytryptamine7 Receptor by Risperidone, 9-OH-Risperidone, and Other Inactivating Antagonists. Mol Pharmacol. 2009 Feb; 75(2): 374–380. |
| 4542 | Jun-ho Lee, et al. Metergoline inhibits the neuronal Nav1.2 voltage-dependent Na+ channels expressed in Xenopus oocytes. Acta Pharmacol Sin. 2014 Jul; 35(7): 862–868. |
| 4543 | P K Eide, et al. The behavioural response to intrathecal serotonin is changed by acute but not by repeated treatment with zimelidine or metergoline. Pharmacol Toxicol. 1991 Nov;69(5):361-4. |J. Neurosci. Res. (1981), 6(1), 1-11; Brain Res. (1980), 189(2), 449-57; Naunyn-Schmiedeberg's Arch. Pharmacol. (2004), 370(2), 114-123 |
| 4544 | Zhang, A., et al., Lacidipine attenuates apoptosis via a caspase-3 dependent pathway in human kidney cells. Cell Physiol Biochem, 2013. 32(4): p. 1040-9. |
| 4545 | van Amsterdam, F.T., et al., Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Radic Biol Med, 1992. 12(3): p. 183-7. |
| 4546 | Kamal, S.M., Possible hepatoprotective effects of lacidipine in irradiated DOCA-salt hypertensive albino rats. Pak J Biol Sci, 2013. 16(21): p. 1353-7. |
| 4547 | Clin. Immunol. (2012), 142(1), 44-48; Expert Opin. Invest. Drugs (2010), 19(12), 1603-1612; Arch. Med. Res. (2008), 39(7), 639-646 |
| 4548 | Shang X, et al. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60. |
| 4549 | Wilson RJ, et al. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol. 2006 Jun;148(3):326-39. |
| 4550 | Robertson FM, et al. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol. 2008;7(4):299-312. |
| 4551 | Parida S, et al. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model. Cancer Biol Ther. 2015;16(6):922-32. |
| 4552 | Eur J Pharmacol 41:53 (1977); Xenobiotica 11:123 (1981) |
| 4553 | Kidoikhammouan S, et al. TNP-470, a methionine aminopeptidase-2 inhibitor, inhibits cell proliferation, migration and invasion of human cholangiocarcinoma cells in vitro. Asian Pac J Cancer Prev. 2012;13 Suppl:155-60. |
| 4554 | White HM, et al. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice. Obesity (Silver Spring). 2012 Oct;20(10):2003-9. |
| 4555 | Kozikowski AP, et al. Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and LearningImpairments in a Mouse Model of Fragile X Syndrome. ACS Chem Neurosci. 2019 Mar 20;10(3):1679-1695. |
| 4556 | Hu K, et al. Alpinetin inhibits LPS-induced inflammatory mediator response by activating PPAR-γ in THP-1-derived macrophages. Eur J Pharmacol. 2013 Dec 5;721(1-3):96-102. |
| 4557 | Tan D, et al. Rhodamine B induces long nucleoplasmic bridges and other nuclear anomalies in Allium cepa root tip cells. Environ Sci Pollut Res Int. 2014 Mar;21(5):3363-70. |
| 4558 | Neurotoxic. Res. (2007), 11(3,4), 151-167; Brain Res. (1970), 24(2), 364-7; Br. J. Pharmacol. (1970), 40(4), 836-46 |
| 4559 | Coetzee WA, et al. Multiplicity of effectors of the cardioprotective agent, diazoxide. Pharmacol Ther. 2013 Nov;140(2):167-75. |
| 4560 | Virgili N, et al. K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action viaantioxidative pathway activation. PLoS One. 2013 Sep 11;8(9):e75189. |
| 4561 | Wu H, et al. Diazoxide Attenuates Postresuscitation Brain Injury in a Rat Model of Asphyxial Cardiac Arrest by Opening Mitochondrial ATP-Sensitive Potassium Channels. Biomed Res Int. 2016;2016:1253842. |
| 4562 | Chowdhury UR, et al. ATP-sensitive potassium (K(ATP)) channel openers diazoxide and nicorandil lower intraocular pressure in vivo. Invest Ophthalmol Vis Sci. 2013 Jul 22;54(7):4892-9. |Curr. Top. Med. Chem. (2006), 6(10), 1031-1047; Ann. N. Y. Acad. Sci. (1968), 150(2), 194-203; Prog. Drug Res. (1969), 13, 101-35 |
| 4563 | Zeng X, et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 2010 Oct 19;18(4):382-95. |
| 4564 | Zeng X, et al. An APC/C inhibitor stabilizes cyclin B1 by prematurely terminating ubiquitination. Nat Chem Biol. 2012 Feb 26;8(4):383-92. |
| 4565 | Toby Wise, et al. Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalised Anxiety Disorder (GAD) by BNC210, a negative allosteric modulator of α7 nAChR. |
| 4566 | Tajiri H, et al. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. Cell Rep. 2017 May 2;19(5):969-980. |
| 4567 | J. Econ. Entomol. (1967), 60(4), 1021-5; Biochem. Pharmacol. (1967), 16(7), 1183-94; J. Agric. Food Chem. (1966), 14(6), 566-72. |
| 4568 | Kopp SR, et, al. Pyrantel in small animal medicine: 30 years on. Vet J. 2008 Nov;178(2):177-84. |
| 4569 | Martin RJ, et, al. Oxantel is an N-type (methyridine and nicotine) agonist not an L-type (levamisole and pyrantel) agonist: classification of cholinergic anthelmintics in Ascaris. Int J Parasitol. 2004 Aug;34(9):1083-90. |
| 4570 | Tritten L, et, al. In vitro and in vivo efficacy of Monepantel (AAD 1566) against laboratory models of human intestinal nematode infections. PLoS Negl Trop Dis. 2011 Dec;5(12):e1457. |
| 4571 | Biochemistry 36:7706 (1997); 40:1719 (2001); Biochem Biophys Acta 1543:69 (2000); Free Radic Res 2003 37:631 (2003) |
| 4572 | Curr. Ther. Res. (1967), 9(7), 338-48; Antimicrob. Agents Chemother. (1962), 1961, 462-73; J. Am. Chem. Soc. (1961), 83, 2773-5 |
| 4573 | Br. J. Clin. Pharmacol. (1978), 5 Suppl 113S-17S; Curr. Ther. Res. (1975), 18(6), 849-54; Br. J. Pharmacol. (1974), 52(3), 431P |
| 4574 | https://clinicaltrials.gov/ct2/show/NCT04381936?term=Empagliflozin&cond=Covid19&draw=2&rank=1 |
| 4575 | Lancet ii:238 (1944); J Antimicrob Chemother 40:587 (1997) |
| 4576 | Kim YH, et al. Anti-wrinkle activity of ziyuglycoside I isolated from a Sanguisorba officinalis root extract and its application as a cosmeceutical ingredient. Biosci Biotechnol Biochem. 2008 Feb;72(2):303-11. Epub 2008 Feb 7. |
| 4577 | Zhu X, et al. Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis. Int J Mol Sci. 2016 Nov 22;17(11). pii: E1903 |
| 4578 | Drugs (1980), 19(4), 249-67; J. Int. Med. Res. (1976), 4(2), 138-43; Clin. Pharmacol. Ther. (1975), 18(5 Pt 1), 530-4 |
| 4579 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Daclatasvir&cntry=&state=&city=&dist= |
| 4580 | Nagashima S, et al. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1044-55. |
| 4581 | Chiba Y, et al. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol. 2009 Nov;41(5):516-24. |
| 4582 | J Pharmacol Exp Ther 136:226 (1962); Toxicol Appl Pharmacol 19:20 (1971) |
| 4583 | Freshness-keeping film. WO2014142218A1. |
| 4584 | Gómez-Outes A, et al. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis. 2011 Feb;5(1):33-59. |
| 4585 | Julia Prescott, et al. PCI-27483, a small molecule inhibitor of Factor VIIa, inhibits growth of BxPC3 pancreatic adenocarcinoma xenograft tumors. Cancer Research May 2008 Volume 68, Issue 9 Supplement. |
| 4586 | Cowart D, et al. A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers. J Clin Pharmacol. 2019 May;59(5):717-730. |
| 4587 | Felker GM, et al. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. Eur J Heart Fail. 2019 Aug;21(8):1022-1031. |
| 4588 | Anticancer Drugs 2009:373|Phytochemistry 19:1573 (1980) |
| 4589 | Wienen W, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98(1):155-62. |
| 4590 | Robert M. Borzilleri, et al. 4-pyridinone compounds and their use for cancer. WO/2009094417/A1. |
| 4591 | Mermerian AH, et al. Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3729-32. |
| 4592 | Huang T, et al. MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell. 2017 Dec 11;32(6):840-855.e8. |
| 4593 | Noble S, et al. Adefovir dipivoxil. Drugs. 1999;58(3):479-489. |
| 4594 | Buti M, et al. Adefovir dipivoxil. Drugs Today (Barc). 2003;39(2):127-135. |
| 4595 | Holmström TH, et al. ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity. Mol Cancer Ther. 2019 Jan;18(1):28-38. |
| 4596 | J Am Chem Soc 72: 158 (1950) |
| 4597 | Tatum PR, et al. Identification of novel SIRT2-selective inhibitors using a click chemistry approach. Bioorg Med Chem Lett. 2014 Apr 15;24(8):1871-4. |
| 4598 | Kim HW, et al. Sirtuin inhibitors, EX527 and AGK2, suppress cell migration by inhibiting HSF1 protein stability. Oncol Rep. 2016 Jan;35(1):235-42. |
| 4599 | Li Y, et al. Poly(ADP-ribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-treated microglial BV2 cells. Neurosci Lett. 2013 Jun 7;544:36-40. |
| 4600 | Zhao T, et al. Selective Inhibition of SIRT2 Improves Outcomes in a Lethal Septic Model. Curr Mol Med. 2015;15(7):634-41. |
| 4601 | Antimicrob Agents Chemother 38:1123 (1994); AIDS 10 :237 (1996); Clin Infect Dis 42:1812 (2006) |
| 4602 | Beliaev A, et al. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase.J Med Chem. 2006 Feb 9;49(3):1191-7. |
| 4603 | Stanley WC, et al. Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor. J Cardiovasc Pharmacol. 1998 Jun;31(6):963-70. |
| 4604 | Stanley WC, et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 Aug;121(8):1803-9. |
| 4605 | Sabbah HN, et al. Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. |
| 4606 | Sakamoto H, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011, 19(5), 679-690. |
| 4607 | Gadgeel S, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 Nov 1;29(11):2214-2222. |
| 4608 | Feng Y, et al. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem. 2008 Nov 13;51(21):6642-5. |
| 4609 | Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89. |
| 4610 | Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28. |
| 4611 | K Hamada, et al. Antitumor Effect of Erythromycin in Mice. Chemotherapy |Antibiot. Chemother. (1971), 17, 52-66; Tet. Lett. (1965), (11), 679-85; Antibiot. Chemother. (1952), 2, 281-3 |
| 4612 | Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400. |
| 4613 | Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72(9):2176-82. |
| 4614 | Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18(13):3571-9. |
| 4615 | Lee GT, et al. Intracrine androgen biosynthesis in renal cell carcinoma. Br J Cancer. 2017 Mar 28;116(7):937-943. |
| 4616 | A O'Donnell, et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancervolume 90, pages2317–2325 (2004) |
| 4617 | Xu X, et al. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. Mol Cancer Ther. 2016 Nov;15(11):2586-2597. |
| 4618 | Antimicrob Agents Chemother 1962:259; Tox Appl Pharmacol 8:368, 380 (1966) |
| 4619 | Liljebris C, et al. Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione. J Pharmacol Exp Ther. 2004 May;309(2):711-9. |
| 4620 | Blum G, et al. Small-molecule inhibitors of SETD8 with cellular activity. ACS Chem Biol. 2014 Nov 21;9(11):2471-8. |
| 4621 | Hwang BM, et al. Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9. BMB Rep. 2013 Nov;46(11):533-8. |
| 4622 | Zhao Y, et al. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. J Med Chem. 2018 Jul 26;61(14):6110-6120. |
| 4623 | Proc Indian Acad Sci Sect A, 24:352, 375 (1946); 25:397 (1947); J Exper Clin Cancer Res 22:581 (2003); Blood 109:5112 (2007) |
| 4624 | Watanabe NA, et al. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother. 2012 Feb;56(2):960-71. |
| 4625 | Hata K, et al. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother. 2011 Oct;55(10):4543-51. |
| 4626 | Guan NanMu, et al. Synergistic inhibition between o-phenanthroline and chloride ion on cold rolled steel corrosion in phosphoric acid. Materials Chemistry and Physics Volume 86, Issue 1, 15 July 2004, Pages 59-68. |
| 4627 | Zi-Qiang Liu, et al. The role of matrix metalloprotease (MMP) to the autolysis of sea cucumber (Stichopus japonicus). J Sci Food Agric. 2019 Oct;99(13):5752-5759. |
| 4628 | Bagal SK, et al. Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9. |
| 4629 | Gleńsk M, et al. In vitro evaluation of the antioxidant and antimicrobial activity of DIMBOA [2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one]. Nat Prod Res. 2016;30(11):1305-1308. |
| 4630 | Sasai H, et al. Species-specific glucosylation of DIMBOA in larvae of the rice Armyworm. Biosci Biotechnol Biochem. 2009;73(6):1333-1338. |
| 4631 | Phuong, T.T.T., Yamamoto, M., Fujii, T. et al. Comparison of the ability to catabolize DIMBOA, a maize antibiotic, between Ostrinia furnacalis and Ostrinia scapulalis(Lepidoptera: Crambidae), with reference to their hybrids. Appl Entomol Zool 51, 143–149 (2016). |
| 4632 | HOFFMAN, Thomas, James., et al. FUNGICIDAL COMPOSITIONS. WO 2018 219773 A1 |
| 4633 | Kamada S, et al. Caspase-4 and caspase-5, members of the ICE/CED-3 family of cysteine proteases, are CrmA-inhibitable proteases.Cell Death Differ. 1997 Aug;4(6):473-8. |
| 4634 | Yang D, et al. Sensing of cytosolic LPS through caspy2 pyrin domain mediates noncanonical inflammasome activation in zebrafish.Nat Commun. 2018 Aug 3;9(1):3052. |
| 4635 | Ferko MA, et al. Effects of metal ions on caspase-1 activation and interleukin-1β release in murine bone marrow-derived macrophages.PLoS One. 2018 Aug 23;13(8):e0199936. |
| 4636 | Newman ZL, et al. CA-074Me protection against anthrax lethal toxin.Infect Immun. 2009 Oct;77(10):4327-36. |
| 4637 | Fortschr Med 95:1108 (1977); Arch Surg 121:1272 (1986); J Pharm Sci 82:231 (1993) |
| 4638 | J Clin Pharmacol 22:264 (1982); Annals Int Med 103:307 (1985) |
| 4639 | Gao C, et al. Rational design and validation of a Tip60 histone acetyltransferase inhibitor. Sci Rep. 2014 Jun 20;4:5372. |
| 4640 | https://clinicaltrials.gov/ct2/show/NCT04952350?term=Atorvastatin&cond=Covid19&draw=2&rank=2 |
| 4641 | Brigandi RA, et al. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. Am J Kidney Dis. 2016 Jun;67(6):861-71 |
| 4642 | Hara K, et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8 |
| 4643 | M R Hellberg, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001 Oct;17(5):421-32. |
| 4644 | Anal Profiles Drug Subs 2:145 (1973) |
| 4645 | Cheng D et al. Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors. ACS Med Chem Lett. 2016 May 10;7(7):676-80. |
| 4646 | Badiola KA, et al. Efficient Synthesis and Anti-Tubercular Activity of a Series of Spirocycles: An Exercise in OpenScience. PLoS One. 2014 Dec 10;9(12):e111782. |
| 4647 | Burger T, et al. Solamargine, a bioactive steroidal alkaloid isolated from Solanum aculeastrum induces non-selective cytotoxicity and P-glycoprotein inhibition. BMC Complement Altern Med. 2018 May 2;18(1):137. |
| 4648 | Sani IK, et al. Solamargine inhibits migration and invasion of human hepatocellular carcinoma cells through down-regulation of matrix metalloproteinases 2 and 9 expression and activity. Toxicol In Vitro. 2015 Aug;29(5):893-900. |
| 4649 | Ding X, et al. Induction of apoptosis in human hepatoma SMMC-7721 cells by solamargine from Solanum nigrum L. J Ethnopharmacol. 2012 Jan 31;139(2):599-604. |
| 4650 | Fu R, et al. Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway. Int J Oncol. 2019 May;54(5):1545-1554. |
| 4651 | Choi ES, et al. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. Sci Rep. 2014 Nov 24;4:7162. |
| 4652 | Vial G, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrialfunction in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015 Jun;64(6):2254-64. |
| 4653 | Detaille D, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072. |
| 4654 | J. Reprod. Med. (1990), 35(1 Suppl), 69-74; Drugs (1980), 19(5), 362-9; Fertil. Steril. (1971), 22(1), 9-18 |
| 4655 | Osborne JD, et al. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). J Med Chem. 2016 Jun 9;59(11):5221-37. |
| 4656 | Walton MI, et al. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma. |
| 4657 | Clin. Endocrinol. (1978), 9(4), 297-302; Br. J. Obstet. Gynaecol. (1980), 87(8), 718-25; Endocrinology (1961), 68, 327-33 |
| 4658 | Kawasaki M, et al. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspaseinhibitor. Am J Pathol. 2000 Aug;157(2):597-603. |
| 4659 | Park S, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke. 2004 Oct;35(10):2412-7. |
| 4660 | Ilangovan R, et al. Inhibition of apoptosis by Z-VAD-fmk in SMN-depleted S2 cells. J Biol Chem. 2003 Aug 15;278(33):30993-9. |
| 4661 | Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett. 2012 Jun 15;22(12):3900-4. |
| 4662 | Bulut G, et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 2012 Jan 19;31(3):269-81. |
| 4663 | Çelik H, et al. Ezrin Inhibition Up-regulates Stress Response Gene Expression. J Biol Chem. 2016 Jun 17;291(25):13257-70. |
| 4664 | http://arianeurosciences.com/science.html |
| 4665 | Planta Med 63:199 (1997) |
| 4666 | Phytochemistry 11:881 (1972); J Nat Prod 47:179 (1981); BMC Med Genomics 1:7 (2008) |
| 4667 | J Indian Chem Soc 28: 225 (1951); 30: 705 (1953); Aust J Chem 9: 111 (1956); 25: 2251 (1972); J Chem Soc 1965: 2239 |
| 4668 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=CHOLECALCIFEROL&cntry=&state=&city=&dist= |
| 4669 | Knychalska-Karwan Z, et al. Multifungin in the treatment of oral candidiasis. Czas Stomatol. 1983 Apr;36(4):313-5. |
| 4670 | I. A. EI-Kady, et al. Effect of Four Pesticides on Aflatoxin Production by Aspergillus flavus IMI89717. Zentralbl. Mikrobiol. 148 (1993),549-557. |
| 4671 | Li Y, et al. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis TargetingChimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable TumorRegression. J Med Chem. 2019 Jan 24;62(2):448-466 |
| 4672 | Isabel Santos, et al. Urogenital Disorders Associated With Oestrogen Deficiency: The Role of Promestriene as Topical Oestrogen Therapy. Gynecol Endocrinol. 2010 Sep;26(9):644-51. |
| 4673 | Lino Del Pup, et al. Promestriene, a Specific Topic Estrogen. Review of 40 Years of Vaginal Atrophy Treatment: Is It Safe Even in Cancer Patients. Anticancer Drugs. 2013 Nov;24(10):989-98. |
| 4674 | AJO Almodovar, et al. Abstract P5-05-07: Promestriene effects on estrogen-sensitive breast cancer cell proliferation in vitro. Cancer Res 2013;73(24 Suppl): Abstract nr P5-05-07. |
| 4675 | De Vry J et al. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novelcannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther. 2004 Aug;310(2):620-32. |
| 4676 | Phytochemistry 4: 127 (1965) |
| 4677 | Fugner, A., et al., In vitro and in vivo studies of the non-sedating antihistamine epinastine. Arzneimittelforschung, 1988. 38(10): p. 1446-53. |
| 4678 | Roeder, T., J. Degen, and M. Gewecke, Epinastine, a highly specific antagonist of insect neuronal octopamine receptors. Eur J Pharmacol, 1998. 349(2-3): p. 171-7. |
| 4679 | Kamei, C., et al., Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol, 1992. 14(1-2): p. 191-205. |
| 4680 | Kohyama, T., et al., A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun, 1997. 230(1): p. 125-8. |
| 4681 | Ohkubo S, et al. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. Mol Cancer Ther. 2015 Jan;14(1):14-22. |
| 4682 | Suzuki R, et al. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with PS-341 in multiple myeloma. Leukemia. 2015 Feb;29(2):510-4. |
| 4683 | Utsugi T. New challenges and inspired answers for anticancer drug discovery and development. Jpn J Clin Oncol. 2013 Oct;43(10):945-53. |
| 4684 | Pharmacotherapy (2003), 23(12), 1573-91; J. Med. Chem. (1967), 10(3), 446-51; Fertil. Steril. (1967), 18(2), 238-56 |
| 4685 | Khazak V, et al. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. |
| 4686 | Lau KS, et al. BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner. PLoS One. 2012;7(7):e41343. |
| 4687 | Nakashima T, et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res. 2010 May 15;16(10):2792-802. |
| 4688 | Pharmacotherapy 2:266 (1982); Drugs 25:544 (1983) |
| 4689 | Bibian M, et al. Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett. 2013 Aug 1;23(15):4374-80. |
| 4690 | Rosenberg LH, et al. Therapeutic targeting of casein kinase 1δ in breast cancer. Sci Transl Med. 2015 Dec 16;7(318):318ra202. |
| 4691 | Haftchenary S, et al. Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. ACS Med Chem Lett. 2013 Sep 8;4(11):1102-1107. |
| 4692 | Thappali SR, et al. Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.Sci Pharm. 2012 Jul-Sep;80(3):633-46. |
| 4693 | Reed NI, et al. Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors. ACS Med Chem Lett. 2016 Aug 30;7(10):902-907. |
| 4694 | Kulkarni JA, et al. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine. 2017 May;13(4):1377-1387. |
| 4695 | Vendetti FP, et al. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of CDDP to resolve ATM-deficient non-small cell lung cancer in vivo. |
| 4696 | Kim HJ, et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int J Cancer. 2017 Jan 1;140(1):109-119. |
| 4697 | Jorda R, et al. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?. J Med Chem. 2018;61(20):9105-9120. |
| 4698 | Han HW, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent. Sci Rep. 2018;8(1):14969. Published 2018 Oct 8. |
| 4699 | Stanetty P, et al. Novel and efficient access to phenylamino-pyrimidine type protein kinase C inhibitors utilizing a Negishi cross-coupling strategy. J Org Chem. 2005;70(13):5215-5220. |
| 4700 | Tornatore L, et al. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7inhibitor and clinical candidate, DTP3. Toxicol Rep. 2019 Apr 19;6:369-379. |
| 4701 | Tornatore L, et al. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. Cancer Cell. 2014 Oct 13;26(4):495-508. |
| 4702 | De Moliner E, et al. Alternative binding modes of an inhibitor to two different kinases. Eur J Biochem. 2003 Aug;270(15):3174-81. |
| 4703 | Orzechowska E, et al. Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability. Oncol Rep. 2012 Jan;27(1):281-5. |
| 4704 | Sarno S, et al. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 2001 May 4;496(1):44-8. |
| 4705 | Ljubimov AV, et al. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4583-91. |
| 4706 | Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415(3):353-65. |
| 4707 | Chen Z, et al. CK2α promotes advanced glycation end products-induced expressions of fibronectin and intercellular adhesion molecule-1 via activating MRTF-A in glomerular mesangial cells. Biochem Pharmacol. 2017 Dec 6;148:41-51. |
| 4708 | Tari LW, et al. Structural basis for the inhibition of Aurora A kinase by a novel class of high affinitydisubstituted pyrimidine inhibitors. Bioorg Med Chem Lett. 2007 Feb 1;17(3):688-91. |
| 4709 | Arch Opthamol 81:184 (1969) |
| 4710 | De Lucca GV, et al. Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177). J Med Chem. 2016 Sep 8;59(17):7915-35. |
| 4711 | https://clinicaltrials.gov/ct2/show/NCT04517396?term=FENOFIBRATE&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04661930?term=FENOFIBRATE&cond=Covid19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=PER-099-20 |
| 4712 | Cecile M. Krejsa. Methods of Using BTK Inhibitors to Treat Dermatoses. US 20170224688 A1. |
| 4713 | Toxicol Appl Pharmacol 14:515 (1969); IARC Monographs 30:183 (1983) |
| 4714 | Shiv K, et al. Abstract 4112: Synthetic luciferin, CycLuc1, improves bioluminescence imaging for intracranial glioblastoma xenografts. 10.1158/1538-7445.AM2018-4112 |
| 4715 | Chem & Ind 1956:1091;Chem Pharm Bull 35:1319 (1987}; Naunyn-Schmiedberg Arch Pharmacol 345:349 (1992} |
| 4716 | Antimicrob Agents Chemother 1968:353, 361, 489; Post Grad Med J 59 Suppl 5:1 (1983) |
| 4717 | Pettipher R, Vinall SL, Xue L, Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther. 2012 Feb;340(2):473-82. |
| 4718 | Vazquez ML, et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. J Med Chem. 2018 Feb 8;61(3):1130-1152. |
| 4719 | O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412. |
| 4720 | Gozgit JM, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther, 2011, 10(6), 1028-1035. |
| 4721 | Uchida T, et al. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Exp Hematol. 2014 May;42(5):369-379.e3. |
| 4722 | Chem Pharm Bull 13:385 (1965); J Chem Soc 1965:2290; Phytochem 13:2315 (1974) |
| 4723 | Arzneim Forsch 6:61 (1956); Antibiot Chemother 7:374 (1957) |
| 4724 | Nature 170:460 (1952); Plant Physiol 90:988 (1989); In Vitro Cell Develop Biology-Plant 30P:124 (1994) |
| 4725 | Lovmar M, et al. Kinetics of macrolide action: the Josamycin and erythromycin cases. J Biol Chem. 2004 Dec 17;279(51):53506-15. |
| 4726 | Osono T, et al. Pharmacokinetics of macrolides, lincosamides and streptogramins. J Antimicrob Chemother. 1985 Jul;16 Suppl A:151-66. |
| 4727 | Su C, et al. Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis. Biomed Pharmacother. 2017 Apr;88:521-528. |
| 4728 | Li M, et al. Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway. Oncol Lett. 2018 Oct;16(4):5006-5012. |
| 4729 | Bustamante JM, et al. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Int J Antimicrob Agents. 2007 Jun;29(6):733-7. |
| 4730 | Luna KP, et al. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomedica. 2009 Sep;29(3):448-55. |
| 4731 | Ann. Med. (1993), 25(2), 155-60; Clin. Pharmacol. Ther. (1966), 7(4), 490-500; Steroids (1963), 2(3), 319-35 |
| 4732 | Zhang L, et al. Design, synthesis and bioevaluation of 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxylic acid derivatives as potent neuroprotective agents. Eur J Med Chem. 2018 May 10;151:27-38. |
| 4733 | Kirchgessner TG, et al. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates. J Pharmacol Exp Ther. 2015 Feb;352(2):305-14. |
| 4734 | Kick E, et al. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ. Bioorg Med Chem Lett. 2015 Jan 15;25(2):372-7. |
| 4735 | Sudbeck EA, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999 Jun;5(6):1569-82. |
| 4736 | Tibbles HE, et al. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem. 2001 May 25;276(21):17815-22. |
| 4737 | https://clinicaltrials.gov/ct2/show/NCT05007522?term=INDOMETHACIN&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04344457?term=INDOMETHACIN&cond=Covid19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200427047215N1 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/05/033544 |
| 4738 | Bergeron RJ, et al. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles. J Med Chem. 2012 Aug 23;55(16):7090-103. |
| 4739 | Liu H, et al. SKF-96365 blocks human ether-à-go-go-related gene potassium channels stably expressed in HEK 293 cells. Pharmacological Research. Pharmacol Res, 2016 Feb, 104:61-9. |
| 4740 | Jing Z, et al. SKF-96365 activates cytoprotective autophagy to delay apoptosis in colorectal cancer cells through inhibition of the calcium/CaMKIIγ/AKT-mediated pathway. Cancer Lett, 2016 Mar 28, 372(2):226-38. |
| 4741 | Susan LaGreca, et al. Identification of selective, orally active Tie2 kinase inhibitors and discovery of CE-245,677 and PF-371,989. Cancer Research. AACR Annual Meeting-Apr 14-18, 2007. |
| 4742 | Hurst RS, et al. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci, 2005, 25(17), 4396-4405. |
| 4743 | Barron SC, et al. An allosteric modulator of alpha7 nicotinic receptors, N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea (PNU-120596), causes conformational changes in the extracellular ligand binding domain similar to those caused by acetylcholine. Mol Pharmacol, 2009 76(2), 253-263. |
| 4744 | Munro G, et al. The α7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat. Br J Pharmacol, 2012, doi: 10.1111/j.1476-5381.2012.02003.x |
| 4745 | Dimitrios C Mastellos, et al. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018 Jul;55(3):167-175. |
| 4746 | Anna Schubart, et al. Small-molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931. |
| 4747 | Nello Mainolfi, et al. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722. |
| 4748 | Grottelli S, et al. The Role of Cyclo(His-Pro) in Neurodegeneration. Int J Mol Sci. 2016 Aug 12;17(8). pii: E1332. |
| 4749 | Minelli A, et al. Cyclo(His-Pro) exerts anti-inflammatory effects by modulating NF-κB and Nrf2 signalling. Int J Biochem Cell Biol. 2012 Mar;44(3):525-35. |
| 4750 | Bellezza I, et al. Neuroinflammation and endoplasmic reticulum stress are coregulated by cyclo(His-Pro) to prevent LPS neurotoxicity. Int J Biochem Cell Biol. 2014 Jun;51:159-69. |
| 4751 | J Econ Entomol 59:1450 (1966) |
| 4752 | https://clinicaltrials.gov/ct2/show/NCT04622865?term=Masitinib&cond=covid-19&draw=2&rank=2 |
| 4753 | Biopharmaceut Drug Dispo 20:301–308 (1999); J Am Acad Dermatol 42,:459 (2000)|Biopharmaceut Drug Dispo 20:301-308 (1999); J Am Acad Dermatol 42,:459 (2000) |
| 4754 | Curr Med Res Opin21:71 (2005); Drugs 66:175 (2006) |
| 4755 | Martinson EA, et al. Inhibition of phospholipase D of human platelets by protein tyrosine kinase inhibitors. Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):627-34. |
| 4756 | Blake RA, et al. Fc gamma receptor II stimulated formation of inositol phosphates in human platelets is blocked by tyrosine kinase inhibitors and associated with tyrosine phosphorylation of the receptor. |
| 4757 | Uings IJ, et al. Tyrosine phosphorylation is involved in receptor coupling to phospholipase D but not phospholipase C in the human neutrophil. Biochem J. 1992 Feb 1;281 (Pt 3):597-600. |
| 4758 | Hideshima T et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18, 23(54), 8766-76. |
| 4759 | Vanderkerken K et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease,reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007 May 15;67(10):4572-7. |
| 4760 | Navas T, et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma. 2008 Oct;49(10):1963-75. |
| 4761 | Medicherla S, et al. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res. 2008 Nov-Dec;28(6A):3827-33. |
| 4762 | Arch Int Pharmacodyn Ther 166:238 (1967); 188:401 (1970); Arzneim Forsch 30:1947 (1980) |
| 4763 | Aust J Chem 41: 1755 (1988) |
| 4764 | Chem Pharm Bull 1:119 (1959); Cancer Res 12:2550 (1998); Mutat Res 480:201 (2001) |
| 4765 | Thomas J. Nelson, et al. Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases. WO2015058191A1. |
| 4766 | Br J Pharmacol 98:1091 (1989); J Neurosrg 76:571 (1992); Cardiovasc Drug Rev 10:333 (1992) |
| 4767 | Contact Dermatitis 6:222 (1980); Acta Derm Venereol 79:211 (1999) |
| 4768 | Biochem Pharmacol 11:674 (1962); 019:911 (1970); Eur J Cancer 8:85 (1972) |
| 4769 | Cheng K, et al. Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists. Sci Adv. 2015;1(3). pii: e1400139. |
| 4770 | Ber 32:326 {1899}; 59:2918 {1926}; J Org Chem 27:381 {1962}; Biochem Pharmacol 79:1337 (2010) |
| 4771 | Malecka KA, et al. Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chem Biol. 2014 Jul 18;9(7):1603-12. |
| 4772 | Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48. |
| 4773 | Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility.December 2009Volume 201, Issue 6, Supplement, Pages S182-S183. |
| 4774 | Liu C, et al. G-Protein-Coupled Estrogen Receptor Antagonist G15 Decreases Estrogen-Induced Development of Non-Small Cell Lung Cancer. Oncol Res. 2019 Feb 21;27(3):283-292 |
| 4775 | Girgert R, et al. Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER. Front Endocrinol (Lausanne). 2019 Jan 9;9:781. |
| 4776 | Duffy MJ, et al. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017 Sep;83:258-265. |
| 4777 | Salim KY, et al. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget. 2016 Jul 5;7(27):41363-41379. |
| 4778 | Lindemann A, et al. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clin Cancer Res. 2019 Sep 15;25(18):5650-5662. |
| 4779 | Elgogary A, et al. Combination therapy with BPTES nanoparticles and targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5328-36. |
| 4780 | Meghan J. Seltzer, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15; 70(22): 8981-8987. |
| 4781 | Lee JS, et al. Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC. Biochem Biophys Res Commun. 2016 Aug 26;477(3):374-82 |
| 4782 | Lee JS, et al. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. Cell Death Dis. 2016 Dec 8;7(12):e2511. |
| 4783 | Anthony L Luz,et al. The High-Production Volume Fungicide Pyraclostrobin Induces Triglyceride Accumulation Associated With Mitochondrial Dysfunction, and Promotes Adipocyte Differentiation Independent of PPARγ Activation, in 3T3-L1 Cells. 2018 Jan 15;393:150-159. |
| 4784 | Alexander H Tuttle, et al.Choice of Vehicle Affects Pyraclostrobin Toxicity in Mice.Chemosphere. 2019 Mar;218:501-506. |
| 4785 | Guzmán-Gutiérrez SL, et al. Linalool and β-pinene exert their antidepressant-like activity through the monoaminergic pathway. Life Sci. 2015 May 1;128:24-9. |
| 4786 | Yang Z , et al. Comparative anti-infectious bronchitis virus (IBV) activity of (-)-pinene: effect on nucleocapsid (N) protein. Molecules. 2011 Jan 25;16(2):1044-54. |
| 4787 | Vats S, et al. A reversible autophagy inhibitor blocks autophagosome-lysosome fusion by preventing Stx17 loading onto autophagosomes. Mol Biol Cell. 2019 Aug 1;30(17):2283-2295. |
| 4788 | Anesth Analg Reanimat 14:225 (1957); Toxicol Appl Pharmacol 1:454 (1959); Anesth Analg 38:265 (1959) |
| 4789 | Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and IR. Future Med Chem. 2009 Sep;1(6):1153-71. |
| 4790 | McKinley ET, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011 May 15;17(10):3332-40. |
| 4791 | Li W, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015 Apr 15;8(4):6563-7. |
| 4792 | Li W, et al. Effect of Chelerythrine Against Endotoxic Shock in Mice and Its Modulation of Inflammatory Mediators in Peritoneal Macrophages Through the Modulation of Mitogen-Activated Protein Kinase (MAPK) Pathway. Inflammation. 2012 Jul 24. |
| 4793 | Pencikova K, et al. Investigation of sanguinarine and chelerythrine effects on LPS-induced inflammatory gene expression in THP-1 cell line. Phytomedicine. 2012 Jul 15;19(10):890-5. Epub 2012 May 14. |
| 4794 | Chen XM, et al. Chelerythrine chloride induces apoptosis in renal cancer HEK-293 and SW-839 cell lines. Oncol Lett. 2016 Jun;11(6):3917-3924 |
| 4795 | Herbert JM, et al. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990 Nov 15;172(3):993-9. |
| 4796 | Chan SL, et al.Identification of chelerythrine as an inhibitor of BclXL function.J Biol Chem. 2003 Jun 6;278(23):20453-6. |
| 4797 | Tang ZH, et al.Induction of reactive oxygen species-stimulated distinctive autophagy by chelerythrine in non-small cell lung cancer cells.Redox Biol. 2017 Aug;12:367-376. |
| 4798 | Brunschwig C, et al. UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00012-18. |
| 4799 | Suresh PS, et al. Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer. Biomed Chromatogr. 2017 Jun 21. |
| 4800 | Behrendt HJ, et al. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. |
| 4801 | Sumoylation inhibitor TAK-981. |
| 4802 | TAK-981. |
| 4803 | Zehentbauer FM, et al. Fluorescence spectroscopy of Rhodamine 6G: concentration and solvent effects. Spectrochim Acta A Mol Biomol Spectrosc. 2014;121:147-51. |
| 4804 | Kutushov M, et al. Low concentrations of Rhodamine 6G selectively destroy tumor cells and improve survival of melanoma transplanted mice. Neoplasma. 2013;60(3):262-73. |
| 4805 | Jain RK, et al. Measuring leukocyte-endothelial interactions in mice. Cold Spring Harb Protoc. 2013 Jun 1;2013(6):561-3. |
| 4806 | Nakamura A, et al. Inhibition of GCN2 sensitizes ASNS-low cancer cells by disrupting the amino acid response. Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7776-E7785. |
| 4807 | Matheny CJ, et al. Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Chem Biol. 2013 Nov 21;20(11):1352-63. |
| 4808 | Dai Y, et al. Effect of pinaverium bromide on stress-induced colonic smooth muscle contractility disorder in rats. World J Gastroenterol. 2003 Mar;9(3):557-61. |
| 4809 | Am J Nursing 62:24 (1962); Toxicol Appl Pharmacol 74:293 (1984) |
| 4810 | Nature 173:71, 72 (1954); Cancer 10:889 (0157); Histochem Cell Biol 119:405 (2003) |
| 4811 | Palmer WS, et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem. 2016 Feb 25;59(4):1440-54. |
| 4812 | Long-Sheng Chang, et al. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar;19(3):731-741. |
| 4813 | Long-Sheng Chang, et al. Abstract 1950: The eIF4A inhibitors didesmethylrocaglamide and rocaglamide as effective treatments for pediatric bone and soft-tissue sarcomas. Cancer Res 2020;80(16 Suppl):Abstract nr 1950. |
| 4814 | Song X, et al. Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A. 2016 May 3;113(18):4970-5. |
| 4815 | Murakami M, et al. Cefcapene Pivoxil Hydrochloride Is a Potentially New Treatment for Palmoplantar Pustulosis with Pustulotic Arthro-Osteitis.Dermatology. 2015;231(4):304-11. |
| 4816 | Kawada A, et al. Drug eruption induced by cefcapene pivoxil hydrochloride.Contact Dermatitis. 2001 Mar;44(3):197. |
| 4817 | Sekiya Y, et al. Comparative efficacies of different antibiotic treatments to eradicate nontypeable Haemophilus influenzae infection.BMC Infect Dis. 2008 Feb 7;8:15. |
| 4818 | Anauate MC, et al. Effect of isolated fractions of Harpagophytum procumbens D.C. (devil's claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay. Phytother Res. 2010 Sep;24(9):1365-9. |
| 4819 | Bishop A C, et al. Generation of Monospecific Nanomolar Tyrosine Kinase Inhibitors via a Chemical Genetic Approach. Journal of the American Chemical Society, 1999, 121(4):627-631. |
| 4820 | Bishop AC, et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature. 2000 Sep 21;407(6802):395-401. |
| 4821 | Larochelle S, et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell. 2007 Mar 23;25(6):839-50. |
| 4822 | Honda A, et al. Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo. ACS Med Chem Lett. 2015 Nov 13;7(1):72-6. |
| 4823 | Dowdle WE, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol. 2014 Nov;16(11):1069-79. |
| 4824 | Jackson KJ, et al. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
 Psychopharmacology (Berl). 2010 Jun;210(2):285-94. |
| 4825 | Schank JR, et al. 
The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.
 Addict Biol. 2012 May;17(3):634-47. doi: 10.1111/j.1369-1600.2012.00455.x. |
| 4826 | Beardsley PM, et al. 
Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce |
| 4827 | De SK, et al. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem. 2009 Apr 9;52(7):1943-52. |
| 4828 | Augustine C, et al. Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro. Neuroscience. 2014 Aug 22;274:1-10. |
| 4829 | Serizawa F, et al. Pretreatment of human cerebrovascular endothelial cells with CO-releasing molecule-3 interferes with JNK/AP-1 signaling and suppresses LPS-induced proadhesive phenotype. Microcirculation. 2015 Jan;22(1):28-36. |
| 4830 | Cox L, et al. Levomepromazine for nausea and vomiting in palliative care. Cochrane Database Syst Rev. 2015 Nov 2;(11):CD009420. |
| 4831 | Sivaraman P, et al. Levomepromazine for schizophrenia. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD007779. |
| 4832 | JAMA 80:1617 (1923); Br J Clin Pharmacol 25:261 (1988); Indian J Pediatrics 59:646 (1992) |
| 4833 | Steggerda SM, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017 Dec 19;5(1):101. |
| 4834 | Environ Health Perspect 49:81 (1983) |
| 4835 | Yuyama H, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498(1-3):171-7. |
| 4836 | Banerjee S, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 combination in prostate cancer. Cancer Res. 2007 Apr 15;67(8):3818-26. |
| 4837 | Weiss J, et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol. 2011 Oct;68(4):1093-8. |
| 4838 | Biomed Res 22:103 (2001); Proc 12th Int Lupin Conf Sept 14 (2008) |
| 4839 | Alam A, et al. SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol Cancer Ther. 2012 Aug;11(8):1637-49. |
| 4840 | G.G. Allan, et al. The 18α-epimer of α-boswellic acid: conformational diagnosis of triterpenoids by ultraviolet absorption spectroscopy. Phytochemistry
 Volume 10, Issue 6, June 1971, Pages 1363–1366 |
| 4841 | Glennon JC, et al. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse. 2006 Dec 15;60(8):599-608. |
| 4842 | Jones CA, et al. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. Eur Neuropsychopharmacol. 2010 Aug;20(8):582-593. |
| 4843 | https://clinicaltrials.gov/ct2/show/NCT04389580?term=Tamoxifen&cond=covid&draw=2&rank=2 |
| 4844 | Wu Y, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. |
| 4845 | Linerixibat (GSK2330672) granted Orphan Status. September 24, 2019. |
| 4846 | Wang Y, et al. HNF4α Regulates CSAD to Couple Hepatic Taurine Production to Bile Acid Synthesis in Mice. Gene Expr. 2018 Aug 22;18(3):187-196. |
| 4847 | Xie XQ, et al. Discovery of novel INK4C small-molecule inhibitors to promote human and murine hematopoietic stem cell ex vivo expansion. Sci Rep. 2015 Dec 18;5:18115. |
| 4848 | Joy L Nishikawa, et al.Inhibiting fungal multidrug resistance by disrupting an activator-Mediator interaction. Nature. 2016 Feb 25;530(7591):485-9. |
| 4849 | Clin Radiol 33:231 (1982); Anal Profiles Drug Subst 17:115 (1988)| |
| 4850 | Longo DL, et, al. Iopamidol as a responsive MRI-chemical exchange saturation transfer contrast agent for pH mapping of kidneys: In vivo studies in mice at 7 T. Magn Reson Med. 2011 Jan;65(1):202-11. | |
| 4851 | James F Hainfeld, et al. Small, Long Blood Half-Life Iodine Nanoparticle for Vascular and Tumor Imaging. Sci Rep |
| 4852 | Shuai Chen, et al. Metabolomic analysis of the toxic effect of chronic exposure of cadmium on rat urine. Environ Sci Pollut Res Int. 2018 Feb;25(4):3765-3774. |
| 4853 | M Sato, et al. Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I). Teratology. 1995 Sep;52(3):143-8. |
| 4854 | Katharine L Sackton, et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature. 2014 Oct 30;514(7524):646-9. |
| 4855 | Katherine V Richeson, et al. Paradoxical mitotic exit induced by a small molecule inhibitor of APC/C Cdc20. Nat Chem Biol. 2020 May;16(5):546-555. |
| 4856 | Susanne Lub, et al. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget. 2016 Jan 26;7(4):4062-76. |
| 4857 | Eur. J. Contracept. Reprod. Health Care (2004), 9(3), 182-193; Obstet. Gynecol. (2005), 105(5 Pt 1), 1128-35; Ann. N. Y. Acad. Sci. (1958), 71, 560-71 |
| 4858 | Chuang SH, et al. Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy. Eur J Med Chem. 2020 Apr 1;191:112118. |
| 4859 | Biochem Pharmacol 30: 1105 (1981) |
| 4860 | Koteswari LL, et al. A comparative anticancer study on procyanidin C1 against receptor positive and receptor negative breast cancer. Nat Prod Res. 2019 Jan 8:1-8. |
| 4861 | Am J Vet Res 65:503 (2004) |
| 4862 | Atsuo Tahara, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):423-36. |
| 4863 | Shiho Komatsu, et al. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J. 2020 Jan 28;67(1):99-106. |
| 4864 | Emma Budd, et al. 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors. US 7998990 B2. |
| 4865 | Smith PF, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017 Nov;83(11):2367-2376. |
| 4866 | Hill RJ, Bradshaw JM, Bisconte A, Tam D, Owens TD, Brameld KA, Smith PF, Funk JO, Goldstein DM, Nunn PA. Preclinical Characterization of PRN1008, a Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a RAT Model of Collagen-Induced Arthritis. Annals of the Rheumatic Diseases 2015; 74(Suppl 2): 216. |
| 4867 | Sakoguchi H, et al. Growth inhibitory effect of D-arabinose against the nematode Caenorhabditis elegans: Discovery of a novel bioactive monosaccharide. Bioorg Med Chem Lett. 2016 Feb 1;26(3):726-729. |
| 4868 | Rutkowski B, et al. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Kidney Int Suppl. 2003 May;(84):S19-21. |
| 4869 | Foote KM, et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013 Mar 14 |
| 4870 | Kikuchi A, et al. In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).Invest New Drugs. 2014 Oct;32(5):860-70. |
| 4871 | Lancet 344:1724 (1994); J Pesticide Reform 23:(2):10 (2003) |
| 4872 | Quintieri L, et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res. 2005 Feb 15;11(4):1608-17. |
| 4873 | Cazzamalli S, et al. Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma. Mol Cancer Ther. 2016 Dec;15(12):2926-2935. |
| 4874 | Pengxuan Zhao, et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020 Sep;10(9):1589-1600. |
| 4875 | Joanne Lundy, Interim data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α-galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer. GASTROINTESTINAL CANCER—GASTROESOPHAGEAL, PANCREATIC, AND HEPATOBILIARY |
| 4876 | Chung PY, et al. Identification, by gene expression profiling analysis, of novel gene targets in Staphylococcus aureus treated with betulinaldehyde. Res Microbiol. 2013 May;164(4):319-26. |
| 4877 | Chung PY, et al. Transcriptional profiles of the response of methicillin-resistant Staphylococcus aureus to pentacyclic triterpenoids. PLoS One. 2013;8(2):e56687. |
| 4878 | J Biol Chem 277:12824 (2002); Am J Trop Med Hyg 74:457 (2006) |
| 4879 | https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200412047042N1 |
| 4880 | JM Watts, et al. A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). |
| 4881 | Justin A. Caravella, et al. Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020. |
| 4882 | Am. J. Physiol. (1991), 261(3 Pt 2), F452-8; Am. J. Cardiol. (1960), 5, 402-6; Acta Pharmacol. Toxicol. (1959), 15, 265-74 |
| 4883 | Catarinella M, et al. BTB-1: a small molecule inhibitor of the mitotic motor protein Kif18A. Angew Chem Int Ed Engl. 2009;48(48):9072-6. |
| 4884 | Braun J, et al. Synthesis and biological evaluation of optimized inhibitors of the mitotic kinesin Kif18A. ACS Chem Biol. 2015 Feb 20;10(2):554-60. |
| 4885 | Semwal RB, et al. Gingerols and shogaols: Important nutraceutical principles from ginger. Phytochemistry. 2015 Sep;117:554-68. |
| 4886 | Peng F, et al. Cytotoxic, cytoprotective and antioxidant effects of isolated phenolic compounds from fresh ginger. Fitoterapia. 2012 Apr;83(3):568-85. |
| 4887 | Sang S, et al. Increased growth inhibitory effects on human cancer cells and anti-inflammatory potency of shogaols from Zingiber officinale relative to gingerols. J Agric Food Chem. 2009 Nov 25;57(22):10645-50. |
| 4888 | Bak MJ, et al. 6-shogaol-rich extract from ginger up-regulated the antioxidant defense systems in cells and mice. Molecules. 2012 Jul 4;17(7):8037-55. |
| 4889 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=RIBOFLAVIN&cntry=&state=&city=&dist=&Search=Search |
| 4890 | Satoshi Nakanishi. et al. MS-444, a new inhibitor of myosin light chain kinase from <i>Micromonosporasp</i>.KY7123. The Journal Of Antibiotics. 1995,48(9):948-951. |
| 4891 | Fernando F. Blanco.et al, Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget. 2016 Nov 8; 7(45): 74043-74058. |
| 4892 | Hornung B, et al. Medium chain length fatty acids stimulate triacylglycerol synthesis in tissue culture cells. Biochem Pharmacol. 1992 Jan 22;43(2):175-81. |
| 4893 | Das SK, et al. Effect of undecanoic acid on phospholipid metabolism in Trichophyton rubrum. Sabouraudia. 1982 Dec;20(4):267-72. |
| 4894 | Das SK, et al. Effect of undecanoic acid on the production of exocellular lipolytic and keratinolytic enzymes by undecanoic acid-sensitive and -resistant strains of Trichophyton rubrum. Sabouraudia. 1982 Sep;20(3):179-84. |
| 4895 | Coppa M, et al. Effect of a hay-based diet or different upland grazing systems on milk volatile compounds. J Agric Food Chem. 2011 May 11;59(9):4947-54. |
| 4896 | Zhao Q, et al. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. |
| 4897 | Liu B, et al. Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells. Mol Med Rep. 2016 Jul;14(1):159-64. |
| 4898 | Yu G, et al. Diosmetin ameliorates the severity of cerulein-induced acute pancreatitis in mice by inhibiting the activation of the nuclear factor-κB. Int J Clin Exp Pathol. 2014 Apr 15;7(5):2133-42. |
| 4899 | Altun M, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol. 2011 Nov 23;18(11):1401-12. |
| 4900 | Bertuccio CA, et al. Anterograde trafficking of KCa3.1 in polarized epithelia is Rab1- and Rab8-dependent and recycling endosome-independent. PLoS One. 2014 Mar 14;9(3):e92013. |
| 4901 | Seiberlich V, et al. The small molecule inhibitor PR-619 of deubiquitinating enzymes affects the microtubule network and causes protein aggregate formation in neural cells: implications for neurodegenerative diseases. Biochim Biophys Acta. 2012 Nov;1823(1 |
| 4902 | Kuan-Lin Kuo, et al. The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study. Cells. 2019 Oct 17;8(10):1268. |
| 4903 | Theriault JR, et al. Discovery of a Small Molecule Activator of the Hypoxia Inducible Factor Pathway. Probe Reports from the NIH Molecular Libraries Program. |
| 4904 | Theriault JR, et al. Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway. Bioorg Med Chem Lett. 2012 Jan 1;22(1):76-81. |
| 4905 | Chen H, et al. Effect of hypoxia-inducible factor-1/vascular endothelial growth factor signaling pathway on spinal cord injury in rats.Exp Ther Med. 2017 Mar;13(3):861-866. |
| 4906 | He L, et al. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013 Oct 4;312:36-47. |
| 4907 | Yang L, et al. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol. 2009 Dec;87(6):933-42. |
| 4908 | Li HD, et al. Wogonin attenuates inflammation by activating PPAR-γ in alcoholic liver disease. Int Immunopharmacol. 2017 Sep;50:95-106. |
| 4909 | F P Bymaster, et al. Xanomeline Compared to Other Muscarinic Agents on Stimulation of Phosphoinositide Hydrolysis in Vivo and Other Cholinomimetic Effects. Brain Res. 1998 Jun 8; 795(1-2):179-90. |
| 4910 | J Ind Hyg Toxicol 30:373 (1948); Develop Reprod Toxicol 68:144 (2003) |
| 4911 | Kowalski RJ, et al. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem. 1997 Jan 24;272(4):2534-41. |
| 4912 | Cheng KL, et al. Novel microtubule-targeting agents - the epothilones. Biologics. 2008 Dec;2(4):789-811. |
| 4913 | https://clinicaltrials.gov/ct2/show/NCT05056558?term=Baricitinib&cond=covid-19&draw=2&rank=3 |
| 4914 | Forbes R, et al. ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial. Trials. 2018;19(1):616. Published 2018 Nov 9. |
| 4915 | Gibson GR. A clinical appraisal of methenamine hippurate in urinary tract infections. Med J Aust. 1970;1(4):167‐170. |
| 4916 | Hu E,et al. Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41. |
| 4917 | Chem Ber 103:3674 (1970); Experientia 28:380 (1972); Phytochemistry 12:1787 (1973); IARC Monog 31:213 Suppl 7:71 (1983); Antiviral Res 12:99 (1989) |
| 4918 | Kim HJ, et al. Biotransformed Metabolites of the Hop Prenylflavanone Isoxanthohumol. Molecules. 2019 Jan 22;24(3). |
| 4919 | Lepak AJ, et al. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764-9. |
| 4920 | Steven Fishbane, et al. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney Int Rep. 2020 Jan 28;5(5):600-610. |
| 4921 | Steven Fishbane, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients With Pruritus. N Engl J Med. 2020 Jan 16;382(3):222-232. |
| 4922 | https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20201004048923N1 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200319046819N1 |
| 4923 | Menezes DL, et al. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther. 2012 Mar;11(3):730-9. |
| 4924 | McBride CM, et al. Design, structure-activity relationship, and in vivo characterization of the development candidate NVP-HSP990. J Med Chem. 2014 Nov 13;57(21):9124-9. |
| 4925 | Lamottke B, et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol. 2012 May;88(5):406-15. |
| 4926 | https://clinicaltrials.gov/ct2/show/NCT04708340?term=THIAMINE&cond=covid&draw=2&rank=2 |
| 4927 | WO 2016022605 A1 |
| 4928 | Sørensen E, et al. The selective 5-HT(1A) receptor antagonist p-MPPI antagonizes sleep--waking and behavioural effects of 8-OH-DPAT in rats. Behav Brain Res. 2001 Jun;121(1-2):181-7. |
| 4929 | Cao BJ, et al. Anxiolytic-like profile of p-MPPI, a novel 5HT1A receptor antagonist, in the murine elevated plus-maze. Psychopharmacology (Berl). 1997 Feb;129(4):365-71. |
| 4930 | Hirose M et al. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidicantagonist. Bioorg Med Chem Lett, 2003 Dec 15, 13(24):4497-9. |
| 4931 | R Mould et al. Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. Br J Pharmacol. 2014 Jan; 171(2): 351-363. |
| 4932 | Tabaeizadeh M, et al. The differential effects of OX1R and OX2R selective antagonists on morphine conditioned place preference in naïve versus morphine-dependent mice. Behav Brain Res. 2013 Jan 15;237:41-8. |
| 4933 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=POLYMYXIN+B&cntry=&state=&city=&dist=&Search=Search |
| 4934 | CAPONIGRO, Giordano, et al. THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR. WO 2018051306 A1 20180322 |
| 4935 | Becker DJ, et al. Fucose: biosynthesis and biological function in mammals. Glycobiology. 2003 Jul;13(7):41R-53R. |
| 4936 | Ikezoe T, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer. 2011 Nov 15;129(10):2512-21. |
| 4937 | Yang J, et al. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells. Mol Cancer Ther. 2010 Dec;9(12):3386-95. |
| 4938 | Valenciano AL, et al. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor. Bioorg Med Chem. 2016 Oct 1;24(19):4647-51. |
| 4939 | Gozgit JM, et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43. |
| 4940 | Mitsiades CS, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar;5(3):221-30. |
| 4941 | Warshamana-Greene GS, et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther. 2004 May;3(5):527-35. |
| 4942 | Patwardhan PP et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget, 2016 Jan 26;7(4):4093-109. |
| 4943 | Du W, et al. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight. 2018 Nov 2;3(21). pii: 124184. |
| 4944 | Christopher Chapple, et al. Tamsulosin: an overview. World J Urol. 2002 Apr;19(6):397-404. |
| 4945 | William G. Montgomery, BA, et al. Tamsulosin Attenuates Abdominal Aortic Aneurysm Growth. Surgery. 2018 Nov; 164(5): 1087–1092. |
| 4946 | J Biochem Toxicol. 6: 37(1991); Arch Toxicol 75: 221 (2001) |
| 4947 | Exp. Clin. Endocrinol. Diabetes (2010), 118(10), 678-684. ; Med. Chem. (2010), 6(4), 239-246; J. Clin. Pharmacol. (1981), 21(8-9), 365-84 |
| 4948 | Drugs Today (1976), 12(12), 500-2; Antimicrob. Agents Chemother. (1966), 573-80. |
| 4949 | Okaniwa M, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. |
| 4950 | Nakamura A, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013 Oct 11. |
| 4951 | Chen XH, et al. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004 Jul;25(7):927-31. |
| 4952 | J Org Chem 13: 448 (1948) |
| 4953 | Meuwly P, et al. Ortho-anisic acid as internal standard for the simultaneous quantitation of salicylic acid and its putative biosynthetic precursors in cucumber leaves. Anal Biochem. 1993 Nov 1;214(2):500-5. |
| 4954 | Cancer Res 53:5176 (1993); Arch Dermatol 134:25 (1998); J Am Acad Dermatol 43:S1 (2000) |
| 4955 | Wang JM, et al. Ferulic acid prevents liver injury and increases the anti-tumor effect of diosbulbin B in vivo. J Zhejiang Univ Sci B. 2014 Jun;15(6):540-7. |
| 4956 | Ma Y, et al. Diosbulbin B-induced liver injury in mice and its mechanism. Hum Exp Toxicol. 2014 Jul;33(7):729-36. |
| 4957 | Barker CA, et al. Degradation of MAC13243 and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone LolA. Bioorg Med Chem Lett. 2013 Apr 15;23(8):2426-31. |
| 4958 | Pathania R, et al. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat Chem Biol. 2009 Nov;5(11):849-56. |
| 4959 | Sexton JZ, et al. Novel Inhibitors of E. coli RecA ATPase Activity. Curr Chem Genomics. 2010;4:34-42. Published 2010 May 26. |
| 4960 | Shimamura T, et al. Ganetespib (STA-9090), a Non-Geldanamycin HSP90 Inhibitor, has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer.
 Clin Cancer Res. 2012 Jul 17. |
| 4961 | Ying W, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
 Mol Cancer Ther. 2012 Feb;11(2):475-84. |
| 4962 | London CA, et al. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.
 PLoS One. 2011;6(11):e27018. |
| 4963 | Proia DA, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.
 PLoS One. 2011 Apr 14;6(4):e18552. |
| 4964 | Stewart E, et al. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell. 2018 Sep 10;34(3):411-426.e19. |
| 4965 | Germain AR, et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. Bioorg Med Chem Lett. 2012 May 15;22(10):3571-4. |
| 4966 | Rees MG, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016 Feb;12(2):109-16. |
| 4967 | Li S, et al. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein. Eur J Med Chem. 2016 Nov 29;124:1006-1018. |
| 4968 | Lou Y, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011 May 1;71(9):3364-76. |
| 4969 | Lock FE, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013 Oct 31;32(44):5210-9. |
| 4970 | Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. |
| 4971 | EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo |
| 4972 | Tagat JR, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem. 2004 May 6;47(10):2405-8. |
| 4973 | Strizki JM, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9. |
| 4974 | Antimicrob. Agents Chemother. (1964), 305-10; Antimicrob. Agents Chemother. (1962), 1961, 611-19; J. Chem. Soc. (1963), 491-7 |
| 4975 | Am J Obst & Gynec 51:660 (1946); Acta Anatomica 23:180 (1955); PNAS 58:2329 (1967) |
| 4976 | Cancer Chemother Pharmacol 15:161 (1985); Acta Neurol Scand 73:449 (1986); Jpn J Clin Oncol 38:176 (2008)| |
| 4977 | Dipartimento di Chimica, Università degli Studi della Basilicata, Potenza, In vitro toxicity of N3-methyl-5'-deoxy-5-fluorouridine, a novel metabolite of doxifluridine: a bioanalytical investigation. J Pharm Biomed Anal. 1998 May;17(1):11-6. |
| 4978 | Baek IH, Lee BY, Kim MS, Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs. Eur J Drug Metab Pharmacokinet. 2013 Apr 7. |
| 4979 | Yoshikawa T, Tsuburaya A, Shimada K, A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 2009;12(4):212-8. |
| 4980 | Kennedy DG, et al. Zeranol is formed from Fusarium spp. toxins in cattle in vivo. Food Addit Contam. 1998 May-Jun;15(4):393-400. |
| 4981 | Yuri T, et al. Biphasic effects of zeranol on the growth of estrogen receptor-positive human breast carcinoma cells. Oncol Rep. 2006 Dec;16(6):1307-12. |
| 4982 | Neuropharmacology (1977), 16(12), 833-9; J. Pharmacol. Exp. Ther. (1958), 123, 230-7; Acta ophthalmol. (1976), 54(4), 456-72 |
| 4983 | Kevin R. Webster, et al. eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2015 126:1554. |
| 4984 | Xu Y, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019 Feb;25(2):301-311. |
| 4985 | Inflammopharmacology (1995), 3(4), 335-45; Med. Res. Rev. (1987), 7(1), 1-28; J. Med. Chem. (1976), 19(6), 787-92 |
| 4986 | Tumber A, et al. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell Chem Biol. 2017 Mar 16;24(3):371-380. |
| 4987 | ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases |
| 4988 | ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018. |
| 4989 | Andorn, A.C., M.A. Carlson, and R.C. Gilkeson, Specific [3H]UK 14,304 binding in human cortex occurs at multiple high affinity states with alpha 2-adrenergic selectivity and differing affinities for GTP. Life Sci, 1988. 43(22): p. 1805-12. |
| 4990 | Cambridge, D., UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol, 1981. 72(4): p. 413-5. |
| 4991 | Chopin, P., F.C. Colpaert, and M. Marien, Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther, 1999. 288(2): p. 798-804. |
| 4992 | https://clinicaltrials.gov/ct2/show/NCT04484493?term=Mometasone+furoate&cond=COVID-19&draw=2&rank=1 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20190804044429N6 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200522047542N1 |
| 4993 | Cerezo M et al. Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. Cancer Cell. 2016 Jun 13;29(6):805-19. |
| 4994 | Ruggiero C, et al. The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. Mol Cell Endocrinol. 2018 Oct 15;474:57-64. |
| 4995 | Duo Xu, et al. Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers (Basel). 2019 Oct; 11(10): 1502. |
| 4996 | Liang Y, et al. 
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
 PLoS One. 2012;7(2):e30555. |Drugs of the Future 36:351 (2010) |
| 4997 | J Drug Dev 5:235 (1993); Antimicrob Agents Chemother 39:1 (1995); 40:1935 (1996) |
| 4998 | Endocrinology (1977), 100(2), 513-19; Steroids (1969), 13(2), 163-77; J. Pharm. Sci. (1994), 83(6), 874-7 |
| 4999 | Hetrick B, et al. Small molecules CK-666 and CK-869 inhibit actin-related protein 2/3 complex by blocking an activating conformational change. Chem Biol. 2013 May 23;20(5):701-12. |
| 5000 | Yamagishi Y, et al. Use of CK-548 and CK-869 as Arp2/3 complex inhibitors directly suppresses microtubule assembly both in vitro and in vivo. Biochem Biophys Res Commun. 2018 Feb 12;496(3):834-839. |
| 5001 | Hamanaka N, et al. YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification. Cancer Res. 2019 Nov 15;79(22):5734-5745. |
| 5002 | Song SB, et al. Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res. 2012 Apr;36(2):146-52. |
| 5003 | Lu C, et al. Inhibition of L-type Ca<sup>2+</sup> current by ginsenoside Rd in rat ventricular myocytes. J Ginseng Res. 2015 Apr;39(2):169-77. |
| 5004 | Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc<sup>Min/+</sup> mice. Sci Rep. 2017 Oct 2;7(1):12552. |
| 5005 | Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006 Jun;91(2):356-64. |
| 5006 | Antimicrob Agents Chemother 32:1576 (1988); J Clin Pharmacol 28:246 (1988) |
| 5007 | Moser C, et al. Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice. Phytomedicine. 2014 Sep 25;21(11):1382-9. |
| 5008 | Am. J. Psychiatry (1970), 127(2), 199-207; Pharm. J. (1969), 203(5530), 503-6; Prog. Brain Res. (2000), 126, 433-453 |
| 5009 | Rubaiy HN, et al. Picomolar, selective, and subtype-specific small-molecule inhibition of TRPC1/4/5 channels. J Biol Chem. 2017 May 19;292(20):8158-8173. |
| 5010 | Lou K,et al. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Sci Signal. 2019 May 28;12(583). pii: eaaw9450. |
| 5011 | Yamada M, et al. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2017 Dec;47(12):1090-1103. |
| 5012 | J Neurochem 54: 699 (1990) |
| 5013 | Nicholas D.P. Cosford, et al. Small molecule fatty acid synthase inhibitors. WO2015134790A1. |
| 5014 | Arch Pharmazie 302:294 (1968); Z Lebensm Unters Forsch 160:325 (1976); Cancer Res 37:3458 (1977); J Appl Toxicol 11:235 (1991) |
| 5015 | Rainey MD, et al. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008 Sep 15;68(18):7466-74. |
| 5016 | Guo K, et al. Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors. J Biomol Screen. 2014 Apr;19(4):538-46. |
| 5017 | W?sierska-G?dek J, et al. Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells. J Cancer Prev. 2014 Jun;19(2):125-36. |
| 5018 | Drugs 49:467 (1995)| |
| 5019 | Cruciani F, Brigidi P, Calanni F et al. Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota. Antimicrob Agents Chemother. 2012 Aug;56(8):4062-70. |
| 5020 | Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother. 2012 Feb;13(3):433-40. |
| 5021 | Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther. 2011 Jul;33(7):812-27. |
| 5022 | Cottreau J, Baker SF, DuPont HL, Garey KW. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul;8(7):747-60. |
| 5023 | Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. |
| 5024 | Ojetti V, Lauritano EC, Barbaro F et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):675-82. |
| 5025 | Arzneim Forsch 21:206 (1971); Drugs 18:329 (1979); Pharmacotherapy 5:63 (1985) |
| 5026 | Agios. Targeting MAT2A in MTAP-deleted Cancers. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, Chicago, IL, USA |
| 5027 | J Pharmacol Exp Therap 81:1 (1944); Biochem J 312:315 (1995) |
| 5028 | Ranjithkumar Chellian, et al. Biphasic Effects of α-Asarone on Immobility in the Tail Suspension Test: Evidence for the Involvement of the Noradrenergic and Serotonergic Systems in Its Antidepressant-Like Activity. Front Pharmacol. 2016; 7: 72. |
| 5029 | Byung-Wook Kim, et al. α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease. Neuropharmacology, Volume 97, October 2015, Pages 46–57 |
| 5030 | Hye-Jung Park, et al. Effect of α-asarone on angiogenesis and matrix metalloproteinase. Environmental Toxicology and Pharmacology, Volume 39, Issue 3, May 2015, Pages 1107–1114 |
| 5031 | Seifert H, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017 Jul 10. |
| 5032 | Zhao M, et al. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2017 Jun 27;61(7). |
| 5033 | Xiao XY, et al. Fluorocyclines: a potent, broad spectrum antibacterial agent. J Med Chem. 2012 Jan 26;55(2):597-605. |
| 5034 | Sutcliffe JA, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. |
| 5035 | Grossman TH, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015 May;59(5):2567-71. |
| 5036 | N. Engl. J. Med. (1980), 302(22), 1237-43; Ann. Phys. Med. (1966), Suppl7-16, ; J. Pharmacol. Exp. Ther. (1965), 148, 373-9 |
| 5037 | J Am Chem Soc 53: 4114 (1931); Cancer Res 45:2584 (1985); 47:3783 (1987); J Invest Dermatol 92:64 (1989) |
| 5038 | Proc. R. Soc. Med. (1948), 41(9), 593-606; Br. J. Pharmacol. Chemother. (1947), 2(4), 241-50; Mod. Trends Neurol. (1975), 6205-21 |
| 5039 | Falgueyret JP, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005 Dec 1;48(24):7535-43. |
| 5040 | Vasiljeva O, et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007;13(4):387-403. |
| 5041 | Jerome C, et al. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2011 Dec;22(12):3001-11. |
| 5042 | Janjua, N. and S.A. Mayer, Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care, 2003. 9(2): p. 113-9. |
| 5043 | Allen, G.S., et al., Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med, 1983. 308(11): p. 619-24. |Am. J. Cardiol. (1985), 55(3), 144B-148B; Naunyn-Schmiedeberg's Arch. Pharmacol. (1979), 310(1), 69-78; Br. J. Pharmacol. (1979), 67(3), 409P-410P |
| 5044 | Gilmartin AG, et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat Chem Biol. 2014 Mar;10(3):181-7. |
| 5045 | Esfandiari A, et al. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. Mol Cancer Ther. 2016 Mar;15(3):379-91. |
| 5046 | Watts CA, et al. Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes. Chem Biol. 2013 Nov 21;20(11):1399-410. |
| 5047 | Li K, et al. Inhibition of sperm capacitation and fertilizing capacity by adjudin is mediated by chloride and its channels in humans. Hum Reprod. 2013 Jan;28(1):47-59. |
| 5048 | Li X, et al. Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells. J Mater Chem B. 2015 Feb 28;3(8):1556-1564. |
| 5049 | Xie QR, et al. Male contraceptive Adjudin is a potential anti-cancer drug. Biochem Pharmacol. 2013 Feb 1;85(3):345-55. |
| 5050 | https://clinicaltrials.gov/ct2/show/NCT04757857?term=Rivaroxaban&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04504032?term=Rivaroxaban&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04715295?term=Rivaroxaban&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04416048?term=Rivaroxaban&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04508023?term=Rivaroxaban&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04640181?term=Rivaroxaban&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04662684?term=Rivaroxaban&cond=COVID-19&draw=2&rank=7 https://clinicaltrials.gov/ct2/show/NCT04394377?term=Rivaroxaban&cond=COVID-19&draw=2&rank=9 https://clinicaltrials.gov/ct2/show/NCT04324463?term=Rivaroxaban&cond=COVID-19&draw=2&rank=10 https://clinicaltrials.gov/ct2/show/NCT04333407?term=Rivaroxaban&cond=COVID-19&draw=2&rank=11 https://clinicaltrials.gov/ct2/show/NCT04736901?term=Rivaroxaban&cond=COVID-19&draw=2&rank=12 |
| 5051 | Antimicrob Agents Chemother 14:454, 614 (1978); J Antimicrob Chemother 4:343 (1978)| |
| 5052 | Chambers HF, et al. Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrob Agents Chemother. 1992 Mar;36(3):656-61. |
| 5053 | Antimicrob Agents Chemother 41:2492 (1997), 42:161 (1998); 46:2546 (2002); N Engl J Med 346:225 (2002)| |
| 5054 | Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics. 2011 Jun;12(6):861-72. doi: 10.2217/pgs.11.18. |
| 5055 | Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009 Dec;68(6):906-15. doi: 10.1111/j.1365-2125.2009.03534.x. |
| 5056 | Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther. 2004 Aug;2(4):485-97. |
| 5057 | Louis D. Saravolatz, Section Editor, Leonard B. Johnson, et al. Voriconazole: A New Triazole Antifungal Agent. Clin Infect Dis. 2003,36 (5): 630-637. |
| 5058 | John R. Perfect, Kieren A. Marr, Thomas J. Walsh, et al. Voriconazole Treatment for Less-Common, Emerging, or Refractory Fungal Infections. Clin Infect Dis. 2003, 36 (9): 1122-1131. |
| 5059 | Khoufache K, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013 Jan;123(1):206-14. |
| 5060 | Kehinde O, et al. Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):98-105. |
| 5061 | https://clinicaltrials.gov/ct2/show/NCT04666753?term=OROTIC+ACID&cond=covid-19&draw=2&rank=1 |
| 5062 | Benzyl urea derivatives for activating tgf-beta signaling. US 20160039756 A1. 2016. Feb |
| 5063 | Liu Y, et al. Saikosaponin A Protects From Pressure Overload-Induced Cardiac Fibrosis via Inhibiting Fibroblast Activation or Endothelial Cell EndMT. Int J Biol Sci. 2018 Oct 31;14(13):1923-1934. |
| 5064 | Zhang Y, et al. Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. Cell Chem Biol. 2019 Jan 31. pii: S2451-9456(19)30030-3. |
| 5065 | Yu Wang, et al. PCC0208009, an indirect IDO1 inhibitor, alleviates neuropathic pain and co-morbidities by regulating synaptic plasticity of ACC and amygdala. Biochem Pharmacol. 2020 Jul;177:113926. |
| 5066 | David K Williams, et al. Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Bioorg Med Chem Lett. 2018 Feb 15;28(4):732-736. |
| 5067 | Shanyue Sun, et al. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models. Int J Immunopathol Pharmacol. Jan-Dec 2018;32:2058738418787991. |
| 5068 | Salvatore CA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther. 2008 Feb;324(2):416-21. Epub 2007 Nov 26. |
| 5069 | Moore EL, et al. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine. Eur J Pharmacol. 2009 Jan 14;602(2-3):250-4. |
| 5070 | Roller S, et al. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Xenobiotica. 2009 Jan;39(1):33-45. |
| 5071 | Chem Lett 1973:445; Phytochem 17:1438 (1978) |
| 5072 | Caupos E, et al. Photodegradation of estrone enhanced by dissolved organic matter under simulated sunlight. Water Res. 2011;45(11):3341-3350. |
| 5073 | de Padua Mansur A, et al. Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease. ScientificWorldJournal. 2012;2012:363595. |Anal Profiles Drug Subs 12:135 (1983) |
| 5074 | Ren Hang, et al. Synthesis of 3'-Azido-D/L-nucleosides. Chinese Journal of Organic Chemistry, 2018, 38(1): 138-147. |
| 5075 | Yang X, et al. Garcinone D, a natural xanthone promotes C17.2 neural stem cell proliferation: Possible involvement of STAT3/Cyclin D1 pathway and Nrf2/HO-1 pathway. Neurosci Lett. 2016 Jul 28;626:6-12. |
| 5076 | Sipos W, et al. Escin inhibits type I allergic dermatitis in a novel porcine model. Int Arch Allergy Immunol. 2013;161(1):44-52. |Arzneimittel-Forsch 13: 385 (1963) |
| 5077 | Nah SY, et al. A trace component of ginseng that inhibits Ca<sup>2+</sup> channels through a pertussis toxin-sensitive G protein. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8739-43. |
| 5078 | Mogil JS, et al. Ginsenoside Rf, a trace component of ginseng root, produces antinociception in mice. Brain Res. 1998 May 11;792(2):218-28. |
| 5079 | Loganzo F, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003 Apr 15;63(8):1838-45. |
| 5080 | Yan D, et al, Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem, 2012, 287(11), 8598-8612. |
| 5081 | Henderson WR Jr, et al, Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA, 2010, 107(32), 14309-14314. |
| 5082 | Emami KH, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA, 2004, 101(34), 12682-12687. |
| 5083 | Liu Y, et al. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res. 2017 Sep 11;36(1):125. |
| 5084 | Smith SH, et al. Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin. PLoS One. 2016 Feb 12;11(2):e0147979. |
| 5085 | Cencic R, et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1046-51. |
| 5086 | Shuda M, et al. CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5875-82. |
| 5087 | Hitosugi T, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell. 2012 Nov 13;22(5):585-600. |
| 5088 | Biochem. J. (1986), 235(2), 313-22; Nature (1984), 309(5963), 63-6; Nat. Prod. Rep. (2010), 27(10), 1403-1430 |
| 5089 | Formulary 37:68 (2002); Expert Rev Neurother 5:11 (2005) |
| 5090 | Fertil. Steril. (1965), 16, 97-100; Appl. Thera. (1964), 6, 511-8; JAMA, J. Am. Med. Assoc. (1964), 188, 1115-20| |
| 5091 | H Kappus, et al. Affinity of ethynyl-estradiol and mestranol for the uterine estrogen receptor and for the microsomal mixed function oxidase of the liver. J Steroid Biochem. 1973 Mar;4(2):121-8. |
| 5092 | J W Goldzieher, et al. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 2):2114-9. |
| 5093 | S Y Jiang, et al. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol. 1995 Dec;23(6):712-9. |
| 5094 | Fujii T, et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016 May;21(117):373-80. |
| 5095 | Ma T, et al. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. J Med Chem. 2018 Oct 25;61(20):8981-9003. |
| 5096 | Hagiya H, et al. Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of Fosfluconazole and micafungin. Intern Med. 2013;52(18):2139-43. |
| 5097 | Yuan H, et al. Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs. Drug Metab Dispos. 2009 Jul;37(7):1443-7. |
| 5098 | Aoyama T, et al. Pharmacokinetics of fluconazole and Fosfluconazole after intraperitoneal administration to peritoneal dialysis rats. Drug Metab Pharmacokinet. 2005 Dec;20(6):485-90. |
| 5099 | Phytochemistry 17: 1417 (1978); J Biol Chem 286:27718 (2011) |
| 5100 | Cheng AC, et al. Rosmanol potently induces apoptosis through both the mitochondrial apoptotic pathway and death receptor pathway in human colon adenocarcinoma COLO 205 cells. Food Chem Toxicol. 2011 Feb;49(2):485-93. |
| 5101 | Loussouarn M, et al. Carnosic Acid and Carnosol, Two Major Antioxidants of Rosemary, Act through Different Mechanisms. Plant Physiol. 2017 Nov;175(3):1381-1394. |
| 5102 | Kedei N, et al. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004 May 1;64(9):3243-55. |
| 5103 | Hampson P, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood. 2005 Aug 15;106(4):1362-8. |
| 5104 | Ghoul A, et al. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res. 2009 May 15;69(10):4260-9. |
| 5105 | Ber 58: 2267 (1925); J Nat Prod 28: 73 (1965)|J Nat Prod 28: 73 (1965); Can J Chem 58: 2770 (1980) |
| 5106 | Drugs (2004), 64(20), 2315-2343; J. Pharm. Pharmacol. (1982), 34(9), 562-9; J. Med. Chem. (1978), 21(12), 1260-4 |
| 5107 | Gazz Chim Ital 99:915 (1969); 101: 797 (1971); Chem Abs 123:193603p (1995) |
| 5108 | Kim JE, et al. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila). 2011 Apr;4(4):582-91. |
| 5109 | Hu S, et al. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen activated protein kinase kinase signaling pathways. Mol Med Rep. 2015 Nov;12(5):6745-51. |
| 5110 | Okolotowicz KJ, et al. Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activationpathway. Bioorg Med Chem. 2010 Mar 1;18(5):1918-24. |
| 5111 | Shi R, et al. Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C. ACS Chem Biol. 2010 Mar 19;5(3):287-99. |
| 5112 | Peddibhotla S, et al. Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. J Med Chem. 2010 Jun 24;53(12):4793-7. |
| 5113 | JACS 80:1691 (1958); Aust J Chem 23:2539 (1970); Tetrahedron 27:3919 (1971); Phytochemistry 12:232 (1973) |
| 5114 | Am J Med Sci 114:459 (1897) |
| 5115 | Lu J, et al. Structure-activity relationship studies of small-molecule inhibitors of Wnt response. Bioorg Med Chem Lett. 2009 Jul 15;19(14):3825-7. |
| 5116 | Zhang X, et al. Macrophage migration inhibitory factor promotes proliferation and neuronal differentiation of neural stem/precursor cells through Wnt/β-catenin signal pathway. Int J Biol Sci. 2013 Nov 28;9(10):1108-20. |
| 5117 | Gupta PS, et al. Regulation and Regulatory Role of WNT Signaling in Potentiating FSH Action during Bovine Dominant Follicle Selection. PLoS One. 2014 Jun 17;9(6):e100201. |
| 5118 | H Y Whang, et al. Chlorphenesin: an antigen-associated immunosuppressant. Infect Immun. 1970 Jul;2(1):60-4. |
| 5119 | Jingyi Wang, et al. Toxicity of the cosmetic preservatives parabens, phenoxyethanol and chlorphenesin on human meibomian gland epithelial cells. Exp Eye Res. 2020 Jul;196:108057. |
| 5120 | Arzneim Forsch 11:682, 695 (1961); Chemotherapy 14:195 (1969) |
| 5121 | Obata T, et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol. 1992 Nov;60(3):227-37. |
| 5122 | Fang SH, et al. Nuclear translocation of cysteinyl leukotriene receptor 1 is involved in oxygen-glucose deprivation-induced damage to endothelial cells. Acta Pharmacol Sin. 2012 Dec;33(12):1511-7. |
| 5123 | Ogata M, et al. Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice. Infect Immun. 1992 Jun;60(6):2432-7. |
| 5124 | Int Pharmopsychiatry 14:213 (1979); Life Sci 24:2201 (1979) |
| 5125 | Sulsky R, et al. 5-Carboxamido-1,3,2-dioxaphosphorinanes, potent inhibitors of MTP. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5067-70. |
| 5126 | Davis KA. et al. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Am J Health Syst Pharm. 2014 Jun 15;71(12):1001-8. |
| 5127 | Dhote V, et al. Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats. Clin Exp Pharmacol Physiol. 2011 May;38(5):338-44. |
| 5128 | Chem Pharm Bull 17:1390 (1969); 42:138 (1994) |
| 5129 | https://clinicaltrials.gov/ct2/show/NCT04366050?term=Ramipril&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04591210?term=Ramipril&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04467931?term=Ramipril&cond=COVID-19&draw=2&rank=5 |
| 5130 | Abdenur JE, et al. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab. 2006 Jan;87(1):48-53. |
| 5131 | Waites KB, et al. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. |
| 5132 | Ince D, et al. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. |
| 5133 | Zhao X, et al. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003 Mar;47(3):1023-7. |
| 5134 | J Am Acad Dermatol 44: 67 (2001); Lancet 368: 1339 (2006)|JACS 77:1676 (1955); JAMA 200:619 (1967); Nucl Acids Res 31:1331 (2003) |
| 5135 | ThomasBriggs, et al. Allocholic acid, the major component in bile from the river carpsucker, Carpiodes carpio (Rafinesque) (Catostomidae). Comp Biochem Physiol B. 1972 Jul 15;42(3):493-6. |
| 5136 | Li W, et al. The olfactory system of migratory adult sea lamprey (Petromyzon marinus) is specifically and acutely sensitive to unique bile acids released by conspecific larvae. J Gen Physiol. 1995 May;105(5):569-87. |
| 5137 | Mendoza ME, et al. Physiological characteristics of allo-cholic acid. J Lipid Res. 2003 Jan;44(1):84-92. |
| 5138 | Kluge AF, et al. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg Med Chem Lett. 2018 Aug 15;28(15):2655-2659. |
| 5139 | Algharrawi KH, et al. Direct conversion of theophylline to 3-methylxanthine by metabolically engineered E. coli. Microb Cell Fact. 2015 Dec 21;14:203. |
| 5140 | Youn H, et al. 1-Methylxanthine enhances the radiosensitivity of tumor cells. Int J Radiat Biol. 2009 Feb;85(2):167-74. |
| 5141 | Rose M, et, al. Isosorbide as a renewable platform chemical for versatile applications--quo vadis? ChemSusChem. 2012 Jan 9;5(1):167-76. |
| 5142 | Nozawa I, et, al. Efficacy of long-term administration of isosorbide for Ménière's disease. ORL J Otorhinolaryngol Relat Spec. May-Jun 1995;57(3):135-40. |
| 5143 | Newman RA, et, al. Gallium nitrate (NSC-15200) induced toxicity in the rat: a pharmacologic, histopathologic and microanalytical investigation. Cancer. 1979 Nov;44(5):1728-40. |
| 5144 | Vidomanova E, et al. Microfluidic profiling of apoptosis-related genes after treatment with BH3-mimetic agents in astrocyte and glioblastoma cell lines. Oncol Rep. 2016 Dec;36(6):3188-3196. |
| 5145 | Budke B, et, al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 2012 Aug;40(15):7347-57. |
| 5146 | Shi Y, et, al. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors. Neoplasia. 2019 Jun;21(6):533-544. |
| 5147 | Chem Abs 92:55042v (1980); Chem Pharm Bull 54:368 (2006) |
| 5148 | Hanna Tinel, et al. Abstract 13624: A Novel Chymase Inhibitor BAY 1142524 Reduces Fibrosis and Improves Cardiac Function After Myocardial Infarction in Hamster. Circulation. 2018;136:A13624. |
| 5149 | Kanefendt F, et al. Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2018 Jun 7. |
| 5150 | J Org Chem 25: 1434 (1960) |
| 5151 | Helv Chim Acta 25:797 (1942); J Biol Chem 238: 3846 (1963) |
| 5152 | Haarberg HE, et al. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther. 2013 Jun;12(6):901-12. |
| 5153 | Paraiso KH, et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May 1;18(9):2502-14. |
| 5154 | Bussenius J, et al. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5396-404. |
| 5155 | Sundqvist M, et al. Similarities and differences between the responses induced in human phagocytes through activation of the medium chain fatty acid receptor GPR84 and the short chain fatty acid receptor FFA2R. Biochim Biophys Acta Mol Cell Res. 2018 May;1865(5):695-708. |
| 5156 | F. Vanhoutte, et al. Human safety, pharmacokinetics and pharmacodynamics of the GPR84 antagonist GLPG1205, a potential new approach to treat IBD. |
| 5157 | L.Saniere, et al. Characterization of GLPG1205 in Mouse Fibrosis Models: A Potent and Selective Antagonist of GPR84 for Treatment of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2019;199:A1046 |
| 5158 | F. Vanhoutte, et al. Human safety, pharmacokinetics and pharmacodynamics |
| 5159 | Swaroop Vakkalankaa, et al. Inhibition of PI3Kδ kinase by a selective, small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth. |
| 5160 | Deng C, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017 Jan 5;129(1):88-99 |
| 5161 | Guan SP, et al. Protective role of 14-deoxy-11,12-didehydroandrographolide, a noncytotoxic analogue ofandrographolide, in allergic airway inflammation. J Nat Prod. 2011 Jun 24;74(6):1484-90. |
| 5162 | Khiar S, et al. Identification of a small molecule that primes the type I interferon response to cytosolic DNA. Sci Rep. 2017 May 31;7(1):2561. |
| 5163 | J Nat Prod 59:425 (1996) |
| 5164 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Benazepril&cond=Covid19&draw=2&rank=2 |
| 5165 | Masood A, et al. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther. 2009 Nov;331(2):690-9. |
| 5166 | Bubb KJ, et al. Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. Circulation. 2014 Aug 5;130(6):496-507. |
| 5167 | Bavik C, et al. Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity. PLoS One. 2015 May 13;10(5):e0124940. |
| 5168 | Kiser PD, et al. Catalytic mechanism of a retinoid isomerase essential for vertebrate vision. Nat Chem Biol. 2015 Jun;11(6):409-15. |
| 5169 | Carcinogenesis 21: 1879 (2000) |
| 5170 | Biochem Pharmacol 60:1367 (2000); Curr Cancer Drug Targets 2:227 (2002); Invest New Drugs 28:139 (2010); Eur J Med Chem 62:98 (2013) |
| 5171 | Glatthar R, et al. Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors. J Med Chem. 2016 Aug 25;59(16):7544-60. |
| 5172 | Curr Ther Res 46:44 (1989) |
| 5173 | Siemeister G, et al. BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Ishington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 287. doi:10.1158/1538-7445.AM2017-287 |
| 5174 | Klein MT, et al. Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther. 2011 Jun;337(3):860-867. |
| 5175 | McKune CM, et al. Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther. 2001 Apr;297(1):88-95. |
| 5176 | Klein MT, et al. Distribution of 5-ht(1E) receptors in the mammalian brain and cerebral vasculature: an immunohistochemical and pharmacological study. Br J Pharmacol. 2012 Jun;166(4):1290-302. |
| 5177 | Granados-Soto V, et al. The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats. Neuroscience. 2010 Jan 20;165(2):561-8. |
| 5178 | J Invest Dermatol 34:51 (1960) |
| 5179 | Choi SH , et al. Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neurosci Res. 2002 Feb 1;67(3):411-21. |
| 5180 | Taniguchi Y, et al. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 2006 Sep 18;580(21):5003-8. Epub 2006 Aug 17. |
| 5181 | Keswani AN , et al The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects. J Cardiovasc Pharmacol Ther. 2009 Jun;14(2):116-24. |
| 5182 | Jakubík J, et al. Divergence of allosteric effects of Rapacuronium on binding and function of muscarinic receptors. BMC Pharmacol. 2009 Dec 28;9:15. |
| 5183 | Vizi ES, et al. A new short-acting non-depolarizing muscle relaxant (SZ1677) without cardiovascular side-effects. Acta Anaesthesiol Scand. 2003 Mar;47(3):291-300. |
| 5184 | Col Czech Chem Commun 19: 805 (1954) |
| 5185 | Cavalli Z, et al. Prolonged Cefoxitin Infusion Using Mobile Elastomeric Infusors In Outpatients With Bone And Joint Infection. J Bone Jt Infect. 2018 Sep 7;3(4):182-186. |
| 5186 | Akama T, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2129-32. |
| 5187 | Nazarian R, et al. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009 Nov;10(11):1236-42. |
| 5188 | Nazarian R, et al. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009 Nov;10(11):1236-42. |
| 5189 | Zhang N. Biphasic effects of sodium danshensu on vessel function in isolated rat aorta. Acta Pharmacol Sin, 2010 Apr, 31(4):421-8. |
| 5190 | Tian Wang et al. Danshensu ameliorates the cognitive decline in streptozotocin-induced diabetic mice by attenuating advanced glycation end product-mediated neuroinflammation. J Neuroimmunol, 2012 Apr, 245(1-2):79-86. |
| 5191 | Duan L, et al. KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes. Chem Biol. 2015 Sep 17;22(9):1185-96. |
| 5192 | Mustapha Haddach, Jerome Michaux, Michael K, Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor. ACS Med. Chem. Lett., 2012, 3 (2), pp 135-139 |
| 5193 | Padmanabhan A, Gosc EB, Bieberich CJ. Stabilization of the prostate-specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells. J Cell Biochem. 2013 May;114(5):1050-7. |
| 5194 | Jpn J Pharmacol 52:35 (1990); J Allergy Clin Immunol 87:23 (1991); Clin Pharmacol Ther 55:441 (1994) |
| 5195 | Grobelny D, et al. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992 Aug 11;31(31):7152-4. |
| 5196 | Schultz GS, et al. Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases. Invest Ophthalmol Vis Sci. 1992 Nov;33(12):3325-31. |
| 5197 | Li C, et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol. 2002 Jun 5;39(11):1852-8. |
| 5198 | Leppert D, et al. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 1995 May 1;154(9):4379-89. |
| 5199 | Yamamoto M, et al. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem. 1998 Apr 9;41(8):1209-17. |
| 5200 | Liang X, et al. Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. J Med Chem. 2017 Mar 9;60(5):1793-1816. |
| 5201 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7. WO 2013030218 A1 |
| 5202 | Tetrahedron 23:1769 (1967); Phytochemistry 13:2327 (1974) |
| 5203 | Weber O, et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 2002 May;54(2):69-78. |
| 5204 | Stray SJ, et al. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit. 2006 Nov-Dec;19(6):542-8. |
| 5205 | Wu GY, et al. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J Chemother. 2008 Aug;20(4):458-67. |
| 5206 | Geldenhuys WJ, et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34. |
| 5207 | Lavalle CR, et al. Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol. 2010 May 5;10:5. |
| 5208 | James Sinnett-Smith, et al. Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling. Am J Physiol Cell Physiol. 2014 May 15; 306(10): C961-C971. |
| 5209 | J Org Chem 16:749 (1971); Adv Can Res 7:383 (1963) |
| 5210 | https://clinicaltrials.gov/ct2/show/NCT04387786?term=ALBUTEROL&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04681079?term=ALBUTEROL&cond=Covid19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT05045937?term=ALBUTEROL&cond=Covid19&draw=2&rank=4 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT0465517 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04387786 |
| 5211 | Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20. |
| 5212 | Bonnevaux H, et al. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71. |
| 5213 | Prabhakaran J, et al. Radiosynthesis and in Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain. ACS Chem Neurosci. 2017 Aug 16;8(8):1697-1703. |
| 5214 | Moses O. Evbuomwan, et al. Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist. Blood (2017) 130 (Supplement 1): 3197. |
| 5215 | Sarah E M Herman, et al. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Clin Cancer Res. 2015 Oct 15;21(20):4642-51. |
| 5216 | Eva Szenes, et al. TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. Leukemia. 2020 Sep;34(9):2498-2502. |
| 5217 | H Rahimi, et al. Aberrant regulation of the integrin very late antigen-4 in systemic lupus erythematosus. Lupus. 2013 Mar;22(3):297-306. |
| 5218 | Ferguson FM, et al. Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. Cell Chem Biol. 2019 Mar 11. pii: S2451-9456(19)30070-4. |
| 5219 | Kang Y, et al. Role of focal adhesion kinase in regulating YB-1-mediated resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. |
| 5220 | Wang CF, et al. Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat. Anesth Analg. 2008 Oct;107(4):1397-405. |
| 5221 | Wang CF, et al. Bulleyaconitine A isolated from aconitum plant displays long-acting local anesthetic properties in vitro and in vivo. Anesthesiology. 2007 Jul;107(1):82-90. |
| 5222 | Weng WY, et al. A pharmacokinetic study of intramuscular administration of bulleyaconitine A in healthy volunteers. Biol Pharm Bull. 2005 Apr;28(4):747-9. |
| 5223 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=METOLAZONE&cond=covid&draw=2&rank=2 |
| 5224 | El-Gamal, M.I. and C.H. Oh, Current status of carbapenem antibiotics. Curr Top Med Chem, 2010. 10(18): p. 1882-97. |
| 5225 | Fujimoto, K., et al., Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. Antimicrob Agents Chemother, 2013. 57(2): p. 697-707. |
| 5226 | Kato, K., et al., Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Mol Pharm, 2010. 7(5): p. 1747-56. |
| 5227 | Merchenthaler I, et al. Treatment with an orally bioavailable prodrug of 17β-estradiol alleviates hot flushes without hormonal effects in the periphery. Sci Rep. 2016 Aug 1;6:30721. |
| 5228 | Stickles AM, et al. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. Antimicrob Agents Chemother. 2015 Apr;59(4):1977-82. |
| 5229 | Thiazolopyridine sirtuin modulating compounds. WO 2010071853 A1 |
| 5230 | Liu X, et al. Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. Biochem Pharmacol. 2016 Mar 1;103:118-28. |
| 5231 | Probst BL, et al. RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity. PLoS One. 2015 Apr 21;10(4):e0122942. |
| 5232 | Goldman DC, et al. The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice. Radiat Res. 2015 Mar;183(3):338-44 |
| 5233 | Peng Han, et al. RTA-408 Protects Kidney from Ischemia-Reperfusion Injury in Mice via Activating Nrf2 and Downstream GSH Biosynthesis Gene. Oxid Med Cell Longev. 24 December 2017. |
| 5234 | J. Pharmacol. Exp. Ther. (1950), 98, 300-4; J. Am. Chem. Soc. (1944), 66, 1516-20; Chem. Res. Toxicol. (2001), 14(4), 409-415 |
| 5235 | J Chem Soc 129:2336 (1926); Mutat Res 54:297 (1978); 66:223 (1979); Br J Can 79: 1340 (1999); Life Sci 78:825 (2006) |
| 5236 | Bonaventure P, et al. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J Pharmacol Exp Ther. 2015 Sep;354(3):471-82. |
| 5237 | 1. Lunde CS, et al. Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. Nat Commun. 2019 Jun 27; 10(1):2816. |
| 5238 | J Org Chem 31:205 (1966); 57:387 (1992); J Infect Dis 167:21 (1993)| |
| 5239 | Moyle GJ, et al. The role of stavudine in the management of adults with HIV infection. Antivir Ther. 1997;2(4):207-218. |
| 5240 | Riddler SA, et al. Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Antiviral Res. 1995;27(3):189-203. |
| 5241 | La Rosa F, et al. Stavudine Reduces NLRP3 Inflammasome Activation and Modulates Amyloid-β Autophagy. J Alzheimers Dis. 2019;72(2):401-412. |
| 5242 | Ferraresi R, et al. Protective effect of acetyl-L-carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett. 2006;580(28-29):6612-6616. |
| 5243 | Beria I, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. |
| 5244 | Valsasina B, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16. |
| 5245 | Casolaro A, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424. |
| 5246 | Krueger AB, et al. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cellmigration. J Biol Chem. 2014 Jun 6;289(23):16349-61. |
| 5247 | Kennett GA, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):609-20. |
| 5248 | Bromidge SM, et al. 6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist. J Med Chem. 1997 Oct 24;40(22):3494-6. |
| 5249 | Dalton GL, et al. Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse. Psychopharmacology (Berl). 2006 Mar;185(1):45-57. |
| 5250 | Jonathan E. Tsang, et al. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. ACS Med. Chem. Lett. 2020. May 1. |
| 5251 | Biol Bull 96:233 (1949); J Physiol 237:187 (1974); Biotechniques 37:418, 420, 422 (2004); Int J Thermophys 31:572 (2010) |
| 5252 | Wurdak H, et al. A small molecule accelerates neuronal differentiation in the adult rat. Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16542-7. |
| 5253 | Polson ES, et al. KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Sci Transl Med. 2018 Aug 15;10(454). pii: eaar2718. |
| 5254 | Plant Physiol 127:1256 (2001); J Agric Food Chem 57:5480 (2009) |
| 5255 | Zhang J, et al. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett. 2012 Apr 1;317(1):24-32. |
| 5256 | Tetrahedron 3:230 (1958); Korean J Physiol Pharmacol 14:257 (2010); Arch Pharm Res 33:1843 (2010) |
| 5257 | Biochem Biophys Res Commun 387:444 (2009) |
| 5258 | Cautain B, et al. Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling. PLoS One. 2016 Dec 9;11(12):e0167491. |
| 5259 | Bonhaus DW, et al. RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol. 1999 Jul;127(5):1075-82. |
| 5260 | Bassil AK, et al. Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology. Br J Pharmacol. 2009 Sep;158(1):252-8 |
| 5261 | Derocq JM, et al. In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747. J Pharmacol Exp Ther. 1995 Jan;272(1):224-30. |
| 5262 | Silve S, et al. The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol Cell Biol. 1996 Jun;16(6):2719-27. |
| 5263 | J Chem Soc (C) 1967:145; Tet Lett 1967:2147; Phytochem 21:2753 (1982); |
| 5264 | http://en.wikipedia.org/wiki/3,4-Diaminopyridine#cite_note-4 |
| 5265 | Wang M, et al. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56. |
| 5266 | Kim S, et al. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12. |
| 5267 | Avian Diseases 52:407 (2008) |
| 5268 | Wang Q, et al. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. Eur J Med Chem. 2018 Apr 25;150:366-384. |
| 5269 | Schentag JJ, et al. Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials. Pharmacotherapy. 1991;11(1):2-19. |
| 5270 | PCT Int. Appl. (2012), WO 2012015677 A1 20120202. |
| 5271 | Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. Biotechnology Information (US); 2012-2017 Mar 23. |
| 5272 | Hussein AFA, et al. Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus. Antiviral Res. 2020 May;177:104782. |
| 5273 | Weber O, et al. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res. 2001 Mar;49(3):179-89. |
| 5274 | Reefschlaeger J, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother. 2001 Dec;48(6):757-67. |
| 5275 | Rafatian G, et al. Increase of autophagy and attenuation of apoptosis by Salvigenin promote survival of SH-SY5Y cells following treatment with H₂O₂. Mol Cell Biochem. 2012 Dec;371(1-2):9-22. |
| 5276 | Noori S, et al. Antitumor and immunomodulatory effects of salvigenin on tumor bearing mice. Cell Immunol. 2013 Nov-Dec;286(1-2):16-21. |
| 5277 | Basu D, et al. Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther. 2014 Jun;13(6):1457-67. |
| 5278 | Greenblatt HM, et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. |
| 5279 | Heinrich M, et al. Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol. 2004 Jun;92(2-3):147-62. |
| 5280 | Br J Clin Pharmacol 25:417 (1988); Expert Opin Pharmacother 4:2057 (2003) |
| 5281 | Warner KA, et al. Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3550-9. |
| 5282 | Zhang Q, et al. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281-319. |
| 5283 | J Pharmacol Exp Ther 180:411 (1972); Chest 94:845 (1988); JAMA 283:1445 (2000) |
| 5284 | Imbimbo BP, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretasemodulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease withoutcausing peripheral toxicity. J Pharmacol Exp Ther. 2007 Dec;323(3):822-830. |
| 5285 | Mango D, et al. Electrophysiological and metabolic effects of CHF5074 in the hippocampus: protection against in vitro ischemia. Pharmacol Res. 2014 Mar;81:83-90. |
| 5286 | K Iwai, et al. A novel CDC7-selective inhibitor TAK-931 with potent antitumor activity. European Journal of Cancer , 2016 , 69 (1) :S34. |
| 5287 | Shang RF et al. Synthesis and biological evaluation of new pleuromutilin derivatives as antibacterial agents. Molecules. 2014 Nov 19;19(11):19050-65. |
| 5288 | Tet Letters 1963, 281; J Nat Prod 67:454 (2004) |
| 5289 | Food Cosmet Toxicol 2:327 (1964); J Pharm Pharmacol 21:681 (1969); 24:145 (1972) |
| 5290 | Curr. Probl. Epilepsy (1986), 4, 165-77; Br. J. Clin. Pharmacol. (1985), 20(6), 619-29; Epilepsia (1986), 27(5), 483-9 |
| 5291 | Karpov AS, et al. Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor. ACS Med Chem Lett. 2015 May 22;6(7):776-81. |
| 5292 | Vuong L, et al. An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res. 2019 Jan 23. pii: canres.2244.2018. |
| 5293 | Sastry BV, et al. Relationships between chemical structure and inhibition of choline acetyltransferase by 2-(alpha-naphthoyl)ethyltrimethylammonium and related compounds. Pharmacol Res Commun. 1988 Sep;20(9):751-71. |
| 5294 | B V Sastry, et al. 2-(alpha-Naphthoyl)ethyltrimethylammonium iodide and its beta-isomer: new selective, stable and fluorescent inhibitors of choline acetyltransferase. J Pharmacol Exp Ther. 1988 Apr;245(1):72-80. |
| 5295 | Antimicrob Agents Chemother 1970:117, 123 |
| 5296 | https://clinicaltrials.gov/ct2/show/NCT04348695?term=SIMVASTATIN&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04407273?term=SIMVASTATIN&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT02735707?term=SIMVASTATIN&cond=COVID-19&draw=2&rank=4 |
| 5297 | Zhou J, et al. A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission. Autophagy. 2015;11(8):1259-79. |
| 5298 | Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16. |
| 5299 | Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345. |
| 5300 | Rakonczay Z Jr, et al. Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats. Free Radic Biol Med. 2002 Jun 15;32(12):1283-92. |
| 5301 | Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13(7):482-96. |
| 5302 | Halberstadt AL, et al. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009 Jul;34(8):1958-67. |
| 5303 | Welmaker GS, et al. Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1991-4. |
| 5304 | Kristof RA, et al. Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):379-81. |
| 5305 | Bodey GP, et al. Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother. 1977 Jan;11(1):74-9. |
| 5306 | Keeling CI, et al. New components of the honey bee (<i>Apis mellifera</i> L.) queen retinue pheromone. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4486-91. |
| 5307 | König S, et al. Soluble phenylpropanoids are involved in the defense response of Arabidopsis against <i>Verticillium longisporum</i>. New Phytol. 2014 May;202(3):823-37. |
| 5308 | He Y, et al. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways. Biochem Biophys Res Commun. 2014 Jul 4;449(3):344-50. |
| 5309 | Zhou E, et al. Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways. Int Immunopharmacol. 2014 Sep;22(1):133-40. |
| 5310 | Sa F, et al. Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo. Neurosci Lett. 2015 Apr 23;593:7-12. |
| 5311 | Zhang LQ, et al. Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and AKT/GSK3β pathways. J Ethnopharmacol. 2015 Apr 29. pii: S0378-8741(15)00306-2. |
| 5312 | Chang M, et al.PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.Mol Cancer Ther. 2010 Sep;9(9):2478-87. |
| 5313 | Nathanael Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use. WO2017185031A1. |
| 5314 | Edward S. Kim, et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study. |
| 5315 | Int J Dermatol 19:51 (1980) |
| 5316 | Nature 316:126 (1985); Anticancer Drugs 2:343 (1991); Ann Oncol 4 Suppl 3:S15 (1993) |
| 5317 | Estévez S, et al. Eupatorin-induced cell death in human leukemia cells is dependent on caspases and activates the mitogen-activated protein kinase pathway. PLoS One. 2014 Nov 12;9(11):e112536. |
| 5318 | Gao Y et al. Genkwanin inhibits proinflammatory mediators mainly through the regulation of miR-101/MKP-1/MAPK pathway in LPS-activated macrophages. PLoS One. 2014 May 6;9(5):e96741. |
| 5319 | Ghosh S, et al. An RNAi-based high-throughput screening assay to identify small molecule inhibitors of hepatitis B virus replication.J Biol Chem. 2017 Jul 28;292(30):12577-12588. |
| 5320 | Daniel P Zimmer, et al. Abstract 16938: IW-1973 is a Potent Soluble Guanylate Cyclase Stimulator in vitro and in vivo With Extensive Tissue Distribution. |
| 5321 | Paola Magnaghi, et al. Covalent and allosteric inhibitors of the ATPATP ase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013 Jul 28. doi: 10.1038/nchembio.1313. |
| 5322 | Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:198-202. |
| 5323 | Gupta K, et al. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999 Feb 24;281(8):736-8. |
| 5324 | Gupta K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20. |Anal Profiles Drug Subs 5:345 (1976); Am J Obstet Gynecol 191:182 (2004) |
| 5325 | Stella Chaviaras, et al. Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology (Berl). 2010 May;210(1):35-43. |
| 5326 | Gerald Gimpl, et al. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur J Pharmacol. 2005 Mar 7;510(1-2):9-16. |
| 5327 | David Feifel, et al. The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol. 2012 May;22(5):374-8. |
| 5328 | J. Photochem. Photobiol., B (1998), 44(1), 69-76; Photochem. Photobiol. (1996), 64(4), 688-693; Photochem. Photobiol. (1992), 55(4), 549-60 |
| 5329 | Scannevin RH, et al. Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) thatallosterically inhibits zymogen activation. J Biol Chem. 2017 Oct 27;292(43):17963-17974. |
| 5330 | J Chem Soc 1950: 2376 |
| 5331 | Neeraj Mahindroo, et al. Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway. Bioorg Med Chem. 2010 Jul 1;18(13):4801-11. |
| 5332 | Cisar JS, et al. Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders. J Med Chem. 2018 Oct 25;61(20):9062-9084. |
| 5333 | Flavia Mercer Pernasetti, et al. Combinations of tgfb inhibitors and cdk inhibitors for the treatment of breast cancer. Patent WO2020058820A1. |
| 5334 | Blake JF, et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Developme |
| 5335 | Kirk Robarge, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014. |
| 5336 | MICHAEL LAI. Opportunity for Pharmaceutical Intervention in Lung Cancer: Selective Inhibition of JAK1/2 to Eliminate EMT-Derived Mesenchymal Cells. |
| 5337 | Shahzad B, et al. Role of 24-epibrassinolide (EBL) in mediating heavy metal and pesticide induced oxidative stress in plants: A review. Ecotoxicol Environ Saf. 2018 Jan;147:935-944. |
| 5338 | Obakan P, et al. Activation of polyamine catabolic enzymes involved in diverse responses against epibrassinolide-induced apoptosis in LNCaP and DU145 prostate cancer cell lines.Amino Acids. 2014 Mar;46(3):553-64. |
| 5339 | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000492-36 |
| 5340 | Kobayashi, H., Y. Hasegawa, and H. Ono, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol, 1996. 311(1): p. 29-35. |
| 5341 | Honda, M., T. Nishida, and H. Ono, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol, 2003. 458(1-2): p. 91-9. |
| 5342 | Plé PA, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem. 2004 Feb 12;47(4):871-87. |
| 5343 | Yezhelyev MV, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res. 2004 Dec 1;10(23):8028-36. |
| 5344 | Phytochemistry 12:421 (1973); Chem Pharm Bull 26:2036 (1978); Planta Medi 64:134 (1998) |
| 5345 | Su S, et al. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. J Med Chem. 2019 Aug 22;62(16):7575-7582. |
| 5346 | Lessene G, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013 Jun;9(6):390-7. |
| 5347 | Abed MN, et al. Antagonism of Bcl-XL is necessary for synergy between NSC 241240 and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 2016 Apr 14;9:25. |
| 5348 | Liao Q, et al. Germacrone inhibits early stages of influenza virus infection. Antiviral Res. 2013 Dec;100(3):578-88. |
| 5349 | Ryu S, et al. Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. Biol Pharm Bull. 2013;36(3):467-74. |
| 5350 | Chi YH, et al. Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist. Biol Pharm Bull. 2013;36(7):1208-15. |
| 5351 | Lee HW, et al. Effect of age on the pharmacokinetics of fimasartan (BR-A-657). Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1337-44. |
| 5352 | Shin KH, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol. 2011 Nov;58(5):492-9. |
| 5353 | Phytochemistry 14: 1829 (1975) |
| 5354 | J Neurochem 25: 797 (1975); Life Sci 19: 701 (1976) |
| 5355 | Hwang SY, et al. Synthesis and biological effect of chrom-4-one derivatives as functional inhibitors of heat shockprotein 27. Eur J Med Chem. 2017 Oct 20;139:892-900. |
| 5356 | Younghwa Na, et al. Methods for treating pulmonary fibrosis using chromenone derivatives. |
| 5357 | Venezian A, et al. The Influence of the Plant Growth Regulator Maleic Hydrazide on Egyptian Broomrape Early Developmental Stages and Its Control Efficacy in Tomato under Greenhouse and Field Conditions. Front Plant Sci. 2017;8:691. Published 2017 May 16. |
| 5358 | Swietlińska Z, et al. Cytotoxic effects of maleic hydrazide. Mutat Res. 1978;55(1):15-30. |
| 5359 | Yurdakok B, et al. Cytotoxic effects of etephon and maleic hydrazide in Vero, Hep2, HepG2 cells. Drug Chem Toxicol. 2014;37(4):459-465. |
| 5360 | Chakrabarti D, et al. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum.J Biol Chem. 2002 Nov 1; 277(44):42066-73. Epub 2002 Aug 22. |
| 5361 | Ducker GS, et al. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11404-11409. |
| 5362 | Burgeson JR, et al. Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. Bioorg Med Chem Lett. 2013 Feb 1;23(3):750-6. |
| 5363 | Larson RA, et al. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008 Nov;82(21):10768-75. |
| 5364 | Cashman KA, et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 2011 Apr;90(1):70-9. |
| 5365 | Gao H, et al. Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIalpha/beta poison. Cancer Res. 2000 Nov 1;60(21):5937-40. |
| 5366 | Branda RF, et al. Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells. Biochem Pharmacol. 1988 Dec 1;37(23):4557-64. |
| 5367 | Chambers MS, et al. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties. J Med Chem. 2004 Nov 18;47(24):5829-32. |
| 5368 | Atack JR, et al. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. J Pharmacol Exp Ther. 2009 Nov;331(2):470-84. |
| 5369 | Eimerbrink MJ, et al. Administration of the inverse benzodiazepine agonist MRK-016 rescues acquisition and memory consolidation following peripheral administration of bacterial endotoxin. Behav Brain Res. 2015 Jul 15;288:50-3. |
| 5370 | Byrd DJ, et al. The analysis of indolic tryptophan metabolites in human urine. Thin-layer chromatography and in situ quantitation. J Chromatogr. 1974 Jul 17;94(0):85-106. |
| 5371 | HARTMANN F, et al. [Indolepatterns in the urine of liver patients]. Klin Wochenschr. 1962 Jul 15;40:721-9. |
| 5372 | Sun S, et al. Jatrorrhizine reduces 5-HT and NE uptake via inhibition of uptake-2 transporters and produces antidepressant-like action in mice. Xenobiotica. 2019 Oct;49(10):1237-1243. |
| 5373 | Xiaofei Jiang, et al. Synthesis and Biological Evaluation of Novel Jatrorrhizine Derivatives with Amino Groups Linked at the 3-Position as Inhibitors of Acetylcholinesterase. Research Article Volume 2017 |
| 5374 | C W Wright, et al. In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids. J Nat Prod. 2000 Dec;63(12):1638-40. |
| 5375 | MN Dickler, et al. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC). AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD5-10. |
| 5376 | Biochem Biophys Res Commun 81:176 (1978) |
| 5377 | Zhang L, et al. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling. J Proteome Res. 2013 Jul 5;12(7):3104-16. |
| 5378 | Proc. Am. Soc. Hortic. Sci. (1956), 67, 312-23; Proc. R. Soc. London, Ser. A (1931), 134, 372-84; Pharmazie (1983), 38(11), 755-8 |
| 5379 | Digestion 51 18 (1992) |
| 5380 | Arora S, et al. Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res. 2003 Oct 15;63(20):6894-9. |
| 5381 | Chen Z, et al. 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem. 2011 Dec 23;286(51):43951-8. |
| 5382 | Novaes JT, et al. Disposition, Metabolism and Histone Deacetylase and Acetyltransferase Inhibition Activity of Tetrahydrocurcumin and Other Curcuminoids. Pharmaceutics. 2017 Oct 12;9(4). pii: E45. |
| 5383 | Smith CJ, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8. |
| 5384 | Lampiasi N, et al. The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Mol Med. 2006 Feb;17(2):245-52. |
| 5385 | Teng XW, et al. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat. J Pharm Pharm Sci. 2003 May-Aug;6(2):205-10. |
| 5386 | Solt LA, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012 Mar 29;485(7396):62-68. |
| 5387 | Riendeau D, et al. Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg Med Chem Lett. 2004;14(5):1201-1203. |
| 5388 | Paudel S, et al. Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators. Pharmaceutics. 2019;11(9):479. Published 2019 Sep 16. |
| 5389 | Phytochemistry 15: 1773 (1976); Pharmazie 34: 426 (1979) |
| 5390 | Am. J. Dig. Dis. (1960), 5, 639-54; Arch. Int. Pharmacodyn. Ther. (1959), 121, 78-84; J. Am. Pharm. Assoc. (1957), 46, 592-4 |
| 5391 | JACS 61: 175 (1939); Tetrahedron 19: 773 (1963) |
| 5392 | Zhang YH, et al. 3,5-Dicaffeoylquinic acid isolated from Artemisia argyi and its ester derivatives exert anti-leucyl-tRNA synthetase of Giardia lamblia (GlLeuRS) and potential anti-giardial effects. Fitoterapia. 2012 Oct;83(7):1281-5. |
| 5393 | Malarz J, et al. Long-term cultured hairy roots of chicory-a rich source of hydroxycinnamates and 8-deoxylactucin glucoside. Appl Biochem Biotechnol. 2013 Dec;171(7):1589-601. |
| 5394 | Wan C, et al. Isolation and identification of phenolic compounds from Gynura divaricata leaves. Pharmacogn Mag. 2011 Apr;7(26):101-8. |
| 5395 | Reinhard J, et al. Monosaccharide-linked inhibitors of O(6)-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships. J Med Chem. 2001 Nov 22;44(24):4050-61. |
| 5396 | Clemons M, et al. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer. 2005 Nov 14;93(10):1152-6. |
| 5397 | Lee E Schechter, et al. Neuropharmacological Profile of Novel and Selective 5-HT6 Receptor Agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology. 2008 May;33(6):1323-35. |
| 5398 | Teresa Riccioni, et al. ST1936 Stimulates cAMP, Ca2+, ERK1/2 and Fyn Kinase Through a Full Activation of Cloned Human 5-HT6 Receptors. Eur J Pharmacol. 2011 Jul 1;661(1-3):8-14. |
| 5399 | R Hong, Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium. |
| 5400 | Shang Y, et al. Cucurbitacin-B inhibits neuroblastoma cell proliferation through up-regulation of PTEN. Eur Rev Med Pharmacol Sci. 2014;18(21):3297-303. |
| 5401 | Zhang M, et al. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. Mol Med Rep. 2014 Dec;10(6):2905-11. |
| 5402 | Gupta P, et al. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget. 2014 Apr 15;5(7):1812-28. |
| 5403 | Guo J, et al. Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner. PLoS One. 2014 Feb 4;9(2):e88140. |
| 5404 | Lannutti BJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 2011, 117(2), 591-594. |
| 5405 | Herman SE, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood, 2010, 116(12), 2078-2088. |
| 5406 | Low PC, et al. PI3Kδ inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model. Nat Commun. 2014 Mar 14;5:3450. |
| 5407 | Cooney J, et al. Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies. Clin Cancer Res. 2018 Mar 1;24(5):1103-1113. |
| 5408 | Chest (2010), 138(2, Suppl.), 18S-24S; Allergy (2001), 56(12), 1114-1120; Br. J. Pharmacol. (1970), 38(4), 758-70 |
| 5409 | Ohori M, et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun. 2005 Oct 14;336(1):357-63. |
| 5410 | Ohori M, et al. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2007 Jan;374(4):311-6. |
| 5411 | Honda M, et al. Mesothelioma cell proliferation through autocrine activation of PDGF-ββ receptor. Cell Physiol Biochem. 2012;29(5-6):667-74 |
| 5412 | Sreekanth GP, et al. Role of ERK1/2 signaling in dengue virus-induced liver injury. Virus Res. 2014 Aug 8;188:15-26 |
| 5413 | Aust J Sci Res, Ser A 5:401 (1952); Planta Med 42:400 (1981) |
| 5414 | Neu HC. In vitro activity of midecamycin, a new macrolide antibiotic. Antimicrob Agents Chemother. 1983 Sep;24(3):443-4. |
| 5415 | Cong L, et al. Cloning and characterization of genes encoded in dTDP-D-mycaminose biosynthetic pathway from amidecamycin-producing strain, Streptomyces mycarofaciens. Acta Biochim Biophys Sin (Shanghai). 2007 Mar;39(3):187-93. |
| 5416 | Jonathan D. Bohbot, et al. Insect Repellents: Modulators of Mosquito Odorant Receptor Activity. PLoS One. 2010; 5(8): e12138. |
| 5417 | Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. |
| 5418 | Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18. |
| 5419 | Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96. |
| 5420 | Clark K, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104. |
| 5421 | Petherick KJ, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem. 2015 May 1;290(18):11376-83. |
| 5422 | Zhu Z, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. 26.37Cancer Discov. 2014 Apr;4(4):452-65. |
| 5423 | Araújo FA, Rocha MA, Capettini LS, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (fluvastatin) decreases inflammatory angiogenesis in mice. APMIS. 2012 24. [Epub ahead of print] |
| 5424 | Makabe S, Takahashi Y, Watanabe H, et al. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis. 2010 Dec;213(2):377-84. |
| 5425 | Zhang W, Wu J, Zhou L, et al. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010 Dec;48(12):1167-74. |
| 5426 | Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81. |
| 5427 | https://clinicaltrials.gov/ct2/show/NCT04890626?term=Tenofovir&cond=covid&draw=2&rank=8 |
| 5428 | Jennings LE, et al. BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability. Bioorg Med Chem. 2018 Jul 15;26(11):2937-2957. |
| 5429 | Lin TA, et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry.?2004 Aug 31;43(34):11056-62. |
| 5430 | Colley T, et al. In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02280-16. |
| 5431 | Colley T, et al. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. Sci Rep. 2019 Jul 1;9(1):9482. |
| 5432 | J Rheumatol 23 Suppl 44:64 (1996); Pharmacotherapy 7:165 (1987); Mult Scler 1:379 (1996)| |
| 5433 | Patel, A.A., R.A. Swerlick, and C.O. McCall, Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol, 2006. 55(3): p. 369-89. |
| 5434 | Maltzman, J.S. and G.A. Koretzky, Azathioprine: old drug, new actions. J Clin Invest, 2003. 111(8): p. 1122-4. |
| 5435 | Dubinsky, M.C., Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol, 2004. 2(9): p. 731-43. |
| 5436 | Sov Med 12, 26 (1941); Science 327:348 (2010) |
| 5437 | Haubner R, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001 Feb;42(2):326-36. |
| 5438 | J Pharm Sci 71:565 (1982); Int J Tissue React 5:35 (1983) |
| 5439 | Chest 105:1765 (1994); Int J Toxicol 27 Suppl 2:71 (2008) |
| 5440 | Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8(42):72167-72181. |
| 5441 | Am. J. Obstet. Gynecol. (1978), 130(3), 294-9; J. Lab. Clin. Med. (1977), 90(4), 638-44 |
| 5442 | Acta Pharmacol Toxicol 5:110 (1949); J Physiol 451: 91 (1992); Microscopy Res Techn 69:108 (2006) |
| 5443 | Pharmacol. Ther. (2003), 99(2), 167-181; Antibiotics 1979), 5(1), 214-34; J. Am. Chem. Soc. (1955), 77, 6404-5 |
| 5444 | Curr. Allergy Asthma Rep. (2009), 9(2), 101-106; Appl. Thera. (1967), 9(1), 55-9; J. Allergy (1962), 33, 479-84 |
| 5445 | Guo C, et al. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. Immunity. 2016 Oct 18;45(4):944. |
| 5446 | Lon HK, et al. Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. Clin Pharmacol Drug Dev. 2018 Jul 27. |
| 5447 | Chen L, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol. 2005 Jun;79(11):7095-103. |
| 5448 | Hernekamp JF, et al. Cinanserin reduces plasma extravasation after burn plasma transfer in rats. Burns. 2013 Sep;39(6):1226-33. |
| 5449 | Leysen JE, et al. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015-22. |
| 5450 | Can J Chem 47: 2733 (1969); 61: 2055 (1983); Phytochemistry 12: 937 (1973) |
| 5451 | Ford AP, et al. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications foralpha1-adrenoceptor classification. Br J Pharmacol. 1997 Jul;121(6):1127-35. |
| 5452 | Minneman KP, et al. Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. |
| 5453 | Wang J, et al. Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway. Front Biosci (Landmark Ed). 2016 Jan 1;21:502-13. |
| 5454 | Lazou A, et al. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. Biochem J. 1998 Jun 1;332 ( Pt 2):459-65. |
| 5455 | Li NJ, et al. Effect of phenylephrine on alveolar fluid clearance in ventilator-induced lung injury. Chin Med Sci J. 2013 Mar;28(1):1-6. |
| 5456 | Lin Z, et al. Anti-lung Cancer Effects of Polyphyllin VI and VII Potentially Correlate with Apoptosis In Vitro and In Vivo. Phytother Res. 2015 Oct;29(10):1568-76. |
| 5457 | Liu Y, et al. Molecular Mechanisms of Apoptosis in HepaRG Cell Line Induced by Polyphyllin VI via the Fas Death Pathway and Mitochondrial-Dependent Pathway. Toxins (Basel). 2018 May 15;10(5). pii: E201. |
| 5458 | Jin-Feng Teng, et al. Polyphyllin VI Induces Caspase-1-Mediated Pyroptosis via the Induction of ROS/NF-κB/NLRP3/GSDMD Signal Axis in Non-Small Cell Lung Cancer. Cancers (Basel). 2020 Jan 13;12(1):193. |
| 5459 | J Parasitology 74:931 (1988); Lancet 1:1397 (1989)| |
| 5460 | Diaferia, M., et al., Efficacy of toltrazuril 5 % suspension (Baycox(R), Bayer) and diclazuril (Vecoxan(R), Janssen-Cilag) in the control of Eimeria spp. in lambs. Parasitol Res, 2013. 112 Suppl 1: p. 163-8. |
| 5461 | http://www.huvepharma.com/products/view/190 |
| 5462 | Herbert JM, et al. Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C. J Nat Prod. 1991 Nov-Dec;54(6):1595-600. |
| 5463 | Li Y, et al. Verbascoside Alleviates Atopic Dermatitis-Like Symptoms in Mice via Its Potent Anti-Inflammatory Effect. Int Arch Allergy Immunol. 2018;175(4):220-230. |
| 5464 | Amin B, et al. The Effect of Verbascoside in Neuropathic Pain Induced by Chronic Constriction Injury in Rats. Phytother Res. 2016 Jan;30(1):128-35. |
| 5465 | Expert Opin. Drug Metab. Toxicol. (2009), 5(3), 333-343; Lung (2008), 186(Suppl. 1), S70-S73; Drugs (1996), 52(6), 875-881 |
| 5466 | Fantin VR et al. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell. 2002 Jul;2(1):29-42. |
| 5467 | Fantin VR et al. F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell. Cancer Res. 2004 Jan 1;64(1):329-36. |
| 5468 | https://clinicaltrials.gov/ct2/show/NCT04380376?term=MELPHALAN&cond=covid&draw=2&rank=1 |
| 5469 | Baek SH, et al. Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase. Molecules. 2017 Feb 13;22(2). pii: E276. |
| 5470 | Comp. Biochem. Physiol., Part C: Toxicol. Pharmacol. (1987), 86(2), 225-32; Nature (1979), 281(5727), 148-50; J. Ment. Sci. (1962), 108, 101-4 |
| 5471 | https://clinicaltrials.gov/ct2/show/NCT04394117?term=IRBESARTAN&cond=covid&draw=2&rank=2 |
| 5472 | Jain R, et al. Polyaniline-graphene oxide nanocomposite sensor for quantification of calcium channel blocker levamlodipine. Mater Sci Eng C Mater Biol Appl. 2016 Aug 1;65:205-14. |
| 5473 | Drugs (2006), 66(18), 2397-2416; Drugs (1995), 50(2), 396-415; J. Med. Chem. (1989), 32(8), 1738-43 |
| 5474 | Gal S, et al. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J Neural Transm Suppl. 2006;(70):447-456. |
| 5475 | Zheng H, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem. 2005;95(1):68-78. |
| 5476 | Gal S, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem. 2005;95(1):79-88. |
| 5477 | Gal S, et al. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res. 2010;17(1):15-27. |
| 5478 | Pelletier JC, et al. (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-catenin agonist that increases bone formation rate. J Med Chem. 2009 Nov 26;52(22):6962-5. |
| 5479 | L Enochson, et al. GDF5 reduces MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition. Osteoarthritis Cartilage. 2014 Apr;22(4):566-77. |
| 5480 | Gong X, et al. Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discov. 2018 Oct 29. pii: CD-18-0469. |
| 5481 | CNS Drugs (2010), 24(9), 769-796; Expert Opin. Drug Metab. Toxicol. (2007), 3(5), 741-753; Drugs Future (2001), 26(2), 115-120 |
| 5482 | Zhang P, et al. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model. J Pharmacol Exp Ther. 2015 Jan;352(1):139-47. |
| 5483 | Chen YY, et al. Demethyleneberberine alleviates inflammatory bowel disease in mice through regulating NF-κB signaling and T-helper cell homeostasis. Inflamm Res. 2017 Feb;66(2):187-196. |
| 5484 | Qiang X, et al. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Biochem Biophys Res Commun. 2016 Apr 15;472(4):603-9. |
| 5485 | Hodge RJ, et al. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes. Clin Pharmacol Drug Dev. 2013 Jul;2(3):213-22. |
| 5486 | https://clinicaltrials.gov/ct2/show/NCT04351724?term=Candesartan&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04591210?term=Candesartan&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04394117?term=Candesartan&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04467931?term=Candesartan&cond=COVID-19&draw=2&rank=5 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001302-30-AT |
| 5487 | J Am Chem Soc 93: 2325 (1971) |
| 5488 | Choi WS, et al. Veratric acid inhibits iNOS expression through the regulation of PI3K activation and histone acetylation in LPS-stimulated RAW264.7 cells. Int J Mol Med. 2015 Jan;35(1):202-10. |
| 5489 | Saravanakumar M, et al. Oral administration of veratric acid, a constituent of vegetables and fruits, prevents cardiovascular remodelling in hypertensive rats: a functional evaluation. Br J Nutr. 2015 Nov 14;114(9):1385-94. |
| 5490 | Shin SW, et al. Antagonist effects of veratric acid against UVB-induced cell damages. Molecules. 2013 May 10;18(5):5405-19. |
| 5491 | Astudillo L et al. The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis. Cancer Res. 2016 Jun 15;76(12):3593-603. |
| 5492 | Jung JA, et al. Pharmacokinetic comparison of the maleate and free base formulations of LB80380, a novel nucleotide analog, in healthy male volunteers. Int J Clin Pharmacol Ther. 2012 Sep;50(9):657-64. |
| 5493 | Yuen MF, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther. 2006;11(8):977-83. |
| 5494 | Hamaguchi W, et al. Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors. Chem Pharm Bull (Tokyo). 2014;62(12):1200-1213. |
| 5495 | Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009 Aug 27;52(16):5188-5196. |
| 5496 | Tetrahedron 21: 2697 (1965) |
| 5497 | Poce G et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One. 2013;8(2) |
| 5498 | Deidda D et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 1998 Nov;42(11):3035-7. |
| 5499 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=PENBUTOLOL+&cntry=&state=&city=&dist=&Search=Search |
| 5500 | Doe C, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. |
| 5501 | Monica A. Konerman, et al. Overview of Clinical Treatment Trials for NASH.Curr Hepatol Rep. 2017 Dec;16(4): 366-373. |
| 5502 | Yang XN, et al. Metabolic Activation of Elemicin Leads to the Inhibition of Stearoyl-CoA Desaturase 1. Chem Res Toxicol. 2019 Sep 10. |
| 5503 | Yang SH, et al. Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5277-81. |
| 5504 | Young Bok Lee, et al. 5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents. WO 2008063548 A2. |
| 5505 | Jamialahmadi K, et al. Protective effects of glucosamine hydrochloride against free radical-induced erythrocytes damage. Environ Toxicol Pharmacol. 2014 Jul;38(1):212-9. |
| 5506 | Jo JR, et al. Short-term treatment with glucosamine hydrochloride specifically downregulates hypoxia-inducible factor-1α at the protein level in YD-8 human tongue cancer cells. Int J Oncol. 2014 May;44(5):1699-706. |
| 5507 | Park J, et al. Glucosamine hydrochloride exerts a protective effect against unilateral ureteral obstruction-induced renal fibrosis by attenuating TGF-β signaling. J Mol Med (Berl). 2013 Nov;91(11):1273-84. |
| 5508 | Bruyère O, et al. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S12-7. |
| 5509 | George I, et al. Use of beta-D-galactosidase and beta-D-glucuronidase activities for quantitative detection of totaland fecal coliforms in wastewater. Can J Microbiol. 2001 Jul;47(7):670-5. |
| 5510 | Sanyo Kenkyusho Nempo 39:1 (1987); J Antimicrob Chemother 26 Suppl E:1 (1990)| |
| 5511 | Iqbal S, et al. In vitro Spectroscopic studies on drug interaction of cefpodoxime proxetil and H2 receptor blockers. Pak J Pharm Sci. 2019 Mar;32(2 (Supplementary)):881-887. |
| 5512 | Jamieson S, et al. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J, 2011, 438(1), 53-62. |
| 5513 | Sun M, et al. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A, 2010, 107(35), 15547-15552. |
| 5514 | https://clinicaltrials.gov/ct2/show/NCT04470622?term=Aprepitant&cond=covid&draw=2&rank=1 |
| 5515 | Andrew D Napper, et al. Discovery of Indoles as Potent and Selective Inhibitors of the Deacetylase SIRT1. J Med Chem. 2005 Dec 15;48(25):8045-54. |
| 5516 | Thomas Shenk, et al. Sirtuin Modulators as Inhibitors of Cytomegalovirus. US20160296523A1. |
| 5517 | Huber KV, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508(7495):222-7. |
| 5518 | Dai X, et al. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. J Exp Clin Cancer Res. 2017 Sep 7;36(1):120. |
| 5519 | Drew AE, et al. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Sci Rep. 2017 Dec 21;7(1):17993. |
| 5520 | J Chem Soc 1959:1406; Alkaloids 33:1 (1988) |
| 5521 | Vo DT, et al. Insect nicotinic acetylcholine receptor agonists as flea adulticides in small animals. J Vet Pharmacol Ther. 2010 Aug;33(4):315-22. |
| 5522 | Rust MK, et al. Efficacy and longevity of nitenpyram against adult cat fleas (Siphonaptera: Pulicidae). J Med Entomol. 2003 Sep;40(5):678-81. |
| 5523 | Zhan Y, et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat Chem Biol. 2008 Sep;4(9):548-56. |
| 5524 | J Am Chem Soc 74: 3211 (1952) |
| 5525 | Shimada H, et al. Biologically active acylglycerides from the berries of saw-palmetto (Serenoa repens). J Nat Prod. 1997 Apr;60(4):417-8. |
| 5526 | Vandevoorde S, et al. Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun. 2005 Nov 11;337(1):104-9. |
| 5527 | Jumina, et al. Monomyristin and Monopalmitin Derivatives: Synthesis and Evaluation as Potential Antibacterial and Antifungal Agents. Molecules. 2018 Nov 29;23(12). pii: E3141 |
| 5528 | Moritz AE, et al. Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist. J Med Chem. 2020;63(10):5526‐5567. |
| 5529 | Giner-Larza EM et al.Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity.Eur J Pharmacol.Sep 28;428(1):137-43.doi:10.1016/S0014-2999(01)01290-0(2001) |
| 5530 | Fabio Mengoni.Anti-HIV Activity of Oleanolic Acid on Infected Human Mononuclear Cells.Planta Med 68(2): 111-114.DOI: 10.1055/s-2002-20256(2002) |
| 5531 | Endocrine Res 5:161 (1978); Pharmacol Biochem Behavior,14:831 (1981); Behavioral Neurosci 111:825 (1997); 119:821 (2005) |
| 5532 | Curr. Opin. Oncol. (1997), 9(6), 569-78; Gynecol. Oncol. (1993), 51(1), 104-8; Semin. Oncol. (1992), 19(6 Suppl 12), 65-71 |
| 5533 | Oncogene 26:258 (2007) |
| 5534 | Sarau HM, et al. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J Pharmacol Exp Ther. 2000 Oct;295(1):373-81. |
| 5535 | Shepherd JA, et al. Antibacterial action of 2-bromo-2-nitropropane-1,3-diol (bronopol). Antimicrob Agents Chemother. 1988 Nov;32(11):1693-8. |J Pharm Pharmacol 16 Suppl:127T (1964); J Soc Cosmet Chem 28:3 (1977) |
| 5536 | Kumar D, et al.Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. Eur J Med Chem. 2018 Mar 25;148:436-452. |
| 5537 | A single dose of the beta-secretase inhibitor, e2609, decreases CSF bace1 enzymatic activity in cynomolgus monkeys. Alzheimer’s & Dementia, 8(4), P224. |
| 5538 | Wang Z, et al. An LC-MS/MS method for simultaneous determination of 1,5-dicaffeoylquinic acid and 1-O-acetylbritannilactone in rat plasma and its application to a pharmacokinetic study. |
| 5539 | Xiao HB, et al. 1,5-dicaffeoylquinic acid protects primary neurons from amyloid β 1-42-induced apoptosis via PI3K/Akt signaling pathway. Chin Med J (Engl). 2011 Sep;124(17):2628-35. |
| 5540 | Cao X, et al. 1, 5-Dicaffeoylquinic acid-mediated glutathione synthesis through activation of Nrf2 protects against OGD/reperfusion-induced oxidative stress in astrocytes. Brain Res. 2010 Aug 6;1347:142-8. |
| 5541 | https://clinicaltrials.gov/ct2/show/NCT04389567?term=Famotidine&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04504240?term=Famotidine&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04370262?term=Famotidine&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04565392?term=Famotidine&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04724720?term=Famotidine&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT05043350?term=Famotidine&cond=COVID-19&draw=2&rank=8 https://clinicaltrials.gov/ct2/show/NCT04621149?term=Famotidine&cond=COVID-19&draw=2&rank=9 |
| 5542 | Sachan S, et al. Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken. Vaccine. 2015 Aug 26;33(36):4526-32. |
| 5543 | Brugnolo F, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol. 2003 Feb;111(2):380-8. |
| 5544 | Zhou ZX, et al. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus). Dev Comp Immunol. 2015 Mar;49(1):113-20. |
| 5545 | PNAS 93:9742 (1996); J Biol Chem 276:46946 (2001); Current Med Chem 10:1795 (2003) |
| 5546 | Cui R, et al. Effects of noradrenergic and serotonergic systems on risk-based decision-making and center arena activity in open field in rats. Eur J Pharmacol. 2018 Sep 27. pii: S0014-2999(18)30566-1. |
| 5547 | Mitchell EB, et al. Efficacy of afoxolaner against Ixodes scapularis ticks in dogs.Vet Parasitol. 2014 Apr 2;201(3-4):223-5. |
| 5548 | Beugnet F, et al. Afoxolaner against fleas: immediate efficacy and resultant mortality after short exposure on dogs.Parasite. 2014;21:42. |
| 5549 | Hayakawa N, et al. Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201. Bioorg Med Chem. 2014 Jun 1;22(11):3021-9. |
| 5550 | Guckian, Kevin, et al. Preparation of naphthalenes and isoquinolines as ATX modulating agents. WO 2014018881 A1. |
| 5551 | Seeman P, et al. Dopamine receptor pharmacology. Trends Pharmacol Sci. 1994 Jul;15(7):264-70. |
| 5552 | Barton KM, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014 Aug 19;9(8):e102684. |
| 5553 | Lundh M, et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015 Jul;17(7):703-7. |
| 5554 | Wagner FF, et al. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chem Biol. 2016 Feb 19;11(2):363-74. |
| 5555 | López-Cervantes M, et al. Chemical enhancers for the absorption of substances through the skin: Laurocapram and its derivatives. Drug Dev Ind Pharm. 2006 Mar;32(3):267-86. |
| 5556 | Bran JL, et al. Clinical and in vitro evaluation of cephapirin, a new cephalosporin antibiotic. Antimicrob Agents Chemother. 1972 Jan;1(1):35-40. |
| 5557 | Br J Pharmacol 3:237 (1948); J Chem Soc 1953:1102; Chem & Ind 1957:1510; Ann 619:96 (1958); Eur J Med Chem 5:129 (1970) |
| 5558 | Van Zandt MC, et al. Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potentinhibitors of human arginases I and II for treatment of myocardial reperfusion injury. J Med Chem. 2013 Mar 28;56(6):2568-80. |
| 5559 | Huang Y, et al. Sophocarpine inhibits the growth of gastric cancer cells via autophagy and apoptosis. Front Biosci (Landmark Ed). 2019 Mar 1;24:616-627. |
| 5560 | Farmaco Ed Prat 34:202 (1979); Arzneim Forsch 33:277, 290 (1983); Drugs Aging 2:58 (1992) |
| 5561 | Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7. |
| 5562 | Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4 |
| 5563 | Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26 |
| 5564 | Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9. |
| 5565 | Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14. |
| 5566 | Invest. Radiol. (1988), 23(Suppl. 1), S79-S83; Invest. Radiol. (1990), 25 Suppl 1S107-8; Invest. Radiol. (1990), 25(1), 46-51 |
| 5567 | Garcia Fortanet J, et al. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. J Med Chem. 2016 Sep 8;59(17):7773-82. |
| 5568 | Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016 Jul 7;535(7610):148-52. |
| 5569 | Cancer Letters 170:15 (2001) |
| 5570 | Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47. |
| 5571 | Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47. |
| 5572 | Grange JM, et al. Activity of bromhexine and ambroxol, semi-synthetic derivatives of vasicine from the Indian shrub Adhatoda vasica, against Mycobacterium tuberculosis in vitro. J Ethnopharmacol. 1996 Jan;50(1):49-53. |
| 5573 | https://clinicaltrials.gov/ct2/show/NCT04920760?term=RETINOL&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04877509?term=RETINOL&cond=Covid19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04900415?term=RETINOL&cond=Covid19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT05002530?term=RETINOL&cond=Covid19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04568096?term=RETINOL&cond=Covid19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04751669?term=RETINOL&cond=Covid19&draw=2&rank=8 |
| 5574 | Heffron TP, et al. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2408-11. |
| 5575 | Park SH, et al. Identification of acetylshikonin as the novel CYP2J2 inhibitor with anti-cancer activity in HepG2 cells. Phytomedicine. 2017 Jan 15;24:134-140. |
| 5576 | Shon JC, et al. Acetylshikonin is a novel non-selective cytochrome P450 inhibitor. Biopharm Drug Dispos. 2017 Dec;38(9):553-556. |
| 5577 | Wang Y, et al. Acetylshikonin, a Novel AChE Inhibitor, Inhibits Apoptosis via Upregulation of Heme Oxygenase-1 Expression in SH-SY5Y Cells. Evid Based Complement Alternat Med. 2013;2013:937370. |
| 5578 | Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. |
| 5579 | Pauls E, et al. Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cells. J Biol Chem. 2012 Jun 1;287(23):19216-28. |
| 5580 | Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737. |
| 5581 | Massillon D, et al. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem J. 1994 Apr 1;299 (Pt 1):123-8. |
| 5582 | Ugarkar BG, et al. Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. J Med Chem. 2000 Jul 27;43(15):2883-93. |
| 5583 | García-Villafranca J, et al. Effects of 5-iodotubercidin on hepatic fatty acid metabolism mediated by the inhibition of acetyl-CoA carboxylase. Biochem Pharmacol. 2002 Jun 1;63(11):1997-2000. |
| 5584 | De Antoni A, et al. A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B. J Cell Biol. 2012 Oct 15;199(2):269-84. |
| 5585 | Acharya MM, et al. Adenosine Kinase Inhibition Protects against Cranial Radiation-Induced Cognitive Dysfunction. Front Mol Neurosci. 2016 Jun 3;9:42. |
| 5586 | Pharm J 2:184 (1976) |
| 5587 | Corti A, et al. γ-Glutamyltransferase enzyme activity of cancer cells modulates L-γ-glutamyl-p-nitroanilide (GPNA) cytotoxicity. Sci Rep. 2019 Jan 29;9(1):891. |
| 5588 | J. Am. Chem. Soc. (1957), 79, 4561-3; Med. Klin. (1963), 58, 1722-6; Br. J. Vener. Dis. (1962), 38, 157-60 |
| 5589 | Xiang C, et al. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer. Int J Biol Markers. 2018 Aug;33(3):314-320. |
| 5590 | Z Naturforsch 21b: 714 (1966); J Nat Sci Found Sri Lanka 40:43 (2012) |
| 5591 | https://clinicaltrials.gov/ct2/show/NCT04483973?term=EBSELEN&cond=covid-19&draw=2&rank=1 |
| 5592 | Stocker SL, et al. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol. 2012 Sep;74(3):477-89. |
| 5593 | Adam Kenneth, et al. Heterocyclic amides useful as protein modulators.patent WO2017175147A1 |
| 5594 | Pharmacotherapy 31: 65 (1997)| |
| 5595 | Harris MG, et al. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1993 Jan-Feb;3(1):9-25. |
| 5596 | Ask K, et al. Metabolism of nilutamide in rat lung. Biochem Pharmacol. 2006 Jan 12;71(3):377-85. |
| 5597 | Zhang Y, et al. Protective Effects of Amarogentin against Carbon Tetrachloride-Induced Liver Fibrosis in Mice. Molecules. 2017 May 6;22(5). pii: E754. |
| 5598 | Wölfle U, et al. Amarogentin Displays Immunomodulatory Effects in Human Mast Cells and Keratinocytes. Mediators Inflamm. 2015;2015:630128. |
| 5599 | Zhao JG, et al. Amarogentin secoiridoid inhibits in vivo cancer cell growth in xenograft mice model and induces apoptosis in human gastric cancer cells (SNU-16) through G2/M cell cycle arrest and PI3K/Akt signalling pathway. J BUON. 2016 May-Jun;21(3):609-17. |
| 5600 | Nicodeme E, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010 Dec 23;468(7327):1119-23. |
| 5601 | Asangani IA, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014 Jun 12;510(7504):278-82. |
| 5602 | Chaidos A, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014 Jan 30;123(5):697-705. |
| 5603 | J Chem Soc 1961:1854; Agric Biol Chem 30:617 (1966); Phytochemistry 10:894 (1971); 11:1911 (1972); Cancer Res 39:844 (1979); J Med Chem 22:589 (1979) |
| 5604 | Mallinger A, et al. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. J Med Chem. 2016 Feb 11;59(3):1078-101. |
| 5605 | Bulawa, C.E., et al., Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A, 2012. 109(24): p. 9629-34. |
| 5606 | Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8. |
| 5607 | https://clinicaltrials.gov/ct2/show/NCT04824365?term=Pyruvic+acid&cond=covid&draw=2&rank=2 |
| 5608 | Food Cosmat Toxicol 11:1059 (1973) |
| 5609 | Tetrahedron 19: 209 (1963); Phytochemistry 6: 883 (1967) |
| 5610 | https://clinicaltrials.gov/ct2/show/NCT04751227?term=MODAFINIL&cond=COVID-19&draw=2&rank=1 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20170903036041N3 |
| 5611 | McNeil MB, et al. Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors. mSphere. 2020;5(5):e00985-20. Published 2020 Oct 14. |
| 5612 | Grzegorzewicz AE, et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol. 2012;8(4):334-341. Published 2012 Feb 19. |
| 5613 | Schuhmann-Giampieri G, et al. Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. J Pharm Sci. 1993 Aug;82(8):799-803. |
| 5614 | Kouchak M, et al. Effects of various penetration enhancers on penetration of aminophylline through shed snake skin. Jundishapur J Nat Pharm Prod. 2014 Feb;9(1):24-9. |
| 5615 | Wu L, et al. 5,7,3',4'-Tetramethoxyflavone exhibits chondroprotective activity by targeting β-catenin signaling in vivo and in vitro. Biochem Biophys Res Commun. 2014 Sep 26;452(3):682-8. |
| 5616 | Garner TP, et al. Small-molecule allosteric inhibitors of BAX. Nat Chem Biol. 2019 Apr;15(4):322-330. |
| 5617 | ARYL SULFONOHYDRAZIDES. WO2016/138472Al. |
| 5618 | Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res, 2010, 70(1), 288-298. |
| 5619 | You W, et al. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats. J Neurol Sci. 2016 Aug 15;367:224-31. |
| 5620 | Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2017 Oct 27. |
| 5621 | Huang LS, et al. 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J Biol Chem. 2006 Mar 3;281(9):5965-72. |
| 5622 | Chomcheon P, et al. 3-Nitropropionic acid (3-NPA), a potent antimycobacterial agent from endophytic fungi: is 3-NPA in some plants produced by endophytes? J Nat Prod. 2005 Jul;68(7):1103-5. |Nature 164: 575 (1949) |
| 5623 | Haste NM, et al. Activity of the thiopeptide antibiotic nosiheptide against contemporary strains of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo). 2012 Dec;65(12):593-8. |
| 5624 | Yu Y, et al. Nosiheptide biosynthesis featuring a unique indole side ring formation on the characteristic thiopeptide framework. ACS Chem Biol. 2009 Oct 16;4(10):855-64. |
| 5625 | JACS 49:1594 (1927); Food Cosmet Toxicol 14:525 (1976) |
| 5626 | Nutr Rep Int 9:245 (1974); Lipids 16:423 (1981); Antibiot Annu 1954-55:980 |
| 5627 | Scand J Rheumatol 5:126 (1976); Suppl 33:50 (1980); Suppl 36:1 (1980) |
| 5628 | Angiolology 53:273 (2002); Biochem J 373:941 (2003) |
| 5629 | Desoximetasone, From Wikipedia |
| 5630 | Huang M, et al. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 2017 Apr 2;398:12-21 |
| 5631 | Mohammad HP, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69. |
| 5632 | F.Porte-Thomé, et al. Development of Rimeporide, a sodium-hydrogen exchanger (NHE-1) inhibitor, for patients with Duchenne muscular dystrophy. Neuromuscular Disorders. October 2015 Oct 25:259-260. |
| 5633 | Suzuki T, et al. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptorand ErbB2 tyrosine kinase inhibitor. Cancer Sci. 2007 Dec;98(12):1977-84. |
| 5634 | Paíno T et al. The novel pan-PIM kinase inhibitor, PIM447, displays dual anti-myeloma and bone protective effects, and potently synergizes with current standards of care. Clin Cancer Res. 2016 Jul 20. |
| 5635 | Burger MT et al. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies. 
 J Med Chem. 2015 Nov 12;58(21):8373-86. |
| 5636 | Peters TL et al. Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.
 Oncotarget. 2016 Aug 20 |
| 5637 | Eur J Clin Pharmacol 55:53 (1999); Drugs 57:921 (1999) |
| 5638 | Yin T, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014 Jun;13(6):1442-56. Mol Cancer Ther. 2014 Jun;13(6):1442-56. |
| 5639 | Pizzonero M, et al. Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem. 2014 Dec 11;57(23):10044-57. |
| 5640 | J. Invest. Dermatol. (1974), 63(3), 292-7; Biochem. Pharmacol. (1972), 21(16), 2161-7; Steroids (1965), 6(3), 339-49 |
| 5641 | Wagner J, et al. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. |
| 5642 | Varun Vijay Prabhu, et al. Potent anti-cancer activity of the imipridone ONC206: A selective dopamine D2-like receptor antagonist. AACR Annual Meeting 2017, April 1-5, 2017; Washington, DC. |
| 5643 | Kauko O, et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. |
| 5644 | Guerrero, T. Global reactivity indexes and nonparametric statistics in the study of the proapoptotic activity of coumarins. International Journal of Quantum Chemistry, , e25902. |
| 5645 | Knauf U, et al. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol. 2001 Aug;21(16):5500-11. |
| 5646 | Ishida M, et al. Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells. Circ Res. 2003 Dec 12;93(12):1218-24. Epub 2003 Nov 6 |
| 5647 | Chrestensen CA, et al. Loss of MNK function sensitizes fibroblasts to serum-withdrawal induced apoptosis. Genes Cells. 2007 Oct;12(10):1133-40. |
| 5648 | Lim S, et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):E2298-307 |
| 5649 | J Chem Soc 1986: 1491 |
| 5650 | Zhi J, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995 Nov;35(11):1103-8. |
| 5651 | Padwal R, et al. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;(3):CD004094. |
| 5652 | Zhang E, et al. Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. Nutrients. 2018 Mar 15;10(3). pii: E353. |J Clin Pharmacol 35:1103 (1995); JAMA 281:235 (1999); J Clin Pharmacol 43 :428 (2003) |
| 5653 | https://clinicaltrials.gov/ct2/show/NCT04348305?term=HYDROCORTISONE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04359511?term=HYDROCORTISONE&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04456439?term=HYDROCORTISONE&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT02735707?term=HYDROCORTISONE&cond=COVID-19&draw=2&rank=8 |
| 5654 | Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094. |
| 5655 | Athanasios Papakyriakou, et al. Computational Investigation of Darapladib and Rilapladib Binding to Platelet Activating Factor Receptor. A Possible Mechanism of Their Involvement in Atherosclerosis. International Journal of Chemistry; Vol. 6, No. 1; 2014. |
| 5656 | Oyo Yakuri 13:197, 317 (1977)[CA 88:83591 (1978)] |
| 5657 | Davidson M, et al. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 Jul 28:appiajp201717010122. |
| 5658 | J. Clin. Psychiatry (1981), 42(12), 463-9; Dis. Nerv. Syst. (1972), 33(8), 529-34; J. Clin. Pharmacol. New Drugs (1972), 12(8), 349-55 |
| 5659 | Su BN, et al. Chemical constituents of the fruits of <i>Morinda citrifolia</i> (Noni) and their antioxidant activity.J Nat Prod. 2005 Apr;68(4):592-5. |
| 5660 | Kim B, et al. Baohuoside I suppresses invasion of cervical and breast cancer cells through the downregulation of CXCR4 chemokine receptor expression. Biochemistry. 2014 Dec 9;53(48):7562-9. |
| 5661 | Song J, et al. Reactive oxygen species-mediated mitochondrial pathway is involved in Baohuoside I-induced apoptosis in human non-small cell lung cancer. Chem Biol Interact. 2012 Jul 30;199(1):9-17. |
| 5662 | Wang L, et al. The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via β-catenin-dependent signaling. Oncol Rep. 2011 Nov;26(5):1149-56. |
| 5663 | Chen CT, et al. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. Am J Cancer Res. 2015 Nov 15;5(12):3560-9. |Eur J Pediatr 143:196 (1985); J Inher Metab Dis 19:220 (1996); Eur J Pediatr 157:996 (1998) |
| 5664 | Garvey EP, et al. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem. 1997 Feb 21;272(8):4959-63. |
| 5665 | Shi Q, et al. 1400W ameliorates acute hypobaric hypoxia/reoxygenation-induced cognitive deficits by suppressing the induction of inducible nitric oxide synthase in rat cerebral cortex microglia. Behav Brain Res. 2017 Feb 15;319:188-199. |
| 5666 | Rus A, et al. Inducible NOS inhibitor 1400W reduces hypoxia/re-oxygenation injury in rat lung. Redox Rep. 2010;15(4):169-78. |
| 5667 | Tomochika K, et al. Effects of peanut-skin procyanidin A1 on degranulation of RBL-2H3 cells. Biosci Biotechnol Biochem. 2011;75(9):1644-8. |
| 5668 | Takano F, et al. Aqueous extract of peanut skin and its main constituent procyanidin A1 suppress serum IgE and IgG1 levels in mice-immunized with ovalbumin. Biol Pharm Bull. 2007 May;30(5):922-7. |
| 5669 | Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. Nat Commun. 2019 Aug 21;10(1):3758. |
| 5670 | Lee S, et al. Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain. Mol Pain. 2018 Jan-Dec;14:1744806918764979. |
| 5671 | Zhen Xu, et al. Efficient Strategies for Microglia Replacement in the Central Nervous System. Cell Rep. 2020 Aug 11;32(6):108041. |
| 5672 | Zhao X, et al. Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis. Mol Cell Biochem. 2015 Feb;400(1-2):1-7. |
| 5673 | Liu J, et al. Oleanolic acid inhibits proliferation and invasiveness of Kras-transformed cells via autophagy. J Nutr Biochem. 2014 Nov;25(11):1154-60. |
| 5674 | Liu J, et al. p38 MAPK signaling mediates mitochondrial apoptosis in cancer cells induced by oleanolic acid. Asian Pac J Cancer Prev. 2014;15(11):4519-25. |
| 5675 | Martín R, et al. Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease. J Mol Cell Cardiol. 2014 Jul;72:250-62. |
| 5676 | Caroline M Robb, et al. Characterization of CDK(5) Inhibitor, 20-223 (Aka CP668863) for Colorectal Cancer Therapy. Oncotarget. 2017 Dec 28;9(4):5216-5232. |
| 5677 | Hunt JT, et al. Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem. 2000 Oct 5;43(20):3587-95. |
| 5678 | Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61(20):7507-17. |
| 5679 | Arzneim. Forsch. (1988), 38(8), 1159-62; Arzneim. Forsch. (1988), 38(8), 1144-50; Arzneim. Forsch. (1988), 38(8), 1141-3, |
| 5680 | Patsharaporn T Sarasombath, et al. First study of topical selamectin efficacy for treating cats naturally infected with Brugia malayi and Brugia pahangi under field conditions. Parasitol Res. 2019 Apr;118(4):1289-1297. |
| 5681 | J Griffin, et al. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J Vet Pharmacol Ther. 2005 Jun;28(3):257-65. |Vet Parasitol 91:223, 377 (2000); Can Vet J 43:767 (2002) |
| 5682 | Brain Res 465:243 (1989); TiPS 20:268 (1999) |
| 5683 | Albaugh, P. et al. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS MEDICINAL CHEMISTRY LETTERS, 2012; 3 (2): 140 |
| 5684 | Aristizabal Prada ET, et al. Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Endocr Relat Cancer. 2018 May;25(5):547-560. |
| 5685 | Masner, P., et al. Possible methionine biosynthesis inhibition by pyrimidinamine fungicides. Pestic. Sci. 42(3),163-166 (1994). |
| 5686 | Frances Orton, et al. Widely used pesticides with previously unknown endocrine activity revealed as in vitro antiandrogens. Environ Health Perspect. 2011 Jun;119(6):794-800. |
| 5687 | Cusimano A, et al. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget. 2015 Jan 30;6(3):1707-22. |
| 5688 | Wong TW, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6186-93. |
| 5689 | Torres MA, et al. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61. |
| 5690 | Huang P, et al. Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother. 2008 Apr;52(4):1419-29. |
| 5691 | J Econ Entomol 58:1043 (1965); Toxicol Appl Pharmacol 21:315 (1972) |
| 5692 | Clemett D, Markham A. Linezolid. Drugs. 2000 Apr;59(4):815-27; discussion 828. |
| 5693 | Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32(1):66-88. |
| 5694 | Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61(4):525-51. |
| 5695 | He MZ, Jiang YW, Cai C.
 Mechanisms and epidemiology of linezolid resistance in staphylococci.Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):360-2. |
| 5696 | Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G.
 Linezolid is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA class II Transgenic Mice.
 Antimicrob Agents Chemother. 2012 Jul 30. |Ann. N. Y. Acad. Sci. (2011), 1222, 49-54; Antimicrob. Agents Chemother. (1996), 40(4), 1039-40; J. Med. Chem. (1996), 39(3), 673-9 |
| 5697 | Helena Mistry, et al. Small molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther Published OnlineFirst October 15, 2013. |
| 5698 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=CHLOROTHIAZIDE&cond=Covid19&draw=2&rank=2 |
| 5699 | J Chem Soc (C) 1966:114; 1967:145; Tet Lett 1967:3459 |
| 5700 | Mariappan A, et al. Inhibition of CPAP-tubulin interaction prevents proliferation of centrosome-amplified cancer cells. EMBO J. 2019 Jan 15;38(2). pii: e99876. |
| 5701 | Chen X, et al. The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.Br J Clin Pharmacol. 2014 Dec;78(6):1298-314. |
| 5702 | Zhou D, et al. A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.Br J Clin Pharmacol. 2012 Jul;74(1):98-108. |
| 5703 | Nomura T, et al. Potentiating α2 subunit containing perisomatic GABAA receptors protects against seizures in a mouse model of Dravet syndrome.J Physiol. 2019 Aug;597(16):4293-4307. |
| 5704 | AZD7325,Mechanism of action: Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAAα2,3) positive modulator |
| 5705 | Agric Biol Chem 47:2397, 2925 (1983); 48:2847 (1984); 55:2117 (1991) |
| 5706 | https://clinicaltrials.gov/ct2/show/NCT04707703?term=Isavuconazonium&cond=COVID-19&draw=2&rank=1 |
| 5707 | aq KIO4 + catechol + pyrogallol |
| 5708 | Zhang LQ, et al. Accumulation of catechins and expression of catechin synthetic genes in Camellia sinensis at different developmental stages. Bot Stud. 2016 Dec;57(1):31. |
| 5709 | Zhou H, et al. C-geranylated flavanones from YingDe black tea and their antioxidant and α-glucosidase inhibition activities. Food Chem. 2017 Nov 15;235:227-233. |
| 5710 | Sahebkar A, et al. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014 Mar;15(4):493-503. |
| 5711 | Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97. |
| 5712 | Choi YJ, et al. Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012 Feb;220(2):470-6. |
| 5713 | Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017 Jul 31;1(7):663-674. |
| 5714 | Phytochemistry 6: 863 (1967); Eur J Pharmacol 269: 269; 271: 87 (1994) |
| 5715 | JACS 71:4126 (1949)| |
| 5716 | Jenkins, D.J., et al., Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. N Engl J Med, 1993. 329(1): p. 21-6. |
| 5717 | Goldberg, A.A., et al., Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget, 2011. 2(10): p. 761-82. |
| 5718 | Matsubara, T., et al., TGF-beta-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. J Lipid Res, 2012. 53(12): p. 2698-707. |
| 5719 | Yang R, et al. Metabolomic analysis of cholestatic liver damage in mice. Food Chem Toxicol. 2018 Jul 14;120:253-260. |
| 5720 | J Pharmacol Exp Ther 237:937 (1986); J Antimicrob Agents 14:75, 81 (2000) |
| 5721 | Neant I, et al. 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. Exp Cell Res. 1988 May;176(1):68-79. |
| 5722 | Meijer L, et al. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol Ther. 1999 May-Jun;82(2-3):279-84. |
| 5723 | Psychopharmacol Bull 26:147, 311 (1990); N Engl J Med 342:1462 (2000) |
| 5724 | J. Invest. Dermatol. (1965), 45(5), 347-54; Arch. Dermatol. (1964), 89, 404-10; Skin (1963), 2, 311-2 |
| 5725 | Am. J. Med. (1986), 80(6B), 2-14; J. Clin. Invest. (1949), 28, 934-9; Science (1949), 109(2830), 305-7 |
| 5726 | Tsuchida K, et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med. 2017 Feb;103:236-247. |
| 5727 | Keller TL, et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7. |
| 5728 | Cui Z, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2016 Sep;75(9):1714-21. |
| 5729 | Tracy L McGaha, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002 Mar;118(3):461-70. |
| 5730 | https://clinicaltrials.gov/ct2/show/NCT04280588?term=Fingolimod&cond=covid&draw=2&rank=1 |
| 5731 | Koichi Hirose, et al. GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway inflammation in mice. Biochem Biophys Res Commun. 2008 Sep 26;374(3):507-11. |
| 5732 | Hiroto Nakajima, et al. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res Commun. 2008 Apr 18;368(4):1007-13. |
| 5733 | Weir MC, et al. Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. ACS Chem Biol. 2018 Jun 15;13(6):1551-1559. |
| 5734 | Ann. Rev. Entomol. (2005), 50, 447-477; Arch. Insect Biochem. Physiol. (2003), 54(1), 1-13; Neurochem. Res. (1993), 18(8), 869-74 |
| 5735 | Valentina Zuliani, et al. Advances in Design and Development of Sodium Channel Blockers. Ion Channels and Their Inhibitors pp 79-115. |
| 5736 | Faravelli, et al. P.3.f.022 Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia. |
| 5737 | Infection 21:106 (1993); Antimicrob Agents Chemother 37:2298 (1993) |
| 5738 | Wang DZ, et al. Studies on the alkaloids of Cephalotaxus. IX. Semi-synthesis of cephalotaxine esters and their anti-leukemic activity Yao Xue Xue Bao. 1992;27(3):178-84. |
| 5739 | Efferth T, et al. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jan;367(1):56-67. |
| 5740 | Zheng-Zong Lai, et al. Cephalotaxine inhibits Zika infection by impeding viral replication and stability. Biochem Biophys Res Commun. 2020 Feb 19; 522(4): 1052–1058. |
| 5741 | Local A, et al. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. Mol Cancer Ther. 2018 Jun;17(6):1177-1186. |
| 5742 | Hongying Zhang, et al. Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia. Blood 2016 128:1716. |
| 5743 | Haruka Tsuchiya, et al. Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis. Ann Rheum Dis. 2020 Nov2;annrheumdis-2020-218189. |
| 5744 | Sørensen MD, et al. Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity. Bioorg Med Chem. 2003 Dec 1;11(24):5461-84. |
| 5745 | Blavier L, et al. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol Ther. 2010 Jul 15;10(2):198-208. |
| 5746 | Shalinsky DR, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999 Jun 30;878:236-70. |
| 5747 | Ozerdem U, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res. 2000 Jun;20(6):447-53. |
| 5748 | Irie T, et al. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors. Eur J Med Chem. 2017 Apr 21;130:406-418. |
| 5749 | Klumpp K, et al. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem. 2006 Feb 17;281(7):3793-9. |
| 5750 | Smith DB, et al. Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett. 2007 May 1;17(9):2570-6. |
| 5751 | Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-1450. |
| 5752 | Lin YW, Beharry ZM, Hill EG, et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 ;115(4):824-33. |
| 5753 | Beharry Z, Mahajan S, Zemskova M,et al. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A. 2011;108(2):528-33. |
| 5754 | Lo YL, et al. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci. 2008 Sep 2;35(1-2):52-67. |
| 5755 | Tochio T, et al. 1-Kestose, the Smallest Fructooligosaccharide Component, Which Efficiently Stimulates Faecalibacterium prausnitzii as Well as Bifidobacteria in Humans. Foods. 2018 Sep 1;7(9). pii: E140. |
| 5756 | Takumi Tochio, et al. 1-Kestose, the Smallest Fructooligosaccharide Component, Which Efficiently Stimulates Faecalibacterium prausnitzii as Well as Bifidobacteria in Humans. Foods. 2018 Sep 1;7(9):140. |
| 5757 | Pick A, et al. Specific inhibitors of the breast cancer resistance protein (BCRP). ChemMedChem. 2010 Sep 3;5(9):1498-505. |
| 5758 | Hyman JM, et al. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14132-7. |
| 5759 | Wu H, et al. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science. 2014 Apr 4;344(6179):58-64. |
| 5760 | Bai Q, et al. Investigation of allosteric modulation mechanism of metabotropic glutamate receptor 1 by molecular dynamics simulations, free energy and weak interaction analysis. Sci Rep. 2016 Feb 18;6:21763. |
| 5761 | Yamasaki T, et al. In vivo measurement of the affinity and density of metabotropic glutamate receptor subtype 1 in rat brain using 18F-FITM in small-animal PET. J Nucl Med. 2012 Oct;53(10):1601-7. |
| 5762 | Xie L, et al. Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe (18) F-FITM. Int J Cancer. 2014 Oct 15;135(8):1852-9. |
| 5763 | DaCosta Byfield S, et al. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2004 Mar;65(3):744-52. |
| 5764 | Sutariya V, et al. Thermoreversible gel for delivery of receptor-like kinase 5 inhibitor SB-505124 for glaucoma filtration surgery. Pharm Dev Technol. 2013 Jul-Aug;18(4):957-62. |
| 5765 | Sapitro J, et al. Suppression of transforming growth factor-β effects in rabbit subconjunctival fibroblasts by receptor-like kinase 5 inhibitor. Mol Vis. 2010 Sep 16;16:1880-92. |
| 5766 | Marini KD, et al. Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Sci Transl Med. 2018 Jul 25;10(451). pii: eaat3504. |
| 5767 | Liu F, et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem. 2009 Dec 24;52(24):7950-3. |
| 5768 | Liu F, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53(15):5844-57. |
| 5769 | Cho YS, et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med Chem Lett. 2017 Sep 18;8(10):1116-1121. |
| 5770 | Courtney D DiNardo, et al. A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations. Blood, 128(22), 1073. |
| 5771 | Ogo Y, et al. IGF-1 gene expression is differentially regulated by estrogen receptors α and β in mouse endometrial stromal cells and ovarian granulosa cells. J Reprod Dev. 2014;60(3):216-23. Epub 2014 Mar 25. |
| 5772 | Dennis R Compton, et al. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. J Med Chem. 2004 Nov 18;47(24):5872-93. |
| 5773 | Lv H, et al. Isovitexin Exerts Anti-Inflammatory and Anti-Oxidant Activities on Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting MAPK and NF-κB and Activating HO-1/Nrf2 Pathways. Int J Biol Sci. 2016 Jan 1;12(1):72-86. |
| 5774 | Hu JJ, et al. Isovitexin alleviates liver injury induced by lipopolysaccharide/d-galactosamine by activating Nrf2 and inhibiting NF-κB activation. Microb Pathog. 2018 Mar 29;119:86-92. |
| 5775 | Hsieh C, et al. Varlitinib to demonstrate anti-tumour efficacy in patient-derived hepatocellular carcinoma xenograft models. Journal of Clinical Oncology 34, no. 15_suppl |
| 5776 | Miknis G, et al. ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2.Proc Amer Assoc Cancer Res, Volume 46, 2005 |
| 5777 | Tang R, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer. 2009 Jun 23;9:199. |
| 5778 | Invest. Radiol. (1990), 25(Suppl. 1), S100-S101; Invest. Radiol. (1989), 24 Suppl 1S33-4; Invest. Radiol. (1989), 24(2), 133-7 |
| 5779 | Meunier J, et al. The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's d |
| 5780 | Weissmiller AM, et al. A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One. 2015 Feb 24;10(2):e0118379. |
| 5781 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=VERAPAMIL+&cntry=&state=&city=&dist=&Search=Search |
| 5782 | Wei P, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010 Jun;9(6):1618-28. |
| 5783 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=CYANOCOBALAMIN&cntry=&state=&city=&dist= |
| 5784 | Arch. Int. Pharmacodyn. Ther. (1967), 170(2), 461-7; J. Pharmacol. Exp. Ther. (1952), 104, 387-95; Arch. Exp. Pathol. Pharmakol. (1943), 202, 201-8 |
| 5785 | Monatsh 59: 161 (1932); J Org Chem 35: 2294 (1970) |
| 5786 | Matsuda Y, et al. Effects of malotilate on alcoholic liver injury in rats. Alcohol Clin Exp Res. 1988;12(5):665-670. |
| 5787 | Vermeer MA, Wilson JH, Zijlstra FJ, Vincent JE. Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells. Agents Actions. 1989;26(1-2):252-253. |
| 5788 | Poeschl A, et al. Malotilate reduces collagen synthesis and cell migration activity of fibroblasts in vitro. Biochem Pharmacol. 1987;36(22):3957-3963. |
| 5789 | Zijlstra FJ, et al. Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells. Eur J Pharmacol. 1989;159(3):291-295. |
| 5790 | Wakasugi J, et al. Action of malotilate on reduced serum cholesterol level in rats with carbon tetrachloride-induced liver damage. Jpn J Pharmacol. 1985;38(4):391-401. |
| 5791 | Wang Y, et al. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E884-93. |
| 5792 | Steinfeld T, et al. In vitro characterization of TD-4208, a lung-selective and long-acting muscarinic antagonist bronchodilator (Abstract). Am J Respir Crit Care Med 179:A4553. |
| 5793 | Pulido-Rios MT, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013 Aug;346(2):241-50. |
| 5794 | Altun M, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol. 2011 Nov 23;18(11):1401-12. |
| 5795 | Fan YH, et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 2013 Oct 17;4:e867. |
| 5796 | Audinot V, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. |
| 5797 | Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64. |
| 5798 | Aguiar CC, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol. 2013 Aug;33(6):825-35. |
| 5799 | Stockwell SR, et al.Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. PLoS One. 2012;7(1):e28568. |
| 5800 | Bruch J, et al. PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med. 2017 Mar;9(3):371-384. |
| 5801 | Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97. |
| 5802 | Lebon W, et al. Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs. Parasit Vectors. 2016 Sep 2;9(1):485. |
| 5803 | Valentina M Merola, et al. Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats. Vet Clin North Am Small Anim Pract. 2012 Mar;42(2):313-33, vii. |
| 5804 | Dejan Cvejic, et al. Efficacy of a single dose of milbemycin oxime/praziquantel combination tablets, Milpro(®), against adult Echinococcus multilocularis in dogs and both adult and immature E. multilocularis in young cats. Parasitol Res. 2016 Mar;115(3):1195-202. |
| 5805 | Chen, H. X. et al. Antidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist. PloS one 8, e83271, doi:10.1371/journal.pone.0083271 (2013). |
| 5806 | Qin, J. J. et al. The role of activation of the 5-HT1A receptor and adenylate cyclase in the antidepressant-like effect of YL-0919, a dual 5-HT1A agonist and selective serotonin reuptake inhibitor. Neuroscience letters 582, 104-108, 2014.09.009 (2014) |
| 5807 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Minoxidil+&cntry=&state=&city=&dist=&Search=Search |
| 5808 | Smith SH, et al. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. J Invest Dermatol. 2017 Oct;137(10):2110-2119. |
| 5809 | Liang S, et al. Effect of quercetin 7-rhamnoside on glycochenodeoxycholic acid-induced L-02 human normal livercell apoptosis. Int J Mol Med. 2013 Aug;32(2):323-30. |
| 5810 | Gonzalez B, et al. Glycochenodeoxycholic acid (GCDC) induced hepatocyte apoptosis is associated with early modulation of intracellular PKC activity. Mol Cell Biochem. 2000 Apr;207(1-2):19-27. |
| 5811 | Ali S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother. 2008 Dec;52(12):4356-69. |
| 5812 | Ma H, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species. J Biol Chem. 2007 Oct 12;282(41):29812-20. Epub 2007 Aug 13. |
| 5813 | Ahn KS, et al. Corosolic acid isolated from the fruit of Crataegus pinnatifida var. psilosa is a protein kinase C inhibitor as well as a cytotoxic agent. Planta Med. 1998 Jun;64(5):468-70. |
| 5814 | LI Biao, et al. Mechanism of antitumor action of corosolic acid. China Journal of Modern Medicine, 
 2015-08 |
| 5815 | Ki Hyun Yoo, et al. Corosolic Acid Exhibits Anti-angiogenic and Anti-lymphangiogenic Effects on In Vitro Endothelial Cells and on an In Vivo CT-26 Colon Carcinoma Animal Model. Phytotherapy Research, 2015
 , 29 (5): 14–723 |
| 5816 | https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04939090 |
| 5817 | Wood M, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124-35. |
| 5818 | Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86. |
| 5819 | Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors. Eur J Pharmacol. 2016 Oct 5;788:183-91. |
| 5820 | Radad K, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP+ and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 2014;52(2):179-86. |
| 5821 | Kupperman E, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80. |
| 5822 | J Pharmacol Exp Ther 89:205 (1947); J Clin Pharmacol J New Drugs 7:150 (1967) |
| 5823 | Vaidya S, et al. Degradation of Chrysene by Enriched Bacterial Consortium. Front Microbiol. 2018 Jun 26;9:1333. |
| 5824 | Tanaka K, et al. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol. 1995 Apr;67(4):305-14. |
| 5825 | Sun Y, et al. Anti-rheumatic drug iguratimod protects against cancer-induced bone pain and bone destruction in a rat model. Oncol Lett. 2017 Jun;13(6):4849-4856. |
| 5826 | Iguratimod, et al. Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential. J Biol Chem. 2016 Dec 16;291(51):26502-26514. |
| 5827 | Yin Q, et al. An Inhaled Inhibitor of Myristoylated Alanine-Rich C Kinase Substrate Reverses LPS-Induced Acute Lung Injury in Mice. Am J Respir Cell Mol Biol. 2016 Nov;55(5):617-622. |
| 5828 | J Chem Soc 1954: 473 |
| 5829 | Masson D, et al. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2054-60. |
| 5830 | Hanieh H, et al. Pinocembrin, a novel histidine decarboxylase inhibitor with anti-allergic potential in in vitro. Eur J Pharmacol. 2017 Nov 5;814:178-186. |
| 5831 | Oliva CR, et al. Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells. J Biol Chem. 2016 Nov 11;291(46):24188-24199. Epub 2016 Sep 27. |
| 5832 | Suzuki T, et al. In vitro antimicrobial activity of wall teichoic acid biosynthesis inhibitors against Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011 Feb;55(2):767-74. |
| 5833 | Johnson TW, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014 Jun 12;57(11):4720-44. |
| 5834 | Zou HY, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking PF-02341066-resistant ROS1 mutations. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8 |
| 5835 | Homan KT, et al. Crystal Structure of G Protein-coupled Receptor Kinase 5 in Complex with a Rationally DesignedInhibitor. J Biol Chem. 2015 Aug 21;290(34):20649-59. |
| 5836 | Gloaguen C, et al. First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies. J Med Chem. 2015 Feb 26;58(4):1644-68. |
| 5837 | Groo AC, et al. Comparison of 2 strategies to enhance Pyridoclax solubility: Nanoemulsion delivery system versus salt synthesis. Eur J Pharm Sci. 2017 Jan 15;97:218-226. |
| 5838 | Napasawan Plabutong, et al. The Inhibitory Effect of Validamycin A on Aspergillus flavus. Int J Microbiol. 2020; 2020: 3972415. |
| 5839 | Zhi-Jiang Wang, et al. The effect of validamycin A on tyrosinase: inhibition kinetics and computational simulation. Int J Biol Macromol. 2013 Apr;55:15-23. |
| 5840 | N Asano, et al. Effect of validamycins on glycohydrolases of Rhizoctonia solani. J Antibiot (Tokyo). 1987 Apr;40(4):526-32. |
| 5841 | Ivanes F, et al. The compound BTB06584 is an IF1 -dependent selective inhibitor of the mitochondrial F1 Fo-ATPase. Br J Pharmacol. 2014 Sep;171(18):4193-4206. |
| 5842 | Chi S, et al. Genus Tinospora: Ethnopharmacology, Phytochemistry, and Pharmacology.Evid Based Complement Alternat Med. 2016;2016:9232593. |
| 5843 | Swanson CJ, et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94. |
| 5844 | Ash BL, et al. The galanin-3 receptor antagonist, SNAP 37889, reduces operant responding for ethanol in alcohol-preferring rats. Regul Pept. 2011 Jan 17;166(1-3):59-67. |
| 5845 | https://clinicaltrials.gov/ct2/show/NCT04363060?term=Clavulanate&cond=COVID-19&draw=2&rank=1 |
| 5846 | Jiang J, et al. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3591-3596. |
| 5847 | Kang X, et al. Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Sci Rep. 2017 Aug 25;7(1):9459. |
| 5848 | https://clinicaltrials.gov/ct2/show/NCT04771000?term=Ambrisentan&cond=covid&draw=2&rank=1 |
| 5849 | Neil E. Paterson, Jennifer Ricciardi, Caitlin Wetzler, et al. Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone. Neuroscience Research. 2011, 69(1): 41-50. |
| 5850 | Saviana Di Giovanni, Simona Eleuteri, Katerina E. Paleologou, et al. Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity. The Journal of Biological Chemistry, 2010, 285, 14941-14954. |
| 5851 | Panos Bitsios, Panos Roussos1. Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia. Pharmacogenomics. 2001,12 (4): 559-566. |
| 5852 | M.A. Vieira-Coelho, P. Soares-da-Silva. Ontogenic aspects of liver and kidney catechol-O- methyltransferase sensitivity to tolcapone. British Journal of Pharmacology.1996,117 (3):516-520. |
| 5853 | J. Dingemanse, K. Jorga, G. Zurcher,et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. British Journal of Clinical Pharmacology
 1995, 40 (3):253-262. |
| 5854 | Forester SC, et al. Gut metabolites of anthocyanins, gallic acid, 3-O-methylgallic acid, and 2,4,6-trihydroxybenzaldehyde, inhibit cell proliferation of Caco-2 cells. J Agric Food Chem. 2010 May 12;58(9):5320-7. |
| 5855 | Forester SC, The anthocyanin metabolites gallic acid, 3-O-methylgallic acid, and 2,4,6-trihydroxybenzaldehyde decrease human colon cancer cell viability by regulating pro-oncogenic signals. Mol Carcinog. 2014 Jun;53(6):432-9. |
| 5856 | https://clinicaltrials.gov/ct2/show/NCT04883528?term=Sacubitril&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04467931?term=Sacubitril&cond=Covid19&draw=2&rank=2 |
| 5857 | Zhang G, et al. Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells. Oncotarget. 2016 Mar 3. |
| 5858 | Yu Y, et al. Immunomodulatory Effects of Cinobufagin on Murine Lymphocytes and Macrophages. Evid Based Complement Alternat Med. 2015;2015:835263. |
| 5859 | Baek SH, et al. Cinobufagin exerts anti-proliferative and pro-apoptotic effects through the modulation ROS-mediated MAPKs signaling pathway. Immunopharmacol Immunotoxicol. 2015 Jun;37(3):265-73. |
| 5860 | Jiun-Yih Yeh, et al. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. The Prostate
 Volume 54, Issue 2, pages 112–124, 1 February 2003 |
| 5861 | Yu CH, et al. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Science, 2008, 99 (12): 2467-2476 |
| 5862 | Peng Bei, et al. Progress in study on basic and clinical application in treating liver cancer by Cinobufagin Injection. Drug Evaluation Research, 2011-01 |
| 5863 | J Clin Psychiatry54:119 (1993); J Am Med Assoc 283:3082 (2000) |
| 5864 | Hongying Zhang, et al. CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3/PAN-BTK INHIBITOR. EHA. Jun 14, 2019; 265993; PF203. |
| 5865 | Hongying Zhang, et al. Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients. Cancer Research. July 2019. 79 (13): Supplement. |
| 5866 | Hongying Zhang, et al. Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro. July 2018. Cancer Research. 78 (13): Supplement. |
| 5867 | https://clinicaltrials.gov/ct2/show/NCT04361643?term=Lenalidomide&cond=covid&draw=2&rank=1 |
| 5868 | https://clinicaltrials.gov/ct2/show/NCT04456049?term=Enzalutamide&cond=Covid19&draw=2&rank=1 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-002027-10-SE |
| 5869 | Fukuoka, Y., et al., In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother, 1993. 37(3): p. 384-92. |
| 5870 | Muratani, T., M. Inoue, and S. Mitsuhashi, In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother, 1992. 36(10): p. 2293-303. |Antimicrob Agents Chemother 37:384 (1993); Chem Pharm Bull 42:2569 (1994); Jpn J Antibiot 55:412 (2002) |
| 5871 | Theodoropoulos PA, et al. Cytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping. Biochem Pharmacol. 1994 May 18;47(10):1875-81. |
| 5872 | Trendowski M, et al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9. |
| 5873 | Zhou C, et al. The effect of Cytochalasin B and Jasplakinolide on depolymerization of actin filaments in goose muscles during postmortem conditioning. Food Res Int. 2016 Dec;90:1-7. |
| 5874 | Drugs 55:729 (1998); J Am Med Assoc 285:1155 (2001) |
| 5875 | Funnell T, et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel smallmolecule inhibitor. Nat Commun. 2017 Feb 23;8(1):7. |
| 5876 | https://clinicaltrials.gov/ct2/show/NCT04513314?term=Valproic+acid&cond=covid&draw=2&rank=1 |
| 5877 | Clin Terap 10:670 (1956); Br Heart J 21:315 (1959); J Fac Pharm Ankara 11:160 (1981) |
| 5878 | J Med Chem 9:892 (1966); Toxicol Appl Pharmacol 21:405 (1972) |
| 5879 | Skolnick P1, et al. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol. 2003 Feb 14;461(2-3):99-104. |
| 5880 | Levin ED, et al. Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats. Eur J Pharmacol. 2015 Jun 20;764:30-37. |
| 5881 | Acta Chem Scand 8:703 (1954); Proc Soc Exper Biol Med 183:227 (1986); In Vitro Cell Dev Biol 23:422 (1987); J Agr Food Chem 40:1425 (1992); Urol Clin North Am 21:85 (1994) |
| 5882 | Yipin Lu, et al. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem. 2006 Jun 29;49(13):3759-62. |
| 5883 | Sanjeev Shangary, et al. Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy. Annu Rev Pharmacol Toxicol. 2009;49:223-41. |
| 5884 | Pigm. Cell Melanoma Res. (2011), 24(4), 673-9, ; J. Eur. Acad. Dermatol. Venereol. (2011), 25(7), 749-57, ; Cutis (1983), 32(4), 343-4, 346 |
| 5885 | Wojnarowicz PM, et al. A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization. Cell Rep. 2019 Oct 1;29(1):62-75.e7. |
| 5886 | Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365. |
| 5887 | Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367(1):71-81. |
| 5888 | Thyroid (2001), 11(6), 561-567; J. Am. Pharm. Assoc. (1959), 48, 368-79; J. Am. Chem. Soc. (1949), 71, 3753-5 |
| 5889 | Niesor EJ, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010, 51(12), 3443-3454. |
| 5890 | Dong B, et al. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 2014 Aug;235(2):449-62. |
| 5891 | Tan EY, et al. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos. 2010, 38(3), 459-473. |
| 5892 | Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293. |
| 5893 | Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538-44. |
| 5894 | Tardif JC et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation, 2004 Nov 23, 110(21):3372-7. |
| 5895 | Raal FJ et al. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygousfamilial hypercholesterolemia. Atherosclerosis, 2003 Dec, 171(2):273-9. |
| 5896 | Delsing DJ et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation, 2001 Apr 3, 103(13):1778-86. |
| 5897 | New Engl J. Med, 238:787 (1948); Clin Cancer Res 11:8089 (2005) |
| 5898 | Karam Chand, et al. Synthesis, Antiproliferative, and c-Src Kinase Inhibitory Activities of 4-Oxo-4H-1-benzopyran Derivatives. J. Heterocycl. Chem. 2014. |
| 5899 | Houston SA, et al. An investigation of the antiplatelet effects of succinobucol (AGI-1067). Platelets. 2017 May;28(3):295-300. |
| 5900 | Colle D, et al. Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity. Mol Neurobiol. 2016 Mar;53(2):1280-95. |
| 5901 | Dan Z, et al. A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer. Theranostics. 2016 Jan 25;6(3):435-45. |
| 5902 | Biopolymers (1996), 40(1), 141-55; Bacteriol. Rev. (1977), 41(2), 449-74; J. Biol. Chem. (1941), 141, 171-85 |
| 5903 | J Pharmacol Exp Therap 127:66 (1959) |
| 5904 | Williams K, et al. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993 Oct;44(4):851-9. |
| 5905 | Kobayashi T, et al. Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology. 2006 Mar;31(3):516-24. |
| 5906 | Liddle J, et al. The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. |
| 5907 | Lee B, et al. Timosaponin AIII, a saponin isolated from Anemarrhena asphodeloides, ameliorates learning and memory deficits in mice. Pharmacol Biochem Behav. 2009 Aug;93(2):121-7. |
| 5908 | King FW, et al. Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress. PLoS One. 2009 Sep 30;4(9):e7283. |
| 5909 | Int. J. Dermatol. (1977), 16(4), 267-73; J. Am. Chem. Soc. (1936), 58, 1314; Am. J. Med. (1952), 12(4), 440-6 |
| 5910 | Oballa RM, et al. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.J Med Chem. 2011 Jul 28;54(14):5082-96. Epub 2011 Jun 28. |
| 5911 | Uhl M, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004 Nov 1;64(21):7954-61. |
| 5912 | Ge R, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4315-30. |
| 5913 | Sun Y, et al. Inhibition of intimal hyperplasia in murine aortic allografts by the oral administration of the transforming growth factor-beta receptor I kinase inhibitor SD-208. J Heart Lung Transplant. 2014 Jun;33(6):654-61. |
| 5914 | Tatsumi Y, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May;57(5):2405-9. |
| 5915 | Tatsum Y, et al. KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. Microbiol Immunol. 2002;46(7):425-32. |
| 5916 | Podurgiel SJ et al. The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine. Behav Brain Res. 2016 Feb 1;298(Pt B):188-91. |
| 5917 | Peter D et al. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. J Biol Chem. 1996 Feb 9;271(6):2979-86. |
| 5918 | Ber 71:106 (1938); Arzneim Forsch 11:915 (1961); J Am Acad Dermatol 18:693 (1988) |
| 5919 | Xie FF, et al. Volasertib suppresses tumor growth in cervical cancer. Am J Cancer Res. 2015 Nov 15;5(12):3548-59. |
| 5920 | Abbou S, et al. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity in Pediatric Malignancies. Anticancer Res. 2016 Feb;36(2):599-609. |
| 5921 | Rudolph D, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.Clin Cancer Res. 2009 May 1;15(9):3094-102. Epub |
| 5922 | Bilodeau MT, Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3178-82. |
| 5923 | Ellinghaus P, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2013 Oct;2(5):611-24. |
| 5924 | Helbig L, et al. BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. Radiat Oncol. 2014 Sep 19;9:207. |
| 5925 | Dieter Dorsch, et al. Triazolo[4,5-d]pyrimidine derivatives. WO2013110309A1. |
| 5926 | Liu L, et al. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011 Jul;338(1):154-63. |
| 5927 | Liu L, et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab Dispos. 2011 Oct;39(10):1840-9. |
| 5928 | Kawabata K, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991 Jun 14;177(2):814-20. |
| 5929 | Yuichiro Toda, et al. A neutrophil elastase inhibitor, sivelestat, ameliorates lung injury after hemorrhagic shock in rats. Int J Mol Med. 2007 Feb;19(2):237-43. |
| 5930 | Tomoharu Kono, et al. Neutrophil elastase inhibitor, sivelestat sodium hydrate prevents ischemia-reperfusion injury in the rat bladder. Mol Cell Biochem. 2008 Apr;311(1-2):87-92. |
| 5931 | Adeleh Sahebnasagh, et al. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. J Clin Pharm Ther. 2020 Aug 28. |
| 5932 | Arzneim Forsch 30:314, 348 (1980); Proc West Pharmacol Soc 45:104 (2002); Annals Hepatol 8:141 (2009) |
| 5933 | Omer G, et, al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020 Apr 24; 368(6489): 387-394. |
| 5934 | https://clinicaltrials.gov/ct2/show/NCT04368377?term=Tirofiban&cond=covid&draw=2&rank=1 |
| 5935 | Chem Pharm 18:1937 (1970); Am Nutr Metab 35:292 (1991) |
| 5936 | Baoliang P, et al. Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. Vet Res Commun. 2006 Apr;30(3):263-70. |
| 5937 | Visser M, et al. The treatment of bovine sarcoptic mange (Sarcoptes scabiei var. bovis) using eprinomectin extended-release injection. Vet Parasitol. 2013 Mar 1;192(4):359-64. |
| 5938 | Shoop WL, et al. Eprinomectin: a novel avermectin for use as a topical endectocide for cattle. Int J Parasitol. 1996 Nov;26(11):1237-42. |Vet. Parasitol. (1997), 73(1,2), 153-161; Am. J. Vet. Res. (1997), 58(6), 612-614; Int. J. Parasitol. (1996), 26(11), 1237-1242 |
| 5939 | J Nat Prod 39: 412 (1976) |
| 5940 | https://clinicaltrials.gov/ct2/show/NCT04836806?term=CETIRIZINE&cond=COVID-19&draw=2&rank=1 |
| 5941 | Nicole Buschmann, et al. Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO2015059668A1. |
| 5942 | Hierro C, et al. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin Oncol. 2015 Dec;42(6):801-19. |
| 5943 | Weidner LD, et al. The Inhibitor Ko143 Is Not Specific for ABCG2. J Pharmacol Exp Ther. 2015 Sep;354(3):384-93. |
| 5944 | JD Allen et al. Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C. Mol. Cancer Ther. 2002, 1, 417-425. |
| 5945 | Wen JH, et al. Effect of Ursolic Acid on Breast Cancer Resistance Protein-mediated Transport of ZD 4522 In Vivo and Vitro. Chin Med Sci J. 2015 Dec;30(4):218-25. |
| 5946 | Hou J, et al. Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012 Jul;66:232-9. |
| 5947 | Liu K, et al. Metabolism of KO143, an ABCG2 inhibitor. Drug Metab Pharmacokinet. 2017 Aug;32(4):193-200. |
| 5948 | Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535. |
| 5949 | J Org Chem 32:3992 (1967) |
| 5950 | Das A, et al. Interaction of aloe active compounds with calf thymus DNA. J Mol Recognit. 2019 Oct;32(10):e2786. |
| 5951 | J Neurochem 44:247 (1985); Neuropharmacology 32:833 (1993) |
| 5952 | Tetrahedron 18:1049 (1962); J Chem Soc (C) 1967:2234| |
| 5953 | Miao M, et al. Effects of verbenalin on prostatitis mouse model. Saudi J Biol Sci. 2016 Jan;23(1):S148-57. |
| 5954 | Cao L, et al. The protective role of verbenalin in rat model of focal cerebral ischemia reperfusion. Saudi J Biol Sci. 2018 Sep;25(6):1170-1177. |
| 5955 | Hafiza Salaha Mahrosh, et al. An in silico approach to target RNA-dependent RNA polymerase of COVID-19 with naturally occurring phytochemicals. Environ Dev Sustain. 2021 Apr 3;1-14. |
| 5956 | Li W, et al. cRGD Peptide-Conjugated Pyropheophorbide-a Photosensitizers for Tumor Targeting in Photodynamic Therapy. Mol Pharm. 2018 Apr 2;15(4):1505-1514. |
| 5957 | J Org Chem 28:1086 (1963); Int J Cosmet Sci 28:103 (2006); Cancer Lett 287:123 (2010) |
| 5958 | Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7(7), 1851-1863. |
| 5959 | Sako Y, et al. TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects. Neuropsychopharmacology. 2018 Aug 1. doi: 10.1038/s41386-018-0168-8. |
| 5960 | Ann Acad Brasil Cienc 42 (suplemento): 45 (1970); Tetrahedron 25: 4617 (1969); Phytochemistry 10: 1417 (1971); 31: 93 (1992) |
| 5961 | Warrilow AG, et al. Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob Agents Chemother. 2013 Mar;57(3):1352-60. |
| 5962 | Justin J J Leahy, et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7. |
| 5963 | Yang C, et al. NU7441 Enhances the Radiosensitivity of Liver Cancer Cells. Cell Physiol Biochem. 2016;38(5):1897-905 |
| 5964 | Hardcastle IR, et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46 |
| 5965 | Ember SW, et al. The acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem Biol. 2014 Feb 25. |
| 5966 | Robert F, et al. Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. Genome Med. 2015 Aug 27;7:93 |
| 5967 | Ndubaku CO, et al. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety. ACS Med Chem Lett. 2015 Oct 31;6(12):1241-6. |
| 5968 | Rudolph J, et al. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window. J Med Chem. 2016 Jun 9;59(11):5520-41. |
| 5969 | https://clinicaltrials.gov/ct2/show/NCT04604223?term=PIOGLITAZONE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04535700?term=PIOGLITAZONE&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04500639?term=PIOGLITAZONE&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04473274?term=PIOGLITAZONE&cond=COVID-19&draw=2&rank=4 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001929-31-ES |
| 5970 | https://clinicaltrials.gov/ct2/show/NCT04361214?term=LEFLUNOMIDE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT05007678?term=LEFLUNOMIDE&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04532372?term=LEFLUNOMIDE&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04434118?term=LEFLUNOMIDE&cond=COVID-19&draw=2&rank=4 https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000030058 https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000033372 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-002952-18-GB |
| 5971 | Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806. |
| 5972 | Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65(11):4789-98. |
| 5973 | So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9(9):e107616. |
| 5974 | Waaler J, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012 Jun 1;72(11):2822-32. |
| 5975 | Burlacu CL, et al. Update on local anesthetics: focus on levobupivacaine. Ther Clin Risk Manag. 2008 Apr;4(2):381-92. |
| 5976 | Gulec D, et al. Intrathecal bupivacaine or levobupivacaine: which should be used for elderly patients? J Int Med Res. 2014 Apr;42(2):376-85. |
| 5977 | Chen BJ, et al. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci. 2014 Sep 13;10(10):1084-96. |
| 5978 | Dimitris Stellas, et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst. 2014 Oct 11;106(12):dju320. |
| 5979 | Reprod Toxicol 29:132 (2010); J Pediatr Nurs 25 :400 (2010) |
| 5980 | Follmann M, et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem. 2017 Jun 22;60(12):5146-5161. |
| 5981 | https://clinicaltrials.gov/ct2/show/NCT04470297?term=Ramelteon&cond=COVID-19&draw=2&rank=1 |
| 5982 | Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18. |
| 5983 | Ma F, et al. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010 Sep;7(5):381-8. |
| 5984 | Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306. |
| 5985 | Olmos D, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30. |
| 5986 | Degenhardt Y, et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther. 2010 Jul;9(7):2079-89 |
| 5987 | Gilmartin AG, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009 Sep 1;69(17):6969-77. |
| 5988 | Chou YS, et al. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. Int J Oncol. 2016 Mar;48(3):1187-94. |
| 5989 | Clin Drug Invest 5 Suppl 1:4, 50, 60, 73, 96 (1993) |
| 5990 | Wingrove PB, et al. The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4569-73. |
| 5991 | Sanna E, et al. Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60. |
| 5992 | Green AR, et al. A behavioural and neurochemical study in rats of the pharmacology of loreclezole, a novel allosteric modulator of the GABAA receptor. Neuropharmacology. 1996;35(9-10):1243-50. |
| 5993 | Gendreau SB, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res. 2007 Jun 15;13(12):3713-23. |
| 5994 | Clegg NJ, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. |
| 5995 | Smith MR, et al. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 May 6. pii: S0302-2838(16)30133 |
| 5996 | Takashi Narui, et al. Water and deprodone proprionate -containing external preparations. EP 0473810 B1. |
| 5997 | W L Duax, et al. Steroid Dehydrogenase Structures, Mechanism of Action, and Disease. Vitam Horm. 2000;58:121-48. |
| 5998 | Hossein Hosseinzadeh, et al. Anticonvulsant, Sedative and Muscle Relaxant Effects of Carbenoxolone in Mice. BMC Pharmacol. 2003 Apr 29;3:3. |
| 5999 | Ismar R Haga, et al. Carbenoxolone-mediated Cytotoxicity Inhibits Vaccinia Virus Replication in a Human Keratinocyte Cell Line. Sci Rep. 2018 Nov 16;8(1):16956. |
| 6000 | Zhao H, et al. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest. Oncol Res. 2016;23(5):237-48 |
| 6001 | Dong Y, et al. Raltitrexed's effect on the development of neural tube defects in mice is associated with DNA damage, apoptosis, and proliferation. Mol Cell Biochem. 2015 Jan;398(1-2):223-31. |
| 6002 | Xue S, et al. Raltitrexed induces mitochondrial-mediated apoptosis in SGC7901 human gastric cancer cells. Mol Med Rep. 2014 Oct;10(4):1927-34. |
| 6003 | Waldman BC, et al. Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. DNA Repair (Amst). 2008 Oct 1;7(10):1624-35. |
| 6004 | Future Oncol. (2009), 5(1), 33-42; J. Med. Chem. (1978), 21(12), 1315-18; J. Clin. Hematol. Oncol. (1977), 7(1), 197-209 |
| 6005 | Cornelia Dorner-Ciossek, et al. BI 409306, a novel phosphodiesterase 9A inhibitor, part I: potency, selectivity and in-vitro functional characterization on synaptic plasticity. International Congress on Schizophrenia Research. |
| 6006 | Shirai, K., & Matsuoka, M. (1996). Structure and properties of hematein derivatives. Dyes and Pigments, 32(3), 159–169. |
| 6007 | Hung MS, et al. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograftmodel.Int J Oncol. 2013 Nov;43(5):1517-22. |
| 6008 | Pundir CS, Devi R. Biosensing methods for xanthine determination: a review. Enzyme Microb Technol. 2014;57:55-62. |
| 6009 | David A. Taylor, et al. Central Nervous SystemStimulants. |
| 6010 | Ashihara H, et al. Xanthine Alkaloids: Occurrence, Biosynthesis, and Function in Plants. Prog Chem Org Nat Prod. 2017;105:1-88. |
| 6011 | O'Neill PM, et al. Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J Med Chem. 2009 Mar 12;52(5):1408-15. |
| 6012 | Am J Vet Res 38:465 (1977) |
| 6013 | JACS 37:2734 (1915); J Chem Soc 113:188 (1918) |
| 6014 | Am J Clin Oncology 13:477 (1990) |
| 6015 | Nguyen JT, et al. Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7533-8. Epub 2003 Jun 13. |
| 6016 | Uboh CE, et al. Pharmacokinetics of penicillin G procaine versus penicillin G potassium and procaine hydrochloride in horses. Am J Vet Res. 2000 Jul;61(7):811-5. |
| 6017 | Burmańczuk A, et al. Withdrawal of Amoxicillin and Penicillin G Procaine from Milk after Intramammary Administration in Dairy Cows with Mastitis. J Vet Res. 2017 Apr 4;61(1):37-43. |
| 6018 | Biochem Pharmacol 17:1647 (1968) |
| 6019 | Eur J Clin Pharmacol 26:603 (1984); Drug Dev Res 9:249 (1986) |
| 6020 | Shimamoto Y, et al. Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine. Jpn J Cancer Res. 2001 Mar;92(3):343-51. |
| 6021 | Abdelrahim M, et al. TAS-106: preclinical, clinical and beyond. Oncology. 2013;85(6):356-363. |
| 6022 | Hammond-Thelin LA, et al. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Invest New Drugs. 2012;30(1):316-326. |
| 6023 | J Chem Soc 1963: 1461; Steroids 75:1137 (2010) |
| 6024 | Arzneim Forsch 32:633 (1982); 35:1753 (1985); Z Hautkrankhr 61 Suppl 1:1 (1986) |
| 6025 | https://clinicaltrials.gov/ct2/results?cond=Covid19&term=Norepinephrine&cntry=&state=&city=&dist= |
| 6026 | Villa GR, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Nov 14;30(5):683-693. |
| 6027 | Giannarelli C, et al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J. 2012 Jan;33(2):264-73. |
| 6028 | Quinet EM, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res. 2009 Dec;50(12):2358-70. |
| 6029 | DiBlasio-Smith EA, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med. 2008 Oct 16;6:59. |
| 6030 | ray NS, Wodicka L, Thunnissen AM et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8. |
| 6031 | Wen-Liang Wang, et al. Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacol Sin. 2020 Jul 31. |
| 6032 | Br. J. Anaesth. (1970), 42(3), 235-48; J. Pharmacol. Exp. Ther. (1950), 100(No. 4;Pt. 1), 489-501; J. Pharmacol. Exp. Ther. (1950), 100, 201-9 |
| 6033 | Int J Toxicol 16:117 (1997) |
| 6034 | Mautino, et al. Preparation of fused imidazole derivatives as IDO inhibitors. From PCT Int. Appl. (2012), 20121018. |
| 6035 | Cosmet. Sci. Technol. Ser. (2006), 30, 135-151; Skin Pharmacol. Physiol. (2005), 18(6), 253-62; J. Am. Acad. Dermatol. (1983), 9(3), 354-60 |
| 6036 | Adv. Neurol. (2002), 88, 147-157; Drugs (1979), 17(3), 161-81; Br. J. Pharmacol. (1977), 61(1), 118P-19P |
| 6037 | By Foote, et al. Morpholinopyrimidines as ATR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl. (2011), WO 2011154737 A1 20111215. |
| 6038 | Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutatedand Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907. |
| 6039 | https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20081019001369N4 |
| 6040 | Helmut Ripperger,et al.Steroidal alkaloid glycosides from Solanum suaveolens.Phytochemistry, 46(7), 1997, 1279-1282. |
| 6041 | Tinsley JM et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One. 2011 May 6;6(5):e19189. |
| 6042 | Tinsley J et al. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol. 2015 Jun;55(6):698-707. |
| 6043 | Guiraud S et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet. 2015 Aug 1;24(15):4212-24. |
| 6044 | Chancellor DR, et al. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J Med Chem. 2011;54(9):3241-3250. |
| 6045 | Chatzopoulou M, et al. Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-trans-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid. J Med Chem. 2020;63(5):2547-2556. |
| 6046 | Stachelek GC, et al. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors. Mol Cancer Res. 2015 Oct;13(10):1389-97. |
| 6047 | John David Harlin, et al. Compounds for the modulation of rip2 kinase activity. WO2017046036A1. |
| 6048 | J.Chem.Soc.1930: 508; 1954: 2012 |
| 6049 | Protein Kinase C Inhibitor LXS196 |
| 6050 | US20180179181. |
| 6051 | Cui H, et al. Dual effects of propyl gallate and its methylglyoxal adduct on carbonyl stress and oxidative stress. Food Chem. 2018 Nov 1;265:227-232. |
| 6052 | Wang J, et al. Scavenging of Acrolein by Food-Grade Antioxidant Propyl Gallate in a Model Reaction System and Cakes. J Agric Food Chem. 2019 Aug 7;67(31):8520-8526. |
| 6053 | Sha S, et al. Antihypertensive effects of fargesin in vitro and in vivo via attenuating oxidative stress and promoting nitric oxide release. Can J Physiol Pharmacol. 2016 Aug;94(8):900-6. |
| 6054 | Yue B, et al. Anti-Inflammatory Effects of Fargesin on Chemically Induced Inflammatory Bowel Disease in Mice. Molecules. 2018 Jun 7;23(6). |
| 6055 | Pham TH, et al. Fargesin exerts anti-inflammatory effects in THP-1 monocytes by suppressing PKC-dependent AP-1 and NF-ĸB signaling. Phytomedicine. 2017 Jan 15;24:96-103. |
| 6056 | Wang X, et al. Fargesin as a potential β₁ adrenergic receptor antagonist protects the hearts against ischemia/reperfusion injury in rats via attenuating oxidative stress and apoptosis. Fitoterapia. 2015 Sep;105:16-25. |
| 6057 | Yu S, et al. Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells. BMC Complement Altern Med. 2018 Feb 14;18(1):59. |
| 6058 | Chen H, et al. Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/Akt/NF-κB signaling pathway. Oncol Rep. 2017 Feb;37(2):865-870. |
| 6059 | Déciga-Campos M, et al. Antinociceptive and anti-inflammatory effects of compounds isolated from Scaphyglottis livida and Maxillaria densa. J Ethnopharmacol. 2007 Nov 1;114(2):161-8. |
| 6060 | Lanza M, et al. CGP 52432: a novel potent and selective GABAB autoreceptor antagonist in rat cerebral cortex. Eur J Pharmacol. 1993 Jun 24;237(2-3):191-5. |
| 6061 | Sweeney FF, et al. Activation but not blockade of GABAB receptors during early-life alters anxiety in adulthood in BALB/c mice. Neuropharmacology. 2014 Jun;81:303-10. |
| 6062 | Kobuchi S, et al. Mechanisms underlying the renoprotective effect of GABA against ischaemia/reperfusion-induced renal injury in rats. Clin Exp Pharmacol Physiol. 2015 Mar;42(3):278-86. |
| 6063 | J Chem Soc 1932:2795; JACS 63:1462 (1941); Food Cosmet Toxicol 2:327 (1964) |
| 6064 | Angiology (1987), 38(2 Pt 2), 174-83; Ann. Intern. Med. (1982), 96(3), 337-43; J. Pharmacol. Exp. Ther. (1962), 136(1), 114-24 |
| 6065 | Pharmacol Rev 23:1 (1971); Br Med J 327:1332 (2003) |
| 6066 | Harder A, et al. Mechanisms of action of emodepside. Parasitol Res. 2005 Oct;97 Suppl 1:S1-10. |
| 6067 | Buxton SK, et al. On the mode of action of emodepside: slow effects on membrane potential and voltage-activated currents in Ascaris suum. Br J Pharmacol. 2011 Sep;164(2b):453-70. |
| 6068 | Kulke D, et al. Characterization of the Ca2+-gated and voltage-dependent K+-channel Slo-1 of nematodes and its interaction with emodepside. PLoS Negl Trop Dis. 2014 Dec 18;8(12):e3401. |
| 6069 | Bull K, et al. Effects of the novel anthelmintic emodepside on the locomotion, egg-laying behaviour and development of Caenorhabditis elegans. Int J Parasitol. 2007 May;37(6):627-36. |
| 6070 | Shen Z, et al. In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters. Clin Drug Investig. 2016 Jun;36(6):443-52 |
| 6071 | Sattui SE, et al. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):145-59. |
| 6072 | L.Yeh, et al. RDEA594, a potential uric acid lowering agent througn inhibition of uric acid reuptake ,shows better pharmacokinetics rhan its prodrug RDEA806. 2008 ACR/ARHP Annual Scientific Meeting, 24-29 October 2008, USA. |
| 6073 | Martinez-Garcia M, et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res. 2012 Sep 1;18(17):4806-19. |
| 6074 | Iizuka-Ohashi M, et al. Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells. Oncotarget. 2018 Apr 13;9(28):19597-19612. |
| 6075 | Ishii N, et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 2013 Jul 1;73(13):4050-4060. |
| 6076 | Kircik LH.
 Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: a pilot study.
 J Drugs Dermatol. 2012 Jul 1;11(7):858-60. |
| 6077 | Candel FJ, Morales G, Picazo JJ.
 In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates.
 Rev Esp Quimioter. 2011 Sep;24(3):127-30. |
| 6078 | Pérez-Trallero E, Tamayo E, Montes M, García-Arenzana JM, Iriarte V.
 In vitro activities of retapamulin and 16 other antimicrobial agents against recently obtained Streptococcus pyogenes isolates.
 Antimicrob Agents Chemother. 2011 May;55(5):2406-8. |
| 6079 | Weinberg JM, Tyring SK.
 Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus.
 J Drugs Dermatol. 2010 Oct;9(10):1198-204. |
| 6080 | Retapamulin: focus on its use in the treatment of uncomplicated superficial skin infections and impetigo By Jacobs, Michael R.From Expert Review of Dermatology (2010), 5(5), 505-517. |
| 6081 | Muammer Kendirci, et al. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther Clin Risk Manag. 2007 Jun;3(2):277-89. |
| 6082 | Rabab H Sayed, et al. Dapoxetine attenuates testosterone-induced prostatic hyperplasia in rats by the regulation of inflammatory and apoptotic proteins. Toxicol Appl Pharmacol. 2016 Nov 15;311:52-60. |
| 6083 | Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. |
| 6084 | Sakamaki JI, et al. Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and LysosomalFunction. Mol Cell. 2017 May 18;66(4):517-532.e9. |
| 6085 | Matzuk MM, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012 Aug 17;150(4):673-84. |
| 6086 | https://clinicaltrials.gov/ct2/show/NCT04558463?term=Oseltamivir&cond=covid&draw=2&rank=1 |
| 6087 | J. Econ. Entomol. (1986), 79(5), 1192-5; J. Med. Entomol. (1984), 21(4), 427-31; Vet. Rec. (1980), 106(14), 306-7 |
| 6088 | Regenass U, et al. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res. 1994 Jun 15;54(12):3210-7. |
| 6089 | Kramer DL, et al. Lysosomal sequestration of polyamine analogues in Chinese hamster ovary cells resistant to the S-adenosylmethionine decarboxylase inhibitor, CGP-48664. Cancer Res. 1998 Sep 1;58(17):3883-90. |
| 6090 | Xu W, et al. Two potent cytochrome P450 2D6 inhibitors found in <i>Rhodiola rosea</i>. Pharmazie. 2013 Dec;68(12):974-6. |
| 6091 | Li FJ, et al. Molecular interaction studies of acetylcholinesterase with potential acetylcholinesterase inhibitors from the root of <i>Rhodiola crenulata</i> using molecular docking and isothermal titration calorimetry methods. Int J Biol Macromol. 2017 Nov;104(Pt A):527-532. |
| 6092 | Choe KI, et al. The antioxidant and anti-inflammatory effects of phenolic compounds isolated from the root of <i>Rhodiola sachalinensis</i> A. BOR. Molecules. 2012 Sep 27;17(10):11484-94. |
| 6093 | Mowbray CE, et al. Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602. |
| 6094 | Hadrava V, et al. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology. 1995 Oct;34(10):1311-26. |
| 6095 | Schoeffter P, et al. Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br J Pharmacol. 1988 Nov;95(3):975-85. |
| 6096 | Rodgers RJ, et al. Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan. Pharmacol Biochem Behav. 1994 Aug;48(4):959-63. |
| 6097 | J Med Chem 24:408 (1981); Phytomed 5:469 (1998); Biol Pharm Bull. 30:324 (2007) |
| 6098 | Max Seidy Saito, et al. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem. 2016 Dec;31(6):1591-601. |
| 6099 | James E. Bradner, et al. Bivalent bromodomain inhibtors and uses thereof. WO2017091673A2. |
| 6100 | Wang X, et al. A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. EMBO J. 2017 May 2;36(9):1243-1260. |
| 6101 | Klotz KN, et al. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91. |
| 6102 | Soliño M, et al. Adenosine A1 receptor: A neuroprotective target in light induced retinal degeneration. PLoS One. 2018 Jun 18;13(6):e0198838. |
| 6103 | Bradbury RH, et al. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1945-8. |
| 6104 | Sarah A Loddick, Rob Bradbury, Nicola Broadbent. Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1 |
| 6105 | Wilkinson ST, et al. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today. 2019 Feb;24(2):606-615. |
| 6106 | Maisch, B., et al., [Pregnancy and cardiomyopathies]. Herz, 2003. 28(3): p. 196-208. |
| 6107 | Snyders, D.J. and A. Chaudhary, High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol, 1996. 49(6): p. 949-55. |
| 6108 | Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 Jun 1;60(11):2926-35. |
| 6109 | Karan G, et al. Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Mol Cancer Ther. 2016 Apr;15(4):574-582. |
| 6110 | J Lab Clin Med 41:78 (1953) |
| 6111 | Mitchell T, et al. The mitochondria-targeted antioxidant mitoquinone protects against cold storage injury of renaltubular cells and rat kidneys. J Pharmacol Exp Ther. 2011 Mar;336(3):682-92. |
| 6112 | Huang W, et al. Effects of the mitochondria-targeted antioxidant mitoquinone in murine acute pancreatitis. Mediators Inflamm. 2015;2015:901780. |
| 6113 | Werkström V, et al. Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator AZD5423 after Inhalation in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2016 Dec;119(6):574-581. |
| 6114 | Gauvreau GM, et al. A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7. |
| 6115 | J Agric Food Chem. 47:1533 (1999); 52:5396 (2004) |
| 6116 | Xing Y, et al. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3. Pharmacol Res. 2018 Sep;135:166-180. |
| 6117 | Yang GW, et al. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis. Int J Mol Sci. 2015 Oct 12;16(10):24011-31. |
| 6118 | Zeni AL, et al. Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system. Eur J Pharmacol. 2012 Mar 15;679(1-3):68-74. |
| 6119 | Renault K, et, al. Covalent Modification of Biomolecules through Maleimide-Based Labeling Strategies. Bioconjug Chem. 2018 Aug 15;29(8):2497-2513. |
| 6120 | Zhang S, et, al. A Maleimide-functionalized Tetraphenylethene for Measuring and Imaging Unfolded Proteins in Cells. Chem Asian J. 2019 Mar 15;14(6):904-909. |
| 6121 | Chen W, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016 Nov 3;539(7627):112-117. |
| 6122 | Cho H, et al. On-Target Efficacy of a HIF2α Antagonist in Preclinical Kidney Cancer Models. Nature. Nature. 2016 Nov 3;539(7627):107-111. |
| 6123 | Wehn PM, et al. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem. 2018 Nov 8;61(21):9691-9721. |
| 6124 | Felts AS, et al. Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. J Med Chem. 2017 Jun 22;60(12):5072-5085. |
| 6125 | Kolkhof P, et al. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017 Jul;234(1):T125-T140. |
| 6126 | Sonam Grover, et al. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus. BMC Bioinformatics. 2014; 15(Suppl 16): S13. |
| 6127 | Oleg G Chepurny, et al. Non-conventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. J Biol Chem. 2019 Mar 8;294(10):3514-3531. |
| 6128 | Angela Kim, et al. AVP-induced counter-regulatory glucagon is diminished in type 1 diabetes. bioRxiv. January 31, 2020. |
| 6129 | Fryer RM, et al. Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors. Journal of Pharmacology and Experimental Therapeutics (2012), 340(3), 492-500. |
| 6130 | Edgar AJ, et al. A combination of SILAC and nucleotide acyl phosphate labelling reveals unexpected targets of the Rsk inhibitor BI-D1870. Biosci Rep. 2013 Dec 17. |
| 6131 | Tang H, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5. |
| 6132 | Jiang D, et al. Monomethyl Fumarate Protects the Retina From Light-Induced Retinopathy. Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1275-1285. |
| 6133 | Sghaier R, et al. Dimethyl fumarate and monomethyl fumarate attenuate oxidative stress and mitochondrialalterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7β-hydroxycholesterol. J Steroid Biochem Mol Biol. 2019 Nov;194:105432. |
| 6134 | Nguyen HC, et al. Post-PKS tailoring steps of the spiramycin macrolactone ring in Streptomyces ambofaciens. Antimicrob Agents Chemother. 2013 Aug;57(8):3836-42. |
| 6135 | Etewa SE, et al. Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice. J Parasit Dis. 2018 Mar;42(1):102-113. |
| 6136 | Guo HY, et al. Synthesis and Biological Evaluation of (+)-Usnic Acid Derivatives as Potential Anti-Toxoplasma gondii Agents. J Agric Food Chem. 2019 Aug 28;67(34):9630-9642. |J Am Chem Soc 91: 3401 (1969) |
| 6137 | Fedoriw A, et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2019 Jul 8;36(1):100-114.e25. |
| 6138 | Drugs 65:1317 (2005); Expert Opin Invest Drugs 15:155 (2006)| |
| 6139 | Jitkova Y, et al. A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One. 2014 May 28;9(5):e95281. |
| 6140 | Falagas ME, et al. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. Int J Antimicrob Agents. 2018 Aug;52(2):269-271. |
| 6141 | Weyermann P, et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One. 2009;4(3):e4774. |
| 6142 | Jiang F, et al. Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. J Med Chem. 2018 Nov 8;61(21):9513-9533. |
| 6143 | Kundu S, et al. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J Immunol. 2010 Jun 1;184(11):6529-36. |
| 6144 | Clin Pharm 9:165 (1990) |
| 6145 | Baader E, et al. Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues. Biochem J. 1994 Jun 1;300 (Pt 2):525-30. |
| 6146 | Milkiewicz M, et al. Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J Physiol. 2004 Oct 1;560(Pt 1):21-6. |
| 6147 | Schultz K, et al. Prolyl hydroxylase 2 deficiency limits proliferation of vascular smooth muscle cells by hypoxia-inducible factor-1{alpha}-dependent mechanisms. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L921-7. |
| 6148 | Li X, et al. Up-regulation of hypoxia-inducible factor-1α enhanced the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats. Acta Biochim Biophys Sin (Shanghai). 2014 Feb;46(2):112-8. |
| 6149 | Singh A, et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model.Sci Rep. 2020 Jan 31;10(1):1597. |
| 6150 | M B Youdim, et al. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001 Jan;132(2):500-6. |
| 6151 | Drugs Today (2009), 45(3), 213-225; Curr. Med. Res. Opin. (2010), 26(6), 1269-1275; Synthesis (1995), (7), 766-8 |
| 6152 | Lancet 343:1479 (1994) |
| 6153 | Aygoren-Pursun E, et al. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. J Allergy Clin Immunol. 2016 Sep;138(3):934-936.e5. |
| 6154 | Cornpropst M, et al. Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study. Allergy. 2016;71(12):1676-1683. |
| 6155 | Seifert, R., et al., Histamine increases cytosolic Ca2+ in dibutyryl-cAMP-differentiated HL-60 cells via H1 receptors and is an incomplete secretagogue. Mol Pharmacol, 1992. 42(2): p. 227-34. |
| 6156 | Schran, H.F., et al., The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol, 1996. 36(10): p. 911-22. |
| 6157 | Eli Wallace, Ph.D. PT2385: HIF-2α Antagonist for the Treatment of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016. |
| 6158 | Xie C, et al. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308. |
| 6159 | Wallace EM, et al. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500. |
| 6160 | Experientia 37:963 (1981); JACS 103:4216 (1981) |
| 6161 | Vangamudi B, et al. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Res. 2015 Sep 15;75(18):3865-78. |
| 6162 | Fedorov O, et al. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci Adv. 2015 Nov 13;1(10):e1500723. |
| 6163 | Gerstenberger BS, et al. Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit. J Med Chem. 2016 May 26;59(10):4800-11. |
| 6164 | Tamura T, et al. Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism. Nat Commun. 2016 Nov 18;7:13384. |
| 6165 | Dmitry Borkin, et al. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016 Feb 11;59(3):892-913. |
| 6166 | Rohit Malik, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015 Apr;21(4):344-52. |
| 6167 | Jia H, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014 Sep 25;57(18):7577-89. |
| 6168 | Gavine PR, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015 Jan;9(1):323-33. |
| 6169 | Bryson, Paul D. et al. A small molecule inhibits HCV replication and alters NS4B's subcellular distribution Antiviral Research (2010), 87(1), 1-8. |
| 6170 | Cho, Nam-Joon et al. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Science Translational Medicine (2010), 2(15), No pp. given. |
| 6171 | Bannister T, et al. ML311: A Small Molecule that Potently and Selectively Disrupts the Protein-Protein Interaction of Mcl-1 and Bim: A Probe for Studying Lymphoid Tumorigenesis. Biotechnology Information (US); 2010-2012 Apr 16. |
| 6172 | Krige D, et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008 Aug 15;68(16):6669-79. |
| 6173 | Jenkins C, et al. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia. Leuk Res. 2011 May;35(5):677-81. |
| 6174 | Smith EM, et al. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway. Oncotarget. 2015 Jul 10;6(19):17314-27. |
| 6175 | Skoumbourdis AP, et al. Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3686-92. |
| 6176 | Ryou C, et al. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest. 2003 Jun;83(6):837-43. |
| 6177 | Veiga-Santos P, et al. SQ109, a new drug lead for Chagas disease. Antimicrob Agents Chemother. 2015 Apr;59(4):1950-61. |
| 6178 | Jia L, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol. 2005 Jan;144(1):80-7 |
| 6179 | Jia L, et al. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85. |
| 6180 | Zhang YK, et al. Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2270-4. |
| 6181 | Akama Tsutomu, et al. Preparation of boron-containing small molecules as anti-inflammatory agents. From PCT Int. Appl. (2009), WO 2009111676 A2 20090911. |
| 6182 | Kawai S, et, al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94. |
| 6183 | Hirate K, et, al. Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. |
| 6184 | Kameyama T, et, al. Analgesic and antiinflammatory effects of 2-(10,11-dihydro-10-oxo-dibenzo[b,f]thiepin-2-yl)propionic acid in rat and mouse. Arzneimittelforschung. 1987 Jan;37(1):19-26. |
| 6185 | https://clinicaltrials.gov/ct2/show/NCT05035186?term=Levofloxacin&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT02735707?term=Levofloxacin&cond=COVID-19&draw=2&rank=4 https://trialsearch.who.int/Trial2.aspx?TrialID=RBR-3rywwg |
| 6186 | Wurz RP, et al. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS Med Chem Lett. 2015 Jul 27;6(9):987-92. |
| 6187 | J Clin Pharmacol 20:347 (1980); Pharmacotherapy 7:16 (1987) |
| 6188 | Ann Rheum Dis 60:158 (2001); Toxicol Appl Pharmacol 250:130 (2011) |
| 6189 | Nozaki C, et al. δ-Opioid Mechanisms for ADL5747 and ADL5859 Effects in Mice: Analgesia, Locomotion, and Receptor Internalization.J Pharmacol Exp Ther. 2012 Sep;342(3):799-807. |
| 6190 | Le Bourdonnec B, et al. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).J Med Chem. 2009 Sep 24;52(18):5685-702. |
| 6191 | Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).J Med Chem. 2008 Oct 9;51(19):5893-6. Epub 2008 Sep 13. |
| 6192 | Le Bourdonnec B et al. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859) J Med Chem. 2008 Oct 9;51(19):5893-6. |
| 6193 | https://clinicaltrials.gov/ct2/show/NCT04454307?term=TRAMADOL&cond=COVID-19&draw=2&rank=1 |
| 6194 | Zhang H, et al. Microbial production of sabinene--a new terpene-based precursor of advanced biofuel. |
| 6195 | Okuda Y, et al. Editor's Highlight: Mode of Action Analysis for Rat Hepatocellular Tumors Produced by the Synthetic Pyrethroid Momfluorothrin: Evidence for Activation of the Constitutive Androstane Receptor and Mitogenicity in Rat Hepatocytes. Toxicol Sci. 2017 Aug 1;158(2):412-430. |
| 6196 | https://clinicaltrials.gov/ct2/show/NCT05018975?term=Tazemetostat&cond=covid&draw=2&rank=1 |
| 6197 | Hutterer C, et al. A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother. 2015 Apr;59(4):2062-71. |
| 6198 | Ikeda K, et al. Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells. Tohoku J Exp Med. 2011;224(4):263-71. |
| 6199 | Nakano N, et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Int Heart J. 2010 May;51(3):188-92. |
| 6200 | Suzuki S, et al. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters. Circ J. 2007 Dec;71(12):1970-6. |
| 6201 | Lee TS, et al. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. |
| 6202 | Ito M, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017 Jan;133(1):25-33. |
| 6203 | Chen Y, et al. Discovery of a Novel Dual Histone Deacetylases (HDACs) and Mammalian Target of Rapamycin (mTOR) Target Inhibitor as a Promising Strategy for Cancer Therapy. J Med Chem. 2019 Jan 10. |
| 6204 | Chemotherapy (1976), 22(3-4), 183-9; Antimicrob. Agents Chemother. (1965), 937-46; Antimicrob. Agents Chemother. (1965), (Oct.), 257-62 |
| 6205 | Takle AK, et al. The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4373-6. |
| 6206 | Shelton JG, et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia. 2003 Sep;17(9):1765-82. |
| 6207 | Berger A, et al. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol. 2014 Feb;134(2):430-440. |
| 6208 | J Med Chem 24: 1377 (1981); 26: 895 (1983); Drugs of the Future 9: 597 (1984) |
| 6209 | J Chem Soc 107:872 (1915); Chem Abs 43:5086 (1949) |
| 6210 | Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56(4):481-95. |
| 6211 | Bridges JW, et al. Species differences in the metabolism and excretion of sulphasomidine andsulphamethomidine. Biochem J. 1969 Jan;111(2):173-9. |
| 6212 | Melander A, et, al. Therapeutic equivalence of sulfaisodimidine 2 g twice daily and 1 g four times daily in lower urinary tract infections. Acta Med Scand. 1982;211(5):361-4. |
| 6213 | J. Soc. Cosmet. Chem. (1984), 35(8), 439-45; Int. J. Dermatol. (1983), 22(4), 247-55; Int. J. Cosmet. Sci. (1979), 1(6), 341-61 |
| 6214 | Wang DD, et al. Rare ginsenoside Ia synthesized from F1 by cloning and overexpression of the UDP-glycosyltransferase gene from Bacillus subtilis: synthesis, characterization, and in vitromelanogenesis inhibition activity in BL6B16 cells. J Ginseng Res. 2018 Jan;42(1):42-49. |
| 6215 | Qin M, et al. Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling. Front Pharmacol. 2017 Dec 22;8:953. |
| 6216 | Rikitake Y, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005 Oct;36(10):2251-7. Epub 2005 Sep 1. |
| 6217 | Masago T, et al. Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: an experimental rat model. Int J Urol. 2009 Oct;16(10):842-7. |
| 6218 | Saito M, et al. Hydroxyfasudil ameliorates penile dysfunction in the male spontaneously hypertensive rat. Pharmacol Res. 2012 Oct;66(4):325-31. |
| 6219 | Gai, L., Cai, N., Wang, L., Xu, X. & Kong, X. Ursolic acid induces apoptosis via Akt/NF-kappaB signaling suppression in T24 human bladder cancer cells. Molecular medicine reports 7, 1673-1677, doi:10.3892/mmr.2013.1364 (2013). |
| 6220 | Manu, K. A. & Kuttan, G. Ursolic acid induces apoptosis by activating p53 and caspase-3 gene expressions and suppressing NF-kappaB mediated activation of bcl-2 in B16F-10 melanoma cells. International immunopharmacology 8, 974-981, doi:10.1016/j.intimp.2008.02.013 (2008). |
| 6221 | Shanmugam, M. K. et al. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. Journal of molecular medicine 89, 713-727, doi:10.1007/s00109-011-0746-2 (2011). |
| 6222 | Julien LEFRANC, et al. 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists. WO2019101641A1. |
| 6223 | Ramesh T et al.Development and validation of a stability-indicating RP-HPLC assay method and stress degradation studies ondapiprazole. J Chromatogr Sci. 2013 Oct;51(9):856-60. |
| 6224 | Marx-Gross S et al. Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels.
 J Cataract Refract Surg. 2005 Jul;31(7):1372-6. |
| 6225 | Ren C, et al. Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7949-7954. |
| 6226 | https://clinicaltrials.gov/ct2/show/NCT04570254?term=Vitamin+E&cond=Covid19&draw=2&rank=1 |
| 6227 | thalimide derivative and application thereof as enzyme inhibitor and pesticide
 . Patent CN 103641825 A |
| 6228 | Lapuerta P, et al. Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome. Clin. Invest. (Lond.) (2015) 5(5), 447–456 |
| 6229 | US20080153852 |
| 6230 | Arzneim Forsch 30:409, 415 (1980); Drugs 34:222 (1987) |
| 6231 | Mousavi SH, et al. Comparative analysis of the cytotoxic effect of 7-prenyloxycoumarin compounds and herniarin on MCF-7 cell line. Avicenna J Phytomed. 2015 Nov-Dec;5(6):520-30. |
| 6232 | Haghighitalab A, et al. Enhancement of cisplatin cytotoxicity in combination with herniarin in vitro. Drug Chem Toxicol. 2014 Apr;37(2):156-62. |
| 6233 | E.G. Romanowski, et al. A Novel Topical Antiviral Agent, PCL–016 (Picolinic Acid), Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model. ARVO Annual Meeting Abstract. May 2005 Volume 46, Issue 13. |
| 6234 | Manetti F. Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials. Eur J Med Chem. 2018 Jul 15;155:445-458. |
| 6235 | Guzmán-Soto I, et al, Leuprolide acetate, a GnRH agonist, improves experimental autoimmune encephalomyelitis: a possible therapy for multiple sclerosis. Neurochem Res. 2012 Oct;37(10):2190-7. |
| 6236 | Gina Lama, et al. Leuprorelin Acetate Long-Lasting Effects on GnRH Receptors of Prostate Cancer Cells: An Atomic Force Microscopy Study of Agonist/Receptor Interaction. PLoS One. 2013; 8(1): e52530. |
| 6237 | J Pharmacol Exp Ther 96:151 (1949) |
| 6238 | Shima, Fumi, et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proceedings of the National Academy of Sciences of the United States of America (2013), 110(20), 8182-8187, |
| 6239 | Shima F, et al. Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction. Enzymes. 2013;34 Pt. B:1-23 |
| 6240 | Diagnostics 207:65 (1978); Int J Clin Pharmacol Res 5:175 (1985) |
| 6241 | https://clinicaltrials.gov/ct2/results?cond=covid&term=Rabeprazole+&cntry=&state=&city=&dist= |
| 6242 | Hammitzsch A, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73. |
| 6243 | Tao J, Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomed Pharmacother. 2018 Oct;106:1727-1733. |
| 6244 | Hay DA, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc. 2014 Jul 2;136(26):9308-19. |
| 6245 | Kim SJ, et al. The ameliorative effect of sophoricoside on mast cell-mediated allergic inflammation in vivo and in vitro. Molecules. 2013 May 22;18(5):6113-27. |
| 6246 | Eur J Clin Pharmacol 14:281 (1978); N Engl J Med 310:101 (1984) |
| 6247 | J Chem Soc 1954:1392 |
| 6248 | Jiang X, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun. 2017 Dec 13;8(1):2099. |
| 6249 | Clin Toxicol 16:269 (1980); N Engl J Med 315:1241 (1986);; JAMA 280:1777 (1998) |
| 6250 | Feldman RI, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. |
| 6251 | Zhu XX, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab. 2018 Sep;20(9):2113-2120. |
| 6252 | Wang P, et al. Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus. J Diabetes Res. 2017;2017:5812607. |
| 6253 | https://clinicaltrials.gov/ct2/show/NCT04937543?term=Beclometasone&cond=covid&draw=2&rank=1 |
| 6254 | William A.Ayer, et al. Synthesis of camalexin and related phytoalexins. Tetrahedron. Volume 48, Issue 14, 1992, Pages 2919-2924. |
| 6255 | Glawischnig E. Camalexin. Phytochemistry. 2007 Feb;68(4):401-6. |
| 6256 | Mezencev R, et al. Antiproliferative and cancer chemopreventive activity of phytoalexins: focus on indole phytoalexins from crucifers. Neoplasma. 2003;50(4):239-45. |
| 6257 | M.B. Kosa, et al. Ocular and Systemic Pharmacokinetics of AG-013958 With Sub-Tenon Administration To Cynomologus Monkeys. Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5379. |
| 6258 | Heffron TP, et al. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326). J Med Chem. 2016 Feb 11;59(3):985-1002. |
| 6259 | Ramsden N, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8. |
| 6260 | Vivas L, et al. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J Antimicrob Chemother. 2007 Apr;59(4):658-65. |
| 6261 | Ruiyuan Cao, et al. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro. ACS Infect. Dis. 2020 Jul. |
| 6262 | Kozikowski AP, et al. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem. 2008 Aug 14;51(15):4370-3. |
| 6263 | Wang Z, et al. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep. 2016 Jul;36(1):589-97. |
| 6264 | K Beckh, et al. Elimination of the Low-Molecular Weight Proteinase Inhibitor Camostate (FOY 305) and Its Degradation Products by the Rat Liver. Res Exp Med (Berl). 1987;187(6):401-6. |
| 6265 | Ai Maekawa, et al. Camostat Mesilate Inhibits Prostasin Activity and Reduces Blood Pressure and Renal Injury in Salt-Sensitive Hypertension. J Hypertens . 2009 Jan;27(1):181-9. |
| 6266 | Markus Hoffmann, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv. 2020 Aug 5;2020.08.05.237651. |
| 6267 | Indian J Biochem Biophys 28:381 (1991); Mutation Res/DNA Repair 485:269 (2001); Mol Cancer Ther 5:893 (2006) |
| 6268 | Guo XD, et al. Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance. Acta Pharmacol Sin. 2016 Sep;37(10):1281-1297. |
| 6269 | Wright BD, et al. The lipid kinase PIP5K1C regulates pain signaling and sensitization. Neuron. 2014 May 21;82(4):836-47. |
| 6270 | Peng W, et al. Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer. EBioMedicine. 2019 Jun;44:375-386. |
| 6271 | Wright BD, et al. Development of a High-Throughput Screening Assay to Identify Inhibitors of the Lipid Kinase PIP5K1C. J Biomol Screen. 2015 Jun;20(5):655-62. |
| 6272 | Brehmer D, et al. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics. 2004 May;3(5):490-500. |
| 6273 | Lang W, et al. Biodecolorization of a food azo dye by the deep sea Dermacoccus abyssi MT1.1(T) strain from the Mariana Trench.J Environ Manage. 2014 Jan;132:155-64. |
| 6274 | Meng T, et al. In Vitro and In Vivo Inhibition of the Infectivity of Human Enterovirus 71 by a Sulfonated Food Azo Dye, Brilliant Black BN.J Virol. 2019 Aug 13;93(17). |
| 6275 | Yan C, et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014 Nov 20;515(7527):443-447. |
| 6276 | Arienti KL, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. |
| 6277 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Azithromycin&cntry=&state=&city=&dist= |
| 6278 | J Pharm Pharmacol 10:40 (1958) |
| 6279 | Postgrad Med J 46:409 (1970); Singapore Med J 33:523 (1992); Chem Res Toxicol 20:10 (2007) |
| 6280 | Liu M, et al. Identification of indole-3-carboxylic acids as non-ATP-competitive Polo-like kinase 1 (Plk1) inhibitors. Bioorg Med Chem Lett. 2015 Feb 1;25(3):431-4. |
| 6281 | Yin Z, et al. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. ACS Chem Biol. 2013 Feb 15;8(2):303-8. |
| 6282 | Vakeva L, Ranki A, Hahtola S.
 Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
 Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359. |
| 6283 | Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P.
 Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene.
 Case Rep Dermatol. 2012 Jan;4(1):56-60. |
| 6284 | Orendas P, Kubatka P, Kajo K, Stollarova N, Kassayova M, Bojkova B, Pec M, Nosal V, Kiskova T, Zihlavnikova K, Karsnakova R.
 Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis.
 Neoplasma. 2012;59(4):469-74. |
| 6285 | Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME, Chomienne C.
 Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer.
 Clin Cancer Res. 2012 Jan 15;18(2):442-53. |
| 6286 | Gui Y, et al. Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1. J Pain. 2019 Jan 17. pii: S1526-5900(18)30607-2. |
| 6287 | Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4791. |
| 6288 | Liu S, et al. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis. Clin Cancer Res. 2019 Dec 19. pii: clincanres.1373.2019. |
| 6289 | Gao F, et al. Impairment in function and expression of transient receptor potential vanilloid type 4 in Dahl salt-sensitive rats: significance and mechanism. Hypertension. 2010 Apr;55(4):1018-25. |
| 6290 | Dihydrocapsaicin, et al. Dihydrocapsaicin (DHC) enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat. Brain Res. 2017 Sep 15;1671:18-25. |
| 6291 | Anchoori RK, et al. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.PLoS One. 2011;6(8):e23888. |
| 6292 | Davies BR, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. |
| 6293 | Chang YT, et al. Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. Chembiochem. 2002 Sep 2;3(9):897-901. |
| 6294 | Shi S, et al. Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study. |J Antimicrob Chemother 10:151 (1982); 11 Suppl A:1 (1983); Drugs 30:382 (1985) |
| 6295 | Battistella C, et al. Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzyme-Directed Assembly. Adv Healthc Mater. 2019 Dec;8(23):e1901105. |
| 6296 | Shinchi H, et al. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjug Chem. 2015 Aug 19;26(8):1713-23. |
| 6297 | Copland JA, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13;25(16):2304-17. |
| 6298 | Marlow LA, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009 Feb 15;69(4):1536-44. |
| 6299 | Cancer 6:142 (1953); Cancer Treat Rev 26:257 (2000) |
| 6300 | Biol. Pharm. Bull. (1999), 22(11), 1234-1236; J. Med. Chem. (1979), 22(7), 840-4 |
| 6301 | Linda N. Casillas, et al. Amino-quinolines as kinase inhibitors. PCT Int. Appl. (2014), WO 2014043437 A1 20140320. |
| 6302 | Scales SJ, et al. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009, 30(6), 303-312. |
| 6303 | Zhang Y, et al. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia. 2009, 11(1), 96-101. |
| 6304 | Tian F, et al. The hedgehog pathway inhibitor GDC-0449 alters intracellular Ca<sup>2+</sup> homeostasis and inhibits cell growth in NSC 119875-resistant lung cancer cells. Anticancer Res. 2012, 32(1), 89-94. |
| 6305 | Wong H, et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res. 2011, 17(14), 4682-4692. |
| 6306 | Elhenawy AA, et al. Possible antifibrotic effect of GDC-0449 (Vismodegib), a hedgehog-pathway inhibitor, in mice model of Schistosoma-induced liver fibrosis. Parasitol Int. 2017 Oct;66(5):545-554. |
| 6307 | Ma W, et al. Reduced Smoothened level rescued Aβ-induced memory deficits and neuronal inflammation in animal models of Alzheimer's disease. J Genet Genomics. 2018 May 20;45(5):237-246. |
| 6308 | 1. https://clinicaltrials.gov/ct2/show/NCT04824365?term=Medroxyprogesterone&cond=Covid19&draw=2&rank=2 2. https://clinicaltrials.gov/ct2/show/NCT04871815?term=Medroxyprogesterone&cond=Covid19&draw=2&rank=1 3. https://clinicaltrials.gov/ct2/show/NCT04488081?term=Medroxyprogesterone&cond=Covid19&draw=2&rank=3 |
| 6309 | Corcostegui, R., et al., Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D, 2005. 6(6): p. 371-84. |
| 6310 | Jauregizar, N., et al., Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet, 2009. 48(8): p. 543-54. |
| 6311 | Placencio VR, et al. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. PLoS One. 2015 Jul 24;10(7):e0133786. |
| 6312 | Jeong BY, et al. Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model. PLoS One. 2016 Jun 3;11(6):e0157012. |
| 6313 | Satow A et al. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. |
| 6314 | Pinkerton AB, et al. Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators. J Med Chem. 2019 Aug 20. |
| 6315 | Eccles, Suzanne A., et al. NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research (2008), 68(8), 2850-2860. |
| 6316 | Best OG, et al. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with NSC 118218 against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leuk Lymphoma. 2012 Jul 9. |
| 6317 | Moser C, et al. Stoeltzing O.Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res. 2012 Jul;32(7):2551-61. |
| 6318 | Westendorf J, et al. The genotoxicity of lucidin, a natural component of Rubia tinctorum L., and lucidinethylether, a component of ethanolic Rubia extracts. Cell Biol Toxicol. 1988 Jun;4(2):225-39. |
| 6319 | Westendorf J, et al. Carcinogenicity and DNA adduct formation observed in ACI rats after long-term treatment with madder root, Rubia tinctorum L. Carcinogenesis. 1998 Dec;19(12):2163-8. |
| 6320 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=METOPROLOL+&cntry=&state=&city=&dist=&Search=Search |
| 6321 | Jang SW, et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3876-81. |
| 6322 | J Chem Soc 1944:306; J Sci Ind Res 11B:458 (1952) |
| 6323 | Br J Pharmacol 16:170 (1961); Q Rev Chem Soc 21:231 (1967) |
| 6324 | Ryder NS, et al. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992 Feb;126 Suppl 39:2-8. |
| 6325 | Mieth H, et al. Preclinical evaluation of terbinafine in vivo. Clin Exp Dermatol. 1989 Mar;14(2):104-8. |
| 6326 | Ciftci E, et al. Mupirocin vs terbinafine in impetigo.Indian J Pediatr. 2002 Aug;69(8):679-82. |Proc 13th Int Congr Chemother 6:116/52 (1983); Br Med J 318:1031 (1999) |
| 6327 | Kang TH, et al. Atractylenolide III, a sesquiterpenoid, induces apoptosis in human lung carcinoma A549 cells via mitochondria-mediated death pathway. Food Chem Toxicol. 2011 Feb;49(2):514-9. |
| 6328 | Wang KT, et al. Gastroprotective activity of atractylenolide III from Atractylodes ovata on ethanol-induced gastric ulcer in vitro and in vivo. J Pharm Pharmacol. 2010 Mar;62(3):381-8. |
| 6329 | Kim HK, et al. Toxicity of atractylon and atractylenolide III Identified in Atractylodes ovata rhizome to Dermatophagoides farinae and Dermatophagoides pteronyssinus. J Agric Food Chem. 2007 Jul 25;55(15):6027-31. |
| 6330 | Wong H, et al. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metab Dispos. 2013 Dec;41(12):2104-13. |
| 6331 | Chen L, et al. Periplocin promotes wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase. Phytomedicine. 2019 Apr;57:72-83. |
| 6332 | Cheng CF, et al. Antitumor Effect of Periplocin in TRAIL-Resistant Human Hepatocellular Carcinoma Cells through Downregulation of IAPs. Evid Based Complement Alternat Med. 2013;2013:958025. |
| 6333 | Tet Letters 1959: 17; Chem Ber 92: 1904 (1959) |
| 6334 | Surgery 84:603 (1978); Eur J Clin Pharmacol 31:79 (1986); Dev Pharmacol Ther 20:167 (1993) |
| 6335 | Amanda L Garner, et al. Design, synthesis, and biological activities of closantel analogues: structural promiscuity and its impact on Onchocerca volvulus. J Med Chem. 2011 Jun 9;54(11):3963-72. |
| 6336 | G E Swan, et al. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. J S Afr Vet Assoc. 1999 Jun;70(2):61-70. |
| 6337 | Shusuke Ono, et al. Transdermal patch preparation. JP2002363070A. |
| 6338 | J Am Chem Soc 75: 3500 (1953) |
| 6339 | Shieh PC, et al. Induction of apoptosis by |
| 6340 | -shogaol via reactive oxygen species generation, glutathione depletion, and caspase activation in human leukemia cells. J Agric Food Chem. 2010 Mar 24;58(6):3847-54. |
| 6341 | van Breemen RB, et al. Cyclooxygenase-2 inhibitors in ginger (Zingiber officinale). Fitoterapia. 2011 Jan;82(1):38-43. |
| 6342 | Nurtjahja-Tjendraputra E, et al. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res. 2003;111(4-5):259-65. |
| 6343 | Shieh PC, et al. Induction of apoptosis by |
| 6344 | -shogaol via reactive oxygen species generation, glutathione depletion, and caspase activation in human leukemia cells. J Agric Food Chem. 2010 Mar 24;58(6):3847-54. |
| 6345 | Phytochemistry 17: 1395 (1978); Tetrahedron 21: 2683 (1965); Planta Med 64:153 (1998) |
| 6346 | Toxicol Appl Pharmacol 7:53 (1965); Anal Profiles Drug Subs 16:611 (1986) |
| 6347 | Cai TY, et al. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α. Mol Cancer Ther. 2014 Mar;13(3):630-42. |
| 6348 | Sliwinska J, et al. Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca2? balance protein levels. Oxid Med Cell Longev. 2012;2012:890826. |
| 6349 | McKay DB, et al. Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6. |
| 6350 | Pandya P, et al. Molecular recognition pattern of cytotoxic alkaloid vinblastine with multiple targets. J Mol Graph Model. 2014 Nov;54:1-9. |
| 6351 | Calvi?o E, et al. JNK and NFκB dependence of apoptosis induced by vinblastine in human acute promyelocytic leukaemia cells. Cell Biochem Funct. 2015 Jun;33(4):211-9. |
| 6352 | Selimovic D, et al. Vinblastine-induced apoptosis of melanoma cells is mediated by Ras homologous A protein (Rho A) via mitochondrial and non-mitochondrial-dependent mechanisms. Apoptosis. 2013 Aug;18(8):980-97. |
| 6353 | Bánóczi Z, et al. Synthesis and in vitro antitumor effect of vinblastine derivative-oligoarginine conjugates. Bioconjug Chem. 2010 Nov 17;21(11):1948-55. |
| 6354 | Demont Emmanuel Hubert, et al. Preparation of 4-(8-methoxy-1-(1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole, its salts and isomers and their use as bromodomain inhibitors. From PCT Int. Appl. (2013), WO 2013024104 A1 20130221. |
| 6355 | Pierce JW, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesionmolecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997 Aug 22;272(34):21096-103. |
| 6356 | Nasu K, et al. Application of the nuclear factor-kappaB inhibitor BAY 11-7085 for the treatment of endometriosis: an in vitro study. Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E16-23. |
| 6357 | Liang Z, et al. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7(4):e34038. |
| 6358 | Harris KS, et al. Rapid optimization of a peptide inhibitor of malaria parasite invasion by comprehensive N-methyl scanning. J Biol Chem. 2009 Apr 3;284(14):9361-71. |
| 6359 | J Het Chem 29:583 (1992); Int J Biochem 25:1873 (1993) |
| 6360 | Daniela Angst, et al. Novel amino pyrimidine derivatives. Patent WO2015079417A1. |
| 6361 | Kolkhir P, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2019 Aug 23. |
| 6362 | Lei Y, et al. Vaccarin ameliorates insulin resistance and steatosis by activating the AMPK signaling pathway. Eur J Pharmacol. 2019 May 15;851:13-24. |
| 6363 | Hou B,et al. Vaccarin hastens wound healing by promoting angiogenesis via activation of MAPK/ERK and PI3K/AKT signaling pathways in vivo. Acta Cir Bras. 2020 Feb 7;34(12):e201901202. |
| 6364 | Napier C, et al. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol, 1999, 368(2-3), 259-268. |
| 6365 | MaassenVanDenBrink A, et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology, 2000, 55(10), 1524-1530. |
| 6366 | Gupta P, et al. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist. Eur J Pharmacol, 2000, 398(1), 73-81. |
| 6367 | Hoskin KL, et al. The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res, 2004, 998(1), 91-99. |
| 6368 | Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. |
| 6369 | Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity. Chirality. 2013 May;25(5):281-7. |
| 6370 | Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5628-33. |
| 6371 | Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502. |
| 6372 | Yan Xue, et al. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation. 2021 Mar 1;105(3):550-560. |
| 6373 | Endocrinology 53:221 (1953); Biochem Biophys Res Commun 319:677 (2004) |
| 6374 | Pakistan J Biol Sci 6:1125 (2003) |
| 6375 | Patyna S, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82. |
| 6376 | Cuny GD, et al. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3491-4. |
| 6377 | Gregory D Cuny, et al. Structure-activity Relationship Study of Acridine Analogs as Haspin and DYRK2 Kinase Inhibitors. Bioorg Med Chem Lett |
| 6378 | Tetrahedron 21:1509 (1965); Phytochemistry 17:957 (1978); 39:839 (1995); Br J Pharmacol 112:9 (1994)| |
| 6379 | Nakshatri H, et al. NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death Dis. 2015 Jan 22;6:e1608. |
| 6380 | Zhao X, et al. Parthenolide induces apoptosis via TNFRSF10B and PMAIP1 pathways in human lung cancer cells. J Exp Clin Cancer Res. 2014 Jan 6;33:3. |
| 6381 | Barbier-Torres L, et al. Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1. Hepatology. 2015 Oct;62(4):1237-48. |
| 6382 | Discafani CM, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol. 1999 Apr 15;57(8):917-25. |
| 6383 | Sweeney WE, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000 Jan;57(1):33-40. |
| 6384 | Greulich H, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov;2(11):e313. |
| 6385 | Kobayashi S, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15;65(16):7096-101. |
| 6386 | Ponnusamy S, et al. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Res. 2017 Nov 15;77(22):6282-6298. |
| 6387 | Lin EC, et al. ERK5 kinase activity is dispensable for cellular immune response and proliferation. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11865-11870. |
| 6388 | Gastroenterology 83:1062 (1982); Am J Gastroenterol 81:141 (1986); Expert Opinion Pharmacother 6:69 (2005) |
| 6389 | Chen H, et al. 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. Bioorg Med Chem Lett. 2012 Jun 15;22(12):4038-43. |
| 6390 | Schwandt ML, et al. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. Neuropsychopharmacology. 2016 Nov;41(12):2818-2829. |
| 6391 | Nakamura M, et al. Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo. Exp Eye Res. 1997 Oct;65(4):569-74. |
| 6392 | Umezawa H, et al. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo). 1970 May;23(5):259-62. |
| 6393 | Seelmeier S, et al. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6612-6. |
| 6394 | Campbell JE, et al. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Med Chem Lett. 2015 Mar 4;6(5):491-495. |
| 6395 | J Org Chem 44:2580 (1979); Appl Microbiol 18:660 (1969); Cancer Res 57:3429 (1997); Proc Natl Acad Sci 95:3380 (1998); JNCI I95:291 (2003)| |
| 6396 | Mehta R, et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One. 2013 Jun 10;8(6):e65113. |
| 6397 | Yang YL, et al. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. PLoS One. 2013;8(1):e54736. |
| 6398 | Li Z, et al. Deguelin, a natural rotenoid, inhibits mouse myeloma cell growth in vitro via induction of apoptosis. Oncol Lett. 2012 Oct;4(4):677-681. |
| 6399 | Kang HW, et al. Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Dig Dis Sci. 2012 Nov;57(11):2873-82. |
| 6400 | Van Hout A, et al. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One. 2017 Apr 14;12(4):e0176057. |
| 6401 | Wu B, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010 Nov 19;330(6007):1066-71. |
| 6402 | Tulotta C, et al. Inhibition of signaling between human CXCR4 and zebrafish ligands by the small molecule IT1timpairs the formation of triple-negative breast cancer early metastases in a zebrafish xenograft model. Dis Model Mech. 2016 Feb;9(2):141-53. |
| 6403 | J Agric Food Chem 38:1368 (1990); Antimicrob Agents Chemother 36:1810 (1992); Jpn J Pharmacol 63:487 (1993) |
| 6404 | https://clinicaltrials.gov/ct2/show/NCT05047952?term=Vortioxetine&cond=covid&draw=2&rank=1 |
| 6405 | Abe M, et al. Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines. ACS Med Chem Lett. 2017 Sep 1;8(10):1110-1115. |
| 6406 | Rath VL, et al. How glutaminyl-tRNA synthetase selects glutamine. Structure. 1998 Apr 15;6(4):439-49. |
| 6407 | Fang P, et al. Structural basis for full-spectrum inhibition of translational functions on a tRNA synthetase. Nat Commun. 2015 Mar 31;6:6402. |
| 6408 | Neal J, et, al. The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms. Mol Microbiol. 2009 Apr; 72(2): 442-58. |
| 6409 | Wahafu A, et, al. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. Pathol Res Pract. 2019 Nov; 215(11): 152617. |
| 6410 | Hu Y, et, al. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral. Int J Mol Sci. 2017 Sep 8;18(9):1929. |
| 6411 | https://clinicaltrials.gov/ct2/show/NCT04330300?term=Quinapril&cond=covid&draw=2&rank=1 |
| 6412 | Nakane M, et al. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Neuropharmacology. 2005 Jul;49(1):112-21. |
| 6413 | Hou YP, et al. Impact of fluazinam on morphological and physiological characteristics of Sclerotinia sclerotiorum. Pestic Biochem Physiol. 2019 Mar;155:81-89. |
| 6414 | Dow RL, et al. Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core. Bioorg Med Chem Lett. 2011 Oct 15;21(20):6122-5. |
| 6415 | Dow RL, et al. Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. ACS Med Chem Lett. 2011 Mar 18;2(5):407-12. |
| 6416 | Wang L, et al. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat Chem Biol. 2012 Dec;8(12):982-9. |
| 6417 | Kwiatkowski N, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31;511(7511):616-20. |
| 6418 | Zeng M, et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 Nov 13;7. pii: e39030. |
| 6419 | Christensen CL, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014 Dec 8;26(6):909-22. |
| 6420 | Chipumuro, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014 Nov 20;159(5):1126-39. ? |
| 6421 | Jiang YY, et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut. 2016 May 10. pii: gutjnl-2016-311818. |
| 6422 | Jiang YY, et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut. 2016 May 10. pii: gutjnl-2016-311818. |
| 6423 | Talpur R, et al. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009 Feb;5(2):195-210. |
| 6424 | Nagpal S, et al. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acidreceptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ. 1996 Dec;7(12):1783-91. |
| 6425 | Tang-Liu DD, et al. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet. 1999 Oct;37(4):273-87. |
| 6426 | Tet Letters 1964:2607 |
| 6427 | J Gen Physiol 20:879 (1937) |
| 6428 | Szliszka E, et, al. Inhibition of inflammatory mediators by neobavaisoflavone in activated RAW264.7 macrophages. Molecules. 2011 May 3;16(5):3701-12. |
| 6429 | Szliszka E, et, al. Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. Pharmacol Rep. 2011;63(1):139-48. |
| 6430 | Chen H, et, al. Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways. J Cell Mol Med. 2020 Aug;24(16):9067-9084. |
| 6431 | Sun NJ, et, al. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod. 1998 Mar;61(3):362-6. |
| 6432 | Tsai WJ, et, al. Antiplatelet flavonoids from seeds of Psoralea corylifolia. J Nat Prod. 1996 Jul;59(7):671-2. |
| 6433 | Grither WR, et al. Inhibition of tumor-microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain. Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7786-E7794. |
| 6434 | Sarah Bethune, et al. Crystal forms of an alk2 inhibitor. WO2020086963A1. |
| 6435 | Eden, R.J., et al., Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav, 1991. 38(1): p. 147-54. |
| 6436 | Mavrikaki M, et al. Ropinirole regulates emotionality and neuronal activity markers in the limbic forebrain. Int J Neuropsychopharmacol. 2014 Dec;17(12):1981-93. |
| 6437 | Casara P, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018 Apr 13;9(28):20075-20088. |
| 6438 | Gelman F, et al. Flibanserin for hypoactive sexual desire disorder: place in therapy. Ther Adv Chronic Dis. 2017 Jan;8(1):16-25. |
| 6439 | Invernizzi RW, et al. Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. |
| 6440 | Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure and Function Tällberg, 14-17 June 2019 |
| 6441 | Jianbiao Zhou, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2019 Nov7;haematol.2019.230482. |
| 6442 | Kapoor S, et al. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363. |
| 6443 | Ballou LM, et al. Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. J Biol Chem. 2007 Aug 17;282(33):24463-70. |
| 6444 | J Antibiotics 27: 814 (1954)| |
| 6445 | Lu D, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7. |
| 6446 | Zhou J, et al. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactiveoxygen species. Toxicol Lett. 2013 Oct 24;222(2):139-45. |
| 6447 | Wang F, et al. Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo. PLoS One. 2012; 7(12): e50638. |
| 6448 | Qu H, et al. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8(7):578-82. |
| 6449 | Klose J, et al. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916. |
| 6450 | Naujokat C, et al. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658. |
| 6451 | Walton KM, et al. Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9. |
| 6452 | MihoAsahi, et al. Fluxametamide: A novel isoxazoline insecticide that acts via distinctive antagonism of insect ligand-gated chloride channels. Pesticide Biochemistry and Physiology. |
| 6453 | Scheuer, E. and E. Warshaw, Allergy to corticosteroids: update and review of epidemiology, clinical characteristics, and structural cross-reactivity. Am J Contact Dermat, 2003. 14(4): p. 179-87. |
| 6454 | J Med Chem 45:1757 (2002); J Thromb Haemost 2:1573 (2004); J Clin Pharmacol 45:555 (2005) |
| 6455 | Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17. |
| 6456 | Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17. |
| 6457 | Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91. |
| 6458 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=PROPOFOL&cntry=&state=&city=&dist= |
| 6459 | Mizuguchi T, et al. A minimally cytotoxic CD4 mimic as an HIV entry inhibitor. Bioorg Med Chem Lett. 2016 Jan 15;26(2):397-400. |
| 6460 | Hashimoto C, et al. A CD4 mimic as an HIV entry inhibitor: pharmacokinetics. Bioorg Med Chem. 2013 Dec 15;21(24):7884-9. |
| 6461 | Eur. Heart J. (1983), 4(9), 655-61; Eur. J. Clin. Pharmacol. (1982), 23(1), 11-4; Eur. J. Clin. Pharmacol. (1980), 18(3), 231-5 |
| 6462 | Arch Biochem Biophys.1955 59:106 (1955); Plant Physiol 6:688 (1961) |
| 6463 | Vilaplana-Pérez C, et al. Hydroxytyrosol and potential uses in cardiovascular diseases, cancer, and AIDS. Front Nutr. 2014 Oct 27;1:18. |
| 6464 | Martínez L, et al. Hydroxytyrosol: Health Benefits and Use as Functional Ingredient in Meat. Medicines (Basel). 2018 Jan 23;5(1). |
| 6465 | O Shimada, et al. Hydroxyl radical scavenging action of tinoridine. Agents Actions. 1986 Nov;19(3-4):208-14. |
| 6466 | Yasuda H, et al. The protective effect of tinoridine against carbon tetrachloride hepatotoxicity. Toxicol Appl Pharmacol. 1980 Mar 15;52(3):407-13. |
| 6467 | Phytochemistry 13: 1805 (1974) |
| 6468 | Sun JJ, Kim HJ, Seo HG, et al. YS49,1-(alpha-naphtylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline,regulates angiotensin II-stimulated ROS production, JNK phosphorylation and vascular smooth muscle cell proliferation via the induction of heme oxygenase-1. Life Sci. 2008;82(11-12):600-7. |
| 6469 | Kang YJ, et al. Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br J Pharmacol. 1999 Sep;128(2):357-64. |
| 6470 | Hsu YH, et al. RhoA-mediated inhibition of vascular endothelial cell mobility: positive feedback through reduced cytosolic p21 and p27. J Cell Physiol. 2014 Oct;229(10):1455-65. |
| 6471 | https://clinicaltrials.gov/ct2/show/NCT04883528?term=Valsartan&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04591210?term=Valsartan&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04467931?term=Valsartan&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04394117?term=Valsartan&cond=COVID-19&draw=2&rank=6 |
| 6472 | Charoenteeraboon J, et al. Induction of human cholesterol 7alpha-hydroxylase in HepG2 cells by 2,4,6-trihydroxyacetophenone. Eur J Pharmacol. 2005 May 16;515(1-3):43-6. |
| 6473 | Piyachaturawat P, et al. Choleretic activity of phloracetophenone in rats: structure-function studies using acetophenone analogues. Eur J Pharmacol. 2000 Jan 10;387(2):221-7. |
| 6474 | Leverson JD, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015 Jan 15;6:e1590. |
| 6475 | Qing Wang, et al. A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML. Oncol Lett. 2019 Nov;18(5):5481-5489. |
| 6476 | Science 220:1304 (1983); Am J Psychiatry 140:1235 (1983) |
| 6477 | Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95. |
| 6478 | Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14. |
| 6479 | Obonyo CO, et al. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect Dis. 2010 Sep;10(9):603-11. |
| 6480 | Gawad J, et al. Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1): challenging target for antitubercular drug discovery. Chem Cent J. 2018 Jun 23;12(1):72. |
| 6481 | Cantó C, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protectsagainst high-fat diet-induced obesity. Cell Metab. 2012 Jun 6;15(6):838-47. |
| 6482 | Bing Gong, et al. Nicotinamide Riboside Restores Cognition Through an Upregulation of Proliferator-Activated Receptor-γ Coactivator 1α Regulated β-Secretase 1 Degradation and Mitochondrial Gene Expression in Alzheimer's Mouse Models. Neurobiol Aging. 2013 Jun;34(6):1581-8. |
| 6483 | Collin D Heer, et al. Coronavirus and PARP Expression Dysregulate the NAD Metabolome: A Potentially Actionable Component of Innate Immunity. bioRxiv. 2020 Apr 30;2020.04.17.047480. |
| 6484 | Pileidis FD, et al. Levulinic Acid Biorefineries: New Challenges for Efficient Utilization of Biomass. ChemSusChem. 2016 Mar 21;9(6):562-82. |
| 6485 | Clin. Exp. Dermatol. (1979), 4(4), 501-7; Prog. Clin. Biol. Res. (1988), 260, 63-75; J. Steroid Biochem. (1987), 28(4), 379-84 |
| 6486 | https://clinicaltrials.gov/ct2/show/NCT04348513?term=Liothyronine&cond=covid&draw=2&rank=1 |
| 6487 | Tantai JC, et al. Heterophyllin B inhibits the adhesion and invasion of ECA-109 human esophageal carcinoma cells by targeting PI3K/AKT/β-catenin signaling. Mol Med Rep. 2016 Feb;13(2):1097-104. |
| 6488 | Moyer BJ, et al. Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1. Toxicol Appl Pharmacol. 2016 Jun 1;300:13-24. |
| 6489 | Sakakibara K, et al. Kynurenine causes vasodilation and hypotension induced by activation of KCNQ-encoded voltage-dependent K(+) channels. J Pharmacol Sci. 2015 Sep;129(1):31-7. |
| 6490 | Nozaki K, et al. Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab. 1992 May;12(3):400-7. |
| 6491 | Br J Anesth 53 Suppl 3,:3S (1981); Crit Rev Toxicol 20:31 (1989) |
| 6492 | Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40. |
| 6493 | Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4. |
| 6494 | https://clinicaltrials.gov/ct2/show/NCT04429555?term=Ibudilast&cond=covid-19&draw=2&rank=1 |
| 6495 | Yin QK, et al. Discovery of Isaindigotone Derivatives as Novel Bloom's Syndrome Protein (BLM) Helicase Inhibitors That Disrupt the BLM/DNA Interactions and Regulate the Homologous Recombination Repair. J Med Chem. 2019 Mar 28;62(6):3147-3162. |
| 6496 | Hong J, et al. Identification and characterization of small-molecule inducers of epidermal keratinocyte differentiation. ACS Chem Biol. 2007 Mar 20;2(3):171-5. |
| 6497 | OREXIN RECEPTOR ANTAGONIST PROVEN EFFECTIVE FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE IN CLINICAL DEVELOPMENT PROGRAM OF MORE THAN 2,000 PATIENTS. 2019. |
| 6498 | HIGHLIGHTS OF PRESCRIBING INFORMATION |
| 6499 | Konner J, et al. Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
 Invest New Drugs. 2012 Dec;30(6):2294-302. |
| 6500 | Brunden KR, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
 J Neurosci. 2010 Oct 13;30(41):13861-6. |
| 6501 | Dymock BW, et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5. |
| 6502 | Sharp SY, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther. 2007 Apr;6(4):1198-211. |
| 6503 | Sun X, et al. Inhibition of hepatic stellate cell proliferation by heat shock protein 90 inhibitors in vitro. Mol Cell Biochem. 2009 Oct;330(1-2):181-5. |
| 6504 | Jack C Exell, et al. Cellularly Active N-hydroxyurea FEN1 Inhibitors Block Substrate Entry to the Active Site. Nat Chem Biol. 2016 Oct;12(10):815-21. |
| 6505 | Lee H, et al. Genotoxicity of 1,3-dithiane and 1,4-dithiane in the CHO/SCE assay and the Salmonella/microsomal test. Mutat Res. 1994 Jun;321(4):213-8. |
| 6506 | Martinez RA, et al. Synthesis of isotopically labeled 1,3-dithiane. J Labelled Comp Radiopharm. 2014 May 15;57(5):338-41. |
| 6507 | Hobaika, Z.; Zargarian, L.; Maroun, R. G.; Mauffret, O.; Burke, T. R., Jr.; Fermandjian, S. HIV-1 Integrase and Virus and Cell DNAs: Complex Formation and Perturbation by Inhibitors of Integration. Neurochemical Research (2010), 35(6), 888-893. |
| 6508 | Loizidou, Eriketi Z.; Zeinalipour-Yazdi, Constantinos D.; Christofides, Tasos; Kostrikis, Leondios G. Analysis of binding parameters of HIV-1 integrase inhibitors: Correlates of drug inhibition and resistance. Bioorganic & Medicinal Chemistry (2009), 17(13), 4806-4818. |
| 6509 | Kawasuji T.Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 1. Molecular Design and Establishment of an Advanced Two-Metal Binding Pharmacophore.J Med Chem. 2012 Sep 10. |
| 6510 | Yan A, Xuan S, Hu X.Classification of Active and Weakly Active ST Inhibitors of HIV-1 Integrase Using a Support Vector Machine.Comb Chem High Throughput Screen. 2012 Aug 28. |
| 6511 | Yu S, Zhao G.Development of Polyphenols as HIV-1 Integrase Inhibitors: A Summary and Perspective.Curr Med Chem. 2012 Aug 27. |
| 6512 | Murphy BG, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018 Jun;219:226-233. |
| 6513 | Katherine Yang, et al. What Do We Know About Remdesivir Drug Interactions? Clin Transl Sci. 2020 May 13;10.1111/cts.12815. |
| 6514 | Victoria C. Yan, et al. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. ACS Med. Chem. Lett. 2020. |
| 6515 | Toxicol Appl Pharmacol 23:606 (1972); 30:129 (1974) |
| 6516 | Saugstad OD, et al. Hypoxanthine as an indicator of hypoxia: its role in health and disease through free radical production. Pediatr Res. 1988 Feb;23(2):143-50. |
| 6517 | J Lab Clin Med 105:132 (1985); Carbohydrate Polymers 64:85 (2006) |
| 6518 | Zhang X, et al. Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation. Sci Rep. 2015 Jul 29;5:12579. |
| 6519 | Xiao JH, et al. Effects of isoliensinine on proliferation of porcine coronary arterial smooth muscle cells induced by phenylephrine. Yao Xue Xue Bao. 2005 Feb;40(2):105-10. |
| 6520 | Yamaoka M, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
 J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28. |
| 6521 | Kaku, Tomohiro., et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. From Bioorganic & Medicinal Chemistry (2011), 19(21), 6 |
| 6522 | Arzneim. Forsch. (1986), 36(8), 1191-4; Chim. Ther. (1973), 8(5), 588-96; Agric. Biol. Chem. (1968), 32(11), 1341-8. |
| 6523 | Park SN, et al. Antimicrobial effect of linalool and α-terpineol against periodontopathic and cariogenic bacteria. Anaerobe. 2012 Jun;18(3):369-72. |
| 6524 | Park MJ, et al. Effect of citral, eugenol, nerolidol and alpha-terpineol on the ultrastructural changes of Trichophyton mentagrophytes. Fitoterapia. 2009 Jul;80(5):290-6. |
| 6525 | Krishnan P, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015 Feb;59(2):979-87 |
| 6526 | DeGoey DA, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57 |
| 6527 | Riccio ES, et al. Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13. Environ Mol Mutagen. 2001;38(1):69-79. |
| 6528 | Shizhuang Weng, et al. Detection of Pirimiphos-Methyl in Wheat Using Surface-Enhanced Raman Spectroscopy and Chemometric Methods. Molecules. 2019 Apr 30;24(9):1691. |
| 6529 | Pål A Olsvik, et al. In Vitro Toxicity of Pirimiphos-Methyl in Atlantic Salmon Hepatocytes. Toxicol In Vitro. 2017 Mar;39:1-14. |
| 6530 | Esther Borrás, et al. Atmospheric Degradation of the Organothiophosphate Insecticide - Pirimiphos-methyl. Sci Total Environ. 2017 Feb 1;579:1-9. |
| 6531 | Sun Y, et al. Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One. 2013 May 14;8(5):e63354. |
| 6532 | Chikazawa M, et al. Identification of Functional Food Factors as β2-Adrenergic Receptor Agonists and Their Potential Roles in Skeletal Muscle. J Nutr Sci Vitaminol (Tokyo). 2018;64(1):68-74. |
| 6533 | Tanaka H, et al. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Mol Pharmacol. 1999 Feb;55(2):356-63. |
| 6534 | SOLUBILIZED COMPOSITIONS FOR CONTROLLED PROLIFERATION OF STEM CELLS / GENERATING INNER EAR HAIR CELLS USING GSK3 INHIBITORS: III. 20170252449 A1 |
| 6535 | Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108(8):1657-1666. |
| 6536 | Shin HM, et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett. 2004 Jul 30;571(1-3):50-4. |
| 6537 | Kumar A, et al. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab. 2011 Aug;13(8):750-8. |
| 6538 | Wang S, et al. Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents. J Med Chem. 2015 Aug 27;58(16):6678-96. |
| 6539 | Li RF,et al. Effects of Evodiamine on the Pharmacokinetics of Dapoxetine and Its Metabolite Desmethyl Dapoxetine inRats. Pharmacology. 2016;97(1-2):43-7. |
| 6540 | Shi L, et al. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis. Tumour Biol. 2016 Sep;37(9):12791-12803. |
| 6541 | Roy SM, et al. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci. 2015 Apr 15;6(4):666-80. |
| 6542 | Shan B, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5686-91. |
| 6543 | Ind Chin Belg 17:735 (1952); Arch Neurol 27:129 (1972) |
| 6544 | J Org Chem 23:951 (1958) |
| 6545 | Arhin FF, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008 May;52(5):1597-1603. |
| 6546 | Cincinelli R, et al. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem. 2003 Mar 13;46(6):909-12. |
| 6547 | Garattini E, et al. ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood. 2004 Jan 1;103(1):194-207. |
| 6548 | Jiri Neuzil, et al. Sensitization of Mesothelioma to TRAIL Apoptosis by Inhibition of Histone Deacetylase: Role of Bcl-xL Down-Regulation. Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91. |
| 6549 | V M Richon, et al. A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases.Proc Natl Acad Sci U S A |
| 6550 | Li Ning, et al. Suberoyl Bishydroxamic Acid Activates notch1 Signaling and Suppresses Tumor Progression in an Animal Model of Medullary Thyroid Carcinoma. Ann Surg Oncol. 2008 Sep;15(9):2600-5. |
| 6551 | Tang YJ, Zhao W, Li HM. Novel tandem biotransformation process for the biosynthesis of a novel compound, 4-(2,3,5,6-tetramethylpyrazine-1)-4'-demethylepipodophyllotoxin. Appl Environ Microbiol. 2011 May;77(9):3023-34. |
| 6552 | Dhawan D, Balasubramanian S, Amonkar AJ, Chemopreventive effect of 4'-demethyl epipodophyllotoxin on DMBA/TPA-induced mouse skin carcinogenesis. Carcinogenesis. 1999 Jun;20(6):997-1003. |
| 6553 | Nachtergaele S, et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol. 2012 Jan 8;8(2):211-20. |
| 6554 | Nedelcu D, et al, Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signaling. Nat Chem Biol. 2013 Sep;9(9):557-64. |
| 6555 | Scott JS, et al. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma. J Med Chem. 2017 Dec 28;60(24):10071-10091. |
| 6556 | Fang, Y., et al. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol, 2012. 59(3): p. 260-7. |
| 6557 | Kroller-Schon, S., et al. Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress. Basic Res Cardiol, 2011. 106(6): p. 1147-58. |
| 6558 | WO2011143669A2. |
| 6559 | af Forselles KJ, et al. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol. 2011 Dec;164(7):1847-1856. |
| 6560 | Birrell MA, et al. Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br J Pharmacol. 2013 Jan;168(1):129-138. |
| 6561 | Moulder-Thompson S, et al. Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup> Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clin Cancer Res. 2017 Jan 4. pii: clincanres.1496.2016. |
| 6562 | Abstract: In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 852. doi:1538-7445.AM2012-852 |
| 6563 | P. Lee, et al. In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with RP-56976. Cancer Research |
| 6564 | Otake Y, Walle T. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab Dispos. 2002 Feb;30(2):103-5. |
| 6565 | Martineti V, Tognarini I, Azzari C et al. Inhibition of in vitro growth and arrest in the G0/G1 phase of HCT8 line human colon cancer cells by kaempferide triglycoside from Dianthus caryophyllus. Phytother Res. 2010 Sep;24(9):1302-8. |
| 6566 | Pahua-Ramos, Maria Elena; Ortiz-Moreno, Alicia; Chamorro-Cevallos, German et al. Hypolipidemic Effect of Avocado (Persea americana Mill) Seed in a Hypercholesterolemic Mouse Model. Plant Foods for Human Nutrition (New York, NY, United States) (2012), 67(1), 10-16. |
| 6567 | Soucek, Pavel; Kondrova, Eliska; Hermanek, Josef et al. New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals. Anti-Cancer Drugs (2011), 22(2), 176-184. |
| 6568 | Mitrocotsa D, et al. Evaluation of the antiviral activity of kaempferol and its glycosides against human cytomegalovirus. Planta Med. 2000 May;66(4):377-9. |
| 6569 | Yang K, et al. Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes. Drug Metab Lett. 2010 Aug;4(3):129-33. |
| 6570 | Sun Q, et al. 1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. Drug Metab Dispos. 2011 Sep;39(9):1674-9. |
| 6571 | Stringer RA, et al. 1-Aminobenzotriazole modulates oral drug pharmacokinetics through cytochrome P450 inhibition and delay of gastric emptying in rats. Drug Metab Dispos. 2014 Jul;42(7):1117-24. |
| 6572 | Kraft R, et al. Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl)anthranilic acid. Br J Pharmacol. 2006 Jun;148(3):264-73. |
| 6573 | Harteneck C, et al. N-(p-amylcinnamoyl)anthranilic acid (ACA): a phospholipase A(2) inhibitor and TRP channel blocker. Cardiovasc Drug Rev. 2007 Spring;25(1):61-75. |
| 6574 | Gwanyanya A, et al. Inhibition of the calcium-activated chloride current in cardiac ventricular myocytes by N-(p-amylcinnamoyl)anthranilic acid (ACA). Biochem Biophys Res Commun. 2010 Nov 19;402(3):531-6. |
| 6575 | McKeage K. Finafloxacin: first global approval. Drugs. 2015 Apr;75(6):687-93. |
| 6576 | J Org Chem 41: 2087 (1976); 43: 1430 (1978); Eur J Biochem 99: 623 (1979); Antimicrobial Agents Chemother 14: 69 (1978) |
| 6577 | https://clinicaltrials.gov/ct2/results?cond=covid&term=Aliskiren&cntry=&state=&city=&dist= |
| 6578 | Varchi G, et al. Synthesis of deserpidine from reserpine. J Nat Prod. 2005 Nov;68(11):1629-31. |
| 6579 | Zhang H, et al. Liquid chromatography/tandem mass spectrometry method for the quantification of deserpidine in human plasma: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 1;877(27):3221-5. |
| 6580 | Fulton SC, et al. Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines. Fed Proc. 1976 Dec;35(14):2558-62. |
| 6581 | Chem Pharm Bull 37:2103 (1989); J Am Acad Dermatol 25:674 (1991); Eur J Clin Microbial Infect Dis 11:943 (1992) |
| 6582 | Arzneim Forsch 14:996 (1964); Curr Vet Ther 6:115 (1977); Anal Profiles Drug Subs 15:563 (1986) |
| 6583 | Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38. |
| 6584 | Adari BR et al. Synthesis of rebaudioside-A by enzymatic transglycosylation of stevioside present in the leaves of Stevia rebaudiana Bertoni. Food Chem. 2016 Jun 1;200:154-8. |
| 6585 | Abudula R et al. Rebaudioside A directly stimulates insulin secretion from pancreatic beta cells: a glucose-dependent action via inhibition of ATP-sensitive K-channels. Diabetes Obes Metab. 2008 Nov;10(11):1074-85. |
| 6586 | Williams LD et al. Genotoxicity studies on a high-purity rebaudioside A preparation. Food Chem Toxicol. 2009 Aug;47(8):1831-6. |
| 6587 | Hum Exp Toxicol 10:159 (1991) |
| 6588 | Fedorov O, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76. |
| 6589 | Grant SK, et al. Kinase inhibition that hinges on halogen bonds. Chem Biol. 2011 Jan 28;18(1):3-4. |
| 6590 | Lin CC, et al. Effects of punicalagin and punicalin on carrageenan-induced inflammation in rats. Am J Chin Med. 1999;27(3-4):371-6. |
| 6591 | Liu C, et al. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral Res. 2016 Oct;134:97-107. |
| 6592 | Artis DR, et al. Scaffold-based discovery of Indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. |
| 6593 | Safavi M, et al. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurologicaland inflammatory disorders. Expert Opin Drug Discov. 2013 Jun;8(6):733-51. |
| 6594 | Smith SJ, et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol. 2004 Dec;66(6):1679-89. |
| 6595 | Expert Opin. Pharmacother. (2009), 10(16), 2709-2721; Drugs (2008), 68(8), 1067-1088; Br. J. Pharmacol. Chemother. (1963), 21, 39-44 |
| 6596 | Soni MG, et al. Evaluation of the health aspects of methyl paraben: a review of the published literature. Food Chem Toxicol. 2002 Oct;40(10):1335-73. |
| 6597 | Gandalovi?ová A, et al. Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. Trends Cancer. 2017 Jun;3(6):391-406. |
| 6598 | Unbekandt M, et al. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. Cell Commun Signal. 2014 Oct 5;12:54. |
| 6599 | Kato T, et al. Binding profile of SM-9018, a novel antipsychotic candidate. pn J Pharmacol. 1990 Dec;54(4):478-81. |
| 6600 | Hagiwara H, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol. 2008 Jun;18(6):448-54. |
| 6601 | Lu, Jingning; Yue, Jun; Wu, Jing et al. In vitro and in vivo Activities of a New Lead Compound I2906 against Mycobacterium tuberculosis. Pharmacology (2010), 85(6), 365-371. |
| 6602 | Kim DK. Inhibitory effect of corynoline isolated from the aerial parts of Corydalis incisa on the acetylcholinesterase. Arch Pharm Res. 2002 Dec;25(6):817-9. |
| 6603 | Liu B, et al. Corynoline Exhibits Anti-inflammatory Effects in Lipopolysaccharide (LPS)-Stimulated Human Umbilical Vein Endothelial Cells through Activating Nrf2. Inflammation. 2018 Oct;41(5):1640-1647. |
| 6604 | https://clinicaltrials.gov/ct2/show/NCT04409834?term=Clopidogrel&cond=covid&draw=2&rank=2 https://clinicaltrials.gov/ct2/results?cond=covid&term=Clopidogrel&cntry=&state=&city=&dist= |
| 6605 | David RP Guay. Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag. 2005 Jun; 1(2): 157–167. |
| 6606 | Eric S Rovner, et al. Trospium chloride in the management of overactive bladder. Drugs. 2004;64(21):2433-46. |
| 6607 | Deng X, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem. 2013;70:758-767. |
| 6608 | Maeve Conneighton, et al. Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia. |
| 6609 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION. APPLIED THERAPEUTICS, INC. |
| 6610 | Eur J Biochem 229:558 (1995)Biochem J 338:783 (1999); J Mol Neurosci 17:45 (2001) |
| 6611 | Ronald Fiscus, et al. ODQ, an inhibitor of soluble guanylyl cyclase (nitric oxide-activated enzyme), enhances the pro-apoptotic effects of cisplatin in human mesothelioma cells. Cancer Res May 1 2007 (67) (9 Supplement) LB-43. |
| 6612 | Zacharowski K, et al. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med. 2001;29(8):1599-1608. |
| 6613 | Nadezhda I Ryabokon, et al. A 1,4-dihydropyridine Derivative Reduces DNA Damage and Stimulates DNA Repair in Human Cells in Vitro. Mutat Res. 2005 Nov 10;587(1-2):52-8. |
| 6614 | E Buraka, et al. DNA-binding Studies of AV-153, an Antimutagenic and DNA Repair-Stimulating Derivative of 1,4-dihydropiridine. Chem Biol Interact. 2014 Sep 5;220:200-7. |
| 6615 | Lidija Milkovic, et al. Antioxidative 1,4-Dihydropyridine Derivatives Modulate Oxidative Stress and Growth of Human Osteoblast-Like Cells In Vitro. Antioxidants (Basel). 2018 Sep 19;7(9):123. |
| 6616 | Pearce LR, et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55. |
| 6617 | Zhang Y, et al. Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells. Mol Cancer Ther. 2015 Mar;14(3):799-809. |
| 6618 | Hsu WY, et al. Urinary nucleosides as biomarkers of breast, colon, lung, and gastric cancer in Taiwanese. PLoS One. 2013 Dec 19;8(12):e81701. |
| 6619 | Haro C, et al. Taurolidine, an antiseptic for the prevention of central venous catheter-related infections. Rev Chilena Infectol. 2019 Aug;36(4):414-420. |
| 6620 | Stendel R, et al. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res. 2004 Mar-Apr;24(2C):1143-7. |
| 6621 | Di Paolo J, et al. FRI0049 Preclinical Characterization of GS-9876, A Novel, Oral SYK Inhibitor That Shows Efficacy in Multiple Established Rat Models of Collagen-Induced Arthritis.Annals of the Rheumatic Diseases 2016;75:443-444. |
| 6622 | Clarke AS, et al. Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis. Thromb Res. 2018 Oct;170:109-118. |
| 6623 | Kivitz AJ, et al. GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study [abstract]. Arthritis Rheumatol.2018; 70 (suppl 10). |
| 6624 | Eur J Pediatr 142:147 (1984); Arch Dis Child 64:1061 (1989); Biochem J 382:831 (2004) |
| 6625 | Ann. Pharmacother. (2006), 40(10), 1804-1813; Antimicrob. Agents Chemother. (1977), 11(4), 631-7; Proc. Soc. Exp. Biol. Med. (1970), 133(2), 490-2| |
| 6626 | Rutgeerts, P., et al., Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology, 2005. 128(4): p. 856-61. |
| 6627 | Goldstein, E.J., V.L. Sutter, and S.M. Finegold, Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538. Antimicrob Agents Chemother, 1978. 14(4): p. 609-13. |
| 6628 | Geppert T, et al. Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions. Angew Chem Int Ed Engl. 2012 Jan 2;51(1):258-61. |
| 6629 | Ann Chim 56:232 (1966); Bioorg Med Chem 18:7 (2010); Fitotherapia 83:1548 (2012) |
| 6630 | Sonoiki E, et al. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nat Commun. 2017;8:14574. Published 2017 Mar 6. |
| 6631 | Abraham RJ, et al. Robenidine Analogues as Gram-Positive Antibacterial Agents. J Med Chem. 2016 Mar 10;59(5):2126-38. |
| 6632 | Liu C, et al. Influence of three coccidiostats on the pharmacokinetics of florfenicol in rabbits. Exp Anim. 2015;64(1):73-9. |
| 6633 | Ann NY Acad Sci 89:348 (1960); IARC Monographs 12:29 (1976) |
| 6634 | Experientia 26:776 (1970); Z Naturforsch 26b:419 (1971); Sbornik lek 84:212 (1982); Rehabilitacia 16:77 (1983); Biochem Pharmacol 63:533 (2002)| |
| 6635 | Somm E, et al. β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. JCI Insight. 2017 Apr 20;2(8). pii: 91809. |
| 6636 | Wang X, et al. Acidified bile acids enhance tumor progression and telomerase activity of gastric cancer in micedependent on c-Myc expression. Cancer Med. 2017 Apr;6(4):788-797. |
| 6637 | Ogoshi Y, et al. Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. ACS Med Chem Lett. 2017 Nov 20;8(12):1320-1325. |
| 6638 | Chavan, B. B., et al. Identification and characterization of vilazodone metabolites in rats and microsomes by ultrahigh-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 2017. 31(23), 1974–1984. |
| 6639 | Yoshida Y, et al. Stereo-selective interaction of enantiomers of diniconazole, a fungicide, with purified P-450/14DM from yeast. Biochem Biophys Res Commun. 1986 May 29;137(1):513-519. |
| 6640 | Richard DJ, et al. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. Bioorg Med Chem. 2013 Nov 1;21(21):6642-9. |
| 6641 | Jiangxue Han, et al. IMB-XH1 identified as a novel inhibitor of New Delhi metallo-β-lactamase-1. |
| 6642 | Hao HZ, et al. Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies. Eur J Pharmacol. 2015 Jan 5;746:63-9. |
| 6643 | Leopoldo M, et al. Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III. J Med Chem. 2008 Sep 25;51(18):5813-22. |
| 6644 | Norouzi-Javidan A, et al. Effect of 5-HT7 receptor agonist, LP-211, on micturition following spinal cord injury in male rats. Am J Transl Res. 2016 Jun 15;8(6):2525-33. eCollection 2016. |
| 6645 | Beaudet G, et al. LP-211, a selective 5-HT7 receptor agonist, increases novelty-preference and promotes risk-prone behavior in rats. Synapse. 2017 Dec;71(12). |
| 6646 | Vickers RJ, et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug;48(2):137-43. |
| 6647 | Seri E Aflalo, et al. Tyrphostin AG-555 inhibits early and late stages of Moloney murine leukemia virus replication cycle. International Journal of Oncology. 1997. |
| 6648 | Nir Osherov, et al. Tyrphostin AG494 blocks Cdk2 activation Nir Osherov. FEBS Letters 410 (1997) 187-190. |
| 6649 | Sabine Baars, et al. Tyrphostin AG 555 Inhibits Bovine Papillomavirus Transcription by Changing the Ratio between E2 Transactivator/Repressor Function. Vol. 278, No. 39, Issue of September 26, pp. 37306–37313, 2003. |
| 6650 | Calixto-Campos C, et al. Vanillic acid Inhibits Inflammatory Pain by Inhibiting Neutrophil Recruitment, Oxidative Stress, Cytokine Production, and NFκB Activation in Mice. J Nat Prod. 2015 Aug 28;78(8):1799-808. |
| 6651 | Amin FU, et al. Vanillic acid attenuates Aβ<sub>1-42</sub>-induced oxidative stress and cognitive impairment in mice. Sci Rep. 2017 Jan 18;7:40753. |
| 6652 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=TRIAMTERENE&cond=covid&draw=2&rank=1 |
| 6653 | Párrizas M, et al. Specific inhibition of IGF-1R and IR tyrosine kinase activity and biological function by tyrphostins. Endocrinology. 1997 Apr;138(4):1427-33. |
| 6654 | Deutsch E, et al. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer. 2004 Nov 1;91(9):1735-41. |
| 6655 | Carmine AA, et al. Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1983 Oct;26(4):279-333. |
| 6656 | J Biol Chem 202:91 (1953) |
| 6657 | Sarkar O , et al. Nitric oxide attenuates overexpression of Giα proteins in vascular smooth muscle cells from SHR: Role of ROS and ROS-mediated signaling. PLoS One. 2017 Jul 10;12(7):e0179301. |
| 6658 | Tegeder I , et al. Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci Lett. 2002 Oct 31;332(2):146-50. |
| 6659 | Tobias Polte, et al. Atrial natriuretic peptide reduces cyclosporin toxicity in renal cells: role of cGMP and heme oxygenase-1. Free Radic Biol Med. 2002 Jan 1;32(1):56-63. |
| 6660 | Junzo Kamei, et al. Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in mice. Pain. 2005 Sep;117(1-2):112-20. |
| 6661 | Elza D van Deel, et al. Vasomotor control in mice overexpressing human endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1144-53. |
| 6662 | Kim MS, et al. Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget. 2017 Aug 10;8(41):70916-70940. |
| 6663 | McTavish D, et al. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89. |
| 6664 | Yamaguchi K, et al. Analysis of tolfenpyrad and its metabolites in plasma in a tolfenpyrad poisoning case. J Anal Toxicol. 2012 Sep;36(7):529-37. |
| 6665 | Hikiji W, et al. Acute fatal poisoning with Tolfenpyrad. J Forensic Leg Med. 2013 Nov;20(8):962-4. |
| 6666 | Wu H, et al. SlnM gene overexpression with different promoters on natamycin production in Streptomyces lydicus A02. J Ind Microbiol Biotechnol. 2014 Jan;41(1):163-72. |
| 6667 | Yvonne Maria te Welscher, et al. Polyene antibiotic that inhibits membrane transport proteins. Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11156-9. |Acta Chem. Scand. (1964), 18(1), 126-34; Antibiot. Chemother. (1963), 11, 261-72; Antibiot. Chemother. (1960), 10, 285-6 |
| 6668 | Lee JY, et al. Isolation and antifungal activity of kakuol, a propiophenone derivative from <i>Asarum sieboldii</i> rhizome. Pest Manag Sci. 2005 Aug;61(8):821-5. |
| 6669 | Chun-Jun Li, et al. Saxagliptin Induces β-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1α In Vivo and In Vitro. Front Endocrinol (Lausanne). 2017 Nov 27;8:326. |
| 6670 | Darshan J Dave. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother. 2011 Oct;2(4):230-5. |
| 6671 | Carolyn F Deacon, et al. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther. 2009 May;26(5):488-99. |
| 6672 | Papp, Z, et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012 Aug 23;159(2):82-7. |
| 6673 | Buzard DJ, et al. Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. ACS Med Chem Lett. 2014 Nov 4;5(12):1313-7. |
| 6674 | Ishikawa Y, et al. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells. Mol Cancer Ther. 2017 Feb;16(2):273-284. |
| 6675 | Robarge M, et al. Isoindole-imide compounds, compositions, and uses thereof. US20030096841A1 |
| 6676 | Ludbrook VJ, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016 May;174(5):985-95. |
| 6677 | Zimmermann AG, et al. Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog Nucleic Acid Res Mol Biol. 1998;61:181-209. |
| 6678 | Huang M, et al. Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar disruption. Leuk Res. 2008 Jan;32(1):131-41. |
| 6679 | Floryk D, et al. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer. 2008 Nov 15;123(10):2294-302. |
| 6680 | Nerolidol, et al. In vitro antileishmanial and cytotoxic activities of nerolidol are associated with changes in plasma membrane dynamics. Biochim Biophys Acta Biomembr. 2019 Jun 1;1861(6):1049-1056. |
| 6681 | Hormigo S, et al. The selective neurotoxin DSP-4 impairs the noradrenergic projections from the locus coeruleus to the inferior colliculus in rats. Front Neural Circuits. 2012 Jun 28;6:41. |
| 6682 | Jaim-Etcheverry G, et al. DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain Res. 1980 Apr 28;188(2):513-23. |
| 6683 | Briejer MR, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001 Jun 29;423(1):71-83. |
| 6684 | Johnson DE, et al. The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations. J Pharmacol Exp Ther. 2012 Jun;341(3):681-91. |
| 6685 | Koltun ES, et al. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. |
| 6686 | Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9(11):e113300. |
| 6687 | J Org Chem 26: 1318 (1961) |
| 6688 | Trauner M, et al. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801. |
| 6689 | Patel K, et al. Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 Mar 1. |
| 6690 | P. Schwab, et al. The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH. April 2018,Volume 68, Supplement 1, Pages S471-S472. |
| 6691 | Zachar Z, Marecek J, Maturo C et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl). 2011 Nov;89(11):1137-48. |
| 6692 | Lee KC, Shorr R, Rodriguez R et al. Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism. Drug Metab Lett. 2011 Aug;5(3):163-82. |
| 6693 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome |
| 6694 | Ringer DP, et al. Alteration in de novo pyrimidine biosynthesis during uridine reversal of pyrazofurin-inhibited DNA synthesis. Neuropsychopharmacology. J Biochem Toxicol. 1991 Spring;6(1):19-27. |
| 6695 | Peters GJ, et al. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines. Nucleosides Nucleotides Nucleic Acids. 2018;37(6):329-339. |
| 6696 | WO 2011090738 A2 |
| 6697 | Int. J. Food Microbiol. (1996), 29(2-3), 241-54; Int. J. Food Microbiol. (1994), 24(1-2), 283-93; Int. J. Food Microbiol. (1988), 7(4), 349-52 |
| 6698 | Snead JL, et al. A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol. 2007 Nov;14(11):1261-72. |
| 6699 | Nguyen H, et al. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2. J Biol Chem. 2015 May 29;290(22):13641-13653. |
| 6700 | Mahajan K, et al. 
 Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol. 2012 Apr;180(4):1386-93. |
| 6701 | Mahajan K, et al. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem. 2012 Jun 22;287(26):22112-22. |
| 6702 | Mahajan K, et al. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate. 2010 Sep 1;70(12):1274-85. |
| 6703 | Morgillo F, et al. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. J Med Chem. 2017 Sep 14;60(17):7447-7458. |
| 6704 | Cui Q, et al. Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated MultidrugResistance in Cancer Cells. Front Oncol. 2019 Apr 25;9:313. |
| 6705 | J Chem Soc 1963: 980 |
| 6706 | Quaranta L, et al. Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2007 Jun;1(2):93-97. |
| 6707 | Zimmermann G, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013 May 30;497(7451):638-42. |
| 6708 | Agalioti T, et al. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017 May 16;8:15205. doi: 10.1038/ncomms15205. |
| 6709 | Kluter S, et al. Displacement assay for the detection of stabilizers of inactive kinase conformations. J Med Chem. 2010 Jan 14;53(1):357-67. |
| 6710 | Draoui N, et al. Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. Bioorg Med Chem. 2013 Nov 15;21(22):7107-17. |
| 6711 | Cyril Corbet, et al. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat Commun. 2018 Mar 23;9(1):1208. |
| 6712 | anal Profiles Drug Subs 2:409 (1973); 17:749 (1988) |
| 6713 | Phytochemistry 17: 1383, 1401 (1990) |
| 6714 | Shokoohi GR, et al. In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives.Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00635-17. |
| 6715 | Nakamura A, et al. Anti-inflammatory effect of lanoconazole on 12-O-tetradecanoylphorbol-13-acetate- and 2,4,6-trinitrophenyl chloride-induced skin inflammation in mice.Mycoses. 2020 Feb;63(2):189-196. |
| 6716 | Furukawa K, et al. Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans.J Antimicrob Chemother. 2000 Sep;46(3):443-50. |
| 6717 | Porcu A, et al. In vitro and in vivo pharmacological characterization of SSD114, a novel GABAB positive allosteric modulator. Eur J Pharmacol. 2016 Nov 15;791:115-123. |
| 6718 | Cheney IW, et al. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1679-83. |
| 6719 | Chen JF, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001 May 15;21(10):RC143. |
| 6720 | Shiozaki S, et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl). 1999 Nov;147(1):90-5. |
| 6721 | Kanda T, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000 Apr;162(2):321-7. |
| 6722 | Brambilla R, et al. Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003 Aug;43(2):190-4. |
| 6723 | Mihara T, et al. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J Pharm |
| 6724 | Andrew C McCreary, et al. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology. 2007 Jan;32(1):78-94. |
| 6725 | Liesbeth A Bruins Slot, et al. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol. 2006 Mar 18;534(1-3):63-70. |
| 6726 | Wu YE, et al. Gelsemine alleviates both neuropathic pain and sleep disturbance in partial sciatic nerve ligation mice. Acta Pharmacol Sin. 2015 Nov;36(11):1308-17. |
| 6727 | J Indian Chem Soc 12: 421 (1935); J Nat Prod 53:1302 (1990) |
| 6728 | Genthe JR, et al. Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway. ACS Chem Biol. 2017 Sep 15;12(9):2436-2447. |
| 6729 | Zaytseva YY, et al. Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget. 2018 May 15;9(37):24787-24800. |
| 6730 | Heuer TS, et al. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression. EBioMedicine. 2017 Feb;16:51-62. |
| 6731 | Helv Chim Acta 25:988 (1942); JACS 57:1755 (1935) |
| 6732 | Shmuklarsky MJ, et al. Comparison of beta-artemether and beta-arteether against malaria parasites in vitro and in vivo. Am J Trop Med Hyg. 1993 Mar;48(3):377-84. |
| 6733 | Li QG, et al. Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):213-23. |
| 6734 | J. Soc. Cosmet. Chem. (1979), 30(1), 25-39; Nature (1973), 241(5388), 321-5; Chim. Ther. (1972), 7(6), 427-33 |
| 6735 | J. Clin. Psychiatry (1984), 45(10 Pt 2), 3-9; Experientia (1965), 21, 39; Dis. Nerv. Syst. (1964), 25, 42-4 |
| 6736 | Thress K, et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009 Jul; 8(7):1818-27. |
| 6737 | Kang SI et al. Sinensetin enhances adipogenesis and lipolysis by increasing cyclic adenosine monophosphate levels in 3T3-L1 adipocytes. Biol Pharm Bull. 2015;38(4):552-8. |
| 6738 | Shin HS et al. Sinensetin attenuates LPS-induced inflammation by regulating the protein level of IκB-α.
 Biosci Biotechnol Biochem. 2012;76(4):847-9. |
| 6739 | Lam IK et al. In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: identifying sinensetin as a novel antiangiogenesis agent. Mol Nutr Food Res. 2012 Jun;56(6):945-56. |
| 6740 | Andrade JM, et al. Combining in vitro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration. Chem Biol Interact. 2016 Jul 25;254:135-45. |
| 6741 | Fernando PM, et al. Rosmarinic Acid Attenuates Cell Damage against UVB Radiation-Induced Oxidative Stress via Enhancing Antioxidant Effects in Human HaCaT Cells. Biomol Ther (Seoul). 2016 Jan;24(1):75-84. |
| 6742 | Jin BR, et al. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation. Sci Rep. 2017 Apr 6;7:46252. |
| 6743 | Z Naturforsch 59c: 384 (2004) |
| 6744 | J Psychosocial Nurse Mental Health 49:19 (2011); Psychopharmacology 1:3 81 (2011) |
| 6745 | Igoe N, et al. Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins. J Med Chem. 2017 Aug 24;60(16):6998-7011. |
| 6746 | Ber 74:595 (1941); Monatsh Chem 84:217 (1953); Life Sci 72:199 (2002) |
| 6747 | Aoki M, et al. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1. J Virol. 2012 Dec;86(24):13384-96. |
| 6748 | Li F, et al. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. |
| 6749 | Elborn JS, et al. Phase 1 Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. Clin Transl Sci. 2016 Nov 2 |
| 6750 | Elborn JS, et al. Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction. Clin Transl Sci. 2016 Oct 28. |
| 6751 | Gabor Csjernyik, et al. Compounds and their use as bace inhibitors. WO2012087237A1. |
| 6752 | Neurosci. Biobehav. Rev. (2002), 26(1), 61-67; Science (1949), 109, 574; Ann. Otol., Rhinol., Laryngol. (1950), 59(3), 622-30 |
| 6753 | Engers DW, et al. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of mL347 as an ALK2 versus ALK3 selective mLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. |
| 6754 | Neely MD, et al. DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem Neurosci. 2012 Jun 20;3(6):482-91. |
| 6755 | Sheng Y, et al. DMH1 (4-[6-(4-isopropoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) inhibits chemotherapeutic drug-induced autophagy. Acta Pharm Sin B. 2015 Jul;5(4):330-6. |
| 6756 | Hover LD, et al. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Lett. 2015 Nov 1;368(1):79-87. |
| 6757 | Hao J, et al. DMH1, a small molecule inhibitor of BMP type i receptors, suppresses growth and invasion of lung cancer. PLoS One. 2014 Mar 6;9(6):e90748. |
| 6758 | J Pharmacol Exp Ther 79:127 (1943); Phytochemistry 7: 503 (1968) |
| 6759 | Bemi V, et al. Deoxyadenosine metabolism in a human colon-carcinoma cell line (LoVo) in relation to its cytotoxic effect in combination with deoxycoformycin. Int J Cancer. 1998 Mar 2;75(5):713-20. |
| 6760 | https://clinicaltrials.gov/ct2/show/NCT04334629?term=IBUPROFEN&cond=covid&draw=2&rank=3 |
| 6761 | Jing H, et al. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell. 2016 Mar 14;29(3):297-310. |
| 6762 | Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015 |
| 6763 | Alan H. Shih, et al. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. Blood 2014 124:437. |
| 6764 | https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&cond=Covid19&draw=2&rank=1; https://clinicaltrials.gov/ct2/show/NCT04252885?term=Umifenovir&cond=Covid19&draw=2&rank=4 |
| 6765 | Miyazaki T, et al. Discovery of novel 4-phenyl-2-(pyrrolidinyl)nicotinamide derivatives as potent Nav1.1 activators. Bioorg Med Chem Lett. 2019 Mar 15;29(6):815-820. |
| 6766 | Gellibert F, et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506. |
| 6767 | Ichida JK, et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell. 2009 Nov 6;5(5):491-503. |
| 6768 | Jin X, et, al. Undecanoic acid, lauric acid, and N-tridecanoic acid inhibit Escherichia coli persistence and biofilm formation. J Microbiol Biotechnol. 2020 Oct 13. |
| 6769 | Curr Med Res Opin 8:9 (1982); Drugs 34:289 (1987); Anal Profiles Drug Subs Excip 22:431 (1993) |
| 6770 | Acta Derm.-Venereol. (1991), 71(2), 148-50 |
| 6771 | Agents Actions (1980), 10(3), 258-65; Rheumatology (2003), 42(9), 1093-100 |
| 6772 | Kim HJ et al. Neuroprotective Effect of Chebulagic Acid via Autophagy Induction in SH-SY5Y Cells.
 Biomol Ther (Seoul). 2014 Jul;22(4):275-81. |
| 6773 | Liu Y et al. Chebulagic acid inhibits the LPS-induced expression of TNF-α and IL-1β in endothelial cells by suppressing MAPK activation. Exp Ther Med. 2015 Jul;10(1):263-268. |
| 6774 | Athira AP et al. Inhibition of Angiogenesis In Vitro by Chebulagic Acid: A COX-LOX Dual Inhibitor. Int J Vasc Med. 2013;2013:843897. |
| 6775 | Maggie C. Duncan, et al. Virtual Screening Identifies Chebulagic Acid as an Inhibitor of the M2(S31N) Viral Ion Channel and Influenza A Virus. Molecules 2020, 25, 2903. |
| 6776 | RuikunDu, et al. Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CLpro. Antivir Res. 2021, 105075. |
| 6777 | Clin Infect Dis 33:1476 (2001)Chem Rev 105:449 (2005); Ann Pharmacother 39:863 (2005) |
| 6778 | Christopher JM, et, al. Chemical and genetic engineering of selective ion channel-ligand interactions. Science. 2011 Sep 2; 333(6047): 1292-6. |
| 6779 | https://clinicaltrials.gov/ct2/show/NCT04707534?term=Dexamethasone&cond=COVID-19&draw=2&rank=1 |
| 6780 | Wang H, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res. 2012 Dec;40(22):11518-30. |
| 6781 | Fader LD, et al. Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. ACS Med Chem Lett. 2014 Apr 16;5(6):711-6. |
| 6782 | Withana NP, et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012 Mar 1;72(5):1199-209. |
| 6783 | Bell-McGuinn KM, et al. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007 Aug 1;67(15):7378-85. |
| 6784 | Schurigt U, et al. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem. 2008 Aug;389(8):1067-74. |
| 6785 | Václav Zima, et al. Unraveling the Anti-Influenza Effect of Flavonoids: Experimental Validation of Luteolin and its Congeners as Potent Influenza Endonuclease Inhibitors. Eur J Med Chem. 22 August 2020, 112754. |
| 6786 | Tet Lett 1978: 1699; 33: 5846 (1992) |
| 6787 | Zheng J, et al. Thiol-dependent DNA cleavage by aminomethylated Beaucage's reagent. Org Biomol Chem. 2010 Mar 21;8(6):1293-5. |
| 6788 | Beilei Wang, et al. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. Eur J Med Chem. 13 September 2018. |
| 6789 | Proc Soc Exp Biol Med 107:245 (1961); Anal Profiles Drug Subs Excip 22:489 (1993) |
| 6790 | Masuda M, et al. TNIK inhibition abrogates colorectal cancer stemness. Nat Commun. 2016 Aug 26;7:12586. |
| 6791 | Tet Lett 1979:1043 |
| 6792 | Lancet 1:1309 (1988); Headache 30 Suppl 2:554 (1990); N Engl J Med 325:316 (1991) |
| 6793 | Won SJ, et al. Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2). ACS Chem Biol. 2016 Dec 16;11(12):3374-3382. |
| 6794 | Adibekian A, et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2). |
| 6795 | Vujic I, et al. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9;7(6):7297-306. |
| 6796 | Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7. |
| 6797 | Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87. |
| 6798 | Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7. |
| 6799 | Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000. |
| 6800 | Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7. |
| 6801 | Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. |
| 6802 | Arch Pharmacol Res 10: 50 (1987) |
| 6803 | Cessna SG, et al. Oxalic acid, a pathogenicity factor for Sclerotinia sclerotiorum, suppresses the oxidative burst of the host plant. Plant Cell. 2000 Nov;12(11):2191-200. |
| 6804 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=HYDROCHLOROTHIAZIDE&cond=Covid19&draw=2&rank=2 |
| 6805 | Illig CR, et al. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. Bioorg Med Chem Lett. 2008 Mar 1;18(5):1642-8. |
| 6806 | Drugs (1984), 29(1), 6-44; Arzneim. Forsch. (1978), 28(11), 2082-7; Arch. Int. Pharmacodyn. Ther. (1973), 204(1), 37-55 |
| 6807 | Am J Dis Child 104:669 (1962); Arzneim Forsch 15:441 (1965); Calif Med 107:344 (1967); Chemotherapy 14:37,195 (1969) |
| 6808 | Kozuka C, et al. Impact of brown rice-specific γ-oryzanol on epigenetic modulation of dopamine D2 receptors in brain striatum in high-fat-diet-induced obesity in mice. Diabetologia. 2017 Aug;60(8):1502-1511. |
| 6809 | J Biol Chem 232:159 (1958); Arzneim Forsch 28:1119 (1978); J Immunol 139:202 (1987); Pflugers Arch 431:549 (1996) |
| 6810 | Liu J, et al. In Silico Discovery of a Small Molecule Suppressing Lung Carcinoma A549 Cells Proliferation and Inducing Autophagy via mTOR Pathway Inhibition. Mol Pharm. 2018 Nov 5;15(11):5427-5436. |
| 6811 | Rich IN, et al. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood. 2000 Feb 15;95(4):1427-34. |
| 6812 | Wilson L, et al. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology. 2006 Sep 30;353(2):294-306. Epub 2006 Jul 3. |
| 6813 | Yan C, et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014 Nov 20;515(7527):443-7. |
| 6814 | Purohit R, et al. YC-1 binding to the β subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the α subunit. Biochemistry. 2014 Jan 14;53(1):101-14. |
| 6815 | Kong J, et al. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Mol Cancer. 2014 Jan 13;13:7. |
| 6816 | Chang LC, et al. YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK. Br J Pharmacol. 2014 Sep;171(17):4010-25. |
| 6817 | Komsuoglu Celikyurt I, et al. Effects of YC-1 on Learning and Memory Functions of Aged Rats. Med Sci Monit Basic Res. 2014 Aug 21;20:130-7. |
| 6818 | Kavlock R, et al. Toxicity studies with decamethrin, a synthetic pyrethroid insecticide. J Environ Pathol Toxicol. 1979;2(3):751-765. |
| 6819 | Ray DE. An EEG investigation of decamethrin-induced choreoathetosis in the rat. Exp Brain Res. 1980;38(2):221-227. |
| 6820 | Bourin M, et al. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev. 2004 Fall;10(3):219-29. |
| 6821 | Vendrell-Criado V, et al. Photobehavior of the antipsychotic drug cyamemazine in a supramolecular gel protective environment. J Photochem Photobiol B. 2020 Jan;202:111686. |
| 6822 | Lyseng-Williamson KA, et al. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231-56. |
| 6823 | Nakamura J, et al. Target pharmacology of topiramate, a new antiepileptic drug. Nihon Yakurigaku Zasshi. 2000 Jan;115(1):53-7. |
| 6824 | Kaminski RM, et al. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104. |Int J Clin Pract 59:961 (2005); Clin Ther 27:154 (2005) |
| 6825 | Science 115:84 (1952; Mutat Res 32:3 (1975) |
| 6826 | Atkins C, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013 Mar 15;73(6):1993-2002. |
| 6827 | Krishnamoorthy J, et al. Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications. Cell Cycle. 2014 Mar 1;13(5):801-6. |
| 6828 | Ando T, et al. GSK2656157, a PERK inhibitor, reduced LPS-induced IL-1β production through inhibiting Caspase 1 activation in macrophage-like J774.1 cells. Immunopharmacol Immunotoxicol. 2016 Aug;38(4):298-302. |
| 6829 | Zhao Q, et al. Thioredoxin-interacting protein links endoplasmic reticulum stress to inflammatory brain injury and apoptosis after subarachnoid haemorrhage. J Neuroinflammation. 2017 May 11;14(1):104. |
| 6830 | J Biol Chem 285:33727 (2010) |
| 6831 | He F, et al. Antitumor effects of dammarane-type saponins from steamed Notoginseng. Pharmacogn Mag. 2014 Jul;10(39):314-7. |
| 6832 | Zhu JR, et al. Protective effects of ginsenoside Rb(3) on oxygen and glucose deprivation-induced ischemic injury in PC12 cells. Acta Pharmacol Sin. 2010 Mar;31(3):273-80. |
| 6833 | Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc<sup>Min/+</sup> mice. Sci Rep. 2017 Oct 2;7(1):12552. |
| 6834 | Murray, Brion W., et al. Small-molecule p21-activated kinase inhibitor PF3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proceedings of the National Academy of Sciences of the United States of America (2010), 107(20), 9446-9451, S94 |
| 6835 | Zhao ZS, et al. Do PAKs make good drug targets? F1000 Biol Rep. 2010 Sep 23;2:70. |
| 6836 | Ryu BJ, et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings. Mol Cell Biochem. 2014 Apr;389(1-2):69-77. |
| 6837 | Pitts TM, et al. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol. 2013 Mar 28;4:35. |
| 6838 | Kolos JM, et al. FKBP Ligands-Where We Are and Where to Go? Front Pharmacol. 2018 Dec 5;9:1425. |
| 6839 | Wu X, et al. Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library. ACS Comb Sci. 2011 Sep 12;13(5):486-95. |
| 6840 | Zhang X, et al. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nat Chem Biol. 2019 Jul;15(7):737-746. |
| 6841 | Ann NY Acad Sci 80:626 (1959); Arch Intern Med.105:583 (1960); Anesthesiology 22:335 (1961) |
| 6842 | Takahashi RH, et al. CYP1A1-Mediated Intramolecular Rearrangement of Aminoazepane in GDC-0339. Drug Metab Dispos. 2017 Oct;45(10):1084-1092. |
| 6843 | Wang X, et al. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. J Med Chem. 2019 Feb 28;62(4):2140-2153. |
| 6844 | J Chem Soc 1955:105 |
| 6845 | Park J, et al. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011 Jan;55(1):22-7. |
| 6846 | Filippopoulos T, et al. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008 Jul-Aug;24(4):302-7. |
| 6847 | Farrell MS, et al. In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS One. 2016 Mar 10;11(3):e0150602. |
| 6848 | Chan JD, et al. Pharmacological profiling an abundantly expressed schistosome serotonergic GPCR identifies nuciferine as a potent antagonist. Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):364-370. |
| 6849 | Li, Junguang, et al. Guacetisal crystal form compound and its preparation method. CN 106866420 A. |
| 6850 | Eur. J. Pharmacol. (2001), 415(1), 1-11; Tet. Lett. (1969), (13), 1007-10; Cancer Chemother. Rep. (1969), 53(1), 33-7 |
| 6851 | Wakita H, et al. E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1+ Leukocyte Trafficking in Mice with Colitis. Mol Pharmacol. 2017 Nov;92(5):502-509. |
| 6852 | https://clinicaltrials.gov/ct2/show/NCT04325633?term=Naproxen&cond=COVID-19&draw=2&rank=1 |
| 6853 | Wolf VG, et al. Octyl gallate, a food additive with potential beneficial properties to treat Helicobacter pylori infection. Food Funct. 2017 Jul 19;8(7):2500-2511. |
| 6854 | Wang Q, et al. Octyl gallate: An antioxidant demonstrating selective and sensitive fluorescent property. Food Chem. 2017 Mar 15;219:268-273. |
| 6855 | Uozaki M, et al. Antiviral effect of octyl gallate against DNA and RNA viruses. Antiviral Res. 2007 Feb;73(2):85-91. |
| 6856 | Biophys Res Commun 38:181 (1970) |
| 6857 | Ann 726:125 (9169); Phytochem 22:1045 (1983); Planta Med 53:62 (1987)| |
| 6858 | Su-Hong Lu et al. Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats. 
 Evid Based Complement Alternat Med, 2015, Oct 19 |
| 6859 | Diego Rodríguez-Hernández et al. Hederagenin as a triterpene template for the development of new antitumor compounds. Eur J Med Chem, 2015 Nov 13, 105:57-62 |
| 6860 | Chul Won Lee et al. Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice.
 Int Immunopharmacol, 2015 Dec, 29(2):528-37. |
| 6861 | Lain S, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. |
| 6862 | Yuan H, et al. Tenovin-6 impairs autophagy by inhibiting autophagic flux. Cell Death Dis. 2017 Feb 9;8(2):e2608. |
| 6863 | Yuan H, et al. Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy. Oncotarget. 2017 Feb 28;8(9):14912-14924. |
| 6864 | Dai W, et al. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep. 2016 Mar 4;6:22622. |
| 6865 | Ladds MJGW, et al. Exploitation of DHODH and p53 activation as therapeutic targets - a case study in polypharmacology [published online ahead of print, 2020 Sep 8]. J Biol Chem. 2020;jbc.RA119.012056. |
| 6866 | Pharmacotherapy (1984), 4(6), 334-42; Drugs (1980), 19(6), 397-411; Clin. Allergy (1980), 10(1), 65-70 |
| 6867 | Med Clin North Am 79:817 (1995) |
| 6868 | M Shahid, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. |
| 6869 | Olivia Frånberg, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008 Feb;196(3):417-29. |
| 6870 | Tan PK, et al. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep. 2017 Apr 6;7(1):665. |
| 6871 | Malamed, S.F., S. Gagnon, and D. Leblanc, A comparison between articaine HCl and lidocaine HCl in pediatric dental patients. Pediatr Dent, 2000. 22(4): p. 307-11. |
| 6872 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=CEFTRIAXONE&cntry=&state=&city=&dist= |
| 6873 | Na Z, et al. Protein-Protein Interaction Inhibitors of BRCA1 Discovered Using Small Molecule Microarrays. Methods Mol Biol. 2017;1518:139-156. |
| 6874 | Fontan L, et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 2012 Dec 11;22(6):812-24. |
| 6875 | Rev Clin Exp 135:539 (1974); 141:51 (1976); Med Klin 181:78 (1976) |
| 6876 | Carew JS, et al. Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis. Clin Cancer Res. 2017 Jun 1;23(11):2869-2879. |
| 6877 | Gut 29:1666 (1988); Eur J Nutrit 46:307 (2007) |
| 6878 | Alberati D, et al. Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012 Feb;62(2):1152-61. |
| 6879 | Pinard E, et al. Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia. J Me |
| 6880 | By Lai, et al. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J Med Chem. 2015 Jun 25;58(12):4888-904. |
| 6881 | Joseph JD, et al. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife. 2016 Jul 13;5. pii: e15828. doi: 10.7554/eLife.15828 |
| 6882 | Fu Y, et al. The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. Biochem Biophys Res Commun. 2003 Oct 17;310(2):391-7. |
| 6883 | Hu W, et al. Suppression of Nestin reveals a critical role for p38-EGFR pathway in neural progenitor cell proliferation. Oncotarget. 2016 Dec 27;7(52):87052-87063. |
| 6884 | Kummer JL, et al. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem. 1997 Aug 15;272(33):20490-4. |
| 6885 | Khan JA, et al. p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization. Mol Endocrinol. 2011 Oct;25(10):1710-24. |
| 6886 | Zhang Z, et al. PD169316, a specific p38 inhibitor, shows antiviral activity against Enterovirus71. Virology. 2017 Aug;508:150-158. |
| 6887 | S Franks, et al. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. Br Med J (Clin Res Ed). 1983 Apr 9;286(6372):1177-9. |
| 6888 | Daniela Uberti, et al. Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur J Pharmacol. 2002 Jan 2;434(1-2):17-20. |
| 6889 | Alin Ciobica, et al. The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease. J Physiol Biochem. 2012 Mar;68(1):59-69. |
| 6890 | Arch Otolaryngology 62:143 (1955); N Engl J Med 275:112 (1966); Br J Ophthalmol 92:149 (2008) |
| 6891 | https://clinicaltrials.gov/ct2/results?term=Nitazoxanide&cond=COVID-19&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=e&age_v=&gndr=&type=&rslt= |
| 6892 | Eur J Cancer Clin Oncol 24:1415 (1988) |
| 6893 | Folia Psychiatr. Neurol. Jpn. (1983), 37(2), 137-44; D-Amino Acids in Chemistry, Life Sci., and Biotechnology (2011), 173-212; Mod. Pharmacol.-Toxicol. (1978), 12, 489-508.| |
| 6894 | Li E, et al. D-Phenylalanine inhibits biofilm development of a marine microbe, Pseudoalteromonas sp. SC2014. FEMS Microbiol Lett. 2016 Sep;363(18). |
| 6895 | Ding X, et al. Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors. Bioorg Med Chem Lett. 2018 May 15;28(9):1615-1620. |
| 6896 | Safadi R, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1. |
| 6897 | Iruarrizaga-Lejarreta M, et al. Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatol Commun. 2017 Nov;1(9):911-927. |
| 6898 | Planta Med 22: 434 (1972) |
| 6899 | Chiesi M, et al. Structural dependency of the inhibitory action of benzodiazepines and related compounds on the mitochondrial Na+-Ca2+ exchanger. Biochem Pharmacol. 1988 Nov 15;37(22):4399-403. |
| 6900 | Ruiz A, et al. CGP37157, an inhibitor of the mitochondrial Na+/Ca2+ exchanger, protects neurons from excitotoxicity by blocking voltage-gated Ca2+ channels. Cell Death Dis. 2014 Apr 10;5:e1156. |
| 6901 | Scherzed A, et al. Effects of salinomycin and CGP37157 on head and neck squamous cell carcinoma cell lines in vitro. Mol Med Rep. 2015 Sep;12(3):4455-61. |
| 6902 | Hu W, et al. Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-κB activation in LPS-induced RAW264.7 macrophage cells. Pharmacol Rep. 2011;63(3):781-9. |
| 6903 | Zhang H, et al. Puerarin: a novel antagonist to inward rectifier potassium channel (IK1). Mol Cell Biochem. 2011 Jun;352(1-2):117-23. |
| 6904 | Zhao L,et al. Protective Effects of Genistein and Puerarin against Chronic Alcohol-Induced Liver Injury in Mice via Antioxidant, Anti-inflammatory, and Anti-apoptotic Mechanisms.
 J Agric Food Chem. 2016 Sep 28;64(38):7291-7. |
| 6905 | Pan X, et al. Effect of Puerarin on Expression of ICAM-1 and TNF-α in Kidneys of Diabetic Rats. Med Sci Monit. 2015 Jul 23;21:2134-40. |Chem Pharm Bull 8:688 (1960) |
| 6906 | Cancer Lett 69:203 (1993) |
| 6907 | Clin Exper Dermatol 6:133 (1981); Anal Profiles Drug Subs 10:705 (1981) |
| 6908 | Cirillo P, et al. Fructose induces prothrombotic phenotype in human endothelial cells : A new role for "added sugar" in cardio-metabolic risk. J Thromb Thrombolysis. 2015 Nov;40(4):444-51. |
| 6909 | Patel C, et al. Effect of dietary fructose on portal and systemic serum fructose levels in rats and in KHK-/- and GLUT5-/- mice. Am J Physiol Gastrointest Liver Physiol. 2015 Nov 1;309(9):G779-90. |
| 6910 | Chen YK, et al. Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. ACS Med Chem Lett. 2017 Jul 27;8(8):869-874. |
| 6911 | Metzger E, et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res. 2017 Sep 7. pii: canres.1754. |
| 6912 | Cushing TD, et al. Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease. J Med Chem. 2015 Jan 8;58(1):480-511. |
| 6913 | King AJ, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res, 2006, 66(23), 11100-11105. |
| 6914 | Takle AK, et al. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett, 2006, 16(2), 378-381. |
| 6915 | Smalley KS, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther, 2008, 7(9), 2876-2883. |
| 6916 | Rigas AC, et al. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 2007 Dec 6;26(55):7611-7619. |
| 6917 | Cohen-Jonathan E, et al. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat Res. 1999 Oct;152(4):404-11. |
| 6918 | Nakazawa H, et al. Role of protein farnesylation in burn-induced metabolic derangements and insulin resistance in mouse skeletal muscle. PLoS One. 2015 Jan 16;10(1):e0116633. |
| 6919 | Virtanen SS, et al. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells. Cell Biol Int. 2010 Aug;34(8):815-26. |
| 6920 | Bordier BB, et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol. 2002 Oct;76(20):10465-72. |
| 6921 | Science 243:1611 (1989) |
| 6922 | Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507. |
| 6923 | Wang Q, et al. Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. Eur J Med Chem. 2019 Feb 1;163:671-689. |
| 6924 | Chapeau EA, et al. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3151-3156. |
| 6925 | Furet P, et al. Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. Bioorg Med Chem Lett. 2016 Oct 1;26(19):4837-41. |
| 6926 | Stéphane F, et al. Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials. Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1224. |
| 6927 | Smil D, et al. Discovery of a Dual PRMT5-PRMT7 Inhibitor.ACS Med Chem Lett. 2015 Mar 2;6(4):408-12. |
| 6928 | Nagai Y, et al. PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targetedp185erbB2/neu Tumor Immunotherapy.Front Immunol. 2019 Feb 8;10:174. |
| 6929 | Arzneim Forsch 31:1309 (1981); Expert Opin Drug Saf 4:235 (2005) |
| 6930 | Sheng X, et al. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019 Jan 24;10(1):323. |
| 6931 | Logue SE, et al. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat Commun. 2018 Aug 15;9(1):3267. |
| 6932 | Chin PC, et al. The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem, 2004, 90(3), 595-608. |
| 6933 | Lei Y, et al. The Raf-1 inhibitor GW5074 and NSC 34521 suppress sidestream smoke-induced airway hyperresponsiveness in mice. Respir Res, 2008, 9(1), 71. |
| 6934 | Weijie You, et al. Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules. Angew. Chem. Int. Ed. 2017, 56, 1007-1011. |
| 6935 | Sara Iachettini, et al. Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease (2018) 9:996. |
| 6936 | Lad L, et al. Mechanism of inhibition of human KSP by ispinesib. Biochemistry. 2008 Mar 18;47(11):3576-85. |
| 6937 | Purcell JW, et al. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin Cancer Res. 2010 Jan 15;16(2):566-76. |
| 6938 | Davis DA, et al. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer. 2006 Jan 24;6:22. |
| 6939 | Eur. J. Pharmacol. (1970), 12(3), 342-7; Br. J. Pharmacol. Chemother. (1954), 9(2), 218-23; Circulation (1950), 2(6), 828-36 |
| 6940 | Kaul R, et al. [Penetration and action of edoxudine in vitro and in vivo]. Arzneimittelforschung. 1989 Mar;39(3):366-8. |Antimicrob. Agents Chemother. (1976), 10(1), 119-22; Biochem. Pharmacol. (1975), 24(10), 1073-8; J. Med. Chem. (1969), 12, 533-4 |
| 6941 | Gietzen K, et al. Comparison of the calmodulin antagonists compound 48/80 and calmidazolium. Biochem J. 1983 Dec 15;216(3):611-6. |
| 6942 | Lee J, et al. Calmidazolium chloride inhibits growth of murine embryonal carcinoma cells, a model of cancer stem-like cells. Toxicol In Vitro. 2016 Sep;35:86-92. |
| 6943 | Budu A, et al. Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135. |
| 6944 | Toyocamycin, et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2012 Jul;2(7):e79. |
| 6945 | Savall BM, et al. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H4 receptor antagonists. J Med Chem. 2014 Mar 27;57(6):2429-39. |
| 6946 | Murata Y, et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. |
| 6947 | Cermakova K, et al. Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation. Molecules. 2018 Aug 6;23(8). pii: E1958. |
| 6948 | SGC3027 for PRMT7. |
| 6949 | Binghui Shen, et al. Dna2 inhibitors for cancer treatment. US20170226063A1. |
| 6950 | Sheikh IA, et al. The Epac1 signaling pathway regulates Cl- secretion via modulation of apical KCNN4c channels in diarrhea. J Biol Chem. 2013 Jul 12;288(28):20404-15 |
| 6951 | Chen S, et al. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Mol Cancer. 2010 Jan 29;9:23. |
| 6952 | McGuire TF, et al. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem. 1996 Nov 1;271(44):27402-7. |
| 6953 | Tetrahedron 7:257 (1959); Phytomedicine 16:258 (2009) |
| 6954 | https://clinicaltrials.gov/ct2/show/NCT04847661?term=MEFLOQUINE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04347031?term=MEFLOQUINE&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04501783?term=MEFLOQUINE&cond=COVID-19&draw=2&rank=3 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001194-69-ES |
| 6955 | An Acad Brasil Cienc 42 (suplemento): 45 (1970) |
| 6956 | Nakao R, et al. Evaluation of efficacy of bruceine A, a natural quassinoid compound extracted from a medicinal plant, Brucea javanica, for canine babesiosis. J Vet Med Sci. 2009 Jan;71(1):33-41. |
| 6957 | Comoy E, et al. Iso-homovanillic acid determination in human urine. Clin Chim Acta. 1971 Dec;35(2):369-75. |
| 6958 | Geva M, et al. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum Mol Genet. 2016 Sep 15;25(18):3975-3987. |
| 6959 | Squitieri F, et al. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse J Cell Mol Med. 2015 Nov;19(11):2540-8. model. |
| 6960 | Hongmiao Pan, et al. Evaluation of impact of exposure of Sudan azo dyes and their metabolites on human intestinal bacteria. Anaerobe. 2012 Aug;18(4):445-53. |
| 6961 | Crockett SL, et al. Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness. Pediatr Res. 2019 Dec 9. |
| 6962 | He X, et al. Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases. ACS Med Chem Lett. 2017 Sep 27;8(10):1048-1053. |
| 6963 | Melanie-Jayne R. Howes, et al. Acetylcholinesterase inhibitors of natural origin. International Journal of Research in Pharmaceutical and Biomedical Sciences 3(SI 1):67-86. |
| 6964 | Kuryatov A, et al. Roles of accessory subunits in alpha4beta2(*) nicotinic receptors. Mol Pharmacol. 2008 Jul;74(1):132-43. |
| 6965 | Kita Y, et al. Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl). 2013 Feb;225(3):543-51. |J. Clin. Psychiatry (2000), 61(10), 710-1; Int. J. Neuropharmacol. (1968), 7(1), 7-14; Br. J. Anaesth. (1967), 39(12), 963-8 |
| 6966 | Int. J. Fertil. (1964), 9(1), 129-35; Metab., Clin. Exp. (1965), 14SUPPL:451-6; Appl. Thera. (1964), 6, 503-7 |
| 6967 | Fukumitsu S, et al. Anti-inflammatory and anti-arthritic effects of pentacyclic triterpenoids maslinic acid through NF-κB inactivation. Mol Nutr Food Res. 2016 Feb;60(2):399-409. |
| 6968 | Doukas J, et, al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. |
| 6969 | Terashima H, et al. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. Eur J Pharmacol. 2014 Jul 5;734:60-6. |
| 6970 | Cabitza P, et al. Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study. Eur Rev Med Pharmacol Sci. 2008 Jul-Aug;12(4):229-35. |
| 6971 | Frandisco Colomer Rusinvol, et al. Effects of Two Diffferent Doses of Eperisone in the Treatment of Acute Low Back Pain. The Journal of Applied Research. |
| 6972 | Bavage S, et al. Clinical efficacy and safety of eperisone for low back pain: A systematic literature review. Pharmacol Rep. 2016 Oct;68(5):903-12. |
| 6973 | Salvatore CA, Moore EL, Calamari A, Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60. |
| 6974 | Hewitt DJ, Aurora SK, Dodick DW, Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011 Apr;31(6):712-22. |
| 6975 | Arch. Toxicol. Suppl. (1985), 833-42; Crit. Rev. Biochem. (1981), 10(3), 171-212; Am. J. Med. (1947), 2(3), 251 |
| 6976 | Zhang W et al. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res. 2011 Apr;63(4):284-93. |
| 6977 | Golub AG, et al. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Eur J Med Chem. 2011 Mar;46(3):870-6. |
| 6978 | Nemeth G, et al. Novel, selective CDK9 inhibitors for the treatment of HIV infection. Curr Med Chem. 2011;18(3):342-358. |
| 6979 | Axelson M, et al. The identification of the weak oestrogen equol [7-hydroxy-3-(4'-hydroxyphenyl)chroman] in human urine. Biochem J. 1982 Feb 1;201(2):353-7. |
| 6980 | Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. human intestinal bacterial flora. |
| 6981 | Wang J, et al. Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor. Genet Mol Res. 2014 Jul 4;13(3):5055-63. |
| 6982 | Gimenez I,et al. Renal and vascular actions of equol in the rat. J Hypertens. 1997 Nov;15(11):1303-8. |
| 6983 | Choi EJ, et al. Anticancer mechanism of equol in 7,12-dimethylbenz(a)anthracene-treated animals. Int J Oncol. 2011 Sep;39(3):747-54. |
| 6984 | Isaacs JT, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73(4):1386-99. |
| 6985 | Isaacs JT, et al. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 2014 Sep 30;5(18):8093-106. |
| 6986 | Olsson A, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010 May 17;9:107. |
| 6987 | Gao L, et al. Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation. Cancer Lett. 2019 Jul 10;454:215-223. |
| 6988 | Choi YJ, et al. Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion. PLoS One. 2012;7(8):e43418. |
| 6989 | Zhou J, et al.Administration of follicle-stimulating hormone induces autophagy via upregulation of HIF-1α in mouse granulosa cells.Cell Death Dis. 2017 Aug 17;8(8):e3001. |
| 6990 | Han Y, et al. 2,5-dihydroxyacetophenone isolated from <i>Rehmanniae Radix</i> Preparata inhibits inflammatoryresponses in lipopolysaccharide-stimulated RAW264.7 macrophages. J Med Food. 2012 Jun;15(6):505-10. |
| 6991 | Antimicrob Agents Chemother 19:226 (1981); 21:1 (1982); 31:826 (1987); Rev Infect Dis 3:408 (1981) |
| 6992 | Jiang R, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332-8. |
| 6993 | Yamaori S, et al. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. |
| 6994 | James J. Carberry , et al. Composition of Olivetol and Method of Use to Reduce or Inhibit the Effects of Tetrahydrocannabinol in the Human Body. US20170143644A1 |
| 6995 | Wang Y, et al. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. |
| 6996 | J Chem Soc 1942:391; Phytochemistry 22:2087 (1983) |
| 6997 | Arzneim Forsch 10:255 (1960); 14:195 (1964); 20:693 (1970) |
| 6998 | Watson AM, et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGEactivation in diabetic apolipoprotein E knockout mice. Diabetes. 2012 Aug;61(8):2105-13. |
| 6999 | Wang H, et al. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats. Am J Physiol Heart Circ Physiol. 2015 Oct;309(7):H1130-40. |
| 7000 | Huang RY, et al. 18β-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS One. 2014 Apr 2;9(4):e93690. |
| 7001 | Zhou J, et al. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Sci Rep. 2015 Sep 2;5:13713. |
| 7002 | Yang G, et al. Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats. Evid Based Complement Alternat Med. 2017;2017:3470320. |
| 7003 | Wang L, et al. Hypotensive effect and toxicology of total alkaloids and veratramine from roots and rhizomes of Veratrum nigrum L. in spontaneously hypertensive rats. Pharmazie. 2008 Aug;63(8):606-10. |
| 7004 | Li HJ, et al. Puqienine F, a novel veratramine alkaloid from the bulbs of Fritillaria puqiensis. Chem Pharm Bull (Tokyo). 2006 May;54(5):722-4. |
| 7005 | Arzneim Forsch 19:1222 (1969); Toxicol Appl Pharmacol 18:185 (1971) |
| 7006 | L. Stipkovits, et al. The efficacy of valnemulin (Econor®) in the control of disease caused by experimental infection of calves with Mycoplasma bovis. Research in Veterinary Science, Volume 78, Issue 3, June 2005, Pages 207–215. |
| 7007 | Tet. Lett. (1971), (8), 685-90; Ann. N. Y. Acad. Sci. (1960), 89, 258-66; Mycoses (1996), 39(9-10), 329-39 |
| 7008 | Muñoz M, et al. The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. Cancers (Basel). 2010 Apr 20;2(2):611-23. |
| 7009 | Cascieri MA, et al. Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J Biol Chem. 1994 Mar 4;269(9):6587-91. |
| 7010 | Kuo HP, et al. Lipopolysaccharide enhances neurogenic plasma exudation in guinea-pig airways. Br J Pharmacol. 1998 Oct;125(4):711-6. |
| 7011 | Hong L, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013 Mar 22;288(12):8531-43. |
| 7012 | Surviladze Z, et al. A Potent and Selective Inhibitor of Cdc42 GTPase. Probe Reports from the NIH Molecular Libraries Program |
| 7013 | Hanin G, et al. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet. 2014 Sep 1;23(17):4569-80. |
| 7014 | Wei J, et al. An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature. 2019 Apr;568(7753):566-570. |
| 7015 | Wikoff WR, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3698-703. |
| 7016 | Reiter RJ, et al. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann N Y Acad Sci. 1998 Nov 20;854:410-24. |
| 7017 | de Mello VDet al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study. Sci Rep. 2017 Apr 11;7:46337. doi: 10.1038/srep46337. |
| 7018 | Lancet 365:947 (2005); J Clin Pharmacol 45:878 (2005) |
| 7019 | Drugs 27:301 (1984); J Diabetes Complications 14:201 (2000); Metabolism 50: 688 (2001) |
| 7020 | Schroder D, et al. Identification of a new membrane-permeable inhibitor against inositol-1,4,5-trisphosphate-3-kinase A. Biochem Biophys Res Commun. 2013 Sep 20;439(2):228-34. |
| 7021 | Steroids 65: 171 (2000) |
| 7022 | Ricciarelli R, et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. Sci Rep. 2017 Apr 12;7:46320. |
| 7023 | Gurney ME, et al. Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders. J Med Chem. 2019 May 23;62(10):4884-4901. |
| 7024 | J Chem Soc 1957: 2988; Chem Pharm Bull 17: 1390 (1969); 42: 138 (1994); Helv Chim Acta 66: 1843 (1983) |
| 7025 | Yeo SCM, et al. Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism. Br J Pharmacol. 2017 Jul;174(13):2043-2059. |
| 7026 | Liang Y, et al. SESN2/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers. Autophagy. 2016 Aug 2;12(8):1229-39. |
| 7027 | Jiang G, et al. Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis. Cancer Prev Res (Phila). 2016 Jul;9(7):567-80. |
| 7028 | Aoyama T, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology. 2012 Dec;56(6):2316-27. |
| 7029 | Green DE, et al. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol. 2012 Nov;47(5):718-26. |
| 7030 | M.J. Gunthorpe et al. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology, 2004 Jan, 46(1):133-49. |
| 7031 | Gavva NR et al. Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1. Mol Pharmacol, 2005 Dec, 68(6), 1524-33. |
| 7032 | DALLY, Robert Dean, et al. CDC7 Inhibitors. 18 September 2014. WO2014143601A1. |
| 7033 | Sun L, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003 Mar 27;46(7):1116-9. |
| 7034 | Ali MM, et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 2011 Mar 2;30(5):894-905. |
| 7035 | O'Farrell AM, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. |
| 7036 | Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can |
| 7037 | Toxicol Appl Pharmacol 73:411 (1984); Toxicol Lett 28:99 (1985) |
| 7038 | Toxicol Appl Pharmacol 2:379 (1960) |
| 7039 | Am J Cardiol 45:1250 (1980); 47:123 (1981); Durgs 39:720 (1990) |
| 7040 | Roskoski R Jr,Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Pharmacol Res. 2016 May;107:249-275. |
| 7041 | Joshi KS, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6(3):918-25. |
| 7042 | Joshi KS,et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34. |
| 7043 | Liu H, et al. Development of 18F-labeled picolinamide probes for PET imaging of malignant melanoma. J Med Chem. 2013;56(3):895‐901. |
| 7044 | Baumann, et al. Preparation of 4,5,6,7-tetrahydrobenzothiazolyl- or 5,6,7,8-tetrahydroquinazolinylphenylamine derivatives as modulators for amyloid beta. WO2009087127A1 |
| 7045 | Yi Y, et al. Z-Ligustilide Exerted Hormetic Effect on Growth and Detoxification Enzymes of Spodoptera lituraLarvae. Evid Based Complement Alternat Med. 2018 Jul 2;2018:7104513. |
| 7046 | Genovese C, et al. Effects of a new combination of plant extracts plus d-mannose for the management of uncomplicated recurrent urinary tract infections. J Chemother. 2018 Apr;30(2):107-114. |
| 7047 | Biochem Biophys Res Comm 276: 278 (2000) |
| 7048 | https://clinicaltrials.gov/ct2/show/NCT04729491?term=dutasteride&cond=covid&draw=2&rank=1 |
| 7049 | Cryobiology 30:313 (1993); Histochemistry 101:215 (1994); Contact Dermatitis 33:352 (1995) |
| 7050 | Qi W, et al. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancercells. Oncogene. 2008 Jul 10;27(30):4210-20. |
| 7051 | Harris KC, et al. Prevention of noise-induced hearing loss with Src-PTK inhibitors. Hear Res. 2005 Oct;208(1-2):14-25. |
| 7052 | Bielefeld EC, et al. A comparison of the protective effects of systemic administration of a pro-glutathione drug and a Src-PTK inhibitor against noise-induced hearing loss. Noise Health. 2005 Oct-Dec;7(29):24-30. |
| 7053 | Wang SW, et al. Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation. Food Chem Toxicol. 2018 Apr;114:227-236. |
| 7054 | Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508(7495):215-21. |
| 7055 | Saleh A, et, al. Development and validation of method for TH588 and TH287, potent MTH1 inhibitors and new anti-cancer agents, for pharmacokinetic studies in mice plasma. J Pharm Biomed Anal. 2015 Feb;104:1-11. |
| 7056 | Br J Clin Pharmacol 41:141 (1996); Expert Opin Pharmacother 6:1019 (2005) |
| 7057 | Campaner E, et al. A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. Nat Commun. 2017 Jun 9;8:15772. |
| 7058 | Kiso T, et al. Screening for microtubule-disrupting antifungal agents by using a mitotic-arrest mutant of Aspergillus nidulans and novel action of phenylalanine derivatives accompanying tubulin loss. Antimicrob Agents Chemother. 2004 May;48(5):1739-48 |
| 7059 | Venghateri JB, et al. Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at thevinblastine site. PLoS One. 2013 Oct 4;8(10):e75182. |
| 7060 | Wang SK, et, al. Discovery of Small Molecules for Repressing Cap-Independent Translation of Human Vascular Endothelial Growth Factor (hVEGF) as Novel Antitumor Agents. J Med Chem. 2017 Jul 13;60(13):5306-5319. |
| 7061 | Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. |
| 7062 | Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. |
| 7063 | Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2015 Jul 1:1-16. |
| 7064 | Wang LH, et al. SYP-5, a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. Eur J Pharmacol. 2016 Nov 15;791:560-568. |
| 7065 | Bruno RD, et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.Steroid |
| 7066 | DeVore NM, et al. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.Nature. 2012 Jan 22;482(7383):116-9. |
| 7067 | Soifer HS, et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.J Biol Chem. 2012 Feb 3;287(6):3777-87. Epub 2011 Dec 15. |
| 7068 | Shearman, M.S., Beher, D., Clarke, E.E., Lewis, H.D., Harrison, T., Hunt, P., |
| 7069 | Guanghui Yang, et al. Structural basis of γ-secretase inhibition and modulation by small molecule drugs. Cell. 2021 Jan 21;184(2):521-533.e14. |
| 7070 | Jonas Sjölund, et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest. 2008 Jan;118(1):217-28. |
| 7071 | Kazunori Kawaguchi, et al. Jagged1 DNA Copy Number Variation Is Associated with Poor Outcome in Liver Cancer. Am J Pathol. 2016 Aug;186(8):2055-2067. |
| 7072 | Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014 Dec;16(12):1180-91. |
| 7073 | Zilka O, et al. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent Sci. 2017 Mar 22;3(3):232-243 |
| 7074 | Gu L, et al. Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment. Cancer Cell. 2016 Oct 10;30(4):623-636 |
| 7075 | Elshafay A, et al. Ginsenoside Rk1 bioactivity: a systematic review. PeerJ. 2017 Nov 17;5:e3993. |
| 7076 | Yu Q,et al. Ginsenoside Rk1 suppresses pro-inflammatory responses in lipopolysaccharide-stimulated RAW264.7 cells by inhibiting the Jak2/Stat3 pathway. Chin J Nat Med. 2017 Oct;15(10):751-757. |
| 7077 | Hong Y, et al. Ginsenoside Rk1 induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells. Toxicology. 2019 Apr 15;418:22-31. |
| 7078 | Expert Opin. Drug Metab. Toxicol. (2011), 7(7), 847-855; Clin. Pharmacol. Ther. (1970), 11(6), 789-801; Biochem. Med. (1970), 4(3-4), 357-9 |
| 7079 | Postgrad Med J 64:752 (1988) |
| 7080 | Woo SM, et al. Jaceosidin induces apoptosis through Bax activation and down-regulation of Mcl-1 and c-FLIP expression in human renal carcinoma Caki cells. Chem Biol Interact. 2016 Dec 25;260:168-175. |
| 7081 | Lee JG, et al. Jaceosidin, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation. Food Chem Toxicol. 2013 May;55:214-21. |
| 7082 | Min SW, et al. Inhibitory effect of eupatilin and jaceosidin isolated from Artemisia princeps on carrageenan-induced inflammation in mice. J Ethnopharmacol. 2009 Sep 25;125(3):497-500. |
| 7083 | Sanu O, et al. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9. |
| 7084 | Philip J Ryan, et al. Oxytocin-receptor-expressing Neurons in the Parabrachial Nucleus Regulate Fluid Intake. Nat Neurosci. 2017 Dec;20(12):1722-1733. |
| 7085 | Zhang J, et al. The Effect of 4-hydroxybenzaldehyde on the γ-aminobutyric Acid Type A Receptor. Malays J Med Sci. 2017 Mar;24(2):94-99. |
| 7086 | Park JJ, et al. Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway. Cell Oncol (Dordr). 2015 Jan 6. |
| 7087 | Park SH, et al. IRAK4 as a Molecular Target in the Amelioration of Innate Immunity-Related Endotoxic Shock and Acute Liver Injury by Chlorogenic Acid. J Immunol. 2015 Feb 1;194(3):1122-30. |
| 7088 | Kang JW, et al. Protective Effects of Chlorogenic Acid against Experimental Reflux Esophagitis in Rats. Biomol Ther (Seoul). 2014 Sep;22(5):420-5. |Phytochemistry 15: 703 (1976); Biochem J 361: 57 (2002) |
| 7089 | Wrigley JD, et al. Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating EnzymeSubfamily. ACS Chem Biol. 2017 Dec 15;12(12):3113-3125. |
| 7090 | Xiao-Meng Wang, et al. The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer. Nature Cancer volume 1, pages811–825(2020). |
| 7091 | Hershberger P, et al. Small Molecule Agonists for the Neurotensin 1 Receptor (NTR1 Agonists). Probe Reports from the NIH Molecular Libraries Program |
| 7092 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=TENOFOVIR&cntry=&state=&city=&dist= |
| 7093 | Lee M, et al. Water-Soluble MMP-9 Inhibitor Reduces Lesion Volume after Severe Traumatic Brain Injury. ACS Chem Neurosci. 2015 Oct 21;6(10):1658-64. |
| 7094 | Stephen Brown, et al. Potent and Selective Mechanism-Based Inhibition of GelatinasesJ. Am. Chem. Soc.2000122286799-6800 |
| 7095 | Bonfil RD, et al. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer. 2006, 118(11), 2721-2726. |
| 7096 | Cui J, et al. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener. 2012, 15, 7-21. |
| 7097 | Pandith H, et al. Effect of Siam weed extract and its bioactive component scutellarein tetramethyl ether on anti-inflammatory activity through NF-κB pathway. J Ethnopharmacol. 2013 May 20;147(2):434-41. |
| 7098 | Maia GL, et al. Flavonoids from Praxelis clematidea R.M. King and Robinson modulate bacterial drug resistance. Molecules. 2011 Jun 10;16(6):4828-35. |
| 7099 | Triratana T, et al. Effect of Eupatorium odoratum on blood coagulation. J Med Assoc Thai. 1991 May;74(5):283-7. |
| 7100 | Shames DS, et al. Loss of NAPRT1 Expression by Tumor-specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors. Clin Cancer Res. 2013 Dec 15;19(24):6912-23. |
| 7101 | Zabka TS, et al. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. Toxicol Sci. 2015 Mar;144(1):163-72. |
| 7102 | Kleiman RJ, et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther. 2012 May;341(2):396-409. |
| 7103 | Hutson, P. H, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and |
| 7104 | J Pharmacol Exp Ther 113:178 (1955); J Pharm Sci 64:1702 (1975) |
| 7105 | J. Clin. Psychopharmacol. (1989), 9(4), 268-76; Neuropharmacology (1983), 22(3A), 273-8; Nature (1967), 216(5115), 578-9 |
| 7106 | J Pharm Pharmacol 9: 855 (1957) |
| 7107 | Chem Ber 65: 175, 1668 (1932); J Nat Prod 62:821 (1999) |
| 7108 | Cha PH, et al. Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation. Nat Chem Biol. 2016 Aug;12(8):593-600. |
| 7109 | J Chem Soc 123: 3003 (1923) |
| 7110 | Ayrton AD, et al. Anthraflavic acid inhibits the mutagenicity of the food mutagen IQ: mechanism of action. Mutat Res. 1988 Mar-Apr;207(3-4):121-5. |
| 7111 | Drugs 15:429 (1978) |
| 7112 | Gao C, et al. Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4919-22. |
| 7113 | Nielsen, O.H., H.W. Verspaget, and J. Elmgreen, Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther, 1988. 2(3): p. 203-11. |
| 7114 | Gionchetti, P., et al., Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci, 1991. 36(2): p. 174-8. |
| 7115 | Brown, W.A., et al., 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci, 2000. 45(8): p. 1578-84. |
| 7116 | McTier TL, et al. Discovery of sarolaner: A novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs. Vet Parasitol. 2016 May 30;222:3-11. |
| 7117 | JACS 41:681 (1919); Science 263:966 (1994); Biochem J 316:247 (1996); J Pharmacol Exp Therap 288:544 (1999); Trends Pharmacol Sci 21:187 (2000); Mol Pharmacol 59:24 (2001) |
| 7118 | Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.J Biol Chem. 2014 Feb 14;289(7):4432-43. |
| 7119 | Wu CY, et al. A novel inhibitor of pyruvate dehydrogenase kinase stimulates myocardial carbohydrate oxidation in diet-induced obesity.J Biol Chem. 2018 Jun 22;293(25):9604-9613. |
| 7120 | Hamour AA, et al. Successful treatment of AIDS-related cryptosporidial sclerosing cholangitis. AIDS. 1993 Nov;7(11):1449-51. |
| 7121 | Agostinis P et al. Hypericin in cancer treatment: more light on the way.
 Int J Biochem Cell Biol. 2002 Mar;34(3):221-41. |
| 7122 | Lenard J et al. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses usinghypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):158-62. |
| 7123 | Hwang MS et al. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
 Anticancer Res. 2001 Jul-Aug;21(4A):2649-55. |
| 7124 | Iconaru LI, et al. Discovery of Small Molecules that Inhibit the Disordered Protein, p27(Kip1). Sci Rep. 2015 Oct 28;5:15686. |
| 7125 | J. Pharm. Res. (2011), 4(8), 2755-2757; Oncologia (1965), 19(4), 285-93; Nature (1965), 205, 479-81 |
| 7126 | Hayet E, et al. Antibacterial and cytotoxic activity of the acetone extract of the flowers of Salvia sclarea and some natural products.Pak J Pharm Sci. 2007 Apr;20(2):146-8. |J Soc Chim Tunisie 4:903 (1996); Pak J Pharm Sci 20:146 (2007) |
| 7127 | Witvrouw M, et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS. 1999 Aug 20;13(12):1477-83. |
| 7128 | Baskaran R, et al. Neferine prevents NF-κB translocation and protects muscle cells from oxidative stress and apoptosis induced by hypoxia. Biofactors. 2016 Jul 8;42(4):407-17. |
| 7129 | Liu X, et al. Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice. Oncotarget. 2016 Sep 20;7(38):61703-61715. |
| 7130 | Bai Y, et al. Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in A549 human lung cancer cells. Pharmacogn Mag. 2014 Jul;10(39):318-24. |
| 7131 | Ma W, et al. Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels. Atherosclerosis. 2015 Apr;239(2):566-70. |
| 7132 | Adibekian A et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 1 (LYPLA1). National Center for Biotechnology Information (US); 2010- 2013 Apr 08. |
| 7133 | Li W, et al. BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro. J Thorac Oncol. 2011 Nov;6(11):1801-9. |
| 7134 | Uegaki T, et al. Inhibitor of apoptosis proteins (IAPs) may be effective therapeutic targets for treating endometriosis. Hum Reprod. 2015 Jan;30(1):149-58. |
| 7135 | J Chem Soc 1939: 956, 958; 1956:4170; PNAS 107:2687 (2009) |
| 7136 | Voogd CE, et al. The mutagenic action of nitroimidazoles. II. Tinidazole, ipronidazole, panidazole and ornidazole. Mutat Res. 1977 Apr;48(2):155-61. |
| 7137 | Botero D, et al. Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Trans R Soc Trop Med Hyg. 1977;71(6):508-11. |
| 7138 | Hunt E, et al. Erythromycin A 11,12-methylene acetal. J Antibiot (Tokyo). 1988 Nov;41(11):1644-8. |
| 7139 | Schoemaker H, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. 
 J Pharmacol Exp Ther. 1997 Jan;280(1):83-97. |
| 7140 | Pawar GR, et al. Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice. Acta Pol Pharm. 2009 May-Jun;66(3):327-31. |
| 7141 | Huang M, et al. Structure-based design of HSPA5 inhibitors: from peptide to small molecule inhibitors. Bioorg Med Chem Lett. 2013;23(10):3044‐3050. |
| 7142 | Bull Chem Soc Jpn 39:2313 (1966); J Pharm Sci 55:1378 (1966); Phytochemistry 6:1395 (1967) |
| 7143 | Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1. |
| 7144 | Marco H Hofmann, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019. |
| 7145 | Rose NR, Woon EC, Tumber A, Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem. 2012 Jul 26;55(14):6639-43. |
| 7146 | Roy SS, et, al. Exploration of teratogenic and genotoxic effects of fruit ripening retardant Alar (Daminozide) on model organism Drosophila melanogaster. Interdiscip Toxicol. 2018 May;11(1):27-37. |
| 7147 | Merlos M, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997 Jan;280(1):114-21. |
| 7148 | Queralt M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000 Jul;49(7):355-60. |
| 7149 | Lv XX, et al. Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents. PLoS One. 2013 Jul 15;8(7):e68631. |
| 7150 | Blaquiere N, et al. Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing Kinase. J Med Chem. 2018 Aug 9;61(15):6801-6813. |
| 7151 | https://clinicaltrials.gov/ct2/show/NCT04610567?term=Methotrexate&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04352465?term=Methotrexate&cond=Covid19&draw=2&rank=2 |
| 7152 | Ko GA, et al. <i>Sageretia thea</i> fruit extracts rich in methyl linoleate and methyl linolenate downregulate melanogenesis via the Akt/GSK3β signaling pathway. Nutr Res Pract. 2018 Feb;12(1):3-12. |
| 7153 | Leoni A, et al. 2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014). Expert Opin Ther Pat. 2016;26(2):149-73. |
| 7154 | Kaur M, et al. Oxindole: A chemical prism carrying plethora of therapeutic benefits. Eur J Med Chem. 2016 Nov 10;123:858-894. |
| 7155 | JACS 60:1146 (1938); 72:375 (1950); Tetrahedron 15:100 (1961); 18:1433 (1962) |
| 7156 | Tanya L Wallace, et al. RG3487, a Novel Nicotinic α7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents. J Pharmacol Exp Ther. 2011 Jan;336(1):242-53. |
| 7157 | Chan-Penebre E, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432-7. |
| 7158 | Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016 Mar 11;351(6278):1214-8. |
| 7159 | Ge D, et al. Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy. 2014 Jun;10(6):957-71. |
| 7160 | Peng N, et al. An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E<sup>-</sup>/<sup>-</sup> mice. Sci Rep. 2014 Jul 1;4:5519. |
| 7161 | Huaxing Pei, et al. Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 955. |
| 7162 | Xu G, et al. Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors. Eur J Med Chem. 2020 Apr 29;198:112354. |
| 7163 | J Natl Cancer Inst 99:828 (2007); Lung Cancer 59:1 (2008) |
| 7164 | Xiang Y, et al. Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4550-4. |
| 7165 | Collett MS, et al. Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model. J Infect Dis. 2017 Feb 1;215(3):335-343. |
| 7166 | JACS 75:1242 (1953) |
| 7167 | Annu Rev Pharmacol Toxicol 20:235 (1980); Clin Pharmacol Therap 71:153 (2002) |
| 7168 | Biochem Pharmacol 40:821 (1990) |
| 7169 | Cha PH, et al. Hovenia dulcis Thunb extract and its ingredient methyl vanillate activate Wnt/β-catenin pathway and increase bone mass in growing or ovariectomized mice. PLoS One. 2014 Jan 22;9(1):e85546. |
| 7170 | Zhou T, et al. Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 2019 Mar 6;10(3):226. |
| 7171 | Chem Pharm Bull 32:3267 (1984) |
| 7172 | Bhat R, Xue Y, Berg S, Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 2003 Nov 14;278(46):45937-45. |
| 7173 | Carter YM, et al. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther. 2014 May;15(5):510-5. |
| 7174 | Koh SH, et al. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp Neurol. 2007 Jun;205(2):336-46 |
| 7175 | Martins DF, et al. The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice. J Pain. 2011 Mar;12(3):315-22. |
| 7176 | J. Med. Chem. (1968), 11(2), 342-7; J. Org. Chem. (1960), 25, 1860-5. ; Pharmazie (1958), 13, 619-22. |
| 7177 | Berger SB, et al. Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015 Jul 27;1:15009. |
| 7178 | Risinger AL, et al. ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther. 2011 Mar;336(3):652-60. |
| 7179 | Carew JS, et al. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. PLoS One. 2012;7(1):e31120. |
| 7180 | Gao L, et al. A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. Chin Med J (Engl). 2015 May 5;128(9):1160-4. |
| 7181 | Liu X, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127-38. |
| 7182 | Baltschukat S, et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019 May 15;25(10):3164-3175. |
| 7183 | Kamath K, et al. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther. 2006 Sep;5(9):2225-33. |
| 7184 | Aquino-Gálvez A, et al. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia. Oncol Rep. 2016 Jan;35(1):577-83. |
| 7185 | Xu L, et al. 2-Methoxyestradiol Alleviates Experimental Autoimmune Uveitis by Inhibiting Lymphocytes Proliferation and T Cell Differentiation. Biomed Res Int. 2016;2016:7948345. |
| 7186 | Kang SH, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 2006, 66(24),11991-11997. |
| 7187 | LaVallee TM, et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptorsalpha and beta. Cancer Res. 2002 Jul 1;62(13):3691-7. |
| 7188 | Chen Y, et al. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 2008;15(1):171-182. |
| 7189 | https://clinicaltrials.gov/ct2/show/NCT04407390?term=NIACINAMIDE&cond=covid&draw=2&rank=1 |
| 7190 | Sudo T, et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol. 2000 Feb 15;59(4):347-56. |
| 7191 | Popp TA, et al. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors. J Med Chem. 2016 Oct 13;59(19):8889-8912. |
| 7192 | Cerchia C, et al. Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism, and in Vitro Efficacy against Melanoma Cell Lines. J Med Chem. 2019 Aug 8;62(15):7089-7110. |
| 7193 | Kordulewska NK, et al. Changes in gene expression induced by histamine, fexofenadine and osthole: Expression of histamine H1 receptor, COX-2, NF-κB, CCR1, chemokine CCL5/RANTES and interleukin-1β in PBMC allergic and non-allergic patients. Immunobiology. |
| 7194 | Tang DZ, et al. Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res. 2010 Jun;25(6):1234-45. |
| 7195 | Sun W, et al. Osthole pretreatment alleviates TNBS-induced colitis in mice via both cAMP/PKA-dependent and independent pathways. Acta Pharmacol Sin. 2017 Aug;38(8):1120-1128. |
| 7196 | Zhang ZR, et al. Osthole: A Review on Its Bioactivities, Pharmacological Properties, and Potential as Alternative Medicine. Evid Based Complement Alternat Med. 2015;2015:919616. |
| 7197 | Trifu V, et al. Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream. Br J Dermatol. 2011 Jul;165(1):177-83. |
| 7198 | Celasco G, et al. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881-6. |
| 7199 | Biochem J 148:527 (1975); Arch Biochem Biophys 193:76 (1979); J Biol Chem 258:7974 (1983) |
| 7200 | Brit J Exper Path 28:1 (1947) |
| 7201 | Pharmaceut Chem J 18:736 (1985); J Med Chem 51:219 (2008)| |
| 7202 | Schmitz B, et al. BF-1--a novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs. Eur J Pharmacol. 2015 Mar 15;751:73-80. |
| 7203 | Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35. |
| 7204 | Durães F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel). 2019 Apr 21;12(2):63. |
| 7205 | Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313. |
| 7206 | Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78(18):1931-1937. |
| 7207 | Exp Biol Med 73:131 (1950); PNAS 94:4895 (1997) |
| 7208 | Gwak J, et al. Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation. ell Res. 2012 Jan;22(1):237-47. |
| 7209 | Ohashi W, et al. SKL2001 suppresses colon cancer spheroid growth through regulation of the E-cadherin/β-Catenin complex. Biochem Biophys Res Commun. 2017 Nov 25;493(3):1342-1348. |
| 7210 | Bain G, et al. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis. J Pharmacol Exp Ther. 2017 Jan;360(1):1-13. Epub 2016 Oct 17. |
| 7211 | Allen RA, et al. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ. J Pharmacol Exp Ther. 2017 Apr 25. pii: jpet.116.237347. |
| 7212 | 1. Wang KK et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6687-92. |
| 7213 | 2. Squier MK , et al. Calpain and calpastatin regulate neutrophil apoptosis. J Cell Physiol. 1999 Mar;178(3):311-9. |
| 7214 | We?wer M et al. A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett, 2012 Dec 13, 3(12):1034-1038. |
| 7215 | Spoonamore J et al. Screen for Inhibitors of STK33 Kinase Activity. National Center for Biotechnology Information (US); 2010-2011 Dec 16. |
| 7216 | Sun EL, et al. Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction. Neoplasma. 2017;64(6):869-879. |
| 7217 | .Jiang X, Kim HE, Shu H, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science, 2003, 299(5604): 223-226. |
| 7218 | Nguyen JT, et al. Direct activation of the apoptosis machinery as a mechanism to target cancer cells.Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7533-8. |
| 7219 | Rebhun JF, et al. Identification of glabridin as a bioactive compound in licorice (Glycyrrhiza glabra L.) extract that activates human peroxisome proliferator-activated receptor gamma (PPARγ). Fitoterapia. 2015 Oct;106:55-61. |
| 7220 | Chen CT, et al. Glabridin induces apoptosis and cell cycle arrest in oral cancer cells through the JNK1/2 signaling pathway. Environ Toxicol. 2018 Jun;33(6):679-685. |
| 7221 | El-Ashmawy NE, et al. Downregulation of iNOS and elevation of cAMP mediate the anti-inflammatory effect of glabridin in rats with ulcerative colitis. Inflammopharmacology. 2018 Apr;26(2):551-559. |
| 7222 | https://clinicaltrials.gov/ct2/show/NCT04946162?term=tadalafil&cond=COVID-19&draw=2&rank=1 |
| 7223 | Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. |
| 7224 | Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. |
| 7225 | Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. |
| 7226 | Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302. |
| 7227 | https://clinicaltrials.gov/ct2/show/NCT04730934?term=PREGABALIN&cond=covid&draw=2&rank=1 |
| 7228 | J. Allergy Clin. Immunol. (2000), 106(4 Suppl), S179-90; Arch. Dermatol. (1964), 89, 561; J. Am. Osteopath. Assoc. (1963), 63, 257-60 |
| 7229 | S Eathiraj, et al. Targeting PCI-32765-Resistant BTK-C481S Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK. Clinical Lymphoma Myeloma & Leukemia, 2016, 16: S47-S48. |
| 7230 | Murugesan N, et al. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005 Jan 13;48(1):171-9. |
| 7231 | Liu K, et al. Chemical Modulation of Cell Fate in Stem Cell Therapeutics and Regenerative Medicine. Cell Chem Biol. 2016 Aug 18;23(8):893-916. |
| 7232 | Cao N, et al. Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science. 2016 Jun 3;352(6290):1216-20. |
| 7233 | https://clinicaltrials.gov/ct2/show/NCT04396314?term=Sertraline&cond=Covid19&draw=2&rank=1 |
| 7234 | Cui LY, et al. Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: a randomized, double-blind trial. Chin Med J (Engl). 2013;126(18):3405-10. |
| 7235 | Zhao W, et al. 3-N-butylphthalide improves neuronal morphology after chronic cerebral ischemia. Neural Regen Res. 2014 Apr 1;9(7):719-26. |
| 7236 | Wang X, et al. Design, synthesis and biological evaluation of hydrogen sulfide releasing derivatives of 3-n-butylphthalide as potential antiplatelet and antithrombotic agents. Org Biomol Chem. 2014 Aug 21;12(31):5995-6004. |
| 7237 | Wang F, et al. Improvement of cognitive deficits in SAMP8 mice by 3-n-butylphthalide. Neurol Res. 2014 Mar;36(3):224-33. |
| 7238 | Stern L, Perry R, Ofek P, Many A, Shabat D, Satchi-Fainaro R. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug Chem. 2009;20(3):500-510. |
| 7239 | James C. Powers, et al. Propenoyl hydrazides. US7482379B2. |
| 7240 | Poreba M, et al. Counter Selection Substrate Library Strategy for Developing Specific Protease Substrates and Probes. Cell Chem Biol. 2016;23(8):1023-1035. |
| 7241 | Jung E, et al. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102. |
| 7242 | Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64. |
| 7243 | JACS 74:1485 (1952); Br J Radiol 49:769 (1976); Clin Chem 23:292 (1977) |
| 7244 | Shimozono R et al. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol. 2013 Jul, 84(1):62-70. |
| 7245 | Kiue A, et al. Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice. Br J Cancer. 1991 Aug;64(2):221-6. |
| 7246 | Powell J, et al. Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells. J Med Chem. 2018 May 10;61(9):4135-4154. |
| 7247 | Huangshu, et al. 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH and their preparation |
| 7248 | Neel Jasani, et al. Abstract 1649: Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent. Cancer Research. August 2015, Volume 75, Issue 15. |
| 7249 | William Michael Gallatin, et al. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof. WO2019046778. |
| 7250 | Ye Y, et al. Atractylenolide II induces G1 cell-cycle arrest and apoptosis in B16 melanoma cells. J Ethnopharmacol. 2011 Jun 14;136(1):279-82. |
| 7251 | Fu XQ, et al. Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II. Exp Dermatol. 2014 Nov;23(11):855-7. |
| 7252 | Eur J Pharmacol 233:119 (1993); Biochem Biophys Res Commun 199:147 (1994); 225:525 (1996) |
| 7253 | Chidambara Murthy KN, et al. Obacunone and obacunone glucoside inhibit human colon cancer (SW480) cells by the induction of apoptosis. Food Chem Toxicol. 2011 Jul;49(7):1616-25. |
| 7254 | Palomer A, et al. Modeling cyclooxygenase inhibition. Implication of active site hydration on the selectivity ofketoprofen analogues. J Med Chem. 2000 Jun 1;43(11):2280-4. |
| 7255 | Hyer ML, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018 Feb;24(2):186-193. |
| 7256 | Best SR, et al. TAK-243, a small molecule inhibitor of ubiquitin-activating enzyme (UAE), induces ER stress and apoptosis in diffuse large B-cell lymphoma (DLBCL) cells. Blood 2017 130:1533. |
| 7257 | Samir H. Barghout, et al. TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML). Blood 2017, 130:814. |
| 7258 | J Antimicrob Chemother 22 Suppl C 9 (1988); 39:829 (1997) |
| 7259 | Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. |
| 7260 | Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. |
| 7261 | J Toxicol Clin Exper 7:373 (1987); Alcohol Clin Exper Res 12:516 (1988)|Clin. Toxicol. (2010), 48(5), 401-406; N. Engl. J. Med. (2009), 360(21), 2216-23; Med. Toxicol. (1986), 1(5), 309-34 |
| 7262 | Environ Sci Technol 30:2449 (1996) |
| 7263 | Filip LACO,et al. 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis. WO2015119579A1. |
| 7264 | Eldstrom J, et al. The molecular basis of high-affinity binding of the antiarrhythmic compound Vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol. 2007 Dec;72(6):1522-34. |
| 7265 | Chiba T, et al. Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. J Pharmacol Sci. 2016 Mar;130(3):170-6. |
| 7266 | Kost GC, et al. A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-Fluoro-2-Methoxyquinoxalin-3-yl)Aminocarbonyl] Piperazine (RX-5902), Interferes With β-Catenin Function Through Y593 Phospho-p68 RNA Helicase.J Cell Biochem. 2015 Aug;116(8):1595-601. |
| 7267 | Capasso A, et al. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.Nov;18(11):1916-1925. |
| 7268 | Fed Proc 36:143 (1977); Clin Rheumatol 5:359 (1986); 13:60 (1994) |
| 7269 | Hou W, et al. MMP2-Targeting and Redox-Responsive PEGylated Chlorin e6 Nanoparticles for Cancer Near-Infrared Imaging and Photodynamic Therapy. ACS Appl Mater Interfaces. 2016 Jan 20;8(2):1447-57. |
| 7270 | Zhu L, et al. Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials. 2014 Apr;35(13):4213-22. |
| 7271 | Liu FH, et al. Enzyme-sensitive cytotoxic peptide-dendrimer conjugates enhance cell apoptosis and deep tumor penetration. Biomater Sci. 2018 Feb 27;6(3):604-613. |
| 7272 | Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305. |
| 7273 | Liang X, et al. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 Mar 15;823:27-34. |
| 7274 | Straubhaar B, et al. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf. 2006;29(1):79-90. |
| 7275 | DIETMAR TRENK, et al. Age-dependent differences in the effect of phenprocoumon on the vitamin K1-epoxide cycle in rats. Trenk D. J Pharm Pharmacol. 1980 Dec;32(12):828-32. |
| 7276 | Da-Woon Jung, et al. A Unique Small Molecule Inhibitor of Enolase Clarifies Its Role in Fundamental Biological Processes.ACS Chem. Biol., 2013, 8 (6), pp 1271–1282 |
| 7277 | Hall BJ, et al. Flumazenil-independent positive modulation of gamma-aminobutyric acid action by 6-methylflavone at human recombinant alpha1beta2gamma2L and alpha1beta2 GABAA receptors. Eur J Pharmacol. 2004 Apr 26;491(1):1-8. |
| 7278 | Babich H, et al. Theaflavin-3-gallate and theaflavin-3'-gallate, polyphenols in black tea with prooxidant properties. Basic Clin Pharmacol Toxicol. 2008 Jul;103(1):66-74. |Tet Lets 1970: 5237 |
| 7279 | Yu T, et al. Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core. ACS Med Chem Lett. 2010 Jun 7;1(5):214-8. |
| 7280 | Basso AD, et al. SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors. Cancer Chemother Pharmacol. 2011 Oct;68(4):923-33. |
| 7281 | Atherosclerosis 29:477 (1978); 31:421, 429 (1978); Drugs 33:539 (1987) |
| 7282 | Tsuboi T, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247(1):89-102. |
| 7283 | Swainston Harrison T, et al. Limaprost. Drugs. 2007;67(1):109-18; discussion 119-20. |
| 7284 | Murata K, et al. PGE1 Attenuates IL-1β-induced NGF Expression in Human Intervertebral Disc Cells. Spine (Phila Pa 1976). 2016 Jun;41(12):E710-6. |
| 7285 | Hache J, et al. The pharmacology of 1841 CERM, a new analgesic. Arzneimittelforschung. 1978;28(4):642-5. |
| 7286 | Nilsson BM. 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents. J Med Chem. 2006 Jul 13;49(14):4023-34. |
| 7287 | Kucharczyk N, et al. Metabolites of 2-(3-trifluoromethylphenyl)tetrahydro-1,4-oxazine (CERM) 1841) in rats and dogs. Xenobiotica. 1979 Nov;9(11):703-11. |
| 7288 | Drugs (2011), 71(15), 2031-2065; Eur. J. Pharmacol. (1974), 26(1), 9-14; Psychopharmacologia (1975), 43(1), 53-61 |
| 7289 | El-Hawash SA, et al. Cyanoacetic acid hydrazones of 3-(and 4-)acetylpyridine and some derived ring systems as potential antitumor and anti-HCV agents. Arch Pharm (Weinheim). 2006 Jan;339(1):14-23. |
| 7290 | Norman P. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin Ther Pat. 2013 Jan;23(1):113-7. |
| 7291 | Wong YL. et al. Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science. 2015 Jun 5;348(6239):1155-60. |
| 7292 | Spona, J. and J. Huber, Pharmacological and endocrine profiles of gestodene. Int J Fertil, 1987. 32 Suppl: p. 6-14. |
| 7293 | Pollow, K., et al., Lack of binding of gestodene to estrogen receptor in human breast cancer tissue. Eur J Cancer, 1990. 26(5): p. 608-10. |
| 7294 | Yi F, et al. Discovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1. J Virol. 2017 Jun 9;91(13). pii: e02418-16. |
| 7295 | Huang CW, et al. A novel slow-releasing hydrogen sulfide donor, FW1256, exerts anti-inflammatory effects in mouse macrophages and in vivo. Pharmacol Res. 2016 Nov;113(Pt A):533-546. |
| 7296 | Feng W, et al. Discovery of New H2S Releasing Phosphordithioates and 2,3-Dihydro-2-phenyl-2-sulfanylenebenzo[d][1,3,2]oxazaphospholes with Improved Antiproliferative Activity. J Med Chem. 2015 Aug 27;58(16):6456-80. |
| 7297 | Biochem J 162:297 (1977); J Vasc Res 40:531 (2003)| |
| 7298 | Noda S, et al. Menaquinone-4 (vitamin K2) up-regulates expression of human intestinal alkaline phosphatase in Caco-2 cells. Nutr Res. 2016 Nov;36(11):1269-1276. |
| 7299 | Kim M, et al. Vitamin K1 (phylloquinone) and K2 (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice. J Clin Biochem Nutr. 2013 Sep;53(2):108-13. |
| 7300 | Adv Pharmacol Chemother 15:289 (1978); Lancet 2:627 (1985); Arch Intern Med 105:32 (1986); Cancer Cells 2:106 (1990) |
| 7301 | Tawaraishi T, et al. Identification of a novel series of potent and selective CCR6 inhibitors as biological probes. Bioorg Med Chem Lett. 2018 Oct 1;28(18):3067-3072. |
| 7302 | Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002 Aug 12;21(35):5483-95. |
| 7303 | Creusot F, et al. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidineand 5-aza-2'-deoxycytidine. J Biol Chem. 1982 Feb 25;257(4):2041-8. |
| 7304 | Li LH,et al. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970 Nov;30(11):2760-9. |
| 7305 | Marycz K, et al. 5-Azacytidine and Resveratrol Enhance Chondrogenic Differentiation of Metabolic Syndrome-Derived Mesenchymal Stem Cells by Modulating Autophagy.Oxid Med Cell Longev. 2019 May 12;2019:1523140. |Cancer Treat Rep 71:737, 959 (1987); N Engl J Med 329:845 (1993) |
| 7306 | Xiaoxuan Tian, et al. Delineation of Platelet Activation Pathway of Scutellarein Revealed Its Intracellular Target as Protein Kinase C. Biological and Pharmaceutical Bulletin
 Vol. 39 (2016) No. 2 p. 181-191 |
| 7307 | Sung NY, et al. Scutellarein Reduces Inflammatory Responses by Inhibiting Src Kinase Activity. Korean J Physiol Pharmacol. 2015 Sep;19(5):441-9. |
| 7308 | Experientia 19:394 (1963); Anal Profiles Drug Subs 4:294 (1975) |
| 7309 | Yang HJ, et al. Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Biochem Pharmacol. 2011 Sep 1;82(5):524-34. |
| 7310 | Suman S, et al. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells.Br J Cancer. 2013 Nov 12;109(10):2587-96. |
| 7311 | Shoemaker AR, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 2006 Sep 1;66(17):8731-9. |
| 7312 | Levkoff LH, et al. Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo. Neoplasia. 2008 Aug;10(8):804-16. |
| 7313 | Rothaeusler K, et al. Assessment of cell proliferation by 5-bromodeoxyuridine (BrdU) labeling for multicolor flow cytometry. Curr Protoc Cytom. 2007 Apr;Chapter 7:Unit7.31 |
| 7314 | https://clinicaltrials.gov/ct2/show/NCT04278404?term=Bosentan&cond=covid&draw=2&rank=1 |
| 7315 | Hagner, P.R.et al.CC-122, a pleiotropic pathway modifier, mimics an IFN response and has antitumor activity in DLBCL.Blood.Aug 6;126(6):779-89. |
| 7316 | Rasco DW, et al. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin Cancer Res. 2019 Jan 1;25(1):90-98. |
| 7317 | Palacino J, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015 Jul;11(7):511-517. |
| 7318 | Cheung AK, et al. Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem. 2018 Dec 27;61(24):11021-11036. |
| 7319 | Doi T, et al. Characterization of the decomposition of compounds derived from imidazolidinyl urea in cosmetics and patch test materials. Contact Dermatitis. 2012 Nov;67(5):284-92. |
| 7320 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=QUINAPRIL&cond=covid&draw=2&rank=2 |
| 7321 | Rozier L, et al. The MRN-CtIP pathway is required for metaphase chromosome alignment. Mol Cell. 2013 Mar 28;49(6):1097-107. |
| 7322 | Lee JH, et al. Ataxia telangiectasia-mutated (ATM) kinase activity is regulated by ATP-driven conformational changes in the Mre11/Rad50/Nbs1 (MRN) complex. J Biol Chem. 2013 May 3;288(18):12840-51. |
| 7323 | Garner KM, et al. Corrected structure of Mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2009 Mar;5(3):129-30. |
| 7324 | Wang Y, et al. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ. ACS Chem Biol. 2010 Nov 19;5(11):1029-34. |
| 7325 | Wang Y, Billon C, Walker JK, Burris TP. Therapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of Autism. ACS Chem Neurosci. 2016;7(2):143-148. |
| 7326 | Jang, S.W., et al., Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol, 2009. 16(6): p. 644-56. |
| 7327 | Kim Lawson. A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia. Biomedicines. 2017 Jun; 5(2): 24. |
| 7328 | S Neil Vaishnavi , et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. |
| 7329 | Arzneim Forsch 40:693, 800, 806 (1990); 44:64 (1994) |
| 7330 | Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49(15):4606-15. |
| 7331 | Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116(1):45-53. |
| 7332 | Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel). 2016 Aug 24;8(9). pii: E77. |
| 7333 | Barber-Rotenberg JS, et al.
 Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.
 Oncotarget. 2012 Feb;3(2):172-82. |
| 7334 | Rahim S, et al.
 YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
 PLoS One. 2011 Apr 29;6(4):e19343. |
| 7335 | Erkizan HV, et al.
 A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.
 Nat Med. 2009 Jul;15(7):750-6. |
| 7336 | Acta Endocrinol. (1948), 1(3), 248-57; Am. J. Med. Sci. (1947), 214(4), 349-62; Acta Med. Scand. (1946), 125, 263-82 |
| 7337 | Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. |
| 7338 | Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597-638. |
| 7339 | Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115. |
| 7340 | Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12. |
| 7341 | Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4. |
| 7342 | Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39(3):189-197. |
| 7343 | PNAS 93:9090 (1996) |
| 7344 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=BUMETANIDE&cond=covid&draw=2&rank=1 |
| 7345 | Li Z, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015 Jul 16;523(7560):347-51. |
| 7346 | Simard J, et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol. 1986 Mar;44(3):261-70. |
| 7347 | Luthy IA, et al. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem. 1988 Nov;31(5):845-52. |
| 7348 | Crawford ED, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419-24. |
| 7349 | Marchetti B, et al. Characteristics of flutamide action on prostatic and testicular functions in the rat. J Steroid Biochem. 1988 Jun;29(6):691-8. |Methods Princ. Med. Chem. (2008), 39, 249-304; J. Urol. (1975), 114(4), 564-8; Urology (1976), 8(3), 231-3 |
| 7350 | Parasitology (1992), 105 Suppl, S49-60; J. Lab. Clin. Med. (1948), 33(1), 216-35; J. Am. Med. Assoc. (1947), 135(11), 708-12 |
| 7351 | Mueck AO, et al. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids. 2011 May;76(6):531-9. |
| 7352 | Takagi M, et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs. 2003 Nov;21(4):387-99. |
| 7353 | Garland LL, et al. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 1;12(17):5182-9. |
| 7354 | Tanaka H, et al. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res. 2003 Oct 15;63(20):6942-7. |
| 7355 | Christensen MD, et al. Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression. J Control Release. 2015 Apr 28;204:20-9. |
| 7356 | J Med Chem 26:759 (1983); PNAS 80:2767 (1983); N Engl J Med 335:721 (1996) |
| 7357 | Totzke J, et al. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017 Aug 17;24(8):1029-1039. |
| 7358 | Totzke J, et al. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017 Aug 17;24(8):1029-1039.e7. |
| 7359 | FEMS Microbiol. Rev. (2004), 28(5), 519-542; Antimicrob. Agents Chemother. (1980), 18(2), 311-16; Naturwissenschaften (1980), 67(2), 89-90| |
| 7360 | Al-Shahrani S, et al. Florfenicol induces early embryonic death in eggs collected from treated hens. BMC Vet Res. 2015 Aug 18;11(1):213. |
| 7361 | Corinna Kehrenberg, et al. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Molecular Microbiology
 Volume 57, Issue 4, pages 1064–1073, August 2005 |
| 7362 | Wang X, et al. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res. 2013 Nov 1;73(21):6516-25. |
| 7363 | Byers LA, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 1;19(1):279-90. |
| 7364 | Chenjing Zhu, et al. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153. |
| 7365 | Sorensen SM, et al. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther. 1993 Aug;266(2):684-91. |
| 7366 | Ardayfio PA, et al. The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J Pharmacol Exp Ther. 2008 Dec;327(3):891-7. |
| 7367 | Eur J Clin Pharmacol 46:271 (1994); Prostate 25:46 (1994); Cardiovasc Drug Rev 12:32 (1994) |
| 7368 | Tan L et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A, 2014 Nov 11, 111(45):E4869-77 |
| 7369 | Sanz G, et al. Gallein, a Gβγ subunit signalling inhibitor, inhibits metastatic spread of tumour cells expressing OR51E2 and exposed to its odorant ligand. BMC Res Notes. 2017 Oct 30;10(1):541. |
| 7370 | Lillie RD, et al. Hematoxylin substitutes: gallein as a biological stain. Stain Technol. 1974 Nov;49(6):339-46. |
| 7371 | Duffey MO, et al. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905). J Med Chem. 2012 Jan 12;55(1):197-208. |
| 7372 | Shi JQ, et al. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Mol Cancer Ther. 2012 Sep;11(9):2045-53. |
| 7373 | J Chem Soc 1944: 415 |
| 7374 | Mark J. Milla, et al. Antiparkinsonian Agent Piribedil Displays Antagonist Properties at Native, Rat, and Cloned, Human α2 -Adrenoceptors: Cellular and Functional Characterization. JPET, 2001, 297 (3) 876-887. |
| 7375 | Brit J Pharmacol 3:305 (1948) |
| 7376 | SCHULZE, Volker, et al. PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES. WO2014198647A2 |
| 7377 | Somm E, et al. β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. JCI Insight. 2017 Apr 20;2(8). pii: 91809. |
| 7378 | Wang X, et al. Acidified bile acids enhance tumor progression and telomerase activity of gastric cancer in micedependent on c-Myc expression. Cancer Med. 2017 Apr;6(4):788-797. |
| 7379 | Dhar N, et al. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob Agents Chemother. 2015 Feb;59(2):1308-19. |
| 7380 | https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-000320-35-CZ |
| 7381 | Toldo S, et al. The NLRP3 Inflammasome Inhibitor, Dapansutrile, Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse. J Cardiovasc Pharmacol. 2019 Apr;73(4):215-222. |
| 7382 | Biochemistry 10:3728 (1971); J Biol Chem 250:5221 (1975) |
| 7383 | Anscombe E, et al. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chem Biol. 2015 Sep 17;22(9):1159-1164. |
| 7384 | Anette Breindl, et al. Ribosome allows for multiple shots on giant goal. |
| 7385 | Piva R, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008 Mar 1;111(5):2765-75. |
| 7386 | J Am Acad Dermatol 15:494 (1986); 16:346 (1987); Int J Cosmet Sci 10:53 (1988) |
| 7387 | Verschueren KH, et al,. A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. Chem Biol. 2008 Jun;15(6):597-606. |
| 7388 | Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. |
| 7389 | Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789. |
| 7390 | Ning Zhang, et al. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018 Mar; 39(3): 1034–1042. |
| 7391 | Halle C F Moore, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32. |
| 7392 | Plant Physiol. (1977), 60(1), 109-14; Pharmacology (1976), 14(1), 52-7 |
| 7393 | 3-Epiursolic Acid, et al. Triterpenoids as novel natural inhibitors of human cathepsin L. Chem Biodivers. 2014 Sep;11(9):1354-63. |
| 7394 | Meijer L, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol. 2003 Dec;10(12):1255-66. |
| 7395 | Hsu MJ, et al. Antiherpetic potential of 6-bromoindirubin-3'-acetoxime (BIO-acetoxime) in human oral epithelial cells. Arch Virol. 2013 Jun;158(6):1287-96. |
| 7396 | Aourz N, et al. Identification of GSK-3 as a Potential Therapeutic Entry Point for Epilepsy. ACS Chem Neurosci. 2018 Nov 6. |
| 7397 | Chen X, et al. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One. 2013 May 21;8(5):e63697. |
| 7398 | You P, et al. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation. Biomed Pharmacother. 2018 Feb;98:619-625. |
| 7399 | Wang X, et al. A rapid and efficient extraction method based on industrial MCM-41-miniaturized matrix solid-phase dispersion extraction with response surface methodology for simultaneous quantification of six flavonoids in Pollen typhae by ultra-high-performance liquid chromatography. J Sep Sci. 2019 Jul;42(14):2426-2434. |
| 7400 | Li WL, et al. Inhibitory effects of Schisandrin A and Schisandrin B on CYP3A activity. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):163-9. |
| 7401 | Li WL, et al. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):187-92. |
| 7402 | Clin. Drug Invest. (2008), 28(9), 533-552; J. Pharm. Pharmacol. (1972), 24(9), 741-2; Fitoterapia (1968), 39(2), 54-9 |
| 7403 | Int Arch Allergy Appl Immunol 79:231 (1986); 82:66 (1987); J Oral Maxillofac Surg 51:243 (1993) |
| 7404 | Fujita H, et al. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol Cancer Ther. 2013 Dec;12(12):2685-96. |
| 7405 | Nakade J, et al. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 2014 Jun;9(6):775-83. |
| 7406 | Curr Ther Res 29:24 (1981); 31:638 (1982); Drugs 28:38 (1984) |
| 7407 | J Neurosci Methods 71:205 (1997) |
| 7408 | JACS 78:395 (1956) |
| 7409 | Drugs 51:621 (1996)| |
| 7410 | Petrina MAB, et al. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017 Oct;47:115-119. |
| 7411 | Lanteri CA, Trumpower BL, Tidwell RR, DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2004 Oct;48(10):3968-74. |
| 7412 | Midgley I, Fitzpatrick K, Taylor LM, Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride). Drug Metab Dispos. 2007 Jun;35(6):955-67. |
| 7413 | Sturk LM, Brock JL, Bagnell CR, Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. Acta Trop. 2004 Jul;91(2):131-43. |
| 7414 | In vitro inhibitory activity against Trypanosoma brucei rhodesiense - BioAssay Summary. |
| 7415 | Pabreza LA, et al. [3H]cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol. 1991 Jan;39(1):9-12. |
| 7416 | Grebenstein PE, et al. The effects of noncontingent and self-administered cytisine on body weight and meal patterns in male Sprague-Dawley rats. Pharmacol Biochem Behav. 2013 Sep;110:192-200. |
| 7417 | Walker N, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med. 2014 Dec 18;371(25):2353-62. |
| 7418 | Yu L, et al. Cytisine induces endoplasmic reticulum stress caused by calcium overload in HepG2 cells. Oncol Rep. 2018 Mar;39(3):1475-1484. |
| 7419 | Exp. Eye Res. (2001), 72(3), 331-339; Neurosci. Lett. (1980), 20(3), 347-50; Eur. J. Pharmacol. (1976), 36(2), 413-21 |
| 7420 | Vanover KE, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317(2):910-8. |
| 7421 | Vanover KE, et al. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008 Oct;90(4):540-4. |
| 7422 | Wang S, et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-5865. |
| 7423 | Hoffman-Luca CG, et al. Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo. Clin Cancer Res. 2015 Jun 1;21(11):2558-2568. |
| 7424 | Mol Pharmacol 29: 331 (1986) |
| 7425 | eur J Clin Pharmacol 45:113 (1993); Diabetologia 37:703 (1994)| |
| 7426 | Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476. |
| 7427 | JACS 78:5273 (1956) |
| 7428 | Konishi Y, et al. Effect of dose on the carcinogenic activity of orally administered N-bis(2-hydroxypropyl)nitrosamine in rats. Gan. 1978 Aug;69(4):573-7. |
| 7429 | Zhang J, et al. Low dose of Bisphenol A enhance the susceptibility of thyroid carcinoma stimulated by DHPN and iodine excess in F344 rats. Oncotarget. 2017 Jul 22;8(41):69874-69887. |
| 7430 | Khan F, et al. Carvacrol Induced Program Cell Death and Cell Cycle Arrest in Androgen-Independent Human Prostate Cancer Cells via Inhibition of Notch Signaling. Anticancer Agents Med Chem. 2019 Jul 31. |
| 7431 | Ding Q, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013 Jul 25;56(14):5979-83. |
| 7432 | Higgins B, et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin Cancer Res. 2014, 20(14), 3742-3752. |
| 7433 | Vet Rec 113:608 (1983); 114:60 (1984) |
| 7434 | Prichard BN, et al. Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1985 Oct;30(4):313-32. |
| 7435 | Hannaert P, et al. Beneficial effects of xipamide on pH and Ca2+ ions of cardiac cells. Arch Mal Coeur Vaiss. 1990 Jul;83(8):1271-4. |
| 7436 | https://clinicaltrials.gov/ct2/show/NCT04356690?term=Etoposide&cond=COVID-19&draw=2&rank=1 |
| 7437 | Ricci and Taira Adrenoceptor involvement in the cardiovascular responses to B-HT 920 in sinoaortic denervated rats. Gen.Pharmacol. (1999)32 29. |
| 7438 | Eur J Pharmacol. 1997 May 1;325(2-3):137-44. |
| 7439 | Kohno Y, Fukuzaki K, Kitahara K, Koja T.Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum.Eur J Pharmacol. 1997 Jan 29;319(2-3):197-205. |
| 7440 | Momiyama T, Sasa M, Takaori S.Inhibition by talipexole, a thiazolo-azepine derivative, of dopaminergic neurons in the ventral tegmental area.Life Sci. 1991;49(7):535-43. |
| 7441 | Nishikawa T, Yamada S, Tsuda A, Tanaka M, Koga I, Uchida Y.Chronic treatment with talipexole dihydrochloride on abnormal involuntary movement in humans.Clin Neuropharmacol. 1990 Jun;13(3):259-63. |
| 7442 | Robertson, G.S., et al., In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther, 1993. 264(3): p. 1344-51. |
| 7443 | Niklas Uhlenbrock, et al. Structural and chemical insights into the covalentallosteric inhibition of the protein kinase Akt. Chem Sci., 2019, 10, 3573. |
| 7444 | Niesor EJ, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010, 51(12), 3443-3454. |
| 7445 | Shinkai H, et al. J Med Chem. bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. 2000, 43(19), 3566-3572. |
| 7446 | Huang Z, et al. Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells. Am J Physiol Endocrinol Metab. 2003, 284(6), E1210-E1219. |
| 7447 | Chen SK, et al. Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor. Bioorg Med Chem Lett. 2012 May 1;22(9):3261-4. |
| 7448 | Hagel M, et al. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov. 2015 Apr;5(4):424-37. |
| 7449 | Pharm. Chem. J. (Transl. Khim.-Farm. Zh.) (2004), 38(3), 117-119; Dokl. Biochem. Biophys. (2003), 391, 201-203. |
| 7450 | Pharmacol. Res. Comm. (1969), 1(3), 303-9; Arch. Int. Pharmacodyn. Ther. (1963), 145, 378-95; J. Med. Chem. (1963), 6, 97-101 |
| 7451 | Int J Impotency Res 16:470 (2004); Expert Opin Pharmacother 5:923 (2004) |
| 7452 | Moradi H, et al. Functional thiamine deficiency in end-stage renal disease: malnutrition despite ample nutrients. Kidney Int. 2016 Aug;90(2):252-254. |
| 7453 | Wang J, et al. Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Exp Hematol Oncol. 2013 Jul 27;2:18. |
| 7454 | Wada K, et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol. 2005 Jan 10;507(1-3):145-51. Epub 2005 Jan 1. |
| 7455 | Fernandez-Varo G, et al. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol. 2003 Jun;38(6):755-61. |
| 7456 | Yatsu T, et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol. 1999 Jul 9;376(3):239-46. |
| 7457 | Nakayamada S, et al. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs. 2016 Oct;30(5):407-419. |
| 7458 | J. Voss, et al. THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects. doi 10.1136/annrheumdis-2014-eular.3823. |
| 7459 | Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23. |
| 7460 | Shibata N, et al. Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands. J Med Chem. 2018 Jan 25;61(2):543-575. |
| 7461 | Zhang W, et al. Salvianolic acid A attenuates ischemia reperfusion induced rat brain damage by protecting the blood brain barrier through MMP-9 inhibition and anti-inflammation. Chin J Nat Med. 2018 Mar;16(3):184-193. |
| 7462 | Drugs (1989), 38(5), 703-56; Chem. Commun. (1976), (6), 206-8; Antimicrob. Agents Chemother. (1976), 9(4), 595-9 |
| 7463 | Yang J, et al. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol. 2011 Feb 25;18(2):177-86 |
| 7464 | Shapiro LP, et al. Corticosteroid-induced dendrite loss and behavioral deficiencies can be blocked by activation of Abl2/Arg kinase. Mol Cell Neurosci. 2017 Oct 26;85:226-234. |
| 7465 | Gartner M, et al. Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5. Chembiochem. 2005 Jul;6(7):1173-7. |
| 7466 | Sun XD, et al. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Acta Pharmacol Sin. 2011 Dec;32(12):1543-8. |
| 7467 | Lüke J, et al. The effect of adjuvant dimethylenastron, a mitotic Kinesin Eg5 inhibitor, in experimental glaucoma filtration surgery. Curr Eye Res. 2010 Dec;35(12):1090-8. |
| 7468 | Chatterjee A, et al. Connective tissue growth factor dependent collagen gene expression induced by MAS agonist AR234960 in human cardiac fibroblasts. PLoS One. 2017 Dec 29;12(12):e0190217. |
| 7469 | https://clinicaltrials.gov/ct2/show/NCT04385771?term=Dobutamine&cond=Covid19&draw=2&rank=6; https://clinicaltrials.gov/ct2/show/NCT04389463?term=Dobutamine&cond=Covid19&draw=2&rank=1 |
| 7470 | JACS 67:2079 (1945); Chem Pharm Bull 42:2143 (1994) |
| 7471 | Phytochemistry 17: 1401 (1978); J Pharm Pharmacol 46:118 (1994); Planta Med 62:98 (1996) |
| 7472 | Tralau-Stewart CJ, et al. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther, 2011, 337(1), 145-154. |
| 7473 | Nials AT, et al. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther, 2011, 337(1), 137-144. |
| 7474 | Knight JS, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. 2015 Dec;74(12):2199-206. |
| 7475 | Ann Rev Biochem 15: 155 (1946); Helv Chim Acta 42: 1418 (1959); 45: 1244 (1962); 50: 2299 (1967) |
| 7476 | Austral J Chem 27:2385 (1974); Tetrahedron Letts 31:6977 (1990) |
| 7477 | Food Chem Toxicol 20:697 (1982); Compr Med Chem 1:7 (1990) |
| 7478 | Timmers M, et al. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor.Alzheimers Dement (N Y). 2016 Aug 24;2(3):202-212. |
| 7479 | Gonnot V, et al. Expedient synthesis of mequitazine an antihistaminic drug by palladium catalyzed allylic alkylation of sodium phenothiazinate. Chem Pharm Bull (Tokyo). 2009 Nov;57(11):1300-2. |
| 7480 | El-Nakeeb MA, et a. In vitro antibacterial activity of some antihistaminics belonging to different groups against multi-drug resistant clinical isolates. Braz J Microbiol. 2011 Jul;42(3):980-91. |
| 7481 | Martinez-Mir I, et al. Antihistaminic and anticholinergic activities of mequitazine in comparison with clemizole. J Pharm Pharmacol. 1988 Sep;40(9):655-6. |
| 7482 | Satake N, et al. Possible mechanisms of vasoinhibitory effects of mequitazine, an antiallergic agent, on the contractions of isolated rat aorta induced by K+, phenylephrine, 5-hydroxytryptamine, and Ca2+. J Cardiovasc Pharmacol. 1994 Apr;23(4):669-73. |
| 7483 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=DILTIAZEM&cond=COVID-19&draw=2&rank=3 |
| 7484 | Iwaki A, et al. Biomass conversion inhibitors furfural and 5-hydroxymethylfurfural induce formation of messenger RNP granules and attenuate translation activity in Saccharomyces cerevisiae. Appl Environ Microbiol. 2013 Mar;79(5):1661-7. |
| 7485 | Burnette BL, et al. SD0006: a potent, selective and orally available inhibitor of p38 kinase. Pharmacology. 2009;84(1):42-60. |
| 7486 | Walker JK, et al. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2634-8. |
| 7487 | Ren X, et al. A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury. FASEB J. 2017 Feb;31(2):711-718. |
| 7488 | Ligneau X, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther. 2007 Jan;320(1):365-75. |
| 7489 | Dudek M, et al. H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by LY170053 in mice. Metab Brain Dis. 2016 Oct;31(5):1023-9. |
| 7490 | Uguen M, et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H? receptor inverse agonist/antagonist compared with CRL 40476. Br J Pharmacol. 2013 Jun;169(3):632-44. |
| 7491 | Kim YM, et al. A citrus flavonoid, 6-demethoxytangeretin, suppresses production and gene expression of interleukin-6 in human mast cell-1 via anaplastic lymphoma kinase and mitogen-activated protein kinase pathways. Biol Pharm Bull. 2014;37(5):871-6. Epub 2014 Feb 5. |
| 7492 | Kawahata I, et al. Potent activity of nobiletin-rich Citrus reticulata peel extract to facilitate cAMP/PKA/ERK/CREB signaling associated with learning and memory in cultured hippocampal neurons: identification of the substances responsible for the pharmacological action. J Neural Transm (Vienna). 2013 Oct;120(10):1397-409. |
| 7493 | Hammill JT, et al. Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem. 2018 Apr 12;61(7):2694-2706. |
| 7494 | Diabetes Res Clin Pract 12:53 (1991); Yakuri To Chiryo 25 Suppl 1:S5, S9 (1997)| |
| 7495 | Christopher J. Dunn, et al. Nateglinide. OFILE Drugs 2000 Sep: 60 (3): 6. |
| 7496 | Shiling Hu, et al. Interaction of nateglinide with KATP channel in h-cells underlies its unique insulinotropic action. European Journal of Pharmacology. 442 (2002) 163-171. |
| 7497 | Jian Luo, et al. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism. 2013 Jan;62(1):90-9. |
| 7498 | Duffy NA, et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86. |
| 7499 | Fresno M, et al. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977 Jan;72(2):323-30. |
| 7500 | Kaur P, et al. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother. 2013 Jan;57(1):155-67. |
| 7501 | Piao YF, et al. Growth inhibition of human myeloid leukemia cells in vitro by harringtonine. Gan To Kagaku Ryoho. 1990 Feb;17(2):281-5. |
| 7502 | Bioorg Med Chem 16:7516 (2008) Biochim Biophys Acta1813:1465 (2011)| |
| 7503 | Lin M, et al. The protective effect of Baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med. 2014 Jan 13;14:19. |
| 7504 | Ju XN, et al. Baicalin protects against thrombin induced cell injury in SH-SY5Y cells. Int J Clin Exp Pathol. 2015 Nov 1;8(11):14021-7. |
| 7505 | Neu HC, et al. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J. 1987 Oct;6(10):958-62. |
| 7506 | Unemo M, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. |
| 7507 | Zhang Z, et al. Identification, synthesis, and safety assessment of forchlorfenuron (1-(2-chloro-4-pyridyl)-3-phenylurea) and its metabolites in kiwifruits. J Agric Food Chem. 2015 Mar 25;63(11):3059-66. |
| 7508 | Chen W, et al. Dissipation and residue of forchlorfenuron in citrus fruits. Bull Environ Contam Toxicol. 2013 Jun;90(6):756-60. |
| 7509 | Naunyn Schmeidebergs Arch Pharmacol 363:429 (2001) |
| 7510 | Wu G, et al. Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal.
 Cancer Res. 2008 Oct 15;68(20):8393-9. |
| 7511 | Shilong Zheng, et al. Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion. ACS Med Chem Lett. 2013 Feb 14; 4(2): 191–196. |
| 7512 | Yongxia Zhu, et al. Small Molecule TH-39 Potentially Targets Hec1/Nek2 Interaction and Exhibits Antitumor Efficacy in K562 Cells via G0/G1 Cell Cycle Arrest and Apoptosis Induction. Cell Physiol Biochem. 2016;40(1-2):297-308. |
| 7513 | Giorguieff MF, et al. Presynaptic effect of L-glutamic acid on the release of dopamine in rat striatal slices. Neurosci Lett. 1977 Oct;6(1):73-7. |
| 7514 | Method for separating epigoitrin and goitrin contained in DL-goitrin. CN104030999A. |
| 7515 | Mark H Norman, et al. Selective Class I Phosphoinositide 3-kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511. J Med Chem. 2012 Sep 13;55(17):7796-816. |
| 7516 | Bissinger EM, et al. Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg Med Chem. 2011 Jun 15;19(12):3717-3731. |
| 7517 | Mitul Goel, et al. Effect of Ent-norsecurinine, an Alkaloid, on Spore Germination of Some Fun. Mycobiology 30(4): 225-227 (2002). |
| 7518 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Chloroquine+&cntry=&state=&city=&dist= |
| 7519 | J Chem Soc 1933: 274 |
| 7520 | Zhang Y, et al. Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. J Immunol. 2012 Oct 15;189(8):3914-3924. |
| 7521 | Bai Z, et al. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by theautotaxin/lysophosphatidic acid axis. J Immunol. 2013 Mar 1;190(5):2036-2048. |
| 7522 | Anderson VE, et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011 Jan 15;71(2):463-72. |
| 7523 | Caldwell JJ, et al. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J Med Chem. 2011 Jan 27;54(2):580-90. |
| 7524 | Digby GJ, et al. Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode. ACS Chem Neurosci. 2012 Dec 19;3(12):1025-36. |
| 7525 | Lebois EP, et al. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci. 2010;1(2):104-121. |
| 7526 | Digby GJ, et al. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. J Neurosci. 2012 Jun 20;32(25):8532-44. |
| 7527 | J Biol Chem 80: 15 (1928) |
| 7528 | Cao JP, et al. Triacetonamine formation in a bio-oil from fast pyrolysis of sewage sludge using acetone as the absorption solvent. Bioresour Technol. 2010 Jun;101(11):4242-5. |
| 7529 | Reyna DE, et al. Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. Cancer Cell. 2017 Oct 9;32(4):490-505.e10. |
| 7530 | Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901. |
| 7531 | Biancur DE, et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutaminemetabolism. Nat Commun. 2017 Jul 3;8:15965. |
| 7532 | Zhou WJ, et al. Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism. Cell Commun Signal. 2019 Aug 20;17(1):99. |
| 7533 | Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-1450. |
| 7534 | Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.Ann Hepatol. 2012 Jan-Feb;11(1):15-31. |
| 7535 | Yen-Liang Chen, et al. Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. J Virol. 2014 Feb;88(3):1740-7. |
| 7536 | Tsiang M, et al. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. |
| 7537 | Wei ZL, et al. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J Org Chem. 2003 Nov 14;68(23):9116-8. |
| 7538 | Mosti MP, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-δ agonist GW 501516 on bone and muscle in ovariectomized rats. Endocrinology. 2014 Jun;155(6):2178-89. |
| 7539 | Yang X, et al. GW 501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLoS One. 2011;6(9):e25271. |
| 7540 | Chen W, et al. A metabolomic study of the PPARδ agonist GW 501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015 May 6;5:9884. |
| 7541 | Ji Y, et al. PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis. Front Pharmacol. 2018 Jun 28;9:648. |
| 7542 | Sestanj K, et al. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. J Med Chem. 1984 Mar;27(3):255-6. |
| 7543 | Simard-Duquesne N, et al. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Metabolism. 1985 Oct;34(10):885-92. |
| 7544 | Srivastava S, et al. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ Res. 2009 Oct 9;105(8):793-802. |
| 7545 | Leung YM, et al. Inhibition of voltage-gated K+ channels and Ca2+ channels by diphenidol. Pharmacol Rep. 2012;64(3):739-44. |
| 7546 | Leung YM, et al. Diphenidol inhibited sodium currents and produced spinal anesthesia. Neuropharmacology. 2010 Jun;58(7):1147-52. |
| 7547 | Andersson M, et al. Muscarinic receptor subtypes involved in urothelium-derived relaxatory effects in the inflamed rat urinary bladder. Auton Neurosci. 2012 Sep 25;170(1-2):5-11. |
| 7548 | Qian LH, et al. Inhibition of regrowth of prostatic glandular cells by epristeride. Acta Pharmacol Sin. 2001 Sep;22(9):847-50. |
| 7549 | https://clinicaltrials.gov/ct2/show/NCT02735707?term=Tazobactam&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04394182?term=Tazobactam&cond=COVID-19&draw=2&rank=3 |
| 7550 | J Cancer Res 50:5084 (1990) |
| 7551 | Cui S, et al. [Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study]. Zhonghua Yi Xue Za Zhi. 2002 Apr 25;82(8):538-40. |
| 7552 | https://clinicaltrials.gov/ct2/show/NCT04353180?term=ISOTRETINON&cond=COVID-19&draw=2&rank=1 |
| 7553 | Torrance CJ, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000 Sep;6(9):1024-8. |
| 7554 | Nunes M, et al. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther. 2004 Jan;3(1):21-7. |
| 7555 | Yakugaku Zasshi 115: 773 (1995) |
| 7556 | Khakh BS, et al. Allosteric control of gating and kinetics at P2X(4) receptor channels. J Neurosci. 1999 Sep 1;19(17):7289-99. |
| 7557 | Priel A, et al. Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol. 2004 Mar;123(3):281-93. |
| 7558 | Wagstaff KM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012 May 1;443(3):851-6. |
| 7559 | Raza S, et al. Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes with Viral Replication. Microorganisms. 2020 Mar 13;8(3). pii: E409. |
| 7560 | Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. |Science 221:823 (1983); J Vet Pharmacol Ther 7:1 (1984) |
| 7561 | Yu B, et al. Protective effects of tenuigenin on Staphylococcus aureus-induced pneumonia in mice. Microb Pathog. 2017 Sep;110:385-389. |
| 7562 | Bhalodi AA, et al. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model. Antimicrob Agents Chemother. 2012 Dec;56(12):6160-5. |
| 7563 | So W, et al. Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter. Antimicrob Agents Chemother. 2014 Nov;58(11):6931-3. |
| 7564 | Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37. |
| 7565 | Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201. |
| 7566 | Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. |
| 7567 | Williams DR, et al. An apoptosis-inducing small molecule that binds to heat shock protein 70. Angew Chem Int Ed Engl. 2008;47(39):7466-9. |
| 7568 | Cho HJ, et al. Probing the effect of an inhibitor of an ATPase domain of Hsc70 on clathrin-mediated endocytosis. Mol Biosyst. 2015 Oct;11(10):2763-9. |
| 7569 | Ko SK, et al. A small molecule inhibitor of ATPase activity of HSP70 induces apoptosis and has antitumor activities. Chem Biol. 2015 Mar 19;22(3):391-403. |
| 7570 | Zhao H, et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes. 2007 May;56(5):1210-8. |
| 7571 | Chai L, et al. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int J Oncol. 2011 Mar;38(3):701-11. |
| 7572 | Shen W, et al. Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons. J Neurochem. 2014 Jun;129(5):884-94 |
| 7573 | Natoli TA, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. 2010 Jul;16(7):788-92. |
| 7574 | Paizs M, et al. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler. 2011 Sep;12(5):340-4. |
| 7575 | Denes L, et al. Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia. Brain Res Bull. 2006 Jul 31;70(3):260-2. Epub 2006 Mar 31. |
| 7576 | Nelson EA, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15;112(13):5095-102. |
| 7577 | Zhu Y, et al. Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep. 2016 Feb 2;6:20253. |Ann Pharm Fr 21:287 (1963) |
| 7578 | Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrobial Agents and Chemotherapy (2012), 56(7), 3498-3507. |
| 7579 | Nettles RE, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012 Oct 1;206(7):1002-11. |
| 7580 | Kato N, et al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem. 2011 Dec 1;19(23):7221-7. |
| 7581 | Ervinna N, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013 Mar;154(3):1260-70. |
| 7582 | Yano W, et al. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice. J Diabetes Investig. 2017 Mar;8(2):155-160. |
| 7583 | Yoon SC, et al. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem. Patient Prefer Adherence. 2017 Jul 24;11:1265-1271. |
| 7584 | Garnock-Jones KP, et al. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015 Mar;75(4):419-25. |
| 7585 | Mátyás C, et al. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol. 2015 Oct 31;14:145. |
| 7586 | Reinke Y, et al. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. Format: AbstractSend to Eur J Pharmaco |
| 7587 | Cosyns SM, et al. Influence of cinaciguat on gastrointestinal motility in apo-sGC mice. Neurogastroenterol Motil. 2014 Nov;26(11):1573-85. |
| 7588 | WO 2013014448 A1 |
| 7589 | Coll Czech Chem Comm 31: 3373 (1966) |
| 7590 | Br Vet J 133:211 (1977); J Parasitol 65:555 (1979); 68:603 (1982) |
| 7591 | J. Pharm. Pharmacol. (1998), 50(11), 1299-1305; Compt. Rend. (1951), 232, 2232-3; J. Physiol. (1950), 42, 877-89 |
| 7592 | Martinez Botella G, et al. Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one: A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor. J Med Chem. 2017 Sep 28;60(18):7810-7819. |
| 7593 | Giblin GM, et al. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem. 2007 May 31;50(11):2597-600. |
| 7594 | Szczepankiewicz BG, et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. |
| 7595 | Wang JW, et al. Gastrodin protects retinal ganglion cells through inhibiting microglial-mediated neuroinflammation in an acute ocular hypertension model. Int J Ophthalmol. 2017 Oct 18;10(10):1483-1489. |
| 7596 | Debenham JS, et al. Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia. J Med Chem. 2016 Dec 22;59(24):11039-11049. |
| 7597 | Eur. J. Pharmacol. (2006), 535(1-3), 234-242; J. Pharm. Pharmacol. (1970), 22(8), 637-8; Psychopharmacologia (1967), 11(1), 65-78 |
| 7598 | Nature 290:201 (1981); Atherosclerosis 112:187 (1995); J Am Coll Nutrition 18:426 (1999) |
| 7599 | Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88. |
| 7600 | Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308. |
| 7601 | Hofer M, et al. Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ-irradiated mice. Radiat Environ Biophys. 2014 Mar;53(1):211-215. |
| 7602 | Abedi H, et al. Mitochondrial and caspase pathways are involved in the induction of apoptosis by IB-MECA in ovarian cancer cell lines. Tumour Biol. 2014 Nov;35(11):11027-11039. |
| 7603 | Shin Y, et al. Activation of Phosphoinositide Breakdown and Elevation of Intracellular Calcium in a Rat RBL-2H3 Mast Cell Line by Adenosine Analogs: Involvement of A(3)-Adenosine Receptors? Drug Dev Res. 1996 Sep 1;39(1):36-46. |
| 7604 | Chandan Sarkar, et al. Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. Front Pharmacol. 2020; 11: 572870. |
| 7605 | Yang X, et al.Exosome-encapsulated antibiotic against intracellular infections of methicillin-resistant Staphylococcus aureus. Int J Nanomedicine. 2018 Nov 29;13:8095-8104. |
| 7606 | Pemberton N, et al. Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors. J Med Chem. 2018 Jun 28;61(12):5435-5441. |
| 7607 | Helal CJ, et al. Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor. J Med Chem. 2017 Jul 13;60(13):5673-5698. |
| 7608 | Guo W, et al. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res. 2008 Sep 15;68(18):7403-8. |
| 7609 | Guo W, et al. Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Mol Cancer Ther. 2009 Feb;8(2):441-8. |
| 7610 | TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloridechannel conductance in airway and intestinal epithelial cells. J Biol Chem. 2011 Jan 21;286(3):2365-74. |
| 7611 | De La Fuente R, et al. Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloridechannel. Mol Pharmacol. 2008 Mar;73(3):758-68. |
| 7612 | Pin-Yi Liu, et al. TMEM16A Inhibition Preserves Blood-Brain Barrier Integrity After Ischemic Stroke.Front Cell Neurosci. 2019 Aug 6;13:360. |
| 7613 | Kawai J, et al. Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with In Vivo Anti-Tumor Activity. J Med Chem. 2019 Oct 22. |
| 7614 | Liu R, et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor Elbasvir. Antimicrob Agents Chemother. 2015 Nov;59(11):6922-6929. |
| 7615 | Lahser FC, et al. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. Antimicrob Agents Chemother. 2016 A |
| 7616 | Motawaj M, Arrang JM.
 Ciproxifan, a histamine H3-receptorantagonist / inverse agonist, modulates methamphetamine-induced sensitization in mice.
 Eur J Neurosci. 2011 Apr;33(7):1197-204. doi: 10.1111/j.1460-9568.2011.07618.x. |
| 7617 | Bardgett ME, Davis NN, Schultheis PJ, Griffith MS. Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol Learn Mem. 2011 Jan;95(1):64-72. |
| 7618 | Bardgett ME, Points M, Kleier J, Blankenship M, Griffith MS. The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats. Neuropharmacology. 2010 Nov;59(6):492-502. |
| 7619 | Day M, et al . Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem Pharmacol. 2007 Apr 15;73(8):1123-34. |
| 7620 | Pillot C, Héron A, Schwartz JC, Arrang JM. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur J Neurosci. 2003 Jan;17(2):307-14. |
| 7621 | Ligneau X, et, al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther. 1998 Nov;287(2):658-66. |
| 7622 | Pharmazie 20:441 (1965); J Org Chem 40:1567 (1975); Food Chem Toxicol 26:297 (1988); Cancer Res 35:3493 (1993); Bioxhim Biophys Acta 1315:15 (1996) |
| 7623 | Hobson AD, et al. Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based DrugDesign. J Med Chem. 2018 Dec 27;61(24):11074-11100. |
| 7624 | Stein, D.S., et al., A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS, 1996. 10(5): p. 485-92. |
| 7625 | Liu, F., et al., Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol, 2005. 354(4): p. 789-800. |
| 7626 | Patel N, et al. Curr Drug Targets. 2018;19(16):1958-1967. doi: 10.2174/1389450119666180406113428. |
| 7627 | Antimicrob Agents Chemother 2009, 53:1840 (2009) |
| 7628 | Johannes JW, et al. Structure-Based Design of Selective Noncovalent CDK12 Inhibitors. ChemMedChem. 2018 Feb 6;13(3):231-235. |
| 7629 | https://clinicaltrials.gov/ct2/show/NCT04354805?term=CHLORPROMAZINE&cond=Covid19&draw=2&rank=2 |
| 7630 | Buckle DR, et al. Relaxant effects of the potassium channel activators BRL 38227 and pinacidil on guinea-pig and human airway smooth muscle, and blockade of their effects by glibenclamide and BRL 31660. Pulm Pharmacol. 1993 Mar;6(1):77-86. |
| 7631 | Bareggi SR, et al. Pharmacodynamics and pharmacokinetics of pinacidil in normotensive volunteers after repeated doses of a new slow-release tablet formulation. Arzneimittelforschung. 1999 Jan;49(1):21-5. |
| 7632 | Gollasch M, et al. Pinacidil relaxes porcine and human coronary arteries by activating ATP-dependent potassium channels in smooth muscle cells. J Pharmacol Exp Ther. 1995 Nov;275(2):681-92. |
| 7633 | Sun L, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity towardparticular receptor tyrosine kinases. J Med Chem. 1998 Jul 2;41(14):2588-603. |
| 7634 | J Am Vet Med Assoc 194:45 (1989); 202: 71 (1993) |
| 7635 | Methylatropine. |
| 7636 | Nurminen ML, et al. Central inhibition of nitric oxide synthesis increases blood pressure and heart rate in anesthetized rats. Methods Find Exp Clin Pharmacol. 1997 Jan-Feb;19(1):35-41. |
| 7637 | Kim K, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol, 2010, 149(4), 537-549. |
| 7638 | Yoon J, et al. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res, 2011, 71(2), 445-453. |
| 7639 | Park SJ, et al. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci. 2013 Dec;346(6):494-8. |
| 7640 | Keith JM, et al. Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. ACS Med Chem Lett. 2015 Nov 2;6(12):1204-8. |
| 7641 | Wien. Tieraerztl. Monatsschr. (1966), 53(12), 795-802; Am. J. Vet. Res. (1966), 27(121), 1755-8; J. Trop. Med. Hyg. (1980), 83(2), 71-4 |
| 7642 | John K. Eaton, et al. Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors. Biorxiv. 2018. |
| 7643 | Weïwer M, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6. |
| 7644 | Wang DD, et al. CT-707, a Novel FAK Inhibitor, Synergizes with XL184 to Suppress Hepatocellular Carcinoma by Blocking XL184-Induced FAK Activation. Mol Cancer Ther. 2016 Dec;15(12):2916-2925. |
| 7645 | Bull Chem Soc Jpn 45:2616 (1972) |
| 7646 | Acta Derm Venereol Suppl (Stockh) 183:1 [1994] |
| 7647 | Science 310:670 (2005); Proc Natl Acad Sci 104:2372 (2007); Nature Chem Biol 7:7172 (2011) |
| 7648 | Barradell LB, et al. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1992 Nov;44(5):800-34. |
| 7649 | Hu T, et al. Probing the interaction of cefodizime with human serum albumin using multi-spectroscopic and molecular docking techniques. J Pharm Biomed Anal. 2015 Mar 25;107:325-32. |
| 7650 | Apoptosis (1997), 2(3), 257-264; Biochim. Biophys. Acta (1966), 119(1), 120-9; J. Am. Chem. Soc. (1947), 69(2), 474 |
| 7651 | J Dis Child 94:80 (1957); Public Health 9:114 (2001); Rev Panam Salud Publica 9:114 (2001) |
| 7652 | Lapierre JM, et al. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J Med Chem. 2016 Jul 14;59(13):6455-69. |
| 7653 | Devki Nandan, et al. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. PLoS One. 2018 Nov 6;13(11):e0206920. |
| 7654 | Biochem J 27:986 (1933); Molecules 15:7840 (2010) |
| 7655 | Ma Z, et al. Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509. |
| 7656 | Yu TX, et al. Structure-activity relationship of tubeimosides in anti-inflammatory, antitumor, and antitumor-promoting effects. Acta Pharmacol Sin. 2001 May;22(5):463-8. |
| 7657 | Syvälahti EK, et al. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol. 1988 Feb;62(2):90-4. |
| 7658 | J Biol Chem 213:433 (1955); J Med Chem 38:923 (1995); PLoS ONE 7: e34138 (2012) |
| 7659 | Rebecca Newton, et al. Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET V804M Kinase. ACS Med Chem Lett. 2020 Feb 28;11(4):497-505. |
| 7660 | Ismail IH, et al. A small molecule inhibitor of polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks. J Biol Chem. 2013 Sep 13;288(37):26944-54. |
| 7661 | Can Res 61:8492 (2001); J Clin Oncol 23:3923 (2005) |
| 7662 | Helv Chim Acta 11:789 (1928) |
| 7663 | Valacyclovir. New indication: for genital herpes, simpler administration. Can Fam Physician. 1999 Jul;45:1698-700, 1703-5. |
| 7664 | Lycke J, et al. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother. 2003 Aug;47(8):2438-41. |
| 7665 | Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murineimmunosuppression model. Antimicrob Agents Chemother. 1995 May;39(5):1114-9. |
| 7666 | Dhaliwal DK, Romanowski EG, Yates KA, Valacyclovir inhibits recovery of ocular HSV-1 after experimental reactivation by excimer laser keratectomy. Cornea. 1999 Nov;18(6):693-9. |
| 7667 | Guo A, Hu P, Balimane PV, Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.J Pharmacol Exp Ther. 1999 Apr;289(1):448-54. |
| 7668 | Huber RE, et al. Strong inhibitory effect of furanoses and sugar lactones on beta-galactosidase Escherichia coli. Biochemistry. 1987 Mar 24;26(6):1526-31. |
| 7669 | Cui F, et al. Toxicity of three strobilurins (kresoxim-methyl, pyraclostrobin, and trifloxystrobin) on Daphnia magna. Environ Toxicol Chem. 2017 Jan;36(1):182-189. |
| 7670 | Gururaja TL, et al. A class of small molecules that inhibit TNFalpha-induced survival and death pathways viaprevention of interactions between TNFalphaRI, TRADD, and RIP1. Chem Biol. 2007 Oct;14(10):1105-18. |
| 7671 | King MD, et al. TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebralhemorrhage in mice. Neurosci Lett. 2013 May 10;542:92-6. |
| 7672 | Yamashita S, et al. 
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
 Neoplasia. 2012 Jan;14(1):74-83. |
| 7673 | Yang Z, et al. 
ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.
 Nat Med. 2007 Mar;13(3):348-53. |
| 7674 | Lee SO, et al. 
New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs non-stem/progenitor cells.
 J Mol Cell Biol. 2012 Jul 24. |
| 7675 | Ma W, et al. Targeting androgen receptor with ASC-J9 attenuates cardiac injury and dysfunction in experimental autoimmune myocarditis by reducing M1-like macrophage. Biochem Biophys Res Commun. 2017 Apr 15;485(4):746-752. doi: 10.1016/j.bbrc.2017.02.123. Epub 2017 Feb 27. |
| 7676 | J Chem Soc 1956:632; Pharmacology 71:174 (2004); Mol Med Reports 2:509 (2009)| |
| 7677 | Arya A, et al. Bioflavonoid hesperetin overcome bicalutamide induced toxicity by co-delivery in novel SNEDDS formulations: Optimization, in vivo evaluation and uptake mechanism. Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:954-964 |
| 7678 | Liu D, et al. Inhibitory Effect of Hesperetin and Naringenin on Human UDP-Glucuronosyltransferase Enzymes: Implications for Herb-Drug Interactions. Biol Pharm Bull. 2016;39(12):2052-2059. |
| 7679 | Oo A, et al. In silico study on anti-Chikungunya virus activity of hesperetin. PeerJ. 2016 Oct 26;4:e2602. eCollection 2016. |
| 7680 | Shagirtha K, et al. Neuroprotective efficacy of hesperetin against cadmium induced oxidative stress in the brain of rats. Toxicol Ind Health. 2016 Nov 1. pii: 0748233716665301 |
| 7681 | Bai X, et al. The protective effect of the natural compound hesperetin against fulminant hepatitis in vivo and in vitro. Br J Pharmacol. 2017 Jan;174(1):41-56 |
| 7682 | Li Q, et al. Hesperetin Induces Apoptosis in Human Glioblastoma Cells via p38 MAPK Activation. Nutr Cancer. 2019 Jul 11:1-8. |
| 7683 | Brenton John SHORT, et al. Compositions and methods for obtaining enriched mesenchymal stem cell cultures. US20160032248A1. |
| 7684 | J Clin Pharmacol 3:167 (1963); Br Med J 2:288 (1964); J Occupational Med 8:658 (1966) |
| 7685 | Guerreiro PS, et al. The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel. Chem Biol Drug Des. 2017 Oct;90(4):561-571. |
| 7686 | Cesaratto L, et al. Specific inhibition of the redox activity of ape1/ref-1 by e3330 blocks tnf-α-induced activation of IL-8 production in liver cancer cell lines. PLoS One. 2013 Aug 15;8(8):e70909. |
| 7687 | Hiramoto M, et al. Nuclear targeted suppression of NF-kappa B activity by the novel quinone derivative E3330. J Immunol. 1998 Jan 15;160(2):810-9. |
| 7688 | Zou GM, et al. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther. 2008 Jul;7(7):2012-21. |
| 7689 | Ber 70:1253 (1937); Ann Appl Biol 57:501 (1966) |
| 7690 | El-Gendy N, et al. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int J Pharm. 2010 May 31;391(1-2):305-12. |
| 7691 | Dakota B Ward, et al. Radiocontrast Agent Diatrizoic Acid Induces Mitophagy and Oxidative Stress via Calcium Dysregulation. Int J Mol Sci. 2019 Aug 21;20(17):4074. |
| 7692 | Johnson DS, et al. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96. |
| 7693 | Ahn K, et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther. 2011 Jul;338(1):114-24. |
| 7694 | Buntyn RW, et al. Inhibition of Endocannabinoid-Metabolizing Enzymes in Peripheral Tissues Following Developmental Chlorpyrifos Exposure in Rats. Int J Toxicol. 2017 Jan 1:1091581817725272. |
| 7695 | John L. Nitiss, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. |
| 7696 | Hee-KyungRhee,et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8. |
| 7697 | P D Foglesong, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5. |
| 7698 | Nesstor Pilco-Ferreto, et al. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016 Aug;49(2):753-62. |
| 7699 | Regine Lüpertz, et al. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010 May 27;271(3):115-21. |
| 7700 | Penelope D Ottewell, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. |
| 7701 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Terazosin&cond=Covid19&draw=2&rank=1 |
| 7702 | Patterson J, et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol. 2008 May;61(6):923-32. |
| 7703 | Scaltriti M, et al. Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Mol Cancer Ther. 2011 May;10(5):817-24. |
| 7704 | Sydor JR, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17408-13. Epub 2006 Nov 7. |
| 7705 | Biochem J 77: 315 (1960) |
| 7706 | Burshtein G, Friedman M, Greenberg S, Hoffman A. Transepithelial Transport of a Natural Cholinesterase Inhibitor, Huperzine A, along the Gastrointestinal Tract: the Role of Ionization on Absorption Mechanism. Planta Med. 2013 Jan 23. |
| 7707 | Ruan Q, Liu F, Gao Z, et al. The anti-inflamm-aging and hepatoprotective effects of huperzine A in d-galactose-treated rats. Mech Ageing Dev. 2013 Jan 8. pii: S0047-6374(12)00182-0. |
| 7708 | Zhang HY. New insights into huperzine A for the treatment of Alzheimer's disease. Acta Pharmacol Sin. 2012 Sep;33(9):1170-5. |
| 7709 | Wang J, Zhang HY, Tang XC. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res. 2010 Mar;88(4):807-15. doi: 10.1002/jnr.22237. |
| 7710 | Park P, Schachter S, Yaksh T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. Neurosci Lett. 2010 Feb 5;470(1):6-9. doi: 10.1016/j.neulet.2009.12.033. |
| 7711 | https://clinicaltrials.gov/ct2/show/NCT04519125?term=Emtricitabine&cond=covid&draw=2&rank=3 |
| 7712 | Vinogradova M, et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol. 2016 Jul;12(7):531-8. |
| 7713 | Benjamin R. Leadem. NOVEL HISTONE DEMETHYLASE INHIBITORS SYNERGISTICALLY |
| 7714 | Drugs 11:423 (1976); J Antimicrob Chemother 10 Suppl A:1:(1982)| |
| 7715 | Nord CE, et al. Tinidazole--microbiology, pharmacology and efficacy in anaerobic infections. Infection. 1983;11(1):54-60. |
| 7716 | enteric-coated TRPM8 agonist D-3263 hydrochloride |
| 7717 | Ning X, et al. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase. Eur J Med Chem. 2017 Sep 29;138:343-352. |
| 7718 | Phytochemistry 11: 2122 (1972); 62, 203 (2003); Mol Nutr Food Res 54:967 (2010) |
| 7719 | J Chem Soc 1949: 663 |
| 7720 | Korotchkina L, et al. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.Leukemia. 2020 Jan 2. |
| 7721 | Chefetz I, et al. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. Cell Rep. 2019 Mar 12;26(11):3061-3075.e6. |
| 7722 | Yoon YJ, et al. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J Biol Chem. 2011 Jan 21;286(3):1737-47 |
| 7723 | Samarasinghe B, et al. Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux. Biochem Pharmacol. 2014 Feb 1;87(3):445-55 |
| 7724 | APMIS (2000), 108(12), 793-804; Ann. Intern. Med. (1995), 122(10), 778-88; Eur. J. Cancer (1992), 28A(6-7), 1182-9 |
| 7725 | Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71. |
| 7726 | Kumagami, T., et al., Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther, 2014. 30(4): p. 340-5. |
| 7727 | Inoue, K., A. Tanaka, and G. Tomita, Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol, 2013. 7: p. 1411-6. |
| 7728 | Monti JM, et al. Effects of the 5-HT6 receptor antagonists SB-399885 and RO-4368554 and of the 5-HT(2A) receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light-dark cycle. Behav Brain Res. 2011 Jan 1;216(1):381-8. |
| 7729 | Steroids 11:133 (1968); 12:517, 689 (1968); N Engl J Med 331:347 (1994)| |
| 7730 | S A Beck, et al. Effect of megestrol acetate on weight loss induced by tumour necrosis factor alpha and a cachexia-inducing tumour (MAC16) in NMRI mice. Br J Cancer. 1990 Sep;62(3):420-4. |
| 7731 | L Panasci, et al. Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem Pharmacol. 1996 Oct 11;52(7):1097-102. |
| 7732 | J Geller, et al. Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue. Prostate. 1982;3(1):11-5. |
| 7733 | J H von Roenn, et al. Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1988 Nov 15;109(10):840-1. |
| 7734 | Vincenzo Musolino, et al. Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):555-566. |
| 7735 | Xie Q, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology. 2002 Sep;36(3):592-601. |
| 7736 | Keene CD, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. |
| 7737 | Lejia Xu, et al. CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2. Mol Ther Oncolytics. 2019 Dec 27;16:100-110. |
| 7738 | Kun Zhang, et al. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of ZD1839 on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo. Thorac Cancer. 2020 Jun;11(6):1566-1577. |
| 7739 | Sadhu C, et al. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol. 2003 Mar 1;170(5):2647-54. |
| 7740 | Zheng L, et al. Inactivation of PI3Kδ induces vascular injury and promotes aneurysm development by upregulating the AP-1/MMP-12 pathway in macrophages. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):368-77. |
| 7741 | El-Hashim AZ, et al. Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3Kδ/Akt and NFκB induction in a murine asthma model. Sci Rep. 2017 Aug 30;7(1):9919. |
| 7742 | Lindgren AE, et al. PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3. ACS Chem Biol. 2013 Aug 16;8(8):1698-703. |
| 7743 | Ann NY Acad Sci 235:364 (1974); J Antimicrob Chemother 11:467 (1983); 48:209 (2001) |
| 7744 | Shirude PS et al. Lead optimization of 1,4-azaindoles as antimycobacterial agents. J Med Chem. 2014 Jul 10;57(13):5728-37. |
| 7745 | J Pharmacol Exper Ther 89:205 (1947); Int J Oral Surg 11:304 (1982); Human Exper Toxicol 13:658 (1994) |
| 7746 | Benjamin Richard BELLENIE, et al. Benzimidazolone derived inhibitors of bcl6. WO2018215801A1. |
| 7747 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=TERBUTALINE+&cntry=&state=&city=&dist=&Search=Search |
| 7748 | Sigel E, et al. The antiepileptic drug AWD 131-138 stimulates different recombinant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site. Neurosci Lett. 1998 Apr 3;245(2):85-8. |
| 7749 | Yasar S, et al. Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys. Eur J Pharmacol. 2003 Apr 4;465(3):257-65. |
| 7750 | Loscher W, et al. Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia. 2004 Oct;45(10):1228-39. |
| 7751 | https://clinicaltrials.gov/ct2/show/NCT04488081?term=CELECOXIB&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04757792?term=CELECOXIB&cond=COVID-19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200907048644N1 |
| 7752 | Macia E, et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006 Jun;10(6):839-50. |
| 7753 | Mues MB, et al. Dynasore disrupts trafficking of herpes simplex virus proteins. J Virol. 2015 Jul;89(13):6673-84. |
| 7754 | Gao D, et al. Dynasore protects mitochondria and improves cardiac lusitropy in Langendorff perfused mouse heart. PLoS One. 2013 Apr 15;8(4):e60967. |
| 7755 | Li G, et al. Dynasore Improves Motor Function Recovery via Inhibition of Neuronal Apoptosis and Astrocytic Proliferation after Spinal Cord Injury in Rats. Mol Neurobiol. 2016 Nov 7. |
| 7756 | He X, et al. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat Chem Biol. 2017 Nov;13(11):1164-1171. |
| 7757 | Guntuku L, et al. IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo. Oncogene. 2018 Aug 30. |
| 7758 | Med Exp 11:191 (1964); Anal Profiles Drug Subs 9:87 !980); J Clin Pharm Ther 20:31 (1995) |
| 7759 | J Pharmacol Exper Ther 84:358 (1945); 93:26 (1948) |
| 7760 | Dieterle A, et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer. 2009 Aug 15;125(4):932-41. |
| 7761 | Gürsel DB, et al. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma. Neuro Oncol. 2011 Jun;13(6):610-21 |
| 7762 | Kucera LS, et al. Activity of triciribine and triciribine-5'-monophosphate against human immunodeficiency virus types 1 and 2. AIDS Res Hum Retroviruses. 1993 Apr;9(4):307-14. |
| 7763 | Abdalla M, et al. The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. Br J Pharmacol. 2015 Aug;172(16):4173-88. |
| 7764 | Nare B, et al. Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy. Antimicrob Agents Chemother. 2002 Feb;46(2):300-7. |
| 7765 | Wang K, et al. Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway. Biochem Pharmacol. 2018 Sep;155:494-509. |
| 7766 | Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. |
| 7767 | Lu Z, et al. S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway. Curr Cancer Drug Targets. 2016;16(5):455-65. |
| 7768 | Horiuchi H, et al. S-equol nantioselectively activates cAMP-protein kinase A signaling and reduces alloxan-induced cell death in INS-1 pancreatic β-cells. J Nutr Sci Vitaminol (Tokyo). 2014;60(4):291-6. |
| 7769 | Aho ER, et al. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Cell Rep. 2019 Mar 12;26(11):2916-2928.e13. |
| 7770 | J Chem Soc 1977:706; Invest New Drugs 27:517 (2009) |
| 7771 | Perflubron, From Wikipedia, the free encyclopedia |
| 7772 | Perflubron |
| 7773 | Chen, X., Y. Zheng, and Y. Shen, Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem, 2006. 13(1): p. 109-16. |
| 7774 | Ikenoue, T., et al., Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull, 1997. 20(4): p. 354-9. |
| 7775 | Moritoh, Y., K. Takeuchi, and M. Hazama, Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab, 2010. 12(3): p. 224-33. |
| 7776 | Toxicol Appl Pharmacol 18:185 (1971); Clin Toxicol 6:439 (1973) |
| 7777 | JACS 63:263 (1941); Science 133:1923 (1961) |
| 7778 | Davis MI, et al. Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models. J Biol Chem. 2016 Nov 18;291(47):24628-24640. |
| 7779 | Hashimoto M, et al. Inhibition of ubiquitin-specific protease 2 causes accumulation of reactive oxygen species, mitochondria dysfunction, and intracellular ATP decrement in C2C12 myoblasts. Physiol Rep. 2019 Jul;7(14):e14193. |
| 7780 | Wang T, et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem. 2003 Sep 25;46(20):4236-9. |
| 7781 | Ho HT, et al. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol. 2006 Apr;80(8):4017-25. |
| 7782 | Guo Q, et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol. 2003 Oct;77(19):10528-36 |
| 7783 | Kalk P, et al. The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol. 2007 Aug;151(7):1025-32. |
| 7784 | Life Sci 5:2279 (1966); Anal Profiles Drug Subst Excip 24:277 (1996) |
| 7785 | Sayegh J, et al. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29;288(13):9408-17. |
| 7786 | https://clinicaltrials.gov/ct2/show/NCT04834752?term=OMEPRAZOLE&cond=covid&draw=2&rank=1 |
| 7787 | https://clinicaltrials.gov/ct2/show/NCT04578236?term=Captopril&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04355429?term=Captopril&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04345406?term=Captopril&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04467931?term=Captopril&cond=COVID-19&draw=2&rank=5 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001700-42-FR |
| 7788 | Liu J, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. |
| 7789 | Tammela T, et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 May 18;545(7654):355-359. |
| 7790 | Ber 42: 3194 (1909) |
| 7791 | Caroline Joy, et al. 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, |
| 7792 | Ma C, et al. Genipin stimulates glucose transport in C2C12 myotubes via IRS-1 and calcium- dependent mechanism. J Endocrinol. 2012 Dec 20. |
| 7793 | Kim BC, et al. Genipin-induced apoptosis in hepatoma cells is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of mitochondrial pathway. Biochem Pharmacol. 2005 Nov 1;70(9):1398-407. |
| 7794 | Ye D, et al. Genipin normalizes depression-like behavior induced by prenatal stress through inhibiting DNMT1. Epigenetics. 2018 Mar 9:1-22. |
| 7795 | Borkin D, et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015 Apr 13;27(4):589-602. |
| 7796 | J Pharmacol Exp Ther 323:265 (2007); Anesth Analg 107:2048 (2008) |
| 7797 | J Chem Soc 1933: 1170; Physiol Rev 25: 255 (1945) |
| 7798 | Burbridge MF, et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther. 2013 Sep;12(9):1749-62. |
| 7799 | J Chem Soc 1949:1498 |
| 7800 | Mortensen DS, et al. Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. J Med Chem. 2015 Jul 23;58(14):5599-5608. |
| 7801 | Takahashi G, et al. Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol. 2015 Oct 15;765:15-23. |
| 7802 | Traini E, et al. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipidwith a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9. |
| 7803 | Lee SH, et al. Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. Brain Res. 2017 Jan 1;1654(Pt A):66-76. |
| 7804 | Traini E, et al. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipidwith a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9. |
| 7805 | Young WB, et al. Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834. Bioorg Med Chem Lett. 2015 Mar 15;25(6):1333-7 |
| 7806 | Deng Y, et al. In vitro inhibition and induction of human liver cytochrome P450 enzymes by gentiopicroside: potent effect on CYP2A6. Drug Metab Pharmacokinet. 2013;28(4):339-44. Epub 2013 Feb 19. |
| 7807 | Yang Y, et al. Protective effect of gentiopicroside from Gentiana macrophylla Pall. in ethanol-induced gastric mucosal injury in mice. Phytother Res. 2018 Feb;32(2):259-266. |
| 7808 | Chen F, et al. Gentiopicroside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and JNK signaling pathways. Biomed Pharmacother. 2018 Apr;100:142-146. |
| 7809 | Ohana RF, et al. Deciphering the Cellular Targets of Bioactive Compounds Using a Chloroalkane Capture Tag. ACS Chem Biol. 2015 Oct 16;10(10):2316-24. |
| 7810 | PNAS 88:355 (1991); J Pharmacol Exp Ther 266:468 (1993) |
| 7811 | Yuan Luo, et al. Inhibitors and Inactivators of Protein Arginine Deiminase 4: Functional and Structural Characterization. Biochemistry. 2006 Oct 3; 45(39): 11727–11736. |
| 7812 | Chumanevich AA, et al. Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G929-38. |
| 7813 | Witalison EE, et al. Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer. Oncotarget. 2015 Nov 3;6(34):36053-62. |
| 7814 | Biron BM, et al., Cl-Amidine Prevents Histone 3 Citrullination and Neutrophil Extracellular Trap Formation, and Improves Survival in a Murine Sepsis Model. J Innate Immun. 2017;9(1):22-32. |
| 7815 | Or CR, et al. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells. Int J Mol Sci. 2016 Dec 27;18(1). |
| 7816 | Nguyen M, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7. Epub 2007 Nov 26. |
| 7817 | Sulkshane P, et al. BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells. Oncotarget. 2016 Aug 5;8(36):60060-60079. |
| 7818 | Ehrenkaufer G, et al. Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity. PLoS Negl Trop Dis. 2020 Mar 20;14(3):e0008150. |
| 7819 | Ozlem Aksu Dönmez, et al. Simultaneous Determination of Potassium Guaiacolsulfonate, Guaifenesin, Diphenhydramine HCl and Carbetapentane Citrate in Syrups by Using HPLC-DAD Coupled With Partial Least Squares Multivariate Calibration. Talanta. 2011 Feb 15;83(5):1601-5. |
| 7820 | Thi Huong Hoa Le, et al. Development and Validation of an HPLC Method for Simultaneous Assay of Potassium Guaiacolsulfonate and Sodium Benzoate in Pediatric Oral Powder. J Anal Methods Chem. 2019 Mar 7;2019:6143061. |
| 7821 | Chen JM, et al. Production of a bioactive sweetener steviolbioside via specific hydrolyzing ester linkage of stevioside with a β-galactosidase. Food Chem. 2016 Apr 1;196:155-60. |
| 7822 | Wang X, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014 Jan 2;505(7481):117-20. |
| 7823 | Li Y, et al. Genome-wide detection of high abundance N6-methyladenosine sites by microarray. RNA. 2015 Aug;21(8):1511-8. |
| 7824 | Dang W, et al. N6-Methyladenosine and Viral Infection. Front Microbiol. 2019 Mar 5;10:417. |
| 7825 | Yamamura Y, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105(4):787-91. |
| 7826 | Yamaguchi K, et al. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn J Clin Oncol. 2011 Jan;41(1):148-52. |
| 7827 | Willems E, et al. Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell. 2012 Aug 3;11(2):242-52. |
| 7828 | Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW. |
| 7829 | Am. J. Obstet. Gynecol. (2001), 185(2, Suppl.), S24-S31; Regul. Toxicol. Pharmacol. (2001), 34(1), 53-61; J. Am. Chem. Soc. (1959), 81, 436-8| |
| 7830 | Muneyyirci-Delale O, et al. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43(1):24-7. |
| 7831 | Kaser DJ, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012 Apr;25(2):105-8. |
| 7832 | Maier WE, et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001 Aug;34(1):53-61. |
| 7833 | Cheng DC, et al. Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atherosclerosis. 1983 Jan;46(1):41-8. |
| 7834 | Wan Z, et al. Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing. PLoS One. 2012;7(6):e39225. |
| 7835 | Guo B, et al. Fangchinoline as a kinase inhibitor targets FAK and suppresses FAK-mediated signaling pathway in A549. J Drug Target. 2015 Apr;23(3):266-74. |
| 7836 | Fan B, et al. Fangchinoline Induces Apoptosis, Autophagy and Energetic Impairment in Bladder Cancer. Cell Physiol Biochem. 2017;43(3):1003-1011. |
| 7837 | Liu X, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012 Jan 15;18(2):510-23. |
| 7838 | Ma W, et al. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6590-5. |
| 7839 | Yin S, et al. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One. 2017 Aug 17;12(8):e0183578. |
| 7840 | Ma W, et al. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6590-5. |
| 7841 | Choi BY, et al. Clofilium, a potassium channel blocker, induces apoptosis of human promyelocytic leukemia (HL-60) cells via Bcl-2-insensitive activation of caspase-3. Cancer Lett. 1999 Dec 1;147(1-2):85-93. |
| 7842 | Ward TA, et al. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes. PLoS One. 2017 Jun 19;12(6):e0179278. |
| 7843 | Nature 176:697 (1955); Int J Exper Botany 78:155 (2009); Toxicon 57:176 (2011) |
| 7844 | Lowe JA 3rd, et al. The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter [published correction appears in Bioorg Med Chem Lett. 2009 Aug 15;19(16):4885. Bronk, Brian S [added]; Schaeffer, Eric [added]]. Bioorg Med Chem Lett. 2009;19(11):2974-2976. |
| 7845 | Liu CN, Pettersen B, Seitis G, Osgood S, Somps C. GlyT1 inhibitor reduces oscillatory potentials of the electroretinogram in rats. Cutan Ocul Toxicol. 2014;33(3):206-211. |
| 7846 | Issaeva N, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004 Dec;10(12):1321-8. Epub 2004 Nov 21. |
| 7847 | Nieves-Neira W, et al. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol Pharmacol. 1999 Sep;56(3):478-84. |
| 7848 | Zhao CY, et al. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res. 2010 Apr 15;70(8):3372-81. |
| 7849 | Prog. Neuro-Psychopharmacol. Biol. Psychiatry (2011), 35(2), 380-389; Expert Opin. Pharmacother. (2004), 5(11), 2255-2262; Mamm. Genome (2011), 22(7-8), 486-94 |
| 7850 | https://clinicaltrials.gov/ct2/show/NCT04330300?term=Olmesartan&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04394117?term=Olmesartan&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04467931?term=Olmesartan&cond=COVID-19&draw=2&rank=3 |
| 7851 | Joseph Grimsby, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003 Jul 18;301(5631):370-3. |
| 7852 | Nancy-Ellen Haynes, et al. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675). J Med Chem. 2010 May 13;53(9):3618-25. |
| 7853 | Clare PM, et al. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J Biol Chem. 2001 Dec 21;276(51):48292-9. |
| 7854 | Saura J, et al. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci. 1992 May;12(5):1977-99. |
| 7855 | Bondiolotti GP, et al. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem Pharmacol. 1995 Jun 29;50(1):97-102. |
| 7856 | Guimaraes J, et al. The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37. |
| 7857 | Suzuki T, et al. MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology. 1995 Jun;50(6):357-62. |
| 7858 | ScottSoby, et al. Detoxification of the phytoalexins maackiain and medicarpin by fungal pathogens of alfalfa. Phytochemistry. 1996 Feb;14(3):759-765. |
| 7859 | Hicks A, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007 Oct;323(1):202-9. |
| 7860 | Andersson KE, et al. Selective β3-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013 Oct;190(4):1173-80. |
| 7861 | Wu YD, et al. Brassinolide, a plant sterol from pollen of Brassica napus L., induces apoptosis in human prostate cancer PC-3 cells. Pharmazie. 2007 May;62(5):392-5. |
| 7862 | Xian LJ, et al. Reversing effect of brassinolide on multidrug resistance of-CCRF-VCR1000 cells and a preliminary investigation on its mechanisms. Yao Xue Xue Bao. 2005 Feb;40(2):117-21. |
| 7863 | Wrighton DC, et al. Mechanism of inhibition of mouse Slo3 (KCa 5.1) potassium channels by quinine, quinidine and barium. Br J Pharmacol. 2015 Sep;172(17):4355-63. |
| 7864 | Cheng KI, et al. Application of quinidine on rat sciatic nerve decreases the amplitude and increases the latency of evoked responses. J Anesth. 2014 Aug;28(4):559-68. |
| 7865 | Phytotherapy Res 4:11 (1990); J Chemical Ecol 35:383 (2009); J Med Plants Res 5:5324 (2011); Fibrogenesis Tissue Repair 3:1 (2010) |
| 7866 | J. Med. Chem. (1983), 26(6), 916-22; Epilepsia (2004), 45(11), 1338-1343; Curr. Opin. Neurol. (2003), 16(2), 203-211 |
| 7867 | Liang J, et al. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. Bioorg Med Chem Lett. 2016 Aug 15;26(16):4036-41. |
| 7868 | Luo G, et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem. 2012 Dec 13;55(23):10644-51. |
| 7869 | Zheng N, et al. Improved liquid-liquid extraction with inter-well volume replacement dilution workflow and its application to quantify BMS-927711 in rat dried blood spots by UHPLC-MS/MS. J Pharm Biomed Anal. 2014 Feb;89:240-50. |
| 7870 | Compt Rendu 243:609 (1956) |
| 7871 | Br J Pharmacol Chemother 13:339 (1958); Nature 184:554 (1959); Br J Pharmacol 14:202 (1959); Br Med J 1:13 (1961) |
| 7872 | Hall TG, et al. Preclinical Activity of ARQ-087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594. |
| 7873 | Balek L, et al. ARQ-087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3. Bone. 2017 Dec;105:57-66. |
| 7874 | Yeo H, et al. Synthesis and antiviral activity of helioxanthin analogues. J Med Chem. 2005 Jan 27;48(2):534-46. |
| 7875 | Li Y, et al. Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative. Antivir Chem Chemother. 2005;16(3):193-201. |
| 7876 | Sagara Y, et al. Tyrphostins protect neuronal cells from oxidative stress. J Biol Chem. 2002 Sep 27;277(39):36204-15. |
| 7877 | Yoneda T, et al. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 1991 Aug 15;51(16):4430-5. |
| 7878 | J Am Chem Soc 89: 676, 681 (1967) |
| 7879 | Njomen E, et al. Small Molecule Modulation of Proteasome Assembly. Biochemistry. 2018 Jul 17;57(28):4214-4224. |
| 7880 | Lin L, et al. STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells. Int J Oncol. 2016 Oct 12. |
| 7881 | John S McMurray, et al. A new small-molecule Stat3 inhibitor. Chem Biol. 2006 Nov;13(11):1123-4. |
| 7882 | Tsubasa Yokota, et al. STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model. Nephrol Dial Transplant. 2018 Feb 1;33(2):214-223. |
| 7883 | Schafer, U., et al., Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors. J Pharmacol Exp Ther, 2002. 303(3): p. 1163-70. |
| 7884 | Chan, C.K., et al., Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine. Neuroscience, 2005. 132(4): p. 991-1007. |
| 7885 | Muranaka Y, et al. TAS-301, an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries. J Pharmacol Exp Ther. 1998 Jun;285(3):1280-6. |
| 7886 | Sasaki E, et al. TAS-301 blocks receptor-operated calcium influx and inhibits rat vascular smooth muscle cell proliferation induced by basic fibroblast growth factor and platelet-derived growth factor. Jpn J Pharmacol. 2000 Nov;84(3):252-8. |
| 7887 | JACS 54:1058 (1962); Naturwissenschaften 51:637 (1964); 52:132 (1965); Japan J Can Res 77:197 (1986); J Curr Pharn Des 7:1181 (2001)| |
| 7888 | Prakash V, et al. Mechanism of interaction of vinca alkaloids with tubulin: catharanthine and vindoline. Biochemistry. 1991 Jan 22;30(3):873-80. |
| 7889 | Somana Siva Prasad, et al. A QUALITY BY DESIGN APPROACH FOR DEVELOPMENT OF SIMPLE AND ROBUST REVERSED PHASE STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF IBRUTINIB AND ITS IMPURITIES. |
| 7890 | Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. |
| 7891 | Liu N, et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Org Biomol Chem. 2015 May 14;13(18):5147-57. |
| 7892 | Hedrick E, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015 Jun 2;10(6):e0128308. |
| 7893 | Gammone MA, et al. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar Drugs. 2015 Apr 13;13(4):2196-214. |
| 7894 | Karyn Bouhana, et al. LOXO-101, a pan TRK inhibitor, For The Treatment Of TRK-driven Cancers. |
| 7895 | Nagasubramanian R, et al. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer. 2016 Aug;63(8):1468-70. |
| 7896 | Doebele RC, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049-57. |
| 7897 | Doebele RC, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049-57. |
| 7898 | Kathryn G, et al. Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia. Blood 2016 128:278. |
| 7899 | Rak R, et al. Novel LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model. Oncoscience. 2014 Jan 1;1(1):39-48. eCollection 2014. |
| 7900 | Mashiach-Farkash E, et al. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget. 2012 Jun;3(6):629-39. |
| 7901 | Eur. J. Pharmacol. (1981), 73(4), 333-42; J. Med. Chem. (1977), 20(6), 821-6; Arch. Intern. Med. (2006), 166(7), 719-728 |
| 7902 | Bourne JA, et al . SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev. 2001 Winter;7(4):399-414. |
| 7903 | Millan MJ, et al. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology (Berl). 2001 Jun;156(1):58-62. |
| 7904 | Kuzhikandathil EV, et al. Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupledinwardly rectifying potassium channels. Mol Pharmacol. 2002 Jul;62(1):119-26. |
| 7905 | Wang YH, et al. Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway. Acta Pharmacol Sin. 2020 Feb;41(2):173-180. |
| 7906 | Crockett SL, et al. Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness. Pediatr Res. 2019 Dec 9. |
| 7907 | Zhang J, et al. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells. Oncotarget. 2017 Jan 31;8(5):7625-7636. |
| 7908 | Kulsum S et al. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by Aldehydedehydrogenase 1 A1 inhibition.
 Mol Carcinog. 2016 Jul 6. |
| 7909 | Yang SM, et al. Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1(ALDH1A1). J Med Chem. 2015 Aug 13;58(15):5967-5978. |
| 7910 | Zhou W, et al. Mechanisms of improved aortic stiffness by arotinolol in spontaneously hypertensive rats.PLoS One. 2014 Feb 12;9(2):e88722. |
| 7911 | Hiroshi TSUCHIHASHI, et al. Characteristics of 1251-lodocyanopindolol Binding to 8-Adrenergic and Serotonin-1B Receptors of Rat Brain: Selectivity of 19-Adrenergic Agents |
| 7912 | Lu RN, et al. Unconjugated Bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease. J Thromb Haemost. 2015 Jun;13(6):1064-72. |
| 7913 | Mölzer C, et al. Bilirubin and related tetrapyrroles inhibit food-borne mutagenesis: a mechanism for antigenotoxic action against a model epoxide. J Nat Prod. 2013 Oct 25;76(10):1958-65. |Proc Natl Acad Sci 84:5918 (1987) |
| 7914 | Lancet 2:1060 (1953); Food Cosmet Toxicl 2:327 (1964) |
| 7915 | Changzhi Xu, et al. Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistancey. Oncol Rep. 2019 Jun;41(6):3499-3507. |
| 7916 | Qiu JL, et al. The selective mGluR5 agonist CHPG attenuates SO<sub>2</sub>-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. Neurochem Int. 2015 Jun-Jul;85-86:46-52. |
| 7917 | Chen T, et al. The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway. Int J Mol Med. 2012 Apr;29(4):630-6. |
| 7918 | Matsebatlela TM, et al. 3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages. Chem Biol Interact. 2015 May 25;233:95-105. |
| 7919 | Cook GJ, et al. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014 Nov 17;9(11):e112619. |
| 7920 | Bamborough P, et al. GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. ACS Med Chem Lett. 2016 May 9;7(6):552-7. |
| 7921 | Shao X, et al. Preparation of Fe2O3-Clorprenaline/Tetraphenylborate Nanospheres and Their Application as Ion Selective Electrode for Determination of Clorprenaline in Pork. Nanoscale Res Lett. 2016 Dec;11(1):178. |
| 7922 | Shen S, et al. Determination of beta2-agonists by ion chromatography with direct conductivity detection. J Pharm Biomed Anal. 2005 Jun 1;38(1):166-72. |
| 7923 | Daniele RP, et al. A potassium ionophore (valinomycin) inhibits lymphocyte proliferation by its effects on the cell membrane. Proc Natl Acad Sci U S A. 1976 Oct;73(10):3599-602. |
| 7924 | Tosteson DC, et al. The effect of valinomycin on potassium and sodium permeability of HK and LK sheep red cells. J Gen Physiol. 1967 Dec;50(11):2513-25. |
| 7925 | Abdalah R, et al. Valinomycin-induced apoptosis in Chinese hamster ovary cells. Neurosci Lett. 2006 Sep 11;405(1-2):68-73. |
| 7926 | Kondapalli C, et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2012 May;2(5):120080. |
| 7927 | Siemeister G, et al. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther. 2012 Oct;11(10):2265-73. |
| 7928 | Lücking U, et al. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer. ChemMedChem. 2013 Jul;8(7):1067-85. |
| 7929 | Walterscheid JP, et al. Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17420-5. |
| 7930 | Viiri J, et al. Cis-urocanic acid suppresses UV-B-induced interleukin-6 and -8 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro. Mol Vis. 2009 Sep 8;15:1799-805. |
| 7931 | Kim SA, et al. A novel cereblon modulator for targeted protein degradation. Eur J Med Chem. 2019 Mar 15;166:65-74. |
| 7932 | Ren Y, et al. Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-InteractingProtein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome. J Med Chem. 2017 Feb 9;60(3):972-986. |
| 7933 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Clonidine&cond=covid&draw=2&rank=2 |
| 7934 | Iwao Ojima, et al. Efficient and Practical Asymmetric Synthesis of the Taxol C-13 Side Chain, N-Benzoyl-(2R,3S)-3-phenylisoserinea,n d Its Analogues via Chiral3-Hydroxy-4-aryl-&lactams through Chiral Ester Enolate-Imine Cyclocondensation. |
| 7935 | https://clinicaltrials.gov/ct2/show/NCT04485130?term=DISULFIRAM&cond=covid&draw=2&rank=1 |
| 7936 | J Org Chem 42:2637 (1977); Am J Psychiatry 150:321 (1993) |
| 7937 | Biol. Pharm. Bull. (1995), 18(8), 1145-7; Biorg. Med. Chem. Lett. (1992), 2(8), 871-6; Adv. Behav. Biol. (1990), 38B, 409-13 |
| 7938 | https://clinicaltrials.gov/ct2/show/NCT04357457?term=Almitrine&cond=Covid19&draw=2&rank=1 |
| 7939 | https://clinicaltrials.gov/ct2/show/NCT04336904?term=Favipiravir&cond=covid&draw=1&rank=1 |
| 7940 | Kai S, et al. Pre-clinical evaluation of cinobufotalin as a potential anti-lung cancer agent. Biochem Biophys Res Commun. 2014 Sep 26;452(3):768-74. |
| 7941 | Br. J. Pharmacol. (1990), 99(4), 753-61; J. Pharmacol. Exp. Ther. (1964), 146(3), 354-8; J. Am. Chem. Soc. (1947), 69, 2902-6 |
| 7942 | Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508(7495):215-21. |
| 7943 | Innaimo SF, et al. Identification of?BMS-200475?as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 Jul;41(7):1444-8. |
| 7944 | Rivkin A, et al. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin.?2005 Nov;21(11):1845-56. |
| 7945 | Genovesi EV, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside?BMS-200475?in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother.?1998 Dec;42(12):3209-17. |
| 7946 | Monatsh Chem 61:147 (1932); Chem Pharm Bull 56:1551 (2008); Polar Biol 32:1033 (2009) |
| 7947 | Huang Y, et al. Picroside II protects against sepsis via suppressing inflammation in mice. Am J Transl Res. 2016 Dec 15;8(12):5519-5531. eCollection 2016. |
| 7948 | Zhai L, et al. Picroside II protects the blood-brain barrier by inhibiting the oxidative signaling pathway in cerebral ischemia-reperfusion injury. PLoS One. 2017 Apr 7;12(4):e0174414. |
| 7949 | Christian Lavedan, et al. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology. 2015 Apr;91:142-7. |
| 7950 | Keating GM, et al. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs. 2016 Mar 22. |
| 7951 | Br J Pharmac 37:476 (1969); Environ Mutagen 4:83-91 (1982) |
| 7952 | Mi Y, et al. Momordin Ic couples apoptosis with autophagy in human hepatoblastoma cancer cells by reactive oxygen species (ROS)-mediated PI3K/Akt and MAPK signaling pathways. Free Radic Biol Med. 2016 Jan;90:230-42. |
| 7953 | Wang J, et al. Suppressive effects of Momordin Ic on HepG2 cell migration and invasion by regulating MMP-9 and adhesion molecules: Involvement of p38 and JNK pathways. Toxicol In Vitro. 2019 Apr;56:75-83. |
| 7954 | Gavathiotis E, et al. Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol. 2012 Jul;8(7):639-45. |
| 7955 | Graf C, et al. Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol Pharmacol. 2008 Oct;74(4):925-32. |
| 7956 | Graf C, et al. A secondary assay for ceramide kinase inhibitors based on cell growth inhibition by short-chain ceramides. Anal Biochem. 2009 Jan 1;384(1):166-9. |
| 7957 | Pastukhov O,et al. The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death.Br J Pharmacol. 2014 Dec;171(24):5829-44. |
| 7958 | J Biol Chem 139:121 (1941); Biochem J 36:113 (1942) |
| 7959 | Bray M, et al. Meeting report: 31st International Conference on Antiviral Research. Antiviral Res. 2018 Oct;158:88-102. |
| 7960 | Chang J, et al. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res. 2013;98(3):432‐440. |
| 7961 | Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.ACS Med Chem Lett. 2017 Jan 17;8(2):157-162. |
| 7962 | Ma J, et al. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Antiviral Res. 2018 Feb;150:112-122. |
| 7963 | Moore, WJ, et al. Modulation of Wnt Signaling Through Inhibition of Secreted Frizzled-Related Protein I (sFRP-1) with N-Substituted Piperidinyl Diphenylsulfonyl Sulfonamides. Journal of Medicinal Chemistry (2009), 52(1), 105-116. |
| 7964 | Bodine PV, et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone. 2009 Jun;44(6):1063-8. |
| 7965 | Oguz A, et al. Topical N-acetylcysteine improves wound healing comparable to dexpanthenol: an experimental study. Int Surg. 2015 Apr;100(4):656-61. |Antimicrob. Agents Chemother. (2005), 49(2), 632-637; Free Radical Biol. Med. (1995), 19(6), 767-72; Int. J. Vitam. Nutr. Res., Suppl. (1983), 24, 53-67 |
| 7966 | Cheng D, et al. Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity. J Med Chem. 2011 Jul 14;54(13):4928-32. |
| 7967 | Kobayashi T, et al. Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis. Inflamm Res. 2005 Jun;54(6):249-55. |
| 7968 | Xiao-Yi Xiong, et al. Toll-Like Receptor 4/MyD88-Mediated Signaling of Hepcidin Expression Causing Brain Iron Accumulation, Oxidative Injury, and Cognitive Impairment After Intracerebral Hemorrhage. Circulation. 2016 Oct 4;134(14):1025-1038. |
| 7969 | Kazi A, et al. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol. 2009 Apr;29(8):2254-63. |
| 7970 | Kuchay S, et al. PTEN counteracts FBXL2 to promote IP3R3- and Ca<sup>2+</sup>-mediated apoptosis limiting tumour growth. Nature. 2017 Jun 22;546(7659):554-558. |
| 7971 | Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7. |
| 7972 | Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88. |
| 7973 | Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70. |
| 7974 | Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361- |
| 7975 | Kinnunen U, et al. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):301-3. |
| 7976 | J Cell Biol 122:523 (1993); Yanbian Yixueyuan Xuebao 18:85 (1995); J Pharmacol Exp Therap 312:686 (2005) |
| 7977 | D Herman et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol, 2006 Oct, 2(10):551-8. |
| 7978 | Jia H, et, al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis. 2012 May;46(2):351-61. |
| 7979 | Thomas EA, et, al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15564-9. |
| 7980 | J. Antimicrob. Chemother. (1984), 14(2), 157-63; J. Antimicrob. Chemother. (1980), 6(3), 389-92 |
| 7981 | Br J Clin Pharmacol 18:343 (1984); Eur J Clin Pharmacol 27:135 (1984); Eur Heart J 6:8845 (1985) |
| 7982 | French KJ, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63(18):5962-9. |
| 7983 | French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318(2):596-603. |
| 7984 | Biochem Pharmacol 29: 833 (1980); J Med Chem 30: 1 (1987) |
| 7985 | Petrova E, et al. Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. Oncogene. 2014 Jan 27. doi: 10.1038/onc.2013.575. |
| 7986 | Petrova E, et al. Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling.Nat Chem Biol. 2013 Apr;9(4):247-9. |
| 7987 | Naka K, et al. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. Biochem Biophys Res Commun. 2005 May 13;330(3):871-9. |
| 7988 | Saijo M, et al. Inhibitory effect of Mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. Antiviral Res. 2005 Jun;66(2-3):159-63. |
| 7989 | Kamada H, et al. Effect of Mizoribine on collagen-induced arthritis in mice. Jpn J Pharmacol. 1996 Feb;70(2):169-75. |Pediatr. Int. (2002), 44(2), 205-209; Pediatr. Int. (2002), 44(2), 196-198; Curr. Med. Chem. (1999), 6(7), 575-597 |
| 7990 | Yu X, et al. Allele-specific p53 mutant reactivation. Cancer Cell. 2012 May 15;21(5):614-25. |
| 7991 | https://clinicaltrials.gov/ct2/show/NCT04328012 |
| 7992 | https://clinicaltrials.gov/ct2/show/NCT04568876?term=PALMIDROL&cond=covid&draw=2&rank=1 |
| 7993 | Rossette MC, et al. The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain B. Phytother Res. 2017 Oct;31(10):1607-1613. |
| 7994 | Li X, et al. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation. Cell Commun Signal. 2019 Mar 18;17(1):25. |
| 7995 | Phytochem 17:829 (1978) |
| 7996 | Zaharevitz DW, et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 1999 Jun 1;59(11):2566-9. |
| 7997 | Lyssiotis CA, et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):8912-7. |
| 7998 | F Yu, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 2011 May 5;30(18):2161-72. |
| 7999 | Hagiwara M, et al. Selective modulation of calcium-dependent myosin phosphorylation by novel protein kinase inhibitors, isoquinolinesulfonamide derivatives. Mol Pharmacol. 1987 Jul;32(1):7-12. |
| 8000 | Kamimura T, et al. Ceftizoxime (Ceftizoxime), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1979 Nov;16(5):540-8. |
| 8001 | Murakawa T, et al. Pharmacokinetics of ceftizoxime in animals after parenteral dosing. Antimicrob Agents Chemother. 1980 Feb;17(2):157-64. |
| 8002 | Chem Pharm Bull 30:2797 (1982); Biochemistry 21:4096 (1982) |
| 8003 | Huang X, et al. Endothelial p110γPI3K Mediates Endothelial Regeneration and Vascular Repair After Inflammatory Vascular Injury. Circulation. 2016 Mar 15;133(11):1093-103. |
| 8004 | Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005 Sep;11(9):936-43. |
| 8005 | Azzi J, et al. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012 Jun;61(6):1509-18. Epub 2012 Mar 8. |
| 8006 | Wei X, et al. A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res Commun. 2010 Jun 25;397(2):311-7. Epub 2010 May 26. |
| 8007 | Yang T, et al. A small molecule TrkB/TrkC neurotrophin receptor co-activator with distinctive effects on neuronal survival and process outgrowth. Neuropharmacology. 2016 Nov;110(Pt A):343-61. |
| 8008 | Giraud C, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.Drug Metab Dispos. 2006 Apr;34(4):608-11. Epub 2006 Jan 13. |
| 8009 | Cao D, et al. Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome. Epilepsia. 2012 Jul;53(7):1140-5. |
| 8010 | FMoureau, et al. A reversible monoamine oxidase inhibitor, toloxatone: spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD). European Journal of Medicinal Chemistry. 1994, 29(4):269-277. |
| 8011 | John L Wallace, et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol. 2010 Mar;159(6):1236-46. |
| 8012 | Paola De Cicco, et al. ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo. Pharmacol Res. 2016 Dec;114:67-73. |
| 8013 | Bruno Schneider Herrera, et al. The H2S-releasing naproxen derivative, ATB-346, inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis. Med Gas Res. 2015 Feb 27;5:4. |
| 8014 | panelEduardoEkundi-Valentim, et al. P4 Antiinflammatory and antinociceptive effects of ATB-346, a gastric sparing hydrogen sulfide-releasing naproxen, in rats with carrageenan-induced knee joint synovitis. Nitric Oxide. Volume 27, Supplement 2, 15 September 2012, Page S13. |
| 8015 | https://clinicaltrials.gov/ct2/show/NCT04789499?term=THEOPHYLLINE&cond=Covid19&draw=2&rank=1 |
| 8016 | Phytochemistry 22:625 (1983); Asian Pacific J Cancer Prev 10:695 (2009); Int J Pharmacol 6:419 (2010) |
| 8017 | Farmaco Ed Sci 36:201, 220 (1981); Int J Clin Pharmacol Res 11 Suppl 1:101 (1982) |
| 8018 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=METHYLPREDNISOLONE+&cntry=&state=&city=&dist=&Search=Search |
| 8019 | Lee A.Dawson, et al. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Neuropharmacology Volume 50, Issue 8, June 2006, Pages 975-983 |
| 8020 | Scott C, et al. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist. Neuropharmacology. 2006 Jun;50(8):984-90. Epub 2006 Mar 20. |
| 8021 | Pharmazie (1991), 46(9), 646-50; J. Immunopharmacol. (1985), 7(3), 303-12; J. Drugs Dermatol. (2011), 10(10), 1102-5 |
| 8022 | Mooiman KD, et al. Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metab Dispos. 2013 Aug;41(8):1494-504. |
| 8023 | Deep G, et al. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis. 2007 Jul;28(7):1533-42. |
| 8024 | Deep G, et al. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene. 2008 Jun 26;27(28):3986-98. |
| 8025 | Pferschy-Wenzig EM, et al. Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J Nat Prod. 2014 Apr 25;77(4):842-7. |
| 8026 | Acta Physiol. Hung. (1989), 74(2), 169-74; Experientia (1981), 37(8), 890-2; J. Atheroscler. Res. (1968), 8(2), 265-76 |
| 8027 | Klunk W, et al. Benzothiazole derivative compounds, compositions and uses. WO2004083195 A1 |
| 8028 | Chen YK, et al. Apoptosis induced by 2-aryl benzothiazoles-mediated photodynamic therapy in melanomas via mitochondrial dysfunction. Chem Res Toxicol. 2014 Jul 21;27(7):1187-98. |
| 8029 | Watanabe Y, et al. Pirmenol inhibits muscarinic acetylcholine receptor-operated K+ current in the guinea pig heart. Eur J Pharmacol. 1997 Oct 29;338(1):71-4. |
| 8030 | Schardein JL, et al. Preclinical toxicology studies with a new antiarrhythmic agent: Pirmenol hydrochloride (CI-845). Toxicol Appl Pharmacol. 1980 Nov;56(2):294-301. |
| 8031 | Hewitt L, et al. Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. J Cell Biol. 2010 Jul 12;190(1):25-34. |
| 8032 | Liu X, et al. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells. Oncotarget. 2015 Oct 27;6(33):34309-20. |
| 8033 | Gurden MD, et al. Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance. Cancer Res. 2015 Aug 15;75(16):3340-54. |
| 8034 | Mitamura K, et al. Determination of sulfates of androsterone and epiandrosterone in human serum using isotope diluted liquid chromatography-electrospray ionization-mass spectrometry. Biomed Chromatogr. 2005 Dec;19(10):796-801. |J Am Chem Soc 75: 2275 (9153) |
| 8035 | Patent WO 2013014448 A1. 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
 . |
| 8036 | Sun YY, Lin SH et al. Cell type-specific dependency on the PI3K/Akt signaling pathway for the endogenous Epo and VEGF induction by baicalein in neurons versus astrocytes. 2013 Jul 19;8(7):e69019. |
| 8037 | Hofmann C, et al. PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform. Br J Haematol. 2014 Aug;166(4):529-39. |
| 8038 | Tyagi S. Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats. Can J Physiol Pharmacol. 2012 Jul, 90(7), 881-5. |
| 8039 | Jingyi Wang, et al. MiR-1976 Knockdown Promotes Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties Inducing Triple-Negative Breast Cancer Metastasis. Cell Death Dis. 2020 Jul 3;11(7):500. |
| 8040 | Vet Med (Prague) 13:619 (1968); Anal Profiles Drug Subs 6:515 (1977) |
| 8041 | https://clinicaltrials.gov/ct2/show/NCT04977960?term=Canrenone&cond=COVID-19&draw=2&rank=1 |
| 8042 | CR Hebd Seances Acad Sci 249:306 (1959); Cancer Res 57:420 (1997) |
| 8043 | Miduturu CV, et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinaseinhibitors. Chem Biol. 2011 Jul 29;18(7):868-79. |
| 8044 | Adv. Hematol. (2011), e-pub 865870, 17 pp; Nat. Clin. Pract. Oncol. (2008), 5(9), 543-56; Cancer (1949), 2(1), 1-17 |
| 8045 | Hiasa Y, et al. DL-Serine: promoting activity on renal tumorigenesis by N-ethyl-N-hydroxyethylnitrosamine in rats. J Natl Cancer Inst. 1984 Jul;73(1):297-9. |
| 8046 | VARMA, J. P., et al. Effect of Alanine, Serine and Glutamic Acid on the Multiplication of Tobacco Mosaic Virus in Tobacco. Journal of Phytopathology. 1967, 58(1), 53-58. |
| 8047 | https://clinicaltrials.gov/ct2/show/NCT04467086?term=PROPRANOLOL&cond=Covid19&draw=2&rank=1 |
| 8048 | Najafov A, et al. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J.?2011 Jan 15;433(2):357-69. |
| 8049 | Qi L, et al. PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell Int.?2015 Sep 29;15:91. |
| 8050 | Scortegagna M, et al. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9. |
| 8051 | Borán MS, et al. The cyclic GMP-protein kinase G pathway regulates cytoskeleton dynamics and motility in astrocytes. J Neurochem. 2007 Jul;102(1):216-30. |
| 8052 | Sane DC, et al. Cyclic GMP analogs inhibit gamma thrombin-induced arachidonic acid release in human platelets. Biochem Biophys Res Commun. 1989 Dec 15;165(2):708-14. |
| 8053 | Soares AC, et al. Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K(+) channels in the rat PGE2-induced hyperalgesic paw. Br J Pharmacol. 2001 Sep;134(1):127-31. |
| 8054 | You Jung Kim, et al. Antimelanogenic Activity of 3,4-dihydroxyacetophenone: Inhibition of Tyrosinase and MITF. Biosci Biotechnol Biochem. 2006 Feb;70(2):532-4. |
| 8055 | Xiao Ruan, et al. Autotoxicity and Allelopathy of 3,4-dihydroxyacetophenone Isolated From Picea Schrenkiana Needles. Molecules. 2011 Oct 24;16(10):8874-93. |
| 8056 | https://clinicaltrials.gov/ct2/show/NCT04456153?term=ATOVAQUONE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04339426?term=ATOVAQUONE&cond=COVID-19&draw=2&rank=2 |
| 8057 | Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9. |
| 8058 | Keppner S, et al. Fate of primary cells at the G?/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15. |
| 8059 | Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16. |
| 8060 | Harrigan JA, et al.Deubiquitylating enzymes and drug discovery: emerging opportunities.Nat Rev Drug Discov. 2018 Jan;17(1):57-78. |
| 8061 | Nishi Kumari, et al. Targeting the Ubiquitin Proteasome System in Cancer. Neoplasm. 2017 Dec. |
| 8062 | Denise Rageot, et al. Abstract 140: Discovery and biological evaluation of PQR530, a highly potent dual pan-PI3K/mTORC1/2 inhibitor. Cancer Res 2017;77(13 Suppl). |
| 8063 | Rageot D, et al. (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. J Med Chem. 2019;62(13):6241-6261. |
| 8064 | Qifan Zhou, et al. Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. New Journal of Chemistry. 10 Jan 2020. |
| 8065 | Prakash A, et al. Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria. BioDrugs. 1998 Jul;10(1):41-63. |
| 8066 | Life Sci 38:951 (1986); J Bone Miner Res 1:206 (1986); JAMA 285:1482 (2001) |
| 8067 | Guillon CD, et al. Azetidinones as vasopressin V1a antagonists. Bioorg Med Chem. 2007 Mar 1;15(5):2054-80. |
| 8068 | Fabio KM, et al. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013 Jun;102(6):2033-2043. |
| 8069 | Tet Letts 25:4059 (1984); Prog Neural Psychopharmacol Biolog Psychiatry 21:697 (1997); Hum Psychopharmacol Clin Exp 14:63 (1999) |
| 8070 | Cancer Chemother. Pharmacol. (2011), 67(1), 183-192; J. Med. Chem. (2004), 47(1), 218-223; Prog. Cancer Res. Ther. (1978), 7, 389-401 |
| 8071 | Sadegh Ghanbar, et al. New Generation of N-Chloramine/QAC Composite Biocides: Efficient Antimicrobial Agents To Target Antibiotic-Resistant Bacteria in the Presence of Organic Load. ACS Omega. 2018 Aug 22;3(8):9699-9709. |
| 8072 | Tsuyoshi Mitani, et al. Zinc-related actions of sublethal levels of benzalkonium chloride: Potentiation of benzalkonium cytotoxicity by zinc. Chem Biol Interact. 2017 Apr 25;268:31-36. |
| 8073 | Pietra C, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexiasyndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):329-37. |
| 8074 | Surg Gynecol Obstet 89:692 (1949); Stanford Med Bull 9:96 (1951); J Am Dent Assoc 106:319 {1983) |
| 8075 | J Pharmacol Exper Ther 161:14 (1968); J Pharm Pharmacol 24:289 (1972); Adv Neurol 45:493 (1987) |
| 8076 | Antibiotics (1979), 5(1), 154-75; Prog. Drug Res. (1977), 21, 9-104; J. Bacteriol. (1964), 88, 1112-8 |
| 8077 | Wang ZG, et al. Impacts of dimethyl phthalate on the bacterial community and functions in black soils. Front Microbiol. 2015 May 5;6:405. |
| 8078 | Wu H, et al. Engeletin Alleviates Lipopolysaccharide-Induced Endometritis in Mice by Inhibiting TLR4-mediated NF-κB Activation. J Agric Food Chem. 2016 Aug 10;64(31):6171-8. |
| 8079 | Boyd S, et al. Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3. J Med Chem. 2015 Apr 23;58(8):3611-25. |
| 8080 | J. Med. Entomol. (1981), 18(5), 357-61; J. Am. Acad. Dermatol. (2008), 58(5), 865-71; J. Med. Entomol. (1978), 14(5), 536-41 |
| 8081 | Fr. M. (1968),patent FR 6092 date 19680722, ; Antibiot. Chemother. (1956), 6, 261-6. |
| 8082 | Demont EH, et al. 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. (2014) ACS Med Chem Lett. 5(11):1190-1195. |
| 8083 | Wylie S.Palmer, et al. Development of small molecule inhibitors of BRPF1 and TRIM24 bromodomains Discovery Today: Technologies Volume 19, March 2016, Pages 65-71. |
| 8084 | Srikanth Appikonda, et al. Cross-talk between chromatin acetylation and SUMOylation of tripartite motif-containing protein 24 (TRIM24) impacts cell adhesionJ Biol Chem. 2018 May 11;293(19):7476-7485. |
| 8085 | Kim SC, et al. Hordenine, a single compound produced during barley germination, inhibits melanogenesis in human melanocytes. Food Chem. 2013 Nov 1;141(1):174-81. |
| 8086 | Drugs 22:165 (1981); 28:292 (1984); Am J Med 81 Suppl 5B:1 (1986) |
| 8087 | Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55. |
| 8088 | Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64. |
| 8089 | Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10(3): p. 168-72. |
| 8090 | James LI, et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol. 2013 Mar;9(3):184-91. |
| 8091 | Arnzneim Forsch 15:727 (1965); Chem Pharm Bull 16:1726, 2269 (1968) |
| 8092 | Gibbs NK, et al. Recent advances in urocanic acid photochemistry, photobiology and photoimmunology. Photochem Photobiol Sci. 2008 Jun;7(6):655-67. |
| 8093 | Haug BE, et al. Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. J Med Chem. 2016 Apr 14;59(7):2918-27. |
| 8094 | Camilio KA, et al. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother. 2014 Jun;63(6):601-13. |
| 8095 | Grebien F et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
 Nat Chem Biol. 2015 Aug;11(8):571-8. |
| 8096 | Getlik M et al. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). J Med Chem. 2016 Mar 24;59(6):2478-96. |
| 8097 | S.Blum, et al. Biochemistry of termite defenses: Coptotermes, rhinotermes and Cornitermes species. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry. 1982. |
| 8098 | Arch Immunol Ther Exp 16:804 (1968); Anal Profiles Drug Subs 7:401 (1978) |
| 8099 | Cassani C, et al. Synthesis of 9-amino(9-deoxy)epi cinchona alkaloids, general chiral organocatalysts for the stereoselective functionalization of carbonyl compounds. Nat Protoc. 2013 Feb;8(2):325-44. |
| 8100 | Vito VD, et al. Detection and quantification of the selective EP4 receptor antagonist CJ-023423 (grapiprant) in canine plasma by HPLC with spectrofluorimetric detection. J Pharm Biomed Anal. 2016 Jan 25;118:251-8. |
| 8101 | Nagahisa A, et al. Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. J Vet Pharmacol Ther. 2017 Jun;40(3):285-292. |
| 8102 | Rausch-Derra LC, et al. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs.Am J Vet Res. 2015 Oct;76(10):853-9. |
| 8103 | Li, X., Y. Zhang, and Z. Shi, Ritodrine in the treatment of preterm labour: a meta-analysis. Indian J Med Res, 2005. 121(2): p. 120-7. |
| 8104 | Medicinal Chemistry of Adrenergics and Cholinergics |
| 8105 | Bold G, et al. A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. J Med Chem. 2016 Jan 14;59(1):132-46. |
| 8106 | Halin C, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008 Jul;173(1):265-77. |
| 8107 | Dueweke TJ, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 1993 May;37(5):1127-31. |
| 8108 | Mayland Chang, et al. Metabolism of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine In Mice. Research Article |
| 8109 | Hong WD, et al. AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis. Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1414-1419. |
| 8110 | Furusawa J, et al. Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Int Immunopharmacol. 2009 Apr;9(4):499-507. |
| 8111 | Si L, et al. Licochalcone D induces apoptosis and inhibits migration and invasion in human melanoma A375 cells. Oncol Rep. 2018 May;39(5):2160-2170. |
| 8112 | King C, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26. |
| 8113 | Wang G, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8(9):e76662. |
| 8114 | Antimicrob Agents Chemother 5:25, 33, 38 (1974); Drugs 17:1 (1979) |
| 8115 | Chim. Therap. (1966), (2), 65-70; J. Med. Chem. (1979), 22(5), 554-9; Arch. Int. Pharmacodyn. Ther. (1976), 224(1), 30-42 |
| 8116 | Prasad PV, et al. Single-dose pharmacokinetics of Nestorone, a potential female-contraceptive.Steroids. 2010 Mar;75(3):252-64. Epub 2010 Jan 11. |
| 8117 | Hussain R, et al. Progesterone and Nestorone facilitate axon remyelination: a role for progesterone receptors. Endocrinology. 2011 Oct;152(10):3820-31. |
| 8118 | Hingorani P, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-40. |
| 8119 | Jones B, et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84. |
| 8120 | Nafstad I, et, al. Teratogenic effects of the organophosphorus compound fenchlorphos in rabbits. Acta Vet Scand. 1983;24(3):295-304. |
| 8121 | Rimkus SA, et, al. A pharmacological screen for compounds that rescue the developmental lethality of a Drosophila ATM mutant. PLoS One. 2018 Jan 16;13(1):e0190821. |
| 8122 | Clin Pharmacokinet 26:107 (1994). Agents Actions. 39:157 (1993). |
| 8123 | Coghlan MP, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000 Oct;7(10):793-803. |
| 8124 | Pizarro JG, et al. Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons. Int J Dev Neurosci. 2008 May-Jun;26(3-4):269-76. |
| 8125 | MacAulay K, et al. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur J Biochem. 2003 Sep;270(18):3829-38. |
| 8126 | https://clinicaltrials.gov/ct2/show/NCT04979221?term=Cyproheptadine&cond=Covid19&draw=2&rank=1 |
| 8127 | Brandt MR, et al. Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity. J Pharmacol Exp Ther. 2005 Jun;313(3):1379-86. |
| 8128 | Kinney WA, et al. Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid(EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere. J Med Chem. 1998 Jan 15;41(2):236-46. |
| 8129 | Bonaventure P, et al. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. J Pharmacol Exp Ther. 2012 Aug;342(2):429-40. |
| 8130 | Odaka H, et al. Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. PLoS One. 2014 Jun 10;9(6):e99271. |
| 8131 | Jefferson F, et al. A dopamine receptor d2-type agonist attenuates the ability of stress to alter sleep in mice. Endocrinology. 2014 Nov;155(11):4411-21. |
| 8132 | Nomoto A, et al. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, Nilvadipine. Atherosclerosis. 1988 Aug;72(2-3):213-9. |
| 8133 | Nomoto A, et al. Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery. Atherosclerosis. 1987 Apr;64(2-3):255-61. |
| 8134 | Sugawara H, et al. Antioxidant effects of calcium antagonists on rat myocardial membrane lipid peroxidation. Hypertens Res. 1996 Dec;19(4):223-8. |
| 8135 | Yamazaki H, et al. Preservation of retinal morphology and functions in royal college surgeons rat by Nilvadipine, a Ca(2+) antagonist. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):919-26. |
| 8136 | Lai Q, et al. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3. Eur J Med Chem. 2018 Aug 5;156:162-179. |
| 8137 | Thomas Durand-Reville, et al. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder. WO 2008030579 A2. |
| 8138 | Gasser PJ, et al. Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organiccation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci. 2006 Aug 23;26(34):8758-8766. |
| 8139 | Nawrotek A, et al. PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling. Nat Chem Biol. 2019 Feb 11. doi: 10.1038/s41589-019-0228-3. |
| 8140 | https://clinicaltrials.gov/ct2/show/NCT04584684?term=CETYLPYRIDINIUM&cond=covid&draw=2&rank=7 |
| 8141 | Kyriakopoulos CE, et al. A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Invest New Drugs. 2016 Apr;34(2):225-30. |
| 8142 | An Acad Brasil Cienc 42 (suplemento): 45 (1970); Tetrahedron 25:4617 (1969) |
| 8143 | Farmakol. Toksikol. (1967), 30(3), 301-3; Farmakol. Toksikol. (1965), 28(3), 290-1. ; Farmakol. Toksikol. (1957), 20(No. 4), 20-6. |
| 8144 | Johnson LA, et al. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014 Jan;20(1):154-65. |
| 8145 | Haak AJ, et al. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther. 2014 Jun;349(3):480-6. |
| 8146 | Bell JL, et al. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3826-32. |
| 8147 | Seal J, et al. Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett. 2012 Apr 15;22(8):2968-72. |
| 8148 | Chaidos A, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014 Jan 30;123(5):697-705. |
| 8149 | Hou J, et al. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis. 2019 Jun 24;10(7):493. |
| 8150 | Li Y, et al. GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):E5697-705. |
| 8151 | Hua Zhang, et al. Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. Curr Biol. 2014 Nov 3;24(21):2501-8. |
| 8152 | Ying Han, et al. Insulin mitigates apoptosis of porcine follicular granulosa cells by downregulating BimEL. Reprod Biol. 2019 Sep;19(3):293-298. |
| 8153 | Am J Vet Res 38:2037 (1977); Am J Trop Med Hyg 31:263 (1982) |
| 8154 | Shin HJ, et al. Inhibitory effects of chelidonic acid on IL-6 production by blocking NF-κB and caspase-1 in HMC-1 cells. Immunopharmacol Immunotoxicol. 2011 Dec;33(4):614-9. |
| 8155 | Porter TG, et al. Chelidonic acid and other conformationally restricted substrate analogues as inhibitors of rat brain glutamate decarboxylase. Biochem Pharmacol. 1985 Dec 1;34(23):4145-50. |
| 8156 | Oh HA, et al. Beneficial effects of chelidonic acid on a model of allergic rhinitis. Send to Int Immunopharmacol. 2011 Jan;11(1):39-45. |
| 8157 | Walburger A, et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science. 2004 Jun 18;304(5678):1800-4. |
| 8158 | Santhi N, et al. Insights from the molecular docking of withanolide derivatives to the target protein PknG from Mycobacterium tuberculosis. Bioinformation. 2011;7(1):1-4. |
| 8159 | Scherr N, et al. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12151-6. |
| 8160 | Watson M, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol. 2009 Nov;29(21):5872-88. |
| 8161 | Cerna D, et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. J Biol Chem. 2012 Jun 22;287(26):22408-17. |
| 8162 | Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916. |
| 8163 | C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23. |
| 8164 | Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364(2):198-206. |
| 8165 | Aust J Chem 23:2539 (1970); Tetrahedron 27:3919 (1971); Phytochem 12:232 (1973); J Oral Sci 51:401 (2009); J Med Entomol 47:249 (2010) |
| 8166 | Sudbeck EA, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999 Jun;5(6):1569-82. |
| 8167 | Oh YB, et al. Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice. Exp Mol Med. 2013 May 17;45:e23 |
| 8168 | Uckun FM, et al. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline. Clin Cancer Res. 1999 Oct;5(10):2954-62. |
| 8169 | Xia F, et al. IL4 (interleukin 4) induces autophagy in B cells leading to exacerbated asthma. Autophagy. 2018;14(3):450-464. |
| 8170 | Tolman EL, et al. Anticandidal activities of terconazole, a broad-spectrum antimycotic. Antimicrob Agents Chemother. 1986 Jun;29(6):986-91. |
| 8171 | Van Cutsem J, et al. The in vitro activity of terconazole against yeasts: its topical long-acting therapeutic efficacy in experimental vaginal candidiasis in rats. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1200-6. |Chemotherapy 29:322 (1983); Pharmacotherapeutica 4:525 (1986) |
| 8172 | Arch Biochem Biophys 91: 271 (1960); Biochem J 101: 735 (1966) |
| 8173 | Meister S, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science. 2011 Dec 9;334(6061):1372-7. |
| 8174 | Ren X, Pan X, Zhang Z, Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013 Feb 14;56(3):879-94. |
| 8175 | Clin Endocrinol 10:655 (1979) |
| 8176 | Antimicrob Agents Chemother 6:144 (1974); J Antibiotics 28:573 (1975); 30:945 (1977); 35:1 (1982) |
| 8177 | Dandan Wang, et al, Development and Validation of a RP-HPLC Method for the Simultaneous Determination of Aceglutamide and Oxiracetam in an Injection Formulation, Journal of Chromatographic Science, Volume 53, Issue 5, May/June 2015, Pages 767–770, |Acupuncture & Electro-Therap Res Intl J 17:61 (1992) |
| 8178 | Emmanuel N, et al. Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. Cell Rep. 2017 Jun 27;19(13):2665-2680. |
| 8179 | J Chem Soc 1952:3949; J Gen Microbiol 34:51 (1964)| |
| 8180 | Brilhante RSN, et al. In vitro activity of azole derivatives and griseofulvin against planktonic and biofilm growth of clinical isolates of dermatophytes. Mycoses. 2018 Jul;61(7):449-454. |
| 8181 | Schmeel LC, et al. Griseofulvin Efficiently Induces Apoptosis in In Vitro Treatment of Lymphoma and Multiple Myeloma. Anticancer Res. 2017 May;37(5):2289-2295. |
| 8182 | Scott LJ, et al. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs. 2001;61(10):1455-500. |Antimicrob Agents Chemother 9:511 (1976); 12:47 (1977); Drugs 17:233 (1979) |
| 8183 | Rath T et al. Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett. 2011 May;2(3):483-488. |
| 8184 | Wohlauer M et al. Nebulized hypertonic saline attenuates acute lung injury following trauma and hemorrhagic shock via inhibition of matrix metalloproteinase-13. Crit Care Med. 2012 Sep;40(9):2647-53. |
| 8185 | George J, et al. MMP-13 deletion decreases profibrogenic molecules and attenuates N-nitrosodimethylamine-induced liver injury and fibrosis in mice. J Cell Mol Med. 2017 Dec;21(12):3821-3835. |
| 8186 | Wang M,et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013 Jan 8;15(1):R5. |
| 8187 | Ding Y, et al. Pre-treated theaflavin-3,3'-digallate has a higher inhibitory effect on the HCT116 cell line. Food Nutr Res. 2017 Nov 15;61(1):1400340. |
| 8188 | Xiangling Cui, et al. Identification of Theaflavin-3,3'-Digallate as a Novel Zika Virus Protease Inhibitor. Front Pharmacol. 2020 Oct 21;11:514313. |
| 8189 | Ann NY Acad Sci 51: 177 (1948); JACS 74: 4976 (1952); 76: 3568 (1954) |
| 8190 | JACS 108: 3016 (1986); Phytochemistry 29: 2551 (1990) |
| 8191 | Nicholas D. Adams, et al. Fatty acid synthase inhibitors. WO2012064642A1. |
| 8192 | McCabe MT, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Dec 6;492(7427):108-12. |
| 8193 | Sato T, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep. 2013 May 29;3:1911. |
| 8194 | Piali L, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547-56. |
| 8195 | Bolli MH, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010 May 27;53(10):4198-211. |
| 8196 | Brossard P, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76(6):888-96. |
| 8197 | Nasole E, et al. Effects of alpha lipoic acid and its R+ enantiomer supplemented to hyperbaric oxygen therapy on interleukin-6, TNF-α and EGF production in chronic leg wound healing. J Enzyme Inhib Med Chem. 2014 Apr;29(2):297-302. |
| 8198 | Sasaki T, et al. A new anthelmintic cyclodepsipeptide, PF1022A. J Antibiot (Tokyo). 1992 May;45(5):692-7. |
| 8199 | Dornetshuber R, et al. Effects of the anthelmintic drug PF1022A on mammalian tissue and cells. Biochem Pharmacol. 2009 Apr 15;77(8):1437-44. |
| 8200 | Nwosu U, et al. Efficacy of the cyclooctadepsipeptide PF1022A against Heligmosomoides bakeri in vitro and in vivo. Parasitology. 2011 Aug;138(9):1193-201. |
| 8201 | Chauhan D, et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013;19(11):3019-3031. |
| 8202 | Ray A, et al. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016;174(3):397-409. |
| 8203 | McAndrews KM, et, al. Mechanisms associated with biogenesis of exosomes in cancer. Mol Cancer. 2019 Mar 30;18(1):52. |
| 8204 | Jirousek MR, et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996 Jul 5;39(14):2664-71. |
| 8205 | Kunt T, et al. The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol. 2007 Nov;1(6):929-35. |
| 8206 | Wang ZB, et al. LY333531, a PKCβ inhibitor, attenuates glomerular endothelial cell apoptosis in the early stage of mouse diabetic nephropathy via down-regulating swiprosin-1. Acta Pharmacol Sin. 2017 Jul;38(7):1009-1023. |
| 8207 | Nonaka A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2702-6. |
| 8208 | Wang, X.,et al. New Route for Conversion of Camptothecin to 7-Ethylcamptothecin and 7-Propylcamptothecin. Synthetic Communications, 2007,37(3), 519–523. |
| 8209 | Clin Exp Dermatol 7:543 (1982); Dermatologica 166 Suppl 1:1 (1983) |
| 8210 | Mony L, et al. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol. 2009 Aug;157(8):1301-17. |
| 8211 | Rammes G, et al. The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (Aβ) species on long-term potentiation (LTP). Neuropharmacology. 2018 Sep 15;140:184-192. |
| 8212 | Mullier B, et al. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors. Neuropharmacology. 2017 Sep 1;123:322-331. |
| 8213 | Glanzer JG, et al. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res. 2014 Sep 15;74(18):5165-72. |
| 8214 | Sandra E Burke, et al. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev. 2006 Jun 3;58(3):437-46. |
| 8215 | Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. |
| 8216 | Clin. Pharmacol. Ther. (1964), 5, 49-62; J. Am. Chem. Soc. (1945), 67, 933-9 |
| 8217 | Chauhan D, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11;22(3):345-58. |
| 8218 | Trends Biochem Sci 7:156 (1982); Metab Brain Dis 8:151 (1993) |
| 8219 | Anguiano J, et al. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. Nat Chem Biol. 2013 Jun;9(6):374-82. |
| 8220 | Philip Wing-Lok Ho, et al. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy. 2020 Feb;16(2):347-370. |
| 8221 | Olmstead AW, LeBlanc GL. Low exposure concentration effects of methoprene on endocrine-regulated processes in the crustacean Daphnia magna. Toxicol Sci. 2001;62(2):268-273. |
| 8222 | Monteiro JP, et al. Toxicity of methoprene as assessed by the use of a model microorganism. Toxicol In Vitro. 2005;19(7):951-956. |
| 8223 | Ozer HG, et al. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discov. 2018 Apr;8(4):458-477. |
| 8224 | https://clinicaltrials.gov/ct2/show/NCT04348305?term=HYDROCORTISONE&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04359511?term=HYDROCORTISONE&cond=Covid19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04456439?term=HYDROCORTISONE&cond=Covid19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT02735707?term=HYDROCORTISONE&cond=Covid19&draw=2&rank=8 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2015-002340-14-NL https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04348305 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001395-15-DK |
| 8225 | Scott DA, et al. Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4591-6. |
| 8226 | Boulter L, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. Send to J Clin Invest. 2015 Mar 2;125(3):1269-85. |
| 8227 | Planta Med 16:182 (1968; J Chem Soc 1979:2696; J Nat Prod 43:708 (1980) |
| 8228 | Lundin A, et al. Two novel fusion inhibitors of human respiratory syncytial virus. Antiviral Res. 2010 Dec;88(3):317-24. |
| 8229 | Barbachyn MR, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem. 1996;39(3):680-685. |
| 8230 | Nicole Salazar-Austin, et al. Sutezolid. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2559-2563). CRC Press. |
| 8231 | Zhu T, et al. Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2014;58(6):3306-3311. |
| 8232 | Smith PF, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. |
| 8233 | Salzwedel K, et al. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007 Jul-Sep;9(3):162-72. |
| 8234 | Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13. |
| 8235 | Huang DM, et al. Modulation of anti-adhesion molecule MUC-1 is associated with arctiin-induced growth inhibition in PC-3 cells. Prostate. 2004 May 15;59(3):260-7. |
| 8236 | Knipping K, et al. In vitro and in vivo anti-allergic effects of Arctium lappa L. Exp Biol Med (Maywood). 2008 Nov;233(11):1469-77. |
| 8237 | Zeng Y, et al. Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Lett. 2005 May 26;222(2):145-51. |
| 8238 | Wu JG, et al. Ameliorative effects of arctiin from Arctium lappa on experimental glomerulonephritis in rats. Phytomedicine. 2009 Nov;16(11):1033-41. |
| 8239 | Ma ST, et al. Effect of arctiin on glomerular filtration barrier damage in STZ-induced diabetic nephropathy rats. Phytother Res. 2013 Oct;27(10):1474-80. |
| 8240 | Matsuzaki Y, et al. Arctiin induces cell growth inhibition through the down-regulation of cyclin D1 expression. Oncol Rep. 2008 Mar;19(3):721-7. |
| 8241 | http://www.truthinaging.com/ingredients/etidronic-acid |
| 8242 | Biggadike K, et al. Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma. J Med Chem. 2016 Mar 10;59(5):1711-26. |
| 8243 | Veve MP, et al. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20. |
| 8244 | Chen SF, et al. Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations. J Mol Model. 2013 Nov;19(11):5097-5112. |
| 8245 | Freeman-Cook KD, et al. Design of selective, ATP-competitive inhibitors of Akt. J Med Chem. 2010 Jun 24;53(12):4615-4622. |
| 8246 | Drugs Cosmet Ind 109(3):36, 171 (1971); Toxicology 3:33 (1975); Ind Med Surg 38(2):64 (1969) |
| 8247 | Zhang LQ, et al. Aloesin Suppresses Cell Growth and Metastasis in Ovarian Cancer SKOV3 Cells through the Inhibition of the MAPK Signaling Pathway. Anal Cell Pathol (Amst). 2017;2017:8158254. |
| 8248 | Wahedi HM, et al. Aloesin from Aloe vera accelerates skin wound healing by modulating MAPK/Rho and Smad signaling pathways in vitro and in vivo. Phytomedicine. 2017 May 15;28:19-26. |
| 8249 | SMITH L, ROLITETRACYCLINE, AN ANTIBIOTIC FOR PARENTERAL USE. (SYNTETRIN, VELACYCLINE). JAMA. 1964 Jan 11;187:141. |
| 8250 | Rolitetracycline |
| 8251 | Blackwood R K, et al. Structure–Activity Relationships in the Tetracycline Series. Advances in applied microbiology, 1970, 13:237-266. |
| 8252 | Gao H, et al. Saikosaponin A inhibits IL-1β-induced inflammatory mediators in human osteoarthritis chondrocytes by activating LXRα. Oncotarget. 2017 Sep 30;8(51):88941-88950. |
| 8253 | Etienne Thoreau, et al. Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1736-1741. |
| 8254 | J Aubert, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol. 2018 Aug;179(2):442-456. |
| 8255 | Costales MG, et al. Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. J Am Chem Soc. 2017 Mar 8; 139(9):3446-3455. |
| 8256 | Z Naturforsch B 18: 284 (1963) |
| 8257 | Antimicrob Agents Chemother 1969:244; 1:35, 303 (1972) |
| 8258 | Drugs 21:401 (1981); Psychopharmacol 95 Suppl:1 (1988); J Clin Psychiatry 66:469 (2005) |
| 8259 | Xiang P, et al. Effects of organophosphorus flame retardant TDCPP on normal human corneal epithelial cells: Implications for human health. Environ Pollut. 2017 Nov;230:22-30. |
| 8260 | Killilea DW, et al. Flame retardant tris(1,3-dichloro-2-propyl)phosphate (TDCPP) toxicity is attenuated by N-acetylcysteine in human kidney cells. Toxicol Rep. 2017 May 17;4:260-264. |
| 8261 | J Neural Transm Suppl. 52:39 (1998) |
| 8262 | Allard M, et al. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. J Pharm Biomed Anal. 2017 Aug 5;142:42-48. |
| 8263 | JAMA 178:1000 (1961); FEBS Lett 199:92 (1986); Drugs 55:191 (1998) |
| 8264 | Arzneim Forsch 35:703, 844 (1985); |
| 8265 | Fang Z, et al. Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors. Bioorg Med Chem Lett. 2017 Jul 15;27(14):3201-3204. |
| 8266 | Yamada K, Furukawa T. [Behavioral effects of a new antidepressant, setiptiline]. Nihon Yakurigaku Zasshi. 1991 Jan;97(1):31-9. |
| 8267 | Kamimura M, Aoba A, Yamaguchi N et al. The effect of age on plasma level of setiptiline maleate in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Oct;18(6):1015-26. |
| 8268 | Kuniyoshi M, Nakamura J, Miura C, Inanaga K. Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Mar;18(2):339-46. |
| 8269 | Niho T, Ito C, Shibutani Y, Hashizume H, Yamaguchi K. [Pharmacological properties of MO-8282, a novel antidepressant]. Nihon Yakurigaku Zasshi. 1986 Oct;88(4):309-20. |
| 8270 | Al-Shamma HA et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther. 2010 Jan;332(1):281-90. |
| 8271 | Teegarden BR et al. Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia. J Med Chem. 2010 Mar 11;53(5):1923-36. |
| 8272 | Cid JM, et al. Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor. J Med Chem. 2014 Aug 14;57(15):6495-512. |
| 8273 | Yeo H, et al. Synthesis and antiviral activity of helioxanthin analogues. J Med Chem. 2005 Jan 27;48(2):534-46. |
| 8274 | Ying C, et al. Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. Antivir Chem Chemother. 2010;21(2):97-103. |
| 8275 | Kim DJ, et al. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res. 2012 Jun 15;72(12):3060-8. |
| 8276 | Hermanson SB, et al. Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation.PLoS One. 2012;7(8):e43580. Epub 2012 Aug 28. |
| 8277 | Deng, Xianming., et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology (2011), 7(4), 203-205. |
| 8278 | Koshibu K, et al. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease. Pharmacology. 2015;96(5-6):240-7. |
| 8279 | Weygant N, et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014 May 6;13:103. |
| 8280 | M I Gluckman, et al. The pharmacology of iprindole, a new antidepressant. Psychopharmacologia. 1969;15(3):169-85. |
| 8281 | Yijun Deng, et al. Process Development of the Soft Histone Deacetylate Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation. Org. Process Res. Dev. 2016, 20, 10, 1812-1820. |
| 8282 | Cho IH, et al. Astragalin inhibits airway eotaxin-1 induction and epithelial apoptosis through modulating oxidative stress-responsive MAPK signaling. BMC Pulm Med. 2014 Jul 29;14:122. |
| 8283 | Li F, et al. Inhibitory effects of astragalin on lipopolysaccharide-induced inflammatory response in mouse mammary epithelial cells. J Surg Res. 2014 Dec;192(2):573-81. |
| 8284 | Li F, et al. Astragalin suppresses inflammatory responses via down-regulation of NF-κB signaling pathway in lipopolysaccharide-induced mastitis in a murine model. Int Immunopharmacol. 2013 Oct;17(2):478-82. |
| 8285 | Kim MS, et al. Inhibitory effect of astragalin on expression of lipopolysaccharide-induced inflammatory mediators through NF-κB in macrophages. Arch Pharm Res. 2011 Dec;34(12):2101-7. |
| 8286 | Soromou LW, et al. Astragalin attenuates lipopolysaccharide-induced inflammatory responses by down-regulating NF-κB signaling pathway. Biochem Biophys Res Commun. 2012 Mar 9;419(2):256-61. |
| 8287 | Lancet 349:528 (1997); Eur J Clin Pharmacol 56:263 (2000) |
| 8288 | Wang JH, et al. Effects of bavachin and its regulation of melanin synthesis in A375 cells. Biomed Rep. 2016 Jul;5(1):87-92. Epub 2016 May 20. |
| 8289 | Lee H, et al. Bavachin from Psoralea corylifolia Improves Insulin-Dependent Glucose Uptake through Insulin Signaling and AMPK Activation in 3T3-L1 Adipocytes. Int J Mol Sci. 2016 Apr 8;17(4):527 |
| 8290 | Zarmouh NO, et al. Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B. Evid Based Complement Alternat Med. 2015;2015:852194 |
| 8291 | Park J, et al. Activation of Estrogen Receptor by Bavachin from Psoralea corylifolia. Biomol Ther (Seoul). 2012 Mar;20(2):183-8 |
| 8292 | Sateesha S, et al. Formulation development and rheological studies of palatable cefetamet pivoxil hydrochloride dry powdersuspension. Daru. 2011;19(2):118-125. |
| 8293 | J Pract Chem 89:11 (1914) |
| 8294 | J Chem Soc 99:270 (1911); J Sci Technol Sect B 25:157 (1944); 33:54 (1951); 38:718 (1957) |
| 8295 | Kerres N, et al. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6. Cell Rep. 2017 Sep 19;20(12):2860-2875. |
| 8296 | Zheng Y, et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol. 2003 Mar-Apr;47(2):158-65. |
| 8297 | Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation. 2002 Nov 15;74(9):1335-41. |
| 8298 | Kovalenko M, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994 Dec 1;54(23):6106-14. |
| 8299 | Ludewig D, et al. PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res. 2000 Jan;299(1):97-103. |
| 8300 | Zhang Q, et al. Small-molecule synergist of the Wnt/beta-catenin signaling pathway. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7444-8. |
| 8301 | Manish K. Singh, et al. Structure-activity Relationship Studies of QS11, a Small Molecule Wnt Synergistic Agonist. Bioorg Med Chem Lett. 2015 Nov 1; 25(21): 4838–4842. |
| 8302 | J Org Chem 19:1774 (1954); Aust J Chem 20: 1277 (1967)| |
| 8303 | Pan JX, et al. Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma. Am J Cancer Res. 2018 Jan 1;8(1):154-164. eCollection 2018. |
| 8304 | J Antimicrob Chemother 41:149 (1998); 51:497 (2003) |
| 8305 | Johannes JW, et al. Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1138-43. |
| 8306 | Xie HZ, et al. Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors. J Biomol Struct Dyn. 2011 Aug;29(1):165-79. |
| 8307 | Kim DE, et al. The protective effect of hispidin against hydrogen peroxide-induced apoptosis in H9c2 cardiomyoblast cells through Akt/GSK-3β and ERK1/2 signaling pathway. Exp Cell Res. 2014 Oct 1;327(2):264-75. |
| 8308 | Sun DX, et al. Inhibitory effects of curcumenol on human liver cytochrome P450 enzymes. Phytother Res. 2010 Aug;24(8):1213-6. |
| 8309 | Lo JY, et al. Curcumenol isolated from Curcuma zedoaria suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells. Food Funct. 2015 Nov;6(11):3550-9. |
| 8310 | Du Yeon Bang, et al.Toxicological Characterization of Phthalic Acid. Toxicol Res 2011;27:191−203 |
| 8311 | Zhang X, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9623-8. |
| 8312 | De Simone V, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015 Jul;34(27):3493-503. |
| 8313 | J Org Chem 11:610 (1946) |
| 8314 | Ouyang L, et al. Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson's Disease Treatment. J Med Chem. 2018 Apr 12;61(7):2776-2792. |
| 8315 | Costa-Mattioli M, et al. eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell. 2007 Apr 6;129(1):195-206. |
| 8316 | Yahiro K, et al. Regulation of subtilase cytotoxin-induced cell death by an RNA-dependent protein kinase-like endoplasmic reticulum kinase-dependent proteasome pathway in HeLa cells. Infect Immun. 2012 May;80(5):1803-14. |
| 8317 | Dunyak BM, et al. Selective Targeting of Cells via Bispecific Molecules That Exploit Coexpression of TwoIntracellular Proteins. ACS Chem Biol. 2015 Nov 20;10(11):2441-7. |
| 8318 | Gillman KW, et al. Letter Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. Med Chem Lett, 2010, 1 (3), 120-124. |
| 8319 | Crump CJ, et al. BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry. 2012 Sep 18;51(37):7209-11. |
| 8320 | Xie M, et al. γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer. J Cell Biochem. 2015 Jun;116(6):1019-27. |
| 8321 | Borghys H, et al. A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators. J Alzheimers Dis. 2012;28(4):809-22. |
| 8322 | Arzneim Forsch 15:1441 (1965); Pediatrics 88:215 (1991) |
| 8323 | Yakugaku Zasshi 87: 325 (1967); Arch Insect Biochem Phsiol 33: 231 (1996); J Neurosci 18: 8886 (1998) |
| 8324 | Valavanidis A, et al. 8-hydroxy-2' -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):120-39. |
| 8325 | Xiang Y, et al. Paeoniflorin: a monoterpene glycoside from plants of Paeoniaceae family with diverse anticancer activities. J Pharm Pharmacol. 2020;72(4):483-495. |
| 8326 | Cao BY, et al. Paeoniflorin, a potent natural compound, protects PC12 cells from MPP+ and acidic damage via autophagic pathway. J Ethnopharmacol. 2010;131(1):122-129. |
| 8327 | Yan D, et al. Paeoniflorin, a novel heat shock protein-inducing compound. Cell Stress Chaperones. 2004;9(4):378-389. |
| 8328 | Hampel P, et al. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B. Sci Rep. 2018 Jun 29;8(1):9877. |
| 8329 | Kim EJ, et al. Pharmacokinetics and pharmacodynamics of intravenous azosemide in mutant Nagaseanalbuminemic rats. Drug Metab Dispos. 2003 Feb;31(2):194-201. |
| 8330 | Arch Int Pharmacodyn Ther 163:284 (1966) |
| 8331 | Arzneim Forsch 18:524 (1968) |
| 8332 | Diaz P, et al. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, theHuman Liver Retinoic Acid Hydroxylase. J Med Chem. 2016 Mar 24;59(6):2579-95. |
| 8333 | Topletz AR, et al. Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in theelimination of active retinoids. Mol Pharmacol. 2015;87(3):430-41. |
| 8334 | Faith Stevison, et al. CYP26 Inhibition Increases Retinoic Acid Concentrations in Target Tissues and Alters Retinoid Signaling |
| 8335 | Tripathy S, et al.All-Trans-Retinoic Acid Enhances Mitochondrial Function in Models of Human Liver. Mol Pharmacol. 2016 May;89(5):560-74. |
| 8336 | Bovenschen HJ, et al. Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. Br J Dermatol. 2007 Feb;156(2):263-70. |
| 8337 | Am. J. Hosp. Pharm. (1980), 37(9), 1199-205; Antibiot. Annu. (1960), 893-8; Antibiot. Annu. (1959), 364-74| |
| 8338 | David E. Kleiner, et al. Learn more about Erythromycin Estolate. Biomaterials and Medical Device - Associated Infections, 2015 |
| 8339 | Lu X, et al. Integrated systems toxicology approaches identified the possible involvement of ABC transporters pathway in erythromycin estolate-induced liver injury in rat. Food Chem Toxicol. 2014 Mar;65:343-55. |
| 8340 | Miyabayashi T et al. Wnt/beta-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci U S A, 2007 Mar 27, 104(13):5668-73. |
| 8341 | D'Alise AM, et al. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol Cancer Ther. 2008 May;7(5):1140-9. |
| 8342 | Qin HX, et al. Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo. Cytotechnology. 2013 Aug;65(4):643-53. |
| 8343 | Leysen JE, et al. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol. 1985 Jun;27(6):600-11. |Headache 30:439 (1990); Sleep 16:647 (1993); Prog Neuropsycho Biol Psychiatry 32:1879 (2008) |
| 8344 | Allensworth JL, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat. 2013 Jan;137(2):359-71. |
| 8345 | Krepler C, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013 Apr 1;19(7):1784-94. |
| 8346 | Nguyen QD, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013 Jul 15;19(14):3914-24. |
| 8347 | Benetatos CA, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79. |
| 8348 | Cao Y, et al. Licochalcone B, a chalcone derivative from Glycyrrhiza inflata, as a multifunctional agent for the treatment of Alzheimer's disease. Nat Prod Res. 2018 Oct 22:1-4. |
| 8349 | https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/03/032385 |
| 8350 | Biochim Biophys Res Commun 189:280 (1992); Experientia 52:865 (1996) |
| 8351 | Sahu PK, et al. Structure-based Discovery of Narirutin as a Shikimate Kinase Inhibitor with Anti-tubercular Potency.Curr Comput Aided Drug Des. 2019 Oct 25. |
| 8352 | Funaguchi N, et al. Narirutin inhibits airway inflammation in an allergic mouse model.Clin Exp Pharmacol Physiol. 2007 Aug;34(8):766-70. |
| 8353 | Lazo JS, et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol. 2002 Apr;61(4):720-8. |
| 8354 | Dubey NK, et al. NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway. Int J Mol Sci. 2018 May 31;19(6). pii: E1625. |
| 8355 | Czodrowski P, et al. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. J Med Chem. 2016 Oct 27;59(20):9337-9349. |
| 8356 | Nan A, et al. N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs. J Control Release. 2001 Dec 13;77(3):233-43. |
| 8357 | Hao Tang, et al. Comb-like Poly(N-(2-hydroxypropyl) methacrylamide) Doxorubicin Conjugates: The Influence of Polymer Architecture and Composition on the Biological Properties. Chinese Journal of Polymer Science volume 36, pages1225-1238(2018). |
| 8358 | C D Morris, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer. 2005 Jun 20;92(12):2148-52. |
| 8359 | Laura Rosanò, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011 Apr 15;17(8):2350-60. |
| 8360 | Laura Rosanò, et al. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther. 2007 Jul;6(7):2003-11. |
| 8361 | https://clinicaltrials.gov/ct2/show/NCT04278404?term=Cefepime&cond=covid&draw=2&rank=1 |
| 8362 | Praxis (2001), 90(33), 1346-9; J. Vet. Med., Ser. B (1997), 44(4), 193-7 |
| 8363 | Patel K, et al. ACTB-1003: An oral kinase inhibitor targeting cancer mutations (FGFR), angiogenesis (VEGFR2, TEK), and induction of apoptosis (RSK and p70S6K). Journal of Clinical Oncology 28, no. 15 DOI: 10.1200/jco.2010.28.15_suppl.e13665 |
| 8364 | Helv Chim Acta 20: 705 (1937) |
| 8365 | Xin ZC, et al. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8. |
| 8366 | Lu YF, et al. Icariin is a PPARα activator inducing lipid metabolic gene expression in mice. Molecules. 2014 Nov 6;19(11):18179-91. |
| 8367 | Hu Y, et al. Effects and mechanisms of icariin on atherosclerosis. Int J Clin Exp Med. 2015 Mar 15;8(3):3585-9. |
| 8368 | Chen M, et al. Effects of icariin on reproductive functions in male rats. Molecules. 2014 Jul 3;19(7):9502-14. |
| 8369 | Liu D, et al. Icariin protects rabbit BMSCs against OGD-induced apoptosis by inhibiting ERs-mediated autophagy via MAPK signaling pathway. Life Sci. 2020 Apr 26:117730. |Planta Med 61: 523 (1995); J Chromatog A 963: 239 (2002) |
| 8370 | Browne LJ, et al. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34(2):725-36. |
| 8371 | Gunson DE, et al. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer. 1995 Jul;72(1):72-5. |
| 8372 | Morales-Montor J, et al. Inhibition of p-450 aromatase prevents feminisation and induces protection during cysticercosis. Int J Parasitol. 2002 Oct;32(11):1379-87. |
| 8373 | https://clinicaltrials.gov/ct2/show/NCT04952519?term=AMANTADINE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04894617?term=AMANTADINE&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04854759?term=AMANTADINE&cond=COVID-19&draw=2&rank=3 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-001144-98-PL https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-001177-22-DK |
| 8374 | Ashley C W Pike, et al. Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. EMBO J. 2008 Feb 20;27(4):704-14. |
| 8375 | Oleg Fedorov, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76. |
| 8376 | Ronghui Lin, et al. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11. |
| 8377 | Rabasseda X, et al. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc). 2003 May;39(5):359-71. |
| 8378 | Keam SJ, et al. Brivudin (bromovinyl deoxyuridine). Drugs. 2004;64(18):2091-7; discussion 2098-9. |
| 8379 | Senisterra G, et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J. 2013 Jan 1;449(1):151-159. |
| 8380 | Eur. J. Clin. Pharmacol. (1975), 8(3-4), 233-40; J. Pharmacol. Exp. Ther. (1953), 109, 372-6; J. Pharmacol. (1940), 70, 165-70 |
| 8381 | J Am Chem Soc 70: 3165 (1948); Proc Ind Acad Sci 35A:233 (1952); Ber 92:2071 (1959); J Appl Toxicol 11:85 (1991); Pediatrics 7:707 (1996) |
| 8382 | Wang L, et al. Development of dimeric modulators for anti-apoptotic Bcl-2 proteins. Bioorg Med Chem Lett. 2008 Jan 1;18(1):236-40. |
| 8383 | Porter JR, et al. Profiling small molecule inhibitors against helix-receptor interactions: the Bcl-2 family inhibitor BH3I-1 potently inhibits p53/hDM2. Chem Commun (Camb). 2010 Nov 14;46(42):8020-2. |
| 8384 | Degterev A, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 2001 Feb;3(2):173-82. |
| 8385 | Ber 56: 875 (1923); J Org Chem 33: 2785 (1968) |
| 8386 | Clarke JH, et al. The function of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) explored using a specific inhibitor that targets the PI5P-binding site. Biochem J. 2015 Mar 1;466(2):359-67. |
| 8387 | Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311(2):502-9. |
| 8388 | Dittrich Ch, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80. |
| 8389 | Arzneim Forsch 26:1404 (1976); Thorax, 32:717 (1977); Circulation 101:2213 (2000) |
| 8390 | Aimin Song, et al. A convenient synthesis of coumarin-3-carboxylic acids via Knoevenagel condensation of Meldrum's acid with ortho-hydroxyaryl aldehydes or ketones. Tetrahedron Letters. 2003 Feb;44(9): 1755-1758. |
| 8391 | Kostova I, et al. New Samarium(III), Gadolinium(III), and Dysprosium(III) Complexes of Coumarin-3-Carboxylic Acid as Antiproliferative Agents. Met Based Drugs. 2007;2007:15925. |
| 8392 | Clin Ter 56:121 (9171); Acta Med Scand 1984 Suppl 680:1 |
| 8393 | Drug Intell. Clin. Pharm. (1985), 19(1), 5-12; Arzneim. Forsch. (1976), 26(5A), 981-5; Arzneim. Forsch. (1974), 24(4), 573-6 |
| 8394 | Blonanserin |
| 8395 | Saori Takeuchi, et al. Blonanserin ameliorates social deficit through dopamine-D 3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. Neurochem Int. 2019 Sep;128:127-134. |
| 8396 | Morokutti-Kurz M , et al. Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat. Int J Gen Med. 2017 Feb 28;10:53-60. |
| 8397 | Matthews D, et al. Spectrum of bactericidal action of amylmetacresol/2,4-dichlorobenzyl alcohol lozenges against oropharyngeal organisms implicated in pharyngitis. Int J Gen Med. 2018 Nov 28;11:451-456. |
| 8398 | Steven B, et al. Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics: December 2009; Volume 8, Issue 12, Supplement 1. |
| 8399 | Wen W, et al. Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitors. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4562-6. |
| 8400 | Kaufmann K, et al. ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chem Neurosci. 2013 Sep 18;4(9):1278-86. |
| 8401 | https://clinicaltrials.gov/ct2/show/NCT03262051?term=FLURBIPROFEN&cond=Covid19&draw=2&rank=1 |
| 8402 | Chem Commun 1967:30; JACS 91:3400 (1969); Natural Toxins 7:305 (1999) |
| 8403 | Cottone P, et al. FG 7142 specifically reduces meal size and the rate and regularity of sustained feeding in female rats: evidence that benzodiazepine inverse agonists reduce food palatability.Neuropsychopharmacology. 2007 May;32(5):1069-81. Epub 2006 Nov 1. |
| 8404 | Parenti MD, et al. Discovery of novel and selective SIRT6 inhibitors. J Med Chem. 2014 Jun 12;57(11):4796-804. |
| 8405 | Cea M, et al. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 3;127(9):1138-50. |
| 8406 | Jiang H, et al. SIRT6 Inhibitor, OSS_128167 Restricts Hepatitis B Virus Transcription and Replication Through Targeting Transcription Factor Peroxisome Proliferator-Activated Receptors α. Front Pharmacol. 2019 Oct 25;10:1270. |
| 8407 | Nicodeme E, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010 Dec 23;468(7327):1119-23. |
| 8408 | Filippakopoulos P, et al. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014 May;13(5):337-56. |
| 8409 | Venkateshwar Rao GUMMADI, et al. Bicyclic heterocyclyl derivatives as irak4 inhibitors. WO2015104688A1. |
| 8410 | Cui B, et al. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A. J Clin Endocrinol Metab. 2014 Jun;99(6):E962-70. |
| 8411 | Zhang Z, et al. Targeting cancer stem cells with p53 modulators. Oncotarget. 2016 Apr 8. |
| 8412 | Rao CV, et al. Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia. 2013 Sep;15(9):1018-27. |
| 8413 | https://clinicaltrials.gov/ct2/show/NCT04591210?term=Enalaprilat&cond=Covid19&draw=2&rank=3 |
| 8414 | Nam HJ, et al. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett. 2011 Mar 28;302(2):155-65. |
| 8415 | Cha MY, et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in CP-358774-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54. |
| 8416 | Kang MH, et al. Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. Cancer Res Treat. 2015 Mar 5. |
| 8417 | Klein J. Phenserine. Expert Opin Investig Drugs. 2007 Jul;16(7):1087-97. |
| 8418 | Asuni AA, et al. Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model. Ann Neurol. 2014 May;75(5):684-99. |
| 8419 | Janas AM, et al. The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats. Life Sci. 2005 Jan 21;76(10):1073-81. |
| 8420 | Johnström P, et al. Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. Nucl Med Biol. 2015 Jun;42(6):555-60. |
| 8421 | Jucaite A, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700. |
| 8422 | Curr Sci 48:534 (1979) |
| 8423 | T M Lin, et al. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs. J Pharmacol Exp Ther. 1986 Nov;239(2):406-10. |
| 8424 | Shen Li, et al. Abstract 4004: The H2 receptor antagonist nizatidine inhibits carcinogenesis in two rodent models of hepatocellular carcinoma. Tumor Biology. Cancer research. |
| 8425 | Ahmed S. Alazzouni, et al. Comparative histological and histochemical studies between ranitidine and nizatidine in treatment of peptic ulcer with evaluation of their adverse effects on male sex hormones. The Journal of Basic and Applied Zoology volume |Clin Pharmacol Ther 37:162 (1985); Arzneim Forsch 39:240 (1989) |
| 8426 | Chem Ind 1957:47; Phytochemistry 14:309 (1975); Br J Cancer 72:1380 (1995): Cancer Lett 114:207 (1997); Carcinogenesis 23:1677 (2002) |
| 8427 | Lo YC, et al. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential. Sci Rep. 2017 Sep 12;7(1):11261. |
| 8428 | Havercroft JC, et al. Binding of parbendazole to tubulin and its influence on microtubules in tissue-culture cells as revealed by immunofluorescence microscopy. J Cell Sci. 1981 Jun;49:195-204. |
| 8429 | Foster KE, et al. A mutant beta-tubulin confers resistance to the action of benzimidazole-carbamate microtubule inhibitors both in vivo and in vitro. Eur J Biochem. 1987 Mar 16;163(3):449-55. |
| 8430 | Roupe KA, et al. Preparative enzymatic synthesis and HPLC analysis of rhapontigenin: applications to metabolism, pharmacokinetics and anti-cancer studies.J Pharm Pharm Sci. 2005 Aug 22;8(3):374-86. |
| 8431 | Yeh YH, et al. Rhapontigenin inhibits TGF-β-mediated epithelial‑mesenchymal transition via the PI3K/AKT/mTOR pathway and is not associated with HIF-1α degradation.Oncol Rep. 2016 May;35(5):2887-95. |
| 8432 | Park EK, et al. Antithrombotic and antiallergic activities of rhaponticin from Rhei Rhizoma are activated by human intestinal bacteria.Arch Pharm Res. 2002 Aug;25(4):528-33. |
| 8433 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=NICARDIPINE&cond=covid&draw=2&rank=3 |
| 8434 | Zhang C, et al. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). Eur J Med Chem. 2018 May 10;151:304-314. |
| 8435 | Ann Pharm Fr 20:463 (1962) |
| 8436 | Biochem. Pharmacol. (1979), 28(14), 2161-5; J. Pharm. Pharmacol. (1979), 31(5), 344-7; Naunyn-Schmiedeberg's Arch. Pharmacol. (1980), 315(2), 89-102 |
| 8437 | Z Naturforsch B 25: 49 (1970) |
| 8438 | Crandon JL, et al. In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens. 2015 Aug 18;4(3):620-5. |
| 8439 | Crandon JL, et al. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015 May;59(5):2688-94. |
| 8440 | Casey J N Mathison , et al. Efficacy and Tolerability of Pyrazolo[1,5- a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma. ACS Med Chem Lett. 2020 Feb 12;11(4):558-565. |
| 8441 | Aliment Pharmacol Ther 19:655 (2004); Biochem Pharmacol 71:837 (2006) |
| 8442 | J Am Chem Soc 93: 3546 (1971)| |
| 8443 | Wada, K., et al., Isolation of bilobalide and ginkgolide A from Ginkgo biloba L. shorten the sleeping time induced in mice by anesthetics. Biol Pharm Bull, 1993. 16(2): p. 210-2. |
| 8444 | Ahlemeyer, B. and J. Krieglstein, Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry, 2003. 36(S 1): p. 8-14. |
| 8445 | Pure Appl. Chem. (1993), 65(3), 515-20; Invest. Radiol. (1992), 27(Suppl. 1), 2-6; Inorg. Chem. (1991), 30(6), 1265-9 |
| 8446 | Singh A, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol. 2016 Nov 18;11(11):3214-3225. |
| 8447 | Xinnong Liu, et al. Isoliquiritigenin ameliorates acute pancreatitis in mice via inhibition of oxidative stress and modulation of the Nrf2/HO-1 pathway. Oxid Med Cell Longev. 20 March 2018. |
| 8448 | Xian P, et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice.Theranostics. 2019 Aug 14;9(20):5956-5975. |
| 8449 | Remacle AG, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 2012 May 1;72(9):2339-49. |
| 8450 | Wang Z, et al. Eriocitrin from lemon suppresses the proliferation of human hepatocellular carcinoma cells through inducing apoptosis and arresting cell cycle. Cancer Chemother Pharmacol. 2016 Dec;78(6):1143-1150. |
| 8451 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Fostamatinib&cntry=&state=&city=&dist= |
| 8452 | Kanbara Y, et al. Nanomolar concentration of triclocarban increases the vulnerability of rat thymocytes to oxidative stress. J Toxicol Sci. 2013 Feb;38(1):49-55. |
| 8453 | Huang H, et al. The in vitro estrogenic activities of triclosan and triclocarban. J Appl Toxicol. 2014 Sep;34(9):1060-7. |
| 8454 | Kennedy RC, et al. Early life triclocarban exposure during lactation affects neonate rat survival. Reprod Sci. 2015 Jan;22(1):75-89. |
| 8455 | Reynoird N, et al. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreaticcancer. Genes Dev. 2016 Apr 1;30(7):772-85. |
| 8456 | Eggert E, et al. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2. J Med Chem. 2016 May 26;59(10):4578-600. |
| 8457 | Meihua She, et al. Piromelatine, a Novel Melatonin Receptor Agonist, Stabilizes Metabolic Profiles and Ameliorates Insulin Resistance in Chronic Sleep Restricted Rats. Eur J Pharmacol. 2014 Mar 15;727:60-5. |
| 8458 | L Huang, et al. Blood Pressure Reducing Effects of Piromelatine and Melatonin in Spontaneously Hypertensive Rats. Eur Rev Med Pharmacol Sci. 2013 Sep;17(18):2449-56. |
| 8459 | Yuan-Yuan Liu, et al. Piromelatine Exerts Antinociceptive Effect via Melatonin, Opioid, and 5HT1A Receptors and Hypnotic Effect via Melatonin Receptors in a Mouse Model of Neuropathic Pain. Psychopharmacology (Berl). 2014 Oct;231(20):3973-85. |
| 8460 | Phytochem 35:331 (1994) |
| 8461 | Kwon G, et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis. Oncotarget. 2017 Jun 16;8(43):74217-74232. |
| 8462 | Cha JJ, et al. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest. 2017 Apr;97(4):419-431. |
| 8463 | Guangrong Zheng, et al. Agents de dégradation de protéines bcl-2 pour le traitement du cancer. WO2019144117A1. |
| 8464 | https://clinicaltrials.gov/ct2/show/NCT04482621?term=Decitabine&cond=covid-19&draw=2&rank=1 |
| 8465 | Paick, J.S., et al., Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med, 2008. 5(11): p. 2672-80. |
| 8466 | Kim, B.H., et al., Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther, 2009. 31(6): p. 1234-43. |
| 8467 | Shin, K.H., et al., The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther, 2009. 31(12): p. 3009-20. |
| 8468 | Arch. Int. Pharmacodyn. Ther. (1991), 314, 90-104; J. Pharmacol. Exp. Ther. (1954), 110, 188-204; J. Am. Pharm. Assoc. (1954), 43, 35-8 |
| 8469 | Ohta H, et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.Mol Pharmacol, 2003, 64(4), 994-1005. |
| 8470 | Moughal NA, et al. Protean agonism of the lysophosphatidic acid receptor-1 with Ki16425 reduces nerve growth factor-induced neurite outgrowth in pheochromocytoma 12 cells. J Neurochem, 2006, 98(6), 1920-1929. |
| 8471 | Ma L, et al. Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. J Neurochem, 2009, 109(2), 603-610. |
| 8472 | Yu FX, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012 Aug 17;150(4):780-91. |
| 8473 | Huang F, et al. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol. 2011 Jun 17;6(6):628-35. |
| 8474 | Huang F, et al. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS One. 2014 Jun 27;9(6):e100993. |
| 8475 | Jia Y, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016 Jun 2;534(7605):129-32. |
| 8476 | Wang S, et al. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 2017 Jan 28;385:51-54. |
| 8477 | Dransfield PJ, et al. Novel Series of Potent Glucokinase Activators Leading to the Discovery of AM-2394. ACS Med Chem Lett. 2016 May 23;7(7):714-8. |
| 8478 | Vincent BM, et al. A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance. Cell Chem Biol. 2016 Aug 18;23(8):978-991. |
| 8479 | Am J Cardiol 84:511 (1999); Circulation 100:21 (1999); Drugs Aging 14:63 (1999) |
| 8480 | J Gastroenterol Hepatol 18:851 (2003); Am J Physiol Heart Circ Physiol 289:H2514 (2005) |
| 8481 | J. Cardiovasc. Pharmacol. (1987), 10(Suppl. 12), S100-S103; Drugs (1983), 26(3), 212-29; Clin. Pharmacol. Ther. (1976), 19(6), 732-7 |
| 8482 | Kirshner JR, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 2008 Aug;7(8):2319-27. |
| 8483 | Bair JS, et al. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death. J Am Chem Soc. 2010 Apr 21;132(15):5469-7 |
| 8484 | Liam M Guthrie, et al. Elesclomol alleviates Menkes pathology and mortality by escorting Cu to cuproenzymes in mice. Science. 2020 May 8;368(6491):620-625. |
| 8485 | Starenki D, et al. Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo. Endocrinol Metab (Seoul). 2015 Dec;30(4):593-603. |
| 8486 | Li X, et al. Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. ACS Med Chem Lett. 2013 Nov 14;4(11). |
| 8487 | Weisberg EL, et al. In vivo administration of MKT-077 causes partial yet reversible impairment of mitochondrial function. Cancer Res. 1996 Feb 1;56(3):551-5. |
| 8488 | Zisapel N. Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-411. |
| 8489 | Horoszok L, et al. A single-dose, randomized, double-blind, double dummy, placebo and positive-controlled, five-way cross-over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects. Hum Psychopharmacol. 2014 May;29(3):266-273. |
| 8490 | Mohammadi Ziarani G, et al. The molecular diversity scope of 4-hydroxycoumarin in the synthesis of heterocyclic compounds via multicomponent reactions. Mol Divers. 2019 Jan 29. doi: 10.1007/s11030-019-09918-7. |
| 8491 | Haskell CA, et al. Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol. 2006 Jan;69(1):309-16. |
| 8492 | Helv Chim Acta 11: 864 (1928) |
| 8493 | Asano S, et al. 5,6,7,8-Tetrahydropyrido[4,3-d]pyrimidines as novel class of potent and highly selective CaMKII inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6696-8. |
| 8494 | Morrison R, et al. Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines. Eur J Med Chem. 2016 Mar 3;110:326-39. |
| 8495 | Cuendet M, et al. Multiple myeloma regression mediated by bruceantin. Clin Cancer Res. 2004 Feb 1;10(3):1170-9. |
| 8496 | Cuendet M, et al. Antitumor activity of bruceantin: an old drug with new promise. J Nat Prod. 2004 Feb;67(2):269-72. |
| 8497 | Xi Chen, Shijun Zhong, Xiao Zhu, et al. Rational Design of Human DNA Ligase Inhibitors that Target Cellular DNA Replication and Repair. Cancer Res 2008; 68: (9). May 1, 2008 |
| 8498 | Prangsaengtong O, et al. Enhancement of Lymphangiogenesis In Vitro via the Regulations of HIF-1α Expression and Nuclear Translocation by Deoxyshikonin. Evid Based Complement Alternat Med. 2013;2013:148297. |
| 8499 | Zhang S, et al. Antibacterial effects of Traditional Chinese Medicine monomers against Streptococcus pneumoniae via inhibiting pneumococcal histidine kinase (VicK). Front Microbiol. 2015 May 20;6:479. |
| 8500 | Zhang L, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. |
| 8501 | Lee JW, et al. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLoS One. 2015 Apr 21;10(4):e0122628. |
| 8502 | Best JL et al. Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17622-7 |
| 8503 | Sun H, et al. Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila). 2008 Oct;1(5):316-28. |
| 8504 | Jeong HU, et al. Inhibitory effects of cedrol, β-cedrene, and thujopsene on cytochrome P450 enzyme activities in human liver microsomes. J Toxicol Environ Health A. 2014;77(22-24):1522-32. |
| 8505 | Jin MH, et al. Cedrol Enhances Extracellular Matrix Production in Dermal Fibroblasts in a MAPK-Dependent Manner. Ann Dermatol. 2012 Feb;24(1):16-21 |J Org Chem 43: 1964 (1978); Ann Dermatol 2012 24:16 (2012) |
| 8506 | Balzarini J, et al. Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett. 1997 Jun 30;410(2-3):324-8. |
| 8507 | Emert-Sedlak LA, et al. Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem Biol. 2013 Jan 24;20(1):82-91. |
| 8508 | Callaghan CK, Hok V, Della-Chiesa A, et al. Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457. Neuropharmacology. 2012 Oct;63(5):890-7. |
| 8509 | Codony X, Vela JM, Ramírez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol. 2011 Feb;11(1):94-100. |
| 8510 | Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011 May;26(5):536-44. |
| 8511 | Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res. 2010 Aug;7(5):374-85. |
| 8512 | Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics. 2008 Jul;5(3):458-69. |
| 8513 | SB-742457 |
| 8514 | Phytochemistry 11: 3515 (1972) |
| 8515 | Wang Y, et al. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. Chem Biol. 2015 Feb 19;22(2):273-284. |
| 8516 | Carcinogenesis 6:237 (1985) |
| 8517 | https://clinicaltrials.gov/ct2/show/NCT04399356?term=Niclosamide&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04753619?term=Niclosamide&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04558021?term=Niclosamide&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04858425?term=Niclosamide&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04542434?term=Niclosamide&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04436458?term=Niclosamide&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04603924?term=Niclosamide&cond=COVID-19&draw=2&rank=7 https://clinicaltrials.gov/ct2/show/NCT04932915?term=Niclosamide&cond=COVID-19&draw=2&rank=10 https://clinicaltrials.gov/ct2/show/NCT04870333?term=Niclosamide&cond=COVID-19&draw=2&rank=11 https://clinicaltrials.gov/ct2/show/NCT04644705?term=Niclosamide&cond=COVID-19&draw=2&rank=16 |
| 8518 | Bicker J, et al. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. Eur J Pharm Sci. 2018 May 30;117:35-40. |
| 8519 | Igreja B, et al. Effects of Zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure. Eur J Pharmacol. 2019 Jan 5;842:125-132. |
| 8520 | Boubia B, et al. Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. J Med Chem. 2018 Feb 27. |
| 8521 | Ruzehaji N, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016 Dec;75(12):2175-2183. |
| 8522 | Phytochemistry 14: 2524 (1975); Life Sci 68: 841 (2001) |
| 8523 | Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002, 1(5), 421-432. |
| 8524 | Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 2004, 104(9), 2912-2918. |
| 8525 | Yang JJ, et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 2010 Dec;4(4):201-12. |
| 8526 | Cutaneous Med Practitioner 34:190 (1984); Contact Dermatitis 12:213 91985)| |
| 8527 | Hong J, et al. Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor. Immunopharmacol Immunotoxicol. 2012 Dec;34(6):912-918. |
| 8528 | Berman B, et al. Modulation of expression of epidermal Langerhans cell properties following in situ exposure to glucocorticosteroids. J Invest Dermatol. 1983 Mar;80(3):168-171. |
| 8529 | Quevedo WC Jr, et al. Influence of depigmenting chemical agents on hair and skin color in yellow (pheomelanic) and black (eumelanic) mice. Pigment Cell Res.1990 Mar-Apr;3(2):71-79. |
| 8530 | Pertovaara A, et al.Pharmacological properties, central nervous system effects, and potential therapeutic applicationsof atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev. 2005 Autumn;11(3):273-88. |
| 8531 | Mathy JE, et al, Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother. 2008 Sep;52(9):3267-75. |
| 8532 | Guedj J, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. |
| 8533 | Wang G, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol. 2013 Feb;9(2):84-9. |
| 8534 | Lasko LM, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. 2017 Oct 5;550(7674):128-132. |
| 8535 | Wei W, et al. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer. 2010 May 15;126(10):2426-36. |
| 8536 | Franci G, et al. Identification and characterization of PKF118-310 as a KDM4A inhibitor. Epigenetics. 2017 Mar 4;12(3):198-205. |
| 8537 | Hancox U, et al. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with RP-56976. Mol Cancer Ther. 2015 Jan;14(1):48-58. |
| 8538 | Arch Ind Hyg Occup Med 4:119 (1951) |
| 8539 | Heightman TD, et al. Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J Med Chem. 2018 Jun 14;61(11):4978-4992. |
| 8540 | Biochim Biophys Acta 32:295 (1959); J Med Chem 6:428 (1963); Brit Med J 2:989 (1964); Ann Surg Oncology 5:106 (1998)| |
| 8541 | Seth AK, et al. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications.Pharm Dev Technol. 2004 Aug;9(3):277-89. |
| 8542 | Fauth E, et al. Comparison of spontaneous and idoxuridine-induced micronuclei by chromosome painting. Mutat Res. 1999 Apr 6;440(2):147-56. |
| 8543 | Otto SE. Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. |
| 8544 | De Clercq E. Specific targets for antiviral drugs. Biochem J. 1982;205(1):1-13. |
| 8545 | Strawn LM, et al. Flk-1 as a target for tumor growth inhibition.Cancer Res. 1996 Aug 1;56(15):3540-5. |
| 8546 | Boguslawski G, et al. SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro.J Biol Chem. 2004 Feb 13;279(7):5716-24. |
| 8547 | Arbiser JL, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.Am J Pathol. 2000 Apr;156(4):1469-76. |
| 8548 | Mesti T, et al. Metabolic impact of anti-angiogenic agents on U87 glioma cells.PLoS One. 2014 Jun 12;9(6):e99198. |
| 8549 | Shearstone JR, et al. Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2. PLoS One. 2016 Apr 13;11(4):e0153767. |
| 8550 | J Am Chem Soc 48: 2987 (1926) |
| 8551 | Cheng TC, et al. Potent anti-cancer effect of 3'-hydroxypterostilbene in human colon xenograft tumors. PLoS One. 2014 Nov 12;9(11):e111814. |
| 8552 | Fed Proc 24:641 (1965); Br J Cancer 41:630 (1980) |
| 8553 | Li L, et al. Fluid shear stress inhibits TNF-mediated JNK activation via MEK5-BMK1 in endothelial cells. Biochem Biophys Res Commun. 2008 May 23;370(1):159-63. |
| 8554 | Tatake RJ, et al. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun. 2008 Dec 5;377(1):120-5. |
| 8555 | Badshah II, et al. Erk5 is a mediator to TGFβ1-induced loss of phenotype and function in human podocytes. Front Pharmacol. 2014 Apr 21;5:71. |
| 8556 | Li M, et al. Synthesis and Evaluation of Diphenyl Conjugated Imidazole Derivatives as Potential Glutaminyl Cyclase Inhibitors for Treatment of Alzheimer's Disease. J Med Chem. 2017 Aug 10;60(15):6664-6677. |
| 8557 | Zubovych IO, et al. A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines. Mol Cancer Ther. 2016 Jan;15(1):23-36. |
| 8558 | Kim HS, et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013 Oct 24;155(3):552-66. |
| 8559 | Zhao P, et al. Antiviral, anti-parasitic, and cytotoxic effects of 5,6-dihydroxyindole (DHI), a reactive compound generated by phenoloxidase during insect immune response. Insect Biochem Mol Biol. 2011 Sep;41(9):645-52. |
| 8560 | Heiduschka P, et al. Melanin precursor 5,6-dihydroxyindol: protective effects and cytotoxicity on retinal cells in vitroand in vivo. Toxicol Pathol. 2007 Dec;35(7):1030-8. |
| 8561 | Yumi Ahn, et al. 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145025A2. |
| 8562 | Chen L, et al. Expression of gonadotropin-releasing hormone receptor and effect of gonadotropin-releasing hormone analogue on proliferation of cultured gastric smooth muscle cells of rats. World J Gastroenterol. 2004 Jun 15;10(12):1780-4. |
| 8563 | Chen L, et al. Distribution, cloning and sequencing of GnRH, its receptor, and effects of gastric acid secretion of GnRH analogue in gastric parietal cells of rats. Life Sci. 2005 Feb 4;76(12):1351-65. |
| 8564 | Michael Edward Flaugh, et al. 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists. US 5708187 A. |
| 8565 | Cai Q, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011 Apr 28;54(8):2714-26. |
| 8566 | Brunckhorst MK, et al. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther. 2012 Jul;13(9):804-11. |
| 8567 | Zhang T, et al. Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharm Drug Dispos. 2013 Sep;34(6): |
| 8568 | Palumbo, A., et al. 2-thiouracil is a selective inhibitor of neuronal nitric oxide synthase antagonising tetrahydrobiopterin-dependent enzyme activation and dimerisation. FEBS Lett, 2000. 485(2-3): p. 109-12. |
| 8569 | Napolitano, A., et al., Mechanism of selective incorporation of the melanoma seeker 2-thiouracil into growing melanin. J Med Chem, 1996. 39(26): p. 5192-201. |Nature 168:113 (1951); J Gen Microbiol 16:160 (1954); Proc Royal Soc B 169 89 (1967); J Gen Virol 56:219 (1981) |
| 8570 | J Drug Target 18:589 (2010) |
| 8571 | Drugs 40:291 (1990) |
| 8572 | J Chem Soc 1952:2916; Phytocehmistry 9: 1669 (1970) |
| 8573 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=GUANFACINE&cond=Covid19&draw=2&rank=1 |
| 8574 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=BENDROFLUMETHIAZIDE&cond=covid&draw=2&rank=2 |
| 8575 | Seol Y, et al. Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors. Mol Cancer Ther. 2015 Nov;14(11):2552-9. |
| 8576 | Winter GE, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015 Jun 19;348(6241):1376-81. |
| 8577 | Nikolovska-Coleska Z, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem. 2004;47(10):2430-2440. |
| 8578 | Ahn KS, et al. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol. 2007;71(1):209-219. |
| 8579 | Lee YJ, et al. XIAP inhibitor embelin induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells. Environ Toxicol. 2017;32(11):2371-2378. |
| 8580 | Anal Profiles Drug Subs 20:627 (1991); Fundam Appl Toxicol 18:46 (1992) |
| 8581 | Komatsu S, et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer. 2015 Jan 20;112(2):357-64. |
| 8582 | Ferguson AD, et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011 Sep 7;19(9):1262-73. |
| 8583 | Li LX, et al. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease. J Clin Invest. 2017 Jun 30;127(7):2751-2764. |
| 8584 | Abouelhassan Y, et al. Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria. Int J Antimicrob Agents. 2017 Feb;49(2):247-251. |J Clin Pharmacol Biopharm 17:475 (1979); Pathol Biol 35:879 (1987) |
| 8585 | Liu Q, et al. Effect of daurisoline on HERG channel electrophysiological function and protein expression. J Nat Prod. 2012 Sep 28;75(9):1539-45. |
| 8586 | Wu MY, et al. Natural autophagy blockers, dauricine (DAC) and daurisoline (DAS), sensitize cancer cells tocamptothecin-induced toxicity. Oncotarget. 2017 Sep 8;8(44):77673-77684. |
| 8587 | Shi SJ, et al. Pharmacokinetic-pharmacodynamic modeling of daurisoline and dauricine in beagle dogs. Acta Pharmacol Sin. 2003 Oct;24(10):1011-5. |
| 8588 | X. Zhu, et al. GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment. |
| 8589 | Koji Matsumoto, et al. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. J Pharmacol Exp Ther. 2018 Dec;367(3):509-517. |
| 8590 | Photoderm Photoimmunol Photomed 19:242 (2003); J Colloid Interface Sci 276:354 (2004) |
| 8591 | J Pharmacol Exp Therap 148:252 (1962); 172:409 (1970)| |
| 8592 | Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM). Biochem J. 2017;474(22):3763-3765. Published 2017 Nov 6. |
| 8593 | Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43(12):587-591. |
| 8594 | Rosazza JP, et al. Microbial hydroxylation of 1,4-cineole. Appl Environ Microbiol. 1987 Oct;53(10):2482-6. |
| 8595 | Takaishi M, et al. 1,8-cineole, a TRPM8 agonist, is a novel natural antagonist of human TRPA1. Mol Pain. 2012 Nov 29;8:86. |
| 8596 | LaPensee CR, et al. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology. 2016 May;157(5):1775-88. |
| 8597 | Wang X , et al. Intratracheal administration of isosorbide dinitrate improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction. Exp Ther Med. 2017 Aug;14(2):1399-1408. |
| 8598 | Zhao X, et al. Cardioprotective Effect of Isosorbide Dinitrate Postconditioning Against Rat Myocardial Ischemia-Reperfusion Injury In Vivo. Med Sci Monit. 2019 Mar 2;25:1629-1636. |Am. Heart J. (1985), 110(1 Pt 2), 264-8; Drugs (1982), 23(3), 165-94; Am. J. Cardiol. (1976), 37(2), 263-8 |
| 8599 | Imhof I, et al. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).Hepatology. 2011 Apr;53(4):1090-9. |
| 8600 | Seiwert, Scott D., et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrobial Agents and Chemotherapy (2008), 52(12), 4432-4441. |
| 8601 | Bartels DJ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008 Sep 15;198(6):800-7. |
| 8602 | Seneca N, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011 Dec;218(3):579-8 |
| 8603 | Kiss B, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. |
| 8604 | Zimnisky R, et al. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013 Mar;226(1):91-100. |
| 8605 | Gao Y, et al. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect. 2015 Feb;3(1):e00073. |
| 8606 | Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013 Feb;30(2):114-26. |
| 8607 | Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80. |
| 8608 | Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194. |
| 8609 | Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206 |
| 8610 | Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589. |
| 8611 | Cavet ME, et al. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):52-60. |
| 8612 | Raldúa D, et al. BLT-1, a specific inhibitor of the HDL receptor SR-BI, induces a copper-dependent phenotype during zebrafish development. Toxicol Lett. 2007 Dec 10;175(1-3):1-7. Epub 2007 Aug 22. |
| 8613 | Nieland TJ, et al. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry. 2008 Jan 8;47(1):460-72. |
| 8614 | Nieland TJ, et al. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptorSR-BI. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15422-7. |
| 8615 | Hirofumi Ohashi, et al. Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments. Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. |
| 8616 | Battaglia, G., et al., Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther, 1998. 12(10): p. 1003-10. |
| 8617 | Clave, P., et al., Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther, 2011. 34(4): p. 432-42. |
| 8618 | Lindqvist, S., et al., The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol, 2002. 137(7): p. 1134-42. |
| 8619 | Gandia, L., et al., Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells. Br J Pharmacol, 1996. 117(3): p. 463-470. |
| 8620 | Helv Chim Acta 19:1107 (1936); 20:978 (1937); JACS 70:1454 (1948) |
| 8621 | Ilona GUTCHER, et al. 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer. WO2018146010A1 |
| 8622 | Zhi Q, et al. Oncogenic miR-544 is an important molecular target in gastric cancer. Anticancer Agents Med Chem. 2013 Feb;13(2):270-5. |
| 8623 | Wittman M, et al. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem. 2005 Sep 8;48(18):5639-43. |
| 8624 | Litzenburger BC, et al. BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res. 2009 Jan 1;15(1):226-37. |
| 8625 | J Chem Soc 1960:1408; Pharmazie 38:102 (1983) |
| 8626 | JAMA 140:121 (1949); Eur J Clin Pharmacol 55:761 (2000) |
| 8627 | Wood ER, Kuyper L, Petrov KG, Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7. |
| 8628 | Eun Joo Jung, Choong Won Kim, Deok Ryong Kim. Cytosolic accumulation of γH2AX is associated with tropomyosin-related kinase A-induced cell death in U2OS cells. Exp Mol Med. 2008 June 30; 40(3): 276-285. |
| 8629 | Takahara A, et al. Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized guinea pigs. J Pharmacol Sci. 2012;120(3):165-75. |
| 8630 | Catania MA, et al. Pharmacological and clinical overview of cloperastine in treatment of cough. Ther Clin Risk Manag. 2011;7:83-92. |
| 8631 | Bach A, et al. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci Rep. 2015 Jul 16;5:12157. |
| 8632 | Smith AE, et al. Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors. Behav Brain Res. 2016 May 15;305:23-9. |
| 8633 | Doucet MV, et al. Small-molecule inhibitors at the PSD-95/nNOS interface protect against glutamate-induced neuronal atrophy in primary cortical neurons. Neuroscience. 2015 Aug 20;301:421-38. |
| 8634 | Clark RW, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7. |
| 8635 | Hu X, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 2009 May;150(5):2211-9. |
| 8636 | Barter PJ, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 Nov 22;357(21):2109-22. |
| 8637 | Morehouse LA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007 Jun;48(6):1263-72. |
| 8638 | Harikumar KB, et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2010 May;9(5):1136-46. |
| 8639 | Int J Obes 22:32, Suppl 1:S18 (1998); |
| 8640 | J Neurolog Sci 100:70 (1990); Reactions Weekly 1144,:5 (2007) |
| 8641 | Biochem Pharmacol 46:2327 (1993); 65:51 (2003); Biochem Mol Biol Int 38:1171 (1996) |
| 8642 | Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012 Feb 1;7(1):36-40. |
| 8643 | Nijevitch AA, et al. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy withnifuratel to furazolidone. Aliment Pharmacol Ther. 2005 Nov 1;22(9):881-7. |
| 8644 | Nijevitch AA, et al. Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children. Helicobacter. 2007 Apr;12(2):132-5. |
| 8645 | https://clinicaltrials.gov/ct2/show/NCT04647669?term=Acalabrutinib&cond=covid&draw=2&rank=4 |
| 8646 | Yang, et al. Synthesis and structure-activity relationship of nuciferine derivatives as potential acetylcholinesterase inhibitors. Medicinal Chemistry Research June 2014, Volume 23, Issue 6, pp 3178–3186 |
| 8647 | Singal A. Butenafine and superficial mycoses: current status. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):999-1005. |
| 8648 | Kokjohn K, Bradley M, Griffiths B, Ghannoum M. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol. 2003 Sep;42 Suppl 1:11-7. |
| 8649 | Syed TA, Maibach HI. Butenafine hydrochloride: for the treatment of interdigital tinea pedis. Expert Opin Pharmacother. 2000 Mar;1(3):467-73. |
| 8650 | McNeely W, Spencer CM. Butenafine. Drugs. 1998 Mar;55(3):405-12; discussion 413. |
| 8651 | Butenafine |
| 8652 | Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARα antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72. |
| 8653 | Stebbins KJ, et al. In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist. Eur J Pharmacol. 2017 Aug 15;809:130-140. |
| 8654 | J Pharm Pharmacol 23:950 (1971); 24:281 (1972); 28:670 (1976); Biochem J 166:639 (1977) |
| 8655 | Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88. |
| 8656 | Kaski SW, et al. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.J Pharmacol Exp Ther. 2019 Nov;371(2):487-499. |
| 8657 | Endoh T, et al. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.Life Sci. 1999;65(16):1685-94. |
| 8658 | Psychopharmacologia 6:1 (1964); Toxicol Appl Pharmacol 21:315 (1972); Nature 252:52 (1974) |
| 8659 | Drugs Future 14:347 (1989); Eur J Clin Pharmacol 43:513 (1992) |
| 8660 | Konstitution und Vorkommen der Organischen Pflanzenstoffe,2nd edn, # 2095 (1972); Anal Profiles Drug Subst 23:99 (1994) |
| 8661 | Kim DJ, et al. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer Prev Res (Phila). 2011 Nov;4(11):1842-51. |
| 8662 | J Prakt Chemie 337:351 (1995); Microbiol Mol Biol Rev 68:132 (2004); Microbiology 153:2817 (2007) |
| 8663 | https://clinicaltrials.gov/ct2/show/NCT04375397?term=Ibrutinib&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04665115?term=Ibrutinib&cond=Covid19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04439006?term=Ibrutinib&cond=Covid19&draw=2&rank=3 |
| 8664 | Buckley DL, et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol. 2015 Aug 21;10(8):1831-7. |
| 8665 | https://clinicaltrials.gov/ct2/show/NCT04834752?term=LANSOPRAZOLE&cond=covid&draw=1&rank=2 |
| 8666 | Moustakim M, et al. Discovery of an MLLT1/3 YEATS Domain Chemical Probe. Angew Chem Int Ed Engl. 2018 Dec 10;57(50):16302-16307. |
| 8667 | JACS 77: 1392, 2662 (1955); 78: 1375, 3693 (1956); 82: 3971 (1960) |
| 8668 | Webber S, et al. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol. 1996;37(6):509-17. |
| 8669 | McGuire JJ, et al. Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines. |
| 8670 | Biochim. Biophys. Acta, Bioenerg. (1975), 396(2), 210-19; Br. Vet. J. (1968), 124(5), 209-18; Chem. Ind. (1968), (2), 56-7 |
| 8671 | https://clinicaltrials.gov/ct2/show/NCT04509999?term=Bicalutamide&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04374279?term=Bicalutamide&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04652765?term=Bicalutamide&cond=COVID-19&draw=2&rank=3 |
| 8672 | Am J Vet Res 48:1050 (1987) |
| 8673 | Lee YK, et al. Chelidonine Induces Caspase-Dependent and Caspase-Independent Cell Death through G2/M Arrest in the T98G Human Glioblastoma Cell Line. Evid Based Complement Alternat Med. 2019 May 26;2019:6318179. |
| 8674 | Kim YB, et al. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene. 1999 Apr 15;18(15):2461-70. |
| 8675 | Wang YL, et al. HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines. Curr Mol Med. 2016;16(3):232-42. |
| 8676 | Faghihloo E, et al. The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line. Cancer Gene Ther. 2016 Nov;23(11):396-399. |
| 8677 | Mistry H, et al. Small molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther. 2013 Dec;12(12):2651-62. |
| 8678 | Anal Profiles Drug Subs 14:135 (1985); J Laryngol Otol 101:666 (1987) |
| 8679 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=INDAPAMIDE&cond=covid&draw=2&rank=2 |
| 8680 | Gokhan Adas,, et al. Use of albendazole sulfoxide, albendazole sulfone, and combined solutions as scolicidal agents on hydatid cysts (in vitro study). |
| 8681 | Lam F, et al. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget. 2014 Sep 15;5(17):7691-704. |
| 8682 | Elisabeth Walsby, et al. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget. 2014 Jan; 5(2): 375–385. |
| 8683 | Muhammed H Rahaman, et al. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Invest New Drugs. 2019 Aug;37(4):625-635. |
| 8684 | Alexandra Sorvina, et al. CDKI-73 is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion. Cells. 2020 Feb 5;9(2):372. |
| 8685 | Shao Xie, et al. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacol Sin. 2016 Nov; 37(11): 1481–1489. |
| 8686 | Sader HS, et al. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. |
| 8687 | Moya B, et al. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob Agents Chemother. 2017 May 24;61(6). |
| 8688 | Mashhoon N, et al. Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60. |
| 8689 | Stöter M, et al. Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells. Oncogene. 2005 Dec 1;24(54):7964-75. |
| 8690 | Brockschmidt C, et al. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo. Gut. 2008 Jun;57(6):799-806. |
| 8691 | Kukimoto-Niino M, et al. Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4. Acta Crystallogr D Biol Crystallogr. 2011 Sep;67(Pt 9):763-73. |
| 8692 | J Chem Soc 1945:540; Ann Appl Biol 57:501 (1966); Pure Appl Chem 42:57 (1975); Carcinogenesis 23:1667 (2002) |
| 8693 | Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem, 2009, 52(16), 5188-5196. |
| 8694 | Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther, 2009, 331(2), 574-590. |
| 8695 | https://clinicaltrials.gov/ct2/show/NCT04349410?term=Clindamycin&cond=Covid19&draw=2&rank=1 |
| 8696 | Bul Soc Chim Fr 1972: 3292 |
| 8697 | Troxler T, et al. The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders. ChemMedChem. 2019 Jul 3;14(13):1238-1247. |
| 8698 | Lu J, et al. Overexpression of ULK1 Represents a Potential Diagnostic Marker for Clear Cell RenalCarcinoma and the Antitumor Effects of SBI-0206965. EBioMedicine. 2018 Aug;34:85-93. |
| 8699 | Egan DF, et al. Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. Mol Cell. 2015 Jul 16;59(2):285-97. |
| 8700 | Wilkinson SE, et al. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J. 1993 Sep 1;294 (Pt 2):335-7. |
| 8701 | Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. |
| 8702 | Tian F, et al. Inhibition of protein kinase C protects against paraoxon-mediated neuronal cell death. Neurotoxicology. 2007 Jul;28(4):843-9. Epub 2007 Apr 20. |
| 8703 | Hambleton M, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006 Aug 8;114(6):574-82. |
| 8704 | Gustafsson NMS, et al. Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination. Nat Commun. 2018 Sep 24;9(1):3872. |
| 8705 | JACS 71:2053 (1949) |
| 8706 | J Steroid Biochem Mol Biol 65:143 (1998) |
| 8707 | Naijue Zhu, et al. Tyrphostin Tumor Growth Inhibitors of EGFR and ErbB2 Tyrosine Kinase. J Chem Crystallogr. 2007, 37, 679–683. |
| 8708 | Sheikhi M, et al. Investigation of Adsorption Tyrphostin AG528 Anticancer Drug Upon the CNT(6,6-6) Nanotube: A DFT Study. Curr Mol Med. 2019;19(2):91-104. |
| 8709 | Pardo JM, et al. Biochemical basis of resistance to hygromycin B in Streptomyces hygroscopicus--the producing organism. J Gen Microbiol. 1985 Jun;131(6):1289-98. |
| 8710 | González A, et al. Studies on the mode of action of hygromycin B, an inhibitor of translocation in eukaryotes. Biochim Biophys Acta. 1978 Dec 21;521(2):459-69. |
| 8711 | Pfister P, et al. Role of 16S rRNA Helix 44 in Ribosomal Resistance to Hygromycin B. Antimicrob Agents Chemother. 2003 May;47(5):1496-502. |JACS 80:2714 (1958); J Org Chem 27:2793 (1962); Anal Biochem 1963:303;Tetrahedron 35:1207 (1979) |
| 8712 | Bloch A, et al. On the mode of action of 7-deaza-adenosine (Tubercidin). Biochim Biophys Acta. 1967 Mar 29;138(1):10-25. |
| 8713 | Kouni MH, et al. Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5'-monophosphate for the treatment of schistosomiasis. Antimicrob Agents Chemother. 1989 Jun;33(6):824-7. |
| 8714 | Bergstrom DE, et al. Antiviral activity of C-5 substituted tubercidin analogues. J Med Chem. 1984 Mar;27(3):285-92. |
| 8715 | Li J, et al. Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat Chem Biol. 2017 May;13(5):486-493. |
| 8716 | PharmD CM, et al. Capecitabine: A review. Clinical Therapeutics. 2005 Jan; 27(1): 23-44. |
| 8717 | Guichard SM, et al. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. Eur J Cancer. 2008 Jan;44(2):310-7. |J Clin Oncol19:2282, 4097 (2001); Drugs61:2309 (2001) |
| 8718 | Xu Z, et al. Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold. |
| 8719 | Hwee DT, et al. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J Pharmacol Exp Ther. 2015 Apr;353(1):159-68. |
| 8720 | Andrews JA, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018 May;57(5):729-734. |
| 8721 | Carcinogenesis 9:131 (1988); Nutr Cancer 29:152 (1997); Arch Biochem Biphys 340:279 (1997) |
| 8722 | White JR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem. 1998 Apr 24;273(17):10095-8. |
| 8723 | Wang B, et al. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 2006 Mar 15;66(6):3071-7. |
| 8724 | Herz J, et al. Role of Neutrophils in Exacerbation of Brain Injury After Focal Cerebral Ischemia in Hyperlipidemic Mice. Stroke. 2015 Oct;46(10):2916-25. |
| 8725 | Wang LY, et al. CXCL5 signaling is a shared pathway of neuroinflammation and blood-brain barrier injury contributing to white matter injury in the immature brain. J Neuroinflammation. 2016 Jan 6;13:6. |
| 8726 | Shi ZR, et al. Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis. J Autoimmun. 2018 May;89:30-40. |
| 8727 | https://clinicaltrials.gov/ct2/show/NCT04349410?term=Clindamycin+palmitate&cond=COVID-19&draw=2&rank=1 |
| 8728 | Bosc D, et al. A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4B. Sci Rep. 2018 Aug 3;8(1):11653. doi: 10.1038/s41598-018-29900-x. |
| 8729 | Ann Rev Pharmacol Toxicol 24:329 (1984); Contraception 39:579 (1989); 65:259 (2002); Parasitol Res 86:665 (2000)|J Am Chem Soc 60: 2193 (1938) |
| 8730 | Tateishi N, et al. Dietary supplementation with arachidonic acid increases arachidonic acid content in paw, but does not affect arthritis severity or prostaglandin E2 content in rat adjuvant-induced arthritis model. Lipids Health Dis. 2015 Jan 16;14:3. |J Pharmacol Exp Ther 258:452 (1991); 304:139 (2003); J Lipid Res 40:2177 (1999); Curr Med Chem 14:1940 (2007) |
| 8731 | Slack RJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344(1):218-30 |
| 8732 | Kempsford R, et al. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256- |
| 8733 | Harrell AW, et al. Metabolism and disposition of Vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41(1):89-100. |
| 8734 | Calzetta L, et al. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Jul 14. pii: S0014-2999(17)30470-3. |
| 8735 | Indian J Med Res 55:1084 (1967); Toxicol Appl Pharmacol 18:185 (1971) |
| 8736 | Dar AC, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.Nature. 2012 Jun 6;486(7401):80-4. |
| 8737 | Liu H, et al. Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.Cell Rep. 2017 Feb 28;18(9):2088-2095. |
| 8738 | CZC-8004 is a pan-kinase inhibitor, with low micromolar IC<sub>50</sub> values for tyrosine kinase. |
| 8739 | Bantscheff M, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007 Sep;25(9):1035-44. |
| 8740 | Antimicrob Agents Chemother 34:1204 (1990); 35:1940 (1991) |
| 8741 | Bethge WA, et al. Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD. Bone Marrow Transplant. 2014 Sep;49(9):1198-204. |
| 8742 | Dalla Rosa L, et al. Cordycepin (3'-deoxyadenosine) pentostatin (deoxycoformycin) combination treatment of mice experimentally infected with Trypanosoma evansi. Parasitology. 2013 Apr;140(5):663-71. |
| 8743 | Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418. |
| 8744 | Miller DW, et al. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers. Neurourol Urodyn, 2011, 30(8), 1633-1638. |
| 8745 | Iijima K, et al. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol, 2007, 52(3), 842-847. |
| 8746 | Ross-Macdonald P, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther. 2008 Nov;7(11):3490-8. |
| 8747 | Petrilli A, et al. LIM Domain Kinases as Potential Therapeutic Targets for Neurofibromatosis Type 2.Oncogene. Oncogene. 2014 Jul 3;33(27):3571-82. |
| 8748 | Lunardi P, et al. Effects of Hippocampal LIMK Inhibition on Memory Acquisition, Consolidation, Retrieval, Reconsolidation, and Extinction. Mol Neurobiol. 2017 Jan 13. |
| 8749 | https://clinicaltrials.gov/ct2/show/NCT04643691?term=Spironolactone&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04424134?term=Spironolactone&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04826822?term=Spironolactone&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04345887?term=Spironolactone&cond=COVID-19&draw=2&rank=5 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04345887 |
| 8750 | Farmakol. Toksikol. (1961), 24, 304-9. ; Nature (1959), 184(Suppl. No. 22), 1707-9 |
| 8751 | Christensen JG, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003 Nov 1;63(21):7345-55. |
| 8752 | Ma PC. et al. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005 Mar 15;11(6):2312-9. |
| 8753 | Peters GJ, et al. Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57. |
| 8754 | Yang MY, et al. A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine. Anticancer Res. 2014 Dec;34(12):6951-9. |
| 8755 | Pavlik CM,et al. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33. |
| 8756 | J Insect Physiol 20:2135 (1974); J Chem Ecol 16:2167 (1990) |
| 8757 | Bazzi W, et al. The inhibitory effect of micafungin on biofilm formation by Pseudomonas aeruginosa. Biofouling. 2013 Jul 23. |
| 8758 | Kai H, et al. Synergistic antifungal activity of KB425796-C in combination with micafungin against Aspergillus fumigat us and its efficacy in murine infection models. J Antibiot (Tokyo). 2013 Jun 12. |
| 8759 | Jinzenji A, et al. Antiallodynic action of 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methyoxyphenyl)-4-piperidinol (NNC05-2090), a betaine/GABA transporter inhibitor. J Pharmacol Sci. 2014;125(2):217-26. |
| 8760 | Kreitzer MA, et al. Glutamate modulation of GABA transport in retinal horizontal cells of the skate. J Physiol. 2003 Feb 1;546(Pt 3):717-31. |
| 8761 | Barakat L, et al. GAT-1 and reversible GABA transport in Bergmann glia in slices. J Neurophysiol. 2002 Sep;88(3):1407-19. |
| 8762 | Takahashi, H.K., et al., Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol, 2006. 70(2): p. 450-3. |
| 8763 | Sprowl, J.A., et al., Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther, 2013. 94(5): p. 585-92. |
| 8764 | Zheng, Y., et al., Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol, 2013. 54(1): p. 74-83. |
| 8765 | Fukuda, M., K. Kusama, and H. Sakashita, Cimetidine inhibits salivary gland tumor cell adhesion to neural cells and induces apoptosis by blocking NCAM expression. BMC Cancer, 2008. 8: p. 376. |
| 8766 | Longhini, R., et al., Cimetidine Reduces the Alveolar Bone Loss in Induced Periodontitis in Rat Molars. J Periodontol, 2013. |
| 8767 | M J Smit, et al. Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6802-7. |J Int Med Res 3:86 (1975); Br J Pharmacol 53:435p (1975); Scand J Gasroenterol 21 Suppl 121:1 (1986) |
| 8768 | Rohde JM, et al. Discovery of ML367, inhibitor of ATAD5 stabilization. Probe Reports from the NIH Molecular Libraries Program. |
| 8769 | Rao AU, et al. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1068-72. |
| 8770 | Huang X, et al. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorg Med Chem Lett. 2012 Jan 1;22(1):65-70. |
| 8771 | Huang X, et al. Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors. ACS Med Chem Lett. 2011 Jun 24;2(8):632-7. |
| 8772 | Li Z, et al. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology. 2005 Nov;30(11):1986-95. |
| 8773 | Odagaki Y, et al. Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes. J Psychopharmacol. 2016 Sep;30(9):896-912 |
| 8774 | Sugawara Y, et al. Electrophysiological evidence showing muscarinic agonist-antagonist activities of N-desmethylclozapine using hippocampal excitatory and inhibitory neurons. Brain Res. 2016 Jul 1;1642:255-62 |
| 8775 | Gigout S, et al. Different pharmacology of N-desmethylclozapine at human and rat M2 and M 4 mAChRs in neocortex. Naunyn Schmiedebergs Arch Pharmacol. 2015 May;388(5):487-96 |
| 8776 | Himmerich H, et al. Impact of clozapine, N-desmethylclozapine and chlorpromazine on thromboxane production in vitro. Med Chem. 2012 Nov;8(6):1032-8. |
| 8777 | Medigeshi GR, et al. N-Desmethylclozapine, Fluoxetine and Salmeterol inhibit post-entry stages of dengue virus life-cycle. Antimicrob Agents Chemother. 2016 Aug 29. |
| 8778 | Sanders MA, et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. Mol Cancer Ther. 2013 Apr;12(4):373-83. |
| 8779 | Amy J Scott-Thomas , et al. 2-Aminoacetophenone as a Potential Breath Biomarker for Pseudomonas Aeruginosa in the Cystic Fibrosis Lung. BMC Pulm Med. 2010 Nov 7;10:56. |
| 8780 | https://clinicaltrials.gov/ct2/results?recrs=&cond=COVID-19&term=ATORVASTATIN&cntry=&state=&city=&dist= |
| 8781 | Acta Vet. Brno (1969), 38(1), 137-45; J. Protozool. (1967), 14(3), 379-81; Poultry Sci. (1967), 46(2), 391-6 |
| 8782 | Connor HE, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia. 1997 May;17(3):145-52. |
| 8783 | Expert Opin. Pharmacother. (2005), 6(5), 777-785; Curr. Ther. Res. (1983), 34(5), 777-94; Nature (1968), 219(5150), 164 |
| 8784 | V B Ciofalo, et al. Anti-nociceptive Activity of Clonixin in Rhesus Monkeys. Jpn J Pharmacol. 1972 Dec;22(6):749-53. |
| 8785 | J S Finch, et al. Clonixin: A Clinical Evaluation of a New Oral Analgesic. J Clin Pharmacol New Drugs. Sep-Oct 1971;11(5):371-7. |
| 8786 | Zak KM, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016 May 24;7(21):30323-35. |
| 8787 | Ashizawa T, et al. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomed Res. 2019;40(6):243-250. |
| 8788 | Ng HJ, et al. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A. 2007 May 8;104(19):8059-64. Epub 2007 Apr 30. |
| 8789 | J Chromatog 446:237 (1988) |
| 8790 | Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52(2), 379-388. |
| 8791 | Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005. |
| 8792 | Santo L, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15;17(10):3259-71 |
| 8793 | Tso SC, et al. Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase. J Biol Chem. 2014 Jul 25;289(30):20583-93. |
| 8794 | Friberg A, et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem. 2013 Jan 10;56(1):15-30. |
| 8795 | U Klages, et al. Degradation of 4-chlorophenylacetic Acid by a Pseudomonas Species. J Bacteriol. 1981 Apr;146(1):64-8. |
| 8796 | Neil Sidell, et al. Inhibition of Estrogen-Induced Mammary Tumor Formation in MMTV-aromatase Transgenic Mice by 4-chlorophenylacetate. Cancer Lett. 2007 Jun 28;251(2):302-10. |
| 8797 | Lobera M, et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25. |
| 8798 | Guerriero JL, et al. Class IIa HDAC inhibition reduces breast tumors and metastases through anti-tumor macrophages. Nature. 2017 Mar 16;543(7645):428-432. |
| 8799 | Ionac M et al. Oxaceprol, an atypical inhibitor of inflammation and joint damage. Pharmacol Res, 1996 Jun, 33(6):367-73. |
| 8800 | Harpreet Singh Pawar, et al. Comparative evaluation of therapeutic efficacy of intra-articular oxaceprol with conventional modalities in osteoarthritis animal model. Clin Rheumatol. 2018 Aug;37(8):2195-2201. |
| 8801 | M Ionac, et al. Oxaceprol, an atypical inhibitor of inflammation and joint damage. Pharmacol Res. 1996 Jun;33(6):367-73. |
| 8802 | M J Parnham, et al. Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol. Biochem Pharmacol. 1999 Jul 15;58(2):209-15. |
| 8803 | N. J. Laping, et al. Inhibition of Transforming Growth Factor (TGF)-β1-Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542. |
| 8804 | Inman GJ, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol, 2002, 62(1), 65-74. |
| 8805 | Halder SK, et al. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia, 2005, 7(5), 509-521. |
| 8806 | Matsuyama S, et al. SB-431542 inhibits transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res, 2003, 63(22), 7791-7798. |
| 8807 | Sato M, et al. Differential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model. PLoS One. 2015 May 18;10(5):e0126483. |
| 8808 | Ma J, et al. Growth differentiation factor 11 improves neurobehavioral recovery and stimulates angiogenesis in rats subjected to cerebral ischemia/reperfusion. Brain Res Bull. 2018 Feb 9;139:38-47 |
| 8809 | Doh-Ura K, et al. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol. 2000 May;74(10):4894-7. |
| 8810 | Konjar S, et al. Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. Immunology. 2010 Oct;131(2):257-67. |
| 8811 | Mullins SR, et al. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol Chem. 2012 Dec;393(12):1405-16. |
| 8812 | Hook G, et al. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. J Alzheimers Dis. 2011;26(2):387-408. |
| 8813 | Cheng XW, et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008 Aug;173(2):358-69. |
| 8814 | Ji Yeun Kim, et al. Safe, High-Throughput Screening of Natural Compounds of MERS-CoV Entry Inhibitors Using a Pseudovirus Expressing MERS-CoV Spike Protein. Int J Antimicrob Agents. 2018 Nov;52(5):730-732. |
| 8815 | Noguchi JK, et al. Sulbactam: a beta-lactamase inhibitor. Clin Pharm. 1988;7(1):37-51. |
| 8816 | Lin HS, et al. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Infect Dis (Lond). 2015;47(6):370-378. |
| 8817 | Betrosian AP, et al. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol. 2009;5(9):1099-1112. |J Antimicrob Chemother 17:389 (1986); Drugs 33:577 (1987) |
| 8818 | LIAO, Daiqing, et al. HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT. WO 2015153516 A1. |
| 8819 | Burns CJ, et al. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. Mol Cancer Ther. 2009 Nov;8(11):3036-45. |
| 8820 | Monaghan K, et al. CYT997 causes apoptosis in human multiple myeloma. Invest New Drugs. 2011 Apr;29(2):232-8. |
| 8821 | Ya Cao, wt al. Mitochondrial ROS Accumulation Inhibiting JAK2/STAT3 Pathway Is a Critical Modulator of CYT997-induced Autophagy and Apoptosis in Gastric Cancer. J Exp Clin Cancer Res. 2020 Jun 23;39(1):119. |
| 8822 | J Urol 117:690 (1970); N Engl J Med 300:1459 (1977); 315:1386 (1986) |
| 8823 | DTP Datawarehouse Index Results. |
| 8824 | J Biollaz, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995;47(5):455-60. |
| 8825 | Sangly P Srinivas, et al. Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3273-8. |
| 8826 | Belal M Ali, et al. Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich's carcinoma grown in mice: role of thioredoxin-interacting protein. Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1271-82. |
| 8827 | Junjian Wang, et al. ROR-γ Drives Androgen Receptor Expression and Represents a Therapeutic Target in Castration-Resistant Prostate Cancer. Nat Med. 2016 May;22(5):488-96. |
| 8828 | Yan Zhang, et al. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. J Med Chem. 2019 May 9;62(9):4716-4730. |
| 8829 | Huang Q, et al. Notopterol-induced apoptosis and differentiation in human acute myeloid leukemia HL-60 cells. Drug Des Devel Ther. 2019 Jun 6;13:1927-1940. |
| 8830 | Mutat Res 308:191 (1994) |
| 8831 | Biftu T, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12. |
| 8832 | Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. |
| 8833 | Waffo-Téguo P, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. Nutr Cancer. 2001;40(2):173-9. |
| 8834 | Pullar IA, et al. The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. Eur J Pharmacol, 2004, 493(1-3), 85-93. |
| 8835 | Choi IS, et al. 5-HT(1B) receptors inhibit glutamate release from primary afferent terminals in rat medullary dorsal horn neurons. Br J Pharmacol, 2012,167(2), 356-367. |
| 8836 | Biochem Biophys Res Commun 315:589 (2004); Arch Biochem Biophys 476:113 (2008); J Translational Med 9: 45 (2011) |
| 8837 | Benschop KS, et al. Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient. J Gen Virol. 2015 Mar;96(Pt 3):571-9. |
| 8838 | Lacroix C, et al. http://www.ncbi.nlm. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Virol J. 2015 Jul 14;12:106. |
| 8839 | Acta Pharmacologica et Toxicologica 11:68 (1955); Nursing Res 11:109 (1962) |
| 8840 | Pesticide Biochem Physiol 3:160 (1973); J Pesticide Ref 17:14 (1997) |
| 8841 | Arzneim Forsch 17:495 (1967); 22:389 (1972) |
| 8842 | https://clinicaltrials.gov/ct2/show/NCT04349410?term=PRIMAQUINE&cond=COVID-19&draw=2&rank=1 |
| 8843 | J Med Chem 30: 1 (1987) |
| 8844 | Li Y, et al. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. J Med Chem. 2018 Dec 27;61(24):11398-11414. |
| 8845 | Ulusu NN, et al. Abietic acid inhibits lipoxygenase activity. Phytother Res. 2002 Feb;16(1):88-90. |
| 8846 | Fernández MA, et al. Anti-inflammatory activity of abietic acid, a diterpene isolated from Pimenta racemosa var. grissea. J Pharm Pharmacol. 2001 Jun;53(6):867-72. |
| 8847 | Acta Pharmacol Toxicol 11:307 (1955); Dis Chest 42;379 (1962) |
| 8848 | Luo G, et al. Tyrosol attenuates pro-inflammatory cytokines from cultured astrocytes and NF-κB activation in in vitro oxygen glucose deprivation. Neurochem Int. 2018 Dec;121:140-145. |
| 8849 | Muriana FJG, et al. Tyrosol and its metabolites as antioxidative and anti-inflammatory molecules in human endothelial cells. Food Funct. 2017 Aug 1;8(8):2905-2914. |
| 8850 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Nifedipine&cond=COVID-19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000032314 |
| 8851 | Kalmuk J, et al. Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget. 2015 Sep 15;6(27):24376-92. |
| 8852 | Zhai X, et al. Discovery and Optimization of Novel 5-Indolyl-7-arylimidazo[1,2-a]pyridine-8-carbonitrile Derivatives as Potent Antitubulin Agents Targeting Colchicine-binding Site. Sci Rep. 2017 Feb 27;7:43398. |
| 8853 | S. P. Anthony, et al. EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition. Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007) 14043-14043. |
| 8854 | Drugs (1987), 33(3), 183-241; Antimicrob. Agents Chemother. (1980), 17(6), 993-1000; J. Med. Chem. (1979), 22(12), 1435-6 |
| 8855 | Yang X, et al. Antitumor Effects of Purified Protosappanin B Extracted From Lignum Sappan. Integr Cancer Ther. 2016 Mar;15(1):87-95. |
| 8856 | Yang X, et al. Protosappanin B promotes apoptosis and causes G1 cell cycle arrest in human bladder cancer cells. Sci Rep. 2019 Jan 31;9(1):1048. |
| 8857 | Devisscher L, et al. Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy. J Med Chem. 2018 Nov 21;61(22):10126-10140. |
| 8858 | J Nat Prod 55:194 (1992) |
| 8859 | Wu C, et al. Psoralen inhibits bone metastasis of breast cancer in mice. Fitoterapia. 2013 Dec;91:205-10. |
| 8860 | Li Yin, et al. A novel psoralen derivative-MPFC enhances melanogenesis via activation of p38 MAPK and PKA signaling pathways in B16 cells. Int J Mol Med. 2018 Jun;41(6):3727-3735. |
| 8861 | Jadhav A, et al. Catharanthine dilates small mesenteric arteries and decreases heart rate and cardiac contractility by inhibition of voltage-operated calcium channels on vascular smooth muscle cells and cardiomyocytes. J Pharmacol Exp Ther. 2013 Jun;345(3):383-92. |
| 8862 | Isobe Y, et al. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J Med Chem. 2006 Mar 23;49(6):2088-95. |
| 8863 | Koga-Yamakawa E, et al. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int J Cancer. 2013 Feb 1;132(3):580-90. |
| 8864 | Chambers MS, et al. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties. J Med Chem. 2004 Nov 18;47(24):5829-32. |
| 8865 | Leppä E, et al. Agonistic effects of the beta-carboline DMCM revealed in GABA(A) receptor gamma 2 subunit F77I point-mutated mice. Neuropharmacology. 2005 Mar;48(4):469-78. |
| 8866 | Pharmacol. Biochem. Prop. Drug Subst. (1977), 1, 215-31; J. Med. Chem. (1976), 19(5), 721-3; J. Invest. Dermatol. (1976), 66(3), 157-60 |
| 8867 | Jarvis MF, et al. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochem Pharmacol. 2014 Jun 15;89(4):536-44. |
| 8868 | Xiong Y, et al. Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.J Med Chem. 2012 Jul 12; |
| 8869 | Vigushin DM et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001 Apr;7(4):971-6. |
| 8870 | Karolczak-Bayatti M, et al. Expression of the GTP-Binding Protein Gαs in Human Myometrial Cells is Regulated by Ubiquitination and Protein Degradation: Involvement of Proteasomal Inhibition by Trichostatin A.,Reprod Sci. 2012 Aug 8. |
| 8871 | Hu X, et al. Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner.,Stem Cells Dev. 2012 Aug 8. |
| 8872 | Azechi T, et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. J Atheroscler Thromb. 2013;20(6):538-47. |
| 8873 | Losman JA, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29;339(6127):1621-5. |
| 8874 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Mefloquine+&cntry=&state=&city=&dist=&Search=Search |
| 8875 | Arkin MR, et al. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004 Apr;3(4):301-17. |
| 8876 | Niederhauser O, et al. NGF ligand alters NGF signaling via p75(NTR) and trkA. J Neurosci Res. 2000 Aug 1;61(3):263-72. |
| 8877 | Minuesa G, et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun. 2019 Jun 19;10(1):2691. |
| 8878 | Arzneim Forsch 38:1079, 1120 (1988); Arzneim Forsch 43:856 (1993)| |
| 8879 | Geisen, K., Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung, 1988. 38(8): p. 1120-30. |
| 8880 | Liu, F., et al., Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons. Neurosci Lett, 2013. 557 Pt B: p. 90-4. |
| 8881 | Basit, A., M. Riaz, and A. Fawwad, Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag, 2012. 8: p. 463-72. |
| 8882 | Huertas D, et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene. 2012 Mar 15;31(11):1408-18. |
| 8883 | Han L, et al. Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor. J Cancer. 2017 Aug 25;8(15):2933-2943. |
| 8884 | Jones M, ET AL. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89(9):1620-1628. |
| 8885 | Munde M, et al. Structure-dependent inhibition of the ETS-family transcription factor PU.1 by novel heterocyclic diamidines. Nucleic Acids Res. 2014 Jan;42(2):1379-90. |
| 8886 | Stephens DC, et al. Pharmacologic efficacy of PU.1 inhibition by heterocyclic dications: a mechanistic analysis. Nucleic Acids Res. 2016 May 19;44(9):4005-13. |
| 8887 | Antony-Debré I, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest. 2017 Dec 1;127(12):4297-4313. |
| 8888 | Blackie JA, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1067-70. |
| 8889 | Hu MM, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis inLDLR-deficient mice. Acta Pharmacol Sin. 2011 Oct;32(10):1253-1258. |
| 8890 | Nakai R, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res. 2009 May 1;69(9):3901-9. |
| 8891 | De Iuliis F, et al. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells. Invest New Drugs. 2016 Aug;34(4):399-406. |
| 8892 | Arzneim Forsch 32:1153, 1157 (1982); Clin Rev Allergy 11:5 (1993) |
| 8893 | Curbete MM, et al. A Critical Review of the Properties of Fusidic Acid and Analytical Methods for Its Determination. Crit Rev Anal Chem. 2016;46(4):352-360. |
| 8894 | Payne AJ, et al. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol Res. 2013;112(11):3859-3863. |
| 8895 | Cortes J, et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood 2008 112:3232 |
| 8896 | Douglas O, et al. Abstract C192: Characterization of the target profile of XL228, a multi‐targeted protein kinase inhibitor in phase 1 clinical development. Mol Cancer Ther 2009;8(12 Suppl):C192. |
| 8897 | Shah N, et al. Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228. Blood 2007 110:474; |
| 8898 | J Am Chem Soc 80: 6148 (1958); 83: 4627 (1961) |
| 8899 | Komiya T, et al. A novel free radical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4. |
| 8900 | Yokota R, et al. A novel hydroxyl radical scavenger, nicaraven, protects the liver from warm ischemia and reperfusion injury. Surgery. 2000 Jun;127(6):661-9. |
| 8901 | Ali H, et al. The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures. |
| 8902 | Nicaraven attenuates radiation-induced injury in hematopoietic stem/progenitor cells in mice. PLoS One. 2013;8(3):e60023. |
| 8903 | Justinova Z, et al. The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys. Biol Psychiatry. 2015 Oct 1;78(7):452-62. |
| 8904 | Rieke S et al. Combination effects of (tri)azole fungicides on hormone production and xenobiotic metabolism in a humanplacental cell line. Int J Environ Res Public Health. 2014 Sep 17;11(9):9660-79. |
| 8905 | Peffer RC et al. Mouse liver effects of cyproconazole, a triazole fungicide: role of the constitutive androstane receptor. Toxicol Sci. 2007 Sep;99(1):315-25. |
| 8906 | J Clin Endocrinol Metab 75:901 (1992) |
| 8907 | https://clinicaltrials.gov/ct2/show/NCT04604678?term=METFORMIN&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04625985?term=METFORMIN&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04626089?term=METFORMIN&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04510194?term=METFORMIN&cond=COVID-19&draw=2&rank=4 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04856007 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04727424 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04621669 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04604678 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04626089 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04625985 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04510194 |
| 8908 | Li J, et al. Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-β peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer's disease. Brain Res. 2016 Jul 1;1642:327-335. |
| 8909 | Pharmacotherapy (1989), 9(4), 245-59; Circulation Res. (1975), 36(1), 185-96; J. Clin. Invest. (1974), 53(5), 1265-73 |
| 8910 | Yu W, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012;3:1288. doi: 10.1038/ncomms2304. |
| 8911 | https://clinicaltrials.gov/ct2/show/NCT05037266?term=Aminophylline&cond=Covid19&draw=2&rank=1 |
| 8912 | https://clinicaltrials.gov/ct2/show/NCT04709172?term=Cefditoren&cond=covid&draw=2&rank=1 |
| 8913 | Acta Physiol Scand 40:338 (1957) |
| 8914 | Xiaolin Zi, et al. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res. 2005 Apr 15;65(8):3479-86. |
| 8915 | https://clinicaltrials.gov/ct2/show/NCT04590222?term=PHENELZINE&cond=covid&draw=2&rank=1 |
| 8916 | Astorgues-Xerri L, et al. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. Eur J Cancer. 2014 Sep;50(14):2463-77. |
| 8917 | Zucchetti M, et al. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol. 2013 Oct;72(4):879-87. |
| 8918 | J Am Chem Soc 67: 1609 (1945) |
| 8919 | Taylor AM, et al. Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). ACS Med Chem Lett. 2016 Mar 15;7(5):531-6. |
| 8920 | De Palma AM, et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009 May;53(5):1850-7. |
| 8921 | Albulescu L, et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017 Apr;140:37-44. |
| 8922 | Juteau H, et al. Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. Bioorg Med Chem. 2001 Aug;9(8):1977-84. |
| 8923 | Saltiel E, et al. Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1986 Sep;32(3):222-59. |
| 8924 | Dudley MN, et al. Review of cefonicid, a long-acting cephalosporin. Clin Pharm. 1984 Jan-Feb;3(1):23-32. |
| 8925 | Del Rosso, J.Q., Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis, 2004. 73(1 Suppl): p. 29-33. |
| 8926 | Mastrolorenzo, A. and C.T. Supuran, Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs, 2000. 7(1): p. 49-54. |
| 8927 | http://www.drugs.com/mtm/klaron.html |
| 8928 | Roth, H.W., et al., [The effective antibacterial spectrum of sulfacetamide]. Klin Monbl Augenheilkd, 1992. 200(3): p. 182-6. |
| 8929 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Nebivolol+&cntry=&state=&city=&dist=&Search=Search |
| 8930 | Zeng Q, et al. Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J Med Chem. 2015 Oct 22;58(20):8200-15. |
| 8931 | Xu HE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature. 2002 Feb 14;415(6873):813-7. |
| 8932 | Abu Aboud O, et al. Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysisinhibition in kidney cancer cells. PLoS One. 2013 Aug 7;8(8):e71115. |
| 8933 | Abu Aboud O, et al. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8. |
| 8934 | https://clinicaltrials.gov/ct2/show/NCT04372602?term=Duvelisib&cond=covid-19&draw=2&rank=1 |
| 8935 | Michel Faure, et al. Pharmacodynamic markers associated with cyclin-dependent kinase inhibitors. From PCT Int. Appl. (2012), WO 2012131594A1 |
| 8936 | J Chem Soc 1960:3827; 1962:5095; 1967:1026; 1969:864; 1970:421; J Med Chem 51:6495 (2008) |
| 8937 | Karlin J, et al. Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. Mol Cancer Ther. 2018 Aug;17(8):1637-1647. |
| 8938 | Marshall JC, et al. The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production. J Carcinog. 2007 Nov 27;6:17. |
| 8939 | Matsumoto T, et al. Effect of a non-steroidal anti-inflammatory drug (amfenac sodium) on polymorphonuclear leukocytes. Pharmacol Res Commun. 1982 Jun;14(6):523-32. |
| 8940 | Gonsiorek W, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther. 2007 Aug;322(2):477-85. |
| 8941 | Chapman RW, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther. 2007 Aug;322(2):486-93. |
| 8942 | Ning Y, et al. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to NSC 266046 in preclinical colon cancer models. Mol Cancer Ther. 2012 Jun;11(6):1353-64. |
| 8943 | Boehme SA, et al. A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol. 2009 Jan;21(1):81-93. |
| 8944 | Miller D, et al. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. Allergy Asthma Proc. 2017 Mar 1;38(2):157-164. |
| 8945 | Lukacs NW, et al. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2008 Nov;295(5):L767-79. |
| 8946 | Pöhler R, et al. A Non-Competitive Inhibitor of VCP/p97 and VPS4 Reveals Conserved Allosteric Circuits in Type I and II AAA ATPases. Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1576-1580. |
| 8947 | Mol. Pharmacol. (1976), 12(1), 16-31; Br. J. Pharmacol. (1972), 45(3), 510-18; Recl. Trav. Chim. Pays-Bas Belg. (1959), 78, 22-42| |
| 8948 | Falkay G, et al. Affinity of tocolytic agents on human placental and myometrial beta-adrenergic receptors. J Perinat Med. 1986;14(2):109-13. |
| 8949 | Kretschy N, et al. In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen. Br J Cancer. 2013 Feb 19;108(3):570-8. |
| 8950 | Hill JW, et al. Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening. PLoS One. 2014 May 7;9(5):e96761. |
| 8951 | Chem Rev 17: 187 (1935); Anal Profiles Drug Subst 3:149 (1974); Clin Pharmacokinet 2:292 (1977); Can J Chem 68:272 (1990)| |
| 8952 | Zhang YZ, et al. Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of α-Tubulin and Inhibition of Microtubule Formation. Molecules. 2016 Mar 18;21(3). |
| 8953 | Li Y, et al. Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles. Bioorg Med Chem Lett. 2016 Jan 15;26(2):551-555. |
| 8954 | McCauley JA, et al. NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. |
| 8955 | J Chem Soc 1938:1004; Phytochemistry 14:309 (1975); J Cancer Res 92:1322 (2001); Biochem Pharmacol 65:2065 (2003); Mol Cancer Ther 3:839 (2004) |
| 8956 | Clin. Chem. (1989), 35(5), 721-5; Science (1967), 156(3771), 21-37; Circulation (1960), 22, 1125-32 |
| 8957 | Yin C, et al. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell. 2019 Feb 21;176(5):1113-1127.e16. |
| 8958 | Arch Dermatol 119:463 (1983) |
| 8959 | Luo Y, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther. 2005 Jun;4(6):977-86. |
| 8960 | Zheng J, et al. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Lett. 2010 Oct 1;296(1):74-87. |
| 8961 | Gallia GL, et al. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 2009 Feb;8(2):386-93. |
| 8962 | Zhao Y, et al. Estrogen receptor alpha and beta regulate actin polymerization and spatial memory through an SRC-1/mTORC2-dependent pathway in the hippocampus of female mice. J Steroid Biochem Mol Biol. 2017 Nov;174:96-113. |
| 8963 | https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=covid&draw=2&rank=3 |
| 8964 | Frank C. Dorsey, et al. Abstract 5245: Identification and characterization of the IDO1 inhibitor LY3381916. Cancer Research. 2018, 78(13). |
| 8965 | Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94(12):1777-1784. |
| 8966 | Arul D, et al. Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol Oncol Res. 2013 Oct;19(4):763-70. |
| 8967 | Ahamad MS, et al. Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinomacell through ROS generation and cell cycle arrest. PLoS One. 2014 Oct 16;9(10):e110003. |
| 8968 | Cho KW, et al. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor α proteinexpression and decreases plasma triglyceride and adiposity in rats. Eur J Nutr. 2011 Mar;50(2):81-8. |
| 8969 | Mulvihill EE, et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDLreceptor-null mice with diet-induced insulin resistance. Diabetes. 2009 Oct;58(10):2198-210. |
| 8970 | Chen S, et al. Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1. Food Chem Toxicol. 2012 Sep;50(9):3025-31. |
| 8971 | Frabasile S, et al. The citrus flavanone naringenin impairs dengue virus replication in human cells. Sci Rep. 2017 Feb 3;7:41864. |Ann Nutr Metab 43:173 (1999); Biochem Biophys Res Commun 265:410 (1999) |
| 8972 | J. Soc. Cosmet. Chem. (1978), 29(9), 525-36; J. Soc. Cosmet. Chem. (1969), 20(10), 639-51; Br. J. Dermatol. (1969), 81(10), 731-6 |
| 8973 | Works MG, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J Immunol. 2014 Oct 1;193(7):3278-87. |
| 8974 | Han S, et al. Improving fascin inhibitors to block tumor cell migration and metastasis. Mol Oncol. 2016;10(7):966-980. |
| 8975 | Vincent Chung, et al. Abstract C053: NP-G2-044, a novel fascin inhibitor, blocks tumor metastasis and increases antitumor immune response. |
| 8976 | Fascin Inhibitor NP-G2-044. |
| 8977 | Biochem Pharmacol 42:699 (1991); Am J Physiol 270:H1165 |
| 8978 | Komoda H, Inoue T, Node K. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens. 2010 Jan;32(2):121-8. |
| 8979 | Kain V, Kumar S, Sitasawad SL. Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis. Cardiovasc Diabetol. 2011 Nov 4;10:97. |
| 8980 | Takano Y, Ueyama T, Ishikura F. Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker. J Cardiol. 2012 Jul;60(1):18-22. |
| 8981 | Shimizu T, Tanaka T, Iso T et al. Azelnidipine inhibits MSX2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells. Int Heart J. 2012;53(5):331-5. |
| 8982 | Ohyama T, Sato K, Kishimoto K et al. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. Br J Pharmacol. 2012 Feb;165(4b):1173-87. |
| 8983 | Arch Neurol 34:313 (1977); Clin Therapeut 27:568 (2005); Indian J Crit Care Med 13:221 (2009) |
| 8984 | Mu W, et al. Recent research on 3-phenyllactic acid, a broad-spectrum antimicrobial compound. Appl Microbiol Biotechnol. 2012 Sep;95(5):1155-63. |
| 8985 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Moexipril&cond=Covid19&draw=2&rank=1 |
| 8986 | McCullough PA, et al. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effectsof bardoxolone methyl. Drug Des Devel Ther. 2012;6:141-9. |
| 8987 | Hong DS, et al.
 A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.
 Clin Cancer Res. 2012 Jun 15;18(12):3396-406. |
| 8988 | Reisman SA, et al.
 Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney.
 J Am Soc Nephrol. 2012 Oct;23(10):1663-73. |
| 8989 | Dinh CH, et al. Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice. ScientificWorldJournal. 2015;2015:549352. |
| 8990 | N Matsubara, et al. In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin. Antimicrob Agents Chemother. 1979 Dec;16(6):731-5. |
| 8991 | Pedro H.Di Rocco, et al. Aerosol treatment with cefoperazone or gentamicin protects granulocytopenic mice from acute Pseudomonas aeruginosa pneumonia. European Journal of Pharmaceutical Sciences Volume 1, Issue 6, June 1994, Pages 285-289. |Antimicrob Agents Chemother 17:129 (1980); Drugs 22:423 (1981) |
| 8992 | Environ Res 29:1 (1982); Mutat Res 278:31 (1992); Toxicological Sci 51:202 (1999) |
| 8993 | Lin X, et al. Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence. Mol Pharmacol. 2018 Feb;93(2):49-62. |
| 8994 | Shen F, et al. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. |
| 8995 | Takashima A,et al. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014 Apr 18;9(4):1003-14. |
| 8996 | Adhikari AA, et al. Development of a covalent inhibitor of gut bacterial bile salt hydrolases.Nat Chem Biol. 2020 Mar;16(3):318-326. |
| 8997 | Chan DA, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011 Aug 3;3(94):94ra70. |
| 8998 | Dedda CD, et al. Pharmacological Targeting of GLUT1 to Control Autoreactive T Cell Responses. International Journal of Molecular Sciences. 2019 Oct 8; 20(19):4962. |
| 8999 | Wang L, et al. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis. Molecular Neurodegeneration, 2019 Jan 11; 14(1):2. |
| 9000 | Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. |
| 9001 | Cancer 48:2575 (1981); N Engl J Med 314:119 (1986); J Natl Cancer Inst 81:1840 (1989) |
| 9002 | Misako Nagasaka, et al. Beyond osimertinib: The development of 3 rd-generation EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2020 Dec 15;S1556-0864(20)31105-9. |
| 9003 | Baker W, et al. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and β-agonists for the treatment of pulmonary inflammation and bronchoconstriction. WO 2008076265 A1. |
| 9004 | Wang J, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011 Dec 1;71(23):7238-49. |
| 9005 | Tan L, et al. Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem. 2015 Aug 27;58(16):6589-6606. |
| 9006 | King A, et al. In vitro antibacterial activity and susceptibility of cefsulodin, an antipseudomonal cephalosporin, to beta-lactamases. Antimicrob Agents Chemother. 1980 Feb;17(2):165-9. |
| 9007 | Gotoh N, et al. Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23. |
| 9008 | Alonso JL, et al. Differential susceptibility of aeromonads and coliforms to cefsulodin. Appl Environ Microbiol. 1996 Jun;62(6):1885-8. |
| 9009 | Fan X, et al. Cefradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of T-LAK cell-originated protein kinase. Oncotarget. 2016 Apr 26;7(17):24633-45. |Curr Ther Res 14:101, 496 (1972) |
| 9010 | Popovici-Muller J, et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1Mutant Cancers. ACS Med Chem Lett. 2018 Jan 19;9(4):300-305. |
| 9011 | Sidorova YA, et al. A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat. Front Pharmacol. 2017 Jun 21;8:365. |
| 9012 | Mould DP, et al. Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1. J Med Chem. 2017 Oct 12;60(19):7984-7999. |
| 9013 | Haydn T, et al. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells. Cell Death Dis. 2017 Jun 15;8(6):e2879. |
| 9014 | F. Faghihia, et al. The effect of purmorphamine and sirolimus on osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Biomedicine & Pharmacotherapy. 2013, 67(1): 31-38. |
| 9015 | Gu D, et al. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. J Biol Chem. 2012 Nov 2;287(45):38356-66. |
| 9016 | Beloti MM, et al. Purmorphamine enhances osteogenic activity of human osteoblasts derived from bone marrow mesenchymal cells. Cell Biol Int. 2005 Jul;29(7):537-41. |
| 9017 | Mani N, et al. Preclinical profile of AB-423, an inhibitor of Hepatitis B virus pgRNA encapsidation. Antimicrob Agents Chemother. 2018 Mar 19. |
| 9018 | James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO2017007612A1. |
| 9019 | Lee CC, et al. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Leuk Lymphoma. 2010 May;51(5):897-905. |
| 9020 | Yingze Ye, et al. Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway. Front Cell Neurosci. 2019 Dec 16;13:553. |
| 9021 | Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. |
| 9022 | Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24. |
| 9023 | Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107(1):257-64. |
| 9024 | Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3(2):333-9. |
| 9025 | Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec;12(67):471-80. |
| 9026 | Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13;281(2):1107-18. |
| 9027 | Orhan IE, et al. Pteryxin - A promising butyrylcholinesterase-inhibiting coumarin derivative from Mutellina purpurea. Food Chem Toxicol. 2017 Nov;109(Pt 2):970-974. |
| 9028 | Nugara RN, et al. Pteryxin: a coumarin in Peucedanum japonicum Thunb leaves exerts antiobesity activity through modulation of adipogenic gene network. Nutrition. 2014 Oct;30(10):1177-84. |
| 9029 | Kolbinger FR, et al. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. Arch Toxicol. 2018 Aug;92(8):2649-2664. |
| 9030 | Lancet, 1:588 (1974); 1:536 (1976); 2:109 (1976) |
| 9031 | Mair ID, et al. Pharmacological characterization of a rat 5-hydroxytryptamine type3 receptor subunit (r5-HT<sub>3A(b)</sub>) expressed in <i>Xenopus laevis</i> oocytes. Br J Pharmacol. 1998 Aug;124(8):1667-74. |
| 9032 | Ataee R, et al. Study of 5HT3 and HT4 receptor expression in HT29 cell line and human colon adenocarcinoma tissues. Arch Iran Med. 2010 Mar;13(2):120-5. |
| 9033 | de Vries A, et al. Characterisation of c-Fos expression in the central nervous system of mice following right atrialinjections of the 5-HT3 receptor agonist Phenylbiguanide. Auton Neurosci. 2005 Dec 30;123(1-2):62-75. |
| 9034 | https://clinicaltrials.gov/ct2/show/NCT04489446?term=SILDENAFIL&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04304313?term=SILDENAFIL&cond=COVID-19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN16806663 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/01/030533 |
| 9035 | JACS 68:697 (1946); Stem Cells 12:44 (1994) |
| 9036 | Arzneim Forsch 2:165 (1952); 3:503 (1953); Cephalagia 16:441 (1996) |
| 9037 | Callaghan, et al. Cefuroxime sodium, a New Cephalosporin Antibiotic: Activity in Vitro. Antimicrob Agents Chemother. 1976 Mar;9(3):511-9. |
| 9038 | D M Ryan, et al. Cefuroxime sodium, a New Cephalosporin Antibiotic: Activity in Vivo. Antimicrob Agents Chemother. 1976 Mar;9(3):520-5. |
| 9039 | Hart JR, et al. Inhibitor of MYC identified in a Kröhnke pyridine library. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12556-61. |
| 9040 | Peter B, et al. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018 Apr;32(4):1016-1022. |
| 9041 | McLaughlin J, et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113. |
| 9042 | Maryam Shariati, et al. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019 Nov;28(11):977-988. |
| 9043 | Bioorg Chem 8:17 (1979); Int J Biochem 14:691 (1982) |
| 9044 | J Med Chem 13:957 (1970); Chem Pharm Bull 40:2191 (1992) |
| 9045 | Acta Dermatovenerol Croat 15:80 (2007); J Cell Mol Med. 13:1086 (2009) |
| 9046 | Chem Rev 12: 181 (1933); Phytochemistry 26: 2423 (1987) |
| 9047 | Choi, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters (2009), 19(15), 4467-4470. |
| 9048 | Song W, et al. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Oncogene. 2017 Jun 5. |
| 9049 | Fundam. Clin. Pharmacol. (2003), 17(2), 217-225; Int. J. Dermatol. (1992), 31(5), 357-8; Int. J. Dermatol. (1982), 21(10), 611-3 |
| 9050 | Tetrahedron 19: 621 (1963); Cancer Chemother Pharmacol 40:444 (1997); J Biol Chem 278:1346 (2003)| |
| 9051 | Lindnér PG, et al. Digitonin enhances the efficacy of carboplatin in liver tumour after intra-arterial administration. Cancer Chemother Pharmacol. 1997;40(5):444-8. |
| 9052 | Leendert van Dalsen, et al. <i>In meso</i> Crystallogenesis. Compatibility of the Lipid Cubic Phase With the Synthetic Digitonin Analogue, Glyco-Diosgenin. J Appl Crystallogr. 2020 Mar 25;53(Pt 2):530-535. |
| 9053 | Griesdale, D.E., Etomidate for intubation of patients who have sepsis or septic shock - where do we go from here? Crit Care, 2012. 16(6): p. 189. |
| 9054 | Veronica A Preda, et al. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol. 2012 Aug;167(2):137-43. |Anesthesiology (2011), 114(3), 695-707; Recent Adv. Anaesth. Analg. (1979), 13, 1-22; Anaesthesiol. Resusc. (1977), 106, 25-30 |
| 9055 | Daigle SR, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12;20(1):53-65. |
| 9056 | Chen L, et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr;27(4):813-22. |
| 9057 | J. Neurosci. (1993), 13(9), 3904-15; Curr. Ther. Res. (1967), 9(6), 288-92; J. Org. Chem. (1961), 26, 2814-18 |
| 9058 | Shen HC, et al. Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate. J Med Chem. 2010 Mar 25;53(6):2666-70. |
| 9059 | Kim HY, et al. Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor. Arch Pharm Res. 2015 Jun;38(6):1019-32. |
| 9060 | Viswanatha GL, et al. Alleviation of transient global ischemia/reperfusion-induced brain injury in rats with 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose isolated from Mangifera indica. Eur J Pharmacol. 2013 Nov 15;720(1-3):286-93. |
| 9061 | Kim YH, et al. 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose increases a population of T regulatory cells and inhibits IgE production in ovalbumin-sensitized mice. Int Immunopharmacol. 2015 May;26(1):30-6. |
| 9062 | Ahn D, et al. The Longevity Properties of 1,2,3,4,6-Penta-O-Galloyl-β-D-Glucose from Curcuma longa in Caenorhabditis elegans. Biomol Ther (Seoul). 2013 Nov;21(6):442-6. |
| 9063 | Tu Z, et al. Pentagalloylglucose Inhibits the Replication of Rabies Virus via Mediation of the miR-455/SOCS3/STAT3/IL-6 Pathway. J Virol. 2019 Aug 28;93(18). pii: e00539-19. |
| 9064 | Redrobe JP, et al. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl). 1998 Jul;138(1):1-8. |
| 9065 | Deecher DC, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. |
| 9066 | JAMA 206:2897 (1968); Scand J Gastroenterol 15:277 (1980) |
| 9067 | Croft DN, et al. Gastric bleeding and benorylate, a new aspirin. Br Med J. 1972 Sep 2;3(5826):545-7. |
| 9068 | Castell JV, et al. Effects of benorylate and impacina on the metabolism of cultured hepatocytes. Xenobiotica. 1985 Aug-Sep;15(8-9):743-9. |
| 9069 | Wright V, et al. A review of benorylate - a new antirheumatic drug. Scand J Rheumatol Suppl. 1975;13:5-8. |
| 9070 | A. Bennett , et al. Inhibition of Prostaglandin Synthesis by Benorylate. Rheumatology, Volume XII, Issue suppl, 1 January 1973, Pages 101-105. |
| 9071 | Sch?n A, Madani N, Klein JC, Hubicki A, Ng D, Yang X, Smith AB 3rd, Sodroski J, Freire E.
 Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.
 Biochemistry. 2006 Sep 12;45(36):10973-80. |
| 9072 | Singh IP, Chauthe SK.
 Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004-2010.
 Expert Opin Ther Pat. 2011 Mar;21(3):399-416. |
| 9073 | Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK.
 Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
 Virology. 2005 Sep 1;339(2):213-25. |
| 9074 | Narumi, Tetsuo et al. CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorganic & Medicinal Chemistry Letters (2010), 20(19), 5853-5858. |
| 9075 | Falcoz C, et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98. |
| 9076 | Liu L, et al. Enzymatic preparation of 20(S, R)-protopanaxadiol by transformation of 20(S, R)-Rg3 from blackginseng. Phytochemistry. 2010 Sep;71(13):1514-20. |
| 9077 | Yue PY, et al. The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol. 2006 Aug 14;72(4):437-45. |
| 9078 | Liu XJ, et al. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer. 2012 Aug;31(8):373-80. |
| 9079 | Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Jul 18. |
| 9080 | Gerstenberger BS, et al. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases [published online ahead of print, 2020 Aug 25]. J Med Chem. 2020;10.1021/acs.jmedchem.0c00948. |
| 9081 | Anesthesiology 28:735 (1967); N Eng J Med 326:1661 (1992) |
| 9082 | Pasquier B. SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells. Autophagy. 2015 Apr 3;11(4):725-6. |
| 9083 | Manzoor S, et al. Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance. Sci Rep. 2018 Feb 19;8(1):3305. |
| 9084 | Götz MG, et al. Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens. J Med Chem. 2008 May 8;51(9):2816-32. |
| 9085 | Tohma D, et al. An estrogen antagonist, cyclofenil, has anti-dengue-virus activity. Arch Virol. 2019 Jan;164(1):225-234. |
| 9086 | Arrieta-Cruz I, et al. Estrogen Receptors Alpha and Beta in POA-AHA Region Regulate Asymmetrically Ovulation. Cell Mol Neurobiol. 2019 Nov;39(8):1139-1149. |
| 9087 | Proc Indian Acad Sci Sect A 26:189 (1947); 32:250 (1950) |
| 9088 | Topal M, et al. Antioxidant, antiradical, and anticholinergic properties of cynarin purified from the Illyrian thistle (Onopordum illyricum L.). J Enzyme Inhib Med Chem. 2016;31(2):266-75. |
| 9089 | Dong GC, et al. Blocking effect of an immuno-suppressive agent, cynarin, on CD28 of T-cell receptor. Pharm Res. 2009 Feb;26(2):375-81. |
| 9090 | J Med Chem 10:891 (); J Med Microbiol 10:233 (1977);| |
| 9091 | Zaghdoudi M, et al. Direct and indirect electrochemical reduction prior to a biological treatment for dimetridazoleremoval. J Hazard Mater. 2017 Aug 5;335:10-17. |
| 9092 | J Pharm Pharmacol 33:741 (1981); Epilepsia 24:394, 422 (1983); Curr Ther Res 34:7 (1983) |
| 9093 | Yue EW, et al. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. ACS Med Chem Lett. 2017 Mar 6;8(5):486-491. |
| 9094 | https://clinicaltrials.gov/ct2/show/NCT04828564?term=Ribavirin&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04494399?term=Ribavirin&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04392427?term=Ribavirin&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04959786?term=Ribavirin&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04276688?term=Ribavirin&cond=COVID-19&draw=2&rank=9 https://clinicaltrials.gov/ct2/show/NCT04664010?term=Ribavirin&cond=COVID-19&draw=2&rank=10 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04563208 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04494399 |
| 9095 | Liu F, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-8942. |
| 9096 | Wang L, et al. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis. 2018 Jan 26;9(2):129 |
| 9097 | Ii M, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. |
| 9098 | Yamada M, et al. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. J Med Chem. 2005 Nov 17;48(23):7457-67. |
| 9099 | Yuko Ono, et al. TAK-242, a Specific Inhibitor of Toll-like Receptor 4 Signalling, Prevents Endotoxemia-Induced Skeletal Muscle Wasting in Mice. Sci Rep. 2020 Jan 20;10(1):694. |
| 9100 | Sandip Murarka, et al. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site. Chemistry. 2017 May 2;23(25):6083-6093. |
| 9101 | Liang Chi, et al. Effects of the Artificial Sweetener Neotame on the Gut Microbiome and Fecal Metabolites in Mice. Molecules. 2018 Feb 9;23(2):367. |
| 9102 | Anuradha Kumari, et al. Stability of Aspartame and Neotame in Pasteurized and In-Bottle Sterilized Flavoured Milk. Food Chem. 2016 Apr 1;196:533-8. |
| 9103 | https://clinicaltrials.gov/ct2/show/NCT04413864?term=dexmedetomidine&cond=COVID-19&draw=2&rank=2 |
| 9104 | FENG, Yen, et al. HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF. WO 2011072243A1. |
| 9105 | Fed. Proc. (1969), 28(4), 1386-403; Br. J. Anaesth. (1965), 37(9), 688-705; Am. J. Health-Syst. Pharm. (2006), 63(7), 623-634 |
| 9106 | Potjewyd F, et al. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader. Cell Chem Biol. 2020 Jan 16;27(1):47-56.e15. |
| 9107 | Guangcai Y, et al. The pyrido-pyrimidines of 2- imines -5- ketone group -2,5- dihydros -1-H- two. CN107141287A. |
| 9108 | Kazi A, et al. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem. 2014 Apr 25;289(17):11906-15. |
| 9109 | Lifeng Sun, et al. The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. Sci Signal. 2017 Apr 18;10(475):eaai8583. |
| 9110 | Li SZ, et al. ALLN hinders HCT116 tumor growth through Bax-dependent apoptosis. Biochem Biophys Res Commun. 2013 Jul 26;437(2):325-330. |
| 9111 | John P. Santa Maria, Jr., et al. Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase. ACS Chem Biol. 2017 Sep 15; 12(9): 2448–2456. |
| 9112 | Liu M, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 1998 Nov 1;58(21):4947-56. |
| 9113 | Chaponis D, et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011 Aug;104(1):179-89. |
| 9114 | Koh C,et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Oct;15(10):1167-1174. |
| 9115 | US patent US 3793458; Phytochemistry (Elsevier) (1981), 20(11), 2465-9; Compt. Rend. (1960), 251, 1790-2|US patent US�3793458; Phytochemistry (Elsevier) (1981), 20(11), 2465-9; Compt. Rend. (1960), 251, 1790-2 |
| 9116 | James DI, et al. First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to AZD2281. ACS Chem Biol. 2016 Nov 18;11(11):3179-3190. Epub 2016 Oct 12. |
| 9117 | Gravells P, et al. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase. DNA Repair (Amst). 2017 Apr;52:81-91. |
| 9118 | Agents Actions 11:741 (1981); J Int Med Res 10:325 (1982); Arthritis Rheum 25:698, 923 (1982) |
| 9119 | Qu N, et al. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J. 2003 Oct 15;375(Pt 2):465-70. |
| 9120 | Jansson-Löfmark R, et al. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. Antimicrob Agents Chemother. 2015 Feb;59(2):1299-307. |
| 9121 | Porvasnik SL, et al. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther. 2010 Aug;334(2):364-72. |
| 9122 | Svejda B, et al. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer. 2010 Jun 15;116(12):2902-12. |
| 9123 | Warburton R.R., et al. Online University. |
| 9124 | Liang M, et al. Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist. ACS Med Chem Lett. 2012 Oct 1;3(12):985-990. |
| 9125 | Evans CA, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 2016 Jul 22;7(9):862-7. |
| 9126 | De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016 Nov 17;539(7629):443-447. |
| 9127 | Lin M, et al. Euphorbia factor L2 induces apoptosis in A549 cells through the mitochondrial pathway. Acta Pharm Sin B. 2017 Jan;7(1):59-64. |
| 9128 | Schnellrath LC, et al. Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture. Int J Antimicrob Agents. 2011 Nov;38(5):435-41. |
| 9129 | Qing M, et al. Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob Agents Chemother. 2010 Sep;54(9):3686-95. |
| 9130 | Xu X, et al. In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium. J Immunol. 1998 Jan 15;160(2):846-53. |
| 9131 | Zeping Zuo, et al. Bifunctional Naphtho[2,3-d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production. J Med Chem. 2020 Jun 4. |
| 9132 | Asquith CRM, et al. SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK). J Med Chem. 2019 Feb 26. |
| 9133 | Bruick Richard Keith, et al. HIF-2α inhibitors for treating iron overload disorders. From PCT Int. Appl. (2016), WO 2016057242 A1 20160414. |
| 9134 | Dixon Darryl David, et al. Preparation of cyclic sulfone and sulfoximine analogs as HIF-2α inhibitors. From PCT Int. Appl. (2015), WO 2015095048 A1 20150625. |
| 9135 | Hirata K, et al. A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons. J Pharmacol Exp Ther. 2005 Jul;314(1):252-9. |
| 9136 | Kimura T, et al. T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-beta peptide. Br J Pharmacol. 2009 Jun;157(3):451-63. |
| 9137 | Kim JY, et al. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. Biol Pharm Bull. 2014;37(2):255-61. |
| 9138 | Kang TH, et al. Cytotoxic lavandulyl flavanones from Sophora flavescens. J Nat Prod. 2000 May;63(5):680-1. |
| 9139 | Gonsalves FC, et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci USA. 2011 Apr 12;108(15):5954-63. |
| 9140 | Bilir B, et al. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 2013 Nov 4;11:280. |
| 9141 | https://clinicaltrials.gov/ct2/show/NCT04718285?term=Montelukast&cond=covid&draw=2&rank=3 |
| 9142 | Colloton M, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005 Feb;67(2):467-76. |
| 9143 | D.A. Bushinsky, et al. Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int. 2006 May;69(9):1586-92. |
| 9144 | Liu R, et al. A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro. Cell Physiol Biochem. 2017 Jan 27;41(2 |
| 9145 | Chauhan D, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15;17(16):5311-21. |
| 9146 | Kupperman E, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80. |
| 9147 | Basavaraj Girennavar et al. Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit. Bioorganic & Medicinal Chemistry.June 2007, Pages 3684-3691 |
| 9148 | Yucheng Zhao et al. Cloning, Functional Characterization, and Catalytic Mechanism of a Bergaptol O-Methyltransferase from Peucedanum praeruptorum Dunn. Front Plant Sci, 2016, 7: 722. |
| 9149 | Pardanani A, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009, 23(8), 1441-1445. |
| 9150 | Monaghan KA, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia, 2011, 25(12), 1891-1899. |
| 9151 | Tyner JW, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25), 5232-5240. |
| 9152 | Kitajima S, et al.Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.Cancer Cell. 2018 Sep 10;34(3):439-452.e6. doi: 10.1016/j.ccell.2018.08.009. |
| 9153 | Mol Microbiol 42:553 (2001); BMC Physiology 1:7 (2001) |
| 9154 | Bodnar AL, et al. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J Med Chem. 2005 Feb 24;48(4):905-8. |
| 9155 | Li F, et al. The protective effect of PNU-282987, a selective α7 nicotinic acetylcholine receptor agonist, on the hepatic ischemia-reperfusion injury is associated with the inhibition of high-mobility group box 1 protein expression and nuclear factor κB activation in mice. Shock. 2013 Feb;39(2):197-203. |
| 9156 | Stuckenholz V, et al. The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. J Parkinsons Dis. 2013;3(2):161-72. |
| 9157 | Mesa-Gresa P, et al. Behavioral effects of different enriched environments in mice treated with the cholinergic agonist PNU-282987. Behav Processes. 2014 Mar;103:117-24. |
| 9158 | Dong Jun Yu, et al. Effect of ischemic preconditioning combined with α7 nAchR agonists on limb ischemia-reperfusion lung injury in rat. Biomed Res. 2017; Special Issue: ISSN 0970. |
| 9159 | Yenugonda V,et al. A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. J Transl Med. 2017 Oct 18;15(1):210. |
| 9160 | Peter Richardson. Usl-311 for use in the treatment of cancer. WO2018162924A1 |
| 9161 | J Pharmacol Exp Ther 90:68 (1947); 94:29, 76 (1948) |
| 9162 | Radhakrishnan EK, et al. |
| 9163 | -Gingerol induces caspase-dependent apoptosis and prevents PMA-induced proliferation in colon cancer cells by inhibiting MAPK/AP-1 signaling. PLoS One. 2014 Aug 26;9(8):e104401. |
| 9164 | Chang KW, et al. 6-Gingerol modulates proinflammatory responses in dextran sodium sulfate (DSS)-treated Caco-2 cells and experimental colitis in mice through adenosine monophosphate-activated protein kinase (AMPK) activation. Food Funct. 2015 Oct;6(10):3334-41. |
| 9165 | Fan J, et al. 6-Gingerol inhibits osteosarcoma cell proliferation through apoptosis and AMPK activation. Tumour Biol. 2015 Feb;36(2):1135-41. |
| 9166 | Sun L, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor r |
| 9167 | Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can |
| 9168 | O'Farrell AM, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16. |
| 9169 | Watterson SH, et al. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers. J Med Chem. 2016 Oct 13;59(19):9173-9200. |
| 9170 | Kathleen M. Gillooly, et al. Bruton'styrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. PLoS One. 2017; 12(7): e0181782. |
| 9171 | Jin l, et, al. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. Eur J Pharmacol. 2008 Mar 17;582(1-3):162-7. |
| 9172 | Jeong HJ, et, al. Inhibition of TNF-alpha and IL-6 production by Aucubin through blockade of NF-kappaB activation RBL-2H3 mast cells. Cytokine. 2002 Jun 7;18(5):252-9. |
| 9173 | Zeng X, et, al. A review of the pharmacology and toxicology of aucubin. Fitoterapia. 2020 Jan;140:104443. |
| 9174 | Xue HY, et, al. Protective effects of aucubin on H₂O₂-induced apoptosis in PC12 cells. Phytother Res. 2012 Mar;26(3):369-74. |
| 9175 | Chang LM, et, al. Aucubin: potential antidote for alpha-amanitin poisoning. J Toxicol Clin Toxicol. 1984 Jul;22(1):77-85. |
| 9176 | Zhou Y, et, al. Aucubin Alleviates Bleomycin-Induced Pulmonary Fibrosis in a Mouse Model. Inflammation. 2017 Dec;40(6):2062-2073. |
| 9177 | J Chem Soc 1936:1399; US patent appl 10/691,033; (2003) Neurobiol Aging 31(6):10 (2010) |
| 9178 | Ann. Rheum. Dis. (1955), 14, 251-8; J. Am. Chem. Soc. (1954), 76, 1455-6; Science (1954), 120, 496-7 |
| 9179 | Seeland S, et al. ATP-induced cellular stress and mitochondrial toxicity in cells expressing purinergic P2X7 receptor. Pharmacol Res Perspect. 2015 Mar;3(2):e00123. |
| 9180 | Elsby R, et al. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. Eur J Pharm Sci. 2011 May 18;43(1-2):41-9. |
| 9181 | Hu H, et al. Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-κB pathways in the cartilage tissue of rats with osteoarthritis. Int J Mol Med. 2016 Dec;38(6):1922-1932. |
| 9182 | Oettel M, et al. Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations. Zentralbl Gynakol. 1997;119(12):597-606. |
| 9183 | Meena R, et al. Extended intervention time and evaluation of sperm suppression by dienogest plus testosterone undecanoate in male rat. Contraception. 2012 Jan;85(1):113-21. |
| 9184 | Leverson JD, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med.?2015 Mar 18;7(279):279 |
| 9185 | Tao ZF, et al. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. |
| 9186 | Zhang H, et al. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer. 2015 Jul 2;14:126. |
| 9187 | Martin J. Gunthorpe, et al. Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor. JPET June 2007 vol. 321 no. 3 1183-1192. |
| 9188 | Rami HK, et al. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3287-91. |
| 9189 | Luo H, et al. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia. 2010 Oct;24(10):1807-9. |
| 9190 | Zhao J, et al. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2013 Nov 10. |
| 9191 | Gong A, et al. Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos. 2010 Aug;38(8):1328-40. |
| 9192 | Johansson C, et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol. 2016 Jul;12(7):539-45. |
| 9193 | Hatzivassiliou G, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6. |
| 9194 | Takahashi RH, et al. Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor. Drug Metab Dispos. 2015 Dec;43(12):1929-1933. |
| 9195 | Tsujihata Y,et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.J Pharmacol Exp |
| 9196 | Yoshiyuki Tsujihata, et al. TAK-875, an Orally Available GPR40/FFA1 Agonist Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats. JPET July 13, 2011 |
| 9197 | Nagatake T, et al. 17,18-EpETE-GPR40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. J Allergy Clin Immunol. 2017 Dec 26. pii: S0091-6749(17)32949-4. |
| 9198 | Urano Y, et al. Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. Chem Biol Interact. 2018 Sep 20;296:185-197. |
| 9199 | Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016 |
| 9200 | Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017. |
| 9201 | Fan F, et al. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci Transl Med. 2016 Aug 17;8(352):352ra108. |
| 9202 | Rashid M, et, al. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci. 2003 May 30;73(2):193-207. |
| 9203 | Maruyama K, et, al. MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay. J Pharmacobiodyn. 1991 Apr;14(4):177-81. |
| 9204 | Kataoka H, et, al. Inhibitory Effect of Serotonin Antagonist on Leukocyte-Endothelial Interactions In Vivo and In Vitro. PLoS One. 2016 Jan 29;11(1):e0147929. |
| 9205 | Stevens T, et al. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther. 2011 Oct;339(1):313-20. |
| 9206 | Li H, et al. Neutrophil extracellular traps contribute to the pathogenesis of acid-aspiration-induced ALI/ARDS. Oncotarget. 2017 Nov 28;9(2):1772-1784. |
| 9207 | Tannous BA, et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst. 2013 Sep 4;105(17):1322-31. |
| 9208 | Ye XY, et al. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem. 2017 Jun 22;60(12):4932-4948. |
| 9209 | J. Antimicrob. Chemother. (1981), 7(6), 643-8; J. Antimicrob. Chemother. (1977), 3(6), 615-20; Antimicrob. Agents Chemother. (1975), 7(4), 483-5 |
| 9210 | Nam KW, et al. Inhibitory effects of furoquinoline alkaloids from Melicope confusa and Dictamnus albus against human phosphodiesterase 5 (hPDE5A) in vitro. Arch Pharm Res. 2005 Jun;28(6):675-9. |
| 9211 | Circ Res 86:580 (2000); Am J Cardiovasc Drugs 3:361 (2003); Circulation 118:1250 (2008) |
| 9212 | Kung PP, et al. Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer. Mol Cancer Ther. 2014 Aug;13(8):2104-15. |
| 9213 | JACS 52:5051 (1930); 53:733 (1931); Chem Rev 12, 181 (1933); J Chem Soc 1966:749 |
| 9214 | Rowbottom MW, et al. Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2). J Med Chem. 2017 May 25;60(10):4403-4423. |
| 9215 | Shi X, et al. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther. 2010 Apr 15;9(8):640-50. |
| 9216 | Ber 66: 1137 (1933); Ghana J Sci 10: 82 (1970) |
| 9217 | Wang L, et al. Endoplasmic reticulum stress triggered by Soyasapogenol B promotes apoptosis and autophagy in colorectal cancer. Life Sci. 2019 Feb 1;218:16-24. |
| 9218 | Wang L, et al. Soyasapogenol B exhibits anti-growth and anti-metastatic activities in clear cell renal cell carcinoma. Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):551-563. |
| 9219 | Giles, C.J., et al., Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J Vet Pharmacol Ther, 1991. 14(4): p. 400-10. |
| 9220 | McGuirk, P.R., et al., Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine. J Med Chem, 1992. 35(4): p. 611-20. |
| 9221 | Clin Pharmacol Ther 20:661 (1976); J Pharm Pharmacol 31:787 (1979) |
| 9222 | Bajpai V, et al. Rapid screening for the adulterants of Berberis aristata using direct analysis in real-time mass spectrometry and principal component analysis for discrimination. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2015;32(6):799-807. |
| 9223 | Laco F, et al. Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. J Mol Cell Cardiol. 2015 Mar;80:56-70. |
| 9224 | Jiedong Liang, et al. The activation of BDNF reduced inflammation in a spinal cord injury model by TrkB/p38 MAPK signaling. Exp Ther Med. 2019 Mar;17(3):1688-1696. |
| 9225 | Renna M et al. Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem. 2010 Apr 9;285(15):11061-7. |
| 9226 | Shen D et al. Novel cell- and tissue-based assays for detecting misfolded and aggregated protein accumulation within aggresomes and inclusion bodies. Cell Biochem Biophys. 2011 Jul;60(3):173-85. |
| 9227 | Tian Y et al. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 2011 Jun;25(6):1934-42. |
| 9228 | Nekova TS, et al. Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/Bpreferentially within a protective bone marrow microenvironment. Br J Haematol. 2014 Oct;167(2):272-4. |
| 9229 | Koukourakis MI, et al. SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Invest New Drugs. 2018 Oct;36(5):773-781. |
| 9230 | Liang Q, et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat Chem Biol. 2014 Apr;10(4):298-304. |
| 9231 | Dexheimer TS, et al. Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex. National Center for Biotechnology Information; 2010-2012 Oct 23. |
| 9232 | Hirschberg H, et al. ALA- and ALA-ester-mediated photodynamic therapy of human glioma spheroids. J Neurooncol. 2002 Mar;57(1):1-7. |
| 9233 | Brunner H, et al. The effects of 5-aminolevulinic acid esters on protoporphyrin IX production in human adenocarcinoma cell lines. Photochem Photobiol. 2001 Nov;74(5):721-5. |
| 9234 | Tunstall RG, et al. Porphyrin accumulation induced by 5-aminolaevulinic acid esters in tumour cells growing in vitro and in vivo. Br J Cancer. 2002 Jul 15;87(2):246-50. |
| 9235 | J Pharmacol Exp Ther 125:330 (1959); Digestive Dis Sci 12:1122 (1986) |
| 9236 | https://clinicaltrials.gov/ct2/show/NCT04387292?term=FLUORESCEIN&cond=Covid19&draw=2&rank=3 |
| 9237 | Rabik CA, Njoku MC, Dolan ME. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev. 2006;32(4):261‐276. |
| 9238 | Konduri, Santhi D et al. Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research vol. 15,19 (2009): 6087-95. |
| 9239 | Lindemann L, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther. 2015 Apr;353(1):213-33. |
| 9240 | Jaeschke G, et al. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. |
| 9241 | Sanjeeva Reddy, et al. Abstract 792: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. |
| 9242 | Kobayakawa J, et al. G2-M arrest and antimitotic activity mediated by casticin, a flavonoid isolated from Viticis Fructus (Vitex rotundifolia Linne fil.). Cancer Lett. 2004 May 10;208(1):59-64. |
| 9243 | Zhou L, et al. Casticin attenuates liver fibrosis and hepatic stellate cell activation by blocking TGF-β/Smad signaling pathway. Oncotarget. 2017 Apr 27;8(34):56267-56280. |
| 9244 | Lee JH, et al. Casticin inhibits growth and enhances ionizing radiation-induced apoptosis through the suppression of STAT3 signaling cascade. J Cell Biochem. 2018 Dec 5. |
| 9245 | Cazar, et al. Antimicrobial Butyrolactone I Derivatives from the Ecuadorian Soil Fungus Aspergillus terreus Thorn. var terreus. World Journal of Microbiology and Biotechnology, 2005,21(6-7), 1067–1075. |
| 9246 | Drugs 8:1 (`974); N Engl J Med 343:625 (2000) |
| 9247 | Kuduk Scott D, et al. Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators. From PCT Int. Appl. (2012), WO 2012047702 A1 20120412. |
| 9248 | Kuduk Scott D, et al. Benzoquinazolinone derivatives as M1 receptor positive allosteric modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases. From PCT Int. Appl. (2010), WO 2010059773 A1 20100527. |
| 9249 | Mascarenhas JO, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017 Feb;102(2):327-335. |
| 9250 | Alain Lescoat, et al. Combined Anti-Fibrotic and Anti-Inflammatory Properties of JAK-inhibitors on Macrophages in Vitro and in Vivo: Perspectives for Scleroderma-Associated Interstitial Lung Disease. Biochem Pharmacol. 2020 Jun 17;114103. |
| 9251 | Arnt J, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. |
| 9252 | Witten L, et al. Characterization of [<sup>3</sup>H]Lu AE60157 ([<sup>3</sup>H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline) binding to 5-hydroxytryptamine<sub>6</sub> (5-HT<sub>6</sub>) receptors in vivo. |
| 9253 | Fensome A, et al. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018 Oct 11;61(19):8597-8612. |
| 9254 | Compounds and compositions as protein kinase inhibitors
. Patent WO 2011025927 A1 |
| 9255 | Li Z, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44. |
| 9256 | https://clinicaltrials.gov/ct2/show/NCT04559074term=AMLODIPINE&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04467931?term=AMLODIPINE&cond=Covid19&draw=2&rank=3 https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN16393332 |
| 9257 | McGowan KM et al, Continued optimization of the M5 NAM ML375: Discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies. Bioorg Med Chem Lett. 2017 Mar 15;27(6):1356-1359. |
| 9258 | Doll S, et al. FSP1 is a glutathione-independent ferroptosis suppressor.Nature. 2019 Nov;575(7784):693-698. |
| 9259 | J Am Chem Soc 76: 4048 (1954); Molecules 17:5187 (2012} |
| 9260 | JAMA 186:1082 (1963) |
| 9261 | Rasmussen HS, et al. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75. |
| 9262 | Yu M, et al. Incorporation of Bulky and Cationic Cyclam-Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity. ChemistryOpen. 2013 Jun;2(3):99-105. |
| 9263 | van Wijngaarden J, et al. An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. Biochem Biophys Res Commun. 2010 Jan 8;391(2):1161-5. |
| 9264 | Skipper JB, et al. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. ORL J Otorhinolaryngol Relat Spec. 2009;71(1):1-5. |
| 9265 | https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200608047686N1 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20180612040068N1 |
| 9266 | Urick AK, et al. Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules. ACS Chem Biol. 2015 Oct 16;10(10):2246-56. |
| 9267 | Drug Action Drug Resist. Bact. (1975), 2, 77-111; Antimicrob. Agents Chemother. (1963), 161, 138-47; J. Med. Chem. (1963), 6, 463-4 |
| 9268 | Jarvis A, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010 Mar 11;53(5):2215-26. |
| 9269 | Grun D, et al. VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors. Oncogene. 2016 Aug 18;35(33):4379-87. |
| 9270 | https://clinicaltrials.gov/ct2/show/NCT04338802?term=Nintedanib&cond=COVID-19&draw=2&rank=1 |
| 9271 | Sivanandam M, et al. Investigation of activation mechanism and conformational stability of N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxybenzamide and N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamidein the active site of p300 histone acetyl transferase enzyme by molecular dynamics and binding free-energy studies. J Biomol Struct Dyn. 2018 Oct 9:1-38. |
| 9272 | Han X, Zhao L, et al. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231. |
| 9273 | Nature (1962), 195, 1300-1; Nature (1961), 192, 1183-4; Am. J. Med. Sci. (1965), 245(4), 399-412 |
| 9274 | Dedic N, et al. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther. 2019 Oct;371(1):1-14. |
| 9275 | Brogden RN, et al. Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease. Drugs. 1994 Jan;47(1):93-115. |
| 9276 | Sewing KF, et al. Calcium channel antagonists verapamil and gallopamil are powerful inhibitors of acid secretion in isolated and enriched guinea pig parietal cells. Pharmacology. 1983;27(1):9-14. |
| 9277 | Kirchengast M, et al. Reperfusion arrhythmias in closed-chest rats: the effect of myocardial noradrenaline depletion and Ca2(+)-antagonism. Clin Exp Pharmacol Physiol. 1991 Apr;18(4):217-21. |
| 9278 | H Kutchai, et al. Inhibition of the Na,K-ATPase of Canine Renal Medulla by Several Local Anesthetics. Pharmacol Res. 2001 Apr;43(4):399-403. |
| 9279 | Chloroprocaine HCl Injection. |
| 9280 | Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol. 1997 Oct;81(4):169-72. |
| 9281 | Fullhase, Claudius; Soler, Roberto; Gratzke, Christian et al. Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. Journal of Urology (New York, NY, United States) (2010), 184(2), 783-789. |
| 9282 | B Malhotra, et al. The Design and Development of Fesoterodine as a Prodrug of 5-hydroxymethyl Tolterodine (5-HMT), the Active Metabolite of Tolterodine. Curr Med Chem. 2009;16(33):4481-9. |
| 9283 | Naoki Aizawa, et al. Selective Inhibitory Effect of Imidafenacin and 5-hydroxymethyl Tolterodine on Capsaicin Sensitive C Fibers of the Primary Bladder Mechanosensitive Afferent Nerves in the Rat. J Urol. 2015 Apr;193(4):1423-32. |
| 9284 | Inoue T, et al. 
 Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma.
 World J Surg Oncol. 2012 Aug 20;10(1):167. |
| 9285 | Bowen JM, et al. 
 Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea.
 Cancer Biol Ther. 2012 Nov 1;13(13). |
| 9286 | Sun FK, et al. 
 Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
 Chin Med J (Engl). 2012 Jun;125(12):2231-4. |
| 9287 | Thamm DH.
 Tyrosine kinase inhibitor special issue.
 Vet Comp Oncol. 2012 Sep;10(3):161-2. doi: 10.1111/j.1476-5829.2012.00339.x. |
| 9288 | Eriksson A, et al. 
 The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia.
 Blood Cancer J. 2012 Aug 3;2:e81. doi: 10.1038/bcj.2012.28. |
| 9289 | Paul MK, et al. Tyrosine kinase - Role and significance in Cancer. Int J Med Sci. 2004;1(2):101-115. |
| 9290 | J Chem Soc 1982:2505; J Org Chem 49:4716 (1984); Chem Lett 1990:2015 |
| 9291 | Faria C, et al. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014 Jan;7(1):50-8. |
| 9292 | Schwartzberg L, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014 Feb;22(2):469-77. |
| 9293 | Knupp, C.A., et al., Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther, 1991. 49(5): p. 523-35. |
| 9294 | Bissuel, F., et al., Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med, 1994. 235(4): p. 367-71. |
| 9295 | Singh D, Cadden P, Hunter M, Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013 Jan;41(1):46-52. |
| 9296 | Horak F, Zieglmayer P, Zieglmayer R, The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012 Dec;67(12):1572-9. |
| 9297 | Pettipher R, Vinall SL, Xue L, Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther. 2012 Feb;340(2):473-82. |
| 9298 | Wang H, et al. CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2012 May 25;422(1):103-8. |
| 9299 | Alao JP, et al. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation. Radiat Oncol. 2009 Nov 10;4:51. |
| 9300 | Williams TM, et al. Molecular imaging of the ATM kinase activity. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):969-77. |
| 9301 | Boitano AE, et al.
 Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells. 
Science. 2010 Sep 10;329(5997):1345-8. |
| 9302 | Gao H, et al. Suppression of homeobox transcription factor VentX promotes expansion of human hematopoietic stem/multipotent progenitor cells. J Biol Chem. 2012 Aug 24;287(35):29979-87. |
| 9303 | Liansheng Li, et al. Inhibitors of kras g12c. WO 2015054572 A1. |
| 9304 | David G Davies, et al. A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. J Bacteriol. 2009 Mar;191(5):1393-403. |
| 9305 | Anal Profiles Drug Subs 2:523 (1973) |
| 9306 | Wang D, et al. Identification of polymethoxylated flavones from green tangerine peel (Pericarpium Citri Reticulatae Viride) by chromatographic and spectroscopic techniques. J Pharm Biomed Anal. 2007 May 9;44(1):63-9. |
| 9307 | Bai J, et al. Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: Food/herb-drug interactions and structure-activity relationships. Toxicol Appl Pharmacol. 2019 Apr 15;369:49-59. |
| 9308 | Kanda Panthong, et al. Prenylated flavone from roots of a hybrid between Artocarpus heterophyllus and Artocarpus integer and its biological activities. Journal of the Brazilian Chemical Society. Print version ISSN 0103-5053 |
| 9309 | J Chem Soc 1971: 1318 |
| 9310 | De Nicola GR, et al. Novel gram-scale production of enantiopure R-sulforaphane from Tuscan black kale seeds. Molecules. 2014 May 27;19(6):6975-86. |
| 9311 | Abdull Razis AF, et al. The natural chemopreventive phytochemical R-sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Int J Cancer. 2011 Jun 15;128(12):2775-82. |
| 9312 | Ma DL, et al. In vivo antioxidant activity of deacetylasperulosidic Acid in noni. J Anal Methods Chem. 2013;2013:804504. |
| 9313 | Murata K, et al. Activation of cell-mediated immunity by Morinda citrifolia fruit extract and its constituents. Nat Prod Commun. 2014 Apr;9(4):445-50. |
| 9314 | Cancer Res Clin Oncol 125:589 (1999); Int J Mol Med 7:645 (2001); Breast Cencer Res Treatment 76:195 (2002)| |
| 9315 | Wang N, et al. (-)-Epigallocatechin-3-gallate Inhibits Fibrillogenesis of Chicken Cystatin. J Agric Food Chem. 2015 Jan 26 |
| 9316 | Chung SS, et al. Curcumin and Epigallocatechin Gallate Inhibit the Cancer Stem Cell Phenotype via Down-regulation of STAT3-NFκB Signaling. Anticancer Res. 2015 Jan;35(1):39-46. |
| 9317 | Lee P, et al. Effects of Epigallocatechin gallate against Enterococcus faecalis biofilm and virulence. Arch Oral Biol. 2015 Mar;60(3):393-9. |
| 9318 | Kaldor et al (1995) Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease. Bioorg.Med.Chem.Lett. 5 721. |
| 9319 | Yerino GA, Halabe EK, Zini E, Feleder EC.
 Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects.
 Arzneimittelforschung. 2011;61(8):481-7. |
| 9320 | Branham ML, Moyo T, Govender T.
 Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement.
 Eur J Pharm Biopharm. 2012 Jan;80(1):194-202. |
| 9321 | Brouwers J, Vermeire K, Grammen C, Schols D, Augustijns P.
 Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: a case study with saquinavir.
 Antiviral Res. 2011 Aug;91(2):217-23. |
| 9322 | Knechten H, Lutz T, Pulik P, Martin T, Tappe A, Jaeger H.
 Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate. |
| 9323 | Leal AS, et al. The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Sci Rep. 2019 May 8;9(1):7072. |
| 9324 | Yu-Wai-Man C, et al. Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis. Sci Rep. 2017 Mar 31;7(1):518. |
| 9325 | Christman JK, et al. 5-Methyl-2'-deoxycytidine in single-stranded DNA can act in cis to signal de novo DNA methylation. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7347-51. |
| 9326 | Testillano PS, et al. The 5-methyl-deoxy-cytidine (5mdC) localization to reveal in situ the dynamics of DNA methylation chromatin pattern in a variety of plant organ and tissue cells during development. Physiol Plant. 2013 Sep;149(1):104-13. |
| 9327 | J Neural Transmission 43:113 (1978); J Neuroscience 15:5574 (1995) |
| 9328 | Muvaffak A, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol Cancer Res. 2014 Jul;12(7):1055-66. |
| 9329 | Bowen TE, et al. Effect of cupric sulfate on the prophylactic efficacy of 2-acetylamino-5nitrothiazole, nifursol and ipronidazole against histomoniasis in turkeys. Poult Sci. 1971 Nov;50(6):1668-72. |
| 9330 | Jorge Barbosa, et al.Detection, accumulation, distribution, and depletion of furaltadone and nifursol residues in poultry muscle, liver, and gizzard. J Agric Food Chem. 2011 Nov 23;59(22):11927-34. |J AOAC 58:694 (1975); Anal Chem 318:522 (1984); Anal ChimiActa 529:339- (2005) |
| 9331 | Xiong Y, et al. Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1(SPIN1). J Med Chem. 2019 Jul 24. |
| 9332 | Wang F, et al. A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts. Mol Oncol. 2014 Dec;8(8):1640-52. |
| 9333 | Seervi M, et al. ERO1α-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1). Cell Death Dis. 2013 Dec 19;4:e968. |
| 9334 | Putt KS, et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006 Oct;2(10):543-50. |
| 9335 | J Am Chem Soc 88:3888 (1966)| |
| 9336 | Hertzberg RP, et al. Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. J Biol Chem. 1990 Nov 5;265(31):19287-95. |
| 9337 | Hsiang YH, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985 Nov 25;260(27):14873-8. |
| 9338 | Luzzio MJ, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. |
| 9339 | Helv Chim Acta 17:1319 (1934); Chem Pharm Bull 24:2340 (1976); Z Naturforsch 59:249 (2004); 65:551 (2010); Braz J Pharm Sci 47:861 (2011) |
| 9340 | Carboni S, et al. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther. 2004;310(1):25-32. |
| 9341 | Charlene F. Barroga, et al. Diketones and hydroxyketones as catenin signaling pathway activators. WO2012024404A1. |
| 9342 | Lim W, et al. Coumestrol suppresses proliferation of ES2 human epithelial ovarian cancer cells. J Endocrinol. 2016 Mar;228(3):149-60. |
| 9343 | Zafar A, et al. Cytotoxic activity of soy phytoestrogen coumestrol against human breast cancer MCF-7 cells: Insights into the molecular mechanism. Food Chem Toxicol. 2017 Jan;99:149-161. |
| 9344 | Ethambutol. Tuberculosis (Edinb), 2008. 88(2): p. 102-5. |
| 9345 | Rastogi, N., V. Labrousse, and K.S. Goh, In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol, 1996. 33(3): p. 167-75. |
| 9346 | Kaur, D. and G.K. Khuller, In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria. Int J Antimicrob Agents, 2001. 17(1): p. 51-5. |
| 9347 | US 2018/0044344 A1. |
| 9348 | NCI Drug Dictionary |
| 9349 | Appl Microbiol Biotechnol 82:333 (2009) |
| 9350 | J Antibiot Ser A 18:101 (1965); Tet Lett 1966:1239 |
| 9351 | Doukas J, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37. |
| 9352 | Palanki MS, et al. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem. 2008 Mar 27;51(6):1546-59. |
| 9353 | Agric. Biol. Chem. (1985), 49(3), 719-24; Jpn. J. Pharmacol. (1977), 27(1), 71-8; Jpn. J. Pharmacol. (1969), 19(2), 224-33 |
| 9354 | Kajimoto K, et al. Contribution of phosphodiesterase isozymes to the regulation of the L-type calcium current in human cardiac myocytes. Br J Pharmacol. 1997 Aug;121(8):1549-56. |
| 9355 | Iwasaki A, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol. 1999 Apr;33(5):1400-7. |
| 9356 | Ratia K, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24. |
| 9357 | JACS 40:1716 (1918); J Biol Chem 180:703 (1949); Arzneim-Forsch 9:22 (1959) |
| 9358 | Beckers T et al. Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997 Aug 15;251(1):17-23. |
| 9359 | Gründker C et al. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003 Oct 7;1:65. |
| 9360 | Nayagam VM, et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen. 2006 Dec;11(8):959-67. |
| 9361 | Singh IR, et al. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One. 2010 Apr 1;5(4):e9948. |
| 9362 | Endocr Rev 3:299 (1982) |
| 9363 | Alex, D. et al. Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. Journal of cellular biochemistry 109, 339-346, doi:10.1002/jcb.22405 (2010) |
| 9364 | Elizabeth Grace Carideo Cunniff, et al. Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of |
| 9365 | Sun QZ, et al. Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers. J Med Chem. 2017 Jul 27;60(14):6337-6352. |
| 9366 | Hossain A, et al. Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice. Exp Eye Res. 2016 Aug;149:100-6 |
| 9367 | Qian X, et al. Inhibition of p38 MAPK Phosphorylation Is Critical for Bestatin to Enhance ATRA-Induced Cell Differentiation in Acute Promyelocytic Leukemia NB4 Cells. Am J Ther. 2016 May-Jun;23(3):e680-9. |
| 9368 | Lis M, et al. The effects of bestatin on humoral response to sheep erythrocytes in non-treated and cyclophosphamide-immunocompromised mice. Immunopharmacol Immunotoxicol. 2013 Feb;35(1):133-8 |
| 9369 | Poloz Y, et al. Bestatin inhibits cell growth, cell division, and spore cell differentiation in Dictyostelium discoideum. Eukaryot Cell. 2012 Apr;11(4):545-57 |
| 9370 | Eikelboom JW, Weitz JI.Otamixaban in acute coronary syndromes.Lancet. 2009 Sep 5;374(9692):762-4. Epub 2009 Aug 28. |
| 9371 | Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2009 Sep 5;374(9692):787-95. Epub 2009 Aug 28. |
| 9372 | Guertin KR, Choi YM.The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Curr Med Chem. 2007;14(23):2471-81. |
| 9373 | Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators.Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.Circulation. 2007 May 22;115(20):2642-51. Epub 2007 May 14. |
| 9374 | Guertin, Kevin R.; Choi, Yong-Mi.The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development.Current Medicinal Chemistry (2007), 14(23), 2471-2481. |
| 9375 | Yamaji M, et al. Novel ATP-competitive Akt inhibitor Afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. |
| 9376 | Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9(6):e100880 |
| 9377 | D Stewart, at al. Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother. 1977 May;11(5):865-70. |
| 9378 | S H Zinner, et al. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct;20(4):463-9. |
| 9379 | Jennifer L Weisman, et al. Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des. 2006 Jun;67(6):409-16. |
| 9380 | J Chem Soc 1954: 1242; Angew Chem., 68: 13 (1956) |
| 9381 | Burris HA 3rd, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist. 2005 Mar;10(3):183-90. |
| 9382 | Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000. Drugs R D. 2004;5(5):305-11. |
| 9383 | Rubitecan |
| 9384 | Xia M, et al. Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther. 2013 Jul;14(7):638-47. |
| 9385 | Br J Clin Pract 30:197 (1976); Eur J Anesthesiol 3:27 (1986) |
| 9386 | Kim BS, et al. QStatin, a Selective Inhibitor of Quorum Sensing in Vibrio Species. MBio. 2018 Jan 30;9(1). pii: e02262-17. |
| 9387 | Changyou Zhou, et al. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors. WO 2013097225 A1. |
| 9388 | Friedlander M, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019 Sep;20(9):1306-1315. |
| 9389 | Zhiyu Tang, et al. Abstract 1653: BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models. Cancer Research. August 2015, Volume 75, Issue 15. |
| 9390 | Shiv K. Gupta, et al. Abstract 3505: Inhibition of PARP activity by BGB-290 potentiates efficacy of NSC 362856 in patient derived xenografts of glioblastoma multiforme. Cancer Research. August 2015, Volume 75, Issue 15 |
| 9391 | Saverio Alberti, et al. Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network. WO2013171777A2. |
| 9392 | Toxicol Appl Pharmacol 18:185 (1971); Curr Ther Res 21:587 (1977) |
| 9393 | Grassia, G., et al., The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res, 2009. 84(3): p. 485-93. |
| 9394 | Zoja C, Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int. 1998 Mar;53(3):726-34. |
| 9395 | Benavides-Serrato A, et al. Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxicin glioblastoma. PLoS One. 2019 Feb 6;14(2):e0212160. |
| 9396 | Liu F, et al. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J Med Chem. 2011 Sep 8;54(17):6139-50. |
| 9397 | Yin MB, et al. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol. 2000 Mar;57(3):453-9. |
| 9398 | Van Hattum AH, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6. |
| 9399 | Tetrahedron 23:2499 (1967); J Chem Soc 1969:365; 1981:1697. |
| 9400 | Dourado M, et al. CD26/DPPIV expression and 8-azaguanine response in T-acute lymphoblastic leukaemia cell lines in culture. Pathophysiology. 2007 May;14(1):3-10. |
| 9401 | De Clercq E1. Guanosine analogues as anti-herpesvirus agents. Nucleosides Nucleotides Nucleic Acids. 2000 Oct-Dec;19(10-12):1531-41. |
| 9402 | F Breillout , et al. Association of SIBA treatment and a Met-depleted diet inhibits in vitro growth and in vivo metastatic spread of experimental tumor cell lines. Clin Exp Metastasis. Jan-Feb 1988;6(1):3-16. |
| 9403 | B Jacquemont, et al. Inhibition of viral RNA methylation in herpes simplex virus type 1-infected cells by 5' S-isobutyl-adenosine. J Virol. 1977 Apr;22(1):160-7. |
| 9404 | Jules Levin. Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. 2019 Nov 8-12. |
| 9405 | Benjamin Ryan. Selgantolimod Shows Promise as Treatment for Hepatitis B. November 18, 2019. |
| 9406 | Romas Geleziunas, et al. Modulators of toll-like receptors for the treatment of hiv. US20170071944A1. |
| 9407 | J Biosci Bioeng 107:296 (2009); Anticancer Res 30:445 (2010); Molecules 18:8046 (2013) |
| 9408 | Buys ES, et al. Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. Nitric Oxide. 2018 Aug 1;78:72-80. |
| 9409 | Martyn DC, et al. High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1280-3. |
| 9410 | Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60. |
| 9411 | Sharma S, et al. Neuroprotective role of Indirubin-3'-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun. 2014 Oct 3;452(4):1009-15. |
| 9412 | Blazevic T, et al. Indirubin-3'-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res. 2014 Mar 1;101(3):522-32. |
| 9413 | Chen Z, et al. Resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. |
| 9414 | Vigueira PA, et al. The beneficial metabolic effects of sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Exp Physiol. 2017 Aug 1;102(8):985-999. |
| 9415 | Br J Clin Pharmacol 9:569 (1980); 11:171 (1981); Therapie 37:75 (1982) |
| 9416 | Ivachtchenko AV, et al. AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation. J Alzheimers Dis. 2017;58(4):1043-1063. |
| 9417 | Antimicrob Agents Chemother 53:1840 (2009) |
| 9418 | Fowler ML, et al. Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: Case study of PI4KIIIβ with Rab11. Protein Sci. 2016 Apr;25(4):826-39. |
| 9419 | McNamara CW, et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature. 2013 Dec 12;504(7479):248-253. |
| 9420 | Kuttruff, C. A., et al. Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo. ACS Medicinal Chemistry Letters, 8(12), 1252–1257. |
| 9421 | Wagner F, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology. 2011 Jul;54(1):50-9. |
| 9422 | Guanghui Yi, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012 Feb;56(2):830-7. |
| 9423 | Eur J Pharmacol 513:173 (2005); Molecules 15:7985 (2010); J Biol Chem 285:11714 (2010) |
| 9424 | Difluprednate, From Wikipedia |
| 9425 | Hu M, et al.Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.Oncotarget. 2015 Jun 20;6(17):15348-61. |
| 9426 | Zu-Guo Zheng, et al. Discovery of a Potent SCAP Degrader That Ameliorates HFD-induced Obesity, Hyperlipidemia and Insulin Resistance via an Autophagy-Independent Lysosomal Pathway. Autophagy. 2020 May 20;1-22. |
| 9427 | .Liu, R. et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment cell & melanoma research 25, 630-638, doi:10.1111/j.1755-148X.2012.01036.x (2012). |
| 9428 | Sharma LK, et al. A therapeutic approach to pantothenate kinase associated neurodegeneration. Nat Commun. 2018 Oct 23;9(1):4399. |
| 9429 | Bowers EM, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010 May 28;17(5):471-82. |
| 9430 | Oike T, et al. C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe. Radiother Oncol. 2014 May;111(2):222-7. |
| 9431 | Zheng WW, et al. EDAG positively regulates erythroid differentiation and modifies GATA1 acetylation through recruiting p300. Stem Cells. 2014 Aug;32(8):2278-89. |
| 9432 | Zhen Fan, et al. Type 2 diabetes-induced overactivation of P300 contributes to skeletal muscle atrophy by inhibiting autophagic flux. Life Sci. 2020 Aug 10;258:118243. |
| 9433 | Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72. |
| 9434 | White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20. |
| 9435 | Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94. |
| 9436 | Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33. |
| 9437 | Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97. |
| 9438 | Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19 |Pharmacother 5: 78 (1985) |
| 9439 | Miyazawa M, et al. Metabolism of (-)-fenchone by CYP2A6 and CYP2B6 in human liver microsomes. Xenobiotica. 2007;37(2):194-204. |
| 9440 | Pharmazie (1972), 27(8), 522-3; Arzneim. Forsch. (1958), 8, 181-90; N. Engl. J. Med. (1960), 263, 748-50,963-5 |
| 9441 | Arch Toxicol 32:1 (1974); Ann Clin Biochem 25:504 (1988) |
| 9442 | Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. |
| 9443 | Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells.Chin Med J (Engl). 2012 Sep;125(18):3332-5. |
| 9444 | Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44-51. |
| 9445 | Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529-36. |
| 9446 | Maldonado M, et al. ROCK inhibitor primes human induced pluripotent stem cells to selectively differentiate towardsmesendodermal lineage via epithelial-mesenchymal transition-like modulation. Stem Cell Res. 2016 Sep;17(2):222-227. |
| 9447 | Dale L. Boger, et al. Critical Role of the Linking Amide in CC-1065 and the Duocarmycins: Implications on the Source of DNA Alkylation Catalysis. J. Am. Chem. Soc. 1998, 120, 11554-11557. |
| 9448 | Bradley WD, et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem Biol. 2014 Nov 20;21(11):1463-1475. |
| 9449 | Bruno NC, et al. Design and Preparation of New Palladium Precatalysts for C-C and C-N Cross-Coupling Reactions. Chem Sci. 2013;4:916-920. |
| 9450 | Brustovetsky T, et al. KB-R7943, an inhibitor of the reverse Na+ /Ca2+ exchanger, blocks N-methyl-D-aspartate receptor and inhibits mitochondrial complex I. Br J Pharmacol. 2011 Jan;162(1):255-70. |
| 9451 | Barrientos G, et al. The Na+/Ca2+ exchange inhibitor 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate(KB-R7943) also blocks ryanodine receptors type 1 (RyR1) and type 2 (RyR2) channels. Mol Pharmacol. 2009 Sep;76(3):560-8. |
| 9452 | Cheng H, et al. High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943. Br J Pharmacol. 2012 Apr;165(7):2260-73. |
| 9453 | Long Z, et al. The reverse-mode NCX1 activity inhibitor KB-R7943 promotes prostate cancer cell death by activating the JNK pathway and blocking autophagic flux. Oncotarget. 2016;7(27):42059-70. |
| 9454 | J Am Pharm Assoc 39:557 (1950); Anal Profiles Drug Subs 12:623 (1983)| |
| 9455 | Ghorbani A. Mechanisms of antidiabetic effects of flavonoid rutin. Biomed Pharmacother. 2017;96:305-312. |
| 9456 | Habtemariam S. Rutin as a Natural Therapy for Alzheimer's Disease: Insights into its Mechanisms of Action. Curr Med Chem. 2016;23(9):860-873. |
| 9457 | Xu PX, et al. Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation. Behav Brain Res. 2014;264:173-180. |
| 9458 | Abdel-Aleem GA, et al. Rutin hydrate ameliorates cadmium chloride-induced spatial memory loss and neural apoptosis in rats by enhancing levels of acetylcholine, inhibiting JNK and ERK1/2 activation and activating mTOR signalling. Arch Physiol Biochem. 2018;124(4):367-377. |
| 9459 | Biochem Pharmacol 18:891 (1969); Toxicol Appl Pharmacol 18:185 (1971) |
| 9460 | Ling Z, et al. Effect of carboprost tromethamine in prevention of postpartum hemorrhage in cesarean section. Pak J Pharm Sci. 2018 Sep;31(5(Special)):2257-2262. |
| 9461 | Bai J, et al. A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery. Exp Ther Med. 2014 Jan;7(1):46-50. Epub 2013 Nov 1. |
| 9462 | Prehosp Disast Med 20:324 (2005); Pakistan Vet J 29:11 (2009); J Psychopharmacol 24:203 (2010) |
| 9463 | Nestor O. Concha, et al. Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1α Endoribonuclease Activity. Molecular Pharmacology December 2015, 88 (6) 1011-1023. |
| 9464 | J. Hyg. (1972), 70(2), 313-23; Pflugers Arch. (1987), 409(3), 251-7 |
| 9465 | J Med Chem 36: 2219 (1993) |
| 9466 | Solit DB, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.Clin Cancer Res, 2002, 8(5), 986-993. |
| 9467 | Raja, Srikumar M., et al. 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biology & Therapy (2008), 7(10), 163 |
| 9468 | Zhang J, et al. The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.Clin Exp Med. 2012 Sep 7. |
| 9469 | Newman B, et al. HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells.Cancer Res. 2012 Sep 1;72(17):4551-61. Epub 2012 Jun 29. |
| 9470 | Kamal A, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003 Sep 25;425(6956):407-10. |
| 9471 | Enomoto A, et al. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition. Eur J Cancer. 2013 Nov;49(16):3547-58. |
| 9472 | J Med Genet 20:307 (1983); Am J Med 91:315 (1991); Ann Pharmacother 39:1128 (2005) |
| 9473 | Ber 51:1347 (1918); J Pharm Pharmacol 5:448 (1953); Cancer Res 51:813 (1991) |
| 9474 | Cheng Y, et al. Effects of phillyrin and forsythoside A on rat cytochrome P450 activities in vivo and in vitro. Xenobiotica. 2017 Apr;47(4):297-303. |
| 9475 | Do MT, et al. Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling. Food Chem. 2013 Jan 15;136(2):415-25. |
| 9476 | Qu XY, et al. Protective effects of phillyrin against influenza A virus in vivo. Arch Pharm Res. 2016 Jul;39(7):998-1005. |
| 9477 | Hennessy EJ, et al. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919. |
| 9478 | Qin Hao, et al. IF-γ and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNFα-independent manner,Cancer Cell Int. 2018; 18: 84. |
| 9479 | Arrau S, et al. Antinociceptive activity of Quillaja saponaria Mol. saponin extract, quillaic acid and derivatives in mice. J Ethnopharmacol. 2011 Jan 7;133(1):164-7. |
| 9480 | Rodríguez-Díaz M, et al. Topical anti-inflammatory activity of quillaic acid from Quillaja saponaria Mol. and some derivatives. J Pharm Pharmacol. 2011 May;63(5):718-24. |
| 9481 | Zhou HJ, et al. Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). J Med Chem. 2015 Dec 24;58(24):9480-97. |
| 9482 | Min BK, et al. Pyruvate Dehydrogenase Kinase Is a Metabolic Checkpoint for Polarization of Macrophages to the M1 Phenotype. Front Immunol. 2019 May 7;10:944. |
| 9483 | Ludovic Juen, et al. New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias. J Med Chem. 2017 Jul 27;60(14):6119-6136. |
| 9484 | Barreyro FJ, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015 Mar;35(3):953-66. |
| 9485 | Hoglen NC, et al. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-te trafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther. 2004 May;309(2):634-40. |
| 9486 | McCall M, et al. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery. 2011 Jul;150(1):48-55. |
| 9487 | Tian J, et al. Combination of Emricasan with AP24534 Synergistically Reduces Ischemia/Reperfusion Injury in Rat Brain Through Simultaneous Prevention of Apoptosis and Necroptosis. Transl Stroke Res. 2017 Nov 4. |
| 9488 | Gracia-Sancho J, et al. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatol Commun. 2019 Apr 22;3(7):987-1000. |
| 9489 | Xu M, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016 Oct;22(10):1101-1107. |
| 9490 | Chen LL, et al. Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway. J Neuroimmune Pharmacol. 2014 Jun;9(3):380-7. |
| 9491 | Sakakibara I, et, al. Effect of oxindole alkaloids from the hooks of Uncaria macrophylla on thiopental-induced hypnosis. Phytomedicine. 1998 Apr;5(2):83-6. |
| 9492 | Biochem Pharmacol 12:1329 (1963); Xenobiotica 23:473 (1993) |
| 9493 | Haley E. Ramsey, et al. A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia. Cancer Discov. August 28, 2018. |
| 9494 | Tae Hwan Kim, et al. In Vivo Absorption and Disposition of α-Cedrene, a Sesquiterpene Constituent of Cedarwood Oil, in Female and Male Rats. Drug Metab Pharmacokinet. 2015 Apr;30(2):168-73. |
| 9495 | Jadhav PK, et al. Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm. ACS Med Chem Lett. 2014 Aug 27;5(10):1138-42. |
| 9496 | Payne CD, et al. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. Br J Clin Pharmacol. 2014 Dec;78(6):1334-42. |
| 9497 | Experientia 20: 562 (1964); Chem Ber 102: 2083 (1969); J Appl Pharmaceut Sci 02(08):74 (2012)| |
| 9498 | Rao YK, et al. Insulin-Mimetic Action of Rhoifolin and Cosmosiin Isolated from <i>Citrus grandis</i> (L.) Osbeck Leaves: Enhanced Adiponectin Secretion and Insulin Receptor Phosphorylation in 3T3-L1 Cells. Evid Based Complement Alternat Med. 2011;2011:624375. |
| 9499 | Liao S, et al. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. J Cell Physiol. 2019 Aug;234(10):17600-17611. |
| 9500 | James ML, et al. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2008 May;49(5):814-22. |
| 9501 | Harhausen D, et al. Specific imaging of inflammation with the 18 kDa translocator protein ligand DPA-714 in animal models of epilepsy and stroke. PLoS One. 2013 Aug 2;8(8):e69529. |
| 9502 | Waldschmidt HV, et al. Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors. J Med Chem. 2016 Apr 28;59(8):3793-807. |
| 9503 | Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85. |
| 9504 | Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129. |
| 9505 | Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36. |
| 9506 | Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244. |
| 9507 | Ann Rheum Dis 44:194 (1985); Anal Profiles Drug Subs 5:515 (1976) |
| 9508 | Guo XX, et al. p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells. Protein Cell. 2014 Mar;5(3):224-34. |
| 9509 | Wang M, et al. Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model. Oncol Lett. 2017 Feb;13(2):681-685. |
| 9510 | Futaki N, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994 Jan;47(1):55-9. |
| 9511 | Futaki N, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol. 1993 Jan;24(1):105-10. |
| 9512 | J Org Chem 19:1633 (1954) |
| 9513 | Radwan FF et al. Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. J Cell Biochem. 2015 Jan;116(1):102-14. |
| 9514 | Yao X et al. Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin.
 Planta Med. 2012 Nov;78(16):1740-8. |
| 9515 | Gill BS et al. Evaluating anti-oxidant potential of ganoderic acid A in STAT 3 pathway in prostate cancer. Mol Biol Rep. 2016 Sep 17. |
| 9516 | Shao J et al. [Ganoderic acid A suppresses proliferation and invasion and induces apoptosis in human osteosarcoma cells]. Nan Fang Yi Ke Da Xue Xue Bao. 2015 May;35(5):619-24. |
| 9517 | Yang X, et al. Isolation and identification of an antioxidant flavonoid compound from citrus-processing by-product. J Sci Food Agric. 2011 Aug 15;91(10):1925-7. |
| 9518 | Holder S, et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007 Jan;6(1):163-72. |
| 9519 | Baek S, et al. Structural and functional analysis of the natural JNK1 inhibitor quercetagetin. J Mol Biol. 2013 Jan 23;425(2):411-23. |
| 9520 | Caubet MS, et al. Determination of urinary 13C-caffeine metabolites by liquid chromatography-mass spectrometry: the use of metabolic ratios to assess CYP1A2 activity. J Pharm Biomed Anal. 2004 Feb 4;34(2):379-89. |
| 9521 | Bitencourt TA, et al. Trans-chalcone and quercetin down-regulate fatty acid synthase gene expression and reduce ergosterol content in the human pathogenic dermatophyte Trichophyton rubrum. BMC Complement Altern Med. 2013 Sep 17;13:229. |
| 9522 | Tian D, et al. Overexpression of steroidogenic acute regulatory protein in rat aortic endothelial cells attenuates palmitic acid-induced inflammation and reduction in nitric oxide bioavailability. Cardiovasc Diabetol. 2012 Nov 21;11:144. |
| 9523 | Cheng G, et al. Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob/ob mice. PLoS One. 2013 Sep 27;8(9):e75980. |
| 9524 | Zhu MX, et al. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells in vitro. Exp Cell Res. 2015 Feb 15;331(2):387-98. |
| 9525 | Lin S, et al. Novel strategy for immunomodulation: Dissolving microneedle array encapsulating thymopentin fabricated by modified two-step molding technology. Eur J Pharm Biopharm. 2018 Jan;122:104-112. |
| 9526 | Minson KA, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630. |
| 9527 | Lee JW, et al. A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angew Chem Int Ed Engl. 2011 Nov 4;50(45):10608-11. |
| 9528 | Hideki Tokushige, et al. Effects of Topical Administration of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Ocular Tissues in Rabbits and Monkeys Invest. Ophthalmol. Vis. Sci. July 2007 vol. 48no. 7 3216-3222 |
| 9529 | Tokushige H, et al. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res. 2011 Oct;36(10):964-70. |
| 9530 | Watabe H, et al. Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries.Jpn J Ophthalmol. 2011 Jul;55(4):411-7. Epub 2011 Jun 11. |
| 9531 | Aust J Chem 24:2427 (1971); Tet Lett 1972:2965; Phytochemistry 13:633 (1974); 15:1791, 2006 (1976); 32:1083 (1993) |
| 9532 | Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. |
| 9533 | Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984-92. |
| 9534 | Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305(3):1222-32. |
| 9535 | Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8(8):e71754. |
| 9536 | Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. |
| 9537 | Liu D, et al. Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.). Gen Comp Endocrinol. 2016 Mar 1;228:1-8. |
| 9538 | Yang Z, et al. Dauricine induces apoptosis, inhibits proliferation and invasion through inhibiting NF-kappaB signaling pathway in colon cancer cells. J Cell Physiol. 2010 Oct;225(1):266-75. |
| 9539 | Shadomy S, et al. Further in vitro studies with oxiconazole nitrate. Diagn Microbiol Infect Dis. 1988 Apr;9(4):231-7. |
| 9540 | ?zdemir S, et al. Effects of topical oxiconazole and boric acid in alcohol solutions to rat inner ears. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1023-7. |Arzneimittelforschung 32:17 (1992) |
| 9541 | Bar-Peled L, et al. Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. Cell. 2017 Oct 19;171(3):696-709.e23. |
| 9542 | Jung HA, et al. Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase. Arch Pharm Res. 2008 Nov;31(11):1405-12. |
| 9543 | Kobayashi Y, et al. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Med. 1995 Oct;61(5):414-8. |
| 9544 | Dinkova-Kostova AT, et al. Bis(2-hydroxybenzylidene)acetone, a potent inducer of the phase 2 response, causes apoptosis in mouse leukemia cells through a p53-independent, caspase-mediated pathway. Cancer Lett. 2007 Jan 8;245(1-2):341-9. |
| 9545 | https://clinicaltrials.gov/ct2/show/NCT04531748?term=Toremifene&cond=COVID-19&draw=2&rank=1 |
| 9546 | Hepato-Gastroenterology (2007), 54(73), 195-200; Respiration (1998), 65(4), 304-308; Scand. J. Gastroenterol. (1996), 31(11), 1059-1062 |
| 9547 | Br J Clin Pract 40:276 (1985) |
| 9548 | Li X, et al. Corilagin, a promising medicinal herbal agent. Biomed Pharmacother. 2018 Mar;99:43-50. |
| 9549 | Chu DT et al. Synthesis and biological properties of A-71497: a prodrug of tosufloxacin. Drugs Exp Clin Res. 1990;16(9):435-43. |
| 9550 | Deng FY et al. [Mn2+-cTMAB-sensitized fluorescent microscopic determination of tosufloxacin tosylate based on a self-ordered ring. Guang Pu Xue Yu Guang Pu Fen Xi. 2014 Feb;34(2):445-9. |
| 9551 | Chu DT et al. Synthesis and biological properties of A-71497: a prodrug of tosufloxacin. Drugs Exp Clin Res, 1990, 16(9):435-43. |
| 9552 | Dokla EME, et al. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. Eur J Med Chem. 2019 Aug 9;182:111607. |
| 9553 | R S Thrall, et al. Eprazinone Alters Lung Lavage Lipid Levels and Transtracheal Ion Transport. Exp Lung Res. May-Jun 1992;18(3):409-20. |
| 9554 | Yvonne Krautscheid, et al. Pharmacophore Modeling, Virtual Screening, and in Vitro Testing Reveal Haloperidol, Eprazinone, and Fenbutrazate as Neurokinin Receptors Ligands. J Chem Inf Model. 2014 Jun 23;54(6):1747-57. |
| 9555 | Comp. Biochem. Physiol., C:(1988), 91C(2), 525-33; Ann. Trop. Med. Parasitol. (1970), 64(4), 525-31; J. Med. Chem. (1969), 12(5), 1066-79 |
| 9556 | J Chem Soc 1963: 1477; Eur J Cancer 32A: 146 (1996); J Biol Chem 271: 2262 (1996); Carcinogenesis 10: 2325 (1994) |
| 9557 | Andruska ND, et al. Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression. Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4737-42. |
| 9558 | Arzneim Forsch 27:684 (1977); Scand J Gastroenterol 17 Suppl 81:1 (1982) |
| 9559 | J Neurophysiol 27:408 (1964); Anesthesiology 63:A366 (1985) |
| 9560 | Furonaka M, Hattori N, Tanimoto T, Senoo T, Ishikawa N, Fujitaka K, Haruta Y, Yokoyama A, Kohno N.
 Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice.
 J Pharmacol Exp Ther. 2009 Jan;328(1):55-61. |
| 9561 | Yanagihara Y, et, al. Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2). Regulation of human IgE response. Jpn J Pharmacol. 1993 Jan;61(1):31-9. |
| 9562 | Zhao GD, et, al. Effect of suplatast tosilate (IPD-1151T) on a mouse model of asthma: inhibition of eosinophilic inflammation and bronchial hyperresponsiveness. Int Arch Allergy Immunol. 2000 Feb;121(2):116-22. |
| 9563 | Kurokawa M, et, al. Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 2001 Dec;10(6):333-7. |
| 9564 | Jiang Y et al. Shikonin Inhibits Intestinal Calcium-Activated Chloride Channels and Prevents Rotaviral Diarrhea. Front Pharmacol. 2016 Aug 23;7:270. |
| 9565 | Li W, et al. Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation. PLoS One. 2015 May 11;10(5):e0126459. |
| 9566 | Yan Y, et al. Shikonin Promotes Skin Cell Proliferation and Inhibits Nuclear Factor-κB Translocation via Proteasome Inhibition In Vitro. Chin Med J (Engl). 2015 Aug 20;128(16):2228-33. |
| 9567 | Zhang FY, et al. Shikonin Inhibits the Migration and Invasion of Human Glioblastoma Cells by Targeting Phosphorylated β-Catenin and Phosphorylated PI3K/Akt: A Potential Mechanism for the Anti-Glioma Efficacy of a Traditional Chinese Herbal Medicine. Int J Mol Sci. 2015 Oct 9;16(10):23823-48. |
| 9568 | Fu D, et al. Shikonin inhibits inflammation and chondrocyte apoptosis by regulation of the PI3K/Akt signaling pathway in a rat model of osteoarthritis. Exp Ther Med. 2016 Oct;12(4):2735-2740. |
| 9569 | Kathleen M McAndrews, et al. Mechanisms associated with biogenesis of exosomes in cancer. Mol Cancer. 2019 Mar 30;18(1):52. |
| 9570 | Jernej Zorman, et al. Shikonin Suppresses NLRP3 and AIM2 Inflammasomes by Direct Inhibition of Caspase-1. PLoS One. 2016 Jul 28;11(7):e0159826. |
| 9571 | Kumar S, et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone. 2010 Feb;46(2):534-42. |
| 9572 | Matsuo Y, et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22;6(259):259ra145. |
| 9573 | Stefka AT, et al. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 Jan;9(1):324-334. |
| 9574 | Cheeseman MD, et al. Discovery of a Chemical Probe Bisamide (CCT251236): An OrallyBioavailable Efficacious Pirin Ligand from a Heat ShockTranscription Factor 1 (HSF1) Phenotypic Screen. J Med Chem. 2017 Jan 12;60(1):180-201. |
| 9575 | J. Am. Pharm. Assoc. (1949), 10, 488-91; Br. Med. J. (1959), 2(5152), 606-9; J. Invest. Dermatol. (1950), 15(3), 257-63 |
| 9576 | Sun L, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019 Apr 4;4(7). |
| 9577 | Lu X, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 30;543(7647):728-732. |
| 9578 | https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCT2071200023 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04471662 |
| 9579 | Han P, et al. Inhibitory effects of 4-chlorosalicylic acid on mushroom tyrosinase and its antimicrobial activities. 107 (2), 797-803, 2008 |
| 9580 | Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424-6. |
| 9581 | King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14(9):2004-1 |
| 9582 | Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7(3):473-483. |
| 9583 | Nakamichi K, et al. Stabilization of sodium guaiazulene sulfonate in granules for tableting prepared using a twin-screw extruder. Eur J Pharm Biopharm. 2003 Nov;56(3):347-54. |
| 9584 | Cao T, et al. Synthesis and Biological Evaluation of 3, 8-dimethyl-5-isopropylazulene Derivatives as Anti-gastric Ulcer Agent. Chem Biol Drug Des. 2016 Aug;88(2):264-71. |
| 9585 | Brown DA, et, al. The effects of some centrally acting drugs on ganglionic transmission in the cat. |
| 9586 | Jurima-Romet M, et, al. Induction of CYP3A and associated terfenadine N-dealkylation in rat hepatocytes cocultured with 3T3 cells. Cell Biol Toxicol. 1995 Dec;11(6):313-27. |
| 9587 | BRAUN DL, et, al. The pharmacologic activity of alpha-(4-piperidyl)-benzhydrol hydrochloride (azacyclonol hydrochloride); an ataractive agent. J Pharmacol Exp Ther. 1956 Oct;118(2):153-61. |
| 9588 | Harris PA, ET AL. Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862. |
| 9589 | Yi G, Deval J, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56(2):830-837. |
| 9590 | Li P, Dorsch W, et al. Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates. ACS Med Chem Lett. 2017;8(2):251-255. Published 2017 Jan 31. |
| 9591 | M. Rodriguez-Torres et al. SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS Journal of Hepatology Volume 52, Supplement 1 , Page S14, April 2010 |
| 9592 | Trans. N. Y. Acad. Sci. (1953), 16, 2-13; Q. J. Pharm. Pharmacol. (1944), 17, 88-95; Arch. Ophthalmol. (1940), 23, 340-50 |
| 9593 | Rabindran SK, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res, 2004, 64(11), 3958-3965. |
| 9594 | Yoshioka T, et al. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci. 2018 Apr;109(4):1166-1176. |
| 9595 | Gordon RK, et al. Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem. 2003 Sep;270(17):3507-17. |
| 9596 | Jeong SY, et al. 3-deazaadenosine, a S-adenosylhomocysteine hydrolase inhibitor, has dual effects on NF-kappaB regulation. Inhibition of NF-kappaB transcriptional activity and promotion of IkappaBalpha degradation. J Biol Chem. 1999 Jul 2;274(27):18981-8. |
| 9597 | Sedding DG, et al. 3-Deazaadenosine prevents smooth muscle cell proliferation and neointima formation by interfering with Ras signaling. Circ Res. 2009 May 22;104(10):1192-200. |
| 9598 | Lim KB, et al. Treatment of uncomplicated gonorrhoea with rosoxacin (acrosoxacin).Br J Vener Dis. 1984 Jun;60(3):157-60. |
| 9599 | Poxton IR, et al. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 Apr;5(4):539-48. |
| 9600 | Jones P, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85. |
| 9601 | J Clin Psychiatry 45: 12 (1984); Int Pharmacopsychiatry 17: 21 (1982); hepatotoxic at clinical dose (125mg) |
| 9602 | Yan-You Huang, et al.D1/D5 Receptors and Histone Deacetylation Mediate the Gateway Effect of LTP in Hippocampal Dentate Gyrus. |
| 9603 | Melissa A Stouffer, et al. SKF-83566, a D1-dopamine Receptor Antagonist, Inhibits the Dopamine Transporter. J Neurochem. 2011 Sep;118(5):714-20. |
| 9604 | E H Ohlstein, et al. SCH 23390 and SK&F 83566 are antagonists at vascular dopamine and serotonin receptors. Eur J Pharmacol. 1985 Jan 22;108(2):205-8. |
| 9605 | Jason M Conley, et al. Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor. J Pharmacol Exp Ther. 2013 Nov;347(2):276-87 |
| 9606 | Yan-You Huang, et al. D1/D5 receptors and histone deacetylation mediate the Gateway Effect of LTP in hippocampal dentate gyrus. Learn Mem. 2014 Feb 18;21(3):153-60. doi: 10.1101/lm.032292.113. |
| 9607 | Milite C, et al. A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach. J Med Chem. 2015 Mar 26;58(6):2779-98. |
| 9608 | Son JY et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis, 2014 Jul, 13(7):1704-16. |
| 9609 | Naka K, et al. Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells. Cancer Sci. 2016 Feb;107(2):140-8. |
| 9610 | https://clinicaltrials.gov/ct2/show/NCT04445337?term=BUPIVACAINE&cond=Covid19&draw=2&rank=1 |
| 9611 | Monatsh Chem 61: 147 (1932) |
| 9612 | Jones N, et al. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain Res Bull. 2013 Sep;98:163-9. |
| 9613 | Brian C. Shook, et al. Adenosine A2A Receptor Antagonists and Parkinson’s Disease. ACS Chem Neurosci. 2011 Oct 19; 2(10): 555-567. |
| 9614 | I D BEDFORD, et al. The effect of Pymetrozine, a feeding inhibitor of Homoptera, in preventing transmission of cauliflower mosaic caulimovirus by the aphid species Myzus persicae (Sulzer). Annals of Applied Biology. 1998 Jun; 132(3): 453-462 |
| 9615 | Paul Harrewijn, et al. Pymetrozine, a Fast-Acting and Selective Inhibitor of Aphid Feeding. In-situ Studies with Electronic Monitoring of Feeding Behaviour. Pest Management Science. 1997 Feb;49(2):130-140. |
| 9616 | Curr Ther Res 16:124 (1974); JAMA 215:783 (1971) |
| 9617 | J Chem Soc 1953:1852 |
| 9618 | Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509. |
| 9619 | Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710. |
| 9620 | Int. J. Chemoinf. Chem. Eng. (2011), 1(2), 15-35; Int. J. Mol. Sci. (2006), 7(1), 12-34; Experientia (1964), 20(10), 582-3 |
| 9621 | J Obstet Gynecol 104:1053 (1969); 110:111 (1971); Br J Med J 3:144 (1971) |
| 9622 | Kahraman A, et al. Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Hepatol Res. 2009 Aug;39(8):805-813. |
| 9623 | Johnson JL, et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res. 2006 Aug 1;71(3):586-595. |
| 9624 | Annalen 485: 247 (1931); J Chem Soc 1955: 3252; J Immunopharmacol 7: 33 (1985); Arzneim-Forsch 44: 1223 (1994) |
| 9625 | Wolfson E, et al. Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer. Cell Death Dis. 2018 Jan 19;9(2):47. |
| 9626 | He H, et al. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J. 2001 May-Jun;7(3):191-202. |
| 9627 | Ling J, et al. Identifying key genes, pathways and screening therapeutic agents for manganese-induced Alzheimer disease using bioinformatics analysis. Medicine (Baltimore). 2018 Jun;97(22):e10775. |
| 9628 | Rahman A, et al. Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation. Elife. 2019 Oct 15;8. pii: e50990. |
| 9629 | Gazit A, et al. Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem. 1993 Nov 12;36(23):3556-64. |
| 9630 | Rai G, et al. Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). J Med Chem. 2017 Nov 22;60(22):9184-9204. |
| 9631 | J Biol Chem 255:2816 (1980) |
| 9632 | Huband MD, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother. 2015 Jan;59(1):467-74. |
| 9633 | Proc Soc Exp Biol Med 158:402 (1978); Biochim Biophys Acta 1472:651 (1999); Biochem Biokhimiia 65:869 (2000); Mol Cancer 9:2 (2010) |
| 9634 | Husak VV, et al. Acute exposure to the penconazole-containing fungicide Topas partially augments antioxidant potential in goldfish tissues. Comp Biochem Physiol C Toxicol Pharmacol. 2017;193:1-8. |
| 9635 | Chaâbane M, et al. Penconazole alters redox status, cholinergic function, and membrane-bound ATPases in the cerebrum and cerebellum of adult rats. Hum Exp Toxicol. 2017;36(8):854-866. |
| 9636 | Semple G, et al. 3-(1H-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice. J. Med. Chem., 2008, 51 (16), pp 5101-5108 |
| 9637 | Lai E1, et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol. 2008 Oct;2(5):375-383. |
| 9638 | Buckley G, et al. IRAK-4 inhibitors. Part 1: a series of amides. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3211-4. |
| 9639 | Perron A, et al. Small-molecule screening yields a compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone. J Biol Chem. 2018 May 25;293(21):8285-8294. |
| 9640 | Nayar AS, et al. Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay. J Bacteriol. 2015 May;197(10):1726-34. |
| 9641 | Melanie Cushion, et al. Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia. VOLUME 25, ISSUE 3, SUPPLEMENT, S366, MARCH 01, 2019. |
| 9642 | Sofjan AK, et al. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 Sep;14:58-64. |
| 9643 | J Chem Soc 1952: 1042; 1958: 2987 |
| 9644 | Miyamoto N, et al. Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor. Bioorg Med Chem. 2013 Apr 15;21(8):2333-2345. |
| 9645 | Awazu Y, et al. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase. Cancer Sci. 2013 Apr;104(4):486-94. |
| 9646 | Fu ZG, et al. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget. 2016 Feb 23;7(8):9429-47. |
| 9647 | Spinello I, et al. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. Haematologica. 2019 May;104(5):973-985. |
| 9648 | https://clinicaltrials.gov/ct2/show/NCT04363060?term=Amoxicillin&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT05035186?term=Amoxicillin&cond=COVID-19&draw=2&rank=2 |
| 9649 | Kye-Im Jeon et al. Vinpocetine inhibits NF-κB-dependent inflammation via an IKK-dependent but PDE-independent mechanism PNAS May 25, 2010 vol. 107 no. 21 9795-9800 |
| 9650 | Patyar S, et al. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011;63(3):618-28. |
| 9651 | Alexandre E. Medina Vinpocetine as a potent antiinflammatory agent PNAS June 1, 2010, Vol. 107, No. 22 9921-9922. |Arzneimittel-Forsch 26: 1907 (1976) |
| 9652 | Wijemanne S, et al. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017;376:129‐132. |
| 9653 | Searles RV, et al. Aqueous humor dynamics in anesthetized rats infused with intracameral apraclonidine. Pharmacology. 1999;58(4):220‐226. |
| 9654 | Moschos SJ, et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 Feb 22;3(4). pii: 92352. |
| 9655 | J Am Chem Soc 59: 616 (1937); Phychopharmacol 199:161 (2008); Proc Nat Acad Sci 107:6498 (2010 ) |
| 9656 | https://clinicaltrials.gov/ct2/show/NCT04591210?term=Perindopril&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04467931?term=Perindopril&cond=COVID-19&draw=2&rank=3 |
| 9657 | Huang F, et al. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Res. 2016 May 19;44(9):4189-99. |
| 9658 | Hengel SR, et al. Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy. Cell Chem Biol. 2017 Sep 21;24(9):1101-1119. |
| 9659 | Sullivan-Reed K, et al. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep. 2018 Jun 12;23(11):3127-3136. |
| 9660 | Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019 Apr 15;35(4):677-691.e10. |
| 9661 | JACS 73:3758 (1951); J Med Chem 14:462 (1971) |
| 9662 | https://clinicaltrials.gov/ct2/show/NCT04394117?term=Olmesartan&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04467931?term=Olmesartan&cond=COVID-19&draw=2&rank=3 |
| 9663 | Beebe JS, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003 Nov 1;63(21):7301-9. |
| 9664 | Zhang, H. et al. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethylthiazolyl thiourea derivatives trovirdine and MSC-127. |
| 9665 | Cantrell, A.S. et al. Phenethylthiazolylthiourea (PETT) compounds as a newclass of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. |
| 9666 | Monatsh Chem 63: 201 (1933); Aust J Chem 19: 1755 (1966); Brit J Pharmacol 167:(2012) |
| 9667 | Riccio G, et al. A Negative Allosteric Modulator of WNT Receptor Frizzled 4 Switches into an Allosteric Agonist. Biochemistry. 2018 Feb 6;57(5):839-851. |
| 9668 | Diasio RB, et al. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol. 1998 Jul;46(1):1-4. |
| 9669 | Whitley RJ, et al. Sorivudine: a potent inhibitor of varicella zoster virus replication.Adv Exp Med Biol. 1996;394:41-4. |
| 9670 | https://clinicaltrials.gov/ct2/show/NCT04374474?term=EUCALYPTOL&cond=COVID-19&draw=2&rank=2 |
| 9671 | Pukkila-Worley R, et al. Stimulation of host immune defenses by a small molecule protects C. elegans from bacterial infection. PLoS Genet. 2012;8(6):e1002733. |
| 9672 | Maurice Raymond Verschoyle Finlay, et al. Amino-triazolopyridine compounds and their use in treating cancer. WO2018114999A1. |
| 9673 | Cheng H, et al. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J Med Chem. 2016 Mar 10;59(5):2005-24. doi: 10.1021/acs.jmedchem.5b01633. Epub 2016 Jan 28. |
| 9674 | Bill Severson, et al. Anti-viral treatment and assay to screen for anti-viral agent. WO 2011097607 A1 |
| 9675 | Sarah A Comerford, et al. Acetate dependence of tumors. Cell. 2014 Dec 18;159(7):1591-602. |
| 9676 | Mandava NB, et al. Phytotoxins in Rhizoctonia solani: isolation and biological activity of m-hydroxy- and m-methoxyphenylacetic acids. J Agric Food Chem. 1980 Jan-Feb;28(1):71-5. |
| 9677 | Shishodia S, et al. Guggulsterone for Chemoprevention of Cancer. Curr Pharm Des. 2016;22(3):294-306. |
| 9678 | Che X, et al. Protective effects of guggulsterone against colitis are associated with the suppression of TREM-1 and modulation of macrophages. Am J Physiol Gastrointest Liver Physiol. 2018 Jul 1;315(1):G128-G139. |
| 9679 | Junichi Kitanaka, et al. Brain Histamine N-Methyltransferase As a Possible Target of Treatment for Methamphetamine Overdose. Drug Target Insights. 2016 Mar 2;10:1-7. |
| 9680 | Zhong Chen, et al. Effects of brain histamine on memory deficit induced by nucleus basalis-lesion in rats. Acta Pharmacol Sin. 2002 Jan;23(1):66-70. |
| 9681 | John R Horton, et al. Structural basis for inhibition of histamine N-methyltransferase by diverse drugs. J Mol Biol. 2005 Oct 21;353(2):334-344. |
| 9682 | Dunlop J, et al. Characterization of Vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther. 2011 Jun;337(3):673-80. |
| 9683 | Tong Z, et al. Species differences in the formation of Vabicaserin carbamoyl glucuronide. Drug Metab Dispos. 2010 Apr;38(4):581-90. |
| 9684 | Gotoh Y, et al. Novel antibacterial compounds specifically targeting the essential WalR response regulator. J Antibiot (Tokyo). 2010 Mar;63(3):127-34. |
| 9685 | Friedman B, Cirulli J.
 Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V(2)-receptor antagonist tolvaptan.
 J Crit Care. 2012 Aug 8. |
| 9686 | Inomata T.
 Tolvaptan (vasopressin receptor antagonist).Nihon Rinsho. 2011 Nov;69 Suppl 9:408-11. |
| 9687 | Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators.
 Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
 J Cardiovasc Med (Hagerstown). 2012 Jul;13(7):415-22. |
| 9688 | Y Yamamura et al. OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats. J. Pharmacol. 
 Exp. Ther. 1998, 287(3), 860-867. |
| 9689 | RW Schrier et al. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. N Engl J Med 2006, 355, 2099-2112. |
| 9690 | J Pharm Pharmacol 15:472 (1963); J Pharmacol Exp Ther 187:365 (1973); Science 206:470 (1979) |
| 9691 | Kimani SG, et al. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Sci Rep. 2017 Mar 8;7:43908. |
| 9692 | Wu KH, et al. Cys32 and His105 are the critical residues for the calcium-dependent cysteine proteolyticactivity of CvaB, an ATP-binding cassette transporter. J Biol Chem. 2004 Jan 9;279(2):901-9. |
| 9693 | Hatase O , et al. Specific inhibition of phosphate transport in mitochondria by N-ethylmaleimide. Journal of Bioenergetics, 1973, 5(1):1-15. |
| 9694 | Choo YS, et al. Detection of protein ubiquitination. J Vis Exp. 2009;(30):1293. Published 2009 Aug 19. doi:10.3791/1293 |
| 9695 | Bull Chim Farm 112:782 (1953); Drugs 13:321 (!977) |
| 9696 | Hedrick E, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015 Jun 2;10(6):e0128308. |
| 9697 | Hedrick E, et al. NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration. Mol Cell Biol. 2016 Apr 15;36(9):1383-94. |
| 9698 | Neef DW, et al. A direct regulatory interaction between chaperonin TRiC and stress-responsive transcription factor HSF1. Cell Rep. 2014 Nov 6;9(3):955-66. |
| 9699 | Neef DW, et al. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010 Jan 19;8(1):e1000291. |
| 9700 | Huang CY, et al. Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death. Cell Death Dis. 2016 Nov 3;7(11):e2455. |
| 9701 | Marcus Steinemann, et al. The chaperonin TRiC/CCT is essential for the action of bacterial glycosylating protein toxins like <i>Clostridium difficile</i> toxins A and B. Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9580-9585. |
| 9702 | Wagner J, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 Jun;125(6):795-813. |
| 9703 | Martinez Hernandez A, et al. The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Mol Med. 2018;10(1):32-47. |
| 9704 | Heras-Garvin A, et al. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2019;34(2):255-263. |
| 9705 | J. Pharm. Sci. (1973), 62(6), 948-51; J. Med. Chem. (1967), 10(5), 807-10; Anaesthesia (2004), 59(4), 364-373 |
| 9706 | Kawas RF, et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017 Oct 6;292(40):16571-16577. |
| 9707 | Stern JA, et al. A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS One. 2016 Dec 14;11(12):e0168407. |
| 9708 | Green EM, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016 Feb 5;351(6273):617-21. |
| 9709 | Yan Y, et al. Decomposition of 3,5-dinitrobenzamide in aqueous solution during UV/H2O2 and UV/TiO2oxidation processes. Environ Sci Pollut Res Int. 2017 Feb;24(6):5360-5369. |Arch. Biochem. Biophys. (2001), 393(2), 199-206; Mol. Pharmacol. (1977), 13(2), 269-82; Radiat. Res. (1976), 65(3), 529-39 |
| 9710 | JACS 61:2832 (1939); 62:651 (1940); 63:1253 (1941); 68:406 (1946) |
| 9711 | J Agric Food Chem 46:3468 (1998); Cancer Lett 172:103 (2001) |
| 9712 | Sali TM, et al. Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathog. 2015 Dec 8;11(12):e1005324. |
| 9713 | Kenichi Shimada, et al. Global Survey of Cell Death Mechanisms Reveals Metabolic Regulation of Ferroptosis. Nat Chem Biol. 2016 Jul;12(7):497-503. |
| 9714 | Ammirati M, et al. Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. ACS Med Chem Lett. 2015 Oct 6;6(11):1128-33. |
| 9715 | Roth Flach RJ, et al. Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis. Nat Commun. 2015 Dec 21;6:8995. |
| 9716 | Sonntag Y, et al. Identification and characterization of potent and selective aquaporin-3 and aquaporin-7 inhibitors. J Biol Chem. 2019 May 3;294(18):7377-7387. |
| 9717 | Woodfield JC, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9. |
| 9718 | Scholz H, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7. |
| 9719 | Gums JG, et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother. 2008 Jan;42(1):71-9. |
| 9720 | Gums JG, et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother. 2008 Jan;42(1):71-9. |
| 9721 | E L Francke, et al. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. Am J Med. 1981 Sep;71(3):435-42. |
| 9722 | Na YJ, et al. [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. Biochem Pharmacol. 2007 Sep 1;74(5):780-6. |
| 9723 | Hirano T, et al. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression. Mol Cancer. 2015 Apr 19;14:90. doi: 10.1186/s12943-015-0364-7. |
| 9724 | Drugs (1998), 56(4), 523-535; J. Pharmacol. Exp. Ther. (1993), 265(3), 1272-9; Mol. Pharmacol. (1983), 23(3), 585-93 |
| 9725 | Bromberg KD, et al. The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 2017 Mar;13(3):317-324. |
| 9726 | Abulwerdi FA, et al. Selective Small-Molecule Targeting of a Triple Helix Encoded by the Long Noncoding RNA, MALAT1. ACS Chem Biol. 2019 Feb 15;14(2):223-235. |
| 9727 | Tully DC, et al. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). J Med Chem. 2017 Dec 8. |
| 9728 | Roquinimex, From Wikipedia |
| 9729 | Liu Q, et al. Roquinimex inhibits dextran sodium sulfate-induced murine colitis. Inflamm Res. 2003 Feb;52(2):64-8. |
| 9730 | Tian WZ, et al. Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Acta Neurol Scand. 1998 Aug;98(2):94-101. |
| 9731 | Desroy N, et al. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem. 2017 May 11;60(9):3580-3590. |
| 9732 | Phytochemistry 4: 411 (1968) |
| 9733 | Proc Chem Soc 1959: 150 |
| 9734 | Hancock AA, et al. Actions of terazosin and its enantiomers at subtypes of alpha 1- and alpha 2-adrenoceptors in vitro. J Recept Signal Transduct Res. 1995 Sep-Dec;15(7-8):863-85. |
| 9735 | Pan BS, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. |
| 9736 | J Chem Soc 1963:980 |
| 9737 | Mamoru Ohtoyo, et al. Scintillation Proximity Assay to Detect the Changes in Cellular Dihydrosphingosine 1-Phosphate Levels. Lipids. 2016 Oct;51(10):1207-1216. |
| 9738 | M J Connor, et al. Epidermal Pyridoxal 5'-phosphate Depletion, Inhibition of DNA Synthesis, and Inhibition of the Expression of Ornithine Decarboxylase Activity by the Vitamin B-6 Antagonist 4'-deoxypyridoxine. J Invest Dermatol. 1983 Aug;81(2):136-9. |
| 9739 | D L Martin, et al. Glutamate-dependent Active-Site Labeling of Brain Glutamate Decarboxylase. J Neurochem. 1990 Aug;55(2):524-32. |
| 9740 | Zhou BN, et al. Some progress on the chemistry of natural bioactive terpenoids from Chinese medicinal plants. Mem Inst Oswaldo Cruz. 1991;86 Suppl 2:219-26. |
| 9741 | Wang WC, et al. [Endocrine activity of pseudolaric acids A and B and their effects on sex hormones, prostaglandins, uteri, and fetuses]. Zhongguo Yao Li Xue Bao. 1991 Mar;12(2):187-90. |
| 9742 | Wei N, et al. The immunosuppressive activity of pseudolaric acid B on T lymphocytes in vitro. Phytother Res. 2013 Jul;27(7):980-5. |
| 9743 | Yu J, et al. Pseudolaric acid B inhibits the secretion of hepatitis B virus. Oncol Rep. 2017 Jan;37(1):519-525. |
| 9744 | Yu J, et al. Pseudolaric acid B activates autophagy in MCF-7 human breast cancer cells to prevent cell death. Oncol Lett. 2016 Mar;11(3):1731-1737. |
| 9745 | Alberts AW, et al. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J-15J. |
| 9746 | Kah J, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012 Sep;28(3):1077-83. |
| 9747 | Frishman WH, et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437-48. |
| 9748 | Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. |
| 9749 | Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006 Jul;60(1):45-55. |PNAS 77:3957 (1980); Int J Oncol 12:717 (1998) |
| 9750 | Eur J Pharmacol 368:259 (1999); CNS Drugs 12:325 (1999); Neurology 54:156 (2000) |
| 9751 | Brock WA, et al. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 2004 Mar 18;205(2):155-60. |
| 9752 | Mason KA, et al. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs. 2008 Feb;26(1):1-5. Epub 2007 Jul 13. |
| 9753 | Mitchell LH, et al. Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 ToolCompound. ACS Med Chem Lett. 2015 Apr 6;6(6):655-659. |
| 9754 | Brit J Dermatol 119:615 (1988); Int J Dermatol 30:467 (1991) |
| 9755 | Koya E, et al. Targeted disruption of cocaine-activated nucleus accumbens neurons prevents context-specific sensitization. Nat Neurosci. 2009 Aug;12(8):1069-73. |
| 9756 | Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7. |
| 9757 | Farquhar D, et al. Suicide gene therapy using E. coli beta-galactosidase.Cancer Chemother Pharmacol. Cancer Chemother Pharmacol. 2002 Jul;50(1):65-70. |
| 9758 | Leysen JE, et al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol. 1992 Mar;41(3):494-508. |
| 9759 | Cosi C, et al. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. |
| 9760 | Rijnders HJ, et al. The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity. Psychopharmacology (Berl). 1993;111(1):55-61. |
| 9761 | Meyers CD, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis. 2015 Feb 18;14:8. |
| 9762 | Kulmatycki K, et al. Evaluation of a potential transporter-mediated drug interaction between ZD 4522 and pradigastat, a novel DGAT-1 inhibitor. Int J Clin Pharmacol Ther. 2015 May;53(5):345-55. |
| 9763 | Charles DanielMeyersMD, et al. The DGAT1 inhibitor pradigastat decreases chylomicron secretion and prevents postprandial triglyceride elevation in humans. Journal of Clinical Lipidology. Volume 7, Issue 3, May-June 2013, Page 285. |
| 9764 | Nagai H, et al. Effects of MKS-492 on antigen-induced bronchoconstriction and allergic reaction in guinea pigs and rats. Jpn J Pharmacol. 1993 Dec;63(4):405-13. |
| 9765 | Morley J, et, al. SDZ MKS 492. Agents Actions Suppl. 1991;34:403-10. |
| 9766 | Olson CM, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019 Jun 20;26(6):792-803.e10. |
| 9767 | Yamazaki T, et al. Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits matrix metalloproteinase-7 expression and cell invasion of human hepatoma cells.Biol Pharm Bull. 2010;33(10):1716-22. |
| 9768 | Jin J , et al. Isofraxidin targets the TLR4/MD-2 axis to prevent osteoarthritis development.Food Funct. 2018 Nov 14;9(11):5641-5652. |
| 9769 | Kounnas MZ, et al. NGP 555, a γ-Secretase Modulator, Lowers the Amyloid Biomarker, Aβ42, in Cerebrospinal Fluid while Preventing Alzheimer's Disease Cognitive Decline in Rodents. Alzheimers Dement (N Y). 2017 Jan;3(1):65-73. |
| 9770 | Lomovskaya O, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother. 2001 Jan;45(1):105-16. |
| 9771 | Kurin?i? M, et al. Effects of efflux pump inhibitors on erythromycin, ciprofloxacin, and tetracycline resistance in Campylobacter spp. isolates. Microb Drug Resist. 2012 Oct;18(5):492-501. |
| 9772 | Lamers RP, et al. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One. 2013;8(3):e60666. |
| 9773 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Omeprazole+&cntry=&state=&city=&dist=&Search=Search |
| 9774 | Semenas J, et al. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98. |
| 9775 | Sarwar M, et al. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes MDV3100 resistance in prostate cancer cells. Oncotarget. 2016 Sep 27;7(39):63065-63081. |
| 9776 | Rath KS et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res. 2014 Apr 15;74(8):2316-27. |
| 9777 | Tierney BJ et al. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biol Ther. 2012 Jul;13(9):766-75 |
| 9778 | Hu Y, et al. A novel STAT3 inhibitor HO-3867 induces cell apoptosis by reactive oxygen species-dependent endoplasmic reticulum stress in human pancreatic cancer cells. Anticancer Drugs. 2017 Apr;28(4):392-400. |
| 9779 | J Chem Soc 1944:249; 1958:179; J Pharmacy Pharmacol 52:119 (2000); Biochem Pharmacol 83:531 (2012); Neuropharmacol 63:593 (2012) |
| 9780 | Faqi AS, Lanphear C, Gill S, Colagiovanni DB.Juvenile toxicity study of faropenem medoxomil in beagle puppies.Reprod Toxicol. 2010 Dec;30(4):619-24. Epub 2010 Aug 11. |
| 9781 | Hadley JA, Tillotson GS, Tosiello R, Echols RM.Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.Expert Rev Anti Infect Ther. 2006 Dec;4(6):923-37. |
| 9782 | Siegert R, Berg O, Gehanno P, Leiberman A, Martinkenas JL, Nikolaidis P, Arvis P, Alefelder M, Reimnitz P.Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults.Eur Arch Otorhinolaryngol. 2003 Apr;260(4):186-94. Epub 2002 Oct 11. |
| 9783 | Upchurch J, Rosemore M, Tosiello R, Kowalsky S, Echols R.Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis.Otolaryngol Head Neck Surg. 2006 Oct;135(4):511-7. |
| 9784 | Gettig, Jacob P.; Crank, Christopher W.; Philbrik, Alexander H. Faropenem medoxomil. Annals of Pharmacotherapy (2008), 42(1), 80-90. |
| 9785 | J Wildlife Diseases 36:670 (2000); J Wildlife Management 73:210 (2009) |
| 9786 | https://clinicaltrials.gov/ct2/show/NCT04715295?term=DOXYCYCLINE&cond=covid&draw=2&rank=1 |
| 9787 | Drugs (2003), 63(19), 2051-2077; Ann. Pharmacother. (2003), 37(2), 237-246; Allergy (1995), 50(3), 200-3| |
| 9788 | Geha, R.S. and E.O. Meltzer, Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol, 2001. 107(4): p. 751-62. |
| 9789 | Schroeder, J.T., et al., Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy, 2001. 31(9): p. 1369-77. |
| 9790 | Anthes, J.C., et al., Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol, 2002. 449(3): p. 229-37. |
| 9791 | McClellan K, et al. Desloratadine. Drugs. 2001;61(6):789-797. |
| 9792 | Arthritis Rheum 6:36 (1963); 12:472 (1969); Farmaco Ed Sci 26:191 (1971) |
| 9793 | Jarvis MF, et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther. 2000 Dec;295(3):1156-64. |
| 9794 | Parkinson FE, et al. The Effect of Endogenous Adenosine on Neuronal Activity in Rats: An FDG PET Study. J Neuroimaging. 2016 Jul;26(4):403-5. |
| 9795 | Lancet (1980), 1(8158), 14-16; Symp. Dtsch. Ges. Endokrinol. (1969), No. 15, 142-4; Steroids (1969), 13(2), 163-77 |
| 9796 | Bull Soc Chim Fr 1961: 1993 |
| 9797 | Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford). 2015 Sep 30. pii: kev355. |
| 9798 | https://clinicaltrials.gov/ct2/show/NCT04834401?term=Diroximel&cond=covid&draw=2&rank=1 |
| 9799 | Lever JR, et al. Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse. 2006 May;59(6):350-8. |
| 9800 | Tuerxun T, et al. SA4503, a sigma-1 receptor agonist, prevents cultured cortical neurons from oxidative stress-induced cell death via suppression of MAPK pathway activation and glutamate receptor expression. Neurosci Lett. 2010 Jan 29;469(3):303-8. |
| 9801 | Bayes M, et al. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jul-Aug;27(6):411-61. |
| 9802 | Nagendra Kumar Kaushik, et al. Biomedical importance of indoles. Molecules. 2013 Jun 6;18(6):6620-62. |
| 9803 | Ludmila Gerber, Tania M. Welzel, Stefan Zeuzem. New therapeutic strategies in HCV: polymerase inhibitors. Liver International. 2013,33(s1): 85-92 |
| 9804 | Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161. |
| 9805 | Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703 |
| 9806 | Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164 |
| 9807 | Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection |
| 9808 | Kanski, J.J., Carbonic anhydrase inhibitors and osmotic agents in glaucoma. Carbonic anhydrase inhibitors. Br J Ophthalmol, 1968. 52(8): p. 642-3. |
| 9809 | Rucquoy, M. and L. Sorel, Diclofenamide in the treatment of therapy-resistant epilepsy. Acta Neurol Belg, 1978. 78(3): p. 174-82. |
| 9810 | Arthur G. Romero, et al. Synthesis of the Selective D2 Receptor Agonist PNU-95666E from
 D-Phenylalanine Using a Sequential Oxidative Cyclization
 Strategy. J. Org. Chem. 1997, 62, 6582-6587 |
| 9811 | Yu D, et al. The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2015;43(1):291-302. |
| 9812 | He K, et al. The safety and anti-hypercholesterolemic effect of coptisine in Syrian golden hamsters. Lipids. 2015 Feb;50(2):185-94. |
| 9813 | Rao PC, et al. Coptisine-induced cell cycle arrest at G2/M phase and reactive oxygen species-dependent mitochondria-mediated apoptosis in non-small-cell lung cancer A549 cells. Tumour Biol. 2017 Mar;39(3):1010428317694565. |
| 9814 | Zhou X, et al. Inhibition activity of a traditional Chinese herbal formula Huang-Lian-Jie-Du-Tang and its major components found in its plasma profile on neuraminidase-1. Sci Rep. 2017 Nov 14;7(1):15549. |
| 9815 | Lefranc J, et al. Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor. J Med Chem. 2020 Jan 10. |
| 9816 | Willmann M, et al. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest. 2009;39(5):384-394. |
| 9817 | Bache M, et al. Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma--an in vitro study of cytotoxicity and radiosensitization. Int J Mol Sci. 2014 Oct 30;15(11):19777-90. |
| 9818 | JACS 74:1871 (1952); Psychopharmacol 64:123 (1979); Steroids 56:33 (1991) |
| 9819 | TNO155: SHP2 inhibitor |
| 9820 | Biochem Pharmacol 60:1367-79. (2000); Invest New Drugs 28:139 (2010); Eur J Med Chem 62:98 (2013) |
| 9821 | Farmaco Ed Sci 10:710 (1955) |
| 9822 | Toxicol Appl Pharmacol 1:524; Acta Neurologica Belgica 60:320 (1960); Lyon Medical 215:1051 (1966) |
| 9823 | J Chem Soc, 1953, 603; Antibiotics I (Verlag), 1967, p 611 |
| 9824 | Akashi, A., et al., [Cardiovascular pharmacology of cinepazide, a new cerebral vasodilator (author's transl)]. Nihon Yakurigaku Zasshi, 1979. 75(5): p. 507-16. |
| 9825 | Jun Ni , et al. Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2020 Jul 14;20(1):282. |
| 9826 | Science (1978), 4358, 819-21; Virology (1984), 135(1), 293-6; Biochim. Biophys. Acta (1981), 652(1), 90-8 |
| 9827 | Anticancer Res 15:709 (1995); Biochem Mol Biol Int 39:1125 (1996); Biochemistry 45:4727 (2006) |
| 9828 | Lancet 2:688, 828 (1937); Br J Vener Dis 28:210 (1952); Br Med J 1961:1282 |
| 9829 | Winrow CJ, et al. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology. 2012 Feb;62(2):978-87. |
| 9830 | Coleman PJ, et al. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem. 2012 Mar 5;7(3):415-24, 337. |
| 9831 | https://clinicaltrials.gov/ct2/show/NCT04467931 |
| 9832 | Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127. |
| 9833 | Stosic-Grujicic S, et al. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J Pharmacol Exp Ther. 2007 Mar;320(3):1038-49. |
| 9834 | Danijela Maksimovic-Ivanic, et al. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol Cancer Ther. 2008 Mar;7(3):510-20. |
| 9835 | K Mangano, et al. Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. Br J Pharmacol. 2008 Nov;155(5):722-30. |
| 9836 | Hyun-Ji Kim, et al. Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man. Archives of Pharmacal Research volume 19, Article number: 297 (1996) |
| 9837 | Mollereau, et al. Agonist and Antagonist Activities on Human NPFF(2) Receptors of the NPY Ligands GR231118 and BIBP3226. Br J Pharmacol.2001 May;133(1):1-4. |
| 9838 | Clin Med 74:41 (1967); Postgrad Med J 52:501 (1976); J Laryngol Otol 90:833 (1976) |
| 9839 | Baghdasaryan A, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mousecholangiopathy model by promoting biliary HCO3- output. Hepatology. 2011 Oct;54(4):1303-1312. |
| 9840 | Rizzo G, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor andTGR5 agonist. Mol Pharmacol. 2010 Oct;78(4):617-630. |
| 9841 | Nature 177:1182 (1956); Eur J Pharmacol 76:461 (1981); Archives of Pharmacol 323:149 (1983); Naunyn Schmied Arch Pharmacol 323:149 (1983) |
| 9842 | Food Cosmet Toxicol 6:313 (1968); 11:735 (1973) |
| 9843 | Hamdouchi C, et al. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916. |
| 9844 | Chiang YM, et al. Ethyl caffeate suppresses NF-kappaB activation and its downstream inflammatory mediators, iNOS, COX-2, and PGE2 in vitro or in mouse skin. Br J Pharmacol. 2005 Oct;146(3):352-63. |
| 9845 | Ouyang WC, et al. Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation. Cancer Chemother Pharmacol. 2017 Aug;80(2):411-419. |
| 9846 | Seo JS, et al. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017 Feb 27;18(1):14. |
| 9847 | Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866. |
| 9848 | Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883. |
| 9849 | Waffo-Téguo P, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. Nutr Cancer. 2001;40(2):173-9. |
| 9850 | Takizawa Y, et al. Pharmacokinetics of (-)-epicatechin-3-O-gallate, an active component of Onpi-to, in rats. Biol Pharm Bull. 2003 May;26(5):608-12. |
| 9851 | The human glutathione transferase P1-1 specific inhibitor TER 117 designed for overcomingcytostatic-drug resistance is also a strong inhibitor of glyoxalase I. Mol Pharmacol. 2000 Mar;57(3):619-24. |
| 9852 | McMillan DH, et al. Attenuation of lung fibrosis in mice with a clinically relevant inhibitor of glutathione-S-transferase π. JCI Insight. 2016 Jun 2;1(8). pii: e85717. |
| 9853 | Wu F, et al. Synthesis, in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of esculentoside A. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6430-3. Epub 2007 Oct 5. |
| 9854 | Ma H, et al. The effect of esculentoside A on lupus nephritis-prone BXSB mice. Arch Med Sci. 2013 Apr 20;9(2):354-60. |
| 9855 | Zhong WT, et al. Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. J Surg Res. 2013 Nov;185(1):364-72. |
| 9856 | Ju DW, et al. Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice. Pharmacology. 1998 Apr;56(4):187-95 |
| 9857 | Application A537 – Reduction in the energy factor assigned to Maltitol: Final Assessment Report (PDF), Food Standards Australia New Zealand, 5 October 2005, retrieved 27 January 2014. |
| 9858 | Nolen BJ, et al. Characterization of two classes of small molecule inhibitors of Arp2/3 complex. Nature. 2009 Aug 20;460(7258):1031-4. |
| 9859 | Kwon KW, et al. Migration of T cells on surfaces containing complex nanotopography. PLoS One. 2013 Sep 12;8(9):e73960. |
| 9860 | Arch. Int. Pharmacodyn. Ther. (1960), 129, 249-63; Br. J. Pharmacol. Chemother. (1961), 16, 209-17. ; Minerva Med. (1960), 4091-4. |
| 9861 | Z Physiol Chem 244: 153 (1936) |
| 9862 | Sun G, You Y, Li H, et al. Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I. Eur J Med Chem. 2020;200:112466. |
| 9863 | Liu KK, et al. Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity. ACS Med Chem Lett. 2011 Sep 19;2(11):809-813. |
| 9864 | J Agric Food Chem 44:1647 (1996); J Ethnopharmacol106:208 (2006); Brain Res1388:141 (2011) |
| 9865 | Li P, et al. Inhibitory effect of desoxyrhaponticin and rhaponticin, two natural stilbene glycosides from the Tibetan nutritional food Rheum tanguticum Maxim. ex Balf., on fatty acid synthase and human breast cancer cells. |
| 9866 | Wyce A, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One. 2013 Aug 23;8(8):e72967. |
| 9867 | Gosmini R, et al. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem. 2014 Oct 9;57(19):8111-31. |
| 9868 | Liu GY, et al. 20S-protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and -independent pathways. J Nat Prod. 2007 Feb;70(2):259-64. |
| 9869 | Zhao Y, et al. 20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells. Planta Med. 2009 Aug;75(10):1124-8. |
| 9870 | J Chem Soc 105: 2354 (1914) |
| 9871 | Henderson JL, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32. |
| 9872 | Mendivil-Perez M, et al. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease. Neurochem Res. 2016 Oct;41(10):2675-2692. |
| 9873 | Daher JP, et al. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. J Biol Chem. 2015 Aug 7;290(32):19433-44. |
| 9874 | Int J Dermatol 32:365 (1993); Anal Profiles Drug Subs Excip 23:471 (1994) |
| 9875 | Subramaniam Prem S, et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer cell (2012), 21(4), 459-72. |
| 9876 | Matyskiela ME, et al. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. J Med Chem. 2017 Apr 20. |
| 9877 | Leung, E. and F. Mitchelson, Modification by hexamethonium of the muscarinic receptors blocking activity of pancuronium and homatropine in isolated tissues of the guinea-pig. Eur J Pharmacol, 1982. 80(1): p. 11-7. |
| 9878 | Gilani, S.A. and L.B. Cobbin, Interaction of himbacine with carbachol at muscarinic receptors of heart and smooth muscle. Arch Int Pharmacodyn Ther, 1987. 290(1): p. 46-53. |
| 9879 | Cramer, M.B., L.A. Cates, and D.E. Clarke, Rectal absorption of homatropine [14C]methylbromide in the rat. J Pharm Pharmacol, 1978. 30(5): p. 284-6. |
| 9880 | Vakkalanka S, et al. RP6530, a dual PI3K δ/γ inhibitor, potentiates ruxolitinib activity in the JAK2-V617F mutant erythroleukemia cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2704. doi:10.1158/1538-7445.AM2015-2704 |
| 9881 | Carmelo C, et al. A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies. Blood 2015 126:1495; |
| 9882 | Chan KH, et al. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. |
| 9883 | Leverson JD, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015 Mar 18;7(279):279ra40. |
| 9884 | Vandyck K, et al. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV). J Med Chem. 2018 Jul 26;61(14):6247-6260. |
| 9885 | Yi P, et al. Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans. Drug Metab Dispos. 2012 Dec;40(12):2354-64. |
| 9886 | Rohle D, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013 May 3;340(6132):626-30. |
| 9887 | Molenaar RJ, et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res. 2015 Nov 15;75(22):4790-802. |
| 9888 | Xiang Q, et al. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. Eur J Med Chem. 2018 Mar 10;147:238-252. |
| 9889 | Ren Y, et al. Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification. Oncotarget. 2017 Apr 19;8(31):50832-50844. |
| 9890 | P, S, Si & Related Compounds, 86:263 (1994) |
| 9891 | Takenobu Nii, et al. The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199. ASH. 2017. |
| 9892 | Lev A, et al. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 2017 Sep 12;8(47):81776-81793. |
| 9893 | Wagner J, et al. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. |
| 9894 | Guerrero M, et al. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). J Med Chem. 2019 Feb 28;62(4):1761-1780. |
| 9895 | Antimicrob Agents Chemother 22:213 (1982); 26:578 (1984) |
| 9896 | Gordon MH, et al. Antioxidant activity of hydroxytyrosol acetate compared with that of other olive oil polyphenols.J Agric Food Chem. 2001 May;49(5):2480-5. |
| 9897 | Nishikawa, J. and A. Kast, Toxicity study with sodium picosulfate in cultured liver cells of rabbit, rat and man. Arzneimittelforschung, 1981. 31(2): p. 321-5. |
| 9898 | Geboes, K., et al., Effects of 'contact laxatives' on intestinal and colonic epithelial cell proliferation. Pharmacology, 1993. 47 Suppl 1: p. 187-95. |
| 9899 | Fioramonti, J., C. Dupuy, and L. Bueno, In vivo motility of rat colon chronically pretreated with sennosides. Pharmacology, 1993. 47 Suppl 1: p. 155-61. |
| 9900 | https://clinicaltrials.gov/ct2/show/NCT02735707?term=Piperacillin&cond=Covid19&draw=2&rank=2 |
| 9901 | Dev. Ind. Microbiol. Ser. (1977), 18, 471-85; J. Antibiot. (1978), 31(1), 1-6; Clin. Microbiol. Rev. (2003), 16(2), 175-188 |
| 9902 | Kim E, et al. The memory-enhancing effect of erucic acid on scopolamine-induced cognitive impairment in mice. Pharmacol Biochem Behav. 2016 Mar;142:85-90. |
| 9903 | Naunyn Schmiedebergs Arch Pharmacol 274:192 (1972); Pharmacol Biochem Behav 23:43 (1985) |
| 9904 | Santofimia-Castaño P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28. |
| 9905 | Santofimia-Castaño P, et al. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Cells. 2019;8(11):1453. Published 2019 Nov 17. |
| 9906 | Veena Agarwal, et al. A synergistic pharmaceutical combination for the treatment of pancreatic cancer. WO2012123889A1. |
| 9907 | Iwai K, et al. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Mol Med. 2018 Jun;10(6). pii: e8289. |
| 9908 | Angell RM, et al. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301. |
| 9909 | Coughlin K, et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res. 2014;20(12):3174-3186. |
| 9910 | Burrows F, et al. KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5168. doi:10.1158/1538-7445.AM2017-5168. |
| 9911 | Huang P, et al. Selective HDAC inhibition by ACY-241 enhances the activity of NSC 125973 in solid tumor models. Oncotarget. 2017 Jan 10;8(2):2694-2707. |
| 9912 | Manion MK, et al. A new type of Ca(2+) channel blocker that targets Ca(2+) sensors and prevents Ca(2+)-mediated apoptosis. FASEB J. 2000 Jul;14(10):1297-306. |
| 9913 | Ferdek PE, et al. BH3 mimetic-elicited Ca2+ signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca<sup>2+</sup>-like peptides. Cell Death Dis. 2017 Mar 2;8(3):e2640. |
| 9914 | Koeberle, Solveigh C.; Romir, Johannes; Fischer, Stefan et al. Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nature Chemical Biology (2012), 8(2), 141-143. |
| 9915 | Koeberle, Solveigh C.; Fischer, Stefan; Schollmeyer, Dieter et al. Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase. Journal of Medicinal Chemistry (2012), 55(12), 5868-5877. |
| 9916 | Bristow LJ, et al. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci. 1997 Jun;18(6):186-8. |
| 9917 | Patel S, et al. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Nov;283(2):636-47. |
| 9918 | Kulagowski JJ, et al. 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem. 1996 May 10;39(10):1941-2. |
| 9919 | EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019. |
| 9920 | Cook JJ, et al. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci. 2010;30(19):6743-6750. |
| 9921 | Krop I, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012;30(19):2307-2313. |
| 9922 | Thomas Andresen. Reversible linkers and use thereof. WO2019050977A1. |
| 9923 | Sha Y, et al. Loureirin B promotes insulin secretion through inhibition of KATP channel and influx of intracellular calcium. J Cell Biochem. 2017 Aug 17. |
| 9924 | He T, et al. Loureirin B Inhibits Hypertrophic Scar Formation via Inhibition of the TGF-β1-ERK/JNK Pathway. Cell Physiol Biochem. 2015;37(2):666-76. |
| 9925 | Bai X, et al. Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway. Exp Dermatol. 2015 May;24(5):355-60. |
| 9926 | Yu Jiang, et al. Bioactivity-Guided Fractionation of the Traditional Chinese Medicine Resina Draconis Reveals Loureirin B as a PAI-1 Inhibitor. Evidence-Based Complementary and Alternative Medicine |
| 9927 | Serban F, et al. Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma. J Immunoassay Immunochem. 2017;38(1):21-33. |
| 9928 | Strawn LM, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 1996 Aug 1;56(15):3540-5. |
| 9929 | Kim TS, et al. The ZFHX3 (ATBF1) transcription factor induces PDGFRB, which activates ATM in the cytoplasm to protect cerebellar neurons from oxidative stress. Dis Model Mech. 2010 Nov-Dec;3(11-12):752-62. |
| 9930 | Kroll J, et al. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 1997 Dec 19;272(51):32521-7. |
| 9931 | Clark JL, et al. Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methyl-cytidine, a Potent Inhibitor of Hepatitis C Virus Replication. J Med Chem. 2005 Aug 25;48(17):5504-8. |
| 9932 | Ma H, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species.
 J Biol Chem. 2007 Oct 12;282(41):29 |
| 9933 | Wang P, et al. An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem. 2009 Sep 4;74(17):6819-24. |
| 9934 | Xin Z, et al. Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors. ACS Med Chem Lett. 2020;11(4):485-490. Published 2020 Feb 12. |
| 9935 | Yang JH et al. Echinocystic acid inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and ERK signaling pathways. Biochem Biophys Res Commun. 2016 Sep 2;477(4):673-7. |
| 9936 | Ma Z et al. Echinocystic Acid Inhibits IL-1β-Induced COX-2 and iNOS Expression in Human Osteoarthritis Chondrocytes. Inflammation. 2016 Apr;39(2):543-9. |
| 9937 | Li S et al. Echinocystic acid reduces reserpine-induced pain/depression dyad in mice. Metab Brain Dis. 2016 Apr;31(2):455-63. |
| 9938 | Shang X, et al. Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol. 2012 Jun 22;19(6):699-710. |
| 9939 | Shang X, et al. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60. |
| 9940 | Francis TC, et al. The Selective RhoA Inhibitor Rhosin Promotes Stress Resiliency Through Enhancing D1-Medium Spiny Neuron Plasticity and Reducing Hyperexcitability. Biol Psychiatry. 2019;85(12):1001-1010. |
| 9941 | J. Med. Pharm. Chem. (1960), 2, 57-77; Arzneim. Forsch. (1955), 5, 72-3; J. Int. Med. Res. (1991), 19(2), 71-87 |
| 9942 | Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17(1). |
| 9943 | Madan B, et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene. 2015 Aug 10. doi: 10.1038/onc.2015.280. |
| 9944 | Fundamental Appl Toxicol 33:38 (1996); Am J Vet Res 66:966 (2005) |
| 9945 | Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
 Lancet. 2014 May 10;383(9929):1637-47. |
| 9946 | Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38. |
| 9947 | Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
 Lancet. 2014 May 10;383(9929):1637-47. |
| 9948 | Suguru Koyama,et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy. |
| 9949 | Y Liu, et al. BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway. Br J Pharmacol. 2013 Feb;168(3):632-43. |
| 9950 | Yan Zhou, et al. Tolerogenic dendritic cells induced by BD750 ameliorate proinflammatory T cell responses and experimental autoimmune encephalitis in mice. Mol Med. 2017 Oct;23:204-214. |
| 9951 | Bull Soc Chim Belg 70:585 (1961) |
| 9952 | Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37. |
| 9953 | Agarwal E, et al. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer. 2014 Mar 1;14:145. |
| 9954 | Xing Y, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 Jul 5;21(1):78. |
| 9955 | Li Yan, et al. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. 2009. |
| 9956 | Feng Y et al. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Res, 2015 Dec 15, 75(24):5211-8. |
| 9957 | Kim M, et al. Neochlorogenic Acid Inhibits Lipopolysaccharide-Induced Activation and Pro-inflammatory Responses in BV2 Microglial Cells. Neurochem Res. 2015 Sep;40(9):1792-8. |
| 9958 | Int J Immunother 9:85 (1993); 10:35 (1994); Arzneim Forsch 44:1448 (1994); Arch Pharmacal Research 31: 1153 (2008)| |
| 9959 | Ashok Mahashur, et al. Pidotimod: In-depth review of current evidence. Lung India |
| 9960 | Ning Zhao, et al. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019 Oct;17(10):803-818. |
| 9961 | Kramer A, et al. Small molecules intercept Notch signaling and the early secretory pathway. Nat Chem Biol. 2013 Nov;9(11):731-8. |
| 9962 | Nasr Bouzaiene N et al. Effect of apigenin-7-glucoside, genkwanin and naringenin on tyrosinase activity and melanin synthesis in B16F10 melanoma cells. Life Sci. 2016 Jan 1;144:80-5. |
| 9963 | Samet I et al. Olive leaf components apigenin 7-glucoside and luteolin 7-glucoside direct human hematopoietic stem cell differentiation towards erythroid lineage. Differentiation. 2015 Jun;89(5):146-55. |
| 9964 | Deoxyguanosine, From Wikipedia |
| 9965 | JACS 65:2126 (1943) |
| 9966 | Bachegowda L, et al. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Res. 2016 Aug 15;76(16):4841-4849. |
| 9967 | http://pdsp.med.unc.edu/pdsp.php |
| 9968 | Hajak, G., et al., Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry, 2001. 62(6): p. 453-63. |
| 9969 | Acta Phsiol Acad Sci hung 18:149 (1960); Arzneim Forsch 11:257 (1961) |
| 9970 | Kuang P, et al. Separation and purification of sulforaphene from radish seeds using macroporous resin and preparative high-performance liquid chromatography. Food Chem. 2013 Jan 15;136(2):342-7. |
| 9971 | Anita M. Brinker, et al. Herbicidal activity of sulforaphene from stock (Matthiola incana). Journal of Chemical Ecology. Vol. 19. No. 10, 1993. |
| 9972 | Mondal A, et al. Sulforaphene promotes Bax/Bcl2, MAPK-dependent human gastric cancer AGS cells apoptosis and inhibits migration via EGFR, p-ERK1/2 down-regulation. General Physiology and Biophysics, 27 Nov 2015, 35(1):25-34. |
| 9973 | Ren K, et al. Sulforaphene enhances radiosensitivity of hepatocellular carcinoma through suppression of the NF-κB pathway. J Biochem Mol Toxicol. 2017 Aug;31(8). |
| 9974 | Noa M, et al. Tiamulin-nitrovin interaction in pigs: a case report and experimental reproduction. Vet Hum Toxicol. 2000 Oct;42(5):286-8. |
| 9975 | Dreyfuss J, et al. Metabolism of tritium- and carbon-14-labeled tiamulin in dogs, rats, and pigs. J Antibiot (Tokyo). 1979 May;32(5):496-503. |
| 9976 | Islam KM, et al. The activity and compatibility of the antibiotic tiamulin with other drugs in poultry medicine--A review. Poult Sci. 2009 Nov;88(11):2353-9. |
| 9977 | Knapp CM, et al. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol Biochem Behav. 2001 Apr;68(4):797-803. |
| 9978 | Elsherbiny NM, et al. Reno-protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1. Eur Cytokine Netw. 2012 Jul-Sep;23(3):78-86. |
| 9979 | Zhu YR, et al. Bufotalin-induced apoptosis in osteoblastoma cells is associated with endoplasmic reticulum stress activation. Biochem Biophys Res Commun. 2014 Aug 15;451(1):112-8. |
| 9980 | Zhang DM, et al. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Eur J Pharmacol. 2012 Oct 5;692(1-3):19-28. |
| 9981 | J Pharmacol Exp Therap 218:217 (1981); Drug Dev Res 6:263 (1985) |
| 9982 | Kalluri HS, et al. D609 inhibits the proliferation of neural progenitor cells.Neuroreport. 2010 Jul 14;21(10):700-3. |
| 9983 | Milhas D, et al. The Tricyclodecan-9-yl-xanthogenate D609 Triggers Ceramide Increase and Enhances FasL-Induced Caspase-Dependent and -Independent Cell Death in T Lymphocytes.Int J Mol Sci. 2012;13(7):8834-52. Epub 2012 Jul 16. |
| 9984 | Gusain A, et al. Anti-proliferative effects of tricyclodecan-9-yl-xanthogenate (D609) involve ceramide and cell cycle inhibition.Mol Neurobiol. 2012 Jun;45(3):455-64. Epub 2012 Mar 14. |
| 9985 | Delu Che, et al. Mivacurium Induce Mast Cell Activation and Pseudo-Allergic Reactions via MAS-related G Protein Coupled receptor-X2. Cell Immunol. 2018 Oct;332:121-128. |
| 9986 | J E Caldwell. New Skeletal Muscle Relaxants. Int Anesthesiol Clin. Winter 1995;33(1):39-60. |
| 9987 | Matthias Paul, et al. The Potency of New Muscle Relaxants on Recombinant Muscle-Type Acetylcholine Receptors. Anesth Analg. 2002 Mar;94(3):597-603; table of contents. |
| 9988 | F Knoflach, et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7 |
| 9989 | Kamondanai Hemstapat, et al. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol Pharmacol. 2006 Aug;70(2):616-26. |
| 9990 | Douglas J Sheffler, et al. Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells. Neuropharmacology. 2008 Sep;55(4):419-27 |
| 9991 | BOSS, Christoph, et al. USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES. WO2015083094A1. |
| 9992 | Biochem J 35:1311 (1941); J Pharmacol Exp Ther 80:217 (1944) |
| 9993 | Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7. |
| 9994 | Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53. |
| 9995 | Noh EM, et al. Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2009 Jan;48(1):45-8. |
| 9996 | Huang F, et al. Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase. PLoS One. 2019 Jun 14;14(6):e0218449. |
| 9997 | Hosokawa Y, et al. Alkannin inhibits CCL3 and CCL5 production in human periodontal ligament cells. Cell Biol Int. 2016 Dec;40(12):1380-1385. |
| 9998 | Huu Tung N, et al. Naphthoquinone components from Alkanna tinctoria (L.) Tausch show significant antiproliferative effects on human colorectal cancer cells. Phytother Res. 2013 Jan;27(1):66-70. |
| 9999 | Xue W, et al. Alkannin Inhibited Hepatic Inflammation in Diabetic Db/Db Mice. Cell Physiol Biochem. 2018;45(6):2461-2470. |
| 10000 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=FOSINOPRIL&cond=COVID-19&draw=2&rank=2 |
| 10001 | J. Am. Med. Assoc. (1948), 137(10), 858-61; J. Am. Chem. Soc. (1920), 42, 2355-66; JAMA, J. Am. Med. Assoc. (1919), 73, 1483-91 |
| 10002 | Rebbapragada I, et al. Molecular Determinants of GS-9620-Dependent TLR7 Activation. PLoS One. 2016 Jan 19;11(1):e0146835. |
| 10003 | Lanford RE, et al. GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology. 2013 Feb 13. pii: S0016-5085(13)00169-8. |
| 10004 | D Tumas, et al. Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist. |
| 10005 | Park SJ, et al. Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery. Biomol Ther (Seoul). 2017 Jan 1;25(1):80-90. |
| 10006 | Jo E, et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol. 2005 Jun;12(6):703-15. |
| 10007 | Dong J, et al. Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice. Clin Exp Immunol. 2014 Jul;177(1):94-101. |
| 10008 | Usuki A, et al. The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol. 2003;12 Suppl 2:43-50. |
| 10009 | Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep, 2014 Mar, 9(1):44-9. |
| 10010 | Harriet S. Walter et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 2016 Jan 28, 127(4): 411-419. |
| 10011 | Kearn J, et al. Fluensulfone is a nematicide with a mode of action distinct from anticholinesterases and macrocyclic lactones. Pestic Biochem Physiol. 2014 Feb;109:44-57. |
| 10012 | Strupp C, et al. Relationship of metabolism and cell proliferation to the mode of action of fluensulfone-induced mouse lung tumors: analysis of their human relevance using the IPCS framework. Toxicol Sci. 2012 Jul;128(1):284-94. |
| 10013 | Mannisto P, et al. Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. Int J Clin Pharmacol Biopharm. 1979 Jun;17(6):264-70. |
| 10014 | Slapsyte G, et al. Cytogenetic analysis of children under long-term antibacterial therapy with nitroheterocyclic compound furagin. Mutat Res. 2001 Apr 5;491(1-2):25-30. |
| 10015 | Dybowski B, et al. Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. Int J Antimicrob Agents. 2008 Feb;31(2):130-4. |
| 10016 | Mistry DK, et al. Actions of steroids and bemegride on the GABAA receptor of mouse spinal neurones in culture.Exp Physiol, 1990, 75(2),199-209. |
| 10017 | Arblaster CI, et al. Studies on the development of physical dependence on barbitone in the rat and rat atrium.
 Farmaco Sci. 1986 Jan, 41(1), 3-22. |
| 10018 | Mohedas AH, et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013;8(6):1291-302. |
| 10019 | Alexander LT et al. Type II Inhibitors Targeting CDK2. ACS Chem Biol. 2015 Sep 18;10(9):2116-25. |
| 10020 | Tang J,et al. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.J Exp Clin Cancer Res. 2018 Feb 27;37(1):40. |
| 10021 | Adhikari AA, et al. Development of a covalent inhibitor of gut bacterial bile salt hydrolases. Nat Chem Biol. 2020 Mar;16(3):318-326. |
| 10022 | Harikrishnan H, et al. Anti-Inflammatory Effects of Hypophyllanthin and Niranthin Through Downregulation of NF-κB/MAPKs/PI3K-Akt Signaling Pathways. Inflammation. 2018 Jun;41(3):984-995. |
| 10023 | Sukhaphirom N, et al. Phyllanthin and hypophyllanthin inhibit function of P-gp but not MRP2 in Caco-2 cells. J Pharm Pharmacol. 2013 Feb;65(2):292-9. |
| 10024 | Toxicol Appl Pharmacol 14:515 (1969); Toxicol Pathol 11:12 (1983) |
| 10025 | Bo Yan, et al. Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein.ChemCommun (Camb). 2017 Mar 28;53(26):3637-3640. |
| 10026 | Sorscher EJ, et al. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemother Pharmacol. 2012 Aug;70(2):321-9. |
| 10027 | Kikuchi E, et al. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Th |Semin. Oncol. (1993), 20(5, Suppl. 7), 2-12; Cancer Res. (1980), 40(10), 3610-15; Cancer Res. (1984), 44(9), 4183-6 |
| 10028 | Ciarlo C, A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development. Elife. 2017 Aug 23;6. pii: e29145. |
| 10029 | de Chaffoy de Courcelles DC, et al. R 59 022, a diacylglycerol kinase inhibitor. Its effect on diacylglycerol and thrombin-induced C kinase activation in the intact platelet. J Biol Chem. 1985 Dec 15;260(29):15762-70. |
| 10030 | Nunn DL, et al. A diacylglycerol kinase inhibitor, R59022, potentiates secretion by and aggregation of thrombin-stimulated human platelets. Biochem J. 1987 May 1;243(3):809-13. |
| 10031 | Jones JA, et al. Influence of phorbol esters, and diacylglycerol kinase and lipase inhibitors on noradrenalinerelease and phosphoinositide hydrolysis in chromaffin cells. Br J Pharmacol. 1990 Nov;101(3):521-6. |
| 10032 | Boroda S, et al. Dual activities of ritanserin and R59022 as DGKα inhibitors and serotonin receptor antagonists. Biochem Pharmacol. 2017 Jan 1;123:29-39. |
| 10033 | Stewart CM, et al. A Diacylglycerol Kinase Inhibitor, R-59-022, Blocks Filovirus Internalization in Host Cells. Viruses. 2019 Mar 1;11(3). pii: E206. |
| 10034 | Marwan Fakih, et al, Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12Cinhibitor, in advanced solid tumors. Journal of Clinical Oncology. |
| 10035 | Karen Rex, et al. Abstract 3090: In vivo characterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models. Experimental and Molecular Therapeutics. |
| 10036 | Brian A. Lanman, et al.Abstract 4455: Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12C for the treatment of solid tumors. Cancer Chemistry. |
| 10037 | Canon J, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217-223. |
| 10038 | Scott JS, et al. Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017). J Med Chem. 2012 Jun 28;55(12):5951-64. |
| 10039 | Toxicol Appl Pharmacol 5:507 (1963); J Environ Qual 37:963 (2008) |
| 10040 | Karl W. Mollison, et al. Compounds and methods for treatment and prevention of diseases. US 20080171763 A1. |
| 10041 | Ballou LM, et al. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008 Nov;1(1-4):27-36. |
| 10042 | Biochem Pharmacol 46:1887 (1993); Antimicrob Agents Chemother 43:492 (1999)| |
| 10043 | Huang H, et al. Cepharanthine, an alkaloid from Stephania cepharantha Hayata, inhibits the inflammatory response in the RAW264.7 cell and mouse models. Inflammation. 2014 Feb;37(1):235-46. |
| 10044 | Nagano M, et al. Cepharanthine, an anti-inflammatory drug, suppresses mitochondrial membrane permeability transition. Physiol Chem Phys Med NMR. 2003;35(2):131-43. |
| 10045 | Kao MC, et al. Salutary Effects of Cepharanthine against Skeletal Muscle and Kidney Injuries following Limb Ischemia/Reperfusion. Evid Based Complement Alternat Med. 2015;2015:504061. |
| 10046 | Gao S, et al. Cepharanthine Induces Autophagy, Apoptosis and Cell Cycle Arrest in Breast Cancer Cells. Cell Physiol Biochem. 2017;41(4):1633-1648. |
| 10047 | Matsuda K, et al. Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity. Bioorg Med Chem Lett. 2014 May 1;24(9):2115-7. |
| 10048 | Dillon,GH et al.U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.Molecular Pharmacology October 1993, 44 (4) 860-865 |
| 10049 | J Chem Soc 1940:787; J Shenyang Pharm Univ 18:211 (2001); Res J Pharm Biol Chem Sci 2:886 (2011) |
| 10050 | Drug Metab Dispos 14:331 (1986) |
| 10051 | J. Pharmacol. Exp. Ther. (2008), 324(3), 883-93; Psychopharmacologia (1969), 15(2), 144-52; JAMA, J. Am. Med. Assoc. (1967), 200(10), 881-2 |
| 10052 | Fernández de Arriba A, et al. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. Mol Pharmacol. 1999 Apr;55(4):753-60. |
| 10053 | Duran, X., et al., Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2. J Thromb Haemost, 2008. 6(8): p. 1385-92. |
| 10054 | De Miguel, L.S., et al., A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function. Eur J Clin Invest, 2000. 30(9): p. 811-7. |
| 10055 | Hemmerling M, et al. Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. J Med Chem. 2017 Oct 26;60(20):8591-8605. |
| 10056 | Fichtner M, et al. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2738-43. |
| 10057 | Erondu N, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006 Oct;4(4):275-82. |
| 10058 | Arzneim Forsch 19:1263 (1969); 22:1947 (1972) |
| 10059 | Yeung et al (2007) Molecular expression and pharmacological identification of a role for Kv7 channels in murine vascular reactivity. Br.J.Pharmacol. 151 758. |
| 10060 | Gordon R, Sofia RD, Diamantis W.
 Effect of flupirtine maleate on the nociceptive pathway, EEG, evoked potentials and polysynaptic reflexes in laboratory animals.
 Postgrad Med J. 1987;63 Suppl 3:49-55. |
| 10061 | Hedges A, Warrington SJ, Turner P, Niebch G.
 Flupirtine maleate and antipyrine half-life.
 Eur J Clin Pharmacol. 1987;33(4):437. |
| 10062 | Powell-Jackson P, Williams R.
 Use of flupirtine maleate as an analgesic in patients with liver disease.
 Br J Clin Pract. 1985 Feb;39(2):63-6. |
| 10063 | Diamantis W, Gordon R, Sofia RD.
 Analgesic activity following combined oral administration of flupirtine maleate and peripherally acting analgesics in mice and rats.
 Postgrad Med J. 1987;63 Suppl 3:29-34. |
| 10064 | Yoneda T, et al. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 1991 Aug 15;51(16):4430-5. |
| 10065 | Reddy KB, et al. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 1;52(13):3636-41. |
| 10066 | Int J Pharmaceut 1:189 (1978) |
| 10067 | Alexandra Borodovsky, et al. Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5580. |
| 10068 | Wylie AA, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017 Mar 30;543(7647):733-737. |
| 10069 | Shin DS, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009 Jan 1;69(1):193-202. |
| 10070 | Huang Y, et al. Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. Fertil Steril. 2014 Aug;102(2):589-596.e4. |
| 10071 | Ge Y, et al. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells. Leuk Lymphoma. 2014 Jun 25:1-9. |
| 10072 | Kim EJ, et al. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol. 2007 Jul;72(1):62-72. Epub 2007 Apr 11. |Chem Pharm Bull 10:112 (1962); Planta Med 24:190 (1973); Exp Mol Med 37:133(2005); |
| 10073 | Ouyang L, et al. Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That InducesAMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer. J Med Chem. 2017 Dec 28;60(24):9990-10012. |
| 10074 | Gut 13:859 (1972); Carcinogenesis 18:517 (1997); Evid Based Nurs 14:61 (2011) |
| 10075 | Kang JI, et al. Columbianadin Inhibits Cell Proliferation by Inducing Apoptosis and Necroptosis in HCT116 Colon Cancer Cells. Biomol Ther (Seoul). 2016 May 1;24(3):320-7. |
| 10076 | Zhang YB, et al. Tissue distribution study of columbianadin and its active metabolite columbianetin in rats. Biomed Chromatogr. 2016 Feb;30(2):256-62. |
| 10077 | Mehrling T, et al. The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. Anticancer Agents Med Chem. 2016;16(1):20-8. |
| 10078 | Anal Profiles Drug Subs 1:367 (1972)| |
| 10079 | http://www.drugbank.ca/drugs/DB08908#targets |
| 10080 | Lung Health Study Research, G., Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med, 2000. 343(26): p. 1902-9. |
| 10081 | Zhen Xiang, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci 2020; 16(13):2382-2391. |
| 10082 | Eur J Pharmacol 3:157 (1968); Toxicol Appl Pharmacol 10:148 (1967); Arzneim Forsch 37:587 (1987) |
| 10083 | Zhang Z, et al. Amentoflavone protects hippocampal neurons: anti-inflammatory, antioxidative, and antiapoptotic effects. Neural Regen Res. 2015 Jul;10(7):1125-33. |
| 10084 | Xu P, et al. Amentoflavone acts as a radioprotector for irradiated v79 cells by regulating reactive oxygen species (ROS), cell cycle and mitochondrial mass. Asian Pac J Cancer Prev. 2014;15(18):7521-6. |
| 10085 | Yang Y, et al. [Amentoflavone induces apoptosis in SW480 human colorectal cancer cells via regulating β-catenin and caspase-3 expressions]. Nan Fang Yi Ke Da Xue Xue Bao. 2014 Jun;34(7):1035-8. |
| 10086 | The Effect and Mechanism of Apoptosis Induced by Desacetylcinobufotalin (DEBF) in Human Hepatocellular Carcinoma HepG2 Cells |
| 10087 | Myers RW, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiachypertrophy. Science. 2017 Aug 4;357(6350):507-511. |
| 10088 | Drug Metab Dispos 22:895 (1994); Leuk Res 24:1009 (2000); Anticancer Drugs13:181 (2002) |
| 10089 | Leslie CP, et al. Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist. J Med Chem. 2010 Dec 9;53(23):8228-8240. |
| 10090 | Zanasi A, et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015 May 31;10(1):19. |
| 10091 | Bleiberg H, et al. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol. 1988;22(4):316-20. |
| 10092 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=SODIUM+MONOFLUOROPHOSPHATE&cntry=&state=&city=&dist=&Search=Search |
| 10093 | Liehr JG, et al. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9220-4. |
| 10094 | J. Pharm. Pharmacol. (1970), 22(2), 101-3; J. Pharmacol. Exp. Ther. (1957), 120, 512-27; Am. J. Med. Sci. (1953), 226, 164-71 |
| 10095 | Barnard DL, et al. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother. 2004 May;48(5):1766-72. |
| 10096 | Andries K, et al. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviralactivity. Antimicrob Agents Chemother. 1992 Jan;36(1):100-7. |
| 10097 | J Biol Chem 269: 24637 ((1994); Biochemistry 35: 6969 (1996); Eur J Cell Biol 23: 312 (1981) |
| 10098 | Int. J. Dermatol. (1977), 16(4), 267-73; J. Med. Pharm. Chem. (1962), 5, 389-97 |
| 10099 | Briggs CA, et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav. 1997;57(1-2):231-241. |
| 10100 | Zhang R, et al. N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine. J Pharmacol Exp Ther. 2006;317(3):1276-1284. |
| 10101 | Mei Z, et al. α7 nAchR agonist GTS 21 reduces radiation induced lung injury. Oncol Rep. 2018;40(4):2287-2297. |
| 10102 | Kirchgessner TG, et al. Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils. Cell Metab. 2016 Aug 9;24(2):223-33. |
| 10103 | Baell JB et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature. 2018 Aug;560(7717):253-257. |
| 10104 | Peng F, et al. In vitro and in vivo antibacterial activity of Pogostone.Chin Med J (Engl). 2014;127(23):4001-5. |
| 10105 | Cao ZX, et al. Pogostone induces autophagy and apoptosis involving PI3K/Akt/mTOR axis in human colorectal carcinoma HCT116 cells.J Ethnopharmacol. 2017 Apr 18;202:20-27. |
| 10106 | Li, Y.C., [A clinical study on lamivudine treatment for advanced schistosomisis with chronic B hepatits]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi, 2013. 25(5): p. 548-9, 551. |
| 10107 | Zhang, C.E., et al., [Effects of lamivudine on growth of intestinal characteristic bacteria by microcalorimetry in vitro]. Yao Xue Xue Bao, 2013. 48(10): p. 1590-4. |J. Med. Chem. (1993), 36(2), 181-95; J. Biol. Chem. (1992), 267(31), 22414-20; Antimicrob. Agents Chemother. (1992), 36(1), 202-5 |
| 10108 | Ewton DZ, et al. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. Mol Cancer Ther. 2011 Nov;10(11):2104-14. |
| 10109 | Anderson K, et al. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6610-5. |
| 10110 | Minerva Med 58:3653 (1967); Eur J Pharmacol 64:69 (1980); Science 219:1449 (1983) |
| 10111 | Ann. N. Y. Acad. Sci. (1976), 274, 143-73; Fed. Proc. (1946), 5, 263; Fed. Proc. (1946), 5(1 Pt 2), 198 |
| 10112 | Agola JO, et al. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. ACS Chem Biol. 2012 Jun 15;7(6):1095-108. |
| 10113 | Lam T, et al. Small Molecule Inhibition of Rab7 Impairs B Cell Class Switching and Plasma Cell Survival To Dampen the Autoantibody Response in Murine Lupus. J Immunol. 2016 Nov 15;197(10):3792-3805. |
| 10114 | Ann Acad Bras Cienc 36:29 (1964); J Org Chem 36:1832 (1971) |
| 10115 | Xiao H, et al. A Novel Positive Feedback Loop Between NTSR1 and Wnt/β-Catenin Contributes to Tumor Growth of Glioblastoma. Cell Physiol Biochem. 2017 Oct 24;43(5):2133-2142. |
| 10116 | Chatterjee SS, et al. Inhibition of β-catenin-TCF1 interaction delays differentiation of mouse embryonic stem cells. J Cell Biol. 2015 Oct 12;211(1):39-51. |
| 10117 | Sharma A, et al. Mitigation of sepsis-induced inflammatory responses and organ injury through targeting Wnt/β-catenin signaling. doi: 10.1038/s41598-017-08711-6. |
| 10118 | Burkhart C, et al. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget. 2014 Nov 30;5(22):11038-53. |
| 10119 | Gasparian AV, et al. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med. 2011 Aug 10;3(95):95ra74. |
| 10120 | Eyre TA, et al. Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors? Oncotarget. 2018 Dec 18;9(99):37280-37281. |
| 10121 | Eyre TA, et al. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 2019 Jan 1;125(1):99-108. |
| 10122 | Psychopharmacol 119: 222 (1995) |
| 10123 | Buzard DJ, et al. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4332-4335. |
| 10124 | Semple G, et al. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improvedprofile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-1755. |
| 10125 | Huan Y, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017 Jun 28;7(1):4351. |
| 10126 | Badura L, et al. An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions. J Pharmacol Exp Ther. 2007 Aug;322(2):730-8. Epub 2007 May 14. |
| 10127 | Cheong JK, et al. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/? and Wnt/β-catenin independent inhibition of mitotic spindle formation. Oncogene. 2011 Jun 2;30(22):2558-69. |
| 10128 | Kennaway DJ, et al. Acute inhibition of casein kinase 1δ/ε rapidly delays peripheral clock gene rhythms. Mol Cell Biochem. 2015 Jan;398(1-2):195-206. |
| 10129 | Cheung K, et al. BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):2952-2957. |
| 10130 | Lim EJ, et al. Anti-angiogenic, anti-inflammatory and anti-nociceptive activity of 4-hydroxybenzyl alcohol. J Pharm Pharmacol. 2007 Sep;59(9):1235-40. |
| 10131 | Laschke MW, et al. In vitro and in vivo evaluation of the anti-angiogenic actions of 4-hydroxybenzyl alcohol. Br J Pharmacol. 2011 Jun;163(4):835-44. |
| 10132 | Laschke MW, et al. 4-hydroxybenzyl alcohol: a novel inhibitor of tumor angiogenesis and growth. Life Sci. 2013 Jul 19;93(1):44-50. |
| 10133 | Yu SS, et al. Neuroprotective effect of 4-hydroxybenzyl alcohol against transient focal cerebral ischemia via anti-apoptosis in rats. Brain Res. 2010 Jan 13;1308:167-75. |
| 10134 | Mykosen 1:162 (1958); Br Med J 1:1731 (1960) |
| 10135 | Gan, X., et al., Treatment of mice with cromolyn sodium after reperfusion, but not prior to ischemia, attenuates small intestinal ischemia-reperfusion injury. Mol Med Rep, 2013. 8(3): p. 928-34. |
| 10136 | Ng, G. and A. Ohlsson, Cromolyn sodium for the prevention of chronic lung disease in preterm infants. Cochrane Database Syst Rev, 2012. 6: p. CD003059. |
| 10137 | Huang L, et al. Sinomenine-induced histamine release-like anaphylactoid reactions are blocked by tranilast via inhibiting NF-κB signaling. Pharmacol Res. 2017 Aug 31. pii: S1043-6618(17)30796-X. |
| 10138 | Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. |
| 10139 | Bennett CN, et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002 Aug 23;277(34):30998-1004. |
| 10140 | Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.BMC Res Notes. 2014 Apr 29;7:273. |
| 10141 | Wang X, et al. Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation. Sci Rep. 2015 Apr 10;5:8566. |
| 10142 | Ye S, et al. Pleiotropy of glycogen synthase kinase-3 inhibition by CHIR99021 promotes self-renewal of embryonic stem cells from refractory mouse strains. PLoS One. 2012;7(4):e35892. |
| 10143 | Expert Opin. Pharmacother. (2006), 7(16), 2179-2202; Drugs (1983), 26(6), 468-502; Circulation Res. (1979), 45(5), 666-77 |
| 10144 | Drugs 59:521 (2000) |
| 10145 | Panek RL, et al. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J Pharmacol Exp Ther. 1998 Jul;286(1):569-77. |
| 10146 | Fuhrmann, U., et al., The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception, 1996. 54(4): p. 243-51. |
| 10147 | Muhn, P., et al., Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception, 1995. 51(2): p. 99-110. |
| 10148 | Warming, L., et al., Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric, 2004. 7(1): p. 103-11. |J. Med. Chem. (1985), 28(5), 546-50; Arzneim. Forsch. (1984), 34(3), 241-6; Angew. Chem. (1982), 94(9), 718-19 |
| 10149 | Kamsteeg M, et al. Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003 May 1;22(17):2611-20. |
| 10150 | Mahoney S, et al. The effects of phenoxodiol on the cell cycle of prostate cancer cell lines. Cancer Cell Int. 2014 Nov 8;14(1):110. |
| 10151 | Baker SJ, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006 Jul 27;49(15):4447-50. |
| 10152 | Zhou XL, et al. Post-transfer editing by a eukaryotic leucyl-tRNA synthetase resistant to the broad-spectrum drug AN2690. Biochem J. 2010 Sep 1;430(2):325-33. |
| 10153 | Butler LM, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr;7(4):962-70. |
| 10154 | Kutko MC, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.Clin Cancer Res. 2003 Nov 15;9(15):5749-55. |
| 10155 | White KM, et al. Broad Spectrum Inhibitor of Influenza A and B Viruses Targeting the Viral Nucleoprotein. ACS Infect Dis. 2018 Feb 9;4(2):146-157. |
| 10156 | Oo ZY, et al. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo. Clin Cancer Res. 2018 Mar 13. doi: 10.1158/1078-0432.CCR-17-2701. |
| 10157 | Laroche-Clary A, et al. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018 Apr 1;29(4):1023-1029. |
| 10158 | Di Tullio A, et al. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017 Nov 22;8(1):1679. |
| 10159 | Liang X, et al. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. J Med Chem. 2019 Apr 25;62(8):3898-3923. |
| 10160 | J Sastre. Ebastine in allergic rhinitis and chronic idiopathic urticarial. Allergy. 2008 Dec;63 Suppl 89:1-20. |
| 10161 | Fu-Ming Tsai, et al. Extracellular Signal-Regulated Kinase Mediates Ebastine-Induced Human Follicle Dermal Papilla Cell Proliferation. Biomed Res Int. 2019 Feb 11;2019:6360503. |
| 10162 | Fujii, et al. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats. Arzneimittelforschung. 1994 Apr;44(4):527-38. |
| 10163 | Progress in Organic Chemistry 1: 1 (1952); Acta Pharmacologica Sinica 28:1851 (2007) |
| 10164 | Abdel-Ghany R, et al. Impact of Exposure to Fenitrothion on Vital Organs in Rats. J Toxicol. 2016;2016:5609734. |
| 10165 | Qing Hong, et al. A microcosm study on bioremediation of fenitrothion-contaminated soil using Burkholderia sp. FDS-1. International Biodeterioration & Biodegradation |
| 10166 | Itoh A, et al. Tricin inhibits the CCL5 induction required for efficient growth of human cytomegalovirus. Microbiol Immunol. 2018 May;62(5):341-347. |
| 10167 | Sadanari H, et al. The anti-human cytomegalovirus drug tricin inhibits cyclin-dependent kinase 9. FEBS Open Bio. 2018 Feb 20;8(4):646-654. |
| 10168 | Chung DJ, et al. Inhibition of the Proliferation and Invasion of C6 Glioma Cells by Tricin via the Upregulation of Focal-Adhesion-Kinase-Targeting MicroRNA-7. J Agric Food Chem. 2018 Jul 5;66(26):6708-6716. |
| 10169 | Okabe S, et al. New TNF-alpha releasing inhibitors, geraniin and corilagin, in leaves of Acer nikoense, Megusurino-ki. Biol Pharm Bull. 2001 Oct;24(10):1145-8. |
| 10170 | Wang X, et al. Geraniin suppresses ovarian cancer growth through inhibition of NF-κB activation and downregulation of Mcl-1 expression. J Biochem Mol Toxicol. 2017 Sep;31(9). |
| 10171 | Am. J. Trop. Med. Hyg. (1986), 35(6), 1110-16; J. Insect Pathol. (1960), 2, 124-33; J. Am. Pharm. Assoc., Sci. Ed. (1948), 37, 272-5 |
| 10172 | Ahn K, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 2009 Apr 24;16(4):411-20. |
| 10173 | Booker L, et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol, 2012, 165(8), 2485-2496. |
| 10174 | Wasilewski A, et, al. Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study. Acta Biochim Pol. 2017;64(3):519-525. |
| 10175 | Chao SW, et al. Total Synthesis of Hispidulin and the Structural Basis for Its Inhibition of Proto-oncogene KinasePim-1. J Nat Prod. 2015 Aug 28;78(8):1969-76. |
| 10176 | Gao H, et al. Hispidulin induces apoptosis through mitochondrial dysfunction and inhibition of P13k/Akt signalling pathway in HepG2 cancer cells. Cell Biochem Biophys. 2014 May;69(1):27-34. |
| 10177 | Zhou R, et al. Hispidulin exerts anti-osteoporotic activity in ovariectomized mice via activating AMPK signaling pathway. Cell Biochem Biophys. 2014 Jun;69(2):311-7. |
| 10178 | Lin TY, et al. Protective effect of hispidulin on kainic acid-induced seizures and neurotoxicity in rats. Eur J Pharmacol. 2015 May 15;755:6-15. |
| 10179 | Wang Y, et al. P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate. PLoS One. 2016 Apr 12;11(4):e0153312. |
| 10180 | Hayashi-Takagi A, et al. PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6461-6. |
| 10181 | Choi SJ, et al. Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg Med Chem Lett. 2010 Mar 15;20(6):2033-7. |
| 10182 | Kim SA, et al. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res. 2007 Jan 1;13(1):253-9. |
| 10183 | Hazra S, et al. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry. 2014 Jun 10;53(22):3671-8 |
| 10184 | Seenama C, et al. In vitro activity of tebipenem against Burkholderia pseudomallei. Int J Antimicrob Agents. 2013 Oct;42(4):375. |
| 10185 | Li H, et al. In vitro antibacterial activities of two novel oral antibiotics, tebipenem and cefditoren, and other comparators against community-acquired respiratory tract infection-associated bacterial pathogens: A multicentre study in China. Int J Antimicrob Agents. 2014 Jan;43(1):92-3. |
| 10186 | Wängler C, et, al. Improved syntheses and applicability of different DOTA building blocks for multiply derivatized scaffolds. Bioorg Med Chem. 2008 Mar 1; 16(5): 2606-16. |
| 10187 | Gazit A, et al. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52. |
| 10188 | Nanzer AM, et al. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol. 2004 Aug;151(2):233-40. |
| 10189 | Hohnholt MC, et al. The tricarboxylic acid cycle activity in cultured primary astrocytes is strongly accelerated by the protein tyrosine kinase inhibitor tyrphostin 23. Neurochem Int. 2017 Jan;102:13-21. |
| 10190 | Ann Marie Bode, et al. Inhibitors of beta-catenin in treatment of colorectal cancer. Patent US20150374662A1. |
| 10191 | Aust J Chem 48: 883 (1995) |
| 10192 | Beeharry N, et al. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Cancer Biol Ther. 2015;16(9):1397-406. |
| 10193 | Hasinoff BB, et al. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform. J Pharmacol Exp Ther. 2016 Feb;356(2):397-409. |
| 10194 | Cavalletti E, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs. 2007 Jun;25(3):187-95. |
| 10195 | Ubiali F, et al. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. J Immunol. 2008 Feb 15;180(4):2696-703. |
| 10196 | Vadim Makarov et al. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 fromMycobacterium tuberculosis. Antimicrob Agents Chemother, 2015 Aug, 59(8): 4446-4452. |
| 10197 | Makarov V, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science. 2009 May 8;324(5928):801-4. |
| 10198 | Norma Alejandra González-Martínez et al. In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis. PLoS Negl Trop Dis, 2015 Oct, 9(10): e0004022. |
| 10199 | Papandreou I, et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011 Jan 27;117(4):1311-4. |
| 10200 | Chien W, et al. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Oncotarget. 2014 Jul 15;5(13):4881-94. |
| 10201 | Namba T, et al. Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway. Oncotarget. 2015 Aug 21;6(24):19990-20001. |
| 10202 | Medina, et al. 5-(1H-Benzo[d]imidazol-2-yl)pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)pyridin-2-amine derivatives as c-MYC and p300/CBP histone acetyltransferase inhibitors for treating cancer and their preparation. |
| 10203 | Xiao Y, et al. Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway rendersthem sensitive to NAMPT inhibition with GNE-618. Neoplasia. 2013 Oct;15(10):1151-60. |
| 10204 | Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36. |
| 10205 | Green SR, et al. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer. 2010 Oct 26;103(9):1391-9. |
| 10206 | Rosenthal KS, et al. Tromantadine: inhibitor of early and late events in herpes simplex virus replication. Antimicrob Agents Chemother. 1982 Dec;22(6):1031-6. |
| 10207 | McMillin DW, Delmore J, Negri J et al. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb;152(4):420-32. |
| 10208 | Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013 Sep 15;19(18):5003-15. |
| 10209 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Fluticasone&cntry=&state=&city=&dist= |
| 10210 | Jr FA, et, al. Gas chromatographic determination of diethyl fumarate in malathion extracts and preparations used for control of body lice. J Econ Entomol. 1968 Apr;61(2):457-9. |
| 10211 | Lahti A, et, al. Contact urticaria from diethyl fumarate. Contact Dermatitis. 1985 Mar;12(3):139-40. |
| 10212 | Jin C, et al. Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake. J Med Chem. 2018 Aug 9;61(15):6748-6758. |
| 10213 | Rao SP, et al. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci Transl Med. 2013 Dec 4;5(214):214ra168. |
| 10214 | Biomed Pharmacother 49:197 (1995); J Impotence Res 14 Suppl 1:S53 (2002) |
| 10215 | Indian J Chem B 15:492 (1977) |
| 10216 | Obstet. Gynecol. (2005), 105(5, Pt. 1), 1128-1135; Fertil. Steril. (1957), 8, 50-79; J. Clin. Endocrinol. Metab. (1955), 15, 923-30| |
| 10217 | Armstrong J. Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP. N Engl J Med. 2011 May 5;364(18):1689-91. |
| 10218 | Hauth JC, et al. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol. 1983 May 15;146(2):187-90. |
| 10219 | Arzneim Forsch 27:2163 (1977); J Pharmacol Pharm 31:127 (1979); Farmaco Ed Sci 34:299 (1979) |
| 10220 | J Biol Chem 268:3654 (1993) |
| 10221 | Crascì L, et al. Correlating In Vitro Target-Oriented Screening and Docking: Inhibition of Matrix Metalloproteinases Activities by Flavonoids. Planta Med. 2017 Jul;83(11):901-911. |
| 10222 | Deng W, et al. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN. Biomed Pharmacother. 2018 Nov;107:1505-1513. |
| 10223 | Tetrahedron 21:1453 (1965) |
| 10224 | Eketjäll S, et al. AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. J Alzheimers Dis. 2016;50(4):1109-23. |
| 10225 | Shor B, et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res, 2008, 68(8), 2934-2943. |
| 10226 | Wu L, et al. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res, 2005, 65(7), 2825-2831. |
| 10227 | Teachey DT, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood, 2006, 107(3), 1149-1155. |
| 10228 | Geoerger B, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res, 2001, 61(4), 1527-1532. |
| 10229 | Ravikumar B, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004 Jun;36(6):585-95. Epub 2004 May 16. |
| 10230 | Frost P, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004 Dec 15;104(13):4181-7. Epub 2004 Aug 10. |
| 10231 | Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. |
| 10232 | Jason C. Choi, et al. Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci Transl Med. 2012 Jul 25; 4(144): 144ra102. |
| 10233 | Purohit A, et al. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res. 2000 Jul 1;60(13):3394-6. |
| 10234 | Raobaikady B, et al. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):351-8. |
| 10235 | Han R, et al. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and NSC 123127 for enhanced therapeutic efficacy. J Drug Target. 2016 Jun 29:1-28. [Epub ahead of print] |
| 10236 | McQuade RM, et al. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol Motil. 2016 Jun 28. |
| 10237 | Zeng Q, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to NSC 119875 or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem. 2016 Jul;418(1-2):137-46. |
| 10238 | Yin L, et al. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag. 2017 Feb 7;13:117-130. |
| 10239 | Jones DH, et al. Ten-Year and Beyond Follow-up After Treatment With Highly Purified Liquid-Injectable Silicone for HIV-Associated Facial Lipoatrophy: A Report of 164 Patients. Dermatol Surg. 2019 Jul;45(7):941-948. |
| 10240 | Snyder SM, et al. Initial Experience with Topical Fluorouracil for Treatment of HIV-Associated Anal Intraepithelial Neoplasia. J Int Assoc Physicians AIDS Care (Chic). 2011;10(2):83-88. |
| 10241 | Pek Yee Lum, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell. 2004 Jan 9;116(1):121-37. |
| 10242 | Eur J Pharmacol 11:139 (1970); Br Med J 2:710 (1971); J Clin Pharmacol 17:252 (1977) |
| 10243 | Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47. |
| 10244 | Yuanyuan Wang, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2020 Nov 21;113030. |
| 10245 | Niels Møller Andersen, et al. Inhibition of Protein Synthesis on the Ribosome by Tildipirosin Compared with Other Veterinary Macrolides. Antimicrob Agents Chemother. 2012 Nov; 56(11): 6033–6036. |
| 10246 | Ayse Er, et al. Effects of tylosin on serum cytokine levels in healthy and lipopolysaccharide-treated mice. Acta Vet Hung. 2010 Mar;58(1):75-81. |
| 10247 | Mingfu Liu, et al. Resistance to the macrolide antibiotic tylosin is conferred by single methylations at 23S rRNA nucleotides G748 and A2058 acting in synergy. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23): 14658–14663. |
| 10248 | Carlo Pinna, et al. In Vitro Evaluation of the Effects of Tylosin on the Composition and Metabolism of Canine Fecal Microbiota. Animals (Basel). 2020 Jan; 10(1): 98. |
| 10249 | Marcus F. Boehm, et al. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors. |
| 10250 | Ceballos-Alcantarilla E, et al. Haptens, bioconjugates, and antibodies for penthiopyrad immunosensing. Analyst. 2014 Nov 7;139(21):5358-61. |
| 10251 | Qian L, et al. Effects of penthiopyrad on the development and behaviour of zebrafish in early-life stages. Chemosphere. 2019 Jan;214:184-194. |
| 10252 | Paton DM, et al. Bioavailability and half-life of two preparations of flucloxacillin. N Z Med J. 1982 Nov 10;95(719):766-8. |
| 10253 | Williams J, et al.Sweat tests and flucloxacillin. Arch Dis Child. 1988 Jul;63(7):847-8. |
| 10254 | Everett JR, et al. 19F NMR spectroscopy study of the metabolites of flucloxacillin in rat urine. J Pharm Pharmacol. 1985 Dec;37(12):869-73. |
| 10255 | Nichols RJ, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 Sep;20(9):1064-1073. |
| 10256 | J Chem Soc 1927: 3028 |
| 10257 | Johansson C, et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol. 2016 Jul;12(7):539-45. |
| 10258 | Blair LP, et al. KDM5 lysine demethylases are involved in maintenance of 3'UTR length. Sci Adv. 2016 Nov 18;2(11):e1501662. |
| 10259 | Neuropharmacol 39:1653 (2000) |
| 10260 | Nyati S, et al. The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signaling. Sci Signal. 2015 Jan 6;8(358):ra1. |
| 10261 | Gao J, et al. Cytotoxic cycloartane triterpene saponins from Actaea asiatica. J Nat Prod. 2006 Oct;69(10):1500-2. |
| 10262 | Ber 27: 3115 (1984); 34: 1804 (1901); 43: 2398 (1910) |
| 10263 | Br Med J 2:1423 (1976); Southern Med J 73:1053 (1980); Int J Morphol 25:717 (2007) |
| 10264 | Clark K, et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91. |
| 10265 | Brown FC, et al. MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov. 2018 Apr;8(4):478-497. |
| 10266 | Hutchinson LD, et al. Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses.Cell Death Dis. 2020 Jan 22;11(1):49. |
| 10267 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=QUETIAPINE&cntry=&state=&city=&dist=&Search=Search |
| 10268 | Cao G, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011 Dec;52(12):2169-76. |
| 10269 | J Chem Soc 1966: 506 |
| 10270 | https://clinicaltrials.gov/ct2/show/NCT04456439?term=DIPHENHYDRAMINE&cond=Covid19&draw=2&rank=1 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200504047298N3 |
| 10271 | Phytochemistry 12: 391 (1973) |
| 10272 | Drugs Today (1978), 14(3), 101-7; Eur. J. Clin. Invest. (1971), 1(5), 336-44; Science (1969), 165(3899), 1264-6 |
| 10273 | Kuwano K, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007 Sep;322(3):1181-8. |
| 10274 | Mous DS, et al. Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature. Am J Physiol Lung Cell Mol Physiol. 2018 May 10. |
| 10275 | Alves MS, et al. Identification of clinical isolates of indole-positive and indole-negative Klebsiella spp. J Clin Microbiol. 2006 Oct;44(10):3640-6. |
| 10276 | Taldone T, et al. Heat shock protein 70 inhibitors. 2. 2,5'-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70. J Med Chem. 2014 Feb 27;57(4):1208-24. |
| 10277 | PLoS One 7:e49191 (2012) |
| 10278 | Vakana E, et al. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget. 2017 Feb 7;8(6):9251-9266 |
| 10279 | Chen SH, et al. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discov. 2016 Mar;6(3):300-15 |
| 10280 | Peng SB, et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell. 2015 Sep 14;28(3):384-98 |
| 10281 | Henry JR, et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumo |
| 10282 | Takimoto-Shimomura T, et al. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Invest New Drugs. 2018 Jun 21. |
| 10283 | Cai Xiong, et al. Deazapurines, thienopyrimidines and furopyrimidines as phosphoinositide 3-kinase inhibitors with a zinc binding moiety and their preparation and use in the treatment of diseases. From U.S. Pat. Appl. Publ. (2012), US 20120088764 A1 20120412. |
| 10284 | JAMA 200:619 (1967): Haematologica 85:1011 (2000) |
| 10285 | Maria Ahn, et al. Potent, Dual cIAP1/XIAP Antagonists Induce Apoptosis in a Melanoma Stem Cell Population. |
| 10286 | Chen KF, et al. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem Pharmacol. 2012 Aug 1;84(3):268-77. |
| 10287 | Dhuria S, et al. Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects. J Clin Pharmacol. 2013 Jun;53(6):642-53. |
| 10288 | Infante JR, et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014 Oct 1;32(28):3103-10. |
| 10289 | https://clinicaltrials.gov/ct2/show/NCT04871828?term=Zafirlukast&cond=covid&draw=2&rank=1 |
| 10290 | Xu GW, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 2010 Mar 18;115(11):2251-9. |
| 10291 | Zhang K, et al. Demethylzeylasteral inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis. Cell Death Dis. 2018 Oct 10;9(10):1035. |
| 10292 | Li L, et al. Demethylzeylasteral (T-96) inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways. Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):593-603. |
| 10293 | Wang Q, et al. Demethylzeylasteral ameliorates inflammation in a rat model of unilateral ureteral obstruction through inhibiting activation of the NF‑κB pathway. Mol Med Rep. 2017 Jul;16(1):373-379. |
| 10294 | Zhao Y, et al. Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells. Cell Death Dis. 2017 Oct 26;8(10):e3133. |
| 10295 | Experimental study of the anti-atherosclerotic effect of demethylzeylasteral. Exp Ther Med. 2017 Jun;13(6):2787-2792. |
| 10296 | Walker K.Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1.IDrugs. 2010 Nov;13(11):743-5. |
| 10297 | E. Amtmann, et al. Inhibition of high risk HPV-31 in human cervical epithelial cells in vitro by the PC-PLC inhibitor LMV-601. ICID, March 2010, 14: e465. |
| 10298 | Cheng Q, et al. G-1 exerts neuroprotective effects through G protein-coupled estrogen receptor 1 following spinal cord injury in mice. Biosci Rep. 2016 Aug 31;36(4). pii: e00373. |
| 10299 | Kurt AH, et al. Oxidative/antioxidative enzyme-mediated antiproliferative and proapoptotic effects of the GPER1 agonist G-1 on lung cancer cells. Oncol Lett. 2015 Nov;10(5):3177-3182. |
| 10300 | Chimento A, et al. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo. Oncotarget. 2015 Aug 7;6(22):19190-203. |
| 10301 | Mor M, et al. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem, 2004, 47(21), 4998-5008. |
| 10302 | Tham CS, et al. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett, 2007, 581(16), 2899-2904. |
| 10303 | Fegley D, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2005 Apr;313(1):352-8. |
| 10304 | Jayamanne A, et al. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol, 2006, 147(3), 281-288. |
| 10305 | Howe JA, et al. Selective small-molecule inhibition of an RNA structural element. Nature. 2015 Oct 29;526(7575):672-7. |
| 10306 | Krukowski K, et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017 Jun;158(6):1126-1137. |
| 10307 | Vahagn C Nikolian, et al. Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2019 Feb;86(2):232-239. |
| 10308 | Warrilow AG, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7. |
| 10309 | Garvey EP, et al. VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. Antimicrob Agents Chemother. 2015 Apr;59(4):1992-7. |
| 10310 | Timothy A Lewis, et al. Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing. ACS Med Chem Lett. 2019 Oct 18;10(11):1537-1542. |
| 10311 | Am J Med 84:94 (1988); Ann Intern Med 116:33 (1992); Br Med J 328:545 (2004) |
| 10312 | Cancer Treat Rev17:233 (1990); Prog Exp Tumor Res34:90 (1992); Cancer Chemother Pharmacol 32:90 (1993) |
| 10313 | Jiang W, et al. Breviscapine attenuatted contrast medium-induced nephropathy via PKC/Akt/MAPK signalling in diabetic mice. Am J Transl Res. 2016 Feb 15;8(2):329-41. |
| 10314 | McCormack PL, et al. Iobitridol: a review of its use as a contrast medium in diagnostic imaging. Clin Drug Investig. 2013 Feb;33(2):155-66. |
| 10315 | Andreas Janzer, et al. Abstract DDT02-04: BAY 2402234: A novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies. AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. |
| 10316 | WO/2015/153871A2 |
| 10317 | Spender LC, et al. Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor βSuperfamily Type 1 Receptors. Mol Pharmacol. 2019 Feb;95(2):222-234. |
| 10318 | Shimura K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74. |
| 10319 | Dukes M, et al. The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol. 1996 Jul;58(4):439-45. |Breast Cancer Res Treat 30:103 (1994); J Steroid Biochem Mol Biol 53:175 (1995); Cancer 79:730 (1997) |
| 10320 | https://clinicaltrials.gov/ct2/show/NCT04631536?term=Nicorandil&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04813471?term=Nicorandil&cond=COVID-19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/04/032648 |
| 10321 | Bhattacharjee AK, et al. Discovery of subtype selective muscarinic receptor antagonists as alternatives to atropine using in silico pharmacophore modeling and virtual screening methods. Bioorg Med Chem. 2013 May 1;21(9):2651-62. |
| 10322 | Nishikawa M, et al. Analysis of methylbenactyzium bromide in human urine by thin-layer chromatography and pyrolysis gas chromatography. Forensic Sci Int. 1991 Mar;49(2):197-203. |
| 10323 | Morris EJ, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013 Jul;3(7):742-50. |
| 10324 | Int J Toxicol 11:487 (1992); J Pharm Pharmacol 51:543 (1999) |
| 10325 | William C Wright, et al. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. J Med Chem. 2020 Feb 13;63(3):1415-1433. |
| 10326 | Steven R Feldman, et al. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009;10(6):397-406. |
| 10327 | M Zeigler, et al. Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with Cyclosporin A and clobetasol propionate. Lab Invest. 2001 Sep;81(9):1253-61. |J Am Acad Dermatol 15:246 (1986) |
| 10328 | Kwag J, et al. Evidence for neuroprotective effect of sulbutiamine against oxygen-glucose deprivation in rat hippocampal CA1 pyramidal neurons. Biol Pharm Bull. 2011;34(11):1759-64. |
| 10329 | Kang KD, et al. Sulbutiamine counteracts trophic factor deprivation induced apoptotic cell death in transformed retinal ganglion cells. Neurochem Res. 2010 Nov;35(11):1828-39. |
| 10330 | Chem Biol Interact 80:109 (1991); Food Chem Toxicol 37:1027 (1999) |
| 10331 | Lancet 247:731 (1946) |
| 10332 | Zhi-Xing Qing, et al. Anticancer and Reversing Multidrug Resistance Activities of Natural Isoquinoline Alkaloids and Their Structure-activity Relationship. Curr Med Chem |
| 10333 | Huang W, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016 Feb 11;35(6):783-92 |
| 10334 | Ma Y, et al. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res. 2008 Aug 1;68(15):6292-9. |
| 10335 | Kurtyka CA, et al. E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One. 2014 May 15;9(5):e96357. |
| 10336 | Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60. |
| 10337 | Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb;41(2):445-56. |
| 10338 | Kalgutkar AS, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011 Sep;39(9):1609-19. |
| 10339 | Jaeger K, et al. Structural Basis for Allosteric Ligand Recognition in the Human CC Chemokine Receptor 7. Cell. 2019 Aug 22;178(5):1222-1230.e10. |
| 10340 | Liang Y, et al. Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Acta Pharmacol Sin. 2009 Dec;30(12):1659-65. |
| 10341 | Meng Z, et al. Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca<sup>2+</sup>/calmodulin-dependent protein kinase II. Mol Cancer Ther. 2013 Oct;12(10):2067-77. |
| 10342 | Sadarangani A, et al. GLI2 inhibition abrogates human leukemia stem cell dormancy. J Transl Med. 2015 Mar 21;13:98. |
| 10343 | Shi J, et al. Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293cells. Br J Pharmacol. 2007 Sep;152(1):122-31. |
| 10344 | Yu J, et al. Dexmedetomidine-Induced Contraction in the Isolated Endothelium-Denuded Rat Aorta Involves PKC-δ-mediated JNK Phosphorylation. Int J Med Sci. 2015 Sep 4;12(9):727-36 |
| 10345 | Luh C, et al. Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury. J Neurochem. 2010 Feb;112(4):1015-25. |
| 10346 | Pobbati AV, et, al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635. |
| 10347 | Schmidt A, et al. Structures of three inhibitor complexes provide insight into the reaction mechanism of the human methylenetetrahydrofolate dehydrogenase/cyclohydrolase. Biochemistry. 2000 May 30;39(21):6325-35. |
| 10348 | Tedeschi PM, et al. Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development. Mol Cancer Res. 2015 Oct;13(10):1361-6. |
| 10349 | Gustafsson R, et al. Crystal Structure of the Emerging Cancer Target MTHFD2 in Complex with a Substrate-Based Inhibitor. Cancer Res. 2017 Feb 15;77(4):937-948. |
| 10350 | Huai-Qiang Ju, et al.Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst. 2019 Jun 1;111(6):584-596. |
| 10351 | Zhan Y, et al. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. J Clin Invest. 2017 Nov 1;127(11):4179-4192. |
| 10352 | Champion C, et al. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS One. 2010 Aug 24;5(8):e12388. |
| 10353 | Cheng JC, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003 Mar 5;95(5):399-409. |
| 10354 | Billam M, et al. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat. 2010 Apr;120(3):581-92. |
| 10355 | Lemaire M, et al. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol. 2009 Feb;63(3):411-6. |
| 10356 | J. Pharmacol. Exp. Ther. (1979), 211(3), 678-85; Eur. J. Rheumatol. Inflammation (1978), 1(3), 308-11; Br. J. Clin. Pharmacol. (1977), 4, Suppl. 1, 7-13 |
| 10357 | Cho JY, Antimicrobial activity of 4-hydroxybenzoic acid and trans 4-hydroxycinnamic acid isolated and identified from rice hull. Biosci Biotechnol Biochem. 1998 Nov;62(11):2273-6. |
| 10358 | Tin-Yun Ho, et al. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007 May;74(2):92-101. |
| 10359 | Ying Feng, et al. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Br J Pharmacol. 2010 Sep;161(1):113-26. |
| 10360 | Stefania Sarno, et al. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther. Feb-Mar 2002;93(2-3):159-68. |
| 10361 | Ackermann TF, et al. EMD638683, a novel SGK inhibitor with antihypertensive potency. Cell Physiol Biochem. 2011;28(1):137-46. |
| 10362 | Sgk1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas US 20110060050 A1 |
| 10363 | Biochem. Pharmacol. (1978), 27(10), 1445-54; J. Pharmacol. Exp. Ther. (1976), 197(1), 66-78; Ann. Allergy (1968), 26(9), 493-8 |
| 10364 | Biochem Biophys Res Commun 228:153 (1996) |
| 10365 | J Gen Microbiol 34:51 (1964) |
| 10366 | Taylor DM, et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem Biol. 2011 Jun 17;6(6):540-6. |
| 10367 | Chopra V, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2012 Dec 27;2(6):1492-7. |
| 10368 | Szego EM, et al. Sirtuin 2 enhances dopaminergic differentiation via the AKT/GSK-3β/β-catenin pathway. Neurobiol Aging. 2017 Aug;56:7-16. |
| 10369 | Anchoori RK, et al. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. 2013 Dec 9;24(6):791-805. |
| 10370 | Peng X, et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. |
| 10371 | Stuber G, et al. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. Mol Cancer. 2009 Mar 26;8:23. |
| 10372 | Sallman DA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021;39(14):1584-1594. |
| 10373 | Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement. |
| 10374 | Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement |
| 10375 | Ulrich Lücking, et al. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020 Jul 9;63(13):7293-7325. |
| 10376 | Andiappan Murugan, et al. Exploiting the Differential Reactivities of Halogen Atoms: Development of a Scalable Route to IKK2 Inhibitor AZD3264. Org Process Res Dev. 2014 Apr 29;18(5): 646-651. |
| 10377 | Narimatsu E, Niiya T, Takahashi K, Pralidoxime inhibits paraoxon-induced depression of rocuronium-neuromuscular block in a time-dependentfashion. Am J Emerg Med. 2012 Jul;30(6):901-7. |
| 10378 | Wicks TC. The pharmacology of rocuronium bromide (ORG 9426). AANA J. 1994 Feb;62(1):33-8. |
| 10379 | Wierda JM, Kleef UW, Lambalk LM, The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth. 1991 May;38(4 Pt 1):430-5. |
| 10380 | Khuenl-Brady K, Castagnoli KP, Canfell PC, The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. Anesthesiology. 1990 Apr;72(4):669-74. |
| 10381 | Methyl aminolevulinate, From Wikipedia |
| 10382 | Einem Lindeman T, et al. The resveratrol analogue, 2,3',4,5'-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene. Mutagenesis. 2011 Sep;26(5):629-35. |
| 10383 | Jennings BL, et al. Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats. Cardiovasc Drugs Ther. 2014 Apr;28(2):145-61. |
| 10384 | Sanghee Kim, et al. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. |
| 10385 | Eur J Pharmacol 313:265 (1996) |
| 10386 | Tetrahedron 29:125 (1973); Arch Intern Med 163:1448 (2003); Biochim Biophys Acta 1723: 270 (2005); Mol Carcinog 45:422 (2006)| |
| 10387 | Sahoo M, et al. Identification of Suitable Natural Inhibitor against Influenza A (H1N1) Neuraminidase Protein by Molecular Docking. Genomics Inform. 2016 Sep;14(3):96-103. |
| 10388 | Liu J, et al. A small-molecule agonist of the Wnt signaling pathway. Angew Chem Int Ed Engl. 2005 Mar 18;44(13):1987-90. |
| 10389 | Ying Jiang, et al. Pizotifen inhibits the proliferation and invasion of gastric cancer cells. Exp Ther Med. 2020 Feb;19(2):817-824. |
| 10390 | Yunlong Meng, et al. Exposure to pyrimethanil induces developmental toxicity and cardiotoxicity in zebrafish. Chemosphere. 2020 Sep;255:126889. |
| 10391 | Helv Chim Acta 45: 1183, 1206, 2285 (1992) |
| 10392 | Antibiot Chemother11:587 (1961) |
| 10393 | Antimicrob Agents Chemother 8:518 (1975); 13:971 (1978) |
| 10394 | Liu C, et al. Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition. Am J Cancer Res. 2015 Mar 15;5(4):1308-18. |
| 10395 | Naoki Harada, et al. Mogrol Derived from Siraitia grosvenorii Mogrosides Suppresses 3T3-L1 Adipocyte Differentiation by Reducing cAMP-Response Element-Binding Protein Phosphorylation and Increasing AMP-Activated Protein Kinase Phosphorylation. PLoS One. 2 |
| 10396 | Badger, A.M., et al., Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage, 2000. 8(6): p. 434-43. |
| 10397 | Kim AL , et al. Role of p38 MAPK in UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. J Invest Dermatol. 2005 Jun;124(6):1318-25. |
| 10398 | Ward, K.W., et al., SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics. Xenobiotica, 2002. 32(3): p. 221-33. |
| 10399 | Chen W, et al. L-rhamnose antigen: a promising alternative to α-gal for cancer immunotherapies. ACS Chem Biol. 2011 Feb 18;6(2):185-91. |
| 10400 | Zuhl MN , et al. Effects of oral glutamine supplementation on exercise-induced gastrointestinal permeability and tight junction protein expression. J Appl Physiol (1985). 2014 Jan 15;116(2):183-91. |
| 10401 | Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997 Nov 1;57(21):4838-48. |
| 10402 | Ali S, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther, 2008, 7(6), 1708-1719. |
| 10403 | Marchetti S, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-typ |
| 10404 | Adachi K, et al. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci. 2010 Aug;35(4):503-14. |
| 10405 | JACS 75: 4675 (1953); Exp Parasitol 28:25 (1970) |
| 10406 | Br J Clin Pharmacol 6:221 (1978); Clin Toxicol 41:849 (2003); Brain Res 1069:96 (2006) |
| 10407 | Onda K, et al. Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia. Hypertension. 2015 Apr;65(4):855-62. |
| 10408 | J Pharmacol Exp Ther 229:851 (1984); J Neurol Neurosurg Psychiatry 48:933 (1985) |
| 10409 | Okamura N, et al. Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.J Pharmacol Exp Ther. 2008 Jun;325(3):893-901. |
| 10410 | Ensho T, et al. Neuropeptide S increases motor activity and thermogenesis in the rat through sympathetic activation.Neuropeptides. 2017 Oct;65:21-27. |
| 10411 | J Chem Soc 1963: 2506, 2515 |
| 10412 | PNAS 104:4389 (2007); Cancer Res72:5363 (2012)| |
| 10413 | Ganguly S, et al. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015 Oct 13;6(31):31767-79. |
| 10414 | Huang M, et al. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther. 2013 Feb;12(2):184-94. |
| 10415 | Xu P, et al. Triptolide Inhibited Cytotoxicity of Differentiated PC12 Cells Induced by Amyloid-Beta25-35 via the Autophagy Pathway. PLoS One. 2015 Nov 10;10(11):e0142719. |
| 10416 | Kong LL, et al. Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. Sci Rep. 2015 Jul 2;5:11747. |
| 10417 | Zhang W, et al. Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism. Int J Mol Sci. 2016 Dec 19;17(12). pii: E2139. |
| 10418 | Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9(8):e105617. |
| 10419 | Donnelly-Roberts DL et al. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology, 2009 Jan, 56(1):223-9. |
| 10420 | Yingbo He et al. The role of microglial P2X7: modulation of cell death and cytokine release. Neuroinflammation, 2017 Jul, 14(1):135. |
| 10421 | Paola Fabbrizio et al. P2X7 Receptor Activation Modulates Autophagy in SOD1-G93A Mouse Microglia.Cell Neurosci, 2017 Aug, 11:249. |
| 10422 | Food Chem Toxicol 42:45 (2004); Bioorg Med Chem Letts 15:2745 (2005); Environ Toxicol Pharmacol 22:15 (2006) |
| 10423 | M Ozaki, et al. In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob Agents Chemother. 1991 Dec;35(12):2496-9. |
| 10424 | Guillem Prats, et al. Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41. |J Clin Pharmacol 34:930 (1994); Pulm Pharmacol Ther 19:20, 30 (2006) |
| 10425 | Oksenberg D, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016 Oct;175(1):141-53. |
| 10426 | Int. J. Fertil. (1991), 36 Suppl 316-25; Br. Med. J. (1962), 2(5311), 1016-9; J. Clin. Endocrinol. Metab. (1962), 22, 1033-9 |
| 10427 | Yamada K, et al. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. J Med Chem. 2017 Aug 24;60(16):7099-7107. |
| 10428 | Sáenz JB, et al. Golgicide A reveals essential roles for GBF1 in Golgi assembly and function. Nat Chem Biol. 2009 Mar;5(3):157-65. |
| 10429 | van der Linden L, et al. Differential effects of the putative GBF1 inhibitors Golgicide A and AG1478 on enterovirus replication. J Virol. 2010 Aug;84(15):7535-42. |
| 10430 | DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun;1(1):54-67. |
| 10431 | Kuse Y, et al. Microglia increases the proliferation of retinal precursor cells during postnatal development. Mol Vis. 2018 Jul 30;24:536-545. eCollection 2018. |
| 10432 | Lee JH, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2019 Mar 2. |
| 10433 | Merry TL, et al. The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice. Int J Obes (Lond). 2020;44(1):245-253. |
| 10434 | Hocker HJ, et al. LIBSA--a method for the determination of ligand-binding preference to allosteric sites on receptor ensembles. J Chem Inf Model. 2014 Feb 24;54(2):530-538. |
| 10435 | Sun Q, et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6140-6143 |
| 10436 | Zisterer DM, et al. Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents. J Pharmacol Exp Ther. 2000 Apr;293(1):48-59. |
| 10437 | Mc Gee MM, et al. Caspase-3 is not essential for DNA fragmentation in MCF-7 cells during apoptosis induced by the pyrrolo-1,5-benzoxazepine, PBOX-6. FEBS Lett. 2002 Mar 27;515(1-3):66-70. |
| 10438 | Bane FT, et al. The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1, in malignant hematopoietic cells. J Pharmacol Exp Ther. 2009 Apr;329(1):38-47. |
| 10439 | Physiol Behav 80:489 (2004); Development 134:455 (2007) |
| 10440 | Kang AD, et al. ON01210.Na (Ex-RAD) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355. |
| 10441 | Gierach I, et al. Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors α-1 and β-1. FEBS Open Bio. 2012 Aug 15;2:247-53. |
| 10442 | Johansson L, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10297-302. |
| 10443 | Villicev CM, et al. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol. 2007 Apr;193(1):21-9. |
| 10444 | Aust J Chem 30:1827 (1977); Planta Med 64:153 (1998) |
| 10445 | Tian LL, Zhou Z, Zhang Q, et al. Protective effect of (+/-) isoborneol against 6-OHDA-induced apoptosis in SH-SY5Y cells. Cell Physiol Biochem. 2007;20(6):1019‐1032. |
| 10446 | Armaka M, Papanikolaou E, Sivropoulou A, Arsenakis M. Antiviral properties of isoborneol, a potent inhibitor of herpes simplex virus type 1. Antiviral Res. 1999;43(2):79‐92. |
| 10447 | Li S, et al. High metastaticgastric and breast cancer cells consume oleic acid in an AMPK dependent manner. PLoS One. 2014 May 13;9(5):e97330. |
| 10448 | Jack-Hays MG, et al. Activation of Na+/K(+)-ATPase by fatty acids, acylglycerols, and related amphiphiles: structure-activity relationship. Biochim Biophys Acta. 1996 Feb 21;1279(1):43-8. |
| 10449 | Bezençon O, et al. Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. J Med Chem. 2017 Dec 14;60(23):9769-9789. |
| 10450 | Sakagami H, et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1728. doi:10.1158/1538-7445.AM2014-1728 |
| 10451 | Konagai S, et al. ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2586. doi:10.1158/1538-7445.AM2015-2586 |
| 10452 | Challapalli A, et al. 3'-Deoxy-3'-<sup>18</sup>F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer. Eur J Nucl Med Mol Imaging. 2015 May;42(6):831-40. |
| 10453 | Baković J, et al. A key metabolic integrator, coenzyme A, modulates the activity of peroxiredoxin 5 via covalent modification. Mol Cell Biochem. 2019 Aug 2. |
| 10454 | Ma L, et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis. Mol Med Rep. 2015 Sep;12(3):4196-4202. |
| 10455 | Abu-Elsaad N, et al. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin. Pharmacol Rep. 2019 Aug;71(4):688-694. |
| 10456 | Xiuwen Tang, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011 Jun 1;50(11):1599-609. |
| 10457 | Khan MK, et al. Dietary phytochemicals as potent chemotherapeutic agents against breast cancer: Inhibition of NF-κB pathway via molecular interactions in rel homology domain of its precursor protein p105. Pharmacogn Mag. 2013 Jan;9(33):51-7. |
| 10458 | Jiang Y, et al. Caffeoylquinic acid derivatives rich extract from Gnaphalium pensylvanicum willd. Ameliorates hyperuricemia and acute gouty arthritis in animal model. BMC Complement Altern Med. 2017 Jun 17;17(1):320. |
| 10459 | Han Y, et al. PD-1/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopy. Anal Biochem. 2018 Apr 15;547:52-56. |
| 10460 | Sugahara K et al. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2016 Oct 7. |
| 10461 | Kappos L et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148-59. |
| 10462 | https://clinicaltrials.gov/ct2/show/NCT04900129?term=Diclofenac&cond=COVID-19&draw=2&rank=1 |
| 10463 | Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338. |
| 10464 | Yang H, et al. Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem. 2018 May 24;61(10):4348-4369. |
| 10465 | Arch Int Pharmacodyn 184:233 (1970); Neuropharmacology 44:739 (2003) |
| 10466 | Guiard BP, et al. Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. Int J Neuropsychopharmacol. 2011 Mar;14(2):211-23. |
| 10467 | DeLorenzo C, et al. SEP-225289 serotonin and dopamine transporter occupancy: a PET study. |
| 10468 | Gedda K et al. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase.
 Biochem Pharmacol. 2007 Jan 15;73(2):198-205. |
| 10469 | Kahrilas PJ et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1385-91. |
| 10470 | Megan G Marks, et al. Effects of Putative Hydroxylated Thalidomide Metabolites on Blood Vessel Density in the Chorioallantoic Membrane (CAM) Assay and on Tumor and Endothelial Cell Proliferation. Biol Pharm Bull. 2002 May;25(5):597-604. |
| 10471 | Chem Ber 67:411, 766 (1934); Z Naturforsch C 59:249 (2004); Planta Med 74(9):DOI 10, 1055/s-0028-1084226 |
| 10472 | Peng L, et al. Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation. ACS Med Chem Lett. 2019 Apr 12;10(5):767-772. |
| 10473 | Mylecharane EJ, et al. 5-HT2 receptor antagonists and migraine therapy. J Neurol. 1991;238 Suppl 1:S45-52. |
| 10474 | Lin OA, et al. The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PLoS One. 2014 Jan 23;9(1):e87026. |
| 10475 | Ujházy E, et al. Teratological and cytogenetical evaluation of two antihistamines (pipethiadene and pizotifen maleate) in mice. Agents Actions. 1988 Apr;23(3-4):376-8. |
| 10476 | Sung B, et al. Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med. 2012 Nov 15;53(10):1977-87. |
| 10477 | Santicioli P, et al. Effect of capsazepine on the release of calcitonin gene-related peptide-like immunoreactivity (CGRP-LI) induced by low pH, capsaicin and potassium in rat soleus muscle. Br J Pharmacol. 1993 Oct;110(2):609-12. |
| 10478 | Cabral LD, et al. The Transient Receptor Potential Vanilloid 1 Antagonist Capsazepine Improves the Impaired Lung Mechanics during Endotoxemia. Basic Clin Pharmacol Toxicol. 2016 Nov;119(5):421-427. |
| 10479 | Wang J, et al. Anti-inflammatory and retinal protective effects of capsaicin on ischaemia-induced injuries through the release of endogenous somatostatin. Clin Exp Pharmacol Physiol. 2017 Jul;44(7):803-814. |
| 10480 | Reverdy C, et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol. 2012 Apr 20;19(4):467-77. |
| 10481 | Robbins JD, et al. Forskolin carbamates: binding and activation studies with type I adenylyl cyclase. J Med Chem. 1996 Jul 5;39(14):2745-52. |
| 10482 | Rodriguez G, et al. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex. J Biol Chem. 2013 Mar 8;288(10):7137-46. |
| 10483 | Matsumiya W, et al. Forskolin modifies retinal vascular development in Mrp4-knockout mice. Invest Ophthalmol Vis Sci. 2012 Dec 7;53(13):8029-35. |
| 10484 | Ríos-Silva M, et al. Effect of chronic administration of forskolin on glycemia and oxidative stress in rats with and without experimental diabetes. Int J Med Sci. 2014 Mar 11;11(5):448-52. |
| 10485 | Mayati A, et al. Functional polarization of human hepatoma HepaRG cells in response to forskolin. Sci Rep. 2018 Oct 31;8(1):16115. |
| 10486 | Awad JA, et al. Interactions of forskolin and adenylate cyclase. Effects on substrate kinetics and protection against inactivation by heat and N-ethylmaleimide. J Biol Chem. 1983 Mar 10;258(5):2960-5. |
| 10487 | Seamon KB, et al. Structure-activity relationships for activation of adenylate cyclase by the diterpene forskolin and its derivatives. J Med Chem. 1983 Mar;26(3):436-9. |
| 10488 | Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. |
| 10489 | Song M, et al. Targeting AKT with oridonin inhibits growth of esophageal squamous cell carcinoma in vitro and patient derived xenografts in vivo. Mol Cancer Ther. 2018 Apr 25. pii: molcanther.0823.2017. |
| 10490 | Sun B, et al. Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 2018 Feb 1;9(35):23878-23889. |
| 10491 | Veronick Benoy, et al. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. Neurotherapeutics. 2017 Apr; 14(2): 417-428. |
| 10492 | Jeanine Jochems et al. Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability. Neuropsychopharmacology. 2014 Jan; 39(2): 389-400. |
| 10493 | Steroids 1959:90; Prog Chem Org Nat Prod 27:131 (1969) |
| 10494 | Curr. Opin. Nephrol. Hypertens. (1995), 4(6), 510-3; Exp. Mol. Pathol. (1963), 2665-80; J. Med. Chem. (1963), 6, 24-6 |
| 10495 | Chem Pharm Bull 22:128 (1974); J Med Chem 30:440 (1987); J Biol Chem 262:988 (1987)| |
| 10496 | Adkins JC, et al. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.Drugs. 1997 Jun;53(6):1054-80 |
| 10497 | Jin MJ, et al. Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2. |
| 10498 | Montano R, et al. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther. 2012 Feb;11(2):427-38. |
| 10499 | Guzi TJ, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602. |
| 10500 | Xu M, et al. Scoparone Protects Against Pancreatic Fibrosis via TGF-β/Smad Signaling in Rats. Cell Physiol Biochem. 2016;40(1-2):277-286. Epub 2016 Nov 18. |
| 10501 | Carrico D, et al. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. Bioorg Med Chem. 2005 Feb 1;13(3):677-88. |
| 10502 | Zhang H, et al. Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discov. 2016 Sep;6(9):1006-21. |
| 10503 | Jansen PA et al. Discovery of small molecule vanin inhibitors: new tools to study metabolism and disease. ACS Chem Biol. 2013 Mar 15;8(3):530-4. |
| 10504 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=Reserpine&cond=COVID-19&draw=2&rank=1 |
| 10505 | Sato T, et al. DPP8 is a novel therapeutic target for multiple myeloma. Sci Rep. 2019 Dec 2;9(1):18094. |
| 10506 | Leen Heirbaut, et al. Probing for improved selectivity with dipeptidederived inhibitors of dipeptidyl peptidases 8 and 9: the impact of P1-variation. MedChemComm. 2016, 7. |
| 10507 | https://clinicaltrials.gov/ct2/show/NCT04349410?term=CLINDAMYCIN&cond=COVID-19&draw=2&rank=1 |
| 10508 | Li QG, et al. Pharmacology and toxicology of artelinic acid: preclinical investigations on pharmacokinetics, metabolism, protein and red blood cell binding, and acute and anorectic toxicities. Trans R Soc Trop Med Hyg. 1998 May-Jun;92(3):332-40. |
| 10509 | Hartell MG, et al. Nuclear magnetic resonance and molecular modeling analysis of the interaction of the antimalarial drugs artelinic acid and artesunic acid with beta-cyclodextrin. J Pharm Sci. 2004 Aug;93(8):2076-89. |
| 10510 | Santosh S Kulkarni, et al. Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorg Med Chem. 2006 Jun 1;14(11):3625-34. |
| 10511 | Jihong Cui, et al. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. Oncotarget. 2017 Jan 3;8(1):1007-1022. |
| 10512 | Anal Profiles Drug Subs 2:551 (1973) |
| 10513 | purvalanol B (CID 448991) - Compound BioActivity Data |
| 10514 | Knockaert M, et al. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene. 2002 Sep 19;21(42):6413-24. |
| 10515 | Suh W, et al. Chemical Constituents Identified from Fruit Body of <i>Cordyceps bassiana</i> and Their Anti-Inflammatory Activity. Biomol Ther (Seoul). 2017 Mar 1;25(2):165-170. |
| 10516 | Heinemann V, et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70. |
| 10517 | Froriep D, et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system. Xenobiotica. 2013 Sep;43(9):780-4. |
| 10518 | Park C, et al. HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats. J Pharm Biomed Anal. 2018 Feb 20;150:39-42. |
| 10519 | Ichiro Hayakawa, et al. Derives d'imidazopyridine. WO2002034748A1. |
| 10520 | https://clinicaltrials.gov/ct2/show/NCT04539626?term=Ethynyl+Estradiol&cond=covid&draw=2&rank=1 |
| 10521 | Noemí Mañé, et al. BPTU, an allosteric antagonist of P2Y1 receptor, blocks nerve mediated inhibitory neuromuscular responses in the gastrointestinal tract of rodents. Neuropharmacology. 2016 Nov;110(Pt A):376-385. |
| 10522 | Dandan Zhang, et al. Two disparate ligand binding sites in the human P2Y1 receptor. Nature. 2015 Apr 16; 520(7547): 317–321. |
| 10523 | Derf A, et al. a natural product from the plant Aegle marmelos, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast [published correction appears in Bioorg Med Chem Lett. 2019 Aug 15;29(16):2437-2438]. Bioorg Med Chem Lett. 2019;29(3):454‐460. |
| 10524 | Nugroho AE, et al. Effects of aegeline, a main alkaloid of Aegle Marmelos Correa leaves, on the histamine release from mast cells. Pak J Pharm Sci. 2011;24(3):359‐367. |
| 10525 | Stuckey JI, et al. A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. Nat Chem Biol. 2016 Mar;12(3):180-7. |
| 10526 | DiNardo CD, et al. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncol. 2013 Aug;9(8):1073-82. |
| 10527 | Cuzzocrea S, et al. The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation. Am J Pathol. 2000 Jul;157(1):145-58. |
| 10528 | J Biol Chem 64: 123; 65: 491 (1925) |
| 10529 | Rogers JL, et al. Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. J Med Chem. 2013 Feb 28;56(4):1739-47. |
| 10530 | Cho SY, et al. Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS. J Pharm Biomed Anal. 2013 Mar 5;75:138-44. |
| 10531 | Park IW, et al. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene. 2007 Aug 16;26(38):5635-42. |
| 10532 | Neel Jasani, et al. Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. |
| 10533 | Chopra SL, et al. Effect of Ampicillin on E. Coli of Swine Origin. Can J Comp Med Vet Sci. 1963 Sep;27(9):223-7. |
| 10534 | Lund B, et al. Ampicillin in portal and peripheral blood and bile after oral administration of ampicillin andpivampicillin. Eur J Clin Pharmacol. 1974;7(2):133-5. |
| 10535 | Lee KE, et al. The neuroprotective mechanism of ampicillin in a mouse model of transient forebrain ischemia. Korean J Physiol Pharmacol. 2016 Mar;20(2):185-92. |
| 10536 | Chen ZF, et al. Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL28170. Brain Res. 1997 Sep 19;769(1):188-92. |
| 10537 | Li PA, et al. Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett. 1998 May 8;247(1):17-20. |
| 10538 | Ai J, et al. Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma. 2007 Jun;24(6):960-78. |
| 10539 | De Strooper B, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999 Apr 8;398(6727):518-22. |
| 10540 | Kharatmal SB, et al. Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. Neuropharmacology. 2015 Oct;97:113-21. |
| 10541 | John Bruce Patterson, et al. Ire-1a inhibitors. WO 2008154484 A1 |
| 10542 | Tokita K, et al. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol. 2005 Dec 19;527(1-3):111-20. |
| 10543 | McCarthy AD, et al. FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease. Pharmacol Biochem Behav. 2011 Mar;98(1):76-80. |
| 10544 | Dong JQ, et al. Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans. Drug Metab Dispos. 2016 Feb;44(2):209-19. |
| 10545 | Ruggeri RB, et al. Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases. J Med Chem. 20 |
| 10546 | Lansdell MI, et al. Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans. J Med Chem. 2010 Apr 22;53(8):3183-97. |
| 10547 | Modi ME, et al. Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65. |
| 10548 | Chen S, et al. Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening. J Med Chem. 2014 Nov 13;57(21):9028-41. |
| 10549 | Ni J, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov. 2012 May;2(5):425-33. |
| 10550 | Huh S et al. Melanogenesis inhibitory effect of fatty acid alkyl esters isolated from Oxalis triangularis. Biol Pharm Bull, 2010, 33(7):1242-5. |
| 10551 | Li X et al. Benchmark Calculations for Bond Dissociation Enthalpies of Unsaturated Methyl Esters and the Bond Dissociation Enthalpies of Methyl Linolenate. J Phys Chem A, 2016, Jun 16, 120(23):4025-36 |
| 10552 | Saori Okuda et al. Impact of Lipid Physical State on the Oxidation of Methyl Linolenate in Oil-in-Water Emulsions. |
| 10553 | K J Simons, et al. An investigation of the H1-receptor antagonist triprolidine: pharmacokinetics and antihistaminic effects. J Allergy Clin Immunol. 1986 Feb;77(2):326-30. |
| 10554 | D L Deal, et al. Disposition and metabolism of triprolidine in mice. Drug Metab Dispos. Nov-Dec 1992;20(6):920-7. |
| 10555 | Jann-Inn Tzeng, et al. Spinal sensory and motor blockade by intrathecal doxylamine and triprolidine in rats. J Pharm Pharmacol. 2018 Dec;70(12):1654-1661. |
| 10556 | Li Y, et al. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol Cell Biol. 1998 Aug;18(8):4719-31. |
| 10557 | Schadendorf D, et al. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol. 1996 Dec;135(6 Pt 2):1889-98. |
| 10558 | Choi SH, et al. Targeted Disruption of Myc-Max Oncoprotein Complex by a Small Molecule. ACS Chem Biol. 2017 Nov 17;12(11):2715-2719. |
| 10559 | ARYL SULFONOHYDRAZIDES. WO2017027400A1. |
| 10560 | Elwood F, et al. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. J Pharmacol Exp Ther. 2017 May;361(2):229-244. |
| 10561 | Bonazzoli E, et al. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. |
| 10562 | Steven L. Wagner, et al. Potent gamma-secretase modulators. WO2016070107A1. |
| 10563 | Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69. |
| 10564 | Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9. |
| 10565 | Wang Z, et al. Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drugcandidate ZM241385. PLoS One. 2010 Nov 8;5(11):e13883. doi: 10.1371/journal.pone.0013883. |
| 10566 | Linden J, et al. Characterization of human A(2B) adenosine receptors: radioligandbinding, western blotting, and coupling to G(q) in human embryonickidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13. |
| 10567 | Poucher SM, et al. The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosinereceptor antagonist. Br J Pharmacol. 1995 Jul;115(6):1096-102. |
| 10568 | Ludwig S, et al. Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. Cancer Immunol Immunother. 2019 Jul;68(7):1133-1141. |
| 10569 | Allaudeen HS, et al. Selective inhibition of DNA replication in herpes simplex virus infected cells by 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine. J Biol Chem. 1982 Oct 25;257(20):11879-82. |
| 10570 | Lopez C, et al. 2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother. 1980 May;17(5):803-6. |
| 10571 | Herold JM, et al. Structure–activity relationships of methyl-lysine reader antagonists. MedChemComm. 2012;3(45):45–51. |
| 10572 | Stearns BA, et al. Novel tricyclic antagonists of the prostaglandin D<sub>2</sub> receptor DP2 with efficacy in a murine modelof allergic rhinitis. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4647-51. |
| 10573 | Sugimoto H, et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D<sub>2</sub>-induced eosinophil migration in vitro. J Pharmacol Exp Ther. 2003 Apr;305(1):347-52. |
| 10574 | Haba R, et al. Central CRTH2, a second prostaglandin D<sub>2</sub> receptor, mediates emotional impairment in the lipopolysaccharide and tumor-induced sickness behavior model. J Neurosci. 2014 Feb 12;34(7):2514-23. |
| 10575 | Flint M, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
 Antimicrob Agents Chemother. 2009 Feb;53(2):401-11. |
| 10576 | Reich S, et al. Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase.
 J Biol Chem. 2010 Apr 30;285(18):13685-93. |
| 10577 | Osawa Y, et al. Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice. EBioMedicine. 2015 Oct 8;2(11):1751-8. |
| 10578 | J Auton Nerv Syst 79: 191 (2000); hepatotoxic at clinical dose (480mg) |
| 10579 | JT Kellis Jr, et al. Inhibition of human estrogen synthetase (aromatase) by flavones. Science. 1984 Sep. 225 (4666):1032-1034. |
| 10580 | Eun Ji Kim, et al. Apoptosis of DU145 human prostate cancer cells induced by dehydrocostus lactone isolated from the root of Saussurea lappa. Food and Chemical Toxicology
 Volume 46, Issue 12, December 2008, Pages 3651–3658 |
| 10581 | Oh GS, et al. Dehydrocostus lactone enhances tumor necrosis factor-alpha-induced apoptosis of human leukemia HL-60 cells. Immunopharmacol Immunotoxicol. 2004 May;26(2):163-75. |
| 10582 | Lee HJ, et al. A sesquiterpene, dehydrocostus lactone, inhibits the expression of inducible nitric oxide synthase and TNF-alpha in LPS-activated macrophages. Planta Med. 1999 Mar;65(2):104-8. |
| 10583 | Taniguchi M, et al. COSTUNOLIDE AND DEHYDROCOSTUS LACTONE AS INHIBITORS OF KILLING FUNCTION OF CYTOTOXIC T LYMPHOCYTES. Bioscience, Biotechnology, and Biochemistry, 1995, 59 (11): 2064-2067 |
| 10584 | Liu Jiasen, et al. STUDIES ON THE ACTIVE PRINCIPLES OF SCHISANDRA SPHENANTHERA REHD. ET WILS. THE STRUCTURES OF SCHISANTHERIN A, B, C, D, E, AND THE RELATED COMPOUNDS. Science China Mathematics, 1978, (4) |
| 10585 | Egile C, et al. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94. |
| 10586 | A P Toner et al. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivoactivity against prostate cancer and circumvents MDR1 resistance. Br J Cancer, 2013 Oct 15, 109(8): 2131-2141. |
| 10587 | Huang Y, et al. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities. ACS Chem Biol. 2014 Mar 21;9(3):802-11. |
| 10588 | Florent Beaufils, et al. Abstract 1336: Structure-activity relationship studies, synthesis, and biological evaluation of PQR620, a highly potent and selective mTORC1/2 inhibitor. Cancer Research; 2016 Apr 16-20. |
| 10589 | Chiara Tarantelli, et al. Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax. Blood 2016 128:3017. |
| 10590 | Int. J. Pharm. (2011), 408(1-2), 27-38; Int. J. Cosmet. Sci. (1979), 1(6), 341-61; J. Soc. Cosmet. Chem. (1978), 29(9), 525-36 |
| 10591 | Bavetsias V, et al. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem. 2010 Jul 22;53(14):5213-28. |
| 10592 | Faisal A, et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther. 2011 Nov;10(11):2115-23. |
| 10593 | Pharmacol Ther 76:141 (1997); Blood 93:268 (1999); N Engl J Med 339:1341 (1998) |
| 10594 | Sarah Fernandes, et al. Abstract 15707: MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence. Circulation. 2019;140:A15707 |
| 10595 | Voors AA, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020;22(9):1649-1658. |
| 10596 | J Clin Invest 49:2036 (1970); Arch Gen Psychiatry 29:402 (1973); J Thorac Cardiovasc Surg 126:448 (2003) |
| 10597 | Liu FY, et al. Effect of panaxatriol on hematogenesis and granulocyte-macrophage colony stimulating factor in radiation injured mice. Saudi Med J. 2007 Dec;28(12):1791-5. |
| 10598 | Sato T, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9. |
| 10599 | Matsumoto K, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011 Jan;336(1):95-103. |
| 10600 | Eur J Cancer Clin Oncol 25 Suppl 1: S21, S29, S41 (1989); Anaesth AnaIg 75: 561 (1992); Lancet 340:1223 (1992); 341:185 (1993)| |
| 10601 | Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65. |
| 10602 | Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):255-65. |
| 10603 | Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50. |
| 10604 | Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16. |
| 10605 | Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83. |
| 10606 | Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31. |
| 10607 | D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4(8):1198-204. |
| 10608 | Ho CY, et al. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem. 2005 Dec 29;48(26):8163-73. |
| 10609 | J Chem Soc 81: 203 (1902); PNAS 97: 4790 (2000) |
| 10610 | Lu H, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res. 2012 Jan 15;18(2):499-509. |
| 10611 | Dietsch GN, et al. Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity. PLoS One. 2016 Feb 29;11(2):e0148764. |
| 10612 | Gully D, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):65-9. |
| 10613 | Griebel G, et al. Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci Biobehav Rev. 2001 Dec;25(7-8):619-26. |
| 10614 | Felszeghy K, et al. Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference. Neuropsychopharmacology. 2007 Dec;32(12):2601-10. |
| 10615 | Zhu GF, et al. Eriodictyol, a plant flavonoid, attenuates LPS-induced acute lung injury through its antioxidative and anti-inflammatory activity. Exp Ther Med. 2015 Dec;10(6):2259-2266. Epub 2015 Oct 23. |
| 10616 | Jing X, et al. Eriodictyol Attenuates β-Amyloid 25-35 Peptide-Induced Oxidative Cell Death in Primary Cultured Neurons by Activation of Nrf2. Neurochem Res. 2015 Jul;40(7):1463-71. |
| 10617 | Václav Zima, et al. Unraveling the Anti-Influenza Effect of Flavonoids: Experimental Validation of Luteolin and its Congeners as Potent Influenza Endonuclease Inhibitors. Eur J Med Chem. 22 August 2020, 112754. |
| 10618 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=NICOTINE+&cntry=&state=&city=&dist=&Search=Search |
| 10619 | Muneyyirci-Delale O, et al. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43(1):24-7. |
| 10620 | Kaser DJ, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012 Apr;25(2):105-8. |
| 10621 | Maier WE, et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001 Aug;34(1):53-61. |
| 10622 | Cheng DC, et al. Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atherosclerosis. 1983 Jan;46(1):41-8. |Drugs (1973), 6(3), 169-81; JAMA, J. Am. Med. Assoc. (1962), 180(5), 359-61; J. Clin. Endocrinol. Metab. (1962), 22, 1033-9 |
| 10623 | Chou TF et al. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem, 2013 Feb, 8(2):297-312. |
| 10624 | Chou TF, et al. Selective, reversible inhibitors of the AAA ATPase p97. Probe Reports from the NIH Molecular Libraries Program. April 14, 2011. |
| 10625 | Ann Pharmacother 34:1419 (2000); Lupus 19:10 1229 (2010) |
| 10626 | Meneghetti F, et al. Crystallographic and NMR Investigation of Ergometrine and Methylergometrine, Two Alkaloids from Claviceps purpurea. Molecules. 2020 Jan 14;25(2). pii: E331. |
| 10627 | Koehler PJ, et al. History of methysergide in migraine. Cephalalgia. 2008 Nov;28(11):1126-35. |
| 10628 | Tfelt-Hansen P, et al. Methylergometrine antagonizes 5 HT in the temporal artery. Eur J Clin Pharmacol. 1987;33(1):77-9. |
| 10629 | Sharp SY, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther. 2007 Apr;6(4):1198-211. |
| 10630 | Fiedler LR, et al. MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo. Cell Stem Cell. 2019 Mar 1. pii: S1934-5909(19)30013-X. |
| 10631 | JACS 82:2974 (1960); Appl Microbiol 16:961 (1968) |
| 10632 | Namdar, R. and C. Valdez, Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. Drugs Today (Barc), 2011. 47(12): p. 883-90. |
| 10633 | Mahvan, T.D., W.A. Buckley, and J.R. Hornecker, Alcaftadine for the prevention of itching associated with allergic conjunctivitis. Ann Pharmacother, 2012. 46(7-8): p. 1025-32. |
| 10634 | Jain P, et al. Design, synthesis and biological evaluation of some novel benzimidazole derivatives for their potential anticonvulsant activity. Arch Pharm Res. 2010 Jul;33(7):971-80. |
| 10635 | Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet. 1984 May-Jun;9(3):222-38. |
| 10636 | Ambekar CS, et al. Chloramphenicol succinate, a competitive substrate and inhibitor of succinate dehydrogenase: possible reason for its toxicity. Toxicol In Vitro. 2004 Aug;18(4):441-7. |
| 10637 | Turton JA, et al. Haemotoxicity of chloramphenicol succinate in the CD-1 mouse and Wistar Hanover rat. Hum Exp Toxicol. 1999 Sep;18(9):566-76. |
| 10638 | Nature 158: 515 (1946); Chem Commun 1970: 1020 |
| 10639 | Neurogastroenterol. Motil. (2008), 20(2), 99-112; Gut (1985), 26(3), 246-51; J. Pharm. Pharmacol. (1984), 36(2), 139-40 |
| 10640 | Song JH, et al. Inhibition of UDP-Glucuronosyltransferases (UGTs) Activity by constituents of Schisandra chinensis. Phytother Res. 2015 Jun 18. |
| 10641 | Yu LH, et al. Schisanhenol attenuated ox-LDL-induced apoptosis and reactive oxygen species generation in bovine aorta endothelial cells in vitro. J Asian Nat Prod Res. 2008 Jul-Aug;10(7-8):799-806. |
| 10642 | Wang QY, et al. Schisanhenol derivatives and their biological evaluation against tobacco mosaic virus (TMV). Fitoterapia. 2015 Mar;101:117-24. |
| 10643 | Xue JY, et al. Antioxidant activity of two dibenzocyclooctene lignans on the aged and ischemic brain in rats. Free Radic Biol Med. 1992;12(2):127-35. |
| 10644 | Uesugi T, et al. Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy isoflavones, daidzin, genistin, and glycitin. Biol Pharm Bull. 2001 Apr;24(4):368-72. |
| 10645 | Li XH, et al. Effect of daidzin, genistin, and glycitin on osteogenic and adipogenic differentiation of bone marrow stromal cells and adipocytic transdifferentiation of osteoblasts. Acta Pharmacol Sin. 2005 Sep;26(9):1081-6. |
| 10646 | Zhang L, et al. Glycitin regulates osteoblasts through TGF-β or AKT signaling pathways in bone marrow stem cells. Exp Ther Med. 2016 Nov;12(5):3063-3067. |
| 10647 | Lin Z, et al. In vitro anti-tumour activities of quinolizidine alkaloids derived from Sophora flavescens Ait. Basic Clin Pharmacol Toxicol. 2011 May;108(5):304-9. |
| 10648 | Yuan XY, et al. Effects and mechanisms of aloperine on 2, 4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice. Eur J Pharmacol. 2010 Mar 10;629(1-3):147-52. |
| 10649 | Le P, et al. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nat Chem. 2019 Dec 16. |
| 10650 | Szymon Klossowski, et al. Menin Inhibitor MI-3454 Induces Remission in <i>MLL1</i>-rearranged and <i>NPM1</i>-mutated Models of Leukemia. J Clin Invest. 2020 Feb 3;130(2):981-997. |
| 10651 | Millner OE Jr, et al. Flurofamide: a potent inhibitor of bacterial urease with potential clinical utility in the treatment of infection induced urinary stones. J Urol. 1982 Feb;127(2):346-50. |
| 10652 | Chang MR, et al. Synthetic RORγt Agonists Enhance Protective Immunity. ACS Chem Biol. 2016 Apr 15;11(4):1012-8. |
| 10653 | Science 169:1213 (1970); Proc Soc Exp Biol Med 137:357 (1971) |
| 10654 | Martin L, et al. Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations. Cancer Res. 2014 Jun 1;74(11):3104-1 |
| 10655 | https://clinicaltrials.gov/ct2/show/NCT04830735?term=Dasatinib&cond=covid&draw=2&rank=1 |
| 10656 | Nowlan ML, et al. Acotiamide: first global approval. Drugs. 2013 Aug;73(12):1377-83. |
| 10657 | Attia KAM, et al. Spectrofluorimetric determination of acotiamide hydrochloride trihydrate in the presence of its oxidative degradation product. Luminescence. 2018 Jun;33(4):806-811. |
| 10658 | Sim MK et al. Muscarinic receptors in the aortae of normo- and hypertensive rats: a binding study.
 Clin Exp Hypertens. 1993 Mar;15(2):409-21. |
| 10659 | Bryant SM et al. Intramuscular ophthalmic homatropine vs. atropine to prevent lethality in rates with dichlorvos poisoning. J Med Toxicol. 2006 Dec;2(4):156-9. |
| 10660 | Leung E et al. Modification by hexamethonium of the muscarinic receptors blocking activity of pancuronium and homatropine in isolated tissues of the guinea-pig.
 Eur J Pharmacol. 1982 May 7;80(1):11-7. |
| 10661 | Chen Q, et al. Pharmacokinetics and tolerance of dehydroandrographolide succinate injection after intravenous administration in healthy Chinese volunteers. Acta Pharmacol Sin. 2012 Oct;33(10):1332-6. |
| 10662 | Chao WW, et al. Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chin Med. 2010 May 13;5:17. |
| 10663 | Basak A, et al. Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters. Biochem J. 1999 Feb 15;338 ( Pt 1):107-13. |
| 10664 | Zhu T, et al. Dehydroandrographolide succinate inhibits oxidative stress in mice with lipopolysaccharide-induced acute lung injury by inactivating iNOS. Nan Fang Yi Ke Da Xue Xue Bao. 2012 Sep;32(9):1238-41. |
| 10665 | Chen H, et al. Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents. Bioorg Med Chem Lett. 2014 May 15;24(10):2353-9. |
| 10666 | Hirai H, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-FU. Cancer Biol Ther. 2010 Apr;9(7):514-22. |
| 10667 | Bridges KA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011 Sep 1;17(17):5638-48. Epub 2011 Jul 28. |
| 10668 | Rajeshkumar NV, et al. MK-1775, a potent Wee1 inhibitor, synergizes with NSC 613327 to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.Clin Cancer Res. 2011 May 1;17(9):2799-806. Epub 2011 Mar 9. |
| 10669 | Carlino L, et al. Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural andPharmacological Perspective. J Med Chem. 2016 Oct 27;59(20):9305-9320. |
| 10670 | Andrews FH, et al. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1072-E1080. |
| 10671 | Shannon-Lowe CD, et al. The effects of Maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae. 2010 Dec 7;1(1):4. |
| 10672 | Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72. |
| 10673 | https://clinicaltrials.gov/ct2/show/NCT04478071?term=Vadadustat&cond=covid-19&draw=2&rank=1 |
| 10674 | Zhu J, et al. Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nucleartranslocation via regulating PI3K/Akt pathway. Cell Death Dis. 2018 Jun 13;9(6):708. |
| 10675 | Bronzo AL et al. Felypressin increases blood pressure during dental procedures in hypertensive patients. Arq Bras Cardiol. 2012 Aug;99(2):724-31. |
| 10676 | Cecanho R et al. Cardiovascular effects of felypressin. Anesth Prog. 2006 Winter;53(4):119-25. |
| 10677 | Rahman, et al. Allicin and Other Functional Active Components in Garlic: Health Benefits and Bioavailability[J]. International Journal of Food Properties, 2007, 10(2):245-268. |
| 10678 | Müller A, et al. Allicin Induces Thiol Stress in Bacteria through S-Allylmercapto Modification of ProteinCysteines. J Biol Chem. 2016 May 27;291(22):11477-90. |
| 10679 | Johnson CN, et al. Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase. ACS Med Chem Lett. 2014 May 23;6(1):25-30. |
| 10680 | Beke L, et al. MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. Biosci Rep. 2015 Oct 2;35(6). pii: e00267. |
| 10681 | http://en.wikipedia.org/wiki/Xylitol |Pharm Acta Helv 23: 153 (1948); JACS 104: 1109 (1982); J Chem Soc 1983: 1553 |
| 10682 | Jaime-Figueroa S, et al. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. 2020 Feb 1;30(3):126877. |
| 10683 | Ber 21: 3404 (1888); Biochem J 122: 503 (1971) |
| 10684 | Steele JW, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry. 2013 Aug;18(8):889-97. |
| 10685 | Le TK, et al. Highly regioselective hydroxylation of polydatin, a resveratrol glucoside, for one-step synthesis of astringin, a piceatannol glucoside, by P450 BM3. Enzyme Microb Technol. 2017 Feb;97:34-42. |
| 10686 | Pehrson R, et al. AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure. J Pharmacol Exp Ther. 2018 Jun;365(3):567-572. |
| 10687 | Zhang YJ, et al. In silico design and synthesis of piperazine-1-pyrrolidine-2,5-dione scaffold-based novel malic enzyme inhibitors. Bioorg Med Chem Lett. 2006 Feb;16(3):525-8. Epub 2005 Nov 8. |
| 10688 | Fernandes L, et al. Malic Enzyme 1 (ME1) is pro-oncogenic in ApcMin/+ mice. Sci Rep. 2018 Sep 24;8(1):14268. |
| 10689 | Fujimoto J, et al. Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. ACS Med Chem Lett. 2019 Sep 19;10(10):1498-1503. |
| 10690 | Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. |
| 10691 | Chaussade C, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007 Jun 15;404(3):449-58. |
| 10692 | Duong HQ, et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol. 2014 Mar;44(3):959-69. |
| 10693 | Bott-Flügel L, et al. Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism. PLoS One. 2011 Mar 28;6(3):e18048. |
| 10694 | Bailey IR, et al. Optimization of Thermolytic Response to A1 Adenosine Receptor Agonists in Rats. J Pharmacol Exp Ther. 2017 Sep;362(3):424-430. |
| 10695 | Yeh TK, et al. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3596-600. |
| 10696 | Gizachew D, et al. Aflatoxin B1 (AFB1) production by Aspergillus flavus and Aspergillus parasiticus on ground Nyjer seeds: The effect of water activity and temperature. Int J Food Microbiol. 2019 May 2;296:8-13. |
| 10697 | Aguilar F, et al. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8586-90. |
| 10698 | Melamine |
| 10699 | Liu IM, et al. Mediation of beta-endorphin by isoferulic acid to lower plasma glucose in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2003 Dec;307(3):1196-204. |
| 10700 | Sakai S, et al. Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. Mediators Inflamm. 2001 Apr;10(2):93-6. |
| 10701 | Benson CA, et al. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J Antimicrob Chemother. 1987 Aug;20(2):191-6. |
| 10702 | Miniter PM, et al. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother. 1987 Aug;31(8):1199-203. |
| 10703 | Allen NE, et al. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987 Jul;31(7):1093-9. |
| 10704 | Bhide RS, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem, 2006, 49 (7), 2143-2146. |
| 10705 | Huynh H, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 2008, 14(19), 6146-6153. |
| 10706 | Nakamura I, et al. Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLoS One. 2015 Nov 3;10(11):e0142355. |
| 10707 | J Pharmacol Exp Therap 278:771 (1996); Life Sci 70:3097 (2002)| |
| 10708 | Cincin ZB, et al. Apoptotic Effects of Quercitrin on DLD-1 Colon Cancer Cell Line. Pathol Oncol Res. 2015 Apr;21(2):333-8. |
| 10709 | Ma JQ, et al. Quercitrin offers protection against brain injury in mice by inhibiting oxidative stress and inflammation. Food Funct. 2016 Jan 20;7(1):549-56. |
| 10710 | Li W, et al. Quercitrin ameliorates the development of systemic lupus erythematosus-like disease in a chronic graft-versus-host murine model. Am J Physiol Renal Physiol. 2016 Feb 24:ajprenal.00249.2015. |
| 10711 | Chen G, et al. The metabolites of a mangrove endophytic fungus, Penicillium thomi. J Asian Nat Prod Res. 2007 Mar;9(2):159-64. |
| 10712 | Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15. |
| 10713 | Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. |
| 10714 | Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin(STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5198-204. |
| 10715 | Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27(7):621-36. |
| 10716 | Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells.
 J Lipid Res. 2003 Feb;44(2):415-23. |
| 10717 | Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724. |
| 10718 | Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419(2):447-55. |
| 10719 | O'Connor RS, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018 Apr 19;8(1):6289. |
| 10720 | Garcia-Echeverria C, et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008 Sep 18;27(41):5511-26. |
| 10721 | Yu P, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13(5):1078-91. |
| 10722 | Peter G. Smith, et al. Abstract DDT01-04: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer.AACR Annual Meeting 2017; April 1-5. |
| 10723 | Amy H Kim, et al. H3B-6545, a selective estrogen receptor covalent antagonist, prevents bone loss in ovariectomized Sprague-Dawley rats. J Pharmacol Toxicol Methods. Sep-Oct 2019;99:106595. |
| 10724 | https://clinicaltrials.gov/ct2/show/NCT04382586?term=zanubrutinib&cond=COVID-19&draw=2&rank=1 |
| 10725 | Review Article: Rifabutin in the Treatment of Refractory Helicobacter pylori Infection 
 J. P. Gisbert, X. Calvet Issue Alimentary Pharmacology & Therapeutics Volume 35, Issue 2, pages 209-221, January 2012 |
| 10726 | Vourvahis M, Davis J, Wang R, Layton G, Choo HW, Chong CL, Tawadrous M.
 Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-o-desacetyl-rifabutin in healthy subjects.
 Antimicrob Agents Chemother. 2012 Aug;56(8):4303-9. |
| 10727 | Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X.
 Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.
 Aliment Pharmacol Ther. 2012 Apr;35(8):941-7. doi: 10.1111/j.1365-2036.2012.05053.x. |
| 10728 | Gisbert JP, Calvet X.
 Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.
 Aliment Pharmacol Ther. 2012 Jan;35(2):209-21. doi: 10.1111/j.1365-2036.2011.04937.x. |
| 10729 | Horne DJ, Spitters C, Narita M.
 Experience with rifabutin replacing rifampin in the treatment of tuberculosis.
 Int J Tuberc Lung Dis. 2011 Nov;15(11):1485-9, i. |
| 10730 | Masaru Takagi, et al. Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol. 2010 Aug;96(2):259-66. |
| 10731 | Koh-Ichi Sakata, et al. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 2011 Sep;102(9):1712-6. |
| 10732 | Masakazu Fukushima, et al. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep. 2010 Nov;24(5):1307-13. |
| 10733 | Anal Profiles Drug Subs 20:627 (1991); Fundam Appl Toxicol 18:48 (1992) |
| 10734 | The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterialmetallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39(7):1629-31. |
| 10735 | Blanca Humanes, et al. Protective Effects of Cilastatin Against Vancomycin-Induced Nephrotoxicity. Biomed Res Int. 2015;2015:704382. |
| 10736 | P J Petersen, et al. In Vitro and in Vivo Activities of LJC10,627, a New Carbapenem With Stability to Dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35(1):203-7. |
| 10737 | Ade Arsianti, et al. Synthesis and in vitro antimalarial activity of alkyl esters of gallate as a growth inhibitor of plasmodium falciparum. Oriental Journal of Chemistry, 34(2), 655-662. |
| 10738 | Kim B, et al. Differential effects of alkyl gallates on quorum sensing in Pseudomonas aeruginosa. Sci Rep. 2019;9(1):7741. Published 2019 May 23. |
| 10739 | Cavalca LB, et al. Hexyl gallate for the control of citrus canker caused by Xanthomonas citri subsp citri [published online ahead of print, 2020 Aug 6]. Microbiologyopen. 2020;e1104. |
| 10740 | Xiang-Lei Yang, et al. INHIBITION OF NEDDYLATION USING GLYCYL-tRNA SYNTHETASE INHIBITORS. WO 2017066459 A1. |
| 10741 | J Chem Soc 1966:114 |
| 10742 | Peng SB, et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015 Feb;14(2):480-90. |
| 10743 | Cho BS, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 9;126(2):222-32. |
| 10744 | JACS 60:1553 (1938); J Org Chem 12:275 (1947)| |
| 10745 | Eaves KL, et, al. High pressure liquid chromatographic determination of sulfanitran and dinsed in medicated feeds and premixes. J Assoc Off Anal Chem. 1977 Sep;60(5):1064-6. |
| 10746 | Zelcer N, et, al. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44. |
| 10747 | Kelly MJ, et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014 May 22;57(10):3912-23. |
| 10748 | Sotaro Sadahiro, Toshiyuki Suzuki, Akira Tanaka, et al. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemotherapy and Pharmacology. 2012, 70 (2): 285-291. |
| 10749 | José L. Ariasa, et al. Engineering of an antitumor (core/shell) magnetic nanoformulation based on the chemotherapy agent ftorafur. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2011,384(1-3): 157-163. |
| 10750 | Gabriel N. Hortobagyi, William Heim, Laura Hutchins, et al. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010, 116(6): 1440-1445. |
| 10751 | K. Fujita, H. Nakayama, W. Ichikawa, et al. Pharmacokinetics of 5-Fluorouracil in Elderly Japanese Patients with Cancer Treated with S-1 (a Combination of Tegafur and Dihydropyrimidine Dehydrogenase Inhibitor 5-Chloro-2,4-dihydroxypyridine). Drug Metab Dispos. 2009 Jul;37(7):1375-7. doi: 10.1124/dmd.109.027052. Epub 2009 Apr 23. |
| 10752 | Tegafur-uracil |
| 10753 | Am. J. Obstet. Gynecol. (1994), 170(5 Pt 2), 1543-9; Proc. Soc. Exp. Biol. Med. (1960), 103, 175-7; J. Am. Chem. Soc. (1958), 80, 2904-5| |
| 10754 | Schindler AE, et al. Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80. |
| 10755 | J. Pharmacol. Exp. Ther. (1950), 99, 215-25; J. Pharmacol. Exp. Ther. (1949), 97, 150-6; Nature (1948), 161, 718 |
| 10756 | Arindam Talukdar, et al. Discovery and Development of a Small Molecule Library With Lumazine Synthase Inhibitory Activity. J Org Chem. 2009 Aug 7;74(15):5123-34. |
| 10757 | Wang X, et al. Conformation-specific effects of Raf kinase inhibitors. J Med Chem. 2012 Sep 13;55(17):7332-41. |
| 10758 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=RABEPRAZOLE+&cntry=&state=&city=&dist=&Search=Search |
| 10759 | Lee JH et al. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15704-9. |
| 10760 | Li ZY et al. HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway. Neurochem Int. 2016 Oct;99:239-51. |
| 10761 | Kalgutkar AS, et al. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. Drug Metab Dispos. 2007 Nov;35(11):2111-8. Epub 2007 Aug 8. |
| 10762 | Kalgutkar AS, et al. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica. 2004 Aug;34(8):755-70. |
| 10763 | JACS 80:2911 (1958); 85:1547 (1963) |
| 10764 | J Chem Soc 1928:229; 1929:1399; 1931:3206; Anticancer Res 17:3293 (1997) |
| 10765 | Bénardeau A, Benz J, Binggeli A, et al. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett. 2009 May 1;19(9):2468-73. |
| 10766 | Yan Chen, et al. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. Diab Vasc Dis Res. 2017 Mar; 14(2): 152–162. |
| 10767 | Valérie Boujon, et al. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice. J Mol Med (Berl). 2019; 97(8): 1127-1138. |
| 10768 | Suzuki E, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007 Mar 1;67(5):2351-9. |
| 10769 | Fu K, et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):665-71. |
| 10770 | Engebretsen KV, et al. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J Mol Cell Cardiol. 2014 Nov;76:148-57. |
| 10771 | Yan-Er Wang, et al. Hederacolchiside A1 suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway. Chinese Herbal Medicines.Volume 10, Issue 2, April 2018, Pages 215-222 |
| 10772 | Kang N, et al. Antischistosomal Properties of Hederacolchiside A1 Isolated from <i>Pulsatilla chinensis</i>. Molecules. 2018 Jun 13;23(6). |
| 10773 | Kim JC, et al. Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of NSC 125973 as a novel P-glycoprotein inhibitor. Int J Pharm. 2016 Jun 15;506(1-2):93-101. |
| 10774 | Joo KM, et al. Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors. Int J Oncol. 2008 Oct;33(4):705-12. |
| 10775 | Chem Pharm Bull 10:112 (1962); Phytochemistry 24:815 (1985); Biochem Pharmacol 67:1647 (2004); World J Gastroenter 10:2024 (2004); Exp Mol Med 38:256 (2006) |
| 10776 | Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53(17):6337-54. |
| 10777 | Keisuke Ohnishi, et al. Angiotensin-Converting Enzyme Inhibitor Does Not Suppress Renal Angiotensin II Levels in Angiotensin I–Infused Rats. J Pharmacol Sci. 2013; 122(2): 103–108. |
| 10778 | Yuma Ishizaki, et al. Development of a Caco-2 Cell Line Carrying the Human Intestine-Type CES Expression Profile as a Promising Tool for Ester-Containing Drug Permeability Studies. Biol Pharm Bull. 2018;41(5):697-706. |
| 10779 | Eur. J. Rheumatol. Inflammation (1981), 4(1), 3-10; Drugs Today (1977), 13(5), 200-5; Arzneim. Forsch. (1973), 23(8), 1100-7 |
| 10780 | Basic Res. Cardiol. (1978), 73(2), 133-46; Basic Res. Cardiol. (1976), 71(6), 652-7; Arzneim. Forsch. (1976), 26(10), 1819-26 |
| 10781 | Sau K, et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem. 2003 Sep 26;278(39):37561-8. Epub 2003 Jul 14. |
| 10782 | Barwicz J, et al. The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids. 1997 Feb 28;85(2):145-55. |
| 10783 | Ramos H, et al. Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J Membr Biol. 1996 Jul;152(1):65-75. |
| 10784 | Demaimay R, et al. Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J Gen Virol. 1994 Sep;75 (Pt 9):2499-503. |
| 10785 | Adams ML, et al. Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules. 2003 May-Jun;4(3):750-7. |New Engl J Med 296: 784 (1977) |
| 10786 | S Oishi, et al. Effects of propyl paraben on the male reproductive system. Food Chem Toxicol. 2002 Dec;40(12):1807-13. |
| 10787 | Gal A, et, al. Propylparaben inhibits mouse cultured antral follicle growth, alters steroidogenesis, and upregulates levels of cell-cycle and apoptosis regulators. Reprod Toxicol. 2019 Oct;89:100-106. |
| 10788 | Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products. Int J Toxicol. 2008;27 Suppl 4:1-82. |
| 10789 | Cheung A, et al. A small-molecule inhibitor of skeletal muscle myosin II. Nat Cell Biol. 2002 Jan;4(1):83-8. |
| 10790 | Shaw MA, et, al. Mechanism of inhibition of skeletal muscle actomyosin by N-benzyl-p-toluenesulfonamide. Biochemistry. 2003 May 27;42(20):6128-35. |
| 10791 | You X, et al. Retinoid X receptor-alpha mediates (R )-flurbiprofen's effect on the levels of Alzheimer's beta-amyloid. J Neurochem. 2009 Oct;111(1):142-9. |
| 10792 | Wanngren J, et al. Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production. J Biol Chem. 2012 Sep 21;287(39):32640-50. |
| 10793 | Schmitz K, et al. R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice. EMBO Mol Med. 2014 Sep 30;6(11):1398-422. |
| 10794 | https://clinicaltrials.gov/ct2/show/NCT04355936?term=TELMISARTAN&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04360551?term=TELMISARTAN&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04359953?term=TELMISARTAN&cond=COVID-19&draw=2&rank=3 https://clinicaltrials.gov/ct2/show/NCT04715763?term=TELMISARTAN&cond=COVID-19&draw=2&rank=4 https://clinicaltrials.gov/ct2/show/NCT04510662?term=TELMISARTAN&cond=COVID-19&draw=2&rank=5 https://clinicaltrials.gov/ct2/show/NCT04466241?term=TELMISARTAN&cond=COVID-19&draw=2&rank=6 https://clinicaltrials.gov/ct2/show/NCT04920838?term=TELMISARTAN&cond=COVID-19&draw=2&rank=7 https://clinicaltrials.gov/ct2/show/NCT04356495?term=TELMISARTAN&cond=COVID-19&draw=2&rank=8 https://clinicaltrials.gov/ct2/show/NCT04330300?term=TELMISARTAN&cond=COVID-19&draw=2&rank=9 https://clinicaltrials.gov/ct2/show/NCT04394117?term=TELMISARTAN&cond=COVID-19&draw=2&rank=10 https://clinicaltrials.gov/ct2/show/NCT04467931?term=TELMISARTAN&cond=COVID-19&draw=2&rank=11 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/03/032385 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04715763 https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001303-16-FR https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04920838 |
| 10795 | Arzneim Forsch 20:1206 (1970); Jpn J Exp Med 41:459 (1971) |
| 10796 | Batra S, et al. Bioassay, determination and separation of enantiomers of atenolol by direct and indirect approaches using liquid chromatography: A review. Biomed Chromatogr. 2018 Jan;32(1). |
| 10797 | Stoschitzky K, et al. Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality. 1993;5(1):15-9. |
| 10798 | Ihara M, et al. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol. 1992;20 Suppl 12:S11-S14. |
| 10799 | Sakamoto A, et al. Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists. J Biol Chem. 1993 Apr 25;268(12):8547-53. |
| 10800 | Erdogan H et al. The protective effects of endothelin-A receptor antagonist BQ-123 in pentylenetetrazole-induced seizure in rats. Hum Exp Toxicol, 2014 Oct, 33(10):1008-16. |
| 10801 | Zamora MA, et al. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 1993;9(4):429-433. |
| 10802 | Douglas SA, et al. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens. 1994;12(5):561-567. |
| 10803 | Neurosci Biobehav Rev 16:193 (1992); J Ocul Pharmacol 10:591 (1994); Lipids 31:115 (1996)| |
| 10804 | Horrocks LA, et al. Health benefits of docosahexaenoic acid (DHA). Pharmacol Res. 1999 Sep;40(3):211-25. |
| 10805 | Gharami K, et al. Essential role of docosahexaenoic acid towards development of a smarter brain. Neurochem Int. 2015 Oct;89:51-62. |
| 10806 | Lengqvist J, et al. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid Xreceptor alpha ligand-binding domain. Mol Cell Proteomics. 2004 Jul;3(7):692-703. |
| 10807 | Gamoh S, et al. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience. 1999;93(1):237-41. |
| 10808 | Ozsoy O, et al. The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease. Neurochem Int. 2011 Oct;59(5):664-70. |
| 10809 | Bridget M. Cole, et al. PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS. US20140274933. |
| 10810 | Costi R, et al. Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase. J Med Chem. 2007 Apr 19;50(8):1973-7. Epub 2007 Mar 10. |
| 10811 | Laird AD, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res, 2000, 60(15), 4152-4160. |
| 10812 | Smolich BD, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001, 97(5), 1413-1421. |
| 10813 | Marzola P, et al. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res, 2004, 10(2), 739-750. |
| 10814 | Kim HC, et al. Augmentation of chemotherapeutic infusion effect by TSU-68, an oral targeted antiangiogenic agent, in a rabbit VX2 liver tumor model. Cardiovasc Intervent Radiol. 2012 Feb;35(1):168-75 |
| 10815 | Wu P, et al. Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped Dimer. Structure. 2019 Jan 2;27(1):125-133.e4. |
| 10816 | Chenard BL, et al. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem. 1995 Aug 4;38(16):3138-45. |
| 10817 | Poleszak E, et al. Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. Metab Brain Dis. 2016 Aug;31(4):803-14. |
| 10818 | Naspolini AP, et al. Traxoprodil decreases pentylenetetrazol-induced seizures. Epilepsy Res. 2012 Jun;100(1-2):12-9. |
| 10819 | Chen Y, et al. Pachymic acid inhibits tumorigenesis in gallbladder carcinoma cells. Int J Clin Exp Med. 2015 Oct 15;8(10):17781-8. |
| 10820 | Ma J, et al. Pachymic acid induces apoptosis via activating ROS-dependent JNK and ER stress pathways in lung cancer cells. Cancer Cell Int. 2015 Aug 5;15:78. |
| 10821 | Roth GJ, et al. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI). J Med Chem. 2010 Oct 28;53(20):7287-95. |
| 10822 | Lu Z, et al. Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-p53-ROS positive feedback loop in PC-12 cells. |
| 10823 | Zhengle Tang, et al. In vivo toxicological evaluation of Anisomycin. Toxicol Lett. 2012 Jan 5;208(1):1-11. |
| 10824 | Gao X, et al. Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKIIδ expression in the aged atrium. Cardiovasc Res. 2018 Apr 1;114(5):737-746. |
| 10825 | Synthesis Marina Macías-Silva, et al. Anisomycin is a Multifunctional Drug: More than Just a Tool to Inhibit Protein. Current Chemical Biology, 2010, 4, 124-132. |
| 10826 | Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71. |
| 10827 | Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72(9):2176-82. |
| 10828 | Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400. |
| 10829 | Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18(13):3571-9. |
| 10830 | Kumar SV, et al. Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. Biomed Chromatogr. 2013 Feb;27(2):203-7. |
| 10831 | Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400. |
| 10832 | Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70. |
| 10833 | Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol, 2009. 5(8): p. 981-7. |
| 10834 | Grassi G, et, al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. Oct-Dec 2017;8(4):155-165. |
| 10835 | John T. Hunt Discovery of Ixabepilone. Mol Cancer Ther February 2009 8; 275 |
| 10836 | Mitro, Nico., et al. LXR and TSPO as new therapeutic targets to increase the levels of neuroactive steroids in the central nervous system of diabetic animals. Neurochemistry International (2012), 60(6), 616-621. |
| 10837 | Guo, Deliang., et al. An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. Cancer Discovery (2011), 1(5), 442-456. |
| 10838 | Spyridon, Michael., et al. LXR as a novel antithrombotic target. Blood (2011), 117(21), 5751-5761. |
| 10839 | Collins JL, et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem. 2002 May 9;45(10):1963-6. |
| 10840 | Hyeryoung Jung, et al. Isoflavones as modulators of adenosine monophosphate-activated protein kinase. Applied Biological Chemistry. 2016. 59, 217-225. |
| 10841 | Cancer Treat Rep 70:1059 (1986); Adv Cancer Res 72:197 (1998); J Biol Chem 278:12461 (2003)| |
| 10842 | Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6. |
| 10843 | Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58. |
| 10844 | Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7. |
| 10845 | Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3. |
| 10846 | Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79(4):685-91. |
| 10847 | Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4(4):439-44. |
| 10848 | Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9(3):e00756-18. Published 2018 May 8. |
| 10849 | Eur. J. Pharmacol. (1983), 90(2-3), 263-8; Neuroendocrinology (1982), 35(1), 32-6; Nature (1981), 294(5843), 763-5 |
| 10850 | Roy J, et al. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selectiveprostate cancer cell targeting. J Med Chem. 2015 Apr 9;58(7):3094-103. |
| 10851 | Lv Q, et al. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Mol Pharm. 2018 May 7;15(5):1842-1852. |
| 10852 | Peng ZH, et al. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specificmembrane antigen expressing prostate cancer. J Drug Target. 2013 Dec;21(10):968-80. |
| 10853 | J Chem Soc 1960:4613; Phytochemistry 19:71 (1980); 36:971 (1994); Leukemia Res 23:217 (1999); Chem Phys Lipids 133:125 (2005); Apoptosis 12:685 (2007)| |
| 10854 | Robert Tisserand, et al. Sclareol.Constituent profiles |
| 10855 | Amornvit J, et al. A novel p.T139M mutation in HSPB1 highlighting the phenotypic spectrum in a family. Brain Behav. 2017 Jul 21;7(8):e00774. |
| 10856 | Qiu Z, et al. Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors. ACS Med Chem Lett. 2016 Jun 25;7(8):802-6. |
| 10857 | https://jrct.niph.go.jp/latest-detail/jRCTs061200002 |
| 10858 | Hsu YC, et al. Therapeutic ROS targeting of GADD45γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. Cell Death Dis. 2014 Apr 24;5:e1198. |
| 10859 | Murtaza M, et al. Cucurbitacin E reduces obesity and related metabolic dysfunction in mice by targeting JAK-STAT5 signaling pathway. PLoS One. 2017 Jun 9;12(6):e0178910. |
| 10860 | Wei W, et al. Curcumol: From Plant Roots to Cancer Roots. Int J Biol Sci. 2019;15(8):1600-1609. Published 2019 Jun 4. |
| 10861 | Zhang J, et al. Curcumol Exerts Anticancer Effect in Cholangiocarcinoma Cells via Down-Regulating CDKL3. Front Physiol. 2018;9:234. Published 2018 Mar 20. |
| 10862 | Wang J, et al. Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3β/cyclin D1 pathway. J Ethnopharmacol. 2018;210:1-9. |
| 10863 | Ning L, et al. Curcumol Suppresses Breast Cancer Cell Metastasis by Inhibiting MMP-9 Via JNK1/2 and Akt-Dependent NF-κB Signaling Pathways. Integr Cancer Ther. 2016;15(2):216-225. |
| 10864 | McGonigle S, et al. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. Oncotarget. 2015 Dec 1;6(38):41307-23. |
| 10865 | Mol. Pharmacol. (2010), 78(4), 560-568; Int. J. Parasitol. (1991), 21(6), 697-702; Scand. J. Infect. Dis. (1982), 14(4), 297-9 |
| 10866 | Dhakal H, et al. Inhibitory effects of orientin in mast cell-mediated allergic inflammation. Pharmacol Rep. 2020 Jan 24. |
| 10867 | Guo D, et al. Orientin and neuropathic pain in rats with spinal nerve ligation. 61Int Immunopharmacol. 2018 May;58:72-79. |
| 10868 | J Steroid Biochem Mol Biol 41:185 (1992); J Clin Endocrin Metab 81:3686 (1966) |
| 10869 | Onoda T, et al. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J Nat Prod. 1989 Nov-Dec;52(6):1252-7. |
| 10870 | Hu DE, et al. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. Br J Pharmacol. 1995 Jan;114(2):262-8. |
| 10871 | Gubellini P, et al. Endogenous neurotrophins are required for the induction of GABAergic long-term potentiation in the neonatal rat hippocampus. J Neurosci. 2005 Jun 15;25(24):5796-802. |
| 10872 | Wu CP, et al. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-MediatedMultidrug Resistance in Cancer Cell Lines. Mol Pharm. 2019 Jul 1;16(7):3040-3052. |
| 10873 | Evans EK, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017 Nov 1;9(414). pii: eaao1690. |
| 10874 | Erica Evans, et al. Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations.Blood 2015 126:568. |
| 10875 | Filocamo G et al. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.
 Mol Cancer Ther. 2016 Jun;15(6):1177-89. |
| 10876 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Tetracycline+&cntry=&state=&city=&dist=&Search=Search |
| 10877 | Zhang, W., et al., Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. J Med Chem, 2013. 56(23): p. 9683-92. |
| 10878 | Xiaodong Wang, et al. Pyrimidine compounds for the treatment of cancer.WO2013177168A1. |
| 10879 | Evans GB, et al. Second generation transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase. J Med Chem. 2005 Jul 14;48(14):4679-89. |
| 10880 | Basu I, et al. A transition state analogue of 5'-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J Biol Chem. 2007 Jul 20;282(29):21477-86. |
| 10881 | Ahmad B, et al. A Review on Pharmacological Properties of Zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-butanone). ScientificWorldJournal. 2015;2015:816364. |
| 10882 | Ahmad B, et al. Zingerone (4-(4-hydroxy-3-methylphenyl) butan-2-one) protects against alloxan-induced diabetes via alleviation of oxidative stress and inflammation: Probable role of NF-kB activation. Saudi Pharm J. 2018 Dec;26(8):1137-1145. |
| 10883 | Choi JS, et al. Zingerone Suppresses Tumor Development through Decreasing Cyclin D1 Expression and Inducing Mitotic Arrest. Int J Mol Sci. 2018 Sep 19;19(9). |
| 10884 | Li L, et al. Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. Toxicol Appl Pharmacol. 2015 Aug 1;286(3):224-33. |
| 10885 | Fleseriu M, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary. 2016 Apr;19(2):138-48. |
| 10886 | Xu Y, et al. Protective mechanisms of CA074-me (other than cathepsin-B inhibition) against programmed necrosis induced by global cerebral ischemia/reperfusion injury in rats. Brain Res Bull. 2016 Jan;120:97-105 |
| 10887 | Patel N, et al. CA-074Me compound inhibits osteoclastogenesis via suppression of the NFATc1 and c-FOS signaling pathways. J Orthop Res. 2015 Oct;33(10):1474-86 |
| 10888 | Zhang L, et al. Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis. Lab Invest. 2015 Jan;95(1):65-77 |
| 10889 | Can Pharm J 97:30 (1964); Food Cosmet Toxicol 4:389 (1966); Neurosci Letts 318:163 (2002); IARC Monographs 16:187 (1978); Int J Integrated Biol 6:6 (2009) |
| 10890 | Moraes, L., et al. Leishmanicidal Activity of (+)-Phyllanthidine and the Phytochemical Profile of Margaritaria nobilis (Phyllanthaceae). Molecules, 2015;20(12), 22157–22169. |
| 10891 | Upton AM, et al. In Vitro and In Vivo Activities of the Nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. |
| 10892 | Tasneen R, et al. Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):129-35. |
| 10893 | Reisman SA, et al. Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney.
 J Am Soc Nephrol. 2012 Aug 2. |
| 10894 | McCullough PA, et al. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl. Drug Des Devel Ther. 2012;6:141-9. |
| 10895 | Sieber-Ruckstuhl NS, et al. Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism. J Vet Intern Med. 2019 May;33(3):1266-1271. |
| 10896 | Masticatory Muscle Myositis: Pathogenesis, Diagnosis, and Treatment. |
| 10897 | Cabanillas Stanchi KM, et al. Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma. Cancer Biol Ther. 2015;16(9):1353-63. |
| 10898 | J Med Chem 18:71 (1975); Neurosci Biobehav Rev 16:481 (1992) |
| 10899 | Adv Drug Res 12:247 (1977); Drugs 36:67 (1988) |
| 10900 | Chem Heterocyclic Compounds 31:639 (1995); Chinese J Clinicians 4:920 (2010) |
| 10901 | Li S, et al. Antifungal activity of camptothecin, trifolin, and hyperoside isolated from Camptotheca acuminata. J Agric Food Chem. 2005 Jan 12;53(1):32-7. |
| 10902 | Tetrahedron 21: 3505 (1965) |
| 10903 | Chem Ber 108:2481 (1975); Infection 5:183 (1977); Antimicrob Agents Chemother 20:214 (1981); US Pat 1981, 4 304 856; J Antibiot 35: 921, 1675 (1982) |
| 10904 | Wang X, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther, 2003, 2(11):1085-1092. |
| 10905 | Sattler M, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res, 2003, 63(17), 5462-5469. |
| 10906 | Ma PC, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res, 2005, 65(4), 1479-1488. |
| 10907 | Kihara Y, et al. Lysophospholipid receptors in drug discovery. Exp Cell Res. 2015 May 1;333(2):171-7. |
| 10908 | Glenn Rosen, et al. LPA1 antagonists BMS-986020 and BMS-986234 for idiopathic pulmonary fibrosis: Preclinical evaluation of hepatobiliary homeostasis. European Respiratory Journal. |
| 10909 | Palmer SM, et al. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018 Nov;154(5):1061-1069. |
| 10910 | Adrienne Pena, et al. Autoradiographic evaluation of [18F]BMT-083133, a lysophosphatidic acid receptor 1 (LPA1) radioligand. The jornal of nuclear medicine. |
| 10911 | Parry-Weeks, L.C. and D.W. Holtan, Effect of altrenogest on pregnancy maintenance in unsynchronized equine embryo recipients. J Reprod Fertil Suppl, 1987. 35: p. 433-8. |
| 10912 | Daels, P.F., et al., Persistence of the luteal phase following ovulation during altrenogest treatment in mares. Theriogenology, 1996. 46(5): p. 799-811. |J Anim Sci 49:729 (1979); 52:831 (1981) |
| 10913 | https://clinicaltrials.gov/ct2/show/NCT04360122?term=Levamisole&cond=Covid19&draw=2&rank=2; https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20201124049480N1 |
| 10914 | Cuello F, et al. 
Evidence for direct regulation of myocardial Na+/H+ exchanger isoform 1 phosphorylation and activity by 90-kDa ribosomal S6 kinase (RSK): effects of the novel and specific RSK inhibitor fmk on responses to alpha1-adrenergic stimulation. |
| 10915 | Bain J, et al. 
The selectivity of protein kinase inhibitors: a further update.
 Biochem J. 2007 Dec 15;408(3):297-315. |
| 10916 | Kang S, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007 Sep;12(3):187-9. |
| 10917 | Jang MJ, et al. Saikosaponin D isolated from Bupleurum falcatum inhibits selectin-mediated cell adhesion. Molecules. 2014 Dec 4;19(12):20340-9. |
| 10918 | Liu A, et al. Saikosaponin d protects against acetaminophen-induced hepatotoxicity by inhibiting NF-κB and STAT3 signaling. Chem Biol Interact. 2014 Nov 5;223:80-6. |
| 10919 | Que R, et al. Estrogen receptor-β-dependent effects of saikosaponin‑d on the suppression of oxidative stress-induced rat hepatic stellate cell activation. Int J Mol Med. 2018 Mar;41(3):1357-1364. |
| 10920 | Berthois Y, et al. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2496-500. |
| 10921 | Pick E, et al. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods. 1980;38(1-2):161-70. |
| 10922 | Ito M, et al. Discovery of Novel 1,4-Diacylpiperazines as Selective and Cell-Active eIF4A3 Inhibitors. J Med Chem. 2017 Apr 27;60(8):3335-3351. |
| 10923 | J Pharmacol Exp Ther 58:337 (1936) |
| 10924 | Biochem J 28:828, 1321 (1934); J Colloid Interface Sci 94:131 (1989) |
| 10925 | Wong YL, et al. Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science. 2015 Jun 5;348(6239):1155-60. |
| 10926 | Denu RA, et al. Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res. 2018 Jan 12. |
| 10927 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=BUDESONIDE&cntry=&state=&city=&dist= |
| 10928 | Kunick C, et al. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. |
| 10929 | Rogawski, M.A. and W. Loscher, The neurobiology of antiepileptic drugs. Nat Rev Neurosci, 2004. 5(7): p. 553-64. |
| 10930 | Porter, R.J., et al., Mechanisms of action of antiseizure drugs. Handb Clin Neurol, 2012. 108: p. 663-81. |
| 10931 | Balaji, S., Medical therapy for sudden death. Pediatr Clin North Am, 2004. 51(5): p. 1379-87. |
| 10932 | Michaela Nelson, et al. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. Mol Cancer. 2015 Jan 27;14(1):13. |
| 10933 | Nakanishi Y, et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58. |
| 10934 | Nakanishi Y, et al. Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1. Mol Cancer Ther. 2015 Mar;14(3):704-12. |
| 10935 | Nakanishi Y, et al. ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor. Mol Cancer Ther. 2015 Dec;14(12):2831-9. |
| 10936 | Br. J. Pharmacol. (1974), 51(2), 237-47; Br. J. Pharmacol. Chemother. (1967), 30(1), 155-65; Br. J. Pharmacol. Chemother. (1963), 20, 362-77 |
| 10937 | Coletti A, et al. Fragment-based approach to identify IDO1 inhibitor building blocks. Eur J Med Chem. 2017 Dec 1;141:169-177. |
| 10938 | Mol Pharmacol 6:597 (1970)|Eur J Pharmacol 170: 35 (1989) |
| 10939 | Proc. Natl. Acad. Sci. U. S. A. (1980), 77(5), 2748-52; Biochem. Pharmacol. (1979), 28(17), 2680-2; Cancer Res. (1976), 36(3), 905-16| |
| 10940 | Park H, et al. Nocodazole is a high-affinity ligand for the cancer-related kinases ABL, c-KIT, BRAF, and MEK. ChemMedChem. 2012 Jan 2;7(1):53-6. |
| 10941 | Keliang Xu, et al. Interaction of nocodazole with tubulin isotypes. Drug Development Research 2002 |
| 10942 | Wang YJ, et al. R-41400 potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice. Mol Carcinog. 2002 Aug;34(4):199-210. |
| 10943 | Signoretto E, et al. Nocodazole Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem. 2016;38(1):379-92. |
| 10944 | Zhang JP, et al. Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage. Genome Biol. 2017 Feb 20;18(1):35. |
| 10945 | J Pharmacol.Exp Ther 304:531 (2003); 314:1177 (2005); Anesth Analg 106:1778 (2008) |
| 10946 | Biochem J 27: 727 (1933); Phytochemistry 19: 1573 (1980) |
| 10947 | Bonate et al Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat.Rev.Drug Discov. (2006)5 855. |
| 10948 | Ghanem H, Kantarjian H, Ohanian M, Jabbour E.The Role of Clofarabine in Acute Myeloid Leukemia.Leuk Lymphoma. 2012 Sep 7. |
| 10949 | Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ.Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.Pediatr Blood Cancer. 2012 Aug 8. doi: 10.1002/pbc.24264. |
| 10950 | Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M.Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling.Leuk Res. 2012 Aug 9. |
| 10951 | Aye Y, Brignole EJ, Long MJ, Chittuluru J, Drennan CL, Asturias FJ, Stubbe J.Clofarabine Targets the Large Subunit (α) of Human Ribonucleotide Reductase in Live Cells by Assembly into Persistent Hexamers.Chem Biol. 2012 Jul 27;19(7):799-805. |
| 10952 | Shi X, et al. Anticancer activity of bergenin against cervical cancer cells involves apoptosis, cell cycle arrest, inhibition of cell migration and the STAT3 signalling pathway. Exp Ther Med. 2019 May;17(5):3525-3529. |
| 10953 | Yun J, et al. Bergenin decreases the morphine-induced physical dependence via antioxidative activity in mice. Arch Pharm Res. 2015 Jun;38(6):1248-54. |
| 10954 | de Oliveira CM, et al. Antinociceptive properties of bergenin. J Nat Prod. 2011 Oct 28;74(10):2062-8. |J Ethnopharm 69:79 (2000); 72:469 (2000); 112:401 (2007) |
| 10955 | Bhatnagar AS, et, al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1021-7. |
| 10956 | Mitropoulou TN, et, al. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 2003 Mar 20;104(2):155-60. |
| 10957 | Schieweck K, et, al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):633-6. |
| 10958 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Naproxen+&cntry=&state=&city=&dist=&Search=Search |
| 10959 | J Biol Chem 168: 373 (1947) |
| 10960 | https://clinicaltrials.gov/ct2/show/NCT04351763?term=AMIODARONE&cond=covid&draw=2&rank=1 |
| 10961 | Hohmann AG, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005 Jun 23;435(7045):1108-12. |
| 10962 | King AR, et al. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol. 2007 Dec;14(12):1357-65. |
| 10963 | Duncan M, et al. Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2008 Dec;295(6):G1255-65. |
| 10964 | Guindon J, et al. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol. 2011 Aug;163(7):1464-78. |
| 10965 | Abass K, et al. Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem Biol Interact. 2010 May 14;185(3):163-173. |
| 10966 | Paul E. Hughes, et al. AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models. Cancer Res October 1, 2014 74; 728 |
| 10967 | Cecchi F, et al. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jun;16(6):553-572. |
| 10968 | Boland S, et al. Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorganic & Medicinal Chemistry Letters (2015), 25(18), 4005-4010. |
| 10969 | Harrison BA, et al. Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma. ACS Medicinal Chemistry Letters (2015), 6(1), 84-88. |
| 10970 | Liu C, et al. Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. ACS Med Chem Lett. 2019 Feb 21;10(3):383-388. |
| 10971 | Berger DM, et al. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6519-23. |
| 10972 | J Pharmacol Exp Ther 102:208 (1951); Anal Profiles Drug Subs 10:639 (1981) |
| 10973 | Harvey SC, et al. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem. 1996 Nov;67(5):1953-9. |
| 10974 | Tabbara RI, et al. Nicotine enhances responding for conditioned reinforcement via α4β2 nicotinic acetylcholine receptors in the ventral tegmental area, but not the nucleus accumbens or the prefrontal cortex. Neuropharmacology. 2019 Apr;148:68-76. |
| 10975 | Clementson S, et al. Enantioselective Total Synthesis of (+)-Dihydro-β-erythroidine. J Am Chem Soc. 2019 Jun 5;141(22):8783-8786. |
| 10976 | Wang Y, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001 Nov 15;61(22):8211-7. |
| 10977 | Mark C de Gooijer, et al. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Invest New Drugs. 2018 Jun;36(3):380-387. |
| 10978 | Hollenbeck CB, et al. An introduction to the nutrition and metabolism of choline. Cent Nerv Syst Agents Med Chem. 2012 Jun;12(2):100-13. |
| 10979 | Corbin KD, et al. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012 Mar;28(2):159-65. |
| 10980 | Shinobu Kuwae, et al. Development of a chemically defined platform fed-batch culture media for monoclonal antibody-producing CHO cell lines with optimized choline content. Cytotechnology. 2018 Jun;70(3):939-948. |
| 10981 | Rebecca C Schugar, et al. Role of choline deficiency in the Fatty liver phenotype of mice fed a low protein, very low carbohydrate ketogenic diet. PLoS One. 2013 Aug 29;8(8):e74806. |
| 10982 | J Biol Chem 160:35 (1945); 166:325 (1946); 171:551 (1947). 178:727 (1949) |
| 10983 | Langston J W, Irwin I. MPTP Neurotoxicity: An Overview and Characterization of Phases of Toxicity. II. Selective Accumulation of MPP in the Substantia Nigra: A Key to Neurotoxicity (Question). Life Sci., 1985, 36, No. 3, 201-12. |
| 10984 | Hsu K S, et al. Potentiation of MPTP by 4-Phenylpyridine on the Neuromuscular Blockade in Mouse Phrenic Nerve-Diaphragm. Neuropharmacology, 1993, 32, No. 9, 877-83. |
| 10985 | Sun XL, et al. Gas1 up-regulation is inducible and contributes to cell apoptosis in reactive astrocytes in the substantia nigra of LPS and MPTP models. J Neuroinflammation. 2016 Jul 8;13(1):180. |
| 10986 | Nature 207:594 (1965); Commun Chem Pathol Pharmacol 9:601 (1974) |
| 10987 | Batson J, et al. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease. ACS Chem Biol. 2017 Mar 17;12(3):825-832. |
| 10988 | Yang Y, et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 2007 Oct 1;67(19):9472-81. |
| 10989 | Kapuria V, et al. Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. Biochem Pharmacol. 2011 Aug 15;82(4):341-9. |
| 10990 | J. Laborde, et al. Synthesis, oxidation potential and anti–mycobacterial activity of isoniazid and analogues: insights into the molecular isoniazid activation mechanism. ChemistrySelect, 1(2), 172–179. |
| 10991 | (1978);J Neurochem 30:1377 (1978); Chirality 7:434 (1995); Epilepsy Res 86:113 (2009)| (1978);J Neurochem 30:1377 (1978); Chirality 7:434 (1995); Epilepsy Res 86:113 (2009) |
| 10992 | Int. Rev. Neurobiol. (2010), 95, 191-205; Naunyn-Schmiedeberg's Arch. Pharmacol. (1992), 346(3), 262-6; Br. J. Pharmacol. (1992), 105(3), 569-74| |
| 10993 | E Nissinen, et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):262-6. |
| 10994 | Shiming Peng, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci Transl Med |
| 10995 | J. Pharmacol. Exp. Ther. (1968), 161(2), 335-41; Epilepsy Res. (1996), 23(1), 15-36; Neurosci. Lett. (1989), 98(1), 74-8 |
| 10996 | Crit. Rev. Toxicol. (1988), 19(2), 87-112; Anesthesiology (1953), 14, 466-72; J. Pharmacol. Exp. Ther. (1953), 108, 488-95 |
| 10997 | J Am Chem Soc 75: 1916 (1953) |
| 10998 | Ber 65:1009 (1932); Int Immunopharmacol 5:219 (2005); Antiviral Res 83:186 (2009) |
| 10999 | Honoré T, et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science. 1988;241(4866):701-703. |
| 11000 | DNQX selectively depolarizes thalamic reticular nucleus (TRN) neurons<sup> |
| 11001 | </sup>. |
| 11002 | Sharp JW, et al. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 1995;687(1-2):114-124. |
| 11003 | J Biol Chem 168:257 (1947); Cancer Letts 278:34 (2009) |
| 11004 | Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415(3):353-65. |
| 11005 | WO2015034820 A1 |
| 11006 | Dedov, V.N., et al. Gingerols: a novel class of vanilloid receptor (VR1) agonists. Br. J. Pharmacol. 137(6), 793-798 (2002). |
| 11007 | Chrubasik, S., et al. Zingiberis rhizoma: A comprehensive review on the ginger effect and efficacy profiles. Phytomedicine 12(9), 684-701 (2005). |
| 11008 | Kao RY, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28(6):600-605. |
| 11009 | Appl. Biochem. Microbiol. (2010), 46(2), 159-165; J. Pharm. Pharmacol. (1959), 11421-6; Nature (1957), 180(4599), 1425-6 |
| 11010 | Thakare VN, et al. Attenuation of acute restraint stress-induced depressive like behavior and hippocampal alterations with protocatechuic acid treatment in mice. Metab Brain Dis. 2016 Oct 26 |
| 11011 | Adefegha SA, et al. Alterations of Na+/K+-ATPase, cholinergic and antioxidant enzymes activity by protocatechuic acid in cadmium-induced neurotoxicity and oxidative stress in Wistar rats. Biomed Pharmacother. 2016 Oct;83:559-568 |
| 11012 | Hornedo-Ortega R, et al. Protocatechuic Acid: Inhibition of Fibril Formation, Destabilization of Preformed Fibrils of Amyloid-β and α-Synuclein, and Neuroprotection. J Agric Food Chem. 2016 Oct 10. |
| 11013 | Haselmayer P, et al. Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Front Immunol. 2014 May 22;5:233. |
| 11014 | Acta Anatomica 110:113 (1981) |
| 11015 | Wang SC, et al. An ERRbeta/gamma agonist modulates GRalpha expression, and glucocorticoid responsive gene expression in skeletal muscle cells. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):146-52. |
| 11016 | Rangwala SM, et al. Estrogen-related receptor gamma is a key regulator of muscle mitochondrial activity and oxidative capacity. J Biol Chem. 2010 Jul 16;285(29):22619-29. |
| 11017 | Cal West Med 37:405 (1932); J Pharmacol. Exper Ther 45:273 (1932). |
| 11018 | Sari Y, et al. Neuroimmunophilin GPI-1046 reduces ethanol consumption in part through activation of GLT1 in alcohol-preferring rats. Neuroscience. 2012 Dec 27;227:327-35. |
| 11019 | Eberling JL, et al. The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp Neurol. 2002 Dec;178(2):236-42. |
| 11020 | Scott Letendre, et al. Neurologic Complications of HIV Disease and Their Treatment. Top HIV Med. Apr-May 2007;15(2):32-9. |
| 11021 | Toxicol. Appl. Pharmacol. (1971), 20(4), 522-37; Steroids (1965), 5(5), 615-35; J. Am. Chem. Soc. (1959), 81, 4573-4| |
| 11022 | Kahanek, N., C. Gelbard, and A. Hebert, Desonide: a review of formulations, efficacy and safety. Expert Opin Investig Drugs, 2008. 17(7): p. 1097-104. |
| 11023 | Castanedo-Cazares, J.P., et al., Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol, 2013. 6: p. 29-36. |
| 11024 | Parish, D. and N. Scheinfeld, Desonide foam: a review. Drugs Today (Barc), 2008. 44(1): p. 55-62. |
| 11025 | He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002 Feb;42(2):199-209. |
| 11026 | Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Mol Pain. 2015 Aug 28;11:51. |
| 11027 | J Clin Pharmacol 4: 86, 288 (1964); Psychosomatics 1965 6:1 (1965); Biochem Pharmacol 15:1309 (1966) |
| 11028 | Marc Verleye, et al. Effects of etifoxine on ligand binding to GABA(A) receptors in rodents. Neurosci Res. 2002 Oct;44(2):167-72. |
| 11029 | Alain Hamon, et al. The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology. 2003 Sep;45(3):293-303. |
| 11030 | Marc Verleye, et al. Differential effects of etifoxine on anxiety-like behaviour and convulsions in BALB/cByJ and C57BL/6J mice: any relation to overexpression of central GABAA receptor beta2 subunits? Eur Neuropsychopharmacol. 2011 Jun;21(6):457-70. |
| 11031 | Kazuyuki Kuramoto, et al. Development of a Potent and Orally Active Activator of Adenosine Monophosphate-Activated Protein Kinase (AMPK), ASP4132, as a Clinical Candidate for the Treatment of Human Cancer. Bioorg Med Chem. 2020 Mar 1;28(5):115307. |
| 11032 | Hovinga CA, et al. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy. 2001 Nov;21(11):1375-88. |
| 11033 | Royer I, et al. Paclitaxel metabolites in human plasma and urine: identification of 6 alpha-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom. 1995;9(6):495-502. |
| 11034 | Ringel I, et al. Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J Pharmacol Exp Ther. 1987 Aug;242(2):692-8. |
| 11035 | Yuen E, et al. Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects. Cancer Chemother Pharmacol. 2019 Mar;83(3):483-492. |
| 11036 | Mäemets-Allas K, et al. The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells. Biochem Biophys Res Commun. 2016 May 20;474(1):118-125. |
| 11037 | Bhagat TD, et al. Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. J Biol Chem. 2017 Jan 20;292(3):837-846. |
| 11038 | Mark H. Bender, et al. Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer. Experimental and Molecular Therapeutics. 2013. |
| 11039 | Tetrahedron 21: 2683 (1965) |
| 11040 | Med Pharmacol Exp 15:545 (1966): J Pharm Pharmacol 55:1379 (2003) |
| 11041 | Gao Y, et al. Suppressive effects of irisflorentin on LPS-induced inflammatory responses in RAW 264.7 macrophages. Exp Biol Med (Maywood). 2014 Aug;239(8):1018-1024. |
| 11042 | Siwinska J, et al. Identification of QTLs affecting scopolin and scopoletin biosynthesis in Arabidopsisthaliana. BMC Plant Biol. 2014 Oct 18;14:280. |
| 11043 | Yoo A, et al. Scopolin ameliorates high-fat diet induced hepatic steatosis in mice: potential involvement of SIRT1-mediated signaling cascades in the liver. Sci Rep. 2017 May 22;7(1):2251. |
| 11044 | Timmermann DB, et al. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307. |
| 11045 | J Nat Prod 45:105 (1982) |
| 11046 | Bull Soc Chim Belg 40:385 (1931); J Org Chem 43:3749 (1977) |
| 11047 | Sijbesma H, et al. Eltoprazine, a drug which reduces aggressive behaviour, binds selectively to 5-HT1 receptor sites in the rat brain: an autoradiographic study. Eur J Pharmacol. 1990 Feb 20;177(1-2):55-66. |
| 11048 | Joels M, et al. Eltoprazine suppresses hyperpolarizing responses to serotonin in rat hippocampus. J Pharmacol Exp Ther. 1990 Apr;253(1):284-9. |
| 11049 | Bezard E, et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord. 2013 Jul;28(8):1088-96. |
| 11050 | Rocha B, et al. Chronic mianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels. Eur J Pharmacol. 1994 Sep 1;262(1-2):125-31. |
| 11051 | Burdan F, et al. Formation of the knee joint after prenatal propyphenazone (isopropylantipyrine) administration. Cells Tissues Organs. 2002;171(2-3):145-51. |
| 11052 | Rybak MJ, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. |
| 11053 | Lin AH, et al. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997 Oct;41(10):2127-31. |
| 11054 | Zhou CC, et al. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother. 2002 Mar;46(3):625-9. |
| 11055 | Yuji Nagai, et al. Deschloroclozapine: a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. bioRxiv. |
| 11056 | Anesth Analag 95:1611 (2002); 96:1010 (2003) |
| 11057 | Phytochemistry 29:283 (1990) |
| 11058 | Seely KA, et al. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct;63(5):905-15. |
| 11059 | Zhang B, et al. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. Cell. 2019 Jan 24;176(3):636-648.e13. |
| 11060 | Erdozain, A. M. et al. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain Biochemical Pharmacology (2012), 83(2), 260-268. |
| 11061 | Erdozain, A. M. et al. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain Biochemical Pharmacology (2012), 83(2), 260-268. |
| 11062 | Pratt SE, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013 Mar 1;19(5):1159-68. |
| 11063 | Francia G, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar;11(3):680-9. |
| 11064 | Jialei Sun, et al. Drug Repurposing of Pyrimidine Analogs as Potent Antiviral Compounds Against Human Enterovirus A71 Infection With Potential Clinical Applications. Sci Rep. 2020 May 18;10(1):8159. |
| 11065 | Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435. |
| 11066 | Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232. |
| 11067 | Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-8. |
| 11068 | Mohammed I, et al. SAR and Lead Optimization of an HIV-1 Vif-APOBEC3G Axis Inhibitor. ACS Med Chem Lett. 2012 Jun 14;3(6):465-469. |
| 11069 | Nathans R, et al. Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol. 2008 Oct;26(10):1187-92. |
| 11070 | Jiang M, et al. Evaluation of the Antioxidative, Antibacterial, and Anti-Inflammatory Effects of the Aloe Fermentation Supernatant Containing Lactobacillus plantarum HM218749.1. Mediators Inflamm. 2016;2016:2945650. |
| 11071 | Barrantes E, et al. Inhibition of collagenase and metalloproteinases by aloins and aloe gel. Life Sci. 2003 Jan 3;72(7):843-50. |
| 11072 | Clark K, et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated andregulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91. |
| 11073 | Sundberg TB, et al. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12468-73. |
| 11074 | Patel K, et al.The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. Nat Commun. 2014 Aug 4;5:4535. |
| 11075 | Kast R, et al. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol. 2007 Dec;152(7):1070-80. Epub 2007 Oct 15. |
| 11076 | Almahariq M, et al. A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol Pharmacol. 2013 Jan;83(1):122-8. |
| 11077 | Gong B, et al. Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses. Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19615-20. |
| 11078 | Prahbha N. Ibrahim, et al. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors. WO2007002325A1. |
| 11079 | Martin Hennenberg, et al. Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases. Front Physiol. 2018 Jun 15;9:734. |
| 11080 | Campbell McInnes, et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov;2(11):608-17. |
| 11081 | J Clin Invest 57:1644 (1976); J Clin Endocrin Metab 78:114 (1994) ; Exp Physiol 91.:977 (2006)| |
| 11082 | Smith AJ, et al. Characterisation of CCKB receptors on GH3 pituitary cells: receptor activation is linked to Ca2+ mobilisation. Eur J Pharmacol. 1994 Apr 15;267(2):215-23. |
| 11083 | Tanaka S, et al. Pentagastrin gastroprotection against acid is related to H2 receptor activation but not acid secretion. Gut. 1998 Sep;43(3):334-41. |
| 11084 | Chem. Pharm. Bull. (1969), 17(10), 2000-7; J. Med. Chem. (1968), 11(2), 228-32| |
| 11085 | Yang F, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J. 2016;16(1):83-87. |
| 11086 | Abbate F, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. J Enzyme Inhib Med Chem. 2003;18(4):303-308. |
| 11087 | Sylvest L, et al. Phosphatase inhibitors with anti-angiogenic effect in vitro. APMIS. 2010 Jan;118(1):49-59. |
| 11088 | King AR, et al. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol. 2009 Oct 30;16(10):1045-52. |
| 11089 | Deng Q, et al. Pristimerin inhibits angiogenesis in adjuvant-induced arthritic rats by suppressing VEGFR2 signaling pathways. Int Immunopharmacol. 2015 Dec;29(2):302-13. |
| 11090 | Cho YL, et al. Specific activation of insulin-like growth factor-1 receptor by ginsenoside Rg5 promotes angiogenesis and vasorelaxation. J Biol Chem. 2015 Jan 2;290(1):467-77. |
| 11091 | Li W, et al. Ginsenoside Rg5 Ameliorates Cisplatin-Induced Nephrotoxicity in Mice through Inhibition of Inflammation, Oxidative Stress, and Apoptosis. Nutrients. 2016 Sep 13;8(9). pii: E566. |
| 11092 | Kim SJ, et al. Anti-breast cancer activity of Fine Black ginseng (Panax ginseng Meyer) and ginsenoside Rg5. J Ginseng Res. 2015 Apr;39(2):125-34. |
| 11093 | J Pharmacol Exp Ther 80:233 (1944) |
| 11094 | Actis ML, et al. Identification of the first small-molecule inhibitor of the REV7 DNA repair protein interaction. Bioorg Med Chem. 2016 Sep 15;24(18):4339-4346. |
| 11095 | Stauffer AT, et al. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem. 2002 Jul 19;277(29):26286-92 |
| 11096 | Casaburi I, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle. 2012 Jul 15;11(14):2699-710 |
| 11097 | Kawabe Y, et al. The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells. Biochem Biophys Res Commun. 1995 Mar 8;208(1):405-11. |
| 11098 | Ao M, et al. Chenodeoxycholic acid stimulates Cl(-) secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. Am J Physiol Cell Physiol. 2013 Aug 15;305(4):C447-56 |
| 11099 | Noh K, et al. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β. Drug Metab |
| 11100 | Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. |
| 11101 | Chem & Ind 1965: 562 |
| 11102 | Eur J Biochem 74:19 (1977); J Clin Invest 63:1172 (1979) |
| 11103 | MACLEOD AJ, et al. LINCOMYCIN: A NEW ANTIBIOTIC ACTIVE AGAINST STAPHYLOCOCCI AND OTHER GRAM-POSITIVE COCCI: CLINICAL AND LABORATORY STUDIES. Can Med Assoc J. 1964 Nov 14;91:1056-60. |
| 11104 | Lin AH, et al. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997 Oct;41(10):2127-31. |
| 11105 | P R McMaster, et al. The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice. Am J Trop Med Hyg. 1973 Jan;22(1):14-7. |
| 11106 | De Sarro G, et al. Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. Eur J Pharmacol. 1999 Mar 5;368(2-3):149-59. |
| 11107 | Rizzo M, et al. Determination of new 2,3-benzodiazepines in rat plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1999 Aug 20;731(2):207-15. |
| 11108 | Stepulak A, et al. AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther. 2007 Dec;6(12):1908-15. |
| 11109 | Park JS, et al. Role of spinal cord alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in complete Freund's adjuvant-induced inflammatory pain. Mol Pain. 2008 Dec 30;4:67. |
| 11110 | R L Mellgren, et al. Inhibition of growth of human TE2 and C-33A cells by the cell-permeant calpain inhibitor benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone. Exp Cell Res. 1994 Nov;215(1):164-71. |
| 11111 | L Björck, et al. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol |
| 11112 | Laura Riva, et al.A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. bioRxiv. 2020 Apr 17;2020.04.16.044016. |
| 11113 | Bhide RS, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem, 2006, 49 (7), 2143-2146. |
| 11114 | Huynh H, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 2008, |
| 11115 | Nakamura I, et al. Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLoS One. 2015 Nov 3;10(11):e0142355. |
| 11116 | Chen Z, et al. Anti-tumor effects of bakuchiol, an analogue of resveratrol, on human lung adenocarcinoma A549 cell line. Eur J Pharmacol. 2010 Sep 25;643(2-3):170-9. |
| 11117 | Xu Y, et al. In vitro evidence for bakuchiol's influence towards drug metabolism through inhibition of UDP-glucuronosyltransferase (UGT) 2B7. Afr Health Sci. 2014 Sep;14(3):564-9. |
| 11118 | Li YG, et al. Fructus Psoraleae contains natural compounds with potent inhibitory effects towards human carboxylesterase 2. Fitoterapia. 2015 Jan 13;101C:99-106. |
| 11119 | Lau KM, et al. Anti-dermatophytic activity of bakuchiol: in vitro mechanistic studies and in vivo tinea pedis-inhibiting activity in a guinea pig model. Phytomedicine. 2014 Jun 15;21(7):942-5. |
| 11120 | Wang M, et al. The first synthesis of [11C]J147, a new potential PET agent for imaging of Alzheimer's disease. Bioorg Med Chem Lett. 2013 Jan 15;23(2):524-7. |
| 11121 | Chen Q, et al. A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease. PLoS One. 2011;6(12):e27865. |
| 11122 | Prior M, et al. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement. 2016 Jun;12(6):678-86. |
| 11123 | Prior M, et al. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther. 2013 May 14;5(3):25. |
| 11124 | Liu M, et al. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. |
| 11125 | Arzneim Forsch 15:1441 (1965); Chemotherapy 14:195 (1969) |
| 11126 | Frampton CS, et al. Two polymorphic forms of the oxathiin systemic fungicide active carboxine. Acta Crystallogr E Crystallogr Commun. 2018 Nov 9;74(Pt 12):1741-1745. |
| 11127 | G.A.White, et al. Oxathiin carboxamides highly active against carboxin-resistant succinic dehydrogenase complexes from carboxin-selected mutants of <i>Ustilago maydis</i> and <i>Aspergillus nidulans</i>. Pestic Biochem Physiol. 1978 Oct;9(2):165-182. |
| 11128 | Schallreuter KU, et al. Cytotoxicity of 6-biopterin to human melanocytes. Biochem Biophys Res Commun. 1994 Oct 14;204(1):43-8. |
| 11129 | Yang G, et al. Hydroxysafflor yellow A inhibits lipopolysaccharide-induced proliferation and migration of vascular smooth muscle cells via Toll-like receptor-4 pathway. Int J Clin Exp Med. 2015 Apr 15;8(4):5295-302. |
| 11130 | Zhu HJ, et al. Hydroxysafflor yellow A (HYSA) inhibited the proliferation and differentiation of 3T3-L1 preadipocytes. Cytotechnology. 2015 Mar 7. |
| 11131 | He Y, et al. Protective effects of hydroxysafflor yellow A (HSYA) on alcohol-induced liver injury in rats. J Physiol Biochem. 2015 Mar;71(1):69-78. |
| 11132 | Jin M, et al. Hydroxysafflor yellow A attenuate lipopolysaccharide-induced endothelium inflammatory injury. Chin J Integr Med. 2015 May 27. |
| 11133 | Wang Y, et al. A cyclic AMP analog, 8-Br-cAMP, enhances the induction of pluripotency in human fibroblast cells. Stem Cell Rev. 2011 Jun;7(2):331-41. |
| 11134 | J Vet Diag Invest 5:541 (1993); Vet Rec 137:483 (1995) |
| 11135 | Dr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829. |
| 11136 | Ashvinikumar V. Gavai, et al. Abstract 1643: BMS-983970, an oral pan-Notch inhibitor for the treatment of cancer. Cancer Res October 1, 2014 74; 1643. |
| 11137 | Lee S, et al. Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by <i>Cryptosporidium hominis</i>. Antimicrob Agents Chemother. 2018 Jun 26;62(7). |
| 11138 | Chetty N, et al. Effects of the novel 5-HT3 agonist MKC-733 on the rat, mouse and guinea pig digestive tract. Pharmacology. 2008;81(2):104-9. Epub 2007 Oct 19. |
| 11139 | Coleman NS, et al. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther. 2003 Nov 15;18(10):1039-48. |
| 11140 | Wang J, et al. Baseline Sensitivity of Fusarium virguliforme to Fluopyram Fungicide. Plant Dis. 2017 Apr;101(4):576-582. |
| 11141 | Min-Zhu Huang, et al. Therapeutic effects of acetylspiramycin and garlicin on cryptosporidiosis among drug users. Int J Parasitol Drugs Drug Resist |
| 11142 | Acetylspiramycin |
| 11143 | Lemaire S, et al. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. |
| 11144 | Locke JB, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.
 Antimicrob Agents Chemother. 2010 Dec;54(12):5337-43. |
| 11145 | Qiong Zhang, et al. Discovery of EGFR Selective 4,6-disubstituted Pyrimidines From a Combinatorial Kinase-Directed Heterocycle Library. J Am Chem Soc. 2006 Feb 22;128(7):2182-3. |
| 11146 | Zhiwei Yu, et al. Novel Irreversible EGFR Tyrosine Kinase Inhibitor 324674 Sensitizes Human Colon Carcinoma HT29 and SW480 Cells to Apoptosis by Blocking the EGFR Pathway. Biochem Biophys Res Commun. 2011 Aug 12;411(4):751-6. |
| 11147 | Lee JS, et al. Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling. J Clin Biochem Nutr. 2012 Sep;51(2):77-83. |
| 11148 | Krishna S, et al. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br J Clin Pharmacol. 1993 Dec;36(6):585-91. |
| 11149 | Tie, H., et al., Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br. J. Pharmacol. 130, 1967-1975, (2000) Traebert. |
| 11150 | Puyang X, et al. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. Cancer Discov. 2018 Sep;8(9):1176-1193. |
| 11151 | Hao S, et al. Effects of Resibufogenin and Cinobufagin on voltage-gated potassium channels in primary cultures of rat hippocampal neurons. Toxicol In Vitro. 2011 Dec;25(8):1644-53. |
| 11152 | Uddin MN, et al. Resibufogenin administration prevents oxidative stress in a rat model of human preeclampsia. Hypertens Pregnancy. 2012;31(1):70-8. |
| 11153 | Ichikawa M, et al. Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells. PLoS One. 2015 Jun 29;10(6):e0129851. |
| 11154 | Hao S, et al. Effects of resibufogenin on voltage-gated sodium channels in cultured rat hippocampal neurons. Neurosci Lett. 2011 Aug 26;501(2):112-6. |
| 11155 | Zheng J, et al. Novel microbial transformation of resibufogenin by Absidia coerules. Nat Prod Commun. 2011 Nov;6(11):1581-4. |
| 11156 | Xin XL, et al. Novel microbial transformation of resibufogenin by Fusarium solani. J Asian Nat Prod Res. 2011 Sep;13(9):831-7. |
| 11157 | Su HP , et al. Structural characterization of nonactive site, TrkA-selective kinase inhibitors. Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):E297-E306. |
| 11158 | Carver J, et al. A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. PLoS One. 2014 Aug 5;9(8):e103836. |
| 11159 | Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. |
| 11160 | van der Schaar HM, et al. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ. Antimicrob Agents Chemother. 2013 Oct;57(10):4971-81. |
| 11161 | V Saarnio. Antiviral Molecules of Enteroviruses. 13.1.2017. |
| 11162 | Cardama GA, et al. Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med Chem. 2014;14(6):840-51. |
| 11163 | Nazareno González, et al. Computational and in vitro Pharmacodynamics Characterization of 1A-116 Rac1 Inhibitor: Relevance of Trp56 in Its Biological Activity. Front Cell Dev Biol. 2020 Apr 15;8:240. |
| 11164 | JACS 58:572 (1936); Indian J Chem 6:681 (1968); Fitoterapia 1990:387 |
| 11165 | Stocker JW, et al. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003 Mar 15;101(6):2412-8. |
| 11166 | Van Der Velden J, et al. K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. PLoS One. 2013 Jun 24;8(6):e66886. |
| 11167 | Mamouei Z, et al. Alexidine Dihydrochloride Has Broad-Spectrum Activities against Diverse Fungal Pathogens. mSphere. 2018 Oct 31;3(5). pii: e00539-18. |
| 11168 | Dig Dis Sci 28:609 (1983); Drugs 56:83:1998 |
| 11169 | Tchilibon S, et al. Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg Med Chem. 2004 May 1;12(9):2021-34. |
| 11170 | James Elliott Bradner, et al. Male contraceptive compositions and methods of use. Patent WO 2011143657 A1. |
| 11171 | Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. |
| 11172 | Sakamaki JI, et al. Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and LysosomalFunction. Mol Cell. 2017 May 18;66(4):517-532.e9. |
| 11173 | Prog Clin Biol Res 97:373 (1982); Biochem Soc Trans 15:65 (1987) |
| 11174 | Das DS, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov;30(11):2187-2197. |
| 11175 | Cabrales P, et al. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages. Transl Oncol. 2019 Apr;12(4):626-632. |
| 11176 | Yalcin O, et al. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malar J. 2015 May 28;14:218. |
| 11177 | Jochems J, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014 Jan;39(2):389-400. |
| 11178 | Regna NL, et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan;162:58-73. |
| 11179 | Mithraprabhu S, et al. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol. 2013 Aug;162(4):559-62. |
| 11180 | Arzneim-Forsch 37: 1265 (1987) |
| 11181 | https://clinicaltrials.gov/ct2/show/NCT04941131?term=CHLORHEXIDINE&cond=Covid19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04584684?term=CHLORHEXIDINE&cond=Covid19&draw=2&rank=11 https://clinicaltrials.gov/ct2/show/NCT04603794?term=CHLORHEXIDINE&cond=Covid19&draw=2&rank=2 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200527047581N2 https://trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024028 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04723446 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04719208 https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN10197987 https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN95933274 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200527047581N1 https://trialsearch.who.int/Trial2.aspx?TrialID=RBR-10hj7jyn https://trialsearch.who.int/Trial2.aspx?TrialID=RBR-3q6wqdf |
| 11182 | Schermuly RT, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008 Oct;32(4):881-91. |
| 11183 | Schermuly RT, et al. Riociguat for the treatment of pulmonary hypertension.
 Expert Opin Investig Drugs. 2011 Apr;20(4):567-76. |
| 11184 | Donda K, et al. Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth. PLoS One. 2018 Jul 10;13(7):e0199927. |
| 11185 | J Pharm Soc Japan 73: 481 (1953); Experientia 47: 195 (1991); Biochem Pharmacol 47: 2063 (1994) |
| 11186 | J. Pharmacol. Exp. Ther. (1980), 213(3), 504-8; J. Pharmacol. Exp. Ther. (1973), 185(3), 620-32; Br. J. Pharmacol. (1970), 40(2), 219-26 |
| 11187 | Hovhannisyan G, et al. Comparative analysis of individual chromosome involvement in micronuclei induced by bleomycin in human leukocytes. Mol Cytogenet. 2016 Jun 21;9:49. |
| 11188 | Jaaskela-Saari HA, et al. Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997;529:241-4. |
| 11189 | Corboz MR, et al. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 2018 Apr;49:95-103. |
| 11190 | Ling Peng, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 2020 Nov 13;11(11):978. |
| 11191 | Kang Miao, et al. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185. |
| 11192 | Yoshimura C, et al. TAS4464, a highly potent and selective inhibitor of NEDD8 activating enzyme, suppresses neddylation and shows antitumor activity in diverse cancer models. Mol Cancer Ther. 2019 May 15. |
| 11193 | Gao Y, et al. CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 1994;55(3):PL61-5. |
| 11194 | Klotz KN, et al. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91. |
| 11195 | Edling CE, et al. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther. 2014 May;15(5):524-32. |
| 11196 | Gurav SD, et al. Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats. Arzneimittelforschung. 2012 Jan;62(1):27-34. |
| 11197 | J Chem Soc 1969: 2403; Phytochemistry 31: 279 |
| 11198 | Luistro L, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 2009, 69(19), 7672-7680. |
| 11199 | Debeb BG, et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012. |
| 11200 | Huynh C, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One. 2011, 6(9), e25264. |
| 11201 | Eur J Pharmacol 41:153 (1977); J Clin Psychiatry 61:896 (2000); 63:331 (2002) |
| 11202 | Eslavath RK, et al. β-N-oxalyl-L-α, β- diaminopropionic acid induces HRE expression by inhibiting HIF-prolyl hydroxylase-2 in normoxic conditions. Eur J Pharmacol. 2016 Nov 15;791:405-411. |
| 11203 | Jie L, et al. Dencichine ameliorates kidney injury in induced type II diabetic nephropathy via the TGF-β/Smad signalling pathway. Eur J Pharmacol. 2017 Oct 5;812:196-205. |
| 11204 | Halwachs S, et al. Assessment of ABCG2-mediated transport of pesticides across the rabbit placenta barrier using a novel MDCKII in vitro model. Toxicol Appl Pharmacol. 2016 Aug 15;305:66-74. |
| 11205 | Manabe M, et al. Evaluation of the estrogenic activities of some pesticides and their combinations using MtT/Se cell proliferation assay. Int J Hyg Environ Health. 2006 Sep;209(5):413-21. |
| 11206 | J Toxicol Environ Health 7:745 (1981); Can Vet J 35:458 (1994) |
| 11207 | Girotti MR, et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell. 2015 Jan 12;27(1):85-96. |
| 11208 | J Chem Ecol 20:281 (1994); 29:253 (2004); Animal Sci 74:461 (2002); Vet Pathol 40:363 (2003) |
| 11209 | Yiming Zhou, et al. A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models. Science |
| 11210 | Barrett JA, et al. Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma. Cancer Gene Ther. 2018;25(5-6):106-116. |
| 11211 | Chiocca EA, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019;11(505):eaaw5680. |
| 11212 | Zahid Q. Bonday, et al. LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. ACS Med. Chem. Lett., 2018, 9 (7), pp 612-617. |
| 11213 | Neurosci Lett 175:41 (1994); Med hypotheses 77:677 (2011) |
| 11214 | Rescifina A, et al. Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis. Eur J Pharm Sci. 2017 Aug 30;106:94-101. |
| 11215 | Oishi K, et al. Glycerol phenylbutyrate for the chronic management of urea cycle disorders. Expert Rev Endocrinol Metab. 2014 Sep;9(5):427-434. |
| 11216 | J Biol Chem 253:1121 (1978); Atherosclerosis 35:259 (1980)| |
| 11217 | Sugazaki M, Hirotani H, Echigo S, et al. Effects of mevastatin on grafted bone in MRL/MpJ mice. Connect Tissue Res. 2010 Apr;51(2):105-12. |
| 11218 | Evangelopoulos ME, Weis J, Krüttgen A. Mevastatin-induced neurite outgrowth of neuroblastoma cells via activation of EGFR. J Neurosci Res. 2009 Jul;87(9):2138-44. |
| 11219 | Wächtershäuser A, et al. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis. 2001 Jul;22(7):1061-7. |
| 11220 | Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001 Apr;32(4):980-6. |
| 11221 | Eye Ear Nose & Throat 33:351 (1954) |
| 11222 | Helv Chim Acta 40: 1242 (1957); J Chem Soc 1961: 1625; 1970: 235; J Food Sci 36: 861 (1971); Antioxid Redox signal |
| 11223 | Arch Biochem Biophys 316:290 (1995); Eur J Pharmacol 262:179 (1995) |
| 11224 | Flatt B, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009 Feb 26;52(4):904-7. |
| 11225 | Evans MJ, et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52. |
| 11226 | Hartman HB, et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res. 2009 Jun;50(6):1090-100. |
| 11227 | Liu T, et al. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2016 Jan;11(1):182-188. |
| 11228 | Pomonis JD, et al. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003 Jul;306(1):387-93. |
| 11229 | Valenzano KJ, et al. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. J Pharmacol Exp Ther. 2003 Jul;306(1):377-86. |
| 11230 | J Biol Chem 281:5877 (2006) |
| 11231 | Goldstein EJ et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms.
 Antimicrob Agents Chemother. 2013 May;57(5):2401-4. |
| 11232 | O'Dwyer K et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment ofcomplicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. |
| 11233 | Poce G, et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One. 2013;8(2):e56980. |
| 11234 | Poce G, et al. Pharmaceutical salt of BM635 with improved bioavailability. Eur J Pharm Sci. 2017 Mar 1;99:17-23. |
| 11235 | Wada Y, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109(3):1156-64. |
| 11236 | Keino H, et al. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122. |
| 11237 | Baldoni D, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014 Mar;69(3):706-14. |
| 11238 | Chilton CH, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014 Mar;69(3):697-705. |
| 11239 | Semmler J, et, al. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol. 1993 Apr;15(3):409-13. |
| 11240 | Wachtel H. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J Pharm Pharmacol. 1983 Jul;35(7):440-4. |
| 11241 | Ortmann R, et, al. Rolipram forms a potent discriminative stimulus in drug discrimination experiments in rats. Psychopharmacology (Berl). 1986;89(3):273-7. |
| 11242 | PCT Int. Appl. (2015), WO 2015165833 A1 20151105. |
| 11243 | U.S. Pat. Appl. Publ. (2016), US 20160081983 A1 20160324. |
| 11244 | Lucas-Hourani M, et al. Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).J Med Chem. 2015 Jul 23;58(14):5579-98. |
| 11245 | Wenyi S, et, al. JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification. Cancer Res. 2015 Nov 15; 75(22): 4923-36. |
| 11246 | Martin MW, et al. Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN). Bioorg Med Chem Lett. 2019 Apr 15;29(8):1001-1006. |
| 11247 | US pat 2941924 (1960) |
| 11248 | Phytpchemistry 15:572 (1976); 19:203 (1980) |
| 11249 | Drugs (1996), 52(Suppl. 5), 24-46; Eur. J. Med. Chem. (1974), 9(4), 381-9; Drugs (1974), 8(3), 168-75 |
| 11250 | Cirstea D, et al. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. |
| 11251 | Ber 33:1478 (1900); Proc Indian Acad Sci Sect A 33:112 (1951) |
| 11252 | Wang Y, et al. Natural plant extract tubeimoside I promotes apoptosis-mediated cell death in cultured human hepatoma (HepG2) cells. Biol Pharm Bull. 2011;34(6):831-8. |
| 11253 | Xu Y, et al. Intrinsic apoptotic pathway and G2/M cell cycle arrest involved in tubeimoside I-induced EC109 cell death. Chin J Cancer Res. 2013 Jun;25(3):312-21. |
| 11254 | Wu Q, et al. Tubeimoside-1 attenuates LPS-induced inflammation in RAW 264.7 macrophages and mouse models. Immunopharmacol Immunotoxicol. 2013 Aug;35(4):514-23. |
| 11255 | Liu HZ, et al. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways. Mol Med Rep. 2011 Sep-Oct;4(5):985-92. |
| 11256 | Chen WJ, et al. Tubeimoside-1 induces G2/M phase arrest and apoptosis in SKOV-3 cells through increase of intracellular Ca2+ and caspase-dependent signaling pathways. Int J Oncol. 2012 Feb;40(2):535-43. |
| 11257 | Drugs 53:511 (1997); 64:1465 (2004) |
| 11258 | N Matsubara, et al. In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin. Antimicrob Agents Chemother. 1979 Dec;16(6):731-5. |
| 11259 | Pedro H.Di Rocco, et al. Aerosol treatment with cefoperazone or gentamicin protects granulocytopenic mice from acute Pseudomonas aeruginosa pneumonia. European Journal of Pharmaceutical Sciences Volume 1, Issue 6, June 1994, Pages 285-289. |
| 11260 | Mani T, et al. Small-molecule inhibition of the uPAR•uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem. 2013 Apr 1;21(7):2145-55. |
| 11261 | Boldyrev AA, et al. The histidine-containing dipeptides, carnosine and anserine: distribution, properties and biological significance. Adv Enzyme Regul. 1990;30:175-94. |
| 11262 | Jun Kaneko, et al. Anserine (beta-alanyl-3-methyl-L-histidine) improves neurovascular-unit dysfunction and spatial memory in aged AβPPswe/PSEN1dE9 Alzheimer's-model mice. Sci Rep. 2017 Oct 3;7(1):12571. |
| 11263 | Perera TP, et al. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small molecule FGFR family inhibitor. Mol Cancer Ther. 2017 Mar 24. pii: molcanther.0589.2016. |
| 11264 | Nilvebrant L. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. |
| 11265 | Andersson SH, et al. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs. Drug Metab Dispos. 1998 Jun;26(6):528-35. |
| 11266 | Cappon GD, et al. Tolterodine does not affect memory assessed by passive-avoidance response test in mice. Eur J Pharmacol. 2008 Jan 28;579(1-3):225-8. |
| 11267 | Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29; 450(7170): 712–716. |
| 11268 | Chini CC, et al. SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res. 2016 May 15;22(10):2496-507. |
| 11269 | J Chem Soc 1955: 1025; Life Sci 25: 1273 (1979); Trends Pharmacol Sci 11: 330 (1990) |
| 11270 | Zhang W, et al. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem. 2013 Dec 12;56(23):9693-700. |
| 11271 | Rentsch G, et al. The effect of prolonged administration of allylisopropylacetylurea to rats on cytochrome P-450 and other liver haemoproteins. Xenobiotica. 1976 Mar;6(3):151-7. |
| 11272 | Fujimoto Y, et al. Fixed drug eruption due to allylisopropylacetylurea. Contact Dermatitis. 1993 May;28(5):282-4. |
| 11273 | Shen MC et al. Dietary stearic acid leads to a reduction of visceral adipose tissue in athymic nude mice. PLoS One. 2014 Sep 15;9(9):e104083. |
| 11274 | Jpn J Pharmacol 71: 129 (1996); Jpn Pharmacol Ther 25:822 (1997) |
| 11275 | Lauth M, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60. |
| 11276 | Joo J, et al. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One. 2009 Oct 27;4(10):e7608. |
| 11277 | Zhang R, et al. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamineand norepinephrine levels in rats. PLoS One. 2014 Mar 10;9(3):e91775. |
| 11278 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=CARVEDILOL&cond=covid&draw=2&rank=4 |
| 11279 | Arch Pharm 293:957 (1960)| |
| 11280 | Thoma K, et al. The photostability of antimycotics. 3. Photostability of locally acting antimycotics. Pharmazie. 1997 May;52(5):362-73. |
| 11281 | Hänel H, et al. Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics. Ann N Y Acad Sci. 1988;544:329-37. |
| 11282 | Osakada F, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci. 2009 Sep 1;122(Pt 17):3169-79. |
| 11283 | Mark G. Frattini, et al. Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo. Blood (2008) 112 (11): 2668. |
| 11284 | Chijiwa T, et al. A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. J Biol Chem. 1989 Mar 25;264(9):4924-7. |
| 11285 | Rena G, et al. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004 Jan;5(1):60-5. |
| 11286 | J Chem Soc 119:423 (1921); J Chinese Chem Soc 7:29 (1939) |
| 11287 | Hennan JK, et al. Effect of Tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost. 2008 Sep;6(9):1558-64. |
| 11288 | Gomes-Giacoia E, et al. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther. 2013 Dec;12(12):2697-708. |
| 11289 | Hennan JK, et al. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther. 2005 Aug;314(2): |
| 11290 | Helv Chim Acta 35: 1318 (1952)| |
| 11291 | Crommentuijn MH, et al. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol. 2015 Dec 11. pii: S1574-7891(15)00226-4. |
| 11292 | Cheung YY, et al. Antiviral activity of lanatoside C against dengue virus infection. Antiviral Res. 2014 Nov;111:93-99. |
| 11293 | Chan, Ho Man, et al. TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF. US20160176882 A1. |
| 11294 | Huang D, et al. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2. Chemphyschem. 2020 Feb 4;21(3):263-271. |
| 11295 | Chem Rev 12: 181 (1933) |
| 11296 | Anal Profiles Drug Subs 9:1 (1970) |
| 11297 | J Neurol Neurosurgery Psychiatry 48:1297 (1985); Dis Colon Rectum 33:867 (1989) |
| 11298 | Yue P,et al. Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res. 2016 Feb 1;76(3):652-63. |
| 11299 | Huchting J, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5. |
| 11300 | Furuta Y, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102. |
| 11301 | Park SJ, Park YJ, Shin JH, et al. A receptor tyrosine kinase inhibitor, Tyrphostin A9 induces cancer cell death through Drp1 dependent mitochondria fragmentation. Biochem Biophys Res Commun. 2011 May 13;408(3):465-70. |
| 11302 | Richard F. Loeser, Christopher B. Forsyth, Allen M. Samarel et al. Fibronectin Fragment Activation of Proline-rich Tyrosine Kinase PYK2 Mediates Integrin Signals Regulating Collagenase-3 Expression by Human Chondrocytes through a Protein Kinase C-dependent Pathway. The Journal of Biological Chemistry, 2003, 278, 24577-24585. |
| 11303 | Michele Fuortes, Maxine Melchior, Hyunsil Han, et al. Role of the tyrosine kinase pyk2 in the integrin-dependent activation of human neutrophils by TNF. J Clin Invest. 1999;104(3):327-335. |
| 11304 | Johan Thyberg . Tyrphostin A9 and wortmannin perturb the Golgi complex and block proliferation of vascular smooth muscle cells. European Journal of Cell Biology.1998,76(1): 33-42 |
| 11305 | R Marhaba, F Mary, C Pelassy, et al. Tyrphostin A9 inhibits calcium release-dependent phosphorylations and calcium entry via calcium release-activated channel in Jurkat T cells. The Journal of Immunology. 1996,157 (4): 1468-1473 |
| 11306 | Kumar N, et al. Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication. J Virol. 2011 Mar;85(6):2818-2 |
| 11307 | Cotelle P.,3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.,Expert Opin Ther Pat. 2011 Nov;21(11):1799-804. |
| 11308 | Al-Mawsawi LQ, Al-Safi RI, Neamati N.,Anti-infectives: clinical progress of HIV-1 integrase inhibitors.,Expert Opin Emerg Drugs. 2008 Jun;13(2):213-25. |
| 11309 | Dayam R, Al-Mawsawi LQ, Neamati N.,HIV-1 integrase inhibitors: an emerging clinical reality.,Drugs R D. 2007;8(3):155-68. |
| 11310 | Dicker IB, et al. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem. 2007 Oct 26;282(43):31186-96. |
| 11311 | Pavey GJ, et al. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model. Bone. 2016 Sep;90:159-67. |
| 11312 | Chakkalakal SA, et al. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation. J Bone Miner Res. 2016 Sep;31(9):1666-75. |
| 11313 | Lees-Shepard JB, et al. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. Elife. 2018 Sep 18;7. pii: e40814. |
| 11314 | Zhang BP, et al. Mangiferin activates Nrf2-antioxidant response element signaling without reducing the sensitivity to etoposide of human myeloid leukemia cells in vitro. Acta Pharmacol Sin. 2014 Feb;35(2):257-66. |
| 11315 | Dilshara MG, et al. Mangiferin inhibits tumor necrosis factor-α-induced matrix metalloproteinase-9 expression and cellular invasion by suppressing nuclear factor-κB activity. BMB Rep. 2015 Oct;48(10):559-64. |J Chem Soc (C) 1966:1685; Phytochemistry 6:741, 1597 (1967); Tetrahedron 23:1363 (1967); Pharm Res 3:307 (1986); Naturwissenschaften 59:651 (1972) |
| 11316 | Stenton GR, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol. 2013 Mar;168(6):1506-18. |
| 11317 | Cross J, et al. AQX-1125, small molecule SHIP1 activator inhibits NSC-125066-induced pulmonary fibrosis. Br J Pharmacol. 2017 Sep;174(18):3045-3057. |
| 11318 | T. Stühmer et al. A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition ).Vol 26, No 15S (May 20 Supplement), 2008: 14694 |
| 11319 | Chargari C, Leteur C, Angevin E, Bashir T, Schoentjes B, Arts J, Janicot M, Bourhis J, Deutsch E.Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.Cancer Lett. 2011 Dec 22;312(2):209-18. |
| 11320 | Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ.Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer. 2012 Aug;59(2):329-32. |
| 11321 | Tabernero J, Dirix L, Sch?ffski P, Cervantes A, Lopez-Martin JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z, Knoblauch R, Zhuang SH.A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.Clin Cancer Res. 2011 Oct 1;17(19):6313-21. Epub 2011 Aug 10. |
| 11322 | Kojima K, Burks JK, Arts J, Andreeff M.The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.Mol Cancer Ther. 2010 Sep;9(9):2545-57. Epub 2010 Aug 24. |
| 11323 | Li M, et al. Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. Neurosci Lett. 2016 Dec 20. pii: S0304-3940(16)30994- |
| 11324 | He CS, et al. Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3. Cell Physiol Biochem. 2016;40(5):1221-1229. Epub 2016 Dec 14. |
| 11325 | Liu L, et al. [Protective effect of astragaloside IV against acute liver failure in experimental mice]. Zhonghua Gan Zang Bing Za Zhi. 2016 Oct 20;24(10):772-777 |
| 11326 | Jiang K, et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2016 Dec 5;42:195-20 |Chem Pharm Bull 31:689, 698, 709, 716 (1983); Planta Med 72:621 (2006); Molecules 16:3896 (2011) |
| 11327 | Phytochemistry 12:193 (1973); J Med Chem 33:147 (1990) |
| 11328 | Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4599-604. |
| 11329 | Kreuz S, et al. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol Cancer. 2015 Dec 8;14:205. |
| 11330 | Harada M, et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015 Nov 10;6(35):37930-47. |
| 11331 | Liu H, et al. Fructus Gardenia (Gardenia jasminoides J. Ellis) phytochemistry, pharmacology ofcardiovascular, and safety with the perspective of new drugs development. J Asian Nat Prod Res. 2013;15(1):94-110. |
| 11332 | Li F, et al. Geniposide attenuates inflammatory response by suppressing P2Y14 receptor and downstream ERK1/2 signaling pathway in oxygen and glucose deprivation-induced brain microvascular endothelial cells. J Ethnopharmacol. 2016 Jun 5;185:77-86. |
| 11333 | Wu SY, et al. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol Sin. 2009 Feb;30(2):202-8. |
| 11334 | Wang J, et al. Geniposide protects against acute alcohol-induced liver injury in mice via up-regulating the expression of the main antioxidant enzymes. Can J Physiol Pharmacol. 2015 Apr;93(4):261-7. |
| 11335 | Gazz Med Ital 131:251, 265 (1972); Lancet 1:68 (1980 |
| 11336 | Rhyasen GW, et al. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. Mol Cancer Ther. 2016 Nov;15(11):2563-2574. |
| 11337 | Br Med J 1:1773 (1960); J Pharmacol Exp Ther 128:122 (1960); 131:271 (1961)| |
| 11338 | Adler RA, et al. Hypercalciuria in hyperprolactinemic rats: effects of benzthiazide. Metabolism. 1986 Jul;35(7):668-72. |
| 11339 | Lee HS, et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol. 2012 Jul 2;6:80. |
| 11340 | Baron AP, et al. Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524. Elife. 2016 Feb 17;5. pii: e12187. |
| 11341 | Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009 Apr 9;458(7239):732-6. |
| 11342 | J. Claire Godbersen, e tal. The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells. |
| 11343 | Lan H, et al. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci Rep. 2016 Apr 11;6:24218. |
| 11344 | Abderrazak A, et al. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation. 2015;131(12):1061-1070. |
| 11345 | Lone SH, et al. Arglabin: From isolation to antitumor evaluation. Chem Biol Interact. 2015;240:180-198. |
| 11346 | L. Johnston, et al. Muscle and joint pain: topical anti-inflammatories and analgesics: therapeutic. Professional Nursing Today, Volume 17, Issue 1, Jan 2013, p. 4-5. |
| 11347 | Xu Z, et al. Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells. J Exp Clin Cancer Res. 2017 Sep 11;36(1):124. |
| 11348 | J Chem Soc 1969: 1824; Acta Cryst C 40: 2068 (1984)| |
| 11349 | Waffo-Téguo P, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. Nutr Cancer. 2001;40(2):173-9. |
| 11350 | Shay J, et al. Molecular Mechanisms and Therapeutic Effects of (-)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration. Oxid Med Cell Longev. 2015;2015:181260. |
| 11351 | Nogueira L, et al. (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle. J Physiol. 2011 Sep 15;589(Pt 18):4615-31. |
| 11352 | LIANA PLES, et al. Is Ulipristal Acetate a Liver Toxic Biomolecule? Toxicity assessment of ulipristal acetate. REV.CHIM.(Bucharest). |
| 11353 | Cochran JC, et al. Monastrol inhibition of the mitotic kinesin Eg5. J BiolChem. 2005 Apr 1;280(13):12658-67. |
| 11354 | Marques LA, et al. Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells. Naunyn Schmiedebergs Arch Pharmacol. 2016 Dec;389(12):1279-1288. |
| 11355 | Mayer TU, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999 Oct 29;286(5441):971-4. |
| 11356 | Hansen JD, et al. Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4692-5. |
| 11357 | Wong H, et al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009 Apr;329(1):360-7. |
| 11358 | Tian G, et al. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry. 2001 Jun 19;40(24):7084-91. |
| 11359 | Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. |
| 11360 | Dogan-Topal B, et al. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:116-123. |
| 11361 | Richard Kim, et al. First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation. EJC. December 2016, Volume 69, Supplement 1, Page S41. |
| 11362 | Lladó-Pelfort L, et al. In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat. Psychopharmacology (Berl). 2012 May;221(2):261-72. |
| 11363 | J Chem Soc 1970: 1710 |
| 11364 | de Groot NS, et al. Ile-phe dipeptide self-assembly: clues to amyloid formation. Biophys J. 2007 Mar 1;92(5):1732-41 |
| 11365 | Li B, et al, Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors. Sci Signal. 2017 Jun 27;10(485). pii: eaak9916. |
| 11366 | J Antimicrobial Chemother 12(suppl A):1 (1983); Drugs 29:105 (1985)| |
| 11367 | Richards DM, et al. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Feb;29(2):105-61. |
| 11368 | Wang C, et al. Acetyl-CoA carboxylase-alpha inhibitor TOFA induces human cancer cell apoptosis. Biochem Biophys Res Commun. 2009 Jul 31;385(3):302-6. |
| 11369 | Li S, et al. TOFA suppresses ovarian cancer cell growth in vitro and in vivo. Mol Med Rep. 2013 Aug;8(2):373-8. |
| 11370 | Guseva NV, et al. TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status. Cancer Biol Ther. 2011 Jul 1;12(1):80-5. |
| 11371 | J Am Chem Soc 63: 1253 (1941); 68: 406 (1946); Fitoterapia 75:209 (2004); Pharmazie 61:552 (2006); Ceska Slov Farm 55:168 (2006) |
| 11372 | Sutherlin DP, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem, 2011, 54(21), 7579-7587. |
| 11373 | Wallin JJ, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther, 2011, 10(12), 2426-2436. |
| 11374 | https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/01/030477 |
| 11375 | Flynn BL, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011 Sep 8;54(17):6014-27. |
| 11376 | Kremmidiotis G, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010 Jun;9(6):1562-73. |
| 11377 | Inglis DJ, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biol Ther. 2014;15(11):1552-60. |
| 11378 | Ramtohul, Yeeman K, et al. Preparation of mannose derivatives via coupling and click cycloaddition reactions for treating bacterial infections. From PCT Int. Appl. (2014), WO 2014100158 A1 20140626. |
| 11379 | W Reinisch, et al. P568 An open-label, multicenter, phase ib, pharmacokinetic (pk) and safety study of a fimh blocker, Sibofimloc (TAK-018/EB8018), in patients with Crohn’s disease (CD), Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020: S479–S480. |
| 11380 | Futami T, et al. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma. Mol Cancer Ther. 2017 Jan;16(1):68-75. |
| 11381 | Meggio F, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234(1):317-22. |
| 11382 | Chae HJ, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000 Oct;42(4):373-81. |
| 11383 | Yoshizawa S, et al. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin.Cancer Res. 1990 Aug 15;50(16):4974-8. |
| 11384 | Nabeshima T, et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J Pharmacol Exp Ther. 1991 May;257(2):562-6. |
| 11385 | Yujie Ren, et al. The ORF3a Protein of SARS-CoV-2 Induces Apoptosis in Cells. Cell Mol Immunol. 2020 Jun 18;1-3. |
| 11386 | Sznaidman ML, et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. Bioorg Med Chem Lett. 2003 May 5;13(9):1517-21. |
| 11387 | Smith SA, et al. Effect of the peroxisome proliferator-activated receptor beta activator GW0742 in rat cultured cerebellar granule neurons. J Neurosci Res. 2004 Jul 15;77(2):240-9. |
| 11388 | Galuppo M, et al. GW0742, a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice. Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1033-46. |
| 11389 | Kuo SC, et al. Activation of receptors δ (PPARδ) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro. Horm Metab Res. 2013 Nov;45(12):880-6. |
| 11390 | J Chem Soc 1986:1491 |
| 11391 | Jelic D, et al. From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials. Antibiotics (Basel). 2016 Sep 1;5(3). pii: E29. |
| 11392 | Hatcher JM, et al. Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. J Med Chem. 2015 Dec 10;58(23):9296-9308. |
| 11393 | Paris D, et al. Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. Eur J Pharmacol. 2011 Nov 30;670(2-3):384-91. |
| 11394 | Xing H, et al. A Pharmacological Comparison of Two Isomeric Nicotinic Receptor Agonists: The Marine Toxin Isoanatabine and the Tobacco Alkaloid Anatabine. Mar Drugs. 2020 Feb 11;18(2). pii: E106. |
| 11395 | eo EJ, et al. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease. Pharmacol Res. 2018 Mar;129:262-273. |
| 11396 | Traxler P, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004 Jul 15;64(14):4931-4941. |
| 11397 | Park et al. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res. 2005 Mar 1;11(5):1963-1973. |
| 11398 | J Chem Soc 1954: 3981; Acta Chem Scand 18: 1979 (1964); 20: 1431 (1966); Phytochemistry 18: 815 (1971) |
| 11399 | Li S, Zhang P, Zhang M, Fu C, Yu L. Functional analysis of a WRKY transcription factor involved in transcriptional activation of the DBAT gene in Taxus chinensis. Plant Biol (Stuttg). 2013 Jan;15(1):19-26. |
| 11400 | Naill MC, Kolewe ME, Roberts SC. Paclitaxel uptake and transport in Taxus cell suspension cultures. Biochem Eng J. 2012 Apr 15;63:50-56. |
| 11401 | Qayum M, Nisar M, Shah MR, et al. Analgesic and antiinflammatory activities of taxoids from Taxus wallichiana Zucc. Phytother Res. 2012 Apr;26(4):552-6. |
| 11402 | Kevin Walker and Rodney Croteau. Taxol biosynthesis: Molecular cloning of a benzoyl- CoA:taxane 2α-O-benzoyltransferase cDNA from Taxus and functional expression in Escherichia coli. PNAS, 2000 , 97（25）：13591-13596. |
| 11403 | J. Org. Chem. (1976), 41(13), 2283-8; J. Med. Chem. (1969), 12(5), 832-6; Am. J. Med. Sci. (1948), 216(1), 20-3 |
| 11404 | Liebich HM, et al. Quantitation of urinary nucleosides by high-performance liquid chromatography. J Chromatogr A. 1997 Feb 28;763(1-2):193-7. |
| 11405 | Xiaoyu Wang, et al. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions. J Cell Mol Med. 2017 Nov;21(11):2926-2936. |
| 11406 | Inflammation 1:415 (1976); Invest Opthalmol 15:104 (`976) |
| 11407 | Li-Huei Tsai, et al. Inhibition of hdac2 to promote memory. patent/US20120101147 |
| 11408 | Schroeder FA, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and altersmouse behavior in two mood-related tests. PLoS One. 2013 Aug 14;8(8):e71323. |
| 11409 | Huang L, et al. Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor. ACS Med Chem Lett. 2018 Feb 6;9(3):268-273. |
| 11410 | Int J Toxicol 21 Suppl 2:95 (2002) |
| 11411 | Agents Actions (1980), 10(1-2), 98-100; Acta Physiol. Polon. (1956), 7, 65-80; J. Physiol. (1986), 81(3), 185-90 |
| 11412 | Jin L, et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell. 2015 Feb 9;27(2):257-70. |
| 11413 | Brit.J.Pharmacol.Chemother. 23: 552 (1964) |
| 11414 | https://clinicaltrials.gov/ct2/show/NCT04278404?term=MEROPENEM&cond=COVID-19&draw=2&rank=2 |
| 11415 | https://clinicaltrials.gov/ct2/show/NCT04792567?term=Siponimod&cond=covid&draw=2&rank=1 |
| 11416 | He Y, et al. Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nat Commun. 2016 Dec 13;7:13122. |
| 11417 | Zhuo Z, et al. Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In Vitro and In Vivo. Sci Rep. 2015 Nov 3;5:16185. |
| 11418 | Thankappan Baburaj, et al. N-Boc-O-Tosyl Hydroxylamine as a Safe and Efficient Nitrogen Source for the N-Amination of Aryl and Alkyl Amines: Electrophylic Amination. |
| 11419 | Meunier J, et al. Brain toxicity and inflammation induced in vivo in mice by the amyloid-β forty-two inducer aftin-4, a roscovitine derivative. J Alzheimers Dis. 2015;44(2):507-24. |
| 11420 | Zhou L, et al. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist. Drug Metab Dispos. 2012 Jun;40(6):1093-103. |
| 11421 | Drugs 13:161 (1977); Clin Ther 7:181 (1985) |
| 11422 | Danloy S et al. Effects of alpha-hederin, a saponin extracted from Hedera helix, on cells cultured in vitro. Planta Med, 1994 Feb, 60(1):45-9. |
| 11423 | Maryam Fallahi et al. Effect of Alpha-Hederin, the active constituent of Nigella sativa, on miRNA-126, IL-13 mRNA levels and inflammation of lungs in ovalbumin-sensitized male rats. Planta Med, 1994 Feb, 60(1):45-9. |
| 11424 | Wang J, et al. α-Hederin induces the apoptosis of gastric cancer cells accompanied by glutathione decrement and reactive oxygen species generation via activating mitochondrial dependent pathway. Phytother Res. 2020;34(3):601-611. |
| 11425 | Klein CH, et al. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell linesharboring oncogenic KRas. Int J Cancer. 2019 Feb 15;144(4):767-776. |
| 11426 | Sharlow ER, et al. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity. PLoS One. 2011;6(10):e25134. |
| 11427 | From PCT Int. Appl. (2013), WO 2013134353 A1 20130912. |
| 11428 | Salem I, et al. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. Breast Cancer Res. 2016 Mar 24;18(1):37. |
| 11429 | Sultana R. Ferulic acid ethyl ester as a potential therapy in neurodegenerative disorders. Biochim Biophys Acta. 2012 May;1822(5):748-52. |
| 11430 | Phuong NT, et al. Anti-inflammatory activity of methyl ferulate isolated from Stemona tuberosa Lour. Asian Pac J Trop Med. 2014 Sep;7S1:S327-31. |
| 11431 | https://clinicaltrials.gov/ct2/show/NCT04748120?term=CIPROFLOXACIN&cond=covid&draw=2&rank=1 |
| 11432 | Ma WW, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017 Jan 1;123(2):345-356. |
| 11433 | Cada DJ, et al. Uridine Triacetate. Hosp Pharm. 2016 Jun;51(6):484-8. |
| 11434 | Quach HT, et al. Eudesmane-Type Sesquiterpene Lactones Inhibit Nuclear Translocation of the Nuclear Factor κB Subunit RelB in Response to a Lymphotoxin β Stimulation. Biol Pharm Bull. 2017;40(10):1669-1677. |
| 11435 | Yinzhi Lin, et al. Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review. |
| 11436 | Mariko Watanabe, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005 Oct 1;106(7):2462-71. |
| 11437 | Bardelle C, et al. Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors. Bioorg Med Chem Lett. 2010;20(21):6242-6245. |
| 11438 | https://clinicaltrials.gov/ct2/show/NCT04475107?term=PYRONARIDINE&cond=covid-19&draw=2&rank=3 |
| 11439 | Wang Q, et al. Tectorigenin Attenuates Palmitate-Induced Endothelial Insulin Resistance via Targeting ROS-Associated Inflammation and IRS-1 Pathway. PLoS One. 2013 Jun 19;8(6):e66417. |
| 11440 | Jiang CP, et al. Pro-apoptotic effects of tectorigenin on human hepatocellular carcinoma HepG2 cells. World J Gastroenterol. 2012 Apr 21;18(15):1753-64. |
| 11441 | Antimicrob Agents Chemother 14:60 (1978); Cell Stress Chaperones 15:309 (2010) |
| 11442 | Marco Donia, Danijela Maksimovic-Ivanic, Sanja Mijatovic, et al. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell cycle. 2011, 10(3): 492 - 499. |
| 11443 | Walmsley Sharon, Avihingsanon Anchalee, Slim Jihad et al. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009,50 (4) :367-374. |
| 11444 | Saquinavir |
| 11445 | Barillari Giovannia, Iovane Andréa, Bacigalupo Ilariaa, et al. Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. AIDS. 2012, 26 (8): 909-919. |
| 11446 | Martha Stefanidou, Carolina Herrera, Naomi Armanasco et al. Saquinavir Inhibits Early Events Associated with Establishment of HIV-1 Infection: Potential Role for Protease Inhibitors in Prevention. Antimicrob. Agents Chemother. 2012, 56 (8): 4381-4390. |
| 11447 | Pethe K, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 2013 Sep;19(9):1157-60. |
| 11448 | Lancet. 273:925 (1957); Br Med J 1: 595 (1960); Pharmacology 33:311 (1986); J Biochem Toxicol 5:245 (1990) |
| 11449 | Minerva Med. (2004), 90, 451-457; Pharmacol. Rev. (1981), 33(1), 1-15; Ann. Intern. Med. (1977), 86(3), 319-21 |
| 11450 | Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18. |
| 11451 | Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats |
| 11452 | Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr;101(8):1036-42. |
| 11453 | Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96. |
| 11454 | J Pharmacol Exp Ther 75:231 (1942) |
| 11455 | Anal Profiles Drug Subs 12:73 (1983) |
| 11456 | Nature 201:706-7 (1964); J Cell Biol (1965), 27:545-50 (1965);.Biochem Pharmacol 57:727-741 (1999) |
| 11457 | Carbendazim |
| 11458 | Yuanxiang Jin, et al. Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. Toxicol Sci. 2015 Sep;147(1):116-26 |
| 11459 | Bilge G. Tuna, et al. Enhanced antitumor activity of carbendazim on HeLa cervical cancer cells by aptamer mediated controlled release. RSC Advances |
| 11460 | Da Prada, M., et al., Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther, 1989. 248(1): p. 400-14. |
| 11461 | Verleye, M., et al., Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes. Brain Res, 2007. 1138: p. 30-8. |
| 11462 | Reul, J.M., et al., Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology, 1994. 60(5): p. 509-19. |
| 11463 | J. Clin. Endocrinol. Metab. (2008), 93(7), 2454-62; Biochem. Med. (1967), 1(3), 280-7; Ann. Intern. Med. (1975), 82(5), 677-9 |
| 11464 | Burwick N, et al. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017 Apr;55:23-32. |
| 11465 | Takahashi N, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012 Nov 29;3:e437. |
| 11466 | Toxicol Appl Pharmacol 14:515 (1969); Vet Med Rev 1:80 (1985) |
| 11467 | Tetrahedron 26: 219 (1970); Tet Letters 1970: 2797; J Chem Soc 1973: 1599; Phytochem 71:1917 (2010) |
| 11468 | Am J Physiol 253:C79 (1987); J Biol Chem 276:11575 (2001) |
| 11469 | Huq, Fazlul; Hossain, Zahed. Molecular modelling analysis of the metabolism of pyrazinamide. Journal of Pharmacology and Toxicology (2006), 1(6), 505-515. |
| 11470 | Mehmedagic, Aida; Verite, Philippe; Menager, Sabine et al. Investigation of the effects of concomitant caffeine administration on the metabolic disposition of pyrazinamide in rats. Biopharmaceutics & Drug Disposition (2002), 23(5), 191-195. |
| 11471 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=ATENOLOL&cond=covid&draw=2&rank=1 |
| 11472 | Veeramani C, et al. Herbacetin, a flaxseed flavonoid, ameliorates high percent dietary fat induced insulin resistance and lipid accumulation through the regulation of hepatic lipid metabolizing and lipid-regulating enzymes. Chem Biol Interact. 2018 May 25;288:49-56. |
| 11473 | Kim DJ, et al. Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity. Cancer Res. 2016 Mar 1;76(5):1146-1157. |
| 11474 | Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9(6):e99988. |
| 11475 | Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89(3):351-7. |
| 11476 | Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89(3):351-7. |
| 11477 | Rothenberg ME, et al. Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study i |
| 11478 | Steven J. McKerrall, et al. Nav1.7 inhibitors for the treatment of chronic pain. Bioorganic & Medicinal Chemistry Letters (2018) |
| 11479 | Takahashi RH,et al.Unequal Absorption of Radiolabeled and Nonradiolabeled Drug from the Oral Dose Leads to Incorrect Estimates of Drug Absorption and Circulating Metabolites in a Mass Balance Study.Drug Metab Lett. 2019;13(1):37-44. |
| 11480 | J Chem Soc 1928:1022; 1970:1219; Life Sci 78(20):7 (2006) |
| 11481 | Yue EW, et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem. 2009 Dec 10;52(23):7364-7. |
| 11482 | Glaser KB, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. |
| 11483 | Shearer BG, et al. Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. J Med Chem. 2010 Feb 25;53(4):1857-61. |
| 11484 | Palkar PS, et al. Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol. 2010 Sep;78(3):419-30. |
| 11485 | Pascolo E, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem. 2002 May 3;277(18):15566-72. |
| 11486 | El-Daly H, et al. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood. 2005 Feb 15;105(4):1742-9. |
| 11487 | Ward RJ, et al. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol. 2005 Sep;68(3):779-86. |
| 11488 | A Röth, et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia. 2007 Dec;21(12):2456-62. |
| 11489 | Meng E, et al. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells. Gynecol Oncol. 2012 Mar;124(3):598-605. |
| 11490 | Stachowicz A, et al. Proteomic Analysis of Mitochondria-Enriched Fraction Isolated from the Frontal Cortex and Hippocampus of Apolipoprotein E Knockout Mice Treated with Alda-1, an Activator of Mitochondrial Aldehyde Dehydrogenase (ALDH2). Int J Mol Sci. |
| 11491 | Stachowicz A, et al. The impact of mitochondrial aldehyde dehydrogenase (ALDH2) activation by Alda-1 on the behavioral and biochemical disturbances in animal model of depression. Brain Behav Immun. 2016 Jan;51:144-53. |
| 11492 | Ikeda T, et al. Effects of Alda-1, an Aldehyde Dehydrogenase-2 Agonist, on Hypoglycemic Neuronal Death. PLoS One. 2015 Jun 17;10(6):e0128844. |
| 11493 | Gomes KM, et al. Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post-myocardial infarction cardiomyopathy: benefits of Alda-1. Int J Cardiol. 2015 Jan 20;179:129-138. |
| 11494 | J Pharm Pharmacol 18:19 (1966) |
| 11495 | Phytochem 17:1440 (1978) |
| 11496 | Balog, et al. Preparation of cycloalkylaryl amide compounds as indoleamine 2,3-dioxygenase and therapeutic uses thereof. From PCT Int. Appl. (2014), WO 2014150677 A1 20140925. |
| 11497 | https://clinicaltrials.gov/ct2/show/study/NCT04362137?term=Ruxolitinib&cond=covid&draw=2&rank=7 |
| 11498 | Yen Ting Chen, et al. Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors. Med.Chem.Commun., 2011, 2, 73-75. |
| 11499 | Yu Chen, et al. A Versatile Polypharmacology Platform Promotes Cytoprotection and Viability of Human Pluripotent and Differentiated Cells. bioRxiv 815761. |
| 11500 | McIver AL, et al. Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors. ChemMedChem. 2017 Feb 3;12(3):207-213. |
| 11501 | J Antimicrob Chemother 31 Suppl C:1 (1993); Drugs 61: 443 (2001) |
| 11502 | https://clinicaltrials.gov/ct2/show/NCT04362137?term=Ruxolitinib&cond=COVID-19&draw=3&rank=9 |
| 11503 | Schmidt A, et al. Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010 May 28;285 |
| 11504 | Han YL, Yu HL, Li D, et al. Inhibitory effects of limonin on six human cytochrome P450 enzymes and P-glycoprotein in vitro. Toxicol In Vitro. 2011 Dec;25(8):1828-33. |
| 11505 | Kotamballi N. Chidambara Murthy, Jayaprakasha, Vinod Kumar, et al. Citrus Limonin and Its Glucoside Inhibit Colon Adenocarcinoma Cell Proliferation through Apoptosis. J. Agric. Food Chem., 2011, 59 (6):2314-2323. |
| 11506 | Mahmoud Zaki El-Readi, Dalia Hamdana, Nawal Farrag, et al. Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. European Journal of Pharmacology. 2010,626 (2-3): 139-145. |
| 11507 | Battinelli L, Mengoni F, Lichtner M, et al. Effect of limonin and nomilin on HIV-1 replication on infected human mononuclear cells. Planta Med. 2003 Oct;69(10):910-3. |
| 11508 | Tanaka T, Kohno H, Tsukio Y, et al. Citrus limonoids obacunone and limonin inhibit azoxymethane-induced colon carcinogenesis in rats. Biofactors. 2000;13(1-4):213-8. |J Chem Soc 1961:255; Planta Med 64:339 (1998); 69:910 (2003} Bioorg & Med Chem 19:2084 (2011); J Agri Food Chem 59:2314 (2011} |
| 11509 | Vallée M, et al. Pregnenolone can protect the brain from cannabis intoxication. Science. 2014 Jan 3;343(6166):94-8. |
| 11510 | Ducharme N, et al. Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur J Pharmacol. 2010 Sep 1;641(2-3):128-34. |
| 11511 | Erickson RI , et al. Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. J Pharmacol Exp Ther. 2017 Jan;360(1):226-238. |
| 11512 | Crawford JJ, et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem. 2018 Mar 22;61(6):2227-2245. |
| 11513 | Ackermann TF, et al. EMD638683, a novel SGK inhibitor with antihypertensive potency. Cell Physiol Biochem. 2011;28(1):137-46. |
| 11514 | Towhid ST, et al. Inhibition of colonic tumor growth by the selective SGK inhibitor EMD638683. Cell Physiol Biochem. 2013;32(4):838-48. |
| 11515 | Xi X, et al. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension. Cardiovasc Toxicol. 2014 Dec;14(4):368-78. |
| 11516 | Zhou H, et al. Inhibition of serum- and glucocorticoid-inducible kinase 1 enhances TLR-mediated inflammation and promotes endotoxin-driven organ failure. FASEB J. 2015 Sep;29(9):3737-49. |
| 11517 | Morley KC, et al. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Subst Abuse Rehabil. 2012 May 28;3:43-7. |
| 11518 | Farde L, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypicalneuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. |
| 11519 | Divac N, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. |
| 11520 | Cai HL, et al. A sensitive LC-MS/MS method for analysis of pericyazine in presence of 7-hydroxypericyazine and pericyazine sulphoxide in human plasma and its application to a comparative bioequivalence study in Chinese healthy volunteers. J Pharm Biomed Anal. 2017;135:67‐74. |
| 11521 | J. Am. Chem. Soc. (1951), 73, 897-900. ; J. Pharmacol. Exp. Ther. (1950), 100, 421-8. ; J. Pharmacol. Exp. Ther. (1950), 99, 465-78. |
| 11522 | Kennedy TL, et al. BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle. Am J Pathol. 2016 Dec;186(12):3246-3260 |
| 11523 | Salah H, et al. The chaperone co-inducer BGP-15 alleviates ventilation-induced diaphragm dysfunction. Sci Transl Med. 2016 Aug 3;8(350):350ra10 |
| 11524 | Sapra G, et al. The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. Nat Commun. 2014 Dec 9;5:5705 |
| 11525 | Literati-Nagy B, et al. Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies. Metab Syndr Relat Disord. 2014 Mar;12(2):125-31 |
| 11526 | Sarszegi Z, et al. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37 |
| 11527 | Szabados E, et al. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem Pharmacol. 2000 Apr 15;59(8):937-45. |
| 11528 | Ho WS, et al. Antiviral activity of daphnoretin isolated from Wikstroemia indica. Phytother Res. 2010 May;24(5):657-61. |
| 11529 | Wang JP, et al. Daphnoretin-induced respiratory burst in rat neutrophils is, probably, mainly through protein kinase C activation. Eur J Pharmacol. 1995 Feb 15;288(3):341-8. |
| 11530 | Yan SB, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44. |
| 11531 | Barat S, et al. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog. 2016 Jan 12. |
| 11532 | J Postgrad Med 30:134 (1984) |
| 11533 | Kaundal RK, et al. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci. 2006 Nov 10;79(24):2293-302. |
| 11534 | Bowman KJ, et al. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer. 1998 Nov;78(10):1269-77. |
| 11535 | Delaney CA, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000 Jul;6(7):2860-7. |
| 11536 | Gobbini M, et al. Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship. J Med Chem. 2008 Aug 14;51(15):4601-8. |
| 11537 | Gobbini M, et al. Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold. Bioorg Med Ch |
| 11538 | Micheletti R, et al. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther. 2002 Nov;303(2):592-600. |
| 11539 | Punit Saraon, et al. A Drug Discovery Platform to Identify Compounds That Inhibit EGFR Triple Mutants.Nat Chem Biol. 2020 May;16(5):577-586. |
| 11540 | Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9. |
| 11541 | Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun;14(3):259-67. |
| 11542 | O'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15;111(4):1816-9. |
| 11543 | Poh MK, et al. U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication. Antiviral Res. 2012 Jan;93(1):191-8. |
| 11544 | Cenedella RJ, et al. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids. 2009 Jun;44(6):477-87. |
| 11545 | Thomas Beckers, et al. 2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Research (2002), 62(11), 3113-3119. |
| 11546 | S Mahboobi, et al. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J Med Chem. 2001 Dec 20;44(26):4535-53. |
| 11547 | Balupuri A, et al. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation. Eur J Med Chem. 2018 Mar 25;148:397-409. |
| 11548 | J. Med. Chem. (1974), 17(5), 513-16; Nature (1967), 214(5088), 597-8; J. Am. Pharm. Assoc. (1958), 47, 744-8 |
| 11549 | Br J Pharmacol 116:2349 (1995); 119:423 (1996) |
| 11550 | Enrica Marchi, et al. Pralatrexate Is Synergistic With the Proteasome Inhibitor Bortezomib in in Vitro and in Vivo Models of T-cell Lymphoid Malignancies. Clin Cancer Res. 2010 Jul 15;16(14):3648-58. |
| 11551 | Francine Foss, et al. Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study. Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. |
| 11552 | Karen Kelly, et al. Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy. J Thorac Oncol. 2012 Jun;7(6):1041-8. |
| 11553 | F M Sirotnak, et al. A New Analogue of 10-deazaaminopterin With Markedly Enhanced Curative Effects Against Human Tumor Xenografts in Mice. Cancer Chemother Pharmacol. 1998;42(4):313-8. |
| 11554 | Mol Pharmacol 13: 38 (1977); Biochem Biophs Acta 763: 276 (1983); Life Sci 63: 265 (1998) |
| 11555 | Borkin D, et al. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016 Feb 11;59(3):892-913. |
| 11556 | Neelakantan S, et al. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett. 2009 Aug 1;19(15):4346-9. |
| 11557 | Mendonca MS, et al. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 Nov;112:318-326. |
| 11558 | Morel KL, et al. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 Oct;35(7):649-661. |
| 11559 | Chiu H, et al. The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. Front Immunol. 2017 Jun 30;8:747. |
| 11560 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=LIOTHYRONINE&cntry=&state=&city=&dist=&Search=Search |
| 11561 | Salomon AR, et al. Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem Biol. 2001 Jan;8(1):71-80. |
| 11562 | Ramió-Lluch L, et al. Oligomycin A-induced inhibition of mitochondrial ATP-synthase activity suppresses boar sperm motility and in vitro capacitation achievement without modifying overall sperm energy levels. Reprod Fertil Dev. 2014;26(6):883-97. |
| 11563 | Curr Ther Res 43:291 (1988); Nat Med 1:244 (1995); Biochem J 347:571 (2000) |
| 11564 | Pingda Ren, et al. Certain chemical entities, compositions and methods. WO 2011008302 A1. |
| 11565 | Huehls AM, et al. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.Cancer Res. 2011 Jul 15;71(14):4944-54. |
| 11566 | Yeo WS, et al. The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus.Sci Rep. 2018 Feb 6;8(1):2521. |
| 11567 | Langman J, et al. Floxuridine and its influence on postnatal cerebellar development. Pediatr Res. 1972 Oct;6(10):758-64. |Pharmacol. Ther. (1981), 13(1), 69-90; Biochim. Biophys. Acta (1977), 473(2), 73-92; Cancer Res. (1963), 23, 1226-43 |
| 11568 | Iglarz M, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008 Dec;327(3):736-45. |
| 11569 | Zhang J, et al. Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. Int J Clin Exp Med. 2015 Oct 15;8(10):18420-6 |
| 11570 | Song Z, et al. Advanced research on anti-tumor effects of amygdalin. J Cancer Res Ther. 2014 Aug;10 Suppl 1:3-7. |
| 11571 | Park HJ,et al. Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells. World J Gastroenterol. 2005 Sep 7;11(33):5156-61. |
| 11572 | Hwang HJ,et al. Antinociceptive effect of amygdalin isolated from Prunus armeniaca on formalin-induced pain in rats. Biol Pharm Bull. 2008 Aug;31(8):1559-64. |JAMA 245:591 (1981); CA Cancer J Clin 41:187 (1991); J Med Plants Res 5:3122 (2011) |
| 11573 | FIDANZE, Steven D., et al. BROMODOMAIN INHIBITORS. WO 2017177955 A1. |
| 11574 | Bertin MJ, et al. Spongosine production by a Vibrio harveyi strain associated with the sponge Tectitethya crypta. J Nat Prod. 2015 Mar 27;78(3):493-9. |
| 11575 | Müller WE, et al. Metabolism of 1-beta-D-arabinofuranosyluracil in mouse L5178Y cells. Cancer Res. 1979 Mar;39(3):1102-7. |
| 11576 | Deshmukh V, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2018 Jan;26(1):18-27. |
| 11577 | Chen F, et al. Naringin Alleviates Diabetic Kidney Disease through Inhibiting Oxidative Stress and Inflammatory Reaction. PLoS One. 2015 Nov 30;10(11):e0143868. |
| 11578 | Raha S, et al. Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. Int J Oncol. 2015 Sep;47(3):1061-9. |
| 11579 | Kulasekaran G, et al. Neuroprotective efficacy of naringin on 3-nitropropionic acid-induced mitochondrial dysfunction through the modulation of Nrf2 signaling pathway in PC12 cells. Mol Cell Biochem. 2015 Nov;409(1-2):199-211. |
| 11580 | Wang D, et al. Naringin Improves Neuronal Insulin Signaling, Brain Mitochondrial Function, and Cognitive Function in High-Fat Diet-Induced Obese Mice. Cell Mol Neurobiol. 2015 Oct;35(7):1061-71. |
| 11581 | WO 2015055071 A1 |
| 11582 | Jiang Y, et al. Discovery of Second-Generation NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization. J Med Chem. 2019 Oct 31. |
| 11583 | https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20210214050350N1 |
| 11584 | J Ind Chem Soc 39:749 (1962) |
| 11585 | J Forensic Sci 52:479 (2007) |
| 11586 | Arch. Intern. Med. (1976), 136(9), 1023-8; Eur. Cytokine Network (2005), 16(2), 144-151; Biochem. Pharmacol. (1964), 13, 1305-17 |
| 11587 | Nature 162: 524 (1948) |
| 11588 | López Y, et al. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria. Antimicrob Agents Chemother. 2013 Dec;57(12):6389-92. |
| 11589 | López Y, et al. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci. J Antimicrob Chemother. 2015 Jan;70(1):57-61 |
| 11590 | Mariotto E, et al. EB-3D a novel choline kinase inhibitor induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells. Biochem Pharmacol. 2018 Sep;155:213-223. |
| 11591 | Sola-Leyva A, et al. Choline kinase inhibitors EB-3D and EB-3P interferes with lipid homeostasis in HepG2 cells. Sci Rep. 2019 Mar 25;9(1):5109. |
| 11592 | Schiaffino-Ortega S, et al. Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1). |
| 11593 | Mariotto E, et al. Choline Kinase Alpha Inhibition by EB-3D Triggers Cellular Senescence, Reduces Tumor Growth and Metastatic Dissemination in Breast Cancer. Cancers (Basel). 2018;10(10):391. Published 2018 Oct 22. |
| 11594 | Biochem Pharmacol 24:717 (1975); Arch Toxicol 41:31 (1978) |
| 11595 | Chem Pharm Bull 19:640 (1971); Phytochemistry 14:1083 (1975) |
| 11596 | Hu Y et al. Role of Chinese herbal medicinal ingredients in secretion of cytokines by PCV2-induced endothelial cells. J Immunotoxicol. 2016;13(2):141-7. |
| 11597 | Liu M et al. Cytotoxicity of the compounds isolated from Pulsatilla chinensis saponins and apoptosis induced by 23-hydroxybetulinic acid. Pharm Biol. 2015 Jan;53(1):1-9. |
| 11598 | Hu Y et al. Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells. Immunopharmacol Immunotoxicol. 2009;31(4):550-5. |
| 11599 | Stoner SC, et al. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther. 2012 May;34(5):1023-40. |
| 11600 | Shahid M, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. |
| 11601 | Ohyama M,et al. Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model. Acta Neuropsychiatr. 2016 Dec;28(6):327-336. |
| 11602 | Ene HM, et al. Effects of repeated asenapine in a battery of tests for anxiety-like behaviours in mice. Acta Neuropsychiatr. 2016 Apr;28(2):85-91. |
| 11603 | J Chem Soc(C) 1966:332; Chem Commun 1972:1276 |
| 11604 | https://docs.google.com/spreadsheets/d/1gsgvDj5NHvWbJOko3xbVtntkm1FxCgXK/edit#gid=377927538 |
| 11605 | Jianqiang Kong, et al. Artemisinic acid: A promising molecule potentially suitable for the semi-synthesis of artemisinin. RSC Adv. 2013. |
| 11606 | Yokota S, et al. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000 Jun 1;60(11):2942-8. |
| 11607 | Koishi M, et al. The effects of KNK437, a novel inhibitor of heat shock protein synthesis, on the acquisition of thermotolerance in a murine transplantable tumor in vivo. Clin Cancer Res. 2001 Jan;7(1):215-9. |
| 11608 | Matsuda K, et al. Effects of KNK437 on heat-induced methylation of histone H3 in human oral squamous cell carcinoma cells. Int J Hyperthermia. 2006 Dec;22(8):729-35. |
| 11609 | Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. |
| 11610 | Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. |
| 11611 | Yuzwa SA, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012 Feb 26;8(4):393-9. |
| 11612 | Andrés-Bergós J, et al. The increase in O-linked N-acetylglucosamine protein modification stimulates chondrogenic differentiation both in vitro and in vivo. J Biol Chem. 2012 Sep 28;287(40):33615-28. |
| 11613 | Ding N, et al. Thiamet-G-mediated inhibition of O-GlcNAcase sensitizes human leukemia cells to microtubule-stabilizing agent NSC 125973. Biochem Biophys Res Commun. 2014 Oct 24;453(3):392-7. |
| 11614 | Buckley GM, et al. IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-a]pyridine binding. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3291-5. |
| 11615 | Li S, et al. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5567-72. |
| 11616 | Mori N, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines andprimary adult T-cell leukemia cells. Blood. 2002 Sep 1;100(5):1828-1834. |
| 11617 | Ritorto MS, et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat Commun. 2014 Aug 27;5:4763. |
| 11618 | Strickson S, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem J. 2013 May 1;451(3):427-437. |
| 11619 | Pierce JW, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997 Aug 22;272(34):21096-103. |
| 11620 | Jun Jacob Hu, et al. Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D. The Preprint Server For Biology, 2018,Jul. 10. |
| 11621 | Chen L , et al. BAY 11-7082, a nuclear factor-κB inhibitor, induces apoptosis and S phase arrest in gastriccancer cells. J Gastroenterol. 2014 May;49(5):864-74. |
| 11622 | Helm JR, et al. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med. 2011 Mar-Apr;25(2):251-60. |
| 11623 | Feldman EC, et al. Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. J Vet Intern Med. 2012 Jul-Aug;26(4):1078-80. |Steroids 32:257 (1978); J Steroid Biochem 21:601 (1984); Pharmaceutical Res 9:464 (1992) |
| 11624 | Gamache DA, Graff G, Brady MT et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. |
| 11625 | Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. |
| 11626 | Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006 Feb;22(2):397-404. |
| 11627 | Marshall JC, Fernandes BF, Di Cesare S et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007 Sep;28(9):2053-8. |
| 11628 | Singh R, Alpern L, Jaffe GJ et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259-69. |
| 11629 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=PIPERACILLIN+&cntry=&state=&city=&dist=&Search=Search |
| 11630 | Appl Microbiol 16:1524 (1968); Appl Environ Microbiol 1991:1 |
| 11631 | Hamik A, et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry. 1990 Jul 15;28(2):99-109. |
| 11632 | Xuefei Huang, et al. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms. Oncotarget. 2017 Nov 24; 8(60): 102705–102720. |
| 11633 | Kyoko Nishitsuji, et al. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress. Eur Neuropsychopharmacol. 2006 Jul;16(5):376-82. |
| 11634 | Shu C, et al. Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach. J Clin Pharmacol. 2011 Apr;51(4):472-81. |
| 11635 | Chen JK, et al. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6. |
| 11636 | Nature 203:1283 (1964); J Pharmacol Exp Ther 149:161 (1965); Drugs 34:311 (1987); N Eng J Med 331:31 (1994) |
| 11637 | Richards T, et al. Cell based functional assays for IDO1 inhibitor screening and characterization. Oncotarget. 2018 Jul 20;9(56):30814-30820. |
| 11638 | Lillian L. Siu, et al. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. AACR; Cancer Res. 2017; 77 (13 Suppl): Abstract nr CT116. |
| 11639 | Kung PP, et al. Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors. J Med Chem. 2016 Sep 22;59(18):8306-25. |
| 11640 | Zhang DM, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 2013 Jun;34(6):1331-42. |
| 11641 | Li M, et al. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol. 2012 May 1;83(9):1251-60. |
| 11642 | Cruz Jdos S, et al. Arenobufagin, a compound in toad venom, blocks Na(+)-K+ pump current in cardiac myocytes. Eur J Pharmacol. 1993 Aug 3;239(1-3):223-6. |
| 11643 | Blake RA, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000 Dec;20(23):9018-27. |
| 11644 | Veracini L, et al. Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas. Oncotarget. 2014 Dec 26. |
| 11645 | Wu ML, et al. Divergent signaling pathways cooperatively regulate TGFβ induction of cysteine-rich protein 2 in vascular smooth muscle cells. Cell Commun Signal. 2014 Mar 28;12:22. |
| 11646 | Ondrusová L, et al. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells. Folia Biol (Praha). 2013;59(4):162-7. |
| 11647 | Kumar A, et al. Pharmacological investigations on possible role of Src kinases in neuroprotective mechanism of ischemic postconditioning in mice. Int J Neurosci. 2014 Oct;124(10):777-86. |
| 11648 | Liu XF, et al. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors. Mol Cancer Ther. 2014 Jan;13(1):82-9. |
| 11649 | Int. J. Mol. Sci. (2006), 7(1), 12-34; Jpn. J. Pharmacol. (1976), 26(1), 111-14; J. Pharmacol. Exp. Ther. (1955), 115, 413-18 |
| 11650 | Helal CJ, et al. Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate. J Med Chem. 2018 Feb 8;61(3):1001-1018. |
| 11651 | J Chem Soc 1948:1936; J Biol Chem 178:439 (1949); Biol Psychiatry 57:343 (2005) |
| 11652 | Kirihara T, et al. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):145-153. |
| 11653 | Fuwa M, et al. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. J Ocul Pharmacol Ther. 2018 Sep;34(7):531-537. |
| 11654 | FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops. |
| 11655 | Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12(6):492-500. |
| 11656 | Vo VA, et al. Avicularin Inhibits Lipopolysaccharide-Induced Inflammatory Response by Suppressing ERK Phosphorylation in RAW 264.7 Macrophages. Biomol Ther (Seoul). 2012 Nov;20(6):532-7. |
| 11657 | Wang Z, et al. Avicularin ameliorates human hepatocellular carcinoma via the regulation of NF‑κB/COX‑2/PPAR‑γ activities. Mol Med Rep. 2019 Jun;19(6):5417-5423. |
| 11658 | Feng J, et, al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300. |
| 11659 | Ta NN, et, al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35. |
| 11660 | Hao FL, et, al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2019 Jan;109:181-187. |
| 11661 | Asakawa T, et, al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85(3-4):122-6. |
| 11662 | Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54. |
| 11663 | Wu F, et al. Estrogen-related receptor alpha (ERRalpha) inverse agonist XCT-790 induces cell death in chemotherapeutic resistant cancer cells. Chem Biol Interact. 2009 Oct 7;181(2):236-42. |
| 11664 | Busch BB, et al. Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha. J Med Chem. 2004 Nov 4;47(23):5593-6. |
| 11665 | Kokabu T, et al. Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells. Cell Oncol (Dordr). 2019 Apr;42(2):223-235. |
| 11666 | Eur Journal Pharmacol 407:61 (2000)| |
| 11667 | Vojo Deretic, et al. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert Opin Drug Metab Toxicol. 2019 Mar;15(3):213-218. |
| 11668 | Anna Migdalska-Richards, et al. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol. 2016 Nov;80(5):766-775. |
| 11669 | J Med Pharm Chem 5: 800 (1962) |
| 11670 | Leal LF, et al. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis. Oncotarget. 2015 Dec 15;6(40):43016-32. |
| 11671 | Trosset JY, et al. Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins. 2006 Jul 1;64(1):60-7. |
| 11672 | Biochem J 369:71 (2003) |
| 11673 | Jin L, et al. Ethoxysanguinarine inhibits viability and induces apoptosis of colorectal cancer cells by inhibiting CIP2A. Int J Oncol. 2018 Mar 16. |
| 11674 | Pi H, et al. SIRT3-SOD2-mROS-dependent autophagy in cadmium-induced hepatotoxicity and salvage by melatonin. Autophagy. 2015;11(7):1037-51. |
| 11675 | Zhai M, et al. Melatonin ameliorates myocardial ischemia reperfusion injury through SIRT3-dependent regulation of oxidative stress and apoptosis. J Pineal Res. 2017 Sep;63(2). |
| 11676 | Galli U, et al. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2. Eur J Med Chem. 2012 Sep;55:58-66. |
| 11677 | Olayanju A, et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammaliancells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 2015 Jan;78:202-12. |
| 11678 | Chen HM, et al. Synergistic antitumor effect of Brusatol combined with Cisplatin on colorectal cancer cells. Int J Mol Med. 2018 Mar;41(3):1447-1454. |
| 11679 | Ren D, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1433-8. |
| 11680 | Wen X, et al. Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor. J Biochem Mol Toxicol. 2015 Jun;29(6):261-6. |
| 11681 | Hu L, et al. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg Med Chem Lett. 2013 May 15;23(10):3039-43. |
| 11682 | Choi HG, et al. Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett. 2012 Aug 9;3(8):658-662. |
| 11683 | Ostrem JM, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 28;503(7477):548-51. |
| 11684 | Lu S, et al. Harnessing allostery: a novel approach to drug discovery. Med Res Rev. 2014 Nov;34(6):1242-85. |
| 11685 | Zhou Y, et al. Calycosin induces apoptosis in human ovarian cancer SKOV3 cells by activating caspases and Bcl-2 family proteins. Tumour Biol. 2015 Feb 12. |
| 11686 | Chen J, et al. Calycosin and genistein induce apoptosis by inactivation of HOTAIR/p-Akt signaling pathway in human breast cancer MCF-7 cells. Cell Physiol Biochem. 2015;35(2):722-8. |
| 11687 | Chen J, et al. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PLoS One. 2014 Mar 11;9(3):e91245. |
| 11688 | Chen J, et al. Calycosin promotes proliferation of estrogen receptor-positive cells via estrogen receptors and ERK1/2 activation in vitro and in vivo. Cancer Lett. 2011 Sep 28;308(2):144-51. |
| 11689 | Kapadia GJ, et al. Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barrvirus early antigen activation assay and the mouse skin two-stage carcinogenesis. Pharmacol Res. 2002 Jun;45(6):499-505. |
| 11690 | Liu Z, et al. Sesamol Induces Human Hepatocellular Carcinoma Cells Apoptosis by Impairing MitochondrialFunction and Suppressing Autophagy. Sci Rep. 2017 Apr 4;7:45728. |
| 11691 | Can J Chem 53:1690 (1975) |
| 11692 | J Am Chem Soc 61: 339 (1939); Carbohydr Res 150: 35 (1986); Biochemistry 32:5848 (1993) |
| 11693 | Carlos L. Arteaga, et al. Combinations of kinase inhibitors for the treatment of cancer. WO 2012006552 A1. |
| 11694 | An Z, et al. T0070907 inhibits repair of radiation-induced DNA damage by targeting RAD51. Toxicol In Vitro. 2016 Dec;37:1-8 |
| 11695 | An Z, et al. T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. Reprod Sci. 2014 Nov;21(11):1352-61. |
| 11696 | Kawahara A, et al. Peroxisome proliferator-activated receptor γ (PPARγ)-independent specific cytotoxicity against immature adipocytes induced by PPARγ antagonist T0070907. Biol Pharm Bull. 2013;36(9):1428-34 |
| 11697 | Lee G, et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002 May 31;277(22):19649-57. Epub 2002 Mar 4 |
| 11698 | Proc Physiol Soc 1936:49P; Soc Endocrinology 81:1431 (1967) |
| 11699 | Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47. |
| 11700 | Ishibashi T, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334(1):171-81. |
| 11701 | Sakine Atila Karaca, et al. Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals. Marmara Pharm J. 2017;21 (4): 931-937. |
| 11702 | Vallée M, et al. Pregnenolone can protect the brain from cannabis intoxication. Science. 2014 Jan 3;343(6166):94-8. |
| 11703 | Ducharme N, et al. Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur J Pharmacol. 2010 Sep 1;641(2-3):128-34. |Brain Res 270:119 (1983); Endocrinology 140:1936 (1999); J Steroid Biochem Mol Biol 75:1 (2000) |
| 11704 | Kim CW, et al. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab. 2017 Aug 1;26(2):394-406.e6. |
| 11705 | Am. J. Cancer (2003), 2(5), 373-390; Pharmacol. Ther. (1989), 43(3), 299-319; J. Med. Chem. (1967), 10(2), 172-4 |
| 11706 | J Mol Biol 13: 269 (1965); 27: 87 (1967) |
| 11707 | Jacobs J, et al. Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. J Med Chem. 2013 Jan 24;56(2):534-46. |
| 11708 | Flores E, et, al. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem. 2003 May;3(3):225-37. |
| 11709 | Yun DK, et, al. Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence. Biomol Ther (Seoul). 2013 Jan;21(1):49-53. |
| 11710 | Sirinarumitr K, et, al. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. J Am Vet Med Assoc. 2001 Apr 15;218(8):1275-80. |Pharmacotherapy 13:309 (1993); N Eng J Med 338:557 (1998) |
| 11711 | Seki T. Availability of D-cysteine as a protectant for cerebellar neurons. Nihon Yakurigaku Zasshi. 2019;154(3):133-137. |
| 11712 | Soutourina J, et al. Role of D-cysteine desulfhydrase in the adaptation of Escherichia coli to D-cysteine. J Biol Chem. 2001 Nov 2;276(44):40864-72. |
| 11713 | Guo X1, et al. Effect of D-cysteine on dual-species biofilms of Streptococcus mutans and Streptococcus sanguinis. Sci Rep. 2019 Apr 30;9(1):6689. |
| 11714 | Helv Chim Acta 11:1062 (1928); JACS 56:2434 (1934) |
| 11715 | Cong L, et al. Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy. Arch Pharm (Weinheim). 2014 Sep;347(9):609-15. |
| 11716 | Serova M, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015 Aug 28;6(25):21614-27 |
| 11717 | Bueno L, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008 Jan;44(1):142-50. |
| 11718 | Herbertz S, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015 Aug 10;9:4479-99. |
| 11719 | Angelis A, et al. Bio-Guided Isolation of Methanol-Soluble Metabolites of Common Spruce (Picea abies) Bark by-Products and Investigation of Their Dermo-Cosmetic Properties. Molecules. 2016 Nov 21;21(11):1586. |
| 11720 | Yang P, et al. Detection of 191 Taxifolin Metabolites and Their Distribution in Rats Using HPLC-ESI-IT-TOF-MS(n). Molecules. 2016 Sep 13;21(9). pii: E1209. |
| 11721 | Lei Ren, et al. Dissecting Efficacy and Metabolic Characteristic Mechanism of Taxifolin on Renal Fibrosis by Multivariate Approach and Ultra-Performance Liquid Chromatography Coupled With Mass Spectrometry-Based Metabolomics Strategy. Front Pharmacol. 2021 Jan 14;11:608511. |
| 11722 | Br J Radiol 49:979 (1976); J Nutr 130:1653 (2000) |
| 11723 | Chen R, et al. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors. Biochemistry. 2017 Jun 27;56(25):3273-3282. |
| 11724 | Br. Med. J. (1967), II(5555), 804-8; Antimicrob. Agents Chemother. (1965), 947-50; J. Org. Chem. (1966), 31(3), 897-9 |
| 11725 | https://clinicaltrials.gov/ct2/show/NCT04396314?term=Paroxetine&cond=Covid19&draw=2&rank=1 |
| 11726 | Sarkar S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol. 2007 Jun;3(6):331-338. |
| 11727 | Routledge C, et al. Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist. Br J Pharmacol. 2000;130(7):1606-1612. |
| 11728 | Fukuhara T, et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11329-33. |
| 11729 | Siqueira RP, et al. Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340). PLoS One. 2015 Aug 5;10(8):e0134882. |
| 11730 | Jiao W, et al. Lathyrol diterpenes as modulators of P-glycoprotein dependent multidrug resistance: structure-activity relationship studies on Euphorbia factor L3 derivatives. J Med Chem. 2015 May 14;58(9):3720-38 |
| 11731 | Schon A, et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry. 2006 Sep 12;45(36):10973-10980. |
| 11732 | Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK.
 Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
 Virology. 2005 Sep 1;339(2):213-25. |
| 11733 | J Med Chem 6:60 (1963); Anal Profiles Drug Subs 1:1 (1972) |
| 11734 | Jeong KC, et al. Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth. J Urol. 2014 Feb;191(2):510-8. |
| 11735 | Mercer DK,et al. Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate.Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02117-18. |
| 11736 | Neelabh, et al. Sequential and Structural Aspects of Antifungal Peptides from Animals, Bacteria and Fungi Based on Bioinformatics Tools.Probiotics Antimicrob Proteins. 2016 Jun;8(2):85-101. |
| 11737 | Novamycin®/NP339 Technology Summary |
| 11738 | Zhanel GG, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997 Apr;41(4):863-5 |
| 11739 | Locke JB, et al. Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6100-7. |
| 11740 | Arch Int Pharmacodyn Ther 8:77 (1901) |
| 11741 | McAfee AT, Landon J, Jones M, et al. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications. Pharmacoepidemiol Drug Saf. 2012 Dec 26. |
| 11742 | Turner M, Wilding E, Cassidy E, Dommett EJ. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res. 2012 Dec 22;243C:28-37. |
| 11743 | Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. |
| 11744 | Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997 Dec;283(3):1305-22. |
| 11745 | Atomoxetine |
| 11746 | Villard V, et al. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011 Aug;25(8):1101-17. |
| 11747 | Valentine Lahmy, et al. Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic andσ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease. Neuropsychopharmacology. 2013 Aug; 38(9): 1706-1723. |
| 11748 | Thu PM, et al. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis. Eur J Pharmacol. 2019 May 5;850:23-34. |
| 11749 | Hamasaki R, et al. Tipepidine activates VTA dopamine neuron via inhibiting dopamine D₂ receptor-mediated inward rectifying K⁺ current. Neuroscience. 2013 Nov 12;252:24-34. |
| 11750 | Kawaura K, et al. Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect in the forced swimming test in adrenocorticotropic hormone-treated rats. Behav Brain Res. 2016 Apr 1;302:269-78. |
| 11751 | Barlind JG, et al. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). J Med Chem. 2012 Dec 13;55(23):10610-29. |
| 11752 | Denison H, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2013 Oct 4. |
| 11753 | Eike Floettmann, et al. Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse. Toxicol Pathol. 2015 Apr;43(3):376-83. |
| 11754 | Mariano G et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest. 2016 Sep 1; 126(9): 3351–3362. |
| 11755 | Gazz Chim acta 49 (II): 47 (1919); Acta Phytochim 1: 109 (1923); Phytochemistry 10: 3298 (1971) |
| 11756 | Magnaghi P, et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013 Sep;9(9):548-56. |
| 11757 | Li Y, et al. Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. Blood. 2011 Jun 16;117(24):6702-13. |
| 11758 | Montales MT, et al. Metformin and soybean-derived bioactive molecules attenuate the expansion of stem cell-like epithelial subpopulation and confer apoptotic sensitivity in human colon cancer cells. Genes Nutr. 2015 Nov;10(6):49. |
| 11759 | Amarjot Kaur Grewal, et al. Neuroprotective effect of pharmacological postconditioning on cerebral ischaemia-reperfusion-induced injury in mice. J Pharm Pharmacol. 2019 Jun;71(6):956-970. |
| 11760 | Chem Biol Interactions 84:277 (1992) |
| 11761 | Nakatsuji T, et al. Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol. 2009 Oct;129(10):2480-8. |
| 11762 | Indian J Chem 13: 835 (1975) |
| 11763 | Lefebvre E, et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016 Jun 27;11(6):e0158156 |
| 11764 | Kuwata T, et al. Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies. Antimicrob Agents Chemother. 2015 Nov 2;60(1):437-5 |
| 11765 | Visseaux B, et al. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. PLoS One. 2015 Aug 6;10(8):e0134904 |
| 11766 | Lalezari J, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. |
| 11767 | Baba M, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 2005 Nov;49(11):4584-91. |
| 11768 | Buchholz M, et al. The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. J Med Chem. 2006 Jan 26;49(2):664-77. |
| 11769 | DiPisa F, et al. The soluble Y115E-Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease. Acta Crystallogr F Struct Biol Commun. 2015 Aug;71(Pt 8):986-92. |
| 11770 | Huang KF, et al. Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding. J Biol Chem. 2011 Apr 8;286(14):12439-49. |
| 11771 | Breast Cancer Res 6:R63 (2004); Int J Engin Tech 1:282 (2009(; J Agric Sci 1 (2009) |
| 11772 | Lee JW, et al. Chemical Control of Mammalian Circadian Behavior through Dual Inhibition of Casein Kinase Iα and δ. J Med Chem. 2019 Feb 28;62(4):1989-1998. |
| 11773 | Rende M et al. Role of nerve growth factor and its receptors in non-nervous cancer growth: efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies antityrosine kinase receptor A and antinerve growth factor: an in-vitro and in-vivo study. Anticancer Drugs. 2006 Sep;17(8):929-41. |
| 11774 | Zhou Y et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 2006 Jan 1;66(1):404-11. |
| 11775 | Levitzki A, et al. Tyrosine kinase inhibition: an approach to drug development. Science. 1995 Mar 24;267(5205):1782-8. |
| 11776 | Pacold ME, et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat Chem Biol. 2016 Jun;12(6):452-8. |
| 11777 | El-Ahmad Y, et al. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo |
| 11778 | annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer. J Med Chem. 2019 Nov 27. |
| 11779 | Monsif Bouaboula, et al. Abstract 943: SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER<sup>+</sup> breast cancer. |
| 11780 | Vedadi M, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Jul 10;7(8):566-74. |
| 11781 | Fu L, et al. Effects of the Histone Methyltransferase Inhibitor UNC0638 on Histone H3K9 Dimethylation of Cultured Ovine Somatic Cells and Development of Resulting Early Cloned Embryos. Reprod Domest Anim. 2014 Apr;49(2):e21-5. |
| 11782 | Singh N, et al. Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells. J Interferon Cytokine Res. 2016 Jan;36(1):37-47. |
| 11783 | Ortiz MI, Rangel-Flores E, Carrillo-Alarcón LC, et al. Prevalence and impact of primary dysmenorrhea among Mexican high school students. Int J Gynaecol Obstet. 2009 Dec;107(3):240-3. |
| 11784 | Swanson JK, English JC 3rd. Serum sickness-like reaction to Pamabrom. J Drugs Dermatol. 2006 Mar;5(3):284-6. |
| 11785 | Di Girolamo G, Sánchez AJ, De Los Santos AR, et al. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea? Expert Opin Pharmacother. 2004 Mar;5(3):561-70. |
| 11786 | Pamabrom |Am Heart J 46:288 (1953); J Drugs Dermatol 5:284 (2006) |
| 11787 | Alao JP, et al. Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86. BMC Cancer. 2014 Nov 20;14:853. |
| 11788 | Finelli E, et al. Patch testing in a case of eslicarbazepine and carbamazepine induced cutaneous reaction. Eur Ann Allergy Clin Immunol. 2018 Sep;50(5):229-231. |
| 11789 | Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014. |
| 11790 | Boyce M, et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. Br J Clin Pharmacol. 2015 May;79(5):744-55. |
| 11791 | Takinami Y, et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.Aliment Pharmacol Ther. 1997 Feb;11(1):113-20. |
| 11792 | Stéphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8. |
| 11793 | J. Med. Chem. (1971), 14(4), 326-8; Br. Med. J. (1969), 4(5680), 399-401; J. Med. Chem. (1968), 11(6), 1118-21 |
| 11794 | Sun L, et al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem. 1999 Dec 16;42(25):5120-30. |
| 11795 | Kachel P, et al. Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue. BMC Cancer. 2015 Mar 18;15:140. |
| 11796 | Trzcińska-Daneluti AM, et al. RNA Interference Screen to Identify Kinases That Suppress Rescue of ΔF508-CFTR. Mol Cell Proteomics. 2015 Jun;14(6):1569-83. |
| 11797 | Izikki M, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest. 2009 Mar;119(3):512-23. |
| 11798 | Yang YZ, et al. Wogonoside displays anti-inflammatory effects through modulating inflammatory mediator expression using RAW264.7 cells. J Ethnopharmacol. 2013 Jun 21;148(1):271-6. |
| 11799 | Sun Y, et al. Wogonoside induces autophagy in MDA-MB-231 cells by regulating MAPK-mTOR pathway. Food Chem Toxicol. 2013 Jan;51:53-60. |
| 11800 | Stanchev M, et al. Synthesis and antimicrobial activity in vitro of new amino acids and peptides containing thiazole and oxazole moieties. Arch Pharm (Weinheim). 1999 Sep;332(9):297-304. |
| 11801 | Chowdhury AR, et al. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit. 2002 Jul;8(7):BR254-65. |
| 11802 | Gao Y, et al. Betulinic acid induces apoptosis and ultrastructural changes in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018 Jan-Feb;42(1):49-54. |
| 11803 | Kalra J, et al. Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice. Naunyn Schmiedebergs Arch Pharmacol. 2017 Dec 26. |
| 11804 | Hashimoto F, et al. Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorg Med Chem. 1997 Dec;5(12):2133-43. |
| 11805 | Kasperczyk H, et al. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene. 2005 Oct 20;24(46):6945-56. |Acta Chem Scand 19:1661 (1965); Nature Medicine 1: 046 (1995) |
| 11806 | Hata K, et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.Antimicrob Agents Chemother. 1996 Oct;40(10):2237-42. |
| 11807 | Fung-Tomc JC, et al. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)Antimicrob Agents Chemother. 1998 Feb;42(2):313-8. |
| 11808 | Hata K, et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.Antimicrob Agents Chemother. 1996 Oct;40(10):2243-7. |
| 11809 | Kanno T, et al. DCP-LA Activates Cytosolic PKCε by Interacting with the Phosphatidylserine Binding/Associating Sites Arg50 and Ile89 in the C2-Like Domain. Cell Physiol Biochem. 2015;37(1):193-200. |
| 11810 | Ardecky R, et al. Functional Antagonists of EBI-2. Probe Reports from the NIH Molecular Libraries Program [Internet]. |
| 11811 | Finlay MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67. |
| 11812 | Li C, et al. SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination. J Exp Clin Cancer Res. 2019 Feb 13;38(1):76. |
| 11813 | Rico-Bautista E, Zhu W, Kitada S, Small Molecule-Induced Mitochondrial Disruption Directs Prostate Cancer Inhibition via UPR Signaling. Oncotarget. 2013 Jul 14. |
| 11814 | Charvin D, et al. Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4. J Med Chem. 2017 Oct 26;60(20):8515-8537. |
| 11815 | Volpi C, et al. Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4. Expert Opin Drug Discov. 2018 May;13(5):411-423. |
| 11816 | Bastos DZL, et, al. Biotransformation of betulinic and betulonic acids by fungi. Phytochemistry. 2007 Mar;68(6):834-9. |
| 11817 | Yang SJ, et, al. Synthesis and biological evaluation of betulonic acid derivatives as antitumor agents. Eur J Med Chem. 2015;96:58-65. |
| 11818 | Sá MS, et, al. Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice. Parasitol Res. 2009 Jul;105(1):275-9. |
| 11819 | Pavlova NI, et, al. Antiviral activity of betulin, betulinic and betulonic acids against some enveloped and non-enveloped viruses. Fitoterapia. 2003 Jul;74(5):489-92. |
| 11820 | Coll Czech Chem Comm 16:168, 626 (1951); Ann Pharm Fr 10:412 (1952); Arzneim-Forsch 3:253 (1953); Experientia 37:680 (1981); Arch Pharm, 330:7 (1997) |
| 11821 | Jiang Y, et al. Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration. Toxicol Sci. 2015 Jan;143(1):107-15. |
| 11822 | Jin J, et al. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. Biopharm Drug Dispos. 2010 May;31(4):264-8. |
| 11823 | Jeong-Seok Kim, et al. Gomisin A modulates aging progress via mitochondrial biogenesis in human diploid fibroblast cells. Clin Exp Pharmacol Physiol. 2018 Jun;45(6):547-555. |
| 11824 | Am Heart J 92:397 (1976); J Urol 157:2132 (1997) |
| 11825 | Abulwerdi F, et al. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2014 Mar;13(3):565-575. |
| 11826 | J Urol 188:668 (2012); J Sex Med 9:2122 (2012)| |
| 11827 | Kotera J, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668-74. |
| 11828 | Wang R, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012 Aug;9(8):2122-9. |
| 11829 | Mochida H, et al. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. J Urol. 2013 Aug;190(2):799-806. |
| 11830 | Indian J Ophthalmol 57:175 (2009) |
| 11831 | Yamamoto N, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther. 2003 Sep;306(3):1174-81. |
| 11832 | Tümmler C, et al. SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro. Cancers (Basel). 2019 Feb 10;11(2). pii: E202. |
| 11833 | Gioia R, et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to AMN107 in chronic myeloid leukemia cells. Blood. 2011 Aug 25;118(8):2211-21. |
| 11834 | Kim SY, et al. Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells. PLoS One. 2015 Dec 31;10(12):e0146073. |
| 11835 | Terashita Z et al. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992 Feb;260(2):748-55. |
| 11836 | M Poeze, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock. 2000 Oct;14(4):421-8. |
| 11837 | https://clinicaltrials.gov/ct2/show/NCT04960202?term=Ritonavir&cond=covid&draw=2&rank=1 |
| 11838 | Beck HP, et al. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41. |
| 11839 | Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67(9), 4408-4417. |
| 11840 | Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322. |
| 11841 | Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. |
| 11842 | Cullinane C, et al. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52(8):1261-7 |
| 11843 | Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75(21):4548-59. |
| 11844 | Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7(349):ra102. |
| 11845 | Tucker ER, et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11(8):996-1006. |
| 11846 | Liu H, et al. Identifying and Targeting Sporadic Oncogenic GeneticLiu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369. |
| 11847 | Frank T. Zenke, et al. Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. Experimental and Molecular Therapeutics. |
| 11848 | Gorecki L, et al. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacol Ther. 2020 Feb 26:107518. |
| 11849 | George KM, et al. Design, Synthesis, and Biological Evaluation of PKD Inhibitors. Pharmaceutics. 2011;3(2):186-228. |
| 11850 | Esther C.Y. Lee et al. Identification of a novel conformationally constrained glucagon receptor antagonist. Bioorg Med Chem Lett, 2014 Feb 1, 24(3):839-44. |
| 11851 | Derek J Nunez, et al. Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). Diabetes Obes Metab. 2018 Feb;20(2):233-237. |
| 11852 | D J Kazierad, et al. Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2016 Aug;18(8):795-802. |
| 11853 | Arzneim Forsch 26:184 (1976) |
| 11854 | Carroll SS, et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009 Mar;53(3):926-34. |
| 11855 | Steed AL, et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science. 2017 Aug 4;357(6350):498-502. |
| 11856 | Liu J, et al. Sensitization of avian pathogenic Escherichia coli to NSC277174 in vitro and in vivo in the presence of surfactin. PLoS One. 2019 Sep 12;14(9):e0222413. |
| 11857 | Wei-Chuan Chena, et al. Applications of a lipopeptide biosurfactant, surfactin, produced by microorganisms. Biochemical Engineering Journal. 103 (2015) 158-169. |
| 11858 | Vollenbroich D, et al. Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis. Biologicals. 1997 Sep;25(3):289-97. |
| 11859 | Deane R, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012 Apr;122(4):1377-92. |
| 11860 | Hong Y, et al. Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-β Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus. Neurochem Res. 2016 May;41(5):1192-9. |
| 11861 | Lian YJ, et al. Ds-HMGB1 and fr-HMGB induce depressive behavior through neuroinflammation in contrast to nonoxid-HMGB1. Brain Behav Immun. 2017 Jan;59:322-332. |
| 11862 | Clin. Ther. (1989), 11(6), 812-9; Pediatr. Infect. Dis. (1982), 1(6), 384-7; Antibiot. Chemother. (1957), 7, 487-9 |
| 11863 | Yan T, et al. Paris saponin VII induces cell cycle arrest and apoptosis by regulating Akt/MAPK pathway and inhibition of P-glycoprotein in K562/ADR cells. Phytother Res. 2018 May;32(5):898-907. |
| 11864 | Li Y, et al. Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells. J Ethnopharmacol. 2019 Mar 25;232:47-54. |
| 11865 | Baba M, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5698-703. |
| 11866 | Takama Y, et al. Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model. Transpl Immunol. 2011 Jul;25(1):49-55. |
| 11867 | Ni J, et al. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br J Pharmacol. 2009 Dec;158(8):2046-56. |
| 11868 | Gao P, et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol. 2003 Feb;73(2):273-80. |
| 11869 | Nature 188:231 (1960); Compr Biochem 21:111 (1971); J Chem Soc(Perkin 1) 1985:1349; Tetrahedron 42:117 (1986) |
| 11870 | Choi WY, et al. Anti-inflammatory, antioxidative and matrix metalloproteinase inhibitory properties of 20(R)-ginsenoside Rh2 in cultured macrophages and keratinocytes. J Pharm Pharmacol. 2013 Feb;65(2):310-6. |
| 11871 | Chung KS, et al. Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression. Carcinogenesis. 2013 Feb;34(2):331-40. |
| 11872 | Choi S, et al. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res. 2009 Oct;26(10):2280-8. |
| 11873 | Kang S, et al. Antiviral activity of 20(R)-ginsenoside Rh2 against murine gammaherpesvirus. J Ginseng Res. 2017 Oct;41(4):496-502. |
| 11874 | Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Jul 18. |
| 11875 | Catlett I, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Annals of the Rheumatic Diseases 2017;76:859. |
| 11876 | Cotten JF, et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg, 2006, 102(3), 779-785. |
| 11877 | Anderson-Beck, R., et al., Doxapram stimulates dopamine release from the intact rat carotid body in vitro. Neurosci Lett, 1995. 187(1): p. 25-8. |
| 11878 | Peers, C., Effects of doxapram on ionic currents recorded in isolated type I cells of the neonatal rat carotid body. Brain Res, 1991. 568(1-2): p. 116-22. |
| 11879 | Lee L, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker. Clin Cancer Res. 2009 Dec 1;15(23):7368-74. |
| 11880 | Tegnebratt T, et al. Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. EJNMMI Res. 2014 Dec;4(1):34. |
| 11881 | Xudan Wei, et al. Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2017 Apr;31(4). |
| 11882 | Anal Profiles Drug Subs 1:397 (1972); 11:615 (1982) |
| 11883 | Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019). |
| 11884 | Brameld KA, et al. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. J Med Chem. 2017 Aug 10;60(15):6516-6527. |
| 11885 | Devendra S Puntambekar, et al. Inhibition of farnesyltransferase: a rational approach to treat cancer? J Enzyme Inhib Med Chem. 2007 Apr;22(2):127-40. |
| 11886 | Martin LA, et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with ICI 47699 acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther. 2007 Sep;6(9):2 |
| 11887 | End DW, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001 Jan 1;61(1):131-7 |
| 11888 | Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. |
| 11889 | Drugs (2011), 71(4), 489-514; Eur. J. Pharmacol. (1995), 286(2), 137-46; Eur. J. Pharmacol. (1992), 222(2-3), 193-203| |
| 11890 | Oliveira AA, et al. Evaluation of levetiracetam effects on pilocarpine-induced seizures: cholinergic muscarinic system involvement. Neurosci Lett. 2005 Sep 16;385(3):184-8. |
| 11891 | Axten JM, et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulu |
| 11892 | Zhang M, et al. Inhibiting the Plasmodium eIF2α Kinase PK4 Prevents Artemisinin-Induced Latency. Cell Host Microbe. 2017 Dec 13;22(6):766-776.e4. |
| 11893 | Naunyn Schmiedebergs Arch Pharmacol 359: 262 (1999) |
| 11894 | Boerrigter G, et al. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.Circ Heart Fail. 2012 Sep 1;5(5):627-34. Epub 2012 Aug 13. |
| 11895 | Liu CH, et al. Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling.Nat Commun. 2017 Feb 9;8:14335. |
| 11896 | Barsyte-Lovejoy D, et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12853-8. |
| 11897 | Drugs Today (1978), 14(5), 205-9; J. Ocul. Pharmacol. (1990), 6(4), 271-8; J. Med. Chem. (1984), 27(6), 810-2 |
| 11898 | Wang Z, et al. Mollugin Has an Anti-Cancer Therapeutic Effect by Inhibiting TNF-α-Induced NF-κB Activation. Int J Mol Sci. 2017 Jul 26;18(8). |
| 11899 | Moon SH, et al. Mollugin enhances the osteogenic action of BMP-2 via the p38-Smad signaling pathway. Arch Pharm Res. 2017 Nov;40(11):1328-1335. |
| 11900 | https://clinicaltrials.gov/ct2/show/NCT04461340?term=Rapamycin&cond=covid&draw=2&rank=4 |
| 11901 | Cencic R, et al. Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol. 2011 Jul;85(13):6381-9. |
| 11902 | Jensen SK, et al. Alpha-tocopherol stereoisomers. Vitam Horm. 2007;76:281-308. |
| 11903 | Manor D, et al. The alpha-tocopherol transfer protein. Vitam Horm. 2007;76:45-65. |
| 11904 | Frederique Tellier , et al. Characterization of Metabolites of Fungicidal Cymoxanil in a Sensitive Strain of Botrytis Cinerea. J Agric Food Chem. 2008 Sep 10;56(17):8050-7. |
| 11905 | Park BC, et al. Asiatic acid induces apoptosis in SK-MEL-2 human melanoma cells. Cancer Lett. 2005 Jan 31;218(1):81-90. |
| 11906 | Huang SS, et al. Antinociceptive activities and the mechanisms of anti-inflammation of asiatic Acid in mice. Evid Based Complement Alternat Med. 2011;2011:895857. |
| 11907 | J Antibiot 23:131 (1970); J Infect Dis 128 Suppl:379 (1973) |
| 11908 | Ruenitz PC, et al. Estrogenic tamoxifen derivatives: categorization of intrinsic estrogenicity in MCF-7 cells. J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6):203-9. |
| 11909 | Lounkine E, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012 Jun 10;486(7403):361-7. |
| 11910 | Kupfer D, et al. Inactivation of the uterine estrogen receptor binding of estradiol during P-450 catalyzed metabolism of chlorotrianisene (TACE). Speculation that TACE antiestrogenic activity involves covalent binding to the estrogen receptor. FEBS Lett. 1990 Feb 12;261(1):59-62. |
| 11911 | Welsh SJ, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003 Mar;2(3):235-43. |
| 11912 | Metcalfe C, et al. Thioredoxin Inhibitors Attenuate Platelet Function and Thrombus Formation. PLoS One. 2016 Oct 7;11(10):e0163006 |
| 11913 | Ramanathan RK, et al. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2109-14. |
| 11914 | Wang F, et al. Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines. Oncol Rep. 2015 Feb;33(2):967-73. |
| 11915 | Lou M, et al. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem. 2017 Jun 2;292(22):9136-9149. |
| 11916 | Japan J Pharmacol 33:301 (1983); Hepato-Gastroenterology 49:193 (2002) |
| 11917 | Lénárt P, et al. The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1. Curr Biol. 2007 Feb 20;17(4):304-15. |
| 11918 | Chen L, et al. BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Med Chem Lett. 2015 May 18;6(7):764-9. |
| 11919 | Steegmaier M, et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo. Current Biology (2007), 17(4), 316-322. |
| 11920 | Malik N, et al. Suppression of IFN β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochem J. 2015 Jun 15;468(3):363-72. |
| 11921 | https://clinicaltrials.gov/ct2/show/NCT04517396?term=FENOFIBRIC+ACID&cond=Covid19&draw=2&rank=1 |
| 11922 | Pignatello MA, et al. Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition. Toxicol Appl Pharmacol. 1997 Feb;142(2):319-27. |
| 11923 | Tran TA, et al. Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. J Med Chem. 2017 Feb 9;60(3):913-927. |
| 11924 | Zhang C, et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5689-94. |
| 11925 | Louvet C, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18895-900. |
| 11926 | Gormally MV, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014 Nov 12;5:5165. |
| 11927 | Daniele S, et al. Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells. ACS Chem Neurosci. 2017 Jan 18;8(1):100-114. |
| 11928 | https://clinicaltrials.gov/ct2/show/NCT04570449?term=FLUOXETINE&cond=COVID-19&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04377308?term=FLUOXETINE&cond=COVID-19&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04780152?term=FLUOXETINE&cond=COVID-19&draw=2&rank=3 https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200904048616N1 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04377308 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04570449 |
| 11929 | J Agri Food Chem 27:1365 (1979); Soil Sci Soc Am J 50:1353 (1986); Fertilizer Res 22:37 (1990), Soil Biol Biochem 42:1425 (2010) |
| 11930 | Edwards A, et al. Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis Model Mech. 2011 Jul;4(4):496-503. |
| 11931 | J Clin Endocrinol Metab 47:1336 (1978); J Neurosci 1:132 (1981); Stereotactic Functional Neurosurgery 69:243 (1997) |
| 11932 | Ann. Biochem. Exp. Med. (1960), 20, 441-8; J. Antimicrob. Chemother. (1980), 6(5), 577-93 |
| 11933 | Cao W, et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep. 2015 Jul 13;5:8477 |
| 11934 | Yi X, Vivien B, Lynch C 3rd. Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pigventricular myocytes. |
| 11935 | Huraux C, Makita T, Szlam F, The vasodilator effects of clevidipine on human internal mammary artery. Anesth Analg. 1997 Nov;85(5):1000-4. |
| 11936 | Ericsson H, et al. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37. |
| 11937 | Ericsson H, et al. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos. 1999 May;27(5):558-64. |
| 11938 | Schwieler JH, et al. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol. 1999 Aug;34(2):268-74. |
| 11939 | Kobayashi Y, et al. Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood. J Antimicrob Chemother. 1992 Dec;30(6):871-2. |
| 11940 | Guay DR, et al. Aztreonam, a new monobactam antimicrobial. Clin Pharm. 1985 Sep-Oct;4(5):516-26. |J Antimicrob Chemother 8 Suppl E:1 (1981); 9:328 (1982); Rev Infect Dis 13 Suppl 7:S591 (1991) |
| 11941 | Isoe T, et al. Inhibition of different steps of the ubiquitin system by CDDP and aclarubicin. Biochim Biophys Acta. 1992 Sep 15;1117(2):131-5. |
| 11942 | Hajji N, et al. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583(1):26-35. |
| 11943 | Iihoshi H, et al. Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells. Toxicol Lett. 2017 Aug 5;277:109-114. |
| 11944 | Hori S, et al. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gan. 1977 Oct;68(5):685-90. |
| 11945 | Med Res Rev 7: 29 (1987); Am J Trop Med Hyg 61:187 (199); Trends Pharmacol Sci 20:199 (1999) |
| 11946 | Akeno-Stuart N, et al. The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells. Cancer Res. 2007 Jul 15;67(14):6956-64. |
| 11947 | Weisberg E, et al. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15;112(13):5161-70. |
| 11948 | Hart S, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011 Nov;25(11):1751-9. |
| 11949 | Hart S, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011 Nov;1(11):e44. |
| 11950 | William AD, et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JA |
| 11951 | Markowitz D, et al. Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma. Mol Cancer Ther. 2016 Aug;15(8):1799-808. |
| 11952 | Ann Rev Biochem 20:4955 (1951); Am J Physiol 203:975 (1962); Diabetes Obesity Metab 11:79 (2009) |
| 11953 | Wu L, et al. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol. 2012 Dec 21;19(12):1515-24. |
| 11954 | Pavlides SC, et al. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer. Endocrinology. 2013 Nov;154(11):4030-45. |
| 11955 | Braestrup C, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J Neurochem. 1990 Feb;54(2):639-47. |
| 11956 | Sheehan, D.V., et al., An open-label study of tiagabine in panic disorder. Psychopharmacol Bull, 2007. 40(3): p. 32-40. |
| 11957 | Henjum, S. and B. Hassel, High-affinity GABA uptake and GABA-metabolizing enzymes in pig forebrain white matter: a quantitative study. Neurochem Int, 2007. 50(2): p. 365-70. |
| 11958 | Bialkowska A, et al. ML264: An Antitumor Agent that Potently and Selectively Inhibits Krüppel-like Factor Five (KLF5) Expression: A Probe for Studying Colon Cancer Development and Progression. |
| 11959 | Ruiz de Sabando A, et al. ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer. Mol Cancer Ther. 2016 Jan;15(1):72-83. |
| 11960 | Patrick R Visperas, et al. Identification of Inhibitors of the Association of ZAP-70 With the T Cell Receptor by High-Throughput Screen. SLAS Discov. 2017 Mar;22(3):324-331. |
| 11961 | Lohar P, et al. Simultaneous bioanalysis and pharmacokinetic interaction study of acebrophylline, levocetirizine and pranlukast in Sprague-Dawley rats. Biomed Chromatogr. 2019 Dec;33(12):e4672. |
| 11962 | Li S, et al. Evaluation of the Antibacterial Effects and Mechanism of Action of Protocatechualdehyde against Ralstonia solanacearum. Molecules. 2016 Jun 9;21(6). |
| 11963 | Choi J, et al. Anticancer activity of protocatechualdehyde in human breast cancer cells. J Med Food. 2014 Aug;17(8):842-8. |
| 11964 | Jeong JB, et al. Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. Biochem Biophys Res Commun. 2013 Jan 4;430(1):381-6. |
| 11965 | Ashok Arasappan, et al. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS<sub>3</sub> Serine Protease Inhibitor. ACS Med Chem Lett. 2010 Feb 15;1(2):64-9. |
| 11966 | X Tong, et al. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS<sub>3</sub> protease. Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70. |
| 11967 | Li ZY, et al. Sophoraflavanone G Induces Apoptosis in Human Leukemia Cells and Blocks MAPK Activation.Am J Chin Med. 2016;44(1):165-76. |
| 11968 | Huang WC, et al. Sophoraflavanone G from Sophora flavescens induces apoptosis in triple-negative breast cancer cells.Phytomedicine. 2019 Aug;61:152852. |
| 11969 | Bonfanti JF, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem. 2008 Feb 28;51(4):875-96. |
| 11970 | Rouan MC, et al. Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. Antimicrob Agents Chemother. 2010 Nov;54(11):4534-9. |
| 11971 | Olszewska W, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011 Aug;38(2):401-8. |
| 11972 | Drugs (1988), 36(1), 32-66; Antimicrob. Agents Chemother. (1985), 28(5), 716-21; J. Med. Chem. (1984), 27(3), 292-301 |
| 11973 | Yi PF, et al. Peimine impairs pro-inflammatory cytokine secretion through the inhibition of the activation of NF-κB and MAPK in LPS-induced RAW264.7 macrophages. Immunopharmacol Immunotoxicol. 2013 Oct;35(5):567-72. |
| 11974 | J. Pharmacol. Exp. Ther. (1957), 120, 46-51; J. Pharm. Chim. (1930), 11, 385-95,429-44; Bull. Soc. Chim. Fr. (1926), 1147-67 |
| 11975 | Li H, The anticholinergic drug oxybutynin inhibits voltage-dependent K<sup>+</sup> channels in coronary arterial smooth muscle cells. Clin Exp Pharmacol Physiol. 2019 Nov;46(11):1030-1036. |
| 11976 | Degterev A, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul;1(2):112-9. |
| 11977 | Linkermann A, et al. The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013 Oct;24(10):1545-57. |
| 11978 | Huang C, et al. Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One. 2013 Jun 28;8(6):e66326. |
| 11979 | Feyen D, et al. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013 Jul 1;99(1):83-91. |
| 11980 | Zhou K, et al. RIP1-RIP3-DRP1 pathway regulates NLRP3 inflammasome activation following subarachnoid hemorrhage. Exp Neurol. 2017 Sep;295:116-124. |
| 11981 | Chan CH et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013 Aug 1;154(3):556-68. |
| 11982 | Chan CH, et al. Skp2: a dream target in the coming age of cancer therapy. Cell Cycle. 2014;13(5):679-80. |
| 11983 | Eur J Clin Pharmacol 45:313 (1993); J Clin Pharmacol 34:335 (1994); Expert Opin Invest Drugs 9:841 (2000); J Clin Psychiatry 4:38 (2002) |
| 11984 | Young SD, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5. |
| 11985 | Held DM, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281(35):25712-22. |
| 11986 | Grobler JA, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007 Mar 16;282(11):8005-10. |
| 11987 | Barb AW, et al. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Biochemistry. 2007 Mar 27;46(12):3793-802. |
| 11988 | Barb AW, et al. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18433-8. |
| 11989 | Tan JH, et al. In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm. Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02223-16. |
| 11990 | Murata T, et al. Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg Med Chem Lett. 2004 Aug 2;14(15):4019-22. |
| 11991 | Sanda T, et al. Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor. Leukemia. 2006 Apr;20(4):590-8. |
| 11992 | WO 2013/100632 A1. |
| 11993 | Bamborough P et al. GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. ACS Med Chem Lett. 2016 May 9;7(6):552-7. |
| 11994 | Nakanishi O, et al. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol Res. 1997;9(2):61-9. |
| 11995 | Naito M, et al. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res. 2002 Feb;8(2):582-8. |
| 11996 | Nokihara H, et al. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells. Jpn J Cancer Res. 2001 Jul;92(7):785-92. |
| 11997 | Katayama R, et al. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci. 2009 Nov;100(11):2060-8. |
| 11998 | Ong CC, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Res. 2015 Apr 23;17:59. |
| 11999 | Mortazavi F, et al. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. BMC Cancer. 2015 May 9;15:381. |
| 12000 | J Cardiovas Pharmacol 8:805 (1986); Eur Neurol 38:31 (1997) |
| 12001 | J Chem Soc 1940: 1370; Proc Chem Soc 1959: 91; Tet Letts 1962: 318 |
| 12002 | https://clinicaltrials.gov/ct2/show/NCT04459533?term=ATRACURIUM&cond=COVID-19&draw=2&rank=1 |
| 12003 | Michael Niesman, et al. Treatment of autoimmune disease. WO2015179847A1. |
| 12004 | Ding X, et al. Purification, antitumor activity in vitro of steroidal glycoalkaloids from black nightshade (Solanum nigrum L.). Food Chem. 2013 Nov 15;141(2):1181-6. |
| 12005 | Ber 67: 59 (1934); Chem Pharm Bull 38: 2498 (1990) |
| 12006 | Moon K, et al. The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 22 (2012) 4979–4985 |
| 12007 | JR Burke, et al. BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis. 2017 ACR/ARHP Annual Meeting, September 18, 2017. |
| 12008 | Watterson SH, et al. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). J Med Chem. 2019 Apr 11;62(7):3228-3250. |
| 12009 | Lazo JS, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 2001 Nov 22;44(24):4042-9. |
| 12010 | Guo J, et al. Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284). Anticancer Res. 2007 Sep-Oct;27(5A):3067-73. |
| 12011 | Coussens NP, et al. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2. J Biol Chem. 2018 Aug 31;293(35):13750-13765. |
| 12012 | I I Scheetz ME, D G Carlson, and M R Schinitsky Frentizole, a novel immunosuppressive, and azathioprine: their comparative effects on host resistance to Pseudomonas aeruginosa, Candida albicans, herpes simplex virus, and influenza (Ann Arbor) virus. Infect Immun. 1977 January; 15(1): 145-148. |
| 12013 | Hatfield SM, Hartley LW, Schmidtke JR. The immunomodulatory action of frentizole, a novel immunosuppressive agent. Immunopharmacology. 1982 Dec;5(2):169-79. |
| 12014 | Xie, Yuli; Deng, Shixian; Chen, Zhenzhang et al. Identification of small-molecule inhibitors of the Aβ-ABAD interaction. Bioorganic & Medicinal Chemistry Letters (2006), 16(17), 4657-4660. |
| 12015 | Fukushima K, et al. Characterization of Human Hippocampal Neural Stem/Progenitor Cells and Their Application to Physiologically Relevant Assays for Multiple Ionotropic Glutamate Receptors. J Biomol Screen. 2014 Sep; 19(8):1174-84. |
| 12016 | Wen Chen, et al. AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets. PLoS One. 2016 Nov 23;11(11):e0166672. |
| 12017 | World Poultry 19:1 (2003); J Appl Poult Res 18:766 (2009) |
| 12018 | Clin Exp Pharmacol Physiol 18: 163 (1991) |
| 12019 | Bul Chem Soc Japan 16: 284 (1941); J Pharm Pharmacol 28:599 (1976) |
| 12020 | Jacobs RT, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011 Jun;5(6):e1151. |
| 12021 | Liu F, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53(15):5844-57. |
| 12022 | Liu F, et al. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J Med Chem. 2011 Sep 8;54(17):6139-50. |
| 12023 | Xiaoqian Zhou , et al. The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis. Gastroenterol Res Pract. 2019 Feb 28;2019:3480732. |
| 12024 | K Shimamoto, et al. Myriatic Effect of 9-(gamma-dimethylamino-propylidene)-10, 10-diemthyl-9, 10-dihydroanthracene Hydrochloride (Melitracen) in Mice and Rats. Acta Sch Med Univ Kioto. 1967 Jul;40(1):38-47. |
| 12025 | Arzneim Forsch 19:1413 (1969); Pharmacotherapy 5:43 (1985) |
| 12026 | Prog Chem Org Nat Prod 9: 225 (1952) |
| 12027 | Floss HG, et al. Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev. 2005 Feb;105(2):621-32. |
| 12028 | Arzneim Forsch 20:1467 (1970); Exp Hematol 2:101 (1974); Mutat Res 168:15 (1986) |
| 12029 | Ohno H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43. |
| 12030 | Boru Hou, et al. Ki20227 influences the morphology of microglia and neurons through inhibition of CSF1R during global ischemia. Int J Clin Exp Pathol. 2016;9(12):12459-12469. |
| 12031 | Renoux G, et al. Isoprinosine as an immunopotentiator. J Immunopharmacol. 1979;1(3):337-56. |
| 12032 | Delaunay JL, et al. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770). Hepatology. 2017 Feb;65(2):560-570 |
| 12033 | Mutyam V, et al. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation. J Cyst Fibros. 2017 Jan;16(1):24-29 |
| 12034 | Hadida S, et al. Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator. J Med Chem. 2014 Dec 11;57(23):9776-9 |
| 12035 | Van Goor F, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30. |
| 12036 | Frank Wu, et al. Kinase inhibitor and use thereof. US20180000819A1. |
| 12037 | Chen J, et al. Dioscin-induced apoptosis of human LNCaP prostate carcinoma cells through activation of caspase-3 and modulation of Bcl-2 protein family. J Huazhong Univ Sci Technolog Med Sci. 2014 Feb;34(1):125-30. |
| 12038 | Qu X, et al. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. Biochem Biophys Res Commun. 2014 Jan 10;443(2):658-65. |
| 12039 | Qin J, et al. Dioscin prevents the mitochondrial apoptosis and attenuates oxidative stress in cardiac H9c2 cells. Drug Res (Stuttg). 2014 Jan;64(1):47-52. |
| 12040 | Ranatunga S, et al. Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. J Med Chem. 2014 May 22;57(10):4289-301. |
| 12041 | Tang CH, et al. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest. 2014 Jun;124(6):2585-98. |
| 12042 | Krawczyk E, et al. Cytotoxic, antiviral (in-vitro and in-vivo), immunomodulatory activity and influence on mitotic divisions of three taxol derivatives: 10-deacetyl-baccatin III, methyl (N-benzoyl-(2'R,3'S)-3'-phenylisoserinate) and N-benzoyl-(2'R,3'S)-3'-phenylisoserine. J Pharm Pharmacol. 2005;57(6):791‐797. |
| 12043 | A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory). |
| 12044 | JACS 63:3165 (1941) |
| 12045 | https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=ACETAMINOPHEN&cntry=&state=&city=&dist= |
| 12046 | Wu CY, et al. Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway. Oncotarget. 2017 Feb 1. |
| 12047 | Ip SP, et al. Dihydroisotanshinone I protects against menadione-induced toxicity in a primary culture of rat hepatocytes. Planta Med. 2002 Dec;68(12):1077-81. |
| 12048 | Helv Chim Acta 8: 140 (1925); Pharmacology 14: 1 (1976) |
| 12049 | Biochem. J. (1972), 127(5), 86P; Nature (1962), 193, 493-4; Arch. Int. Pharmacodyn. Ther. (1955), 103, 120-8 |
| 12050 | Gong Z, et al. Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice. |
| 12051 | Zhao W, et al. Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620colorectal cancer cells. Mol Carcinog. 2018 Feb;57(2):193-200. |
| 12052 | Qiu Z, et al. In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol. 2013 Sep;59:428-37. |
| 12053 | González-Sarrías A, et al. Antiproliferative activity of the ellagic acid-derived gut microbiota isourolithin A and comparison with its urolithin A isomer: the role of cell metabolism.Eur J Nutr. 2017 Mar;56(2):831-841. |
| 12054 | Wang Y, et al. In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells. Toxicol In Vitro. 2015 Aug;29(5):1107-15. |
| 12055 | Ishimoto H, et al. In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5901-4. |
| 12056 | Firestone AJ, et al. Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature. 2012 Mar 18;484(7392):125-9. |
| 12057 | Miao Y, et al. Dynein promotes porcine oocyte meiotic progression by maintaining cytoskeletal structures and cortical granule arrangement. Cell Cycle. 2017;16(21):2139-2145. |
| 12058 | Wen Q, et al. Dynein 1 supports spermatid transport and spermiation during spermatogenesis in the rat testis. Am J Physiol Endocrinol Metab. 2018 Nov 1;315(5):E924-E948. |
| 12059 | Wang X, et al. Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget. 2017 Apr 18;8(16):26245-26255. |
| 12060 | Toyama T, et al. Tamibarotene Ameliorates Bleomycin-Induced Dermal Fibrosis by Modulating Phenotypes of Fibroblasts, Endothelial Cells, and Immune Cells. J Invest Dermatol. 2016 Feb;136(2):387-98. |
| 12061 | Jin Y, et al. Tamibarotene modulates the local immune response in experimental periodontitis. Int Immunopharmacol. 2014 Dec;23(2):537-45. |
| 12062 | Lv XR, et al. Synthetic retinoid Am80 up-regulates apelin expression by promoting interaction of RARα with KLF5 and Sp1 in vascular smooth muscle cells. Biochem J. 2013 Nov 15;456(1):35-46. |
| 12063 | Kitaoka K, et al. The retinoic acid receptor agonist Am80 increases hippocampal ADAM10 in aged SAMP8 mice. Neuropharmacology. 2013 Sep;72:58-65. |
| 12064 | Zabludoff SD, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008 Sep;7(9):2955-66. |
| 12065 | Quin J, et al. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget. 2016 Aug 2;7(31):49800-49818. |
| 12066 | https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN67000769 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04563845 |
| 12067 | Phytochemistry 9: 2537 (1970) |
| 12068 | Hiyoshi H, et al. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. Sci Rep. 2014 Nov 18;4:7095. |
| 12069 | Tochinai R, et al. Combretastatin A4 disodium phosphate-induced myocardial injury. J Toxicol Pathol. 2016 Jul;29(3):163-71. |
| 12070 | Signoretto E, et al. Stimulation of Eryptosis by Combretastatin A4 Phosphate Disodium (CA4P). Cell Physiol Biochem. 2016;38(3):969-8 |
| 12071 | Zhu J, et al. Co-Encapsulation of Combretastatin-A4 Phosphate and Doxorubicin in Polymersomes for Synergistic Therapy of Nasopharyngeal Epidermal Carcinoma. J Biomed Nanotechnol. 2015 Jun;11(6):997-1006. |
| 12072 | Yao N, et al. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo. Tumour Biol. 2015 Nov;36(11):8499-510 |
| 12073 | Medicherla S, et al. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. |
| 12074 | J Bacteriol 98:23 (1969) |
| 12075 | Veraldi S, et al. Isoconazole nitrate: a unique broad-spectrum antimicrobial azole effective in the treatment of dermatomycoses, both as monotherapy and in combination with corticosteroids. Mycoses. 2013 May;56 Suppl 1:3-15. |
| 12076 | Gugnani HC, et al. Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses. 1994 Jan-Feb;37(1-2):39-41. |
| 12077 | Am J Health-System Pharm 65:403 (2008); Psychosomatics 51:80 (2010)| |
| 12078 | Peng L, et al. Paliperidone protects prefrontal cortical neurons from damages caused by MK-801 via Akt1/GSK3β signaling pathway. Schizophr Res. 2013 Jun;147(1):14-23. |
| 12079 | Yang MC, et al. Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology (Berl). 2011 Oct;217(3):397-410. |
| 12080 | Kalman S, et al. 9-hydroxy-risperidone (9OHRIS) prevents stress-induced β-actin overexpression in rat hippocampus. Neuropsychopharmacol Hung. 2010 Sep;12(3):425-31. |
| 12081 | Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163-1191. Published 2014 Oct 13. |
| 12082 | Chem Commun 1968:1390; Phytochemistry 17:1375,1395 (1978) |
| 12083 | Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. |
| 12084 | Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. |
| 12085 | Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839. |
| 12086 | Smith BD, et al. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated DrugResistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015 Sep;14(9):2023-34. |
| 12087 | Rhodes N, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res, 2008, 68(7), 2366-2374. |
| 12088 | Levy DS, et al. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood, 2009, 113(8), 1723-1729. |
| 12089 | Altomare DA, et al. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res, 2010, 16(2), 486-496. |
| 12090 | Konno H, et al. Pro-inflammation Associated with a Gain-of-Function Mutation (R284S) in the Innate Immune Sensor STING. Cell Rep. 2018 Apr 24;23(4):1112-1123. |
| 12091 | Natarajan K, et al. Stafia-1: a STAT5a-Selective Inhibitor Developed via Docking-Based Screening of in Silico O-Phosphorylated Fragments. Chemistry. 2020;26(1):148-154. |
| 12092 | Drugs 28:281 (1984); Anal Profiles Drug Subs 4:47 (1975) |
| 12093 | Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5368-78. |
| 12094 | Kirby WM, et al. Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis. 1973 Oct;128:Suppl:S341-6. |
| 12095 | Edin ML, et al. Effect of cefazolin and vancomycin on osteoblasts in vitro. Clin Orthop Relat Res. 1996 Dec;(333):245-51. |
| 12096 | Engel CK, et al. Structural basis for the highly selective inhibition of MMP-13. Chem Biol. 2005 Feb;12(2):181-9. |
| 12097 | Thomas S. Lisse, et al. Paclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafish. Proc Natl Acad Sci U S A. 2016 Apr 12; 113(15): E2189–E2198. |
| 12098 | Xiong Cai et al Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer J. Med. Chem., 2010, 53 (5), pp 2000–2009 |
| 12099 | Sun H, et al. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Horm Cancer. 2016 Jun;7(3):196-210. |
| 12100 | Zhang L, et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget. 2015 Apr 20;6(11):9073-85. |
| 12101 | Lai CJ, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.Cancer Res. 2010 May 1;70(9):3647-56. Epub 2010 Apr 13. |
| 12102 | Gong L, et al. Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. |
| 12103 | Patsch C, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. 2015 Aug;17(8):994-1003. |
| 12104 | Fertil Steril 12:402 (1961); 28:707 (1977); Hum Reprod Update 2:483 (1996) |
| 12105 | Phytochemistry 4: 523 (1965); J Nat Prod 47:179 (1984) |
| 12106 | Leo Jakman, Characterization of small-molecule GDNF mimics. |
| 12107 | Ivanova L, et al. Molecular Dynamics Simulations of the Interactions between Glial Cell Line-DerivedNeurotrophic Factor Family Receptor GFRα1 and Small-Molecule Ligands. ACS Omega. 2018 Sep 30;3(9):11407-11414. |
| 12108 | Chin NX, et al. In vitro activity of cefquinome, a new cephalosporin, compared with other cephalosporin antibiotics. Diagn Microbiol Infect Dis. 1992 May-Jun;15(4):331-7. |
| 12109 | Johannessen L, et al. Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nat Chem Biol. 2017 Oct;13(10):1102-1108 |
| 12110 | Jain KK. Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs. 2004 Jan;5(1):76-81. |
| 12111 | Nature 210:627 (1966); 211:742 (1966); Ann Revi Plant Biol 6:165 (2005) |
| 12112 | Toxicol Appl Pharmacol 18:185 (1971); Drugs Aging 6:243 (1995) |
| 12113 | J Agr Food Chem 12: 127 ( (1964) |
| 12114 | Korba BE, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
 Antiviral Res. 2008 Jan;77(1):56-63. |
| 12115 | Ashton LV, et al. In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide. Vet Med Int. 2010 Aug 12;2010. pii: 891010. |
| 12116 | Korba BE, et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008 Nov;52(11):4069-71. |
| 12117 | Trabattoni D, et al. Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication. Sci Rep. 2016 Jun 2;6:27148. |
| 12118 | Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45. |
| 12119 | Kaltenmeier CT, et al. A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther. 2017 Apr;361(1):39-50. |
| 12120 | Leirós GJ, et al. Triolein reduces MMP-1 upregulation in dermal fibroblasts generated by ROS production in UVB-irradiated keratinocytes. J Dermatol Sci. 2017 Feb;85(2):124-130. |
| 12121 | Chemotherapy 26:276 (1980) |
| 12122 | Sun H, et al. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016 Apr 5;7(14):18736-49 |
| 12123 | Zhang L, et al. IRE1 inhibition perturbs the unfolded protein response in a pancreatic β-cell line expressing mutant proinsulin, but does not sensitize the cells to apoptosis. BMC Cell Biol. 2014 Jul 10;15:29. |
| 12124 | Mimura N, et al. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14;119(24):5772-81 |
| 12125 | http://www.chemicalland21.com/lifescience/phar/N-METHYL-D-GLUCAMINE.htm |
| 12126 | Souza ALR, et, al. Meglumine-based supra-amphiphile self-assembled in water as a skin drug delivery system: Influence of unfrozen bound water in the system bioadhesiveness. Colloids Surf B Biointerfaces. 2019 Dec 1;184:110523. |Radiology (1992), 183(1), 227-38; AJR, Am. J. Roentgenol. (1991), 156(3), 457-66; J. Protozool. (1981), 28(1), 27-30 |
| 12127 | Christine Lemieux, et al. ARRY-520, a Novel, Highly Selective KSP Inhibitor with Potent Anti-Proliferative Activity. AACR Annual Meeting. 2007. |
| 12128 | BZ Carter, et al. Inhibition of KSP by ARRY-520 Induces Cell Cycle Block and Cell Death via the Mitochondrial Pathway in AML Cells. |
| 12129 | Ki Hyung Kim, et al. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med. 2009; 7: 63. |
| 12130 | https://clinicaltrials.gov/ct2/show/NCT04834752?term=Ranitidine&cond=Covid19&draw=2&rank=1; https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/08/027394 |
| 12131 | Adv. Neurol. (1980), 27, 587-96; Neurology (1983), 33(4), 414-8; Neurology (1981), 31(6), 741-4 |
| 12132 | https://clinicaltrials.gov/ct2/show/NCT04715932?term=Hesperidin&cond=covid-19&draw=2&rank=1 |
| 12133 | J Chem Soc 1969:365; Phytochemistry 44:787 (1997) |
| 12134 | Sparve E et al. Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839. J Pharmacol Exp Ther. 2014 Aug;350(2):469-78. |
| 12135 | Jeppsson F et al. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57. |
| 12136 | Hafner M, et al. Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance. Nature. 2006 Dec 14;444(7121):941-4. |
| 12137 | Tzeng YM, et al. Kaempferitrin activates the insulin signaling pathway and stimulates secretion of adiponectin in 3T3-L1 adipocytes. Eur J Pharmacol. 2009 Apr 1;607(1-3):27-34. |
| 12138 | Alonso-Castro AJ, et al. Kaempferitrin induces apoptosis via intrinsic pathway in HeLa cells and exerts antitumor effects. J Ethnopharmacol. 2013 Jan 30;145(2):476-89. |
| 12139 | Chem Ber 92: 1880 (1959); 100: 2561 (1967) |
| 12140 | https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04630002 |
| 12141 | Gardner CJ, et al. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept. 1996 Aug 27;65(1):45-53. |
| 12142 | Phytochemistry 13:1943 (1974) |
| 12143 | Sato T, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer. 2008;51(6):774-777. |
| 12144 | Iizawa Y, et al. Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice. Antimicrob Agents Chemother. 1993;37(1):100-105. |
| 12145 | Grebien F, et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015 Aug;11(8):571-578. |
| 12146 | Curr Ther Res 35:1033 (1984); 36:293 (1984); Biopharm Drug Dispos 7:301 (1986) |
| 12147 | J Pharm Sci 53:1143 (1964); Toxicol Appl Pharmacol 16:40 (1970) |
| 12148 | Jisu Park, et al. D-tyrosine Negatively Regulates Melanin Synthesis by Competitively Inhibiting Tyrosinase Activity. Pigment Cell Melanoma Res. 2018 May;31(3):374-383. |
| 12149 | Cong Yu, et al. Inhibition of Biofilm Formation by D-tyrosine: Effect of Bacterial Type and D-tyrosine Concentration. Water Res. 2016 Apr 1;92:173-9. |
| 12150 | Mycopathologia (2009), 168(3), 125-134; Pharmacology (1971), 5(6), 359-71; J. Dermatol. Sci. (1990), 1(1), 39-45, |
| 12151 | Jafari E, et al. Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial and cytotoxic activities. Res Pharm Sci. 2016 Jan-Feb;11(1):1-14. |
| 12152 | Hameed A, et al. Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016). Expert Opin Ther Pat. 2018 Apr;28(4):281-297. |
| 12153 | Toxicol Appl Pharmacol 12:486 (1968); Life Sci 22:1555 (1978); Science 201:274 (1978) |
| 12154 | Cannon MV et al. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
 Eur J Heart Fail. 2015 Mar;17(3):273-82. |
| 12155 | van der Hoorn J et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
 Br J Pharmacol. 2011 Apr;162(7):1553-63. |
| 12156 | Zaccara G, et al. Antiepileptic Drugs in Clinical Development: Differentiate or Die? Curr Pharm Des. 2017;23(37):5593-5605. |
| 12157 | Bae YS, et al. Identification of a compound that directly stimulates phospholipase C activity. Mol Pharmacol. 2003;63(5):1043-1050. |
| 12158 | Krjukova J, et al. Phospholipase C activator m-3M3FBS affects Ca2+ homeostasis independently of phospholipase C activation. Br J Pharmacol. 2004;143(1):3-7. |
| 12159 | Lee YN, et al. The novel phospholipase C activator, m-3M3FBS, induces monocytic leukemia cell apoptosis. Cancer Lett. 2005;222(2):227-235. |
| 12160 | Wei Wang , et al. Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice. Gastroenterology. 2014 Oct;147(4):893-902.e2. |
| 12161 | Wei Wang, et al. The Pyrido[b]indole MDM2 Inhibitor SP-141 Exerts Potent Therapeutic Effects in Breast Cancer Models. Nat Commun. 2014 Oct 1;5:5086. |
| 12162 | Rose M, et al. A microbiological assay to estimate the antimicrobial activity of parenteral tildipirosin against foodborne pathogens and commensals in the colon of beef cattle and pigs. J Vet Pharmacol Ther. 2016 Jun;39(3):277-86. |
| 12163 | Confer AW, et al. Clinical disease and lung lesions in calves experimentally inoculated with Histophilus somni five days after metaphylactic administration of tildipirosin or tulathromycin. Am J Vet Res. 2016 Apr;77(4):358-66. |
| 12164 | Angell JW, et al. In vitro susceptibility of contagious ovine digital dermatitis associated Treponema spp. isolates to antimicrobial agents in the UK. Vet Dermatol. 2015 Dec;26(6):484-7, e114-5. |
| 12165 | Michael GB, et al. Increased MICs of gamithromycin and tildipirosin in the presence of the genes erm(42) and msr(E)-mph(E) for bovine Pasteurella multocida and Mannheimia haemolytica. J Antimicrob Chemother. 2012 Jun;67(6):1555-7. |
| 12166 | J. Am. Chem. Soc. (1948), 70, 4001-9; Ann. Allergy (1948), 6, 122-30; J. Lab. Clin. Med. (1948), 33, 319-24 |
| 12167 | Zheng YF, et al. Urinary nucleosides as biological markers for patients with colorectal cancer. World J Gastroenterol. 2005 Jul 7;11(25):3871-6. |
| 12168 | Akwabi-Ameyaw A, et al.Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett, 2008, 18(15), 4339-4343. |
| 12169 | Ma Y, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and resistance. Pharm Res. 2013 May;30(5):1447-57. |
| 12170 | Liu Y, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003 Dec;112(11):1678-87. |
| 12171 | Ozawa Y, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001 Nov;37(17):2275-82. |
| 12172 | Abbate F, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. |
| 12173 | Jann MW, et al. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.CNS Drugs. 2018 Mar;32(3):241-257. |
| 12174 | Rohde M, et al. Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug.Results Pharma Sci. 2014 May 2;4:19-25. |
| 12175 | Liu Y, et al. Antiplatelet effect of a newly developed AMP-activated protein kinase activator YLF-466D. Eur J Pharmacol. 2015 Aug 5;760:81-7. |
| 12176 | Vishnu Murthy M, Srinivas K, Kumar R, Mukkanti K.
 Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase.
 J Pharm Biomed Anal. 2011 Sep 10;56(2):429-35. |
| 12177 | Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H.
 Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist.Nihon Yakurigaku Zasshi. 2010 Aug;136(2):113-20. |
| 12178 | Ruhlmann C, Herrstedt J.
 Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
 Expert Rev Anticancer Ther. 2010 Feb;10(2):137-48. |
| 12179 | Trissel LA, Trusley C, Ben M, Kupiec TC.
 Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.
 Am J Health Syst Pharm. 2007 Jun 1;64(11):1209-13. |
| 12180 | Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglen, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al.2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.J. Med. Chem., 1993, 36 (18), pp 2645-2657 |
| 12181 | Arzneim Forsch 3:19 (1953); J Clin Gastroenterol 36:386 (2003) |
| 12182 | Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. |
| 12183 | Ishibashi Y, et al. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation. Horm Metab Res. 2016 Mar;48(3):191-5. |
| 12184 | Filippakopoulos, et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. |
| 12185 | Mahe M, et al. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med. 2018 Apr;10(4). pii: e8163. |
| 12186 | Peter S, et al. Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase.EMBO Mol Med. 2014 Dec;6(12):1525-41. |
| 12187 | Nutr Res 20:1807 (2000); Ann Nutr Metab 46:93 (2002) |
| 12188 | Feiyang Liu , et al. Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. ACS Chem. Biol., DOI: 10.1021/cb4000629 |
| 12189 | https://clinicaltrials.gov/ct2/show/NCT04467931?term=MINOXIDIL&cond=covid&draw=2&rank=1 |
| 12190 | Mijnders M, et al. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis. Curr Opin Pharmacol. 2017 Jun;34:83-90. |
| 12191 | Kato S, et al. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation. Eur J Pharmacol. 2018 Nov 5;838:138-144. |
We use cookies to ensure you get the best experience on our website. More info.